

Santodonato, L., et al., *Gene Therapy* 4:1246-1255 (1997); and Zhang, J.-F. et al., *Cancer Gene Therapy* 3: 31-38 (1996)), which are herein incorporated by reference. In one embodiment, the cells which are engineered are arterial cells. The arterial cells may be reintroduced into the patient through direct injection to the artery, the tissues surrounding the artery, or through catheter injection.

As discussed in more detail below, the polynucleotide constructs can be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, and the like). The polynucleotide constructs may be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

In one embodiment, the polynucleotide of the present invention is delivered as a naked polynucleotide. The term "naked" polynucleotide, DNA or RNA refers to sequences that are free from any delivery vehicle that acts to assist, promote or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotide of the present invention can also be delivered in liposome formulations and lipofectin formulations and the like can be prepared by methods well known to those skilled in the art. Such methods are described, for example, in U.S. Patent Nos. 5,593,972, 5,589,466, and 5,580,859, which are herein incorporated by reference.

The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Appropriate vectors include pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; pSVK3, pBPV, pMSG and pSVL available from Pharmacia; and pEF1/V5, pcDNA3.1, and pRc/CMV2 available from Invitrogen. Other suitable vectors will be readily apparent to the skilled artisan.

Any strong promoter known to those skilled in the art can be used for driving the expression of the polynucleotide sequence. Suitable promoters include adenoviral promoters, such as the adenoviral major late promoter; or heterologous promoters, such as the cytomegalovirus (CMV) promoter; the respiratory syncytial virus (RSV) promoter; inducible promoters, such as the MMT promoter, the metallothionein promoter; heat shock promoters; the albumin promoter; the ApoA1 promoter; human globin promoters; viral thymidine kinase promoters, such as the Herpes Simplex thymidine kinase promoter; retroviral LTRs; the b-

actin promoter; and human growth hormone promoters. The promoter also may be the native promoter for the polynucleotide of the present invention.

Unlike other gene therapy techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into
5 cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis,
10 ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular, fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the
15 lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example,
20 stem cells of blood or skin fibroblasts. In vivo muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked nucleic acid sequence injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 mg/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more
25 preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration.

30 The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues,

throat or mucous membranes of the nose. In addition, naked DNA constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The naked polynucleotides are delivered by any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical
5 administration, catheter infusion, and so-called "gene guns". These delivery methods are known in the art.

The constructs may also be delivered with delivery vehicles such as viral sequences, viral particles, liposome formulations, lipofectin, precipitating agents, etc. Such methods of delivery are known in the art.

10 In certain embodiments, the polynucleotide constructs are complexed in a liposome preparation. Liposomal preparations for use in the instant invention include cationic (positively charged), anionic (negatively charged) and neutral preparations. However, cationic liposomes are particularly preferred because a tight charge complex can be formed between the cationic liposome and the polyanionic nucleic acid. Cationic liposomes have
15 been shown to mediate intracellular delivery of plasmid DNA (Felgner et al., Proc. Natl. Acad. Sci. USA (1987) 84:7413-7416, which is herein incorporated by reference); mRNA (Malone et al., Proc. Natl. Acad. Sci. USA (1989) 86:6077-6081, which is herein incorporated by reference); and purified transcription factors (Debs et al., J. Biol. Chem. (1990) 265:10189-10192, which is herein incorporated by reference), in functional form.

20 Cationic liposomes are readily available. For example, N[1-2,3-dioleoyloxy)propyl]-N,N,N-triethylammonium (DOTMA) liposomes are particularly useful and are available under the trademark Lipofectin, from GIBCO BRL, Grand Island, N.Y. (See, also, Felgner et al., Proc. Natl. Acad. Sci. USA (1987) 84:7413-7416, which is herein incorporated by reference). Other commercially available liposomes include
25 transfectace (DDAB/DOPE) and DOTAP/DOPE (Boehringer).

Other cationic liposomes can be prepared from readily available materials using techniques well known in the art. See, e.g. PCT Publication No. WO 90/11092 (which is herein incorporated by reference) for a description of the synthesis of DOTAP (1,2-bis(oleoyloxy)-3-(trimethylammonio)propane) liposomes. Preparation of DOTMA liposomes
30 is explained in the literature, see, e.g., P. Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417, which is herein incorporated by reference. Similar methods can be used to prepare liposomes from other cationic lipid materials.

Similarly, anionic and neutral liposomes are readily available, such as from Avanti Polar Lipids (Birmingham, Ala.), or can be easily prepared using readily available materials. Such materials include phosphatidyl, choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG),
5 dioleoylphosphatidyl ethanolamine (DOPE), among others. These materials can also be mixed with the DOTMA and DOTAP starting materials in appropriate ratios. Methods for making liposomes using these materials are well known in the art.

For example, commercially dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), and dioleoylphosphatidyl ethanolamine (DOPE) can
10 be used in various combinations to make conventional liposomes, with or without the addition of cholesterol. Thus, for example, DOPG/DOPC vesicles can be prepared by drying 50 mg each of DOPG and DOPC under a stream of nitrogen gas into a sonication vial. The sample is placed under a vacuum pump overnight and is hydrated the following day with deionized water. The sample is then sonicated for 2 hours in a capped vial, using a Heat
15 Systems model 350 sonicator equipped with an inverted cup (bath type) probe at the maximum setting while the bath is circulated at 15EC. Alternatively, negatively charged vesicles can be prepared without sonication to produce multilamellar vesicles or by extrusion through nucleopore membranes to produce unilamellar vesicles of discrete size. Other methods are known and available to those of skill in the art.

20 The liposomes can comprise multilamellar vesicles (MLVs), small unilamellar vesicles (SUVs), or large unilamellar vesicles (LUVs), with SUVs being preferred. The various liposome-nucleic acid complexes are prepared using methods well known in the art. See, e.g., Straubinger et al., *Methods of Immunology* (1983), 101:512-527, which is herein incorporated by reference. For example, MLVs containing nucleic acid can be prepared by
25 depositing a thin film of phospholipid on the walls of a glass tube and subsequently hydrating with a solution of the material to be encapsulated. SUVs are prepared by extended sonication of MLVs to produce a homogeneous population of unilamellar liposomes. The material to be entrapped is added to a suspension of preformed MLVs and then sonicated. When using liposomes containing cationic lipids, the dried lipid film is resuspended in an appropriate
30 solution such as sterile water or an isotonic buffer solution such as 10 mM Tris/NaCl, sonicated, and then the preformed liposomes are mixed directly with the DNA. The liposome and DNA form a very stable complex due to binding of the positively charged liposomes to

the cationic DNA. SUVs find use with small nucleic acid fragments. LUVs are prepared by a number of methods, well known in the art. Commonly used methods include Ca^{2+} -EDTA chelation (Papahadjopoulos et al., *Biochim. Biophys. Acta* (1975) 394:483; Wilson et al., *Cell* (1979) 17:77); ether injection (Deamer, D. and Bangham, A., *Biochim. Biophys. Acta* (1976) 443:629; Ostro et al., *Biochem. Biophys. Res. Commun.* (1977) 76:836; Fraley et al., Proc. Natl. Acad. Sci. USA (1979) 76:3348); detergent dialysis (Enoch, H. and Strittmatter, P., Proc. Natl. Acad. Sci. USA (1979) 76:145); and reverse-phase evaporation (REV) (Fraley et al., *J. Biol. Chem.* (1980) 255:10431; Szoka, F. and Papahadjopoulos, D., Proc. Natl. Acad. Sci. USA (1978) 75:145; Schaefer-Ridder et al., *Science* (1982) 215:166), which are
10 herein incorporated by reference.

Generally, the ratio of DNA to liposomes will be from about 10:1 to about 1:10. Preferably, the ration will be from about 5:1 to about 1:5. More preferably, the ration will be about 3:1 to about 1:3. Still more preferably, the ratio will be about 1:1.

U.S. Patent No. 5,676,954 (which is herein incorporated by reference) reports on the
15 injection of genetic material, complexed with cationic liposomes carriers, into mice. U.S. Patent Nos. 4,897,355, 4,946,787, 5,049,386, 5,459,127, 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication no. WO 94/9469 (which are herein incorporated by reference) provide cationic lipids for use in transfecting DNA into cells and mammals. U.S. Patent Nos. 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication no.
20 WO 94/9469 (which are herein incorporated by reference) provide methods for delivering DNA-cationic lipid complexes to mammals.

In certain embodiments, cells are engineered, ex vivo or in vivo, using a retroviral particle containing RNA which comprises a sequence encoding a polypeptide of the present invention. Retroviruses from which the retroviral plasmid vectors may be derived include,
25 but are not limited to, Moloney Murine Leukemia Virus, spleen necrosis virus, Rous sarcoma Virus, Harvey Sarcoma Virus, avian leukosis virus, gibbon ape leukemia virus, human immunodeficiency virus, Myeloproliferative Sarcoma Virus, and mammary tumor virus.

The retroviral plasmid vector is employed to transduce packaging cell lines to form producer cell lines. Examples of packaging cells which may be transfected include, but are
30 not limited to, the PE501, PA317, R-2, R-AM, PA12, T19-14X, VT-19-17-H2, RCRE, RCRIP, GP+E-86, GP+envAm12, and DAN cell lines as described in Miller, *Human Gene Therapy* 1:5-14 (1990), which is incorporated herein by reference in its entirety. The vector

may transduce the packaging cells through any means known in the art. Such means include, but are not limited to, electroporation, the use of liposomes, and CaPO_4 precipitation. In one alternative, the retroviral plasmid vector may be encapsulated into a liposome, or coupled to a lipid, and then administered to a host.

5 The producer cell line generates infectious retroviral vector particles which include polynucleotide encoding a polypeptide of the present invention. Such retroviral vector particles then may be employed, to transduce eukaryotic cells, either in vitro or in vivo. The transduced eukaryotic cells will express a polypeptide of the present invention.

 In certain other embodiments, cells are engineered, ex vivo or in vivo, with
10 polynucleotide contained in an adenovirus vector. Adenovirus can be manipulated such that it encodes and expresses a polypeptide of the present invention, and at the same time is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. Adenovirus expression is achieved without integration of the viral DNA into the host cell chromosome, thereby alleviating concerns about insertional mutagenesis. Furthermore, adenoviruses have
15 been used as live enteric vaccines for many years with an excellent safety profile (Schwartz, A. R. et al. (1974) Am. Rev. Respir. Dis. 109:233-238). Finally, adenovirus mediated gene transfer has been demonstrated in a number of instances including transfer of alpha-1-antitrypsin and CFTR to the lungs of cotton rats (Rosenfeld, M. A. et al. (1991) Science 252:431-434; Rosenfeld et al., (1992) Cell 68:143-155). Furthermore, extensive
20 studies to attempt to establish adenovirus as a causative agent in human cancer were uniformly negative (Green, M. et al. (1979) Proc. Natl. Acad. Sci. USA 76:6606).

 Suitable adenoviral vectors useful in the present invention are described, for example, in Kozarsky and Wilson, Curr. Opin. Genet. Devel. 3:499-503 (1993); Rosenfeld et al., Cell 68:143-155 (1992); Engelhardt et al., Human Genet. Ther. 4:759-769 (1993); Yang et al.,
25 Nature Genet. 7:362-369 (1994); Wilson et al., Nature 365:691-692 (1993); and U.S. Patent No. 5,652,224, which are herein incorporated by reference. For example, the adenovirus vector Ad2 is useful and can be grown in human 293 cells. These cells contain the E1 region of adenovirus and constitutively express Ela and Elb, which complement the defective adenoviruses by providing the products of the genes deleted from the vector. In addition to
30 Ad2, other varieties of adenovirus (e.g., Ad3, Ad5, and Ad7) are also useful in the present invention.

Preferably, the adenoviruses used in the present invention are replication deficient. Replication deficient adenoviruses require the aid of a helper virus and/or packaging cell line to form infectious particles. The resulting virus is capable of infecting cells and can express a polynucleotide of interest which is operably linked to a promoter, but cannot replicate in most cells. Replication deficient adenoviruses may be deleted in one or more of all or a portion of the following genes: E1a, E1b, E3, E4, E2a, or L1 through L5.

In certain other embodiments, the cells are engineered, ex vivo or in vivo, using an adeno-associated virus (AAV). AAVs are naturally occurring defective viruses that require helper viruses to produce infectious particles (Muzyczka, N., Curr. Topics in Microbiol. Immunol. 158:97 (1992)). It is also one of the few viruses that may integrate its DNA into non-dividing cells. Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate, but space for exogenous DNA is limited to about 4.5 kb. Methods for producing and using such AAVs are known in the art. See, for example, U.S. Patent Nos. 5,139,941, 5,173,414, 5,354,678, 5,436,146, 5,474,935, 5,478,745, and 5,589,377.

For example, an appropriate AAV vector for use in the present invention will include all the sequences necessary for DNA replication, encapsidation, and host-cell integration. The polynucleotide construct is inserted into the AAV vector using standard cloning methods, such as those found in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press (1989). The recombinant AAV vector is then transfected into packaging cells which are infected with a helper virus, using any standard technique, including lipofection, electroporation, calcium phosphate precipitation, etc. Appropriate helper viruses include adenoviruses, cytomegaloviruses, vaccinia viruses, or herpes viruses. Once the packaging cells are transfected and infected, they will produce infectious AAV viral particles which contain the polynucleotide construct. These viral particles are then used to transduce eukaryotic cells, either ex vivo or in vivo. The transduced cells will contain the polynucleotide construct integrated into its genome, and will express a polypeptide of the invention.

Another method of gene therapy involves operably associating heterologous control regions and endogenous polynucleotide sequences (e.g. encoding a polypeptide of the present invention) via homologous recombination (see, e.g., U.S. Patent No. 5,641,670, issued June 24, 1997; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller et al., Proc.

Natl. Acad. Sci. USA 86:8932-8935 (1989); and Zijlstra et al., Nature 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not normally expressed in the cells, or is expressed at a lower level than desired.

Polynucleotide constructs are made, using standard techniques known in the art, which contain the promoter with targeting sequences flanking the promoter. Suitable promoters are described herein. The targeting sequence is sufficiently complementary to an endogenous sequence to permit homologous recombination of the promoter-targeting sequence with the endogenous sequence. The targeting sequence will be sufficiently near the 5' end of the desired endogenous polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination.

The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter. The amplified promoter and targeting sequences are digested and ligated together.

The promoter-targeting sequence construct is delivered to the cells, either as naked polynucleotide, or in conjunction with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, whole viruses, lipofection, precipitating agents, etc., described in more detail above. The P promoter-targeting sequence can be delivered by any method, included direct needle injection, intravenous injection, topical administration, catheter infusion, particle accelerators, etc. The methods are described in more detail below.

The promoter-targeting sequence construct is taken up by cells. Homologous recombination between the construct and the endogenous sequence takes place, such that an endogenous sequence is placed under the control of the promoter. The promoter then drives the expression of the endogenous sequence.

Preferably, the polynucleotide encoding a polypeptide of the present invention contains a secretory signal sequence that facilitates secretion of the protein. Typically, the signal sequence is positioned in the coding region of the polynucleotide to be expressed towards or at the 5' end of the coding region. The signal sequence may be homologous or heterologous to the polynucleotide of interest and may be homologous or heterologous to the

cells to be transfected. Additionally, the signal sequence may be chemically synthesized using methods known in the art.

Any mode of administration of any of the above-described polynucleotides constructs can be used so long as the mode results in the expression of one or more molecules in an amount sufficient to provide a therapeutic effect. This includes direct needle injection, systemic injection, catheter infusion, biolistic injectors, particle accelerators (i.e., "gene guns"), gelfoam sponge depots, other commercially available depot materials, osmotic pumps (e.g., Alza minipumps), oral or suppositorial solid (tablet or pill) pharmaceutical formulations, and decanting or topical applications during surgery. For example, direct injection of naked calcium phosphate-precipitated plasmid into rat liver and rat spleen or a protein-coated plasmid into the portal vein has resulted in gene expression of the foreign gene in the rat livers (Kaneda et al., Science 243:375 (1989)).

A preferred method of local administration is by direct injection. Preferably, a recombinant molecule of the present invention complexed with a delivery vehicle is administered by direct injection into or locally within the area of arteries. Administration of a composition locally within the area of arteries refers to injecting the composition centimeters and preferably, millimeters within arteries.

Another method of local administration is to contact a polynucleotide construct of the present invention in or around a surgical wound. For example, a patient can undergo surgery and the polynucleotide construct can be coated on the surface of tissue inside the wound or the construct can be injected into areas of tissue inside the wound.

Therapeutic compositions useful in systemic administration, include recombinant molecules of the present invention complexed to a targeted delivery vehicle of the present invention. Suitable delivery vehicles for use with systemic administration comprise liposomes comprising ligands for targeting the vehicle to a particular site.

Preferred methods of systemic administration, include intravenous injection, aerosol, oral and percutaneous (topical) delivery. Intravenous injections can be performed using methods standard in the art. Aerosol delivery can also be performed using methods standard in the art (see, for example, Stribling et al., Proc. Natl. Acad. Sci. USA 189:11277-11281, 1992, which is incorporated herein by reference). Oral delivery can be performed by complexing a polynucleotide construct of the present invention to a carrier capable of withstanding degradation by digestive enzymes in the gut of an animal. Examples of such

carriers, include plastic capsules or tablets, such as those known in the art. Topical delivery can be performed by mixing a polynucleotide construct of the present invention with a lipophilic reagent (e.g., DMSO) that is capable of passing into the skin.

Determining an effective amount of substance to be delivered can depend upon a number of factors including, for example, the chemical structure and biological activity of the substance, the age and weight of the animal, the precise condition requiring treatment and its severity, and the route of administration. The frequency of treatments depends upon a number of factors, such as the amount of polynucleotide constructs administered per dose, as well as the health and history of the subject. The precise amount, number of doses, and timing of doses will be determined by the attending physician or veterinarian.

Therapeutic compositions of the present invention can be administered to any animal, preferably to mammals and birds. Preferred mammals include humans, dogs, cats, mice, rats, rabbits sheep, cattle, horses and pigs, with humans being particularly preferred.

15 **Biological Activities**

Polynucleotides or polypeptides, or agonists or antagonists of the present invention, can be used in assays to test for one or more biological activities. If these polynucleotides or polypeptides, or agonists or antagonists of the present invention, do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides and polypeptides, and agonists or antagonists could be used to treat the associated disease.

Immune Activity

A polypeptide or polynucleotide, or agonists or antagonists of the present invention may be useful in treating deficiencies or disorders of the immune system, by activating or inhibiting the proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune deficiencies or disorders may be genetic, somatic, such as cancer or some autoimmune disorders, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, polynucleotides or polypeptides, or

agonists or antagonists of the present invention can be used as a marker or detector of a particular immune system disease or disorder.

Polynucleotides or polypeptides, or agonists or antagonists of the present invention may be useful in treating or detecting deficiencies or disorders of hematopoietic cells.

5 Polynucleotides or polypeptides, or agonists or antagonists of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat those disorders associated with a decrease in certain (or many) types hematopoietic cells. Examples of immunologic deficiency syndromes include, but are not limited to: blood protein disorders (e.g.
10 agammaglobulinemia, dysgammaglobulinemia), ataxia telangiectasia, common variable immunodeficiency, Digeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria.

15 Moreover, polynucleotides or polypeptides, or agonists or antagonists of the present invention could also be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity (clot formation). For example, by increasing hemostatic or thrombolytic activity, polynucleotides or polypeptides, or agonists or antagonists of the present invention could be used to treat blood coagulation disorders (e.g., afibrinogenemia,
20 factor deficiencies), blood platelet disorders (e.g. thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, polynucleotides or polypeptides, or agonists or antagonists of the present invention that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting. These molecules could be important in the treatment of heart attacks (infarction), strokes, or scarring.

25 Polynucleotides or polypeptides, or agonists or antagonists of the present invention may also be useful in treating or detecting autoimmune disorders. Many autoimmune disorders result from inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of polynucleotides or polypeptides, or agonists or
30 antagonists of the present invention that can inhibit an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune disorders.

Examples of autoimmune disorders that can be treated or detected include, but are not limited to: Addison's Disease, hemolytic anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitus, and autoimmune inflammatory eye disease.

Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated by polynucleotides or polypeptides, or agonists or antagonists of the present invention. Moreover, these molecules can be used to treat anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

Polynucleotides or polypeptides, or agonists or antagonists of the present invention may also be used to treat and/or prevent organ rejection or graft-versus-host disease (GVHD). Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. The administration of polynucleotides or polypeptides, or agonists or antagonists of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD.

Similarly, polynucleotides or polypeptides, or agonists or antagonists of the present invention may also be used to modulate inflammation. For example, polynucleotides or polypeptides, or agonists or antagonists of the present invention may inhibit the proliferation and differentiation of cells involved in an inflammatory response. These molecules can be used to treat inflammatory conditions, both chronic and acute conditions, including chronic prostatitis, granulomatous prostatitis and malacoplakia, inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, or resulting from over production of cytokines (e.g., TNF or IL-1.)

Hyperproliferative Disorders

Polynucleotides or polypeptides, or agonists or antagonists of the present invention can be used to treat or detect hyperproliferative disorders, including neoplasms. Polynucleotides or polypeptides, or agonists or antagonists of the present invention may
5 inhibit the proliferation of the disorder through direct or indirect interactions. Alternatively, Polynucleotides or polypeptides, or agonists or antagonists of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.

For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing
10 T-cells, hyperproliferative disorders can be treated. This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating hyperproliferative disorders, such as a chemotherapeutic agent.

Examples of hyperproliferative disorders that can be treated or detected by
15 Polynucleotides or polypeptides, or agonists or antagonists of the present invention include, but are not limited to neoplasms located in the: colon, abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

20 Similarly, other hyperproliferative disorders can also be treated or detected by polynucleotides or polypeptides, or agonists or antagonists of the present invention. Examples of such hyperproliferative disorders include, but are not limited to: hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenstrom's Macroglobulinemia, Gaucher's Disease,
25 histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

One preferred embodiment utilizes polynucleotides of the present invention to inhibit aberrant cellular division, by gene therapy using the present invention, and/or protein fusions or fragments thereof.

30 Thus, the present invention provides a method for treating cell proliferative disorders by inserting into an abnormally proliferating cell a polynucleotide of the present invention, wherein said polynucleotide represses said expression.

Another embodiment of the present invention provides a method of treating cell-proliferative disorders in individuals comprising administration of one or more active gene copies of the present invention to an abnormally proliferating cell or cells. In a preferred embodiment, polynucleotides of the present invention is a DNA construct comprising a recombinant expression vector effective in expressing a DNA sequence encoding said polynucleotides. In another preferred embodiment of the present invention, the DNA construct encoding the polynucleotides of the present invention is inserted into cells to be treated utilizing a retrovirus, or more preferably an adenoviral vector (See G J. Nabel, et. al., PNAS 1999 96: 324-326, which is hereby incorporated by reference). In a most preferred embodiment, the viral vector is defective and will not transform non-proliferating cells, only proliferating cells. Moreover, in a preferred embodiment, the polynucleotides of the present invention inserted into proliferating cells either alone, or in combination with or fused to other polynucleotides, can then be modulated via an external stimulus (i.e. magnetic, specific small molecule, chemical, or drug administration, etc.), which acts upon the promoter upstream of said polynucleotides to induce expression of the encoded protein product. As such the beneficial therapeutic affect of the present invention may be expressly modulated (i.e. to increase, decrease, or inhibit expression of the present invention) based upon said external stimulus.

Polynucleotides of the present invention may be useful in repressing expression of oncogenic genes or antigens. By "repressing expression of the oncogenic genes " is intended the suppression of the transcription of the gene, the degradation of the gene transcript (pre-message RNA), the inhibition of splicing, the destruction of the messenger RNA, the prevention of the post-translational modifications of the protein, the destruction of the protein, or the inhibition of the normal function of the protein.

For local administration to abnormally proliferating cells, polynucleotides of the present invention may be administered by any method known to those of skill in the art including, but not limited to transfection, electroporation, microinjection of cells, or in vehicles such as liposomes, lipofectin, or as naked polynucleotides, or any other method described throughout the specification. The polynucleotide of the present invention may be delivered by known gene delivery systems such as, but not limited to, retroviral vectors (Gilboa, J. Virology 44:845 (1982); Hocke, Nature 320:275 (1986); Wilson, et al., Proc. Natl. Acad. Sci. U.S.A. 85:3014), vaccinia virus system (Chakrabarty et al., Mol. Cell Biol. 5:3403

(1985) or other efficient DNA delivery systems (Yates et al., Nature 313:812 (1985)) known to those skilled in the art. These references are exemplary only and are hereby incorporated by reference. In order to specifically deliver or transfect cells which are abnormally proliferating and spare non-dividing cells, it is preferable to utilize a retrovirus, or adenoviral
5 (as described in the art and elsewhere herein) delivery system known to those of skill in the art. Since host DNA replication is required for retroviral DNA to integrate and the retrovirus will be unable to self replicate due to the lack of the retrovirus genes needed for its life cycle. Utilizing such a retroviral delivery system for polynucleotides of the present invention will target said gene and constructs to abnormally proliferating cells and will spare the non-
10 dividing normal cells.

The polynucleotides of the present invention may be delivered directly to cell proliferative disorder/disease sites in internal organs, body cavities and the like by use of imaging devices used to guide an injecting needle directly to the disease site. The polynucleotides of the present invention may also be administered to disease sites at the time
15 of surgical intervention.

By "cell proliferative disease" is meant any human or animal disease or disorder, affecting any one or any combination of organs, cavities, or body parts, which is characterized by single or multiple local abnormal proliferations of cells, groups of cells, or tissues, whether benign or malignant.

20 Any amount of the polynucleotides of the present invention may be administered as long as it has a biologically inhibiting effect on the proliferation of the treated cells. Moreover, it is possible to administer more than one of the polynucleotide of the present invention simultaneously to the same site. By "biologically inhibiting" is meant partial or total growth inhibition as well as decreases in the rate of proliferation or growth of the cells.
25 The biologically inhibitory dose may be determined by assessing the effects of the polynucleotides of the present invention on target malignant or abnormally proliferating cell growth in tissue culture, tumor growth in animals and cell cultures, or any other method known to one of ordinary skill in the art.

The present invention is further directed to antibody-based therapies which involve
30 administering of anti-polypeptides and anti-polynucleotide antibodies to a mammalian, preferably human, patient for treating one or more of the described disorders. Methods for producing anti-polypeptides and anti-polynucleotide antibodies polyclonal and monoclonal

antibodies are described in detail elsewhere herein. Such antibodies may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

In particular, the antibodies, fragments and derivatives of the present invention are useful for treating a subject having or developing cell proliferative and/or differentiation disorders as described herein. Such treatment comprises administering a single or multiple doses of the antibody, or a fragment, derivative, or a conjugate thereof.

The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors, for example, which serve to increase the number or activity of effector cells which interact with the antibodies.

It is preferred to use high affinity and/or potent in vivo inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of disorders related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides, including fragments thereof. Preferred binding affinities include those with a dissociation constant or K_d less than $5 \times 10^{-6}M$, $10^{-6}M$, $5 \times 10^{-7}M$, $10^{-7}M$, $5 \times 10^{-8}M$, $10^{-8}M$, $5 \times 10^{-9}M$, $10^{-9}M$, $5 \times 10^{-10}M$, $10^{-10}M$, $5 \times 10^{-11}M$, $10^{-11}M$, $5 \times 10^{-12}M$, $10^{-12}M$, $5 \times 10^{-13}M$, $10^{-13}M$, $5 \times 10^{-14}M$, $10^{-14}M$, $5 \times 10^{-15}M$, and $10^{-15}M$.

Moreover, polypeptides of the present invention are useful in inhibiting the angiogenesis of proliferative cells or tissues, either alone, as a protein fusion, or in combination with other polypeptides directly or indirectly, as described elsewhere herein. In a most preferred embodiment, said anti-angiogenesis effect may be achieved indirectly, for example, through the inhibition of hematopoietic, tumor-specific cells, such as tumor-associated macrophages (See Joseph IB, et al. J Natl Cancer Inst, 90(21):1648-53 (1998),

which is hereby incorporated by reference). Antibodies directed to polypeptides or polynucleotides of the present invention may also result in inhibition of angiogenesis directly, or indirectly (See Witte L, et al., *Cancer Metastasis Rev.* 17(2):155-61 (1998), which is hereby incorporated by reference)).

5 Polypeptides, including protein fusions, of the present invention, or fragments thereof may be useful in inhibiting proliferative cells or tissues through the induction of apoptosis. Said polypeptides may act either directly, or indirectly to induce apoptosis of proliferative cells and tissues, for example in the activation of a death-domain receptor, such as tumor necrosis factor (TNF) receptor-1, CD95 (Fas/APO-1), TNF-receptor-related apoptosis-mediated protein (TRAMP) and TNF-related apoptosis-inducing ligand (TRAIL) receptor-1
10 and -2 (See Schulze-Osthoff K, et.al., *Eur J Biochem* 254(3):439-59 (1998), which is hereby incorporated by reference). Moreover, in another preferred embodiment of the present invention, said polypeptides may induce apoptosis through other mechanisms, such as in the activation of other proteins which will activate apoptosis, or through stimulating the
15 expression of said proteins, either alone or in combination with small molecule drugs or adjuvants, such as apoptonin, galectins, thioredoxins, antiinflammatory proteins (See for example, *Mutat Res* 400(1-2):447-55 (1998), *Med Hypotheses*.50(5):423-33 (1998), *Chem Biol Interact.* Apr 24;111-112:23-34 (1998), *J Mol Med.*76(6):402-12 (1998), *Int J Tissue React*;20(1):3-15 (1998), which are all hereby incorporated by reference).

20 Polypeptides, including protein fusions to, or fragments thereof, of the present invention are useful in inhibiting the metastasis of proliferative cells or tissues. Inhibition may occur as a direct result of administering polypeptides, or antibodies directed to said polypeptides as described elsewhere herein, or indirectly, such as activating the expression of proteins known to inhibit metastasis, for example alpha 4 integrins, (See, e.g., *Curr Top*
25 *Microbiol Immunol* 1998;231:125-41, which is hereby incorporated by reference). Such therapeutic affects of the present invention may be achieved either alone, or in combination with small molecule drugs or adjuvants.

In another embodiment, the invention provides a method of delivering compositions containing the polypeptides of the invention (e.g., compositions containing polypeptides or
30 polypeptide antibodies associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs) to targeted cells expressing the polypeptide of the present invention. Polypeptides or polypeptide antibodies of the invention may be associated with with

heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions. Polypeptides, protein fusions to, or fragments thereof, of the present invention are useful in enhancing the immunogenicity and/or antigenicity of proliferating cells or tissues, either directly, such as would occur if the polypeptides of the present invention 'vaccinated' the immune response to respond to proliferative antigens and immunogens, or indirectly, such as in activating the expression of proteins known to enhance the immune response (e.g. chemokines), to said antigens and immunogens.

10 **Cardiovascular Disorders**

Polynucleotides or polypeptides, or agonists or antagonists of the present invention, may be used to treat cardiovascular disorders, including peripheral artery disease, such as limb ischemia.

Cardiovascular disorders include cardiovascular abnormalities, such as arterio-arterial fistula, arteriovenous fistula, cerebral arteriovenous malformations, congenital heart defects, pulmonary atresia, and Scimitar Syndrome. Congenital heart defects include aortic coarctation, cor triatriatum, coronary vessel anomalies, crisscross heart, dextrocardia, patent ductus arteriosus, Ebstein's anomaly, Eisenmenger complex, hypoplastic left heart syndrome, levocardia, tetralogy of fallot, transposition of great vessels, double outlet right ventricle, tricuspid atresia, persistent truncus arteriosus, and heart septal defects, such as aortopulmonary septal defect, endocardial cushion defects, Lutembacher's Syndrome, trilog
y of Fallot, ventricular heart septal defects.

Cardiovascular disorders also include heart disease, such as arrhythmias, carcinoid heart disease, high cardiac output, low cardiac output, cardiac tamponade, endocarditis (including bacterial), heart aneurysm, cardiac arrest, congestive heart failure, congestive cardiomyopathy, paroxysmal dyspnea, cardiac edema, heart hypertrophy, congestive cardiomyopathy, left ventricular hypertrophy, right ventricular hypertrophy, post-infarction heart rupture, ventricular septal rupture, heart valve diseases, myocardial diseases, myocardial ischemia, pericardial effusion, pericarditis (including constrictive and tuberculous), pneumopericardium, postpericardiotomy syndrome, pulmonary heart disease, rheumatic heart disease, ventricular dysfunction, hyperemia, cardiovascular pregnancy complications, Scimitar Syndrome, cardiovascular syphilis, and cardiovascular tuberculosis.

Arrhythmias include sinus arrhythmia, atrial fibrillation, atrial flutter, bradycardia, extrasystole, Adams-Stokes Syndrome, bundle-branch block, sinoatrial block, long QT syndrome, parasystole, Lown-Ganong-Levine Syndrome, Mahaim-type pre-excitation syndrome, Wolff-Parkinson-White syndrome, sick sinus syndrome, tachycardias, and ventricular fibrillation. Tachycardias include paroxysmal tachycardia, supraventricular tachycardia, accelerated idioventricular rhythm, atrioventricular nodal reentry tachycardia, ectopic atrial tachycardia, ectopic junctional tachycardia, sinoatrial nodal reentry tachycardia, sinus tachycardia, Torsades de Pointes, and ventricular tachycardia.

Heart valve disease include aortic valve insufficiency, aortic valve stenosis, heart murmurs, aortic valve prolapse, mitral valve prolapse, tricuspid valve prolapse, mitral valve insufficiency, mitral valve stenosis, pulmonary atresia, pulmonary valve insufficiency, pulmonary valve stenosis, tricuspid atresia, tricuspid valve insufficiency, and tricuspid valve stenosis.

Myocardial diseases include alcoholic cardiomyopathy, congestive cardiomyopathy, hypertrophic cardiomyopathy, aortic subvalvular stenosis, pulmonary subvalvular stenosis, restrictive cardiomyopathy, Chagas cardiomyopathy, endocardial fibroelastosis, endomyocardial fibrosis, Kearns Syndrome, myocardial reperfusion injury, and myocarditis.

Myocardial ischemias include coronary disease, such as angina pectoris, coronary aneurysm, coronary arteriosclerosis, coronary thrombosis, coronary vasospasm, myocardial infarction and myocardial stunning.

Cardiovascular diseases also include vascular diseases such as aneurysms, angiodysplasia, angiomas, bacillary angiomas, Hippiel-Lindau Disease, Klippel-Trenaunay-Weber Syndrome, Sturge-Weber Syndrome, angioneurotic edema, aortic diseases, Takayasu's Arteritis, aortitis, Leriche's Syndrome, arterial occlusive diseases, arteritis, enarteritis, polyarteritis nodosa, cerebrovascular disorders, diabetic angiopathies, diabetic retinopathy, embolisms, thrombosis, erythromelalgia, hemorrhoids, hepatic veno-occlusive disease, hypertension, hypotension, ischemia, peripheral vascular diseases, phlebitis, pulmonary veno-occlusive disease, Raynaud's disease, CREST syndrome, retinal vein occlusion, Scimitar syndrome, superior vena cava syndrome, telangiectasia, ataxia telangiectasia, hereditary hemorrhagic telangiectasia, varicocele, varicose veins, varicose ulcer, vasculitis, and venous insufficiency.

Aneurysms include dissecting aneurysms, false aneurysms, infected aneurysms, ruptured aneurysms, aortic aneurysms, cerebral aneurysms, coronary aneurysms, heart aneurysms, and iliac aneurysms.

5 Arterial occlusive diseases include arteriosclerosis, intermittent claudication, carotid stenosis, fibromuscular dysplasias, mesenteric vascular occlusion, Moyamoya disease, renal artery obstruction, retinal artery occlusion, and thromboangiitis obliterans.

Cerebrovascular disorders include carotid artery diseases, cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformation, cerebral artery diseases, cerebral embolism and thrombosis, 10 carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, cerebral hemorrhage, epidural hematoma, subdural hematoma, subarachnoid hemorrhage, cerebral infarction, cerebral ischemia (including transient), subclavian steal syndrome, periventricular leukomalacia, vascular headache, cluster headache, migraine, and vertebrobasilar insufficiency.

15 Embolisms include air embolisms, amniotic fluid embolisms, cholesterol embolisms, blue toe syndrome, fat embolisms, pulmonary embolisms, and thromboembolisms. Thrombosis include coronary thrombosis, hepatic vein thrombosis, retinal vein occlusion, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, and thrombophlebitis.

Ischemia includes cerebral ischemia, ischemic colitis, compartment syndromes, 20 anterior compartment syndrome, myocardial ischemia, reperfusion injuries, and peripheral limb ischemia. Vasculitis includes aortitis, arteritis, Behcet's Syndrome, Churg-Strauss Syndrome, mucocutaneous lymph node syndrome, thromboangiitis obliterans, hypersensitivity vasculitis, Schoenlein-Henoch purpura, allergic cutaneous vasculitis, and Wegener's granulomatosis.

25 Polynucleotides or polypeptides, or agonists or antagonists of the present invention, are especially effective for the treatment of critical limb ischemia and coronary disease.

Polypeptides may be administered using any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, biolistic injectors, particle accelerators, gelfoam sponge 30 depots, other commercially available depot materials, osmotic pumps, oral or suppository solid pharmaceutical formulations, decanting or topical applications during surgery, aerosol delivery. Such methods are known in the art. Polypeptides may be administered as part of a

Therapeutic, described in more detail below. Methods of delivering polynucleotides are described in more detail herein.

Anti-Angiogenesis Activity

5 The naturally occurring balance between endogenous stimulators and inhibitors of angiogenesis is one in which inhibitory influences predominate. Rastinejad *et al.*, *Cell* 56:345-355 (1989). In those rare instances in which neovascularization occurs under normal physiological conditions, such as wound healing, organ regeneration, embryonic development, and female reproductive processes, angiogenesis is stringently regulated and
10 spatially and temporally delimited. Under conditions of pathological angiogenesis such as that characterizing solid tumor growth, these regulatory controls fail. Unregulated angiogenesis becomes pathologic and sustains progression of many neoplastic and non-neoplastic diseases. A number of serious diseases are dominated by abnormal neovascularization including solid tumor growth and metastases, arthritis, some types of eye
15 disorders, and psoriasis. See, e.g., reviews by Moses *et al.*, *Biotech.* 9:630-634 (1991); Folkman *et al.*, *N. Engl. J. Med.*, 333:1757-1763 (1995); Auerbach *et al.*, *J. Microvasc. Res.* 29:401-411 (1985); Folkman, *Advances in Cancer Research*, eds. Klein and Weinhouse, Academic Press, New York, pp. 175-203 (1985); Patz, *Am. J. Ophthalmol.* 94:715-743 (1982); and Folkman *et al.*, *Science* 221:719-725 (1983). In a number of pathological
20 conditions, the process of angiogenesis contributes to the disease state. For example, significant data have accumulated which suggest that the growth of solid tumors is dependent on angiogenesis. Folkman and Klagsbrun, *Science* 235:442-447 (1987).

 The polynucleotides encoding a polypeptide of the present invention may be administered along with other polynucleotides encoding an angiogenic protein. Examples of
25 angiogenic proteins include, but are not limited to, acidic and basic fibroblast growth factors, VEGF-1, VEGF-2, VEGF-3, epidermal growth factor alpha and beta, platelet-derived endothelial cell growth factor, platelet-derived growth factor, tumor necrosis factor alpha, hepatocyte growth factor, insulin like growth factor, colony stimulating factor, macrophage colony stimulating factor, granulocyte/macrophage colony stimulating factor, and nitric oxide
30 synthase.

 The present invention provides for treatment of diseases or disorders associated with neovascularization by administration of the polynucleotides and/or polypeptides of the

invention, as well as agonists or antagonists of the present invention. Malignant and metastatic conditions which can be treated with the polynucleotides and polypeptides, or agonists or antagonists of the invention include, but are not limited to, malignancies, solid tumors, and cancers described herein and otherwise known in the art (for a review of such disorders, see Fishman *et al.*, Medicine, 2d Ed., J. B. Lippincott Co., Philadelphia (1985)). Thus, the present invention provides a method of treating an angiogenesis-related disease and/or disorder, comprising administering to an individual in need thereof a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist of the invention. For example, polynucleotides, polypeptides, antagonists and/or agonists may be utilized in a variety of additional methods in order to therapeutically treat a cancer or tumor. Cancers which may be treated with polynucleotides, polypeptides, antagonists and/or agonists include, but are not limited to solid tumors, including breast, ovarian, prostate, lung, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, thyroid cancer; primary tumors and metastases; melanomas; glioblastoma; Kaposi's sarcoma; leiomyosarcoma; non-small cell lung cancer; colorectal cancer; advanced malignancies; and blood born tumors such as leukemias. For example, polynucleotides, polypeptides, antagonists and/or agonists may be delivered topically, in order to treat cancers such as skin cancer, head and neck tumors, breast tumors, and Kaposi's sarcoma.

Within yet other aspects, polynucleotides, polypeptides, antagonists and/or agonists may be utilized to treat superficial forms of bladder cancer by, for example, intravesical administration. Polynucleotides, polypeptides, antagonists and/or agonists may be delivered directly into the tumor, or near the tumor site, via injection or a catheter. Of course, as the artisan of ordinary skill will appreciate, the appropriate mode of administration will vary according to the cancer to be treated. Other modes of delivery are discussed herein.

Polynucleotides, polypeptides, antagonists and/or agonists may be useful in treating other disorders, besides cancers, which involve angiogenesis. These disorders include, but are not limited to: benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; arteriosclerotic plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uveitis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid

arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome; plaque
5 neovascularization; telangiectasia; hemophilic joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis.

For example, within one aspect of the present invention methods are provided for treating hypertrophic scars and keloids, comprising the step of administering a polynucleotide, polypeptide, antagonist and/or agonist of the invention to a hypertrophic scar
10 or keloid.

Within one embodiment of the present invention polynucleotides, polypeptides, antagonists and/or agonists are directly injected into a hypertrophic scar or keloid, in order to prevent the progression of these lesions. This therapy is of particular value in the prophylactic treatment of conditions which are known to result in the development of
15 hypertrophic scars and keloids (e.g., burns), and is preferably initiated after the proliferative phase has had time to progress (approximately 14 days after the initial injury), but before hypertrophic scar or keloid development. As noted above, the present invention also provides methods for treating neovascular diseases of the eye, including for example, corneal neovascularization, neovascular glaucoma, proliferative diabetic retinopathy, retrolental
20 fibroplasia and macular degeneration.

Moreover, Ocular disorders associated with neovascularization which can be treated with the polynucleotides and polypeptides of the present invention (including agonists and/or antagonists) include, but are not limited to: neovascular glaucoma, diabetic retinopathy, retinoblastoma, retrolental fibroplasia, uveitis, retinopathy of prematurity macular
25 degeneration, corneal graft neovascularization, as well as other eye inflammatory diseases, ocular tumors and diseases associated with choroidal or iris neovascularization. See, e.g., reviews by Waltman *et al.*, *Am. J. Ophthalmol.* 85:704-710 (1978) and Gartner *et al.*, *Surv. Ophthalmol.* 22:291-312 (1978).

Thus, within one aspect of the present invention methods are provided for treating
30 neovascular diseases of the eye such as corneal neovascularization (including corneal graft neovascularization), comprising the step of administering to a patient a therapeutically effective amount of a compound (as described above) to the cornea, such that the formation

of blood vessels is inhibited. Briefly, the cornea is a tissue which normally lacks blood vessels. In certain pathological conditions however, capillaries may extend into the cornea from the pericorneal vascular plexus of the limbus. When the cornea becomes vascularized, it also becomes clouded, resulting in a decline in the patient's visual acuity. Visual loss may become complete if the cornea completely opacitates. A wide variety of disorders can result in corneal neovascularization, including for example, corneal infections (e.g., trachoma, herpes simplex keratitis, leishmaniasis and onchocerciasis), immunological processes (e.g., graft rejection and Stevens-Johnson's syndrome), alkali burns, trauma, inflammation (of any cause), toxic and nutritional deficiency states, and as a complication of wearing contact lenses.

Within particularly preferred embodiments of the invention, may be prepared for topical administration in saline (combined with any of the preservatives and antimicrobial agents commonly used in ocular preparations), and administered in eyedrop form. The solution or suspension may be prepared in its pure form and administered several times daily. Alternatively, anti-angiogenic compositions, prepared as described above, may also be administered directly to the cornea. Within preferred embodiments, the anti-angiogenic composition is prepared with a muco-adhesive polymer which binds to cornea. Within further embodiments, the anti-angiogenic factors or anti-angiogenic compositions may be utilized as an adjunct to conventional steroid therapy. Topical therapy may also be useful prophylactically in corneal lesions which are known to have a high probability of inducing an angiogenic response (such as chemical burns). In these instances the treatment, likely in combination with steroids, may be instituted immediately to help prevent subsequent complications.

Within other embodiments, the compounds described above may be injected directly into the corneal stroma by an ophthalmologist under microscopic guidance. The preferred site of injection may vary with the morphology of the individual lesion, but the goal of the administration would be to place the composition at the advancing front of the vasculature (i.e., interspersed between the blood vessels and the normal cornea). In most cases this would involve perilimbal corneal injection to "protect" the cornea from the advancing blood vessels. This method may also be utilized shortly after a corneal insult in order to prophylactically prevent corneal neovascularization. In this situation the material could be injected in the perilimbal cornea interspersed between the corneal lesion and its undesired

potential limbic blood supply. Such methods may also be utilized in a similar fashion to prevent capillary invasion of transplanted corneas. In a sustained-release form injections might only be required 2-3 times per year. A steroid could also be added to the injection solution to reduce inflammation resulting from the injection itself.

- 5 Within another aspect of the present invention, methods are provided for treating neovascular glaucoma, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. In one embodiment, the compound may be administered topically to the eye in order to treat early forms of neovascular glaucoma.
- 10 Within other embodiments, the compound may be implanted by injection into the region of the anterior chamber angle. Within other embodiments, the compound may also be placed in any location such that the compound is continuously released into the aqueous humor. Within another aspect of the present invention, methods are provided for treating proliferative diabetic retinopathy, comprising the step of administering to a patient a
- 15 therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eyes, such that the formation of blood vessels is inhibited.

- Within particularly preferred embodiments of the invention, proliferative diabetic retinopathy may be treated by injection into the aqueous humor or the vitreous, in order to increase the local concentration of the polynucleotide, polypeptide, antagonist and/or agonist
- 20 in the retina. Preferably, this treatment should be initiated prior to the acquisition of severe disease requiring photocoagulation.

- Within another aspect of the present invention, methods are provided for treating retrolental fibroplasia, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such
- 25 that the formation of blood vessels is inhibited. The compound may be administered topically, via intravitreal injection and/or via intraocular implants.

- Additionally, disorders which can be treated with the polynucleotides, polypeptides, agonists and/or antagonists include, but are not limited to, hemangioma, arthritis, psoriasis, angiofibroma, atherosclerotic plaques, delayed wound healing, granulations, hemophilic
- 30 joints, hypertrophic scars, nonunion fractures, Osler-Weber syndrome, pyogenic granuloma, scleroderma, trachoma, and vascular adhesions.

Moreover, disorders and/or states, which can be treated with the the polynucleotides, polypeptides, agonists and/or agonists include, but are not limited to, solid tumors, blood born tumors such as leukemias, tumor metastasis, Kaposi's sarcoma, benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas, rheumatoid arthritis, psoriasis, ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, and uveitis, delayed wound healing, endometriosis, vasculogenesis, granulations, hypertrophic scars (keloids), nonunion fractures, scleroderma, trachoma, vascular adhesions, myocardial angiogenesis, coronary collaterals, cerebral collaterals, arteriovenous malformations, ischemic limb angiogenesis, Osler-Webber Syndrome, plaque neovascularization, telangiectasia, hemophilic joints, angiofibroma fibromuscular dysplasia, wound granulation, Crohn's disease, atherosclerosis, birth control agent by preventing vascularization required for embryo implantation controlling menstruation, diseases that have angiogenesis as a pathologic consequence such as cat scratch disease (Rochelle minalia quintosa), ulcers (Helicobacter pylori), Bartonellosis and bacillary angiomatosis.

In one aspect of the birth control method, an amount of the compound sufficient to block embryo implantation is administered before or after intercourse and fertilization have occurred, thus providing an effective method of birth control, possibly a "morning after" method. Polynucleotides, polypeptides, agonists and/or agonists may also be used in controlling menstruation or administered as either a peritoneal lavage fluid or for peritoneal implantation in the treatment of endometriosis.

Polynucleotides, polypeptides, agonists and/or agonists of the present invention may be incorporated into surgical sutures in order to prevent stitch granulomas.

Polynucleotides, polypeptides, agonists and/or agonists may be utilized in a wide variety of surgical procedures. For example, within one aspect of the present invention a compositions (in the form of, for example, a spray or film) may be utilized to coat or spray an area prior to removal of a tumor, in order to isolate normal surrounding tissues from malignant tissue, and/or to prevent the spread of disease to surrounding tissues. Within other aspects of the present invention, compositions (e.g., in the form of a spray) may be delivered via endoscopic procedures in order to coat tumors, or inhibit angiogenesis in a desired locale. Within yet other aspects of the present invention, surgical meshes which have been coated

with anti- angiogenic compositions of the present invention may be utilized in any procedure wherein a surgical mesh might be utilized. For example, within one embodiment of the invention a surgical mesh laden with an anti-angiogenic composition may be utilized during abdominal cancer resection surgery (e.g., subsequent to colon resection) in order to provide support to the structure, and to release an amount of the anti-angiogenic factor.

Within further aspects of the present invention, methods are provided for treating tumor excision sites, comprising administering a polynucleotide, polypeptide, agonist and/or agonist to the resection margins of a tumor subsequent to excision, such that the local recurrence of cancer and the formation of new blood vessels at the site is inhibited. Within one embodiment of the invention, the anti-angiogenic compound is administered directly to the tumor excision site (e.g., applied by swabbing, brushing or otherwise coating the resection margins of the tumor with the anti-angiogenic compound). Alternatively, the anti-angiogenic compounds may be incorporated into known surgical pastes prior to administration. Within particularly preferred embodiments of the invention, the anti-angiogenic compounds are applied after hepatic resections for malignancy, and after neurosurgical operations.

Within one aspect of the present invention, polynucleotides, polypeptides, agonists and/or agonists may be administered to the resection margin of a wide variety of tumors, including for example, breast, colon, brain and hepatic tumors. For example, within one embodiment of the invention, anti-angiogenic compounds may be administered to the site of a neurological tumor subsequent to excision, such that the formation of new blood vessels at the site are inhibited.

The polynucleotides, polypeptides, agonists and/or agonists of the present invention may also be administered along with other anti-angiogenic factors. Representative examples of other anti-angiogenic factors include: Anti-Invasive Factor, retinoic acid and derivatives thereof, paclitaxel, Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-2, Plasminogen Activator Inhibitor-1, Plasminogen Activator Inhibitor-2, and various forms of the lighter "d group" transition metals.

Lighter "d group" transition metals include, for example, vanadium, molybdenum, tungsten, titanium, niobium, and tantalum species. Such transition metal species may form transition metal complexes. Suitable complexes of the above-mentioned transition metal species include oxo transition metal complexes.

Representative examples of vanadium complexes include oxo vanadium complexes such as vanadate and vanadyl complexes. Suitable vanadate complexes include metavanadate and orthovanadate complexes such as, for example, ammonium metavanadate, sodium metavanadate, and sodium orthovanadate. Suitable vanadyl complexes include, for
5 example, vanadyl acetylacetonate and vanadyl sulfate including vanadyl sulfate hydrates such as vanadyl sulfate mono- and trihydrates.

Representative examples of tungsten and molybdenum complexes also include oxo complexes. Suitable oxo tungsten complexes include tungstate and tungsten oxide complexes. Suitable tungstate complexes include ammonium tungstate, calcium tungstate,
10 sodium tungstate dihydrate, and tungstic acid. Suitable tungsten oxides include tungsten (IV) oxide and tungsten (VI) oxide. Suitable oxo molybdenum complexes include molybdate, molybdenum oxide, and molybdenyl complexes. Suitable molybdate complexes include ammonium molybdate and its hydrates, sodium molybdate and its hydrates, and potassium molybdate and its hydrates. Suitable molybdenum oxides include molybdenum (VI) oxide,
15 molybdenum (VI) oxide, and molybdic acid. Suitable molybdenyl complexes include, for example, molybdenyl acetylacetonate. Other suitable tungsten and molybdenum complexes include hydroxo derivatives derived from, for example, glycerol, tartaric acid, and sugars.

A wide variety of other anti-angiogenic factors may also be utilized within the context of the present invention. Representative examples include platelet factor 4; protamine
20 sulphate; sulphated chitin derivatives (prepared from queen crab shells), (Murata et al., Cancer Res. 51:22-26, 1991); Sulphated Polysaccharide Peptidoglycan Complex (SP- PG) (the function of this compound may be enhanced by the presence of steroids such as estrogen, and tamoxifen citrate); Staurosporine; modulators of matrix metabolism, including for example, proline analogs, cishydroxyproline, d,L-3,4-dehydroproline, Thiaproline,
25 alpha,alpha-dipyridyl, aminopropionitrile fumarate; 4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone; Methotrexate; Mitoxantrone; Heparin; Interferons; 2 Macroglobulin-serum; ChIMP-3 (Pavloff et al., J. Bio. Chem. 267:17321-17326, 1992); Chymostatin (Tomkinson et al., Biochem J. 286:475-480, 1992); Cyclodextrin Tetradeccasulfate; Eponemycin; Camptothecin; Fumagillin (Ingber et al., Nature 348:555-557, 1990); Gold Sodium
30 Thiomalate ("GST"; Matsubara and Ziff, J. Clin. Invest. 79:1440-1446, 1987); anticollagenase-serum; alpha2-antiplasmin (Holmes et al., J. Biol. Chem. 262(4):1659-1664, 1987); Bisantrone (National Cancer Institute); Lobenzarit disodium (N-(2)-carboxyphenyl-4-

chloroanthronilic acid disodium or "CCA"; Takeuchi et al., Agents Actions 36:312-316, 1992); Thalidomide; Angostatic steroid; AGM-1470; carboxynaminimidazole; and metalloproteinase inhibitors such as BB94.

5 **Diseases at the Cellular Level**

Diseases associated with increased cell survival or the inhibition of apoptosis that could be treated or detected by polynucleotides or polypeptides, as well as antagonists or agonists of the present invention, include cancers (such as follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon
10 cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary
15 cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection. In preferred embodiments, polynucleotides, polypeptides, and/or antagonists of the invention are used to inhibit growth, progression,
20 and/or metasis of cancers, in particular those listed above.

Additional diseases or conditions associated with increased cell survival that could be treated or detected by polynucleotides or polypeptides, or agonists or antagonists of the present invention include, but are not limited to, progression, and/or metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g., acute
25 lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not
30 limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's

tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

Diseases associated with increased apoptosis that could be treated or detected by polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, include AIDS; neurodegenerative disorders (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration and brain tumor or prior associated disease); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g., hepatitis related liver injury, ischemia/reperfusion injury, cholestasis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia.

Wound Healing and Epithelial Cell Proliferation

In accordance with yet a further aspect of the present invention, there is provided a process for utilizing polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, for therapeutic purposes, for example, to stimulate epithelial cell proliferation and basal keratinocytes for the purpose of wound healing, and to stimulate hair follicle production and healing of dermal wounds. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, may be clinically useful in stimulating wound healing including surgical wounds, excisional wounds, deep wounds involving damage of the dermis and epidermis, eye tissue wounds, dental tissue wounds, oral cavity

wounds, diabetic ulcers, dermal ulcers, cubitus ulcers, arterial ulcers, venous stasis ulcers, burns resulting from heat exposure or chemicals, and other abnormal wound healing conditions such as uremia, malnutrition, vitamin deficiencies and complications associated with systemic treatment with steroids, radiation therapy and antineoplastic drugs and antimetabolites. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to promote dermal reestablishment subsequent to dermal loss

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to increase the adherence of skin grafts to a wound bed and to stimulate re-epithelialization from the wound bed. The following are types of grafts that polynucleotides or polypeptides, agonists or antagonists of the present invention, could be used to increase adherence to a wound bed: autografts, artificial skin, allografts, autodermic graft, autoepdermic grafts, avacular grafts, Blair-Brown grafts, bone graft, brephoplastic grafts, cutis graft, delayed graft, dermic graft, epidermic graft, fascia graft, full thickness graft, heterologous graft, xenograft, homologous graft, hyperplastic graft, lamellar graft, mesh graft, mucosal graft, Ollier-Thiersch graft, omenpal graft, patch graft, pedicle graft, penetrating graft, split skin graft, thick split graft. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, can be used to promote skin strength and to improve the appearance of aged skin.

It is believed that polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, will also produce changes in hepatocyte proliferation, and epithelial cell proliferation in the lung, breast, pancreas, stomach, small intestine, and large intestine. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could promote proliferation of epithelial cells such as sebocytes, hair follicles, hepatocytes, type II pneumocytes, mucin-producing goblet cells, and other epithelial cells and their progenitors contained within the skin, lung, liver, and gastrointestinal tract. Polynucleotides or polypeptides, agonists or antagonists of the present invention, may promote proliferation of endothelial cells, keratinocytes, and basal keratinocytes.

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could also be used to reduce the side effects of gut toxicity that result from radiation, chemotherapy treatments or viral infections. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, may have a cytoprotective effect on

the small intestine mucosa. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, may also stimulate healing of mucositis (mouth ulcers) that result from chemotherapy and viral infections.

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could further be used in full regeneration of skin in full and partial thickness skin defects, including burns, (i.e., repopulation of hair follicles, sweat glands, and sebaceous glands), treatment of other skin defects such as psoriasis. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to treat epidermolysis bullosa, a defect in adherence of the epidermis to the underlying dermis which results in frequent, open and painful blisters by accelerating reepithelialization of these lesions. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could also be used to treat gastric and duodenal ulcers and help heal by scar formation of the mucosal lining and regeneration of glandular mucosa and duodenal mucosal lining more rapidly. Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, are diseases which result in destruction of the mucosal surface of the small or large intestine, respectively. Thus, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to promote the resurfacing of the mucosal surface to aid more rapid healing and to prevent progression of inflammatory bowel disease. Treatment with polynucleotides or polypeptides, agonists or antagonists of the present invention, is expected to have a significant effect on the production of mucus throughout the gastrointestinal tract and could be used to protect the intestinal mucosa from injurious substances that are ingested or following surgery. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to treat diseases associated with the under expression.

Moreover, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to prevent and heal damage to the lungs due to various pathological states. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, which could stimulate proliferation and differentiation and promote the repair of alveoli and bronchiolar epithelium to prevent or treat acute or chronic lung damage. For example, emphysema, which results in the progressive loss of alveoli, and inhalation injuries, i.e., resulting from smoke inhalation and burns, that cause necrosis of the bronchiolar epithelium and alveoli could be effectively treated using polynucleotides or

polypeptides, agonists or antagonists of the present invention. Also, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to stimulate the proliferation of and differentiation of type II pneumocytes, which may help treat or prevent disease such as hyaline membrane diseases, such as infant respiratory distress syndrome and bronchopulmonary dysplasia, in premature infants.

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could stimulate the proliferation and differentiation of hepatocytes and, thus, could be used to alleviate or treat liver diseases and pathologies such as fulminant liver failure caused by cirrhosis, liver damage caused by viral hepatitis and toxic substances (i.e., acetaminophen, carbon tetrachloride and other hepatotoxins known in the art).

In addition, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to treat or prevent the onset of diabetes mellitus. In patients with newly diagnosed Types I and II diabetes, where some islet cell function remains, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to maintain the islet function so as to alleviate, delay or prevent permanent manifestation of the disease. Also, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used as an auxiliary in islet cell transplantation to improve or promote islet cell function.

Neurological Diseases

In accordance with yet a further aspect of the present invention, there is provided a process for utilizing polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, for therapeutic purposes, for example, to stimulate neurological cell proliferation and/or differentiation. Therefore, polynucleotides, polypeptides, agonists and/or antagonists of the invention may be used to treat and/or detect neurologic diseases. Moreover, polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used as a marker or detector of a particular nervous system disease or disorder.

Examples of neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include brain diseases, such as metabolic brain diseases which includes phenylketonuria such as maternal phenylketonuria, pyruvate carboxylase deficiency, pyruvate dehydrogenase complex deficiency, Wernicke's Encephalopathy, brain edema, brain neoplasms such as

cerebellar neoplasms which include infratentorial neoplasms, cerebral ventricle neoplasms such as choroid plexus neoplasms, hypothalamic neoplasms, supratentorial neoplasms, canavan disease, cerebellar diseases such as cerebellar ataxia which include spinocerebellar degeneration such as ataxia telangiectasia, cerebellar dyssynergia, Friederich's Ataxia, Machado-Joseph Disease, olivopontocerebellar atrophy, cerebellar neoplasms such as infratentorial neoplasms, diffuse cerebral sclerosis such as encephalitis periaxialis, globoid cell leukodystrophy, metachromatic leukodystrophy and subacute sclerosing panencephalitis, cerebrovascular disorders (such as carotid artery diseases which include carotid artery thrombosis, carotid stenosis and Moyamoya Disease, cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformations, cerebral artery diseases, cerebral embolism and thrombosis such as carotid artery thrombosis, sinus thrombosis and Wallenberg's Syndrome, cerebral hemorrhage such as epidural hematoma, subdural hematoma and subarachnoid hemorrhage, cerebral infarction, cerebral ischemia such as transient cerebral ischemia, Subclavian Steal Syndrome and vertebrobasilar insufficiency, vascular dementia such as multi-infarct dementia, periventricular leukomalacia, vascular headache such as cluster headache, migraine, dementia such as AIDS Dementia Complex, presenile dementia such as Alzheimer's Disease and Creutzfeldt-Jakob Syndrome, senile dementia such as Alzheimer's Disease and progressive supranuclear palsy, vascular dementia such as multi-infarct dementia, encephalitis which include encephalitis periaxialis, viral encephalitis such as epidemic encephalitis, Japanese Encephalitis, St. Louis Encephalitis, tick-borne encephalitis and West Nile Fever, acute disseminated encephalomyelitis, meningoencephalitis such as uveomeningoencephalitic syndrome, Postencephalitic Parkinson Disease and subacute sclerosing panencephalitis, encephalomalacia such as periventricular leukomalacia, epilepsy such as generalized epilepsy which includes infantile spasms, absence epilepsy, myoclonic epilepsy which includes MERRF Syndrome, tonic-clonic epilepsy, partial epilepsy such as complex partial epilepsy, frontal lobe epilepsy and temporal lobe epilepsy, post-traumatic epilepsy, status epilepticus such as Epilepsia Partialis Continua, Hallervorden-Spatz Syndrome, hydrocephalus such as Dandy-Walker Syndrome and normal pressure hydrocephalus, hypothalamic diseases such as hypothalamic neoplasms, cerebral malaria, narcolepsy which includes cataplexy, bulbar poliomyelitis, cerebri pseudotumor, Rett Syndrome, Reye's Syndrome, thalamic diseases, cerebral toxoplasmosis, intracranial tuberculoma and Zellweger Syndrome, central nervous

system infections such as AIDS Dementia Complex, Brain Abscess, subdural empyema, encephalomyelitis such as Equine Encephalomyelitis, Venezuelan Equine Encephalomyelitis, Necrotizing Hemorrhagic Encephalomyelitis, Visna, cerebral malaria, meningitis such as arachnoiditis, aseptic meningitis such as viral meningitis which includes lymphocytic choriomeningitis. Bacterial meningitis which includes Haemophilus Meningitis, Listeria Meningitis, Meningococcal Meningitis such as Waterhouse-Friderichsen Syndrome, Pneumococcal Meningitis and meningeal tuberculosis, fungal meningitis such as Cryptococcal Meningitis, subdural effusion, meningoencephalitis such as uve-meningoencephalitic syndrome, myelitis such as transverse myelitis, neurosyphilis such as tabes dorsalis, poliomyelitis which includes bulbar poliomyelitis and postpoliomyelitis syndrome, prion diseases (such as Creutzfeldt-Jakob Syndrome, Bovine Spongiform Encephalopathy, Gerstmann-Straussler Syndrome, Kuru, Scrapie) cerebral toxoplasmosis, central nervous system neoplasms such as brain neoplasms that include cerebellar neoplasms such as infratentorial neoplasms, cerebral ventricle neoplasms such as choroid plexus neoplasms, hypothalamic neoplasms and supratentorial neoplasms, meningeal neoplasms, spinal cord neoplasms which include epidural neoplasms, demyelinating diseases such as Canavan Diseases, diffuse cerebral sclerolysis which includes adrenoleukodystrophy, encephalitis periaxialis, globoid cell leukodystrophy, diffuse cerebral sclerosis such as metachromatic leukodystrophy, allergic encephalomyelitis, necrotizing hemorrhagic encephalomyelitis, progressive multifocal leukoencephalopathy, multiple sclerosis, central pontine myelinolysis, transverse myelitis, neuromyelitis optica, Scrapie, Swayback, Chronic Fatigue Syndrome, Visna, High Pressure Nervous Syndrome, Meningism, spinal cord diseases such as amyotonia congenita, amyotrophic lateral sclerosis, spinal muscular atrophy such as Werdnig-Hoffmann Disease, spinal cord compression, spinal cord neoplasms such as epidural neoplasms, syringomyelia, Tabes Dorsalis, Stiff-Man Syndrome, mental retardation such as Angelman Syndrome, Cri-du-Chat Syndrome, De Lange's Syndrome, Down Syndrome, Gangliosidoses such as gangliosidoses G(M1), Sandhoff Disease, Tay-Sachs Disease, Hartnup Disease, homocystinuria, Laurence-Moon- Biedl Syndrome, Lesch-Nyhan Syndrome, Maple Syrup Urine Disease, mucopolysaccharidosis such as fucosidosis, neuronal ceroid-lipofuscinosis, oculocerebrorenal syndrome, phenylketonuria such as maternal phenylketonuria, Prader-Willi Syndrome, Rett Syndrome, Rubinstein-Taybi Syndrome, Tuberous Sclerosis, WAGR Syndrome, nervous system abnormalities such as

holoprosencephaly, neural tube defects such as anencephaly which includes hydrangencephaly, Arnold-Chairi Deformity, encephalocele, meningocele, meningomyelocele, spinal dysraphism such as spina bifida cystica and spina bifida occulta, hereditary motor and sensory neuropathies which include Charcot-Marie Disease, Hereditary
5 optic atrophy, Refsum's Disease, hereditary spastic paraplegia, Werdnig-Hoffmann Disease, Hereditary Sensory and Autonomic Neuropathies such as Congenital Analgesia and Familial Dysautonomia, Neurologic manifestations (such as agnosia that include Gerstmann's Syndrome, Amnesia such as retrograde amnesia, apraxia, neurogenic bladder, cataplexy, communicative disorders such as hearing disorders that includes deafness, partial hearing
10 loss, loudness recruitment and tinnitus, language disorders such as aphasia which include agraphia, anomia, broca aphasia, and Wernicke Aphasia, Dyslexia such as Acquired Dyslexia, language development disorders, speech disorders such as aphasia which includes anomia, broca aphasia and Wernicke Aphasia, articulation disorders, communicative disorders such as speech disorders which include dysarthria, echolalia, mutism and stuttering,
15 voice disorders such as aphonia and hoarseness, decerebrate state, delirium, fasciculation, hallucinations, meningism, movement disorders such as angelman syndrome, ataxia, athetosis, chorea, dystonia, hypokinesia, muscle hypotonia, myoclonus, tic, torticollis and tremor, muscle hypertonia such as muscle rigidity such as stiff-man syndrome, muscle spasticity, paralysis such as facial paralysis which includes Herpes Zoster Oticus,
20 Gastroparesis, Hemiplegia, ophthalmoplegia such as diplopia, Duane's Syndrome, Horner's Syndrome, Chronic progressive external ophthalmoplegia such as Kearns Syndrome, Bulbar Paralysis, Tropical Spastic Paraparesis, Paraplegia such as Brown-Sequard Syndrome, quadriplegia, respiratory paralysis and vocal cord paralysis, paresis, phantom limb, taste disorders such as ageusia and dysgeusia, vision disorders such as amblyopia, blindness, color
25 vision defects, diplopia, hemianopsia, scotoma and subnormal vision, sleep disorders such as hypersomnia which includes Kleine-Levin Syndrome, insomnia, and somnambulism, spasm such as trismus, unconsciousness such as coma, persistent vegetative state and syncope and vertigo, neuromuscular diseases such as amyotonia congenita, amyotrophic lateral sclerosis, Lambert-Eaton Myasthenic Syndrome, motor neuron disease, muscular atrophy such as
30 spinal muscular atrophy, Charcot-Marie Disease and Werdnig-Hoffmann Disease, Postpoliomyelitis Syndrome, Muscular Dystrophy, Myasthenia Gravis, Myotonia Atrophica, Myotonia Confenita, Nemaline Myopathy, Familial Periodic Paralysis, Multiplex

Paramyoclonus, Tropical Spastic Paraparesis and Stiff-Man Syndrome, peripheral nervous system diseases such as acrodynia, amyloid neuropathies, autonomic nervous system diseases such as Adie's Syndrome, Barre-Lieou Syndrome, Familial Dysautonomia, Horner's Syndrome, Reflex Sympathetic Dystrophy and Shy-Drager Syndrome, Cranial Nerve Diseases such as Acoustic Nerve Diseases such as Acoustic Neuroma which includes Neurofibromatosis 2, Facial Nerve Diseases such as Facial Neuralgia, Melkersson-Rosenthal Syndrome, ocular motility disorders which includes amblyopia, nystagmus, oculomotor nerve paralysis, ophthalmoplegia such as Duane's Syndrome, Horner's Syndrome, Chronic Progressive External Ophthalmoplegia which includes Kearns Syndrome, Strabismus such as Esotropia and Exotropia, Oculomotor Nerve Paralysis, Optic Nerve Diseases such as Optic Atrophy which includes Hereditary Optic Atrophy, Optic Disk Drusen, Optic Neuritis such as Neuromyelitis Optica, Papilledema, Trigeminal Neuralgia, Vocal Cord Paralysis, Demyelinating Diseases such as Neuromyelitis Optica and Swayback, Diabetic neuropathies such as diabetic foot, nerve compression syndromes such as carpal tunnel syndrome, tarsal tunnel syndrome, thoracic outlet syndrome such as cervical rib syndrome, ulnar nerve compression syndrome, neuralgia such as causalgia, cervico-brachial neuralgia, facial neuralgia and trigeminal neuralgia, neuritis such as experimental allergic neuritis, optic neuritis, polyneuritis, polyradiculoneuritis and radiculitis such as polyradiculitis, hereditary motor and sensory neuropathies such as Charcot-Marie Disease, Hereditary Optic Atrophy, Refsum's Disease, Hereditary Spastic Paraplegia and Werdnig-Hoffmann Disease, Hereditary Sensory and Autonomic Neuropathies which include Congenital Analgesia and Familial Dysautonomia, POEMS Syndrome, Sciatica, Gustatory Sweating and Tetany).

Infectious Disease

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention can be used to treat or detect infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated or detected by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention. Examples of viruses, include, but are not limited to Examples of viruses, include, but are not limited to the following DNA and RNA viruses and viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Dengue, EBV, HIV, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza A, Influenza B, and parainfluenza), Papiloma virus, Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiollitis, respiratory syncytial virus, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), Japanese B encephalitis, Junin, Chikungunya, Rift Valley fever, yellow fever, meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat or detect any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat: meningitis, Dengue, EBV, and/or hepatitis (e.g., hepatitis B). In an additional specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat patients nonresponsive to one or more other commercially available hepatitis vaccines. In a further specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat AIDS.

Similarly, bacterial or fungal agents that can cause disease or symptoms and that can be treated or detected by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, include, but not limited to, the following Gram-Negative and Gram-positive bacteria and bacterial families and fungi: Actinomycetales (e.g., Corynebacterium, Mycobacterium, Norcardia), Cryptococcus neoformans, Aspergillosis, Bacillaceae (e.g., Anthrax, Clostridium), Bacteroidaceae, Blastomycosis, Bordetella, Borrelia

(e.g., *Borrelia burgdorferi*, Brucellosis, Candidiasis, *Campylobacter*, Coccidioidomycosis, Cryptococcosis, Dermatocycoses, *E. coli* (e.g., Enterotoxigenic *E. coli* and Enterohemorrhagic *E. coli*), Enterobacteriaceae (*Klebsiella*, *Salmonella* (e.g., *Salmonella typhi*, and *Salmonella paratyphi*), *Serratia*, *Yersinia*), *Erysipelothrix*, *Helicobacter*,
5 *Legionellosis*, *Leptospirosis*, *Listeria*, *Mycoplasmatales*, *Mycobacterium leprae*, *Vibrio cholerae*, *Neisseriaceae* (e.g., *Acinetobacter*, *Gonorrhea*, *Menigococcal*), *Meisseria meningitidis*, *Pasteurellacea* Infections (e.g., *Actinobacillus*, *Heamophilus* (e.g., *Heamophilus influenza type B*), *Pasteurella*), *Pseudomonas*, *Rickettsiaceae*, *Chlamydiaceae*, Syphilis, *Shigella* spp., *Staphylococcal*, *Meningiococcal*, *Pneumococcal* and *Streptococcal* (e.g.,
10 *Streptococcus pneumoniae* and Group B *Streptococcus*). These bacterial or fungal families can cause the following diseases or symptoms, including, but not limited to: bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme
15 Disease, Cat-Scratch Disease, Dysentery, Paratyphoid Fever, food poisoning, Typhoid, pneumonia, *Gonorrhea*, meningitis (e.g., meningitis types A and B), Chlamydia, Syphilis, Diphtheria, Leprosy, Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections.
20 Polynucleotides or polypeptides, agonists or antagonists of the invention, can be used to treat or detect any of these symptoms or diseases. In specific embodiments, Ppolynucleotides, polypeptides, agonists or antagonists of the invention are used to treat: tetanus, Diphtheria, botulism, and/or meningitis type B.

Moreover, parasitic agents causing disease or symptoms that can be treated or
25 detected by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, the following families or class: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis, Toxoplasmosis, Trypanosomiasis, and *Trichomonas* and Sporozoans (e.g., *Plasmodium virax*, *Plasmodium falciparum*,
30 *Plasmodium malariae* and *Plasmodium ovale*). These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic

infections (e.g., AIDS related), malaria, pregnancy complications, and toxoplasmosis. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat or detect any of these symptoms or diseases.

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

Regeneration

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997).) The regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteoarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

Tissues that could be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vasculature (including vascular and lymphatics), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

Moreover, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated include of tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

Similarly, nerve and brain tissue could also be regenerated by using polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, to proliferate and differentiate nerve cells. Diseases that could be treated using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic disorders (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stroke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated using the polynucleotides or polypeptides, as well as agonists or antagonists of the present invention.

Chemotaxis

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may have chemotaxis activity. A chemotactic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may increase chemotactic activity of particular cells. These chemotactic molecules can then be used to treat inflammation, infection, hyperproliferative disorders, or any immune system disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotactic molecules can be used to treat wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat wounds.

It is also contemplated that polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may inhibit chemotactic activity. These molecules could also be used to treat disorders. Thus, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention could be used as an inhibitor of chemotaxis.

Binding Activity

A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules
5 include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide
10 binds, or at least, a fragment of the receptor capable of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the
15 expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled
20 competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

Alternatively, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound
25 with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the
30 polypeptide or by competing with the polypeptide for a substrate.

Additionally, the receptor to which the polypeptide of the present invention binds can be identified by numerous methods known to those of skill in the art, for example, ligand

panning and FACS sorting (Coligan, et al., Current Protocols in Immun., 1(2), Chapter 5, (1991)). For example, expression cloning is employed wherein polyadenylated RNA is prepared from a cell responsive to the polypeptides, for example, NIH3T3 cells which are known to contain multiple receptors for the FGF family proteins, and SC-3 cells, and a
5 cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to the polypeptides. Transfected cells which are grown on glass slides are exposed to the polypeptide of the present invention, after they have been labelled. The polypeptides can be labeled by a variety of means including iodination or inclusion of a recognition site for a site-specific protein kinase.

10 Following fixation and incubation, the slides are subjected to auto-radiographic analysis. Positive pools are identified and sub-pools are prepared and re-transfected using an iterative sub-pooling and re-screening process, eventually yielding a single clones that encodes the putative receptor.

As an alternative approach for receptor identification, the labeled polypeptides can be
15 photoaffinity linked with cell membrane or extract preparations that express the receptor molecule. Cross-linked material is resolved by PAGE analysis and exposed to X-ray film. The labeled complex containing the receptors of the polypeptides can be excised, resolved into peptide fragments, and subjected to protein microsequencing. The amino acid sequence obtained from microsequencing would be used to design a set of degenerate oligonucleotide
20 probes to screen a cDNA library to identify the genes encoding the putative receptors.

Moreover, the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling") may be employed to modulate the activities of the polypeptide of the present invention thereby effectively generating agonists and antagonists of the polypeptide of the present invention. *See generally*, U.S.
25 Patent Nos. 5,605,793, 5,811,238, 5,830,721, 5,834,252, and 5,837,458, and Patten, P. A., *et al.*, *Curr. Opinion Biotechnol.* 8:724-33 (1997); Harayama, S. *Trends Biotechnol.* 16(2):76-82 (1998); Hansson, L. O., *et al.*, *J. Mol. Biol.* 287:265-76 (1999); and Lorenzo, M. M. and Blasco, R. *Biotechniques* 24(2):308-13 (1998) (each of these patents and publications are hereby incorporated by reference). In one embodiment, alteration of polynucleotides and
30 corresponding polypeptides may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments into a desired molecule by homologous, or site-specific, recombination. In another embodiment, polynucleotides and corresponding

polypeptides may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of the polypeptide of the present invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules. In preferred embodiments, the heterologous molecules are family members. In further preferred embodiments, the heterologous molecule is a growth factor such as, for example, platelet-derived growth factor (PDGF), insulin-like growth factor (IGF-I), transforming growth factor (TGF)-alpha, epidermal growth factor (EGF), fibroblast growth factor (FGF), TGF-beta, bone morphogenetic protein (BMP)-2, BMP-4, BMP-5, BMP-6, BMP-7, activins A and B, decapentaplegic(dpp), 60A, OP-2, dorsalin, growth differentiation factors (GDFs), nodal, MIS, inhibin-alpha, TGF-beta1, TGF-beta2, TGF-beta3, TGF-beta5, and glial-derived neurotrophic factor (GDNF).

Other preferred fragments are biologically active fragments of the polypeptide of the present invention. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

Additionally, this invention provides a method of screening compounds to identify those which modulate the action of the polypeptide of the present invention. An example of such an assay comprises combining a mammalian fibroblast cell, a the polypeptide of the present invention, the compound to be screened and $^3\text{[H]}$ thymidine under cell culture conditions where the fibroblast cell would normally proliferate. A control assay may be performed in the absence of the compound to be screened and compared to the amount of fibroblast proliferation in the presence of the compound to determine if the compound stimulates proliferation by determining the uptake of $^3\text{[H]}$ thymidine in each case. The amount of fibroblast cell proliferation is measured by liquid scintillation chromatography which measures the incorporation of $^3\text{[H]}$ thymidine. Both agonist and antagonist compounds may be identified by this procedure.

In another method, a mammalian cell or membrane preparation expressing a receptor for a polypeptide of the present invention is incubated with a labeled polypeptide of the

present invention in the presence of the compound. The ability of the compound to enhance or block this interaction could then be measured. Alternatively, the response of a known second messenger system following interaction of a compound to be screened and the receptor is measured and the ability of the compound to bind to the receptor and elicit a second messenger response is measured to determine if the compound is a potential agonist or antagonist. Such second messenger systems include but are not limited to, cAMP guanylate cyclase, ion channels or phosphoinositide hydrolysis.

All of these above assays can be used as diagnostic or prognostic markers. The molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptides of the invention from suitably manipulated cells or tissues.

Therefore, the invention includes a method of identifying compounds which bind to a polypeptide of the invention comprising the steps of: (a) incubating a candidate binding compound with a polypeptide of the present invention; and (b) determining if binding has occurred. Moreover, the invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with a polypeptide of the present invention, (b) assaying a biological activity, and (b) determining if a biological activity of the polypeptide has been altered.

Targeted Delivery

In another embodiment, the invention provides a method of delivering compositions to targeted cells expressing a receptor for a polypeptide of the invention, or cells expressing a cell bound form of a polypeptide of the invention.

As discussed herein, polypeptides or antibodies of the invention may be associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions. In one embodiment, the invention provides a method for the specific delivery of compositions of the invention to cells by administering polypeptides of the invention (including antibodies) that are associated with heterologous polypeptides or nucleic acids. In one example, the invention provides a method

for delivering a therapeutic protein into the targeted cell. In another example, the invention provides a method for delivering a single stranded nucleic acid (e.g., antisense or ribozymes) or double stranded nucleic acid (e.g., DNA that can integrate into the cell's genome or replicate episomally and that can be transcribed) into the targeted cell.

5 In another embodiment, the invention provides a method for the specific destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention (e.g., polypeptides of the invention or antibodies of the invention) in association with toxins or cytotoxic prodrugs.

By "toxin" is meant compounds that bind and activate endogenous cytotoxic effector
10 systems, radioisotopes, holotoxins, modified toxins, catalytic subunits of toxins, or any molecules or enzymes not normally present in or on the surface of a cell that under defined conditions cause the cell's death. Toxins that may be used according to the methods of the invention include, but are not limited to, radioisotopes known in the art, compounds such as, for example, antibodies (or complement fixing containing portions thereof) that bind an
15 inherent or induced endogenous cytotoxic effector system, thymidine kinase, endonuclease, RNase, alpha toxin, ricin, abrin, *Pseudomonas* exotoxin A, diphtheria toxin, saporin, momordin, gelonin, pokeweed antiviral protein, alpha-sarcin and cholera toxin. By "cytotoxic prodrug" is meant a non-toxic compound that is converted by an enzyme, normally present in the cell, into a cytotoxic compound. Cytotoxic prodrugs that may be
20 used according to the methods of the invention include, but are not limited to, glutamyl derivatives of benzoic acid mustard alkylating agent, phosphate derivatives of etoposide or mitomycin C, cytosine arabinoside, daunorubisin, and phenoxyacetamide derivatives of doxorubicin.

25 **Drug Screening**

Further contemplated is the use of the polypeptides of the present invention, or the polynucleotides encoding these polypeptides, to screen for molecules which modify the activities of the polypeptides of the present invention. Such a method would include contacting the polypeptide of the present invention with a selected compound(s) suspected of
30 having antagonist or agonist activity, and assaying the activity of these polypeptides following binding.

This invention is particularly useful for screening therapeutic compounds by using the

polypeptides of the present invention, or binding fragments thereof, in any of a variety of drug screening techniques. The polypeptide or fragment employed in such a test may be affixed to a solid support, expressed on a cell surface, free in solution, or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells
5 which are stably transformed with recombinant nucleic acids expressing the polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. One may measure, for example, the formulation of complexes between the agent being tested and a polypeptide of the present invention.

Thus, the present invention provides methods of screening for drugs or any other
10 agents which affect activities mediated by the polypeptides of the present invention. These methods comprise contacting such an agent with a polypeptide of the present invention or a fragment thereof and assaying for the presence of a complex between the agent and the polypeptide or a fragment thereof, by methods well known in the art. In such a competitive binding assay, the agents to screen are typically labeled. Following incubation, free agent is
15 separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of a particular agent to bind to the polypeptides of the present invention.

Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to the polypeptides of the present invention, and
20 is described in great detail in European Patent Application 84/03564, published on September 13, 1984, which is incorporated herein by reference herein. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with polypeptides of the present invention and washed. Bound polypeptides are then detected by methods well known
25 in the art. Purified polypeptides are coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies may be used to capture the peptide and immobilize it on the solid support.

This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding polypeptides of the present invention
30 specifically compete with a test compound for binding to the polypeptides or fragments thereof. In this manner, the antibodies are used to detect the presence of any peptide which shares one or more antigenic epitopes with a polypeptide of the invention.

Antisense And Ribozyme (Antagonists)

In specific embodiments, antagonists according to the present invention are nucleic acids corresponding to the sequences contained in SEQ ID NO:X, or the complementary strand thereof, and/or to nucleotide sequences contained in the cDNA contained in the related cDNA clone identified in Table 1. In one embodiment, antisense sequence is generated internally, by the organism, in another embodiment, the antisense sequence is separately administered (see, for example, O'Connor, J., *Neurochem.* 56:560 (1991). *Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression*, CRC Press, Boca Raton, FL (1988). Antisense technology can be used to control gene expression through antisense DNA or RNA, or through triple-helix formation. Antisense techniques are discussed for example, in Okano, J., *Neurochem.* 56:560 (1991); *Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression*, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance, Lee et al., *Nucleic Acids Research* 6:3073 (1979); Cooney et al., *Science* 241:456 (1988); and Dervan et al., *Science* 251:1300 (1991). The methods are based on binding of a polynucleotide to a complementary DNA or RNA.

For example, the use of c-myc and c-myb antisense RNA constructs to inhibit the growth of the non-lymphocytic leukemia cell line HL-60 and other cell lines was previously described. (Wickstrom et al. (1988); Anfossi et al. (1989)). These experiments were performed in vitro by incubating cells with the oligoribonucleotide. A similar procedure for in vivo use is described in WO 91/15580. Briefly, a pair of oligonucleotides for a given antisense RNA is produced as follows: A sequence complimentary to the first 15 bases of the open reading frame is flanked by an EcoRI site on the 5' end and a HindIII site on the 3' end. Next, the pair of oligonucleotides is heated at 90°C for one minute and then annealed in 2X ligation buffer (20mM TRIS HCl pH 7.5, 10mM MgCl₂, 10mM dithiothreitol (DTT) and 0.2 mM ATP) and then ligated to the EcoRI/Hind III site of the retroviral vector PMV7 (WO 91/15580).

For example, the 5' coding portion of a polynucleotide that encodes the polypeptide of the present invention may be used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription thereby preventing transcription and the

production of the receptor. The antisense RNA oligonucleotide hybridizes to the mRNA in vivo and blocks translation of the mRNA molecule into receptor polypeptide.

In one embodiment, the antisense nucleic acid of the invention is produced intracellularly by transcription from an exogenous sequence. For example, a vector or a portion thereof, is transcribed, producing an antisense nucleic acid (RNA) of the invention. Such a vector would contain a sequence encoding the antisense nucleic acid. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in vertebrate cells. Expression of the sequence encoding the polypeptide of the present invention or fragments thereof, can be by any promoter known in the art to act in vertebrate, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include, but are not limited to, the SV40 early promoter region (Bernoist and Chambon, Nature 29:304-310 (1981), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., Cell 22:787-797 (1980), the herpes thymidine promoter (Wagner et al., Proc. Natl. Acad. Sci. U.S.A. 78:1441-1445 (1981), the regulatory sequences of the metallothionein gene (Brinster, et al., Nature 296:39-42 (1982)), etc.

The antisense nucleic acids of the invention comprise a sequence complementary to at least a portion of an RNA transcript of a gene of the present invention. However, absolute complementarity, although preferred, is not required. A sequence "complementary to at least a portion of an RNA," referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex; in the case of double stranded antisense nucleic acids, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the larger the hybridizing nucleic acid, the more base mismatches with a RNA it may contain and still form a stable duplex (or triplex as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

Oligonucleotides that are complementary to the 5' end of the message, e.g., the 5' untranslated sequence up to and including the AUG initiation codon, should work most

efficiently at inhibiting translation. However, sequences complementary to the 3' untranslated sequences of mRNAs have been shown to be effective at inhibiting translation of mRNAs as well. See generally, Wagner, R., 1994, *Nature* 372:333-335. Thus, oligonucleotides complementary to either the 5'- or 3'- non- translated, non-coding regions of polynucleotide sequences described herein could be used in an antisense approach to inhibit translation of endogenous mRNA. Oligonucleotides complementary to the 5' untranslated region of the mRNA should include the complement of the AUG start codon. Antisense oligonucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but could be used in accordance with the invention. Whether designed to hybridize to the 5'-, 3'- or coding region of mRNA of the present invention, antisense nucleic acids should be at least six nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects the oligonucleotide is at least 10 nucleotides, at least 17 nucleotides, at least 25 nucleotides or at least 50 nucleotides.

The polynucleotides of the invention can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. The oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al., 1989, *Proc. Natl. Acad. Sci. U.S.A.* 86:6553-6556; Lemaitre et al., 1987, *Proc. Natl. Acad. Sci.* 84:648-652; PCT Publication No. WO88/09810, published December 15, 1988) or the blood-brain barrier (see, e.g., PCT Publication No. WO89/10134, published April 25, 1988), hybridization-triggered cleavage agents. (See, e.g., Krol et al., 1988, *BioTechniques* 6:958-976) or intercalating agents. (See, e.g., Zon, 1988, *Pharm. Res.* 5:539-549). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

The antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including, but not limited to, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine,

2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 5 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including, but not limited to, arabinose, 2-fluoroarabinose, xylulose, 10 and hexose.

In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group including, but not limited to, a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or 15 analog thereof.

In yet another embodiment, the antisense oligonucleotide is an a-anomeric oligonucleotide. An a-anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual b-units, the strands run parallel to each other (Gautier et al., 1987, Nucl. Acids Res. 15:6625-6641). The oligonucleotide is a 2'-0- 20 methylribonucleotide (Inoue et al., 1987, Nucl. Acids Res. 15:6131-6148), or a chimeric RNA-DNA analogue (Inoue et al., 1987, FEBS Lett. 215:327-330).

Polynucleotides of the invention may be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides 25 may be synthesized by the method of Stein et al. (1988, Nucl. Acids Res. 16:3209), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., 1988, Proc. Natl. Acad. Sci. U.S.A. 85:7448-7451), etc.

While antisense nucleotides complementary to the coding region sequence could be used, those complementary to the transcribed untranslated region are most preferred.

30 Potential antagonists according to the invention also include catalytic RNA, or a ribozyme (See, e.g., PCT International Publication WO 90/11364, published October 4, 1990; Sarver et al, Science 247:1222-1225 (1990). While ribozymes that cleave mRNA at

site specific recognition sequences can be used to destroy mRNAs, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two bases: 5'-UG-3'.

5 The construction and production of hammerhead ribozymes is well known in the art and is described more fully in Haseloff and Gerlach, Nature 334:585-591 (1988). There are numerous potential hammerhead ribozyme cleavage sites within the nucleotide sequence of SEQ ID NO:X. Preferably, the ribozyme is engineered so that the cleavage recognition site is located near the 5' end of the mRNA; i.e., to increase efficiency and minimize the
10 intracellular accumulation of non-functional mRNA transcripts.

As in the antisense approach, the ribozymes of the invention can be composed of modified oligonucleotides (e.g. for improved stability, targeting, etc.) and should be delivered to cells which express in vivo. DNA constructs encoding the ribozyme may be introduced into the cell in the same manner as described above for the introduction of antisense encoding
15 DNA. A preferred method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive promoter, such as, for example, pol III or pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy endogenous messages and inhibit translation. Since ribozymes unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.

20 Antagonist/agonist compounds may be employed to inhibit the cell growth and proliferation effects of the polypeptides of the present invention on neoplastic cells and tissues, i.e. stimulation of angiogenesis of tumors, and, therefore, retard or prevent abnormal cellular growth and proliferation, for example, in tumor formation or growth.

The antagonist/agonist may also be employed to prevent hyper-vascular diseases, and
25 prevent the proliferation of epithelial lens cells after extracapsular cataract surgery. Prevention of the mitogenic activity of the polypeptides of the present invention may also be desirous in cases such as restenosis after balloon angioplasty.

The antagonist/agonist may also be employed to prevent the growth of scar tissue during wound healing.

30 The antagonist/agonist may also be employed to treat the diseases described herein.

Thus, the invention provides a method of treating disorders or diseases, including but not limited to the disorders or diseases listed throughout this application, associated with

overexpression of a polynucleotide of the present invention by administering to a patient (a) an antisense molecule directed to the polynucleotide of the present invention, and/or (b) a ribozyme directed to the polynucleotide of the present invention.

5 **Other Activities**

A polypeptide, polynucleotide, agonist, or antagonist of the present invention, as a result of the ability to stimulate vascular endothelial cell growth, may be employed in treatment for stimulating re-vascularization of ischemic tissues due to various disease conditions such as thrombosis, arteriosclerosis, and other cardiovascular conditions. The
10 polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed to stimulate angiogenesis and limb regeneration, as discussed above.

A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed for treating wounds due to injuries, burns, post-operative tissue repair, and ulcers since they are mitogenic to various cells of different origins, such as fibroblast cells
15 and skeletal muscle cells, and therefore, facilitate the repair or replacement of damaged or diseased tissue.

A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed stimulate neuronal growth and to treat and prevent neuronal damage which occurs in certain neuronal disorders or neuro-degenerative conditions such as Alzheimer's
20 disease, Parkinson's disease, and AIDS-related complex. A polypeptide, polynucleotide, agonist, or antagonist of the present invention may have the ability to stimulate chondrocyte growth, therefore, they may be employed to enhance bone and periodontal regeneration and aid in tissue transplants or bone grafts.

A polypeptide, polynucleotide, agonist, or antagonist of the present invention may be
25 also be employed to prevent skin aging due to sunburn by stimulating keratinocyte growth.

A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed for preventing hair loss, since FGF family members activate hair-forming cells and promotes melanocyte growth. Along the same lines, a polypeptide, polynucleotide, agonist, or antagonist of the present invention may be employed to stimulate growth and
30 differentiation of hematopoietic cells and bone marrow cells when used in combination with other cytokines.

A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed to maintain organs before transplantation or for supporting cell culture of primary tissues. A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed for inducing tissue of mesodermal origin to differentiate in early embryos.

A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, a polypeptide, polynucleotide, agonist, or antagonist of the present invention may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

A polypeptide, polynucleotide, agonist, or antagonist of the present invention may be used to change a mammal's mental state or physical state by influencing biorhythms, cardiac rhythms, depression (including depressive disorders), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

The above-recited applications have uses in a wide variety of hosts. Such hosts include, but are not limited to, human, murine, rabbit, goat, guinea pig, camel, horse, mouse, rat, hamster, pig, micro-pig, chicken, goat, cow, sheep, dog, cat, non-human primate, and human. In specific embodiments, the host is a mouse, rabbit, goat, guinea pig, chicken, rat, hamster, pig, sheep, dog or cat. In preferred embodiments, the host is a mammal. In most preferred embodiments, the host is a human.

Other Preferred Embodiments

Other preferred embodiments of the claimed invention include an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X or the complementary strand thereto, and/or the cDNA in the related cDNA clone contained in the deposit.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions identified as "Start" and "End" in columns 7 and 8 as defined for SEQ ID NO:X in Table 1.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X or the complementary strand thereto, and/or the cDNA in the related cDNA clone contained in the deposit.

Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X or the complementary strand thereto, and/or the cDNA in the related cDNA clone contained in the deposit.

A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:X in the range of positions identified as "Start" and "End" in columns 7 and 8 as defined for SEQ ID NO:X in Table 1.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X or the complementary strand thereto, and/or the cDNA in the related cDNA clone contained in the deposit.

Also preferred is an isolated nucleic acid molecule which hybridizes under stringent hybridization conditions to a nucleic acid molecule comprising a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto, and/or the cDNA in the related cDNA clone contained in the deposit, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

Also preferred is a composition of matter comprising a DNA molecule which comprises a cDNA clone contained in the deposit.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in the nucleotide sequence of the cDNA in the related cDNA clone contained in the deposit.

Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least
5 50 contiguous nucleotides is included in the nucleotide sequence of an open reading frame sequence encoded by the cDNA in the related cDNA clone contained in the deposit.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by the cDNA in the related cDNA clone contained in the
10 deposit.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by the cDNA in the related cDNA clone contained in the deposit.

15 A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence encoded by the cDNA in the related cDNA clone contained in the deposit.

A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a
20 sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto; and a nucleotide sequence encoded by the cDNA in the related cDNA clone contained in the deposit; which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and
25 determining whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.

Also preferred is the above method wherein said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence selected
30 from said group. Similarly, also preferred is the above method wherein said step of comparing sequences is performed by comparing the nucleotide sequence determined from a

nucleic acid molecule in said sample with said sequence selected from said group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto; and a nucleotide sequence encoded by the cDNA in the related cDNA clone contained in the deposit.

Also preferred is the above method for identifying the species, tissue or cell type of a biological sample which comprises a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a nucleotide sequence of SEQ ID NO:X; or the cDNA in the related cDNA clone identified in Table 1 which encodes a protein, wherein the method comprises a step of detecting in a biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto; and a nucleotide sequence of the cDNA in the related cDNA clone contained in the deposit.

Also preferred is the above method for diagnosing a pathological condition which comprises a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the

group consisting of: a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto; and a nucleotide sequence encoded by the cDNA in the related cDNA clone contained in the deposit. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

5 Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a DNA microarray or "chip" of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 100, 150, 200, 250, 300, 500, 1000, 2000, 3000 or 4000 nucleotide sequences, wherein at least one sequence in said DNA microarray or "chip" is at least 95% identical to a sequence of at least 50 contiguous
10 nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto; and a nucleotide sequence encoded by the cDNA in the cDNA clone referenced in Table 1. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least
15 90% identical to a sequence of at least about 10 contiguous amino acids in the polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X; and/or a polypeptide encoded by the cDNA in the related cDNA clone contained in the deposit.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid
20 sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X; and/or a polypeptide encoded by the cDNA in the related cDNA clone contained in the deposit.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X; and/or a
25 polypeptide encoded by the cDNA in the related cDNA clone contained in the deposit.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X; and/or a polypeptide encoded by the cDNA in the related cDNA clone contained in the deposit.

30 Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a polypeptide encoded by the cDNA clone referenced in Table 1.

Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a portion of said polypeptide encoded by the cDNA clone referenced in Table 1; a polypeptide encoded by SEQ ID NO:X; and/or the polypeptide sequence of SEQ ID NO:Y.

5 Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of a polypeptide encoded by the cDNA clone referenced in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid
10 sequence of a polypeptide encoded by the cDNA clone referenced in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of a polypeptide encoded by the cDNA clone referenced in Table 1.

Further preferred is an isolated antibody which binds specifically to a polypeptide
15 comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: a polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X; and a polypeptide encoded by the cDNA in the related cDNA clone contained in the deposit.

Further preferred is a method for detecting in a biological sample a polypeptide
20 comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: a polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X; and a polypeptide encoded by the cDNA in the related cDNA clone referenced in Table 1; which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule
25 in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from
30 said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in

a sequence selected from the group consisting of: a polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X; and a polypeptide encoded by the cDNA in the related cDNA clone referenced in Table 1.

Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X; and a polypeptide encoded by the cDNA in the related cDNA clone referenced in Table 1.

Also preferred is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a nucleic acid sequence identified in Table 1 encoding a polypeptide, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X; and a polypeptide encoded by the cDNA in the related cDNA clone referenced in Table 1.

In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of:

polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X; and a polypeptide encoded by the cDNA in the related cDNA clone referenced in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

Also preferred is an isolated nucleic acid molecule, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X; and a polypeptide encoded by the cDNA in the related cDNA clone referenced in Table 1.

Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a human protein comprising an amino acid sequence selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X; and a polypeptide encoded by the cDNA in the related cDNA clone referenced in Table 1. The isolated polypeptide produced by this method is also preferred.

Also preferred is a method of treatment of an individual in need of an increased level of a protein activity, which method comprises administering to such an individual a therapeutic comprising an amount of an isolated polypeptide, polynucleotide, immunogenic fragment or analogue thereof, binding agent, antibody, or antigen binding fragment of the claimed invention effective to increase the level of said protein activity in said individual.

Also preferred is a method of treatment of an individual in need of a decreased level of a protein activity, which method comprised administering to such an individual a therapeutic comprising an amount of an isolated polypeptide, polynucleotide, immunogenic fragment or analogue thereof, binding agent, antibody, or antigen binding fragment of the claimed invention effective to decrease the level of said protein activity in said individual.

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

*Examples**Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample*

5 Each deposited cDNA clone is contained in a plasmid vector. Table 5 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The following correlates the related plasmid for each phage vector used in constructing the cDNA library. For example, where a
 10 particular clone is identified in Table 5 as being isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

	<u>Vector Used to Construct Library</u>	<u>Corresponding Deposited Plasmid</u>
	Lambda Zap	pBluescript (pBS)
	Uni-Zap XR	pBluescript (pBS)
15	Zap Express	pBK
	lafmid BA	plafmid BA
	pSport1	pSport1
	pCMVSPORT 2.0	pCMVSPORT 2.0
	pCMVSPORT 3.0	pCMVSPORT 3.0
20	pCR [®] 2.1	pCR [®] 2.1

Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128,256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 25 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+
 30 and KS. The S and K refers to the orientation of the polylinker to the T7 and T3

primer sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the fl origin of replication ("ori"), such that in one orientation, single stranded rescue initiated from the fl ori generates sense strand DNA and in the
5 other, antisense.

Vectors pSport1, pCMVSPORT 2.0 and pCMVSPORT 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et
10 al., Focus 15:59 (1993).) Vector lafmid BA (Bento Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR[®]2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. (See, for
15 instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., Bio/Technology 9: (1991).) Preferably, a polynucleotide of the present invention does not comprise the phage vector sequences identified for the particular clone in Table 5, as well as the corresponding plasmid vector sequences designated above.

The deposited material in the sample assigned the ATCC Deposit Number
20 cited by reference to Table 2 and 5 for any given cDNA clone also may contain one or more additional plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA clone referenced in Table 1.

TABLE 5

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HUKA HUKB HUKC HUKD HUKF HUKG	Human Uterine Cancer	Lambda ZAP II	LP01
HCNA HCNB	Human Colon	Lambda Zap II	LP01
HFFA	Human Fetal Brain, random primed	Lambda Zap II	LP01
HTWA	Resting T-Cell	Lambda ZAP II	LP01
HBQA	Early Stage Human Brain, random primed	Lambda ZAP II	LP01
HLMB HLMF HLMG HLMH HLMI HLMJ HLMM HLMN	breast lymph node CDNA library	Lambda ZAP II	LP01
HCQA HCQB	human colon cancer	Lamda ZAP II	LP01
HMEA HMEC HMED HMEF HMEG HMEI HMEJ HMEK HMEI	Human Microvascular Endothelial Cells, fract. A	Lambda ZAP II	LP01
HUSA HUSC	Human Umbilical Vein Endothelial Cells, fract. A	Lambda ZAP II	LP01
HLQA HLQB	Hepatocellular Tumor	Lambda ZAP II	LP01
HHGA HHGB HHGC HHGD	Hemangiopericytoma	Lambda ZAP II	LP01
HSDM	Human Striatum Depression. re-rescue	Lambda ZAP II	LP01
HUSH	H Umbilical Vein Endothelial Cells, frac A, re-excision	Lambda ZAP II	LP01
HSGS	Salivary gland, subtracted	Lambda ZAP II	LP01
HFXA HFXB HFXC HFXD HFXE HFXF HFXG HFXH	Brain frontal cortex	Lambda ZAP II	LP01
HPQA HPQB HPQC	PERM TF274	Lambda ZAP II	LP01
HFXJ HFXK	Brain Frontal Cortex, re-excision	Lambda ZAP II	LP01
HCWA HCWB HCWC HCWD HCWE HCWF HCWG HCWH HCWI HCWJ HCWK	CD34 positive cells (Cord Blood)	ZAP Express	LP02
HCUA HCUB HCUC	CD34 depleted Buffy Coat (Cord Blood)	ZAP Express	LP02
HRSM	A-14 cell line	ZAP Express	LP02
HRSA	A1-CELL LINE	ZAP Express	LP02
HCUD HCUE HCUF HCUG HCUH HCUI	CD34 depleted Buffy Coat (Cord Blood), re-excision	ZAP Express	LP02
HBXE HBXF HBXG	H. Whole Brain #2, re-excision	ZAP Express	LP02
HRLM	L8 cell line	ZAP Express	LP02
HBXA HBXB HBXC HBXD	Human Whole Brain #2 - Oligo dT > 1.5Kb	ZAP Express	LP02
HUDA HUDB HUDC	Testes	ZAP Express	LP02
HHTM HHTN HHTO	H. hypothalamus, frac A;re-excision	ZAP Express	LP02
HHTL	H. hypothalamus, frac A	ZAP Express	LP02
HASA HASD	Human Adult Spleen	Uni-ZAP XR	LP03
HFKC HFKD HFKE HFKF HFKG	Human Fetal Kidney	Uni-ZAP XR	LP03
HE8A HE8B HE8C HE8D HE8E HE8F HE8M HE8N	Human 8 Week Whole Embryo	Uni-ZAP XR	LP03
HGBA HGBD HGBE HGBF HGBG HGBH HGBI	Human Gall Bladder	Uni-ZAP XR	LP03
HLHA HLHB HLHC HLHD HLHE HLHF HLHG HLHH HLHQ	Human Fetal Lung III	Uni-ZAP XR	LP03
HPMA HPMB HPMC HPMD HPME HPMF HPMG HPMH	Human Placenta	Uni-ZAP XR	LP03

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HPRA HPRB HPRC HPRD	Human Prostate	Uni-ZAP XR	LP03
HSIA HSIC HSID HSIE	Human Adult Small Intestine	Uni-ZAP XR	LP03
HTEA HTEB HTEC HTED HTEE HTEF HTEG HTEH HTEI HTEJ HTEK	Human Testes	Uni-ZAP XR	LP03
HTPA HTPB HTPC HTPD HTPE	Human Pancreas Tumor	Uni-ZAP XR	LP03
HTTA HTTB HTTC HTTD HTTE HTTF	Human Testes Tumor	Uni-ZAP XR	LP03
HAPA HAPB HAPC HAPM	Human Adult Pulmonary	Uni-ZAP XR	LP03
HETA HETB HETC HETD HETE HETF HETG HETH HETI	Human Endometrial Tumor	Uni-ZAP XR	LP03
HHFB HHFC HHFD HHFE HHFF HHFG HHFH HHFI	Human Fetal Heart	Uni-ZAP XR	LP03
HHPB HHPC HHPD HHPE HHPF HHPG HHPH	Human Hippocampus	Uni-ZAP XR	LP03
HCE1 HCE2 HCE3 HCE4 HCE5 HCEB HCEC HCED HCEE HCEF HCEG	Human Cerebellum	Uni-ZAP XR	LP03
HUVB HUVC HUVD HUVE	Human Umbilical Vein, Endo. remake	Uni-ZAP XR	LP03
HSTA HSTB HSTC HSTD	Human Skin Tumor	Uni-ZAP XR	LP03
HTAA HTAB HTAC HTAD HTAE	Human Activated T-Cells	Uni-ZAP XR	LP03
HFEA HFEB HFEC	Human Fetal Epithelium (Skin)	Uni-ZAP XR	LP03
HJPA HJPB HJPC HJPD	HUMAN JURKAT MEMBRANE BOUND POLYSOMES	Uni-ZAP XR	LP03
HESA	Human epithelioid sarcoma	Uni-Zap XR	LP03
HLTA HLTB HLTC HLTD HLTE HLTF	Human T-Cell Lymphoma	Uni-ZAP XR	LP03
HFTA HFTB HFTC HFTD	Human Fetal Dura Mater	Uni-ZAP XR	LP03
HRDA HRDB HRDC HRDD HRDE HRDF	Human Rhabdomyosarcoma	Uni-ZAP XR	LP03
HCAA HCAB HCAC	Cem cells cyclohexamide treated	Uni-ZAP XR	LP03
HRGA HRGB HRGC HRGD	Raji Cells, cyclohexamide treated	Uni-ZAP XR	LP03
HSUA HSUB HSUC HSUM	Supt Cells, cyclohexamide treated	Uni-ZAP XR	LP03
HT4A HT4C HT4D	Activated T-Cells, 12 hrs.	Uni-ZAP XR	LP03
HE9A HE9B HE9C HE9D HE9E HE9F HE9G HE9H HE9M HE9N	Nine Week Old Early Stage Human	Uni-ZAP XR	LP03
HATA HATB HATC HATD HATE	Human Adrenal Gland Tumor	Uni-ZAP XR	LP03
HT5A	Activated T-Cells, 24 hrs.	Uni-ZAP XR	LP03
HFGA HFGM	Human Fetal Brain	Uni-ZAP XR	LP03
HNEA HNEB HNEC HNED HNEE	Human Neutrophil	Uni-ZAP XR	LP03
HBGB HBGD	Human Primary Breast Cancer	Uni-ZAP XR	LP03
HBNA HBNB	Human Normal Breast	Uni-ZAP XR	LP03
HCAS	Cem Cells, cyclohexamide treated, subtra	Uni-ZAP XR	LP03
HHPS	Human Hippocampus, subtracted	pBS	LP03
HKCS HKCU	Human Colon Cancer, subtracted	pBS	LP03
HRGS	Raji cells, cyclohexamide treated, subtracted	pBS	LP03
HSUT	Supt cells, cyclohexamide treated, differentially expressed	pBS	LP03
HT4S	Activated T-Cells, 12 hrs, subtracted	Uni-ZAP XR	LP03
HCDA HCDB HCDC HCDD HCDE	Human Chondrosarcoma	Uni-ZAP XR	LP03
HOAA HOAB HOAC	Human Osteosarcoma	Uni-ZAP XR	LP03
HTLA HTLB HTLC HTLD HTLE	Human adult testis, large inserts	Uni-ZAP XR	LP03

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HTLF			
HLMA HLMD HLMD	Breast Lymph node cDNA library	Uni-ZAP XR	LP03
H6EA H6EB H6EC	HL-60, PMA 4H	Uni-ZAP XR	LP03
HTXA HTXB HTXC HTXD HTXE HTXF HTXG HTXH	Activated T-Cell (12hs)/Thiouridine labelledEco	Uni-ZAP XR	LP03
HNFA HNFH HNFJ HNFH HNFH HNFF HNFG HNFH HNFJ	Human Neutrophil, Activated	Uni-ZAP XR	LP03
HTOB HTOC	HUMAN TONSILS, FRACTION 2	Uni-ZAP XR	LP03
HMGB	Human OB MG63 control fraction I	Uni-ZAP XR	LP03
HOPB	Human OB HOS control fraction I	Uni-ZAP XR	LP03
HORB	Human OB HOS treated (10 nM E2) fraction I	Uni-ZAP XR	LP03
HSVA HSVB HSVC	Human Chronic Synovitis	Uni-ZAP XR	LP03
HROA	HUMAN STOMACH	Uni-ZAP XR	LP03
HBJA HBJB HBJC HBJD HBJE HBJF HBJG HBJH HBJI HBJJ HBJK	HUMAN B CELL LYMPHOMA	Uni-ZAP XR	LP03
HCRA HCRB HCRC	human corpus colosum	Uni-ZAP XR	LP03
HODA HODB HODC HODD	human ovarian cancer	Uni-ZAP XR	LP03
HDSA	Dermatofibrosarcoma Protuberance	Uni-ZAP XR	LP03
HMWA HMWB HMWC HMWD HMWE HMWF HMWG HMWH HMWI HMWJ	Bone Marrow Cell Line (RS4;11)	Uni-ZAP XR	LP03
HSOA	stomach cancer (human)	Uni-ZAP XR	LP03
HERA	SKIN	Uni-ZAP XR	LP03
HMDA	Brain-medulloblastoma	Uni-ZAP XR	LP03
HGLA HGLB HGLD	Glioblastoma	Uni-ZAP XR	LP03
HEAA	H. Atrophic Endometrium	Uni-ZAP XR	LP03
HBCA HBCB	H. Lymph node breast Cancer	Uni-ZAP XR	LP03
HPWT	Human Prostate BPH, re-excision	Uni-ZAP XR	LP03
HFVG HFVH HFVI	Fetal Liver, subtraction II	pBS	LP03
HNFI	Human Neutrophils, Activated, re- excision	pBS	LP03
HBMB HBMC HBMD	Human Bone Marrow, re-excision	pBS	LP03
HKML HKMM HKMN	H. Kidney Medulla, re-excision	pBS	LP03
HKIX HKIY	H. Kidney Cortex, subtracted	pBS	LP03
HADT	H. Amygdala Depression, subtracted	pBS	LP03
H6AS	HL-60, untreated, subtracted	Uni-ZAP XR	LP03
H6ES	HL-60, PMA 4H, subtracted	Uni-ZAP XR	LP03
H6BS	HL-60, RA 4h, Subtracted	Uni-ZAP XR	LP03
H6CS	HL-60, PMA 1d, subtracted	Uni-ZAP XR	LP03
HTXJ HTXK	Activated T-cell(12h)/Thiouridine-re- excision	Uni-ZAP XR	LP03
HMSA HMSB HMSC HMSE HMSE HMSF HMSG HMSH HMSI HMSJ HMSK	Monocyte activated	Uni-ZAP XR	LP03
HAGA HAGB HAGC HAGD HAGE HAGF	Human Amygdala	Uni-ZAP XR	LP03
HSRA HSRB HSRE	STROMAL -OSTEOCLASTOMA	Uni-ZAP XR	LP03
HSRD HSRF HSRG HSRH	Human Osteoclastoma Stromal Cells - unamplified	Uni-ZAP XR	LP03
HSQA HSQB HSQC HSQD HSQE	Stromal cell TF274	Uni-ZAP XR	LP03

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HSQF HSQG			
HSKA HSKB HSKC HSKD HSKE HSKF HSKZ	Smooth muscle, serum treated	Uni-ZAP XR	LP03
HSLA HSLB HSLC HSLD HSLE HSLF HSLG	Smooth muscle, control	Uni-ZAP XR	LP03
HSDA HSDD HSDE HSDF HSDG HSDH	Spinal cord	Uni-ZAP XR	LP03
HPWS	Prostate-BPH subtracted II	pBS	LP03
HSKW HSKX HSKY	Smooth Muscle- HASTE normalized	pBS	LP03
HFPB HFPC HFPD	H. Frontal cortex, epileptic; re-excision	Uni-ZAP XR	LP03
HSDI HSDJ HSDK	Spinal Cord, re-excision	Uni-ZAP XR	LP03
HSKN HSKO	Smooth Muscle Serum Treated, Norm	pBS	LP03
HSKG HSKH HSKI	Smooth muscle, serum induced, re-exc	pBS	LP03
HFCA HFCB HFCC HFCD HFCE HFCF	Human Fetal Brain	Uni-ZAP XR	LP04
HPTA HPTB HPTD	Human Pituitary	Uni-ZAP XR	LP04
HTHB HTHC HTHD	Human Thymus	Uni-ZAP XR	LP04
HE6B HE6C HE6D HE6E HE6F HE6G HE6S	Human Whole Six Week Old Embryo	Uni-ZAP XR	LP04
HSSA HSSB HSSC HSSD HSSE HSSF HSSG HSSH HSSI HSSJ HSSK	Human Synovial Sarcoma	Uni-ZAP XR	LP04
HE7T	7 Week Old Early Stage Human, subtracted	Uni-ZAP XR	LP04
HEPA HEPB HEPD	Human Epididymus	Uni-ZAP XR	LP04
HSNA HSNB HSNL HSNM HSNP	Human Synovium	Uni-ZAP XR	LP04
HPFB HPFC HPFD HPFE	Human Prostate Cancer, Stage C fraction	Uni-ZAP XR	LP04
HE2A HE2D HE2E HE2H HE2I HE2M HE2N HE2O	12 Week Old Early Stage Human	Uni-ZAP XR	LP04
HE2B HE2C HE2F HE2G HE2P HE2Q	12 Week Old Early Stage Human, II	Uni-ZAP XR	LP04
HPTS HPTT HPTU	Human Pituitary, subtracted	Uni-ZAP XR	LP04
HAUA HAUB HAUC	Amniotic Cells - TNF induced	Uni-ZAP XR	LP04
HAQA HAQB HAQC HAQD	Amniotic Cells - Primary Culture	Uni-ZAP XR	LP04
HUTA HWTB HUTC	wilm's tumor	Uni-ZAP XR	LP04
HBSD	Bone Cancer, re-excision	Uni-ZAP XR	LP04
HSGB	Salivary gland, re-excision	Uni-ZAP XR	LP04
HSJA HSJB HSJC	Smooth muscle-ILb induced	Uni-ZAP XR	LP04
HSXA HSXB HSXC HSXD	Human Substantia Nigra	Uni-ZAP XR	LP04
HSHA HSHB HSHC	Smooth muscle, IL1b induced	Uni-ZAP XR	LP04
HOUA HOUB HOUN HOUD HOUF	Adipocytes	Uni-ZAP XR	LP04
HPWA HPWB HPWC HPWD HPWE	Prostate BPH	Uni-ZAP XR	LP04
HELA HELB HELC HELD HELE HELF HELG HELH	Endothelial cells-control	Uni-ZAP XR	LP04
HEMA HEMB HEMC HEMD HEME HEMF HEMG HEMH	Endothelial-induced	Uni-ZAP XR	LP04
HBIA HBIB HBIC	Human Brain, Striatum	Uni-ZAP XR	LP04
HHSA HHSB HHSC HHSD HHSE	Human Hypothalamus, Schizophrenia	Uni-ZAP XR	LP04
HNGA HNGB HNGC HNGD HNGE HNGF HNGG HNGH HNGI HNGJ	neutrophils control	Uni-ZAP XR	LP04
HNHA HNH B HNH C HNH D HNH E HNH F HNH G HNH H HNH I HNH J	Neutrophils IL-1 and LPS induced	Uni-ZAP XR	LP04
HSDB HSDC	STRIATUM DEPRESSION	Uni-ZAP XR	LP04

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HHPT	Hypothalamus	Uni-ZAP XR	LP04
HSAT HSAU HSAV HSAW HSAX HSAY HSAZ	Anergic T-cell	Uni-ZAP XR	LP04
HBMS HBMT HBMU HBMV HBMW HBMX	Bone marrow	Uni-ZAP XR	LP04
HOEA HOEB HOEC HOED HOEE HOEF HOEJ	Osteoblasts	Uni-ZAP XR	LP04
HAIA HAIB HAIC HAID HAIE HAIF	Epithelial-TNF α and INF induced	Uni-ZAP XR	LP04
HTGA HTGB HTGC HTGD	Apoptotic T-cell	Uni-ZAP XR	LP04
HMCA HMCB HMCC HMCD HMCE	Macrophage-oxLDL	Uni-ZAP XR	LP04
HMAA HMAB HMAC HMAD HMAE HMAF HMAG	Macrophage (GM-CSF treated)	Uni-ZAP XR	LP04
HPHA	Normal Prostate	Uni-ZAP XR	LP04
HPIA HPIB HPIC	LNCAP prostate cell line	Uni-ZAP XR	LP04
HPJA HPJB HPJC	PC3 Prostate cell line	Uni-ZAP XR	LP04
HOSE HOSF HOSG	Human Osteoclastoma, re-excision	Uni-ZAP XR	LP04
HTGE HTGF	Apoptotic T-cell, re-excision	Uni-ZAP XR	LP04
HMAJ HMAK	H Macrophage (GM-CSF treated), re-excision	Uni-ZAP XR	LP04
HACB HACC HACD	Human Adipose Tissue, re-excision	Uni-ZAP XR	LP04
HFPA	H. Frontal Cortex, Epileptic	Uni-ZAP XR	LP04
HFAL HFAB HFAC HFAD HFAE	Alzheimers, spongy change	Uni-ZAP XR	LP04
HFAM	Frontal Lobe, Dementia	Uni-ZAP XR	LP04
HMIA HMIB HMIC	Human Manic Depression Tissue	Uni-ZAP XR	LP04
HTSA HTSE HTSF HTSG HTSH	Human Thymus	pBS	LP05
HPBA HPBB HPBC HPBD HPBE	Human Pineal Gland	pBS	LP05
HSAA HSAB HSAC	HSA 172 Cells	pBS	LP05
HSBA HSBB HSBC HSBM	HSC172 cells	pBS	LP05
HJAA HJAB HJAC HJAD	Jurkat T-cell G1 phase	pBS	LP05
HJBA HJBB HJBC HJBD	Jurkat T-Cell, S phase	pBS	LP05
HAFA HAFB	Aorta endothelial cells + TNF- α	pBS	LP05
HAWA HAWB HAWC	Human White Adipose	pBS	LP05
HTNA HTNB	Human Thyroid	pBS	LP05
HONA	Normal Ovary, Premenopausal	pBS	LP05
HARA HARB	Human Adult Retina	pBS	LP05
HLJA HLJB	Human Lung	pCMVSPORT 1	LP06
HOFM HOFN HOFO	H. Ovarian Tumor, II, OV5232	pCMVSPORT 2.0	LP07
HOGA HOGB HOGC	OV 10-3-95	pCMVSPORT 2.0	LP07
HCGL	CD34+cells, II	pCMVSPORT 2.0	LP07
HDLA	Hodgkin's Lymphoma I	pCMVSPORT 2.0	LP07
HDTA HDTB HDTC HDTD HDTE	Hodgkin's Lymphoma II	pCMVSPORT 2.0	LP07
HKAA HKAB HKAC HKAD HKAE HKAF HKAG HKAH	Keratinocyte	pCMVSPORT 2.0	LP07
HCIM	CAPFINDER, Crohn's Disease, lib 2	pCMVSPORT 2.0	LP07
HKAL	Keratinocyte, lib 2	pCMVSPORT 2.0	LP07
HKAT	Keratinocyte, lib 3	pCMVSPORT 2.0	LP07
HNDA	Nasal polyps	pCMVSPORT 2.0	LP07
HDRA	H. Primary Dendritic Cells, lib 3	pCMVSPORT 2.0	LP07

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HOHA HOHB HOHC	Human Osteoblasts II	pCMVSPORT2.0	LP07
HLDA HLDB HLDC	Liver. Hepatoma	pCMVSPORT3.0	LP08
HLDN HLDO HLDP	Human Liver, normal	pCMVSPORT3.0	LP08
HMTA	pBMC stimulated w/ poly I/C	pCMVSPORT3.0	LP08
HNTA	NTERA2. control	pCMVSPORT3.0	LP08
HOPA HOPB HOPC HOPD HOPF HOPG HOPH HOPJ HOPK	Primary Dendritic Cells, lib 1	pCMVSPORT3.0	LP08
HOPM HOPN HOPQ HOPP	Primary Dendritic cells, frac 2	pCMVSPORT3.0	LP08
HMUA HMUB HMUC	Myeloid Progenitor Cell Line	pCMVSPORT3.0	LP08
HHEA HHEB HHEC HHED	T Cell helper I	pCMVSPORT3.0	LP08
HHEM HHEN HHEO HHEP	T cell helper II	pCMVSPORT3.0	LP08
HEQA HEQB HEQC	Human endometrial stromal cells	pCMVSPORT3.0	LP08
HJMA HJMB	Human endometrial stromal cells-treated with progesterone	pCMVSPORT3.0	LP08
HSWA HSWB HSWC	Human endometrial stromal cells-treated with estradiol	pCMVSPORT3.0	LP08
HSYA HSYB HSYC	Human Thymus Stromal Cells	pCMVSPORT3.0	LP08
HLWA HLWB HLWC	Human Placenta	pCMVSPORT3.0	LP08
HRAA HRAB HRAC	Rejected Kidney, lib 4	pCMVSPORT3.0	LP08
HMTM	PCR, pBMC I/C treated	PCR II	LP09
HMJA	H. Meningioma, M6	pSport 1	LP10
HMKA HMKB HMKC HMKD HMKE	H. Meningioma, M1	pSport 1	LP10
HUSG HUSI	Human umbilical vein endothelial cells, IL-4 induced	pSport 1	LP10
HUSX HUSY	Human Umbilical Vein Endothelial Cells, uninduced	pSport 1	LP10
HOFA	Ovarian Tumor I, OV5232	pSport 1	LP10
HCFA HCFB HCFC HCFC	T-Cell PHA 16 hrs	pSport 1	LP10
HCFL HCFM HCFN HCFO	T-Cell PHA 24 hrs	pSport 1	LP10
HADA HADC HADD HADE HADF HADG	Human Adipose	pSport 1	LP10
HOVA HOVB HOVC	Human Ovary	pSport 1	LP10
HTWB HTWC HTWD HTWE HTWF	Resting T-Cell Library, II	pSport 1	LP10
HMMA	Spleen metastatic melanoma	pSport 1	LP10
HLYA HLYB HLYC HLYD HLYE	Spleen, Chronic lymphocytic leukemia	pSport 1	LP10
HCGA	CD34+ cell, I	pSport 1	LP10
HEOM HEON	Human Eosinophils	pSport 1	LP10
HTDA	Human Tonsil, Lib 3	pSport 1	LP10
HSPA	Salivary Gland, Lib 2	pSport 1	LP10
HCHA HCHB HCHC	Breast Cancer cell line, MDA 36	pSport 1	LP10
HCHM HCHN	Breast Cancer Cell line, angiogenic	pSport 1	LP10
HCIA	Crohn's Disease	pSport 1	LP10
HDAA HDAB HDAC	HEL cell line	pSport 1	LP10
HABA	Human Astrocyte	pSport 1	LP10
HUFA HUFB HUFC	Ulcerative Colitis	pSport 1	LP10
HNTM	NTERA2 + retinoic acid, 14 days	pSport 1	LP10
HDQA	Primary Dendritic cells, CapFinder2, frac 1	pSport 1	LP10
HDQM	Primary Dendritic Cells, CapFinder, frac	pSport 1	LP10

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
	2		
HLDX	Human Liver, normal.CapFinder	pSport 1	LP10
HULA HULB HULC	Human Dermal Endothelial Cells.untreated	pSport1	LP10
HUMA	Human Dermal Endothelial cells.treated	pSport1	LP10
HCJA	Human Stromal Endometrial fibroblasts, untreated	pSport1	LP10
HCJM	Human Stromal endometrial fibroblasts, treated w/ estradiol	pSport1	LP10
HEDA	Human Stromal endometrial fibroblasts, treated with progesterone	pSport1	LP10
HFNA	Human ovary tumor cell OV350721	pSport1	LP10
HKGA HKGB HKGC HKGD	Merkel Cells	pSport1	LP10
HISA HISB HISC	Pancreas Islet Cell Tumor	pSport1	LP10
HLSA	Skin, burned	pSport1	LP10
HBZA	Prostate.BPH, Lib 2	pSport 1	LP10
HBZS	Prostate BPH,Lib 2, subtracted	pSport 1	LP10
HFIA HFIB HFIC	Synovial Fibroblasts (control)	pSport 1	LP10
HFIH HFII HFIJ	Synovial hypoxia	pSport 1	LP10
HFIT HFIU HFIV	Synovial IL-1/TNF stimulated	pSport 1	LP10
HGCA	Mesangial cell. frac 1	pSport1	LP10
HMVA HMVB HMVC	Bone Marrow Stromal Cell. untreated	pSport1	LP10
HFIX HFII HFIZ	Synovial Fibroblasts (III/TNF), sub1	pSport1	LP10
HFOX HFOY HFOZ	Synovial hypoxia-RSF subtracted	pSport1	LP10
HMQA HMQB HMQC HMQD	Human Activated Monocytes	Uni-ZAP XR	LP11
HLIA HLIB HLIC	Human Liver	pCMVSPORT 1	LP012
HHBA HHBB HHBC HHBD HHBE	Human Heart	pCMVSPORT 1	LP012
HBBA HBBB	Human Brain	pCMVSPORT 1	LP012
HLJA HLJB HLJC HLJD HLJE	Human Lung	pCMVSPORT 1	LP012
HOGA HOGB HOGC	Ovarian Tumor	pCMVSPORT 2.0	LP012
HTJM	Human Tonsils, Lib 2	pCMVSPORT 2.0	LP012
HAMF HAMG	KMH2	pCMVSPORT 3.0	LP012
HAJA HAJB HAJC	L428	pCMVSPORT 3.0	LP012
HWBA HWBB HWBC HWBD HWBE	Dendritic cells, pooled	pCMVSPORT 3.0	LP012
HWAA HWAB HWAC HWAD HWAE	Human Bone Marrow, treated	pCMVSPORT 3.0	LP012
HYAA HYAB HYAC	B Cell lymphoma	pCMVSPORT 3.0	LP012
HWHG HWHH HWHI	Healing groin wound, 6.5 hours post incision	pCMVSPORT 3.0	LP012
HWHP HWHQ HWHR	Healing groin wound; 7.5 hours post incision	pCMVSPORT 3.0	LP012
HARM	Healing groin wound - zero hr post-incision (control)	pCMVSPORT 3.0	LP012
HBIM	Olfactory epithelium; nasalcavity	pCMVSPORT 3.0	LP012
HWDA	Healing Abdomen wound; 70&90 min post incision	pCMVSPORT 3.0	LP012
HWEA	Healing Abdomen Wound;15 days post incision	pCMVSPORT 3.0	LP012
HWJA	Healing Abdomen Wound;21&29 days	pCMVSPORT 3.0	LP012
HNAL	Human Tongue, frac 2	pSport1	LP012
HMJA	H. Meningima, M6	pSport1	LP012
HMKA HMKB HMKC HMKE	H. Meningima, M1	pSport1	LP012

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HOFA	Ovarian Tumor I, OV5232	pSport1	LP012
HCFA HCFB HCFC HCFD	T-Cell PHA 16 hrs	pSport1	LP012
HCFL HCFM HCFN HCFO	T-Cell PHA 24 hrs	pSport1	LP012
HIMMA HMMB HMMC	Spleen metastatic melanoma	pSport1	LP012
HTDA	Human Tonsil, Lib 3	pSport1	LP012
HDBA	Human Fetal Thymus	pSport1	LP012
HDUA	Pericardium	pSport1	LP012
HBZA	Prostate, BPH, Lib 2	pSport1	LP012
HWCA	Larynx tumor	pSport1	LP012
HWKA	Normal lung	pSport1	LP012
HSMB	Bone marrow stroma, treated	pSport1	LP012
HBHM	Normal trachea	pSport1	LP012
HLFC	Human Larynx	pSport1	LP012
HLRB	Siebben Polyposis	pSport1	LP012
HNIA	Mammary Gland	pSport1	LP012
HNJB	Palate carcinoma	pSport1	LP012
HNKA	Palate normal	pSport1	LP012
HMZA	Pharynx carcinoma	pSport1	LP012
HABG	Cheek Carcinoma	pSport1	LP012
HMZM	Pharynx Carcinoma	pSport1	LP012
HDRM	Larynx Carcinoma	pSport1	LP012
HVAA	Pancreas normal PCA4 No	pSport1	LP012
HICA	Tongue carcinoma	pSport1	LP012
HUKA HUKB HUKC HUKD HUKF	Human Uterine Cancer	Lambda ZAP II	LP013
HFFA	Human Fetal Brain, random primed	Lambda ZAP II	LP013
HTUA	Activated T-cell labeled with 4-thioluri	Lambda ZAP II	LP013
HBQA	Early Stage Human Brain, random primed	Lambda ZAP II	LP013
HMEB	Human microvascular Endothelial cells, fract. B	Lambda ZAP II	LP013
HUSH	Human Umbilical Vein Endothelial cells, fract. A, re-excision	Lambda ZAP II	LP013
HLQC HLQD	Hepatocellular tumor, re-excision	Lambda ZAP II	LP013
HTWJ HTWK HTWL	Resting T-cell, re-excision	Lambda ZAP II	LP013
HF6S	Human Whole 6 week Old Embryo (II), sub1	pBluescript	LP013
HHPS	Human Hippocampus, subtracted	pBluescript	LP013
HL1S	LNCAP, differential expression	pBluescript	LP013
HLHS HLHT	Early Stage Human Lung, Subtracted	pBluescript	LP013
HSUS	Supt cells, cyclohexamide treated, subtracted	pBluescript	LP013
HSUT	Supt cells, cyclohexamide treated, differentially expressed	pBluescript	LP013
HSDS	H. Striatum Depression, subtracted	pBluescript	LP013
HPTZ	Human Pituitary, Subtracted VII	pBluescript	LP013
HSDX	H. Striatum Depression, sub1	pBluescript	LP013
HSDZ	H. Striatum Depression, sub1	pBluescript	LP013
HPBA HPBB HPBC HPBD HPBE	Human Pineal Gland	pBluescript SK-	LP013
HRTA	Colorectal Tumor	pBluescript SK-	LP013
HSBA HSBB HSBC HSBM	HSC172 cells	pBluescript SK-	LP013
HJAA HJAB HJAC HJAD	Jurkat T-cell G1 phase	pBluescript SK-	LP013
HJBA HJBB HJBC HJBD	Jurkat T-cell, S1 phase	pBluescript SK-	LP013

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HTNA HTNB	Human Thyroid	pBluescript SK-	LP013
HAHA HAHB	Human Adult Heart	Uni-ZAP XR	LP013
HE6A	Whole 6 week Old Embryo	Uni-ZAP XR	LP013
HFCB HFCD HFCE	Human Fetal Brain	Uni-ZAP XR	LP013
HFKC HFKD HFKE HFKF HFKG	Human Fetal Kidney	Uni-ZAP XR	LP013
HGBA HGBD HGBE HGBF HGBG	Human Gall Bladder	Uni-ZAP XR	LP013
HPRA HPRB HPRC HPRD	Human Prostate	Uni-ZAP XR	LP013
HTEA HTEB HTEC HTED HTEE	Human Testes	Uni-ZAP XR	LP013
HTTA HTTB HTTC HTTD HTTE	Human Testes Tumor	Uni-ZAP XR	LP013
HYBA HYBB	Human Fetal Bone	Uni-ZAP XR	LP013
HFLA	Human Fetal Liver	Uni-ZAP XR	LP013
HHFB HHFC HHFD HHFE HHFF	Human Fetal Heart	Uni-ZAP XR	LP013
HUVB HUV C HUVD HUVE	Human Umbilical Vein, End. remake	Uni-ZAP XR	LP013
HTHB HTHC HTHD	Human Thymus	Uni-ZAP XR	LP013
HSTA HSTB HSTC HSTD	Human Skin Tumor	Uni-ZAP XR	LP013
HTAA HTAB HTAC HTAD HTAE	Human Activated T-cells	Uni-ZAP XR	LP013
HFEA HFEB HFEC	Human Fetal Epithelium (skin)	Uni-ZAP XR	LP013
HJPA HJPB HJPC HJPD	Human Jurkat Membrane Bound Polysomes	Uni-ZAP XR	LP013
HESA	Human Epithelioid Sarcoma	Uni-ZAP XR	LP013
HALS	Human Adult Liver, Subtracted	Uni-ZAP XR	LP013
HFTA HFTB HFTC HFTD	Human Fetal Dura Mater	Uni-ZAP XR	LP013
HCAA HCAB HCAC	Cem cells, cyclohexamide treated	Uni-ZAP XR	LP013
HRGA HRGB HRGC HRGD	Raji Cells, cyclohexamide treated	Uni-ZAP XR	LP013
HE9A HE9B HE9C HE9D HE9E	Nine Week Old Early Stage Human	Uni-ZAP XR	LP013
HSFA	Human Fibrosarcoma	Uni-ZAP XR	LP013
HATA HATB HATC HATD HATE	Human Adrenal Gland Tumor	Uni-ZAP XR	LP013
HTRA	Human Trachea Tumor	Uni-ZAP XR	LP013
HE2A HE2D HE2E HE2H HE2I	12 Week Old Early Stage Human	Uni-ZAP XR	LP013
HE2B HE2C HE2F HE2G HE2P	12 Week Old Early Stage Human, II	Uni-ZAP XR	LP013
HNEA HNEB HNEC HNED HNEE	Human Neutrophil	Uni-ZAP XR	LP013
HBGA	Human Primary Breast Cancer	Uni-ZAP XR	LP013
HPTS HPTT HPTU	Human Pituitary, subtracted	Uni-ZAP XR	LP013
HMQA HMQB HMQC HMQD	Human Activated Monocytes	Uni-ZAP XR	LP013
HOAA HOAB HOAC	Human Osteosarcoma	Uni-ZAP XR	LP013
HTOA HTOD HTOE HTOF HTOG	human tonsils	Uni-ZAP XR	LP013
HMGB	Human OB MG63 control fraction I	Uni-ZAP XR	LP013
HOPB	Human OB HOS control fraction I	Uni-ZAP XR	LP013
HOQB	Human OB HOS treated (1 nM E2) fraction I	Uni-ZAP XR	LP013
HAUA HAUB HAUC	Amniotic Cells - TNF induced	Uni-ZAP XR	LP013
HAQA HAQB HAQC HAQD	Amniotic Cells - Primary Culture	Uni-ZAP XR	LP013
HROA HROC	HUMAN STOMACH	Uni-ZAP XR	LP013
HBJA HBJB HBJC HBJD HBJE	HUMAN B CELL LYMPHOMA	Uni-ZAP XR	LP013
HODA HODB HODC HODD	human ovarian cancer	Uni-ZAP XR	LP013
HCPA	Corpus Callosum	Uni-ZAP XR	LP013
HSOA	stomach cancer (human)	Uni-ZAP XR	LP013
HERA	SKIN	Uni-ZAP XR	LP013
HMDA	Brain-medulloblastoma	Uni-ZAP XR	LP013
HGLA HGLB HGLD	Glioblastoma	Uni-ZAP XR	LP013

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HWTB HWTB HWTC	Wilms' tumor	Uni-ZAP XR	LP013
HEAA	H. Atrophic Endometrium	Uni-ZAP XR	LP013
HAPN HAPN HAPQ HAPR	Human Adult Pulmonary; re-excision	Uni-ZAP XR	LP013
HLTG HLTH	Human T-cell lymphoma; re-excision	Uni-ZAP XR	LP013
HAHC HAHD HAHE	Human Adult Heart; re-excision	Uni-ZAP XR	LP013
HAGA HAGB HAGC HAGD HAGE	Human Amygdala	Uni-ZAP XR	LP013
HSJA HSJB HSJC	Smooth muscle-ILb induced	Uni-ZAP XR	LP013
HSJA HSJB HSJC	Smooth muscle, IL1b induced	Uni-ZAP XR	LP013
HPWA HPWB HPWC HPWD HPWE	Prostate BPH	Uni-ZAP XR	LP013
HPJA HPJB HPJC	LNCAP prostate cell line	Uni-ZAP XR	LP013
HPJA HPJB HPJC	PC3 Prostate cell line	Uni-ZAP XR	LP013
HBTA	Bone Marrow Stroma. TNF&LPS ind	Uni-ZAP XR	LP013
HMCF HMCB HMCH HMCJ HMCJ	Macrophage-oxLDL; re-excision	Uni-ZAP XR	LP013
HAGG HAGH HAGI	Human Amygdala; re-excision	Uni-ZAP XR	LP013
HACA	H. Adipose Tissue	Uni-ZAP XR	LP013
HKFB	K562 + PMA (36 hrs).re-excision	ZAP Express	LP013
HCWT HCWU HCWV	CD34 positive cells (cord blood), re-ex	ZAP Express	LP013
HBWA	Whole brain	ZAP Express	LP013
HBXA HBXB HBXC HBXD	Human Whole Brain #2 - Oligo dT > 1.5Kb	ZAP Express	LP013
HAVM	Temporal cortex-Alzheimer	pT-Adv	LP014
HAVT	Hippocampus, Alzheimer Subtracted	pT-Adv	LP014
HHAS	CHME Cell Line	Uni-ZAP XR	LP014
HAJR	Larynx normal	pSport 1	LP014
HWLE HWLF HWLG HWLH	Colon Normal	pSport 1	LP014
HCRM HCRN HCRO	Colon Carcinoma	pSport 1	LP014
HWLI HWLJ HWLK	Colon Normal	pSport 1	LP014
HWLQ HWLR HWLS HWLT	Colon Tumor	pSport 1	LP014
HBFM	Gastrocnemius Muscle	pSport 1	LP014
HBOD HBOE	Quadriceps Muscle	pSport 1	LP014
HBKD HBKE	Soleus Muscle	pSport 1	LP014
HCCM	Pancreatic Langerhans	pSport 1	LP014
HWGA	Larynx carcinoma	pSport 1	LP014
HWGM HWGN	Larynx carcinoma	pSport 1	LP014
HWLA HWLB HWLC	Normal colon	pSport 1	LP014
HWLM HWLN	Colon Tumor	pSport 1	LP014
HVAM HVAN HVAO	Pancreas Tumor	pSport 1	LP014
HWGQ	Larynx carcinoma	pSport 1	LP014
HAQM HAQN	Salivary Gland	pSport 1	LP014
HASM	Stomach; normal	pSport 1	LP014
HBCM	Uterus; normal	pSport 1	LP014
HCDM	Testis; normal	pSport 1	LP014
HDJM	Brain; normal	pSport 1	LP014
HEFM	Adrenal Gland, normal	pSport 1	LP014
HBAA	Rectum normal	pSport 1	LP014
HFDH	Rectum tumour	pSport 1	LP014
HGAM	Colon, normal	pSport 1	LP014
HHMM	Colon, tumour	pSport 1	LP014
HCLB HCLC	Human Lung Cancer	Lambda Zap II	LP015
HRLA	LI Cell line	ZAP Express	LP015

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
HHAM	Hypothalamus. Alzheimer's	pCMVSPORT 3.0	LP015
HKBA	Ku 812F Basophils Line	pSport 1	LP015
HS2S	Saos2. Dexamethosone Treated	pSport 1	LP016
HA5A	Lung Carcinoma A549 TNFalpha activated	pSport 1	LP016
HTFM	TF-1 Cell Line GM-CSF Treated	pSport 1	LP016
HYAS	Thyroid Tumour	pSport 1	LP016
HUTS	Larynx Normal	pSport 1	LP016
HXOA	Larynx Tumor	pSport 1	LP016
HEAH	Ea.hy.926 cell line	pSport 1	LP016
HINA	Adenocarcinoma Human	pSport 1	LP016
HRMA	Lung Mesothelium	pSport 1	LP016
HLCL	Human Pre-Differentiated Adipocytes	Uni-Zap XR	LP017
HS2A	Saos2 Cells	pSport 1	LP020
HS2I	Saos2 Cells; Vitamin D3 Treated	pSport 1	LP020
HUCM	CHME Cell Line, untreated	pSport 1	LP020
HEPN	Aryepiglottis Normal	pSport 1	LP020
HPSN	Sinus Piniiformis Tumour	pSport 1	LP020
HNSA	Stomach Normal	pSport 1	LP020
HNSM	Stomach Tumour	pSport 1	LP020
HNLA	Liver Normal Met5No	pSport 1	LP020
HUTA	Liver Tumour Met 5 Tu	pSport 1	LP020
HOCN	Colon Normal	pSport 1	LP020
HOCT	Colon Tumor	pSport 1	LP020
HTNT	Tongue Tumour	pSport 1	LP020
HLXN	Larynx Normal	pSport 1	LP020
HLXT	Larynx Tumour	pSport 1	LP020
HTYN	Thymus	pSport 1	LP020
HPLN	Placenta	pSport 1	LP020
HTNG	Tongue Normal	pSport 1	LP020
HZAA	Thyroid Normal (SDCA2 No)	pSport 1	LP020
HWES	Thyroid Thyroiditis	pSport 1	LP020
HFHD	Ficoll Human Stromal Cells, 5Fu treated	pTriplEx2	LP021
HFHM,HFHN	Ficoll Human Stromal Cells, Untreated	pTriplEx2	LP021
HPCI	Hep G2 Cells, lambda library	lambda Zap-CMV XR	LP021
HBCA,HBCB,HBCC	H. Lymph node breast Cancer	Uni-ZAP XR	LP021
HCOK	Chondrocytes	pSPORT1	LP022
HDCA, HDCB, HDCC	Dendritic Cells From CD34 Cells	pSPORT1	LP022
HDMA, HDMB	CD40 activated monocyte dendritic cells	pSPORT1	LP022
HDDM, HDDN, HDDO	LPS activated derived dendritic cells	pSPORT1	LP022
HPCR	Hep G2 Cells, PCR library	lambda Zap-CMV XR	LP022
HAAA, HAAB, HAAC	Lung, Cancer (4005313A3): Invasive Poorly Differentiated Lung Adenocarcinoma	pSPORT1	LP022
HIPA, HIPB, HIPC	Lung, Cancer (4005163 B7): Invasive, Poorly Diff. Adenocarcinoma, Metastatic	pSPORT1	LP022
HOOH, HOOI	Ovary, Cancer: (4004562 B6) Papillary Serous Cystic Neoplasm, Low	pSPORT1	LP022

Libraries owned by Catalog	Catalog Description	Vector	ATCC Deposit
	Malignant Pot		
HIDA	Lung, Normal: (4005313 B1)	pSPORT1	LP022
HUJA.HUJB.HUJC.HUJD.HUJE	B-Cells	pCMVSPORT 3.0	LP022
HNOA.HNOB.HNOC.HNOD	Ovary, Normal: (9805C040R)	pSPORT1	LP022
HNLM	Lung, Normal: (4005313 B1)	pSPORT1	LP022
HSCL	Stromal Cells	pSPORT1	LP022
HAAX	Lung, Cancer: (4005313 A3) Invasive Poorly-differentiated Metastatic lung adenocarcinoma	pSPORT1	LP022
HUUA.HUUB.HUUC.HUUD	B-cells (unstimulated)	pTriplEx2	LP022
HWWA.HWWB.HWWC.HWWD,HWE,HWWF.HWWG	B-cells (stimulated)	pSPORT1	LP022
HCCC	Colon, Cancer: (9808C064R)	pCMVSPORT 3.0	LP023
HPDO HPDP HPDQ HPDR HPD	Ovary, Cancer (9809C332): Poorly differentiated adenocarcinoma	pSport 1	LP023
HPCO HPCP HPCQ HPCT	Ovary, Cancer (15395A1F): Grade II Papillary Carcinoma	pSport 1	LP023
HOCM HOCO HOCQ HOCQ	Ovary, Cancer: (15799A1F) Poorly differentiated carcinoma	pSport 1	LP023
HCBM HCBN HCBO	Breast, Cancer: (4004943 A5)	pSport 1	LP023
HNBT HNBU HNBV	Breast, Normal: (4005522B2)	pSport 1	LP023
HBCP HBCQ	Breast, Cancer: (4005522 A2)	pSport 1	LP023
HBCJ	Breast, Cancer: (9806C012R)	pSport 1	LP023
HSAM HSAN	Stromal cells 3.88	pSport 1	LP023
HVCA HVCB HVCC HVCD	Ovary, Cancer: (4004332 A2)	pSport 1	LP023
HSCK HSEN HSEO	Stromal cells (HBM3.18)	pSport 1	LP023
HSCP HSCQ	stromal cell clone 2.5	pSport 1	LP023
HUXA	Breast Cancer: (4005385 A2)	pSport 1	LP023
HCOM HCON HCOO HCOP HCOQ	Ovary, Cancer (4004650 A3): Well-Differentiated Micropapillary Serous Carcinoma	pSport 1	LP023
HBNM	Breast, Cancer: (9802C020E)	pSport 1	LP023
HVVA HVVB HVVC HVVD HVVE	Human Bone Marrow, treated	pSport 1	LP023

Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 5. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to the nucleotide sequence of SEQ ID NO:X.

5 Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with ^{32}P - γ -ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring, NY (1982).) The plasmid
10 mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate. These plates are screened using
15 Nylon membranes according to routine methods for bacterial colony screening (e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

 Alternatively, two primers of 17-20 nucleotides derived from both ends of the
20 nucleotide sequence of SEQ ID NO:X are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template. The polymerase chain reaction is carried out under routine conditions, for instance, in 25 μl of reaction mixture with 0.5 μg of the above cDNA template. A convenient reaction mixture is 1.5-5 mM MgCl_2 , 0.01% (w/v) gelatin, 20 μM each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of
25 Taq polymerase. Thirty five cycles of PCR (denaturation at 94°C for 1 min; annealing at 55°C for 1 min; elongation at 72°C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA
30 product.

 Several methods are available for the identification of the 5' or 3' non-coding portions of a gene which may not be present in the deposited clone. These methods include but are not

limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5' and 3' "RACE" protocols which are well known in the art. For instance, a method similar to 5' RACE is available for generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et al., Nucleic Acids Res. 21(7):1683-1684 (1993).)

5 Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full
10 length gene.

This above method starts with total RNA isolated from the desired source, although poly-A+ RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the
15 RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

This modified RNA preparation is used as a template for first strand cDNA synthesis
20 using a gene specific oligonucleotide. The first strand synthesis reaction is used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

25

Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide

A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the sequence corresponding to SEQ ID NO:X, according to the method
30 described in Example 1. (See also, Sambrook.)

Example 3: Tissue specific expression analysis

The Human Genome Sciences, Inc. (HGS) database is derived from sequencing tissue specific cDNA libraries. Libraries generated from a particular tissue are selected and the specific tissue expression pattern of EST groups or assembled contigs within these libraries is determined by comparison of the expression patterns of those groups or contigs within the entire database. ESTs which show tissue specific expression are selected.

The original clone from which the specific EST sequence was generated, is obtained from the catalogued library of clones and the insert amplified by PCR using methods known in the art. The PCR product is denatured then transferred in 96 well format to a nylon membrane (Schleicher and Scheull) generating an array filter of tissue specific clones. Housekeeping genes, maize genes, and known tissue specific genes are included on the filters. These targets can be used in signal normalization and to validate assay sensitivity. Additional targets are included to monitor probe length and specificity of hybridization.

Radioactively labeled hybridization probes are generated by first strand cDNA synthesis per the manufacturer's instructions (Life Technologies) from mRNA/RNA samples prepared from the specific tissue being analyzed. The hybridization probes are purified by gel exclusion chromatography, quantitated, and hybridized with the array filters in hybridization bottles at 65°C overnight. The filters are washed under stringent conditions and signals are captured using a Fuji phosphorimager.

Data is extracted using AIS software and following background subtraction, signal normalization is performed. This includes a normalization of filter-wide expression levels between different experimental runs. Genes that are differentially expressed in the tissue of interest are identified and the full length sequence of these clones is generated.

Example 4: Chromosomal Mapping of the Polynucleotides

An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions : 30 seconds, 95°C; 1 minute, 56°C; 1 minute, 70°C. This cycle is repeated 32 times followed by one 5 minute

cycle at 70°C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on either 8% polyacrylamide gels or 3.5 % agarose gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR
5 fragment in the particular somatic cell hybrid.

Example 5: Bacterial Expression of a Polypeptide

A polynucleotide encoding a polypeptide of the present invention is amplified using
10 PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial
15 expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp^r), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.

The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is
20 ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance (Kan^r). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is
25 isolated and confirmed by restriction analysis.

Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D.⁶⁰⁰) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto
30 pyranoside) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4°C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*).

Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4°C or frozen at -80°C.

In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements operatively linked to a polynucleotide of the present invention, called pHE4a. (ATCC Accession Number 209645, deposited on February 25, 1998.) This vector contains: 1) a neomycinphosphotransferase gene as a selection marker, 2) an E. coli origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (*lacIq*). The origin of replication (*oriC*) is derived from pUC19 (LTI, Gaithersburg, MD). The promoter sequence and operator sequences are made synthetically.

DNA can be inserted into the pHEa by restricting the vector with NdeI and XbaI, BamHI, XhoI, or Asp718, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR primers having restriction

sites for NdeI (5' primer) and XbaI, BamHI, XhoI, or Asp718 (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

The engineered vector could easily be substituted in the above protocol to express
5 protein in a bacterial system.

Example 6: Purification of a Polypeptide from an Inclusion Body

The following alternative method can be used to purify a polypeptide expressed in *E*
10 *coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10°C.

Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10°C and the cells harvested by continuous centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell
15 paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then
20 mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is
25 discarded and the polypeptide containing supernatant is incubated at 4°C overnight to allow further GuHCl extraction.

Following high speed centrifugation (30,000 xg) to remove insoluble particles, the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous
30 stirring. The refolded diluted protein solution is kept at 4°C without mixing for 12 hours prior to further purification steps.

To clarify the refolded polypeptide solution, a previously prepared tangential filtration unit equipped with 0.16 μm membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant A_{280} monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

The resultant polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from Commassie blue stained 16% SDS-PAGE gel when 5 μg of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

Example 7: Cloning and Expression of a Polypeptide in a Baculovirus Expression System

In this example, the plasmid shuttle vector pA2 is used to insert a polynucleotide into a baculovirus to express a polypeptide. This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from *E. coli* under

control of a weak *Drosophila* promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

5 Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., *Virology* 170:31-39 (1989).

10 Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon, is amplified using the PCR protocol described in Example 1. If a naturally occurring signal sequence is used to produce the polypeptide of the present invention, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard
15 methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with
20 appropriate restriction enzymes and again purified on a 1% agarose gel.

The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("GeneClean" BIO 101 Inc., La Jolla, Ca.).

25 The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the
30 cloned fragment is confirmed by DNA sequencing.

Five μ g of a plasmid containing the polynucleotide is co-transfected with 1.0 μ g of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA",

Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., *Proc. Natl. Acad. Sci. USA* 84:7413-7417 (1987). One μg of BaculoGold™ virus DNA and 5 μg of the plasmid are mixed in a sterile well of a microtiter plate containing 50 μl of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 μl Lipofectin plus 90 μl Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at 27° C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27° C for four days.

After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 μl of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4° C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5 μCi of ^{35}S -methionine and 5 μCi ^{35}S -cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the produced protein.

Example 8: Expression of a Polypeptide in Mammalian Cells

The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLVI, HIVI and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSPORT 2.0, and pCMVSPORT 3.0. Mammalian host cells that could be used include, human Hela, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as DHFR, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

The transfected gene can also be amplified to express large amounts of the encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., Biotechnology 9:64-68 (1991).) Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279 (1991); Bebbington et al., Bio/Technology 10:169-175 (1992). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used

for the production of proteins.

Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No. 209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart et al., Cell 41:521-530 (1985).) Multiple cloning sites, e.g., with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

Specifically, the plasmid pC6, for example, is digested with appropriate restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1. If a naturally occurring signal sequence is used to produce the polypeptide of the present invention, the vector does not need a second signal peptide. Alternatively, if a naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five μ g of the expression plasmid pC6 or pC4 is cotransfected with 0.5 μ g of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-neo contains a dominant selectable marker, the *neo* gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10,

25, or 50 ng/ml of methotrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well
5 plates containing even higher concentrations of methotrexate (1 μ M, 2 μ M, 5 μ M, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200 μ M. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

10 *Example 9: Protein Fusions*

The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding
15 protein facilitates purification. (See Example 5; see also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the halflife time in vivo. Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion
20 proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

25 Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be
30 ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the

vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

If the naturally occurring signal sequence is used to produce the polypeptide of the present invention, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

Human IgG Fc region:

10 GGGATCCGGAGCCCAAATCTTCTGACAAAACCTCACACATGCCACCGTGCCCAG
CACCTGAATTCGAGGGTGCACCGTCAGTCTTCCTCTTCCCCCAAAACCCAAGGA
CACCTCATGATCTCCCGGACTCCTGAGGTCACATGCGTGGTGGTGGACGTAAGC
CACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCAT
AATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTC
15 AGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGC
AAGGTCTCCAACAAAGCCCTCCCAACCCCCATCGAGAAAACCATCTCCAAGCC
AAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAG
CTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCAAGC
GACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGAC
20 CACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACC
GTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCAT
GAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAAT
GAGTGCGACGGCCGCGACTCTAGAGGAT (SEQ ID NO:837)

25 *Example 10: Production of an Antibody from a Polypeptide*

a) Hybridoma Technology

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells expressing
30 polypeptide of the present invention are administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of polypeptide

of the present invention is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

Monoclonal antibodies specific for polypeptide of the present invention are prepared
5 using hybridoma technology. (Kohler et al., *Nature* 256:495 (1975); Kohler et al., *Eur. J. Immunol.* 6:511 (1976); Kohler et al., *Eur. J. Immunol.* 6:292 (1976); Hammerling et al., in: *Monoclonal Antibodies and T-Cell Hybridomas*, Elsevier, N.Y., pp. 563-681 (1981)). In general, an animal (preferably a mouse) is immunized with polypeptide of the present invention or, more preferably, with a secreted polypeptide of the present invention-
10 expressing cell. Such polypeptide-expressing cells are cultured in any suitable tissue culture medium, preferably in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell
15 line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (*Gastroenterology* 80:225-232 (1981)). The hybridoma cells obtained through such a
20 selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide of the present invention.

Alternatively, additional antibodies capable of binding to polypeptide of the present invention can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is
25 possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the polypeptide of the present invention-specific antibody can be blocked by polypeptide of the
30 present invention. Such antibodies comprise anti-idiotypic antibodies to the polypeptide of the present invention-specific antibody and are used to immunize an animal to induce formation of further polypeptide of the present invention-specific antibodies.

For in vivo use of antibodies in humans, an antibody is "humanized". Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric and humanized antibodies are known in the art and are discussed herein. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

b) Isolation Of Antibody Fragments Directed Against Polypeptide of the Present Invention From A Library Of scFvs

Naturally occurring V-genes isolated from human PBLs are constructed into a library of antibody fragments which contain reactivities against polypeptide of the present invention to which the donor may or may not have been exposed (see e.g., U.S. Patent 5,885,793 incorporated herein by reference in its entirety).

Rescue of the Library. A library of scFvs is constructed from the RNA of human PBLs as described in PCT publication WO 92/01047. To rescue phage displaying antibody fragments, approximately 10⁹ E. coli harboring the phagemid are used to inoculate 50 ml of 2xTY containing 1% glucose and 100 µg/ml of ampicillin (2xTY-AMP-GLU) and grown to an O.D. of 0.8 with shaking. Five ml of this culture is used to inoculate 50 ml of 2xTY-AMP-GLU, 2 x 10⁸ TU of delta gene 3 helper (M13 delta gene III, see PCT publication WO 92/01047) are added and the culture incubated at 37°C for 45 minutes without shaking and then at 37°C for 45 minutes with shaking. The culture is centrifuged at 4000 r.p.m. for 10 min. and the pellet resuspended in 2 liters of 2xTY containing 100 µg/ml ampicillin and 50 µg/ml kanamycin and grown overnight. Phage are prepared as described in PCT publication WO 92/01047.

M13 delta gene III is prepared as follows: M13 delta gene III helper phage does not encode gene III protein, hence the phage(mid) displaying antibody fragments have a greater avidity of binding to antigen. Infectious M13 delta gene III particles are made by growing the helper phage in cells harboring a pUC19 derivative supplying the wild type gene III protein during phage morphogenesis. The culture is incubated for 1 hour at 37° C without shaking and then for a further hour at 37°C with shaking. Cells are spun down (IEC-Centra

8,400 r.p.m. for 10 min), resuspended in 300 ml 2xTY broth containing 100 µg ampicillin/ml and 25 µg kanamycin/ml (2xTY-AMP-KAN) and grown overnight, shaking at 37°C. Phage particles are purified and concentrated from the culture medium by two PEG-precipitations (Sambrook et al., 1990), resuspended in 2 ml PBS and passed through a 0.45 µm filter (Minisart NML; Sartorius) to give a final concentration of approximately 10¹³ transducing units/ml (ampicillin-resistant clones).

Panning of the Library. Immunotubes (Nunc) are coated overnight in PBS with 4 ml of either 100 µg/ml or 10 µg/ml of a polypeptide of the present invention. Tubes are blocked with 2% Marvel-PBS for 2 hours at 37°C and then washed 3 times in PBS. Approximately 10¹³ TU of phage is applied to the tube and incubated for 30 minutes at room temperature tumbling on an over and under turntable and then left to stand for another 1.5 hours. Tubes are washed 10 times with PBS 0.1% Tween-20 and 10 times with PBS. Phage are eluted by adding 1 ml of 100 mM triethylamine and rotating 15 minutes on an under and over turntable after which the solution is immediately neutralized with 0.5 ml of 1.0M Tris-HCl, pH 7.4. Phage are then used to infect 10 ml of mid-log E. coli TG1 by incubating eluted phage with bacteria for 30 minutes at 37°C. The E. coli are then plated on TYE plates containing 1% glucose and 100 µg/ml ampicillin. The resulting bacterial library is then rescued with delta gene 3 helper phage as described above to prepare phage for a subsequent round of selection. This process is then repeated for a total of 4 rounds of affinity purification with tube-washing increased to 20 times with PBS, 0.1% Tween-20 and 20 times with PBS for rounds 3 and 4.

Characterization of Binders. Eluted phage from the 3rd and 4th rounds of selection are used to infect E. coli HB 2151 and soluble scFv is produced (Marks, et al., 1991) from single colonies for assay. ELISAs are performed with microtitre plates coated with either 10 pg/ml of the polypeptide of the present invention in 50 mM bicarbonate pH 9.6. Clones positive in ELISA are further characterized by PCR fingerprinting (see, e.g., PCT publication WO 92/01047) and then by sequencing. These ELISA positive clones may also be further characterized by techniques known in the art, such as, for example, epitope mapping, binding affinity, receptor signal transduction, ability to block or competitively inhibit antibody/antigen binding, and competitive agonistic or antagonistic activity.

Example 11: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide

RNA isolated from entire families or individual patients presenting with a phenotype
5 of interest (such as a disease) is be isolated. cDNA is then generated from these RNA
samples using protocols known in the art. (See, Sambrook.) The cDNA is then used as a
template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X;
and/or the nucleotide sequence of the related cDNA in the cDNA clone contained in a
deposited library. Suggested PCR conditions consist of 35 cycles at 95 degrees C for 30
10 seconds; 60-120 seconds at 52-58 degrees C; and 60-120 seconds at 70 degrees C, using
buffer solutions described in Sidransky et al., Science 252:706 (1991).

PCR products are then sequenced using primers labeled at their 5' end with T4
polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The
intron-exon borders of selected exons is also determined and genomic PCR products
15 analyzed to confirm the results. PCR products harboring suspected mutations is then cloned
and sequenced to validate the results of the direct sequencing.

PCR products is cloned into T-tailed vectors as described in Holton et al., Nucleic
Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United States
Biochemical). Affected individuals are identified by mutations not present in unaffected
20 individuals.

Genomic rearrangements are also observed as a method of determining alterations in
a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2
are nick-translated with digoxigenindeoxy-uridine 5'-triphosphate (Boehringer Mannheim),
and FISH performed as described in Johnson et al., Methods Cell Biol. 35:73-99 (1991).
25 Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA
for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium
iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are
obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination
30 with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable
excitation wavelength filters. (Johnson et al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image

collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

Example 12: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample

A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in Example 10. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbounded polypeptide.

Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbounded conjugate.

Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale). Interpolate the concentration of the polypeptide in the sample using the standard curve.

Example 13: Formulation

The invention also provides methods of treatment and/or prevention of diseases or disorders (such as, for example, any one or more of the diseases or disorders disclosed
5 herein) by administration to a subject of an effective amount of a Therapeutic. By therapeutic is meant a polynucleotides or polypeptides of the invention (including fragments and variants), agonists or antagonists thereof, and/or antibodies thereto, in combination with a pharmaceutically acceptable carrier type (e.g., a sterile carrier).

The Therapeutic will be formulated and dosed in a fashion consistent with good
10 medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the Therapeutic alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of the
15 Therapeutic administered parenterally per dose will be in the range of about 1 μ g/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given
20 continuously, the Therapeutic is typically administered at a dose rate of about 1 μ g/kg/hour to about 50 μ g/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

25 Therapeutics can be administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any. The term "parenteral" as used herein refers to modes of
30 administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics are administered orally, rectally, parenterally, intracistemally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray.

5 "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-release
10 systems. Suitable examples of sustained-release Therapeutics include suitable polymeric materials (such as, for example, semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules), suitable hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, and sparingly soluble derivatives (such as, for example, a sparingly soluble salt).

15 Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman et al., *Biopolymers* 22:547-556 (1983)), poly (2- hydroxyethyl methacrylate) (Langer et al., *J. Biomed. Mater. Res.* 15:167-277 (1981), and Langer, *Chem. Tech.* 12:98-105 (1982)), ethylene vinyl acetate (Langer et al., *Id.*) or poly-D- (-)-3-hydroxybutyric acid (EP 133,988).

20 Sustained-release Therapeutics also include liposomally entrapped Therapeutics of the invention (*see* generally, Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 317 -327 and 353-365 (1989)). Liposomes containing the Therapeutic are prepared by methods known per se: DE 3,218,121; Epstein et al., *Proc. Natl. Acad. Sci. (USA)* 82:3688-3692 (1985); Hwang et al., *Proc. Natl. Acad. Sci.(USA)* 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being
25 adjusted for the optimal Therapeutic.
30

In yet an additional embodiment, the Therapeutics of the invention are delivered by way of a pump (*see* Langer, *supra*; Sefton, *CRC Crit. Ref. Biomed. Eng.* 14:201 (1987);

Buchwald et al., Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med. 321:574 (1989)).

Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

For parenteral administration, in one embodiment, the Therapeutic is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to the Therapeutic.

Generally, the formulations are prepared by contacting the Therapeutic uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The Therapeutic is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

Any pharmaceutical used for therapeutic administration can be sterile. Sterility is

readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutics generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

5 Therapeutics ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous Therapeutic solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized Therapeutic
10 using bacteriostatic Water-for-Injection.

 The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the Therapeutics of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products,
15 which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the Therapeutics may be employed in conjunction with other therapeutic compounds.

 The Therapeutics of the invention may be administered alone or in combination with adjuvants. Adjuvants that may be administered with the Therapeutics of the invention
20 include, but are not limited to, alum, alum plus deoxycholate (ImmunoAg), MTP-PE (Biocine Corp.), QS21 (Genentech, Inc.), BCG, and MPL. In a specific embodiment, Therapeutics of the invention are administered in combination with alum. In another specific embodiment, Therapeutics of the invention are administered in combination with QS-21. Further adjuvants that may be administered with the Therapeutics of the invention include,
25 but are not limited to, Monophosphoryl lipid immunomodulator, AdjuVax 100a, QS-21, QS-18, CRL1005, Aluminum salts, MF-59, and Virosomal adjuvant technology. Vaccines that may be administered with the Therapeutics of the invention include, but are not limited to, vaccines directed toward protection against MMR (measles, mumps, rubella), polio, varicella, tetanus/diphtheria, hepatitis A, hepatitis B, haemophilus influenzae B, whooping
30 cough, pneumonia, influenza, Lyme's Disease, rotavirus, cholera, yellow fever, Japanese encephalitis, poliomyelitis, rabies, typhoid fever, and pertussis. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or

concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate
5 administration of one of the compounds or agents given first, followed by the second.

The Therapeutics of the invention may be administered alone or in combination with other therapeutic agents. Therapeutic agents that may be administered in combination with the Therapeutics of the invention, include but not limited to, other members of the TNF family, chemotherapeutic agents, antibiotics, steroidal and non-steroidal anti-inflammatories,
10 conventional immunotherapeutic agents, cytokines and/or growth factors. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous
15 lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

In one embodiment, the Therapeutics of the invention are administered in combination with members of the TNF family. TNF, TNF-related or TNF-like molecules that may be administered with the Therapeutics of the invention include, but are not limited to, soluble forms of TNF-alpha, lymphotoxin-alpha (LT-alpha, also known as TNF-beta), LT-beta (found in complex heterotrimer LT-alpha2-beta), OPGL, FasL, CD27L, CD30L, CD40L, 4-1BBL, DcR3, OX40L, TNF-gamma (International Publication No. WO 96/14328), AIM-I (International Publication No. WO 97/33899), endokine-alpha (International Publication No. WO 98/07880), TR6 (International Publication No. WO
20 98/30694), OPG, and neutrokin-alpha (International Publication No. WO 98/18921, OX40, and nerve growth factor (NGF), and soluble forms of Fas, CD30, CD27, CD40 and 4-1BB, TR2 (International Publication No. WO 96/34095), DR3 (International Publication No. WO 97/33904), DR4 (International Publication No. WO 98/32856), TR5 (International Publication No. WO 98/30693), TR6 (International Publication No. WO 98/30694), TR7
25 (International Publication No. WO 98/41629), TRANK, TR9 (International Publication No. WO 98/56892), TR10 (International Publication No. WO 98/54202), 312C2 (International Publication No. WO 98/06842), and TR12, and soluble forms CD154, CD70, and CD153.

In certain embodiments, Therapeutics of the invention are administered in combination with antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors. Nucleoside reverse transcriptase inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, RETROVIR™ (zidovudine/AZT), VIDEX™ (didanosine/ddI), HIVID™ (zalcitabine/ddC), ZERIT™ (stavudine/d4T), EPIVIR™ (lamivudine/3TC), and COMBIVIR™ (zidovudine/lamivudine). Non-nucleoside reverse transcriptase inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, VIRAMUNE™ (nevirapine), RESCRIPTOR™ (delavirdine), and SUSTIVA™ (efavirenz). Protease inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, CRIXIVAN™ (indinavir), NORVIR™ (ritonavir), INVIRASE™ (saquinavir), and VIRACEPT™ (nelfinavir). In a specific embodiment, antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors may be used in any combination with Therapeutics of the invention to treat AIDS and/or to prevent or treat HIV infection.

In other embodiments, Therapeutics of the invention may be administered in combination with anti-opportunistic infection agents. Anti-opportunistic agents that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, ATOVAQUONE™, ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, ETHAMBUTOL™, RIFABUTIN™, CLARITHROMYCIN™, AZITHROMYCIN™, GANCICLOVIR™, FOSCARNET™, CIDOFOVIR™, FLUCONAZOLE™, ITRACONAZOLE™, KETOCONAZOLE™, ACYCLOVIR™, FAMCICOLVIR™, PYRIMETHAMINE™, LEUCOVORIN™, NEUPOGEN™ (filgrastim/G-CSF), and LEUKINE™ (sargramostim/GM-CSF). In a specific embodiment, Therapeutics of the invention are used in any combination with TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, and/or ATOVAQUONE™ to prophylactically treat or prevent an opportunistic *Pneumocystis carinii* pneumonia infection. In another specific embodiment, Therapeutics of the invention are used in any combination with ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, and/or ETHAMBUTOL™ to prophylactically treat or

prevent an opportunistic *Mycobacterium avium* complex infection. In another specific embodiment, Therapeutics of the invention are used in any combination with RIFABUTIN™, CLARITHROMYCIN™, and/or AZITHROMYCIN™ to prophylactically treat or prevent an opportunistic *Mycobacterium tuberculosis* infection. In another specific embodiment,

5 Therapeutics of the invention are used in any combination with GANCICLOVIR™, FOSCARNET™, and/or CIDOFOVIR™ to prophylactically treat or prevent an opportunistic cytomegalovirus infection. In another specific embodiment, Therapeutics of the invention are used in any combination with FLUCONAZOLE™, ITRACONAZOLE™, and/or KETOCONAZOLE™ to prophylactically treat or prevent an opportunistic fungal infection.

10 In another specific embodiment, Therapeutics of the invention are used in any combination with ACYCLOVIR™ and/or FAMCICOLVIR™ to prophylactically treat or prevent an opportunistic herpes simplex virus type I and/or type II infection. In another specific embodiment, Therapeutics of the invention are used in any combination with PYRIMETHAMINE™ and/or LEUCOVORIN™ to prophylactically treat or prevent an

15 opportunistic *Toxoplasma gondii* infection. In another specific embodiment, Therapeutics of the invention are used in any combination with LEUCOVORIN™ and/or NEUPOGEN™ to prophylactically treat or prevent an opportunistic bacterial infection.

In a further embodiment, the Therapeutics of the invention are administered in combination with an antiviral agent. Antiviral agents that may be administered with the

20 Therapeutics of the invention include, but are not limited to, acyclovir, ribavirin, amantadine, and remantidine.

In a further embodiment, the Therapeutics of the invention are administered in combination with an antibiotic agent. Antibiotic agents that may be administered with the Therapeutics of the invention include, but are not limited to, amoxicillin, beta-lactamases,

25 aminoglycosides, beta-lactam (glycopeptide), beta-lactamases, Clindamycin, chloramphenicol, cephalosporins, ciprofloxacin, ciprofloxacin, erythromycin, fluoroquinolones, macrolides, metronidazole, penicillins, quinolones, rifampin, streptomycin, sulfonamide, tetracyclines, trimethoprim, trimethoprim-sulfamthoxazole, and vancomycin.

Conventional nonspecific immunosuppressive agents, that may be administered in

30 combination with the Therapeutics of the invention include, but are not limited to, steroids, cyclosporine, cyclosporine analogs, cyclophosphamide methylprednisone, prednisone,

azathioprine, FK-506, 15-deoxyspergualin, and other immunosuppressive agents that act by suppressing the function of responding T cells.

In specific embodiments, Therapeutics of the invention are administered in combination with immunosuppressants. Immunosuppressants preparations that may be administered with the Therapeutics of the invention include, but are not limited to, ORTHOCLONE™ (OKT3), SANDIMMUNE™/NEORAL™/SANGDYA™ (cyclosporin), PROGRAF™ (tacrolimus), CELLCEPT™ (mycophenolate), Azathioprine, glucocorticosteroids, and RAPAMUNE™ (sirolimus). In a specific embodiment, immunosuppressants may be used to prevent rejection of organ or bone marrow transplantation.

In an additional embodiment, Therapeutics of the invention are administered alone or in combination with one or more intravenous immune globulin preparations. Intravenous immune globulin preparations that may be administered with the Therapeutics of the invention include, but not limited to, GAMMAR™, IVEEGAM™, SANDOGLOBULIN™, GAMMAGARD S/D™, and GAMIMUNE™. In a specific embodiment, Therapeutics of the invention are administered in combination with intravenous immune globulin preparations in transplantation therapy (e.g., bone marrow transplant).

In an additional embodiment, the Therapeutics of the invention are administered alone or in combination with an anti-inflammatory agent. Anti-inflammatory agents that may be administered with the Therapeutics of the invention include, but are not limited to, glucocorticoids and the nonsteroidal anti-inflammatories, aminoarylcarboxylic acid derivatives, arylacetic acid derivatives, arylbutyric acid derivatives, arylcarboxylic acids, arylpropionic acid derivatives, pyrazoles, pyrazolones, salicylic acid derivatives, thiazinecarboxamides, e-acetamidocaproic acid, S-adenosylmethionine, 3-amino-4-hydroxybutyric acid, amixetrine, bendazac, benzydamine, bucolome, difenpiramide, ditazol, emorfazone, guaiazulene, nabumetone, nimesulide, orgotein, oxaceprol, paranyline, perisoxal, pifoxime, proquazone, proxazole, and tenidap.

In another embodiment, compositions of the invention are administered in combination with a chemotherapeutic agent. Chemotherapeutic agents that may be administered with the Therapeutics of the invention include, but are not limited to, antibiotic derivatives (e.g., doxorubicin, bleomycin, daunorubicin, and dactinomycin); antiestrogens (e.g., tamoxifen); antimetabolites (e.g., fluorouracil, 5-FU, methotrexate, floxuridine, interferon alpha-2b, glutamic acid, plicamycin, mercaptopurine, and 6-thioguanine);

cytotoxic agents (e.g., carmustine, BCNU, lomustine, CCNU, cytosine arabinoside, cyclophosphamide, estramustine, hydroxyurea, procarbazine, mitomycin, busulfan, cis-platin, and vincristine sulfate); hormones (e.g., medroxyprogesterone, estramustine phosphate sodium, ethinyl estradiol, estradiol, megestrol acetate, methyltestosterone, diethylstilbestrol
5 diphosphate, chlorotrianisene, and testolactone); nitrogen mustard derivatives (e.g., mephallen, chorambucil, mechlorethamine (nitrogen mustard) and thiotepa); steroids and combinations (e.g., bethamethasone sodium phosphate); and others (e.g., dicarbazine, asparaginase, mitotane, vincristine sulfate, vinblastine sulfate, and etoposide).

In a specific embodiment, Therapeutics of the invention are administered in
10 combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or any combination of the components of CHOP. In another embodiment, Therapeutics of the invention are administered in combination with Rituximab. In a further embodiment, Therapeutics of the invention are administered with Rituxmab and CHOP, or Rituxmab and any combination of the components of CHOP.

15 In an additional embodiment, the Therapeutics of the invention are administered in combination with cytokines. Cytokines that may be administered with the Therapeutics of the invention include, but are not limited to, IL2, IL3, IL4, IL5, IL6, IL7, IL10, IL12, IL13, IL15, anti-CD40, CD40L, IFN-gamma and TNF-alpha. In another embodiment, Therapeutics of the invention may be administered with any interleukin, including, but not
20 limited to, IL-1alpha, IL-1beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, and IL-21.

In an additional embodiment, the Therapeutics of the invention are administered in combination with angiogenic proteins. Angiogenic proteins that may be administered with the Therapeutics of the invention include, but are not limited to, Glioma Derived Growth
25 Factor (GDGF), as disclosed in European Patent Number EP-399816; Platelet Derived Growth Factor-A (PDGF-A), as disclosed in European Patent Number EP-682110; Platelet Derived Growth Factor-B (PDGF-B), as disclosed in European Patent Number EP-282317; Placental Growth Factor (PIGF), as disclosed in International Publication Number WO 92/06194; Placental Growth Factor-2 (PIGF-2), as disclosed in Hauser et al., Growth Factors,
30 4:259-268 (1993); Vascular Endothelial Growth Factor (VEGF), as disclosed in International Publication Number WO 90/13649; Vascular Endothelial Growth Factor-A (VEGF-A), as disclosed in European Patent Number EP-506477; Vascular Endothelial Growth Factor-2

(VEGF-2), as disclosed in International Publication Number WO 96/39515; Vascular Endothelial Growth Factor B (VEGF-3); Vascular Endothelial Growth Factor B-186 (VEGF-B186), as disclosed in International Publication Number WO 96/26736; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/02543; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/07832; and Vascular Endothelial Growth Factor-E (VEGF-E), as disclosed in German Patent Number DE19639601. The above mentioned references are incorporated herein by reference herein.

In an additional embodiment, the Therapeutics of the invention are administered in combination with hematopoietic growth factors. Hematopoietic growth factors that may be administered with the Therapeutics of the invention include, but are not limited to, LEUKINE™ (SARGRAMOSTIM™) and NEUPOGEN™ (FILGRASTIM™).

In an additional embodiment, the Therapeutics of the invention are administered in combination with Fibroblast Growth Factors. Fibroblast Growth Factors that may be administered with the Therapeutics of the invention include, but are not limited to, FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-14, and FGF-15.

In additional embodiments, the Therapeutics of the invention are administered in combination with other therapeutic or prophylactic regimens, such as, for example, radiation therapy.

Example 14: Method of Treating Decreased Levels of the Polypeptide

The present invention relates to a method for treating an individual in need of an increased level of a polypeptide of the invention in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an agonist of the invention (including polypeptides of the invention). Moreover, it will be appreciated that conditions caused by a decrease in the standard or normal expression level of a polypeptide of the present invention in an individual can be treated by administering the agonist or antagonist of the present invention. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a Therapeutic comprising an amount of the agonist or

antagonist to increase the activity level of the polypeptide in such an individual.

For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the agonist or antagonist for six consecutive days. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 13.

5

Example 15: Method of Treating Increased Levels of the Polypeptide

The present invention also relates to a method of treating an individual in need of a decreased level of a polypeptide of the invention in the body comprising administering to
10 such an individual a composition comprising a therapeutically effective amount of an antagonist of the invention (including polypeptides and antibodies of the invention).

In one example, antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, due to a variety of etiologies, such as cancer.

15 For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided in Example 13.

20 *Example 16: Method of Treatment Using Gene Therapy-Ex Vivo*

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces.
25 Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated
30 at 37 degree C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer

is trypsinized and scaled into larger flasks.

pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on
5 agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1 using primers and having appropriate restriction sites and initiation/stop codons, if necessary. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a
10 HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the
15 gene of interest properly inserted.

The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now produce
20 infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer
25 cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his.
30 Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

The engineered fibroblasts are then transplanted onto the host, either alone or after

having been grown to confluence on cytodex 3 microcarrier beads.

Example 17: Gene Therapy Using Endogenous Genes Corresponding To Polynucleotides of the Invention

5

Another method of gene therapy according to the present invention involves operably associating the endogenous polynucleotide sequence of the invention with a promoter via homologous recombination as described, for example, in U.S. Patent NO: 5,641,670, issued June 24, 1997; International Publication NO: WO 96/29411, published September 26, 1996; 10 International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., *Proc. Natl. Acad. Sci. USA*, 86:8932-8935 (1989); and Zijlstra et al., *Nature*, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not expressed in the cells, or is expressed at a lower level than desired.

Polynucleotide constructs are made which contain a promoter and targeting 15 sequences, which are homologous to the 5' non-coding sequence of endogenous polynucleotide sequence, flanking the promoter. The targeting sequence will be sufficiently near the 5' end of the polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination. The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct 20 restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter.

The amplified promoter and the amplified targeting sequences are digested with the 25 appropriate restriction enzymes and subsequently treated with calf intestinal phosphatase. The digested promoter and digested targeting sequences are added together in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The construct is size fractionated on an agarose gel then purified by phenol extraction and ethanol precipitation.

30 In this Example, the polynucleotide constructs are administered as naked polynucleotides via electroporation. However, the polynucleotide constructs may also be administered with transfection-facilitating agents, such as liposomes, viral sequences, viral

particles, precipitating agents, etc. Such methods of delivery are known in the art.

Once the cells are transfected, homologous recombination will take place which results in the promoter being operably linked to the endogenous polynucleotide sequence. This results in the expression of polynucleotide corresponding to the polynucleotide in the cell. Expression may be detected by immunological staining, or any other method known in the art.

Fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in DMEM + 10% fetal calf serum. Exponentially growing or early stationary phase fibroblasts are trypsinized and rinsed from the plastic surface with nutrient medium. An aliquot of the cell suspension is removed for counting, and the remaining cells are subjected to centrifugation. The supernatant is aspirated and the pellet is resuspended in 5 ml of electroporation buffer (20 mM HEPES pH 7.3, 137 mM NaCl, 5 mM KCl, 0.7 mM Na₂HPO₄, 6 mM dextrose). The cells are recentrifuged, the supernatant aspirated, and the cells resuspended in electroporation buffer containing 1 mg/ml acetylated bovine serum albumin. The final cell suspension contains approximately 3×10^6 cells/ml. Electroporation should be performed immediately following resuspension.

Plasmid DNA is prepared according to standard techniques. For example, to construct a plasmid for targeting to the locus corresponding to the polynucleotide of the invention, plasmid pUC18 (MBI Fermentas, Amherst, NY) is digested with HindIII. The CMV promoter is amplified by PCR with an XbaI site on the 5' end and a BamHI site on the 3' end. Two non-coding sequences are amplified via PCR: one non-coding sequence (fragment 1) is amplified with a HindIII site at the 5' end and an Xba site at the 3' end; the other non-coding sequence (fragment 2) is amplified with a BamHI site at the 5' end and a HindIII site at the 3' end. The CMV promoter and the fragments (1 and 2) are digested with the appropriate enzymes (CMV promoter - XbaI and BamHI; fragment 1 - XbaI; fragment 2 - BamHI) and ligated together. The resulting ligation product is digested with HindIII, and ligated with the HindIII-digested pUC18 plasmid.

Plasmid DNA is added to a sterile cuvette with a 0.4 cm electrode gap (Bio-Rad). The final DNA concentration is generally at least 120 µg/ml. 0.5 ml of the cell suspension (containing approximately 1.5×10^6 cells) is then added to the cuvette, and the cell suspension and DNA solutions are gently mixed. Electroporation is performed with a Gene-Pulser apparatus (Bio-Rad). Capacitance and voltage are set at 960 µF and 250-300 V,

respectively. As voltage increases, cell survival decreases, but the percentage of surviving cells that stably incorporate the introduced DNA into their genome increases dramatically. Given these parameters, a pulse time of approximately 14-20 mSec should be observed.

Electroporated cells are maintained at room temperature for approximately 5 min, and
5 the contents of the cuvette are then gently removed with a sterile transfer pipette. The cells are added directly to 10 ml of prewarmed nutrient media (DMEM with 15% calf serum) in a 10 cm dish and incubated at 37 degree C. The following day, the media is aspirated and replaced with 10 ml of fresh media and incubated for a further 16-24 hours.

The engineered fibroblasts are then injected into the host, either alone or after having
10 been grown to confluence on cytodex 3 microcarrier beads. The fibroblasts now produce the protein product. The fibroblasts can then be introduced into a patient as described above.

Example 18: Method of Treatment Using Gene Therapy - In Vivo

15 Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide. The polynucleotide of the present invention may be operatively linked to a promoter or any other genetic elements necessary
20 for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, WO90/11092, WO98/11779; U.S. Patent NO. 5693622, 5705151, 5580859; Tabata et al., Cardiovasc. Res. 35(3):470-479 (1997); Chao et al., Pharmacol. Res. 35(6):517-522 (1997); Wolff, Neuromuscul. Disord. 7(5):314-318 (1997); Schwartz et al., Gene Ther. 3(5):405-411 (1996); Tsurumi et al.,
25 Circulation 94(12):3281-3290 (1996) (incorporated herein by reference).

The polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

30 The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell,

including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in Felgner P.L. et al. (1995) Ann. NY Acad. Sci. 772:126-139 and Abdallah B. et al. (1995) Biol. Cell 85(1):1-7) which can be prepared by methods well known to those skilled in the art.

The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 g/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will

appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The dose response effects of injected polynucleotide in muscle *in vivo* is determined as follows. Suitable template DNA for production of mRNA coding for polypeptide of the present invention is prepared in accordance with a standard recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on the anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 um cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A time course for protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of DNA in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice. The results of the above experimentation in mice can be use to extrapolate proper dosages and other treatment parameters in humans and other animals using naked DNA.

Example 19: Transgenic Animals

The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, *e.g.*, baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a specific embodiment, techniques described herein or otherwise known in the art, are used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

Any technique known in the art may be used to introduce the transgene (*i.e.*, polynucleotides of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (Paterson et al., Appl. Microbiol. Biotechnol. 40:691-698 (1994); Carver et al., Biotechnology (NY) 11:1263-1270 (1993); Wright et al., Biotechnology (NY) 9:830-834 (1991); and Hoppe et al., U.S. Pat. No. 4,873,191 (1989)); retrovirus mediated gene transfer into germ lines (Van der Putten et al., Proc. Natl. Acad. Sci., USA 82:6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic stem cells (Thompson et al., Cell 56:313-321 (1989)); electroporation of cells or embryos (Lo, 1983, Mol Cell. Biol. 3:1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (see, *e.g.*, Ulmer et al., Science 259:1745 (1993)); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-mediated gene transfer (Lavitrano et al., Cell 57:717-723 (1989); etc. For a review of such techniques, see Gordon, "Transgenic Animals," Intl. Rev. Cytol. 115:171-229 (1989), which is incorporated by reference herein in its entirety.

Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campell et al., Nature 380:64-66 (1996); Wilmut et al., Nature 385:810-813 (1997)).

The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but not all their cells, *i.e.*, mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, *e.g.*, head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko et al., Proc. Natl. Acad. Sci.

USA 89:6232-6236 (1992)). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type, by following, for example, the teaching of Gu et al. (Gu et al., Science 265:103-106 (1994)). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and reverse transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

5

Example 20: Knock-Out Animals

Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (*E.g.*, see Smithies et al., *Nature* 317:230-234 (1985); Thomas & Capecchi, *Cell* 51:503-512 (1987); Thompson et al., *Cell* 5:313-321 (1989); each of which is incorporated by reference herein in its entirety). For example, a mutant, non-functional polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention *in vivo*. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (*e.g.*, see Thomas & Capecchi 1987 and Thompson 1989, *supra*). However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (*e.g.*, knockouts) are administered to a patient *in vivo*. Such cells may be obtained from the patient (*i.e.*, animal, including human) or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (*e.g.*, lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered *in vitro* using recombinant DNA techniques to introduce the coding

sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, e.g., by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc. The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, e.g., in the circulation, or intraperitoneally.

Alternatively, the cells can be incorporated into a matrix and implanted in the body, e.g., genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson et al. U.S. Patent No. 5,399,349; and Mulligan & Wilson, U.S. Patent No. 5,460,959 each of which is incorporated by reference herein in its entirety).

When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

Transgenic and “knock-out” animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

Example 22: Assays Detecting Stimulation or Inhibition of B cell Proliferation and Differentiation

30

Generation of functional humoral immune responses requires both soluble and cognate signaling between B-lineage cells and their microenvironment. Signals may impart a

positive stimulus that allows a B-lineage cell to continue its programmed development, or a negative stimulus that instructs the cell to arrest its current developmental pathway. To date, numerous stimulatory and inhibitory signals have been found to influence B cell responsiveness including IL-2, IL-4, IL-5, IL-6, IL-7, IL10, IL-13, IL-14 and IL-15.

5 Interestingly, these signals are by themselves weak effectors but can, in combination with various co-stimulatory proteins, induce activation, proliferation, differentiation, homing, tolerance and death among B cell populations.

One of the best studied classes of B-cell co-stimulatory proteins is the TNF-superfamily. Within this family CD40, CD27, and CD30 along with their respective ligands CD154, CD70, and CD153 have been found to regulate a variety of immune responses. Assays which allow for the detection and/or observation of the proliferation and differentiation of these B-cell populations and their precursors are valuable tools in determining the effects various proteins may have on these B-cell populations in terms of proliferation and differentiation. Listed below are two assays designed to allow for the detection of the differentiation, proliferation, or inhibition of B-cell populations and their precursors.

In Vitro Assay- Agonists or antagonists of the invention can be assessed for its ability to induce activation, proliferation, differentiation or inhibition and/or death in B-cell populations and their precursors. The activity of the agonists or antagonists of the invention on purified human tonsillar B cells, measured qualitatively over the dose range from 0.1 to 10,000 ng/mL, is assessed in a standard B-lymphocyte co-stimulation assay in which purified tonsillar B cells are cultured in the presence of either formalin-fixed *Staphylococcus aureus* Cowan I (SAC) or immobilized anti-human IgM antibody as the priming agent. Second signals such as IL-2 and IL-15 synergize with SAC and IgM crosslinking to elicit B cell proliferation as measured by tritiated-thymidine incorporation. Novel synergizing agents can be readily identified using this assay. The assay involves isolating human tonsillar B cells by magnetic bead (MACS) depletion of CD3-positive cells. The resulting cell population is greater than 95% B cells as assessed by expression of CD45R(B220).

Various dilutions of each sample are placed into individual wells of a 96-well plate to which are added 10^5 B-cells suspended in culture medium (RPMI 1640 containing 10% FBS, 5×10^{-5} M 2ME, 100U/ml penicillin, 10ug/ml streptomycin, and 10^{-5} dilution of SAC) in a total volume of 150ul. Proliferation or inhibition is quantitated by a 20h pulse (1uCi/well)

with ³H-thymidine (6.7 Ci/mM) beginning 72h post factor addition. The positive and negative controls are IL2 and medium respectively.

In Vivo Assay- BALB/c mice are injected (i.p.) twice per day with buffer only, or 2 mg/Kg of agonists or antagonists of the invention, or truncated forms thereof. Mice receive this treatment for 4 consecutive days, at which time they are sacrificed and various tissues and serum collected for analyses. Comparison of H&E sections from normal spleens and spleens treated with agonists or antagonists of the invention identify the results of the activity of the agonists or antagonists on spleen cells, such as the diffusion of peri-arterial lymphatic sheaths, and/or significant increases in the nucleated cellularity of the red pulp regions, which may indicate the activation of the differentiation and proliferation of B-cell populations. Immunohistochemical studies using a B cell marker, anti-CD45R(B220), are used to determine whether any physiological changes to splenic cells, such as splenic disorganization, are due to increased B-cell representation within loosely defined B-cell zones that infiltrate established T-cell regions.

Flow cytometric analyses of the spleens from mice treated with agonist or antagonist is used to indicate whether the agonists or antagonists specifically increases the proportion of ThB+, CD45R(B220)dull B cells over that which is observed in control mice. Likewise, a predicted consequence of increased mature B-cell representation in vivo is a relative increase in serum Ig titers. Accordingly, serum IgM and IgA levels are compared between buffer and agonists or antagonists-treated mice.

The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

Example 23: T Cell Proliferation Assay

A CD3-induced proliferation assay is performed on PBMCs and is measured by the uptake of ³H-thymidine. The assay is performed as follows. Ninety-six well plates are coated with 100 µl/well of mAb to CD3 (HIT3a, Pharmingen) or isotype-matched control mAb (B33.1) overnight at 4 degrees C (1 µg/ml in .05M bicarbonate buffer, pH 9.5), then washed three times with PBS. PBMC are isolated by F/H gradient centrifugation from human peripheral blood and added to quadruplicate wells (5 x 10⁴/well) of mAb coated plates

in RPMI containing 10% FCS and P/S in the presence of varying concentrations of agonists or antagonists of the invention (total volume 200 μ l). Relevant protein buffer and medium alone are controls. After 48 hr. culture at 37 degrees C, plates are spun for 2 min. at 1000 rpm and 100 μ l of supernatant is removed and stored -20 degrees C for measurement of IL-2 (or other cytokines) if effect on proliferation is observed. Wells are supplemented with 100 μ l of medium containing 0.5 uCi of 3 H-thymidine and cultured at 37 degrees C for 18-24 hr. Wells are harvested and incorporation of 3 H-thymidine used as a measure of proliferation. Anti-CD3 alone is the positive control for proliferation. IL-2 (100 U/ml) is also used as a control which enhances proliferation. Control antibody which does not induce proliferation of T cells is used as the negative controls for the effects of agonists or antagonists of the invention.

The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

Example 24: Effect of Agonists or Antagonists of the Invention on the Expression of MHC Class II, Costimulatory and Adhesion Molecules and Cell Differentiation of Monocytes and Monocyte-Derived Human Dendritic Cells

Dendritic cells are generated by the expansion of proliferating precursors found in the peripheral blood: adherent PBMC or elutriated monocytic fractions are cultured for 7-10 days with GM-CSF (50 ng/ml) and IL-4 (20 ng/ml). These dendritic cells have the characteristic phenotype of immature cells (expression of CD1, CD80, CD86, CD40 and MHC class II antigens). Treatment with activating factors, such as TNF- α , causes a rapid change in surface phenotype (increased expression of MHC class I and II, costimulatory and adhesion molecules, downregulation of FC γ RII, upregulation of CD83). These changes correlate with increased antigen-presenting capacity and with functional maturation of the dendritic cells.

FACS analysis of surface antigens is performed as follows. Cells are treated 1-3 days with increasing concentrations of agonist or antagonist of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degrees C. After an additional wash, the labeled cells are analyzed by flow

cytometry on a FACScan (Becton Dickinson).

Effect on the production of cytokines. Cytokines generated by dendritic cells, in particular IL-12, are important in the initiation of T-cell dependent immune responses. IL-12 strongly influences the development of Th1 helper T-cell immune response, and induces cytotoxic T and NK cell function. An ELISA is used to measure the IL-12 release as follows. Dendritic cells (10^6 /ml) are treated with increasing concentrations of agonists or antagonists of the invention for 24 hours. LPS (100 ng/ml) is added to the cell culture as positive control. Supernatants from the cell cultures are then collected and analyzed for IL-12 content using commercial ELISA kit (e.g., R & D Systems (Minneapolis, MN)). The standard protocols provided with the kits are used.

Effect on the expression of MHC Class II, costimulatory and adhesion molecules. Three major families of cell surface antigens can be identified on monocytes: adhesion molecules, molecules involved in antigen presentation, and Fc receptor. Modulation of the expression of MHC class II antigens and other costimulatory molecules, such as B7 and ICAM-1, may result in changes in the antigen presenting capacity of monocytes and ability to induce T cell activation. Increase expression of Fc receptors may correlate with improved monocyte cytotoxic activity, cytokine release and phagocytosis.

FACS analysis is used to examine the surface antigens as follows. Monocytes are treated 1-5 days with increasing concentrations of agonists or antagonists of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degreesC. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

Monocyte activation and/or increased survival. Assays for molecules that activate (or alternatively, inactivate) monocytes and/or increase monocyte survival (or alternatively, decrease monocyte survival) are known in the art and may routinely be applied to determine whether a molecule of the invention functions as an inhibitor or activator of monocytes. Agonists or antagonists of the invention can be screened using the three assays described below. For each of these assays, Peripheral blood mononuclear cells (PBMC) are purified

from single donor leukopacks (American Red Cross, Baltimore, MD) by centrifugation through a Histopaque gradient (Sigma). Monocytes are isolated from PBMC by counterflow centrifugal elutriation.

- 5 Monocyte Survival Assay. Human peripheral blood monocytes progressively lose viability when cultured in absence of serum or other stimuli. Their death results from internally regulated process (apoptosis). Addition to the culture of activating factors, such as TNF-alpha dramatically improves cell survival and prevents DNA fragmentation. Propidium iodide (PI) staining is used to measure apoptosis as follows. Monocytes are cultured for 48 hours in
- 10 polypropylene tubes in serum-free medium (positive control), in the presence of 100 ng/ml TNF-alpha (negative control), and in the presence of varying concentrations of the compound to be tested. Cells are suspended at a concentration of 2×10^6 /ml in PBS containing PI at a final concentration of 5 μ g/ml, and then incubated at room temperature for 5 minutes before FACSscan analysis. PI uptake has been demonstrated to correlate with DNA fragmentation in
- 15 this experimental paradigm.

- Effect on cytokine release. An important function of monocytes/macrophages is their regulatory activity on other cellular populations of the immune system through the release of cytokines after stimulation. An ELISA to measure cytokine release is performed as follows.
- 20 Human monocytes are incubated at a density of 5×10^5 cells/ml with increasing concentrations of agonists or antagonists of the invention and under the same conditions, but in the absence of agonists or antagonists. For IL-12 production, the cells are primed overnight with IFN (100 U/ml) in presence of agonist or antagonist of the invention. LPS (10 ng/ml) is then added. Conditioned media are collected after 24h and kept frozen until use.
- 25 Measurement of TNF-alpha, IL-10, MCP-1 and IL-8 is then performed using a commercially available ELISA kit (e. g, R & D Systems (Minneapolis, MN)) and applying the standard protocols provided with the kit.

- Oxidative burst. Purified monocytes are plated in 96-w plate at 2×10^5 cell/well. Increasing
- 30 concentrations of agonists or antagonists of the invention are added to the wells in a total volume of 0.2 ml culture medium (RPMI 1640 + 10% FCS, glutamine and antibiotics). After 3 days incubation, the plates are centrifuged and the medium is removed from the wells. To

the macrophage monolayers, 0.2 ml per well of phenol red solution (140 mM NaCl, 10 mM potassium phosphate buffer pH 7.0, 5.5 mM dextrose, 0.56 mM phenol red and 19 U/ml of HRPO) is added, together with the stimulant (200 nM PMA). The plates are incubated at 37°C for 2 hours and the reaction is stopped by adding 20 µl 1N NaOH per well. The absorbance is read at 610 nm. To calculate the amount of H₂O₂ produced by the macrophages, a standard curve of a H₂O₂ solution of known molarity is performed for each experiment.

The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

Example 25: Biological Effects of Agonists or Antagonists of the Invention

Astrocyte and Neuronal Assays.

Agonists or antagonists of the invention, expressed in *Escherichia coli* and purified as described above, can be tested for activity in promoting the survival, neurite outgrowth, or phenotypic differentiation of cortical neuronal cells and for inducing the proliferation of glial fibrillary acidic protein immunopositive cells, astrocytes. The selection of cortical cells for the bioassay is based on the prevalent expression of FGF-1 and FGF-2 in cortical structures and on the previously reported enhancement of cortical neuronal survival resulting from FGF-2 treatment. A thymidine incorporation assay, for example, can be used to elucidate an agonist or antagonist of the invention's activity on these cells.

Moreover, previous reports describing the biological effects of FGF-2 (basic FGF) on cortical or hippocampal neurons *in vitro* have demonstrated increases in both neuron survival and neurite outgrowth (Walicke et al., "Fibroblast growth factor promotes survival of dissociated hippocampal neurons and enhances neurite extension." *Proc. Natl. Acad. Sci. USA* 83:3012-3016. (1986), assay herein incorporated by reference in its entirety). However, reports from experiments done on PC-12 cells suggest that these two responses are not necessarily synonymous and may depend on not only which FGF is being tested but also on which receptor(s) are expressed on the target cells. Using the primary cortical neuronal

culture paradigm, the ability of an agonist or antagonist of the invention to induce neurite outgrowth can be compared to the response achieved with FGF-2 using, for example, a thymidine incorporation assay.

5 Fibroblast and endothelial cell assays.

Human lung fibroblasts are obtained from Clonetics (San Diego, CA) and maintained in growth media from Clonetics. Dermal microvascular endothelial cells are obtained from Cell Applications (San Diego, CA). For proliferation assays, the human lung fibroblasts and dermal microvascular endothelial cells can be cultured at 5,000 cells/well in a 96-well plate for one day in growth medium. The cells are then incubated for one day in 0.1% BSA basal medium. After replacing the medium with fresh 0.1% BSA medium, the cells are incubated with the test proteins for 3 days. Alamar Blue (Alamar Biosciences, Sacramento, CA) is added to each well to a final concentration of 10%. The cells are incubated for 4 hr. Cell viability is measured by reading in a CytoFluor fluorescence reader. For the PGE₂ assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or agonists or antagonists of the invention with or without IL-1 α for 24 hours. The supernatants are collected and assayed for PGE₂ by EIA kit (Cayman, Ann Arbor, MI). For the IL-6 assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or with or without agonists or antagonists of the invention IL-1 α for 24 hours. The supernatants are collected and assayed for IL-6 by ELISA kit (Endogen, Cambridge, MA).

Human lung fibroblasts are cultured with FGF-2 or agonists or antagonists of the invention for 3 days in basal medium before the addition of Alamar Blue to assess effects on growth of the fibroblasts. FGF-2 should show a stimulation at 10 - 2500 ng/ml which can be used to compare stimulation with agonists or antagonists of the invention.

Parkinson Models.

The loss of motor function in Parkinson's disease is attributed to a deficiency of striatal dopamine resulting from the degeneration of the nigrostriatal dopaminergic projection

neurons. An animal model for Parkinson's that has been extensively characterized involves the systemic administration of 1-methyl-4 phenyl 1,2,3,6-tetrahydropyridine (MPTP). In the CNS, MPTP is taken-up by astrocytes and catabolized by monoamine oxidase B to 1-methyl-4-phenyl pyridine (MPP⁺) and released. Subsequently, MPP⁺ is actively accumulated in
5 dopaminergic neurons by the high-affinity reuptake transporter for dopamine. MPP⁺ is then concentrated in mitochondria by the electrochemical gradient and selectively inhibits nicotinamide adenine disphosphate: ubiquinone oxidoreductionase (complex I), thereby interfering with electron transport and eventually generating oxygen radicals.

It has been demonstrated in tissue culture paradigms that FGF-2 (basic FGF) has
10 trophic activity towards nigral dopaminergic neurons (Ferrari et al., Dev. Biol. 1989). Recently, Dr. Unsicker's group has demonstrated that administering FGF-2 in gel foam implants in the striatum results in the near complete protection of nigral dopaminergic neurons from the toxicity associated with MPTP exposure (Otto and Unsicker, J. Neuroscience, 1990).

15 Based on the data with FGF-2, agonists or antagonists of the invention can be evaluated to determine whether it has an action similar to that of FGF-2 in enhancing dopaminergic neuronal survival *in vitro* and it can also be tested *in vivo* for protection of dopaminergic neurons in the striatum from the damage associated with MPTP treatment. The potential effect of an agonist or antagonist of the invention is first examined *in vitro* in a
20 dopaminergic neuronal cell culture paradigm. The cultures are prepared by dissecting the midbrain floor plate from gestation day 14 Wistar rat embryos. The tissue is dissociated with trypsin and seeded at a density of 200,000 cells/cm² on polyorthinine-laminin coated glass coverslips. The cells are maintained in Dulbecco's Modified Eagle's medium and F12 medium containing hormonal supplements (N1). The cultures are fixed with
25 paraformaldehyde after 8 days *in vitro* and are processed for tyrosine hydroxylase, a specific marker for dopaminergic neurons, immunohistochemical staining. Dissociated cell cultures are prepared from embryonic rats. The culture medium is changed every third day and the factors are also added at that time.

Since the dopaminergic neurons are isolated from animals at gestation day 14, a
30 developmental time which is past the stage when the dopaminergic precursor cells are proliferating, an increase in the number of tyrosine hydroxylase immunopositive neurons would represent an increase in the number of dopaminergic neurons surviving *in vitro*.

Therefore, if an agonist or antagonist of the invention acts to prolong the survival of dopaminergic neurons, it would suggest that the agonist or antagonist may be involved in Parkinson's Disease.

The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

Example 26: The Effect of Agonists or Antagonists of the Invention on the Growth of Vascular Endothelial Cells

On day 1, human umbilical vein endothelial cells (HUVEC) are seeded at $2-5 \times 10^4$ cells/35 mm dish density in M199 medium containing 4% fetal bovine serum (FBS), 16 units/ml heparin, and 50 units/ml endothelial cell growth supplements (ECGS, Biotechnology, Inc.). On day 2, the medium is replaced with M199 containing 10% FBS, 8 units/ml heparin. An agonist or antagonist of the invention, and positive controls, such as VEGF and basic FGF (bFGF) are added, at varying concentrations. On days 4 and 6, the medium is replaced. On day 8, cell number is determined with a Coulter Counter.

An increase in the number of HUVEC cells indicates that the compound of the invention may proliferate vascular endothelial cells, while a decrease in the number of HUVEC cell indicates that the compound of the invention inhibits vascular endothelial cells.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 27: Rat Corneal Wound Healing Model

This animal model shows the effect of an agonist or antagonist of the invention on neovascularization. The experimental protocol includes:

- a) Making a 1-1.5 mm long incision from the center of cornea into the stromal layer.
- b) Inserting a spatula below the lip of the incision facing the outer corner of the

eye.

- c) Making a pocket (its base is 1-1.5 mm from the edge of the eye).
- d) Positioning a pellet, containing 50ng- 5ug of an agonist or antagonist of the invention, within the pocket.
- 5 e) Treatment with an agonist or antagonist of the invention can also be applied topically to the corneal wounds in a dosage range of 20mg - 500mg (daily treatment for five days).

The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test
10 the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

Example 28: Diabetic Mouse and Glucocorticoid-Impaired Wound Healing Models

A. Diabetic db+/db+ Mouse Model.

- 15 To demonstrate that an agonist or antagonist of the invention accelerates the healing process, the genetically diabetic mouse model of wound healing is used. The full thickness wound healing model in the db+/db+ mouse is a well characterized, clinically relevant and reproducible model of impaired wound healing. Healing of the diabetic wound is dependent on formation of granulation tissue and re-epithelialization rather than contraction (Gartner,
20 M.H. *et al.*, *J. Surg. Res.* 52:389 (1992); Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)).

- The diabetic animals have many of the characteristic features observed in Type II diabetes mellitus. Homozygous (db+/db+) mice are obese in comparison to their normal heterozygous (db+/+m) littermates. Mutant diabetic (db+/db+) mice have a single autosomal
25 recessive mutation on chromosome 4 (db+) (Coleman *et al.* *Proc. Natl. Acad. Sci. USA* 77:283-293 (1982)). Animals show polyphagia, polydipsia and polyuria. Mutant diabetic mice (db+/db+) have elevated blood glucose, increased or normal insulin levels, and suppressed cell-mediated immunity (Mandel *et al.*, *J. Immunol.* 120:1375 (1978); Debray-Sachs, M. *et al.*, *Clin. Exp. Immunol.* 51(1):1-7 (1983); Leiter *et al.*, *Am. J. of Pathol.* 114:46-
30 55 (1985)). Peripheral neuropathy, myocardial complications, and microvascular lesions, basement membrane thickening and glomerular filtration abnormalities have been described in these animals (Norido, F. *et al.*, *Exp. Neurol.* 83(2):221-232 (1984); Robertson *et al.*,

Diabetes 29(1):60-67 (1980); Giacomelli *et al.*, *Lab Invest.* 40(4):460-473 (1979); Coleman, D.L., *Diabetes* 31 (Suppl):1-6 (1982)). These homozygous diabetic mice develop hyperglycemia that is resistant to insulin analogous to human type II diabetes (Mandel *et al.*, *J. Immunol.* 120:1375-1377 (1978)).

5 The characteristics observed in these animals suggests that healing in this model may be similar to the healing observed in human diabetes (Greenhalgh, *et al.*, *Am. J. of Pathol.* 136:1235-1246 (1990)).

Genetically diabetic female C57BL/KsJ (db+/db+) mice and their non-diabetic (db+/+m) heterozygous littermates are used in this study (Jackson Laboratories). The
10 animals are purchased at 6 weeks of age and are 8 weeks old at the beginning of the study. Animals are individually housed and received food and water ad libitum. All manipulations are performed using aseptic techniques. The experiments are conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

15 Wounding protocol is performed according to previously reported methods (Tsuboi, R. and Rifkin, D.B., *J. Exp. Med.* 172:245-251 (1990)). Briefly, on the day of wounding, animals are anesthetized with an intraperitoneal injection of Avertin (0.01 mg/mL), 2,2,2-tribromoethanol and 2-methyl-2-butanol dissolved in deionized water. The dorsal region of the animal is shaved and the skin washed with 70% ethanol solution and iodine. The surgical
20 area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is then created using a Keyes tissue punch. Immediately following wounding, the surrounding skin is gently stretched to eliminate wound expansion. The wounds are left open for the duration of the experiment. Application of the treatment is given topically for 5 consecutive days commencing on the day of wounding. Prior to treatment, wounds are gently cleansed with
25 sterile saline and gauze sponges.

Wounds are visually examined and photographed at a fixed distance at the day of surgery and at two day intervals thereafter. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no
30 longer visible and the wound is covered by a continuous epithelium.

An agonist or antagonist of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups

received 50mL of vehicle solution.

Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology and immunohistochemistry. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

Three groups of 10 animals each (5 diabetic and 5 non-diabetic controls) are evaluated: 1) Vehicle placebo control, 2) untreated group, and 3) treated group.

Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total square area of the wound. Contraction is then estimated by establishing the differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64mm², the corresponding size of the dermal punch. Calculations are made using the following formula:

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using a Reichert-Jung microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds are used to assess whether the healing process and the morphologic appearance of the repaired skin is altered by treatment with an agonist or antagonist of the invention. This assessment included verification of the presence of cell accumulation, inflammatory cells, capillaries, fibroblasts, re-epithelialization and epidermal maturity (Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)). A calibrated lens micrometer is used by a blinded observer.

Tissue sections are also stained immunohistochemically with a polyclonal rabbit anti-human keratin antibody using ABC Elite detection system. Human skin is used as a positive tissue control while non-immune IgG is used as a negative control. Keratinocyte growth is determined by evaluating the extent of reepithelialization of the wound using a calibrated lens micrometer.

Proliferating cell nuclear antigen/cyclin (PCNA) in skin specimens is demonstrated by using anti-PCNA antibody (1:50) with an ABC Elite detection system. Human colon cancer served as a positive tissue control and human brain tissue is used as a negative tissue

control. Each specimen included a section with omission of the primary antibody and substitution with non-immune mouse IgG. Ranking of these sections is based on the extent of proliferation on a scale of 0-8, the lower side of the scale reflecting slight proliferation to the higher side reflecting intense proliferation.

- 5 Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is considered significant.

B. Steroid Impaired Rat Model

- The inhibition of wound healing by steroids has been well documented in various *in vitro* and
10 *in vivo* systems (Wahl, Glucocorticoids and Wound healing. In: Anti-Inflammatory Steroid Action: Basic and Clinical Aspects. 280-302 (1989); Wahl *et al.*, *J. Immunol.* 115: 476-481 (1975); Werb *et al.*, *J. Exp. Med.* 147:1684-1694 (1978)). Glucocorticoids retard wound healing by inhibiting angiogenesis, decreasing vascular permeability (Ebert *et al.*, *Am. Intern. Med.* 37:701-705 (1952)), fibroblast proliferation, and collagen synthesis (Beck *et al.*,
15 *Growth Factors.* 5: 295-304 (1991); Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978)) and producing a transient reduction of circulating monocytes (Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989)). The systemic administration of steroids to impaired wound healing is a well establish
20 phenomenon in rats (Beck *et al.*, *Growth Factors.* 5: 295-304 (1991); Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989); Pierce *et al.*, *Proc. Natl. Acad. Sci. USA* 86: 2229-2233 (1989)).

- To demonstrate that an agonist or antagonist of the invention can accelerate the
25 healing process, the effects of multiple topical applications of the agonist or antagonist on full thickness excisional skin wounds in rats in which healing has been impaired by the systemic administration of methylprednisolone is assessed.

- Young adult male Sprague Dawley rats weighing 250-300 g (Charles River Laboratories) are used in this example. The animals are purchased at 8 weeks of age and are
30 9 weeks old at the beginning of the study. The healing response of rats is impaired by the systemic administration of methylprednisolone (17mg/kg/rat intramuscularly) at the time of wounding. Animals are individually housed and received food and water *ad libitum*. All

manipulations are performed using aseptic techniques. This study is conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

5 The wounding protocol is followed according to section A, above. On the day of wounding, animals are anesthetized with an intramuscular injection of ketamine (50 mg/kg) and xylazine (5 mg/kg). The dorsal region of the animal is shaved and the skin washed with 70% ethanol and iodine solutions. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is created using a Keyes tissue punch. The wounds are left open for the duration of the experiment. Applications of the testing materials
10 are given topically once a day for 7 consecutive days commencing on the day of wounding and subsequent to methylprednisolone administration. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

Wounds are visually examined and photographed at a fixed distance at the day of wounding and at the end of treatment. Wound closure is determined by daily measurement on
15 days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

The agonist or antagonist of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups
20 received 50mL of vehicle solution.

Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

25 Four groups of 10 animals each (5 with methylprednisolone and 5 without glucocorticoid) are evaluated: 1) Untreated group 2) Vehicle placebo control 3) treated groups.

Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total area of the wound. Closure is then estimated by establishing the
30 differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64mm², the corresponding size of the dermal punch. Calculations are made using the following formula:

[Open area on day 8] - [Open area on day 1] / [Open area on day 1]

Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned
5 perpendicular to the wound surface (5mm) and cut using an Olympus microtome. Routine
hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds.
Histologic examination of the wounds allows assessment of whether the healing process and
the morphologic appearance of the repaired skin is improved by treatment with an agonist or
antagonist of the invention. A calibrated lens micrometer is used by a blinded observer to
10 determine the distance of the wound gap.

Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is
considered significant.

The studies described in this example tested activity of agonists or antagonists of the
invention. However, one skilled in the art could easily modify the exemplified studies to test
15 the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

Example 29: Lymphadema Animal Model

The purpose of this experimental approach is to create an appropriate and consistent
20 lymphedema model for testing the therapeutic effects of an agonist or antagonist of the
invention in lymphangiogenesis and re-establishment of the lymphatic circulatory system in
the rat hind limb. Effectiveness is measured by swelling volume of the affected limb,
quantification of the amount of lymphatic vasculature, total blood plasma protein, and
histopathology. Acute lymphedema is observed for 7-10 days. Perhaps more importantly,
25 the chronic progress of the edema is followed for up to 3-4 weeks.

Prior to beginning surgery, blood sample is drawn for protein concentration analysis.
Male rats weighing approximately ~350g are dosed with Pentobarbital. Subsequently, the
right legs are shaved from knee to hip. The shaved area is swabbed with gauze soaked in
70% EtOH. Blood is drawn for serum total protein testing. Circumference and volumetric
30 measurements are made prior to injecting dye into paws after marking 2 measurement levels
(0.5 cm above heel, at mid-pt of dorsal paw). The intradermal dorsum of both right and left
paws are injected with 0.05 ml of 1% Evan's Blue. Circumference and volumetric

measurements are then made following injection of dye into paws.

Using the knee joint as a landmark, a mid-leg inguinal incision is made circumferentially allowing the femoral vessels to be located. Forceps and hemostats are used to dissect and separate the skin flaps. After locating the femoral vessels, the lymphatic vessel
5 that runs along side and underneath the vessel(s) is located. The main lymphatic vessels in this area are then electrically coagulated or suture ligated.

Using a microscope, muscles in back of the leg (near the semitendinosus and adductors) are bluntly dissected. The popliteal lymph node is then located. The 2 proximal and 2 distal lymphatic vessels and distal blood supply of the popliteal node are then and
10 ligated by suturing. The popliteal lymph node, and any accompanying adipose tissue, is then removed by cutting connective tissues.

Care is taken to control any mild bleeding resulting from this procedure. After lymphatics are occluded, the skin flaps are sealed by using liquid skin (Vetbond) (AJ Buck). The separated skin edges are sealed to the underlying muscle tissue while leaving a gap of
15 ~0.5 cm around the leg. Skin also may be anchored by suturing to underlying muscle when necessary.

To avoid infection, animals are housed individually with mesh (no bedding). Recovering animals are checked daily through the optimal edematous peak, which typically occurred by day 5-7. The plateau edematous peak are then observed. To evaluate the
20 intensity of the lymphedema, the circumference and volumes of 2 designated places on each paw before operation and daily for 7 days are measured. The effect plasma proteins on lymphedema is determined and whether protein analysis is a useful testing perimeter is also investigated. The weights of both control and edematous limbs are evaluated at 2 places. Analysis is performed in a blind manner.

25 Circumference Measurements: Under brief gas anesthetic to prevent limb movement, a cloth tape is used to measure limb circumference. Measurements are done at the ankle bone and dorsal paw by 2 different people then those 2 readings are averaged. Readings are taken from both control and edematous limbs.

Volumetric Measurements: On the day of surgery, animals are anesthetized with
30 Pentobarbital and are tested prior to surgery. For daily volumetrics animals are under brief halothane anesthetic (rapid immobilization and quick recovery), both legs are shaved and equally marked using waterproof marker on legs. Legs are first dipped in water, then dipped

into instrument to each marked level then measured by Buxco edema software(Chen/Victor). Data is recorded by one person, while the other is dipping the limb to marked area.

Blood-plasma protein measurements: Blood is drawn, spun, and serum separated prior to surgery and then at conclusion for total protein and Ca²⁺ comparison.

5 Limb Weight Comparison: After drawing blood, the animal is prepared for tissue collection. The limbs are amputated using a quillitine, then both experimental and control legs are cut at the ligature and weighed. A second weighing is done as the tibio-cacaneal joint is disarticulated and the foot is weighed.

10 Histological Preparations: The transverse muscle located behind the knee (popliteal) area is dissected and arranged in a metal mold, filled with freezeGel, dipped into cold methylbutane, placed into labeled sample bags at - 80EC until sectioning. Upon sectioning, the muscle is observed under fluorescent microscopy for lymphatics..

The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test
15 the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

Example 30: Suppression of TNF alpha-induced adhesion molecule expression by a Agonist or Antagonist of the Invention

20 The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules (CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in both normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial
25 leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells (EC). The expression of these molecules and others on the vascular endothelium determines the efficiency with which leukocytes may adhere to the local vasculature and extravasate into the local tissue during the development of an inflammatory response. The local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

30 Tumor necrosis factor alpha (TNF-a), a potent proinflammatory cytokine, is a stimulator of all three CAMs on endothelial cells and may be involved in a wide variety of inflammatory responses, often resulting in a pathological outcome.

The potential of an agonist or antagonist of the invention to mediate a suppression of TNF- α induced CAM expression can be examined. A modified ELISA assay which uses ECs as a solid phase absorbent is employed to measure the amount of CAM expression on TNF- α treated ECs when co-stimulated with a member of the FGF family of proteins.

5 To perform the experiment, human umbilical vein endothelial cell (HUVEC) cultures are obtained from pooled cord harvests and maintained in growth medium (EGM-2; Clonetics, San Diego, CA) supplemented with 10% FCS and 1% penicillin/streptomycin in a 37 degree C humidified incubator containing 5% CO₂. HUVECs are seeded in 96-well plates at concentrations of 1×10^4 cells/well in EGM medium at 37 degree C for 18-24 hrs or
10 until confluent. The monolayers are subsequently washed 3 times with a serum-free solution of RPMI-1640 supplemented with 100 U/ml penicillin and 100 mg/ml streptomycin, and treated with a given cytokine and/or growth factor(s) for 24 h at 37 degree C. Following incubation, the cells are then evaluated for CAM expression.

Human Umbilical Vein Endothelial cells (HUVECs) are grown in a standard 96 well
15 plate to confluence. Growth medium is removed from the cells and replaced with 90 μ l of 199 Medium (10% FBS). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10 μ l volumes). Plates are incubated at 37 degree C for either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are aspirated to remove medium and 100 μ l of 0.1% paraformaldehyde-PBS(with Ca⁺⁺ and Mg⁺⁺) is added
20 to each well. Plates are held at 4°C for 30 min.

Fixative is then removed from the wells and wells are washed 1X with PBS(+Ca,Mg)+0.5% BSA and drained. Do not allow the wells to dry. Add 10 μ l of diluted primary antibody to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10 μ g/ml (1:10 dilution of 0.1
25 mg/ml stock antibody). Cells are incubated at 37°C for 30 min. in a humidified environment. Wells are washed X3 with PBS(+Ca,Mg)+0.5% BSA.

Then add 20 μ l of diluted ExtrAvidin-Alkaline Phosphatase (1:5,000 dilution) to each well and incubated at 37°C for 30 min. Wells are washed X3 with PBS(+Ca,Mg)+0.5% BSA. 1 tablet of p-Nitrophenol Phosphate pNPP is dissolved in 5 ml of glycine buffer (pH
30 10.4). 100 μ l of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of the ExtrAvidin-Alkaline Phosphatase in glycine buffer: 1:5,000 (10^0) > $10^{-0.5}$ > 10^{-1} > $10^{-1.5}$. 5 μ l of each dilution is added to triplicate

wells and the resulting AP content in each well is 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100 μ l of pNPP reagent must then be added to each of the standard wells. The plate must be incubated at 37°C for 4h. A volume of 50 μ l of 3M NaOH is added to all wells. The results are quantified on a plate reader at 405 nm. The background subtraction option is used on
5 blank wells filled with glycine buffer only. The template is set up to indicate the concentration of AP-conjugate in each standard well [5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test
10 the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

Example 31: Production Of Polypeptide of the Invention For High-Throughput Screening Assays

15 The following protocol produces a supernatant containing polypeptide of the present invention to be tested. This supernatant can then be used in the Screening Assays described in Examples 33-42.

First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a working
20 solution of 50ug/ml. Add 200 μ l of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each well (note: a 12-channel pipetter may be used with tips on every other channel). Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for
25 up to two weeks.

Plate 293T cells (do not carry cells past P+20) at 2×10^5 cells/well in .5ml DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine (12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

30 The next day, mix together in a sterile solution basin: 300 μ l Lipofectamine (18324-012 Gibco/BRL) and 5ml Optimem I (31985070 Gibco/BRL)/96-well plate. With a small volume multi-channel pipetter, aliquot approximately 2ug of an expression vector containing

a polynucleotide insert, produced by the methods described in Examples 8-10, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45 minutes. After about 20 minutes, use a multi-channel pipetter to add
5 150ul Optimem I to each well. As a control, one plate of vector DNA lacking an insert should be transfected with each set of transfections.

Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates of cells, and then
10 person B rinses each well with .5-1ml PBS. Person A then aspirates off PBS rinse, and person B, using a 12-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37 degree C for 6 hours.

While cells are incubating, prepare appropriate media, either 1%BSA in DMEM with
15 1x penstrep, or HGS CHO-5 media (116.6 mg/L of CaCl₂ (anhyd); 0.00130 mg/L CuSO₄-5H₂O; 0.050 mg/L of Fe(NO₃)₃-9H₂O; 0.417 mg/L of FeSO₄-7H₂O; 311.80 mg/L of KCl; 28.64 mg/L of MgCl₂; 48.84 mg/L of MgSO₄; 6995.50 mg/L of NaCl; 2400.0 mg/L of NaHCO₃; 62.50 mg/L of NaH₂PO₄-H₂O; 71.02 mg/L of Na₂HPO₄; .4320 mg/L of ZnSO₄-7H₂O; .002 mg/L of Arachidonic Acid ; 1.022 mg/L of Cholesterol; .070 mg/L of DL-alpha-
20 Tocopherol-Acetate; 0.0520 mg/L of Linoleic Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of Oleic Acid; 0.010 mg/L of Palmitic Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-Glucose; 130.85 mg/ml of L- Alanine; 147.50 mg/ml of L- Arginine-HCL; 7.50 mg/ml of L-Asparagine-H₂O; 6.65 mg/ml of L-Aspartic Acid; 29.56
25 mg/ml of L-Cystine-2HCL-H₂O; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L- Glutamic Acid; 365.0 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L- Histidine-HCL-H₂O; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalanine; 40.0 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22
30 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tyrosine-2Na-2H₂O; and 99.65 mg/ml of L-

Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319 mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; 0.680 mg/L of Vitamin B₁₂; 25 mM of

5 HEPES Buffer; 2.39 mg/L of Na Hypoxanthine; 0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL; 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed with Oleic Acid; 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal Acetate. Adjust

10 osmolarity to 327 mOsm) with 2mm glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for endotoxin assay in 15ml polystyrene conical.

The transfection reaction is terminated, preferably by tag-teaming, at the end of the incubation period. Person A aspirates off the transfection media, while person B adds 1.5ml

15 appropriate media to each well. Incubate at 37 degree C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants from each well can then be used in the assays described in Examples 33-40.

20 It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the polypeptide of the present invention directly (e.g., as a secreted protein) or by polypeptide of the present invention inducing expression of other proteins, which are then secreted into the supernatant. Thus, the invention further provides a method of identifying the protein in the supernatant

25 characterized by an activity in a particular assay.

Example 32: Construction of GAS Reporter Construct

One signal transduction pathway involved in the differentiation and proliferation of

30 cells is called the Jaks-STATs pathway. Activated proteins in the Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements

alter the expression of the associated gene.

GAS and ISRE elements are recognized by a class of transcription factors called Signal Transducers and Activators of Transcription, or "STATs." There are six members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class 1, cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.

The STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2, Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are generally catalytically inactive in resting cells.

The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, Ann. Rev. Biochem. 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b) Class 2 includes IFN-a, IFN-g, and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO:838)).

Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway can be identified.

381

			<u>JAKs</u>			<u>STATS GAS(elements) or ISRE</u>
	<u>Ligand</u>	<u>tyk2</u>	<u>Jak1</u>	<u>Jak2</u>	<u>Jak3</u>	
	<u>IFN family</u>					
5	IFN-a/B	+	+	-	-	1,2,3 ISRE
	IFN-g		+	+	-	1 GAS (IRF1>Lys6>IFP)
	IL-10	+	?	?	-	1,3
	<u>gp130 family</u>					
10	IL-6 (Pleiotrohic)	+	+	+	?	1,3 GAS (IRF1>Lys6>IFP)
	IL-11(Pleiotrohic)	?	+	?	?	1,3
	OnM(Pleiotrohic)	?	+	+	?	1,3
	LIF(Pleiotrohic)	?	+	+	?	1,3
	CNTF(Pleiotrohic)	-/+	+	+	?	1,3
15	G-CSF(Pleiotrohic)	?	+	?	?	1,3
	IL-12(Pleiotrohic)	+	-	+	+	1,3
	<u>g-C family</u>					
	IL-2 (lymphocytes)	-	+	-	+	1,3,5 GAS
20	IL-4 (lymph/myeloid)	-	+	-	+	6 GAS (IRF1 = IFP
	>>Ly6)(IgH)					
	IL-7 (lymphocytes)	-	+	-	+	5 GAS
	IL-9 (lymphocytes)	-	+	-	+	5 GAS
	IL-13 (lymphocyte)	-	+	?	?	6 GAS
25	IL-15	?	+	?	+	5 GAS
	<u>gp140 family</u>					
	IL-3 (myeloid)	-	-	+	-	5 GAS (IRF1>IFP>>Ly6)
	IL-5 (myeloid)	-	-	+	-	5 GAS
30	GM-CSF (myeloid)	-	-	+	-	5 GAS
	<u>Growth hormone family</u>					
	GH	?	-	+	-	5
	PRL	?	+/-	+	-	1,3,5
35	EPO	?	-	+	-	5 GAS(B-

382

CAS>IRF1=IFP>>Ly6)

Receptor Tyrosine Kinases

	EGF	?	+	+	-	1,3	GAS (IRF1)
5	PDGF	?	+	+	-	1,3	
	CSF-1	?	+	+	-	1,3	GAS (not IRF1)

To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 33-34, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., Immunity 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:

10 5':GCGCCTCGAGATTTCCCGAAATCTAGATTTCCCGAAATGATTTCCCG
GAAATGATTTCCCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID NO:839)

The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTTGGCAAAGCCTAGGC:3' (SEQ ID NO:840)

15 PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:

20 5':CTCGAGATTTCCCGAAATCTAGATTTCCCGAAATGATTTCCCGAAA
TGATTTCCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCG
CCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCAGTTCCGCCATTCT
CCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCC
TCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTA
25 GGCTTTTGGCAAAAAGCTT:3' (SEQ ID NO:841)

With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter
30 molecules that can be used instead of SEAP include chloramphenicol

acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS-SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using Sall and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding as described in Examples 33-34.

Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 35 and 36. However, many other promoters can be substituted using the protocols described in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, IL-2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

25

Example 33: High-Throughput Screening Assay for T-cell Activity.

The following protocol is used to assess T-cell activity by identifying factors, and determining whether supernate containing a polypeptide of the invention proliferates and/or differentiates T-cells. T-cell activity is assessed using the

30

GAS/SEAP/Neo construct produced in Example 32. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC
5 Accession No. CRL-1582) cells can also be used.

Jurkat T-cells are lymphoblastic CD4⁺ Th1 helper cells. In order to generate stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately
10 20,000 cells per well and transfectants resistant to 1 mg/ml gentamicin selected. Resistant colonies are expanded and then tested for their response to increasing concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

Specifically, the following protocol will yield sufficient cells for 75 wells
15 containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in RPMI + 10% serum with 1%Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life Technologies) with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

20 During the incubation period, count cell concentration, spin down the required number of cells (10^7 per transfection), and resuspend in OPTI-MEM to a final concentration of 10^7 cells/ml. Then add 1ml of 1×10^7 cells in OPTI-MEM to T25 flask and incubate at 37 degree C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

25 The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Gentamicin, and 1% Pen-Strep. These cells are treated with supernatants containing polypeptide of the present invention or polypeptide of the present invention induced polypeptides as produced by the protocol described in Example 31.

30 On the day of treatment with the supernatant, the cells should be washed and

resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100 million cells) are required.

- 5 Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100, 000 cells per well).

 After all the plates have been seeded, 50 ul of the supernatants are transferred directly from the 96 well plate containing the supernatants into each well using a 12
10 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the assay.

 The 96 well dishes containing Jurkat cells treated with supernatants are placed in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul
15 samples from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophene covers) and stored at -20 degree C until SEAP assays are performed according to Example 37. The plates containing the remaining treated cells are placed at 4 degree C and serve as a source of material for repeating the assay on a specific well if desired.

- 20 As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the positive control wells.

 The above protocol may be used in the generation of both transient, as well as, stable transfected cells, which would be apparent to those of skill in the art.

25

Example 34: High-Throughput Screening Assay Identifying Myeloid Activity

- The following protocol is used to assess myeloid activity of polypeptide of the present invention by determining whether polypeptide of the present invention
30 proliferates and/or differentiates myeloid cells. Myeloid cell activity is assessed using

the GAS/SEAP/Neo construct produced in Example 32. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

5 To transiently transfect U937 cells with the GAS/SEAP/Neo construct produced in Example 32, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell Growth & Differentiation, 5:259-265) is used. First, harvest 2×10^7 U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml
10 penicillin and 100 mg/ml streptomycin.

Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM KCl, 375 uM $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$, 1 mM MgCl_2 , and 675 uM CaCl_2 . Incubate at 37 degrees C for 45 min.

15 Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37 degree C for 36 hr.

The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 ug/ml G418 for couple of passages.

20 These cells are tested by harvesting 1×10^8 cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described growth medium, with a final density of 5×10^5 cells/ml. Plate 200 ul cells per well in the 96-well plate (or 1×10^5 cells/well).

25 Add 50 ul of the supernatant prepared by the protocol described in Example 31. Incubate at 37 degree C for 48 to 72 hr. As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate U937 cells. Over 30 fold induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 37.

30 *Example 35: High-Throughput Screening Assay Identifying Neuronal Activity.*

When cells undergo differentiation and proliferation, a group of genes are activated through many different signal transduction pathways. One of these genes, EGR1 (early growth response gene 1), is induced in various tissues and cell types upon activation. The promoter of EGR1 is responsible for such induction. Using the EGR1 promoter linked to reporter molecules, activation of cells can be assessed by polypeptide of the present invention.

Particularly, the following protocol is used to assess neuronal activity in PC12 cell lines. PC12 cells (rat pheochromocytoma cells) are known to proliferate and/or differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor). The EGR1 gene expression is activated during this treatment. Thus, by stably transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells by polypeptide of the present invention can be assessed.

The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO:842)

5' GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO:843)

Using the GAS:SEAP/Neo vector produced in Example 32, EGR1 amplified product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1 promoter.

To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and

allowed to air dry for 2 hr.

PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker) containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is done every three to four days. Cells are removed from the plates by scraping and resuspended with pipetting up and down for more than 15 times.

Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine protocol described in Example 31. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.

To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS (Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count the cell number and add more low serum medium to reach final cell density as 5×10^5 cells/ml.

Add 200 ul of the cell suspension to each well of 96-well plate (equivalent to 1×10^5 cells/well). Add 50 ul supernatant produced by Example 31, 37 degree C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be used, such as 50 ng/ul of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 37.

Example 36: High-Throughput Screening Assay for T-cell Activity

NF-KB (Nuclear Factor KB) is a transcription factor activated by a wide

variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF-KB regulates the expression of genes involved in immune cell activation, control of apoptosis (NF- KB appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

In non-stimulated conditions, NF- KB is retained in the cytoplasm with I-KB (Inhibitor KB). However, upon stimulation, I- KB is phosphorylated and degraded, causing NF- KB to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF- KB include IL-2, IL-6, GM-CSF, ICAM-1 and class I MHC.

Due to its central role and ability to respond to a range of stimuli, reporter constructs utilizing the NF-KB promoter element are used to screen the supernatants produced in Example 31. Activators or inhibitors of NF-KB would be useful in treating, preventing, and/or diagnosing diseases. For example, inhibitors of NF-KB could be used to treat those diseases related to the acute or chronic activation of NF-KB, such as rheumatoid arthritis.

To construct a vector containing the NF-KB promoter element, a PCR based strategy is employed. The upstream primer contains four tandem copies of the NF-KB binding site (GGGGACTTCCCC) (SEQ ID NO:844), 18 bp of sequence complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:

5':GCGGCCTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGAC
TTTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO:845)

The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:

5':GCGGCAAGCTTTTGGCAAAGCCTAGGC:3' (SEQ ID NO:840)

PCR amplification is performed using the SV40 promoter template present in the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene)

Sequencing with the T7 and T3 primers confirms the insert contains the following sequence:

5':CTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGACTTTCC
ATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCC
5 ATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGA
CTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTA
TTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAA
GCTT:3' (SEQ ID NO:846)

Next, replace the SV40 minimal promoter element present in the pSEAP2-
10 promoter plasmid (Clontech) with this NF-KB/SV40 fragment using XhoI and
HindIII. However, this vector does not contain a neomycin resistance gene, and
therefore, is not preferred for mammalian expression systems.

In order to generate stable mammalian cell lines, the NF-KB/SV40/SEAP
cassette is removed from the above NF-KB/SEAP vector using restriction enzymes
15 SalI and NotI, and inserted into a vector containing neomycin resistance. Particularly,
the NF-KB/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the
GFP gene, after restricting pGFP-1 with SalI and NotI.

Once NF-KB/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are
created and maintained according to the protocol described in Example 33. Similarly,
20 the method for assaying supernatants with these stable Jurkat T-cells is also described
in Example 33. As a positive control, exogenous TNF alpha (0.1, 1, 10 ng) is added to
wells H9, H10, and H11, with a 5-10 fold activation typically observed.

Example 37: Assay for SEAP Activity

25

As a reporter molecule for the assays described in Examples 33-36, SEAP
activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the
following general procedure. The Tropix Phospho-light Kit supplies the Dilution,
Assay, and Reaction Buffers used below.

30 Prime a dispenser with the 2.5x Dilution Buffer and dispense 15 ul of 2.5x

dilution buffer into Optiplates containing 35 ul of a supernatant. Seal the plates with a plastic sealer and incubate at 65 degree C for 30 min. Separate the Optiplates to avoid uneven heating.

- Cool the samples to room temperature for 15 minutes. Empty the dispenser and prime with the Assay Buffer. Add 50 ml Assay Buffer and incubate at room temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below). Add 50 ul Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at each time and start the second set 10 minutes later.

Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

Reaction Buffer Formulation:

15

# of plates	Rxn buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5
13	75	3.75
14	80	4
15	85	4.25
16	90	4.5
17	95	4.75
18	100	5
19	105	5.25
20	110	5.5
21	115	5.75
22	120	6
23	125	6.25

393

24	130	6.5
25	135	6.75
26	140	7
27	145	7.25
28	150	7.5
29	155	7.75
30	160	8
31	165	8.25
32	170	8.5
33	175	8.75
34	180	9
35	185	9.25
36	190	9.5
37	195	9.75
38	200	10
39	205	10.25
40	210	10.5
41	215	10.75
42	220	11
43	225	11.25
44	230	11.5
45	235	11.75
46	240	12
47	245	12.25
48	250	12.5
49	255	12.75
50	260	13

Example 38: High-Throughput Screening Assay Identifying Changes in Small Molecule Concentration and Membrane Permeability

Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-4 (Molecular Probes, Inc.; catalog no. F-14202), used here.

For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO₂ incubator for 20 hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

A stock solution of 1 mg/ml fluo-4 is made in 10% pluronic acid DMSO. To load the cells with fluo-4, 50 ul of 12 ug/ml fluo-4 is added to each well. The plate is incubated at 37 degrees C in a CO₂ incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 ul of buffer.

For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to 2.5×10^6 cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-4 solution in 10% pluronic acid DMSO is added to each ml of cell suspension. The tube is then placed in a 37 degrees C water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to 1×10^6 cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley Cell Wash with 200 ul, followed by an aspiration step to 100 ul final volume.

For a non-cell based assay, each well contains a fluorescent molecule, such as

fluo-4 . The supernatant is added to the well, and a change in fluorescence is detected.

To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm; and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an extracellular signaling event caused by the a molecule, either polypeptide of the present invention or a molecule induced by polypeptide of the present invention, which has resulted in an increase in the intracellular Ca^{++} concentration.

10

Example 40: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity

The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

Because of the wide range of known factors capable of stimulating tyrosine kinase activity, identifying whether polypeptide of the present invention or a molecule induced by polypeptide of the present invention is capable of activating tyrosine kinase signal transduction pathways is of interest. Therefore, the following protocol

30

is designed to identify such molecules capable of activating the tyrosine kinase signal transduction pathways.

Seed target cells (e.g., primary keratinocytes) at a density of approximately 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford, MA), or calf serum, rinsed with PBS and stored at 4 degree C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as described by the manufacturer Alamar Biosciences, Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford, MA) are used to cover the Loprodyne Silent Screen Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

To prepare extracts, A431 cells are seeded onto the nylon membranes of Loprodyne plates (20,000/200ml/well) and cultured overnight in complete medium. Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in Example 31, the medium was removed and 100 ml of extraction buffer ((20 mM HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na₃VO₄, 2 mM Na₄P₂O₇ and a cocktail of protease inhibitors (# 1836170) obtained from Boehringer Mannheim (Indianapolis, IN) is added to each well and the plate is shaken on a rotating shaker for 5 minutes at 4°C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane bottoms of each well using house vacuum. Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on ice. To obtain extracts clarified by centrifugation, the content of each well, after detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 4

degree C at 16,000 x g.

Test the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described here.

5 Generally, the tyrosine kinase activity of a supernatant is evaluated by determining its ability to phosphorylate a tyrosine residue on a specific substrate (a biotinylated peptide). Biotinylated peptides that can be used for this purpose include PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for
10 a range of tyrosine kinases and are available from Boehringer Mannheim.

The tyrosine kinase reaction is set up by adding the following components in order. First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg₂⁺ (5mM ATP/50mM MgCl₂), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride, pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM MgCl₂, 5 mM MnCl₂,
15 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(1mM), and then 5ul of water. Mix the components gently and preincubate the reaction mix at 30 degree C for 2 min. Initiate the reaction by adding 10ul of the control enzyme or the filtered supernatant.

The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mM EDTA and place the reactions on ice.

20 Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction mixture to a microtiter plate (MTP) module and incubating at 37 degree C for 20 min. This allows the streptavidin coated 96 well plate to associate with the biotinylated peptide. Wash the MTP module with 300ul/well of PBS four times. Next add 75 ul of anti-phosphotyrosine antibody conjugated to horse radish peroxidase(anti-P-Tyr-
25 POD(0.5u/ml)) to each well and incubate at 37 degree C for one hour. Wash the well as above.

Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound
30 peroxidase activity is quantitated using an ELISA reader and reflects the level of

tyrosine kinase activity.

Example 41: High-Throughput Screening Assay Identifying Phosphorylation Activity

5 As a potential alternative and/or compliment to the assay of protein tyrosine kinase activity described in Example 40, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be used. For example, as described below one particular assay can detect tyrosine phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other
10 molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase, Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.

 Specifically, assay plates are made by coating the wells of a 96-well ELISA
15 plate with 0.1ml of protein G (1ug/ml) for 2 hr at room temp, (RT). The plates are then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against Erk-1 and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody
20 detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4 degree C until use.

 A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants
25 obtained in Example 31 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

 After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit)
30 antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the

Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased
5 fluorescent signal over background indicates a phosphorylation by polypeptide of the present invention or a molecule induced by polypeptide of the present invention.

Example 42: Assay for the Stimulation of Bone Marrow CD34+ Cell Proliferation

10 This assay is based on the ability of human CD34+ to proliferate in the presence of hematopoietic growth factors and evaluates the ability of isolated polypeptides expressed in mammalian cells to stimulate proliferation of CD34+ cells.

It has been previously shown that most mature precursors will respond to only a single signal. More immature precursors require at least two signals to respond.
15 Therefore, to test the effect of polypeptides on hematopoietic activity of a wide range of progenitor cells, the assay contains a given polypeptide in the presence or absence of other hematopoietic growth factors. Isolated cells are cultured for 5 days in the presence of Stem Cell Factor (SCF) in combination with tested sample. SCF alone has a very limited effect on the proliferation of bone marrow (BM) cells, acting in
20 such conditions only as a "survival" factor. However, combined with any factor exhibiting stimulatory effect on these cells (e.g., IL-3), SCF will cause a synergistic effect. Therefore, if the tested polypeptide has a stimulatory effect on a hematopoietic progenitors, such activity can be easily detected. Since normal BM cells have a low level of cycling cells, it is likely that any inhibitory effect of a given polypeptide, or
25 agonists or antagonists thereof, might not be detected. Accordingly, assays for an inhibitory effect on progenitors is preferably tested in cells that are first subjected to *in vitro* stimulation with SCF+IL+3, and then contacted with the compound that is being evaluated for inhibition of such induced proliferation.

Briefly, CD34+ cells are isolated using methods known in the art. The cells
30 are thawed and resuspended in medium (QBSF 60 serum-free medium with 1% L-

glutamine (500ml) Quality Biological, Inc., Gaithersburg, MD Cat# 160-204-101). After several gentle centrifugation steps at 200 x g, cells are allowed to rest for one hour. The cell count is adjusted to 2.5×10^5 cells/ml. During this time, 100 μ l of sterile water is added to the peripheral wells of a 96-well plate. The cytokines that
5 can be tested with a given polypeptide in this assay is rhSCF (R&D Systems, Minneapolis, MN, Cat# 255-SC) at 50 ng/ml alone and in combination with rhSCF and rhIL-3 (R&D Systems, Minneapolis, MN, Cat# 203-ML) at 30 ng/ml. After one hour, 10 μ l of prepared cytokines, 50 μ l of the supernatants prepared in Example 31 (supernatants at 1:2 dilution = 50 μ l) and 20 μ l of diluted cells are added to the media
10 which is already present in the wells to allow for a final total volume of 100 μ l. The plates are then placed in a 37°C/5% CO₂ incubator for five days.

Eighteen hours before the assay is harvested, 0.5 μ Ci/well of [3H] Thymidine is added in a 10 μ l volume to each well to determine the proliferation rate. The experiment is terminated by harvesting the cells from each 96-well plate to a filtermat
15 using the Tomtec Harvester 96. After harvesting, the filtermats are dried, trimmed and placed into OmniFilter assemblies consisting of one OmniFilter plate and one OmniFilter Tray. 60 μ l Microscint is added to each well and the plate sealed with TopSeal-A press-on sealing film. A bar code 15 sticker is affixed to the first plate for counting. The sealed plates is then loaded and the level of radioactivity determined
20 via the Packard Top Count and the printed data collected for analysis. The level of radioactivity reflects the amount of cell proliferation.

The studies described in this example test the activity of a given polypeptide to stimulate bone marrow CD34+ cell proliferation. One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene
25 therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof. As a nonlimiting example, potential antagonists tested in this assay would be expected to inhibit cell proliferation in the presence of cytokines and/or to increase the inhibition of cell proliferation in the presence of cytokines and a given polypeptide. In contrast, potential agonists tested in this assay would be expected to enhance cell
30 proliferation and/or to decrease the inhibition of cell proliferation in the presence of

cytokines and a given polypeptide.

The ability of a gene to stimulate the proliferation of bone marrow CD34+ cells indicates that polynucleotides and polypeptides corresponding to the gene are useful for the diagnosis and treatment of disorders affecting the immune system and hematopoiesis. Representative uses are described in the “Immune Activity” and
5 “Infectious Disease” sections above, and elsewhere herein.

Example 43: Assay for Extracellular Matrix Enhanced Cell Response (EMECR)

10 The objective of the Extracellular Matrix Enhanced Cell Response (EMECR) assay is to identify gene products (e.g., isolated polypeptides) that act on the hematopoietic stem cells in the context of the extracellular matrix (ECM) induced signal.

Cells respond to the regulatory factors in the context of signal(s) received from
15 the surrounding microenvironment. For example, fibroblasts, and endothelial and epithelial stem cells fail to replicate in the absence of signals from the ECM. Hematopoietic stem cells can undergo self-renewal in the bone marrow, but not in *in vitro* suspension culture. The ability of stem cells to undergo self-renewal *in vitro* is dependent upon their interaction with the stromal cells and the ECM protein
20 fibronectin (fn). Adhesion of cells to fn is mediated by the $\alpha_5\beta_1$ and $\alpha_4\beta_1$ integrin receptors, which are expressed by human and mouse hematopoietic stem cells. The factor(s) which integrate with the ECM environment and responsible for stimulating stem cell self-renewal has not yet been identified. Discovery of such factors should be of great interest in gene therapy and bone marrow transplant applications

25 Briefly, polystyrene, non tissue culture treated, 96-well plates are coated with fn fragment at a coating concentration of $0.2 \mu\text{g}/\text{cm}^2$. Mouse bone marrow cells are plated (1,000 cells/well) in 0.2 ml of serum-free medium. Cells cultured in the presence of IL-3 (5 ng/ml) + SCF (50 ng/ml) would serve as the positive control, conditions under which little self-renewal but pronounced differentiation of the stem

cells is to be expected. Gene products of the invention (e.g., including, but not limited to, polynucleotides and polypeptides of the present invention, and supernatants produced in Example 31), are tested with appropriate negative controls in the presence and absence of SCF(5.0 ng/ml), where test factor supernates represent 10% of the total assay volume. The plated cells are then allowed to grow by incubating in a low oxygen environment (5% CO₂, 7% O₂, and 88% N₂) tissue culture incubator for 7 days. The number of proliferating cells within the wells is then quantitated by measuring thymidine incorporation into cellular DNA. Verification of the positive hits in the assay will require phenotypic characterization of the cells, which can be accomplished by scaling up of the culture system and using appropriate antibody reagents against cell surface antigens and FACScan.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

If a particular polypeptide of the present invention is found to be a stimulator of hematopoietic progenitors, polynucleotides and polypeptides corresponding to the gene encoding said polypeptide may be useful for the diagnosis and treatment of disorders affecting the immune system and hematopoiesis. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections above, and elsewhere herein. The gene product may also be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Additionally, the polynucleotides and/or polypeptides of the gene of interest and/or agonists and/or antagonists thereof, may also be employed to inhibit the proliferation and differentiation of hematopoietic cells and therefore may be employed to protect bone marrow stem cells from chemotherapeutic agents during chemotherapy. This antiproliferative effect may allow administration of higher doses of chemotherapeutic agents and, therefore, more effective chemotherapeutic treatment.

Moreover, polynucleotides and polypeptides corresponding to the gene of

interest may also be useful for the treatment and diagnosis of hematopoietic related disorders such as, for example, anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.

Example 44: Human Dermal Fibroblast and Aortic Smooth Muscle Cell Proliferation

The polypeptide of interest is added to cultures of normal human dermal fibroblasts (NHDF) and human aortic smooth muscle cells (AoSMC) and two co-assays are performed with each sample. The first assay examines the effect of the polypeptide of interest on the proliferation of normal human dermal fibroblasts (NHDF) or aortic smooth muscle cells (AoSMC). Aberrant growth of fibroblasts or smooth muscle cells is a part of several pathological processes, including fibrosis, and restenosis. The second assay examines IL6 production by both NHDF and SMC. IL6 production is an indication of functional activation. Activated cells will have increased production of a number of cytokines and other factors, which can result in a proinflammatory or immunomodulatory outcome. Assays are run with and without co-TNF α stimulation, in order to check for costimulatory or inhibitory activity.

Briefly, on day 1, 96-well black plates are set up with 1000 cells/well (NHDF) or 2000 cells/well (AoSMC) in 100 μ l culture media. NHDF culture media contains: Clonetics FB basal media, 1mg/ml hFGF, 5mg/ml insulin, 50mg/ml gentamycin, 2%FBS, while AoSMC culture media contains Clonetics SM basal media, 0.5 μ g/ml hEGF, 5mg/ml insulin, 1 μ g/ml hFGF, 50mg/ml gentamycin, 50 μ g/ml Amphotericin B, 5%FBS. After incubation at 37°C for at least 4-5 hours, culture media is aspirated and replaced with growth arrest media. Growth arrest media for NHDF contains fibroblast basal media, 50mg/ml gentamycin, 2% FBS, while growth arrest media for AoSMC contains SM basal media, 50mg/ml gentamycin, 50 μ g/ml Amphotericin B, 0.4% FBS. Incubate at 37°C until day 2.

On day 2, serial dilutions and templates of the polypeptide of interest are designed such that they always include media controls and known-protein controls. For both stimulation and inhibition experiments, proteins are diluted in growth arrest media. For inhibition experiments, TNFa is added to a final concentration of 2ng/ml (NHDF) or 5ng/ml (AoSMC). Add 1/3 vol media containing controls or polypeptides
5 of the present invention and incubate at 37°C/5% CO₂ until day 5.

Transfer 60µl from each well to another labeled 96-well plate, cover with a plate-sealer, and store at 4°C until Day 6 (for IL6 ELISA). To the remaining 100 µl in the cell culture plate, aseptically add Alamar Blue in an amount equal to 10% of the
10 culture volume (10µl). Return plates to incubator for 3 to 4 hours. Then measure fluorescence with excitation at 530nm and emission at 590nm using the CytoFluor. This yields the growth stimulation/inhibition data.

On day 5, the IL6 ELISA is performed by coating a 96 well plate with 50-100 ul/well of Anti-Human IL6 Monoclonal antibody diluted in PBS, pH 7.4, incubate ON
15 at room temperature.

On day 6, empty the plates into the sink and blot on paper towels. Prepare Assay Buffer containing PBS with 4% BSA. Block the plates with 200 µl/well of Pierce Super Block blocking buffer in PBS for 1-2 hr and then wash plates with wash buffer (PBS, 0.05% Tween-20). Blot plates on paper towels. Then add 50 µl/well of
20 diluted Anti-Human IL-6 Monoclonal, Biotin-labeled antibody at 0.50 mg/ml. Make dilutions of IL-6 stock in media (30, 10, 3, 1, 0.3, 0 ng/ml). Add duplicate samples to top row of plate. Cover the plates and incubate for 2 hours at RT on shaker. Plates are washed with wash buffer and blotted on paper towels. Dilute EU-labeled Streptavidin 1:1000 in Assay buffer, and add 100 µl/well. Cover the plate and incubate 1 h at RT.
25 Plates are again washed with wash buffer and blotted on paper towels. Add 100 µl/well of Enhancement Solution and shake for 5 minutes. Read the plate on the Wallac DELFIA Fluorometer. Readings from triplicate samples in each assay are tabulated and averaged.

A positive result in this assay suggests AoSMC cell proliferation and that the
30 polypeptide of the present invention may be involved in dermal fibroblast

proliferation and/or smooth muscle cell proliferation. A positive result also suggests many potential uses of polypeptides, polynucleotides, agonists and/or antagonists of the polynucleotide/polypeptide of the present invention which gives a positive result. For example, inflammation and immune responses, wound healing, and angiogenesis, as detailed throughout this specification. Particularly, polypeptides of the present invention and polynucleotides of the present invention may be used in wound healing and dermal regeneration, as well as the promotion of vasculogenesis, both of the blood vessels and lymphatics. The growth of vessels can be used in the treatment of, for example, cardiovascular diseases. Additionally, antagonists of polypeptides and polynucleotides of the invention may be useful in treating diseases, disorders, and/or conditions which involve angiogenesis by acting as an anti-vascular (e.g., anti-angiogenesis). These diseases, disorders, and/or conditions are known in the art and/or are described herein, such as, for example, malignancies, solid tumors, benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; arteriosclerotic plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uveitis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia; hemophilic joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis. Moreover, antagonists of polypeptides and polynucleotides of the invention may be useful in treating anti-hyperproliferative diseases and/or anti-inflammatory known in the art and/or described herein.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

Example 45: Cellular Adhesion Molecule (CAM) Expression on Endothelial Cells

5 The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules (CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in both normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1
10 (VCAM-1), and endothelial leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells (EC). The expression of these molecules and others on the vascular endothelium determines the efficiency with which leukocytes may adhere to the local vasculature and extravasate into the local tissue during the development of an inflammatory response. The local concentration of cytokines and growth factor
15 participate in the modulation of the expression of these CAMs.

Briefly, endothelial cells (e.g., Human Umbilical Vein Endothelial cells (HUVECs)) are grown in a standard 96 well plate to confluence, growth medium is removed from the cells and replaced with 100 µl of 199 Medium (10% fetal bovine serum (FBS)). Samples for testing and positive or negative controls are added to the
20 plate in triplicate (in 10 µl volumes). Plates are then incubated at 37°C for either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are aspirated to remove medium and 100 µl of 0.1% paraformaldehyde-PBS(with Ca++ and Mg++) is added to each well. Plates are held at 4°C for 30 min. Fixative is removed from the wells and wells are washed 1X with PBS(+Ca,Mg) + 0.5% BSA
25 and drained. 10 µl of diluted primary antibody is added to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10 µg/ml (1:10 dilution of 0.1 mg/ml stock antibody). Cells are incubated at 37°C for 30 min. in a humidified environment. Wells are washed three times with PBS(+Ca,Mg) + 0.5% BSA. 20 µl of diluted ExtrAvidin-Alkaline
30 Phosphotase (1:5,000 dilution, referred to herein as the working dilution) are added to

each well and incubated at 37°C for 30 min. Wells are washed three times with PBS(+Ca,Mg)+0.5% BSA. Dissolve 1 tablet of p-Nitrophenol Phosphate pNPP per 5 ml of glycine buffer (pH 10.4). 100 µl of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of the ExtrAvidin-Alkaline Phosphatase in glycine buffer: $1:5,000 (10^0) > 10^{-0.5} > 10^{-1} > 10^{-1.5}$. 5 µl of each dilution is added to triplicate wells and the resulting AP content in each well is 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100 µl of pNPP reagent is then added to each of the standard wells. The plate is incubated at 37°C for 4h. A volume of 50 µl of 3M NaOH is added to all wells. The plate is read on a plate reader at 405 nm using the background subtraction option on blank wells filled with glycine buffer only. Additionally, the template is set up to indicate the concentration of AP-conjugate in each standard well [5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

15 *Example 46: Alamar Blue Endothelial Cells Proliferation Assay*

This assay may be used to quantitatively determine protein mediated inhibition of bFGF-induced proliferation of Bovine Lymphatic Endothelial Cells (LECs), Bovine Aortic Endothelial Cells (BAECs) or Human Microvascular Uterine Myometrial Cells (UTMECs). This assay incorporates a fluorometric growth indicator based on detection of metabolic activity. A standard Alamar Blue Proliferation Assay is prepared in EGM-2MV with 10 ng /ml of bFGF added as a source of endothelial cell stimulation. This assay may be used with a variety of endothelial cells with slight changes in growth medium and cell concentration. Dilutions of the protein batches to be tested are diluted as appropriate. Serum-free medium (GIBCO SFM) without bFGF is used as a non-stimulated control and Angiostatin or TSP-1 are included as a known inhibitory controls.

Briefly, LEC, BAECs or UTMECs are seeded in growth media at a density of 5000 to 2000 cells/well in a 96 well plate and placed at 37-C overnight. After the overnight incubation of the cells, the growth media is removed and replaced with

GIBCO EC-SFM. The cells are treated with the appropriate dilutions of the protein of interest or control protein sample(s) (prepared in SFM) in triplicate wells with additional bFGF to a concentration of 10 ng/ ml. Once the cells have been treated with the samples, the plate(s) is/are placed back in the 37° C incubator for three days.

- 5 After three days 10 ml of stock alamar blue (Biosource Cat# DAL1100) is added to each well and the plate(s) is/are placed back in the 37°C incubator for four hours. The plate(s) are then read at 530nm excitation and 590nm emission using the CytoFluor fluorescence reader. Direct output is recorded in relative fluorescence units.

- 10 Alamar blue is an oxidation-reduction indicator that both fluoresces and changes color in response to chemical reduction of growth medium resulting from cell growth. As cells grow in culture, innate metabolic activity results in a chemical reduction of the immediate surrounding environment. Reduction related to growth causes the indicator to change from oxidized (non-fluorescent blue) form to reduced (fluorescent red) form. i.e. stimulated proliferation will produce a stronger signal and
- 15 inhibited proliferation will produce a weaker signal and the total signal is proportional to the total number of cells as well as their metabolic activity. The background level of activity is observed with the starvation medium alone. This is compared to the output observed from the positive control samples (bFGF in growth medium) and protein dilutions.

20

Example 47: Detection of Inhibition of a Mixed Lymphocyte Reaction

This assay can be used to detect and evaluate inhibition of a Mixed Lymphocyte Reaction (MLR) by gene products (e.g., isolated polypeptides).

- 25 Inhibition of a MLR may be due to a direct effect on cell proliferation and viability, modulation of costimulatory molecules on interacting cells, modulation of adhesiveness between lymphocytes and accessory cells, or modulation of cytokine production by accessory cells. Multiple cells may be targeted by these polypeptides since the peripheral blood mononuclear fraction used in this assay includes T, B and

natural killer lymphocytes, as well as monocytes and dendritic cells.

Polypeptides of interest found to inhibit the MLR may find application in diseases associated with lymphocyte and monocyte activation or proliferation. These include, but are not limited to, diseases such as asthma, arthritis, diabetes, inflammatory skin conditions, psoriasis, eczema, systemic lupus erythematosus, multiple sclerosis, glomerulonephritis, inflammatory bowel disease, crohn's disease, ulcerative colitis, arteriosclerosis, cirrhosis, graft vs. host disease, host vs. graft disease, hepatitis, leukemia and lymphoma.

Briefly, PBMCs from human donors are purified by density gradient centrifugation using Lymphocyte Separation Medium (LSM[®], density 1.0770 g/ml, Organon Teknika Corporation, West Chester, PA). PBMCs from two donors are adjusted to 2×10^6 cells/ml in RPMI-1640 (Life Technologies, Grand Island, NY) supplemented with 10% FCS and 2 mM glutamine. PBMCs from a third donor is adjusted to 2×10^5 cells/ml. Fifty microliters of PBMCs from each donor is added to wells of a 96-well round bottom microtiter plate. Dilutions of test materials (50 μ l) is added in triplicate to microtiter wells. Test samples (of the protein of interest) are added for final dilution of 1:4; rhIL-2 (R&D Systems, Minneapolis, MN, catalog number 202-IL) is added to a final concentration of 1 μ g/ml; anti-CD4 mAb (R&D Systems, clone 34930.11, catalog number MAB379) is added to a final concentration of 10 μ g/ml. Cells are cultured for 7-8 days at 37°C in 5% CO₂, and 1 μ C of [³H] thymidine is added to wells for the last 16 hrs of culture. Cells are harvested and thymidine incorporation determined using a Packard TopCount. Data is expressed as the mean and standard deviation of triplicate determinations.

Samples of the protein of interest are screened in separate experiments and compared to the negative control treatment, anti-CD4 mAb, which inhibits proliferation of lymphocytes and the positive control treatment, IL-2 (either as recombinant material or supernatant), which enhances proliferation of lymphocytes.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

5 The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference. Further, the hard copy of the sequence listing submitted herewith and the corresponding computer readable form are both
10 incorporated herein by reference in their entireties. Moreover, the hard copy of and the corresponding computer readable form of the Sequence Listing of Serial No. 60/124,270 are also incorporated herein by reference in their entireties.

411

Applicant's or agent's file reference number	PA103PCT	International application no.
---	----------	-------------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>72</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209</u> <u>United States of America</u>	
Date of deposit <u>20 May 1997</u>	Accession Number <u>209059</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
RO/US 08 MAR 2000	
Authorized officer <u>Torinda Harrod</u> PCT/Internat'l Appl Processing Div. (703) 305-3670	Authorized officer <u> </u>

ATCC Deposit No. 209059**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2

ATCC Deposit No. 209059

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

414

Applicant's or agent's file reference number	PA103PCT	International application
---	----------	---------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>72</u> line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209</u> <u>United States of America</u>	
Date of deposit <u>20 May 1997</u>	Accession Number <u>209060</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<input checked="" type="checkbox"/> For receiving Office use only This sheet was received with the international application RO/US 08 MAR 2000 Authorized officer Yolanda Harrod PCT/Internat'l Appl Processing Div. (703) 305-3670	<input type="checkbox"/> For International Bureau use only This sheet was received by the International Bureau on: Authorized officer
---	---

ATCC Deposit No. 209060**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2
ATCC Deposit No. 209060

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

417

Applicant's or agent's file reference number	PA103PCT	International application N
--	----------	-----------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>72</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209</u> <u>United States of America</u>	
Date of deposit <u>20 May 1997</u>	Accession Number <u>209061</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
RO/US 03 MAR 2000	
Authorized officer <u>Tolanda Harrod</u> <u>PCT/Internat'l Appl Processing Div.</u> <u>(703) 305-3870</u>	Authorized officer <u></u>

ATCC Deposit No. 209061**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2**ATCC Deposit No. 209061****DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

420

Applicant's or agent's file reference number	PA103PCT	International application
---	----------	---------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>72</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 20 May 1997	Accession Number 209062
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application RO/US 03 MAR 2000	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer Yolanda Harrod PCT/Internat'l Appl Processing Div. (703) 305-3870	Authorized officer

ATCC Deposit No. 209062**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2
ATCC Deposit No. 209062

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

423

Applicant's or agent's file reference number	PA103PCT	International application i
---	----------	-----------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>72</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209</u> <u>United States of America</u>	
Date of deposit <u>20 May 1997</u>	Accession Number <u>209063</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
RO/US 20 MAR 2000	
Authorized officer <u>Yolanda Harrod</u> <u>PCT/Internat'l Appl Processing Div.</u> <u>(703) 305-9670</u>	Authorized officer

ATCC Deposit No. 209063**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2

ATCC Deposit No. 209063

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

426

Applicant's or agent's file reference number	PA103PCT	International application
---	----------	---------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>72</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209</u> <u>United States of America</u>	
Date of deposit <u>20 May 1997</u>	Accession Number <u>209064</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<input checked="" type="checkbox"/> For receiving Office use only This sheet was received with the international application RO/US 09 MAR 2000 Authorized officer Yolanda Harrod PCT/Internat'l Appl Processing Div. (703) 305-3870	<input type="checkbox"/> For International Bureau use only This sheet was received by the International Bureau on: Authorized officer
---	---

ATCC Deposit No. 209064

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2

ATCC Deposit No. 209064

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

429

Applicant's or agent's file reference number	PA103PCT	International application
--	----------	---------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>72</u> . line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209</u> <u>United States of America</u>	
Date of deposit <u>20 May 1997</u>	Accession Number <u>209065</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<input checked="" type="checkbox"/> For receiving Office use only This sheet was received with the international application RO/US 03 MAR 2000 Authorized officer: <u>Glenda Harro</u> <u>PCT/Internat'l Appl Processing Div.</u> <u>(703) 305-3870</u>

<input type="checkbox"/> For International Bureau use only This sheet was received by the International Bureau on:
Authorized officer

ATCC Deposit No. 209065**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2
ATCC Deposit No. 209065

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

432

Applicant's or agent's file reference number	PA103PCT	International application
---	----------	---------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>72</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 20 May 1997	Accession Number 209066
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<input checked="" type="checkbox"/> For receiving Office use only This sheet was received with the international application RO/US 00 MAR 2000 Authorized officer: Yolande Harrod PCT/Int'l Appl Processing Div. (703) 305-3670	<input type="checkbox"/> For International Bureau use only This sheet was received by the International Bureau on: Authorized officer:
---	--

ATCC Deposit No. 209066**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2

ATCC Deposit No. 209066

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

435

Applicant's or agent's file reference number	PA103PCT	International application
---	----------	---------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>72</u> line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 20 May 1997	Accession Number 209067
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application RO/US 03 MAR 2000	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer Yolanda Harrod PCT/Internat'l Appl Processing Div. (703) 905-3870	Authorized officer

ATCC Deposit No. 209067**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2

ATCC Deposit No. 209067

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by an applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

438

Applicant's or agent's file reference number	PA103PCT	International application
---	----------	---------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>72</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 20 May 1997	Accession Number 209068
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<input checked="" type="checkbox"/> For receiving Office use only This sheet was received with the international application RO/US 03 MAR 2000 Authorized officer Yolanda Harrod PCT/Internat'l Appl Processing Div. (703) 305-3870	<input type="checkbox"/> For International Bureau use only This sheet was received by the International Bureau on: Authorized officer
--	---

ATCC Deposit No. 209068**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2
ATCC Deposit No. 209068

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

441

Applicant's or agent's file reference number	PA103PCT	International application
---	----------	---------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>72</u> . line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 20 May 1997	Accession Number 209069
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only <input checked="" type="checkbox"/> This sheet was received with the international application ROUS 05 MAR 2000 Authorized by <u>Victoria Harrold</u> PCT/Internat'l App'l Processing Div. (703) 305-3870	For International Bureau use only <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer
---	---

ATCC Deposit No. 209069**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2
ATCC Deposit No. 209069

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.


444

Applicant's or agent's file reference number	PA103PCT	International application
---	----------	---------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>72</u> . line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 12 January 1998	Accession Number 209579
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<input checked="" type="checkbox"/> For receiving Office use only This sheet was received with the international application 02 MAR 2000 Authorized officer 	<input type="checkbox"/> For International Bureau use only This sheet was received by the International Bureau on: Authorized officer
---	---

ATCC Deposit No. 209579**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2
ATCC Deposit No. 209579

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

447

Applicant's or agent's file reference number	PA103PCT	International application
---	----------	---------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>72</u> . line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 12 January 1998	Accession Number 209578
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only <input checked="" type="checkbox"/> This sheet was received with the international application RO/US 03 MAR 2000 Authorized officer Yolanda Harrod PCT/Internat'l Appl Processing Div. (703) 305-3670	For International Bureau use only <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer
--	--

ATCC Deposit No. 209578**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2

ATCC Deposit No. 209578

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

450

Applicant's or agent's file reference number	PA103PCT	International application
--	----------	---------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>72</u> . line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 16 July 1998	Accession Number 203067
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<input checked="" type="checkbox"/> For receiving Office use only This sheet was received with the international application RO/US 03 MAR 2000 Authorized officer <i>William H. Harrold</i> PCT/International Appl Processing Div. 2001 315-3870	<input type="checkbox"/> For International Bureau use only This sheet was received by the International Bureau on: Authorized officer
---	---

ATCC Deposit No. 203067**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2
ATCC Deposit No. 203067

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

453

Applicant's or agent's file reference number	PA103PCT	International application
---	----------	---------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>72</u> . line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <p style="text-align: center;">American Type Culture Collection</p>	
Address of depositary institution (including postal code and country) <p style="text-align: center;">10801 University Boulevard Manassas, Virginia 20110-2209 United States of America</p>	
Date of deposit <p style="text-align: center;">16 July 1998</p>	Accession Number <p style="text-align: center;">203068</p>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<p>For receiving Office use only</p> <p><input checked="" type="checkbox"/> This sheet was received with the international application</p> <p style="text-align: center;">RO/US 03 MAR 2000</p> <p>Authorized officer Yolanda Harrod PCT/Internat'l Appl Processing Div.</p>	<p>For International Bureau use only</p> <p><input type="checkbox"/> This sheet was received by the International Bureau on:</p> <p>Authorized officer</p>
--	--

ATCC Deposit No. 203068**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2

ATCC Deposit No. 203068

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

456

Applicant's or agent's file reference number	PA103PCT	International application?
--	----------	----------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>72</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 1 February 1999	Accession Number 203609
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<input checked="" type="checkbox"/> For receiving Office use only This sheet was received with the international application RO/US 08 MAR 2000 Authorized officer Yolanda Harrod PCT/Internat'l Appl Processing Div. (703) 305-2671	<input type="checkbox"/> For International Bureau use only This sheet was received by the International Bureau on: Authorized officer
---	---

ATCC Deposit No. 203609**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2

ATCC Deposit No. 203609

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

459

Applicant's or agent's file reference number	PA103PCT	International application No.
---	----------	-------------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>72</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <p>American Type Culture Collection</p>	
Address of depositary institution (including postal code and country) <p>10801 University Boulevard Manassas, Virginia 20110-2209 United States of America</p>	
Date of deposit <p>1 February 1999</p>	Accession Number <p>203610</p>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit") 	

For receiving Office use only <input checked="" type="checkbox"/> This sheet was received with the international application RO/US 06 MAR 2000 Authorized officer Yolanda Harrod PCT/Internat'l Appl Processing Div. (703) 305-3670	For International Bureau use only <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer
---	--

ATCC Deposit No. 203610**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2
ATCC Deposit No. 203610

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

462

Applicant's or agent's file reference number	PA103PCT	International application #
---	----------	-----------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>72</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 17 November 1998	Accession Number 203485
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<input checked="" type="checkbox"/> For receiving Office use only This sheet was received with the international application RO/US 08 MAR 2000 Authorized officer Yolanda Harrod PCT/Internat'l Appl Processing Div. (703) 305-3670	<input type="checkbox"/> For International Bureau use only This sheet was received by the International Bureau on: _____ Authorized officer _____
--	--

ATCC Deposit No. 203485**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2

ATCC Deposit No. 203485

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

465

Applicant's or agent's file reference number	PA103PCT	International application number
---	----------	----------------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>72</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <p style="text-align: center;">American Type Culture Collection</p>	
Address of depositary institution (including postal code and country) <p style="text-align: center;">10801 University Boulevard Manassas, Virginia 20110-2209 United States of America</p>	
Date of deposit <p style="text-align: center;">18 June 1999</p>	Accession Number <p style="text-align: center;">PTA-252</p>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<input checked="" type="checkbox"/> For receiving Office use only This sheet was received with the international application RO/US 03 MAR 2000 Authorized officer <p style="text-align: center;">Volanda Harrod PCT/International Appl Processing Div.</p>	<input type="checkbox"/> For International Bureau use only This sheet was received by the International Bureau on: Authorized officer
---	---

ATCC Deposit No. PTA-252**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2

ATCC Deposit No. PTA-252

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

468

Applicant's or agent's file reference number	PA103PCT	International application No.
--	----------	-------------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>72</u> . line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 18 June 1999	Accession Number PTA-253
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<input checked="" type="checkbox"/> For receiving Office use only This sheet was received with the international application RO/US 03 MAR 2000 Authorized officer Volanda Harrod PCT/Internat'l Appl Processing Div. (703) 305-3670	<input type="checkbox"/> For International Bureau use only This sheet was received by the International Bureau on: Authorized officer
--	---

ATCC Deposit No. PTA-253**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2

ATCC Deposit No. PTA-253

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

471

Applicant's or agent's file reference number	PA103PCT	International application #
---	----------	-----------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>72</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 22 December 1999	Accession Number PTA-1081
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
RO/US 03 MAR 2000 Authorized officer Yolanda Harrod PCT/International Appl Processing Div. (703) 305-3670	Authorized officer

ATCC Deposit No. PTA-1081**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

Page 2

ATCC Deposit No. PTA-1081

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

What Is Claimed Is:

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
- 5 (a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO:X;
- 10 (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO:X;
- (c) a polynucleotide encoding a polypeptide fragment of a polypeptide encoded by SEQ ID NO:X or a polypeptide fragment encoded by the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO:X;
- 15 (d) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO:X;
- (e) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO:X;
- 20 (f) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO:X, having biological activity;
- (g) a polynucleotide which is a variant of SEQ ID NO:X;
- 25 (h) a polynucleotide which is an allelic variant of SEQ ID NO:X;
- (i) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;
- (j) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide
- 30

sequence of only A residues or of only T residues.

2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a protein.

5

3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO:X.

10

4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO:X.

15

5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

20

6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

25

7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.

8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.

30

9. A recombinant host cell produced by the method of claim 8.

10. The recombinant host cell of claim 9 comprising vector sequences.
11. An isolated polypeptide comprising an amino acid sequence at least
5 95% identical to a sequence selected from the group consisting of:
- (a) a polypeptide fragment of SEQ ID NO:Y or of the sequence encoded by the cDNA included in the related cDNA clone;
 - (b) a polypeptide fragment of SEQ ID NO:Y or of the sequence encoded by the cDNA included in the related cDNA clone, having biological activity;
 - 10 (c) a polypeptide domain of SEQ ID NO:Y or of the sequence encoded by the cDNA included in the related cDNA clone;
 - (d) a polypeptide epitope of SEQ ID NO:Y or of the sequence encoded by the cDNA included in the related cDNA clone;
 - (e) a full length protein of SEQ ID NO:Y or of the sequence encoded by the
15 cDNA included in the related cDNA clone;
 - (f) a variant of SEQ ID NO:Y;
 - (g) an allelic variant of SEQ ID NO:Y; or
 - (h) a species homologue of the SEQ ID NO:Y.
- 20 12. The isolated polypeptide of claim 11, wherein the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.
13. An isolated antibody that binds specifically to the isolated polypeptide
25 of claim 11.
14. A recombinant host cell that expresses the isolated polypeptide of claim 11.
- 30 15. A method of making an isolated polypeptide comprising:

(a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and

(b) recovering said polypeptide.

5 16. The polypeptide produced by claim 15.

17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11 or the polynucleotide of claim 1.

10

18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and

15 (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

20 (a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

25 20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:

(a) contacting the polypeptide of claim 11 with a binding partner; and

(b) determining whether the binding partner effects an activity of the polypeptide.

30

21. The gene corresponding to the cDNA sequence of SEQ ID NO:Y.
22. A method of identifying an activity in a biological assay, wherein the method comprises:
- 5 (a) expressing SEQ ID NO:X in a cell;
- (b) isolating the supernatant;
- (c) detecting an activity in a biological assay; and
- (d) identifying the protein in the supernatant having the activity.
- 10 23. The product produced by the method of claim 20.

SEQUENCE LISTING

<110> Craig Rosen,
Steve Ruben

<120> Human Breast and Ovarian Cancer Associated Gene Sequences and
Polypeptides

<130> PA103PCT

<140> Unassigned

<141> 2000-03-08

<150> 60/124,270

<151> 1999-03-12

<160> 846

<170> PatentIn Ver. 2.0

<210> 1

<211> 1913

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (6)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (944)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1418)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1908)

<223> n equals a,t,g, or c

<400> 1

gggtcanagac tggttcctgt ggtatgtgaa gaagtgtgga ggcacaacaa gaatcatctc 60
gacaacaaat ggaggacagg agaggaaatt tgtgggcgga tctggtcaag tgagtgagcg 120
gataatggac ctcttggag accgagtga gctggagagg cctgtgatct acattgacca 180
gacaagagaa aatgtccttg tggagaccct aaaccatgag atgtatgagg ctaaataatgt 240
gattagtgtc attcctccta ctctgggcat gaagattcac ttcaatcccc ctctgccaat 300


```

gatgagaaac cagatgatca ctctgtgtgcc tttgggttca gtcacatcaagt gtatagttta 360
ttataaagag cctttcttga ggaaaaagga ttactgttga accatgatta ttgatggaga 420
agaagctcca gttgcctaca cgttggtatga taccacacct gaaggcaact atgctgccat 480
aatgggattt atcctggccc acaaagccag aaaactggca cgtcttacca aagaggaaag 540
gttgaagaaa ctttgtgaac tctatgccaa ggttctgggt tccctagaag ctctggagcc 600
agtgcattat gaagaaaaga actggtgtga ggagcagtac tctgggggct gctacacaac 660
ttatttcccc cctgggatcc tgactcaata tgggaagggt ctacgccagc cagtggacag 720
gatttacttt gcaggcaccg agactgccac aactggagc ggctacatgg agggggctgt 780
agaggccggg gagagagcag cccgagagat cctgcatgcc atggggaaga tccagagga 840
tgaaatctgg cagtcagaac cagagtctgt ggatgtccct gcacagccca tcaccaccac 900
ctttttggag agacatttgc cctccgtgcc aggcctgctc aggntgattg gattgaccac 960
catcttttca gcaacggctc ttggcttccct ggcccacaaa agggggctac ttgtgagagt 1020
ctaaagagag aggggtgtctg taatcacact ctcttcttac tgtatttggg atatgagttt 1080
ggggaaagag ttgcagtaaa gttccatgaa gacaaatagt gtggagttag gcggggagca 1140
tgaagataaa tccaactctg actgtaaaat acatgggtatc tctttctccg ttgtggcccc 1200
tgcttagtgt cccttacctg gcttagcgtt ctgtttcacc agtttccaag tttattgccc 1260
tcaaaatctt tagaatagtt aaattggctt gtttaagggt cttgctgccc cacaacacac 1320
cttgcccatg cacaaggaat gaatttttct ctaccattat ggctttgtgc ttgttcttcc 1380
tcttacctgt aatagcctca cctccctag ttctttgnca ttcttcttga gaatactgta 1440
ttgtttacagc tgaagacag taaagaccat ttagtcttca cttctgttt tagagttgag 1500
caaactgaag cccacagagc tggaacttaa ttacctaa gccacaataa gccactggta 1560
tctgggggac tagaacacaa atccaacgct tttccacact ctttggtatg tttccccaat 1620
tatcctcctt cactccctgt catagttacc gatggtgtcc cgttgtgtgg gtttactctg 1680
tgctaagttg tcttacactt ctcaaatgct actcagtata tagccttaag tcttactgtt 1740
ttgtgcggtg tgtctccagc tgattttaac ttttttgatg gtagaaattt tatctcttct 1800
tccttttgta tcctccattg tatcttcata caaaggacag tacacacttg ggtaattaaa 1860
aataaaagtt gattgaccat aaaaaaaaaa aaaggggggg ccgcccangg ggg 1913

```

<210> 2

<211> 1425

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (790)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (842)

<223> n equals a,t,g, or c

<400> 2

```

acttatttat cctgcttgaa agctacttgm gatgtgtact gctattctaa acacgtgac 60
tagtttcttt catctctggc ataagattat ataacttaat gttaagtgtc ttgmggcata 120
aaagacaaaa tgtggcttat tttaggatct gttttttcat cgagggtctc ggtatccttt 180
caaagatagt garaagcaga cactgctcct tgtgcagctc tggtagctcc tgcccactgc 240
tgtcacttca agccactggc aatgcttctg tcctogtgtc ttggaggaaa atcacctggg 300
gggagggggc ttcttgtggt aagagcaagt gcaggatga aatgcgaaga ttgcccagc 360
taaaagtggc caagtccgct ttgtgagatg aatacttctc gagaaacttg acaagtatct 420

```

```

ctccatttta ccattatgaa aactatcatt aaaaaaaca gtttagatgc cttctccttt 480
tgagggaaaa aggggtgcttt ttattgtata aagcagcgtc ttatgtatgt tgatatacca 540
ttgtttgaac ttccgtcttt agctgataga ttctcaaata tccttgattt tggatgttca 600
gtatgtttgt gagagaggtt tctgggaaga ctctcttttt gccctcggga aaaagcaaaa 660
tatcaatgtt tgggtgactg tgtaaagctc agtgtgtaag aacatctttt tgtctagggt 720
ttctttctgc tctttattga agacaaacac tcaccaaaaa gaaaaataaa agttttcaga 780
gaaactaatn ttcyttgggc aagagtatta cytaaataatt tkggccyccy aaagttyccc 840
ynagtwagta ctcggacycc tgtgctaatt gtcagcytac atatcattgt atagagactg 900
tttawtctgt accaaactga tttcaaaagt actacattga aaataaacccg gtgactgttt 960
ttcttcataa agttctgctg ttggcatctt cactctttcc aaaatgtatc tgtacatcag 1020
aaatgtcact attccaagtg tctttttagt gtggcttttag tatggcttcc ttttaatat 1080
gtacatacat tgtatctttg ttttatggta ataagtaata aaaatgtaga cttcatatgt 1140
tgtacaaaat gtcctatgta cagaataaaa aagttcatag aaacagcaaa tataggtaag 1200
tggcacaatt atttttcttt agaaaataatc tgtaacttta tgcattagtg aaatgttaag 1260
taccgacata ttttttaaca ttttgtaatt caaaactttt tgttttgaca ttgtttatga 1320
agagaaactt catacacttg ccatttaata tgctctttta tctaattttc aaaaactcta 1380
aaaaacggtg tatcatatgg actaaataaa gaacatgtga atttt 1425

```

<210> 3

<211> 354

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (246)

<223> n equals a,t,g, or c

<400> 3

```

ggcacgagaa ccatttccac tatatatctc ttccgataac taraaattaa awtatattggt 60
gtattatttg caaggagtca aagatgatgt cttttcccag aggcataaac cttagaaatg 120
ctttcgatgg ggatgtttct gtaacactgt gttattctgg atcttcaaat aatagcaaaag 180
ccaattactc taaatgtaaa atttttctat tcccagggtt cacttttggt tggtaggttt 240
tcacgntttt aaatactgtt taatggaaga aaaatacgtg gccaggcgtg gtggctcaca 300
cctgtagccc cggaactttg ggagactgaa gcgggcagat cacgaggtaa ggag 354

```

<210> 4

<211> 514

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (502)

<223> n equals a,t,g, or c

<400> 4

```

agacgcacgc gtactgctcc aacctcagct tccgcctcta cgaccagtgg cgagcctgga 60
tgcagaagtc gcacaagacc cgcaaccagc acaggacgag gggatcctgc cctcgggag 120
acggggcacg gcgagaggtc ctgccagata agctgtaggg gctcaggcca ccctccctgc 180
cacgtggaga cgagagggcc gaacccaaac tggggccacc tctgtacctt cacttcaggg 240

```

```

cacctgagcc accctcagca ggagctgggg tggccctga gctccaacgg ccataacagc 300
tctgactccc acgtgaggcc acctttgggt gcaccccagt ggtgtgtgt gtgtgtgtga 360
gggttggttg agttgcctag aaccctgcc agggctgggg gtgagaaggg gagtcattac 420
tccccattac ctaggggcccc tccaaaagag tccttttaaa taaatgagct atttaggtgc 480
wraaaaaaaa aaaaaaaaaac cncggggggg gcc 514

```

<210> 5

<211> 2035

<212> DNA

<213> Homo sapiens

<400> 5

```

cacgaggaat gacatgaaag cagactgtat tttgtactac ggctttggag atatattcag 60
aataagttca atggtggtga tggaaaatgt gggacagcag aagctttatg agatgggtatc 120
atactgtcaa aacataagca aatgtcgtcg tgtgtgtgat gctcaacatt ttgatgaagt 180
atggaactca gaagcatgta acaaaatgtg cgrtaactgc tgtaaagaca gtgcatttga 240
aagaaagaac ataacagagt actgcagaga tctaatacaag atcctgaagc aggcagaggg 300
amctggaatg gaaaaactca ctcccattgg aaactggatt gattccttgg tgggaaaggg 360
tgcaagcaaaa ctgagagtag caggtgttgt ggctcccaca ctctctcgtg aagatctgga 420
gaagattatt gcacacttts taatacagca gtatcttaaa gaagactaca gttttacagc 480
ttatgctacc atttctgatt tgaaaatagg acctaaagct aatcttctga acaatgaggc 540
acatgctatt actatgcaag tgacaaagtc cacgcagaac tctttcaggg ctgaatcgtc 600
tcaaacttgt cattctgaac aaggtgataa aaagatggag gaaaaaaatt caggcaactt 660
ccagaagaag gctgcaaaaca tgcttcagca atctggttct aagaatacag gagctaagaa 720
aagaaaaatc gatgatgcct gatatgaatg ttactaaatt ttctaattaa agatgggtta 780
tgcatgtata tgccattatt tttgtagtta gacaatagtt tttaaaagaa tttcatagat 840
attttatatg tatggatcta ttttttcaga gcttatctct gaagatctaa acttttgaga 900
atgtttgaaa attagagatc atgaattata taattttcca gtataaaaca agggaaaaat 960
ttttatgtaa aaccctttta atgtaaaata tttgagaata agttcataca atcgtcttaa 1020
gttttttatg cctttatata cttagctata ttttttcttt tgacataact atctttttga 1080
aagcaatatt atactgacag aggctcactg agtgatactt taagttaa atgtagatca 1140
aggatgtcca atcttttggc ttccctgagc cacattggaa gaagaattgt cttgggccgc 1200
acataaaata tgctaacact gatgatagct gatgagctta aaaaaaaat tgcaagaaaa 1260
atctcatgtt ttaagaaagt ttacaaaaaa tgtaaaatat ttgagaataa gttcatgtaa 1320
ttgtcttaag ttttttatgc ctttatatac ttactatata tttttctttt gacataacca 1380
tctttttgaa agcaatatta tactgacaga ggytactga gtgatacttt aagttaaata 1440
tgtagatcag ggatgtccaa tcttttggct tccctgagcc acattggaag aagaattgtc 1500
ttgggccgca cataaaatat gctaacactg acgatagctg atgagcttaa aaaaaaaaaa 1560
attgcaagaa aaatctcatg ttttaagaaa gtttacagat ttgtgttggg ctgcattcaa 1620
agctgttctg ggctgcatta gaccgtggg ctagagttgg acaagcttgt agatgatttc 1680
agggtataaa accagaagta caattcaaca aaaaaggagt aagtcataca tataaatatt 1740
agcaaacgag atattgtctac atctctattt aaagtaaaat acaaccgatt ttaaagttcc 1800
tgaaaccata gccatatttt gacatttcac aaagaatggt tctagtctac tagagtacat 1860
ttggctaagt agataactta cctaaatttg ctccaaagct aaatcacaag taaacatatt 1920
tatgtttaaa acacagaaat aaataactta agatttttat ctaagcggtc agtgttgtrt 1980
tggaagata tatctataaa taaactttga actgatttca aacttaaaaa aaaaa 2035

```

<210> 6

<211> 1196

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (157)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (998)

<223> n equals a,t,g, or c

<400> 6

```

ggtgggtgtg ggactggggg ctgtgagtgt gagtgtgtgc aagagattgc tctgcatgtt 60
tgctgagggc tggagctggg cttttcagag atcgggcatc cctggctctc cagggccagt 120
tggagggtcc caggaggcat gttcttgatg cctgtgntgc ctgaatccaa ttaactgaat 180
tctgaagagt gcatggggta actgtctcag cctttctcct gtctctgcct ctgtcctctg 240
ctccaaatca taaaatctca gagctagaag cactttcaag atcattccat ccagcgcat 300
caatttgcaa gtttaggcgt tgagttccag agagggatgg tagcttgctg aggtcccagt 360
caagcacact tgccattgcc tcagctttcc cctaaacacg gtgtctgtgg tcagggttgg 420
tgaggaggag ctttctgtt ttgcctctcc ttcttcccat tggctacacc catctytggc 480
cctgctgata ccgattcccc tgacatttca ggctaaagcc agcaggraag ggctagggac 540
gggtgccttg gaagcccaca tggagggagt tgggcaagat ttgattcggg gcaggtgtca 600
agacgtgttg gggaaactga ggcccagtgg aatagaagcc agtagaggag gaatctagag 660
gcctcctaga ttaaggcctg cctggaatgg attgggggtg ggtctttgga aaaggagggg 720
accacctct agcccagtct ctcaactgcc cctcctttac agtgagttag atcattggcc 780
gagacctgag tggcttcctt gcacctctg gagaagagcc tcctgcctga accacgtgaa 840
ctgtcatcac ctggcaaccc cagccccagc ctacagccctg cccctttcc ctccttctg 900
gagtgggtgg tacagaagct tggggccaac cctggctcct ctttccccag cttctgtctg 960
tctcactgtc ttccctcccc tccccagct gaggtgtngc cctcaggcct ggtgctgcct 1020
tggagggtct ggggaaggag tgtgtggagg agggaggagg gtgaagactg aggctagggt 1080
ccagaatgga ctggagtga ggcgtgtcta gagtgtgggc tggctgttgt gctggaaagc 1140
tggggacagg ttgatggtaa taaactgctc aatgaccagt gaaaaaaaaa aaaaaa 1196

```

<210> 7

<211> 624

<212> DNA

<213> Homo sapiens

<400> 7

```

attattttca agtcaaaatt tccagtaagg atttacttta catttcattt ggataaatga 60
atcattatat aggtatgtct ttgcttccat tttgagacat ttagattttt acagcctgtt 120
tctatagcat ttgatgttac aactctaagc gtagttcaaa gacatttaaa ttgacaagtt 180
accagttaaa gaatttagaa tatattagat cccatctagt attatatatt ttttctagtt 240
gatcattgag cagtaaatat caaatactcg attagaaggt aatttttaca ttgttttgaa 300
aggggtgaamc aatttatctc ctctggtatt attcttaaac cacagatagg gatagtaggg 360
tagtgaacg mataaatacc tggtagaaga caagagactt gggctctaca cctggctctg 420
cactgatttg ctaagtcata ttggcaatca ccacaccctt cagggaatta gtttcatctg 480
taaaatgcag cggtagtac tatwaaatca tacmaatttc tttgtgcttt gagaatctwt 540
aarggaatgt ctgttgatat tctgagtcga ttttcatttg cttttgttcc agaacggtta 600
aaataaaagca tattatttca tttta 624

```

<210> 8
 <211> 301
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (289)
 <223> n equals a,t,g, or c

<400> 8
 aattcggcac gagcggcgac ggcggcggct ccaagatggc gcaggcgatc tttagaggccc 60
 tggagggaat ggacaatcag accgttcttg ctgtccagtc attattggat ggccaaggag 120
 cagtcctga tccgacaggc cagagtgtca atgcgcccc tgctatccag ccattggatg 180
 acgaggatgt atttctctgc gggaagtgt agaagcaatt caactcgctg ccagcggtta 240
 tgaccacaa gcggaacag tgccagggga atgccccgc cctggccana gtctcactgg 300
 c 301

<210> 9
 <211> 686
 <212> DNA
 <213> Homo sapiens

<400> 9
 acccacgct ccgccaact cctctttcgt ctttctttaa cacacactag gctctttgtg 60
 tattatgatt cagtgtatt tgtaactgtg tcccagtgac caaattgcac tcgactcgat 120
 cagctgttca tccatttcgt gttttttcct gtcaaacatt aatccagcaa atatatgagg 180
 tátttaccaa tttattttct tagtattaca aaataattca ttagcataaa gtacaatagt 240
 gaaatatttg agttgttcg aacctcaatt aatcctgttt tacatttcag acctaaagct 300
 ggcaatcagg agaagaagca ctttggttta aatgtggaga agataacacc ttgattccat 360
 ttcattgtca ttagtgtatt aaccagcagg agagggtgat agccattttt caaatgaaat 420
 accttttatt tccatataat ttttttatt tagagttaa tagctgtttc tatgattatc 480
 ctcaatttcc atatgttact gaacttgaaa aacatcttta aaattcaaac agttccattt 540
 tctctcttgt aagtgttaaa tgtgataaaa gtacatattt taaattgttt tcagctcttg 600
 gatatagcag caataaaaac actaatttgt gggatattta gaaaacctgg agaataaact 660
 catactttaa aagatcaaaa aaaaaa 686

<210> 10
 <211> 397
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (379)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (394)
 <223> n equals a,t,g, or c

<400> 10

```
cacacgctta gcaacctgga gtttgccag aaagtggagc cctgcaacga ccacgtgaga 60
gccaaagctgt cctgggctaa gaagagggat gaggatgacg tgcccactgt gccgtcgact 120
cygggagagg agcgctcta caacccttc ctgcggtgg cgtgagtatg gctgtgtgcc 180
cggggcctcc accgttacgt ggacccttag gaaggcatct ggggactgag tgggtggctg 240
agtgagcatc tctggcttgg gggaggctgc tcattaagtg cctgcctgcc cgscamccc 300
tcggcgccat gctccgcgt gggcagcggg ccctgcgcct cactgcaccc ctccctgcag 360
agaggagccg gtgcgcaant ttcacgggca agnggt 397
```

<210> 11

<211> 563

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (10)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (13)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (37)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (510)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (562)

<223> n equals a,t,g, or c

<400> 11

```
aggcaaaacn gtnagaccga cagtaaccgg atccggnaat tcccgggtac gacccacgcg 60
tccgatata tcagagtaac tggagtagct gggatttact agtagttaa ataaaattca 120
ctcttcaata catgaatgga aacttaaatt tttttttat gtgtccttgc ttatagtta 180
gctgtaataa tttaaccttg tattcttctg ccatattctg tctttttatt acttataaag 240
acaaacaaaa gtaaactctga aggagacyag aagctttgaa attattgttt gggggtttta 300
taaaagcaac tactgtcacc tccatccaga ttcttttaaa ttattgatcc atccatagta 360
tatattgcta ctcatcgaag aatcctcaat aagatttgag tatttaccat atgttgggat 420
actgtgggct ctggagagag gagggggcaa tagagctagg rattaaggaa tcagttgwt 480
aaaatgkgtat atattttatt ccccatnaan taactggact agggaaggga ctaaaaggcc 540
agaaaggggg atgaaaaaaa ant 563
```

<210> 12
<211> 443
<212> DNA
<213> Homo sapiens

<400> 12
gagacctcgg ctccggaatc actgcagccc ccctcgcctt gagccagagc accccgggtc 60
ccgccagccc ctcacactcc cagcaaatg ggcaaggaga agaccacat caacatcgtg 120
gtcatcggcc acgtggactc cggaaagtcc accaccacgg gccacctcat ctacaaatgc 180
ggaggtattg acaaaaggac cattgagaag ttcgagaagg aggcggctga gatggggaag 240
ggatccttca agtatgcctg ggtgctggac aagctgaagg cggasgtgag cgcgrrcatc 300
accatcgaca tctccctctg gaagtctgag accaccaagt actacatcac catcatcgat 360
gcccccgcc accgcgactt catcaagaac atgatcacgg gtacatccca ggcggactgc 420
gcagtgctga tcgtggcggc ggg 443

<210> 13
<211> 2438
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (117)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (681)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (713)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (2413)
<223> n equals a,t,g, or c

<400> 13
cactgggagg ggggtgggga tctgggcaag gtgggtgatt cctcccagga ggtgcttgag 60
gccccgatgg actcctgacc ataatcctag ccccagagaca ccacacctgag ccagggnaac 120
agccccaggg ttggggggtg ccggcatctc ccctagctca ccaggcctgg cctctgggca 180
gtgtggcctc ttggtattt ctgtgtccag ttttgaggc tgagttctgg ttcatgcaga 240
caaagccctg tccttcagtc ttctagaaac agagacaaga aaggcagaca caccgcggcc 300
aggcaccat gtgggcgccc accctgggct ccacacagca gtgtcccctg ccccaraggc 360
cgcagctacc ctcagcctcc aatgcattgg cctctgtacc gcccggcagc cccttctggc 420
cgggtgtggg ttcccaactc cggcctaggc acctccccgc tctccctgtc acgstcatgt 480
cctgtcctgg tcctgatgcc cgttgtctag gagacagagc caagcactgc tcacgtctct 540

```

gccgcctgcg tttggaggcc cctgggctct caccagtc ccacccgcct gcagagaggg 600
aactagggca ccccttgttt ctgttgttcc cgtgaatttt tttcgctatg ggaggcagcc 660
gaggcctggc caatgcggcc nactttcctg agctgtcgct gcctccatgg canagccarg 720
gacccccaga acaagaagac cccccgcag atccctcctg agctcggggg gctctgcctt 780
ctcaggcccc gggcttccct tctccccagc cagaggtgga gccaaagtgt ccagcgtcac 840
tccagtgtc agctgtggct ggaggagctg gcctgtggca cagccctgag tgtcccaagc 900
cgggagccaa cgaagccgga cacggcttca ctgaccagcg gctgtctcaag ccgcaagctc 960
tcagcaagtg cccagtggag cctgccgccc ccrctgggc accgggaccc cctcaccatc 1020
cagtgggccc ggagaaacct gatgaacagt ttggggactc aggaccagat gtccgtctct 1080
cttgcttgag gaatgaagac ctttattcac ccctgccccg ttgcttcccg ctgcacatgg 1140
acagacttca cagcgtctgc tcataggacc tgcattcttc ctggggacga attccactcg 1200
tccaagggac agccacaggc ctggaggccg aggaccacca gcaggcaggt ggactgactg 1260
tgttgggcaa gacctcttcc ctctgggcct gttctcttgg ctgcaataa ggacagcagc 1320
tggtgcccc cctgcctggt gcattgtgt gtgaatccag gaggcagtg acatcgtagg 1380
cagccacggc cccgggtcca ggagaagtgc tccctggagg cacgcaccac tgcttcccac 1440
tggggcccgc ggggcccacg cacgacgtca gctcttacc tcccgcctc ggctaggggt 1500
cctcgggatg ccgttctgtt ccaacctcct gctctgggac gtggacatgc ctcaaggata 1560
cagggagccg gcggcctctc gacggcacgc acttgccctgt tggctgtctg ggctgtgggc 1620
gagcatgggg gctgccagcg tctgttgtgg aaagtagctg ctagtgaat ggctggggcc 1680
gctggggtcc gtcttcacac tgcgcaggtc tcttctgggc gtctgagctg ggggtgggagc 1740
tcctccgcag aaggttgtg ggggtccag tctgtgatcc ttggtgtgt gtgccccact 1800
ccagcctggg gacccactt cagaaggtag gggccgtgtc ccgcggtgct gactgaggcc 1860
tgcttcccc tccccctcct gctgtgtgtg aattccacag ggaccagggc caccgcaggg 1920
actgtctcag aagacttgat tttccgtcc ctttttctcc aactccact gacaaacgtc 1980
cccagcggtt tccacttgt ggcttcaggt gttttcaagc acaaccacc acaacaagca 2040
agtgcatttt cagtcgttgt gctttttgt tttgtgctaa cgtcttacta atttaaagat 2100
gctgtcggca ccatgtttat ttatttcag tggatcatgt cagccttgt gctctgcgtg 2160
gcgcaggtgc catgcctgct ccctgtctgt gtcccagcca cgcagggcca tccactgtga 2220
cgtcggccga ccaggctgga caccctctgc cgagtaatga cgtgtgtggc tgggaccttc 2280
tttattctgt gttaatggct aacctgttac actgggctgg gttgggtagg gtgttctggc 2340
ttttttgtgg ggtttttatt ttaaagaaa cactcaatca tcctaaaaaa aaaaaaaaaa 2400
aaaaaaaaa ttntcggtc cgcaaggga ttcagtgg 2438

```

<210> 14

<211> 2347

<212> DNA

<213> Homo sapiens

<400> 14

```

aattcggcac gmgctgagga ccgcacggaa acggggaagt cagggtggccg ctgccgccgc 60
cgccgccgcg gtttgtcgcc agaaggaaga tggcggtctt ggaggagcag ttgtctgatg 120
aagagaaggc gcgtatagca gcaaaattca tcattcatgc ccctcctgga gaatttaatg 180
agggtttcaa tgatgttcgg ttactgctta ataatacaca tcttctcagg gaaggagcag 240
cccatgcatt tgcacagtat aacttgacc agtttactcc agtaaaaatt gaaggttatg 300
aagatcaggt attgataaca gaacatggcg acttgggaaa tggaaagttt ttggatccaa 360
agaacagaat ctgttttaaa ttgatcact taaggaagga ggcaactgat ccaagacctt 420
gtgaagtaga aaatgcagtt gaatcatgga gaacttcagt agaaactgct ctgagagctt 480
acgtaaaaga acattacccg aatggagtct gcactgtgta tggcaaaaaa atagatggac 540
agcaaacatc tattgcagtc atagaaagcc atcagttcca agcaaaaaat ttttggaatg 600
gtcgttgagg gtcagaatgg aagtttacia tcaactcttc aaccactcaa gtggttgga 660
tcttgaaaat tcaggttcac tattatgaag atggtaatgt tcagctagtg agtcataaag 720

```



```

atatacaaga ttccctaaca gtgtctaagt aagtgc aaac agcaaaagaa tttataaaga 780
ttgtagaagc tgcagaaaat gaataccaga ctgccatcag tgagaattat cagacaatgt 840
cggacactac tttcaaagcc ttacgtcgac agttgccagt tacacgcact aagattgatt 900
ggaacaagat ccttagctac aagattggca aagagatgca gaatgcataa gatgaacatt 960
gcatgaccgg atcatttttag tgtctttgcg ttaaaaaatc attgcaaaag tattctgaac 1020
tgtcaagctg ccagtcaga tgggctgttg ccatttaaaa tcaactgtaat taattagttt 1080
gattagagca caaagcttag ctaatcaacc attatttttc attttgtttg ttctaagagg 1140
attgaaaatc agtttagttt aaatgtcttt ctgtaggccc tttctttctt acaatgaaga 1200
gatgattctt ctagtttatg gttaaaagtt tttgaagtgt ctcaaaaata ttttactaac 1260
tgtaacccta aaattgatgt cttttggttt atgaaatcag taatttttga ttttcccca 1320
gttcttttta atggggtaa taatggacat tctagtttaa ggtggttgat ggatttagcc 1380
atatatgctg ctaaagaaat tgtctacctt ttcttcctca cctgttccat ttatgtaaag 1440
ttgagattag agggaaagca tttctatat caattgtgtt taaacctttc aagaaggtta 1500
tttagctagc ttagtggtga actaaatttt ttttaaaaca ggcaaggctc aatgctgttt 1560
tgagattctg aaattaatga aaatacttat ttcagaaatg catttaatgc tttttttctt 1620
gtgacagtta cgcaaatcag cttgaattcc atatgtccct gagttatttt tatcataaag 1680
ccacaaatgt attataacaa ggcaaatgt aatatatata atcctgaact catgaccatg 1740
ctcgggttta tttttttttt cttggattga aaagtactga aattcaatgt gacattaaaa 1800
tgcaaatttt cctattttatt tgagtagaaa atcacttacc agtgagcata tatattttta 1860
aatactttct ttggatattg taattcttaa ctggttgtaa attagaaaag ctgggattac 1920
atatggtgtg cggttacagt ctaaattttt tcatcctcct atgcatcata agcatgtttg 1980
taatattttc aaaaatagtt ctactgatgc tacaggaatt tcaagcctgt ggtgaatgtt 2040
agtatttacc atagggagtg aagtggagtt atggtttcat tcaatagagt attgcygatt 2100
atacttgagt ggaatccttt cctcacgtac tcccacagac gtctgggcct ggaaattttt 2160
tttttatttt attttattgt tttttttttt agaaaaacac cacttttatt atgtacaata 2220
aaatatttca ttagcttgaa ttgtatagat ttttaaaaat tcaatgaaag catgttgttt 2280
aatttctttt taaaatcact gttgggcttt gaaagcattg agaataaat atgaaattat 2340
gaaaaaa 2347

```

<210> 15

<211> 2006

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (862)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1006)

<223> n equals a,t,g, or c

<400> 15

```

ggcagagctg taccagtggc agcagcaagc cgaatagccc cagcatttcc cttcaatac 60
ttagtaaacac ggagcacaag aggggacctg aggtcacttc ccaaggggtt cagacttcca 120
gccagcatg taaacaagag aaagacgata aggaagagaa gaaagacgca gctgagcaag 180
ttaggaaatc aacattgaat cccaatgcaa aggagttcaa cccacgttcc ttctctcagc 240
caaagccttc tactacccca acttcacctc ggcctcaagc acaaccttagc ccatctatgg 300
tggtcatca acagccaact ccagtttata ctacgcctgt ttgttttgca ccaaatatga 360

```

```

tgtatccagt cccagtgage ccaggcgtgc aacctttata cccaatacct atgacgcccc 420
tgccagtga tcaagccaag acatatagag caggtaaaagt accaaatatg ccccaacagc 480
ggcaagacca gcatcatcag agtgccatga tgcacccagc gtcagcagcg ggcccaccga 540
ttgcagcmac cccaccagct tactccacgc aatatgttgc ctacagtcct cagcagttcc 600
caaatacagc ccttgttcag catgtgccac attatcagtc tcagcatcct catgtctata 660
gtcctgtaat acagggtaat gctagaatga tggcaccacc aacacacgcc cagcctgggt 720
tagtatcttc ttcagcaact cagtacgggg ctcatgagca gacgcatgcg atgtatgcat 780
gtcccaaatt accatacaac aaggagacaa gcccttcttt ctactttgcc atttccacgg 840
gctcccttgc tcagcagtat gngcraccct aacgctaccc tgcacccaca tactccacac 900
cctcagcctt cagctacccc cactggacag cagcaaagcc aacatggtgg aagtcacct 960
gcacccagtc ctgttcagca ccacagcac caggccgccc aggctnctcc atctggccag 1020
tccacagcag cagtcagcca tttaccacgc ggggcttgcg ccaactccac cctccatgac 1080
acctgcctcc aacacgcagt cgccacagaa tagtttccca gcagcacaac agactgtytt 1140
tacgateccat ctttctcag ttcagccggc gtataccaac ccacccaca tggcccacgt 1200
acctcaggct catgtacagt caggaatggt tccttctcat ccaactgccc atgcgccaat 1260
gatgctaata acgacacagc caccggcggt tccccaggcc gccctcgctc aaagtgcact 1320
acagcccatt ccagtcctga caacagcgca tttcccttat atgacgcacc cttcagtaca 1380
agccaccac caacagcagt tgtaaggctg ccctggagga accgaaaggc caaattccct 1440
cctcccttct actgcttcta ccaactggaa gcacagaaaa ctagaatttc atttattttg 1500
tttttaaaat atatatgttg atttcttgta acatccaata ggaatgctaa cagttcactt 1560
gcagtggaag atacttgga cagtagagg catttaggaa cttgggggct attccataat 1620
tccatatgct gtttcagagt cccgcaggta cccagctct gcttgccgaa actggaagtt 1680
atatttttt taataaccct tgaaagtcac gaacacatca gctagcaaaa gaagtaacaa 1740
gagtgtattc tgctgtatt actgctaaaa aaaaaaaaaa aaaaaaatca agacttgga 1800
cgccctttta ctaaacttga caaagtttca gttaaattct accgtcaaac tgacggatta 1860
ttatttataa atcaagtttg atgaggtgat cactgtctac agtggttcaa cttttaagtt 1920
aagggaaaaa cttttacttt gtagataata taaaataaaa acttaaaaaa aatttaaaaa 1980
ataaaaaaag ttttaaaaac tgaaaaa 2006

```

<210> 16

<211> 986

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (613)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (932)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (933)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (985)

<223> n equals a,t,g, or c

<400> 16

```
tcaaagtaac tctgacctc aagccaacag aagcctcaag ttcggctttt cgcttgatgc 60
cagctcttgg cgtgagtgtg gctgaccaga agggaaaaag cacagtggcc tcttcagaag 120
caaaaccagc tgccacgacg cgcacgtgac agggactggg agtgatgcct cccaaagcag 180
gccagaccat caccgttgca acccacgcca agcaaggggc ctgggtggcc agtgggtctg 240
gaactgtcca tacttcagcg gtgtccttac ccagtatgaa tgctgctgtg tccaagactg 300
tagctgtggc ttctggggct gcaagacccc catcagcatc agcacaggag cccccaccgt 360
gcggcaggtc cctgtcagca ccacggttgt gtccacgtcc caggctggga agttgcctac 420
acggatcaca gttccccctc ctgtgatcag ccagccaatg aagggaaga gcgtgggtcac 480
agcccccatc atcaaaggca accttggagc caacctcagt gggttgggga gcaacatcat 540
cctcacaact atgccagcag gactaagct cattgctggc aataagcctg ttagtttctc 600
cactgtctcag canttgcagc agcttcagca gcaaggtcag gccacacagg tgcgcatcca 660
gactgtccct gcatcccatc tccaacaggg aacagcttct ggctcctcca aagcagtctc 720
cactgttggt gtgactacag ctccgtctcc taaacaggca cctgagcaac aatgattatg 780
agagaggatg gcttccgtga aagaccatgc ctggtctgtc ctggctgaga agggaccagg 840
gagttgcacg attgttttaa gctgcctgtt caaggcagcc aggcgagggt gatggcaacg 900
gtggcctggt tygtgggcct ggattctgag cnnngggccat agtgggagca ccctgagaaa 960
ggtcactccc gggttccaaa ggctng 986
```

<210> 17

<211> 1589

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (25)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (555)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (809)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1033)

<223> n equals a,t,g, or c

<400> 17

```
tttgaacttg gggaaacaag gttgncatcc cagtggcctc aaccctccct cagccccctc 60
tgccccccac cccagcctaa gatgaagagg atcgagggtc tgtcagagct gggaggggtt 120
ttcgaagctc agcccacccc cctcattttg gatataggtc agtgaaggcc caggagaggg 180
```

```

ccatgattcg cccaaagcca gacagcaacg gggaggccra gtgcaggctg gcaccgcctt 240
ctctaaatga ggggcctcag gtttgccctga gggcgagggg aggggtggcag gtgaccttct 300
gggaaatggc ttgaagccaa gtcagctttg ccttccacgc tgtctccaga cccccacccc 360
ttccccactg cctgccacc cgtggagatg ggatgcttgc ctagggcctg gtccatgatg 420
gagtcagggt tggggttcgt ggaaagggtg ctgcttccct ctgcctgtcm ctctcaggca 480
tgctgtktg acatcagtgg catggctcca gtctgctgcc ctccatcccg acatggaccc 540
ggagctaaca mtggnccctt agaatcagcc taggggtcag ggaccaagga cccctcamct 600
tgcaacacac agacacamgc acacacacac acaggaggag aaatctcact tttctccatg 660
agttttttct cttgggctga gactggatac tgcccggggc agctgccaga gaagcatcgg 720
aggggaattga ggtctgctcg gccgtcttca ctgcgccccc ggtttggcgg gccaaaggact 780
gccgaccgag gctggagctg gcgtctgtnt tcaagggtt acacgtggag gaatgctccc 840
ccatcctccc cttccctgca aacatggggt tggctggggc cagaagggtg tgatgaagaa 900
aagcgggcca gtgtgggaat gcggaagaa ggaattgact tcgactgtga cctgtgggga 960
tttctcccag ctctagacaa cctgcaaag gactgtttt tcctgagctt ggccagaagg 1020
gggccatgag gntcagtgg actttccacc ccctccctgg cctgttctgt tttgcctgaa 1080
gttggaatga gtgtggctcc cctctattta gcatgacaag cccagggcag gctgtgcgct 1140
gacaaccacc gctccccagc ccagggttcc ccagccctg tggaaaggac taggagcact 1200
gtagtaaatg gcaattcttt gacctcaacc tgtgatgagg ggaggaaact cacctgctgg 1260
ccccctacct gggcacctgg ggagtgggac agagtctggg tgtatttatt ttcctcccca 1320
gcaggtgggg aggggggttg ggggcttgca agtatgtttt agcatgtgtt tggttctggg 1380
gccccttttt actccccctg agctgagatg gaaccctttt tgtgcccag ctgggggcca 1440
tgagctccag ccccccagca accctcctat cacctccct ccttgccctc tgtgtaatca 1500
tttcttgggc cctcctgaaa cttacacaca aaacgttaag tgatgaacat taaatagcaa 1560
agaaagaaaa ataaaaaaaa aaaaaaaaaa 1589

```

<210> 18

<211> 846

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (746)

<223> n equals a,t,g, or c

<400> 18

```

gcaccgcct cgccgtgat gccaccgag acccagtccc ccgggcagcc ggcccagccc 60
gcgcccattg tgccactgca ccagaagcag agccgcatca ccccatcca gaagccgcgg 120
ggcstcgacc ctgtggagat cctgcaggag cgcgagtaca ggctgcaggc tcgcatcgca 180
caccgaattc aggaacttga aaaccttccc gggctccctg ccggggattt gcgaacccaa 240
gcgaccattg agctcaaggc cctcaggctg ctgaacttcc agaggcagct gcgccaggag 300
gtggtggtgt gcatgaggag ggacacagcg ctggagacag ccctcaatgc taaggcctac 360
aagcgcasaa gcgccagtcc ctgcgcgagg cccgcatcac tgagaagctg gagaagcagc 420
agaagatcga gcaggagcgc aagcgccggc agaagcacca ggaatacctc aatagcattc 480
tccagctcgc caaggatttc aaggaatatc acagatccgt cacaggcaaa atccagaagc 540
tgaccaaggc agtgggccacg taccatgcca acacggagcg ggagcagaag aaagagaacg 600
agcggatcga gaaggagcgc atgaggaggc tcatggctga agatgaggag gggtagcgca 660
agctcatcga ccagaagaag gacaagcgcc tggcctacct cttgcagcag acagacgagt 720
acgtggctaa ctcacggagc tgggtncggc acaaggctgc ccaggtcgcc aaggagaaaa 780
agaagaaaaa gaaaaagaag aaggcagaaa atgcagaagg acagacgcct gccattgggc 840
cggatg 846

```

<210> 19
 <211> 2192
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (115)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (2106)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (2118)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (2143)
 <223> n equals a,t,g, or c

<400> 19
 aaacaaaagg cgatattctg cctgggcaaa tctgtgacta atcttcctca agtcataaaa 60
 caaaagctga cacctttata tgagctggta aaggaagtac cttgtgcctc tgtgnaaaaa 120
 actatacctg aaatgggctc ttgaagagta tctggatgaa tttgaccctt gtcattgccg 180
 gccttgtaaa aatggtgggt tggctactgt tgaggggacc cattgtctgt gccattgcaa 240
 accgtacaca tttggtgctg cgtgtgagca aggagtcctc gtagggaatc aagcaggagg 300
 ggttgatgga ggttgaggtt gctgtgcctc ttggagcccc tgtgtccaag ggaagaaaac 360
 aagaagccgt gratgcaaka acccacctcc cagtgggggt gggagatcct gcgttgagga 420
 aacgacagaa agcacacaat gcgaagatga ggagctggag cacttgagggt tgcttgaaac 480
 acattgcttt cctttgtctt tggttccaac agaattctgt ccacacctc ctgccttgaa 540
 agatggattt gttcaagatg aaggtacaat gtttcctgtg gggaaaaatg tagtgtacwc 600
 ttgcaatgaa ggatactctc ttattggaaa cccagtggcc agatgtggag aagatttacg 660
 gtggcttggt ggggaaatgc attgtcagaa aattgcctgt gttctacctg tactgatgga 720
 tggcatacag agtcaccccc aaaaaccttt ctacacagtt ggtgagaagg tgactgtttc 780
 ctgttcagggt ggcattgtct tagaagggtcc ttcagcattt ctctgtggct ccagccttaa 840
 gtggagtcct gagatgaaga atgcccgtct tgtacaaaaa gaaaatccgt taacacaggc 900
 agtgccataa tgtcagcgtt gggagaaact gcagaattca agatgtgttt gtaaaatgcc 960
 ctacgaatgt ggaccttctt tggatgtatg tgctcaagat gagagaagca aaaggatact 1020
 gcctctgaca gtttgcaaga tgcatgttct ccactgtcag ggtagaaatt acacccttac 1080
 tggtagggac agctgtactc tgcctgcctc agctgagaaa gcttgtgggt cctgcccact 1140
 gtggggaaaa tgtgatgctg agagcagcaa atgtgtctgc cgagaagcat cggagtgcga 1200
 ggaagaagggt tttagcattt gtgtggaagt gaacggcaag gagcagacga tgtctgagtg 1260
 tgaggcgggc gctctgagat gcagagggca gagcatctct gtcaccagca taaggccttg 1320
 tgctgcggaa acccagtagg ctctggagg ccmgtgtcag cttgcttggg atccagcagg 1380
 cagctggggc tgagtgaata catctgcaca actgggcact ggacagcttt tccttctcca 1440

```
gtgtctacct tctcctcaa ctcccagcca tctgtataaa cacaatcctt tgttctccca 1500
aatctgaatc gaattactct tttgcctcct ttttaatgtc agtaaggata tgagcctttg 1560
cacaggctgg ctgctgtgtc ttgaaatagg tgttaccttc tctgggcctt ggttttttaa 1620
aatctgtaaa attagaggat tgcactagag aaacttgaat gctccattca ggcctatcat 1680
tttattaagt atgattgaca cagcccatgg gccagaacac actctacaaa atgactagga 1740
taacagaaag aacgtgatct cctgattaga gaggggtggtt ttcctcaatg gaaccaaata 1800
taaagaggac ttgaacaaaa atgacagata caaactatct ctatcctgag tagtaatctc 1860
acacttcata ctatagagtc aaccaccaca gataggratt ccttattctt tttttaattt 1920
ttttaagaca gagtctcact ttgttgccca ggytgagcgc cagtggggtg atctcatctc 1980
cctgcaacct ccgcctcctg ggttcaagcg attcttgtgc ctcagcttcc caagcagctg 2040
gggattacag gtgcccgcga ccacgcccag ctaatttttg ctttttttag agagatgggg 2100
tttcancatg ttggccangc tcgtctccaa ctctgacctc cangtaatcc gcctgccttg 2160
gcctcccaaa gtgctgggat acagacatga ac                                     2192
```

<210> 20

<211> 1011

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (54)

<223> n equals a,t,g, or c

<400> 20

```
ctctaatacg actcactata ggcaaagctg gtagcctgca gtaccggats crgnaattcc 60
cggggatgga agcgtttttg gggctgcggg ccggactttg ggcggggggg ccggccccag 120
gacagtttta ccgcattccr tccactcccg attccttcat ggatccggcg tctgcacttt 180
acagaggtcc aatcacgcgg acccagaacc ccatggtgac cgggacctca gtccctcggcg 240
ttaagttcga gggcggagtg gtgattgccg cagacatgct gggatccctac ggctccttgg 300
ctcgtttccg caacatctct cgcattatgc gagtcaacaa cagtaccatg ctgggtgcct 360
ctggcgacta cgctgatttc cagtatttga agcaagttct cggccagatg gtgattgatg 420
aggagcttct gggagatgga cacagctata gtcctagagc tattcattca tggctgacca 480
gggccatgta cagccggcgc tcgaagatga accctttgtg gaacaccatg gtcacggag 540
gctatgctga tggagagagc ttctcgggtt atgtggacat gcttgggtga gcctatgaag 600
ccccctcgtt ggccactggt tatggtgcat acttggtcca gcctctgctg cgagaagttc 660
tggagaagca gccagtgcta agccagaccg aggccgcga cttagtagaa cgctgcatgc 720
gagtgtgta ctaccgagat gccggttctt acaaccggtt tcaaatcgcc actgtcaccg 780
aaaaaggtgt tgaatatagag ggaccattgt ctacagagac caactgggat attgccaca 840
tgatcagtggt ctttgaatga aatacagatg cattatccag aactgaagtt gccctacttt 900
taactttgaa cttggctagt tcaaagatag actcttcttt tgtaaagtaa ataaattctt 960
caaaatgcaa aaaaaaaaaa aaaaaaaaaa cttcragact agttctctct c 1011
```

<210> 21

<211> 2019

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (2003)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2007)

<223> n equals a,t,g, or c

<400> 21

```
ggcagagccc aattcactcc cttccctcgc agtgactttc tcattctccc tgggtacatc 60
gacttcactg cagaccaggt ggacctgact tctgctctga ccaagaaaat cactcttaag 120
acccactggt tttcctctcc catggacaca gtcacagagg ctgggatggc catagcaatg 180
gcggtgagcc ccatgggggtg tgggggaagg agcaaggact ccatcgctt tccccaagg 240
cattcagtcg tgcttctkgt cacttagtag tagtctcttt ttaatcctgt agcttacagg 300
cgggtattggs ttcatccacc acaactgtac amctgaattc caggccaatg aagttyggaa 360
agtgaaggty wgaagggcaa cgatcattag caagcgctcc tgggaattgc actgaggtgg 420
ggtgggggtg gagtaggggt ttattctaata ttagtattct ttcttccac catgggggtc 480
agttactgag aagaccctga gattctgttt cttaaagcag cagcaataga ccaggtgtac 540
agtgcctcca gcctacccat gtctctaaga tgtgttggtg tgatttggtc ttgtggcact 600
gccaaaggga tcgataagca gagaccccat gcttcagatc aagagcctga tgaaagtagt 660
tcaaagatgc gatgcccttt ctcaccatcc ctttccagaa atatgaacag ggattcatca 720
cagaccctgt ggtcctcagc cccaaggatc gcgtgcggga tgtttttrag gccaaaggccc 780
ggcatggttt ctgcggtatc ccaatcacag acacaggccg gatggggagc cgcttggtgg 840
gcatcatctc ctccaggac attgatttty tcaaagagga ggaacatgac tgtttcttgg 900
aagagataat gacaaaggag gaagacttgg tggtagcccc tgcaggcatc aactgaagg 960
aggcaaatga aattctgcag cgacaagaa gggaaagtgt cccattgtaa atgaagatga 1020
tgagcttggt gccatcattg cccggacaga cctgaagaag aatcgggact acccactagc 1080
ctccaaagat gccaaagaa agctgctgtg tggggcagcc attggcactc atgaggatga 1140
caagtatagg ctggacttgc tcgcccaggc tgggtgtgat gtagtggttt tggactcttc 1200
ccagggaat tccatcttcc agatcaatat gatcaagtac atcaaagaca aataccctaa 1260
tctccaaagtc attggaggca atgtgggtcac tgctgcccag gccaaagaacc tcattgatgc 1320
aggtgtggat gccctgcggg tgggcatggg aagtggctcc atctgcatta cgcagggaagt 1380
gctggcctgt gggcgggccc aagcaacagc agtgtagaag gtgtcagagt atgcacggcg 1440
ctttggtgtt ccggtcattg ctgatggagg aatccaaaat gtgggtcata ttgcgaaagc 1500
cttggccctt ggggctccac agtcatgatg ggctctctcc tggctgccac cactgaggcc 1560
cctggtgaat acttcttttc cgatgggacg cggttaaaga aatatcgcg tatgggttct 1620
ctcgatgcca tggacaagca cctcagcagc cagaacagat atttcagtga agctgacaaa 1680
atcaaagtgg ccaggggagt gtctggtgct gtgcaggaca aagggtcaat ccacaaattt 1740
gtcccttacc tgattgctgg catccaacac tcatgccagg acattggtgc caagagcttg 1800
acccaagtcc gagccatgat gtactctggg gagcttaagt ttgagaagag aacgtcctca 1860
gcccaggtgg aagtgggcgt ccatagcctc cttcgtatg agaagcggct tttctgaaaa 1920
gggatccagc acacctcctc ggtttttttt tcaataaaaag tttagaaaga aaaaaaaaaa 1980
aaaaaaaaat tctcgggggg ggncccncta cccaattgg 2019
```

<210> 22

<211> 2022

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1588)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1615)

<223> n equals a,t,g, or c

<400> 22

```
gctttctggc gggcgctggg agaagacgga cctcacctac aggatccttc ggttcccatg 60
gcagttggtg caggagcagg tgcggcagac gatggcagag gccctaaagg tatggagcga 120
tgtgacgcca ctcaccttta ctgaggtgca cgagggccgt gctgacatca tgatcgactt 180
cgccaggtae tgcatggggg acgacctgcc gtttgatggg cctggggcat cctggcccat 240
gccttcttcc ccaagactca ccgagaaggg gatgtccact tcgactatga tgagacctgg 300
actatcgggg atgaccaggg cacagacctg ctgcaggtgg caccatgaa tttggccacg 360
tgctggggct gcagcacaca acagcagcca aggccctgat gtccgccttc tacacctttc 420
gctaccactt gactctcagc ccagatgact gcagggggcg tcaaacaccta tatggccagc 480
cctggccact gtcacctcca ggacccacgc cctggggccc caggctggga tagacaccaa 540
tgagattgca ccgctggagc cagacgcccc gccagatgcc tgtgaggcct cctttgacgc 600
ggctctccacc atccgaggcg agctcttttt cttcaaaagcg ggctttgtgt ggcgccctccg 660
tgggggccag ctgcagcccc gctaccacgc attggcctct cgccactggc agggactgcc 720
cagccctgtg gacgtgcctt tcgaggatgc ccagggccac atttggttct tccaagggtg 780
tcagtactgg gtgtacgacg gtgaaaagcc agtcctgggc ccgcacccc tcaccgagct 840
gggcctgggt aggttcccg tccatgctgc cttggctctg ggtcccgaga agaacaagat 900
ctacttcttc cgaggcaggg actactggcg tttccacccc agcaccgggc gtgtagacag 960
tcccgctgcc cgcaggccac tgactggaga ggggtgccct ctgagatcga cgctgccttc 1020
caggatgctg atggctatgc ctacttctct cgcgcccgcc tctactggaa gtttgacctt 1080
gtgaagggtg aggtctctga aggttccccc cgtctcgtgg gtcctgactt ctttgctgtg 1140
gcgagcctgc caaacctttc ctctgacctt ggcttgatg ccctcagggg tgctgacccc 1200
tgccaggcca cgaatatcag gctagagacc catggccatc tttgtggctg tgggcaccag 1260
gcatgggact gagcccatgt ctctcaggg ggatgggggt ggggtacaacc accatgacaa 1320
ctgcccggag ggccacgcag gtcgtggtca cctgccagcg actgtctcag actgggcagg 1380
gaggcttttg catgacttaa gaggaagggc agtcttgggc ccgctatgca ggtcctgggc 1440
aaacctggct gccctgtctc catccctgtc cctcagggtg gcaccatggc aggactgggg 1500
gaactggagt gtccttgctg tatccctgtt gtgaggttcc ttccaggggc tggcactgaa 1560
gcaagggtgc tggggcccca tgcccttnca gccctggctg agcaactggg ctgtnagggc 1620
agggccactt cctgagggtc ggtcttggtg ggtgcctgca tctgtctgcc ttctggctga 1680
caatcctgga aatctgttct ccagaatcca ggccaaaaag ttcacagtca aatggggagg 1740
ggtattcttc atgcaggaga ccccaggccc tggaggctgc aacatacctc aatcctgtcc 1800
caggccggat cctcctgaag cccttttcgc agcactgcta tcctccaaag ccattgtaaa 1860
tgtgtgtaca gtgtgtataa accttcttct tctttttttt ttttaaaactg aggattgtca 1920
ttaaacacag ttgttttcta aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1980
aaaaaaaaaa aaaaaggggc gccgctcgcg atctagaact ag 2022
```

<210> 23

<211> 1126

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1126)

<223> n equals a,t,g, or c

<400> 23

```
cccttcccca ctgcacacac ctcagaggct gttcttgggg ccctacacct tgaggagggg 60
caggtaaaact cctgtccttt acacattcgg ctccctggag cagactctgg tcttctttgg 120
gtaaacgtgt gacgggggaa agccaaggtc tggagaagct cccaggaaca ayygatggcc 180
ttgcagcact cacacaggac ccccttcccc taccctcc tctctgccgc aatacaggaa 240
ccccagggg aaagatgagc ttttctaggc tacaattttc tcccaggaag ctttgatttt 300
taccgtttct tccctgtatt ttctttctct actttgagga aaccaaagta accttttgca 360
cctgctctct tgtaatgata tagccagaaa aacgtgttgc cttgaaccac ttccctcatc 420
tctcctccaa gacactgttg acttggtcac cagctcctcc cttgttctct aagttccact 480
gagctccatg tgccccctct accatttgca gagtcctgca cagttttctg gctggagcct 540
agaacaggcc tcccaagttt taggacaaac agctcagttc tagtctctct ggggccacac 600
agaaactctt tttgggctcc tttttctccc tctggatcaa agtaggcagg accatgggac 660
caggtcttgg agctgagcct ctcacctgta ctcttccgaa aaatcctctt cctctgaggc 720
tggtacctag ccttatcctc tgatctccat ggcttccctc tccctcctgc cgactcctgg 780
gttgagctgt tgccctcagtc ccccaacaga tgcttttctg tctctgcctc cctcaccctg 840
agccccctcc ttgctctgca ccccatatg gtcatagcc agatcagctc ctaaccctta 900
tcaccagctg cctcttctgt gggtgaccca ggtccttggt tgctgttgat ttctttccag 960
aggggttgag cagggatcct ggtttcaatg acggttggaa atagaaattt ccagagaaga 1020
gagtattggg tagatatatt ttctgaatac aaagtgatgt gtttaaatac tgcaattaaa 1080
gtgatactga aacacaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaan 1126
```

<210> 24

<211> 2598

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (2304)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2500)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2533)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2553)

<223> n equals a,t,g, or c

<400> 24

```
ggcacagctt gtttttccaa gcagctgttt ggctttccra agcccacttt ctgtctttaa 60
raggtttaa garactacca gaccattttc caatgaatgt cttggtacca ccagaccctg 120
```

```

agttcctatt gattcatcag attttgcatt ggatattcgc atgcctgggg ttacacctaa 180
acagtccgat acatacttct gcatgtctat gcgaatacca gtggatgagg aagccttcgt 240
gattgacttc aagcctcgag ccagcatgga tactgtccat cacatgttac tttttggatg 300
caatatgcct tcatccactg graattactg gttttgtgat gaaggaaacct gtacagataa 360
agccaatatt ctgtatgcct gggcgagaaa tgctccccct acccggtcc ccaaagggtg 420
tggattcaga gttggaggag agactggaag taaatacttt gtactacagg tactatagg 480
ggatattagt gcttttagag ataataacaa ggactgttct ggtgtgtcct tacacctcac 540
acgtctgcc aagcctttaa ttgctggcat gtacctatg atgtctgtt acactgttat 600
cccagcagga gaaaaagtgg tgaattctga catttcatgc cattrtwaaa attatccaat 660
gcatgtcttt gcctatagag ttcacactca ccatttaggt aaggtagtaa gtggatacag 720
agtaaagaaat ggacagtgg cactgattgg acggcagagc cctcagctgc cacaggcttt 780
ctaccctgtg gggcatccag ttgatgtaag ttttgggtgac ctactggctg caagatgtgt 840
attcactggg gaaggaagga cagaagccac acacattggg ggcacgtcta gtgatgaaat 900
gtgcacttat acattatgta ttacatggaa gccaaagcat cagtttcttt catgacctgt 960
accagaatg tagctccaga tatgttcaga accataccac cagaggccaa cattccaatt 1020
cccgtgaagt ctgatatggg tatgatgcat gaacatcata aagaaacaga atataaagat 1080
aagattcctt tactacagca gccaaaacga gaagaagaag aagtgttaga ccagggtgat 1140
ttctattcac tactttccaa gctgctagga gaaaggaag atgtgttca tgtgcacaaa 1200
tataatccta cagaaaaggc agaatcagag tcagacctgg tagctgagat tgcaaatgta 1260
gtccaaaaaa aggatcttgg tcgatctgat gccagagagg gtgcagaaca tgagaggggt 1320
aatgctattc ttgtcagaga cagaattcac aaattccaca gactagtatc taccttgagg 1380
ccaccagaga gcagagtttt ctcatcacag cagcccccac ctggtgaagg cacctgggaa 1440
ccagaacaca caggagattt ccacatggaa gaggcactgg attggcctgg agtatacttg 1500
ttaccaggcm aggtttctgg ggtggctcta gamcctaaga ataacctggg gattttccac 1560
agaggtgacc atgtctggga tggaaactcg tttgacagca agtttgttta ccagcaaata 1620
ggactcggac caattgaaga agacactatt cttgtcatag atccaaataa tgctgcagta 1680
ctccagtcca gtggaaaaaa tctgttttac ttgccacatg gcttgagtat agataaagat 1740
gggaattatt ggttcacaga cgtggctctc catcaggtgt tcaaactgga tccaaacaat 1800
aaagaaggcc ctgtattaat cctgggaagg agcatgcaac caggcagtga ccagaatcac 1860
ttctgtcaac cactgatgt ggtgttgat ccaggcactg gagccattta tgtatcagat 1920
ggttactgca acagcaggat tgtgcagttt tcaccaagtg gaaagtcat cacacagtgg 1980
ggagaagagt cttcaggagg cagtcccttg ccaggccagt tcaactgttc tcacagcttg 2040
gctcttgtgc ctcttttggg ccaattatgt gtggcagacc gggaaaatgg tcggatccag 2100
tgttttaaaa ctgacaccaa agaatttgtg agagagatta agcattcatc atttgggaaga 2160
aatgtatttg caatttcata tataccaggc ttgctctttg cagtgaatgg gaagcctcat 2220
tttggggacc aagaacctgt acaaggattt gtgatgaact tttccaatgg ggaaattatm 2280
gacatcttca agccagtgcg caancctttg gatatgcctc atgatattgt tgcatctgaa 2340
gatgggactg tgtacattgg gagatgctca taccaacacc gtgtgggaag ttccaccttg 2400
gactkgagaa awttgggaac atcggtycag tttaaaaaag ggctggscat tgaggtccag 2460
ggaaatccaa agaagcccg gggcatttgt tgtttcccn ttacaaccct tcgggttatt 2520
ccggtggttg gtnccctggc gggccatggc ccnaatttaa ttccgggtgg aaaaaatccc 2580
aggggccctt tgggaaga

```

<210> 25

<211> 411

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (358)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (368)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (381)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (387)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (392)

<223> n equals a,t,g, or c

<400> 25

```
gcggccgagc tgcagcccg gctcagctc cgccgcggcc gtgaacatgg agcccccgga 60
cgacccggcc caggcgcgcg gggccccgcg gctgctgttg ctcgcagtc tgctggcggc 120
gcaccagat gccaggcg aggtgcgctt gtctgtacct ccgctggtgg aggtgatgcg 180
aggaaagtct gtcattcttg actgcacccc tacgggaacc cagcaccatt atatgctgga 240
atggttcctt accgaccgct cgggagctcg ccccgcccta gcctcggctg agatgcaggg 300
ctctgagctc caggtcacaa tgcacgacac ccggggccgc agtcccccat accagctnng 360
actyccangg ggcgcctggt ngctggnytg anggccark tggcgacgag c 411
```

<210> 26

<211> 657

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (634)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (652)

<223> n equals a,t,g, or c

<400> 26

```
aactgaagaa ttttgagtga attagacctt tatttttcta tctggttgga tgggtggcttt 60
aggggaaggg ggaaaggtgt aggctggggg attgaggtgg ggaatcattt tagctgggtg 120
cagccccctc tcccttcctc cattgcacat gaacatatgt ccatccatat atattcatca 180
gaatgttaat ttattttgct ccctctgtta ggtccatttt ctaagggtag aagaggcaag 240
```

```

tggtagggat gaggtctgat aagaacccag ggtggagagg gagactcctg ggcagccgtt 300
ttcctcatcc tttccctctc ccagtccatt tccaaatgtg gcctccatgt ggggtgctagg 360
gacatgggaa aaaccactgc tatgccattt cttctctctg ttccttcct caccctcgac 420
gggtgtggctg atgatgtctt ctggtgtcat ggtgaccacc cctgttccc tgttctggtg 480
tttccctgt cagtttcccc tctcgccag gtgtgtccc aaaatcccct cagcctcttc 540
tctgcacgtt gctgaaggtc caggcttgcc tcaagttcca tgcttgagca ataaagtggg 600
aacaataaaa cctgggaaaa aaaaaaagg gggncgttct aaagatccc cnagggg 657

```

<210> 27

<211> 1903

<212> DNA

<213> Homo sapiens

<400> 27

```

gggcacggga ctctgcccga ttcggcagag cacaaagttt gactccagtc tggatcgcaa 60
ggacaaattc tcctttgacc tgggaaaagg ggaggtcatc aaggcttggg acattgccat 120
agccaccatg aaggtggggg aggtgtgcc catcacctgc aaaccagaat atgcctacgg 180
ttcagcaggc agtcctccaa agattccccc caatgccacg cttgtatttg aggtggagtt 240
gtttgagttt aagggagaag atctgacgga agaggaagat ggcggaatca ttcgcagaat 300
acagactcgc ggtgaaggct atgctaagcc caatgagggt gctatcgtgg aggttgact 360
ggaagggtag tacaaggaca agctctttga ccagcgggag ctccgctttg agattggcga 420
gggggagaac ctggatctgc cttatggtct ggagagggcc attcagcgca tggagaaagg 480
agaacattcc atcgtgtacc tcaagcccag ctatgctttt ggcagtgttg ggaaggaaaa 540
gttccaaatc ccaccaaatg ctgagctgaa atatgaatta cacctcaaga gttttgaaaa 600
ggccaaggag tcttgggaga tgaattcaga agagaagctg gaacagagca ccatagtga 660
agagcggggc actgtgtact tcaaggaagg taaatacaag caagctttac tacagtataa 720
gaagatcgtg tcttggctgg aatatgagtc tagtttttcc aatgaggag cacagaaagc 780
acaggccctt cgactggcct ctcacctcaa cctggccatg tgtcatctga aactacaggc 840
cttctctgct gccattgaaa gctgtaacaa ggccctagaa ctggacagca acaacgagaa 900
gggcctcttc cgccggggag aggccacact ggccgtgaat gactttgaac tggcacgggc 960
tgatttccag aaggtcctgc agctctaccc caacaacaaa gccgccaaga cccagctggc 1020
tgtgtgccag cagcggatcc gaaggcagct tgcccgggag aagaagctct atgccaatat 1080
gtttgagagg ctggttgagg aggagaacaa ggccaaggca gaggcttctt caggagacca 1140
tcccactgac acagagatga aggaggagca gaagagcaac acggcaggga gccagtctca 1200
gggtgagaca gaagcatagc ccctctccac cagccctact cctgcggctg cctgcccccc 1260
agtctcccca ctccaccctg ttagttttgt aaaaactgaa gaattttgag tgaattagac 1320
ctttattttt ctatctggtt ggtggtggc tttaggggaa ggggaaagg ttaggctgg 1380
gggattgagg tggggaatca ttttagctgg tgtcagcccc tcttcccttc ctccattgca 1440
catgaacata tgtccatcca tatatattca tcagaatgtt aatttatatt gctccctctg 1500
ttaggtccat tttctaagg tagaagaggc aagtggtagg gatgaggtct gataagaacc 1560
cagggtggag agggagactc ctgggcagcc gttttcctca tcctttccct ctcccagtc 1620
atttccaaat gtggcctcca tgtgggtgct agggacatgg gaaaaaccac tgctatgcca 1680
tttcttctct ctgttccctt cctcaccctg acgtgtggcc ctaaggctgt gccacctccc 1740
cctgcccagt ccctggtctc tgtacagtgt ctgtccagga cgtctatcca tccatccttg 1800
acaacctgtc cagatgaggc cactgttatc ccagtctgtg aggggagatc acagcccagg 1860
tgccggccga tgtggagacg ctgatggact tcagtgtgca gga 1903

```

<210> 28

<211> 1333

<212> DNA

<213> Homo sapiens

<220>
<221> misc feature
<222> (1311)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1313)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1319)
<223> n equals a,t,g, or c

<400> 28
ggccgctagt gccagctcg cagaaggcgc tgctgctgga gctcaagggg ctgcaggaag 60
agccggtcga gggattccgc gtgacactgg tggacgaggg cgatctatac aactgggagg 120
tggccatctt cgggcccccc aacacctact acgagggcgg ctacttcaag gcgcgcctca 180
agttcccat cgactacca tactctccac cagccttctg gttcctgacc aagatgtggc 240
accctaacat ctacgagacg ggggacgtgt gtatctccat cctccaccgg ccggtggacg 300
acccccagag cggggagctg ccctcagaga ggtggaaccc cacgcagAAC gtcaggacca 360
ttctcctgag tgtgatctcc ctctgaacg agcccaacac cttctcgccc gcaaacgtgg 420
acgcctccgt gatgtacagg aagtggaaag agagcaaggg gaaggatcgg gagtacacag 480
acatcatccg gaagcaggtc ctggggacaa ggtggacgcg ggtgaacggc gtgaagggtg 540
ccaccacgct ggcgagtag tgcgtgaaga ccaaggcgcc ggcgcccggc gagggttcag 600
acctcttcta cgacgactac tacgaggacg gcgaggtgga ggaggaggcc gacagctgct 660
tcggggacga tgaggatgac tctggcacgg aggagtctg acaccaccag aataaacttg 720
ccgagtttac ctactaggg ccggaccgct ggctccttag acgacagact acctcacgga 780
ggttttggtg tggtcccgct ctctctggt tgtttcgttt tggctttttc tccctcccca 840
tgtctgttct gggttttcac gtgcttcaga gaagaggggc tgccccaccg ccactcacgt 900
cactcggggc tcggtggacg ggcccagggt gggagckgcc ggcccacctg tcccctcggg 960
aggggagctg agcccgaact ctaccggggt ccccgagctt ccggactggc cgcaccccg 1020
aggagccacg ggggcgctgc tgggaacgtg ggcggggggc cgtttcctga cactaccagc 1080
ctgggaggcc cagggtgtagc ggtccgaggg gcccggtcct gcctgtcagc tccaggtcct 1140
ggagccacgt ccagcacaga gtggacggat tcaccgtggc cgactctttt ccctgctttg 1200
gtttgtttga aatctaaata aaactacttt atgagaaaaa aaaaaaaaaa aaaaaaaaaa 1260
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa nanaaaaana 1320
aaaaaaaaaa ttt 1333

<210> 29
<211> 1327
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (573)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1307)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1325)
<223> n equals a,t,g, or c

<400> 29
cttgtttctcc gccgccgccg cccgccgccg ccgcrcrcgc cgcygccgct gccatggctc 60
aatacaagg g cgcgcgcgagc gaggccggcc gcgccatgca cctgatgaag aagcgggaga 120
agcagcgcga gcagatggag cagatgaagc agcgcacgcs ggaggagAAC atcatgaaat 180
ccaacattga caagaagttc tctgcgcact acgacgcggt ggaggcagag ctcaagtcca 240
gcaccgtggg tctcgtgacc ctgaatgaca tgaaggccaa gcaggaggct ctggtgaagg 300
agcgggagaa gcagctggcc aagaaggagc agtccaaggA gctgcagatg aagctggaga 360
agcttcgaga gaaggagcgt aagaaggAag ccaagcggaa gatctccagc ctgtccttca 420
ccctggagga ggaagaagag ggaggcgagg aggaagagga ggcggccatg tatgaggagg 480
agatggaaag ggaagagatc accacgaaga agagaaaact ggggaagaac ccagacgttg 540
acacaagctt cttgcctgat cgagaccgtg agnaggagga gaatcggtt cgggaagagc 600
tgcggcagga gtgggaagcc aagcaggaga agatcaagag tgaggagatc gagatcacct 660
tcagctactg ggatggctct gggcaccggc ggacagtcaa gatgagaaag ggcaacacca 720
tgcagcagtt cctgcagaag gcgctcgaga tccttcggaa agacttcagt gagctgaggt 780
ccgcagggkt ggagcagctc atgtacatca aggaggactt gatcatccct caccatcaca 840
gcttctacga cttcatcgtc accaaggcac gggggaagag tggaccactc ttcaactttg 900
atgttcatga cgatgtgcgg ttgctcagtg acgccactgt ggagaaggat gagtcccatg 960
caggcaaggT ggtgctgagg agctggtacg agaagaacaa gcacatcttt cccgccagcc 1020
gctgggaacc ctacgaccct gaaaagaagt gggacaagta cacgatccgc tgagcatcca 1080
ggaggctgcg cgccccggc tcctcagctc cctcagtgtg ccccgagggtg tcaccgggac 1140
tccaggcacc cgctcccctg cgaccatgcc aggcacgctg ggaggaggac ggcagctgct 1200
cgtgtcctgc ccctgccaca tcagtgactg ctttattctt ttccaataaa gaagtgcacg 1260
tgtcagagct ggagcgcctg cattgtgaga aaaaaaaaaa gaggggnaag aaaaaaaaaa 1320
agggnngg 1327

<210> 30
<211> 709
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (696)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (701)
<223> n equals a,t,g, or c

<400> 30

```

aattcccggg ttcgaccac gcgtccggaa aactgcagct tccttctcac cttgaagaat 60
aatcctagaa aactcacaaa atgtgtgatg cttttgtagg tacctggaaa cttgtctcca 120
gtgaaaactt tgatgattat atgaaagaag taggagtggg ctttgccacc aggaaagtgg 180
ctggcatggc caaacctaac atgatcatca gtgtgaatgg ggatgtgatc accattaaat 240
ctgaaagtac ctttaaaaat actgagattt ccttcatact gggccaggaa tttgacgaag 300
cactgcagat gacaggaaaag tcaagagcac cataacctta gatgggggtg tcctgggtaca 360
tgtgcagaaa tgggatggaa aatcaaccac cataaagaga aaacgagagg atgataaact 420
ggtggtggaa tgcgtcatga aaggcgtcac ttccacgaga gtttatgaga gagcataagc 480
caagggaagt tgacctggac tgaagtgcgc attgaactct acaacattct gtgggatata 540
ttgttcaaaa agatattggt gttttccatg atttagcaag caactaattt tctcccaagc 600
tgattttatt caatatggtt acgttggtta aataaacttt ttttagattt aaaaaaaaaa 660
aaaaaaaaac ycgggggggg gcccggtacc caattngccc nttaggggg 709

```

<210> 31

<211> 1108

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (389)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (397)

<223> n equals a,t,g, or c

<400> 31

```

tgcttatcct tgtgctgatg tttgtggtat ggatgaaacg ccgggataaa gaacgccagg 60
ccaaacaact ttaattgat ccagaagatg atgtaagaga taatatatta aaatatgatg 120
aagaagggtg aggagaagaa gaccaggact atgacttgag ccagctgcag cagcctgaca 180
ctgtggagcc tgatgccatc aagcctgttg gaatcygacg aatggatgaa agacccatcc 240
acgccgagcc ccagtatccg gtccgatctg cagccccaca ccctggagac attggggact 300
tcattaatga gggccttaaa gcggctgaca atgacccac agctccacca tatgactccc 360
tgttagtgtt tgactatgaa ggcagtggnt ccactgntgg gtccttgagc tcccttaatt 420
cctcaagtag tggtggtgag caggactatg attacctgaa cgactggggg ccacggttca 480
agaaacttgc tgacatgtat ggtggaggtg atgactgaac ttcagggtga acttggtttt 540
tgacaagta caaacaattt caactgatat tccccaaaag cattcagaag ctaggcttta 600
actttgtagt ctactagcac agtgcttgct ggaggctttg gcataggctg caaaccaatt 660
tgggctcaga gggaatatca gtgatccata ctgtttggaa aaacactgag ctcagttaca 720
cttgaatttt acagtacaga agcactggga ttttatgtgc ctttttgtag ctttttcaga 780
ttggaattag ttttctgttt aaggctttaa tggtagtgat ttctgaaacg ataagtaaaa 840
gacaaaatat tttgtggttg gagcagtaag ttaaaccatg atatgcttca acacgctttt 900
gttacattgc atttgctttt attaaaatac aaaattaaac aaamaaaaaa actcatggag 960
cgattttatt atcttggggg atgagaccat gagattggaa aatgtacatt acttctagtt 1020
ttagacttta gtttggtttt tttttttttt cactaaaatc ttaaaactta ctcagctggt 1080
tgcaataaaa gggagttttc atatcacc 1108

```

<210> 32

<211> 526

<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (502)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (524)
<223> n equals a,t,g, or c

<400> 32
gaattttttca ttatgttgct tttgaaattt gatgcattcc tcccatttac tttattattg 60
tacacattta acacacagta gcaaattttg aacgatgtga ttgatataac ctaacaaatc 120
tgagccagtt attattagag ttgcagaata gaaacttgaa gtgctaaatg gaataatcca 180
aaggaaattt tttaaagca ggttctagct gaaaaattca actataagaa aattgtattt 240
atataacatt tactattttt gaagactagt gagatttctg taataatttt aattctttta 300
aaagtgaag cttgttgtaa agatattttc tttttgttat tagaaggaaa taaaagaga 360
aaaatttctt tctttcatgg ggcatttgat aatttcagtc tttgacgatt tgtaagccta 420
gaatatacta agctgaataa cagctctttg gcctcagaat tttccagtag ccagtawttc 480
yggattaact aagttggaaa cncytattag gaacctccag tggnga 526

<210> 33
<211> 555
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (494)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (521)
<223> n equals a,t,g, or c

<400> 33
ccggaccctg caccagcga ctgggccccg cgcgcgccct ccgcgagggg ggaggcggcg 60
gctgtgtgcg cagggcccg caccggactg ggaccctggc gtccctccag gccttgccctc 120
ctgcgggags acagtttggc ttcacttctc tgacccagc ctcggccgta aagtgaaga 180
gaccggacca gcttcagctt tcggactctg gttcttggat cgtgtcctct cccctcggc 240
gccctcttcc cccaatctga gccattkcag gcctctgcct gckgccccct ctctcctcgg 300
gatcgggtcc ccagagccac catctcctga gcctcccacc ccgctgcctg ggccctgtgg 360
ttgctgggcc tcccacctca aggaggggaa ggtgtacag cccgaaccg tggagcaatg 420
ccctgtctgg cctccaaaac caaaataaaa ctgggtcact ttacaaaaaa aaaaaaaaaa 480
aagggcccg gaanaccgga ccggtacctg caggcgtaac ngtttcccta tagtgagtgg 540
tattagcgtt gcata 555

<210> 34
 <211> 347
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (288)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (328)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (335)
 <223> n equals a,t,g, or c

<400> 34
 ggggtcgaccc acgcgtccgg accgcgcggc tagtggtgtg aggatctgag ccccggtggtg 60
 gggggtggag gcggctcctg cratctaaag ggacttgaga ctctcaccgg ccgcgcgcca 120
 tgagggccct gtgggtgctg ggccctctcct gctcctgct gaccttcggg tcggtccgar 180
 ctgaygatga agtcgatgtg gatggtacag tggaagagga tctgggtaaa agtagagaag 240
 gttcaaggac agatgatgaa gtagtacaga gagaggaaga agctattnca gttggatgga 300
 ttaaatgcat cccaataag agaacttnag agagnaagtc cagaaaa 347

<210> 35
 <211> 750
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (701)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (731)
 <223> n equals a,t,g, or c

<400> 35
 ggggtggcttc cttgtggttc ctcagtgggtg cctgcaaccc ctggttcacc tccttccagg 60
 ttctggtctc ttccagccat ggctctcaga gtccttctgt taacagcctt gaccttatgt 120
 catgggttca acttggacac tgaaaacgca atgaccttc aagagaacgc aaggggcttc 180
 gggcagagcg tgggtccagct tcagggatcc aggggtggtg ttggagcccc ccaggagata 240
 gtggctgcc acaaagggtg cagcctctac cagtgcgact acagcacagg ctcatgcgag 300
 cccatccacc tgcaggtccc cgtggaggcc gtgaacatgt ccctgggcct gtccctggca 360
 gccaccacca gccccctca gctgctggcc tgtggtccca ccgtgcacca gacttgagct 420

```

gagaacacgt atgtgaaagg gctctgcttc ctgtttggat ccaacctacg gcagcagccc 480
cagaagttcc cagaggccct ccgagggtgt cctcaagarg atagtacat tgccttcttg 540
attgatggct ctggtagcat catcccacat gactttcggc ggatgaagga rtttgtctca 600
actgtgatgg agcaattaaa aaagtccaaa accttggtct ctttgatgca gtactctgaa 660
gaattccgga ttacttttac ttcaaagagt tccagaacaa ncctaacca agatcactgg 720
tgaagccaat nacgcagctg cttggggcgg 750

```

<210> 36

<211> 1291

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (29)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (298)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (695)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (795)

<223> n equals a,t,g, or c

<400> 36

```

aagaaaaatg tactacgcct gtcctgtang aagctgaaga tttttgcaat gcccatgcag 60
gatatcaaga tgatcctgaa aatggtgcag ctggactcta ttgaagattt gggaagtgc 120
ttgtacctgg aagctaccca ccttggcgaa attttctcct tacctgggcc agatgattaa 180
tctgcgtaga ctctctctct cccacatcca tgcactctcc tacatttccc cggagaagga 240
agagcagtat atcgcacagt tcacctctca gttcctcagt ctgcagtgcc tgcagctnct 300
ctatgtggac tctttatctt tccttagagg ccgcctggat cagttgctca ggcacgtgat 360
gaacccttg gaaacctct caataactaa ctgccggctt tcggaagggg atgtgatgca 420
tctgtcccag agtcccagcg tcagtcagct aagtgtcctg agtctaagtg gggcatgct 480
gaccgatgta agtcccagc ccctccaagc tctgctggag agagcctctg ccaccctcca 540
ggacctggtc tttgatgagt gtgggatcac ggatgatcag ctcttgccc tcctgccttc 600
cctgagccac tgctcccagc ttacaacctt aagcttctac gggaattcca tctccatata 660
tgcttgagc agtctctgc agcacctcat cgggntgagc aatctgacct acgtgctgta 720
tcctgtcccc ctggagagtt atgaggacat ccatggtamc ctccamctgg agagggtgct 780
atctgcatgc caggntcagg gagttgctgt gtgarttggg gcggcccagc atggttctgg 840
cttagtgggc aaccctgtc ctactgtgg ggacagaacc ttctatgacc cggagcccat 900
cctgtgcccc tgtttcatgc ctaatarctg ggtgcacata tcaaatgctt cattctgcat 960
acttgacac taaagccagg atgtgcatgc atcttgaagc aacaaagcag ccacagtttc 1020
agacaaatgt tcagtgtgag tgaggaaaac atgttcagtg aggaaaaaac attcagacaa 1080

```

```

atgttcagtg aggaaaaaaa ggggagttgg ggataggcag atgttgactt grggagktaa 1140
tgtgatcttt ggggagatac atcttataga gttagaaata gaatctgaat ttctaaaggg 1200
agawtctggc ttgggaagta catgtaggag ttaatccctg tgtagactgt tgtaaagaaa 1260
ctgttgaaaa taaagagaag caatgtgaag c                               1291

```

<210> 37

<211> 1535

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1413)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1526)

<223> n equals a,t,g, or c

<400> 37

```

ggcacgaggg tacgcagagc ttcgtcttcc agcgcgaaga gatagcgagc ttggcgcggc 60
agtacgctgg gctggaccac gagctggcct tctctcgtct gatcgtggag ctgcggcggc 120
tgcacccagg ccacgtgctg cccgacgagg agctgcagtg ggtgttcgtg aatgcgggtg 180
gctggatggg cgccatgtgc cttctgcacg cctcgtctgc cgagtatgtg ctgctcttcg 240
gcaccgcctt gggctcccg cggcactcgg ggcgctactg ggctgagatc tcggatacca 300
tcctctctgg caccttccac cagtggagag agggcaccac caaaagttag gtcttctacc 360
caggggagac gtagtagcac gggcctggtg aggcaacagc tgtggagtgg gggccaaaca 420
catggatggt ggagtacggc cggggcgctc tcccatccac cctggccttc gcgctggccg 480
acactgtctt cagcaccag gacttcctca ccctcttcta tactcttcgc tcctatgctc 540
ggggcctccg gcttgagctc accacctacc tctttggcca ggacccttga ccagccaggc 600
ctgaaggaag acctgcggat ggacaggagc gggcaggccc gcacatatcc acttgctgga 660
gcccattgtt acagacagg acatacacca tgcagatcct gagttcctgc tgtatgagca 720
gggatatcca tgcttatgta tccaaacaca gagaccatg ggaacaaatg agacacatat 780
agatactgag acctgtgtgt acagtaggac catgcactca caccatctg gagagggagc 840
ccccggtata ccaagggagc cagttgtgtt cagacacaca catcacagct tgactcacta 900
actgaggcct ttccatagct ccacagcttc ccacctcctc cccaccaaac cggggttcta 960
gagttaagga tgggggaggg tattatactg cctcagtctg actcctcaac ccagcagcaa 1020
tttgagggga tgagggggaa gaggagctgc cttttggagg ccccttcac ctgcagctat 1080
gatgcccttc cccttctccc ctgtctcac catatgcctt atccccattc tactcccctg 1140
ctatgcaagt gccctgtgg cttgtcccca accccctcag caacaaagct cagctgggga 1200
acgagagtaa tttgaagaat gcttgaagtc agcgtcttcc attccagaaa gacccccatt 1260
cttccttttg gggatatgat tggaagctgg tttcagccca ggaccaccca ctgaggagag 1320
gatctagaca ggtgggccta attccaaggg gcccttcctg gcctggagaa ggccttttac 1380
acacacacaa cacatacaca cacacacaca canacacata tcacagtttt cacacagccc 1440
ctgtctgcat ctctgtccat ctgtctgttt ctattaataa agatttggtg atctgttcca 1500
aaaaaaaaaa aaaaaaaaaa aaaaangggg gggct                               1535

```

<210> 38

<211> 295

<212> DNA

<213> Homo sapiens

<400> 38

```
ctggtcacac tattacatgc catgcaggca cgcgataaaa cgctggggct ggcaacactg 60
tgcattggcg gcggtcaggg aattgcatg gtgattgaac ggttgaatta atcaataaaa 120
acacccgata gcgaaagtta tcgggtgttt tcttgaacat cgacggcgaa ggtaacccca 180
ttaatcacca gtcaaaactt ttcaccagcg tcactcgcca gcattacgca tcggtacaat 240
aaatgtttcc tgtttctcat tgaccgatcc ttcacgggtg atcagcgtca ttggg      295
```

<210> 39

<211> 1300

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (641)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1297)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1298)

<223> n equals a,t,g, or c

<400> 39

```
gcggactggc agggggcagg gaagctcaaa gatctggggg gctgccagga aaaagcaaat 60
tctggaagtt aatggttttg agtgattttt aaatccttgc tggcgagag gcccgctct 120
ccccggtatc agcgcttcct cattctttga atccgcggct ccgcggtctt cgcgctcaga 180
ccagccggag gaagcctgtt tgcaatttaa gcgggctgtg aacgcccagg gccggcgagg 240
gcggggccga ggcgggccat tttraataaa gaggcgtgcc ttccaggcag gctctataag 300
traccgccgc ggcgagcgtg cgcgckttgc aggtcactgt agcgggactt cttttggttt 360
tctttctctt tggggcacct ctggactcac tccccagcat gaaggcgtg agcccggtgc 420
gcggctgcta cgaggcgtg tgctgcctgt cggaacgcag tctggccatc gcccggggccc 480
gaggggaagg cccggcagct gaggagccgc tgagcttgct ggacgacatg aaccactgct 540
actcccgctt gcggraactg gtaccgggag tcccagagg cactcagctt agccaggtgg 600
aaatcctaca gcgcgtcatc gactacattc tcgacctgca ngtagtcctg gccgagccag 660
ccccggacc ccctgatggc ccccaccttc ccaccagac agccgagctc gctccggaac 720
ttgtcatctc caacgacaaa aggagctttt gccactgact cggccgtgtc ctgacacctc 780
cagaacgcag gtgctggcgc ccgttctgcc tgggaccccg ggaacctctc ctgccggaag 840
ccggacggca gggatgggcc ccaacttcgc cctgcccact tgacttcacc aaatcccttc 900
ctggagacta aacctggtgc tcaggagcga aggactgtga acttggtggc tgaagagcca 960
gagctagctc tggccaccag ctgggcgacg tcacctgct cccacccac ccccaagttc 1020
taaggtctyt tcagagcgtg gaggtgtgga aggagtggct gctctccaaa ctatgccaa 1080
gcggcggcag agctggtctt ctggtctcct tggagaaagg ttctgttgcc ctgatttatg 1140
aactctataa tagagtatat aggttttgta ctttttttac aggaaggtga ctttctgtaa 1200
caatgcgatg tatattaaac tttttataaa agttaacatt ttgcataata aacgattttt 1260
```

aaacaaaaaa aaaaaaaaaa aaggggggcc gccctanngg

1300

<210> 40

<211> 215

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (210)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (213)

<223> n equals a,t,g, or c

<400> 40

cagaaacaga agttcacact aacagagtat gggtttaatt ttcctttgaa tgaaaaggat 60
agaaagataa aattgtgtat tgtaacatg taaataaaat tggagctaata ttgaaactag 120
cttctcaata acttcatctt tctagagact cattacctgt gggcttgctm aacctggact 180
atctggccaa atwgggttga taaaaaaggn atntt 215

<210> 41

<211> 474

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (85)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (216)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (374)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (449)

<223> n equals a,t,g, or c

<400> 41

tcgacccacg cgtccgggag actacggtaa aggcgcgcgc acgcagccaa catgccggtg 60
gcccgagct gggtttgcg caagnctacg tgaccctcgc gagggccctt gagaagtcgc 120

```

ggctcgacca agagctgaag ctgataggcg agtacgggct ccggaacaaa cgtgaggtgt 180
ggagggtcaa gttcaccctg gccaaagatcc gcaagnccgc gcgggarctg ctgacgctgg 240
acgagaagga cccgcggcgc ctgtttgagg gcaatgcctt gcttcggcga ctggtgcgca 300
ttggagtgtc ggacgagggc aagatgaagc tggattatat cctgggtctg aagatgagga 360
ttcttgagga grcntctgca gaccaggtt tttcaagctg gggttggcca atccatccac 420
catgccctgt gctgatccgc caggccacnc aggtccgaaa gcaagtgggtg aaca 474

```

<210> 42

<211> 425

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (375)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (403)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (418)

<223> n equals a,t,g, or c

<400> 42

```

cctcgcccttc gatgaatatg ggcgcccttt cctcatcatc aaggatcagg atcgcaagtc 60
tcgtcttatg ggactggagc tctcaagtct catatcatgg cggcaaaggc tgtagcaaat 120
accatgagaa catcacttgg accaaatgga cttgataaaa tgatggtgga caaggacggc 180
gacgtgacgg tcacaaacga cggtgccacg attctgagca tgatggatgt cgatcaccag 240
attgccaaagc tgatggtgga gctgtccaaa tcccaggatg atgaaatcgg agatggggac 300
cacgggggtg gttgtccttg ccggcgccct gctggaagga ggccgagcag ctgctggacc 360
gcggcattca mccgntcagg atcgccgacg gttacgagca ggntgcccgc attggccntc 420
gagca 425

```

<210> 43

<211> 1187

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (33)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (41)

<223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1149)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1156)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1160)
 <223> n equals a,t,g, or c

<400> 43
 tgtgggaact ggtgggtccc ccgggctggc agnaattggg nacgcgggtc gcggttcttg 60
 tttgtggatc gctgtgatcg tcacttgaca atgcagatct tcgtgaagac tctgactggg 120
 aagaccatca ccctcgaggt tgagcccagt gacaccatcg agaattgtcaa ggcaaagatc 180
 caagataagg aaggcatccc tcctgaccag cagaggctga tctttgctgg aaaacagctg 240
 gaagatggkc gcaccctgtc tgactacaac atccagaaaag agtccaccyt gcacctggtr 300
 ctccgtctca gaggtgggat gcaaattctt gtgaagacac tcaactggcaa gaccatcacc 360
 cttgaggtcg agcccagtga cacyatcgag aacgtcaaag caaagatcca rgacaaggaa 420
 ggcattcctc ctgaccagca gaggttgatc tttgccggaa agcagctgga agatggggcg 480
 accctgtctg actacaacat ccagaaagag tctaccctgc acctggtgct ccgtctcaga 540
 ggtgggatgc agatcttcgt gaagaccctg actggtaaga ccatcacyst cgargtgagg 600
 ccgagtgaac ccattgagaa tgtcaaggca aagatccaag acaagggaagg catccctcct 660
 gaccagcaga ggttgatctt tgctgggaaa cagctggaag atggacgcac cctgtctgac 720
 tacaacatcc agaaagagtc caccctgcac ctggtgctcc gtcttagagg tgggatgcag 780
 atcttcgtga agaccctgac tggttaagacc atcactctcg aagtggagcc gagtgcacac 840
 attgagaatg tcaaggcaaa gatccaagac aaggaaggca tccctcctga ccagcagagg 900
 ttgatctttg ctgggaaaca gctggaagat ggacgcaccc tgcctgacta caacatccag 960
 aaagagtcca ccctgcacct ggtgctccgt ctyagagggt ggatgcagat cttcgtgaag 1020
 accctgactg gtaagaccat cacyctcgaa gtggagccga gtgacacatc ygagaatgtc 1080
 aaggcaagat ccagacaagg aaggcatcct cctgaccagc agargttgat tttgctggga 1140
 aaarcttgn aatggnccan cccttttgat taaaatcccg aaagtcc 1187

<210> 44
 <211> 515
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (217)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (465)

<223> n equals a,t,g, or c

<400> 44

```

ctgcagtacc gtccgaattc ccgggtcgac ccacgcgtcc ggtttgagcc gtcgtgcttc 60
accggtctac ctcgctagca tgtcgggccg cggaagact ggcggaagg ccgcgccaa 120
ggccaagtgc cgtcgtcgc gcgccggcct ccagttccca gtgggccgtg tacaccggct 180
gctgcggaag ggccactacg ccgagcgcgt tggcgcnngc rcgccagtgt acctggcggc 240
agtgtggag tacctcaccg ctgagatcct ggagctggcg ggcaatgcgg ccgcgcgaca 300
caagaagacg cgaatcatcc cccgccacct gcagctggcc atccgcaacg acgaggagct 360
caacaagctg ctggggcgcg tgacgatcgc ccagggaagg cgtgctgccc aacatccagg 420
ccgtgsttgy tgcccaagaa gaccagcgcc accgtggggc cgaangccct tcggggggca 480
agaaagggca accaaggctt cccaaggagt actaa 515

```

<210> 45

<211> 1499

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1476)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1492)

<223> n equals a,t,g, or c

<400> 45

```

gcgagtgcgc gctcctcctc gcccgcgct aggtccatcc cggcccagcc accatgtcca 60
tccacttcag ctcccggca tccgcgaggt caccattaac cagagcctgc tggccccgct 120
gcggctggac gccgaccctt cctccagcg ggtgcgccag gaggagagcg agcagatcaa 180
gacctcaac aacaagtttg ctccttcat cgacaagggt cggtttcttg agcagcagaa 240
caagctgctg gagaccaagt ggacgtgct gcaggagcag aagtcggcca agagcagccg 300
cctcccagac atctttgagg ccagattgc tggccttcg ggtcagcttg aggcactgca 360
ggtggatggg ggccgccttg aggcggagct gcggagcatg caggatgttg tggaggactt 420
caagaataag tacgaagatg aaattaaccg ccgcacagct gctgagaatg agtttgtggt 480
gctgaagaag gatgtggatg ctgcctacat gagcaagggt gagctggagg ccaaggtgga 540
tgccctgaat gatgagatca acttcctcag gacctcaat gagacggagt tgacagagct 600
gcagtcccag atctccgaca catctgtggt gctgtccatg gacaacagtc gctccctgga 660
cctggacggc atcatcgctg aggtcaaggc rcagtatgag gagatggcca aatgcagccg 720
ggctgaggct gaagcctggt accagaccaa gtttgagacc ctccaggccc aggctgggaa 780
gcatggggac gacctccgga ataccggaa tgagatttca gagatgaacc gggccatcca 840
gaggctgcag gctgagatcg acaacatcaa gaaccagcgt gccaaagtgg aggccgccat 900
tgccgaggct gaggagcgtg gggagctggc gctcaaggat gctcgtgcca agcaggagga 960
gctggaagcc gccctgcagc ggccaagca ggatatggca cggcagctgc gtgagtacca 1020
ggaactcatg agcgtgaagc tggccctgga catcgagatc gccacctacc gcaagctgct 1080
ggagggcgag gagagccggg tggctggaga tggagtggga gccgtgaata tctctgtgat 1140
gaattccact ggtggcagta gcagtggcgg tggcattggg ctgacctcg ggggaacct 1200
gggcagcaat gccctgagct tctccagcag tgcgggtcct gggctcctga aggcttattc 1260
catccggacc gcatccgcca gtcgcaggag tgcccgcgac tgagccgcct cccaccactc 1320

```



```

cactcctcca gccaccaccc acaatcacaa gaagattccc acccctgcct cccatgcctg 1380
gtcccaagac agtgagacag tctggaaagt gatgtcagaa tagcttccaa taaagcagcs 1440
tcattctgag gcctgagtga aaaaaaaaaa aaaaanaaaa aaaaaaattt tngggggggg 1499

```

<210> 46

<211> 393

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (167)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (178)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (219)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (359)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (372)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (378)

<223> n equals a,t,g, or c

<400> 46

```

tcgaccacag cgtccggcag cctttctgag ggagcggttg tgtgttcgcc atcttaggaa 60
gaagatgttc tcgtccgttg cgcattctggc cgggcgaacc ccttcaacgc gccccacctg 120
cagctggtac acgatggcct cacgggcacc gaagcagccc cgtgggnacc cccgggcncg 180
ccccgaacgt tcccgaatc tggcagcagc cgtgttggn aagtagcagt tgcgaatatg 240
gctccatgaa gttttatgca ctgtgtggct ttggtggggt ctttaagttgt ggtctgacac 300
acactgctgt cgttcctctg gatttagtga aatgccgaat gcargtggac cccagaant 360
acaagggcak wnttaatngg attctcatta aca 393

```

<210> 47

<211> 238

<212> DNA

<213> Homo sapiens

<400> 47

```
cggatccccg ctcctgcac cagtcgccat tcgggaggcc gctgcgctgc agggcctcgc 60
ggaccgcccg cgaccgcgag ccgggccctc cgcgcggtcc atcgcccact ggacgcccgc 120
cgcggccgga ccggttcaac ttctcatctt tgttcttctt catatactat aggcgtgttg 180
ctgtggttta gtcaaaaagc catgtagaat gcctgccttt tgaagaccac ttttaagg 238
```

<210> 48

<211> 939

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (937)

<223> n equals a,t,g, or c

<400> 48

```
gccaccatct tggaaacgga ggccgagcag agtcgactgg gagcgaccga gcgggcccgc 60
gccgccgcca tgaaccccgga atatgactac ctgtttaagc tgcttttgat tggcgactca 120
ggcgtgggca agtcatgcct gtcctgcgg tttgctgatg acacgtacac agagagctac 180
atcagacca tcggggtgga cttcaagatc cgaaccatcg agctggatgg caaaactatc 240
aaacttcaga tctgggacac agcgggccag gaacggttcc ggaccatcac ttccagctac 300
taccgggggg ctcatggcat catcgtggtg tatgacgtca ctgaccagga atcctacgcc 360
aacgtgaagc agtggtgca ggagattgac cgctatgcc gcgagaacgt caataagctc 420
ctggtgggca acaagagcga cctcaccacc aagaagtggtg tggacaacac cacagccaag 480
gagtttgca actctctggg catccccttc ttggagacga gcgccaagaa tgccaccaat 540
gtcagcagc cgttcatgac catggctgct gaaatcaaaa agcggatggg gcctggagca 600
gcctctgggg gcgagcggcc caatctcaag atcgacagca cccctgtaaa gccggctggc 660
ggtggtctgt gctagsaggg gcacatggag tgggacagga gggggcacct tctccagatg 720
atgtccctgg agggggcagg aggtacctcc ctctccctct cctggggcat ttgagtctgt 780
ggctttgggg tgcctgggc tccccatctc cttctggccc atctgcctgc tgccctgagc 840
cccgttctk tmagggtccc taaaggagga cactcagggc ctgtggcagg cagggcgagg 900
gctgcttggt ctgttgccct taagtgaatt tccaaangc 939
```

<210> 49

<211> 1771

<212> DNA

<213> Homo sapiens

<400> 49

```
tctgaggctc ctggggagtc ggtgggaacg acaccagaag ctcagatgaa gactggccca 60
tttcagagc actccaacca gctgtggaac atcagcgccg tcccttcctg gtccaaagtg 120
aaccagggtc tcatccgcac gtataaggcc gagtgcctgg agaagttccc tgtgatccag 180
cacttcaagt tcgggagcct gctgcccac catcctgtca cgtcgggcta ggaggggcca 240
agccgaagag ccacccaggc cacagttcct gtgcctgcct tccccacccc agcagtggcc 300
cctcccatc ccctccctct gttcgtcccg tttgatgaga ggctgtttac tggggtgggg 360
tggcgagatg ggcttgaggg ggctcagagc ataaggcttc agggcccaag ttgggagaag 420
tgaccaaagt gtagccagtt ttctgagttc ccgtgtgcta gactggccag aagagagggt 480
ctggggcctg gtcactcggc cactctctcc tgtttctggc ctctctctcc ttcactccc 540
```

```

tccagtcttg ttttgagagc aggggctgtt ctgcagcacc kcaggggaagg gaggagagat 600
acctgctgct tccattgctt ttcccttcct ggagtcgatg cctttctaag ggttggagct 660
gtcccttgca ggggcgggtc agtttcccag gccatgccgg ggtggccatc tatgctaggg 720
ctggaagctg aggctggccg ccagctgttg gctgggggtg ggtgggtggg gtcgggtggg 780
ggagaggcct tagctgtcct ggctggtgcc cctcccaggc tccttttcac cctgccccct 840
gggcctgagg cccctgtgtt ccaagcctcc ccctggctct tcagtctctt agcccttggc 900
tttgctgggt ttctgactg tagccacatc tctcccgtc cctaagggtt acctagccaa 960
tggaagctgc ctttgggta ggtgctgggc tcctgggagg gccagatga tggggtgagg 1020
catgtctttc cagaactttc cctggcaggg aggggatggc agaaactcag ggaggggctt 1080
ggggccatt gtatctggag agcctggatt cctcttgga gtcttaggc crgcccactt 1140
tgctaccttt gcgtgctgt gagcctcacc ctggggccct gggccctgct tctctgctcc 1200
cctgggtgat ggggtggccc agaaggtggc agtcccacac cttgtcctcc cacctccctg 1260
aactgtccat tgcttttata gggtgaggta agwgacagcc tcccaagccc aggccttgge 1320
actcagaatg gggccagtgg gggctgggca gggccattga gggccaccgc cgagggtttt 1380
cctagggctg ttcttgggcc tggtctttac aggtcgtcc ccaggcctg cccttctcca 1440
ctgccccctc ctgtgtcttg gtccacacac ccttcaggaa gggggagcac tgagaagcac 1500
agcacagggg ctcagcctgg gatccggtga tggctctggg agaggctggg tcaggagtcc 1560
caaaggctag tgacagtttc tcagaagagg ccagcgtcc acctctctcc cagggccaga 1620
cacccttcc tggtccccc atccccctat ggctcccagc cccttgccac ctcatgtctg 1680
ttcagattaa agcctctgtt ttgcacctgt aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1740
aaaaaaaaaa aaaaaaaaaa aaaaaattt t 1771

```

<210> 50

<211> 397

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (201)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (207)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (352)

<223> n equals a,t,g, or c

<400> 50

```

gggtcgaccc acgcgtccgc tcgtccggg atcgcccgcg ctagagacgc atagcgtctt 60
aatcgtcgc acgcaccggc cctcgtcgc tcgcccgtcc gtgcgcgcgc cgcccagccc 120
accgccaccc tttgcagcca tgtccaccag gtcygtgtcc tcgtcytctt accgcagatg 180
ttcggcgggc ccggcaccgg naggcgnccg agctccacgc gcataacgtg accagtccac 240
ccgcacctac agcctgggca ggcctgcgc cccagcacca gccgcagcct ctamamctcg 300
tccccgggag gcgcgtatgt tcacggctcc ttccgcggtg cgcctgcgga anatgttgcc 360
ccggcgttgc gcttgctggc aggattccgt ggaattt 397

```

<210> 51
<211> 1635
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (1422)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1617)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1620)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1629)
<223> n equals a,t,g, or c

<400> 51
gcccacgcgt ccgcccacgc gtccgcccac gcgtccgcct ctccagccct tctcctgtgt 60
gcctgcctcc tgccgcgcgc accatgacca cctccatccg ccagttcacc tcctccagct 120
ccatcaaggc ctctccgggc ctggggggcg gctcgtcccg cacctcctgc cggctgtctg 180
gcggcctggg tgccggctcc tgcaggctgg gatctgctgg cggcctgggc agcaccctcg 240
ggggtagcag ctactccagc tgctacagct ttggctctgg tgggtggctat ggcagcagct 300
ttgggggtgt tgatgggctg ctggctggag gtgagaaggc caccatgcag aacctcaatg 360
accgcctggc ctctacctg gacaaggctg gtgccctgga ggaggccaac actgagctgg 420
aggtgaagat ccgtgactgg taccagaggc agggccccgg gcccggccgt gactacagcc 480
agtactacag gacaattgag gagctgcaga acaagatcct cacagccacc gtggacaatg 540
ccaacatcct gctacagatt gacaatgccc gtctggctgc tgatgacttc cgcaccaagt 600
ttgagacaga gcaggccctg cgcctgagtg tggaggccga catcaatggc ctgcgcaggg 660
tgctggatga gctgaccctg gccagagccg acctggagat gcagattgag aacctcaagg 720
aggagctggc ctacctgaag aagaaccacg aggaggagat gaacgccctg cgaggccagg 780
tgggtggtga gatcaatgtg gagatggacg ctgcccagg cgtggacctg agccgcaccc 840
tcaacgagat gcgtgaccag tatgagaaga tggcagagaa gaaccgcaag gatgccgagg 900
attggttctt cagcaagaca gaggaactga accgcgaggt ggccaccaac agtgagctgg 960
tgacagagtg caagagtgag atctcggagc tccggcgcac catgcaggcc ttggagatag 1020
agctgcagtc ccagctcagc atgaaagcat ccctggaggg caacctggcg gagacagaga 1080
accgtactg cgtgcagctg tcccagatcc aggggctgat tggcagcgtg gaggagcagc 1140
tggcccagct tcgtgcgag atggagcagc agaaccagga atacaaaatc ctgctggatg 1200
tgaagacgcg gctggagcag gagattgcca cctaccgccg cctgctggag ggagaggatg 1260
cccacctgac tcagtacaag aaagaaccgg tgaccacccg tcaggctcgt accattgtgg 1320
aagaggcca ggatggcaag gtcattctct cccgcgagca ggtccaccag accaccgcgt 1380
gaggactcag ctaccccggc cggccaccca ggaggcagg angcagccgc cccatctgcc 1440
ccacagtctc cggcctctcc agcctcagcc ccctgcttca gtccttccc catgcttcc 1500

```

tgccctgatga caataaaagct tgttgactca gctaaaaaaa aaaaaaaaaa aaaaaaaaaa 1560
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaanttn 1620
gggggggggnc ccccc 1635

```

<210> 52

<211> 1780

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1780)

<223> n equals a,t,g, or c

<400> 52

```

ccgccgccgc cgccgccgcc ggagctctgt agtatggcat cgaggagaat ggagaccaa 60
cctgtgataa cctgtctcaa aaccctctc atcatctact ccttcgtctt ctggatcact 120
ggggtgatcc tgctggctgt tggagtctgg ggcaaaactta ctctgggcac ctatatctcc 180
cttattgccg agaactccac aaatgctccc tatgtgctca tcggaactgg caccactatt 240
gttgtctttg gcctgtttgg atgctttgct acatgtcgtg gtagcccatg gatgctgaaa 300
ctgtatgcca tgtttctgtc cctggtgttc ctggctgagc tcgtagctgg catttcaggg 360
tttgtgtttc gtcatgagat caaggacacc ttcctgagga cttacacgga cgctatgcag 420
acttacaatg gcaatgatga gaggagccgg gcagtggacc atgtgcagcg casctgagct 480
gctgtggtgt gcagaactac accaactgga gcaccagccc ctacttcctg gagcatggca 540
tcccccccag ctgctgcatg aacgaaactg attgtaatcc ccaggatcta cacaatctga 600
ctgtggccgc caccaaagtt aaccagaagg gttgttatga tctggtaact agtttcatgg 660
agactaacat gggaatcatc gctggagtgg cgtttggaat cgcattctcc cagttaattg 720
gcatgctgct ggctgctgt ctgtcccggt tcatcacggc caatcagtat gagatggtgt 780
aaggagaagt ctttcaagaa tgacggaata agagacctgt tttaaaaagg aactgcagca 840
atctttgaaa gacttccaaa gaatgttaga gcacagtaca taatacactt gccctgctcc 900
ctctmccctt taccacaaa cgtgcaactg aactccccc ccagtctctg ctccaccttt 960
cagcccacgt cacgtgtagt gtccattttg tgaagccctg ttgtgccaca gagtgtagcc 1020
aggtccccct gcagctagtc ctagtgaacc tcaccccgag gccctgcatg ggcmrgcccc 1080
tccatctgta cttggtccaa ctgcaactca tcatcgggtg ctgggttatca caccatcgct 1140
ggcccccttg ggccctgcat gtagtgtggg aggtcctgt tagctcctca ctgtggtaaa 1200
tgccacacac ctttaagtag ataagcagac gatagttatc tgttcttttg acttaatctc 1260
atttggtttg attttccctc tactaaggct ttcctacctt cttcaggctg cctaagacat 1320
gtaacgaaac acttcaataa ttgtccatga ggagaaaaaa agcatgtgtc atgcatgaag 1380
gaaactgaac ttgaggtggc ctccctgctt gttacatacc tgggtatgtg taggcagttt 1440
agtgcactct tgccctctcag ttgaaacctg tataaccctg ttacaaagct gtgttggtgc 1500
ttcttgtgaa ggccatgata ttttggtttt cccaatttaa ttgctattgt gttattttac 1560
tacttctctc tgtatttttt cttgcattga cattatagac attgaggacc tcatccaaac 1620
aatttaaaaa tgagtgtgaa gggggaacaa gtcaaaatat ttttaaaaga tcttcaaaaa 1680
taatgcctct gtctagcatg ccaacaagaa tgcatgata ttgtgaacat ttgtgatata 1740
tgtattaata aatagagcaa ttacaagcaa aaaaaaatgn 1780

```

<210> 53

<211> 490

<212> DNA

<213> Homo sapiens

<400> 53
aattcggcag agaattttca tgagtcgcct tcaaaactct cgtgtagggg tgacaatgtg 60
gggggggtggg ggatccagct tattctttta ttttcaagtc cattcttggg gctggtgggg 120
aggcaggaga ataccctcc ctaagccctt agtgtgtgcc gagcttgctt tgtgatgttg 180
gcaggggagg ggagacctgg gtggtgactg agttcccttt atcaaaccct tcaatgggca 240
caaaattgag tgcttgattt taggttttat tttttatga atgtccaaat ctgtgtttcc 300
ccctgccctc ccagactgtg tggccagttg aaagtgtctg gtttgtgttc atctctccct 360
catttctgga gcagggcctg agaccctgcc acatctccta tgctctgcat ccacgcctct 420
tttgacatt aaagggtgat tgatgcaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 480
aaaaaaaaaa 490

<210> 54
<211> 1944
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (466)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (634)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1308)
<223> n equals a,t,g, or c

<400> 54
acgggtacgga attccccggg cgacccacgc gtccgacccc ggacccggag tcgcggagag 60
ctgggcagtg ttggccgctg gcggagcgtt ggggcagcat gaagtgcctg gtcacgggag 120
gcaacgtgaa ggtgctcggc aaggccgtcc actccctgtc ccgcacggg gacgagctct 180
acctggaacc cttggaggac gggtctctcc tccggacggt gaactcctcc cgctctgcct 240
atgcctgctt tctctttgcc ccgctcttct tccagcaata ccaggcagcc acccctgggc 300
aggacctgct gcgctgtaag atcctgatga agtctttcct gtctgtcttc cgctcactgg 360
cgatgctgga gaagacggtg gaaaaatgct gcatctccct gaatggccgg arcagccgcc 420
tggtggtcca gctgcattgc aagttcgggg tgcggaagat camaanctgt ccttcmagga 480
ctgtgagtcc ctgcaggccg tcttcgaccc agcctcgtgc cccacatgc tccgcgcccc 540
agcacggggt ctgggggarg ctgttctgcc cttctctcct gcactggctg aagtgcgct 600
gggcattggc cgtggcgag gktcatcctg gcantaccac gaggaggagg cagacagcac 660
tgccaaagcc atggtgactg agatgtgcct tggagaggag gatttccagc agctgcaggc 720
ccaggaaggg gtggccatca ctttctgcct caaggaatc cgggggctcc tgagctttgc 780
agagtcagca aacttgaatc ttagcattca ttttgatgct ccaggcaggc ccgccatctt 840
caccatcaag gactctttgc tggacggcca ctttgtcttg gccacactct cagacaccga 900
ctcgcactcc caggacctgg gctccccaga gcgtcaccag ccagtgcctc agctccaggc 960
tcacagcaca cccaccccg acgactttgc caatgacgac attgactctt acatgatcgc 1020
catggaaacc actataggca atgagggtcc gcggtgctg ccctccattt ccctttcacc 1080
tggtcccccag cccccaaga gccccggtcc ccactccgag gaggaagatg aggtgagcc 1140

```

cagtacagt cctgggactc cccaccccaa gaagttccgc tcaactgttct tcggtccat 1200
cctggcccct gtacgtcccc cccagggccc cagcctgtgc tggcggaaga cagtgaggg 1260
gaaggctgaa ccaagaacct gaagcctgta cccagaggcc ttggactnag acgaagcccc 1320
agccagtggc agaactgggt ctctcagccc tggggatcag aaagggtggc ttgctggagc 1380
tgagctgttt cactgcctct cgcaggcccc agctggctgt cactgtaaag ctgtcccaca 1440
gcggtcgggc ctgggccgtt atctcccac aamccccarc caatcaggac tttccagact 1500
tggccctgaa ctactgacgt tcctacctct tatttctcat tgagcctcag gctatactcc 1560
agctggccaa ggctggaaac ctgtctccct caggctcacc ttcctaagga aaatgtcata 1620
gtaggtgctg ctggcccctg gtgatccagc ttctctgcca atcatgacct gtcccttcc 1680
gaagtccctg gcatgcatct gggacccccg tggagctgac aagttttcct tgctttcctg 1740
atactctttg gcgctgactt ggaattctaa gagccttggc cccgagtgtg tggctaggg 1800
tgccctggct gggggccggg gccgagactc ccaagcggst ctgtgcagaa gagctgccag 1860
gcagtgtctt agatgtraga cggaggccat ggcgagaatc cagctttgac ctttattcaa 1920
gagaccagat ggggtttgcc cagg                                     1944

```

<210> 55

<211> 994

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (896)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (971)

<223> n equals a,t,g, or c

<400> 55

```

cccccgtagc cagtaccggg tccgcgcctg tccccgaaac ttcgcacccc gtcgaactct 60
cgcgagagcg ktatctgcgt gtcgggacgt gcggaggctc tcaactttccg tcatggcgct 120
gaaggtagcg accgtcgccg gcagcgccgc gaaggcgtgc tcgggccagc ccttctctgc 180
cgtccctggg aggttctagg cgcacacgag gtcccctcga ggaacatctt ttcagaacaa 240
acaattcctc cgtccgctaa gtatggcggg cggcacacgg tgacctgat cccaggggat 300
ggcatcgggc cagagctcat gctgcatgtc aagtccgtct tcaggcacgc atgtgtacca 360
gtggactttg aagaggtgca cgtgagttcc aatgctgatg aagaggacat tcgcaatgcc 420
atcatggcca tccgccgga cgcgtggcc ctgaaggga acatcgaaac caaccataac 480
ctgccaccgt cgcacaaatc tcgaaacaac atccttcgca ccagcctgga cctctatgcc 540
aacgtcatcc actgtaagag ccttccaggc gtggtgaccc ggcacaagga catagacatc 600
ctcattgtcc gggagaacac agaggcgag tacagcagcc tggagcatga gagtgtggcg 660
ggagtgggtg agagcctgaa gatcatcacc aaggccaagt ccctgcgcgt tgccgagtat 720
gccttcaagc tggcgagga gagcgggcgc aagaaagtga cggcctgca caaggccaac 780
atcatgaaac tggcgatgg gcttttcctc cagtgtgca gggaggtggc agcccgytac 840
cctcagwtca ccttcgagaa catgattgtg gataacacca ccatgcagct ggtgtncgg 900
ccccagcagt ttgatgtcat ggtgatgcc aatctctatg gcaacatcgt caaacaatgt 960
ctgcgcggga ntggtcgggg gcccaagctt gttg                                     994

```

<210> 56

<211> 328

<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (123)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (156)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (170)
<223> n equals a,t,g, or c

<400> 56
gggtcgaccc acgcgtccgc ccacgcgtcc ggatgacttc attgccaaag ttgttcaaag 60
gtagccttggt ccctttttca tctgagtccc atttagagat gtataaagaa tgttggtgag 120
tanggcgcgg tggctcacgc ctgtaatccc cacacnttgg gaaggccgan gcaggcggat 180
cacgaggtca gaagattgag accattctgg ctaacatggt gaacccccat ctctactaaa 240
aatacaaaaa ttagtcaggc gcgatggcgg gcacatgtag taccagctac tcggggaggct 300
gatgcagaag aataacttgg aacctggg 328

<210> 57
<211> 1489
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (710)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1109)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1117)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1206)
<223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1211)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1218)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1264)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1311)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1446)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1467)
 <223> n equals a,t,g, or c

<400> 57
 cggcacgagg ggtggtgtgg gtgtgttttag aaaaaagatg cattcctgaa gatctctggt 60
 gctgaagggc ctcgagttcc ttccagagac tgtatttgac acactttagg tacacacaaa 120
 cgaatggtat cacatgcaat attttaatgg agcaatggga gaggctcttt gaaatgggggt 180
 ttgcatcttt ttgtaacatt ttgatttctc tgggtgcctta ttcctacttg atgctggcac 240
 tcacataccc acaagaagct gacacagaag tcagccttag gcgtggggac atatgggtga 300
 tgtttgagca tgcagggggc atggggagtt tgggtgtcagt tgggtggagaa gggactagat 360
 ggcattctctt agccgaggcc aacaggaact gcacaagtcc attatagtca aagttagcaa 420
 ttttgatacg taaacacaat acttcattct tcctcatctg agctttcctt ccttcttctt 480
 tttctatctc taccttctca taaaggtgct gctgctgctg ctaaggtgcc cggagtccag 540
 aatgtccatt aatcactcag gcacgagcct ggcactgcca cgtcagcccc cagcatgacc 600
 aaaccacagg ttctcttgct tggggctgag aactgtcaga tttttctcat caaaaatggt 660
 ttccaaggaa tcagtggtatt acagtttttc tgcattgaaa atgcacttn aaaaaataaa 720
 ttaaagctcc agactgttta aaatatacag agggagcagg ggaaagttaa gcatgtgcta 780
 gtgtctgaac ccagttcagt ttatctccag ttgaaacgat atacactata ttatgtataa 840
 atgtatacac acttcctata tgtatccaca tatatatagt gtatatatta tacatgtata 900
 ggtgtgtata tgtgcatata tacacacatg cacataacaa aatcagatgc tcattacaaa 960
 tccagatgct cattacaaaa ccagatgcta cacaaacagc agcagaggaa acaagggttg 1020
 actcttgcaa cagatcacaa aaaataaaaa cagctacttg cagtgaactt ggtcatttct 1080
 gtatgttcat aaagaatgga tttgtaacna ggaaaanaag gaccagtgtt agtgaaaagg 1140
 gaagatgggg cgaaccatct tgatccgatg cgaatccgta atggtctata tacatttcat 1200

```

cagtantcat ntagtcangt gattgattca gttctgctat gaaacattgt aacacgtacc 1260
cacnactgac aactactcgt gagcgttcat taggagtgac ctaactttgc ntgcctgctc 1320
atgggacgag ctcttaggt ggagataccg gggaatagag aaagatgcac gtctctgcgt 1380
tgctgcgtgc tttaggggc ggtctttacc ttccgtgttg gagtcctccc tgagtccggc 1440
gctggntgcg ggacacggcc cttctcngtg tcccaggcgc tgcttcatt 1489

```

<210> 58

<211> 1283

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (38)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (550)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1242)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1250)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1260)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1263)

<223> n equals a,t,g, or c

<400> 58

```

aggtaatttg aattgagaga gagtaagtga cttgctgnaa aaagggttaa tcaacagcag 60
agctgggatt tgaaccata actctgtcaa agcctccact cctaactcct gttcatgctc 120
ctgtggagaa aatgcttgta gtaacatatt ttaaattgtac taacaagacc agtcatgggm 180
aaatgtttct gagacaaatc tctagtttat gatttaaaac agtacgtttt cttacgtgac 240
gaaaacaaaa agtgtgttaa ttgtttccca gtggttgaag ttatttgcca acaattttac 300
tgtttctctt catctgttta taggatttct ctgcctcttc caaacttttc ctccctgaac 360
ctgaggggta agcattttat ttcccttttag gaaaaacgtc agctgcttgt aaccactgtg 420
tttatgtcaa agcattcatt ttttttagga tatctgaaaa aatgccatat aagaaaaaam 480
tctataaaac atctatwatt ttcgaacca agtacactct tgcattctaw gctttaagtt 540

```

```

aatgcaaan tcctttttcc ttcttcctgc tgcaagtact atctcatcct gatgctcaag 600
agtgtcaggg cctgggtttc caaacagaga ctacctaaa attatttggc gagtagtact 660
ttacacaatt gcctctcccc cacaaatcat aattgtttca gtaaaatggt tacttggttt 720
ttccaagaaa aaactcgttt ttactcattt ttggcctggt tgtttattta gaaactaatc 780
tggattcact ccctctggtt gatacccact caaaaaggac acttctgatt aagacggttg 840
aaactagaga tggacaggtt atcaacgaaa cttctcagca tcacgatgac cttgaataaa 900
aattgcacac actcagtgcg gcaatatatt accagcaaga ataaaaaaga aatccataatc 960
ttaaagaaac agctttcaag tgcctttctg cagtttttca ggagcgcaag atagatttgg 1020
aataggaata agctctagtt cttaacaacc gacactccta caagatttag aaaaaagttt 1080
acaacataat ctagtttaca gaaaaatctt gtgctagaat acttttttaa aggtattttg 1140
aataccatta aaactgcttt tttttttcca gcaagtatcc aaccaacttg gttctgcttc 1200
aataaatctt tggaaaaact maaaaaaaaa aaaaaaaaaa mnggggggggn gcccggggtn 1260
ccnccggggg gcccaagttt tac 1283

```

<210> 59

<211> 740

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (696)

<223> n equals a,t,g, or c

<400> 59

```

agaaggagcg cggggaggac gtacctgtg agatgcgagc cggccaacag cttgcaagca 60
tgctccgctg gaccgagcc tggaggctcc cgcgtgaggg actcggcccc cacggcccta 120
gcttcgagag ggtgcctgtc gcaccagca gcagcagcg cggccgaggg ggcgcccagc 180
cgaggccgct tccgctttcc tacaggcttc tggacgggga ggcagccctc ccggccgctc 240
tctttttgca cgggctcttc ggagcaaaa ctaacttcaa ctccatcgcc aagatcttgg 300
cccagcagac aggcgtagg tgctgacggt ggatgctcgt aaccacggtg acagccccc 360
cagcccagac atgagctacg agatcatgag ccaggacctg caggaccttc tgccccagct 420
gggcctggtg ccctgcgctc tcgttgcca cagcatggga ggaaagacag ccatgctgct 480
ggcactacag aggcagagc tggtggaacg tctcattgct gtagatatca gccagtgga 540
aagcacaggt gtctccact ttgcaaccta tgtggcagcc atgagggcca tcaacatcgc 600
agataggctt gcccgcctcc cgtgcccga aactggcgga tgaacagctc agttctgtca 660
tccagacat gccgctgcg cacacttgct tcaatnaacc tggtagaggt agacgggcgt 720
tttcgtgttg gaggtggaa 740

```

<210> 60

<211> 1291

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (6)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (7)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (147)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1211)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1283)

<223> n equals a,t,g, or c

<400> 60

```

actttnnccc ctcccccttt cctttcccgt ctcacgcgcc aggccgcttg cacatgcgca 60
ttaggtacaa agcctcgctc ttgtcccca tctgtcgttc acacgaactc aagcctttgg 120
cattcggcag ccaatagaat ctaaganatg gcggaaaaat gattccgcct cgggagctaa 180
acttgattgg cagtttagct aaccaatcga gaacgccatt tgtamccctt ggcaggcamc 240
gagctccgctc gtctcgtttc cggcggtcgc gcgctctttt ctcgggacgg gagaggccgt 300
gtagecgtcgc cgttactccg aggagatacc agtcggtaga ggagaagtcg aggttagagg 360
gaactgggag gcactttgct gtctgcaatc gaagttgagg gtgcaaaaat gcagagtaat 420
aaaactttta acttgagaga gcaaaacccat actccaagaa agcatcatca acatcaccac 480
cagcagcagc accaccagca gcaacagcag cagccgccac caccgccaat acctgcaaat 540
gggcaacagg ccagcagcca aaatgaaggc ttgactattg acctgaagaa ttttagaaaa 600
ccaggagaga agaccttcac ccaacgaagc cgtctttttg tgggaaatct tcctcccgac 660
atcactgagg aagaaatgag gaaactatth gagaaatatg gaaaggcagg cgaagtcttc 720
attcataagg ataaaggatt tggctttatc cgcttggaac cccgaaccct agcggagatt 780
gccaaagtgg agctggacaa tatgccactc cgtggaaagc agctgcgtgt gcgctttgcc 840
tgccatagtg catcccttac agttcgaaac cttcctcagt atgtgtccaa cgaactgctg 900
gaagaagcct tttctgtgtt tggccaggta gagagggctg tagtcattgt ggatgatcga 960
ggaaggccct caggaaaagg cattgttgag ttctcaggga agccagctgc tcggaaagct 1020
ctggacagat gcagtgaagg ctcttcctcg ctaaccacat ttctcgtcc tgtgactgtg 1080
gagcccatgg accagttaga tgatgaagag ggacttcag agaagctggt tataaaaaaac 1140
cagcaatttc acaaggaacg agagcagcca cccagatttg cacagcctgg ctcttttka 1200
gtatgaatat ngccatgcgc tgggaaggca ctcatgaga tggagaaagc agcctggggg 1260
gacaagaagt gaagactcct gtntccaaaa a 1291

```

<210> 61

<211> 971

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (856)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (886)

<223> n equals a,t,g, or c

<400> 61

```

ctgcagtacc ggtccggaat tcccgggtcg acccacgcgt ccgggtctgt ggtcctctct 60
cggctcctcg cggctcgcgg cggccgacgg ttcctgggac acctgcttgc ttggcccgtc 120
cggcggtcca gggcttctct gctgcgctcc cggttcgctg gacgggaaga agggctgggc 180
cgtcccgctcc cgtcccccac ggaaccccaa gtgcgcgcgc tgaccgcgtc cagggcgaga 240
tgagcgcgga cgcagcggcc ggggcgcccc tgccccggct ctgctgcctg gagaagggtc 300
cgaacggcta cggcttccac ctgcacgggg agaagggcaa gttggggccag tacatccggc 360
tggtggagcc cggctcgcgg gccgagaagg cggggctgct ggccgggggac cggctggtgg 420
aggtgaacgg cgaaaacgtg gagaaggaga cccaccagca ggtggtgagc cgcacccgcg 480
ccgcactcaa cgcctgtcgc ctgctggtgg tcgaccccgga gacggacgag cagctgcaga 540
agctcggcgt ccaggtccga gaggagctgc tgcgcgccc ggaagcgcgc gggcaggccg 600
agccgcgggc cgcgcgcrag gtgcaggggg ctggcaacga aaatrarcct cgcraggccg 660
acaagagcca cccggagcag cgcgagcttc ggccctcggt ctgtaccatg aagaagggcc 720
ccagtggcta tggcttcaac ctgcacagcg acaagtccaa gccaggccag ttcacccggt 780
cagtggaacc agactccccg gctgaggctt cagggtcccg ggcccaggat cgcattgtgg 840
aggtgatgct tctcgnntct ctccctatct gaactgcccc caaccnctgc agattagcag 900
caccttgggg cagccatcat accatcatgg ggtttgatta gccacgggc attagccaac 960
ctgggaggtt g                                     971

```

<210> 62

<211> 618

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (563)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (598)

<223> n equals a,t,g, or c

<400> 62

```

gggtcgaccc acgcgtccgg cagaaatgaa ggaccacctg ccaagacgaa gagctgggtg 60
ggaccacgcg tgcattttca tcgaaagagt gaacatctag tgggactgaa agttctttgt 120
tgtttcagat tgtagagtgt gattgatgga attggctctgt ggaaattgca ttgtttttat 180
ttctttatgt aatcagttta agtaataggg ggtatatata atcgtaagta ttttaggggtg 240
ggaggggcta ttaagtaatt aagtgggttg ggtagttta aaagttagca tgatatgtat 300
tagataactc tataagtgga catgtgtact tacttgtgat cctttaccct atgattgcta 360
cccttaacga tttcaaataa actcagaggg aactgcaggg agatcaaacc atttagggca 420
aattggacat gaataaaact ctagtgggaa aaagttcaaa ggtgattgaa taaataattt 480
aactttgccc tgggtattaa gtccagggct cccagattgt ggagcagagc cttggagagt 540
acaggatgaa ggagatagat gcncctttga cttgccggga atgaaattgg attaatagnaa 600

```

ggatggtaaa taattcca

618

<210> 63

<211> 1138

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (7)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (15)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (22)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (27)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (29)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1123)

<223> n equals a,t,g, or c

<400> 63

tctatanatc atganaggaa anggtancng acagtacggt cggattcccg ggtcgaccca 60
cgctccgatg acttcacccc tctggagatc ctctggacct tctccatcta cctggagtca 120
gtggccatct tgccgcagct gttcatggtg agcaagaccg gcgaggcggg gaccatcacc 180
agccactact tgttgcgct aggcgtttac cgcacgctct atctcttcaa ctggatctgg 240
cgctaccatt tcgagggctt cttcgacctc atcgccattg tggcaggcct ggtccagaca 300
gtcctctact gcgatttctt ctacctctat atcaccaaag tcctaaaggg gaagaagttg 360
agtttgccgg catagccccg gtcctctcca tctctctcct cggcagcagc gggaggcaga 420
ggaaggcggc agaagatgaa gagctttccc atccaggggt gactttttta agaaccacc 480
tcttgtgctc cccatcccgc ctctgcgagg gtttcagggg gacagtggag gatccaggtc 540
ttggggagct caggacttgg gctgtttgta gttttttgcc ttttagacaa gaaaaaaaaa 600
tctttccact cttagttttt tgattctgat gactcgtttt tcttctactc tgtggcccca 660
atttttataa agtgtttttg agtgtcctat gggccggggc aggggtccaag atcttttccc 720
ttccccaggc ccctcggtc cctcccagat cccaccccca gccccactgg ttgccaaaca 780

```

ctaaatctgc cgacacccat ctgccccacc tcctgccatg gccatgaacc gcgacccccca 840
ctaaatttct agattgggga tagggagaaa gggaggccca ggaaggtctc ccctgatttt 900
ttttcatagt aatttttttc cccagagttt gaattttttg gtcttctcct ggtttttttg 960
caaattaggg gggcccggg ctcaagtgcg ggaagggggc tggcccagg atcccatggc 1020
tctcacacca tgtttttgta cagaactgat ggttgaatct ttgttctctt gaaataaaca 1080
gaagaaaatg aaaccttaaa aaaaaaaaaa aaaaaaaaaa acncgggggg gggcccgg 1138

```

<210> 64

<211> 418

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (365)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (371)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (380)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (391)

<223> n equals a,t,g, or c

<400> 64

```

tgctcatcca gaggagctca ccacagtcac tgcgacagac tgccacaactc accctggcct 60
ggcctcagag aagttgagct actggcctca gttcacacag agcagatgga ggaagagctg 120
gcactaggac ccagggggca ggggggagcc tccctggctg gaagggatgg caggagcgct 180
ggtgcaggta gctatggagc tctggccaac tctgcctggg gaggtcccag gaaggtggcg 240
tcagcatctg cagccgcgtc gacgttgctg gagcctccgc ggaggacca ggagagccgg 300
actaggacca gggccctggg cctccccaca ctcccctggg agaagctggc ggcctctaac 360
agagncccaa ngggcttggg cggtcctggg ncgtgaaaat gttcaagtgc ccgattga 418

```

<210> 65

<211> 2836

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (2834)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2836)

<223> n equals a,t,g, or c

<400> 65

```
aagaaaccgc ccattacaca cccagtaga ccagcagagg aaacttataa cctcgggagg 60
caggtccttc ccctcagtgc ggtcacatac ttccagaaga gcggaccagg gctgctgcca 120
gcacctgcca ctcagagcgc ctctgtcgct gggacccttc agaactctct ttgctcacia 180
gttaccaaaa aaaaaagagc caacatgttg gtattgctgg ctggtatctt tgtggtccac 240
atcgctactg ttattatgct atttgtagc accattgcca atgtctggtt ggtttccaat 300
acggtagatg catcagtagg tctttgaaa aactgtacca acattagctg cagtacagc 360
ctgtcatatg ccagtgaaga tgccctcaag acagtgcagg ccttcattgat tctctctatc 420
atcttctgtg tcattgccct cctggctctt gtgttccagc tcttcaccat ggagaaggga 480
aaccggttct tcctctcagg gggcaccaca ctggtgtgct gscgtgtgat tcttgtgggg 540
tgtccatcta cactagtcat tatgcgaatc gtgatggaac gcataatgcac caccgctatt 600
cctacatcct gggctggatc tgcttctgct tcagcttcat catcggcggt ctctatcttg 660
tcctgagaaa gaaataaggc cggacgagtt catggggatc tggggggtgg ggaggaggaa 720
gccgttgaat ctgggaggga agtgagggtt gctgtacagg aaaaaccgag ataggggagg 780
ggggaggggg aagcaaaagg gggagggtcaa atcccaaacc attactgagg ggattctcta 840
ctgccaagcc cctgccctgg ggagaaagta gttggctagt actttgatgc tcccttgatg 900
gggtccagag agcctccctg cagccaccag acttgccctc cagctgttct tagtgacaca 960
cactgtctgg ggcccatca gctgccacaa caccagcccc acttctgggt catgactga 1020
gggtccacaga cctactgcac tgagttaaaa tagcggtaga agttctggca agagcagata 1080
ctgtctttgt gctgaatacg ctaagcctgg aagccatcct gcccttctga cccaaagcaa 1140
aacatcacat tccagtctga agtgccact ggggggcttt ggctgtgag ccattgtccc 1200
tctttggaac agatatttag ctctgtggaa ttcagtgaac aaatgggagg aggaaagaga 1260
gtttgtaagg tcatgctggt gggttagcta aaccaagaag gagacctttt cacaatggaa 1320
aacctggggg atggtcagag cccagtcgag acctcacaca cggctgtccc tcatggagac 1380
ctcatgccat ggtctttgct aggcctcttg ctgaaagcca aggcagctct tctggagttt 1440
ctctaaagtc actagtgaac aattcggtgg taaaagtacc acacaaacta tgggatccaa 1500
ggggcagttc tgcaacagtg ccatgttagg gttatgtttt taggattccc ctcaatgcag 1560
tcagtgtttc ttttaagtat acaacaggag agagatggac atggctcatt gtagcacaat 1620
cctattactc ttcctctaac atttttgagg aagttttgtc taattatcaa tattgaggat 1680
cagggtcctt aggtcagtg gtagctctgg cttagacacc acctggagtg atcacctctt 1740
ggggaccctg cctatcccac ttcacagggt aggcattggca attctggaag ctgattaaaa 1800
cacacataaa ccaaaaccaa acaacaggcc cttgggtgaa aggtgctata taattgtgaa 1860
gtattaagcc taccgtatct cagccatgat aagaacagag tgcctgcatt cccaggaaaa 1920
tacgaaaatc ccatgagata aataaaaaata taggtgatgg gcagatcttt tctttaaata 1980
aaaaaagcaa aaactcttgt ggtacctagt cagatggtag acgagctgtc tgctgccgca 2040
ggagcacctc tatacaggac ttagaagtag tatgttattc ctggttaagc aggcattgct 2100
ttgccctgga gcagctatct taagccatct cagattctgt ctaaaggggg tttttgggaa 2160
gacgttttct ttatcgccct gagaagatct accccaggga gaactctgaga catcttgctt 2220
acttttcttt attagctttc tctcatcca tttcttttat accttcctt tttggggagt 2280
tgttatgcca tgatttttg ttttatgta aaaggattat tactaattct atttctctat 2340
gtttattcta gtttaaggaa tggtgagggc aagccaccaa attacctagg ctgagggttag 2400
agagattggc cagcaaaaaac tgtgggaaga tgaactttgt cattatgatt tcattatcac 2460
atgattatag aaggctgtct tagtgcaaaa aacatactta catttcagac atatccaaag 2520
ggaataactc cattttgtta agaagttgaa ctatgactgg agtaaaccat gtattccctt 2580
atcttttact tttttctgt gacatttatg tctcatgtaa tttgcattac tctggtggat 2640
tgttctagta ctgtattggg cttcttcggt aatagattat ttcatactat ataattgtaa 2700
```



```
atattttgat acaaagtgtt ataactctag ggatataaaa acagattctg attcccttca 2760
ttgtgtgaat gtttttttct aaaaaaatg tggagaaata tggataatta tgacatttat 2820
ccctcattaa agcngn 2836
```

<210> 66

<211> 2305

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1973)

<223> n equals a,t,g, or c

<400> 66

```
aaacgttccc ggtccttcct gaaccaagct gtggaccctc gtaagcaacc cggacaccga 60
cgcgctcatc tgetggagcc cgagcgsgaa cagcttcacac gtgttcgacc agggccagtt 120
tgccaaggag gtgctgcccc agtacttcaa gcacaacaac atggccagct tcgtgcggca 180
gytcaacatg tatggcttcc ggaaagtggc ccacatcgag cagggcgkcc tggtaagcc 240
agagagagac gacacggagt tccagcacc atgcttcctg cgtggccagg agcagctcct 300
tgagaacatc aagaggaaaag tgaccagtgt gtccaccctg aagagtgaag acataaagat 360
ccgccaggac agcgtcacca agctgctgac ggacgtgcag ctgatgaagg ggaagcagga 420
gtgcatggac tccaagctcc tggccatgaa gcatgagaat gaggtctgtt ggcgggaggt 480
ggccagcctt cggcagaagc atgcccagca acagaaagtc gtcaacaagc tcattcagtt 540
cctgatctca ctggtgcagt caaacgggat cctgggggtg aagagaaaga tccccctgat 600
gctgaacgac agtggctcag cacattccat gcccaagtat agccggcagt tctccctgga 660
gcacgtccac ggctcggggc cctactcggc cccctcccca gcctacagca gctccagcct 720
ctacgcccct gatgctgtgg ccagctctgg acccatcatc tccgacatca ccgagctggc 780
tcctgccagc cccatggcct ccccgggcgg gagcatagac gagaggcccc tatccagcag 840
ccccctggtg cgtgtcaagg aggagccccc cagccgcctc yagagccccc gggtagagga 900
ggcgagtcct gggsgcccat cttccgtgga caccctcttg tccccgaccg ccctcattga 960
ctccatcctg cgggagagtg aacctgcccc cgsctccgtc acagccctca cggacgccag 1020
gggccacacg gacaccgagg gccggcctcc ctcccccccg cccacctcca cccctgaaaa 1080
gtgcctcagc gtasctgcct ggacaagaat gagctcagtg accacttgga tgctatggac 1140
tccaacctgg ataacctgca gacctgctg agcagccacg gcttcagcgt ggacaccagt 1200
gccctgctgg acctgttcag cccctcggtg accgtgcccg acatgagcct gcctgacctt 1260
gacagcagcc tggccagtat ccaagagctc ctgtctcccc aggagcccc caggcctccc 1320
gaggcagaga acagcagccc ggattcaggg aagcagctgg tgcactacac agcgcagcgc 1380
tgctcctgct ggaccccggc tccgtggaca ccgggagcaa cgacctgccg gtgctgtttg 1440
agctgggaga gggctcctac ttctccgaag ggacggcttc gcaagggacc ccaccatctc 1500
cctgctgaca ggctcggagc ctcccaaagc caaggacccc actgtctcct agaggccccg 1560
gaggagctgg gccagcggc caccgccacc cccagtgcag ggctgggtctt ggggaggcag 1620
ggcagcctcg cggctcttgg cactggtggg tcggccgcca tagccccagt aggacaaaag 1680
ggctcgggtc tgggcagcac ctctggtcag gagggtcacc ctggcctgcc agtctgcctt 1740
cccccaacct cgtgtcctgt gggttgggtg ggcttcacag ccacacctgg actgacctgt 1800
caggttggtc atagtcagaa ttgtattttg gatttttaca caactgtccc gttccccgct 1860
ccacagagat acacagatat atacacacag tggatggacg gacaagacag gcagagatct 1920
ataaacagac aggtctctat ctatggcctc catgtgtttc ctctgtccca ggntgggtgcg 1980
gtggttggtg ctgcaatgag gaggggcccc gggcacagaa gggccgggct gcagtggcct 2040
cctgggggaa gacggatgtt gcagctagct ccgtgcctgc ccgactcccc aggaccagca 2100
tgtgcttgca gttctttatt gagggaccag ggggtgggcgc ctcaccttgg ccctgggggt 2160
```

```

ctctggttgt cacaggacca ccaggaaccc ccttcccaag gtgttcgcac tcggacaggt 2220
gatgcggggc gggcacactg tctttctgcc agagccagca ccctgtgtag gcacggggaa 2280
cgggagcctg tcccgtagct ttagg                                     2305

```

<210> 67

<211> 1907

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1221)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1655)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1896)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1904)

<223> n equals a,t,g, or c

<400> 67

```

gacgcccgcc gcctcactgt ttctagcctt cagtggccaa cgttggtagt cattgtgacc 60
tcagcctgaa aatccctgaa attagcatcc aggatatgac agcccagggtg accagcccat 120
cgggcaagac ccatgaggcc gagatcgtgg aaggggagaa ccacacctac tgcacccgct 180
ttgttcccgc tgagatgggc acacacacag tcagcgtgaa gtacaagggc cagcacgtgc 240
ctgggagccc cttccagttc accgtggggc ccctagggga agggggagcc cacaaggtcc 300
gagctggggg ccctggcctg gagagagctg aagctggagt gccagccgaa ttcagtatct 360
ggacccggga agctggtgct ggaggcctgg ccattgctgt cgaggggccc agcaaggctg 420
agatctcttt tgaggaccgc aaggacggct cctgtggtgt ggcttatgtg gtccaggagc 480
caggtgacta cgaagtctca gtcaagttca acgaggaaca cattcccgc agccccttcg 540
tggtgcctgt ggcttctccg tctggcgacg cccgccgcct cactgtttct agccttcagg 600
agtcagggct aaaggtcaac cagccagcct cttttgcagt cagcctgaac ggggccaagg 660
gggcgacgga tgccaagggtg cacagcccct caggagccct ggaggagtgc tatgtcacag 720
aaattgacca agataagtat gctgtgcgct tcatccctcg ggagaatggc gttacctga 780
ttgacgtcaa gttcaacggc acccacatcc ctggaagccc cttcaagatc cgagtggggg 840
agcctgggca tggaggggac ccaggcttgg tgtctgctta cggagcaggt ctggaaggcg 900
gtgtcacagg gaaccagct gagttcgtcg tgaacacgag caatgcggga gctggtgcc 960
tgtcggtgac cattgacggc ccctccaagg tgaagatgga ttgccaggag tgccctgagg 1020
gctaccgctg cacctatacc cccatggcac ctggcagcta cctcatctcc atcaagtacg 1080
gcggccctta ccacattggg ggcagcccct tcaaggccaa agtcacaggc ccccgctctg 1140
tcagcaacca cagcctccac gagacatcat cagtgtttgt agactctctg accaaggcca 1200
cctgtgcccc ccagcatggg nccccgggtc ctgggcctgc tgacgccagc aagtggtggtg 1260

```

```

ccaagggctg gggctgagca aggcctacgt aggccagaag agcagcttca cagtagactg 1320
cagcaaagca ggcaacaaca tgctgctggt gggggttcat ggcccaagga cccctgcga 1380
ggagatcctg gtgaagcacg tgggcagccg gctctacagc gtgtcctacc tgctcaagga 1440
caagggggag tacacactgg tgggtcaaatg gggggacgag cacatcccag gcagccccta 1500
ccgcgttggt gtgccctgag tctggggccc gtgccagccg gcagcccca agcctgcccc 1560
gctaccaag cagccccgcc ctctccccct caaccccgcc ccaggccgcc ctggccgcc 1620
gcctgtcact gcagccgccc ctgccctgtg ccgtncctgc ctcacctgcc tccccagcca 1680
gccgctgacc tctcggcttt cacttgggca gagggagcca tttggtggcg ctgcttgtct 1740
tctttggttc tgggaggggt gagggatggg ggtcctgtac acaaccaccc actagtcttc 1800
ttctccagcc aagaggaata aagttttgct tccattcwma aaaaaaaaaa aaaaaaaaaa 1860
tyggggggggg kccgktaacc caattggcct ttaagngggg ggtntta 1907

```

<210> 68

<211> 815

<212> DNA

<213> Homo sapiens

<400> 68

```

gggtcgaccc acgcgtccgt tttttttaag tgtgaatttt ttattgagat aaacaacagc 60
ataaagaata caagtagcca aatggttttg aaaaaccaa tttagtcaaa gttctaaatt 120
aaaaatagca gttgtgtttc aatttacctt attctagcaa ttwaagtwgg taacatacaa 180
atagttatwc tgatacaaga tattaaagac atactcagtt ttaatcaact acctctcaag 240
aaacagtagg gcctctgtaa aattggagac tgataggttg atcagaaact caccctaaat 300
ctgaacgggt gccgtataa tttgtgacat ctggcaagat ttccctttat gtatatattt 360
taacaatccg cttggacacg acaaaagcca cacttctaac tgcttctggc gaactgattt 420
tatttttaat ttttttcaat aaagatatc ttagatactg aaagaaatag ttaatgagtt 480
tgcatttggt cttgagaaaa tttggctcaa gtccatttgg ctgtagtgtc aacgatgttt 540
ccagtagtgt ttagatttgg tgccttcaaa ggtagttgat taaaaccaag tgtgtcttta 600
atatcttgta tcagaataac tttgtatggt accaacttaa attgctagaa taaggtaaat 660
tgatacacia ctgctatattt taatttagaa ctttgaccta atttgggttt tcaaaacat 720
tttggtact tgtattcttt atgctgttgt ttatttcaat aaaaaattca cacctaaatg 780
tatacttact aaaaaaaaaa aaaaaaaaaa actcg 815

```

<210> 69

<211> 1150

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (14)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (20)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (23)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (25)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1150)

<223> n equals a,t,g, or c

<400> 69

```
ctcgtgcaat tcgngcagan tgntncctgg cctccttttg cttgcccgtg gctgttcctc 60
ctgggtcctc ttgccctggg ctggatgcct tcttcggctc cccctctgca tgtgataact 120
tggggtggcc cttggagctg tgccaaagct acacctcggg gtcctagtct caactggcct 180
gcgtactgct gtgggctcac cccgccttcc tcccacagcc ctgggcgctg cctatggcac 240
agccaagagc ggtaccggca ttgcggccat gtctgtcatg cggccggagc agatcatgaa 300
gtccatcatc ccagtgggca tggtggcat catcgccatc tacggcctgg tggggcagt 360
cctcatcgcc aactccctga atgacgacat cagcctctac aagagcttcc tccagctggg 420
cgccggcctg agcgtgggca tgagcggcct ggcagccggc tttgccatcg gcatcggtgg 480
ggacgctggc gtgcggggca ccgccagca gcccgcacta ttcgtgggca tgatcctgat 540
tctcatcttc gccgaggtgc tcggcctcta cgggtctcatc gtgcacctca tcctctccac 600
aaagtagacc ctctccgagc ccaccagcca cagaatatta tgtaaagacc acccctcctc 660
attccagaac gaacagcctg acacatacgc acggggccgc cgccccagc agttgggtctt 720
gtacatgcgc agtgtcctag tgcccatcgt ctgtttcccc ggccttgccc ccgccccccc 780
cgtgccgtgg acatctgggc ccactcatcg cccctccagg cccccggcgc cccacccctc 840
agagtgtctc gtgtatgcgg atgatttaga attgtcatct ctctttactg gatgtttatt 900
tataaagatc tggcctgttc ctgcgtctgc ggagcggccc ttgtctccca gctatctata 960
accttagcta gagtgtcgcc ttgtgggttc ctgttgctga gacttcctgg atggagccgc 1020
cctcaccgcc gggcccgctg ccctgcgcgg agctgtgtcc aataaagttc ttggatgtga 1080
aaaaaaaaa aaaaaaaaaa aaaaaaaraa aaaaaaaaaa aaaraaaraa aaaaaawaa 1140
gaaaaaaaaa 1150
```

<210> 70

<211> 344

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (287)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (333)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (339)

<223> n equals a,t,g, or c

<400> 70

```
cgcaggctct gcggccgggt tccttcgcgc ggacggggag aaagagagag cgcgaaagag 60
agaggatgtc tctctcagat tggcacctgg cggatgaagct ggctgaccag ccacttgccc 120
caaagtctat tctccagttg ccagagtcag agctgggtga atactctctg gggggctaca 180
gtatttcatt tctgaaacag ctcatgtctg gcaaaactcca ggagtcgggt ccagaccctg 240
agctgattga tctgatatac tgtggccgga agcttaaaga tgaccanacc ttgacttcta 300
cggatttcaa cctggctcca catccatgtt ctncggaant cctg 344
```

<210> 71

<211> 448

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (425)

<223> n equals a,t,g, or c

<400> 71

```
tcgaccacg catccgaaga tgttcttgct gccccttcgc gctgccgggc gagtcgtcct 60
ccgacgtctg ggcgtgaaca gttctgggca cggggtctcg ccgccgcaga catgacgaag 120
ggtcttggtt taggaatcta tagtaaagac aaagaagatg atgtgccaca gtttacgagt 180
gcaggagaga atttcgataa attggtgtct ggaaagtga gagaaatatt gaacatatct 240
ggacctctc tgaaagcagg caaaacccga accttttatg gtctgcatga ggacttcccc 300
agcgtggttg tggtcggcct cggcagaaag gcagctggag tcgatgacca ggaaaactgg 360
cmtgaaggca aagaaaacat cagagtcgcc atgcaacggg gtgcaggcag gttccaagac 420
ctggnaatct cttctgtgga aggtggat 448
```

<210> 72

<211> 2825

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1809)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2093)

<223> n equals a,t,g, or c

<400> 72

```
gagaaggagg tcgcgcggcc tcatcccgga ccgcgccccg ggccgcgcgc gggcccgccg 60
tcagtagggt gctcgcgcgc ccccgccgat cgccatggat cggatgaaga agatcaaagc 120
gcagctgtca atgacactcc gaggtggccg aggcataagc aagaccaatg gtgcccctga 180
gcagataggc ctggatgaga gtggtggtgg tggcggcagt gaccctggag agggcccccac 240
```

```

acgtgctgct cctggggaac ttcgtttctgc acggggccca ctcagctctg caccagagat 300
tgtgcacgag gacttgaaga tgggggtctga tggggagagt gaccaggctt cagccacgtc 360
ctcggatgag gtgcagtctc cagtgaagat gcgtatgcgc aaccatcccc cagcaagat 420
ctccactgag gacatcaaca agcgcctatc actaccagct gacatccggc tgcctgaggg 480
ctacctggag aagctgaccc tcaatagccc catctttgac aagcccctca gccgcgcct 540
ccgtcgtgtc agcctatctg agattggctt tgggaaactg gagacctaca ttaagctgga 600
caaaactggc gaggggtacct atgccaccgt ctacaaaggc aaaagcaagc tcacagacaa 660
ccttggtggc ctcaaggaga tcagactgga acatgaagag ggggcaccct gcaccgccat 720
ccgggaagtg tccctgctca aggacctcaa acacgccaac atcgttacgc tacatgacat 780
tatccacacg gagaagtccc tcacccttgt ctttgagtac ctggacaagg acctgaagca 840
gtacctggat gactgtggga acatcatcaa catgcacaac gtgaaactgt tcctgttcca 900
gctgctccgt ggcctggcct actgccaccg gmagaaggtg ctacaccgag acctcaagcc 960
ccagaacctg ctcatcaacg agaggggaga gctcaagctg gctgactttg gcctggcccc 1020
agccaagtca atcccaacaa agacatactc caatgaggtg gtgacactgt ggtaccggcc 1080
ccctgacatc ctgcttgggg ccacggacta ctccactcag attgacatgt ggggtgtggg 1140
ctgcatcttc tatgagatgg ccacaggccg tccccctctt ccgggctcca cgggtggagg 1200
acagctacac ttcatcttcc gtatcttagg aaccccaact gaggagacgt ggcagggcat 1260
cctgtccaac gaggagttca agacatacaa ctacccaag taccgagccg aggccctttt 1320
gagccacgca ccccgacttg atagcgacgg ggccgacctc ctcaccaagc tgttgacagt 1380
tgagggtcga aatcggtatc ccgcagagga tgccatgaaa catccattct tcctcagctc 1440
gggggagcgg atcccaaac ttctgacac tacttccata tttgcactaa aggagattca 1500
gctacaaaag gaggccagcc ttcgggtctc gtcgatgcct gactcaggca ggccagcttt 1560
ccgctggtg gacaccgagt tctaagccac agaccgaggc cccagcaggc agcggctgga 1620
gggatgccac acccctcaca gggcagcccc caactacatc ttccctgctt actctctgcc 1680
tacctgctg agccatgttc acctgcccac ttgtccctg ctgcctgccc aaacacccca 1740
ccattggcct gtcaacccac ccattggcct gtctgtctgg tgctaacaaa gctctcatca 1800
ctccttcant tggctgtct gtctctgtct tggtagttgc cgggtggacag catggccgtg 1860
ccagcctccc aactgaggc caggtctacc cccatcata ccagcccmma graccaytam 1920
cccacggsca gccaggggtc caragctagc ccaggctggg gatctcgact cagacaagat 1980
ggtgacaatg cttgagttc gaggcatact ctgcctgctt tcctgcctgc cccacctgcc 2040
tcatattgtg tgggcctttt ttgtttgtt tcattcattg ttttttttt tttaattatt 2100
ttaaatgaga tttttgtttt ttttaaatgc aatatctctg tatacagact ggctggggcc 2160
acccctgctg tgtggccctc ccacagtatt ttgtgcaatg aagccctgct cccagccttt 2220
cagagacagg gacacagccc ctatttgga ccctgatcat caccagacc tgggattggc 2280
tatgggaaag catgccacag ccactgcctc tcctacccc gcccgccatc cccagttgca 2340
gggggatctg gggactacca gagactctgg gaaatggaca aggtgggggg cccactctt 2400
tctctcctgc agtcccgtag ctggggcctc ctctctctc agggctctcc cagcccagtc 2460
cccttgcctc catcccactc ggtgctgttg ggtagggggc ctgccaggaa ctgaccagct 2520
cagcgaggag ccataatgtg catatgtgca caagcagggt tgggggaggg ggtgtgagg 2580
ggttggtgcc aggtgttgcc ccctatctcc tggggagggt gaggcagggc agggacagtc 2640
tccaggggtc gtccctggat ggggtggttac ctccccttcc tccaccctaa gccctggggc 2700
cctgaaatgg ggtggggagg caggggtggg agccctccta gtgggtttgg ggggttgggt 2760
tcctgaatgc accataatcg ctgtatgaaa tattaaaaag tctaaagtga aaaaaaaaaa 2820
aaaaa 2825

```

<210> 73

<211> 510

<212> DNA

<213> Homo sapiens

<400> 73

```

atgtacgaga gcgcatccaa agaacctagt agagaaaggt attctaacca ctgagaagca 60
gaatttccts ctatttgaca tgactactca tccagtgacc aatacaacag agaaacagcg 120
actagtga aaacttcaag atagtgtact agagcgggtg gtaaatgacc ctgagcgat 180
ggacaagcga aactagcac tcctgggtgct agccactcc tctgatgtgc tagagaatgt 240
cttctcctct ctgacagatg acaagtatga tgtggcaatg aatcgagcca aggacttagt 300
agaactggac cctgaagtgg aagggaacaa gccyagtgcc acagaratga tctgggctgt 360
gctggcagcc tttyaataaa tcytaaagcc rgyrggtggg tttctycttt tcccctgctg 420
gctggtgact gttcagagac mccwactga gttttgtgtg atgasatgtt ttccatcatt 480
tttcccttyc ttgaatcaga cttgtgaatt 510

```

<210> 74

<211> 458

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (382)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (388)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (424)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (448)

<223> n equals a,t,g, or c

<400> 74

```

gggtcgaccc acgcgtccgc tccacttaa attcaacttc tgcttggttc atctgattct 60
ttcaaggctct taaatgttaa atgaaggggt aaaataggaa ggtatttaag taattagcag 120
gcctcctggg tcttgataac ttcagtgtt ctgggagctg cccggttggc caccagtctc 180
tgtggaatcc aggggcctct tcccaatatg gatttgacca gcacttcaat tagtgagttt 240
ccatkagcat cttagcatta ctctttaata cagacgcctt attttccagg gtttatgaaa 300
gtttaagtga caaccatgga ttgcaggaac agactgttga gaagctgttt ttccagtggg 360
aaagttgggt ccaggagatg angggagnct tgaaatagat cctgggatgg aaacataaaag 420
tggncagcca gattcccatc atgggctncc ccataaaa 458

```

<210> 75

<211> 377

<212> DNA

<213> Homo sapiens

<400> 75

```

gtcctggaaa cacatcaagc tcagctcctg tgtccagctc gcttctctgc tggactcett 60
gatttttttt ttaatcattg ttgatatttg agcagtaacc aggctttttt ttccagatgt 120
tagtccacac ctattcatcc atggaccggc acgatgggtg cccgagccac agctcgcggc 180
tctcccagct gggctcggtg tcccaaggac cctactcgag cgccccgcgc ctgtcccaca 240
ccccgcgctc ggacttccag ccgcctact tcccamcccc ctaccagccg ctcccctamc 300
amcagagcca ggacccttac tcccacgtca amgamcccta tccctgaacc cactgcacca 360
gccccagcaa catccct                                     377

```

<210> 76

<211> 2070

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (20)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (39)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (88)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2068)

<223> n equals a,t,g, or c

<400> 76

```

tcatgaatgg gaatcctggn cccaagaact ccgcttgcn ggcagaggac ctgcagctga 60
ggacctatag cggtgtgccc atgacctnca gtgtatccca gggcaccgcc gtgtgtaata 120
taaagattgg ctgacaaaaa tgtcaggaaa acatgatgtt ggagcttaca tgctaata 180
taagggcgct aatcgtactg aaacagtcac gtcttttaga aaacgagaaa gtaaagtgcc 240
tgctgatctc ttaaagcggg ccttcgtgag gatgagtaca agccctgagg ctttcctggc 300
gctccgctcc cacttcgcca gctctcacgc tctgatatgc atcagccact ggatcctcgg 360
gattggagac agacatctga acaactttat ggtggccatg gagactggcg gcgtgatcgg 420
gatcgacttt gggcatgctg ttggatccgc tacacagttt ctgccagtcc ctgagttgat 480
gccttttcgg ctaactcgcc agtttatcaa tctgatgtta ccaatgaaag aaacgggcct 540
tatgtacagc atcatggtac acgcactccg ggccttcgc tcagaccctg gcctgctcac 600
caacaccatg gatgtgtttg tcaaggagcc ctcccttgat tggaaaaatt ttgaacagaa 660
aatgctgaaa aaaggagggt catggattca agaaataaat gttgctgaaa aaaattggta 720
cccccgacag aaaatatgtt acgctaagag aaagttagca ggtgccaatc cagcagtcac 780
tacttgtgat gagctactcc tgggtcatga gaaggccct gccttcagag actatgtggc 840
tgtggcacga ggaagcaaa atcacacat tcgtgccaa gaaccagaga gtgggctttc 900
agaagagact caagtgaagt gcctgatgga ccaggcaaca gacccaaca tccttggcag 960
aacctgggaa ggatgggagc cctggatgtg aggtctgtgg gagtctgcag atagaaagca 1020

```



```

ttacattggt taaagaatct actatacttt ggttggcagc attccatgag ctgattttcc 1080
tgaaacacta aagagaaatg tcttttgtgc tacagtttcg tagcatgagt tttaatcaag 1140
attatgatga gtaaatgtgt atgggttaaa tcaaagataa ggttatagta acatcaaaga 1200
ttaggtgagg tttatagaaa gatagatata caggcttacc aaagtattaa gtcaagaata 1260
taatatgtga tcagctttca aagcattttac aagtgtgca agttagtga acagctgtct 1320
ccgtaaattg aggaaatgtg gggaaagcctt ggaatgccct tctggttctg gcacattgga 1380
aagcacactc agaaggcttc atcaccaaga ttttgggaga gtaaagctaa gtatagtga 1440
tgtaacattg tagaagcagc ataggaacaa taagaacaat aggtaaagct ataattatgg 1500
cttatattta gaaatgactg catttgatat tttaggatat ttttctaggt tttttccttt 1560
cattttattc tcttctagtt ttgacatttt atgatagatt tgctctctag aaggaaacgt 1620
ctttatttag gagggcaaaa attttgggtca tagcattcac ttttgctatt ccaatctaca 1680
actggaagat acataaaagt gctttgcatt gaatttggga taacttcaaa aatcccatgg 1740
ttgttgtag ggatagtact aagcattttca gttccaggag aataaaagaa attcctatatt 1800
gaaatgaatt cctcatttgg aggaaaaaaa gcatgcattc tagcacaaca agatgaaatt 1860
atggaatata aaagtggctc cttcccatgt gcagtcctg tcccccccg ccagtcctcc 1920
acacccaaac tgtttctgat tggcttttag ctttttgttg tttttttttt tccttctaac 1980
acttgtattt ggaggtctct ctgtgatttt gagaagtata ctcttgagtg tttataaag 2040
tttttttcca aaaaaaaaaa aaaaaaantt 2070

```

<210> 77

<211> 997

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (619)

<223> n equals a,t,g, or c

<400> 77

```

ctcgccctcc tgactcttcc tgcaggtggc tcaggaagga ttcagcctgg ccacttggct 60
aggactctgc cagcaccat ctgagactga cctcttccgg gcctttggac actatgacct 120
tgatgctgcc cttcaggcag gaaacagggc tgggtgccttt tttcacctgc atggccagct 180
tccttccctg gcagtggaga gggcagccaa caggttctaa tgtcagagcc atcctttacc 240
aggtgggcct gcttgtccct gtcttgccct ccacatcact ctactttttg gaaggccatg 300
gctgattaaa gaagtctctg tagtttccca agcaaagtgg aatctagaaa cagtgaataa 360
agttcagata actttgaatt gcattcaaga agtacacttc tttccattg tccgtggctc 420
ttggagtctc cgtgatgcca ggctagagtc tgattatata ataattcaaa atggttaactc 480
ccaaggtaat gctttcttcc atttcatcag gttcttttat cccactgca cccctcccc 540
ttctcccttg cctatctgga tggcttctca gaagctcgcc cctagtcctc cctgccttgg 600
cgggggccag agccactna ctgctgaggc agcactgctc tcgtcagctg tgttgccctt 660
amccaagtgt cttcagaggg ttatgagtta gagtagctgg cctggggaga ggggtccctcc 720
ctgggtttga tctttagggt ctgactttct gcagagaaga tgttttacag atgtgtcaaa 780
gctgatgtaa tgtggttggg ggaggaaatc cagacccaaa gtgtttgtca gctgggtgta 840
caactgccta tgtgatcctc tgtcttaaaa tgatttctgt ctgtgctgcg aaacaaagac 900
aaggtagagt gtttttcttt tttgtaataa tataaagctg tgtgtttctg attggatgat 960
tcactatgtg cattgttccy cctaagtgtc ttttagta 997

```

<210> 78

<211> 1333

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1254)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1297)

<223> n equals a,t,g, or c

<400> 78

```
gagaggagct gctgcgcgcc caggaagcgc cggggcaggc cgagccgccg gccgccgccg 60
aggtgcaggg ggctggcaac gaaaatgagc ctgcgcaggc cgacaagagc caccgcggagc 120
agcgcragct tcggcctcgg ctctgtacca tgaagaaggg cccagtggc tatggcttca 180
acctgcacag cgacaagtcc aagccaggcc agttcatccg gtcagtggaac ccagactccc 240
cggctgaggc ttcaggggctc cgggccaggc atcgcatgtt ggaggtgaac ggggtctgca 300
tggaggggaa gcagcatggg gacgtggtgt ccgccatcag ggctggcggg gacgagacca 360
agctgctggt ggtggacagg gaaactgacg agttcttcaa gaaatgcaga gtgatcccat 420
ctcaggagca cctgaatggt cccctgcctg tgcccttcac caatggggag atacagaagg 480
agaacagtcg tgaagccctg gcagaggcag ccttgagagc ccccaggcca gccctggtga 540
gatccgcctc cagtgcacac agcgaggagc tgaattccca agacagcccc caaaacagg 600
actccacagc gccctcgtct acctcctcct ccgaccccat cctagacttc aacatctccc 660
tggccatggc caaagagagg gccaccaga aacgcagcag caaacgggac ccgcagatgg 720
actggagcaa gaaaaacgaa ctcttcagca acctctgagc gccctgctgc caccagtg 780
ctggcagggc cgagccagca ttccaccca ctttttctc tctccccaat tactccctg 840
aatcaatgta caaatcagca cccacatccc ctttcttgac aaatgatttt tctagagaac 900
tatgttcttc cctgacttta gggaagggtga atgtgttccc gtcctccgc agtcagaaag 960
gagactctgc ctccctcctc ctactgagt gcctcatcct accgggtgtc ccttgccac 1020
cctgcttggg acatcgctgg aacctgcacc atgccaggat catgggacca ggcgagagg 1080
caccctccct tcctcccca tgtgataaat ggggtccagg ctgatcaaag aactytgact 1140
gcagaactgc cgtctctyag ggacagggca tytggtatga cagacctktg gcagacacgt 1200
cttgttttca ttgattttt ttaagagtgc agtattgcag agtctagagg aatntatgtt 1260
tccttgatta acatgatttc ctggttggtta catccanggc aggcagtggc tcagctttaa 1320
atttggtttc cta 1333
```

<210> 79

<211> 560

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (542)

<223> n equals a,t,g, or c

<400> 79

```
caatggggct gaggtgtgtt ccaactgaggc taagatgact gcctttcctg attggccttg 60
gcttttccat acattgtgtg acccttgccc tatgaccctt tggctgacct taccggaagc 120
catgacgaca gcagcctttt gccattagac gcagggtgat ggtgaggatt ccaagggtta 180
```

```

gacaaaactg gttaatctga actaggtgac tgttaccttg cgtgttttgt ggccaaacca 240
ccaccaaaaa cctcacactg tgatgtaagt acttagtgta aaactagtaa acatttttgt 300
aaaatgtaga aatgcatgta atcagttaag ttttatattt tacaatgttc tgtaaaataa 360
aacttagcga ggtaaatcga ataaaggagc agtcactctc taacagattg taggagaggt 420
ttagttggat ttagtctatt tgacttgccc ttaatttaat tttatggcaa atcacaaatg 480
tgtcgaaggt ttagcaatat aatagcaaag tcctactcca gtaaataaaa gttggtatgt 540
tngtacttaa ctttcaaaag                                     560

```

```

<210> 80
<211> 3203
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc feature
<222> (1116)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc feature
<222> (1443)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc feature
<222> (1942)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc feature
<222> (3188)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc feature
<222> (3201)
<223> n equals a,t,g, or c

```

```

<400> 80
cggtagcgct gggtcgcggg cttcgggggt ctgcgctcgc ggctgcctgg actcagcagg 60
cccctggacc atgtcccgcg ccctgcggcc accgctcccg cctctctgct ttttcctttt 120
gttgctggcg gctgccggtg ctcggggccgg gggatacgag acatgcccc aagtgcagcc 180
gaacatgctg aacgtgcacc tgctgcctca cacacatgat gacgtgggct ggctcaaaac 240
cgtggaccag tacttttatg gaatcaagaa tgacatccag cacgccgggtg tgcagtacat 300
cctggactcg gtcattctctg ccttgctggc agatcccacc cgtcgcttca tttacgtgga 360
gattgccttc ttctcccggt ggtggcacca gcagacaaat gccacacagg aagtcgtgctg 420
agaccttggt cgccaggggc gcctggagtt cgccaatggt ggctgggtga tgaacgatga 480
ggcagccacc cactacggtg ccatcggtga ccagatgaca cttgggctgc gctttctgga 540
ggacacattt ggcaatgatg ggcgaccccg tgtggcctgg cacattgacc ctttcggcca 600
ctctcgggag caggcctcgc tgtttgcgca ratgggcttc gacggcttct tctttgggcg 660
ccttgattat caagataagt gggtagcgat gcagaagctg gagatggagc aggtgtggcg 720

```

```

ggccagcacc agcctgaagc ccccgaccgc ggacctcttc actggtgtgc ttcccaatgg 780
ttacaacccg ccaaggaatc tgtgctggga tgtgctgtgt gtcgatcagc cgctggtgga 840
ggaccctcgc agccccgagt acaacgccaa ggagctgggc gattacttcc taaatgtggc 900
cactgcccag ggccggtatt accgcaccaa ccacactgtg atgaccatgg gctcggactt 960
ccaatatgag aatgccaaca tgtggttcaa gaaccttgac aagctcatcc rgctggtaaa 1020
tgcgcaaggc aaaaggaagc agtgtccatg ttctctactc ccccccgct tgttacctct 1080
gggagctgaa caaggccaac ctacactggt cagtgnaaac tgacgacttc ttcccttacg 1140
cggatggccc ccaccagttc tggaccggtt acttttccag tcggccggcc ctcaaacgct 1200
acgagcgcct cagctacaac ttctgcagg tgtgcaacca gctggaggcg ctggtgggccc 1260
tggcgcccaa cgtgggaccc tatggtcccg gagacagtgc acccctcaat gaggcgatgg 1320
ctgtgctcca gcatcacgac gccgtcagcg gcacctcccg ccagcacgtg gccaacgact 1380
acgcgcgcca stttgcggca ggctgggggc cttgcgaggt tcttctgagc aacgcctggc 1440
gcngctcaga ggcttcaaag atcacttcac cttttgccaa cagctaaaca tcagcatctg 1500
cccgtcagc cagacggcgg cgcgcttcca ggtcatcggt tataatcccc tggggcgga 1560
ggtgaattgg atggtacggc tgccgggtcag cgaaggcggt ttcgttgtga aggaccccaa 1620
tggcaggaca gtgcccagcg atgtggtaat atttcccagc tcagacagcc aggcgcaccc 1680
tccggagctg ctgttctcag cctcactgcc cgccctgggc ttcagcacct attcagtagc 1740
ccaggtgcct cgctggaagc ccagggcccg cgcaccacag cccatcccca gaagatcctg 1800
gtccctgct ttaaccatcg aaaatgagca catccgggca acgtttgatc ctgacacagg 1860
gctgttgatg gagattatga acatgaatca gcaactcctg ctgcctgttc gccagacctt 1920
cttctgggtac aacgccagta tnaggtgaca acgaaagtga ccaggcctca ggtgcctaca 1980
tcttcagacc caaccaacag aaaccgctgc ctgtgagccg ctgggctcag atccacctgg 2040
tgaagacacc cttggtgcag gaggtgcacc agaacttctc agcttgggtg tcccagggtg 2100
ttcgcctgta cccaggacag cggcacctgg agctagagtg gtcggtgggg ccgatacctg 2160
tgggcgacac ctgggggaag gaggtcatca gccgttttga cacaccgctg gagacaaagg 2220
gacgttcta cacagacagc aatggccggg agatcctgga gaggagggcg gattatcgac 2280
ccacctgaa actgaaccag acggagcccg tggcaggaaa ctactatcca gtcaacaccc 2340
ggattacat cacggatgga aacatgcagc tgactgtgct gactgaccgc tcccaggggg 2400
gcagcagcct gagagatggc tcgctggagc tcatggtgca ccgaaagctgc tgaaggacga 2460
tggacgcgga gtatcggagc cactaatgga gaacgggtcg ggggcgtggg tgcgagggcg 2520
ccacctggtg ctgctggaca cagcccaggc tgcagccgcc ggacaccggc tcctggcgga 2580
gcaggaggtc ctggcccctc aggtggtgct ggccccgggt ggccggcgccg cctacaatct 2640
cggggtcct ccgcgcacgc agttctcagg gctgcgcagg gacctgccgc cctcgggtga 2700
cctgctcagc ctggccagct ggggccccga aatggtgctg ctgcgcttg agcaccagtt 2760
tgccgtagga gaggattccg gacgtaacct gagegcccc gttaccttga acttgaggga 2820
cctgttctcc accttcacca tcaccgcct gcaggagacc acgctggtgg ccaaccagct 2880
ccgcgaggca gcctccaggc tcaagtggac aacaaacaca ggccccacac cccacaaac 2940
tccgtaccag ctggacccgg ccaacatcac gctggaaccc atggaaatcc gcactttcct 3000
ggcctcagtt caatggaagg aggtggatgg ttaggtctgc tgggatgggc cctccaagcc 3060
caagcctcct gctccggggg cagaccagac tctgactctc ctcttgggct gctgccatta 3120
aaacgctact actaagaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3180
aaatttanaa aaaaaaaaaa naa 3203

```

<210> 81

<211> 1710

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1424)

<223> n equals a,t,g, or c

<400> 81

```
aagagccgaa cggataagag aagaggaggg cgcgkatggc gtcggggcgc cccgaggagc 60
tgtgggaggg cgtggtgggg gccgctgagc gcttccgggc ccggactggc acggagctgg 120
tgctgctgac cgcggccccc cgcaccacc ccgcccgggc ccctgtgect atgctgcca 180
tggtcgagga gccctggcgg aggcagcgcg ccgttgctc cagacatcg cactggcca 240
cagggctgcc actgctgctc ggcctcctgc gccccacca gcaccacagc caccagtc 300
cacaccagc ccacccggc ctaccctggc cagagaggac aacgaggagg acgaggatga 360
gcccacagag acagagacct ccggggagca gctgggcatt agtgataatg gagggctctt 420
tgtgatggat gaggaccca ccctccagga ccttcccccc ttctgtgagt cagacccga 480
gagtacagat gatggcagcc tgagcgagga gacccccgcc ggcccccca cctgctcagt 540
gccccagcc tcagccctac ccacacagca gtacgccaag tccctgcctg tgtctgtgcc 600
cgtytggggc ttcaaggaga agaggacaga ggcgcggtca tcagatgagg agaatgggcc 660
gccctcttcg cccgacctgg accgcctcgc ggcgagcatg cgcgcgctgg tgctgcgaga 720
ggccgaggac acccaggtct tcggggacct gccacggccg cggttaaca ccagcgactt 780
ccagaagctg aagcggaaat attgaagtcc agggaggagg cgcgccgggc cgcgtccgcc 840
ccgtccaca ctacgcccc gcccactcc cggggcctgc taatctgagg ccgatccggg 900
accggcctcc ttgctctcc cattcccaag attgtccgc ctctgccaat ccccgccgct 960
cttccagccc acgacctgcc gcgccgagga gcggcwtctg tcccgttcc cgattgggtc 1020
tgtcgtctct ctccgcctag cgacagattc/cttctattaa gggattggct cgctgagttc 1080
taagctctaa atgggtcaac tcctttgttt tccgcctagc gacaagggat ttgctcgcac 1140
ggcattggct ccatcccta gtcgctggac agctcttttt ttgattggct caaatcctgt 1200
aaagggcttg accagtctct acatagtcac cgtccgcttt tcctgagttc tccctcccaa 1260
ttggctccag cttcctgggg gcgtggccaa gccctcctct tcccagaatt ggcccggggc 1320
cttcaattta cgttctttac actacgggga ctggggtcgt ctttgccac gtcccgacaa 1380
cttgttccct gacccctca gggatggccc caaactgtcc ctgncctctg caccctctt 1440
cattggttcc atccatcccc acaacagcct gccaatcgaa gcccgctccct gcatccagga 1500
tggtaccagc tcccgccct cgcgccccac ctccacaggt gccttaaagg gccctcgtca 1560
cccaaggtgg gggcaggggc cctcactctc cggccctggt gtgggggaga gagtggggg 1620
ttgggggatc ggcagttggg aggggcgctc tgagattaaa gatttttacc tctgagataa 1680
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1710
```

<210> 82

<211> 1379

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (280)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1365)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1378)

<223> n equals a,t,g, or c

<400> 82

```
aattcggcag agctgagccc cgggctgtgc agtccgacgc cgactgaggc acgagcgggt 60
gacgctgggc ctgcagcgcg gagcagaaag cagaaccgcg agagtccctcc ctgctgctgt 120
gtggacgaca cgtgggcaca ggcagaagtg ggcctgtga ccagctgcac tggtttcgtg 180
gaaggaagct ccaggactgg cgggatgggc tcagcctgta tcaaagtcac caaatacttt 240
ctcttcctct tcaacttgat cttctttatc ctgggcgcan tgatcctggg cttcgggggtg 300
tggatcctgg ccgacaagag cagtttcacg tctgtcctgc aaacctcctc cagctcgctt 360
aggatggggg cctatgtctt catcggcgtg ggggcagtca ctatgctcat gggcttcctg 420
ggctgcatcg gcgccgtcaa cgargtccgc tcctgtctgg ggctgtamtt tgctttcctg 480
ctcctgatcc tcattgcccc rgtgacggcc ggggccctct tctacttcaa catgggcaag 540
gtaagccctt ctctccctcc ctcttcaactg ggctggacca accatggggg tgattgactg 600
agtgtggggg atggacaagg aaccccccca gttgtcacag acagatccag taggtgtcag 660
ggacggcctc ctggacacta ttcttgtga atcaaattgg ggagcgtag aagagaaggc 720
ggcaggtgtr ggagtcctcc gctgggcctg gwtcttagcc tgacccccct gctttctagc 780
tgtgtggcct tgggcaagct gcttgccctc atgtgcctgt tccaccatct gtgaaaatgg 840
aaacaataag aaaactgaac tctcagagtg gttgcaaaga ttattcgaga ttatctgagt 900
gaaacacata gcgcattggca ccataagtac tcaataaatg ttattcttgt tattattaag 960
rtactttagc aactattaaa tccatgccac tcaccacaa atgaggttta gaaggagacc 1020
gttaataaaa acatcagctt tgtgtccgag gggagatgtt cagctttcag aaacagaaaa 1080
tcagacttac agcggcttaa agttgaagga catctgttgt tgacttgacc ggaagtctgg 1140
tttggaagct cagaggccct ggttctggct gttgagcatc ctgctgggga tggctttcct 1200
gcattatgac acttacctcg tggttccaag atggctgcca cagcaccagg cacgatgtct 1260
gtgccgctgt ggcctgaaga tggggaagtg ggcagtgcca gacatggcca tcccttttat 1320
ccagaaaagg cgcagtggct catgactgta atccccaata cttanggaag cagaagtng 1379
```

<210> 83

<211> 678

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (602)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (626)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (648)

<223> n equals a,t,g, or c

<400> 83

```
gcaagagcgg aagaaagcgg ctggtacccc ggaagcagtc gctgcaactt ccgggaggtg 60
cttgtgtgcc tgggtgcggga gctacggggc ccagggattg tgtttaaagt agtgcttcta 120
ccaacatgtc ccgtgggtcc agcgcgggtt ttgaccgcca cattaccatt ttttcacccg 180
```

```

agggtcggct ctaccaagta gaatatgctt ttaaggctat taaccagggt ggccttacat 240
cagtagctgt cagagggaaa gactgtgcag taattgtcac acagaagaaa gtacctgaca 300
aattattgga ttccagcaca gtgactcact tattcaagat aactgaaaac attgggtgtg 360
tgatgaccgg aatgacagct gacagcagat cccagggtaca gagggcacgc tatgaggcag 420
ctaactggaa atacaagtat ggctatgaga ttcctgtgga catgctgtgt aaaagaattg 480
ccgatatttc tcagggtctac acacagaatg ctgaaatgag gcctcttggt tgttgatga 540
ttttaattgg tatagatgaa gagcaaggcc ctcagggtata taagtgtgat cctgcagggt 600
antactgtgg ggtttaaacg cactgnagcg ggagttaaac aaactggngt caaccagctt 660
ccttgaaaaa aaagtgga                                     678

```

<210> 84

<211> 2803

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (10)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (50)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (517)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (572)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1926)

<223> n equals a,t,g, or c

<400> 84

```

caacatgagn aatccttctc ctccctctgg ctggcttgga aatscaaaan ctcytcgcaa 60
cgtcccgcga raatctggtt gctctgccgg atggcatctc ggagctcttg attctctcc 120
aggcarcgtt ggagggtctc aggagcgccc tgtctgaag gcagggtgcag catggctggc 180
ttccccagag gagactcttc gccagtagc tctgatctg ctgccgggcc accactgggc 240
tgcaccatct cacacagttg gctctccag aggtgcctat tcatccaaca gggcaagggc 300
tgtagcagca gtccgtcaga cgtgagaagg gtgggagcgg cggactgtga acgctggtag 360
ggccccggcg ctccgagaaa gtcccagttt cgcggtcgcc cttccctacc acgcttccgg 420
cttccggtgt catagctgtg ggatccggaa gtaaaaacac aagccccgcs cccrrgaact 480
cgggaagccg gcgakaagtg tgaggccgcg gtagggnccg atcccgtcc ggagagaagt 540
ctgagtcgca cagctctgca ggcccgcgga antcgacagc gtcattggcag agcagggtggc 600

```

```

cctgagccgg acccaggtgt gcgggatcct gcgggaagag cttttccagg gcgatgcctt 660
ccatcagtcg gatacacaca tattcatcat catgggtgca tcgggtgacc tggccaagaa 720
gaagatctac cccaccatct ggtggctgtt ccgggatggc cttctgcccg aaaacacctt 780
catcgtgggc tatgcccggt cccgcctcac agtggctgac atccgcaaac agagtgaacc 840
cttcttcaag gccaccccag aggagaagct caagctggag gacttctttg cccgcaactc 900
ctatgtggct ggccagtacg atgatgcagc ctccctaccag cgcctcaaca gccacatgaa 960
tgccctccac ctgggggtcac aggccaaccg cctcttctac ctggccttgc ccccgaccgt 1020
ctacgaggcc gtcaccaaga acattcacga gtccctgcatg agccagatag gctggaaccg 1080
catcatcgtg gagaagccct tcgggaggga cctgcagagc tctgaccggc tgtccaacca 1140
catctcctcc ctgttccgtg aggaccagat ctaccgcata gaccactacc tgggcaagga 1200
gatggtgcag aacctcatgg tgctgagatt tgccaacagg atcttcggcc ccatctggaa 1260
ccgggacaac atcgctcgcg ttatcctcac cttcaaggag ccctttggca ctgagggctc 1320
cgggggctat ttgatgaat ttgggatcat ccgggacgtg atgcagaacc acctactgca 1380
gatgctgtgt ctggtggcca tggagaagcc cgcctccacc aactcagatg acgtccgtga 1440
tgagaaggtc aaggtgttga aatgcattct agaggtgcag gccaacaatg tggtcctggg 1500
ccagtacgtg gggaaccccg atggagaggg cgaggccacc aaagggtacc tggacgacct 1560
cacggtgccc cgcgggtcca ccaccgccac ttttgagcgc gtcgtcctct atgtggagaa 1620
tgagargtgg gatgggggtgc ccttcattct gcgctgcggc aaggccctga acgagcgcaa 1680
ggccgaggtg aggtgcagat tccatgatgt ggccggcgac atcttcacc agcagtgcga 1740
gcgcaaccgag ttggtgatcc cgtgcagcc caacgaggcc gtgtacacca agatgatgac 1800
caagaagccg ggcattgttct tcaaccccga ggagtcggag ctggacctga cctacggcaa 1860
cagatacaag aacgtgaagc tccctgacgc ctacgagcgc ctcatcctgg acgtcttctg 1920
cggganccag atgcacttcg tgcgcaggac gagctccgtg aggcctggcg tattttcacc 1980
ccactgctgc accagattga gctggagaag cccaagccca tcccctatat ttatggcagc 2040
cgaggcccca cggaggcaga cgagctgatg aagagagtgg gtttccagta tgagggcacc 2100
tacaagtggg tgaaccccca caagctctga gccctgggca cccacctcca cccccgccac 2160
ggccacccct cttcccgcgc cccgaccccg agtcgggagg actccgggac cattgacctc 2220
agctgcacat tcctggcccc gggtctctggc caccctggcc cggccctcgc tgctgctact 2280
acccgagccc agctacattc ctcatgtgcc aagcactcga gaccatcctg gcccctccag 2340
accctgcctg agccagagg ctgagtcacc tcctccactc actccagccc aacagaagga 2400
aggaggaggg cgcctattcg tctgtcccag agcttattgg cactgggtc tactcctga 2460
gtggggccag ggtgggaggg agggacaagg gggaggaaag gggcgagcac ccacgtgaga 2520
gaatctgcct gtggccttgc ccgccagcct cagtgccact tgacattcct tgtcaccagc 2580
aacatctcga gccccctgga tgtcccctgt cccaccaact ctgcactcca tggccacccc 2640
gtgccacccg taggcagcct ctctgtcata agaaaagcag acgcagcagc tgggaccctt 2700
cccaacctca atgccctgcc attaaatccg caaacagcca aaaaaaaaaa aaaaaaaaaa 2760
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aag 2803

```

<210> 85

<211> 1278

<212> DNA

<213> Homo sapiens

<400> 85

```

tcgaccacag cgtccgcaag aagctttttg agggcctgaa gttcttctctg aaccgagagt 60
gccccgtgag gccctggcct tcatcatcag gagttttggt ggggaagtgt cctgggacaa 120
atctttgtgc attggggcca cctatgacgt cacagactcc cgcatacccc atcagattgt 180
cgaccggcct gggcagcaga cctcagtcac tggcaggtgc tacgtgcagc cccagtrggt 240
gtttgactca gtgaacgcca ggctccttct ccccgctggca gactacttct ctgggggtgca 300
gctgccccca cacctttcac cctttgtgac cgagaaggaa ggagattacg ttccacctga 360
gaaagctgaag ctgctggctc tgcagcgggg agaggaccca ggaaacctga atgagtcaga 420

```



```

agaggaggag gaagaggacg acaacaacga aggtgatggt gatgaagagg gagaaaatga 480
ggaggaggag gaagatgcag aggctggttc agaaaaggag gaagaggccc ggctggcagc 540
cctggaagag cagaggatgg aggggaagaa gcccagggtg atggcaggca ccttgaagct 600
ggaggataag cagcggctgg cccaggagga ggagagttag gccaaagcgc tggccattat 660
gatgatgaag aagcgggaga agtacctgta ccagaagatc atgtttggca agaggcgaaa 720
aatccgagag gccaaacaagc tggcggagaa gcggaaagcc cacgatgagg cggtagggtc 780
tgagaagaag gccaaagaag caaggccgga gtgagtgcct gcggccctc acagggtcga 840
ggccagcccc tagcagctgg atgtggcaga ggcaggccag aggacctaa tgtgatggac 900
cagagtcaact tctcctcctc ctttctccag ccagccctga cccctcatgc tctctggctg 960
ggccagtggg cagccctcgc ttcccttggg tggagctgcc ctgctggtgc ctggtcagag 1020
aagaggcctc tgtgccagc ctgattctct gctcccagga gccagtgaac tgaggtgcag 1080
aggccacccc agccccctac ctactgcccc cattcatcct ggctttccac agccccctc 1140
cacacagttg gaccctgat tctcagggtg ctgtgatggg gtgagggtag ggggagcatt 1200
tgttattaaa tgactggact tttgtgccaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1260
aaaaaaccca cgcgtccg                                     1278

```

<210> 86

<211> 2585

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (2573)

<223> n equals a,t,g, or c

<400> 86

```

tcgaccacg cgtccgcggg ctatttgttg gagcccaagc ctggtggtgg gccttcaaga 60
accccgaggt gtcccttttg gctcgattcc caggaaactc ctcctcaacc cctttggcat 120
cagcattaca agccaaagcc tcaatccagg gcccttcgt actcctaaag cagggataag 180
gacctatcac ttccgctcca ccttgggcga gttccagggt ataatgggca ggaagagagg 240
aaatgtggaa aagggtctgt tggcaaagct gggaccagat ggtgcagctt tcctgcagat 300
tcccgcagaa gagatccctg cctacatgtc tgtgcatcga ctcctgagga agctgctaag 360
tcgatatcgg ctccagtag caaccgaga gaacctgtt atcaatgact gctgcagagg 420
tgctatgctt tcctggcca caggtggcc cactctggaa gcgacctctc tctgttagtc 480
ccagaaattg aagatatgta cagcagcccc tatctgcgcc cctcagaatc tcctatcacc 540
gtcgagggtca actgcaccaa tccaggcacc agatattgct ggatgagtag tgggtcttac 600
atacctggaa ggcaaattat agaagtctca ctgctgaag ctgctgcctc tgccgacctg 660
aagatacaga ttggctgcca cacagatgac ctgaccagg ccagcaagct tttccgaggc 720
ccactcgtaa ttaaccggtg ctgcttgac aaaccacaa aatcgatcac gtgcctctgg 780
ggtggactcc tctatataat tgtgcctcag aacagcaaac tgggttctgt gcctgtcacc 840
gtgaaggggg ctgtgcatgc tccatactac aagctggggg agaccacctt ggaggagtgg 900
aagaggcgta tccaggagaa tccaggcccc tggggagagc tggccacgga caacatcatt 960
ctgaccgtgc cgaccgcaa tcttcgtact ctggagaacc ctgagccgct gctccgcctc 1020
tgggatgagg tgatgcaggc tgtggcgcga ctgggagctg agcccttccc tttgcgcctg 1080
cctcagagga ttgttgccga cgtgcagatc tcagtgggtt ggatgcatgc agggtacccc 1140
atcatgtgcc atctggagtc agtgcaggat ctcataacg agaagctcat cagaaccaag 1200
gggctgtggg gcccgtcca tgagctgggc cgcaaccagc agcggcagga gtgggagttc 1260
ccaccacaca ccaccgaggc camctgcaac ctgtgtgtgt tgtatgtgca tgagacggtc 1320
ttgggcattc ctcgaagccg tgccaatatt gctctgtggc cccagttcg ggagaagaga 1380
gtcagaatct acctgagcaa ggggtccaat gtgaaaaact ggaatgcatg gmccgcaactg 1440

```

```

gaaacgtatt tacagctcca ggaagccttt ggttgggagc cattcatccg tctcttcacc 1500
gagtacagga accagaccaa cttgcccaca gaaaatgttg acaaaatgaa tctgtgggtc 1560
aagatgttct cccaccaagt gcagaagaac ctggctccgt tctttgaggc ctgggctggc 1620
ccatccagaa ggaagtggct accagcctgg cctatctgcc tgaatggaag gaaaatatta 1680
tgaaattgta cctcctcaca cagatgcccc actgaaattg aagtcaagaa atgcaaaaaag 1740
gaactgagca catctcagca aagaaaactg aagggtattg gttataagtg gagaggatct 1800
cagcatatct ctggaagata gaaagtggat gaagcatgat aatgaaagag tgaagaacct 1860
ttcagataaa atgtaagctg atctgaacaa cataacccca aagagacttg cgcacctgaa 1920
aagcttgtct actgaagaat tactccagtt gtaagattga gccctctcct actctcccc 1980
aactcttatg cacagaacac aggcagtctc cactattgat accagttaaa aatttcttgt 2040
tattgttgct gttgttgttt gtataaagga attgaacagg ctgcttgagc agagataaga 2100
gttggtgctc cagaaaaaaa tttctcttct agtggaata agtgccccta ccccagccg 2160
gtcagctaata tctctactga cagctgagac ctccactca agtgcctgtt gccttcaggt 2220
atagaagagg tttcctgaag aaacagacct aactgtacaa cagcagagga aaccatgcc 2280
aactgttata caagttaaca gttatgttga ttcttaaatg gggaatggtg agttagaaat 2340
tcccagacat gggcgatggg gagggaagag grataaggaa aagtcacgag gtaggawtta 2400
gggggccttg aaaatatgac aaactctgag gggaaacaaa grcmatktg gaaagawtaa 2460
cttaatttta attccatctc cagagagatt tgaggtgtat ttaagatgaa aaacaggata 2520
ctacaaagaa acgggaaaac tcaggggttc aagaccagcc taggcaagat ggnaaaaaac 2580
cccc

```

```

<210> 87
<211> 385
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (385)
<223> n equals a,t,g, or c

```

```

<400> 87
gggtcgaccc acgcgtccgc atgaatttgt cacaatctta tcaataatca ttactctgtt 60
ttttatatct caactaaaag tatcaaaaata tagctttcca gaaaaccccg aaccaaagtc 120
actgactaca tcaaagtcta ctacaccttg agaaaacaaa tgaacgaaaa tctattttcc 180
tcattcatta cccaacaat aataggactc cctatcgtaa ttattatcac tatgtttcca 240
agcattatat tcccatcacc tacccgactr aatcaataat cgactscatc tccattccaa 300
caatgattag tgactgaac atscaaaaca aatrttgatc catgccacaa ccaaaaagga 360
caaactggag cccggatatt gatan
385

```

```

<210> 88
<211> 2500
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (429)
<223> n equals a,t,g, or c

```

```

<220>

```

<221> misc feature
<222> (1088)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (2480)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (2482)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (2491)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (2497)
<223> n equals a,t,g, or c

<400> 88
tcgacccaag cgtccgcca cgcgtccgtc tccaccgctg ctgccgccgc cctggccgcc 60
gccgcagtga aagctaagca cttggctgct gttgaggaaa ggaagatcaa atctttggtg 120
gccctgctgg tggagacca gatgaaaaag ttggagatca aacttcggca ctttgaggag 180
ctggagacta tcatggaccg ggagcragaa gcactggagt atcagaggca gcagtccttg 240
gccgacagac aagccttcca catggagcag ctgaagtatg cggagatgag ggctcggcag 300
cagcacttcc aacagatgca ccaacagcag cagcagccac caccagccct gccccaggc 360
tcccagccta tcccccaac aggggctgct gggccacccg caktccatgg cttggctgtg 420
gctccagcnt ctgtagtccc tgctcctgct ggcagtgagg cccctccagg aagtttgggc 480
ccttctgaac agattgggca ggcagggtca actgcagggc cacagcagca gcaaccagct 540
ggagcccccc agcctggggc agtcccacca ggggttcccc cccctggacc ccatggcccc 600
tcaccgttcc ccaaccaaca aactcctccc tcaatgatgc caggggcagt gccaggcagc 660
gggcacccag gcgtggcggg taatgctcct ttgggtttgc cttttggcat gccgcctcct 720
cctcctcctc ctgtcccatc catcatccca ttggttagtc tagctgactc catcagtatt 780
aacctccccg ctctcctaa cctgcatggg catcaccacc atctcccgtt cgccccgggc 840
actctcccc cacctaacct gcctgtgtcc atggcgaacc ctctacatcc taacctgccg 900
gcgaccacca ccatgccatc ttccctgcct ctggggccgg ggctcggatc cgccgcagcc 960
caaagccctg ccattgtggc agctgttcag ggcaacctcc tgcccagtgc cagccactg 1020
ccagaccag gcacccccct gcctccagac cccacagccc cgagccccag gcacggtcac 1080
ccctgtgncc acctccacag tgaggagcca gccagacatc tctccccctc accccctgtg 1140
gacatcacgg ttccaggaac agcccttccc ccaccactgg gaccctcccc agcctggaga 1200
gttcatcact acgtaaggaa agctccttcc gcccctccaa agccctcacc atgcctaaca 1260
gaggcatgca tttttatatc agattattca aggacttctg tttaaaagat gtttataatg 1320
tctgggagag aggataggat gggaaatgctg ccctaaagga agggctgggtg aaagtggtt 1380
atacaagggt ctattaacca cttctaaggg tacacctccc tccaaactac tgcattttct 1440
atggattaaa aaaaaaaaaa aaagtagatt ttaaaaagcc acattggagc tcccttctac 1500
ccactaaaaa ataaccaatt ttacatttt ttgaggggga gtgagtttta ggaaagggga 1560

```

attaagattc cagggagagc tctggggata gaacagggcg cagattccat ctctcccaa 1620
gccccttttt agtgactaag tcaaggcccc aactcccctc cccaccccta cgctgagctt 1680
attcgagttc attcgacta ataatccctc ctgcggcttc ctcatgtgtg ctgttttagg 1740
ccacccagc tcagccaatg attcctttcc ctctgaatgt cagttttgtt tttaaaagtc 1800
acttgcttag ttgatgtcag cgtatgtgta tttgggtggg aaaacctaatt ttcggggatt 1860
tctgtggtag gtaataggag aagaaagggc actgggggct gttctccttc ctccctggg 1920
ctgtatccat ggactcctgg aaggcacaga gaaggagct ataagaggat gtgaagtttt 1980
aaaaacctgaa attgtttttt aaagcactta agcacctcca tattatgact tgggtgggtca 2040
cccccttagct tcctccctct cccaccaaga ctatgagaac ttcagctgat agctgggggc 2100
tcccagatg aggatgcagg gatttgggag cagtgaaga gggtgcccaa ccttgggttg 2160
gaccaaccct tggctcgcag ctcaactctg cttcccgcat tcctgctcca cgtgtccag 2220
cttctcccct gtgacgggaa ggcaggtgtg actccaggct ctgcaactgt tcttcttgg 2280
tcctccacc aggcctttt ttcctcatgt ccccatgtt ctctccctct gcgtcttagc 2340
acctttcttc tgttcaaagt tttctgtaa ttttctctt tttctttct tcttttttt 2400
tttttttata aattaatttg ctttcagttc caaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2460
aaaaaaaaaa aaaaaaaaaa tngagggggg ncccggnacc 2500

```

<210> 89

<211> 1409

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (841)

<223> n equals a,t,g, or c

<400> 89

```

aggagtatgt atttcccgc aagaagaagc tgcaggaata ccgggtctta attaccaccc 60
tcatcactgc cggcagttgg tctcgcccca gtttcccatt gatcacttca cacacatctt 120
catcgatgag gctggccact gcatggagcc tgagaagtct ggtagctata gcagggtga 180
tggaagtaaa ggaaacaggt gatccaggag ggcagctggt gctggcagga gacctcggc 240
agctggggcc tgtgctgctg tccccactga cccagaagca tggactggga tactactgc 300
tggarccgct gctcacctac aactccctgt acaagaagg ccctgatggc tatgaccccc 360
agttcataac caagctgctc cgcaactaca ggtctcatcc caccatcctg gacattccta 420
accagctcta ttatgaagg gagctgcagg cctgtgctga tgtcgtggat cgagaacgct 480
tctgccgctg ggcggsccta cctcgacagg gcttcccat catctttcac ggcgtaatgg 540
gcaaagatga gcgtgaaggc aacagcccat ccttcttcaa ccctgaagag gctgccacag 600
tgacttccta cctgaagctg ctcctggccc cctcctcaa gaagggcaa gctcgcctga 660
gccctcgaag tgtgggcgtc atctcccgt accggaaaca ggtggagaaa atccgttact 720
gcatcaccaa acttgacagg gagcttcgag gactggatga catcaaggac ttgaagggtg 780
gttcagtaga agaattccaa ggccaagaac gaagcgctat cctcatctcc accgtgcgaa 840
nagccagagc tttgtgcagc tggatctgga ctttaatctg ggttccctta agaaccccaa 900
gaggttcaat gtagctgtga cccggcccaa ggcctgctca tcatcgtggg gaacccctt 960
ctcctgggcc atgacctga ctggaaagta ttcctggagt tctgtaaaga aaacggaggg 1020
tataccgggt gtcccttccc tgccaaactg gacctgcaac agggacagaa tttactgcaa 1080
ggctctgagca agctcagccc ctctacctca gggcccccaca gycatgacta cctccccag 1140
gagcgggagg gtgaaggggg cctgtctctg caagtggagc cagagtggag gaatgagctc 1200
tgaagacaca gcacccagcc ttctcgacc agccaagcct taactgcctg cctgacctg 1260
aaccagaacc cagctgaact gcccctcaa gggacaggaa ggctggggga gggagtttac 1320
aaccgaagcc attyacck cctccctgct ggggagaatg acacatcaag ctgctaacaa 1380

```

ttgggggaag gggaaggaag aaaactctg

1409

<210> 90

<211> 1336

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (49)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1284)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1317)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1333)

<223> n equals a,t,g, or c

<400> 90

agaacagtac ctccctctca ctgaggaaga actagaaaaa gaagcaaana aagttgaagg 60
atthgatctg gttcagaagc caagttatta tgttagactg ggatccctgt ctaccaagct 120
tcactcccgt gcctaccagc aggctctcag cagggttaaa gaagctaagc aaaaaagcca 180
acagaccatt tctcagctcc attctactgt tcacctgatt gaatttgcca ggaagaatgt 240
gtatagtgcc aatcagaaaa ttcaggatgc tcaggataag ctctacctct catgggtaga 300
gtggaaaagg agcattggat atgatgatac tgatgagtc cactgtgctg agcacattga 360
gtcagctact cttgcaattg ccgcacacct gactcagcag ctccagacca cgtgccacac 420
cctcctgtcc aacatccaag gtgtaccaca gaacatccaa gatcaagcca agcacatggg 480
ggtgatggca ggcgacatct actcagtgtt ccgcaatgct gcctccttta aagaagtgtc 540
tgacagcctc ctcaattcta gcaaggggca gctgcagaaa atgaaggaat ctttagatga 600
cgtgatggat tatcttggtta acaacacgcc cctcaactgg ctggtaggtc ccttttatcc 660
tcagctgact gagtctcaga atgctcagga ccaagggtgca gagatggaca agagcagcca 720
ggagacccag cgatctgagc ataaaaactca ttaaacctgc ccctatcact agtgcagtgt 780
gtggccagac agatgacacc ttttgttatg ttgaaattaa cttgctaggc aaccctaaat 840
tgggaagcaa gtagctagta taaaggccct caattgtagt tgtttccagc tgaattaaaga 900
gctttaaagt ttctggcatt agcagatgat ttctgttcac ctggtaagaa aagaatgata 960
ggcttgtcag agcctatagc cagaactcag aaaaaattca aatgcactta tgttctcatt 1020
ctatggccat tgtgttgccct ctgttactgt ttgtattgaa taaaaacatc ttcatgtggg 1080
ctggggtaga aactgggtgtc tgctctggtg tgatctgaaa aggcgtcttc actgctttat 1140
ctcatgatgc ttgcttgtaa aacttgattt tagtttttca tttctcaaat aggaatacta 1200
cctttgaatt caataaaatt cactgcagga tagaccagtt aaaaaaaaaa aaaaaaaaaa 1260
aaaagggggg ccgcccaagg grtncccccg agggggggccc cagcttttac cgtggcntgc 1320
gacgtccaaa gcnccc 1336

<210> 91
<211> 787
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (677)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (725)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (742)
<223> n equals a,t,g, or c

<400> 91
ggcacgagct gtggggctgt gggcctgtta ccccaggcg cacagctccc tccggctggg 60
cccaggctcc actcagtgc acggtcgaag tctacatgga gctgcagggc ctggtggacc 120
cgcagatcca gctacctctg ttagccgccc gaagtacaag ttgcagaagc agcttgatag 180
cctcacagcc aggaccccat cagaagggga ggcagggact cagaggcaac aaaagctttc 240
ttccctccag ctggaattgt caaaactgga caaggcagcc tctcacctcc rgcagctgat 300
ggatgagcct ccagccccag ggagcccgga gctctaactc atcatcccca tcagttttcc 360
tccctctcag acctgtcttt gaggacaaac agatttgtca gctgtcaggg tgcagtggga 420
cgtcagagac tatgtggtcc atcgccctca ttgtgtaaag gaggacacag actggcttgg 480
tcgcagtgac tgtggtgtcc ttgagatgct cacattactg cccggcctgc ctcccacctg 540
gaagtctggg aatgaggaga ttgagataaa cttttgaaat cccaaacatg tctgtttatg 600
gctctttggt cccctttgct cccagtggtg acttttgtgc ttctgagttg tccctgaga 660
gcttggtctg ggaaanagg aaggaagggg tcctcactgg aggaagagga acctttctaa 720
gtcangggta aggggaatgg gnacagttgg ttcccgggtc taacctcctt ttctggactg 780
acaagtg 787

<210> 92
<211> 1657
<212> DNA
<213> Homo sapiens

<400> 92
cgcgtccgcc cagcgcgcc cccacgcgtc cggctactca gaggaagggg cggttggtgc 60
ggcctccatt gtctgtgttt taaggcgcca tgagggggtga cagaggccgt ggtcgtggtg 120
ggcgttttgg ttccagagga ggcccaggag gagggttcag gccctttgta ccacatatcc 180
catttgactt ctatttgtgt gaaatggcct ttccccgggt caagccagca cctgatgaaa 240
cttccttcag tgaggccttg ctgaagagga atcaggacct ggctcccaat tctgctgaac 300
aggcatctat cctttctctg gtgacaaaaa taaacaatgt gattgataat ctgattgtgg 360
ctccagggac atttgaagtg caaattgaag aagttcgaca ggtgggatcc tataaaaagg 420
ggacaatgac tacaggacac aatgtggctg acctggtggt gataactcaag attctgcca 480

```
cgttggaagc tgttgctgcc ctggggaaca aagtcgtgga aagcctaaga gcacaggatc 540
cttctgaagt ttttaaccatg ctgaccaacg aaactggcct tgaaatcagt tcttctgatg 600
ctacagtga gattctcatt acaacagtgc cacccaatct tcgaaaactg gatccagaac 660
tccatttggga tatcaaagta ttgcagagtg ccttagcagc catccgacat gcccgctggt 720
tcgaggaaaa tgcttctcag tccacagtta aagttctcat cagactactg aaggacttga 780
ggattcgttt tcctggcttt gagccctca caccctggat ccttgacctg ctaggccatt 840
atgctgtgat gaacaacccc accagacagc ctttggccct aaacgttgca tacaggcgct 900
gcttgcatg tctggctgca ggactgttcc tgccagggtc agtgggtatc actgacctct 960
gtgagagtgg caactttaga gtacacacag tcatgaccct agaacagcag gacatggtct 1020
gctatacagc tcagactctc gtccgaatcc tctcacatgg tggctttagg aagatccttg 1080
gccaggaggg tgatgccagc tatcttgctt ctgaaatatc tacctgggat ggagtgatag 1140
taacaccttc agaaaaggct tatgagaagc caccagagaa gaaggaaagg gaggaagaag 1200
aggagaatac agaagaacca cctcaaggag aggaagaaga aagcatggaa actcaggagt 1260
gacattccct tcactccttt tcctacccaa gggggaagac tggagcctaa gctgcctgct 1320
actgggcttt acatggtgac agacatttcc gtgggtagag gaagatagca ggaagaaaag 1380
taaactccat agaagtgtca ttccactggg ttttgatatt ggcttagctg ccagtctccc 1440
atgtgtgacc tatgccatcc atctataatg gaggatacca acatttcttc ctaatatctc 1500
ataatctcca actcctgaaa acccctctct caactaatac tttgctgttg aaatgttgtg 1560
aaatgttaag tgtctggaag ttttttttct taagaaaaac tattaagta cttcctagta 1620
ggaaaaaaaa aaaaaaaaaa aaacycgggg gttttct 1657
```

<210> 93

<211> 485

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (478)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (485)

<223> n equals a,t,g, or c

<400> 93

```
aattcggcac gaggggttct gcactaacag cctccaagcc ccctggcact tcttttgccc 60
tgagagtgtc ccaggggatt cagagtctcc agaaagatat ggctrggcca actctgttgc 120
ctacctrgcc tgaccagtc ggagcctgac atggtggagg gaaagggaga caagtggggc 180
tgactcgggt ccagaggcca gctaggagg aaaccgcagc ttcctggggc ttgtgtgtga 240
agattcctga cttaggggtg gcttttgttt acaagatgca agaggggaaa cctgtccccg 300
actcatcgag acaacatgcc cagttatcag ggagtcctgt gtcacaaggt ctgtctctgc 360
cattgtaagc aagtgccttg ggcgagctgg cctctgcccc acagtctcat ctgtacaccg 420
acaggggttg tgcctccctc acaggggttg gaacaagagc cakttgggcca attaaaanaa 480
aaaaan 485
```

<210> 94

<211> 764

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (202)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (565)

<223> n equals a,t,g, or c

<400> 94

```

ccccagccag tctgccctct gccatggggg gcggagagga cgaggaggag gccaccgact 60
atggagggac ctacgtgccg actgccgggg aggccgtgcg ggggctagaa acagctctgc 120
grtggttgga gaaccaggac cccagagagg tggggccact gaggctggtg cagttgcgct 180
cactcatcag catggcccg angctggggg gcatcgggca taccacagca ggcccctatg 240
acgggtgtgtg accaggccas cccagtgcac tttctcctgc tgcacttgga gggaggggac 300
atacacacag tctcccatct ctcctccct cccctgggg tggcccaccg catgggtaca 360
gggggttcca ggaatccaaa tccagcatgg cttggaggag ctctgttggg gagaggtcgc 420
cctgcctcac tggcaccctg ggggcacagc tggaagagag gcctggcca tgctcctctc 480
agggcaggca catgtacggg gcatacaagg cacagcgct gttggaacag gtggctgtgt 540
tcctgctctg gcccccgctg ggctngcctc cgcccctgca ccagtcacat gcaactggacg 600
agggccgaaa ctctgtctg ctatcgagcc ctggtgctat gtggccccgg agccacagca 660
caatcatctc agtggcgaa gacaccactt gattctatct ttttttaaca cattaaatct 720
gtttttaaag ataaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaa 764

```

<210> 95

<211> 707

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (45)

<223> n equals a,t,g, or c

<400> 95

```

atthaggtga cactatagaa ggtacgcctg caggtaccgt tccgnaattc ccgggtcgac 60
ccacgcgtgc catcatggcg caggatcaag gtgaaaagga gaaccccatg cgggaacttc 120
gcatccgcaa actctgtctc aacatctgtg ttggggagag tggagacaga ctgacgcgag 180
cagccaaggt gttggagcag ctcacagggc agaccctgt gttttccaaa gctagataca 240
ctgtcagatc ctttggcatc cggagaaatg aaaagattgc tgtccactgc acagtctcag 300
gggccaaggc agaagaaatc ttggagaagg gtctaaaggc gcgggagtat gagttaagaa 360
aaaacaactt ctcagatact ggaaactttg gttttgggat ccaggaaacac atcgatctgg 420
gtatcaaata tgacccaagc attggtatct acggcctgga cttctatgtg gtgctgggta 480
ggccagggtt cagcatcgca gacaagaagc gcaggacagg ctgcattggg gccaaacaca 540
gaatcagcaa agaggaggcc atgcgctggt tccagcagaa gtatgatggg atcatccttc 600
ctggcaataa aattcccggt tctatccaaa agagcaataa aaagttttca gtgaaaaaaa 660
aaaaaaaaa aaaaaaaggg ggcccccttt tgggggtccc ctggggg 707

```

<210> 96

<211> 815
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc feature
 <222> (16)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (45)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (50)
 <223> n equals a,t,g, or c

<400> 96
 aacccccctac tccctnccgt aatTTTTgtA agcccttaaa ataanaaaatn aaaaatycca 60
 taacccccaa agaagaatcc ccccccacatt waggcttggt aagtaaatgc ctccctgaccc 120
 caagcccgaa gatgcccccc attctctwag tgatggcggc gttaggggtt gagagaaggg 180
 aatttggtct aacttcagtt gagagggtgc agtccagaca gcttgactgc ttttaaatga 240
 ccaaagatga cctgtggtaa gcaacctggg catcttagga agcagtcctt ggagaaggca 300
 tgttcccaga aaggtctctg gagggacaaa ctcaactcagt aaaacataat gtatcatcat 360
 gaagaaaact gattctctat gacatgaaat gaaaatttta atgcattgtt ataattacta 420
 atgtacgctg ctgcaggaca ttaataaagt tgctttttta ggctacagtg tctcgatgcc 480
 ataatcagaa cacacttttt ttcctctttc tcccagcttc aaatgcaaat tcatcattgg 540
 gctcacttct aataactgca gtgtttcccg ccttgggctt gcagcagaaa aacctgacaa 600
 catagtgttt gctaaggcag taatttagac ttaccttat ttgtgattac tgtagtgatt 660
 gattgattga ttactattaa ctacaaggta taatttacta tcaccttatt taaattttat 720
 gaattaatth gaatgttttt tacactaact aacttttccc aataaagtcc actatgaaac 780
 cacgacaaaa aaaaaaaaaa aaaaaaaaaa aaaaa 815

<210> 97
 <211> 658
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (627)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (634)
 <223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (635)

<223> n equals a,t,g, or c

<400> 97

```
catcattggc gcggggctgt cagcggcccg acgcggtcct ctacgcccgc cactacaaca 60
tcccggatgat ccatgccttc cgccggggccg tggacgaccc tggcctggtg ttcaaccagc 120
tgcccaagat gctgtacccc gagtaccaca aggtgcacca gatgatgcgg gagcagtcca 180
tcctgtcgcc cagcccctat gagggttacc gcagcctccc caggcaccag ctgctgtgct 240
tcaaggaga ctgccaggcc gtgttccagg acctcgaggg tgtcgagaag gtgtttgggg 300
tctccctggt gctggtcctc atcggtccc accccgacct ctccttctg cctggggcag 360
gggctgactt tgcagtggat cctgaccagc cgctgagcgc caagaggaac cccattgacg 420
tggaccctt caccaccag agcaccgcc agraggcct gtacgccatg gggccgytgg 480
ccggggacaa cttcgtgagg tttgtgcagg ggggcgcctt ggctgtkgcc agctccctgc 540
taagggaaga acagaaccac ctacatcgcc aacctgggtc cagcctraga ggaatacatc 600
ctctgatcga cctcaaattc ggagttncct cttnncttgt caaattgacc gcccaata 658
```

<210> 98

<211> 249

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (248)

<223> n equals a,t,g, or c

<400> 98

```
aaaatggtag acctgacagt accggtccgg caattcccgg gatattgagc tggggttttg 60
agactscct tagagataga gaaacagacc caagaaatgt gctcaattgc aatgggccac 120
atacctagat ctccagatgt ctttcccct ctcttatttt aagttaggtt aagattacta 180
aaacaataaa agctcctaaa aaatcaaaaa aaaaaaaaaa aaaaaaaaaa aaccccgggg 240
ggggcccng 249
```

<210> 99

<211> 752

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (612)

<223> n equals a,t,g, or c

<400> 99

```
acggcttcaa ccgcagcttc tgcggccgca acgccacggt ctacgggaag ggcgtgtatt 60
tcgccaggcg cgctccctg tcggtgcagg accgctact gcccccac gccgatggcc 120
ataaggcggg gttcgtggca cgggtgctga ctggcgacta cgggcagggc cgccgcggtc 180
tgcgggcgcc ccctctgcgg ggtcctggcc acgtgctcct gcgctacgac agcgcctggg 240
actgcatctg ccagcccagc atcttcgtca tcttcacga caccaggcg ctgcccaccc 300
acctcatcac ctgcgargca cgtgccccgc gttcccccg acgaccctc tggrrtcccg 360
```

```

ggccgctccc cagacactta accgaagggg ccaccctctg gcctcctgct tcccaggctc 420
ccagctccgc acaggctgat gctccccgcc cccaactgtg gccgcctgag ctgtccccgg 480
ggasgcccctg cctccctctg cgggctccag aaggcgggtgt gggggatggc ggtcagcagc 540
ggccgagggg ggccgggcta ggtcccagcc tgggcccacc ccaccaccag gggtcagcag 600
agcccaggag gngacaccgy ccgcccgcg ctcccagacc tcgcccagat cggctctgtt 660
gtttgaataa acgtgaacgt gaacccaggc ggaaggacc cgggaaaaaa aaaaaaaaaa 720
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa                                     752

```

<210> 100

<211> 3059

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (14)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (28)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (109)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (3019)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (3047)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (3058)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (3059)

<223> n equals a,t,g, or c

<400> 100

```

ggggtaaaac ccngaaaaa aactccanat tttaattaaa tggcctcctc ccttcccccc 60
ttctttcccc cgtccccca actcccttct ctcgtcctct ttccccccnc cctctccct 120

```

tttctcccca tctttcacct tcctaatttc agtgaaattg gagcgatttg aaattccaat 180
caaggttcga ttaagcccag agccatggac ccctgaaact gggttggttaa ctgatgcttt 240
caaactgaaa aggaaggagc tgaggaacca ttacctcaaa gacattgaac gaatgtatgg 300
gggcaataaa aatgttgttg tcttattgac agttgtgcag gaggtagcct ggtggttttc 360
aacctctaga attttaagcc tttgttgaac tgttagaatg taaggatat cttcttaaag 420
atagagtaaa aagaaaacaa aaccaaaagt tattaaaatt gttgtccggt ttactttaac 480
ttagttttgc atagttctag tgcagctgaa attgaaaagt ttttccctt tagctgtgtt 540
attatagagc agaaattctg tttttaaaaa ttagcctaag atatacttg ttttgtaaag 600
aaaaatattt aatgttgaac aaaataaatt ggagttggag tagaatgtag tttgaggaaa 660
tttgcagctt ccaatgcctc ttgtcttcct atttcagaag tttaaatatt aagcatgaca 720
gaaaatatgt attaacacta ctcaaagcaa aagtgtctgca gggcttttaa attctcttcc 780
aaccatttat cttgaaggaa aaattcaata gtaatatata acmcaaaatc aaataatacc 840
ttagaaggta ttaagattat aattgttgca taggttagat atagagtcac tgtaatgttg 900
tgaataatta cagtgcctaa aataagaata gaacaacata tacaacacca aaaaaatatc 960
agtaatatat ttaaaggga attgagctgc ttttttgaa actttgagat ctaaaaaata 1020
ctgtaattat ttgaatgact aagaggaaag tacatttttt gaaatgctga aaattgcctt 1080
tctgtgttta ttcaactga aaagctgaga ccaagagcaa ggaaggtaaa aagttaacag 1140
gcaaacattt tctcttagaa aagtgataa aatcataagt atttggaatt agaacccttk 1200
cacagcactg aacctgggaa agagatttaa actctgaatt tatctttgat aacagggatt 1260
gattttaaaa tgtacatgta ttaattaca ttgttaattt aaggctgtgt tgctgttgct 1320
gatttttatt ttgatcagta gtttgcattt cagaaagcct ttcattttgc ttttaatttta 1380
gcaaagcggg ttataatgaa tgacttcccc aatatcttgc ttgaacttac aggtgattaa 1440
cttggatgag ttttggaag ttaaaggga gaaaacactg ttatcatttt ttcctgtttg 1500
ggaagagctt agaaactgga aatactagat ttgggagaag ggcagagtta cttgataagg 1560
gactgatgtt tgtgcagtaa cttgggagtg tggtttcttt ttgaatcttt aattaaaacc 1620
tggtattata tatccctgat aaatattcac acttgaacca tagttactgt aaaatgcaaa 1680
aaatcttaat actgttattc tttgcacttt ttcttaatca ttttttatat atatgcata 1740
atatatgtgt gtgtgtgtgt tgcttatgtt gttttgtaca gatgtgggcc accattgcaa 1800
caaaatacat tctttttgct ctaaaatatt tatgaagaaa atacttaaat gttatgtata 1860
tggtgtaaat aagggaaaaa tcaagtatta taaacaagaa tgaaggtttt tgtaaagatt 1920
tctgttcagc gttttgcaag gtaaaatttt aggcaagttt tccctgaagt tatgtgtatg 1980
tgagtattct cattcttccc aacttgcctt tgaagagtga aataccatta ttatcaagta 2040
gactactgtt cagcttttat tccctgccctg ctgtttatcc cttagaagt agtttcttag 2100
acttttccaa tatgtgattt tttttcccat ttagaatggt gattttaaat gtgtgagtgc 2160
atgtactatc ttatctcaga tatttgcacc cccaatctgc ccccaactcc caaaagctag 2220
aacactgcca actgatctgt tataggtcct ttagaaacac ataattaaca cttaaagggtg 2280
ggtgctgcta attctttgca aaaatccaaa tattgttaag ggaccaggga gatgccacta 2340
ccccttgatt ttccatctaa aaatatacat gtttatgtaa acaaatcttt ccatatccat 2400
agtgaacttt caagtattta agcctaaaga ttttgatctc acatttttat acctgtttta 2460
attgctcaca gttattacat acacatcagc catcaactaa agttgtactt taaaaattta 2520
ctacaatatg tacatttcta agtcaaacac ttgtgacttt tgctttaatt ccatgaatgt 2580
tcctgcctcc ttgataattg tatttattct tttttctct agagtagagg tataattgtg 2640
tgatatttca gaaatacaga taaatgattc aaaaagtcac agttaaggag aatcatgttt 2700
ctttgatcat gaataactga ttagtaagtc ttgcctatat tttcctgata gcatatgaca 2760
aatgtttcta aggtaacaag atgagaacag ataaagattg tgtggtgttt tggatttgga 2820
gagaaatatt ttaattttta atgcagttta caaattataa tgtattcata tttgtacttt 2880
ctgttaaaat gcatgattgc agaattgttt agattttgtg tttattcttg atgaaaagct 2940
ttgtttgttc ttgtttttaa gtttgcactc aaatcttaag aaataaatcc acccatgtta 3000
tcaaaaaaaa aaaaaaanc ccgggggggg gcccggaacc aaatccnccc aaggggggnn 3059

<211> 1682
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (52)
<223> n equals a,t,g, or c

<400> 101
ggcacgagga tggawgcctg atgggggtgca gacacagatg gcaccccagg rntgtgccat 60
tccaccagac gtctcctaag acagagtttag agtcaacaat ctttggcagt ccgaggctgg 120
ctagtgggct cttcccagag tggcagagct gggggagaat ggagaacttg gcctcttatac 180
gatgaattaa gcaacaatgt aactgggtctt gacttgtcat attcccccat gcaatcctag 240
gtctgtattg ctcaatttta ggaagccttt gctactccat cagtaggttt agatttgagc 300
ttttgagacc tggctatgga aaagaaagac acttgagaat ttagtggttg ggtctgtaca 360
gatgatgcta cccaatttgg ctttgaagga tcaagtaaca ggttgaaaac tatttttata 420
aaggtaatac tttttcagtt cccttcttcc ttccctctca atccactagc tttcatgttg 480
ggcaaggaaa agttgaggaa ggatggctga tggatgatgga aagctgtgtt aatgggtatga 540
ggaaatgtgtg aaaagtatac acaaagggtc ctgaagctca agtcagagga gtgggaggtc 600
tgatcattgt tgggtgaaaa acgtaagggt attttgtgtt ttttaagttg ttttacaatt 660
ctttctggg gaaattatct ctggagggga aaaagatcca ttctacgtat ccttgtggag 720
aaaagctaaa taacctttaa gaatgtgggt ggtattggag aaagaagatg aattatagct 780
ccggagaatc aagatcttaa gtgaagcctt tctgttcaga tgtgatctat aaaaaatcat 840
aatttgggga aagttaaagc aaatctggct ttgtagtctt gatgttataa gtgactttgt 900
gatcaaactg tcaggcttgg gttcttgtta tagaatgctt ggtatagaaa aacctgtcca 960
tcattaatgg ctaacaacac gtagggactt catgtcatgt caaagatagc tctttgcaag 1020
tgccttgatt aaaccagaaa actgtcatcg ttttaaccaa atatctgaat ggtcatcttg 1080
taactcatgg gtttttgcc tcataagatg gtccactctg tacacaggca ttctctctgc 1140
aataatgttg tatctttgag accgttgtca gtgtacacaa ctcacatcct tcatattgaa 1200
ggtgactcat ttttctgcac acttttttga tgtgatgctt gacgtgaggc ccgacactag 1260
gattctcaat gcaagaatcc agtaccttgc acatagaagt agcaacccat cccttgccta 1320
ttttcatctt gctgttttct tttttttaa aaaatggatg tgacttgttt tgaatgtttt 1380
gtattatact tgtttttgtg tgtgcataaa ttcattctgt aggatcttaa gaaaaagagt 1440
cccagaatgt tgcttctatt attgtgcaca accattgaga ggtgttaciaa gaatgcagtt 1500
aattttaaca tgtgtgatgt gccatgggtg aaaagtacta tcggaataac tctgcagtga 1560
cagaatttga agtttggtc gcacccatc ttttctactg taaatatttc actctcctct 1620
agctatcctt gatgagcttc tcactttaag aataaatgtg tttgatataa aaaaaaaaaa 1680
aa 1682

<210> 102
<211> 938
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (30)
<223> n equals a,t,g, or c

<220>

<221> misc feature
<222> (812)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (913)
<223> n equals a,t,g, or c

<400> 102
cccacgcgtc cgtccgggtg ctccgcgcgn gacctggacg cagagaagcc agagactttc 60
gcttccggct gccgcaggct tcgctgggtgc aggtaaagctc cgcacactct cggccgggtcc 120
cgagtcgcgac tccctcaagg gtgacgcgag ctctgccctt taaccggaaa cgtctccctg 180
ctcaccacac ccccgcgag acgcagtgt gagcacacag ctaccggaca aagagtgcg 240
ccggagctg gagttatggc ggctacggag ccgatcttgg cggccactgg ggtcccgcg 300
gcgggtccac cggagaaact ggaaggagcc ggttcgagct cagcccctga gcgtaactgt 360
gtgggtccct cgtgcgcaga ggcctcaccg cctgcccctg agccttccag tcccaacgcc 420
gcgggtccctg aagccatccc tacgcccga gctgcggcct ccgcggccct ggagctgcct 480
ctcggggccc caccgtgag cgtagscctc aggccgaagc tgaagcgcgc tccacaccag 540
gccccgccgg ctctagactc ggtcccagaga cgttccgcca gcgtttccgg cagttccgct 600
accaggatgc ggccgggtccc cgggaggctt tccggcagct kcgggagctg tcccgccagt 660
ggctgcggcc tgacatccgc accaaggagc agatcgtgga gatgctggtg caagagcagc 720
tgctcgccat cctkcccag ggcgtcggg cccggcgat ccgccgccgc acggatgtgc 780
gcatactgg ctgagcggg gagctcggg cngccagggc cgggcgctct gtgcggactg 840
gggccatgat cggggccggg ggcctgagcc tgggacccca ccccggtgta atgaaaaatg 900
agttttggca gcnaaaaaaa aaaaaaaaaa aagggcgg 938

<210> 103
<211> 2012
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (1993)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (2002)
<223> n equals a,t,g, or c

<400> 103
gctggataat tccagcctgt tagctactca caggaacatg cagaattatt ggctccaggg 60
agttttggag aaagaagggt tacgttttca aacttacaga taacagttga catcaatgct 120
tctctttccc agaacaatct ggagtttgcc agaaaactct gtaaacagga gtcgtgctgt 180
gtgtgaactg taaactcttc tctccaggcg tcgaggggac ctttgcttta ctttgcagct 240
gggctacatc agacgtgtgc attggaaaca taaacttcct taactgggaa aagaatgctt 300
ctctgtcttc maaatarctt tgctatgtga ctttttgcc atcatgaatt ttacatcagt 360
gmtagctctt tgttttacgt gtttcattkg gcaggtcaca aaggctcttg gctaccacac 420
atacgtgcat acacacacac acacacacac acacacacac acacactcat aaaggatttt 480

```

cttttctgct ttaccttta ttttcagtct acttggttg taatgaaagg tagagcctta 540
tttttgaact atatcccaac agaatcgaat ttccattttg ccaagaatta taaaaccctg 600
aggttttaaa attcagtttc ttttctgggg atttaacatg gaaggacttg gagggcaaat 660
ggscagtgat ttggaaargg gaaaaacaaw tcatttcatt taaaattatt caataaccat 720
tgccagcatt tgggattctg agtgctgttt atgaagccct ttcattgata taatttcac 780
tatctctcac aaggctgtaa gcaattccta tgtccatatg gcagtgaagg aatggagatt 840
tgagcaggtt aagggtgttt tcacctggaa gctcttcttt tttttccttc tgccacagta 900
rggtcatcag actgtcagcc ccagcactgg gagccgagta acacgcatgt tctcattaat 960
atccttttct catgttttta ttaaagatat atgcaagttg ccgaaagacg aaggaaacttg 1020
cagggatttc atattaaaat ggtactatga tccaaacacc aaaagctgtg caagattctg 1080
gtatggaggt tgtggtggaa acgaaaacaa atttgatca cagaaagaat gtgaaaagg 1140
ttgcgtcct gtgctcgcca aaccggagt catcagtggt atgggaacct aagcgtgggt 1200
ggccaacatc atatacctct tgaagaagaa ggagtcagcc atcgccaact tgtctctgta 1260
gaagctccgg gtgtagattc cttgcactg tatcatttca tgctttgatt tacactcgaa 1320
ctcgggaggg aacatccctgc tgcagacct atcagtatgg tgctaattgt tctgtggacc 1380
ctcgtctctc gtctccaggc agttctctcg aatactttga atgttggtgta acagttagcc 1440
actgctgtgt tttatgtgaa cattcctatc aatccaaatt cctctggag tttcatgta 1500
tgctgtgtgc aggcataatgt aaagctctga aaataatgca aatgtcacgg ctactctata 1560
tacttttgct tggttcattt ttttccctt ttagttaagc atgactttag atgggaagcc 1620
tgtgtatcgt ggagaaacaa gagaccaact ttttcattcc ctgcccccaa tttccagac 1680
tagatttcaa gctaattttc ttttctgaa gcctctaaca aatgatctag ttcagaagga 1740
agcaaatcc cttaatctat gtgcaccgtt gggaccaatg ccttaattaa agaattttaa 1800
aaagttgtaa tagagaatat ttttggcatt cctctaattgt tgtgtgtttt tttttttgt 1860
gtgctggagg gaggggattt aattttaatt ttaaaatgtt taggaaattt atacaaagaa 1920
actttttaat aaagtatat gaaagttaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1980
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa 2012

```

<210> 104

<211> 1094

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (26)

<223> n equals a,t,g, or c

<400> 104

```

tcctcctggg aagcctggcc tgcctncccc gcaaaagggtg tttttgcgct ggttcaatga 60
atagatgatg cagaggcccc attggagaca cgtgaatggc gtgtgcggcc atcagttccc 120
ggctgggggg caggtgttgc ttcggccccc gccctccggc cggcgtgtgc gagtgcgccc 180
ctggctgtga gtgttgaccg ttcctctccc ctgtacatag cmcgagccag tcctgagtgg 240
gtgactcctg agtgggtgac gcgcagacgg gatttctcag gtcatttgta tggtcgacat 300
gatggctgct gctttggctg ccaccacccc cgggcccagc ctgtctgaaa ttcagggttt 360
aggccgaaaa acccggtggg gaggggtggg gagccggagm tctgtggcgg ggctggaggg 420
ctggggtgca ctttagtttg gggcgggacg ggagccgccg ttgtgactgg cgtggtctgg 480
ctgctgctcc cgaacggagg ggtcgggggt ggcttgctgg gccctcagag cccagtgggt 540
ggctctgact cggtcccta ctccctgcac ccagctgggc gcactgggg cctgcgggtct 600
gaatgtatcc ctccctcag ttttaacctg agctgccgaa cgcacagtgg gccgggggag 660
aggctggggg aagcggggcc caattacgga tcccgggagt tacaggtgcc gacgtgatgt 720
cgcttctctg gtgcccagct cccttctctg tctgagacta gctctggggg tggcgggggc 780

```

```

ccccamacgc tgctcccgc ccaccctgcc cgtgctgctg ctctgtgcct gctgtcagag 840
ccctgggtggg ggaggatgtg gccaccctga gaccggagg agacgggcgt ctgcctgggt 900
ttgcgagag cgccttatgg gtgtggtccg tccagacacc ttgtttcaag ggggatgggc 960
gtgagcgggc aagcagagca tccccaccgc tgagcaagaa ctttttcttg tttttaaac 1020
atcacgtcct catttcacat tggaataaag tgagtttttg aaacctgcga aaaaaaaaaa 1080
aaaaaaaaaa attc 1094

```

<210> 105

<211> 2297

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (30)

<223> n equals a,t,g, or c

<400> 105

```

agctcgtgcg cccgccgtgc cggtcoggan attcccgggt cgacccacgc gtccgatctg 60
tcctgacca tctgcctaatt tccttcctca cagtctgtag ccacttgata tcctagggga 120
aaaggaaggc caggggttca catagggcc cagcgagttt cccaggagtt agagggatgc 180
gaggctaaca agttccaaaa acatctgccc cgatgctcta gtgtttggar gtgggcagga 240
tgagaaacag tgcctgtttg ggggaaaaca ggaaatcttg ttaggcttga gtgaggtgtt 300
tgcttccttc ttgccagcg ctgggttctc tccaccaggt aggttttctg ttgtggtccc 360
gtgggagagg ccagactgga ttattcctcc tttgtgatc ctgggtcaca cttcaccagc 420
cagggctttt gacggagaca gcaaataggc ctctgcaaat caatcaaagg ctgcaacctt 480
atggcctctt ggagacagat gatgactggc aaggactaga gagcaggagt gcctggccag 540
gtcggctctg actctcctga ctctccatcg ctctgtccaa ggagaacccg gagaggctct 600
gggctgattc agaggttact gctttatatt cgtccaaact gtgttagtct aggccttagga 660
cagcttcaga atctgacacc ttgccttgct cttgccacca ggacacctat gtcaacaggc 720
caaacagcca tgcatctata aaggtcata tcttctgcca cctttactgg gttctaaatg 780
ctctctgata attcagagag cattgggtct gggaagagg aagaggaaca ctagaagctc 840
agcatgactt aaacaggttg tagcaaaagc agtttatcat caactctttc agtggtaaac 900
tgtggtttcc ccaagctgca caggaggcca gaaaccacaa gtatgatgac taggaagcct 960
actgtcatga sagtggggag acaggcagca aagcttatga aggaggtaca gaatattctt 1020
tgcggtgtaa gacagaatac gggtttaatc tagtctaggc accagatttt tttcccgtt 1080
gataaggaaa gctagcagaa agtttattta aaccacttct tgagctttat cttttttgac 1140
aatatactgg agaaactttg aagaacaagt tcaaaactgat acatatacac atattttttt 1200
gataatgtaa atacagtgc catgttaacc taccctgcac tgctttaagt gaacatactt 1260
tgaaaaagca ttatgttagc tgagtgatgg ccaagttttt tctctggaca gkaatgtaa 1320
tgtcttactg gaaatgacaa gtttttgctt gatttttttt tttaaacaaa aaatgaaata 1380
taacaagaca aacttatgat aaagtatttg tctttagat cagggttttg ktttgkttt 1440
ttaattttta aatgcaacct tgccccctcc ccagcaaagt cacagctcca tttcagtaaa 1500
ggttggagtc aatatgctct ggttggcagg caacctgta gtcattggaga aaggtatttc 1560
aagatctagt ccaatctttt tctagagaaa aagataatct gaagctcaca aagatgaagt 1620
gacttcctca aaatcacatg gttcaggaca gaaacaagat taaaacctgg atccacagac 1680
tgtgcgcctc agaaggaata atcggtaaat taagaattgc tactcgaagg tgccagaatg 1740
acacaaagga cagaattcct tcccagttg ttaccctagc aaggctaggg agggcatgaa 1800
cacaaacata agaactggtc ttctacactt tctctgaatc atttaggttt aagatgtaa 1860
tgaacaattc tttctttctg ccaagaaaca aagttttgga tgagctttta tatatggaac 1920
ttactccaac aggactgagg gaccaaggaa acatgatggg ggaggcagag agggcaagag 1980

```



```

taaaactgta gcatagcttt tgtcacggtc actagctgat ccctcaggtc tgctgcaaac 2040
acagcatgga ggacacagat gactctttgg tgttggtctt tttgtctgca gtgaatgttc 2100
aacagtttgc ccaggaactg ggggatcata tatgtcttag tggacagggg tctgaagtac 2160
actggaatth actgagaaac ttgtttgtaa aaactatagt taataattat tgcattttct 2220
tacaaaaata tattttggaa aattgtatac tgtcaattaa agtgtttttg tgtaaaaaaa 2280
aaaaaaaaaa actcgtta                                     2297

```

<210> 106

<211> 442

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (419)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (423)

<223> n equals a,t,g, or c

<400> 106

```

tcgacccacg cgtccgcctg tgggacgcgg tgggtggccgt tgggtcggga gagtgagcgg 60
tatttgcmtc gtttttcttg cttgttttcc ccccgttaga ctttgtcggg agagcgcggg 120
tatgggcccgc aagaagaaga agcagctgaa gccgtggtgc tgggtattgta atagagattt 180
tgatgatgag aagattctta tacaacacca aaaagcaaaa cattttaaat gtcataatatg 240
tcataagaag ttgtacacag gacctggctt agctattcat tgcatgcagg tgcataaaga 300
gacaatagat gctgtaccaa atgcatacct gggagaacag acatkgattg gaaatatatg 360
gtatggaarg tattccagaa aaagatatkg atgaaagaag acgacttctt ggaacagana 420
acnccagaga gtccaaaaaa ag                                     442

```

<210> 107

<211> 1019

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (995)

<223> n equals a,t,g, or c

<400> 107

```

ttgatctgcg gctgtcgagg cctgaggcag tggaggctga ggctatgatg gcggccatgg 60
cgacggctcg agtgcggtat gggccgcggg gcgcccaggc gctctggcgc atgccgtggc 120
tgccggtgtt tttgtcgttg gcggcgccgg cggcgccggc agcggcgagg cagcaggtcc 180
cgctggtgct gtggtcgagt gaccgggact tgtgggctcc tgcggccgac actcatgaag 240
gccacatcac cagcgacttg cagctctcta cctacttaga tcccgccctg gagctgggtc 300
ccaggaatgt gctgctgttc ctgcaggaca agctgagcat tgaggatttc acagcatatg 360
gcggtgtgtt tggaacaag caggacagcg ccttttctaa cctagagaat gccctggacc 420
tggccccctc ctcactggtg cttcctgccg tcgactggta tgcagtcagc actctgacca 480

```

cttacctgca ggagaagctc ggggccagcc ccttgcatgt ggacctggcc accctgcggg 540
agctgaagct caatgccagc ctccctgctc tgctgctcat tcgcctgccc tacacagcca 600
gctctggtct gatggcacc agggaagtcc tcacaggcaa cgatgaggtc atcgggcagg 660
tcctgagcac actcaagtcc gaagatgtcc catacacagc ggccctcaca gcgggtccgcc 720
cttccagggt ggcccgtgat gtagccgtgg tggccggagg gctaggctgc cagctgctac 780
aaaaacagcc agtatcacct gtgatccatc ctccctgtgag ttacaatgac accgctcccc 840
ggatcctggt ctggggccaa aacttctctg tggcgtacaa ggaccagtgg gaggacctga 900
ctccctcac ctttgggggtg caggaaactca acctgactgg ctcccttctg aatgactcct 960
ttgccagcty tcaactgacct atgaacgact ctttngtacc acagtgacat taaagtatat 1019

<210> 108

<211> 711

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (642)

<223> n equals a,t,g, or c

<400> 108

cttgaaaact tagtttacta tacatcttgc cctattaata tgttctctta acgtgtgcc 60
ttgttctctt tgaccatttt cctataatga tgttgatgtt caacacctgg actgaatgtc 120
tgttctcaga tcccttggat gttacagatg aggcagtctg actgtccttt ctacttgaaa 180
gattagaata tgtatccaaa tggcattcac gtgtcactta gcaaggtttg ctgatgcttc 240
aaagagctta gtttggyggtt tcctggacgt ggaacaagt atctgagttc cctggagatc 300
aacgggatga ggtgttacag ctgcctccct cttcatgcaa tctggtgagc agtggtgag 360
gcggggagcc agagaaaact gccagttata taacttctct ttggcctttc ttcactctga 420
aaacaaggat aatactgaac tgtaagggtt agtggagagt ttttaattaa aagaatgtgt 480
gaaaagtaca tgacacagta gttgcttgat aatagttact agtagtagta ttcttactaa 540
gacccaatac aaatggatta tttaaaccaa gtttatgagt tgggtttttt cattttcyat 600
ttgtatttta ttaagagtgc ttttcttatg gtgatttttt tnaattgcga tttgatatgg 660
tttggccata tggccccacc caaatcccca tcttggtatta taatccccat g 711

<210> 109

<211> 743

<212> DNA

<213> Homo sapiens

<400> 109

tcgagttttt tttttttttt ttttactttt taaaatttta ttgatgtacc acctgatcaa 60
agcatgggat attttaatag tattatacat aatatattta catagaaaac tttacatagc 120
atttcatatt atataattct gcttattctt tcaaaaattt atacatccat tgggcaagga 180
atggttttca ttaaattacc aatattaaat gcacttaatc attgtgtata ggttaaacca 240
aagtaactat taactaactt ttaggcattt taaggaggta aaacatacat tttacacata 300
aatatttgat gcaaatatgc agataaaaat ttttaaaaat tagaactctg agtaaaacac 360
ctttgataga ttatattggt ttgttttgag agcaaggatt tccagatatg ttcattcttt 420
aaaacactca gctttgggtt ctttggttcc caaactgcaa agctgctgat aacaaaactc 480
caggattcca tgtgagttca gctatgtcta ctttaacaca aatattaaaa cagaattcag 540
raaatgcagt attaaggatc cagcttctat tgaaaccaat atccatttgc atcataacaa 600
caaacatttg aatgagatgg tcacacttgt acttatcagc aggttccttt aataacaaag 660

actactaaat gtatatacctt aatcacaaaa gaacaacaaa aaaaatacag gttttttttt 720
tttcatttcg tacaaaagtc acc 743

<210> 110
<211> 795
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (2)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (645)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (737)
<223> n equals a,t,g, or c

<400> 110
tntctaaatat cagatgtctt tgatgtaagg gtagggaatg gagaaatatt ttcaattgtg 60
tatttgtatt acaaagaact tgaaatttac tttcttagtt gattatatta aatgatgtat 120
atattatatg tggtttataa gctcaacact ggccattttt ttagttttat tgttaaatgg 180
tatttttcta tgtttaatta taatagatct ggctttttct ggatagcata aagatcactg 240
aactatatat atataagara caagagttct atttttagcac aaaggcattt tatattattt 300
attgaatcca taagtttggt ttcgtcaaaa acattccata ttatttctgc tcctttttat 360
ttgtatagtt tgtattttaa agaaatggca gtccttcctg ttcttaatac aataaaattg 420
aaataatgca cctagtaatg tggccgacat ctcttctcac caccatggac tgttttcaac 480
aacagttgat ctctcggctc gtgctgagag ggcgatgcat gtctttcgtc acgtcgggca 540
gcacacctgc tgtgaaatac tgctttcatc tacctcttca gaaggcttct tgcttggtga 600
caagtaaccgc aaaggcttta ttctggactg gctatctcat aaaanggatt tctgtaagac 660
tttgcagtgt cattccctca gaaccyaggt ttgtttctaa agccacggta ttgtccrrgr 720
rccctgtgt ktggggncag gtagctatcc ctcccatgtc attagtaatc ctttaggatt 780
ttaaggtaca atggg 795

<210> 111
<211> 1332
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (1)
<223> n equals a,t,g, or c

<220>
<221> misc feature

<222> (6)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1194)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1237)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1241)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1300)

<223> n equals a,t,g, or c

<400> 111

```
ncgggncagc agctcccagt gtgacctgac aaaaacacgt aggggcaggg acggtcccca 60
ccccaggga cacaaccctt ggtcttgac cagtagagga cacggaggt tcagaccct 120
ctcagaccc tccccacatc tgaaactgcc tcccccaac caccagcagc agcagggccc 180
tcctcccca ccagctctcc ccacagggcc cctcagcatc atggagaccc gcagcggggc 240
ttagccacc ctcaaacca gggccccctg gcacctgggc tctggccgtg tttctggcc 300
agagccccac tttcctaact cgtgctccct tccgccttct tttccgtact gtgaagaaag 360
aactctccac ccagctccc accctgccct ggcctgggtg gaggaactgt gcctccatcc 420
ccagaagaaa cagccccctc tgctgctggg gtgggactgt ctgtgtgccc tgtgggggtc 480
cgtgtgagca ggcccacctg gctccagacc cgcccccaac ctgagacaga accaggctga 540
gccaggcctc cccccacc ccggtttgct gggggctcct ccagccgcc ccatggraag 600
aggcctggtg ccgsetcacc cacagaggtc tgtgccaggt gcgcttctgc aggtggagcc 660
aagctctccc tgaggccaga ggccgggcct gggccgggag cccaggggaa ggccaggctg 720
gacccgggct ycacaccac atccagcctg caggcctctc tgcagtcctc tcacctccc 780
tmacctccc ttcctctgca gtcacctca gctcccttc cttgcccgc tctcccccg 840
ccgccccacc agttaaacg atgaccaaag acctttctta tgccggaagc aaaaaccaaa 900
actttttgtt ggctttttcc tttgtsgcct cccagcacc tgcctccca gtctccacc 960
ccggccccag gctggaagcc tccctccact taagtattg ttttaaacca aagtttacag 1020
tgtctgttgg tggccaagac cttctctctc caccctcct ccatccacc tgaggacct 1080
ggggctcagt ggaggcaggg ccctgcccc cttcccttc cggtcctgg cccagcctgg 1140
ggggaaggga raaaggagg gggaraaagc ggggttcttc acccctcag ggantggggc 1200
acggggagcc ctttcttccc tggacctgg ggcttgnctc ntgggggggc tcttccaaga 1260
accctcttc taagggaacc aagtttcacc cgttcgtggn tgggggatgt tgggatttct 1320
aaggcaaaag ag 1332
```

<210> 112

<211> 743

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (53)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (272)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (275)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (278)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (590)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (618)

<223> n equals a,t,g, or c

<400> 112

```

ttgctggtct gatccatgca catggccagg ctgctaggct cttgtgctgg gcnggaagtc 60
ggtgcggatg gccagctcca ggatgacccg ccgggacccg ctcacaaata aggtggccct 120
ggtaacggcc tccaccgacg ggatcggtt cgcacgccc ggcgtttggc ccaggacagg 180
gccacgtggt cgtcagcagc cggaagcagc agaattgtga ccaggcggtg gcacgctgca 240
rggggagggg ctgagcgtga cgggcacctg tncantgntg gggaaggcgg aggaccggga 300
gcggctggtg gccacggctg tgaagcttca tggaggatc gatatactag tctccaatgc 360
tgctgtcaac cttttctttg gaagcataat ggatgtcact gaggagggtg gggacaagct 420
ctggatggac aaggaaaaag aggaaagcat gaaagaaacc ctgcggataa gaaggtagg 480
cgagccagag gattgtgctg gcatcgtgtc tttcctgtgc tctgaagatg ccagctacat 540
cactggggaa acagtgggtg tgggtggagg aaccccgtec cgcctctgan ggaccgggag 600
acagcccaca ggccagantt gggtcttagc tcctggtgst gttcctgcat tcamccaytg 660
gscttttccc acctygytc amcttactgt tcacctcatc aaatcagttc tgccctgtga 720
aaagatccag cttccctgc cgt 743

```

<210> 113

<211> 1690

<212> DNA

<213> Homo sapiens

<220>
<221> misc feature
<222> (1659)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1664)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1676)
<223> n equals a,t,g, or c

<400> 113
aattcggcac cactcagtc caccaggcctc ggccaggggac acaccgggcca cgtccgcttc 60
ttggctgcag tccagctgcc agatggcttc aacctgctct gcccaacccc accacctccc 120
ccagacacag gccccgagaa gctgccatca ctggagcacc gggactcccc ttggcaccga 180
ggccccgccc ctgccaggcc taaaatgctg gttatcagtg gaggtgatgg ctatgaggac 240
ttccgactca gcagtggggg cgccasagca gtgagactgt gggtcgagac gacagcacia 300
accacctyct cctgtggagg gtgtgaccct gtctgccgtg gcccaggact sgccccgcca 360
cctgccttca gcctgcttgc ctctccctag cccacacgca gactttgacc aggagtatcc 420
agccagggga cacatgtgcy kgertgggct ctgcttgtct tcgcggaaga ttcttgatgg 480
aacaccact ggccagccag gccatggctt ctcccgaacc tctggctgcc ccggtgcttc 540
cagtcgatgat cgggtggggg acatgtgggc tgaccaggac ctctgacctt ggagcttcta 600
ccaaagacac agctgggtct ggacccacg ggsstgggga gggccatgtg caatatttgg 660
agggttttct ggagggcagc aggaaggctg ggggaattccc catgtacagt atttatgttt 720
cttttttagat gtgtaccttc ccaagcactt atttatgcag tgacctgggtc acctgggggtg 780
ggggtgattt gaggaatga catgaggaaa agaaacctat tcctgccctg gggaccaccc 840
tgggactcta accaagcctt cctggaggga cccatgcgcc cctgagcccc attccattca 900
tacagacaca cactacgca cactgcattt ccaaggccct aaacattgcc cgttgacata 960
aactttccag ggcaccagcc tgatggggct gccctcagtc ctctagatca agatgctgac 1020
tattaggggg cagtgaattgc catctgggga cctgtcaggc tttgtcattt cccagtttgt 1080
tggtggtgcc tttagtgggt ccctaatttg ggaacactga tggggccttg gacagggtt 1140
tctctcaggt aggagaaatg ggcccatgat ctctcacag tcgccccag tccttgggcc 1200
tgcttccttg tgtctcatgc actggcacat atggtcacct tggagggcag acctaggagc 1260
ccctctgacc actgaatccg tctccacacc ccttctgcca agggaagccc cttcaggaa 1320
gaccccccaa agctgagggg ctgaatgtag ccttttcaac agagaaggct cccacttgag 1380
agcagcctct acctgacccc ctggaccaca gagagccact ctgacctca gccccctgc 1440
ttcttcagct aaaactccaa aggtttggtt tcagatgggg tttgttttgt tctgttttgt 1500
tttggttttg tttggggttg gtgggtcatt gcggtcttag attatgtttc tcttgctacc 1560
aaacagtcac gtattaactc tctttggatg atgaagttaa aagagtcaat aaatagaaac 1620
accagatgac tgcaaaaaaa aaaaaaaaaa aaaaaaana aanaaaaaaa aaaaaanaaa 1680
aaaaaaaaaa 1690

<210> 114
<211> 620
<212> DNA
<213> Homo sapiens

```

<400> 114
ctctgggcct gggctctgggg gagaggggtg ccaggagagac tcagctctcc ttgggggctg 60
gccagctgac tgaggggtaca caggattggg tctagacctt gatgcctggg tggagggccc 120
ttgtaagggg ccatagcctc ttcaggacca actggaggga gagttaggaa acaccagctc 180
ctgcctgggg cagtgaggga atgggagcag ctgtgggcgc ctcatctcag gcaagtcctc 240
cccaaacctt cagatgcagt gagacctggc ctctctgttg tgcttttcag actttgtttt 300
cagaatgctt ttatctcgag tgtgcccttc ggccctcaca agagcccctg gggagtaggt 360
gggtggcctgt gccgtcatcc ccatttcaaa gcaggagagct gaggtcctgg gaggggaaaag 420
tgcttgccctg aggtccctact gtgttagtggt gtgggcagga ctggaactcg gttctccaac 480
agcccagagc tcaactctttt acaccagag gtggagcagg tggcttaggg ggtgggtatg 540
tacttcacaa gccaatctcc ttcagccagg agtcctggg tgcatttccg tgcagaaac 600
agtaccgagt cccacccctt                                     620

```

<210> 115

<211> 542

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (392)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (412)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (511)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (521)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (535)

<223> n equals a,t,g, or c

<400> 115

```

tcgacccacg cgtccgcttc tcggccctt gtagaacctc tgtcaggttc agcctactcg 60
cctctactcc agcctccact ccggcctcca ccatgtccgt caggtgacct agaagtccta 120
caagggtgcc acctccggcc cccgggcctt cagcagccgc tcctacacca gcgggcctgg 180
ctcccgcatc agctcgtccg cttctctccg ggtgggcggc asttccgggg gggcctgaac 240
agcagcatga gtgtggctcg gggctacggc ggcggggccg gggtatgggg ggcacacagg 300
ccgtctcagt gaaccagagc ctgctgagcc cccttwaagc tggaatkga tcccaacatc 360

```

```

caagctgtgc gcaaccocagg agaaggagca gntcaagacc ttcaacaaca anttggttc 420
gttcatacgac aagtgaagca ctggagcagc agaacaaatt tttggagacc aattggagct 480
tcttaaagca gcagaagacg cgcggagaac ntagacaaat ntgcgagagt aaatnagaac 540
tt                                                    542

```

```

<210> 116
<211> 525
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc feature
<222> (420)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc feature
<222> (424)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc feature
<222> (517)
<223> n equals a,t,g, or c

```

```

<400> 116
aattcaaccg tcgttatccc aaaattcagt tttcactttc caccggccct tccggcacta 60
tgctggatgg tgtaactggag ggaaaactga atgcggcgtt tattgatgga cccattaacc 120
atactgccat cgacgggata ccggtatacc gcgaggaact gatgatcgtc acgccacaag 180
gatatgcgcc agtaaccctg gccagtcagg ttaatggcag taacatttat gccttccgcg 240
ccaattgttc gtatcgtcgc cacttcgaga gctggtttca tgctgacggg gccgctccgg 300
gaactatcca tgagatggag tcttatcacg gaatgttggc ctgtgtgatc gcaggagcag 360
gcattgcgct tattccgcgc tctatgctgg aaagtatgcc ggggcatcac cargttgaan 420
cgknggccgt tagctgagca atggcggttg ttaacaacct ggctggctctg gccgtcgttg 480
tgcgaaaaaa cgttccgctc gaaggggggc ccggtancca attcg                    525

```

```

<210> 117
<211> 728
<212> DNA
<213> Homo sapiens

```

```

<400> 117
aacgagcgcc tgctaggatc agcgggtggtg gttccgcgat ggtaggcggc ggcggggtcg 60
gcggcgccct cctggagaat gccaaacccc tcatctacca gcgctctggg gagcggcctg 120
tgacggcagg cgaggaggac gagcaggttc ccgacagcat cgacgcacgc gagatcttcg 180
atctgattcg ctccatcaat gacccggagc atccactgac gctagaggag ttgaacgtag 240
tagagcaggt gcgggttcag gttagcgacc ccgagagtac agtggctgtg gctttcacac 300
caaccattcc gactgcagc atggccaccc ttattgttct gtccatcaag gtcaagcttc 360
tgcgctccct tcctcagcgt ttcaagatgg acgtgcacat tactccgggg acccatgcct 420
cagagcatgc agtgaacaag caacttgacg ataaggagcg ggtggcagct gccctggaga 480
acaccacact cttggagggt gtgaatcagt gcctgtcagc ccgctcctga gcctggcctt 540

```



```

tgacccctca gcctgcatac tggatccctg gtcccagctc ctgccagggc tgttacggt 600
gttttcttga atcactcaca atgagaaact aacattttgc tttttgtaat aaagttaatt 660
tatattcarw tcaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa acccgggggg 720
gggcccccc 728

```

```

<210> 118
<211> 948
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc feature
<222> (920)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc feature
<222> (944)
<223> n equals a,t,g, or c

```

```

<400> 118
agaagtacgg acccctgaag cccctgccac agaccccgca cctggaggas gacttgaagg 60
aggtgctgcg ttctgaggct ggcacgaac tcatcatcga ggacgacatc aggcccgaga 120
agcagaagag gaagcctggg ctgcggcgga gcccatcaag aaagtccgga agtctctggc 180
tcttgacatt gtggatgagg atgtgaagct gatgatgtcc aactgcccc agtctctatc 240
cttgccgaca actgccccct caaactcttc cagcctcacc ctgtcaggta tcaaagaaga 300
caacagcttg ctcaaccagg gcttcttgca ggccaagccc gagaaggcag cagtggccca 360
gaagccccga agccacttca cgacacctgc ccctatgtcc agtgcctgga agacggtggc 420
ctgcgggggg accagggacc agcttttcat gcaggagaaa gcccggcagc tcctgggccc 480
cctgaagccc agccacacat ctggaccct catcttgtcc tgaggtgttg aggggtgcac 540
gagcccattc tcatgtttac aggggttgtg ggggcagagg gggctctgtg atctgagagt 600
cattcagggtg acctcctgca gggagccttc tgccaccagc ccctccccag actctcaggt 660
ggagcaacag ggccatgtgc tgccctgttg ccgagcccag ctgtgggcgg ctccctggtg 720
taacaacaaa gttccacttc caggtctgcc tggttccctc cccaaggcca caggagctc 780
cgtcagcttc tccaagccc acgtcaggcc tggcctcatc tcagaccctg cttaggatgg 840
gggatgtggc cagggtgtgt cctgtgctca ccctctcttg gtgcattttt ttggaagaat 900
aaaattgcct ctctctttgn aaaaaaaaaa aaaaaaaaaa gggnggcc 948

```

```

<210> 119
<211> 211
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc feature
<222> (123)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc feature
<222> (125)

```

<223> n equals a,t,g, or c

<400> 119

```
tcgacccacg cggtcgcgtt ggtggggctg gctgctttct cgcgtttccc cccaaccccg 60
tccggcctcg cccagcggtt ccaacgcgaa ccaactgcc aaggcgcggc gcggcgctga 120
gcngngcgag tgtgaggaaa ccgccgcctc agccgagcgc gcgggcccgc ccagggcgtt 180
agttttcggc gcgcagtcgc ggtcccccg c 211
```

<210> 120

<211> 1308

<212> DNA

<213> Homo sapiens

<400> 120

```
tcgacccacg cgtccggact gttctaagtg agttcgggtg ggggagcttc acgaggggag 60
gctgctctgt gaaggaaccg cctttctctc cgcgtgtctc acccttttct ccccatatct 120
gtttggacat gagctgaggg caccggtcgc ggccgtcagc ctgttcgcag ctacggcgag 180
gaggggcgcg attgytcctt gttgccgctc cgttagtggt ccgcgtccat tccgcgcggt 240
gtcccgaatt taggggtagg gagaagtgtc agcttcaggc atcgcgaggc gtggcggccc 300
catggccccg ctgggaggcg ccccgcggtt ggtactgctg ttcagcggca agaggaaatc 360
cgggaaggac ttcgtgaccg aggcgctgca gagcagactt ggagctgatg tctgtgctgt 420
cctccggctc tctggtccac tcaaggaaca gtatgctcag gagcatggct tgaacttcca 480
gagactcctg gacaccagca cctacaagga ggcctttcgg aaggacatga tccgctgggg 540
agaggagaaa cgccaggctg acccaggctt cttttgcagg aagattgtgg agggcatctc 600
ccagcccacg tggttggtga gtgacacacg gagagtgtct gacatccagt ggtttcggga 660
ggcctatggg gccgtgacgc agacggtccg cgttgtagcg ttggagcaga gccgacagca 720
gcggggctgg gtgttcacgc caggggtgga cgatgctgag tcagaatgtg gcctggacaa 780
cttcggggac tttgactggg tcatcgagaa ccatggagtt gaacagcgcc tggaggagca 840
gttgagaaac ctgatagaat ttatccgctc cagactttag tctactaggt ctaggagtga 900
gctggggcct gctgaggtgg ggggtgggct gactctgcaa aatgggggtg tccccgatc 960
ctggccgagg tgaggaacag acaggggggg tctagattct gaggggggtg gtggatattg 1020
ggcaaggcag gaaacctctg gagacctcat tttctccatg gggaagacag ccatgctctt 1080
caggaggaga ctccaagggc aaaggagggt gtcttggtg tgcttgaaag cgaaaccctg 1140
ccatatcccc agtgccagtc ccctcagcct gtggtggcct tgcacctga ctggatgttc 1200
tcagcccctt gttctgggca agaaccaga gctccccagt gtggatacta ataaacctct 1260
tggagcacaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaagg 1308
```

<210> 121

<211> 2516

<212> DNA

<213> Homo sapiens

<400> 121

```
gattgacatt ccagtgaat gatgggagtt aattgattta atttagatta gttgaaaatt 60
attacaaaat attctaaaag ggttttttgt ggtacttcaa gaaacctgat tagttttgat 120
ctattgaaat cacaaaagta gaacagggcw ytttattttt gtataattta ggattaggta 180
tgcttctttg ttctaacaag tcatgttttc taacccttct ttcactaagc aaaccagaac 240
agatttgaac tgttatgggt tatatattag tatggagatc agctcagatg acattaaaaa 300
tgccgtagtg ttattcttgt atgcaaatac tttttttccc caaaattagc actttaattt 360
tatttactgt tataatattt gttttcttag attaggtagg aaatcttaat ttggccaccg 420
cctactttga caagtaaata ttacatcata cgattttgca acattaaatt agaacactag 480
```

aaactaaaaa attatgtttc agtgaatgct acaactaagc attttttttt ttttaagaaa 540
acaattgtat tatgttttgt tgccttgcca ctttgagtat cttatctgaa aatctgttcc 600
ttgccatgtt tttctcctgt taacataaac tatgtgccct gtgaatttct ggggactgaa 660
tttgaaattg ctcttgccaa ccgtttgtgg cctggcgtgt atctgaatgc ctgaatatct 720
ccccgctgaa tgaatttcgt attctgccct gaattcactc gggatatattg attggctgga 780
tgatcttggg gccgcccact tgacgtttcc agaagagtca ccgaagaaaa gaaccaggag 840
tgtagaggat gatgaggagg gtcacctgat ctgtcagagt ggagacgtac taagtcaag 900
atgtatagaa ttttttcaa cacttattaa cttttcagat aacataatct atatatagat 960
taagctttca gggatttgga aatctttttt tctttctctt ttttgttttt gttttatttt 1020
tccatttctt ttggtggggg ggattgtatt ttgtcttctt ttagaaatgt aatgtttgtt 1080
atatagaact tccagaacag taatcaaatt aatgaaatta gacctataa ttatgttttt 1140
tgatggtgtt gaccaataaa atatctagtg ataaggaaat ttgtagcatc aactagaata 1200
atctacattg atagcattta ttgtgataag tacattgttt ccacttcttg atatgactga 1260
gatttatttc tctcttttag atgaaattgt tgatacttta ggtgaaggag cttttggaaa 1320
agttgtggag tgcatcgatc ataaagcggg aggtagacat gtagcagtaa aaatagttaa 1380
aaatgtgat agatactgtg aagctgctcg ctcaaaaata caagtcttg aacatctgaa 1440
tacaacagac cccaacagta ctttcgcgtg tgtccagatg ttggaatggt ttgagcatca 1500
tggtcacatt tgcattgttt ttgaactatt gggacttagt acttacgact tcattaaaga 1560
aaatggtttt ctaccatttc gactggatca tatcagaaag atggcatatc agatatgcaa 1620
gtctgtgaat tttttgcaca gtaataagtt gactcacaca gacttaaagc ctgaaaacat 1680
cttatttgtg cagtctgact acacagaggc gtataatccc aaaataaaac gtgatgaacg 1740
caccttaata aatccagata ttaaagttgt agactttggt agtgcaacat atgatgacga 1800
acatcacagt acattggtat ctacaagaca ttatagagca cctgaagtta ttttagccct 1860
aggggtgtcc caacctagtg atgtotggag cataggatgc attcttattg aatactatct 1920
tggttttacc gtatttccaa cacacgatag taaggagcat ttagcaatga tggaaaggat 1980
tcttggaact ctacaaaaac atatgatata gaaaaccagg aaacgtaaat attttcacca 2040
cgatcgatta gactgggatg aacacagttc tgccggcaga tatgtttcaa gacgctgtaa 2100
acctctgaag gaatttatgc tttctcaaga tggtgaacat gagcgtctct ttgacctcat 2160
tcagaaaatg ttggagtatg atccagccaa aagaattact ctcaagagaag ccttaaagca 2220
tcctttcttt gaccttctga agaaaagtat atagatctgt aattggacag ctctctcgaa 2280
gagatcttac agactgtatc agtctaattt ttaaatttta agttattttg tacagctttg 2340
taaattctta acatttttat attgccatgt ttattttgtt tgggtaattt ggttcattaa 2400
gtacatagct aaggtaatga acatcttttt cagtaattgt aaagtgattt attcagaata 2460
aattttttgt gcttatgaaa aaaaaaaaaa aaaaaaaaaa aaaaaaggg aggggg 2516

<210> 122

<211> 1139

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1053)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1124)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1125)

<223> n equals a,t,g, or c

<400> 122

```
gtggcgcacg ggggtgggagc ggacccaggc cgggagcagg cgccgcccgc agtgagaacc 60
ggggccggag ccgggtgcgg atttgctggg gctgagtcgg gggcgcgcg ggcctgacct 120
ctgccctctg acctctcccc tagcaggcga ccatggggaa cgtgttggt gccagctcgc 180
cgcccgcagg gccgccaccg ccgcctgcgc cggccctcgt ggggctgcgc ccacctccgc 240
cctgcgcgcc gggcttcacg ctgccgcgc tgggaggcag cctgggcgcc ggcaccagta 300
cgaktcgarg ttcggaacgg acccccgggg ctgcaaccgc cagcgccctca ggggcccgcg 360
aggatggggc ctgcggctgc ctgcccacc cgggcacatt cgaggagtgc caccggaagt 420
gcaaggagct gtttccatt cagatggagg gtgtcaagct cacagtcaac aaagggttga 480
gtaaccattt tcaggtcaac cacacagtag ccctcagcac aatcggggag tccaactacc 540
acttcggggc cacatatgtg gggacaaagc agctgagtc cacagaggcg ttcctgtac 600
tggtgggtga catggacaac agtggcagtc tcaacgctca ggtcattcac cagctgggccc 660
ccggtctcag gtccaagatg gccatccaga ccagcagtc gaagtttgtg aactggcagg 720
tggacgggga gtatcggggc tctgacttca cagcagccgt caccctgggg aaccagacg 780
tcctcgtggg ttcaggaatc ctctagccc actacctca gagcatcacg ccttgccctg 840
ccctgggtgg agagctggtc taccaccggc ggctggaga ggagggcact gtcattgtctc 900
tagctgggaa atacacattg aacaactggg tggcaacggg aacgttgggc caggcgggca 960
tgcacgcaac atactaccac aaagccagtg accagctgca ggtgggtgtg gagtttgagg 1020
ccagcacaag gwtgcaggac accagcgtct ccnttsgggg accagcttgg aacttcccca 1080
agggccaacc tcytctttca aaggstctgt tgggataagc aaanngggat tcgtgggggt 1139
```

<210> 123

<211> 2114

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1966)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2039)

<223> n equals a,t,g, or c

<400> 123

```
accccgcgcg ccactcgtc gcgtcmgagg gaggagaaa gggcgagttc cggatccctg 60
cctagcgcg ccacacctt actccagaga tcatggctgc cgaggatgtg gtggcgactg 120
gcgcccaccc aagcgatctg gagagcgggc ggctgctgca tgagattttc acgtcgccgc 180
tcaacctgct gctgcttggc ctctgcatct tcctgctcta caagatcgtg cgcggggacc 240
agccggcggc cagcgggcagc agcgacgacg acgagccgcc ccctctgccc cgcctcaagc 300
ggcgcgactt ccccccgcc gagctgcggc gcttcgacgg cgtccaggac ccgcgcatac 360
tcatggccat caacggcaag gtgttcgatg tgaccaaagg ccgcaaattc tacgggcccg 420
aggggcccgt tggggtcttt gctggaagag atgcatccag gggccttgcc acattttgcc 480
tggataagga agcactgaag gatgagtacg atgaccttc tgacctcact gctgcccagc 540
aggagactct gagtgactgg gagtctcagt tcactttcaa gtatcatcac gtgggcaaac 600
```

```

tgctgaagga gggggaggag ccctactgtgt actcagatga ggaagaacca aaagatgaga 660
gtgcccggaa aaatgattaa agcattcagt ggaagtatat ctatttttgt attttgcaaa 720
atcatttgta acagtccact ctgtctttaa aacatagtga ttacaatatt tagaaagttt 780
tgagcacttg ctataagttt tttaattaac atcactagtg acactaataa aattaacttc 840
ttagaatgca tgatgtgttt gtgtgtcaca aatccagaaa gtgaactgca gtgctgtaat 900
acacatgtta atactgtttt tcttctatct gtagttagta caggatgaat ttaaagtgtg 960
ttttcctgag agacaaggaa gacttgggta tttcccaaaa caggtaaaaa tcttaaatgt 1020
gcaccaagag caaaggatca acttttagtc atgatgttct gtaaagacaa caaatccctt 1080
tttttttctc aattgactta actgcatgat ttctgtttta tctacctcta aagcaaatct 1140
gcagtgttcc aaagactttg gtatggatta agcgtgtgcc agtaacaaaa tgaaatctca 1200
aaacagagct cagctgcaaa aaagcatatt ttctgtgttt ctggactgca ctgttgcctt 1260
tgccctcaca tagacactca gacaccctca caaacacagt agtctatagt taggattaaa 1320
ataggatctg aacattcaaa agaaagcttt ggaaaaaaag agctggctgg cctaaaaacc 1380
taaatatatg atgaagattg taggactgtc ttcccaagcc ccatgttcat ggtggggcaa 1440
tggttatttg gttattttac tcaattggtt actctcattt gaaatgaggg agggacatac 1500
agaataggaa cagggtgttg ctctcctaag agccttcagt cacaccctg aaccacgagg 1560
aaacagtaca gtcgctagtc aagtggtttt taaagtaaa gtagtatac aggtaacagt 1620
tattctgttg ttataaaact ataccactg caaaagtagt agtcaagtgt ctaggctttt 1680
gatattgctc ttttggttaa cactaagctt aagtagacta tacagttgta tgaatttgta 1740
aaagtatatg aacacctagt gagatttcaa acttgtaatt gtggttaaat agtcattgta 1800
ttttcttggt aactgtgttt tatgatttta cctcaaatca gaaaacaaaa tgatgtgctt 1860
tggtcagtta ataaaaatgg ttttaccac taaaaaaaaa aaaaaaaggg cgcccgctct 1920
aaaggatccc tcgagggggc caagcttacg cgtgcatgcg acgtcntagc tctctcccta 1980
tagtgagtcg tattataagc taggcactgg ccgctgtttt acaacgtcgt gactgggana 2040
tctgctagct tgggatcttt gtgaaggaac cttacttctg tgggtgtgaca taattggaca 2100
aactacctac agag 2114

```

<210> 124

<211> 583

<212> DNA

<213> Homo sapiens

<400> 124

```

gcccggccta ttcccttggg cttttaaaaa gcgtcttggg tggaggtggg gcaggtgctc 60
accaagcccg cagtaacca agttgcatgt atccccaggg cacttttgtg attcccctgc 120
ttgtgactgc acaccgggac ccactcaat tcaaagacc agactgcttc aaccctacca 180
acttcctgga caagggaag ttccagggca atgatgcttt catgcccttt gcctcagggtg 240
caggcagagg aggaagggga ccagcctgga ctggctctgg ggtacctggg gctcactgtg 300
cacctgtgta ccggaacaa cagatgtgcc tgggcacagg cctggccac tcgggtatct 360
tcctattcct tacggccacc ttacagaggt tctgcctgct ccctgtggtg cgccctggca 420
ccatcaacct cacctgcagt gactggcct gggcagtgtc ccccgagact tccagctcca 480
gccagtggcc tgctgaggtc aggtccact atggtgggct cactggccct caaacctcca 540
taccctccts ggtcaataaa ggccctaaat tgcaaaaaaa aaa 583

```

<210> 125

<211> 1987

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (7)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (14)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (517)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1960)

<223> n equals a,t,g, or c

<400> 125

cagtacngtc cgantccccg gtcgacccac gcgtccgatg gcggcggagg aacctcagca 60
gcagaagcag gagccgctgg gcagcgactc cgaagtgtta actgtctggc ctatgatgaa 120
gccatcatgg ctcagcagga ccgaattcag caagagattg ctgtgcagaa ccctctggtg 180
tcagagcggc tggagctctc ggtcctatac aaggagtatg ctgaagatga caacatctat 240
caacagaaga tcaaggacct ccacaaaaag tactcgtaca tccgcaagac caggcctgac 300
ggcaactgtt tctatcgggc ttctcgattc tcccacttgg aggcactgct ggatgacagc 360
aaggagtgtc agcgggtgaga aggggtgggca ctgggcaccg aggcagggtg gtgtytacct 420
cctccccggg cgagtaggat gtgtctcgag taggggtgtc ycctccttcc cgggcgatgg 480
gctggactct ggcttgcca rgcggggcag tgctgtntcg gccctggcgt ctgggctggt 540
cgaggagccc atgctgggccc cgcctttcca tcccaccccc aggttcaagg ctgtgtctgc 600
caagagcaag gaagacctgg tgtcccaggg cttcactgaa ttcacaattg aggatttcca 660
caacacgttc atggacctga ttgagcaggt ggagaagcag acctctgtcg ccgacctgct 720
ggctccttc aatgaccaga gcacctccga ctacctgtg gtctacctgc ggctgctcac 780
ctcgggctac ctgcagcgcg agagcaagtt cttcgagcac ttcacgagg gtggacggac 840
tgtcaaggag ttctgccagc aggaggtgga gcccatgtgc aaggagagcg accacatcca 900
catcattgcg ctggcccagg cctcagcgt gtccatccag gtggagtaca tggaccgcgg 960
cgagggcggc accaccaatc cgcacatctt cctgagggc tccgagccca aggtctacct 1020
tctctaccgg cctggacact acgatatcct ctacaaatag ggctggctcc agcccgtgc 1080
tgccctgctg ccccccctg ccaggcgcta gacatgtaca gaggttttcc tgtggttgta 1140
aatggtccta ttccaccccc ttcttcctgt cacatgaccc ccccccattg ttatttaaag 1200
ggggtgctgg tgggtgagccg tgtgtgcgtg tccctgctct gctgcccgcc tggctgctct 1260
gtctgctgcc cctccccccc aggtgggtcc cctgctttt cacctatcta ctctgagct 1320
tccccaacag gagcagggtt gaggggcccag gcctcttga ggccctcct gcttcggttg 1380
gttctgcttc cttcccttct tagctggctc aggggcttct atgggacct ggaagttcct 1440
tagggacttg cccagggtcc cagggccacc cacacttcat ctgctccctc ataggcccca 1500
cctccacgtc ccggtctggc cccagacccc agcttctgc cctccaccgg gagtctgcat 1560
ggttgggagt cctgggtgga ggggcctttg tgaggctgga cccggctcag ggcagggtga 1620
ggagctgggc ctcccacagg gtgcccgggc agtgccatcc tgggtgggga gggcagcctt 1680
caaacgtgtg ggggtctamag tcctcaggtc taggcagggc tgccggttct ccacctcccc 1740
atccgccccca ggccccctgc ctgtgcctgc cttgcacccc ctctgcttgg gccacggtgt 1800
ctctgcattg cctgcctttt tgccctcacc tcttttcttc cccgccccct gcacattcgg 1860
gktctcagcc cccaggctgt gagctcctg gggcaggccc tcaataaatg tgaaactgct 1920

gctgcaaaaa aaaaaaaaaa aaaaaaaggg ggccgcttan agatcctcaa gggccaagta 1980
cggtgat 1987

<210> 126

<211> 1451

<212> DNA

<213> Homo sapiens

<400> 126

```

ggtcgaccca cgcgtccgag atggcggagc gcgggtacag cttttcgctg actacattca 60
gcccgctctgg taaacttgtc cagattgaat atgctttggc tgctgtagct ggaggagccc 120
cgtccgctggg aattaaagct gcaaatggtg tgggtattagc aactgagaaa aaacagaaat 180
ccattctgta tgatgagcga agtgtacaca aagtagaacc aattaccaag catatagggt 240
tgggtgtacag tggcatgggc cccgattaca gagtgccttg gcacagagct cgaaaactag 300
ctcaacaata ctatcttggtg taccaagaac ccattcctac agctcagctg gtacagagag 360
tagcttctgt gatgcaagaa tatactcagt cagggtggtg tcgtccatgt ggagtttctt 420
tacttatttg tggttggaat gagggacgac catatttatt tcagtcagat ccatctggag 480
cttactttgc ctggaaagct acagcaatgg gaaagaacta tgtgaatggg aagactttcc 540
ttgagaaaaag atataatgaa gatctggaac ttgaagatgc cattcataca gccatcttaa 600
ccctaaagga aagctttgaa gggcaaatga cagaggataa catagaagtt ggaatctgca 660
atgaagctgg atttaggagg cttactccaa ctgaagttaa ggattacttg gctgccatag 720
cataacaatg aagtgaactg aaaaatccaga atttcagata atctatctac ttaaactatg 780
ttaaagtatg ttttgttttg cagacttttt gcatacttat ttctacatgg tttaaatcga 840
ctgtttttta aatgacactt ataaatccta ataaactgtt aaaccacact tccagccttt 900
taggagttgc taaaatttta acagttattt ccygcttttt atcacagttg atttctgaag 960
actayattgc caagcagaat gatgaaatga ctttttcgtt gtcaggcaat tttggttaag 1020
tcaaactctta atgccctctt cgctatcaga tgttgctgtt gtttcataa agcaaaatgc 1080
tgattttggt aaaaaacatg actgcttcta gagctgggag gatctgcaga ctttcacgga 1140
ttcatggaac aagaaaagaa gcatagggtac ttttaggtgc cattaggtat tgatcagtga 1200
aatcctaagg tgctctatga gattgtacta ggcctatgaa gagtggttaag ccaaatagg 1260
ctccatggga gatacattat gtaaataaat aaacaatggt ttgctggttc ctggtggtgt 1320
ctccacaagt aggtaaacat gtttaaagga acccggttgc ttagattttg ttagactttt 1380
taaactcaag gatgagcata agtgcttgaa ataaaatgct aataacttaag tgtcaaaaaa 1440
aaaaaaaaa a 1451

```

<210> 127

<211> 1234

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (857)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1204)

<223> n equals a,t,g, or c

<220>

<221> misc feature
 <222> (1226)
 <223> n equals a,t,g, or c

<400> 127
 aggttcccag ctagccagta aattctttaa agacaagcat tgtacccttt gcctcagtgt 60
 gccagcacc aacctggcac atgctctatt catgttttcc atgagtgtt catgttagag 120
 gtgtattttg tacacagggt ttatgctggg ggctcagaga gaagtggaca gcagattgtt 180
 ggccctccca ggaagaaaag tccaacagag ctggtgggat gatctcttta aaggtgcca 240
 agagcatgga gctgtagctg tggagcgagt gaccaagagc cctggagaga ccagtaaacc 300
 gagaccattt gcaggagggt gctaccgcct tggggcagca ccagaggag agtctgccta 360
 tgtggcagga gaaaagaggc agcattccag ccaagatgtt catgtagtat tgaaactctg 420
 gaagagtgga ttcagcctgg ataattggaga actcagaagc tacciaagacc catccaatgc 480
 ccagtttctg gagtctatcc gcagagggga ggtgccagca gagcttcgga ggctagctca 540
 cgggtggacag gtgaacttgg atatggagga ccatcgggac gaggactttg tgaagcccaa 600
 aggagccttc aaagccttca ctggcgaggg tcagaaactg ggcagcactg cccccagggtg 660
 ttgagtacca gctctccagc ccaacaggca gaaaatgaag ccaaagccag ctcttccatc 720
 ttaatcgacg aatcagagcc taccacaaac atccaaattc ggcttgacga cggcgggagg 780
 ctggtgcaga aatttaacca cagccacagg atcagcgaca tccgactctt catcgtggat 840
 gcccgccag ccatgntgc caccagcttt atcctcatga ctactttccc gaacaaagag 900
 ctggctgatg agagccagac cctgaaggaa gccaacctgc tcaatgctgt catcgtgcag 960
 cggttaacat aaccgcccag ccagctgcct ggccctccctc ctgtgtttcc catggccagt 1020
 ggccatgcc catggggatc gcccctcctg cccccttggt cacaccagc agtccagtgc 1080
 aacgtctcct ccatagctct gggttcttag atcttggtg gacgtttgtt ttctccttag 1140
 ttgcatttcc tgggtttttg tgatgatcaa tggactttaa tgaaaaaaaa aataaaaaca 1200
 accnaaaggg gggcccggtc ccaatncccc cctt 1234

<210> 128
 <211> 863
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (840)
 <223> n equals a,t,g, or c

<400> 128
 cccacgcgtc cgcaggcgcg ctccgggtgc cgctggctct tcgcacgcgg ccatggccga 60
 ctccgagctg cagctgggtg agcagcggat ccgcagcttc cccgacttcc ccaccccagg 120
 cgtggtattc agggacatct cgcctgcctt gaaggacccc gcctccttcc gcgccgccat 180
 cggcctcctg gcgcgacacc tgaaggcgac ccacgggggc cgcacgcact acatcgcagg 240
 cctagactcc cgaggcttcc tctttggccc ctccctggcc caggagcttg gactgggctg 300
 cgtgctcatc cgaaagcggg ggaagctgcc agggcccaact ctgtgggcct cctattccct 360
 ggagtacggg aaggctgagc tggagattca gaaagacgcc ctggagccag gacagagggt 420
 ggtcgtcgtg gatgatctgc tggccactgg tgggaaccatg aacgctgcct gtgagctgct 480
 gggccgcctg cargctgagg tcctggagtg cgtgagcctg gtggagctga cctcgcttaa 540
 gggcagggag aagctggcac ctgtaccctt cttctctctc ctgcagtatg agtgaccaca 600
 gggcctccca gcccaacatc tccagctgga tcccaggga atatagcct tgggcaactg 660
 cagtaccag gggcaccggc tgcccacagg gaacacattc ctttgctggg gttcagcgcc 720
 tctcctgggg ctggaagtgc caaagcctgg ggcaaagctg tgtttcagcc aactgaacc 780

caattacaca cagcgggaga acgcagtaaa cagctttccc acaaaaaaaaa aaaaaaaaaan 840
aaaaaaaaaa aaaaagggcg gcc 863

<210> 129

<211> 1238

<212> DNA

<213> Homo sapiens

<400> 129

cacagtgtct gctgtgattg agatgcgcac aggttggggg aggtagggcc ttacgcttgt 60
cctcagtggg ggcagtttgc cttagatgac arctgggctc ttcttcacac cacctgcagc 120
ccctccctgc ccctgcccta gctgctgtgt gttcagttgc cttctttcta cctcagccgg 180
cgtggagtgg tctctgtgca gttagtcca cccacacac ccgtctcttg attgagatgt 240
ttctgggtgt tatgggtttc ccgtggagct kggggtgggc gccgtgtacc taagctggag 300
gctggcgctc tccctcagca caggtgggtc agtggccagc aggccatct ggagtgggag 360
tgggcacttc caccgcgccc acaggccatc cggctgtgca ggccagcccc taggagcarg 420
tcccgggtga ctggcagttt tcacggtcta gggccgagac gatggcatgg ggcctagagc 480
atgaggtaga gcagaatgca gaccacgccg ctggatgccg agagaccctg ctctccgagg 540
gaggcatctg tgtcatgctg tgagggtga ggacggggcc ctagtctctg gttttctggt 600
cttaacatcc ttatctgtgt ccgccacgga ggtgactgag ctgctagcga gttgtcctgt 660
cccaggtact tgagttttgg aaaagctgac tcacgcccac ccatctcaca gcccttcctt 720
ggggacagtc gcttccgctt tgacacctca ctctcagttg aataactcaa gcttggtcat 780
cttcagactc gaattcttga gtagaccagc acggcttagc ccaagtctag ttgcagctgc 840
ctcggcaagt ccccatthtc tcaggcagcc ctgaatgggc ctgtttacag gaatggtaa 900
ttgggattgg aaggaatata gcttccagct tcataggcta gggtgaccac ggcttaggaa 960
acagggaaag aaagcaaggc ccttttctct cctttcccgg gatctgtcta ctccacctcc 1020
acgggggagg ccagtgggga agggctgtca cctcttcccc atctgcatga gttctggaac 1080
tctgtctgtg tggctgcttg cttccagctc cccccaatct ccacgcagc gggttcctcc 1140
tgtcttttct acagtgtcat aaaacatcct gccctaccc tctcccaaag gtcaatttta 1200
attctyawca agaagattta tgaggagaag aaaaagaa 1238

<210> 130

<211> 379

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (373)

<223> n equals a,t,g, or c

<400> 130

tggtttgga gctgccaggc tcctgggagg atcgcagtca gcagagcagg gctgaggcct 60
gggggtagga gcagagcctg cscatctgga ggcagcatgt ccaagaaagg gagtggagggt 120
gcagcraagg acccaggggc agagccacgc tggggatgga ccccttcgag gacacgctgc 180
ggyggctgcg tgaggccttc aactgakggc gcacgcggcc ggccgagttc cgggctgcgc 240
actccagggc ctgggccaact tccttcaaga aaacaagcar cttctrcgmg acgtgctggc 300
ccaggaactg cataagccag ctttcgaagg cagacatatc tgagtcatcc tttgccagaa 360
cgagggtgaa tangctctt 379

<210> 131

<211> 1786

<212> DNA

<213> Homo sapiens

<400> 131

```
cctgggcgct aagatggcgg cggcgtgagt tgcattgtgt gtgaggatcc cggggccgcc 60
gcgtcgctcg ggccccgcca tggccgtcac catcacgctc aaaacgctgc agcagcagac 120
cttcaagatc cgcatggagc ctgacgagac ggtgaagggtg ctaaaggaga agatagaagc 180
tgagaagggt cgtgatgcct tccccgtggc tggacagaaa ctcattctatg ccggcaagat 240
cttgagtgac gatgtcccta tcagggaacta tcgcatcgat gagaagaact ttgtggctgt 300
catggtgacc aagaccaaag cgggccaggg tacctcagca cccccagagg cctcaccac 360
agctgcccc aagtcctcta catccttccc gcctgcccc acctcaggca tgtcccatcc 420
cccacctgcc gccagagagg acaagagccc atcagaggaa tccgccccca cgacgtcccc 480
agagtctgtg tcaggctctg ttccctcttc aggtagcagc gggcgagagg aagacgcggc 540
ctccacgcta gtgacgggct ctgagtatga gacgatgctg acggagatca tgtccatggg 600
ctatgagcga gacggggtcg tggccgccct gagagccagc tacaacaacc cccaccgagc 660
cgtggagtat ctgctcacgg gaattcctgg gagccccgag ccggaacacg gttctgtcca 720
ggagagccag gtatcgagc agccggccac ggaagcagga gagaaccccc tggagtccct 780
gcgggaccag cccagttcc agaactatgc gcaggtgatt cagcagaacc ctgcgtgtgt 840
gccccccctg ctccagcagc tgggccagga gaacctcag cttttacagc aaatcagccg 900
gcaccaggag cagttcatcc agatgctgaa cgagccccct ggggagctgg cggacatctc 960
agatgtggag ggggaggtgg gcgccatagg agaggaggcc ccgcagatga actacatcca 1020
ggtgacgccg caggagaaaag aagctataga gaggttgaag gccctgggct tcccagagag 1080
cctggtcatc caggcctatt tcgcgtgtga aaaaaatgag aacttggctg ccaacttctc 1140
cctgagtcag aactttgatg acgagtgatg ccaggaaagg aggccaccga agccccacc 1200
ctacccttat tccatgaaaag ttttataaaa gaaaaaatat atatataatc atgtttattt 1260
aagaaatgga aaaaaaatc aaaaatctta aaaaaacaag caaacagtcc agcttcctgt 1320
cctcctaaag tggccccgtg tcccatctcc cgggccagac agctgtcccc ccgtcctcct 1380
ccccagccca gcctgctcag agaagctggc aggaactggga ggcgacagat gggccccctc 1440
tggcctctgt cccagctctc tgcagccaga cggaaaggcg gctgcttgcc tctccatcct 1500
ccgaaaaacc cctgaggacc ccccccatc ctcttctagg atgaggggaa gctggagccc 1560
caactttgat cctccattgg agtggcccaa atctttccat ctagggcaag tcctgaaagc 1620
ccaaggcccc ctccccagtc tggccttgcc tccagcctgg agaagggcta acatcagctc 1680
attgtcaagg ccacccccac ccagaacag aaccgtgtct ctgataaagg ttttgaagtg 1740
aataaagttt taaaaactaa aaaaaaaaaa aaaaaaaaaa aaaaaa 1786
```

<210> 132

<211> 974

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (165)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (853)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (963)

<223> n equals a,t,g, or c

<400> 132

```

ggcagctaac ctctcatcc ccgctgtggg ttctagcctc tctgaagccc tggacttgat 60
cgagtcggac cctgatgctt ggtgtgacct gagtaaattt gacctccctg aggaaccatc 120
tgcagaggac agtatcaaca acagcctagt gcagctgcaa gcgtncacat cagcagcaag 180
tcctgccacc ccgccagcct tccgccctgg tgcccagtg gaccgagtac cgcctggatg 240
gccacacccat ctcatagcct agccggagca gccggggcga gctgatcccc atctccccc 300
gcactgaagt cgggggctct ggcattggca caccgccctc tgtgctcaag cggcagagga 360
agaggcgtgt ggctctgtcc cctgtcactg agaatagcac cagtctgtcc ttcctggatt 420
cctgtaacag cctcagcccc aagagcacac ctgttaagac cctgcccttc tcgccctccc 480
agtttctgaa cttctggaac aaacaggaca cattggagct ggagagcccc tcgctgacat 540
ccacccaggt gtgcagccag aagggtggtg tcaccacacc actgcaccgg gacaagacac 600
ccctgcacca gaaacatgct gcgtttgtaa cccagatca gaagtactcc atggacaaca 660
ctccccacac gccaaccccc ttcaagaacg ccctggagaa gtacggaccc ctgaagcccc 720
tgccacagac cccgcacctg gaggaggact tgaaggaggt gctgcgttct gaggtggca 780
tcgaactcat catcgaggac gacatcaggc ccgagaagca gaagaggaag cctgggctgc 840
ggcggagccc atncaagaaa gtccggaagt ctctggctct tgacattgtg gatgaggatg 900
tgaagytgat gatgtccaca ytgcccaakt ytttatcctt ggcgacaayt gccccttgca 960
aanttttcca gcct 974

```

<210> 133

<211> 634

<212> DNA

<213> Homo sapiens

<400> 133

```

attcggcacg acgggtgaac ctggccacag ctcaccctgg aacagccaca atgtctgccc 60
cttagagaag aaccctgaaa tcagaccagt ttttgcgccc tcccccttc ctctctgtta 120
cagtgccctt tccaggcctt aagagaagta aaacttagct gcagcgtcag gaggtggacc 180
ccagagtgtg agtggcacgc ttctctgtga acccgtcctc accatgtttg ccacatctgg 240
ggcagtggca gcggggaagc cttactcgtg cagcgaatgt ggcaagagct tctgctacag 300
ctcagtgtg ctgcgacatg aacgagctca cggcggtgac ggccgcttcc gttgcctaga 360
atgcggtgag cgctgtgcac gggctgctga cctccgagcg cacaggcgca cgcctgtgg 420
ccagaccctc tacatctgca gtgagtgcgg acaaagcttc cgccacagcg gccgtcttga 480
cctacacttg ggcgcacacc ggcagcgatg ccgcacttgc ccctgccgca cwtgcgggcg 540
gcgcttcccg caccctcccg cgctgctgct acaccggcgc cgccagcatc tgccagagcg 600
gccccgscgy tgcccgtgt gcgycctcag gttt 634

```

<210> 134

<211> 1855

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1818)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1845)

<223> n equals a,t,g, or c

<400> 134

```
gcccacgcgt cccggcggcgc gcccgagggc gccgcgtgcg gcctgcagga gggcccgtgc 60
ggcgaggggc tgcagtgcgt ggtgcccttc ggggtgccag cctcgccac ggtgcggcgg 120
cgcgcgcagg cccgcctctg tgtgtgcgcc acagcgagcc ggtgtgcggc agcgacgcca 180
acacctacgc caacctgtgc cagctgcgcg ccgccagccg ccgctccgag aggctgcacc 240
ggccgcgggt catcgtcctg cagcgcggag cctgcggcca agggcaggaa gatcccaaca 300
gtttgcgcca taaatataac tttatcgcgg acgtgggtga gaagatcgcc cctgccgtgg 360
ttcatatcga attgtttcgc aagcttccgt tttctaaacg agaggtgccg gtggctagtg 420
ggtctgggtt tattgtgtcg gaagatggac tgatcgtgac aaatgccac gtggtgacca 480
acaagcaccg ggtcaaagt ttgagctgaaga acggtgccac ttacgaagcc aaaatcaagg 540
atgtggatga gaaagcagac atcgactca tcaaaattga ccaccagggc aagctgcctg 600
tcctgctgct tggccgctcc tcagagctgc ggccgggaga gttcgtggtc gccatcgaa 660
gcccgttttc ctttcaaaac acagtcacca ccgggatcgt gagcaccacc cagcgaggcg 720
gcaaagagct ggggctccgc aactcagaca tggactacat ccagaccgac gccatcatca 780
actatgaaa ctcgggaggc ccgttagtaa acctggacgg tgaagtgatt ggaattaaca 840
ctttgaaagt gacagctgga atctcctttg caatcccatc tgataagatt aaaaagttcc 900
tcacggagtc ccatgaccga caggccaaag gaaaagccat caccaagaag aagtatatg 960
gtatccgaat gatgtcactc acgtccagca aagccaaaga gctgaaggac cggcaccggg 1020
acttcccaga cgtgatctca ggagcgtata taattgaagt aattcctgat accccagcag 1080
aagctggtgg tctcaaggaa aacgacgtca taatcagcat caatggacag tccgtggtct 1140
ccgccaatga tgtcagcgac gtcattaaaa gggaaagcac cctgaacatg gtggtccgca 1200
gggtaatgaa gatatcatga tcacagtgat tcccgaagaa attgacccat aggcagaggc 1260
atgagctgga cttcatgttt ccctcaaaga ctctcccgtg gatgacggat gaggactctg 1320
ggctgctgga ataggacact caagactttt gactgccatt ttgtttgttc agtgagact 1380
ccctggccaa cagaatcctt cttgatagtt tgcaggcaaa acaaatgtaa tgttgcagat 1440
ccgcaggcag aagctctgcc cttctgtatc ctatgtatgc agtgtgcttt ttcttgccag 1500
cttgggccat tcttgcttag acagtcagca tttgtctcct cctttaactg agtcatcatc 1560
ttagtccaac taatgcagtc gatacaatgc gtagatagaa gaagccccac gggagccagg 1620
atgggactgg tcgtgtttgt gcttttctcc aagtcagcac ccaaaggcca atgcacagag 1680
accccggtg ggtgagcgt ggcttctcaa acggccgaag ttgcctcttt taggaatctc 1740
tttgaattg ggagcacgat gactctgagt ttgagctatt aaagtacttc ttacacattg 1800
aaaaaaaaa aaaaaaantc cggggggggg cccggtaccc aattngccct ttaag 1855
```

<210> 135

<211> 917

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (913)

<223> n equals a,t,g, or c

<400> 135

```
ggttttttgc gcgtgcatat ggcggtggcg ggtgggggga agggggagat cctgctgcac 60
```

```

tggccgcccc agttgggggg cgagctcggt ggtgacgcgc ggccctcacg tgacccarag 120
ctgcagagcg acgcagcctt cgggtgcagtc gtcactcgcg tctggctacc agctccccgc 180
tgccctgagc tcggcgggct ggcattcggc cgggggaaaa gcggagcagg tctgcgaggc 240
taagtgtctc cgcgcgccac ctccggcgga gaatccggag gagaaggaga ctgcaaggat 300
aggcccagga aaacgaagag atggagcagc ctatgcagaa tggagaggaa gaccgccctt 360
tgggaggagg tgaaggccac cagcctgcag gaaatcgacg gggacaggct cgccgacttg 420
cccctaattt tcgatggggc ataccctaata ggcagatcaa tgatgggatg ggtggagatg 480
gagatgatat ggaaatattc atggaggaga tgagagaaat cagaagaaaa cttagggagc 540
tgcagttgag gaattgtctg cgtatcctta tgggggagct ctctaatac acatgaccatc 600
atgatgaatt ttgccttatg ccttgactcc tgccatttat catgagatta atactgtgat 660
tcccgcgtgt ttctttttcc ttgcattttc ctaatatgcc tttactgatc cgtttgctgt 720
gaaccctatg ttatttccat gtgtcaagtg ggtcttgtgt tgccagcttc tatttgaaga 780
ttgcctttgc actcagtgtg agtttctgtc agcagtagtt tcacccattt gcatggaaaa 840
atttaaagct aataaagcaa tttaaaaagc aaaaaaaaaa aaaaaaaaaa aaaaaamamg 900
ggggggcccc gwnccca                                     917

```

<210> 136

<211> 1271

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1236)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1255)

<223> n equals a,t,g, or c

<400> 136

```

gcaaggcttc ccctctaccc tctctggggc tctcacaac gctgagcccc gcccgcgtga 60
ggcctgtctg cagaatccac ascaaccagc accatgcccc tgayactggg gtactggrac 120
atccgcgggc tgcccaykc catccgcctg ctccctggaat acacagactc aagctaygag 180
gaaaagaagt acacgatggg ggacgctcct gattatgaca gaagccagtg gctgaatgaa 240
aaattcaagc tgggcctgga ctttcccaat ctgccctact tgattgatgg grctcacaag 300
atcacccaga gcaacgccat cctgcggtac attgcccga agcacaacct gtgcggggaa 360
tcagaaaagg agcagattcg cgaagacatt ttggagaacc agtttatgga cagccgtatg 420
cagctggcca aactctgcta tgaccagat tttgagaaac tgaaaccaga atacctgcag 480
gcactccctg aaatgctgaa gctctactca cagtttctgg ggaagcagcc atggtttctt 540
ggggacaaga tcacctttgt ggatttcac gcttatgatg tccttgagag aaaccaagta 600
tttgagcccc gctgcctgga tgccctccca aacctgaagg acttcactc ccgatttgag 660
ggcttgagga agatctctgc ctacatgaag tccagccgct tcctcccaag acctgtgttc 720
acaaagatgg ctgtctgggg caacaagtag ggccttgaag gccaggaggt gggagtgagg 780
agcccatact cagcctgctg ccagcgtgt gcagcgcagc tggactctgc atcccagcac 840
ctgcctctc gtctctttct cctgtttatt cccatcttta ctcccaagac ttcatgtgcc 900
ctcttcactc cccctaaacc cctgtcccat gcaggccctt tgaagcctca gctaccact 960
atccttcgtg aacatcccct cccatcatta ccctccctg cactaaagcc agcctgacct 1020
tccttcctgt tagtggtgt gtctgttta aargcctgcc tggccctcg cctgtggagc 1080
tcagccccga gctgtccccg tgttgcatga aggagcagca ttgactggtt tacaggccct 1140

```

```

gctcctgcag catggtccct gccttaggcc tacctgatgg aagtaaagcc tcaaccacaa 1200
aaaaaaaaa aaaaaatttg gggggggggc cggtanccca tttggccctt tagngggggg 1260
ggtttttaaat t                                     1271

```

<210> 137

<211> 2017

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (295)

<223> n equals a,t,g, or c

<400> 137

```

ggaatgtcat cagtgttgac ccgaatgac agaaaaagac agcttggtat gacattgatg 60
ttgaagtgga tgacaccttg aagaccacaga tgaattcttt tctgctgtcc actgccagcc 120
aacaggagat tgctactcta gacaacaaga caatgactga tgtggtgggt aaccararga 180
rgagcgccga gctgagttct acttccagcc ctgggkcagg aggctgtgtg ccratacttc 240
tactccaagg tgcagcagag acgacaagaa ttagagcaag ccctgggaat ccggnataca 300
tagggcctct cccacagccc tgattcgact gcaccaattc ttgawttggg ccctgtgctg 360
cctgcctcat agtatctgcc ttggtcttgc ttggggcggt ccaggggatg ctgttggttc 420
aaggacaaca ccagaatgaa gaggggtctca caagacacct gttatcctct tctttcacc 480
tatctcttcc cacccccagc ttccctttgc cccacaaagt tcccatgtgc ctgtaccctc 540
ccctggtcta cataggacct ctagatagtg ttagagagag aacatgtagt ggtaatgagt 600
gcttggaatg gattgggcct caggccaggt ggtcttcaag gggaccagct aactgatcct 660
gcccttcaga gaccaggag ttgggagctt tcgctccttc tccaagactc aggcctgtgg 720
gcactctata agctagttga tcttggtctc cctgataaca gaatccaatt tccttccttc 780
cctccacagg tttggaacaa actctccctt cacttggtgc cctgtagcac tacagaaacc 840
ctggttcttg ggctccactg gccccagggt cagtccccag ccctctgggt tgrcctgctg 900
tcagtgtctc tytactcct tagttggggt ccacatcagt attggagttt tgttctttat 960
tgctccctcc cagacactcc ctgtggctgc cctttgtgat tccctcagat ctgcccta 1020
cccgggcatt tgggtggggg aatcttgcct ttcccttca gagccccagg gatctcatct 1080
ggggaaactgt cattgccagc agaggctgtt ccttcctgct gtttgagat gtgactcatt 1140
cattcactca ctccaccctg cctctgcac ccttaatgga gaaacgggcc taaaaccaa 1200
cgggtaaaaa gccctgggac atccctgtct tcctgtccct tgtctgccc 1260
actggtgact tctagggcac tgaggagtga aagcgccag ggctggagaa tagcgctgag 1320
ttgggtttgt gactcttccc tctccctgcc tcacaggatt gtgactcccc agccccctgc 1380
ctcaaagctt cagaccctc aggtagcagc aggacctgt gatcttggcc ccttgatct 1440
gagatggttt ttgcatcttt ccaggagagc ctcacattct tcttccagggt tgtatcccc 1500
ccgagtttagc atatcccagg ctgcagact caacacagca aggggtgggag acagctgggc 1560
acaaaggggg aattccgttc agcatgggct ctaaaaccac agaactgaca aagccccctgc 1620
ttccccacc cctcctcagg ctcttgcgag cacaccccca ccccaaatc cctccctgtt 1680
ctacactggg gacagcagaa tttctcccc tcttccctt tctgcccatt ttccctccct 1740
tgaaaggttg acactggaca accttggggc agctgagccc tggccgcctc ctggctggaa 1800
ccatgagaag gaagctcagt acttcccaca gtgtccctgt tgataactgt ttttattaac 1860
tgaattgttt ttttcatgga ccaaactttt ttttgtactg tccccctatt gatgttacc 1920
agttttaata aaagaatctt ctgaaggatg ggtcctccta cctactgtga gagagctctt 1980
ccctgagctc ttcttccttc aataccatta aaaaaaa 2017

```

<210> 138

<211> 937
<212> DNA
<213> Homo sapiens

<400> 138
gattcaaaca ggcaacaatg acctttttatt ttctgtttgt cccacacctc ccagccttcc 60
acctcctgtt cttcctacct tcttcctttt tgactaaata atccccacct cccttgatca 120
tacagtgagg ctacagtgac tgaggggaga atccctcctg ttcactctcc caaccctgct 180
ccagccccctc agcttcccag accctcatgc agttgggtgt aaattctccc aggagctgtt 240
ttactgtcta cttttcagga ttaaaaaaaaa aatcaaaaact taaaaaaaaa aaagttaa 300
aagcaaaatg gggaggggga ggaagcagtg actttttttt ggtaattatg cgcttttttt 360
taatttttag aatttgtctt ttactgttg gtgggctgtt gatatttcat caagataagc 420
atttctttcc tgagttcagg tgactgagga agagccacaa aacaaaacac aacaaaacca 480
aaccacagaa tcattcttaa cccaactttt tatacgatgc cccagttccc cataactttg 540
cacacaagct tctgtgttca gttgaattgt aactgctttt tgtatttgga gagagtgact 600
attgaacttg aaacctttta ttccgggcgt cttggtagt tctggtgga ttcagtgggt 660
gagaggaag aaggggaggt tggggggctc cttcccttca gaacttgaag tttctccac 720
tgcctcctct ccagtgggtc cccaggtgcc agacccaaaa gcttttccta cagtataacc 780
ctttattttt acttcccctt gactcatatg ttttaacatg attttaacaa actgcactta 840
ttaagaaatg tgtttgccct gttttgtttg gtttcgtttt gttttctttg aataaatgac 900
atggcacctc ctagcaggaa ggaaaaaaaa aaaaaaa 937

<210> 139
<211> 2759
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (171)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1654)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (2743)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (2744)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (2746)
<223> n equals a,t,g, or c

<400> 139

gctagtctca caggaaccca ggcgttgccc ccactcttct ccctcggcta ccaccagagc 60
cggttgaact accgggacga ggctgatgtg ctggaagtgg atcagggcct tgatgatcac 120
aacctgccct gtgatgtcat ctggctagac attgaacatg ctgatggcaa ncgggtatttc 180
acctgggacc ccagtcgctt ccctcagccc ygcaccatgc ttgascgctt ggcttctaag 240
aggcsraagc tgggtggccat cgtagacccc cacatcaagg tggactccgg ctaccgagtt 300
cacgaggagc tgcggaacct ggggctgtat gtwaaaaccc gggatggctc tractatrag 360
ggctgggtgct ggccaggctc agctggttac cctgacttca ctaatcccac gatgagggcc 420
tgggtgggcta acatgttcag ctatgacaat tatgagggct cagctcccaa cctctttgtc 480
tggaatgaca tgaacgaacc atctgtgttc aatgggtcctg aggtcaccat gctcaaggat 540
gcccagcatt atgggggctg ggagcaccgg gatgtgcata acatctatgg cctttatgtg 600
cacatggcga ctgctgatgg gctgagacag cgctctgggg gcatggaacg cccctttgtc 660
ctggccaggg ccttcttcgc tggctcccag cgctttggag ccgtgtggac aggggacaac 720
actgccaggt gggaccattt gaagatctct attcctatgt gtctcagctt ggggctgggtg 780
ggactttcct tctgtggggc ggatgtgggt ggcttcttca aaaaccaga gccagagctg 840
cttgtgcgct ggtaccagat ggggtcttac cagccattct tccgggcaca tgcccacttg 900
gacactgggc gacgagagcc atggctgtta ccactcagc acaatgatat aatccgagat 960
gccttgggac agcgatatct tttgtgccc ttctggtaca ccctcttata tcaggcccat 1020
cggaagga ttcctgtcat gagggccctg tgggtgcagt accctcagga tgtgactacc 1080
ttcaatatag atgatcagta cttgtctggg gatgcgttgc tggttcacc tgtatcagac 1140
tctggagccc atggtgtcca ggtctatctg cctggccaag gggaggtgtg gtatgacatt 1200
caaagctacc agaagcatca tggctcccag accctgtacc tgctgtaac tctaagcagt 1260
atccctgtgt tccagcgtgg agggacaatc gtgcctcgat ggatgcgagt gcggcggctt 1320
tcagaatgta tgaaggatga ccccatcact ctctttgttg cacttagccc tcagggtaca 1380
gctcaaggag agctctttct ggatgatggg cacacgttca actatcagac tcgccaagag 1440
ttcctgtctg gtcgattctc attctctggc aacacccttg tctccagctc agcagaccct 1500
gaaggacact ttgagacacc aatctggatt gagcgggtgg tgataatagg ggctggaaag 1560
ccagcagctg tggactcca gacaaaagga tctccagaaa gccgcctgtc cttccagcat 1620
gaccctgaga cctctgtgtt ggtcctgcgc aagncctggc tcaatgtggc atctgattgg 1680
agtattcacc tgcgataacc caagggatgt tctgggttag ggggagggaa ggggagcatt 1740
agtgtgaga gatattcttt cttctgcctt ggagttcggc cctccccaga cttcacttat 1800
gctagtctaa gaccagatt ctgccaacat ttgggcagga tgagagggt gaccctgggc 1860
tccaaattcc tcttgtgatc tcctcacctc tcccactcca ttgataccaa ctctttccct 1920
tcattccccc aacatcctgt tgccttaact ggagcacatt cacttacgaa caccaggaaa 1980
ccacagggcc cttgtcggcc cttctcttct ccttatttag gagccctgaa ctccccaga 2040
gtctatccat tcatgcctct tgtatgttga tgccacttct tggagaaga tgagggcaat 2100
gagttagggc tccttttccc cttccctccc accagattgc tctcccacct ttcatttctt 2160
cctccagcct ttactcccc ttttatgccc caccgataca ctgggaccac cccttaccoc 2220
ggacaggatg aatggatcaa aggagtggg ttgctaaaga acatcctttt ccctctcatt 2280
ctaccctttt cctctccccg attccttgta gagctgctgc aattcttaga ggggcagttc 2340
tacctcctct gtccctcggc agaaagacgt ttccacacct cttaggggat gcgcattaaa 2400
cttcttttgc ccccttcttg tccccttga ggggcactta agatggagaa atcagttgtg 2460
gtttcagtga atcatgggtca cctgtattta ttgctaggag aagcctgagg gtggggggag 2520
atgatcatgt gtgctcgggg ttggctggaa gccctgggtg gggggttggg ggaggactaa 2580
tggggagtcg gggaatattt gtgggtattt tttttacttc ctcttggttc ccagctgtga 2640
cacgttttga tcaaaggaga aacaataaag ggataaacca taaaaaaaaa aaaaaaaaaa 2700
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aannanaaaa aaaaataaa 2759

<210> 140

<211> 1241

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (317)

<223> n equals a,t,g, or c

<400> 140

```
tcgacccacg cgtccgggag aacggggcga gggcgcgggc cgaccgggag caccgaccat 60
ggcctccaaa tgccccaagt gcgacaagac cgtgtacttc gccgagaagg tgagctccct 120
ggggaaggac tggcacaagt tctgcctcaa gtgcgagcgc tgcagcaaga cgctgacgcc 180
cggggggccac gccgagcatg acgggaagcc gttctgccac aagccgtgct acgccaccct 240
gttcggaccc aaaggcgtga acatcggggg cgcgggctcc tacatctacg agaagcccct 300
ggcgaggggg ccgcagntca ccggcccatc cgaggtcccc gcggcccagc cagaggagcg 360
gaaggcgagc ggccccccga aggscccagc agagcctcca gtgtcaccac tttcaccggg 420
gagcccaaca cgtgcccgcg ctgcagcaag aaggtgtact tcgctgagaa ggtgacgtct 480
ctgggcaagg attggcaccg gccctgcctg cgctgcgagc gctgcgggaa gacactgacc 540
cccggcgggc acgcggagca cgacggccag ccctactgcc acaagccctg ctatggaatc 600
ctcttcggac ccaagggagt gaacaccggt gcggtgggca gctacatcta tgaccgggac 660
cccgaaggca aggtccagcc ctaggctaca gcggctctca tgatgtgggc tcacctgcgc 720
cccagaccct gcagggggcc ccctgcttgg ctctgctggg agagtgtctc gccgccagc 780
cctgcctgca agcccagggc gagtattgga ggaggggcag ccacgggcag agcaccatgc 840
ccatccccga gtctctggtg tgtctgcccc ctctggcatc ctctgggcgt cccatgatcc 900
cttctgtgtc tgcgtgtccg aatccccgtg tgaccctgtc ccagcathtt cccgccgacc 960
ctgcgtgtcc ccgtggcgct gtccgctctc cctctcctgc tgcccaccca cctgccagt 1020
ttatttatgc tcccttcgtg ggtgatggc acgccctcac catgtccctg gcagagggt 1080
tcctccggga tccctgcct ggtgccaca ctgcctcgca agcgctcgcc accctcacgt 1140
ggctcacctg ctgttgagcc ttgtgctgtc aataaacggt ttgaggattg caaaaaaaaa 1200
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa g 1241
```

<210> 141

<211> 3405

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1569)

<223> n equals a,t,g, or c

<400> 141

```
cctttccgat acgtcctaga cccacctgcc cgccggatct ggaataatgt gactcgtg 60
tttgtcacgt gtgtccggca gccagaattc cgagccgtgc taggagaagt ggttctatac 120
tcaggagcca ggcctctctc tcatcagcca ggccccgagg ctcttgccct cccaaagaca 180
gctgctcagc tcaagaaaga ggcaaaagaa cgggagaagc tagagaaatt ccaacagaag 240
cagaagatcc aacagcagca gccacctyca ggggagaaga aacaaaaacc agagaagagg 300
gagaaacggg rtyctggggt cattamctwt gacytcccaa ccccamccgg ggaaaagaaa 360
gatgtcagtg gccccatgcc cgactcctac agccctcggg atgtggaggc tgcctggtac 420
ccttggtggg agcagcaggg cttcttcaag ccagagtatg ggcgtcctaa tgtgtcagca 480
gcaaatcccc gaggtgtctt catgatgtgc atcccccccc ccaatgtrac aggctccctg 540
```

```

cacctgggmc atgcactcac caacgccatc caggactccc tgactcgatg gcaccgcatg 600
cgtggggaga ccaccctgtg gaaccctggc tgtgaccatg caggtattgc caccaggtg 660
gtggtggaga agaagctatg gcgtgagmag ggactgagcc ggcaccagct gggccgcgag 720
gctttctaca ggaagtctgg aagtggaaag aggagaaagg tgaccggatt taccaccagt 780
tgaagaagct tggcagctcc ttggactggg atcgagcctg tttcaccatg gaccctaaac 840
tctcagcagc tgtgacagag gcctttgtcc ggcttcacga ggaaggcatc atctatcgca 900
gtaccgcgct tggttaactgg tcctgcaccc tcaactccgc catctctgac attgaggtg 960
ataagaagga gctgacaggt cgcaccctgc tctccgtgcc tggctacaag gagaaggtg 1020
agttcggggg cctcgtgtcc tttgcctata aggtccaagg ctccagatagc gacgaggagg 1080
tggtgggtgg aacaactcgg atcgagacaa tgctgggaga tgtggctgta gctgtgcacc 1140
ccaaagatac cagataccag cacctgaagg ggaagaacgt gatccacca ttcctgtctc 1200
ggagccttcc cattgtcttc gatgaatttg tggacatgga ctttggcaca ggtgctgtga 1260
agatcacccc cgcacatgac caaaatgact atgaagttag gcagcggcac gggctggagg 1320
ccatcagcat catggactcc cggggggccc tcatcaatgt gcctccgctt ttyctgggccc 1380
tgcccagggt tgaggccagg aaagcgggtg tgggtggcgt gaaggagcgg ggactgttcc 1440
gtggcattga ggacaacccc atggtgggtg cactttgcaa ccggtcgaag gacgtggtag 1500
agcctctgct gcggycgcat gggtagcttc gctgcgggga gatggcccag gctgccagcg 1560
ccgctgtgna ctcgggggtga cctccgcata ctgcctgagg cccatcagcg cacatggyat 1620
gcctggatgg acaacatccg ggagtgggtg atttccaggc agctktggtg gggccatsgc 1680
atcccagcct actttgtmac tgtmagtacc cagcgggtgc ccctggggag gaccctgaat 1740
gggcggtact ggggtgagtgg acgcaatgag gcggaggccc gggagaaggc agccaaggag 1800
ttcggagtgt cccctggaca agatcagctt ccagcaagat gaggatgtat tggatacctg 1860
gttctcctct ggctctctcc cttatccat tttgggctgg ccaaccagtc agaagacctg 1920
agtgtgttct accccgggac actgctggag accggtcatg acatcctctt cttctgggtg 1980
gcccggatgg tcatgctggg cctgaagctc acgggcaggc tgccytttag agaggtctac 2040
ctccatgcca tcgtgcgaga tgctcacggc cgggaagatga gcaagtctct aggcaatgtc 2100
atcgatcccc tggacgtcat ctatggaatc tccttcgagg gcctccacaa ccagctgctg 2160
aacagcaacc tggatcccag cgaggtggag aaggccaaag aagggcagaa agctgacttc 2220
ccagcgggga ttcctgaatg tggcaccgat gctctccggt ttggattatg tgcctacatg 2280
tcccagggtc gtgacatcaa cctggatgtg aaccggatac tgggttaccg ccacttctgc 2340
aacaagctct ggaatgccac caagtttgcc ctctgtggcc ttgggaaggg ttttgtgccc 2400
tcacccacct cccagcccgg aggccatgag agcctgggtg accgctggat ccgcagccgc 2460
ctgacagagg ctgtgaggct cagcaatcaa ggcttccagg cctacgactt cccggccgctc 2520
accactgccc agtacagctt ctggtcttat gagctctgtg atgtctactt ggagtgcctg 2580
aaacctgtac tgaatggggg ggaccagggt gcagctgagt gtgcccgcga gaccctgtac 2640
acttgcttgg acgttggcct gcggtgtctc tcacccttca tgcccttcgt gacggaggag 2700
ctgttccaga ggctgccccg gaggatgccg caagctcccc ctacgctctg tgttaccctc 2760
taccgggagc cctcagagtg ctctggaaag gaccccgagg cagaagccgc ccttgagctg 2820
gcgctaagca tcacgcgagc cgtgcgctcc ctgcgggccc actacaacct cacccgatc 2880
cggcctgact gtttcctgga agtggcggat gaggccacgg gcgcccctggc atcggcgggtg 2940
tcgggctacg tgcaggccct ggccagcgca ggtgtgggtg ctgttctggc cctgggggct 3000
cccgcctccc agggttgcgc tgtggctctg gcttctgac gctgctccat ccacctgcag 3060
cttcaggggc tgggtgaccc tgcacgggag ctgggcaagc tgcaagccaa gcgagttgag 3120
gcccagcggc agggccagcg tctgcgggaa cgccgtgctg cctcgggcta tcctgtcaag 3180
gtgccgctcg aagtccagga ggcagatgaa gccaagctcc aacagacaga agcagagctc 3240
aggaaggtgg atgaggccat cgccctattc cagaagatgc tgtgatccac caccagctt 3300
caccctcac cccagcggc tcaccatggg gatggcagca ataaaatatt tccccacaaa 3360
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaa 3405

```

<210> 142

<211> 2268

<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (2169)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (2196)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (2232)
<223> n equals a,t,g, or c

<400> 142
gcctgcctcg agaggtgtgg ctccctggaga cccacaggc cgatgacttc tgggtgcgagg 60
gagaacctta tccagggtccc aagggtcttcc cttgaagcca ctggcgccca ggagcgggtgg 120
gccgaagacg tgcctaccc taccacaagg gctgtgtctc taccctctag cctgggcgtt 180
ggatctactg gaatgagcag cagccgcttc ctggcagcc ttgggaagca cgggcgactg 240
gacagcagcc gccgggcacg gttatggggg cgggggtggc ggggaggcta gattgtttcc 300
tgggtactgtc actgccactg gggctttgat ttggaggaat ggggcagggg actatctgaa 360
gcgcttccat cctaaagcca taatgaaaat atcttcctct cttccccatt ctatacaaaa 420
tactaagtgg tttcttgct cccactccct accccttagt taaatagggt ttattttcca 480
ctcatgccct tatgcctttt tttcttatag ttttttaact tattgactgt gcatgaccca 540
gtggtttgaa ttgtttttag ttcaagtcac ttgtaaaaac taggtttaag gagatgagct 600
actgtttaaa gtgagctggc ctgcctaatt aattccttgt gaaaactaaa tgattttttc 660
agtttgggga tcattctcac aacataacta tgcattgtaga ggacaagatt tattttcttt 720
cctccctttg cccagtagcc acatctggtt tactcaggca gcatctacta agaaattcag 780
cacctgcata tctctgtgac atggtcactt agagcttacc ttccctatga atctccagat 840
ctgtgagtcg agcagatttc atggtgcaga ttcacctta atgcaaagac tgtattatcc 900
tcacatgact tttttcttg tttactgta ccttaaaaag tgatagagta attctgtatt 960
ttctaaccgg aagattcaaa ggagctgaat gtgttatgct tccaaacaac tgaatgtaaa 1020
acactcctag ccagttgttg cattccctat atttatttac ttccaatatt ttactgtaaa 1080
agtagggaga aatattatgt tgatagttgt ttcatttct ctcaggaaact ttaatgttcc 1140
cgactcgggt gattccagct gtgttgctgg cagtgtgtgc tcaaccctct ccctaaaatg 1200
actgagccct ggggtcatct aatgtggttt tccttaggaa gagatagaag gcacagaaga 1260
tcacagctag agaattgaga attaactata ctactagcca ttttagggca ccaaaacttg 1320
ggattaaaca cttcctactt cccactccca actcctgaaa tgaagtcttg ctatctgtga 1380
ctagttttat tttgtgctt ttaatagtcc gagcagctct acctgttta cacatgtatt 1440
gacaccattt gcttcaggcc atggagcact gtttctccct ttttactatt tataggattc 1500
cgttttttca caagactttt aataaaaaga aattgtagaa ataaacacat taaaatttgc 1560
ccagctgtcg tctaagccct cttgattgac ttgcccaagt ggcaatagag ttctaataatc 1620
tataataaag ggagatttgc tattattagt ggaatgttga ccccgtagt agagaaacag 1680
tacgtgcctt tscctcttta tgcacacaga gaccagggg gagggagtat ttgttcccag 1740
tttttaagat agtataaaaa agcaataact tggtagtgta tttaaaaata aaacaaaaac 1800
aaaacacaaa aagatatatt acaggacatg ccactttatt ataaaacctg acacaggcat 1860
agtaccaagt atttcctgca ttgttgctaa aattgtttta ttgtagctcc acattctggt 1920

```

gtagttttaa atgcctttgg gggcagtttg aagcagttct tcatgccact tagtttgaaa 1980
ataaaattct agrtatgcaa atgattttct tagaaaactt cacaaaaataa aagatcttgt 2040
tttttttcca tagcacagta atgaatgtgg ttatcaatca catacttttt tggattatat 2100
tgtagcaaaa agttgattag cttaccaaga ttattaatag caatgtatgt gttataatac 2160
aacttagtna cattaaagcc tacgaaaact catccnggct gtaggatagt aataaaggaa 2220
gaattatgac tncattatga aaaaaagaag ttttaaagtt ttcaatac 2268

```

<210> 143

<211> 1757

<212> DNA

<213> Homo sapiens

<400> 143

```

aattcggcac gagagcagca tcttatcagt tttgtttatt cgatttctaa aatgtgctga 60
tcctttttaa actcctgctt atctctgcaa caaagaaaaa tattcaaaaa tactgccttc 120
attttcacac acagtgtgta agatgtctga agaccaaata atagctcata aaatcagggtc 180
ctgagatagt taccataaaa gaggaatcct ttgagtgtat gccattgggtg agccgatgag 240
catggaccat agaagggtc atgtagaag gtaaaattgg caaatcataa ttgagaaata 300
tgaaatgtat tcccatatcat aatatgggtat aggggtgtaat gtacctgctt ttgatcactt 360
ttcatttttaa agtgctatctt acttgatctt aaatgttcca tgaactgtta aatttcttaa 420
gttacatagt tactacacca catttatgtg tatgttatgt tttaatagtc aatgatagggt 480
atgtacaatt gataatataa aggggtcat tgaaacttga gagcctgttg agttttgggtt 540
agttgtagat tgcattttta taaaaaaaaa tacagataga ttgatgataa tagatattgg 600
ggcattgttt ctgtctcatg agaattcttt tattcattac cataagcctt cactgatact 660
ataagcatta ttttaaatga cgctgatctt aagtctgaaa taaatggaaa gcagaaaagg 720
tgagccagtt gatttgaatg cattggatat tagtgttaga aacaatgtat agtttagatt 780
gaaactgaac tgacttattt agcacttaaa caaaaatttg acaatgtttt tagttttttt 840
taagacagct tagtgtgtg atacttagaa ttctatgggt tgatgtttct tttagaaatg 900
agaagtatag ttttattttt taatataaaa aatgggttta atactaaac tagtaatttg 960
atactagtgt tttataaaca ttgtaaaata tatcttttaa acaaattatc ttggtagtta 1020
attcataagg gtgggttttg gtaggaatag cagagtactt tcagagggaa aggggagtca 1080
ttcagaagtg atagcatttt atttgtttga atactctgcc agtaaaatca gctgtactta 1140
gaaagtatc tgttgtgtag aataatgat tagagtttac taatcagtga ggatgtcttg 1200
tttttatttt ctgcaaactc tgccctactt taaaatgcat tataacaata cctaattaaa 1260
gataattttg gctctgaaag ttaccttatt ttttgttgag ttagtgaactt catttttctt 1320
gccacaatat aagcttttga gggatttttt taaattgggtg cttttaataa gcaaaaaaat 1380
cccagggttt tattttcttc agtgatacc ctatagaaac tcttaaatgt atttgcgcac 1440
atatatatat atattttctt atgcatgctc gatgcatttt cgtcctgaga aaaatgttct 1500
ctacagaaac taccctgtgt taaaaagaag attggcttaa aatggctact gtgatgggaa 1560
cagtgtctta ggagatgca gcttggaact gaggtaaatt gaatacttta caactgtgggt 1620
ttagagtttg ctttaatgac attgtatgta aaaggtcaca tgattgctgt aattttgtat 1680
tcattatggt ttcctcaata aatgtacatt gatgactatt aaaaaaaaaa aaaaaaaaaa 1740
aaaaaaaaaa aaaaatt 1757

```

<210> 144

<211> 1062

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (52)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1056)

<223> n equals a,t,g, or c

<400> 144

```

accacgcgt ccgcccacgc gtccgcctgg actgtgaccc agccagcacc gnetctccta 60
gtggcaactg gctgggaatg gctgaggggc tacctactgc ttgcggcctg ccagcgggag 120
gaggggggag gaaagaagaa agggggcggg gttgaggggg gcgggcctgg acctggggag 180
tgaaagcgaa agcccgggag actagccggg agaccagaga tctagcgact gaagcagcat 240
ggccaagccg tgtggggtgc gcctgagcgg ggaagcccg aaacagggtg aggtcttcag 300
rcagaatctt ttccaggagg ctgaggaatt cctctacaga ttcttgccac agaaaatcat 360
atacctgaat cagctcttgc aagaggactc cctcaatgtg gctgacttga cttccctccg 420
ggcccactg gacatcccca tcccagacc tccaccaag gatgatgaga tggaaacaga 480
taagcaggag aagaaagaag tccctaagtg tggatttctc cctgggaatg agaaagtcct 540
gtccctgctt gccttgggta agccagaagt ctggactctc aaagagaaat gcattctggt 600
gattacatgg atccaacacc tgatcccaa gattgaagat ggaaatgatt ttggggtagc 660
aatccaggag aaggtgctgg agagggtgaa tgccgtcaag accaaagtgg aagctttcca 720
gacaaccatt tccaagtact tctcagaacg tggggatgct gtggccaagg cctccaagga 780
gactcatgta atggattacc gggccttggg gcatgagcga gatgaggcag cctatgggga 840
gctcagggcc atggtgctgg acctgagggc cttctatgct gagctttatc atatcatcag 900
cagcaacctg gagaaaattg tcaaccctaa ggggtgaaga aagccatcta tgtactgaac 960
ccgggactag aaggaaaata aatgatctat atgttgtgtg gaaaaaaaaa aaaaaaaaaa 1020
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaanaaaa aa 1062

```

<210> 145

<211> 1030

<212> DNA

<213> Homo sapiens

<400> 145

```

aaactgactg ggggtcaattc aagtcattgca ggctgtgaga aacgcggggg cgcgggttcc 60
gcggtcctgg acttggcccc agacagccgg cagggtcgtg gccagaacgc cggccgggac 120
catctgcaca ggcgctcgac agctccaaga cgctgcggcc aagcagaaag ttgaacagaa 180
cgcggctccc agccacacca agttcagcat ttaccctccc attccaggag aggagagctc 240
tctgaggtgg gcaggaaaga aatttgagga gatcccaatt gcacacatta aagcatccca 300
caacaacaca cagatccagg tagtctctgc tagtaatgag ccccttgccct ttgcttcctg 360
tggcacagag ggatttcgga atgccaagaa gggcacaggc atcgcagcac agacagcagg 420
catagccgca gcggcgagag ytaaacaaaa gggcgtgac ccatccgag ttgtggtgaa 480
aggcctgggg ccaggacgct tgtctgccat gcacggactg atcatgggag gcctggaaat 540
gatctcaatc acagacaaca cccaatccc acacaacggc tgccgcccc ggaaggctcg 600
gaagctgtga tgggaaggag gcctgcactt ggacctgacc tcaagcctca gctccagtgg 660
gaccttgtaa aatgctccct gtcagagctc tccagaatat gcttggttga gatccctcag 720
gcagtaaggg agagttttgc ctctttacac agtggccttt gcttgacact ccagctggag 780
atgggtgtgc cccagaagta agctttgcat ctcttacaag aggggagcta caggggcagc 840
cgtgcctagg cccaaactct gctctgagaa aataaatatc tgtaccacct gtcataat 900
tgagattttt tgctttcaga gttacgtaat tcctaattcc tcttgaaaaa gagagtgtga 960
aatgaggtga ggcctcagat gaaagtaaaa tataaatgtg agttgctatt taccagaaaa 1020

```

aaaaaaaaaa

1030

<210> 146

<211> 814

<212> DNA

<213> Homo sapiens

<400> 146

```

ggcacaggcc aggtcgtgcc agcatccgcc ggacgccgga agtggttctc cggccctgcc 60
actgggccat ggagactgtg gcacagtaga ctgtagtgtg aggctcgcgg gggcagtggc 120
catggaggcc gtgtgaacg agctggtgtc tgtggaggac ctgctgaagt ttgaaaagaa 180
atttcagtct gagaaggcag caggctcggg gtccaagagc acgcagtttg agtacgcctg 240
gtgcctgggtg cggacaagta caatgatgac atccgtaaaag gcatcgtgct gctcgaggag 300
ctgtgcccc aagggaagca ggaggaacag cgggattacg tcttctacct gggcgtgggg 360
aactaccggc tcaaggaata cgagaaggcc ttaaagtacg tccgcgggtt gctgcagaca 420
gagccccaga acaaccaggc caaggaactg gagcggtcca ttgacaaggc catgaagaaa 480
gatggactcg tgggcatggc catcgtggga ggcatggccc tgggtgtggc gggactggcc 540
ggactcatcg gacttgtgtg gtccaagtcc aaatcctgaa ggagacgcgg gagcccacgg 600
agaacgctcc aggagggcct gtccatcctc gctgtccttt ccctgttctc cccctgcccc 660
ccgtctctat cctctgtggc cttcagctaa tttctgtctc cctgagattc gtccttcagc 720
ccatcatgtg gctttgggat gagtgtaaat aaaacggggc tgtggcttgg gaaaaaaaaa 780
aaaaaaaaaa aaaaaaaaaa aaaaaagggg gggg                                     814

```

<210> 147

<211> 2678

<212> DNA

<213> Homo sapiens

<400> 147

```

cccacgcgtc cggatgaaca cgatgagaat aatgctgaag ctagtgtgta attatcaaat 60
gaaggggtaa tgaaccatag aagcgaggaa gaacgtgtaa ccgaaacaca gaaaaatgag 120
cgtgttaaga agcaacttca ggcattaaat tcagaattag cccaagccag agatgaaacc 180
aagaaaacac aaaaatgatgt tcttcatgct gagaatgtta aagcaggccg tgataagtac 240
aagactctgc gacagattcg acaaggcaat acaaagcagc gtatcgatga gtttgaagca 300
atgtgagagc tgttatTTTT catatatgtt cttcataagc tgaaccacca acagagaaaa 360
gcaggccttt gcagatatga tggaaatgcat cccaccttgc caaagcactt acaccagttt 420
gactgtgcta gctaaaagac aaatttaagg ggagctcttc aacattaagg cagtatgata 480
tcatgcttgg ttttcttttt tcttttggtc cagggaatgg agaatggtgt tccattgcct 540
cttttcacat ttttttctt tttctttttt ttttctgttg aagattaaca ctaattatca 600
cgtctgacaa atgtgtatgt gtggtttcag ttctgtgtac attttaagg ataatggtga 660
acattttaat gggtttccct tgccctttcc atatttaacc tatttcacca ttctctctca 720
ctcacatttt ctCagtgtgc ccttctctta tctgccatgt ccatagccat aattccacca 780
tcatacagat caggcagtgt ttaaaatgat ggtaggtagc acagtggaca gtctttgatc 840
atcatgtaga atatggctat gaatcaggaa agagattaga acatttaata atgtatgtac 900
agctgggtgct tagttttttt ttaattctaaa ttaattacc ttattggata tttgatattt 960
ggttatTTAA tcacagtcac ctttaacagc ttacactgat tgggtgtttta tctcctgtga 1020
tcctttgatg gctttttttt cctaccattt cacagaggtt tagacagcag tagtagctcc 1080
ctaggagagt ttactgatga aacagcctct gcaagatTTT aaaagtTTTg ttcttttata 1140
gactgattta gaaaaacaaa tgattagtta aaaaaagaaa atatacattt gttggtaact 1200
aatgttattt tttaaaacct ggaccttcc tggragggca gcatataara acatcagtgc 1260
ccgaggaggg gacaacaata ctacctact actacatctg tgatgactgg ttgttcaaac 1320

```

```

acaatggagt gtgtaaggta tatgttttat aattcataac catagcctcg atcatcaaga 1380
aatacttttcg aaatttcatt ttccttcaga atatcttaag agtgctaaat ttttaactgc 1440
ctttttgtcg agtcaaactg tgggattctg atttgattta aaattgtaag ctctctactg 1500
gtatactatc atcctggagg ggtgttgat ggctgagcaa gagagagaga gaatgagaga 1560
gagactgtgt gtgtgtgtgt gtgtgtgtgt actctgtgtg tgtatgagag agagaaatgc 1620
taaccttgta gcatgtgaag aatgtctgta ccttgatacg atagttacat aatcagtata 1680
tttggtttct agatcactgt gcttattttg tttcaatctc tgactaaaaa tacttaaat 1740
tggtttgta attcttattt tagaaattat aattttagtt tatattaatt tcggttatag 1800
cttactgaag aaatctttcc agttagaagg aggttctaatt attcacatgt tctaatactt 1860
tgttttattgt aaaacagcta aatttggaag tacgtaaagc cttgttttct ctgtgtgggt 1920
cagctacttt ccatttggtg ttacacagtc aaatttacat ttatctatta aaattgccat 1980
tttattaaac attttcatgc acagtagatt caagttgtgt ctgaaaatat ctcttggtgt 2040
tttttgattt tgctgacttt aaaaggatta atctgggcag acattatgta aaagaaagg 2100
tgcgtttaat atattttttg aactttgtag gacaaaacat agctgggtta ccttgaaagt 2160
actggtgtac catggtgtgt cacatgcttc agaatcctat ggaagagaat attcctactt 2220
gcagtacatc aaaggaatgg atggtggacc ctactattca tgttttgaga cataaatgtt 2280
cactttaaag caattgcata atagataaaa acctgaactt tcattggatt tttgttaatt 2340
ttcctcattt tgaattatgt gcaactacct agctacatca gtttgatata gtattgaaaa 2400
attatcagtt atattttgcy gtttatgrtc tatttgtagr ttaggrttaa aatggrttta 2460
atccattttt aaggstgtgt gaatttttct aaacaagaac catttgcaat atggatttct 2520
tagagattaa accaattata acttattagc agtsgcgagc acatgttcat atagtcaatg 2580
taaaaatata ctaatgagta tttggtaaat ccagtaggc ttttaccatt agcataaatt 2640
tgtgtgttac ctcgcccgcg accacgctaa gccgaatt 2678

```

<210> 148

<211> 1028

<212> DNA

<213> Homo sapiens

<400> 148

```

ctgcctcagc ctcccagagta gctgggatta caggcacaca ccaccacgcc cggctaattt 60
tttgtgtctt tttagtagag acgggggtttc gctatgttgg ccagactggg cttgaactgc 120
tgacctcgtg atccgccgcg ctcggcctct caaagtgtgt ggattctgtg tgttttgtgc 180
acctccactt taggtaatca tagggagcac atttacagga tggctctaata acatgaaaac 240
aggctagttt caagcaacag caatgtcggg tggaagcag gcgtcatttg ccttgaaaaa 300
agccttttga caacatacag gcattctttt aaaaccaggc tgaaacattt tattcccgag 360
acttaacggt gtgtttcctg tttcttaaac ctagcacctc tgtgtatttg aaaataatga 420
gacatctttc attggatttt ggaaaattgt tccccatggg attctaacct cactaccaaa 480
tgagtgaag cttgattaag agttcttcca tatactagcc tccttggag aagtgatcag 540
aagggtgata gaaggacaga aaggactatt ttaaagttgg actgaaggag aaaaaagcaa 600
aattcttggt tcatcccaat tctagttaga acaaagttaa acccccgtaa tcttaagag 660
aaaatctttg gaggttttaa ttaaactttt tatacattta agtcttggt aatggtgctt 720
taagtgtcaa tgtagcatgt aaaaggcttt gtacagacag gtaaaagttc catttctgag 780
tgatgaaatg taacacttct tcatctttaa cttgaaatca aaactatcag attttatttt 840
tgtataattt aaggaaggta aagttagggg actagaagac tctaaattgg ctctacaga 900
tcaataattt aaatgtaact agttgggatt ttatagttaa aattatattt gtgtatataa 960
cataactaat ctgtaaatg taataaatat atttgcaatt attaaatgtt aagtgatatt 1020
ttggttca 1028

```

<210> 149

<211> 1425

<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (647)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1359)
<223> n equals a,t,g, or c

<400> 149
gcgtctccgg aagtggaggc gggagcggca cggcagccac tgcttggggg agcgggaggg 60
cagactctgg gcgccactcc cgggccgggc atgaacgggc cggcggacgg cgaagtggac 120
tacaaaaaaa aataccggaa tctgaagcgg aagctcaagt tcctcatcta cgagcacgag 180
tgcttccagg aggagctgag gaaagcgcaa aggaaattac tgaagggtgc ccgggacaag 240
agtttcctcc tagaccgact tctgcagtac gagaacgtgg atgaagactc ttcggactca 300
gatgccactg catcatcaga taacagcgag acggaggggg caccacaagt gtctgacaca 360
ccggccccct agaggaagag aagccctccg ctggggggcg cccctctcc ctccagcctc 420
tccctgcctc cttcaacagg gtttccctt caggcctccg ggggtccctc cccatacctg 480
agctcgctgg cctcctcccg ctacccccca ttcccttctg actacctggc cctgcagctg 540
cccgasccca gtcccctrag gcccagcgg gagaaacggc cccgmctgcc ccggaaactc 600
aagatggcgg tgggaccccc cgaytgccct gtgggagggc cgctganctt ccctggccgg 660
ggttytgggg stggggtcgg gamaaccctg amccccctt caccacctaa gatgcccccc 720
cccacgatcc tgagcacggc ccctcggcag atgttcagcg atgcaggtag cggggacgat 780
gccttgatg gagacgatga cctggtgatc gacatcccg agtgaccgtg acatcacgcc 840
atgccacca cggccccgcc cggcgccctc cccgtgccag cacacacgag tccagcttcc 900
tcggaggtgt ttattgatgc ccagctgcca tgctccggcc actgacacaa ccagaaaagg 960
cgtaaacaatg cacgggtgtc ccccaggagg gtgcaggggc cctgccttca aaccccgggc 1020
ccctccaggg gacagttatt taaacgagtg gccgggagca tctgccacct gctggggagg 1080
cagagaccct gcaatggcca cctctttaa agggcagctg tacagggcta ggttttttca 1140
atgaagtttc tgtattaaag gagtggctct gggtttgtt tttgtcctt ttttttgaga 1200
cattctctc ctctgaacct cccctaatac gacctcctc ctgttggggg agagggacgg 1260
ggcagcgtg agaggcagga gtgaggagcg cgggggcctg gggccgggct ctgagcactg 1320
cccgggtgtg cagatgatgg ggggtttgca tatttgcan ggactagcga gtcaggcagg 1380
aggtttgc atgtgaatat agaactccgc agccctcat gagca 1425

<210> 150
<211> 780
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (285)
<223> n equals a,t,g, or c

<400> 150
gctgcgagaa gacgacagaa ggggagagcc aatggaaagg ggctgccgcg cggccgtaaa 60

gagttttag agcagttcgg gtgcggtacg ttgcattccg gtaccggacg ccgagagcgg 120
tttgtctccg tctctggagt tgtaggcgag aggtgatcat gtccggtcgc gggaaacagg 180
gcggcaaaagt gcgagcaaag gccaaatccc gtcctctccc cgccgggcctg cagttcccgg 240
tgggccgagt gcacagactg ctgcgcaaag ggaactacgc ggasnagtgg gcgccggggc 300
gccggtgtac ctggcgcgcg tggtggagta ccttacggcg gagatcctgg agctggctgg 360
caacgcccgcg cgtgacaaca agaagaccag gataattccc cgccacctgc agctcgccat 420
ccgcaacgac gaggagttaa acaagctgct gggcaaaagt accatcgctc agggcgcggt 480
cctgccccaac atccaggccg tgctgctgcc caagaagacg gagagtcaga agacgaagag 540
caaatgaccc tgacgccgcc ctgagggagc tggtctccsc agcaaaggcc cttttcatgg 600
tcgtcccgcg atgtctttga atgtgctgga tgcatggag ggccggtgac atctagcggg 660
gaggtggcg gcgaggggtcc cgccgggagc caataaagt ggtgaaaatc gtaaaaaaaa 720
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 780

<210> 151

<211> 1066

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1061)

<223> n equals a,t,g, or c

<400> 151

ggacccgcca tggcgcgga gaaggtgctg ccgcggtga tcgaggagct ggcccgcgcg 60
gtgcgcgccc tgccggagca actgaacagg ccgcgcgact ccagctcta cgcggtggac 120
tacgagacct tgacgcggcc gttctctgga ccgcggtgc cggtccgggc ctgggcccgc 180
gtgcgcgcg agagccgcct cttgcagctg ctccggccgc tcccgtctt cgccctgggc 240
cgccctggtca cgcgcaagtc ctggctgtgg cagcacgacg agccgtgcta ctggcgccctc 300
acgcgggtgc ggcccgacta cacggcgagc aacttgacc acgggaaggc ctggggcatc 360
ctgaccttca aagacgcctc tttttcttca tcagggaaga ctgagagcga aggcgcggga 420
gatcgaacac gtcatgtacc atgactggcg gctggtgccc aagcacgagg aggaggcctt 480
caccgcgttc acgcgggcgc cggaagacag cctggcctcc gtgccgtacc cgctctcct 540
ccgggcccag attatcgag aacgacagaa aaatggagac acaagcaccg aggagcccat 600
gctgaatgtg cagaggatac gcatggaacc ctgggattac cctgcaaac aggaagacaa 660
aggaagggcc aagggcaccc ccgtctagaa tgccagaacc agcgggtggc cttaggggct 720
gtgaggcagt ggggacctta ttgatgaaag aaaccgtctt tgcgttacac ccgagtcctg 780
ctctcggagc agggagctca ccttcgcgga cgtgttctga gggctctgcat cttagggggg 840
agggctgggg caaatcgcca cctgtgcctt tcctctggcc ctgctgcccc cacaccaaac 900
tccgagggcc cacgctgggg aaagcgggaa gcgctcgctc cctttccccc attagtgtc 960
tctctgcctg gatcccgcca gaagctatga aagggaataa agagaaaaga artamaaaaa 1020
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa nccct 1066

<210> 152

<211> 1649

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1543)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1579)

<223> n equals a,t,g, or c

<400> 152

```
accccggtctc tccaaggagg tgtgacatca tcatcatctc tggccggaag gaaaagtgtg 60
aggctgccaa ggaagctctg gaggcattgg ttcctgtcac cattgaagta gaggtgccct 120
ttgaccttca ccgttacgtt attgggcaga aaggaagtgg gatccgcaag atgatggatg 180
agtttgaggt gaacatacat gtcccggcac ctgagctgca gtctgacatc atcgccatca 240
cgggcctcgc tgcaaatattg gaccggggcca aggctggact gctggagcgt gtgaaggagc 300
tacaggccga gcaggaggac cgggctttta ggagttttta gctgagtgtc actgtagacc 360
ccaaatacca tcccaagatt atcgggagaa agggggcagt aattacccaa atccggttgg 420
agcatgacgt gaacatccag ttctctgata aggacgatgg gaaccagccc caggacccaa 480
ttaccatcac aggttacgaa aagaacacag aagctgccag ggatgctata ctgagaattg 540
tgggtgaact tgagcagatg gtttctgagg acgtcccgtc ggaccaccgc gttcacgccc 600
gcatcattgg tgccgcggc aaagccattc gcaaaatcat ggacgaattc aaggtggaca 660
ttcgcttccc acagagcgga gccccagacc ccaactgcgt cactgtgacg gggctccag 720
agaatgtgga ggaagccatc gaccacatcc tcaatctgga ggaggaaatc ctagctgacg 780
tggtggacag tgaggcgctg caggtataca tgaaaccccc agcacacgaa gaggccaagg 840
caccttccag aggttttgg gtgcgggacg caccctggac cgccagcagc agtgagaagg 900
ctctgacat gagcagctct gaggaatttc ccagctttgg ggctcagggt gctcccaaga 960
ccctcccttg ggccccaaa cgataatgat caaaaagaac agaaccctct ccagcctgct 1020
gacccaaacc caaccacaca atggtttgtc tcaatctgae ccagcggtc gaccctccgt 1080
aaattgttga cgctcttccc ccttcccag gtccgcagg agcctagcgc ctggctgtgt 1140
gtgcggcgc tcctccaggc ctggccgtgc ccgtcagga cctgctccac tgtttaacac 1200
taaaccaagg tcatgagcat tcgtgctaag ataacagact ccagctcctg gtccaccg 1260
catgtcagtc agcactctgg ccttcatcac gagagctccg cagccgtggc taggattcca 1320
cttctgtgt catgacctca ggaaataaac gtccttgact ttataaaagc caaacgtttg 1380
ccctcttctt tccccacct cctcctgcca gtttcccttg gtccagacag tcctgtttgt 1440
ggagtgaat cagcctctc cagctgccag agcgctcag cacaggtgtc agggtgcaag 1500
gaagacctg caatggacag caggaggcag gttcctggag ctnggggggt acctgagagg 1560
cagagggtga cgggttctna ggcagtcctg attttacctg ccgtgggggc tgaaarcacc 1620
aagggtccct gaccctacct ccactgccca 1649
```

<210> 153

<211> 660

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (35)

<223> n equals a,t,g, or c

<400> 153

```
ccggaaattc ccgggtcgac ccacgcgkcc gcggnagwgc tcacacgtgt gctccctgcc 60
ctgctcctgg ccccttgccc ggccgggctg tttctggcca tgggtcgctc ccgccggaca 120
ggcgcgcacc gagcgactc tctagcccgg cagatgaagg cgaacggcgg cggccggact 180
```

tggatgagat tcaccgcgag ctgcggcctc agggatccgc acgaccccag cccgacccaa 240
acgccgagtt cgaccccagac ctgccagggg gcggtctgca ccgctgtctg gcctgcgcga 300
ggtacttcat cgattccacc aacctgaaga cccacttccg atccaaagac cacaagaaaa 360
ggctgaagca gctgagcgtc gagccctaca gtcaggaaga ggcggagagg gcagcgggta 420
tgggatccta tgtgcccccc aggcggctgg cagtgcccac ggaagtgtcc actgagggtcc 480
ctgagatgga tacctctacc tgacatggcc tgaagatgca gggcagagga attgcccattg 540
gacagtgacg caaggactag gctgggaggg agcgtgccaa ccccttttgc ctctggggtt 600
ggggagcggg gggcctcttc ttggtgccct gcccacaata aagggaactgg acaaagagaa 660

<210> 154

<211> 605

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (449)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (574)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (578)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (583)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (587)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (596)

<223> n equals a,t,g, or c

<400> 154

ggcagagctc caccttccat ccggcgccgg ctttcggcgc gacggtcgcc gcgttccatc 60
gtcgcgcggc ccttcggggc cccgagcccg caatgtcggg ccccaacgga gacctgggga 120
tgccggtgga ggcgggagcg gaaggcgagg aggacggctt cggggaagca gaatacgctg 180
ccatcaactc catgctggac cagatcaact cctgtctgga ccacctggag gagaagaatg 240
accacctcca cgccgcctc caggagctgc tggagtccaa ccggcagaca cgcctggagt 300
tccagcagca gctcggggag gccccagtg atgccagccc ctaggctcca agagccccc 360

117

```

accgggaccc aaccctgcct ccctgggcta ggctctggcc tgggcactca mcccctggct 420
tagacamctt ctcaagggct ggcttcang gaccctgggt gggctctgcct gcctgggcca 480
accttcctgc ctgggsctyc ccttggctam ctgggscagc cccaccaac tggcatgccc 540
tcctgggggc caaagaatgg ggctgcaac ccancantt gcntgcncaa cccaanttcc 600
tgggg                                           605

```

<210> 155

<211> 695

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (173)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (499)

<223> n equals a,t,g, or c

<400> 155

```

gaaccctaga aaaaaggatg cagtactaaa gtgtcattca ttcaaagcca ctcctotttt 60
ggtattccac ccattttcca gacggtgaca ctgaggetca ggaagcagta gggacttgca 120
caaagccctt tgggaagcag gctgggaaac agtggaggga ggggtgtccat tanccccaag 180
gagacacagg atctgggctc tktytttsgc cttcctccca gaatacgtg ccatcaactc 240
catgctggac cagatcaact cctgtytgga ccacctggag gagaagaatg accacctcca 300
cgcccgctc caggagctgc tggagtccaa ccggcagaca cgcctggagt tccagcagca 360
gctcggggag gccccagtg atgccagccc ctaggctcca agagccccc accgggaccc 420
aaccctgcct ccctgggcta ggctctggcc tgggcactca ccccctggct tagacacctt 480
ctcaagggct ggcttcang gaccctgggt gggctctgcct gcytgggcca cccttcctgc 540
ctgggrcctc cccttgkcc tactggggcc agcccccacc acctggcatg ccctcctggg 600
gccaaagatg ggctgcaam ccaccattg sctgcccac caattcctgg gcgytcccca 660
wtytgcccag gcttgaatgt tcacatgaaa tgggt                                           695

```

<210> 156

<211> 780

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (289)

<223> n equals a,t,g, or c

<400> 156

```

cgggtgggctc gcgttgaggc tgcggctcatg gagggagcag gagctggatc cggcttccgg 60
aaggagctgg tgagcaggct gctgcacctg cacttcaagg atgacaagac caaagtgagc 120
ggggacgcgc tgcagctcat ggtggagtgt ctgaaggctt tcgttggtga agcagcagtc 180
cgcggcgctg gccaggccca ggcagaagac gcgctccgtg tggacgtgga ccagctggag 240
aaggtgcttc gcagctgctc tggacttcta gggatctcag ccgtggckna ggccaccccc 300

```

118

```

agaggagccc ctggtccaca gaagcaggcc ttgtgtttcc agcggcctct gataagaggc 360
aggggaaggam ctgaaggatt tggarttgat tcaaacaaga tctctgggag tctccagcct 420
gtgcagaagg ggcaggactg cagtgcactg cgggccttgg agtgtccagt ggggacactg 480
gtgtgggaag gggcagcacc tggggagtcc ctgcctctcc tccctgggac aatagtgtgc 540
atgccacccg gggtcctaca ggcagggtgct gggaaaggcc tggccagcag gtagcctgtg 600
tgtttgacaa acagcagctg gcagcgctgc ctctgcccc cattcctgcc acccgacatc 660
aaagctggcg tgtgaccttt ccagccatgc gatattcccc ttggaagatg cttccccagg 720
ctataaattt gttctcacia agcaacatca ataatcaaa actgtctcty ccaaaaaaaaa 780

```

<210> 157

<211> 1127

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1113)

<223> n equals a,t,g, or c

<400> 157

```

aacttcagtg ccctcactgt agaatttaaa agccttactg ttgattgccc atggtggact 60
tgatggagaa attaaatata ttccattatg ctttataaaa tactgtatat gtttcagcaa 120
gttttgggaa tgggagagga caaaaaaag ttacatttaa tctatgcatt ttgccaagc 180
catattgagt tattttacta ctagagacat taggaaacta actgtacaaa agaaccaagt 240
ttaaaagcat tttgtggggt acatcatttc tataattgta taatgtattt ctttgtgggt 300
ttaaatgata aagacattaa gttaacaaac atataagaaa tgtatgcact gtttgaaatg 360
taaattattc ttagaacact ttcaatgggg gttgcattgt ccttttagtg ccttaatttg 420
agataattat tttactgcca tgagtaagta tagaaatttc aaaaaatgta tttcaaaaa 480
attatgtgtg tcagtgaagt ttccattgat aattggttta atttaaaata tttagagggt 540
tgttggactt tcataaattg agtacaatct ttgcatcaaa ctacctgcta caataatgac 600
tttataaaac tgcaaaaaat gtagaagggt gcaccaacat aaaaaggaaa tatggcaata 660
catccatgat gttttccagt taacatagga attaccagat aaactactgt aaactcctgt 720
ccagtaacaa gagttgattc atatggacag tatgatttat tgtttatttt tttaaccaa 780
tacctcctca gtaatttata atggctttgc agtaatgtgt atcagataag aagcactgga 840
aaaccgatcg tctctaggat gatatgcatg tttcaagtgg tattgaaagc cgcactgatg 900
gatatgtaat aataaacata tctgttatta atataactaa gactctgtgc tcatttaatg 960
agaaataaaa gtaatttatg gatgggtatc ttttaatttt actgcaatgt gttttctcat 1020
ggctgaaatg aatggaaaac atacttyaat tagtctctga ttgtatataa atgtttgtga 1080
aattccatgg ttagattaaa gtgtrttggg aanaattctc catgggg 1127

```

<210> 158

<211> 1282

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (120)

<223> n equals a,t,g, or c

<220>

<221> misc feature
<222> (205)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (207)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (236)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (732)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1279)
<223> n equals a,t,g, or c

<400> 158
tgctctacaa atagtaaaaa taaaaaataa aaaaagtagc tgggcgtggt ggtgtgcacc 60
tgtgggtccca gctgcttggg atgctgaggt ggaaggatct cttaaaccce ggaggggtggn 120
aggctgcagt gaacttgcca ttgcaccact ggcaactccag tctgggggac agagtgcagac 180
cccattctcaa aaaagtgttt aattnantat acttgtagtg ggtctatttg catttnaaaa 240
ctgcttttcta gaattaggat agctccctta ggtttaatgt ttgggtgagc aggaatatca 300
gttacccttc cagatcttaa ttctagtttt ttatcactt ttcatgagg tgatctcatc 360
ctcatctcct agcatgtctg gcaattttga tttctgaact ctgtgctacc tcagaggcca 420
gcttccttag ggaaaaatca gtgctgaaat aaagttatat ttcttttct gctctaaata 480
tatagtgggg gaataagaga aatgaagagg aattcctgag aacgtaatta ctagaaactc 540
ccctctccca cgtaatgtct ctcacacacc atggacccct attcccccaa ttgcgaccc 600
cccacccac cccacaacag gtggtgatct ttgtgaagtc tgtgcagcgg tgcattgcct 660
tggcccagct actagtggag cagaacttcc cagccattgc catccaccgt gggatgcccc 720
aggaggagag gntttaaaga ttttcaacga cgaattcttg tggctacca cctatttggc 780
cgaggcatgg acatcgagcg ggtgaacatt gcttttaatt atgacatgcc tgaggattct 840
gacacctacc tgcacgggt ggccagagca ggccgggttg gcaccaagg cttggctatc 900
acatttgtgt ccgatgagaa tgatgccaag atcctcaatg atgtgcagga tgcgtttgag 960
gtcaatatta gtgagctgcc tgatgagata gacatctcct cctacattga acagacacgg 1020
tagaagactc gccatttttg gaatgtgacc gtctgtcctt caggagagga caccaggggtg 1080
gggggtgaagg agacactact gccccaccc ctgacagccc ccaccccatg gcttccatct 1140
tttgcacac caccactcct gaaccccat ttttgatttg tcagaatttt tttttaacaa 1200
aactaaaaat gaaacacatg tgtctgtggt atctaaaaaa aaaaaaaaaa aaawwggggg 1260
ggsgcccgta ccattggnc ct 1282

<210> 159
<211> 1505
<212> DNA

<213> Homo sapiens

<400> 159

```

ttacatgttg cagaagctaa ttgaagagac agataggttt gtagtggtca cagaagagga 60
atcaggcatg agtgaccagt tgtgtggcat tgctgcctgc cagacggatg acatatacaa 120
ccgaaactgc cttattgaat tggtaaacct gtcagatggt tcttcgtgga gcagagacak 180
aaggctgtgt catttgtgtca gctgccaaag cccaactgct gcagtgccag caccatccag 240
cctggtatgg tgatacattg aagcaaaaaga catcctggac ttgcctcttg gatggcatgc 300
agtactttgc caccactgaa agcagcccca cagagcagga tggccgacag ctctgggttag 360
aggtgaagaa tatcgaggag caccggcagc gtagtctgga ctctgtgcag gagctgatgg 420
agagtgggca ggcatgggc ggcatgggta ccacaaccac agattggaac cagccagctg 480
aggcacagca agcccagcaa gtccagcggg taatttcgctg ttgcaactgc cgaatgtact 540
atattagtta cagccatgac attgatcctg aactagcaac tcagattaag ccacctgaag 600
ttcttgagaa ccaggaaaag gaagatctcc taaagaagca ggaaggggct gtggatacct 660
tcaccttat ccacatgag ctggaaattt ccaccaaccc agctcagtat gccatgatcc 720
tgacattgt caacaacctg ctgctccatg tagaacctaa gcggaaggaa catagtgaag 780
agaagcaacg ggtcagggtc cagcttgaga tctctagcaa tccagaggag caacgcagca 840
gcatactgca ttgacaggag gctgtgcggc agcatgtggc ccaaatacga cagctggaga 900
agcagatgta ttctatcatg aagtctttgc aggatgacag caagaatgag aatctgcttg 960
acctgaacca gaagcttcag ttgcagctaa accaggagaa ggccaacctg cagctggaaa 1020
gtgaagaact gaatatcctc atcagggtgt ttaaggattt ccaactgcag cgggctaaca 1080
agatggagct gcgaaagcac aagaagatgt gtagtggtgc cgtcgcaactg agttttactt 1140
tgctcaggca cgggtggcgc tgacagagga agatggacag ctgggaattg ctgaattaga 1200
actgcagagg ttcctctaca gcaagggtgaa taagtctgat gacacagcag aacatcttct 1260
ggagttgggc tgggtttacca tgaacaacct cctccccaat gctgtctata aggtagtact 1320
gcggccccag agctcctgcc agtctgggag acagctagct ctccgcctct tcagcaaagt 1380
tcggccccct gttgggggta tctctgttaa ggagcatttt gaggtaaatg tgggtgctctc 1440
accatccagc tgacacacca ttcttcaca gatgatgggc ttttctttcc tggccgaagt 1500
gtgga 1505

```

<210> 160

<211> 736

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (718)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (723)

<223> n equals a,t,g, or c

<400> 160

```

aggcacgagg gacacttggg gtctggacgc aacggcggcg ggagcatgaa cggccctcca 60
gccttcgagt cgctcttgct cttcaggggc gagaagatca ccattaacaa ggacaccaag 120
gtacccaatg cctgtttatt caccatcaac aaagaagacc acacactggg aaacatcatt 180
aatcacgtg cctgcttccc ctctgccttc tgccgtgatt gtcagtttcc tgaggcctcc 240
ccagccacgc ttcctgtaca gcctgcagaa ctgtgagtca attaaacctc ttttcttcat 300

```

```

aaattaccca gtttctcata gttctttata gcagtgtgaa aacagactaa tggacccttc 360
tggttgaagg aatgcagcca ttctgcttgt ttgactatgt cctttctatt catctctatt 420
tcctgggagg tgtttatcca agtgcaatag gaggtattgg tgaccgcaca gtcccctcag 480
tgttctgcta gtaaatagtt gaagggtgat cattgatctt ctgcgttttc agtctggcat 540
ggaaaagccc ctgtgcaact ggtaaagata tcaataagca cctggtgggt ggcgggggta 600
gtccaggctt gtcttgcaac tgtatgttct cttcagaccc ctccctggcg atgccagatt 660
cactgggctg gcagattctg cccccccaa aaaaaaaaaa aaaatattaa taataaanaa 720
aanagactcc cagggg                                     736

```

<210> 161

<211> 995

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (59)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (889)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (899)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (928)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (933)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (938)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (974)

<223> n equals a,t,g, or c

<400> 161

```

gggtcgaccc acgcgtccgg gcggcctcgg cagcgggtgtt ctgcgcttg cgaasgggnc 60

```



```

tccggctcgg ctgcgggga ctgtgcacga ggttggcgac gcgccccgcc gggccccaga 120
tcaggccgca gagatcggga gccgcgggag cactaaggcg caagggccac agcagcagcc 180
gggctcagag ggtcccagct atgccaaaaa agttgcgctc tggcttgctg ggctgcttgg 240
agctgggtgg actgtgagcg tcgtctatat ctttgaaaac aaccgggtgg acgaaaatgg 300
tgccaagatt cctgatgagt tcgacaatga tccaattctg gtacagcagt tgcgccggac 360
atacaaatat ttcaaagatt atagacagat gatcatcgag cccaccagcc cttgccttct 420
cccagaccct ctgcaggaac cgtactacca gccaccctac acgctcgttt tggagctcac 480
cggcgtcctc ttgcatcctg agtggtcgct ggccactggc tggaggttta agaagcgccc 540
aggcatcgag accttgttcc agcagcttgc ccctttatat gaaattgtca tctttacgtc 600
agagactggc atgactgcgt ttccactcat tgatagtgtg gaccccatg gcttcatctc 660
ctaccgccta ttccgggacg ccacaagata catggatgga caccatgtaa aggatatttc 720
atgtctgaat cgggacccag ctcgagtagt agttgtggac tgcaagaagg aagccttccg 780
cctgcagccc tataacggcg ttgccctgcg gccctgggac ggcaactctg atgaccgggt 840
cttgttgat ctgtctgcct tcctcaagac cattgcactg aatggtgtng gaggacgtng 900
cgaaccgtgc tgggagcatt atgccctngg ganggatnga ccccgctggg cggcttttgc 960
aaacagcggc aaancgggct tagaagcagg gagga 995

```

<210> 162

<211> 1125

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (972)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1023)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1077)

<223> n equals a,t,g, or c

<400> 162

```

gccctagtag ggtccggaat tcccgggtcg acccacgcgt ccgcccacgc gtccgcgctg 60
gtgttgcggc gctggcgaca gtcggggttg cgagcggccc ggggcccggg cggccagggc 120
cgctgcagga cgagaccctg ggtgtggcgt ccgtgccctc gcagtggagg gccgtccagg 180
gcataccgcy ggagacgaaa agttgccaga cggccagcat tgccactgcc agtgcacccg 240
cccaggccag gaatcatgtg gacgcccagg tgcagacgga ggcccccgct cctgtcagcg 300
tgcagccccc gtcccagtay gacataccca ggctcgagc ctttcttcgg agagtggagg 360
ccatggtcat ccgagagctg aacaagaatt ggagagcca cgcgtttgat ggcttcgagg 420
tgaactggac cgagcagcag cagatggtgt cttgtctgta taccctgggc taccgccag 480
cccaagcgca gggctctgcat gtgaccagca tctcctggaa ctccactggc tctgtgggtg 540
cctgtgccta cggccggctg gacctgggg actggagcac gcttaagtcc ttcgtgtgtg 600
cctggaacct ggaccggcga gacctgcgtc cccagcaacc gtcggccgtg gtggaggtcc 660
ccagcgctgt cctgtgtctg gccttccacc ccacgcagcc ctcccamgtc gcaggagggc 720
tgtacagtgg tgaggtgttg gtgtgggacc tgagccgtct tgaggaccgc ctgctgtggc 780

```

```

gcacaggcct gacggatgac acccacacag accctgtgtc ccagggtgtg tggctgccc 840
agcctgggca cagccamcgg ttcagggtgc tkagtgtggc cacygacggg aagggtgtac 900
tctggcargg catcggggta rgccagctgc agttcacaga rggcttcgcc tggttcatkc 960
agcagctgcc anggagcacc aagctcaaga agcatccccg cgggagaccg aggtgggcgc 1020
canggcaggc tttcttcacg tttgacctca ggttttcatt ttggcaggaa gcggttnccg 1080
ttcaattttc ctggcattgg agagcagcct taagggtgtc ccatt 1125

```

<210> 163

<211> 423

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (390)

<223> n equals a,t,g, or c

<400> 163

```

gggtcgaccc acgcgtccga gatggcggtt cgcagcaaga ggccggagca cggcgggccc 60
ccggagctgt tttatgacaa gaatgaagcc cggaaatacg tgcgcaactc acggatgatt 120
gatgtccaga ccaaaatggc tgggcgagct ttggagctcc tttgtctgcc ggaggtcagc 180
cctgttacct cttggatatt ggctgtggtt ctgggctgag tggagattat ctctcgatg 240
aagggcacta ctgggtaggc atcgacatca gccctgccat gctggatgag gccttggacc 300
gagacactga gggagacctg cttctggggg acatgggcca gggcatcccc ttcaaaccag 360
kttcattgat ggatgtatca gcattctgcn aatcagtggc tctgtaatgc aaaccaagaa 420
gtc 423

```

<210> 164

<211> 1642

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1614)

<223> n equals a,t,g, or c

<400> 164

```

acccacgcgt ccggcggtg gcggagcaga acggattgca gggtcagcca tgtcatctga 60
gcctcccca ccaccacagc ccccccacca tcaagcttca gtcgggctgc tggacacccc 120
tcggagcgt gagcgctcac catccctctt gcgsggcaac gtggtcccaa gcccaactgcc 180
cactcgccgg acgaggacct tctcggcgac ggtgcgggct tcacagggcc ccgtctacaa 240
aggagtctgc aaatgcttct gccgggtccaa gggccatggc ttcattaccc cagctgatgg 300
cggccccgac atcttcctgc acatctctga tgtggaaggg gagtatgtcc cagtgggaagg 360
cgacgaggtc acctataaaa tgtgctccat cccacccaag aatgagaagc tgcaggccgt 420
ggaggtcgtc atcactcacc tggcaccagg caccaagcat gagacctggt ctggacatgt 480
catcagctcc taggagatgg tgggaagcacc ccttgcctg tgcttggtgg agactttgag 540
gggaggaggc agcagacact ggagatgaca ttcttcaca cgagacgggg ctccagccgg 600
gcatgggtccc tctcaagtat ctctggagg aaggggtatg gggggcagg gtgggggtgtg 660
gggtgttccc ggccatcagc acagcctatg accattgcaa caacctctca ccatctgaag 720
agcattaaaa gcatttaaaa aggaragggtg cccactgggtg gctgagtggg ggttccaacc 780

```

```

ccatcccagg gagtggatca aggggtggat ttctccagct gctcagacac atgggctcaa 840
cccacagaat ccctcttcct cctggagctg gaggccccag attcccagat ctggccccct 900
ggcagcctga cagggacctt gcgtgacttc tccaaggcaa atttcacact aagtggccct 960
tgcgcctctc ctggggcctg ggcaaagcag ttttctaatt cttggcttgg ttggttctag 1020
gggagctggc ttgaagtggg kggggaaagg cgggggtggc ggtcttttga ttggacggat 1080
gttgccctttt ggtgcctttg cagtgggagg cggcatagct gcctgtcttg ggaagacagt 1140
tctcccagca ctcccacccc tgggcacagc aggtctgtac tgggaggctg aaccctctt 1200
agagcctgac cttttcatct gccttctggt tgtgtgacca tcaactcaaca gccatttcac 1260
agcccctgta attatggcgg cggggggctg ggtgtgtggt ggtgggaagg gcttgtggag 1320
aggacacagt ctttgtttaa aaactttgtc ccgatccatc cagaaaagag taggtagctt 1380
gcacccctgac agcctggcaa agtcaagaaa gttgaaggag aaacatacct ttggagaggg 1440
ggttttcttt aaaactagtg ttaagaaatg cttagggtatt ttttttttct tatttttcat 1500
aactaaagct ttcaccaga gccggctctg tttgcacttt gctgccgaca ttgcaaacctt 1560
tttggcaggg tgggagactg agtctcattc tgcamccag gctggagtgc agtngcccg 1620
tctcagcttt actgcaacct ct 1642

```

<210> 165

<211> 1115

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (390)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (394)

<223> n equals a,t,g, or c

<400> 165

```

aggaatgccg agtactgcag gggctcccca gggagtatgt gaatgccagg cactgtttgc 60
cgtgccaccc tgagtgtcag cccacagaatg gctcagtgc ctgttttggg cgggaggctg 120
accagtgtgt ggctctgtgc catcaagtgg atggcgctgg agtccattct ccgccggcgg 180
ttcaccaccc agagtgatgt gtggagtatt ggtgtgactg tktgggagct gatgactttt 240
ggggccaaac cttacgatgg gatcccagcc cgggaggatc cctgacctgc tggaaaaggg 300
ggagcggtg cccagcccc ccatctgcac cattgatgtc tacatgatca tgggtcaaatg 360
ttggatgatt gactctgaat gtcggccaan attncgggag ttggtgtktg aattctcccc 420
catggccagg gacccccagc gctttgtggt catccagaat gaggacttgg gccagccag 480
tcccttggac agcaccttct accgctcact gctggaggac gatgacatgg gggacctggt 540
ggatgctgag gagtatctgg taccacagca gggcttcttc tgtccagacc ctgccccggg 600
cgctgggggc atggtccacc acaggcaccg cagctcatct accaggagtg gcggtgggga 660
cctgacacta gggctggagc cykctgaaag aggaggcccc caggctctcca ctggcaccct 720
ccgaagggct ggctccgatg tattttratg tgacctggga atgggggcag ccaaggggct 780
gcaaagcctc cccacacatg accccagccc tctacagcgg tacagtgagg accccacagt 840
acccctgccc tctragactg atggctacgt tgccccctg acctgcagcc cccagcctga 900
atatgtgaac cagccagatg ttcggcccca gcccccttcg ccccgagagg gccctctgcc 960
tgctgcccga cctgctggtg ccactctgga aaggsccaag actctctccc cagggagaag 1020
tggggctcgtc aaagagtttt tgcttttggg ggtgccgtgg agaaccgccg gtattgacac 1080
cccaggggag ggagcttgcc cttcagcccc acctt 1115

```

<210> 166
<211> 1066
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (10)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (739)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (968)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1023)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1025)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1042)
<223> n equals a,t,g, or c

<400> 166
gggcacgagn cacctgagcc ccttgtctcg caccggctcc caggagggca cctccatgga 60
gggctccccg cccgctgccc ctgccagagc caggcaccct caagaccagt ctggtggcta 120
ctccaggcat tgacaagctg accgagaagt cccaggtgtc agaggatggc accttgcggt 180
ccctggaacc tgagccccag cagagcttgg aggatggcag cccggctaag ggggagccca 240
gccaggcatg gagggagcag cggcgaccgt ccacctcadc agccagtggg cagtggagcc 300
caacgccaga gtgggtcctc tcctggaagt cgaagctgcc gctgcagacc atcatgagc 360
tgctgcaggt gctggttccg cagtggagaa gatctgcadc gacaagggcc tgacggatga 420
gtctgagatc ctgcggttcc tgacgcatgg caccctgggtg gggctgctgc ccgtgcccc 480
ccccatcctc atccgcaagt accaggccaa ctcgggcact gccatgtggt tccgcacct 540
catgtggggc gtcactatc tgaggaatgt ggacccccct gtctggtacg acaccgacgt 600
gaagctgttt gagatacagc ggggtgtgagg atgaagccga cgaggggctc agtctagggg 660
aaggcagggc cttggtccct gaggcttccc ccattccacca ttctgagctt taaattacca 720
cgatcagggc ctggaacang cagagtggcc ctgagtgtca tgccctagag acccctgtgg 780
ccaggacaat gtgaactggc tcagatcccc ctcaaccctc aggtctggact cacaggagcc 840

126

```

ccatctctgg ggctatgccc caccagagac cactgcccc aacactcgga ctccctcttt 900
aagacctggg ytcagtgtg gcccctcagt gccaccact cctgtgctac ccagcccca 960
gaggcagnaa rccaatgggt cactgttgcc cctaaagggg ggtttttgaa ccaaggggga 1020
aancnacggg gcctggttcc cntttggaaa ggtttccctt gggaaa 1066

```

```

<210> 167
<211> 657
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc feature
<222> (278)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc feature
<222> (564)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc feature
<222> (597)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc feature
<222> (602)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc feature
<222> (635)
<223> n equals a,t,g, or c

```

```

<400> 167
gtcgcgagcg ctgccgtcgg gaggcgctcc gaggttcgag gctgtgcccc gcgaccccg 60
cttcggcgct cggctcgcag gatggatccc gtacccgga cagactcggc gccgctggct 120
ggcctggcct ggctcgtcggc ctctgcaccc ccgccgcggg gkttcagcgc gatctcctgc 180
accgtcgagg gggcaccgcc agctttggca agagcttcgc gcagaaatct ggctacttcc 240
tgtgccttag ttctctgggc agcctagaga accgcanga gaacgtggtg gccgatatcc 300
agatcgtggt ggacaagagc ccctgcccgc tgggcttctc cccgtctgc gamcccatgg 360
attccaaggc ctctgtgtcc aagaagaaac gcatgtgtgt gaarctgttg cccctkggar 420
ccamggacac ggctgtgttt gatgtccggc tgagtgggaa gaccaagaca gtgcctggat 480
cccttcgaat aggggacatg ggcggtttt ccatctggtg caagaaaggc caaggccccg 540
aggccagtgt cccaaagccc cgangtctc agcccgggac atgcaaggc ttctctntgg 600
angcagccag ccagcccaag ttaagggcgg gcctncttgg aagccggaca agcgttc 657

```

```

<210> 168
<211> 1026
<212> DNA

```

<213> Homo sapiens

<220>

<221> misc feature

<222> (1011)

<223> n equals a,t,g, or c

<400> 168

```

ggcacgagga gagatggagg ggcggcaggt gctggagggtc aagatgcagg tggagtacat 60
gtcattcagc gcacacgcgg acgccaaggg catcatgcag ctggtgggccc aggcagagcc 120
gkagagcgtg ctgctggtgc atggcgaggc caagaagatg gagttcctga agcagaagat 180
cgagcaggag ctccgggtca actgctacat gccggccaat ggcgagacgg tgacgctgcc 240
cacaagcccc agcatccccg taggcatctc gctggggctg ctgaagcggg agatggcgca 300
ggggctgctc cctgaggcca agaagcctcg gctcctgcac ggcaccctga tcatgaagga 360
cagcaacttc cggctggtgt cctcagagca agccctcaaa gagctgggtc tggctgagca 420
ccagctgctc ttacactgcc gcgtgcacct gcatgacaca cgcaaggagc aggagacggc 480
attgcgcgtc tacagccacc tcaagagcgt cctgaaggac cactgtgtgc agcacctccc 540
rgacggctct gtgactgtgg agtccgtcct cctccaggcc gccgcccctt ctgaggaccc 600
aggcaccaag gtgctgctgg tctcctggac ctaccaggac gaggagctgg ggagcttctt 660
cacatctctg ctgaagaagg gcctccccca ggccccagc tgaggccggc aactcaccca 720
gccgccacct ctgccctctc ccagctggac agaccctggg cctgcacttc aggactgtgg 780
gtgccctggg tgaacagacc ctgcaggctc catccctggg gacagaggcc ttgtgtcacc 840
tgccctggcc ggcagctgtt tgcagctgaa gaaacaaact ggtctccagg ctgtcttgcc 900
tttattctct gttagggcag gtggtcctag acagcagttt ccagtaaaag ctgaacaaaa 960
aaaaaaaaaa aaaaaattgg gggggggccc gttaccatt tggcctttag nggggggttt 1020
aaatta                                           1026

```

<210> 169

<211> 774

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (730)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (733)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (754)

<223> n equals a,t,g, or c

<400> 169

```

ggcataaaca tcgggtggtg ttcagatcct gctgccggca gctcgaggct aggatggctg 60
gagatgtgag gccctttgtc tcatcacatc cgagcacagc tcagcaagat gctcttagct 120
agraaacaga ttttatgtgt taatgttaaa aattttgcag ttatttatct tgtggatatt 180

```

```

acagaagtgc ctgacttcaa caaaatgtat gagttatacg atccatgtac tgtcatgttt 240
ttcttcagga acaagcacat catgattgac ttggggactg gcaacaacaa caagattaac 300
tgggccatgg aggacaagca ggagatggtg gacatcatcg agacggtgta ccgcggggcc 360
cgcaaargcc gcggcctggt ggtgtccccc aaggactact ccaccaagta ccgctactga 420
ggcgccctca gtctgcgcgg ataaatgtcg tggagccctt tttgtatgga aacgttttaa 480
gctattttaa gcctttggaa aatacaggaa gctccagggc tggagcacct ctgagatgga 540
attgataaca tggctctaac tcaccgaaat aaacaagcac gtggtgagag gagcaggcct 600
acttgtttgt tctcaggaaa cttaatgaat agattactga ttttcctagt caaagttaat 660
tcttaccctt ggagtaaaac gaaggtgttt atcctgtgag cctgtgcgtt ttgcatactg 720
ggttggtttn ctngggcttc ggtgacagca tatnccgcga gctgggcttt aaca 774

```

<210> 170

<211> 402

<212> DNA

<213> Homo sapiens

<400> 170

```

ggcacgagcg gcggtggggc ggacagccgg ggtgcgcact tgggcccccc tggccatggc 60
ggcgaaggtg gacctgagca cctccaccga ctggaaggag gcgaaatcct ttctgaaggg 120
cctgagtgac aagcagcggg aggaacatta cttctgcaag gactttgtca ggctgaagaa 180
gatcccgaca tggaaggaga tggcgaaagg ggtggctgtg aaggtggagg agcccaggta 240
taaaaaggac aagcagctca atgagaaaat ctccctgctc cgagcgaca tcaccaagct 300
ggaggtggac gccatcgtca acgcccgaac cagctccccg ccccgaggga gcctaattaa 360
agatcttcgt tgtggcaaaa aaaaaaaaaa aaaaaaaaaa aa 402

```

<210> 171

<211> 796

<212> DNA

<213> Homo sapiens

<400> 171

```

aggcatcggg gacagccgct gcggcagact cgagccagct caagcccgca gctcgcaggg 60
agatccagct ccgtcctgcc tgcagcagcc caaccctgca caccaccat ggatgtyttc 120
aagaagggtc tctccatcgc caaggagggc gtggtgggtg cgggtgaaaa gaccaagcag 180
ggggtgacgg aagcagctga gaagaccaag gaggggtc tgtatgtggg agccaagacc 240
aaggagaatg ttgtacagag cgtgacctca gtggccgaga agaccaagga gcaggccaac 300
gccgtgagcg aggtctgtgt gagcagcgtc aacactgtgg ccaccaagac cgtggaggag 360
gcggagaaca tcgcggtcac ctccggggtg gtgcgcaagg aggacttgag gccatctgcc 420
ccccaacagg aggtgaggc atccaaagag aaagaggaa tggcagagga ggcccagagt 480
gggggagact agagggttac aggccagcgt ggatgacctg aagagcgtc ctctgccttg 540
gacaccatcc cctcctagca caaggagtgc ccgccttgag tgacatgcgg ctgccacgc 600
tcttgccctc gtctccctgg ccacccttgg cctgtccacc tgtgtgctg caccaacctc 660
actgccctcc ctcgcccca cccaccctct ggtccttctg accccactta tgctgtgtg 720
aatttttttt ttaaatgatt ccaataaaaa cttgagccca ctyctaaaaa aaaaaaaaaa 780
aaaaaaaaag gggccc 796

```

<210> 172

<211> 478

<212> DNA

<213> Homo sapiens

<400> 172

```

aattcggcag agcctggttg cagggcagct aggggtctct gcattctcca catggtctca 60
tgcccccttt tgtcccttac aggaggactt gaggccatct gccccccaac aggaggggtga 120
ggcatccaaa gagaaagagg aagtggcaga ggaggcccag agtgggggag actagagggc 180
tacaggccag cgtggatgac ctgaagagcg ctctctgcc ttggacacca tccccctcta 240
gcacaaggag tgcccgctt gagtgacatg cggtgccca cgctcctgcc ctgctctccc 300
tgggcaccct tggcctgtcc acctgtgtg ctgcaccaac ctactgccc tccctcggcc 360
ccaccacccc tctggtcctt ctgacccac ttatgtgtg gtgaattttt tttttaaatg 420
attccaaata aaacttgagc ccactcctaa aaaaaaaaaa aaaaaaaaaa aaaaaaaa 478

```

<210> 173

<211> 656

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (59)

<223> n equals a,t,g, or c

<400> 173

```

tttcccaatg cctgccacca cggagactca gggccacctg ccaccctccc tcgctgcent 60
ctgcccttgg gatggggcgc tcctgaatgt acgtgggccc cggtgtttac aaggaggtga 120
tcatctacaa cctctgccag aagcagggtg tgagagaagat accactgccc ttttttgcca 180
tgtccctgag cctgtccccc gggaccaccc tcctggctgt tggttttgct gagtgcacgc 240
tgaggctggt agactgtgcc atggggactg cccaagactt tgccggccac gacaacgcag 300
tgcacctgtg caggtttaca cktccgccca ggctgctctt cacggccgcc cgcaacgaga 360
tccttgtgtg ggaggtcccc ggctctgag atgcagcagg gactgtggtg gtgggcatca 420
acgcctggtc atgccaggca cctggacaca ggcttggcag aggcgccagg ttgtcaatgg 480
cctcatgtg ggacaggcca ggattcacgt aaatcgctg gagcaagctg ttgtaaattt 540
ggcgccctgt gaatactttc atacctgttg cccttttgcc taagaaatct ttaatgtttc 600
tatcttgtaa taaacatggg catttattgc aaaaaaaaaa aaaaaaaaaa aaaaaa 656

```

<210> 174

<211> 1891

<212> DNA

<213> Homo sapiens

<400> 174

```

gagccccctc cgagagggga gaccagcggg ccatgacaag ctccaggctt tggttttcgc 60
tgctgctggc ggcagcgttc gcaggacggg cgacggccct ctggccctgg cctcagaact 120
tccaaacctc cgaccagcgc tacgtccttt acccgaacaa ctttcaattc cagtacgatg 180
tcagctcggc cgcgcascgg gctgctcagt cctcgacgag gccttccagc gctatcgtga 240
cctgcttttc ggttccgggt cttggcccg tccttacctc acagggaac ggcatatact 300
ggagaagaat gtgttggttg tctctgtagt cacacctgga tgtaaccagc ttctactttt 360
ggagtcagtg gagaattata ccctgacatc aaatgatgac cagtgtttac tcctctctga 420
gactgtctgg ggagctctcc gaggtctgga gacttttagc cagcttgttt ggaaatctgc 480
tgagggcaca ttctttatca acaagactga gattgaggac tttccccgct ttctcaccg 540
gggcttctg ttggatacat ctgcacatta cctgccactc tctagcatcc tggacactct 600
ggatgtcatg gcgtacaata aattgaacgt gttccactgg catctggtag atgatccttc 660
cttcccatat gagagcttca cttttccaga gctcatgaga aagggtcctt acaaccctgt 720

```



```

caccacatc tacacagcac aggatgtgaa ggagggtcatt gaatacgcac ggctccgggg 780
tatccgtgtg cttgcagagt ttgacactcc tggccacact ttgtcctggg gaccagktat 840
ccctgggatt actgactcct tgctactctg ggtctgagcc ctctggcacc tttggaccag 900
tgaatccag tctcaataat acctatgagt tcatgagcac attcttctta gaagtcagct 960
ctgtcttccc agatttttat cttcatcttg gaggagatga gggtgatttc acctgctgga 1020
agtccaaccc agagatccag gactttatga ggaagaaagg cttcgggtgag gacttcaagc 1080
agctggagtc cttctacatc cagacgctgc tggacatcgt ctcttcttat ggcaagggtc 1140
atgtggtgtg gcaggagggtg tttgataata aagtaaagat tcagccagac acaatcatac 1200
aggtgtggcg agaggatatt ccagtgaact atatgaagga gctggaactg gtcaccaagg 1260
ccggcttccg ggcccttctc tctgccccct ggtacctgaa ccgtatatcc tatggccctg 1320
actggaagga tttctacgta gtggaacccc tggcatttga aggtaccctt gagcagaagg 1380
ctctggtgat tgggtggagag gcttgtatgt ggggagaata tgtggacaac acaaacctgg 1440
tccccaggct ctggcccaga gcargggctg ttgccgaaag gctgtggagc aacaagttga 1500
catctgacct gacatttgcc tatgaacggt tgtcacactt ccgctgtgag ttgctgagge 1560
gaggtgtcca ggcccaaccc ctcaatgtag gcttctgtga gcaggagttt gaacagacct 1620
gagccccagg caccgaggag ggtgctggct gtaggtgaat ggtagtggag ccaggcttcc 1680
actgcatcct ggccagggga cggagccccct tgccttcgtg ccccttgcct gcgtgccccct 1740
gtgcttgag agaaaggggc cgggtgctggc gctcgcatc aataaagagt aatgtggcat 1800
tttctataa taaacatgga ttacctgtgt taaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1860
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa g 1891

```

<210> 175

<211> 2161

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (2153)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2160)

<223> n equals a,t,g, or c

<400> 175

```

cgcttccgtc cacttggcga gtgagacgct gatgggagga tggacrtact ggtgtctgag 60
tgctccgcgc ggctgctgca gcaggaagaa gagattaaat ctctgactgc tgaatttgac 120
cggttgaaaa actgtggctg tttaggagct tctccaaatt tggagcagtt acaagaagaa 180
aatttataat taaagtatcg actgaatatt cttcgaaaga gtcttcaggc agaaaggaac 240
aaaccaacta aaaaatgat taacattatt agccgcctac aagaggtctt tggctatgca 300
attaaggctg catatccaga tttggaaaat cctcctctgc tagtgacacc aagtcagcag 360
gccaaagtgt gggactatca rtgtaatagt gctatgggta tttctcagat gctcaaaacc 420
aaggaacaga aagttaatcc aagagaaatt gctgaaaaca ttaccaaaca cctcccagac 480
aatgaatgta ttgaaaaagt tgaaattgct ggtcctggtt ttattaatgt ccacttaaga 540
aaggattttg tatcagaaca attgaccagt cttctagtga atggagtcca actacctgct 600
ctgggagaga ataaaaaggt tatagttgac ttttctccc ctaatatagc taaagagatg 660
catgtaggcc acctgaggtc aactatcata ggagagagta taagccgcct ctttgaattt 720
gcagggtatg acgtgctcag gttaaatacat gtaggagact gggggacmca gtttggcatg 780
ctcatcgctc acctgcaaga caaatttcca gattatctaa cagtttcacc tcctattggg 840

```

```

gatcttcagg tcttttataa ggaatctaag aagaggtttg atactgagga ggaatttaag 900
aagcgagcat atcagtgtgt agttctgctc cagggtaaaa acccagatat tacaaaaagt 960
tggaagctta tctgtgatgt ctcccgccaa gagttaaata aaatctatga tgcattggac 1020
gtctctttaa tagagagagg ggaatccttc tatcaagata ggatgaatga tattgtaaag 1080
gaatttgaa atagaggatt tgtgcagggt gatgatggca gaaagattgt atttgtccca 1140
gggtgttcca taccattaac catagtaaaa tcagatggag gttataccta tgatacatct 1200
gacctggctg ctattaaaca aagactatct gagggaaaaag cagatatgat tatctatggt 1260
gtggacaatg gacaatctgt gcacttccag acaatatttg ctgctgctca aatgattggt 1320
tggtatgacc ctaaagtaac tcgagtcttc catgctggat ttggtgtggt gctaggggaa 1380
gacaagaaaa agttttaaag acgttcgggt gaaacagtgc gcctcatgga tcttctggga 1440
gaaggactaa aacgatccat ggacaagttg aaggaaaaag aaagagacaa ggtcttaact 1500
gcagaggaat tgaatgctgc tcagacatcc gttgcttatg gctgcatcaa atatgctgac 1560
ctttcccata accggttgaa tgactacatc ttctcctttg acaaaatgct agatgacaga 1620
ggaaatacag ctgcttactt gttgtatgcc ttactagaa tcagggtctat tgcacgtctg 1680
gccaatattg atgaagaaat gctccaaaaa gctgctcgag aaaccaagat tcttttggat 1740
catgagaagg aatggaaact aggccgggtgc attttacggt tccctgagat tctgcaaaag 1800
atttttagatg acttatttct ccacactctc tgtgattata tatatgagct ggcaactgct 1860
ttcacagagt tctatgatag ctgctactgt gtggagaaa atagacagac tggaaaaata 1920
ttgaaggatg acatgtggcg tatgtgtgta tgtgaagcag tagctgtgt catggccaag 1980
gggtttgata tcctgggaat aaaacctgtc caaaggatgt aatccttcat aggtttgaac 2040
actgtgtgtt tttaaccaag tgccattggc actgtttgct tttttacaat catgtggaca 2100
caagcataag taaagaaat ttgtcaacca gaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2160
a

```

<210> 176

<211> 2411

<212> DNA

<213> Homo sapiens

<400> 176

```

gggatcctgg ctaccactct gaatccgata ccgcttctct tagaccgtca ctgagacaac 60
ggttaccgtg acaaccgagc ccgagaaccg gagccttacc atcaaacttc ggaaacggaa 120
gccagagaaa aaggtagaat ggacaagtga cactgtggac aatgaacaca tgggcccggc 180
ctcatcmaaa tgctgctgta tttatgagaa acctcgggac tttggcgaga gctccacgga 240
aagtgatgag gaggaagaag agggctgttg tcatacacac tgtgtacgtg gccaccgcaa 300
aggacggcgt cgtgcaaccc taggaccgac cccaccacc cctccccagc ctctgaccc 360
ttcccagccc cctccagggc caatgcagca ctaaatecct ctctcctcca gcattcctgt 420
gtctgtcttg ccctaaatgt atccatgttg ctacttctcc agccccctcc ttccctctct 480
tctgcctgat agagggaga ggaagaggag gacgaacaga gatcctgaaa ttctgacttg 540
ctgctattcc agaaccagc ctctggtgtt tccccagtc tcatttttcc tcccaatacc 600
cacccttctc tctcgaggga tctaggcacc ttggtcccag tgtcttctt ttgttctcac 660
tgccaaactg cctgtccttg gatctagtta tcttgccct gcaactctca catgagtagc 720
gaacacttaa attgggtttt caacagtcct agcttttact gccagggtcc cagtcagatt 780
ccagggaattt gcgccctaac tttgcttgct aatcctggt tagagctatc ccactaaaat 840
atttaacctt aattcttagt ccttgctgt gagatatgag gtcttacagg agacctcaga 900
gctcccagcc cttctcctcc tgctaaccct tctcacaccc tcaagaggag ttagaaaaga 960
ggctcctgtc attctcacct cttatggaaa atggaataag aaataatcat atcctttctt 1020
cccacccttc tctgttatt taggatttct gacaaagctg gcttgagatt ggtcacttag 1080
agccgactgt ctctctgcc ttttgttttt cagcttcaga gacagatcca atatagtccc 1140
agggacctgg gtctctggga gaggaaggaa gagggaggga gcaaagagat tggggtagt 1200
cccctgtagt acactcttac ctcttacttc ctagactttg atttctccgg cagcccagat 1260

```

```

gttcagttct cttggccct ctctaccct tactgggatc tggttttcat tttccggtcc 1320
ttttgccata cacagttaca gagatcagtc aaatccatac caccactgag atctcattta 1380
ttgccacaga tgcacaaaat aaataaccca aaatcacaaa atgtgttaaa tatgggcccc 1440
tttatactta tggggaagg tktkagactw twcacaagga tgartttgga ratktctgaa 1500
gtattcccag gttkaggarg agagagggga aatagcacca ttggttcctt tccgtgagta 1560
tgtgcgggga gaagtttcaa gaaggttctt atggaaaaaa ggctgtgagc atagaaagca 1620
gtcataggag gttggggaac tagcttgctc ctccccaccc ccagatcctg caaaagaggt 1680
acaaagcttc ccagaggcca cagggccaga ccagagtcaa gcctcttggt ttaggagaaa 1740
cctcagtga caggcagggt agcccagtc ttagatctgt kgggaaggcc ctgagccctt 1800
ctggagctag gagtggcaag agtgggagtc aagtatttga ccagcagagc ctctatgtag 1860
gaatcatggt cactttacca atactgatgg ggagggcctg ttccccattg caggcctaga 1920
atggtttgaa tgggagaagt cagggaagtac tgtagtagct gtaggggaga gaagattctg 1980
agagccagaa ggcmwsgaat ggatttggtt ttgagcaggg acgtggaaac gtggagacca 2040
ggtgaggtct cattattttg gggcgaaaat gtgggttgct attaatactc ctgcaatggg 2100
cgtgtgaatg tgttcccaga aatgagtggg gaattccacc cccaaaaagc agctgcaggg 2160
ccagtgscgg gccaaacttc tagttggaga cgagactcag ctttccgctg gtacaatgcg 2220
gacggagcac gagggtcgca ggtgcagaac agcgggaaga tgcgctcccc agggggccag 2280
ggcctggaag gtaaagcagg tcgagtgagc ggccgtcgta gagagccacc ggccccgctc 2340
ccagtcagg tccamgcgaa atgccgcggc gggggctcaa caccgccag cagggtgggt 2400
tcgggtgccg t 2411

```

<210> 177

<211> 1338

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1234)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1276)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1289)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1326)

<223> n equals a,t,g, or c

<400> 177

```

ggcacgagaa aaaactcaga aatgctaagt gtacttattt gttgaagaaa cttgttacat 60
attactaaca tctttttttt ttatgagaaa tacttttccc ataaccaaaa aattcagtga 120
gcagaatggc cttgcttgag gtttttgcaa atctctcggg tgtctggctt agtgggaggc 180
agctgggccc tcatacctgc ctccgcactt cagctgtttg acataaacc agcttcgtgt 240

```

```

gagtgaagg gaagggcctg gggaccctca gaggttctcg gaccacactt tgagaactcc 300
tcgtctggaa gacaggcctg gggatgccat gtggggtgag ggcttacggg cttggtgtcg 360
ctttgtggag aaccgctggg gtctgaagcg ggtgtcagcc cactgcacc ttggtcttct 420
gggctgtcct gatgccgagg cccacttccc agccatgctg actttgcctc tttccctccc 480
cagcagaaaa atggctacaa acttcctagc acatgagaag atctggttcg acaagttcaa 540
atatgacgac gcagaaagga gattctacga gcagatgaac gggcctgtgg caggtgcctc 600
ccgccaggag aacggcgcca gcgtgaccc cgtgacatt gcgagagcca gagagaacat 660
ccagaaatcc ctggctggaa gctcaggccc cggggcctcc agcggcacca gcggagacca 720
cggtgagctc gtcgtccgga ttgccagtct ggaagtggag aaccagagtc tgcgtggcgt 780
ggtacaggag ctgcagcagg ccatctccaa gctggaggcc cggctgaacg tgctggagaa 840
gagctcgccct ggcaccggg ccacggcccc acagaccag cacgtatctc ccatgcgcca 900
agtggagccc ccagccaaga agccagccac accagcagag gatgacgagg atgatgacat 960
tgacctgttt ggcagtgaca atgaggagga ggacaaggag gcggcacagt tgcgggagga 1020
gcggytamgg caktacggg agaagaaggc caagaagcyt gcaytggtgg ccaagtcctc 1080
catcctgctg gatttcaagc cttggggatg atgagacgga catggctcag ctggaggcct 1140
gtgtgcgctc tatccagctg gacggctggg ctggggggct tccaagctgg tggcctgggc 1200
tacggttatc cggaagctaa caatttcatg tgtngttgga ggacgacaag tgggggacaa 1260
cttgctggag gagganttca ccatttttna ggagcactgc aattttcaaa tcgcattttt 1320
caacanattt gaagcccc 1338

```

<210> 178

<211> 1614

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1213)

<223> n equals a,t,g, or c

<400> 178

```

tgcatgtggt acatcccttc ttctcatcc tcttcatgta cttcarggc tgctttactg 60
cctctaaagc tgagagcttg attccagggc ctgccctgct cctggtggca cccagtggcc 120
tgtactactg gtacctggtc accgagggcc agatcttcat cctcttcac ttacacctct 180
tcgccatgct ggcctcgtc ctgcaccaga agcgcaggcc ctcttccctg acagcaacgg 240
cctcttcttc ttctctctct tcgcactgac cctcttgctt gtggcgctct gggtcgctg 300
gctgtggaat gaccctgttc tcaggaagaa gtaccgggtg gtcactctac tccctragcc 360
ctgggctttc tacacccttc acgtcagcag tcggcactga gtccctggca ccaggctctg 420
gcgctctgct ggggtgggag gtgggccatg gagggcactt gaatacagga gtaggggggg 480
tgtgggtgtg taaccagaga ccgagagcat gagtgggtg tgccctcgtg gcgtggattc 540
gtgtgtgtgt gtgtgtcttg tatatgtgtg cgcagagtgc atcattttca gactctacta 600
tttcogtcaa gtttctgttt gatttggatc atctcaggat cggattctgt tttagagtgt 660
ttctgggcca ggaaccgggc ccctgccctc ctctgcacct gaccacactc cctactcagg 720
gctaagtctgt tcttcccgga catcttctg tagccgtgca ggagagggct ggggtggggca 780
gaggccagga ggggacctgg tgtgtcacct gccaccacc tggctcatcc ctacggccca 840
ccctgacct acattacata ggttacgtca gcctactgtg gctgttgagc aaagcatttc 900
tcctttctg gcctcatttg cactagatgg gcctgtggtc ccaaagtagg tcagtaggtt 960
ggggttgctg acacccttg ggtgcagctt tgggacagat gagtggctct gtcctgtcac 1020
tgccctctcc ctgcctgggg gctatgtgca ctccagacct ctgccaggc tcaggcccat 1080
gaggtatgga gacaccctg cccccaggag ctggaggcac cggccactcc cctggcattc 1140
cagctttgca ggtgacctc ctctacccaa agctctgtcc ccctgctccc actccagaag 1200

```

```

aactgcggca cngccttcgg gcagcctagc cacaggcttt gagcgctgc attcctgggg 1260
gctggagggt ggggtgccaa aggccctgag caaaagccag agctcctctc atcaaagcct 1320
ttacaagggt ctggggccag aggctttgcc ttgacagagt ggcccagggt ttcaaggagg 1380
gaggaacctc cccctacctt ggaccttccc tgtggggggg ctacagagtc agggacagaa 1440
gggaaggggc ccacaggaag tcacagtggg gcccagggat gtgtcagccc ccagccacgg 1500
ggacgcggga ttcaagaatg aagtaaatac agtcacagcc ccaaaaaaaaa aaaaaaaaaa 1560
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaa 1614

```

<210> 179

<211> 4292

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (654)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (4288)

<223> n equals a,t,g, or c

<400> 179

```

ggaaggtcca gagggggcaa acctctttat ttaccacctt ccacaggaat ttggagacca 60
ggacattctg cagatgttca tgccttttgg aaatgttatc tctgctaaag tcttcattga 120
caaacagacc aatctgagca agtgctttgg ttttgtttagc tacgacaatc cagtctctgc 180
acaagctgct atccaagcta tgaatggctt tcagatcggc atgaaacgct tgaagggtgca 240
gctgaagcgt tccaaaaacg acagcaaac ccactgatcc taaccccaga ggctccctgc 300
tctcatctta gcttcttag gacatcttca tgcccgttag ttcacgttt gcctagcatg 360
tccctgtggc gtctcaaaaa aaagtttcat cgtcccgtca ttgtttctga tgtctttctg 420
acctcacatc atatttggtt ctcctactga cctttgatct agtttgacct ttgaaatttg 480
catgtgacct catctagcta tgaattctgg gaagtcaatg tgaaaaacat tegtgcattc 540
atgcaagact gaaatttatt attagacaaa ttcattatag aaaaaacctg tggcaaaaac 600
gtttctttct tatttttttt cttttcctaa aacagacttg aaagtattat acangggatt 660
ggcattcttc ccggtcactg gtaacaatag caatatgtgt ccaggggacac agaattgttg 720
tttctaacag actacttcca aaaacagttt gagaaaaaaa ctgtctgatt ttaagtcctc 780
agaggtctgt aatagttttt acatttttca ggcagtgtaa agttttttga taaggccatt 840
ttaggtggct cactttctca ttaagatata tatatagaac cactttttgt agattagtat 900
aagaaaaata tttaccctgt tttggggcaa atgctaccta tttgtgtcac cttttgctga 960
actcacagtt agacaatcca tggtttaatg cacatgaaat tacctatatt ttatactggt 1020
tcaatgtaca ggagaaaggt tactgtaaac tgtgttatgt tgggtgcttct gtgaattaag 1080
ttgtggtttc atcatgagtc ttaatgttct ttgttgataa gacaagttta gaattggttt 1140
acttaataca aaaaaaaaaa aaagaatttc aaaaaaaaaa gttgtttgct taaaaaaaaa 1200
ttcatgtgag ggaaaaaaa aaaacctatt ccagaataag ttttgtgttg gcttgtgaag 1260
cattgatgtc atttttttta attgtggact atttagatgt gtttgtgttc agcaaaatgt 1320
gatctgtttt tttcttttaa agaaaaaaag tgaaaatata tagtgccaaa ttccaaagggt 1380
acttccttcc tagagcttca gtgtgtttct tgtgagaagt aatttgataa catgggtatt 1440
ttattatgtg ttttgataaa atccctaata tttaaaaaaa aaaacaaaac aaaaaagggt 1500
tacaaagttt gttacttgc tatcctgtgg tcttgttgcc tgaaattggt attgtttggt 1560
atttctctct gatgtttttt gtaagacatt gtataagtgc ccatgtccca cttttttaac 1620

```

```
cactccgcac atcagtgtctg tgaaggcaac ctcaccatgt attttcttca taatctatgg 1680
aaacctctaa ggtgagaaaag ttttgaactt ttaacctttt ctaccagag ctatctggaa 1740
tggtgatgac tttttatact gtcatgattt gagtttgttt tggggtgttt ccaatttgga 1800
tttttttccc tgcattctatc ctctaagttg tttcgggttt actactttgt tctttgggta 1860
agatccaaaa gaaaacagaa aacaattcca cgaggccaat ctaaaggga aaaatcctac 1920
actactttta ctacttttga ttatttctca tttttgggaa aagaattcct aatgtgctac 1980
tagaattcct tcttcagttt taacgagtaa ttggataaac cctgaggga aacggaggta 2040
gattcagcac ctaacaatcc tgtatgcttt tgagatcacg tttagtgtta tgcctagtc 2100
tagaatattt tcatatacct tgcagtaaaa cgactttgtg gcaggacagt ctcttgaggg 2160
gttttgtttc tgtttcctaa atactcctaa ataataattt taatcagcca ttatgctggg 2220
gcatctctga tcccagtagg tacctctgaa tataccaggt gtctggagtt agaagcccat 2280
agccctttcc cagccttttt ggttttttta attgaacaca tttcatctaa gtaaagctca 2340
gttctttatc acaatttact gaccaaatac ctaccagcag ttcctgtctc cactttttaa 2400
agtgccatat gactttctac gaacaggtag cttgtgtctc tgacaaatcc taatgtcacg 2460
cctacagccc caacacaagc tccagtcttc ctcttcggca tgccttgga gcttcttggc 2520
ctcagctccc ctccccgct cagcacctgt ttaggatcag tgtgtgtgga tgggatagcc 2580
ctgggatgga aaggactagc ctctactgat gcaaaaaaac aaaaagcaac acaaacgttt 2640
ccttcttata gcacatgcac ttccttaca tgacatgatt tgtattatcc tcacatgtgt 2700
ttactactgc tggggccttc ctctcatctc tgagggtat tttgtacttt ctgcagcaat 2760
cagcttaata acaacactta ttgcacctgt ctctctctga gaacacggtg tgtctcgaca 2820
cgtaccacgt acgtggaaac acaagagccc accacttgaa tttctaagac catttcattc 2880
tgaaacttct tatcaattac ctaaattctc acgaaaaaca atttactgaa gccgactccc 2940
ctccccatct cctctcaac ctcaaccac ctgcattgat ctccccaga ggaaacactg 3000
agggtagggg acaggaggct caggacgcgc cctctgaatc gagtgtttct tcttcacaag 3060
tcaccaagag aggacatgag ggggaaagtc cttttttgcc cttctccaaa aaataacctt 3120
ccacagagac aaactgtcct tctatccact tttatctttt aataaatatc aaaaggaaaa 3180
agctgcaagg gtgcaagggt cctgtgccag aagaaaacac acacaggga accgcttttt 3240
ttaatcaatt gtagagaata gtcattttta atctaaatta gagaattgtg atacaatggc 3300
agtcctcaaa ggcgtaacga gttcatcttt ctttcacatc aggggttata gttggcttgt 3360
gctactctgg aatcatttta ctgtttgttt ttattatctt aagtgtaat taaaaaaaaa 3420
aaaattttta aaaaacctgt agtttcatta cttttttgaa taatgtcata caaaaaatgt 3480
atttgttttt ttgtgtgtgt agaattgatg tttgtagatt aataatcatt ttgttttaga 3540
ttacaaaata gtttttaaat attgtctgag aaaagccaaa gttaatgcaa cctagtggaa 3600
actgtaagac catttgagta ttgtttgttt tattgatgca tttggatttt gttgtttgat 3660
ggaatttgag caaaaaaaaa aatacgcagg ctttcctatt tctacaactg attgtactta 3720
tgcattttgt accagtggaa cttttttatc tggagattaa aaaaaaaatg gaaatttttg 3780
tggcttgctc tgggtggccc ctgacaatga ctgatttcaa gtttgatttc gggttgattg 3840
attgattgat tgatagaaag aaagttgctt ttcttttgag aattaaaaac tttggcttga 3900
tttctttttt ccctttgctt atatctagca ttagaatttt gtcttaaaat aacagcggta 3960
agtttcactt tttattctgt attgtgcagt tacacaataa ggtaattaga tttagaagta 4020
ctcagtcact ttaagtggat aaatgtatta gttaaaactt tagggtttgc ttttttgctg 4080
tttagatcaa agttttttct gattctctctg tctcattgt gaacataacc gtgtagttag 4140
aacagtcaaa cttatttttg taatgtatgt tattgtgtga tgcagttttt tgctctctgc 4200
tccaatatta aaccattttc ctaataaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 4260
aaaaaaaaaa aaaaaaaaaa aaaaaanaa aa 4292
```

<210> 180

<211> 243

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (235)

<223> n equals a,t,g, or c

<400> 180

```
tcgacccacg cgtccggaga aggtgggctc tgggggggtcc tctgtgggca gcgggggatgc 60
cagctcctcr cgccatcacc atcgccgccg ccggttccac ctrccccaac agcccctgct 120
ccagaggggaa gtgtggtgtg tgggcacaac gggaaacgct aaccaggcac agagctcaac 180
ggagcagaca ctgctgaagc ccaagtgaga aaccacggcg ctttggcgtg taacntggaa 240
tat 243
```

<210> 181

<211> 813

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (266)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (723)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (726)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (738)

<223> n equals a,t,g, or c

<400> 181

```
aattcggcag agaccaggtg tacctgagct acaataacgt ctccctccttg aagatgcttg 60
tggccaagga caactgggtg ctgtcctcgg agatcagtcg ggtccgcctg tacactctgg 120
aggatgacaa gttcctctcc ttccacatgg agatgggtgg gcatgtggat gcagmccagg 180
ccttctgctg gctctcggac ctgmgtcaga ggccagagtg ggacaagcac taccggagcg 240
tggagctagt gcagcaggta gacrangac gacgccatct accacgtcac cagmcctgmc 300
ctcggagggtc acacaaagcc ccaggacttc gtgatcctgg cctcgaggcg gaagccttgt 360
gacaatgggg acccctatgt catcgcgctg aggtcgggtc cgctgcccac acaccgagag 420
acgccagagt acagacgcgg agagaccctc tgctcaggct tctgcctctg gcgcgagggg 480
gaccagctga ccaaggtagc ctgtagtaga ctccgggtcct gtccacagcc ctagctgcc 540
gcaatgctgt cctcacagag gcatagtcgc ccccagctgg gttgtgctcc actgtgacgg 600
tggcccgggg ggaggatgcc agcagcctgc ctatggytgc cagctgtgct gtgagcccag 660
cagcatggcc tgcattctgg aaggacaca ggttgtccag agcccctggc acaactgctg 720
agncanatgc tgtggagnca gctgttacc tgtaagccac tggcccagca cctgcctaca 780
```

gggccagcct ggtggccaca gtgcacgtgg ggg

813

<210> 182

<211> 822

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (37)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (49)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (370)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (567)

<223> n equals a,t,g, or c

<400> 182

ggttttacat gaccgcagtc gccctcagtt tcacccngta ggaatcggnc tggggatgca 60
ccgtgtact ctcttcctcc aggcgggtcc ccggcgctg cgcgcgatcc atgtccatgt 120
ccgcgcctat caataaagtt gctcacttgt tgccggcccg ctagnccgaa aggttgccgcg 180
cgcagmccga gaagtctcgc gatagccagc cgcggctgcc cttgcgcttc ccgagctggc 240
gggggtccgtg gtgcgggatac gagattgcgg gctatggcgc cgaagttttt cgtcagtact 300
gggatatccc cgatggcacc gattgccacc gcaaagccta cagcaccacc agtattgcca 360
gcgtcgtgn cctgaccgcc gctgcctaca gagtcacact caatcctccg ggcaccttcc 420
ttgaaggagt ggctaagggt ggacaataca cgttcactgc agctgctgtc ggggccgtgt 480
ttggcctcac cacctgcac agcggccatg tccgcgagaa gcccgacgac cccctgaact 540
acttcctcgg tggtgcgcc ggaggcntga ctctgggagc acgcacgcac aactacggga 600
ttggcgccgc cgcctgcgtg tactttggca tagcggcctc cctggtcaag atgggccggc 660
tgaggggctg ggagggtgtt gcaaaaccca aggtgtgagc cctgtgcctg ccgggacctc 720
cagcctgcag aatgcgtcca gaaataaatt ctgtgtctgt gtgtgaaaaa aaaaaaaaaa 780
aaaaaaaaat yggggggggg cccskaacca attkccctta ag 822

<210> 183

<211> 1095

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1082)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1094)

<223> n equals a,t,g, or c

<400> 183

```
gcgcggaggc ggcgggcggag cctcctcctg ctgctgctgc gccccatccc cccgcggccg 60
gccagttcca gcccgcaccc cgcgtcgggtg cccgcgcccc tccccgggcc ccgccatggg 120
cctcaccggtg tccgcgctct tttcgcggat cttcgggaag aagcagatgc ggattctcat 180
ggttggcctg gatgcggctg gcaagaccac aatcctgtac aaactgaagt tgggggagat 240
tgtcaccacc atcccaacca taggcttcaa tgtagaaaca gtggaatata agaacatctg 300
tttcacagtc tgggacgtgg gaggccagga caagattcgg cctctgtggc ggcactactt 360
ccagaacact cagggcctca tctttgtggt ggacagtaat gaccgggagc ggggtccaaga 420
atctgctgat gaactccaga agatgctgca ggaggacgag ctgcgggatg cagtgtgct 480
ggtatttgcc aacaagcagg acatgcccac cgccatgccc gtgagcagc tgactgacaa 540
gctggggcta cagcacttac gcagccgcac gtggtatgtc caggccacct gtgccacca 600
aggcacaggt ctgtacgatg gtctggactg gctgtcccac gagctgtcaa agcgctaacc 660
agccaggggc agggccctga tgcccgaag ctctgcgtg catccccggg atgaccagac 720
tcccggactc ctacggcagt gccctttcct ccacttttc ctccccata gccacaggcc 780
tctgctcctg ctctgcctg catgttctct ctggtgttgg agcctggagc cttgctctct 840
gggcacagag ggggtccactc tcctgcctgc tgggacctat ggaaggggct tcctggccaa 900
ggccccctct tccagaggag gagcagggat ctgggtttcc ttttttttt ctgttttggg 960
tgtactctag gggccagggt gggaggggga aggtgagggc ttcgggtggt gctataatgt 1020
ggcactggat cttgagtaat aaatttgctg tggtttgtaa aaaaaaaaa aaaaaacccc 1080
gnggggggcc ccgna 1095
```

<210> 184

<211> 3675

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (2204)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (3329)

<223> n equals a,t,g, or c

<400> 184

```
gcgagaaccg cctggagagc ctgccccgc agatgcgccg cctggtgcac ctgcagacgc 60
tcgtgctcaa tggaaacccc ctgctgcatg cacagctccg gcagctccca gcgatgacgg 120
ccctgcagac cctgcacctg cggagaccca gcgcaccag agcaacctgc ccaccagcct 180
ggaggggtctg agcaacctcg cagacgtgga tctgtcctgc aatgacctga cacgggtgcc 240
cgagtgtctg tacaccctcc ccagcctgcg ccgcctcaac ctgagcagca accagatcac 300
ggagctgtcc ctgtgcatag accagtgggt gcacgtggaa actctgaacc tgtcccgaaa 360
tcagctcacc tcaactgccct cagccatttg caagctgagc aagctgaaga agctgtacct 420
```

```

gaattccaac aagctggact ttgacgggct gccctcaggc attggcaagc tcaccaacct 480
ggaagagttc atggctgcca acaacaacct ggagctggtc cctgaaagtc tctgcaggtg 540
cccaaagctg aggaaacttg tctgaacaa gaaccacctg gtgacctcc cagaagccat 600
ccatttcctg acggagatcg aggtcctgga tgtgcgggag aacccaacc tggatcatgcc 660
gccaagccc gcagaccgtg ccgtgagtg gtacaacatc gacttctcgc tgcagaacca 720
gctgcggcta gcgggtgcct ctctgctac cgtggctgca gctgcagctg cgggagtggg 780
cccaaggacc ctatggctcg caagatgcga ctgcggaggc gcaaggattc agcccaggat 840
gaccaggcca agcaggtgct gaaggcatg tcagatgttg cccaggagaa gaacaaaaag 900
caggaggaga gcgcagatgc ccgggcccc agcgggraagg tgcggcgttg ggaccagggc 960
ctggagaagc ccgccttgac tactccgagt tcttcacgga ggacgtgggc cagctgcccg 1020
gactgaccat ctggcagata gagaacttcg tgctgtstct ggtggaggaa gccttcacg 1080
gcaagttcta cgaggctgac tgctacattg tgctcaagac ctttctggat gacagcggct 1140
ccctcaactg ggagatctac tactggattg gcggggaggc cacactcgac aagaaagctt 1200
gctctgccat ccacgtgtgc aacttgcgca actacctggg tgctgagtgc cgcactgtcc 1260
gggaggagat gggcgatgag agcaggaggt tcctgcaggt gtttgacaac gacatctcct 1320
acattgaggg tggaacagcc agtggttctt acactgtgga agacacacac tatgtcacca 1380
ggatgtatcg tgtgtatggg aaaaagaaca tcaagttgga gcctgtgccc ctcaagggga 1440
cctctctgga cccaaggtt gttttctgc tggaccgagg gctagacatc tacgtatggc 1500
ggggggccca ggccacactg agcagacca ccaaggccag gctctttgca gaaaaatta 1560
acaagaatga gcggaaggg aaggctgaga tcacactgct ggtgcagggc caggagctcc 1620
cagagttctg ggaggcactg ggtggggagc cctctgagat caagaagcac gtgcctgaag 1680
acttctggcc gccgcagccc aagctgtaca aggtgggcct gggcttgggc tacctggagc 1740
tgccacagat caactacaag ctctccgtgg aacataagca gcgtcccaag gtggagctga 1800
tgccaagaat gcggctgctg cagagtctgc tggacacgcg ctgcgttaac attctggact 1860
gttggtccga cgtgttcac tggctcggcc gcaagtcccc gcgcctggtg cgcgctgccg 1920
ccctcaagct gggtcaggag ctgtgcggga tgctgcaccg gccacgcat gccacggtca 1980
gccgcagcct cgagggcacc gaggcgcagg tgttcaaggc caagttcaag aattgggacg 2040
atgtgttgac ggtggactac acacgcaatg cggaggccgt gctgcagagc ccgggtctct 2100
ccgggaaggt gaaacgcgac gccgagaaga aagaccagat gaaggctgac ctactgcgc 2160
ttttctctgc gcggcagccg cccatgtcgc tggccgaggc ggancagctg atggaggagt 2220
ggaacgaaga ctagacggc atggagggtt tcgtgctgga gggcaagaag tttgcgcggc 2280
tgccggaaga ggagtttggc cacttctaca cgcaggactg ctacgtcttc ctctgcagg 2340
actgggtgcc tgtggagtac gaggaggagg aaaagaagga agacaaggag gagaaggccg 2400
agggcaaaga aggcaggaa gcaaccgctg aggcagagga gaagcagcca gaggaggact 2460
tccagtgcac cgtgtacttc tggcagggcc gtgaagcctc caatatgggc tggctcacct 2520
tcacctcag cctgcaaaag aagttcgaga gcctcttccc tgggaagctg gaggtggtac 2580
gcatgacgca gcagcaggag aacccaagt tcctgtccca tttcaagagg aagttcatca 2640
tccaccgggg caagaggaa ggcgtccagg gcgccaaca gccagcctc taccagatcc 2700
gcaccaacgg cagcgcctc tgcaccggg gcatccagat caacaccgac tccagcctcc 2760
tcaactccga gttctgcttc atcctcaagg ttccctttga gagtgaggac aaccagggca 2820
tcgtgtatgc ctgggtgggc cgggcatcag accctgacga agccaagttg gcagaagaca 2880
tcctgaacac catgtttgac acctcctaca gcaagcaggt tatcaacgaa ggtgaggagc 2940
ctgagaactt ctctgggtg ggcattgggg cacagaagcc ctatgatgac gatgccgagt 3000
acatgaacaa cacacgtctc ttccggtgct ccaacgagaa gggctacttt gcagtgactg 3060
agaaatgctc cgacttttgc caagatgacc tggcagatga tgacatcatg ttgctagaca 3120
atggccaaga ggtctacatg tgggtgggga ccagactag ccagggtggag atcaagctga 3180
gcctgaaagg ctgccaaggta tatatccagc acatgcggtc caaggaacat gagcggccgc 3240
gccggtgctg cctggtccgc aagggcaatg agcagcacgc ctttaccgc tgcttccacg 3300
cctggagcgc cttctgcaag gccctggcnt aagacaggct ggcacagccc caggcttggg 3360
gaggaagagg aaggggcctc atccactgtc tgctagcaaa gaatgtactc aggtgacacc 3420
acctgctcca gccacgtcca gtgccacagt cccagtagc ctcaagcagc accaatgggg 3480

```

```
atgaccctga caggtgccct caggggtctg ggaaatccaa ctctctccac agtgtgagtg 3540
cacgtgtgaa gcccctcac tcttccgcta gggataaagc agatgtggat gccctttaag 3600
agatattaaa tgcttttatt ttcaatatta aaaaaaaaaa aaaaaagggc ggccsctcgc 3660
gatctagaac tagtc 3675
```

<210> 185

<211> 1040

<212> DNA

<213> Homo sapiens

<400> 185

```
ggacagagcc tccactgagc tgctgcctgc ccgccacata cccagctgac atgggcaccg 60
caggagccat gcagctgtgc tgggtgatcc tgggttcctt cctgttccga ggccacaact 120
cccagcccac aatgaccagc acctctagct ctcaggaggc ccttgccggt ctaagtctga 180
ccacagagcc agtttcttcc aaccaggat acatcccttc ctcagaggct aacaggccaa 240
gccatctrtc cagcactggc accccaggcg caggtgtccc cagcagtgga agagacggag 300
gcacaagcag agacacattt caaactgttc cccccaattc aaccaccatg agcctgagca 360
tgagggaaga tgcgaccatc ctgcccagcc ccacgtcaga gactgtgctc actgtggctg 420
catttggtgt tatcagcttc attgtcatcc tgggtggtgt ggtgatcatc ctagttggtg 480
tggtcagcct gaggttcaag tgctcgaaga gcaaggagtc tgaagatccc cagaaacctg 540
ggagttcagg gctgtctgaa agctgtctca cagccaatgg agagaaagac agcatcacc 600
ttatctccat gaagaacatc aacatgaata atggcaaaca aagtctctca gcagagaagg 660
ttctttaaaa gcaactttgg gtcccatga gtccaaggat gatgcagctg ccctgtgact 720
acaaggagga agagatggaa ttagtagagg caatgaacca catgtaaatt atttattgt 780
ttcatgtctg cttctagatc taaaggacac tagcattgcc ccagatctgg gagcaagcta 840
ccaacagggg agactcttcc ctgtatggac agctgctgtg gaaatactgc ctgcttctcc 900
cacctcctca gagccacagg aaagaggagg tgacagagag agagcaagga aagtgatgag 960
gtggattgat actttctact ttgcattaaa attattttct agcctgcaaa aaaaaaaaaa 1020
aaaaaaaaaa aaaaactcga 1040
```

<210> 186

<211> 817

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (2)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (26)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (31)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (76)

<223> n equals a,t,g, or c

<400> 186

```

ancagctata gatcatgaca ggcaanggta nactgacagt acggtcggat tcccgggtcs 60
accacacgct ccgcangagc ggccgggtgg cgggaggaac cgttacggga actgaagttg 120
cggattaagc ctgatcaaga tgacaacctc ccaaaagcac cgagacttcg tggcagagcc 180
catgggggag aagccagtgg ggagcctggc tgggattggt gaagtcctgg gcaagaagct 240
ggaggaagg ggttttgaca aggcctatgt tgtccttggc cagtttctgg tgctaaagaa 300
agatgaagac ctcttcggg aatggctgaa agacacttgt ggcgccaacg ccaagcagtc 360
ccgggactgc ttcggatgcc ttcgagagt gtgcgacgcc ttcttgatg gctctctggg 420
aagctctcaa tcccagccc tcatccagag tttgcagccg agtagggact cctcccctgt 480
cctctacgaa ggaaaagatt gctattgtcg tactcacctc cgacgtactc cggggtcttt 540
tgaggagttt ctcccctaac catttcaact tttttttgga ttctcgtct tgcattgcctc 600
ccccgtcctt tttcccttgc cagttccctg gtgacagtta ccagctttcc tgaatggatt 660
cccgcccca tccctcacc ccacctcac tttcaatccg tttgatacca tttggtcct 720
tttttggcag aacagtcact gtccttgtaa agtttttag atcaataaag tcagtggtt 780
tcaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaa 817

```

<210> 187

<211> 1080

<212> DNA

<213> Homo sapiens

<400> 187

```

ctgccctgct gctggaacac cgagccagcc tgagcgctaa ggaccaagac ggctgggagc 60
gctgcacgcc gcggtactg gggccaggtg cctgggtggag ctgctcgtgg cgcacggggc 120
cgacctgaac gcaaagtccc tgatggacga gacgcccctt gatgtgtgcg gggacgagga 180
gggtcgggcc aagctgctgg agctgaagca caagcacgac gccctcctgc gcgccagag 240
ccgcagcgc tccttgctgc gccgcgcac ctccagcgc ggagccgcr ggaagggtgt 300
gaggcggtg agcctaacc agcgcaccga cctgtaccgc aagcagcacg cccaggaggc 360
catcgtgtg caacagccgc cgcaccag cccggagccg cccgaggaca acgatgaccg 420
ccagacaggc gcagagctca ggccgcccgc cccggargag gacaaccccg aagtgggtcag 480
gccgcacaat ggccgagtag ggggtcctcc agtgcggcat ctatactcca agcgactaga 540
ccggagtgtc tcctaccagc tgagccccct ggacagcacc acccccaca ccctggtcca 600
cgacaaggcc caccacacc tggctgacct gaagcggcag cgagctgctg ccaagctgca 660
gcgaccccca cctgaggggc ccgagagccc tgagacagct gagcctggcc tgcctggtga 720
cacggtgacc cccagcctg actgtggctt cagggcaggc ggggaccac ccctgctcaa 780
gtcacagcc ccggcggtgg aggtcccgt ggagaggagg ccgtgctgcc tgctcatgtg 840
aggctgttgc tcagcatgca ggggccctgt cgcgggcaca gcccaaggct gcctccccc 900
gggtgctgcc ctggtgctgc ggggtgcagca cggaacccc ggcttctact gtacaggaca 960
ctggcccctc tcaggctcga agacatgcct ggagggatgt ctggctgcaa agactatctt 1020
taccctgcaa ctcttgataa agggctgttt tgccatggaa aaaaaaaaaa aaaaaaaaaa 1080

```

<210> 188

<211> 1286

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature
 <222> (1245)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1254)
 <223> n equals a,t,g, or c

<400> 188
 gcatgattct tgtttttag agatgcaggc tcaaaaagta atgcatgttt cttcagcaga 60
 actgaattat tcaactgccat atgactctaa acaccaaata cgtaatgcct ctaatgtaaa 120
 gcaccatgac tctagtgtc ttggtgtata ttcttacata ccttttagtg aaaatcctta 180
 tttttcatca tggcctccaa gtggtaccag ttctaagatg tctcttgatt tacctgagaa 240
 gcaagatgga actgtttttc cttcttctct gktgccaaaca tcctctacat ccctcttctc 300
 ttattacaat tcacatgatt ctttatcact gaattctcca accaatattt cctcactatt 360
 gaaccaggag tcagctgtac tagcaactgc tccaaggata gatgatgaaa tccccctcc 420
 acttcctgta cggacacctg aatcatttat tgtggttgag gaagctggag aattctcacc 480
 aaatgttccc aaatccttat cctcagctgt gaaggtaaaa attggaacat cactggaatg 540
 ggggtggaaca tctgaaccaa agaaatttga tgactctgtg atacttagac caagcaagag 600
 tgtaaaaactc cgaagtctta aatcagaact acatcaagat cgttcttctc cccacacctc 660
 tctcccagaa agaactctag agtccttctt tcttgccgat gaagattgta tgcaggccca 720
 atctatagaa acatattcta ctagctatcc tgacaccatg gaaaattcaa catcttcaa 780
 acagacactg aagactcctg gaaaaagttt cacaaggagt aagagtttga aaattttgag 840
 aaacatgaaa aagartatct gtaattcttg cccaccaaac aagcctgcag aatctgttca 900
 gtcaaataac tccagctcat ttctgaattt tggttttgca aaccgtttt caaaacccaa 960
 aggrccaagg aatccaccac caacttgga tatttaataa aactccagat ttataataat 1020
 atgggctgca agtacacctg caaataaaac tactagaata ctgctagtta aaataagtgc 1080
 tctatatgca taatatcaaa tatgaagata tgctaagtgt ttaatagctt ttaaaagaaa 1140
 agcaaaatgc caataagtgc cagttttgca ttttcatatc atttgcatg agttgaaaac 1200
 tgcaaaataa agtttgtcac ttgagcttat gtacagaatg ctatntgggg aacnctttta 1260
 ggatggggtt tatttttcca tttttg 1286

<210> 189
 <211> 1738
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (1480)
 <223> n equals a,t,g, or c

<400> 189
 gcggcgccct cggagccaaa ggcgcgcggc ggacacggcg gggccctcgc gcgcctggag 60
 acgatgccaa agctgcaggg cttcgagttc tggagccgca ccctgcgagg ggcccgccac 120
 gtcgtggccc ccatggtgga ccagagcgag ctggcctgga ggctgctgag ccggcgccac 180
 ggggcacagc tctgctacac gcccattgtg catgcccagg tctttgtccg cracgccaac 240
 taccggaagg agaacctgta ctgcgaggtg tgccccgagg accggccct catcgtgcag 300
 ttctgtgcca atgaccgga ggtgtttgtt caggcggtc tcctggctca ggattactgt 360
 gacgccattg acctgaactt gggctgcca cagatgatag ccaagagagg tcactatggc 420

```

gcctttctgc aggacgagtg ggacctgctc caaagaatga ttttgctggc ccacgagaaa 480
ctctctgttc ctgtcacgtg caaaatccgt gtcttcccgg agattgacaa gaccgtgagt 540
acgcccagat gctggagaag gccggctgcc agttgctgac ggtgcacgga cgcaccaagg 600
agcagaaggg gccctgtcg ggtgcagcgt cctgggagca tatcaaggct gtgcggaagg 660
ctgtggccat ccctgtgttt gctaacggga acatccagt cctgcaggac gtggagcgct 720
gcctccggga caggggtgtg cagggcgtca tgagcgaga gggcaacctg cacaacccc 780
ccctgttcga gggccggagc cctgccgtgt gggagctggc cgaggagtat ctggacatcg 840
tgccggagca cccctgcccc ctgtcctacg tccgggccc cctcttcaag ctgtggcacc 900
acacgctgca ggtgcaccag gagctgcgag aggagctggc caaggtgaag accctggagg 960
gcatcgctgc tgtgagccag gagctgaagc tgcggtgtca ggaggagata tccaggcagg 1020
agggagcgaa gccaccggc gacttgccct tccactggat ctgccagccc tacatccggc 1080
cggggcccag ggaggggagc aaggagaagg caggtgcgcg cascaagcgg gccctggagg 1140
aagaggaggg tggcacggag gtcctgtcca agaacaagca aaagaagcag ctgaggaacc 1200
cccacaagac cttcgacccc tctctgaagc caaaatatgc aaagtgtgac cagtgtggaa 1260
accaaaggg caacagatgt gtgttcagcc tgtgccgcgg ctgctgcaag aagcgagcct 1320
ccaaagagac tgcaactgc ccaggtcacg gattgctttt taaaaccaa ttggagaagt 1380
ctctggcctg gaaagaggcc cagcctgagc tgcaggagcc tcagccagca gcacctggaa 1440
caccaggtgg ctctccgaa gtcattggca gtgcctggn ctgaaggccc acaaccccca 1500
ccccaggac tgctgtgga gcctggacac gtcctactta agaaaatgcc ttttactcag 1560
ggaatctcct gctacttaat gtggaaagac acgccatgt ccccttcgc cactctggg 1620
ggcctgaaa tgctgcagtg gggagcaggc ccaggtgg acctgccctg tcctcagcac 1680
gcgtgtgcaa aagtgaacaa taaatcattt caaagatgaa aaaamaaaa aaaaaaaa 1738

```

<210> 190

<211> 1923

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1829)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1875)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1910)

<223> n equals a,t,g, or c

<400> 190

```

agcacatcaa atgccccac tccaagtacg ggtgcacgtt catcggaac caggacactt 60
acgagaccca cctggagact tgccgcttcg agggcctgaa ggagtttctg cagcagacgg 120
atgaccgctt ccacgagatg cactggctc tggcccagaa ggaccaggag atcgcccttc 180
tgcgctccat gctgggaaag ctctcggaag agatcgacca gctagagaag agcctggagc 240
tcaagtttga cgtcctggac gaaaaccaga gcaagctcag cgaggacctc atggagtttc 300
ggcgggacgc atccatgtta aatgacgagc tgtccacat caacgcgcgg ctgaacatgg 360
gcatcctagg ctctacgac cctcagcaga tcttcaagt caaagggacc tttgtgggccc 420

```

```

accagggccc tgtgtggtgt ctctgctct actccatggg tgacctgctc ttcagtggct 480
cctctgacaa gaccatcaag gtgtgggaca catgtaccac ctacaagtgt cagaagacac 540
tggaggggcca tgatggcatc gtgctggctc tctgcatcca ggggtgcaaa ctctacagcg 600
gctctgcaga ctgcaccatc attgtgtggg acatccagaa cctgcagaag gtgaacacca 660
tccggggccca tgacaacccg gtgtgcacgc tgggtctcctc acacaacgtg ctcttcagcg 720
gctccctgaa ggccatcaag gtctgggaca tcgtggggcac tgagctgaag ttgaagaagg 780
agctcacagg cctcaaccac tgggtgcggg ccctggtggc tgcccagagc tacctgtaca 840
gcggctccta ccagacaatc aagatctggg acatccgaac ccttgactgc atccacgtcc 900
tgcagacgtc tgggtggcagc gtctactcca ttgctgtgac aaatcaccac attgtctgtg 960
gcacctacga gaacctcatc cacgtgtggg acattgagtc caaggagcag gtgcggaccc 1020
tcacgggcca cgtgggcacc gtgtatgcc tggcggtcac ctcgacgcca gaccagacca 1080
aagtcttcag tgcatcctac gaccgggtccc tcagggtctg gagtatggac aacatgatct 1140
gcacgcagac cctgctgcgt caccagggca gtgtcaccgc gctggctgtg tcccggggcc 1200
gactcttctc aggggctgtg gatagcactg tgaaggtttg gacttgctaa caggatccag 1260
gccaggctgt gggttccctt gaaccagccc tggaccttct tgagccaggc tggccacatg 1320
gggtggtctc ggggtttctg cctgccccgt gggcataggt ggacaggctc tggcagccgg 1380
gcagtgcctt ccccgctcca tgctcggcga gcctccctct actcggcact gtccttgctg 1440
cccagccctt ctctgggtgc caggtagcag gcttgccccg gcccacctc catccccacc 1500
ctccatcccc accctagatg gagcgagggc ctttttactc accttttcta ccgtttttag 1560
actgtatgta gatttggtta cctcctggtt gaaataaatg ctccacagac tgtggctgtg 1620
agtggggaca gctcctcggg acaagggggc tgtgtgtggc cttgaggttg gtgtgcacag 1680
gcactggctg ctgtgagtg gggggcatgg ggcagtttcc tttggtggac cccaggaytt 1740
cggsgcamtc cggggsctcc cctccctgct aggaggcaca ccctcagagg agctgcaagc 1800
ccgtggctgc ctgctacatg ccctgcttnc acgtggctgc acgtgacac acccacattc 1860
accaaaccce cccgngccct gggacgcaac cacgccagga ggaggacacn ggccgcccag 1920
agc 1923

```

```

<210> 191
<211> 250
<212> DNA
<213> Homo sapiens

```

```

<400> 191
ccaagtgtgt tgatacatta agctatgaga catctaaaat aatgaaactt ggaacttagt 60
ggaacatgta catgttttca gcatacttaa acccaaaaat cattaatttt cagaacttaa 120
tcagtgtctt tacatttgtt ttttctttta tgctagttagg aaatggagga tgaaratata 180
attgrtgtgt tccaacagca gacgggrggt gtctactgaa aagggaacct gcttctttac 240
tccagaactc 250

```

```

<210> 192
<211> 1902
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc feature
<222> (1)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc feature

```

<222> (8)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (19)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (763)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1898)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1900)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1901)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1902)

<223> n equals a,t,g, or c

<400> 192

ngggacgntg gtagaccanc gcgtaccgct gagtcaratt ttggcatcaa cttgaagggc 60
ccaaaaatca aaggagggtgc ggatgtttca gggggtgtca gtgccccara catcagcctt 120
ggtgaagggc atttragtgt taaagggtcc gggggtgagt ggaagggacc ccaagtctcc 180
tctgctctca acttgacac atctaagttt gctgggggcc ttcatttctc aggaccaaag 240
gtggaaggag gtgtgaaagg aggtcagatt ggactccagg ctcttggtgct gagtgtgtct 300
gggcctcaag gtcacttgga aagtggatct ggaaaagtaa cattccctaa aatgaagatc 360
cccaaattta ctttctctgg ccgtgagctg gttggcagag aaatgggggt ggatgttcac 420
ttccctaaag cagaggccag catccaagct ggtgctggag acggcgagt ggaagagtct 480
gaagtcaaac tgaaaaagtc caagatcaaa atgcccaggt ttaatttttc caaacctaaa 540
gggaaagggt gtgtcactgg ctccaccagaa gcatcaattt ctgggtccaa aggtgacctg 600
aaaagtcaag aggcagcct gggctctctg gaaggagagg cagaggccga agcctcttca 660
ccgaaaggca aattctcctt atttaaaagt aagaagccac ggaccgctg caaattcatt 720
cagtgatgaa agagagttct ctggaccttc caccgcgacg ggnacgctgg agtttgaaag 780
tggggaagtg tctctggaag gtgggaaagt taaagggaaa cacgggaagc tgaaattcgg 840
tacctttggg ggattggggc caaagagcaa aggtcattat gaggtgactg ggagcgatga 900
tgagacaggc aagttacagg ggagtggggg gtccctggcc tctaagaagt cccgactgtc 960
ctcctcttct agcaatgaca gtgggaataa ggttggcatc cagcttcccc aggtggagct 1020


```

gtcagtttcc acaaagaaag agtagcaggc ctttgtatgt gtgtacatat atatatatat 1080
aacaaaacat cagccttggg tgggtgtgtc ctatataaac tccaaaggga aacacaccga 1140
ctgcctcagc aatcatgcaa agaccttgcc tggcccgggtg gcaagcgctg aaaaaccgac 1200
cgctgtagg ctcctggaac tatacagata ggtaaagagt tccaagttcg tccagcccat 1260
gtgcaaagtc aacagtattt gcottaagat ttcatatata tatatttttt tgcattgact 1320
gctgagagct cctgtttact aagcaagctt ttgtgtttat tatcctcatt tttactgaac 1380
attgttagtt ttggggtaat ggaaaccac tttttcattg taatgacttt gggggctttt 1440
gttagtaagg gtgggtgggg tgatgggtg cagacggagg tcaggtcttc ctctttcctg 1500
agactggatc tgttcaaaca gcaaaccgcc acagatggcc cagaggtggt ggtagtcagg 1560
gtgtgtgggt gtttttaggg ttcttttagt ttgtttcttt caccaggggg tgggtgggtccc 1620
agccagtttg gtgctgacgg tgagaggaaa ttagaatctg tttgcaaatt gtccaacca 1680
ccccctcaac atgaggggct tccattttct gtgttttgta agggaaactgt ttccttcatt 1740
ccgccatgtt cctgatatta gttctgattt ctttttaaca aatgttatca tgattaagaa 1800
aatttccagc actttaatgg ccaattaact gagaatgtaa gaaaattgaw gctgtacaag 1860
gcaaataaag ckgttattaa cctgaaaaaa aaaaaanan nn 1902

```

<210> 193

<211> 560

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (20)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (528)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (535)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (559)

<223> n equals a,t,g, or c

<400> 193

```

ttttgcttaa agctatttan gtgacactat agaaggtagc cctgcaggta ccggtccgga 60
attcccgggt cgaccacgc gtccggggtt gcagacggag gtcaggtctt cctctttcct 120
gagactggat ctgttcaaac agcaaacgcc cacagatggc ccagaggtgg tggtagtcag 180
ggtgtgtggg tgtttttagg gttctttagt gttgtttctt tcaccagggt gtggtgggtc 240
cagccagttt ggtgctgacg gtgagaggaa attagaatct gtttgcaaat tgtccaacct 300
acccccctca catgaggggc ttccattttc tgtgttttgt aagggaactg tttccttcatt 360
gccgccatgt tcctgatatt agttctgatt tctttttaac aaatgttatc atgattaaga 420
aaatttccag cactttaatg gccaatatg tgagaatgta agaaaattga tgctgtacaa 480
ggcaataaaa gctgtttatt aaccttgaaa aaaaaaaaaa aaagggngng ccggncccat 540

```

tgccctaggg ggggttaant

560

<210> 194

<211> 590

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (589)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (590)

<223> n equals a,t,g, or c

<400> 194

ctgcaggtagc cgggtccggaa ttccgggtcg cccacgcgtc aggcggcggc gatgaccttc 60
tgccggctgc tgaaccgggtg tggcgaggcg gcgcggagcc tgcccctggg cgccagggtgt 120
ttcgggggtgc ggggtctcgcc gaccggggag aaggtcacgc aactggcca ggtttatgat 180
gataaagact acaggagaat tcggtttgta ggtcgtcaga aagagggtgaa tgaaaacttt 240
gccattgatt tgatagcaga gcagcccggtg agcgagggtg agactcgggt gatagcgtgc 300
gatggcgggcg ggggagctct tggccacca aaagtgtata taaacttgga caaagaaaca 360
aaaaccggca catgcggtta ctgtgggctc cagttcagac agcaccacca ctagagcgtg 420
tggcacgccg ggggtccgc agcatcctgt gagcatttc gcggggaagc tgagcacgtg 480
aagctcgtg gttctgtgc aagggtattc ctggtgctga ataaagggtg ttgctgtcaa 540
gaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaann 590

<210> 195

<211> 691

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (10)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (579)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (618)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (639)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (657)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (672)

<223> n equals a,t,g, or c

<400> 195

```
attggcatcn tctgaaagcg ttttagacag gcagaatctc tgggtctccc tctctgcatt 60
ccccaccag tgaatgaatg agaatctgca tttcttgaga tcataagaat actgacatac 120
agatgagata aaactcatgt gaatatcagt ttttaaggctg gtggttcatt tgttttggtc 180
atattgagtc aggattgact aatgaactgt agaggttttg cattatgcaa atgctcttaa 240
tttcttgat taggaattag acgctcccc ccaagtctta aataatgttt taatctgtat 300
ccttttatta taagaagatt agtaatatc tacagataat aacaacaact ggtatagtat 360
attttattta cattcttcat tcttaggaga aaatgctgag aagcttctgc agttcaagcg 420
ttggttctgg tcaatagtag agaagatgag catgacagaa cgacaagatc ttgkttactt 480
ttggacwtca agcccatcac tgccagccag tgaagaagga ttccagccta tgccctcaat 540
cacaatawga ccaccagatg accmacatct tcctactgna aaatacttgc atttcttggg 600
ctttaccttc ccactctntt cctttaaaca ggattctttna aaccggaaat tgggttancct 660
gccatttagg anccaaaaat tttgggtttt g 691
```

<210> 196

<211> 1772

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (2)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1749)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1769)

<223> n equals a,t,g, or c

<400> 196

```
gnataatgct ggccattttg cctttctgac atttccttgg gaatctgcaa gaacctcccc 60
tttcccttcc cmcaataaga ccatttaagt gtgtgytaaa caactacrga atactaaata 120
aaaagtgttg ccaaaaccaa ccatgaagct gcaaaggctg ttgctcttac tstttcaaat 180
```

```

ttttgcaact ctartgtctc actttttaaag gaacagcttg attgcaaagg agaaaataga 240
taagcaatga akttatctcc aacttcctaa aggccttatga cttctaaaaa gtgaatctat 300
cagcattcca catcagattt aaagcatcaa atgcctgtga aacagcaaag atgggtgaag 360
attgtgctca ttatgtttgt ggagtgtgta ttgattcaca gtagataacg ctggcagtaa 420
gagaaatcaa atgctaagag ttgttgaagc agaaggcggc tgattgttgg taagtcagtg 480
cagttgcata agcagtgtcg tcagaattgg tttgggtgcag gcaatagatt ttgccttcaa 540
gggttcctgt ggatctcagg aaggcatcag tgttgattaa cactcataac tagggagtga 600
stggtagtta cttaagtaat tgaccaaagtg gaaaagggga agtaattaag gaaattggta 660
agtggaggta gtcaggargt tctygtggtt cttacayag attttacagc tttggstttc 720
attttgttta gctaaagtca tggggacaac tcttcaattt agaacttaag ttgaattata 780
aaaatgatgg atataagtgg tagctgtatc tagtgaagtg tctgtcagta agtgaacat 840
tttttgggtg tggcttatcc acaaacagtt tagttgtaga ataaaactta tgagtgcacat 900
ctggaaagta accatgctaa gatggcaagc acactggaaa caattaggcc acttggtctt 960
cttttgctgt attgttttat aagcctactt tacctcccag tcttggaac aagttttagt 1020
tttttattgg ttgggagact agagccaata gtataatgtt ctcaaaggaa acagacttga 1080
gttgttggtg tagaggaact aacccaactt atatgatttt ttttttgtt ttgtcgtgta 1140
gttatggcac tgtcttattt ggaacatttg caactaggga taatacaaca tttttaactc 1200
tcatttgaca acctactact aatcacagac cacaagggtg atgaccaa attatgtggtt 1260
tttgcaactc atagtgtgtc tagcccaatc tttctatact cttacgatta cttgggttaa 1320
cgcyctgtg aggaccttct ggctcttgag ataccctaaa tatttaagat atttagatat 1380
cttgaagata gtataggata tagagattgt accaaatagg aatataagga gtatgttaaa 1440
atgaccagat acctgtttga tagtttactg acctagcaga tgtgtggaaa aggaatcaga 1500
tcttgattct tctgggttta tactgggtgt aaaacagaat gatacagaaa atgttttcct 1560
tgtttaactg gtatgtgaac atagaacttg ggtattatag atcacttttc actttttgga 1620
atgttttgta ttgaaactta ataaaacttt aacatggcaa aaaaaaaaaa aaaaaaaaaa 1680
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1740
aaaaaaagana aaaaaaaaag gggggggccnc cc 1772

```

<210> 197

<211> 675

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (657)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (671)

<223> n equals a,t,g, or c

<400> 197

```

accacgcgt ccggacttcc tcttcgttaa gtcggccttc ccaacatggc gcagtctatt 60
aacatcacgg agctgaatct gccgcagcta gaaatgctca agaaccagct ggaccaggaa 120
gtggagttct tgtccacgtc cattgctcag ctcaaagtgg tacagaccaa gtatgtggaa 180
gccaaaggact gtctgaacgt gctgaacaag agcaacgagg ggaaagaatt actcgtccca 240
ctgacgagtt ctatgtatgt ccctgggaag ctgcatgatg tggaacacgt gctcatcgat 300
gtgggaactg ggtactatgt agagaagaca gctgaggatg ccaaggactt cttcaagagg 360
aagatagatt ttctaaccac gcagatggag aaaatccaac cagctcttca ggagaagcac 420

```

```

gccatgaaac aggccgtcat ggaaatgatg agtcagaaga ttcagcagct cacagccctg 480
ggggcagctc aggctactgc taaggcctga gagtttttgc agaaatgggg cagagggaca 540
ccctttgggc gtggcttcct ggtgatggga agggctctgt gttttaatgc caataaatgt 600
gccagctggg caraaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaccccnngg 660
gggggcccgg naccc 675

```

<210> 198

<211> 557

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (451)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (461)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (464)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (488)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (492)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (495)

<223> n equals a,t,g, or c

<400> 198

```

tttaggtgac acgtatagaa ggtgcctgc aggtaccggw ccggaattcc gggtcgaccc 60
acgcgtccgg gaacacaaga tgccgaaggg aagaaggcga aggggaagaa ggtggccccg 120
gccccgcgg tcgtgaagaa gcaggaggcc aagaaggagg tcaaccgct gttcgagaag 180
cggcccaaga acttcggcat cggtcaggac atccagccca agcgggacct gacgcgcttc 240
gtcaagtggc cgcgctacat ccggctgcag cggcacgcgc gatcctctac aagcggctga 300
aggtgccgcc gccatcaac cagttcacgc aggcgctgga ccgccagacg gccacgcagc 360
ttgcttgaag ctggcgacac attaccggcc cgagacgaag caggagaaga agcagcgggt 420
gttgccccgg gcggagaaga aarcggccgg ncaaggggga nttncggaac aagcggsgcc 480
cgttgtntnc gnaancgggg ttgaaaacgg ttcaacaagt tggttgagga acaagaaggc 540

```

gccattggtt cgttatt

557

<210> 199

<211> 2611

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (3)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2549)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2560)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2585)

<223> n equals a,t,g, or c

<400> 199

```

tcncgggtcg acccaagcgt ccggcgagga gtaccttacc aacttggecc acatggacat 60
cgacaaggac tggaggcccc gctgtacctc acccccagag gctgggccct ctccctccag 120
cgctactacc aagtgggtcca cgaaggggca gaactcaggc acctcgacac tcaggtccag 180
cgctgtgagg acatcctgca gcagctgcag gccgtggtac cccagataga catggaaggg 240
gatcgcaaca tctggatcgt gaagccagga gccaagtccc gcggacgagg catcatgtgc 300
atggaccacc tggaggagat gctgaagctg gtgaacggca accccgtggt gatgaaggac 360
ggcaagtggg tgggtgcagaa gtatatgtag cgccccctcc tcatctttgg caccaagttt 420
gacctcagac agtgggttcct ggtaactgac tggaaacccac ttaccgtgtg gttctaccgc 480
gacagctata tccgcttttc cacgcagccc ttctccctga agaacctgga caactcagtg 540
cacctgtgca acaactccat ccagaagcac ctggagaact catgccatcg gcatccactg 600
cttccgccag acaacatgtg gtctagccag aggttccagg cccacctgca ggagatgggt 660
gccccaaatg cttgggtccac catcatcgtg cctggcatga aggatgctgt gatccacgca 720
cttcagacct cccaggacac cgtgcaatgt cggaaggcca gctttgagct ctatggcgct 780
gacttcgtgt tcggggagga cttccagccc tggctgattg agatcaacgc cagccccacg 840
atggcaccct ccacagcagt cactgcccgg ctctgtgctg gcgtgcaagc tgacaccctg 900
cgcgtggtca ctgaccggak gctggaccgc aactgtgaca caggagcctt tgagctcatc 960
tataagcagc ctgctgtgga ggtgcctcaa tatgtgggca tccggctcct ggtagagggc 1020
ttcaccatca agaagcccat ggcgatgtgt catcgcgga tgggggtccg ccagcagtc 1080
ctctgctgac ccagcgaggc tctggggaag gcaaggactc ggggacccct acccacaggt 1140
cagcttctag gaaaggcact gggggccagga gcctggggca cagtgagaag ccagtctcca 1200
ctgccaccac ttcagccccc ggaaagggga agaaagccga ggtatcagga agtttaagga 1260
agttgcccac gggtgcacag ctcagaaggg gcacagctgg gatgcagacc cagcccgctc 1320
ccacttcccc agcctccaca ccaaggccca gctgccttct ccccatgtac tccgacacca 1380

```

```

gggccaggtc ctcagacgac agcacagcaa gctggtgggc actaaggccc tgtcgaccac 1440
aggcaaggcc ttgaggactc taccacggc taagggtctt atttccctcc caccgaacct 1500
tgatttcaag gtggcaccga gcatcctgaa gccaaagaaag gtgggcctcg acctgtgact 1560
cacacccagt ggacagtgtc gagcacgggg tcagggtgtg agggcacagg cagagggcag 1620
ctcccaggct ggctggcacc ccaagggaag agctggtctc cctcagaagc cccttctctc 1680
acagacttct gatcatctcc ctcttctccc ctcttttcac accgaggctc ctgctctcct 1740
gtgcctccga ggcccccagc tggaagtgcc ttgttgctc tgccctttga agtcggaaca 1800
attcctagca cctgtcgga ggtcaaggcc aaaggcaaat tcaaggccag actgtgacaa 1860
accacaggct gaggcctgcc ccatgaagag gctgagcccc ctgaaacccc tgccccctgt 1920
tggtacattc cagaggcgca ggggcctggg ggatatgaag ctagggaagc ccctgcttcg 1980
attccccact gcccttgtcc tggatccaac accaaataaa aagaaacaag tgaagtattt 2040
ggggcttgac tccattgtc ttggaggktc aagagtggat ggggcgaggc cgtgtacccc 2100
aggttcaca gcaagagcct gaggccatca gcagytctc cgtgcagmga ggcccagaat 2160
tcccaccta ggacagacat ggggcttctt atttagggac tccccagca tctccgatcc 2220
aggggtggg agcgtgacct tcactttaca gatgaagaa ctgagtctga aagaggaggc 2280
atggcttacc caagatcacg tggcagtga tcgacgcagg gacatattgc cagaactgcc 2340
gagcactggg agccccccaa cccagagaa caagccaagc tagcagaatg acacctaccg 2400
ggcataggaa cgtaaatgcc atgagacaag ggaaggattk gcttgctaaa mctcagccct 2460
tytgagaag gcatkgtct atccctctt cagcaaagg gcaaggtcac taaaaatgaa 2520
catccataag ccacaaccac tggagaaant tttgactgn ttagtgtagt tggttgaatg 2580
tgggnccccg gaaagagatg ttacttgga c 2611

```

<210> 200

<211> 2316

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (2280)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2282)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2302)

<223> n equals a,t,g, or c

<400> 200

```

ggcacgagga aacatggagt cctgtaggca aggtcttacc tgaatcagga tgagggagtg 60
gtgggtccag gtggggctgc tggccgtgcc cctgcttgct gcgtacctgc acatcccacc 120
ccctcagctc tccctgccc ttactcatg gaagtcttca ggcaagtttt tcaacttaca 180
gggactcgt atcttctacc aagactctgt ggggtgtggtt ggaagtccag agatagtgtg 240
gctttttacac ggtttttccaa catccagcta cgactggtac aagatttggg aaggtctgac 300
cttgaggttt catcgggtga ttgcccttga tttcttaggc tttggcttca gtgacaaacc 360
gagaccacat cactattcca tatttgagca ggccagcatc gtggaagcgc ttttgcgga 420
tctggggctc cagaaccgca ggatcaacct tctttctcat gactatggag atattgttgc 480

```

```

tcaggagctt ctctacaggt acaagcagaa tcgatctggt cggcttacca taaagagtct 540
ctgtctgtca aatggaggta tctttcctga gactcaccgt ccactccttc tccaaaagct 600
actcaaagat ggagggtgtgc tgtcacccat cctcacacga ctgatgaact tctttgtatt 660
ctctcgaggt ctacccccag tctttgggcc gtatactcgg ccctctgaga gtgagctgtg 720
ggacatgtgg gcagggatcc gcaacaatga cgggaactta gtcattgaca gtctcttaca 780
gtacatcaat cagaggaaga agttcagaag gcgctgggtg ggagctcttg cctctgtaac 840
tatccccatt catcttatct atgggccatt ggatcctgta aatccctatc cagagttttt 900
ggagctgtac aggaaaacgc tgccgcggtc cacagtgtcg attctggatg accacattag 960
ccactatcca cagctagagg atcccatggg cttcttgaat gcataatagg gcttcatcaa 1020
ctccttctga gctggaaaga gtagcttccc tgtattacct cccctactcc cttatstggt 1080
gtgtattoca cttaggaaga aatgcccata agaggtcctg gccatcaaac ataattctct 1140
cacaaagtcc actttactca aattggtgaa cagtgtatag gaagaagcca gcaggagctc 1200
tgactaaggt tgacataata gtccacctcc cattactttg atatctgac aaatgtatag 1260
acttggtttt gttttttgtg ctattaggaa attctgatga gcattactat tcaactgatgc 1320
agaaagacgt tcttttgcac aaaagacttt ttttaacact ttggacttct ctgaaatatt 1380
tagaagtgtt aatttctggc ccacccccaa caggaattct atagtaagga ggaggagaag 1440
gggggctcct tccctctcct cgaatgacgt tatgggcaca tgccttttaa aagttcttta 1500
agcaacacag agctgagtc tctttgtcat acctttggat ttagtgtttc atcagctgtt 1560
tttagttata aacatcttgt taaaatagat attggtttaa atgatacagt attttaggta 1620
tgatttaaga ctatgattta cctatacatt atatatatt tataaagata ctaaaccagc 1680
atacccttac tctgccagag tagtgaagct aattaaacac gtttggtttc tgaataaatt 1740
gaactaaatc caaactatct cctaaaatca caggacatta aggaccaata gcatctgtgc 1800
cagatagtga ctgtatttag ctgggaagac caattctaac agcaaataac agtctgagac 1860
tcctcatacc tcagtgggta gaagcatgtc tctcttgagc tacagtagag ggggaaggat 1920
tggtgtgtag tcaagtcacc atgctgaatg tacactgatt cctttatgat gactgcttaa 1980
ctccccactg cctgtcccag agaggctttc caatgtagct cagtaattcc tgttacttta 2040
cagacaggaa agttccagaa actttaagaa caaactctga aagacctatg agcaaattgt 2100
gctgaatact ttttttttaa agccacattt cattgtctta gtcaaagcag gattattaag 2160
tgattattta aaattcggtt ttttaaatta gcaacttcaa gtataacaac tttgaaactg 2220
gaataagtgt ttattttcta ttaataaaaa tgaattgtga caaaaaaaaaa aaaagggccn 2280
gncccgtttt aaaagggatc cnaagcttta ccgtac 2316

```

<210> 201

<211> 1147

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (5)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (6)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (11)

<223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (12)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (19)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1145)
 <223> n equals a,t,g, or c

<400> 201
 cgcannccac nnggtggang ccgctctaga atatggatcc cccgggactg cagggagtc 60
 aaggtacagt cggcgcggtgc ggagcttggt actgggtact tggcctcatg gcggtccgag 120
 cttcgttcga gaacaactgt gagatcggct gctttgcca gctcaccaac acctactgtc 180
 tggtagcgat cggaggctca gagaacttct acagtgtgtt cgagggcgag ctctccgata 240
 ccattcccgt ggtgcacgcg tctatcgccg gctgccgcat catcgggccc atgtgtgtgg 300
 ggaacaggca cgggtctcctg gtacccaaca ataccaccga ccaggagctg caacacattc 360
 gcaacagcct cccagacaca gtgcagatta ggcggtgga ggagcggctc tcagccttgg 420
 gcaatgtcac cacctgcaat gactacgtgg ccttgggtcca cccagacttg gacagggaga 480
 cagaagaaat tctggcagat gtgctcaagg tggaagtctt cagacagaca gtggccgacc 540
 aggtgctagt aggaagctac tgtgtcttca gcaatcaggg agggctggtg catcccaaga 600
 cttcaattga agaccaggat gagctgtcct ctcttcttca agtccccctt gtggcgggga 660
 ctgtgaaccg aggcagtga gtgattgtg ctgggatggt ggtgaatgac tgggtgtgct 720
 tctgtggcct ggacacaacc agcacagagc tgtcagtggg ggagagtgtc ttcaagctga 780
 atgaagccca gcctagcacc attgccacca gcatgcggga ttccctcatt gacagcctca 840
 cctgagtcac cttccaagtt gttccatggg ctccctggctc tggactgtgg ccaaccttct 900
 ccacattccg cccaatctgt accggatgct ggagggagg tggcagagag ctactggga 960
 ctgaggggct gggcacccaa cccttttcca cctgtgctta tcgcctggat ctatcattac 1020
 tgcaaaaacc tgctctgttg tgctggtgg caggccctgt ggctgctggc tgaggggtct 1080
 gctgtcctgt gccaccccat taaagtgcag ttccctccgg aaaaaaaaaa aaaaaaaggg 1140
 cgcnac 1147

<210> 202
 <211> 688
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (477)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (684)

<223> n equals a,t,g, or c

<400> 202

```
acgtaccggt ccggttaattc cggggtcgac ccacgcgtcc gtcggcgggg cgctggtgag 60
ggagtcgggc cgcgactgtg gtcgttttta taccttcccg cgcggacgcc ggcgctgcc 120
acggaagggc gggtaggacg gagtttcgtc atgttgacca ggcccatttg agatctttga 180
agatatactc aacgtgaggc tctgctgcca tgaaggtgaa gattaagtgc tggaacggcg 240
tggccacttg gctctgggtg gccaacgatg agaactgtgg catctgcagg atggcattta 300
acggatgctg ccctgactgc aagggtgccc ggcacgactg cccgctggtg tggggccagt 360
gtccccactg cttccacatg cattgcatcc tcaagtggct gcacgcacag cagggtgcagc 420
agcactgcc catgtgccgc caggaatgga agttcaagga gtgaggccc acctggntct 480
cgctggaggg gcacctgag actccttcct catgctggcg ccgatggctg ctggggacag 540
cgccctgag ctgcaacaag gtggaacaa gggctggagc tgcgtttgtt ttgccatcac 600
tatgttgaca cttttatcca ataagtgaat actcattaaa ctactcaaat cttaaaaaaa 660
aaaawaaawaa atctcggggg gggncccc 688
```

<210> 203

<211> 304

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (269)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (287)

<223> n equals a,t,g, or c

<400> 203

```
aaatgtgaaa actaaggcct tgcaagccta tgggtcacc aggggtagga tcaggcacct 60
taactctaga gccattctc ctaaccactg agccatgatt gtcttacaat tttgaatact 120
gcaaaactgg aagaattgtc tggctattat ctaagctggt cataagctgg aacaagtaga 180
tctgagggtg agaggagttc tgttttaact aggactgagt ttcaaataga gatgtttcag 240
actatagagg gggaaaaatg gcckgggang tccataaatc taagccngtt tcatggatgt 300
tttt 304
```

<210> 204

<211> 417

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (380)

<223> n equals a,t,g, or c

<400> 204

```
gggtcgaccc acgcgtccgc gcgggcgggg acggagctcg gcgtgcttgc tgctggaggg 60
```

```

tgatggccct gcaaggctgt gggctccgac ctcaccggga gtcgamarcg agaggttcgc 120
cgaagagcga ggttctgggc gagcgctgaa cgccggcccc aagcaccgcc ggtctttaca 180
cagtccgcgt ccacagactc tgacgaagac gtggatctgc tctcgcttta gctgctcgcg 240
gtctccaga tcatgtccgc gactcctgcg actccgcgcg gaaaaaaaaag tttgccaggc 300
gtggactcaa tgacytttcc aastgtgcgc ctcgytgcc tggaccggtt gagegcggtt 360
gcccaagttg aactttttgn ggggaggggt ttctctaagg gctgttgtct caatggg 417

```

<210> 205

<211> 551

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (450)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (458)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (471)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (484)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (519)

<223> n equals a,t,g, or c

<400> 205

```

gggtcgaccc acgcgtccga ctagttctag atcgcgagcg gcccgcctt tttttttttt 60
tttttttttt tggtttccag agtttggtt tattttgcag tacagaaatc atctggagcc 120
gtctgagaca gacatccctg aagcggaggc tctgtcaaata caatactgcg tcgcacttrg 180
tccgttgagg aagccacacc tggggtacaa aagaagcttc tacgtttacc cgctgtacca 240
cggatttctt tcccctttgc tcttaccat tttaccagg gaaaacaccg cacagaggct 300
tccctcgga tgacgctcgg gtctggagtt gggttagaat tgtgggcccg cgtgacccc 360
acctgtggct gtgttccgtg gccctgtcct aaacagctga cgggacacag acgtagaggg 420
gcgggggcac gcagggatgc tgttccaan tcacgganta tctgggtggc ntcgcaatgg 480
ccantgggac agatggcacg tgaaaggggc cgttccggn tcaagcggc agaagcaca 540
gaccgcggag g 551

```

<210> 206

<211> 1101

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (21)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (479)

<223> n equals a,t,g, or c

<400> 206

```

tcccgggtcg acccacgcgt nccgcccgt ggaggctgga gcttccgggc cctggaaagg 60
gggtcccgcg cgccccgggt cggaggcaga cccctgggtt tgggggacat gggcatttgg 120
ggcgcttgaa cccaagacct ctggatgagc tgccccgttc agaccatgga tcctgagggtg 180
accttgctgc tgcagtgcct tggcgggggc ctgcccagc agcagataca ggccgagctg 240
agccccgccc atgaccgtcg cccactgcc aagtggggac aggccatcac tgccatctgg 300
gagaccgggc taaaggccca accctggctc ttcgacgccc ccaagttccg cctgcactca 360
gccaccctgg cgctatttgg ctctggggg ccacagctgc tcctgcgcct gggccttact 420
tcctaccgag acttcctggg caccaactgg tccagctcag ctgcctggct gcgacasang 480
gggtgccaccg actggggtga cagcaggcc tatctggcgg acccactggg ggtgggctgct 540
gcactagcca cagccgatga ctcccttgy ttcctgcgcc gctcccggca ggtggctgag 600
gcccctgggc tgggtggacgt acctgggtgg caccctgagc ctccagccct gtgccctggt 660
ggcagcccc agcaccagga cctcgctggg cagctggtgg tacatgaact cttttccagt 720
gtccttcagg agatctgtga tgaggtgaac ctgcccgtgc tcaccctgag ccagccccctg 780
ctgttkggca tcgcccga aa tgagaccagt gctggccgag ccagtgccga gttctatgtc 840
cagtgcagcc tgacttctga gcaggtgagg aagcactacc tgagtggggg acccgaggcc 900
cacgagtcta caggaatctt ctttgtggag acacagaacg tgcggagatt gcccagagacg 960
gagatgtggg ctgaactctg cccctcgcca aaggcgccat catcctctac aaccgggttc 1020
agggaaagtcc cactggagcg gccctagggt cccagccct actccgccc ctctgaaaaat 1080
aataaacgac tttattcttg g                                     1101

```

<210> 207

<211> 515

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (428)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (439)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (449)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (456)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (474)

<223> n equals a,t,g, or c

<400> 207

```
gggtcgaccc acgcgtccgc ccacgcgtcc ggcr gataga gcgccatgaa ggccctcgggc 60
acactgcgag aatacaaggt ggtggggcgc tgcctgcccc cccccc aaatg tcgcactccg 120
ccgctgtatc gcatgcgaat ctttgacac taaacacgtgg tcgccaaagtc ccgcttttgg 180
tactttgtgt ctcagctgaa aaagatgaag aagtcctcag gggaaatcgt ctactgtgga 240
caggtgtttg agaaatcccc cttgcgagtg aagaacttcg gcatctggct gcgctatgac 300
tcgagaagcg gtaccacaaa catgtaccgg ggagtaccgg ggacctgacc amcgcgggcg 360
ccgtcaccca gtggttaccg agacatgggc gcccgacacc gttgcccag cgcattcgat 420
tccagatnct tgaagtggna ggagattgnc agccanfaat tgccgcccgg ccancattca 480
agcatttcca aggattccaa gatcaattcc cattg 515
```

<210> 208

<211> 269

<212> DNA

<213> Homo sapiens

<400> 208

```
aagcattgtg ggtaaaggcc tggaggcagg aaagtgaagg acaatttcaa gaaactcagt 60
tcatcaattt tcatcaacac cttcctgggc catgcctggg tactgagraa cccagccctg 120
aatctggaca tcattttccc tttagagca tagaatgcag ggggatccag ggaatgggtt 180
aacagaagag gaagctggwt caaggagacc tttgcgtacc aggtgaagg ttttgaactt 240
tgttcttgca ggcaggcaga gcacggaca 269
```

<210> 209

<211> 734

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (278)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (732)

<223> n equals a,t,g, or c

<400> 209

```
cgactgggttg ttaccgagga agatggcggc gccagacccg aggcgctagg gaagatcgca 60
ccgcggacgc ccgctgagct tggcgacagg gccgaccagg agctgggtgac tgccctcatg 120
tgtgatttgc ggcggccagc ggcagggtggg atgatggact tggcctacgt ctgtgagtgg 180
gagaaatggt ccaagagcac ccactgccca tcggtgcccc tggcctgcgc ctggtcctgc 240
cgaaatctca tcgccttcac catggacctg cgcacgantg accaggacct gaccgcgatg 300
atccacatcc tggacacgga gcacccctgg gacctgcact cgatcccctc agagcaccac 360
gaggccatca cctgcctgga gtgggaccag tcaggctccc ggctcctgtc agcagatgcc 420
gacgggcaga tcaagtgtct gagcatggcg gaccacctgg ctaatagctg ggagagctca 480
gtgggcagcc tagtggaggg ggacccatt gtggccctgt cctggctgca caatgggtgtg 540
aaactggccc tgcacgtgga gaagtcgggc gcctccagct tcggggagaa gttctcccga 600
gtcaagtctt caccygttct cacgctgttc ggcggaagc catggagggc tggatcgcg 660
tgacggtcag cggcctggtc accgtgtccc tgctgwaasc agcgggcagg tgctgacgtc 720
caccgagagc tntt 734
```

<210> 210

<211> 658

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (561)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (567)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (577)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (580)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (636)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (654)

<223> n equals a,t,g, or c

<400> 210

```

ccccccagcg ttgagggttta tcacgacagc ctgtgccgaa aaatctggcg tgaggatgat 60
aaatggcatg tcattttttcg tgcagacggc tgggagcaac atattaccgc ccgctatctg 120
gtcggtgccg atggcgcaaa ctcgatggtg cggcgacatc tctaccggga tcatcaaate 180
cgtaaatatg tcgctatcca gcagtgggtc gcggagaaac atccggtgcc gttctactcc 240
tgcattcttg ataattcgat aactaactgt tattcatgga gtatcagcaa agacggktat 300
tttatctttg gcggtgccta tccaatggaa agacggtcag acgsgtttca sgacgcttra 360
agagaaaatg agcgcctttc agttccagtt tggtaagacg gtgaaaagcg aaaaatgcac 420
gggtgctgtt tccctcgcgc tggcaggatt ttgtctgctg taaggacaac gcctttcttg 480
attggtgaac ggcgggattt atcagcgcca gctcgtgga agggattagc tatgcgctgg 540
atagcacaga catttctgctg ntcgtgntac tgaacancn gagaagctca ataccgttac 600
tggcgcgcca cccgaaactg gggttaaactc ttcgnaaga tataaaaagc catnctga 658

```

<210> 211

<211> 204

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (91)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (94)

<223> n equals a,t,g, or c

<400> 211

```

attcggagag ccatctctga cagttagagc cgatatcact ggaagatatt caatcgtctc 60
tatgcttacg acctgcagat acagtctgtt nttncacatg aagaaagtct caagttgctg 120
aagactgaat tgtaagaaaa atctccagcc cttctgtctg cagcttgaga cttgaaccag 180
agagtgtgag agctgctgtt ggag                                     204

```

<210> 212

<211> 1271

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1222)

<223> n equals a,t,g, or c

<400> 212

```

ttccgcagcc ttgccccagc ccaactcccc tctcacccta ccacagagca tggtaaatac 60
caagcccagag aagacggagg aggactcaga ggaggtgagg gagcagaaac acaagacctt 120
cgtggaaaaa tacgagaaac agatcaagca ctttggcatg cttcgccgct gggatgacag 180
ccaaaagtac ctgtcagaca acgtccacct ggtgtgcgag gagacagcca attacctggt 240
catttgggtgc attgacctag aggtggagga gaaatgtgca ctcattggagc aggtggccca 300
ccagacaatc gtcatgcaat ttatcctgga gctggccaag agcctaaagg tggacccccg 360
ggcctgcttc cggcagttct tcactaagat taagacagcc gatcgccagt acatggaggg 420

```

```
cttcaacgac gagctggaag ccttcaagga gcgtgtgcgg ggccgtgcc a gctgcgcat 480
cgagaaggcc atgaaggagt acgaggagga ggagcgcaag aagcggctcg gccccggcgg 540
cctggacccc gtcgaggtct acgagtccct ccctgaggaa ctccagaagt gcttcgatgt 600
gaaggacgtg cagatgctgc aggacgccat cagcaagatg gacccaccg acgcaaagta 660
ccacatgcag cgctgcattg actctggcct ctgggtcccc aactctaagg ccagcgaggc 720
caaggaggga gaggaggcag gtcttgggga cccattactg gaagctgttc ccaagacggg 780
cgatgagaag gatgtcagtg tgtgacctgc cccagctacc accgccacct gcttccaggc 840
ccctatgtgc cccttttcag aaaacagata gatgccatct cgcccgctcc tgacttcctc 900
tacttgcgct gctcggccca gcctgggggg cccgccagc cctccctggc ctctccactg 960
tctccactct ccagcgccca ttcaagtctc tgctttgagt caaggggctt cactgcctgc 1020
agccccccat cagcattatg ccaaaggccc ggggggtccg ggaagggcag aggtcaccag 1080
gctggtctac caggtagttg gggagggtcc ccagccaagg ggccggctct cgtcactggg 1140
ctctgttttc actgttcgtc tgctgtctgt gtcttctatt tggcaaacag caatgatctt 1200
ccaataaaaag atttcagatg cnaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaacaaaaa 1260
aaaaaaaaaa g 1271
```

<210> 213

<211> 1025

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (991)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1007)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1019)

<223> n equals a,t,g, or c

<400> 213

```
cggacgcgtg ggcgagcgtg atagccaaca ggaaccggga gcgggggtccc gggactggga 60
agaaacggcg gccgggaggg ggctccgggg accatggggc tcctgaccat tctgaagaag 120
atgaagcaga aagagcggga gctgcgactg ctcatgcttg gcctggacaa tgctggaaag 180
acaaccatcc tgaagaagtt caatggggag gacatcgaca ccattcctccc aacgctgggc 240
ttcaacatca agaccctgga gcaccgagga ttcaagctga acatctggga tgtgggtggc 300
cagaagtccc tgcggtccta ctggcggaac tactttgaga gcaccgatgg cctcatctgg 360
gtagtggaca gcgcagaccg ccagcgcatg caggactgcc agcgggagct ccagagcctg 420
ctggtggagg agcgctgggc cggagcaacc ctctcatct ttgctaataa gcaggacctg 480
cctggagcac tgcctcttaa cgccatccgc gaggyectgg agctggactc catccgcagc 540
caccactggg gcatccaggg ctgcagcgcc gtcaccgggg agaacctgct gccgggcatc 600
gactggctcc tggatgacat ttccagccgc attttcacag ctgactgaac cactccagat 660
gccccccacc tagcagtcca ggtccctcaa ccttcaccaa aactaccba tgggggggttg 720
ggagtcagcc ggccaaacta aactccccc tcctccaccc cagcctgctg ctgctactgc 780
tgcccgcgtg tgctctgtgg ccaccgggct cccatggcgg gagggctgtg ccctggctgt 840
```



```

ctctctggct cctgacctgg cctttggcta ccataccaag aagagagggc tgggcgggga 900
ggagctgcta ctgctgctac cgaggctgtg ggcctcatcc ttcactcagt tgtgaaataa 960
accgctcctt gccccgmaaa aaaaaaaaaa naaaaaaaaa aaaaaanccc ggggggggnc 1020
ccgga                                     1025

```

```

<210> 214
<211> 351
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc feature
<222> (332)
<223> n equals a,t,g, or c

```

```

<400> 214
ggcacgagtr aactatatac ctcaaagaat tagaaaaaga agaacaact aagctcaaag 60
ttagcagaag gaaggaaata gtaaatatta cagcagaagt aaagtagagg ctagaaaaat 120
aataaaaaag atcaacaaaa tggatattgt tctcatacta tgataaagac atacttgaga 180
accgcattat ttatggggaa aagaagttaa attgactcac agttccacag gctgtacagg 240
aggcatggct tagggaggcc tcagggaac ttagratcca tggtggaagg tgkargagga 300
agcatgcacc atcttcactg gccagagcag gnggagagag agcaaatttg g 351

```

```

<210> 215
<211> 1087
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc feature
<222> (1075)
<223> n equals a,t,g, or c

```

```

<400> 215
gctggagtcc cagtccaccc gccacgcccg agcagggcct gtccgccttc tacctctcct 60
actttgacat gctgtaccct gaggacagca gctgggcagc caaggcccct ggggccagca 120
gtcgggagga gccacctgag gagcctgagc agtgcccggg cattgacagc caagccccag 180
cgggcagcct ggacttggtg cccggcgggc tgaccttga ggagcactcg ctggagcagg 240
tgacgtccat ggtggtgggc gaagtgtctc aggacatcga gacggcctgc aagctgtctc 300
acatcacgcg agatcccatg gactggagcc ccagcaatgt gcagaagtgg ctccgtgtga 360
cagagcacca ataccggctg cccccatgg gcaaggcctt ccaggagctg gcgggcaagg 420
agctgtgctc catgtcggag gagcagttcc gccagcgtc gccctgggt ggggatgtgc 480
tgacgcccc cctggacatc tggaagttag cggcctggat gaaagagcgg acttcacctg 540
gggcgattca ctactgtgcc tcgaccagtg aggagagctg gaccgacagc gaggtggagt 600
catcatgctc cgggcagccc atccacctgt ggcagttcct caaggagttg ctactcaagc 660
cccacagcta tggcgccttc attaggtggc tcaacaagga gaagggcac ttcaaaattg 720
aggactcagc ccaggtggcc cggctgtrgg gcatccgcaa gaaccgtccc gccatgaact 780
acgacaagct gagccgctcc atccgscagt attacaagaa gggcatcatc cggaagccag 840
acatctycca gcgsctcgtc taccagttcg tgcaccccat ctgagtgcct ggcccagggc 900
ctgaaacccg ccctcagggg cctctctcct gcctgccctg cctcagccag gccctgagat 960
gggggaaaac ggcagtctgc tctgctgctc tgaccttcag agcccaaggt caaggagggg 1020

```

caaccaactg cccaggggga tatgggtcct cttggggcct tcggggaccct ggggncaagg 1080
ggcttttc 1087

<210> 216

<211> 1977

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (8)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (11)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1873)

<223> n equals a,t,g, or c

<400> 216

cgcctgcngg naccggtccg gaattcccgg gtcgaccac gcgtccggca gaagaagagg 60
aggaggaaga tgaggaagag gaggaagaag aggaggagga ggaggaagaa gagcctcagc 120
agcgagggca gggagagaag tcagccacgc cctcacggaa gattctggac cctaactactg 180
gggagccagc tcccggtgctg tcctccccac ctctgcaga cgtctccacc ttcctggctt 240
ttccctctcc agagaagctg ctgcgccctag ggcccaagag ctccgtgctg atagcccagc 300
agactgacac gtctgacccc gagaaggtgg tctctgcctt cctaaagggtg tcatctgtgt 360
tcaaggacga agctactgtg aggatggcag tgcaggatgc agtagatgcc ctgatgcaga 420
aggctttcaa ctctcgtcc ttcaactcca acaccttctt caccaggctc ctctgtcaca 480
tgggtctgct caagagtga gacaaggtca aggccattgc caacctgtac ggccccctga 540
tggcgctgaa ccacatggtg cagcaggact atttcccaa ggcccttgca cccctgctgc 600
tggcgcttctg gaccaagccc aacagcggcc tgggaatcctg ctctctogcc cgccacagtc 660
tgctgcagac gctgtacaag gtctagactc aaagcctctc ccattcccttg gcctggacca 720
gtgagctggg gagggactcg gatgaactga ggcgagcctt acgccattgc cttggacagg 780
actctggcca caggcagggc ggggtctgtgt cccatgtgtc ctgtcagtc cctgagtatg 840
tgtgtgggtg tggcgcatgt gcaggctctgt gcctcctgtc gggatttggg ttttaacgtc 900
ttctgctggc ccagccctgc tctgttgttg ggagttggcc cccaggggaa agggctgtga 960
gctgctccgc cattaaactc acctccacct gagggcgctc tgctgatctc cgcctgggcc 1020
ctgatggccg tccccacca cctgccttcc ggcccgctc cctggcggag caraaccar 1080
ggagttgccc gcgtgctgtc cttccctctt gtgttgtgat tgggttgtt cctgcccctgc 1140
ctggggctgc ttctcgtcac caagccctgg tcctgcggca gctgtcacc ctaccatcca 1200
taccactgtg ctgaccgctc agcctgaaga gcagagaatg ccatgggttg gactgtgggg 1260
gtcggatcgt ggggttgttg gcagaggga accctgggcc ccacaccgtg tggacaggca 1320
gacaccagat tgtccaggag caggagctgc tgggactgcg ctggccccgg acctagtggg 1380
ccttctcctg gctgctgaga tctcgtctgt gactggcctg gctggagggg gactgttgac 1440
aaccctaaagc tgttctccag tctggggagg gagaggcagg gtccccaatg tccgagctgc 1500
atctggacgc tgcctctaaa ggacctctg gggcagggga gcggtagggt ctggactggg 1560
cagatgctgt atgacctccc tgagcaccgc tgactgcccc atgctttccc ctttgtgctc 1620

```

tgtgtgtgtc tggctgtgcc cgggggcttc acaaataaag tcgtgtggca gcttcagaga 1680
ctcagaaact ctcactgaaa gcgggtagat ctcggggggcc gttgtacgtg gagtcccacc 1740
tcggcagagc atgcggcccc gcagcagtc tgggggcagt cagccctgca gaagggcccc 1800
gcctcggcct caggcactac ctgggaagt gtcagtcctga gtggggggccc attttcctgc 1860
ctggscacac ctnaccacgc accctgcctt tgggctgcag ctcgcttgcc ttctgcgttg 1920
ctccttcact atggaagcca cctcccttgg gatcctttgc tccactgcca catatgt 1977

```

<210> 217

<211> 2815

<212> DNA

<213> Homo sapiens

<400> 217

```

aattcccggg tcgacccacg cgtccggggc cccgcgtctg agcccagagg gctgtggagt 60
gtcccggcgg gcccgcagca ccccgcgct gtcgggtccc cgtccgggtc tttcgctttg 120
gcttccaact agttaaatgc ccttgagcgc ggggttccgc ggcccggctc ttcgcccccg 180
cggcgcgagt tgagccggtt cccgcgcgtg tccgcgcggg cgtccgcaca gcggctctgc 240
agggtcgcgg gccagcgtcc ggccaccgct cggccgccac tcaaggctca cgcgtcgatg 300
tgtagctaca tagttatctg tgtacatcca cgtgggggca tttttctcct gcttaatgag 360
gacttgactc gggagcaagt gtgaatcatt gccggggctg ggaaaggagg aaggcgcatt 420
taacccctc ccacccctct ccatgtccgt gtgtcactcg gtcgggtcca cctggcgcgg 480
ccggtcctgg ggctcgtgct gctgttgacg acgacgacga cgacgggggc tgcctctgct 540
gtcccgggag tttcctcctg ctccggccac acagctcctg gggattgttc ctcttcgaac 600
cagaacctcg gcctgaccgg cactttggct ccaaaataac tttatttttg ggggagaaag 660
cacatcacga accagtcaaa atcgtgggtt atttctgtaa cgtgaagact tctgctcttt 720
tttctttgtt tgtttttttc gtaaacatct ggggtgtatat caaacggcaa gatgtccagt 780
aatgtcccgg cggatatgat aaatttgccg ctcatttttg taagcggaaa aacaaaagag 840
ttcctgtttt ctctaacga ttctgtttct gacattgcaa agcatgtata tgacaattgg 900
ccaatggact gggaagaaga gcaggtcagc agtccaaata ttctacgact tatttatcaa 960
ggacgatttc tacatggaaa tgtcacatta ggagcattaa aacttccttt tggcaaaaca 1020
acagtgatgc atttggtggc cagagagaca ttaccagagc caaactctca aggtcagagg 1080
aatcgtgaga agactggaga gagtaattgt tgtgtaatcc tgtaaacact gtctgcctag 1140
tgtgatgtga tatagtcttt gtctttcatg ctgctgggac agaaaagacc cgacattgct 1200
tcagaaaccg ttcagaacag tctgcctgta aacacatgga actgaattac cacatgaaca 1260
ctgtcatctt ttctcatgaa agtaaaaaga accaagaaca tttttcactc tgatttttta 1320
tttcttgat tttttgttga gctgttttaa cacatattgg tttttgaatg cagtcaatct 1380
ccaggggaaa agttaacaag ttatctttcg tagcagaaac cattttgctg ccacaaaatt 1440
ttcatcatca gaactaataa atcaagtgtt ccaaatacaa tttgactaa aaagattggc 1500
attattttcc tcatcagcag aatttataac agtgtgtggg atctagaaat acttatatat 1560
acaattccac actggaagac actcagcaat taatgaagt aattactggg ccaacttgag 1620
aggaaaaaat ggaaaagaaa ctaaaatgtt ggggtgaattc taccaaagtc agccgtgggtg 1680
gctgcactgg cacagaatac taaactgagt gtgactattt tcaactgcaac aaatgaaaaa 1740
acaaaatgtg cctgttttaa gactcagta gagggctgat gaaactaatt tttttcctt 1800
taagacatgc actcttgagt cctacagtaa ctgagtgttt gtttagacag cacaagaagg 1860
ggtagagtg cgtctcctag ccttaatgtg ggagggtagt ttcagtcact catcgcttt 1920
cattattgtg crgaatat attgaaacct attgatcaat tttatgtatt tgaatatcag 1980
caaattgaaa ttttccataa ttatcattaa tttgtaacca catccagtgt catgcttact 2040
ccttagagtt cagatgaatt cttaaaatta aaaaaaact ccatagtact aattttgktt 2100
ctttatatag tttgcgtttg atattagtgc ttgcaattgt attaaagtca aaagctgatt 2160
tttatggcat acacaagaat gccacttttt cttttatttc ataccaataa tttaaagatt 2220
gatatgctaa aaacaatttg cacagcacta aagcatgagc tactttcatc taaacctgta 2280

```

```

aaaatatgaa agatttttat attttttcac tgggaagaaa ttcttcctgg atgaaattac 2340
aaatatgtgt agaatatatt taataaaaga cttataaaat acctaactac aggacttaaa 2400
atatagattg gcgcgtagta tatagaacaa tattccatat aaataagttt agcctttata 2460
aaaatgaagt tgcaggctga cattacattc tgtacttact aagtgtcaac agcccttaca 2520
aacattaaat gtaaattggt tcaaattggtc agcgttggtt aaatgtaatc atgttatttt 2580
attcattgtt aatgctttga tgaaaaggct ttatatgcag tagatctacg aaaatattgt 2640
tcatactgat cagaattaaa tttgtataga gcagagtttt aaaatgaatg taaatagcac 2700
taaacgtttt ctttctgcaa cctgtactta cagattcttc ctgtaaacta aataaaaaaa 2760
aatgatagt gcaaaaaaaa aaaaaaaggg cggccgctcg cgatctagaa ctagt      2815

```

<210> 218

<211> 1645

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (347)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1643)

<223> n equals a,t,g, or c

<400> 218

```

gcccacgcgt ccggaggcgc gggacaactg ggtcttttgc ggctgcagcg ggcttgtagg 60
tgtccggcct tgctggccca gcaagcctga taagcatgaa gctcttatct ttggtggcgt 120
tggtcgggtg tttgctggtg ccccagctg aagccaacaa gagttctgaa gatatccggt 180
gcaaatgcat ctgtccacct tatagaaaca tcagtgggca catttacaac cagaatgtat 240
cccagaagga ctgcaactgc ctgcacgtgg tggagcccat gccagtgcct ggccatgacg 300
tggaggccta ctgcctgctg tgcgagtga ggtacgagga gcgcagnacc accaccatca 360
aggtcatcat tgcatctac ctgtccgtgg tgggtgccct gttgctctac atggccttcc 420
tgatgctggt ggacctctg atccgaaagc cggatgcata yactgagcaa ctgcacaatg 480
aggaggagaa tgaggatgct cgctctatgg cagcagctgc tgcacccctc gggggacccc 540
gagcaaacac agtcctggag cgtgtggaag gtgccagca gcgttggaag ctgcagggtg 600
aggagcagcg gaagacagtc ttcgatcggc acaagatgct cagctagatg ggctgggtgtg 660
gttgggtcaa ggccccaaca ccattgctgc cagcttccag gctggacaaa gcagggggct 720
acttctccct tccctcgggt ccagtcctcc ctttaaaagc ctgtggcatt tttcctcctt 780
ctccctaact ttagaaatgt tgtacttggc tattttgatt agggaaagagg gatgtggtct 840
ctgatctcyg ttgtcttctt gggctcttgg ggttgaaggg agggggaagg caggccagaa 900
gggaatggag acattcgagg cgccctcagg agtgatgag atctgtctct cctggctcca 960
ctcttgccgc ctccagctc tgagtcttgg gaatgttgtt acccttgga gataaagctg 1020
ggtcttcagg aactcagtg ctgggaggaa agcatggccc agcattcagc atgtgttctt 1080
ttctgcagtg gttctttatc accacctccc tcccagcccc agcgccctcag cccagcccc 1140
agctccagcc ctgaggacag ctctgatggg agagctgggc cccctgagcc cactgggtct 1200
tcagggtgca ctggaagctg gtgttcgctg tcccctgtgc acttctcgca ctggggcatg 1260
gagtggccat gcatactctg ctgccgtcc cctcacctgc acttgagggg tctgggcagt 1320
ccctcctctc cccagtgctc acagtcactg agccagacgg tcggttgga catgagactc 1380
gaggctgagc gtggatctga acaccacagc ccctgtactt ggggtgcctc ttgtccctga 1440
acttcgttgt accagtgcat ggagagaaaa ttttgcctc ttgtcttaga gttgtgtgta 1500

```

```

aatcaaggaa gccatcatta aattgtttta tttctctcaa aaaaaaaaaa aaaaaaaccaa 1560
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1620
aaaaaaaaaa aaaaaaaaaa aangg 1645

```

```

<210> 219
<211> 478
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc feature
<222> (344)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc feature
<222> (415)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc feature
<222> (452)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc feature
<222> (469)
<223> n equals a,t,g, or c

```

```

<400> 219
tcgaccacag cgccgggga attcaaggag acgggggga cgcggtgct ggcgcctcct 60
cgggtttggg gctgccgcca tcagtcggg gatagtggag ctgcctactc tggaggatct 120
gaaagtgcag gaggtgaaag tcagttcttc ggtgtcaaaa gctgccgccc atcactatgg 180
agttcagtgt gacaagccca acaaggagtt catgctctgc cgctgggaag aaaaagaccc 240
ccggcggtgt ttagaggaag gcaagctcgt caacaaktgt gctctggayt tcttcaggca 300
gataaagctt tcaactgtgca gagcctttta cagactattg gacntgcac gactactccg 360
gcctgcagtg ttttcgtcgc tgccgcaaac agcaggccaa ttgacgatg tgtgnggggc 420
aactgggatg gtgcggctga actggggaaa angttccagt caccaaatng aaaacagt 478

```

```

<210> 220
<211> 832
<212> DNA
<213> Homo sapiens

```

```

<400> 220
attttagtag agacaagggt tcaccatggt ggccaggctg gtctcgaact cctggcctca 60
ggtgatccac ctgccttggc ctcccaaagt gctccgatta caggtgkgag ccaccggcc 120
cagccctcc cttgtgtttc aaccaatcgg aagtgaattt aactagatgt agtaaccttt 180
ttttcttta cttctaaaaa agttacagtt tactaataaa gttaagtctg gttctgtcct 240
agaggaaata aattcactat taattcatgt cttaagttac ttgggttaaa acactttcag 300
ccaccagat taattaaagt ggagcagtg agccctggc tgggagatgg cctccagagg 360

```

```

agcagctgca gggcaygttc tgggcttagc gacagaggca agcaaggagc tgggtgtctct 420
ggtagagagg gggtttgatg tatctctgtc ctatgctggc ctctcttctc ctttataaaa 480
tcctctgtgg tcaactgact actgcgtatc gcagtggaat aagactgcac agttgctggc 540
aggtagagtt aaagtcttaa tctatgcatt cagagaaata tttttatatg ctttgtgtaa 600
tttataacaa ggattttttt tttagctttg ttaactgtga attcaccctc cctcctccac 660
tgcataattt aagcatgtgt tcacactgtg tgtaaacatt cactgaagat tttttctttg 720
tgcattgctg actgttcaaa cataacaagt attattaaaa ttaaatatta actgacaaaa 780
aaaaaaaaa aaactcagag gggggggccc gtaccaatt cggccggagt ag 832

```

<210> 221

<211> 1892

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1892)

<223> n equals a,t,g, or c

<400> 221

```

tgactctggg ctagagacct ccccaacaga gctgaggcca aggccgactc cccctctcaa 60
atggcgtagg ctgggcctat gacggcccct gcagtgaggc ctgtactggc tgcgggggac 120
cctgctcatt tgaaaatctg acatcagctg ggcagtcgcc cccctcctcc tttcctccct 180
ctactctgac acagcactta gcacctgaat cttcgtttct ctcccagga cctccattt 240
tccatatcca ggaaaatgtg atgcgccaca ggtatcagcg tctggwtcgc cacttcacgt 300
tttagccaca agtgactcag tggaagatcc agagtcaaca gaggctcgtc aggaagatgt 360
ctacagaaaa ggtagaccaa aaggaggaag ctggggaaaa agagggtgtg ggagaccaga 420
tcaaaggacc ggacaaagag gaggaaccac cagctgctgc atcccagggc caggggtggc 480
gtccagggtg cagagcagct aggaacgcaa ggcctgaacc tggggccaga caccctgctc 540
tcccgcccat ggtcaacgac cctccagtag ctgccttact gtggggccag gaggtggggc 600
aagtcttggc aggcctgccc cgcagctgct gctgcagttt ggggtgtctc tctgcacat 660
cctccttttg ctctgggtgt ctgtcttcct ctatggctcc ttctactatt cctatatgcc 720
gacagtcagc cacctcagcc ctgtgcattt ctactacagg accgactgtg attcctccac 780
cacctcactc tgctccttcc ctgttgccaa tgtctcgtc actaagggtg gacgtgatcg 840
ggtgctgatg tatggacagc cgtatcgtgt taccttagag cttgagctgc cagagtcccc 900
tgtgaatcaa gatttgggca tgttcttggc caccatttcc tgctacacca gaggtggccg 960
aatcatctcc acttcttcgc gttcgggtgat gctgcattac cgctcagacc tgctccagat 1020
gctggacaca ctggtcttct ctagcctcct gctatttggc tttgcagagc agaagcagct 1080
gctggaggtg gaactctacg cagactatag agagaactcg tacgtgccga ccactggagc 1140
gatcattgag atccacagca agcgcatcca cgtgtatgga gcctacctcc gcatccacgc 1200
gcacttcact gggctcagat acctgctata caacttcccg atgacctgcg cttcatagg 1260
tgttgccagc aacttcacct tctcagcgt catcgtgctc ttcaagctaca tgcagtggtg 1320
gtgggggggc atctggcccc gacaccgctt ctctttgcag gttaacatcc gaaaaagaga 1380
caattcccgc aaggaagtcc aacgaaggat ctctgctcat cagccagggc ctgaaggcca 1440
ggaggagtca actccgcaat cagatgttac agaggatggg gagagccctg argatccctc 1500
agggacagag ggtcagctgt ccgaggagga gaaaccagat cagcagcccc tgagcggaga 1560
agaggagcta gagcctgagg ccagtgatgg ttcaggctcc tgggaagatg cagctttgct 1620
gacggaggcc aacctgctg ctctgctcc tgcctctgct tctgcccctg tcctagagac 1680
tctgggcagc tctgaacctg ctgggggtgc tctccgacag cggccacact gctctagttc 1740
ctgaagaaaa ggggcagact cctcacattc cagcactttc ccacctgact cctctcccct 1800
cgtttttctc tcaataaact attttgtgtc agcttcaaaa aaaaaaaaaa aaaaaaaaaa 1860

```

aaaaaaaaa aaaaaaaaaa aaaaaaaaaa an

1892

<210> 222

<211> 868

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (23)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (31)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (45)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (829)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (860)

<223> n equals a,t,g, or c

<400> 222

```
ntttcagcag ttccgcatgc cntccgtgg naagcctgtt cgtgntattg ggcaagaacc 60
cccatgatgc ccaaggccat ccaagggcat ctgaagacca acccagctct ggaaaacctg 120
ttacttcata tccgggggaa tgtggctttg tggtcaccaa ggaggcctca cttgagatca 180
gggacatgct gctggccaat aaggtgccag ctgccgcccg tgctggtgcc atagcccat 240
gtgaggtcac tgtgccagcc cagaacactg gtctggggcc cgagaagacc tccttcttcc 300
aggctttagg catcaccact aaaatctcca gaggaaccat tgaaatcctg agtgatgtgc 360
agctgattaa gaccggagac aaagtgggag ccagtgaagc cacactgctg aacatgctga 420
acatctcccc ctctcctttt gggctgatca tccagcaggt gtttgacaat ggcagcatct 480
acaaccctga agtgcttgac atcacagagg aaactctgca ttctcgcttc ctggaggggtg 540
tccgcaatgt tgccagcgta tgtctgcaga taggttaccc aactgtggca tcagtgtccc 600
attctatcat caatggatac aagcgggtcc tggtttgtc tgtggagact gattacacct 660
ttccacttgc tgaaaaggtc aaggccttct tggtgatcc atctgcattt gtggctgctg 720
cccctgtggc cgctgccacc actgctgcac ctgctgctgc tgcagcccca gccaaagttg 780
```

aagcaaagga agagtcggag gaawcggatg agagkattkt camttcgana atcagcaaaa 840
gcaacaattc cagccagttt attgtgaa 868

<210> 223

<211> 1516

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1493)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1497)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1508)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1509)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1516)

<223> n equals a,t,g, or c

<400> 223

gaatgagcag gataactgtg tcctgattca tgatgtggac caaaggaaca gcgataaaga 60
tatctttggg gatgcctgtg ataactgcct gagtgtctta rataacgacc agaaagacac 120
cgatggggat ggaagaggag atgcctgtga tgatgacatg gatggagatg gaataaaaaa 180
cattctggac aactgccc aaattcccaa tcgtgaccaa cgggacaagg atggtgatgg 240
tgtgggggat gcctgtgaca gttgtcctga tgtcagcaac cctaaccagt ctgatgtgga 300
taatgatctg gttggggact cctgtgacac caatcaggac agtgatggag atgggcacca 360
ggacagcaca gacaactgcc ccaccgtcat taacagtgcc cagctggaca ccgataagga 420
tggaattggg gacgagtgtg atgatgatga tgacaatgat ggtatcccag acctggtgcc 480
ccctggacca gacaactgcc ggctgggtccc caaccagcc caggaggata gcaacagcga 540
cggagtggga gacatctgtg agtctgactt tgaccaggac caggtcatcg atcggatcga 600
cgtctgccca gagaacgcag aggtcacctt gaccagactc agggcttacc agaccgtggt 660
cctggatcct gaaggggatg ccagatcga tcccactgg gtggctcctga accagggcat 720
ggagattgta cagaccatga acagtgatcc tggcctggca gtggggtaca cagcttttaa 780
tggagtgtac ttcgaaggga ccttccatgt gaatacccag acagatgatg actatgcagg 840
ctttatcttt ggctaccaag atagctccag cttctacgtg gtcagtgtgga agcagacgga 900
gcagacatat tggcaagcca cccattccg agcagttgca gaacctggca ttcagctcaa 960
ggctgtgaag tctaagacag gtccagggga gcatctccgg aactccctgt ggcacacggg 1020


```

ggacaccagt gaccagggtca ggctgctgtg gaaggactcc aggaatgtgg gctggaagga 1080
caaggtgtcc taccgctggt tcctacagca caggccccag gtgggctaca tcagggtacg 1140
atattatgaa ggctctgagt tgggtggctga ctctggcgtc accatagaca ccacaatgcg 1200
tgagagccga cttggcggtt tctgcttctc tcaagaaaac atcatctggt ccaacctcaa 1260
gtatcgctgc aatgacacca tccctgagga cttccaagag tttcaaaccg agaatttcga 1320
ccgcttcgat aattaaacca aggaagcaat ctgtaactgc ttttcggaac actaaaacca 1380
tatatatatt aacttcaatt ttctttagct tttaaccaacc caaatatata aaaacgtttt 1440
atgtgaatgt ggcaataaag gagaagagat cattttttaa aaaaaaaaaa aanttcnggg 1500
gggcccgnnc caattn 1516

```

<210> 224

<211> 1306

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (148)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (887)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1242)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1264)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1303)

<223> n equals a,t,g, or c

<400> 224

```

gtccgcgcgg gcctcggacc tgggggcccc ccggacgtgg acggggggcg cgccgggggcc 60
ccggactccg tcggcgccaca tccccgtccc agcgagagaga gccaccccag gaaaagcccc 120
gctggacgag gtcattggctg ccgctgcnst tacaagcctg tccaccagcc ctctccttct 180
ggggggcccc gttgcagcct tcagcccaga gcctggcctg gagccctgga aggaggccct 240
ggtgcggccc ccaggcagct acagcagcag cagcaacagt ggagactggg gatgggacct 300
ggccagtgac cagtctctct cgtccacccc gtcaccccca ctgcccccg aggcagccca 360
ctttctgttt ggggagccca ccctgagaaa aaggaagagc ccggcccagg tcatgttcca 420
gtgtctgtgg aagagctgcg ggaaggtgct gagcacggcg tcggcgatgc agagacacat 480
ccgcctggtg cacctgggga ggcaggcaga gcctgatcag agtgatggtg aggaggactt 540
ctactacaca gagctggatg ttggtgtgga cacgctgacc gacgggctgt ccagcctgac 600

```

```

tccagtgtcc cccacggcct ccatgccgcc tgccttcccc cgcttgagc tgccagagct 660
gctggagccc ccagccctgc ctagtccccct gcggccgcct gccccgccc tgccccgcc 720
ccctgtcctg agcaccgttg ctaacccccca gtctgtcac agtgaccgtg tctaccaggg 780
ctgcctgacg cccgcccgc tggagccgca gcccacggag gtcggagcct gcccaccgc 840
cttgtcctcc aggatcggag tcacctgag gaagccccgc ggcgacnsaa agaagtgccg 900
gaaggtgtat ggcattggagc gccgggacct ctggtgcaca gcctgccgct ggaagaaagc 960
ctgccacggg ttcttggaact aagtccggct cgttcaagaa cataagctac caccttctcc 1020
ctccccaccc cctccaggcc cggggctgaa acagcccgag grcagcccca ggggctggcc 1080
ttcaccagct gcagggtctg cttttacttg ggggtggggg gcggggctga cctgaaccc 1140
tccccccgc caggtcgggg aggggtccca mactcaaag tgcctctaaa gaaaccagct 1200
tttttgact aaaagccaaa aaaaacggg gttcccttta gnccccaagg ggccttgggg 1260
gcancacaacc ttcccgggct tggtggggcc cgtaagattt ttnttc 1306

```

<210> 225

<211> 584

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (486)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (542)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (562)

<223> n equals a,t,g, or c

<400> 225

```

tcgaccacag cgtccggcgt cctctcggag cccgtgcggt cacttagcca agatgcctga 60
ggaaacccag acccaagacc aaccgatgga ggaggaggag gttgagacgt tcgcctttca 120
ggcagaaaty gcscagttga tgcrytgat catcaayacy ttctactcga acaargagat 180
cttcttgagg gactgatctc caactcgtcc gacgctcygg aaaaaatccg atacgagagc 240
ctgaccgacc ccagcaagct cgactcgggg aaggagctgc acattaacct catcccgaa 300
aagcaggacc ggaccctcac catcgtggga taccgggatc gcatgaccaa ggcgacctg 360
atcaacaacc tgggcacat cgccaaktcg gggaccaaag cgttcattga agytctgcag 420
gcgggcgcag atatttcyat gattggccag ttcggggctc ggttctattc ggcctacttg 480
gtggcnagaa ggtgacggg atcaccaagc acaacgatga cgagcattac gcctgggagt 540
cntccgcagg ggctcgttca angttccgca ttgacacagt gaac 584

```

<210> 226

<211> 523

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature
<222> (34)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (498)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (514)
<223> n equals a,t,g, or c

<400> 226
tcgacccacg cgtccgccag cagaaggctg ttgnngggacg tctgccagga ctgcatccag 60
atggtgacag acatccagac tgctgtaagg accaactcca cctttgttga agctttggtg 120
gaccatgcc aagcacagtg tgatctcctg gggcccggca tggctgacat gtgcaagaac 180
tatatcaacc agtattcgga cattgccgtc cagatgatga tgcacatgca acccaaagag 240
atctgtggcc tggttggggt ctgcgaccaa gtgaaggaga tgcccatgca gactctgac 300
cctgccaaag cggctctcaga gaacgtcatc cctgcattgg aactgggtgga gcccattaag 360
aaggacacg tccaggcaaa gaccagtgtt agctgtggag atatgcgagt tacgtggttg 420
aaggaaagtg ccaagctcca ttggacaaca acaggactga ggaagaaata gtttcaggct 480
tggaataatg tgctccantt gccctaagtc ctanctgaac atg 523

<210> 227
<211> 2377
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (2369)
<223> n equals a,t,g, or c

<400> 227
gccgatcccg gagtcggagc cgttccaggt ctgcagccg atctcgctac agccgctcga 60
agtctcggtc ccgcactcgt tctcgatctc ggtcgacctc caagtccaga tccgcacgaa 120
ggtccaagtc caagtcctcg tcggtctcca gatctcgttc gcggtccagg tcccggctctc 180
ggtccaggag tcctcccca gtgtccaaga gggaaatcaa atccaggctc cgatcgaaga 240
gtcccccaa gtctcctgaa gaggaaggag cgggtgtcctc ttaagaaaat ggtaatgtct 300
gggaatccga gacacataac cctaattcat aaatgggatt tggggtagggt ctttttgagt 360
cgtgttaatg taagaatgac tcctatcatt aggagtgtg ctcgagggtt actcaccttt 420
gggagtaata ctgaagagag ggggtctgcag aaaggatgtg tatgaagctt agataataat 480
ggctgtttcg taaactgttt gagacctatt aatgaaaatg actatttctt gctgttttta 540
tccaacgtct gcattttccc cctttaagc tgcggtctcc tgtttgataa aagaatattg 600
gccagtattg cagattttaa ctgatttggc tgatcctcca gggaccagtt tctgtgggag 660
tgtattggar caggtttgtc tttaaatgtt aaagatgcac tatcctctta gagaaacaat 720
cagttcaact attgttgtac tgactgggac ttcatttctt aatggatgtg gcaaaagaat 780
tgcaataaga agcagtgaac atttgaacc ccaaaagaaa gttacaggta ttgcaactggg 840
tggggaaagg atagtgtgtc ttttaactctt aaattgtttg gtcctatttt ttaaaaagga 900

```

aagggcccta agtagctcag atattaaagt agtattctca attaccaaatt gtttcatttg 960
aaacaatttta tcttaatgaa atatagacca attctctgat ctcgagttgt ttttgtttg 1020
atacagccct ttttttttcc ttttttttcc ttccccttac ctttcttcac cttgggttatt 1080
tggccaggaa tacgtaaatt caaacttgta catgctgatg gtagcctttg tgaaattttc 1140
ctaattgggc cttttaaaaa catggctggg tggaacattt ctgtacccta ctggtttgac 1200
cagagcctta gtaagtacgt gcctgaaact gaaaccatgt gcactttaat ggaaggtaa 1260
ctgaacttct tttttttcaa acctagatgt atcggcaagc agtgtaaagc gaggacttgg 1320
ggaaaaagga ccacatagtc catcgaagaa gagtccttgg aacaagcaac tggctattga 1380
aaaggttatt ttgtaacatt tgtctaactt tttacttgtt taagctttgc ctcagttggc 1440
aaacttcatt ttatgtgcca ttttgttgct gttattcaaa tttcttgtaa tttagtga 1500
tgaacgactt cagatttcat tattggattt ggatatttga ggtaaaattt cattttgtta 1560
tatagtgtcg actttttttg tttgaaatta aacagattgg taacctaat tgtggcctcc 1620
tgacttttaa ggaaacgtg tgcagccatt acacacagcc taaagctgtc aagagattga 1680
ctcggcattg ctttcattcc ttaaaattaa aaacctaca aagttggtgt aaatttgtat 1740
atgttattta ctttcagatc taaatggtaa tctgaaccca aatttgtata aagacttttc 1800
aggtgaaaag acttgatttt ttgaaaggat tgtttatcaa acacaattct aatctcttct 1860
cttatgtatt tttgtgcact aggcgcagtt gtgtagcagt tgagtaatgc tggtagctg 1920
ttaagtgggc gtgtgcagt gcagagtgtc tggctgtttc ctgttttctc ccgattgctc 1980
ctgtgtaaag atgccttgct gtgcagaaac aaatggctgt ccagtttatt aaaatgcctg 2040
acaactgcac tccagtcac ccgggccttg catataaata acggagcata cagtgcacac 2100
atctagctga tgataaatat cccttttttt ccctcttccc cctaaaaatg gtaaatctga 2160
tcatatctac atgtatgaac ttaacatgga aaatgttaag gaagcaaag gttgtaactt 2220
tgtaagtact tataacatgg tttatctttt tgcttatgaa tattctgtat tataaccatt 2280
gtttctgtag ttttaattaa acattttctt ggtgttagct tttctcagaa aaaaaaaaaa 2340
aaaaaaaaaa aaaaaaaaaa aaaaaaaang aaaaaag 2377

```

<210> 228

<211> 463

<212> DNA

<213> Homo sapiens

<400> 228

```

aatacatgcc aaatggatca ttaaatgaac tcctacatag gaaaactgaa tatcctgatg 60
ttgcttgaggc attgagattt cgcacctgc atgaaattgc ctttggtgta aattacctgc 120
acaatatgac tcctccttta cttcatcatg acttgaagac tcagaatata ttattggaca 180
atgaatttca tgtaagatt gcagattttg gtttatcaaa gtggcgcatg atgtccctct 240
cacagtcacg aagtagcaaa tctgcaccag aaggaggagc aattatctat atgccacctg 300
aaaactatga acctggacaa aaatcaaggg ccagtatcaa gcacgatata tatagctatg 360
cagttatcac atgggaagtg ktatccagaa aacagccttt tgaagatgac accaatcctt 420
tgcagataat gtatagtgtg tcacaaggac attggactgg tat 463

```

<210> 229

<211> 1232

<212> DNA

<213> Homo sapiens

<400> 229

```

caggtgagca tctgaacaag gggcagtcgg ccagggtggg cttgcgggag tccccacctt 60
gacctctctc cttccagct gccagagcc cagaccaagc atggacgccg tggatgccac 120
catggagaaa ctccgggcac agtgccctgt ccgcggggcc tcgggcatcc agggcctggc 180
caggtttttc cgccaactag accgggacgg gagcagatcc ctggacgctg atgagttccg 240

```

```

gcagggtctg gccaaactcg ggctggtgct ggaccaggcg gaggcagagg gtgtgtgcag 300
gaagtgggac cgcaatggca gcgggacgct ggatctggag gagttccttc gggcgctgcg 360
gccccccatg tcccaggccc gggaggctgt catcgcagct gcatttgcca agctggaccg 420
cagtggggac ggcgtcgtga cggaggacga cctccgcggg gtgtacagtg gccgtgcccc 480
ccccaagggt cgagtgggg agtggaccga ggacgaggtg ctgcgccgct tcctggacaa 540
cttcgactcc tctgagaagg acgggcaggt cacactggcg gaattccagg actactacag 600
cggcgtgagt gcctccatga acacggatga ggagtctctg gccatgatga ccagtgcctg 660
gcagctgtga gcagctccgg ctacgccctg ctgccctggc ctgtcactyc ccaccctgc 720
cggagacctc ccttcctctg gcccttctc ttctgggcag scacaccaca gagcggggag 780
gggcagggtg gggaatggag gctgcaggac tggctagacc aggtccctgc cggtcacca 840
ggcggagggt ggacaaagg cctaacagga gtcactggct caggaccccc gggagaaacg 900
ctctccccac ccacgccatg ctgaccagag gtcttgacgc ccctgtggat gcccccgccg 960
aggtcccccg atccccgcac ccggactgct gctccctgcc cctcccttgc ggggtcccca 1020
ggaagccagg tgacccagg tgggaggctg tgtgtggagg ccattcctga aggaagttaa 1080
gacctgcccc ggtgtggagc gaggggcaca ggggcatcct aacctcagaa actgaaataa 1140
agcctttgaa aaaaaaatct gtaaaacatc aacccccaat cagaagatgg caaatgggga 1200
ataaaaaatg caggtaacac gtcaaaaaaa aa 1232

```

<210> 230

<211> 1063

<212> DNA

<213> Homo sapiens

<400> 230

```

gcccacgcgt ccgctcagcg gctgccaaaca gatcatgagc catcagctcc tctggggcca 60
gctataggac aacagaactc tcaccaaagg accagacaca gtgggcacca tgggacagt 120
tcggctcagc aacgcagagg atgctcagga attcagtgat gtggagagg ccattgagac 180
cctcatcaag aactttcacc agtactccgt ggagggtggg aaggagacgc tgacccttc 240
tgagctacgg gacctggtca ccagcagct gccccatctc atgccgagca actgtggcct 300
ggaagagaaa attgccaaac tgggcagctg caatgactct aaactggagt tcaggagt 360
ctgggagctg attggagaag cggccaagag tgtgaagctg gagaggcctg tccgggggca 420
ctgagaactc cctctggaat tcttgggggg tgttggggag agactgtggg cctggaaata 480
aaacttgtct cctctaccac caccctgtac cctagcctgc acctgtccwc atctctgcaa 540
agttcagctt ccttccccag gtctctgtgc actctgtctt ggatgctctg gggagctcat 600
gggtggagga gtctccacca gagggaggct caggggactg gttgggccag ggatgaatat 660
ttgagggata aaaattgtgt aagagccaaa gaattggtag tagggggaga acagagagga 720
gctgggctat gggaaatgat ttgaataatg gagctgggaa tatggctgga tatctggtac 780
taaaaaaggg tctttaagaa cctacttcct aatctcttcc ccaatccaaa ccatagctgt 840
ctgtccagtg ctctcttcct gcctccagct ctgccccagg ctctcctar actctgtccc 900
tgggctaggg caggggagga gggagagcag ggttggggga gaggtgagg agagtgtgac 960
atgtggggag aggaccagct ggggtgcttg gcattgacag aatgatggtt gktttgatc 1020
atgtgattaa taiaaaaaaa tgaaaaaagt gaaaaaaa aa 1063

```

<210> 231

<211> 1063

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1056)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1061)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1063)

<223> n equals a,t,g, or c

<400> 231

```
gatcaccacc agggagcaga atccgttcca gggattgggg tgagtccgac ttcgagcagc 60
agctgcccc caacatcatg taccagccc gtgactacgt ggagccctgg gcttcgcgta 120
gagtccctag acggggcgaa aacgggaaaa ggggccttaa ctggggcacc tggctccttt 180
gggagctcgg agtttctgac tggcctgcgc aacacctcag aggcaaggkg aacgcgaggg 240
cctataatgc aagaaccaag gcgagtcacg ccctgtcttg gcaaaagagg agtaaagacc 300
cctcagctgc agcccggcag cgcattccta ccaggggtcc gccgccagag ctttcccgcg 360
cggtcggata gttacactac tgtccgggac ttcctagccg tgccgcggac catctcaagt 420
gcttccgcca cactcatcat ggcggtggca gtaagtcact tccgcccggg accggaartg 480
tgggatactg cgagtatggc ggcgtcaaag gtgaagcagg acatgcctcc gccggggggc 540
tatgggcca tcgactacaa acggaacttg ccgcgtcgag gactgtcggg ctacagcatg 600
ctggccatag ggattggaac cctgatctac gggcactgga gcataatgaa gtggaaccgt 660
gagcgcaggc gcctacaaat cgaggacttc gaggctcgca tcgcgctgtt gccactgtta 720
caggcagaaa ccgaccggag gaccttgag atgcttcggg agaacctgga ggaggaggcc 780
atcatcatga aggacgtgcc cgactggaag gtgggggagt ctgtgttcca cacaacccgc 840
tgggtgcccc ccttgatcgg ggagctgtac gggctgcgca ccacagagga ggctctccat 900
gccagccacg gcttcatgtg gtacacgtag gccctgtgcc ctccggccac ctggatccct 960
gccctcccc actgggacgg aataaatgct ctgcagacct gaaaaaaaaa aaaaaaaaaa 1020
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaanaaaa nan 1063
```

<210> 232

<211> 1474

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1337)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1359)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1377)

<223> n equals a,t,g, or c

<400> 232

```
ggattcctac cctcatcacg gcctttgtcc ttgtacctc tcaggcccaa gctggatggc 60
tgcaacatga ttatggccac ctgtctgtct acagaaaacc caagtggaaac caccttgtcc 120
acaaattcgt cattggccac ttaaagggtg cctctgccaa ctggtggaat catcgccact 180
tccagcacca cgccaagcct aacatcttcc acaaggatcc cgatgtgaac atgctgcacg 240
tgtttgttct gggcgaaatgg cagcccatcg agtacggcaa gaagaagctg aaatacctgc 300
cctacaatca ccagcacgaa tacttcttcc tgattgggcc gccgctgctc atccccatgt 360
atttccagta ccagatcatc atgaccatga tcgtccataa gaactgggtg gacctggcct 420
gggccgtcag ctactacatc cggttcttca tcacctacat ccctttctac ggcacacctg 480
gagccctcct tttcctcaac ttcacaggt tcctggagag ccaactgggtt gtgtgggtca 540
cacagatgaa tcacatcgtc atggagattg accaggaggc ctaccgtgac tggttcagta 600
gccagctgac agccacctgc aacgtggagc agtccttctt caacgactgg ttcagtggac 660
accttaactt ccagattgag caccacctct tccccacat gccccggcac aacttacaca 720
agatcgcccc gctggtgaag tctctatgtg ccaagcatgg cattgaatac caggagaagc 780
cgctactgag ggccctgctg gacatcatca ggtccctgaa gaagtctggg aagctgtggc 840
tggacgccta ccttcacaaa tgaagccaca gccccggga cacygtggg aaggggtgca 900
ggtggggtga tggccagagg aatgatgggc ttttgttctg aggggtgtcc gagaggctgg 960
tgtatgcact gctcacggac cccatgttgg atcttctctc ctttctcctc tcctttttct 1020
cttcacatct cccccatagc accctgccct catgggacct gccctccctc agccgtcagc 1080
catcagccat ggccctccca gtgcctccta gcccttctt ccaaggagca gagagggtgc 1140
caccgggggt ggtctgtgac tacctccact ctctgccct aaagatggga ggagaccagc 1200
ggtccatggg tctggcctgt gagtctcccc ttgcagcctg gtcactaggc atcacccccg 1260
ctttggttct tcagatgctc ttggggttca targggcarg tcctagtcgg ggcargggcc 1320
ctgaccctcc cggctnngct taaatctccc tgaacggtng caattggtcc acctttncat 1380
aaaaaaggct gcttgttaca aagtccgggt tttccttctt gcaactcggg taataaccga 1440
aggctctctt aagatgttca agggcccaag gccg 1474
```

<210> 233

<211> 1782

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (8)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (31)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (34)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (591)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1760)

<223> n equals a,t,g, or c

<400> 233

```
aagatganag gctcacccta aaacatcttc ntnctctac cagtgaagact atcaaccatg 60
gatctatcta tctatTTTTT aagcctgcat cacttcttga gataatgagg tttctacctc 120
caaaagcctgc tgggtgagca ccttgctcat tatactggwt ctgaatttac ctctttgaag 180
tttctagatg caccacttcc tgctcacagc ctggaattcg gttaacaagt cagtgtcaac 240
ctacctttcc ctcatgatt tatagacttt tgggagtacc ttctggtagc ttttgtcttc 300
ccataggaaa gaggcccaat cccagtttgt cctcaciaag cggccagctc cgtgatatct 360
cttttgcggg cagagttaag attgtacaca gatccccaca agtaccacgr tttttgcctc 420
aggaaggata aagcacatgt ttgtttctgc tttcgttttc tttttcttt ttttcasgaa 480
gccttatgga gaagtatgtt tctgctttct ttctgrgga agcctagytt ctgggccacg 540
ggactgatcc tgtctacatc ctcttccct ccattctcca tcgtgtctct nccccgctct 600
caccaccacc gtgcccctct ytgsctcagc ttcccctctt cccctgcagt gaggttcctg 660
cgcagcggca ctaagctcat cttccgcccagg aggcctaggc agaaggaagc tggcctgagc 720
caatcacacg atgacctctc caacgcaacg gccacgcccc gtgtccgaaa gaaggccggc 780
agcttttctc gccgccttat caagcgcttt tccttcaaat ccaaacccaa ggccaatggt 840
aaccaccagc cccagctctg aggaccagc tctgaaaggg cacgagttct ctcagcccat 900
tcccacctc cccttccata ccccttctg gatctccagt gcctgggcca ggaaagccct 960
ctgggttccg ggaagccccg tccaccctgg gccatggggc cggttggaag gatacttga 1020
acgggaagca catgagaggt gggcaccggg tgccgaggac atggacgagg gactgggtggc 1080
tgggagggag aggagggccc tgtccggcat gtgtgggtat tccccagaag catTTgcctc 1140
ctgctgagcc tggctccctga gcggagtccc aggggtgetca gctcttcac tgaccttct 1200
tcccttattt attctctttt ctatttatat gtgtggctta ggacctccg tgaacagatg 1260
atagagggca tctctcccag gtgaccttc ttttctgtcc caggaggggtg ggtaattccc 1320
tttgggatgg ggctccaca cctccctcag gtcccccact agaccagcac cagtgtctgc 1380
ctctgagaat gttggcagct cacagagagc agggccggcc cgggatgggg ggcagggtact 1440
ccccacctc ctgcctcccc tctgctcct catccctccc tcccccttta ttaccgtttt 1500
ttgtacttga tgccctctct gtgagcagtg gctctgtggg aaggagggag ccgggagcct 1560
ggtgggaagc cttccccaga gagatggctt taggggcttt atttaaagac tgtgatgatg 1620
gagccacgca aggctgcacc tctgtgtgtt gggagacgat gatgatgtcc attgctgtgt 1680
gatggcttg aatttaattt attaaagtca aattggagtt taaaaaaaaa aaaaaaaaaa 1740
aaattcgggg gggggccctn acccattggc cctaaggggg gg 1782
```

<210> 234

<211> 2208

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1314)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2189)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2202)

<223> n equals a,t,g, or c

<400> 234

```
acagggctcg gagccaagct cagagaacgc caatgacacc atcattttgc gcaacctgaa 60
cccacacagc accatggatt ccacctcctggg ggccttgcca ccctacgcgg tgctgtcctc 120
ctccaacgtg cgcgtcataa aggacaagca gacccaactg aaccgcggct ttgccttcat 180
ccagctctcc accatcgagg cagcccagct gctgcagatc ctgcaggccc tgcacccacc 240
actcactatc gacggcaaga ccacatcaatgt tgagtttgcc aagggttcta agagggacat 300
ggcctccaat gaaggcagtc gcatcagtcg tgcctctgtg gccagcactg ccattgctgc 360
ggcccagtg gcatctcac aggcctccca aggtggggag ggtacctggg ccacctccga 420
ggagccgccc gtcgactaca gctactacca acaggatgag ggctatggca acagccaggg 480
cacagagtct tccctctatg cccatggcta cctcaagggc accaagggcc ctggcatcac 540
tggaacaaa ggggatccca ctggagcagg tcccagggcc tccctagagc ctggggccga 600
ctctgtgtcg atgcaggctt tctctcgcgc ccagcctggt gctgtcctg gcatctacca 660
acaatcagcc gaggcgagca gtagccaggg cactgctgcc aacagccagt cgtataccat 720
catgtcaccg gctgtgtcca aatctgagct ccagagccct acccatccta gttctgctct 780
cccaccggct accagcccca ctgcccagga atcctacagc cagtaccctg tcccgcagct 840
ctctacctac cagtcagatg agacctccgg ctactactat gacccccaga ccggcctcta 900
ctatgacccc aactcccagt attactacaa tgctcagagc cagcagtagc tgtactggga 960
tggggagagg cggacctatg ttcccgccct ggagcagtcg gccgacggac ataaggagac 1020
aggggcaccc tcgaaggagg gcaaagagaa gaaggagaag cacaagacca agacagctca 1080
acagattgcc aaggacatgg aacgctgggc cgcagtcctc aacaaacaaa aagaaaactt 1140
caaaaatagc ttccagccta tcagctccct gcgagatgac gagaggcggg agtcagccac 1200
tgcatagtct ggctatgcca tcctcgagaa gaaggagca ctagccgaga gacagcacac 1260
cagcatggat ctcccgaat tggccagtga cgaccgccc agccctccgc gagnactggt 1320
ggcagcctac agcggggaga gtgacagtga ggaggagcag gacgtgggg gccctgagcg 1380
ggaggagaag ctaccgact ggcagaagct ggcctgtctg ctctgccgac gccagttccc 1440
cagcaaagag gcgctcatcc ggcaccagca gctctcaggg ctccacaagc aaaaccttga 1500
gattcaccgg cgagccact tgtcagaaaa cgagctagaa gcactagaga agaattgacat 1560
ggagcaaatg aagtaccggg accgtgcagc tgaacgcaga gaaaagtatg gcatccccga 1620
gccgccagag cccaagagga ggaagtacgg cggcatatcc acagcctctg tagacttcga 1680
gcagcctact cgggacgggc tgggcagtga caacattggc agtcggatgc tgcaggccat 1740
gggctggaaa gagggcagcg gcctgggccg maagaagcag ggcattgtaa cgccatcga 1800
ggcccaaca cggtgcggg gctccggcct gggcgcagc ggcagtcct acggggtcac 1860
ctcaaccgag tcctacaagg agacactgca caagacaatg gtgaccgct tcaacgaggc 1920
ccagtgaagc gcttcaagag caacttctcc acatgttggg tgtccatcct ggggcaggga 1980
aggacagagt gttggatggc tgggacgggg ccttgcctct gtcggccagc ccactcccca 2040
gccagagagg gcttgaccaa atcaaatga ggtggtgact ttgttgga aattgggctg 2100
ggatcacgct ctgttttgta ataaaagctg aaaagtctga aaaaaaaaaa aaaaaaaac 2160
ccgggggggg gggccggtac ccattttcnc cctaaagtga gnggtttt 2208
```

<210> 235

<211> 2580

<212> DNA

<213> Homo sapiens

<220>
<221> misc feature
<222> (1)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (3)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (2558)
<223> n equals a,t,g, or c

<400> 235
ntncacgcgt cccggggcgcc agaccggcgt ttgcccgtccg gctattagcc tactgtggct 60
agtcaccccc ggggtcccg cttctcggg ctggggccgc cgccaccgc gcaggacggg 120
gaggcgggccc atggcgctcct gcgtggggag ccggacccta agcaaggatg atgtgaacta 180
caaaatgcat ttccggatga tcaacgagca gcaagtggag gacatcacca ttgacttctt 240
ctaccggccg cataccatca ccctgctcag cttcaccatc gtcagcctca tgtacttcgc 300
ctttaccagg gatgactctg ttccagaaga caacatctgg agaggcatcc tctctgttat 360
tttcttcttt cttatcatca gtgtgttagc tttccccaat ggtccgttca ctcgacctca 420
tcagacctta tggcgaaatgg tttttggact cagtgtgctc tacttcctgt tcctgggtatt 480
cctactcttc ctgaatttcg agcagggttaa atctctaatg tattggctag atccaaatct 540
tcgatacgcc acaagggaag cagatgtcat ggagtatgct gtgaactgcc atgtgatcac 600
ctgggagagg attatcagcc actttgatat ttttgcatth ggacatttct ggggctgggc 660
catgaaggcc ttgctgatcc gtagttacgg tctctgctgg acaatcagta ttacctggga 720
gctgactgag ctcttcttca wgcattcctt ccccaatttt gccgagtgtt ggtgggatca 780
agtcattctg gacatcctgt tgtgcaatgg cgggtggcatt tggctgggca tggctgtttg 840
ccggttttta gagatgagga cttaccactg ggcaagcttc aaggacattc ataccaccac 900
cgggaagatc aagagagctg ttctgcagtt cactcctgct agctggacct atgttcgatg 960
gtttgacccc aaatcttctt ttcagagagt agctggagtg taccttttca tgatcatctg 1020
gcagctgact gagttgaata cttcttctt gaagcatatc tttgtgttcc aagccagtca 1080
tccattaagt tggggtagaa ttctctttat tgggtggcatc acagctccca cagtgaagca 1140
gtactacgct tacctcaccg acacacagtg caagcgcgta ggaacacaat gctgggtgtt 1200
tggggtcatt ggtttcctgg aggccattgt ttgcataaaa tttggacaag atctcttctc 1260
taagacccaa ataacttatg ttgtgctttg gcttctttgc gtggccttca ccactttcct 1320
ctgtctgtac ggcatgattt ggtatgcaga acactatggt caccgagaaa agacctactc 1380
ggagtgtgaa gatggcacct acagtccaga gatctcctgg catcacagga aagggaacaa 1440
aggttctgaa gacagccac ccaagcatgc aggcaacaac gaaagccatt cttccaggag 1500
aaggaaatcg cattccaagt caaaagtcac caatggcggt ggaagaaaat gaaaaaccct 1560
ggtaaatcaa agatgttcca gagtgcctag aactgagagg gaaatggaac tcatttgga 1620
ctccccgtga ggaggtcgag gcgcacaggg caagcaggaa gaggcgaggg cacttggggg 1680
tcattatttg agatcgtaag tcttgtttcc cacagacctg gccgcgtcag gcagatcatc 1740
gcctgggggg cttttgcaa cgtgggtct cttctaactt cagcacttga catgcggtca 1800
ccggtggcag cgcggtgtgt tgaagggaac cggtagctat tcattcacag ttgccaagag 1860
cagctccgcg cctgctggat cgtggatgca gcgtaaacat cttccttcag acgaggcatt 1920
aaccatggt ttaatggact ggtcaccagt ttttatttta tttttatgaa tctaccttcc 1980
cattgattga tttaagttca ggccactttt ctgtctttta tttggttact gttgttattt 2040

```

gtttttaagt taggatgctt tttaacagcc tttagaagcc gctgctgaaa ttgatactgg 2100
gggaagggtt ccccttcctt ctagagcaga aaagggagag aggtgttgta ttcctgtttg 2160
gtaacctcag tctcctgtaa gacctcctac cacatggcga gtatacacca atcaggagag 2220
ggtagctgcc tgcataggag cctcgcttcc gattattccc ttccaatat tattcatcca 2280
gacttagcca cagtgcacaa aagcaaacct gctagagagg cagtgaacac cacagcttct 2340
ccccagctag gtgcctttta catcgggttt gttctccttc catggtgtgt tgctgacatt 2400
gtcactgagt cccatgtgag gtgctggtga gtattacctt tcactctgtgc catgctctag 2460
aaccttgacc ttgatagttc accacctctg atggatccct gttttaaata aaaacgattc 2520
actttaagc ctaaaaaaaa aaaaaaattg ggggggggcc cgtaacccaa ttggcccttt 2580

```

<210> 236

<211> 3008

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (3001)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (3008)

<223> n equals a,t,g, or c

<400> 236

```

gtcatcactc tgttgcccag gctggaatgg tgaagtgcag tggcatgata tcggctcagt 60
gcagcctctg tctcccgggt tcaagcgatt ctctgcctc agcctctaaa gagtgtgagg 120
aagaggctgt ctgtgtcatt atgtgtgctg cgggtcaagta taatatccgg ggtcctgccc 180
tcaccccaag aatgaagacc aagcaccgaa tctactatat caccctcttc tccattgtcc 240
tcttgggcct cattgccact ggcatgtttc agttttggcc ccattctatc gagtcctcaa 300
atgactggaa tgtagagaag cgcacatccg tgatgtgccg gttgttaggc tgccagccga 360
cagtcccatc ccagagcggg gggatctcag ttgcagaatg cacacgtgtt ttgatgtcta 420
tcgctgtggc ttcaacccaa agaacaaaat caaggtgtat atctatgctc tgaaaaagta 480
cgtggatgac tttggcgtct ctgtcagcaa caccatctcc cgggagtata atgaactgct 540
catggccatc tcagacagtg actactacac tgatgacatc aaccgggcct gtctgtttgt 600
tccctccatc gatgtgctta accagaacac actgcgcac aaggagacag cacaagcgat 660
ggcccagctc tctaggtggg atcgaggtac gaatcacctg ttgttcaaca tgttgccctg 720
aggtccccc a gattataaca cagccctgga tgtcccaga gacagggccc tgttggtctg 780
tggcggcttt tctacgtgga cttaccggca aggctacgat gtcagcattc ctgtctatag 840
tccactgtca gctgaggtgg atcttccaga gaaaggacca ggtccacggc aatacttctc 900
cctgtcatct caggtgggtc tccatcctga gtacagagag gacctagaag ccctccaggt 960
caaacatgga gagtcagtg tagtactcga taaatgcacc aacctctcag aggtgtctct 1020
ttctgtccgt aagcgtgccc acaagcacca ggtcttcgat taccacagg tgctacagga 1080
ggctactttc tgtgtggttc ttogtgagc tcggctgggc caggcagtat tgagcgatgt 1140
gttacaagct ggctgtgtcc cggttgtcat tgcagactcc tatattttgc ctttctctga 1200
agttcttgac tgaagagag catctgtggt tgtaccagaa gaaaagatgt cagatgtgta 1260
cagtattttg cagagcatcc cccaaagaca gattgaagaa atgcagagac aggcccggtg 1320
gttctgggaa gcgtacttcc agtcaattaa agccattgcc ctggccaccc tgcaagattat 1380
caatgaccgg atctatccat atgtgccat ctctatgaa gaatggaatg accctcctgc 1440
tgtgaagtgg ggcagcgtga gcaatccact cttcctcccg ctgatccac cacagtctca 1500

```

```

agggttcacc gccatagtc tcacctacga ccgagtagag agcctcttcc gggatcatcac 1560
tgaagtgtcc aaggtgcccga gtctatccaa actacttgtc gtctggaata atcagaataa 1620
aaaccctcca gaagattctc tctgcccga aatccgggtt ccattaaaag ttgtgaggac 1680
tgctgaaaac aagttaagta accgtttctt cccttatgat gaaatcgaga cagaagctgt 1740
tctggccatt gatgatgata tcattatgct gacctctgac gagctgcaat ttggttatga 1800
ggctctggcg gaatttcctg accggttggt gggttaccg ggtcgtctgc atctctggga 1860
ccatgagatg aataagtga agtatgagtc tgagtggacg aatgaagtgt ccatggtgct 1920
cactggggca gctttttatc acaagtattt taattacctg tataacctaca aaatgcctgg 1980
ggatatcaag aactgggtag atgctcatat gaactgtgaa gatattgcca tgaacttcct 2040
gggtggccaac gtcacgggaa aagcagttat caaggtaacc ccacgaaaga aattcaagtg 2100
tcctgagtgc acagccatag atgggctttc actagaccaa acacacatgg tggagaggtc 2160
agagtgcatac aacaagtttg cttcagtcct cgggaccatg cctctcaagg tgggtggaaca 2220
ccgagctgac cctgtcctgt acaaagatga ctttcctgag aagctgaaga gcttcccaa 2280
cattggcagc ttatgaaacg tgcattggt ggaggtctga atgtgaggct gggacagagg 2340
gagagaacaa ggctccccag cactctgatg tcagagtagt aggttaaggg tggaaagggtg 2400
acctacttg atcttgcat gcacccacct aaccacttt ctcaagaaca agaacctaga 2460
atgaatatcc aagcacctcg agctatgcaa cctctgttct tgtatttctt atgatctctg 2520
atgggttctt ctgaaaatg ccaagtggaa gactttgttg catgctccag atttaaattc 2580
agctgaggct cccttggtt tcagttccat gtaacaatct ggaaggaaac ttcacggaca 2640
ggaagactgc tggagaagag aagcgtgtta gccatttga ggtctgggga atcatgtaaa 2700
gggtacccag acctcacttt tagttattta catcaatgag ttctttcagg gaaccaaacc 2760
cagaattcgg tgcaaaagcc aaacatcttg gtgggatttg ataaatgcct tgggacctgg 2820
agtgtctggc ttgtgcacag gaagagcacc agccgctgag tcaggatcct gtcagttcca 2880
tgagctattc ctctttggtt tggctttttg atatgattaa aattattttt tattcctttw 2940
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3000
nggggggn                                     3008

```

<210> 237

<211> 877

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (834)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (854)

<223> n equals a,t,g, or c

<400> 237

```

caattattga agtcaagtga tgggcacaga ggattgatag ctcaaataag gcttggtact 60
tgcccttgga aaaagtatgc taggattctg gtgggagggg tagacatata aatggataat 120
ttataatatg atgtaagtac agagagctgt gggaacataa aggaaggaaa atgaacttga 180
gtctgagact gctcacttct attagagccc tcttctgttt tgcttcatgt tcagccttca 240
ggaagaactc atttctgttg ttgacaactg aagttgtctg tcagaaagca atgttgtaag 300
gtgacgtaca gctacatatt tttcctcaa attgaggtga aagggaatttc taaagtaggc 360
attatgttct taatttttat ctgtgaatta agccaccag ctcctcagct ctttctctgt 420
tggccctcta cttcagatta ctttctatga agacaaaaat tttcaaggcc gtcgctatga 480

```

```

ctgtgattgc gactgtgcag atytccacac atacctaaagt cgctgcaact ccattaaagt 540
ggaaggaggc acctgggctg tttatgaaag gcccaacttt gctgggtaca tgtacatctt 600
accacagggg gagtaccctg aataccagcg ttggatgggc ctcaacgacc gcctcagctc 660
ckgcagagct gtttcatctg cctagtggag gccagtataa gattcagatc tttgagaaag 720
gggatttttag tggtcagatg tatgaaacca ccgaagattg cccttccatc atggagcatt 780
tcacatgcga gagaccatcc tgtaagtgtc ggaggtgtct ggattttcta tganctaccc 840
aactaccgtg gcangcagta ctctctggaca agaagga 877

```

<210> 238

<211> 3039

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (170)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (177)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (3039)

<223> n equals a,t,g, or c

<400> 238

```

ccgatgccga cctggctcatc tgggaccccg acagcgtaa aaccatctct gccaaagacac 60
acaacagctc tctcgagtac aacatctttg aaggcatgga gtgccgcggc tccccactgg 120
tggctcatcag ccaggggaag attgtcctgg aggacggcac cctgcatgtn accgaangct 180
ctggacgcta cattccccgg aagcccttcc ctgattttkt ttacaagcgt atcaaggcaa 240
ggagcaggct ggctgagctg agaggggttc ctcgtggcct gtatgacgga cccgtgtgtg 300
aagtgtctgt gacgccaag acagtcactc cagcctctc ggccaagacg tctcctgcc 360
agcagcaggc cccacctgtc cggaacctgc accagtctgg attcagtttg tctggtgtc 420
agattgatga caacattccc cgccgcacca cccagcgtat cgtggcgccc cccggtggc 480
gtgccaacat caccagcctg ggctagagct cctgggctgt gccgtccact ggggactggg 540
gatgggacac ctgaggacat tctgagactt ctttcttctc tccttttttt ttttttgtt 600
ttttttttta agagcctgtg atagttactg tggagcagcc agttcatggg gtcccccttg 660
gggccccaca ccccgctctc caccaagagt tactgatttt gctcatccac ttccctacac 720
atctatgggt atcacacca agactacca ccaagctcat acaggaacc acaccaaca 780
cttagacatg cgaacaagca gccccagcg aggtctcct tcgccttcaa cctcctagt 840
tctgttagca tcttctttt catgggggga gggaagataa agtgaattgc ccagagctgc 900
cttttctttt tcttttttaa aattttaaga agtttcttt gtggggctgg ggaggggccc 960
gggtcaggga gagtcttttt tttttttttt tttaaatact aaattggaac atttaattcc 1020
atattaatac aaggggtttg aactggacat cctaattgat caattacgtc atcaccacgc 1080
tgattccggg tggttggcaa actcatctgt tctgtcctga gaggtccac aatgcccacc 1140
cgcatcgcca ttctgtagtc ttcagggtca gctgttgata aaggggcagg cttgcgttat 1200
tggcctagat tttgtgcag attaaatcct ttgaggatc tcttctcttt taccattttt 1260
ctgcgtgtc tcactctctc tttctctctc tagcttttta attcatgaat attttcgtgt 1320

```

```

ctgtctctct ctctctctgt gtttccctcca gcccttgtct cggagacggt gttttccctcc 1380
cttgccccat tatcttttca cctcccaggt ctaccatttc atggtggtcg ttgggtccgc 1440
ctaaaggatt tgagcgtttg ccattgcaag catagtgtctg tgtcatcctg gtccatgtag 1500
gactggtgct aaccacctgc catcatgagg atgtgtgcta gagtgtggga ccctggccaa 1560
gtgcaggaat gggccatgcc gtctcaccca cagtatcaca ygtggaaccg cagacagggc 1620
ccagaagctt tagaggtagg aggtctcaga accggagaga ttttcctctg tgcagtgtctc 1680
tctggctaaa gtcacggtca aacctaaaca ccgagcctca ttaaccaag tgaaccaacc 1740
aaagtcacca gttcagaagt gctaagctaa taggagtctg acccgagggc ctgctgtcttc 1800
ctggttaagt atcttttgag attctagaac acatgggagc tttttatttt cggggaaaaa 1860
ccgtattttt ttcttgtcca attatttcta aagacacact acatagaaag aggccctata 1920
aactcaaaaa gtcattggga aacttaaaagt ctattctact ttgcaagagg agaaatgtgt 1980
tttatgaacg atagatcaca tcagaactcc tgtggggagg aaacctata aattaaacac 2040
atggccccct tagagaccac aggcgatgtc tgtctccatc cttccctctc cttttctgtc 2100
acctttcccc ctagctgggt cctttggacc taccctgtc cttgtgact tgtgttgcac 2160
tgtattccaa acgtgtttac aggttctctt aagcaatgtt gtatttgca gcttttctga 2220
ataccaaatc tgctttttgt aaagcgtaaa aacatcacaa agtaggtcat tccatcacca 2280
ccctgtgtct tctacacatt ttgccttttg ggatctggtt ggggttttg gttttttgtt 2340
gttgtgtgtt atttgttatt ttaaaggtaa attgcacttt taaaaaata attggttgac 2400
ttaatatatt tgcttttttt ctcacctgca cttagaggaa atttgaacaa gttggaaaaa 2460
aacaattttt gtttcaattc taagaaacac ttgcagctct agtattcact tgagtcttcc 2520
tggttttctc gtaccgggtc atggtaattt ttggttgttt tgggtgtttt cttaaaaaac 2580
aagttaaaac ctgacgattt ctgcaggctg tgtaagcatg tttacctgtt ggcttgcttt 2640
gtgtgtctgt taaatgaatg tcatatgtaa atgctaaaat aaatcgacag tgtctcagaa 2700
ctgaataact gcagtgactt gatgtcttaa aacagtgtag gayttaagaa tagatggttt 2760
ttaatcctgg aaattgtgat tgtgacccat gagtggagga actttcagtt ctaaagctga 2820
taaagtgtgt agccagaaga gtactttttt ttttgtaacc actgtcttga tggcaaaata 2880
attatggtaa aaaacaagtc tcgtgtttat tattccttaa gaactctgtg ttatattacc 2940
atggaacgcc taataaagca aaatgtggtt gtttcaaaaa aaaaaaaaaa aaaaaaaaaa 3000
aaaaaaaaaa aaaaaaaaaa aaccccgggg gggggcccn 3039

```

<210> 239

<211> 1992

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (12)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (13)

<223> n equals a,t,g, or c

<220>

<221> misc feature
<222> (29)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (87)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1989)
<223> n equals a,t,g, or c

<400> 239
nacactcctg annctcccta aatttaatna agctggccct ccaccgcggt ggcgggccgct 60
ctagaactag tggatccccc gggctgnagg aattcggcac gagcgcggtg ctgctgcgcc 120
tgggcatga gctggagatg atccggccca gcgtctaccg caacgtggcg cgtcagctgc 180
acatctccct gcagctctgag cctgtggtga ccgatgcgtt cctggccgtg gctggccaca 240
tcttctctgc aggcacacag tggggcaagg tgggtgccct gtatgcggtg gccgcggggc 300
tggccgtgga ctgtgtgagg caggcccagc ctgccatggt ccacgccctc gtggactgcc 360
tgggggagtt cgtgcgcaag accctggcaa cctggctgcg gagacgcggc ggatggactg 420
atgtcctcaa gtgtgtggtc agcacagacc ctggcctccg ctcccactgg ctggtggctg 480
cactctgcag cttcggccgc ttctgaagg ctgccttctt cgtgctgctg ccagagagat 540
gagctgcccc cctggcagtg gccgcagcct ggccctctgg ccaacgcagg aggccctcag 600
caccggaaca catcttcctc ctccccaccc gagcctggag cactctaacc ctcgagacc 660
ccctaagccc cgttcctccg cagaccaggg ccctccggaa ggggtgagtg gggaggggct 720
ttcctgagcc tggagctggg ctttggggca gcctgcgacc ctccccgctt gtgtcccttc 780
tctgtgatc tctgtgtttt cccttttctt tctggggcca ggaagtcagg gtcaactccc 840
aggcctcaga tgcaggggcc cagaacacct gctctcacct gagccccagg tgaagggggc 900
cgggaaacac tgctctcacc tgagccccag gtgaaggggc ccgggaacac ctgctctcac 960
ctgagcccca ggtgaagggg cccggaacac ctgctctcac ctgagcccca ggtgaagggg 1020
cccgggaaca cctgctctca cctgagcccc aggtgaaggg gcccggaaca cctgctctca 1080
cctgagcccc aggtgaaggg gcccggaaca cctgctctca cctgagcccc aggtgaaggg 1140
gcccggaac acctctcacc tgaacccggg gtcccattcc caggaagaag ggccatctca 1200
ggacatgagt cctcaggggc cctgcacatt caatctgaag gtgaccctgg cctggctgaa 1260
gctggaagag ctgtggggac tcagcctgta aacagagcgt aagggtcaca tgctggttg 1320
ttaatccgtt tctggaggaa gagtatgaca ccacttgtg atggggtcct tgtgcggtgg 1380
ggaccggggc cggcgggctc caggccagca cacctaacc atggatgtgg aacctacggc 1440
cgagaaggaa tgttgcatga gtcggatccc agtccattgt cagtggaggg tgagggtgac 1500
cccattctgt attttctgtgc tcatcctcat acaaccattt ggggatgtgc ctattagggc 1560
tccgtaagaa ctcatatgcc tgggaagccc agccctcag gtgccccac acacagcctt 1620
cccttgacgc ctacatttct aggcacatgt gaggcattct tcctggagcc ccgagccagc 1680
cctgtccctc ccagtgacag catggcactc aggagataca ggctggacat ggggcagtcg 1740
ttctggggag gcctggccta gcagccaccc acctgagccc tcccggccag gcttcgtgct 1800
gggggtggcc atgtgccagg acaggagggt cccggcgga agccagcccc ggactcatcg 1860
tgacattgag atcccactgg agggtagggg tggttaataaa cttctccaaa cgatgcgttg 1920
tcatttttaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1980
aaaaaaaaanc cc 1992

<210> 240

<211> 497
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (387)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (476)
 <223> n equals a,t,g, or c

<400> 240
 ggcagaactg tctgggacag acgctgcccg gatccctgcg gctgcctgca ctctggacca 60
 cgagctctga gaggcagcag ttgagggccg gtgggcagca gctcggaggc tccgcgaggt 120
 gcaggagacg caggcatggc cggtagagctg actcctgagg aggaggccca gtacaaaaag 180
 gctttctccg cggttgacac ggatggaaac ggcacatca atgcccagga gctgggcgcg 240
 gcgctgaagg ccacgggcaa gaacctctcg gaggcccagc taaggaaact catctccgag 300
 gttgacrgcg acggcgacgg cgaaatcagc ttccaggagt tcctgacggc ggcrargaag 360
 gccagggccg gcctggagga cctgcangtc gccttcgcg ccttcgacca ggatggcgac 420
 ggccacatca ccgtggacga gctcaggcgg gccatkgcgg ggytggggma ccttcnagag 480
 attgaccatt ttggagc 497

<210> 241
 <211> 316
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (133)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (311)
 <223> n equals a,t,g, or c

<400> 241
 atcgggcagc ccacacaagc ggcaaaccag aatggcactg gaaatggagc cgcagaggta 60
 cgcgatgagg atcattccag gcgcgattgc actcataagc tggtccgttt tgaaaattcg 120
 tgttcaacga tgaatctgt ggataatagc cacatttcgc cggaagtggg atccgggttag 180
 ccaraaagca ggcaggacgt gatggatatt gtatttatag agcaactttc ggtaatcacc 240
 actattggtg tttacgactg ggrcaacya tcgaacagaa gttagtgttc gatatcgaaa 300
 tggcgtgggg ntaacc 316

<210> 242
 <211> 829
 <212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (3)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (4)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (14)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (47)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (793)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (809)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (814)

<223> n equals a,t,g, or c

<400> 242

ngnntttctt cggngggggg gaataagggg acacagctca cactatntta aggtacgcct 60
gcaggtaccg gtccggaatt cccgggtcga ccacgcgtc cgaaagaaa agaagaaaag 120
aaaaaaagat cttcaaagg gcagatgggt agaaggcata acctctgagg gttaccatta 180
ctattatgat cttatctcag gagcatctca gtgggagaaa cctgaaggat ttcaaggaga 240
cttaaaaaag gtaattgaag catattaata gtgtttttgt tttattcttt acagtgattc 300
gtttcttagg tttttgtaga gttttgctaa gcaactttat ttacaaatac tccactccct 360
ccaccccaa actgtgtcct ttttttccc ataatgcttt tgtagaagg ctggatggag 420
atgaaatagt gatatctggc tgggtgcagt ggctcatgcc tgtaatccca gcactttggg 480

```

aggctgaggc atgtggatca caaggtcagg agttaaagac cagcctggcc aagatgggta 540
aaccctatct ctcctaaaaa ctacaaaaaa attagccagg cgcagtcgca gttgcctgta 600
atcccagcta ctcaggaggc tgagtcaggg gaatcactgg gacctggggc ggcagagggt 660
aacagtgagc cgagattgca ccaccgact ccagcctgga taacaaagta agactccgtc 720
tcaaaaaaaa aaaaaaaaaa agggcgggccg ctctagagga tccctcgagg ggcccaagct 780
tacgcgtgca tknaacgtca taggggctng ggcntttacc tttcccgtc 829

```

<210> 243

<211> 838

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (32)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (51)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (822)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (832)

<223> n equals a,t,g, or c

<400> 243

```

taaacccgaa gtgccaata ataatttaaa anatgttaat ttttttgcc ncctaaattt 60
gccctttcca tccattaaaa atgtccaagt tccaagtgat atgtgcccct aatatccacc 120
ttggatgttg gtgggttttt gaatttttgg gtggttaatc cagttttatt ttgaaaagac 180
gtacttgaat agttacagca tatgtttgaa caggaagtag gaacatgcat acacgaagaa 240
atgctaacgg aaggatttgt tatgtttagg atcttccctt ggaaactaaa aatagaatat 300
taatgacatt actgtttgta gaatgacata tgcagatttt ctcataagca gtcatttgtt 360
ttgccagtaa tgtttgagag acatgtaagt tgaaagtttt gctaaattat aaagctcctt 420
taattcggtt gttttgattc tcttattctc ttgtcttttc taaatgttaa caaaatatat 480
cttaacagat tacatgaaat ttaggaatta tttaaaagtt accattagct ctaaaattaa 540
gattcggatg ctttatttat agtaactgaa gctaataatg ttttatgttt tgattttttg 600
aaatttaatt gtagaagtca ctgccttctg agttttcaaa tagataacca cttttaatat 660
tacactgctt ataatactaa tgtttacaga tatgtttctg tttataacca tataatacat 720
tggctttgtc atattagttt tttttgcaag tagttatgta aaagagatag ataataaaat 780
attaataaac aaaaaaaaaa raaaargctc gagtaarggc anagtggcat gngccata 838

```

<210> 244

<211> 2853

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (2665)

<223> n equals a,t,g, or c

<400> 244

```
ggcacagcaa cagctctggg accatctcag gccccgctgc cctcccctag gccacaggca 60
gccccgtgtc catcttcgtc tatgatgtga agcctggcgc ggaagagcag acccaggtgg 120
ccaaagctgc cttcaagcgc ttcaaaactc tacggcacc caacatcctg gcttacatcg 180
atggactgga gacagaaaaa tgcctccacg tcgtgacaga ggctgtgacc ccgttgggaa 240
tatacctcaa ggcgagagtg gaggtgtgtg gcctgaagga gctggagatc tcctgggggc 300
tacaccagat cgtgaaagcc ctcagcttcc tgggtcaacga ctgcagcctc atccacaaca 360
atgtctgcat ggccgcctgt ttcgtggacc gagctggcga gtggaagctt gggggcctgg 420
actacatgta ttccggcccag ggcaacggtg ggggamctcc ccgcaaggga tccccgagct 480
tgagcagtat gaccccccg agttggctga cagcagtggc agagtggta gagagaagtg 540
gtcagcagac atgtggcgct tgggctgcct catttgggaa gtcttcaatg ggcccctacc 600
tcgggcagca gccctacgca accctgggaa gatcccaaaa acgctgggtg cccattamtg 660
taagctggtg ggagcaaac ccaaggtgcg tcccaaccca gcccgcttcc tgcagaactg 720
ccgggcacct ggtggcttca tgagcaaccg cttttagtaa accaacctct tcctggagga 780
gattcagatc aaagagccag ccgagaagca aaaattcttc caggagctga gcaagagcct 840
ggacgcattc cctgaggatt tctgtcggca caaggtgctg cccagctgc tgaccgcctt 900
cgagttcggc aatgctgggg ccgttgtcct caccgcccctc ttcaaggtgg gcaagttcct 960
gagcgtgtag gagtatcagc agaagatcat ccctgtgtgt gtcaagatgt tctcatccac 1020
tgaccggggc atgcgcaccc gcctcctgca gcagatggag cagttcatcc agtaccttga 1080
cgagccaaca gtcaacaccc agatcttccc ccacgtcgta catggcttcc tggacaccaa 1140
ccctgccatc cgggagcaga cgggtcaagtc catgtgtctc ctggcccca agctgaacga 1200
ggccaacctc aatgtggagc tgatgaagca ctttgcacgg ctacaggcca aggatgaaca 1260
gggccccatc cgctgcaaca ccacagtctg cctgggcaaa atcggtcctt acctcagtgc 1320
tagcaccaga cacagggtcc ttacctctgc cttcagccga gccactaggg acccgtttgc 1380
accgtcccgg gtgcgggtg tcctgggctt tgctgccacc cacaacctct actcaatgaa 1440
cgactgtgcc cagaagatcc tgcctgtgct ctgcgtctc actgtagatc ctgagaaatc 1500
cgtgcgagac caggccttca aggcattcgg agcttctgt ccaaattgga gtctgtgtcg 1560
gaggacccga cccagctgga ggaagtggag aaggatgtcc atgcagcctc cagccctgga 1620
atgggaggag ccgcagctag ctgggcaggc tgggcccgtg ccggggtctc ctcactcacc 1680
tccaagctga tccgttcgca cccaaccact gccccagcc cccaccctg ttctgcccac ccctacaacc 1800
cccaagcctg aaggagttcc tgccccagcc cccaccctg ttctgcccac ccctacaacc 1800
tcaggccact gggagacgca ggaggaggac aaggacacag cagaggacag cagcactgct 1860
gacagatggg acgacgaaga ctggggcagc ctggagcagg aggccgagtc tgtgctggcc 1920
cagcaggacg actggagcac cggggggcaa gtgagccgtg ctagtccagg cagcaactcc 1980
gaccacaaat cctccaaatc cccagagtcc gactggagca gctgggaagc tgagggtctc 2040
tgggaacagg gctggcagga gccaaagctc caggagccac ctcttgacgg tacacggctg 2100
gccagcgagt ataactggg tggcccagag tccagcgaca agggcgaccc cttcgctacc 2160
ctgtctgcac gtcccagcac ccagccgagg ccagactctt ggggtgagga caactgggag 2220
ggcctcgaga ctgacagtcg acaggtcaag gctgagctgg ccgggaagaa gcgcgaggag 2280
cggcgggcgg agatggaggc caaacgcgcc gagaggaagg tggccaaggg ccccatgaag 2340
ctgggagccc ggaagctgga ctgaaccgtg gcggtggccc tttccggctg cggagagccc 2400
gccccacaga tgtatttatt gtacaaacca tgtgagcccg gccgcccagc caggccatct 2460
cacgtgtaca taatcagagc cacaataaat tctatttcac accccttggt ccgggctcag 2520
tctagcccct gggaggcggc tggggtctg cgccgcctc gcagcccgcg cccacgtcag 2580
```

```

acgtgaacat caatttgctt cgaaagccaa gggtaaagag gcacgatytg atttatcagt 2640
ttctaggaac cacctctggg agganagcag gcagcgcccr cgggagacct tacaaccgcc 2700
cgctaaccgg ggaggggggc cggtaggggc gcctcgggty tcaaggcgcc gggaggggtc 2760
wgcgccctg aaggtccctk ggtccgagcc acaagtcggg gcagaagtga ggccgagctc 2820
gcggaaatcc ctcaagtgat caccgaggtc tgg                                     2853

```

<210> 245

<211> 1197

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (218)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1193)

<223> n equals a,t,g, or c

<400> 245

```

gctcgtgccg cggcctgctt ctacctgget gagatcacgc tggccctggg ccatctccac 60
tcccagggca tcatctaccg ggacctcaag cccgagaaca tcatgctcag cagccagggc 120
cacatcaaac tgaccgactt trgactctgc aaggagtcta tccatgaggg cgccgtcact 180
cacaccttct gcggcaccat tgagtacatg gcccctgnag attctggtgc gcagtggcca 240
caaccggggt gtggactggg ggagcctggg ggccctgatg tacgacatgc tactggatc 300
gccgcctttt accgcagaga accggaagaa aaccatggat aagatcatca ggggcaagct 360
ggcactgccc ccctacctca ccccagatgc ccgggacctt gtcaaaaagt ttctgaaacg 420
gaatcccagc cagcggattg ggggtggccc aggggatgct gctgatgtgc agagacatcc 480
ctttttccgg cacatgaatt gggacgacct tctggcctgg cgtgtggacc cccctttcag 540
gccctgtctg cagtcagagg aggacgtgag ccagtttgat acccgcttca caccggcagac 600
gccggtggac agtcctgatg acacagccct cagcgagagt gccaaccagg ccttcctggg 660
cttcacatac gtggcgccgt ctgtcctgga cagcatcaag gagggcttct ccttccagcc 720
caagctgcgc taccacaggc gcctcaacag tagcccccg gcccccgta gccccctcaa 780
gttctccctt tttgaggggt ttcggcccag cccagcctg cggagcccc cggagctacc 840
tctacctcca ctctgccac cggcgccgcc ctcgaccacc gcccctctcc ccatccgtcc 900
cccctcaggg accaagaagt ccaagagggg ccgtgggcgt ccagggcgct aggaagccgg 960
gtgggggtga gggtagccct tgagccctgt ccctgcggct gtgagagcag caggaccctg 1020
ggccagttcc agagacctg ggggtgtgtc ggggggtggg tgtgagtgcg tatgaaagt 1080
tgtgtctgct ggggcagctg tgcccctgaa tcatgggcac ggaggccgcc cgccrmgccc 1140
cgcgctcaac tgctcccgtg gaagattaaa gggctgaatc atgaaaaaaa aaaaaaa 1197

```

<210> 246

<211> 848

<212> DNA

<213> Homo sapiens

<400> 246

```

ggcacgagga gagagacctg gcggccgggc agcatggcgg ggctggagct cttgtcggac 60
cagggtacc gggtaggacg gcggcgcgcc ggggagctgc gcaagatcca ggcgcggatg 120

```

```

ggcgtgttcg cgcaggctga cggctcggcc tacattgagc agggcaaac caaggcactg 180
gctgtgtgtc acggcccga cgagatccgg ggctcccggg ctcgagccct gccggacagg 240
gccctagtga actgtcaata tagttcagcg accttcagca cagggtgagcg caagcracgg 300
ccacatgggg accgtaagtc ctgtgagatg ggcttcgagc tccgccagac ttctgaagca 360
gccatcctca cacagctgca cccacgctcc cagattgata tctatgtgca ggtgctacag 420
gcagatggtg ggacctatgc agcttgtgtg aatgcagcca cgctggcagt gctggatgcc 480
gggataccca tgagagactt tgtgtgtgctg tgctcagctg gcttcgtgga cggcacagcc 540
ctggcggacc tcagccatgt ggaggaagca gctgggtggc cccagctggc cctggccctg 600
ctgccagcct caggacagat tgcgctgctt gagatggatg cccggctgca cgaggaccac 660
ctggagcggg tgttgagggc tgctgcccag gctgcccag atgtgcacac cctcttagat 720
cgagtgttcc ggcagcatgt gcgtgaggcc tctatcttgc tgggggactg accaccagc 780
cacccatgtc cagaataaaa ccctcctctg cccamaaaaa aaaaaaaaaa aaaaaaaaaa 840
aaaaaaaaa 848

```

<210> 247

<211> 1336

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (26)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1336)

<223> n equals a,t,g, or c

<400> 247

```

ccccgcgggg acaaggcccg gacgngccg cggcccgcca gcgcccggc gtctcgcagc 60
aagagagggtg gagaagagcg agtacttgag aaagaagagg aagaagatga tgatgaagat 120
gaagatgaag aagatgatgt gtcagagggc tctgaagtgc ccgagagtga ccgtcctgca 180
ggtgcccagc accaccagct taacggcgag cggggacctc agagtgccaa ggagaggggtc 240
aaggagtgga cccctgctg accgcaccag ggccaggatg aagggcgggg gccagccccg 300
ggcagcggca cccgccaggt gttctccatg gcagccatga acaagggaagg ggaacagct 360
tctkttgcca ccgggccaga ctcccgcctc cccgtgcctt tgccccagc caaaccagcc 420
ctacctgggg ccgacgggac cccctttggc tgtcctcccg ggcgcaaaga gaagccatct 480
gatcccgtcg agtgaccgt gatggatgtc gtcgaatatt ttactgaggc tggattcccg 540
gagcaggcga cagttttcca agagcaggaa attgatggca aatctttgct gctcatgcag 600
cgcacagatg tgctcaccgg cctgtccatc cgcctcgggc cagccctgaa aatctacgag 660
caccacatca agtgcttca gcaaggccac tttgaggatg atgacccga tggcttctta 720
ggctgagcgc ccagcctcac cctgccccca gccattccg gccccatct caccacaagat 780
ccccagagt ccaggagctg gacggggaca ccctcagccc tcataacaga ttccaaggag 840
agggcaccct ctgtcctta tctttgcccc ttgtgtctgt ctcacacaca tctgtcctc 900
agcacgtcgg tgggggagg ggattgctcc ttaaacccca ggtggctgac cctccccacc 960
cagtccagga catttttaga aaaaaaaaaat gaaatgtggg gggcttctca tctccccaag 1020
atcctcttcc gttcagccag atgtttcctg tataaatgtt tggatctgcc tgtttatatt 1080
ggtgggtggt ctttctccc tcccctacca cccatgcccc ccttctcagt ctgcccctgg 1140
cctccagccc ctaggggact agctgggttg gggttcctcg ggccttttct ctctccctc 1200
ttttctttct gttgattgtc gctccagctg gctgtattgc ttttaatat tgcaccgaag 1260

```

ktttttttaa taaaatttta aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1320
 aaaaaaaaaa aaaaan 1336

<210> 248

<211> 1076

<212> DNA

<213> Homo sapiens

<400> 248

gccggagaga gcagttctcc cgggcacctg tgtcagccct gcccttgcc cctaaccacc 60
 tgggtaagtc acaggcgggtg gtgctgtggt tctgggggca ggtcccatg cctccaagga 120
 tgtcgccatc gacatgatgg actctcggac cagccagcag ctgcagctca ttgacgagca 180
 ggattcctac atccagagtc gggcagacac catgcagaac attgagtcga caattgttga 240
 gttgggctcc atctttcagc agttggcaca catggttaag gaacaggagg aaaccattca 300
 gaggatcgac gagaacgtgc taggagccca gctggacgtt gaggccgccc attcagagat 360
 cctcaagtac ttccagtctg tcacctccaa ccggtggctc atggtcaaaa tcttcctcat 420
 cctcattgtc ttcttcacat tctttgtggt cttccttgct tgaaccctct ctactctgag 480
 gcactctgtt ggggtttggg accctcctgg gaaggcaagt ggccagtgt gccactgagc 540
 ctgtgcaggg tacttgggag aaaggccctg tttccctgga actgctaaga atgaccactg 600
 cccctgatcc cccaccctt gcctctggcc accctgtcct cccccacca ccctcaggcc 660
 tatgaaacac acagggttct agatttgaac tctgctgtga agtgactgga agggagcaga 720
 ggccagctgg gggccagtgg gggaggttgt ttccactagg agatttttat aaaccctctc 780
 cagcctctcc caaaggaagc gtggcagca aaggagatg atgcccttac ccaccttctc 840
 gtgagtgaag agaggaagca gccccagga ccaattttcc caattgacct ctttcttctc 900
 ctttcaccat gtgaggcagg gagccctgag cccttcagct gcctgcacaa cccctgacat 960
 tggctgtctg tgactcaatc tgccaaatgt gctgcagctc gttttctccc aattacagca 1020
 agactgtcag cctcaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaa 1076

<210> 249

<211> 2425

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (52)

<223> n equals a,t,g, or c

<400> 249

ccgcagcagt gcccatctcc tgaccagtgc cactgtgatc caagcagtgg gnagtgccca 60
 tgctcccca atgtccaggg ccctagctgt gaccgmtgtg ccccaactt ctggaacctc 120
 accagtggcc atggttgcca gccttgtgcc tgccaccaa gccgggccag aggccmwctt 180
 gcaacgagtt cacagggcag tgccactgcs gtgccggtt tggaggcgcg acttgttctg 240
 agtgccaaga gctccactgg ggagaccctg ggttgcaagt ccatgcctgt rattgtract 300
 ctcgtggaat agatacacct cagtgtcacc gcttcacagg tcaactgcagc tgccgcccag 360
 ggtgtctggt gtgcgtgtg accagtgtgc ccgtggcttc tcaggaatct ttctgcctg 420
 ccatccctgc actgcatgct tcggggattg ggaccgagtg gtgcaggact tggcagcccg 480
 tacacagcgc cttagcagc gggcgagga gttgcaacag acgggtgtgc tgggtgcctt 540
 tgagagcagc ttctggcaca tgaggagaa gctgggcatt gtgcagggca tcgtaggtgc 600
 ccgcaacacc tcagccgcct ccaactgcaca gcttgtggag gccacagagg agctgcggcg 660
 tgaaattggg gaggccactg agcacctgac tcagctcgag gcagacctga cagatgtgca 720

```

agatgagaac ttcaatgcca accatgcact aagtggctct gagcgagata ggcttgcaact 780
taatctcaca ctgcggcagc tcgaccagca tcttgacttg ctcaaacatt caaacttcct 840
gggtgcctat gacagcatcc ggcatgcca tagccagtct gcagaggcag aacgtcgtgc 900
caatacctca gccctggcag tacctagccc tgtgagcaac tcggcaagtg ctcggcatcg 960
gacagaggca ctgatggatg ctgagaagga ggacttcaac agcaaacaca tggccaacca 1020
gcgggcactt ggcaagctct ctgcccatac ccacaccctg agcctgacag acataaatga 1080
gctggtgtgt ggggcaccag gggatgcacc ctgtgctaca agcccttggt ggggtgccgg 1140
ctgtcgagat gaggatgggc agccgcgctg tgggggcctc agctgcaatg gggcagcggc 1200
tacagcagac ctagcactgg gccgggcccg gcacacacag gcagagctgc agcgggcact 1260
ggcagaaggt ggtagcatcc tcagcagagt ggctgagact cgtcggcagg caagcgaggc 1320
acagcagcgg gcccaggcag ccctggacaa ggctaagtct tccaggggac aggtggaaca 1380
ggccaaccag gaacttcaag aacttatcca gagtgtgaag gacttcctca accaggaggg 1440
ggctgatcct gatagcattg aaatggtggc cacacgggtg ctagagctct ccatcccagc 1500
ttcagctgag cagatccagc acctggcggg tgcgattgca gagcgagtcc ggagcctggc 1560
agatgtggat gcgacctctg cacgtactgt aggagatgtg cgtcgtgccg agcagctact 1620
gcaggatgca cggcgggcaa ggagctgggc tgaggatgag aaacagaagg cagagacagt 1680
acaggcagca ctggaggagg cccagcgggc acagggtatt gcccagggtg ccatccgggg 1740
ggcagtggtt gacacacggg acacagagca gaccctgtac caggtagcag agaggatggc 1800
aggtgcagag cgggcaactga gctctgcagg tgaaagggtc cggcagtttg atgctctcct 1860
ggaggctctg aaattgaaac gggcaggaaa tagtctggca gcctctacag cagaagaaac 1920
ggcaggcagt gcccagggtc gtgcccagga ggctgagcag ctgctacgcg gtcctctggg 1980
tgatcagtac cagacggtga aggccctagc tgagcgcaag gcccaagggt tgctggctgc 2040
acaggcaagg gcagaacaac tgcgggatga ggctcgggac ctggttgaag ccgctcagga 2100
caagctgcag cggctacagg aattggaagg cacctatgag gaaaatgagc gggcactgga 2160
gagtaaggca gcccagttgg acgggttggg ggccaggatg cgagcgctgc ttcaagccat 2220
caacttgca gtcagatct acaacacctg ccagtgacct ctgccaagg cctaccccag 2280
ttcctagcac tgccccacat gcatgtctgc ctatgcactg aagagctctt kgcccgagg 2340
gcccccaata aaccagtgtg aacccccaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2400
aaaaaaaaaa aaaaaagaaa aaaaaa 2425

```

<210> 250

<211> 1408

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (252)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1387)

<223> n equals a,t,g, or c

<400> 250

```

acggggctgt gcggagcagc tgtgcagagc tgcaggcgcg cgtcatggct gctttgagac 60
agccccaggt cgcggagtgc tggccgaggc ccggcgagcc ttccgggagg agttcggggc 120
cgagcccag ctagccgtgt cagcgccggg ccgctgcaa cctcatcggg gaacacacgg 180
actacaacca gggcctggtg ctgcctatgg ctctggagct catgacggtg ctggtgggca 240
gccccgcaa gnatgggctg gtgtctctcc tcaccacctc tgagggtgcc gatgagcccc 300

```

```

agcggctgca gtttcactg cccacagccc agcgcctcgct ggagcctggg actcctcggt 360
gggccaaacta tgtcaaggga gtgattcagt actaccacagc tgccccctc cctggcttca 420
gtgcagtggt ggtcagctca gtgcccctgg ggggtggcct gtccagctca gcatccttgg 480
aagtggccac gtacaccttc ctccagcagc tctgtccaga ctcgggcaca atagctgccc 540
gcgcccaggt gtgtcagcag gccgagcaca gcttcgcagg gatgccctgt ggcacatcatg 600
accagttcat ctcaacttat ggacagaaaag gccacgcgct gctcattgac tgcaggctct 660
tggagaccag cctgggtgcca ctctcggacc ccaagctggc cgtgctcatc accaactcta 720
atgtccgcca ctccctggcc tccagcgagt accctgtgcg gcggcgccaa tgtgaagaag 780
tggcccgggc gctgggcaag gaaagcctcc gggaggtaca actggaagag ctagaggctg 840
ccagggaacct ggtgagcaaa gagggcttcc ggcggggccg gcacgtggtg ggggagattc 900
ggcgcacggc ccaggcagcg gccgccctga gacgtggcga ctacagagcc ttgggccgcc 960
tcatggtgga gagccaccgc tcaactcagag acgactatga ggtgagctgc ccagagctgg 1020
accagctggt ggaggctgcg cttgctgtgc ctggggttta tggcagccgc atgacgggcg 1080
gtggtctcgg tggtgcacg gtgacactgc tggaggcctc cgctgctccc cacgccatgc 1140
ggcacatcca ggagcactac ggcgggactg ccaccttcta cctctctcaa gcagccgatg 1200
gagccaaggt gctgtgcttg tgaggcacc caggacagc acacggtgag ggtgcggggc 1260
ctgcaggcca gtcccacggc tctgtgcccg gtgccatctt ccatatccgg gtgctcaata 1320
aacttgtgcc tccaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1380
aaaaaaaaaa aagaaaaaaa aaaaaaaa 1408

```

<210> 251

<211> 494

<212> DNA

<213> Homo sapiens

<400> 251

```

gccggagccc acggtgggtca tggtgccag agcrtctgc atgctggggc tggctcctggc 60
cttctgtctc tccagctctg ctgaggagta cgtgggcctg tctgcaaacc agtgtgccgt 120
gccagccaag gacagggttg actgcggcta ccccatgtc accccaagg agtgcaacaa 180
ccggggctgc tgctttgact ccaggatccc tggagtgcct tgggttttca agcccttga 240
ggaagcagaa tgcaccttct gaggcacctc cagctgcccc cggccggggg atgagaggct 300
cggagcacc ttgccggct gtgattgctg ccaggcactg ttcattctag cttttctgtc 360
cctttgtctc cggaagcgc ttctgctgaa agttcatatc tggagcctga tgtcttaacg 420
aataaaggct ccatgctcca ccgaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 480
aaaaaaaaaa aagg 494

```

<210> 252

<211> 2491

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (6)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (16)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2457)

<223> n equals a,t,g, or c

<400> 252

```
ggcggnggcg cccggnccctc gcccggccacg cagccggccac cgctgctgcc gccctcggcc 60
acgggtcccg acgcgacagt gggcggggcca gcgccgaccc cgctgctgcc cccctcggcc 120
acagcctcgg tcaagatgga gccagagaac aagtacctgc ccgaactcat ggccgagaag 180
gactcgctcg acccgctcctt cactcacgcc atgcagctgc tgacggcaga aattgagaag 240
attcagaaaag gagactcaaa aaaggatgat gaggagaatt acttggaattt attttctcat 300
aagaacatga aactgaaaga gcgagtgtcg atacctgtca agcagtatcc caagttcaat 360
tttgtgggga agattcttgg accacaaggg aatacaatca aaagactgca ggaagagact 420
ggtgcaaaga tctctgtatt gggaaagggc tcaatgagag aaaaagccaa ggaggaagag 480
ctgcgcaaag gtggagaccc caaatatgcc cacttgaata tggatctgca tgtcttcatt 540
gaagtctttg gacccccatg tgaggcttat gctcttatgg cccatgccat ggaggaagtc 600
aagaaatttc tagtaccgga tatgatggat gatatctgtc aggagcaatt tctagagctg 660
tcctacttga atggagtacc tgaacctctc cgtggacgtg gggtgccagt gagaggccgg 720
ggagctgcac ctctccacc acctgttccc agggggccgtg gtgttgacc acctcggggg 780
gctttggtac gtggtacacc agtaagggga gccatcacca gaggtgccac tgtgactcga 840
ggcgtgccac cccacacctac tgtgaggggt gctccagcac caagagcacg gacagcgggc 900
atccagagga tacctttgcc tccacctcct gcaccagaaa catatgaaga atatggatat 960
gatgatacat acgcagaaca aagttaacga gctacgaag gctattacag ccagagtcaa 1020
ggggactcag aatattatga ctatggacat ggggaggttc aagattctta tgaagcttat 1080
ggccaggacg actggaatgg gaccaggccg tcgctgaagg cccctcctgc taggccagtg 1140
aaggagcat acagagagca cccatatgga cgttattaaa aacaaacatg aggggaaaat 1200
atcagttatg agcaaagttg ttactgattt cttgtatctc ccaggattcc tgttgcttta 1260
cccacaacag acaagtaatt gtctaagtgt ttttcttcgt ggtccccttc ttctcccac 1320
cttattccat tcttaactct gcattctggc ttctgtatgt agtattttaa aatgagttaa 1380
aatagattta ggaatattga attaatTTTT taagtgtgta gatgcttttt tctttgttgt 1440
ttaaatataa acagaagtgt accttttata aaaaaaaaaa gaagttgagt aaaaaaaaaa 1500
aacacacaaa cctgttagtt tcaaaaatga cattgcttgc ttaaagggtc tgaagtaaa 1560
gcttggttaag tttctcttag ttttgatttg aggcacccc taaagttgta gttgcagaat 1620
cccaaacctag gctacatttc aaaattcagg gctgtttaag atttaaaatc acaaacatta 1680
acggcagtag gcaccacat gtaaaagtga gctcagacgt ctctaaaaaa tgtttccttt 1740
ataaaagcac atggcggttg aatcttaagg ttaaatttta atatgaaaga tcctcatgaa 1800
ttaaatagtt gatgcaattt ttaacgttaa ttgatataaa aaaaaaaaca acaaaattag 1860
gcttgtaaaa ctgacttttt cattacgtgg gttttgaaat ctagccccag acatactgtg 1920
ttgagagata cttagaggga gggagtaggt tttgaagagg ttgatggtgg tggggaggga 1980
aggcctcctg aattgagttt gatgcagagc tttttagcca tgaagaatct ttcagtcata 2040
gtactaataa ttaaattttc agtattttaaa aagacaaagt attttgtcca tttgagattc 2100
tgactccatg gaaaagttca cttggacgct gggggccaaa gctgttgatt ttcttaagtt 2160
gacggttgtc aatatatcga actgttccca agttagtcaa gtatgtctca acactagcat 2220
gatataaaaa gggacactgc agctgaatga aaaaggaatc aaaatccact ttgtacataa 2280
gttaaaagtc taattggatt tgtaccgtcc tcccattttg ttctcggaag attaaatgct 2340
acatgtgtaa gtctgcctaa ataggtagct taaacttatg tcaaaatgtc tgcagcagtt 2400
tgtcaataaa gtttagtcct tttttaatca aaaaaaaaaa aaaaaaaaaa aggcggnccg 2460
tctagaggat ccaagcttac gaccccgcca t 2491
```

<210> 253

<211> 1125

<212> DNA

<213> Homo sapiens

<400> 253

```
ttcgttttagg tccgctggaa attatgtcct ccgtcggttt tccgcagttt ttccaccaag 60
cgagatattt ttgggagtta ttccctaaat aactgcatta tatgtctcct tcatgacgaa 120
attgctgccg tggagaagac tggaggaaac tcgaggaaga gggagaagcc gacaagtgt 180
cgacgggcta ggaactgtcc tgcttgggtg ttagcgtttc ccgycgggcc agtaaggctg 240
agtgacccgg cgtgctacta ggagaaggac gtacggtcct gctagtagag gaatatgtcg 300
agtttctcta gggcgcccca gcaatgggcc acttttgcta gaatatggta tctcttagat 360
gggaaaatgc agccacctgg caaacttgct gctatggcat ctataagact tcagggatta 420
cataaacctg tgtaccatgc actgagtgc tgtggggatc atgttggtat aatgaacaca 480
agacacattg cattttctgg aaacaaatgg gaacaaaaag tatactcttc gcatactggc 540
taccaggtg gatttagaca agtaacagct gctcagcttc acctgagga tccagtggca 600
attgtaaaac tagctattta tggcatgctg ccaaaaaacc ttcacagaag aacaatgatg 660
gaaaggttgc atctttttcc agatgagtat attccagaag atattcttaa gaatttagta 720
gaggagcttc ctcaaccacg aaaaatacct aaacgtctag atgagtacac acaagaagaa 780
atagacgcct tcccaagatt gtggactcca cctgaagatt atcggctata agagaataag 840
aattgcagaa aataacagtg aagtgttga aactttcttc tgatgagttt ctctaaccata 900
caggatggag taaaacaact gctacagttc agcacctgtt ttatgtgccg aatcactgtg 960
gggaaaggtc aggaagggtg agtccttcaa taggaaattg taattaaaaat ataattttat 1020
agaaccattt ttatgtaatc tgatttgaat gttatagttg ataataataa aatcacttac 1080
ttggttgact atttagtgtt gcatttaatg ataaaaaca gaccc 1125
```

<210> 254

<211> 1409

<212> DNA

<213> Homo sapiens

<400> 254

```
cactttgtct tttcttaagt aattatggta tatataaggc gttgggaaaa aacattttat 60
aatgaaagta ttagggagt caaatgctta ctgtaaatgc ataagagacg ttaaaaaataa 120
cactgcactt tcaggaatgt ttgcttatgg tcctgattag aaagaaacag ttgtctatgc 180
tctgcaatgg tcaatgatga attactaatg ccttattttc taggcatata ataatagttt 240
agagaatgta gaccagataa atttgtttac tgttttaaga aaactaccag tttacttaca 300
gaagattctt ttttccaaac agtaggtttc atccaagacc atttgaagaa ctgcaaaactc 360
tttctcttag aaaagaaaga gggcagccta aaataaacgc aaaatttgct tatactccat 420
cacattcaga tgtcttggtt gtgacttatt accagtgtgg cagagaaccc aagttacatt 480
ttagatcaaa atattcttta ttaggtatt gttaaaaggc tagagcctac aagttgctct 540
tccatgcgtt ggtcaggggg ccctgaaaac actggtaata ttaagagtct ttctcagggt 600
aacttaattg tttcttaatg aacartgttt ccagctacaa attcttycaa taaattgtct 660
tcctttttga aaagtactct catagaagaa atttagcaat ttctcgttga ctgactcagt 720
ctattttaag tattcagaaa agattttgat cccattgag ttaatgctct gccttgaaaa 780
ttatttttct ggatccttgt tagtgataac atttttttct tactgaagggt cagaggatag 840
gaaacaagta tttctcttct ggtatacatg taatgtattc tgtaaaaaag tattcatatt 900
ggcaatttta gttaggcata atatttggtt tgtaattttt aaaacttagt gttttgtctg 960
attaaagcag gcactgatca gggatatctc taagaggtaa ttcacttctt attcctttcc 1020
aataattatt acattctaaa ttttcatcta tgagaaataa caaacaagaa gggaatagaa 1080
ttaaattggg gtataatcta atcttcattg tttaaatggt ttgccttctc accattgaag 1140
ccatttttta tagcctcaga aagaggaaat aatgcctcca ccattttcta cctggtgact 1200
tgaaaattga acttttaagt taggaagaag ttagagtcag ggaacttgta taccactatc 1260
```

```
tatgcagcat tgttatagtc tgattatttc tgtgttttga atatgatttt cctaattgctc 1320
taaataaaaat tttgttaaaa attaattttt tatttaataga tgtgcaaata ttgaatatatt 1380
tagtatattt attaaaagtg gtagtcatt 1409
```

<210> 255

<211> 490

<212> DNA

<213> Homo sapiens

<400> 255

```
acccacgcgt ccgcctctct gtcgtggcgc ggcttccgcg ggtcttctct gcaaattgggc 60
tccgtggcct agcgcceccg tccccgccac ccgtgatcgt gcgccgaggg ccgcgagggg 120
tcgccgccca ggccgccttg gttccacttc cagcaacagc tcctgcagca gtaccgagtg 180
ccccggggaa gccattcccc acccccaggg tctccccaag gctgaccggg gtcattgggtg 240
ggccagcttc tttttcggga agtccaccct ccggttcatt gccacgggtg tggagtccgc 300
agagcactcg gaacctcccc aggcctccag cagcatgamc gcctgtggcc tggctcggga 360
agccccgagg aagcagcccg gcggtcagtc cagcamagcc agcgtgagg ccccgctctg 420
aactgagcgg ttaacaacaa gccccaagcc tkcgggaagc ctagtycaac agagccctcc 480
gggccctttg 490
```

<210> 256

<211> 1233

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (45)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (602)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (931)

<223> n equals a,t,g, or c

<400> 256

```
ggcagagggt ggctcggggc tatgagaacg tgcccattcc ctgtntcacg gtgtggatgg 60
ggagccctgc cctgaggatt acaagtacat ctgagagaac tgcgagacgt ccaccatgaa 120
catcgatcgc aacatcaccc acctgcagca ctgcacgttt gtggacgact gctctagctc 180
caactgcctg tgccggccast tcagcatccg gtgctggtat gacaaggatg ggcgattgct 240
ccaggaattt aacaagattg agcctccgct gattttcgag tgtaaccagg cgtgctcatg 300
ctggagaaac tgcaagaacc gggtcgtaac gagtggcatc aagggtcggc tacagctcta 360
ccgaacagcc aagatgggct ggggggtccg cgccctgcag accatccac aggggacctt 420
catctgcgag tatgtcgggg agctgatctc tgatgctgag gctgatgtga gagaggatga 480
ttcttacctc ttcgacttag acaacaagga tggagagggt tactgcatag atgcccgtta 540
ctatggcaac atcagccgct tcatcaacca cctgtgtgac cccaacatca ttcccgtccg 600
```

```

gntcttcatg ctgcaccaag acctgcgatt tccacgcac gccttcttca gttcccgaga 660
catccggact ggggaggagc tagggtttga ctatggcgac cgcttctggg acatcaaaaag 720
caaataatttc acctgccaat gtggctctga gaagtgaag cactcagccg aagccattgc 780
cctggagcag agccgtctgg cccgcctgga cccacaccct gagctgctgc ccgagctcgg 840
ctccctgcc cctgtcaaca catgagaacg gaccacacc tctytcccca gcatggatgg 900
ccacagctca gccgcctcct ctgccaccag ntgctcgag cccatgcctg ggggtgctgc 960
catcttctct ccccaccacc ctttcacaca ttctgacca gagatcccag ccaggccctg 1020
gaggtctgac agcccctccc tcccagagct ggctcctccc tgggagggca acttcagggc 1080
tggccacccc ccgtgttccc catcctcagt tgaagtttga tgaattgaa tcgggcctct 1140
atgccaaactg gttccttttg ttctcaataa atgttggtt tggtaaaaaa aaaaaaaaaa 1200
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aac 1233

```

<210> 257

<211> 2404

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (2372)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2385)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2395)

<223> n equals a,t,g, or c

<400> 257

```

cggacgggtg gacgggsaag tgggggtgaa aagcggcccg acctgcttgc ggtgtagtgg 60
gcggaccgag cggtggagg tgtgaggatc cgaaccaggg ggtggggggg ggaggcggct 120
cctgcgatcg aaggggactt gagactcacc ggccgcacgc catgagggcc ctgtgggtgc 180
tgggcctctg ctgcgtcctg ctgaccttcg ggtcggtcag agctgacgat gaagttagatg 240
tggatggtac agtagaagag gatctgggta aaagtagaga aggatcaagg acggatgatg 300
aagtagtaca gagagaggaa gaagctattc agttggatgg attaaatgca tcacaaataa 360
gagaacttag agagaagtcg gaaaagttag ccttccaagc cgaagttaac agaattgatg 420
aacttatcat caattcattg tataaaaaata aagagatttt cctgagagaa ctgatttcaa 480
atgcttctga tgcttttagat aagataaggc taatatcact gactgatgaa aatgctcttt 540
ctggaaatga ggaactaaca gtcaaaatta agtgtgataa ggagaagaac ctgctgcatg 600
tcacagacac cgggtgtagga atgaccagag aagagttggt taaaaacctt ggtaccatag 660
ccaaatctgg gacaagcgag tttttaaaca aaatgactga agcacaggaa gatggccagt 720
caacttctga attgattggc cagtttggtg tcggtttcta ttcgccttc cttgtagcag 780
ataaggttat tgtcacttca aaacacaaca acgataccca gcacatctgg gagtctgact 840
ccaatgaatt ttctgtaatt gctgaccaa gaggaacac tctaggacgg ggaacgacaa 900
ttacccttgt cttaaaagaa gaagcatctg attaccttga attggataca attaaaaatc 960
tcgtcaaaaa atattcacag ttcataaact ttcctattta tgtatggagc agcaagactg 1020
aaactgttga ggagcccatg gaggaagaag aagcagccaa agaagagaaa gaagaatctg 1080

```

```

atgatgaagc tgcagtagag gaagaagaag aagaaaagaa accaaagact aaaaaagttg 1140
aagaaacact ctaggacggg gaacgacaat tacccttgtc ttaaaagaag aagcatctga 1200
ttaccttgaa ttggatacaa ttaaaaatct cgtcaaaaaa tattcacagt tcataaaactt 1260
tcctatttat gtatggagca gcaagactga aactggtgag gagcccatgg aggaagaaga 1320
agcagccaaa gaagagaaaag aagaatctga tgatgaagct gcagtagagg aagaagaaga 1380
agaaaagaaa ccaaagacta aaaaagttga aaaaactgtc tgggactggg aacttatgaa 1440
tgatatcaaa ccaatatggc agagaccatc aaaagaagta gaagaagatg aatacaaagc 1500
tttctacaaa tcattttcaa aggaaagtga tgaccccatg gcttatattc actttactgc 1560
tgaaggggaa gttaccttca aatcaatttt atttgtacc acatctgctc cacgtggtct 1620
gtttgacgaa tatggatcta aaaagagcga ttacattaag ctctatgtgc gccgtgtatt 1680
catcacagac gacttccatg atatgatgcc taaatacctc aattttgtca aggggtgtgg 1740
ggactcagat gatctcccct tgaatgtttc cgcgagact cttcagcaac ataaactgct 1800
taaggtgatt aggaagaagc ttgttcgtaa aacgctggac atgatcaaga agattgctga 1860
tgataaatac aatgatactt tttggaaaaga atttggtacc aacatcaagc ttggtgtgat 1920
tgaagaccac tcgaatcgaa cacgtcttgc taaacttctt aggttccagt cttctcatca 1980
tccaactgac attactagcc tagaccagta tgtggaaaaga atgaaggaaa aacaagacaa 2040
aatctacttc atggctgggt ccagcagaaa agaggctgaa tcttctccat ttgttgagcg 2100
acttctgaaa aagggtatg aagttattta cctcacagaa cctgtggatg aatactgtat 2160
tcaggccctt cccgaatttg atgggaagag gttccagaat gttgccaagg aaggagtga 2220
gttcgatgaa agtgagaaaa ctaaggagag tcgtgaagca gttgagaaag aatttgagcc 2280
tctgctgaat tggatgaaag ataaagccct taagggcmag rtactgtggg aaattttacc 2340
aatttgtggg aaatattagt gtccggcatt tnaggggaaa gttntttttt ggggnaacca 2400
aatt

```

<210> 258

<211> 2092

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (4)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (27)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (31)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (60)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2069)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2071)

<223> n equals a,t,g, or c

<400> 258

```
tatncaacaa ctaaaacgac tcactanagg naaaagcagg aacgcctgca ggaaaccggn 60
ccggaattcc cgggtcgacc cagcgcgtcc ctgccgctcc ctttgccgcc gccttagccc 120
gggacccgaa cccagcctct cccctacccg aacaccggcc cgggctccac cgaggcccg 180
gtccccagc ccgtctcgcc gccgccatgg cggaccctaa atacgccgac cttcccgga 240
ttgccaggaa tgagccagat gtttatgaaa ctacgcacct acctgaggat gatcaagcgg 300
agttcgatgc ggaggagctg acaagcacia gtgtggaaca catcattgtc aatcctaata 360
ctgcctatga caagttcaag gacaagagag tggggacaaa gggacttgat ttctcagatc 420
gtattggaaa aaccaagagg acaggatatg aatctggaga atatgagatg cttggagagg 480
gtctgggagt gaaggagaca ccccagcaaa agtaccagcg cctactgcat gaggtccaag 540
agctgacaac tgaagttgaa aaaatcaaga cgacagtga ggagtcagcc acagaggaga 600
agctgacccc tgtgttgctg gctaaacagc tggcagccct gaagcagcag ctggttgctt 660
cccacctgga gaagctgctg ggaccagatg ctgcaatcaa ccttaccgac cccgatggcg 720
ccctggctaa gcgcctacta ctgcagctgg aagcaacaaa gaacagcaaa gggggatcag 780
ggggaaaaac cactgggacc ccccagata gcagccttgt cacttatgaa ctacattctc 840
ggcctgagca ggacaagttc tctcaagctg ccaaagtcgc agaacttgaa aagcgcctga 900
cagagctgga gacagctgta cgttgtgatc aggatgctca gaatcccctt tctgcaggtc 960
tacagggagc ctgtctcatg gagactgtag agctgttgca agcaaagggt agcgccttag 1020
accttgcagt tttggatcaa gtggaggctc ggctacagag tgtcctggga aaggtgaacg 1080
agattgccaa gcataaagcc tctgtagaag atgcagatac acaaagcaag gtgcaccagc 1140
tatatgaaac tatacagcgc tggagcccca ttgcctccac cctccctgag ctggtgcaga 1200
gacttgtcac catcaagcag ctgcacgagc aagccatgca gtttggtcag ctcctgacac 1260
acttggtatc caccagcag atgattgcta attccttgaa ggacaatacc accctcttga 1320
cccaggtgca gacaaccatg cgtgaaaacc tggccacagt tgaggggaac tttgccagca 1380
ttgatgaacg gatgaagaag ctgggaaagt gagcacattt gggagctgga gaacaggggt 1440
tatccctacc cctgtgaact ctgttaacag cttacatagg gtttcccctt tactataact 1500
ctagcatccc catcccattt gacactgggg gcaagggttc ttcttgcagt tggggtttat 1560
acccctcccc tgatgaatac agagtggtag ctagggttg gttatcatca gaaggtggtc 1620
tcccctcagg cctgggggat aaggacgtgg gccagccac atgccaactc atgtccaata 1680
ctgctttgcc tgggtgtggg aaggattggg tcttgtcccc caacacagct tctgtggctg 1740
actgtaatac tgtacaactg tttctgacca ttaaattgct ttgtactctg tgtggcctct 1800
gctgtgtttc ctggggagga agcagcacta ggatatagat attcattcgt cataacaggc 1860
aatctaagcc actctatact acaagagatg gatttaaatt gtaacctgtt cttaccaaag 1920
aactaaataa aaaatgagta cagagccaga gccagagttt caaaatattc tcactgttta 1980
aattaagagt gtctcccata gaaaagcagt ggaggcccca cagggcaagt acaaaacaga 2040
attaaaactc aaaaaaaaaa aaaaaaaanc ncaagggggg gcccggtccc ca 2092
```

<210> 259

<211> 387

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (377)

<223> n equals a,t,g, or c

<400> 259

```
aattcggcac gaggttcat tctctgacct ttctctctcc tcatttcggt gcatgtcctt 60
tctgcagctg cctttcagca caggtagctg cccccaggg ccaccgcttc tttcttgatc 120
ctctttcctt aacagtgact tgggcttgag tctggcaagg aaccttgctt ttagcttcac 180
caccaaggag agagaccaa agcctctgat ttttaatttc cataaaatgt tagaagtata 240
tatatacata tatataattt tttaaatttt tgagtctttg atatgtctaa aatcattcct 300
ctgcctgaag cctkagttag cacatgarga actgtgttca ttaagtgtta ttaatgttga 360
actgaaaaaa aaaaacnggg ggggccg 387
```

<210> 260

<211> 3712

<212> DNA

<213> Homo sapiens

<400> 260

```
tatccccgac gaccggatcc tgaggaggca gctgcggtgg cagctgctga gttctcggtg 60
aaggattttc atttctcctg tcccctcccc tccccacccc atctattaat attattcttt 120
tgaagattct tcggtgtcaa gccgccaaaag tggagagtgc gattgcagaa gggggtgctt 180
ctcgtttcag tgcttcttcg ggcggaggag gaagtagggg tgcacctcag cactatccca 240
agactgctgg caacagcgag ttcctgggga aaacccagg gcaaaacgct cagaaatgga 300
ttcctgcacg aagcactaga cgagatgaca actccgcagc aaacaactcc gcaaacgaaa 360
aagaacgaca tgatgcaatc ttcaggaaaag taagaggcat actaaataag cttactcctg 420
aaaagtttga caagctatgc cttgagctcc tcaatgtggg tgtagagtct aaactcatcc 480
ttaaaggggt catactgctg attgtggaca aagccctaga agagccaaag tatagctcac 540
tgtatgctca gctatgtctg cgattggcag aagatgcacc aaactttgat ggcccagcag 600
cagagggtca accaggacag aagcaaagca ccacattcag acgcctccta atttccaaat 660
tacaagatga atttgaaaac cgaactagaa atggtgatgt ctatgataag cgtgaaaatc 720
ccctcctccc cgaggaggag gaacagagag ccattgctaa gatcaagatg ttgggaaaca 780
tcaaattcat tggagagctt ggcaagcttg atcttattca cgaatctatc cttcataagt 840
gcatcaaaac acttttgaa aagaagaaga gagtccaact caaagatatg ggagaggatt 900
tggagtgctt ctgtcagata atgaggacag tgggacctag attagaccat gaacgagcca 960
agtccttaat ggatcagtac tttgcccgaa tgtgtcctt gatgttaagt aaggaattgc 1020
cagcaaggat tcgtttcctg ctgcaggata ccgtagagtt gcgagaacac cattgggttc 1080
ctcgcagggc ttttcttgac aatggaccaaa agacgatcaa tcaaattcgt caagatgcag 1140
taaaagatct aggggtgttt attcctgctc ctatggctca agggatgaga agtgacttct 1200
ttctggaggg accgttcatg ccacccagga tgaatgga tagggacca cttggaggac 1260
ttgctgatat gtttgacaaa atgccaggta gcggaattgg tactggtcca ggagtatatc 1320
aggatagatt ttcaccacc atgggacgtc atcgttcaaa tcaactcttc aatggccatg 1380
ggggacacat catgcctccc acacaatcgc agtttgaga gatgggaggc aagtttatga 1440
aaagccaggg gctaagccag ccttaccata accagagtca gggactctta tcccagctgc 1500
aaggacagtc gaaggatatg ccacctcggg tttctaagaa aggacagctt aatgcagatg 1560
agattagcct gaggctgtgt cagtcgttcc taatgaataa aaatcaagtg ccaaagcttc 1620
agccccagat aactatgatt cctcctagtg cacaaccacc acgcactcaa acaccacctc 1680
tgggacagac acctcagctt ggtctcaaaa ctaatccacc acttatccag gaaaagcctg 1740
ccaagaccag caaaaagcca ccaccgtcaa aggaagaact ctttaaaact actgaaactg 1800
ttgtgactga atatctaaat agtggaatg caaatgaggc tgtcaatggt gtaagagaaa 1860
tgagggtctc taaacacttt cttcctgaga tgttaagcaa agtaatcatc ctgtcactag 1920
```

```

atagaagcga tgaagataaa gaaaaagcaa gttctttgat cagtttactc aaacaggaag 1980
ggatagccac aagtgacaac ttcatgcagg ctttcctgaa tgtattggac cagtgtccca 2040
aactggaggt tgacatccct ttggtgaaat cctatttagc acagtttgca gctcgtgccca 2100
tcatttcaga gctggtgagc atttcagaac tagctcaacc actagaaagt ggcacccatt 2160
ttcctctctt cctactttgt cttcagcagt tagctaaatt acaagatcga gaatggttaa 2220
cagaactttt tcaacaaagc aaggtcaata tgcagaaaat gctcccagaa attgatcaga 2280
ataaggaccg catggttgag attttggaag gaaagggact gagtttctta ttcccactcc 2340
tcaaattgga gaaggaactg ttgaagcaaa taaagttgga tccatcccct caaaccatat 2400
ataaatggat taaagataac atctctccca aacttcatgt agataaagga tttgtgaaca 2460
tcttaatgac tagcttctta cagtacattt ctagtgaagt aaaccccccc agcgatgaaa 2520
cagattcatc ctctgctcct tccaaagaac agttagagca ggaaaaacaa ctactactat 2580
ctttcaagcc agtaatgcag aaatttcttc atgatcacgt tgatctacaa gtcagtgcc 2640
tgtatgctct ccaggtgcac tgctataaca gcaacttccc aaaaggcatg ttacttcgct 2700
tttttgtgca cttctatgac atggaaatta ttgaagaaga agctttcttg gcttgaaaag 2760
aagatataac ccaagagttt ccgggaaaag gcaaggcttt gttccagggtg aatcagtggc 2820
taacctggtt agaaactgct gaagaagaag aatcagagga agaagctgac taaagaacca 2880
gccaaagcct taaattgtgc aaaacatact gttgctatga tgtaactgca ttgaccta 2940
ccactgcgaa aattcattcc gctgtaatgt tttcacataa tttaaagcag aagcacgtca 3000
gttaggattt ccttctgcat aagggttttt tgtagttaa tgtcttaatc atagtctacc 3060
atcaaatatt ttaggagtat ctttaatggt tagatagtat attagcagca tgcaataatt 3120
acatcataag ttctcaagca gaggcagtct attgcaagga ccttctttgc tgccagttat 3180
cataggctgt ttaagttag aaaactgaat agcaacactg aatactgtag aaatgcactt 3240
tgctcagtaa tacttgagtt gttgcaatat ttgattatcc atttggttgt tacagaaaaa 3300
ttcttaactg taattgatgg ttggtgccgt aatagtatat tgccgtgatt tctacctcta 3360
gtaattgggt ttatgtgcta gattttaata tccttgagcc tgggcaagtg cacaagtctt 3420
tttaaaagaa acatggttta cttgcacaaa actgatcagt tttgagagat cgttaatgcc 3480
cttgaagtgg tttttgtggg tgtgaaacaa atggtgagaa tttgaattgg tccctctat 3540
tatagtattg aaattaagtc tacttaattt atcaagtcac gttcatgccc tgattttata 3600
tacttgtatc tatcaataaa cattgtgata cttgaaaaaa aaaaaaaaaa aaaaaaaaaa 3660
aaaaaaaaaa aaaaaaaaaa aaaaaaaagg aggaaaaaaa aaaaaaaaaa aa 3712

```

<210> 261

<211> 897

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (22)

<223> n equals a,t,g, or c

<400> 261

```

agagctggaa ggaggaggag angaaacctc accttcaggg caaaccaggg agacccttgt 60
ccccggccaa tgccctgct ctgcctggcg agacggtgac ctccccagtc aggctgcacc 120
ccgactacct ctccccggag gagatacaga ggcagctgca ggacatcgag aggcggctgg 180
acgccctgga gctccgcggc gtggagctgg agaagcgact gcgggcggcc gagggagatg 240
acgctgagga tagcctcatg gtggactggt tctggctcat tcacgagaag cagcttctgc 300
tgagacagga gtcagagctg atgtacaagt ccaaggccca gcgtctggag gagcagcagc 360
tgacatcgga gggcgagctg cgccggctca tggccaagcc cgaggctctg aagtcactgc 420
aggagcggcg gcgggagcag gagctgctgg agcartacgt gagcaccgtg aacgaccgca 480
rtgacatcgt ggactcgctk gacgaggacc ggctccsaga acaagaggag gatcagatgc 540

```



```

tgcgggacat gattgagaag ctgggcctcc agaggaagaa gtccaagttc cgcttgtcca 600
agatctggtc accaaaaagc aaaagcagcc cctcccagta gtagccagta gggccgtggg 660
ctcggcccg acctggcatc cggacttgga ctcggggcca tgggcttggc cgggacccgg 720
aaccgggact tgtactcggg gccgtgggct cggcccgac ccggcattcg gacttggact 780
cggaagggc ctctgtccc tacaaggggc atgtggacag caggacctg cgctaccgtc 840
tgtgtctca ataaagaaac cgaccacatg gaaaaaaaaa aaamaaaaaa aaaaaaa 897

```

<210> 262

<211> 1905

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1266)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1791)

<223> n equals a,t,g, or c

<400> 262

```

gctgtgatag cgcgtgagga ggcagaggcc tctggggtgg gatcgcgggc cgtaagtggc 60
tgtggagctg gggtcactgc gcgtgggac catggcctcg gagaagccgc tggcggcagt 120
cacttgtaca gcgccgtca acatcgcggt catcaagtac tggggcaagc gcgatgaaga 180
gctggttctg cccatcaact cctccctgag cgtcactctg caccaggacc agttaaaaac 240
caccacaaca gccgtcatca gcaaggactt caccaggac cggatttgge tgaatggccg 300
ggaggaggat gtggggcagc cgmggctgca ggctgcctg cgggagatcc gctgcctggc 360
ccggaagcgg aggaactcac gggatgggga cccgctgccc tccagcctca gctgcaaggc 420
gcacgtggca tcggtgaaca acttccccac ggctgcgggc ctggcctcct cagcggcggg 480
ctatgcctgc ctagcctaca ccctggcccg tgtctacggc gtggagagtg acctctcaga 540
agtggctcgc cggggctcag gcagcgccts ccggagcctg tatgggggct ttgtggagtg 600
gcagatggga gagcaggccg acgggaagga cagcatcgct cggcaagtgg ccccgagtc 660
acactggcct gaactccgcg tgctcatcct tgtgtgagc gctgagaaga agctgacagg 720
cagtaccgtg ggcattgccc ccagtgtgga gaccagcccc ctgcttcggt tccgggcccga 780
gtccgtggtg cccgcgcgca tggcgagat ggcccgtgc atccgggagc gagacttccc 840
cagcttcgcc cagctgacca tgaaggacag caaccagttc cacgccacct gcctcgacac 900
cttcccgccc atctcttacc tcaatgccat ctctggcgc atcatccacc tggcgaccgc 960
cttcaacgcc caccacgggg acaccaaggc ggcgtaacc tttgacgcgg gcccaatgc 1020
cgtgatcttc accctggacg aactgtggc tgagtttgtg gctgctgtgt ggcacggctt 1080
tccccaggc tcgaatggag acacgtttct gaaggggctg cagggtgagg cggccctct 1140
ctcagctgag ctccaggtg cgctggccat ggagccgacc cccggtggg tcaaatacat 1200
cattgtcact caggtgggga cagggcctca aatcctggat gaccctgcg cccacctcct 1260
gggtcntgac ggctgcccga agccagctgc ctgactgcct cagcagggac cgcattgccg 1320
ttggagaagg ggtggcctcg ccggagctag ggagcggatg tgggtgggctg gccggactcc 1380
tgggacatgt ggggtggggc ttgaccccg gcccatgggc agcttgctgt ggggcagtgc 1440
agggagtcct gcggccgccc aggtgtcagg agaggtcccc gccgagtgtc tcagctgccc 1500
taagctgcac cagcgtttg ccaagatggg atggggaggg ggtatgagaa ctggcagagc 1560
ctcgggtcag cagggtgaa gggctttctc accccagctc tggctatgcc cagttctctg 1620
agaaaggagc tcagtgggga ggtgtccct ccagcggacc aggggaaggg tcactgtgct 1680

```

gggagcagcc tccttgggcc tcaggaaacc accaagtgcc tcggatgggtg gctgcccacg 1740
 gcgcttctgc tgagaccctg ccccgggccc aggtgtctcg gaggggtggct ncccacggcc 1800
 tgggtgtggc tggaatgggtg gcaggagtgg gcaccagtgc ggccccgggtg gccatgggga 1860
 ataaaccagc attgctgcca aaaaaaaaaa aaaaaaaaaa aaaaaa 1905

<210> 263

<211> 1424

<212> DNA

<213> Homo sapiens

<400> 263

acccacgcgt ccgaaatttc aattctcgtg gtaataccag agtagaagga gagggtgact 60
 ttaccgaact gacagccatt ggggaggcag atcggggtgt ggagggtgtg gctgaaggta 120
 gtgactgttt gatttttaaaa agtgtgactg tcagtgtgat ctgttgcttt tctcaatgat 180
 tcagggatac aaatgggctt ctctcattca ttaaaagaaa acgcgacatc tttctaagat 240
 tctctgtggg aaaatgactg tcaataaaat gcgggtttct ggccattcg tcttactttc 300
 attttttgat taaaaatttc tcttgacgca cacaattatg tctgctaate ctcttcttcc 360
 tagagagaga aactgtgctc cttcagtgtt gctgccataa aggggttttg ggaatcgatt 420
 gtaaaagtcc caggttctaa attaaactaaa tgtgtacaga aatgaacgtg taagtaattg 480
 ttctacaggt ctttgcaaca aactgtcact ttcgtctcca gcagaggag ctgtaggaat 540
 agtgcttcca gatgtggtct cccgtgtggg gccagcaat gggggcccct gatgccaaaga 600
 gctctggagg ttcttgaaag aggggacacg aaggaggagt gactgggaag cctcccatgc 660
 caaggagggt ggagggtgcc tggaaatagc tgcctcatgc cacttaggcc atgactggat 720
 ttaatgtcag tgggtgtgcca cagtgcagag gctagacaac tgaaaggggc taccaaggct 780
 gggaaaaaaa tgcaattgtt gctgtgagtg actttgaaag actctggtgc cttgtggtgc 840
 ccttctgaaa ttcaaacagt aatgcaaaag tgtctgcatt agaatttacg gtgtctaaaa 900
 ttcattgttt taaaagagct tgcctacaga tgggtttccac acttgaaatt gtgccctgcg 960
 agttgcatag ctggaagtgc aatgctcagt cctaccttg cctccattaa acatttggtg 1020
 ctctgtggat tgagttgaac gtgttgaggc tttgcaattt cacttgtgtt aaaggctctg 1080
 gcatttttcc atttctatgc aaatttcttt gaagcagaat tgcttgcata tttcttctct 1140
 gccgtcacag aaagcagagt ttctttcaaa cttcactgag gcatcagttg ctctttggca 1200
 atgtccctta accatgatta ttaactaagt ttgtggcttg agtttacaaa ttctacttgt 1260
 tgcattgatg ttcccatgta gtaagtcat ttagtttggt ttgtgaaaaa accctgggct 1320
 gaagttggca tttcagttaa aagaaaaaaa gaaactagtc ccagatttga aaacttgtaa 1380
 taaaattgaa actcactgga aaaaaaaaaa aaaaaaaaaa aaag 1424

<210> 264

<211> 1287

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (111)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (889)

<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1196)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1229)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1284)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1287)
<223> n equals a,t,g, or c

<400> 264
tccgcgcccgc ctccgcccgc gaggaagaca ggcgcgcccgc cgcaccgccca gcgacccccgc 60
ccgcagagtc ccaccgccac aggcctcggg ccagcggcca ggagctgcct nccccagccc 120
ccgtcccgcg gccccagcc gcccccaacc ctgccccacg ggcccggcgc catgagttag 180
ctggagcaac tgagacagga ggccgagcag ctccggaacc agatccggga tgcccgaaaa 240
gcatgtgggg actcaacact gacccagatc acagctgggc tggacccagt ggggagaatc 300
cagatgagga cccggaggac cctccgtggg cacctggcaa agatctatgc catgcactgg 360
gggaccgact caaggctgct ggtcagcgcc tcccaggatg ggaagctcat catctgggac 420
agctacacca ccaacaaggc ccacgccatc ccgctgcgct cctcctgggt aatgacctgt 480
gcctacgcgc cctcagggaa ctttgtggcc tgtgggggggt tggacaacat ctgctccatc 540
tacagcctca agaccgcga ggcaacgtca gggtcagccg ggagctgcct ggccacactg 600
ggtacctgtc gtgttgccgc ttcttgatg acaaccaa catcaccagc tctggggata 660
ccacctgtgc cctgtgggac atgagacag gccagcagac agtgggtttt gctggacaca 720
gtggggatgt gatgtccctg tccctggccc ccgatggccg cacgtttgtg tcaggcgcct 780
gtgatgcctc tatcaagctg tgggacgtgc gggattccat gtgccgacag accttcacgc 840
gccatgaatc cgacatcaat gcagtggctt tcttcccaa cggctacgnc tttcaccacc 900
ggctytgacg acgccamgtg ccgcctcttc gacctgcggg ccgatcagga gctcctcatg 960
tactcccatg acaacatcat ctgtggcatc amctctgtt ccttctcgcg caggawcggc 1020
tgctgctgcg tggctacgam gacttcaact gcaacatctg ggatgccatg aagggcgacc 1080
gtgcaggagt cctcgtggc cacgacaacc gcgtgagtgc ctcgggggtca ccgacgatgg 1140
catggctgtg gccacgggct cctgggactc cttcctcaa atctggaact aatgggccca 1200
acccactgg gcccaagcca ggaaggggnc ctgccttccc cggggccaag gggccttggg 1260
tccctgccct tccaaccaag tttngtn 1287

<210> 265
<211> 991
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature

<222> (421)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (966)

<223> n equals a,t,g, or c

<400> 265

```

gtgggcatcc agctgttgaa taagacctgg aaggagatgc gggctacaca ggaggacttc 60
gacaagggtca tgcagggtgg gcgggagagc tggcccgcac tctggccctg aagcccactt 120
ccctggagct cttccgaacc aagggtgaatg cgctcactta tggggaggtg ctgcggctgc 180
ggcagactga acggctgcac caggagggca cactggctcc ccctatactg gagctgcggg 240
agaagctgaa gccagagctc atgggcctga tccgccagca gcgcttgtc cgctctgtg 300
aggggacgct cttccgcaag atcagcagcc ggcggcgcca ggataagctg tggttctgct 360
gcctgtcccc caaccacaag ctgctgcagt acggagacat ggaggagggc gccagcgct 420
naccctggag agtctgccc agcaactccc tgtggccgac atgagggcac tcctgacagg 480
caaggactgc ccccatgtcc gggagaagg ctccgggaag cagaacaagg acctctatga 540
gttgcccttc tcaatcagct atgaccgtgg ggaggaggaa gcgtacctca acttcattgc 600
cccctccaag cgggagttct acctgtggac agatgggctc agtgccttgc tgggcagtcc 660
catgggcagc gagcagacac ggctggacct ggagcagctg ctgacctagg agaccaagct 720
gcgtctgctg gagctggaga acgtgcccac ccccgagcgg ccacccctg tgcctccacc 780
ccccaccaac ttcaacttct gctatgactg cagcatcgct gaaccttgac agtgtggctg 840
ccatgggcca cagctgcggc cactgcagca gccatgaagg gcagtgggta gaggagtga 900
ggcacccctga ccagcagaga ttgctgcaga aataaagtct gcttggtctt tgggawaaaa 960
aaaaanaaaa aaaaaaaaaa aaaaaaaaaa a

```

<210> 266

<211> 2320

<212> DNA

<213> Homo sapiens

<400> 266

```

tctccctccc tctccttccc gtgtgtccct ccccgcccgg ctggaggctg ctccggaccg 60
ggacgcagag tctgcggacc cggcgccgag ggggccaccc gagacgggc gcgcacgctc 120
cggcctgcgc ccggcccggc catggcgggc ccccgcccgat ctcccgcttc 180
gtctcggtc cggttttta cgccccgcag aagaagtctg gccctgtggt ggcccaaaag 240
cccaaaagtga atcccttccg gcccggggac agcgagcctc ccccggcacc cggggcccag 300
cgcgcacaga tgggcccggg gggcgagatt ccccgccgc ccccggaaga ctttccctg 360
cctccacctc cccttgtggt ggatggcgac gatgcagagg gtgctctggg aggtgccttc 420
ccgcccgcctc ctccccgat cgaggaaatc tttccccctg cgctctgga ggaggagatc 480
ttcccttccc cgccgcctcc tccggaggag gagggagggc ctgaggcccc ataccgcccc 540
caccacagcc cagggagaag gtgagcagta ttgatttga gatcgactct ctgtcctcac 600
tgctggatga catgaccaag aatgatcctt tcaaagcccg ggtgtcatct ggatatgtgc 660
ccccaccagt ggccactcca ttcagttcca agtccagtac caagcctgca gccgggggca 720
cagcaccctt gcctccttgg aagtccctt ccagctccca gcctctgccc caggttccgg 780
ctccggctca gagccagaca cagttccatg ttcagcccca gcccagccc aagcctcagg 840
tccaactcca tgtccagtc cagaccagc ctgtgtcttt ggctaaccac cagccccgag 900
ggccccagc ctcatctccg gctccagccc ctaagttttc tccagtact cctaagttta 960
ctcctgtggc ttccaagttc agtcctggag cccaggtgg atctgggtca caaccaaata 1020
aaaaattggg gcaccccgaa gctctttctg ctggcacagg ctccctcaa cctccagct 1080

```

```
tcacctatgc ccagcagagg gagaagcccc gagtgcagga gaagcagcac cccgtgcccc 1140
caccggctca gaacaaaaaac caggtgcgct cccctggggc cccagggccc ctgactctga 1200
aggaggtgga ggagctggag cagctgaccc agcagctaata gcaggacatg gagcatcctc 1260
agaggcagaa tgtggctgtc aacgaactct gcggccgatg ccatcaaccc ctggcccggg 1320
cgcagcagcc gtccgcgctc tagggcagct gttccacatc gcctgcttca cctgccacca 1380
gtgtgcgcag cagctccagg gccagcagtt ctacagtctg gagggggcgc cgtactgcga 1440
gggctgttac actgacaccc tggagaagtg taacacctgc ggggagccca tctactgaccg 1500
catgctgagg gccacgggca aggcctatca cccgcactgc ttcacctgtg tggctctgcgc 1560
ccgccccctg gagggcacct ccttcacgtg ggaccaggcc aaccggcccc actgtgtccc 1620
cgactaccac aagcagtacg ccccgagggtg ctccgtctgc tctgagccca tcatgcctga 1680
gcctggccga gatgagactg tgcgagtggg cgccttgga aagaacttcc acatgaagtg 1740
ttacaagtgt gaggactgcg ggaagcccct gtcgattgag gcagatgaca atggctgctt 1800
ccccctggac ggtcacgtgc tctgtcggaa gtgccacact gctagagccc agacctgagt 1860
gaggacaggc cctcttcaga ccgcagtcca tgcctcattg tggaccaccc aactgagac 1920
cacctgcccc cacctcagtt attgttttga tgtctagccc ctcccatttc caacctctcc 1980
ctagcatccc aggtgccttg acccaggacc caacatgggtc tagggatgca ggatccccgc 2040
cctggggctc ggtcctcgcc catcctgcag ggattgccc cgtcttcca gacccccac 2100
ctgagggggg caccaggttt agtgcctgtg ctttcaactg tgcacccgcg cctcggccg 2160
gcccccgag cagcctttgt actctgcttg cggagggctg ggagaccctc caggacattc 2220
ccacctccc ccattgctgc aagttgtagc tatagctaca aataaaaaaa aaccttgttt 2280
tccagaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2320
```

<210> 267

<211> 423

<212> DNA

<213> Homo sapiens

<400> 267

```
aattcggcac gaggattgcc ctacccaag tcagtgtgtg gtggcccgaa ccttaggcaa 60
acagcaaact gtcattggca ttgtacaaa gattgcccta cagatgaact gcaagatggg 120
aggrgagctc tggagggtgg acatccccct gaagctcgtg atgatcgttg gcatcgattg 180
tkaccatgac atgacagctg ggcggaggtc aatcgagga tttgttgcca gcatcaatga 240
agggatgacc cgctggttct cacgtgcat atttcaggat agaggacagg agctggtaga 300
tggtgtcaaa gtctgcctgc aagcgctctt gagggcttgg aatagctgca atgagtacat 360
gccagccgg atcatcgtgt accgsgtggc gtaggagacg gccagytgaa aacctgggtg 420
act 423
```

<210> 268

<211> 1846

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1776)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1816)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1832)

<223> n equals a,t,g, or c

<400> 268

```
cgatttatca ggtttataat gcacttcagg agaaagttca ggcagtgtgt gcagatgttg 60
aaaagagtga gcgagttggt gaatcttgtc aggcagaagt gaacaaatta agaagacaaa 120
tcaactcagag gaaaaatgaa aaggaacaag aaagaagatt gcagcaggca gtgttaagca 180
gacagatgcc gtctgaaagc ttggacccag cgttcagtc ctcggatgcc tcctctgggt 240
ttgcagctga akgcagaagt acacttggag atgcagaggc ctcggatcct cctccccctt 300
actctgattt tcacccaaac aatcaagaaa gtactttgag ccactctcgc atggaaagga 360
gtgtctttat gcctcgacct caagctgttg gctcttccaa ttatgcttcc accagtgccg 420
gactgaagta tcctggaagt ggggctgacc ttcctcctcc ccaaagagca gctggagaca 480
gtggtgagga ttcagacgac agtgattatg aaaatttgat tgaccctaca gagccttcta 540
atagtgaata ctcacattca aaggattctc gacccatggc acatcccgc gaggacccca 600
ggaacactca gacctcccag atttaactaa acaaaagaaa ctctccacct agcactgttt 660
ttcttcattg ctactcgaga gggtttttga gaacttaatc tggggggaga actgctttct 720
cagatacctt aactcccgag aagagagtcc ttgtgcacag aacttggtgg agcctccatc 780
cgctgtctct taccttttga tacagtgtgc aagtttcatg acagaatcat taagataatc 840
aaattgtcct aattctggtg cgattcatgg atatactggt aaatttaggc aaagtgaac 900
ttatcagcgt agtttctgtt ctttaaaata aattggaaat tagagactaa gcacaattag 960
tctataaatg ttctataaat caaaaactta cctcttgccac tatcatgcct tgaaatttac 1020
tttttcaaag ggaacaagt ttagcagcag ccttcaaaga acttctttct atgatgagcc 1080
aaattcatct ttgccagaaa agaaattttg ataattccaa gaagcctgat tagaacaat 1140
cagatatacc ttctctgtc tgcagtactt tgtgagataa aagagagggc ttccaacttt 1200
tttctactag cttgatatgt attatcactt aaaatggttg ctttataaaa aaaaaagtag 1260
rgatacta ataccagtaag taatcatcca aataaatacg tcataaaata aattaattat 1320
tttttcyttg atggattaca gtgactactg tgttgactg gcacatttat ggtctctgtt 1380
ctggaatctt ggaggacaca cagcagtggg gaacagaagg agtgagtttt ataatagaaca 1440
gattccagac acggtagggt tagctgagtt catcacagg agatataact catttagatc 1500
ttctgacaaa tcctagtgtt agttttatct gtggaggaaa gacatttaata aataaactgt 1560
ttgggaatct tgggaataa agattcattt tcaagctgaa taaccatact tattttattt 1620
taagttgcc tttggggaat aagtgcattc caagagagtc tctacacatc ctggaagtcg 1680
tcaatgattt ccctttggaa actactttat ttactaatt taaactattt tgtactgatg 1740
tagccctgag gtatgttcag aaaaatgctgt gcactncatt ccatgggaat gaaatgttgg 1800
aaagctgac ttttcnggat ataaaatgtt gnatgatgaa aaaaaa 1846
```

<210> 269

<211> 601

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (536)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (556)

<223> n equals a,t,g, or c

<400> 269

```
ggcacgagct ggggaggagg ggggtggtgac acggtggaga caccgggctag gccagggggc 60
ctgcccttgg gacaggtcca gacccatgga gccccccggg aggagcagca ggtccacagc 120
gtctcatact ctacaccagt attgctgtcc tactcaggtc cttgactcca tgaagcttac 180
cccctcaggc aggctggcag agagcaggga agaggaggag gaggaggaga ctgaggaaga 240
ggaagaggaa gacgctcacc agttctgctg tccggcctcc gagtgcagta gtccctcctc 300
tcggttaactg agaggacaag ggccattttc tatgcagaag caaaagcctt aaccagsccc 360
tccttcccc caccacccc cccgcagatt cccccatggg accctgtccc ctgcttcagg 420
aaccagatgg gcaagcatcg tgcccccttc tccccccacc ttcttcttgg aattcccatc 480
cccactgctg tctcctctgg actccagccc ctgaattaaa gaaactggag ccctangtcc 540
gactaaaatt tggganaagc aaacttggac ttggacttgg aactggatcc tcccgtaccc 600
g 601
```

<210> 270

<211> 880

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (876)

<223> n equals a,t,g, or c

<400> 270

```
aattcggcag agggaaaggg tggggggtcag cctccccaaa atcacatgga ttccccaaagt 60
ggaactagg agcagggagt tgcttgggtg gccgctaaca ccaggctact cttatttttag 120
cttgctaagt tgagatcagc tagacctgct ttcttttctc ctgagctctg catttccctc 180
aatacaagct gcagcctctt tcctcgtttc tagtctcaga aggaaggaga gggaagccat 240
tctcctctag ggactcttca gtctcattta gatgatagtc cttttttttc tacctccata 300
ttagagatgg agctccttcc ttttcctgtt tcttaatttt tgtcttctca ttcttgcttc 360
cctctcacc ctttgccagt tccaccaact agagtgaag acttcctagc catttcatta 420
aatctattct gtatccacca ggtggcagca tcttgtcata cgtgtcagga cttaggactg 480
cggggtttag gttagatgtc acggaaaaag ctagttctgt ggtcaggcgg caccaatgag 540
aaaggaatgc agaccctcca gatgtatcct tgggaaaagc agtaaacc aa ctaatattta 600
ttgaagacct actttgtcct ctacataggg tagcttctgt cagggaatct tggttcttcc 660
caagaaacac tgattttctt tcaggagagc ttcattgtgt catttatttc caccacagca 720
gattttaaga aattataata tgtaatat tt gatattata aagagtatat ctaacgtgaa 780
taaattatga agcataactaa tgagtaccta tgaccataa cacatatata ttaaacatt 840
ttaataacca aaaaaaaaaa aaaaaaaaaa aaaaanaaaa 880
```

<210> 271

<211> 2484

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (194)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (623)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2396)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2484)

<223> n equals a,t,g, or c

<400> 271

aaggagatga ggggccgtga aggggaaccc aggaaactga gtcctgaaag caaggaggaa 60
cttccagaat gaagggcgcc gacactcctt cctgcctttg ctcaagcggc tccttcaccc 120
cgatcaagtt ccttccatt tctccatctg ggggatcctg aacgtgcaca tcctcagaga 180
agccctcctg gggntctcca attctagtgt attgccccct cctatcgatc cccagcgcg 240
ctcatcgggc ctgtggacaa ggacagggtt gaagagagga ttccctggat cgcggaaggg 300
ctgcaggaat ggcacagccc cttccgagga tgccaaagga gcccgggcaa aggaaagtgg 360
ccgtgccggg cctgcctacc actagatccc caccaccta tgactgctca gtcccgtct 420
cctaccacac ccacctttcc cggcccaagc cagcgacccc cgctgactcc ctgcccagtc 480
caaactccaa ggctgggcaa ggcactgatc cactgctgga cagaccggg gcagcctctg 540
ggtgaacagc agcgtgtccg ccggcagcga accgagacca gcgagccgac catgcggctg 600
cacagacttc gtgcgcggct gancgcgggt ggcctgtggg yttctgctgc ttcttgtccg 660
gggccagggc caggactcag ccagtcccat ccggaccaca cacacggggc aggtgctggg 720
gagtcttgtc catgtgaagg gcgccaatgc cgggttccaa accttcctgg gaattccatt 780
tgccaagcca cctctaggtc cgctgcgatt tgcacccct gagccccctg aatcttgag 840
tggtgtgagg gatggaacca cccatccggc catgtgtcta caggacctca ccgcagtga 900
gtcagagttt cttagccagt tcaacatgac cttcccttcc gactccatgt ctgaggactg 960
cctgtacctc agcatctaca cgccggccca tagccatgaa ggctctaacc tgccgggtgat 1020
ggtgtggatc cagggtgtgt cgcttgtttt tggcatggct tccttgatg atggttccat 1080
gctggctgcc ttggagaacg tgggtgtgt catcatccag taccgcctgg gtgtcctggg 1140
cttcttcagc actggagaca agcacgcaac cggcaactgg ggctacctgg accaagtggc 1200
tgactacgc tgggtccagc agaatatcgc ccactttgga ggcaaccctg accgtgtcac 1260
catttttggc gagtctgcgg gtggcacgag tgtgtcttcg ctgtgtgtgt ccccatatc 1320
ccaaggactc ttccacggag ccacatgga gagtggcgtg gccctcctgc ccggcctcat 1380
tgccagctca gctgatgtca tctccacggg ggtggccaac ctgtctgcct gtgaccaagt 1440
tgactctgag gccctgggtg gctgcctgcg gggcaagagt aaagaggaga ttcttgcaat 1500
taacaagcct ttcaagatga tccccggagt ggtggatggg gtcttcctgc ccaggcacc 1560
ccaggagctg ctggcctctg ccgactttca gcctgtccct agcattgttg gtgtcaacaa 1620
caatgaattc ggctggctca tccccagggt catgaggatc tatgataccc agaaggaaat 1680
ggacagagag gcctcccagg ctgctctgca gaaaatgtta acgctgctga tgttgcttcc 1740
tacatttggg gacctgctga gggaggagta cattggggac aatggggatc cccagaccct 1800
ccaagcgcag ttccaggaga tgatggcgga ctccatgttt gtgatccctg cactccaagt 1860
agcacatttt cagtgttccc gggccctgt gtacttctac gaggttccagc atcagcccag 1920
ctggctcaag aacatcaggc caccgcacat gaaggcagac catggtgatg agcttccttt 1980

210

```
tgttttcaga agtttctttg ggggcaacta cattaaattc actgaggaag aggagcagct 2040
aagcaggaag atgatgaagt actgggcaaa ctttgcgaga aatgggaacc ccaatggcga 2100
gggtctgcc aactggccgc tgctcgacca ggaggagcaa tacctgcagc tgaacctaca 2160
gcctgcggtg ggccgggctc tgaaggccca caggctccag ttctggaaga aggcgctgcc 2220
ccaaaagatc caggagctcg aggagcctga agagagacac acagagctgt agctccctgt 2280
gccggggagg aggggggtggg ttcgctgaca gccgagggtc agcctgctgt gccacacac 2340
accactaag gagaaagaag ttgattcctt cattcamttt sgscattcat tcatanttcc 2400
gtccatccat tcagaaagcw tttatttaag attttayttc agggmtwgat kggcccatat 2460
tgtaatttc cccgtttttt gggg                                     2484
```

<210> 272

<211> 751

<212> DNA

<213> Homo sapiens

<400> 272

```
agccaccgcg tgaccactg cccctatgcc gtggccctac ccgagggtggc cccagcccag 60
ccactcaccg aggcactgag ggctctctgc cacgtggggc tctttracct cgccttttgt 120
gccttggttg actgcraccg ccctgtggs gagaagtctt gtgacctcct tctcttctg 180
agggacaaga ttgcttccta cagcagcctg cgggaggcca ggggcagccc caaactgcc 240
tccgcagagg ccamcctgcc gaggtggcgg gcgggtgagc aggccagcc cccaggggac 300
caggagcctg aggcctgtgct ggccatgctc aggtccctag acctggaggg cctgcggagc 360
acgctggcgg agagcagcga ccacgtgga aagagtcccc agtccctcct gcaggacatg 420
ctggccacgg gagccttctt gcagggggac gagggcgact gctactgagc agaaccagag 480
tctgccactg gggctcagga ccaaggagg cagcaccatg tccttctgtg ggacactgcc 540
agccccaggc tccagcccag cccggtggat cctctgggga agccaggacc aggagagaag 600
caagggtcaag aaatcccaca gtttgatgta ttaaagaaat gacttatctt tactcaaat 660
aaatggcatt gaagtctttc tttaaccctt tatgagttaa tttaataata atgatctgag 720
acaaaaaaaa aaaaaaaaaa aaaaaaaaaa a                                     751
```

<210> 273

<211> 3309

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (3279)

<223> n equals a,t,g, or c

<400> 273

```
agaagcagga gggagaagg gacacaggg tcggttgagc cagggtagaa accaagggga 60
gccagggtag aaaccaagg gtcagggtg ggctggagga cacggctgag gtcctcccaa 120
aactgggccc atgtgtgtg acatccccac cagcctcaga tgagacgggc caggacgccc 180
agccacagca agccctgtcc ctttgccgga tccccaaaca ctagagaagc tctcctaacc 240
caaggcggag aatgaagggt gtggcggcag aggaggagg cagcagctga gaggccaggg 300
acagggtgcc tcgccaaagt gtctgagggt tgtcccaggt ggcccagggt gtgcaggtag 360
aacagggtga ggagaggggg tcggctcarg aggaggaggc tgtggctgca gagcctgggr 420
gagcttttag gtgttgagat ggggcagctc tgaatcctag accctggaat agcctgtccc 480
ttttctctgg gtctcgtggt ggagccatga tctgggctgc tctcttgggg aactgggtg 540
gtggttacac agttgacctc tgcctggctc ccccttggtg caactcctgc ctccatcccc 600
```

```

cttgctgggg tccctcatc cacttgaggg cgctgaggg ccaggarcag caggcaagga 660
gcctgggtct aggctaaggg ggtkktgcy cacctcctcc ctgaccctta acactcctgt 720
cctgcccaga ccaacagaga gagctgtccc tgagaccccg gagagaagca gctgccgaaa 780
gctgcagcct tccgcactc tgagaccatg atcttcctcc tgccagggga gagccacca 840
caggccatgt ccagccccac tccctcagc cccaggggt tcttctggc ccctctgagg 900
attccctagg gctgccccgc agaggggytt ccccaagctc tgttttgaag cctgcaatgt 960
ggaaaagtga gaagtcagag ggaacaggac aggtgcagcc gggctctgag gccacacctc 1020
acacctcgct gttccccaac atccccctgag cagtgtgagc tcctctcacc agatgagaag 1080
aggccctgtg catttytttt gtttgtttgt tgctgttttc cccaccccat ccagttctcc 1140
tcagcaaaagc aaattcctta acacctttgg tggagaattt cttaccacaga cttggggctg 1200
tgatgccctt cagtgcgtgg tgagtgcagc gtgtgtgctg gtgcctgtgt gtgaacctgg 1260
gggccatcct ggtggcctgg gagcgtgagg agaggccccc tgtgtgctgg gtgagtgggt 1320
ggtgtggggg caatgcagtg aggcctctctg ggtgaggctc ccaacctggc agtccccagc 1380
ctcccagcat ctgtgagcgt ctgttggaact ttacagaaga gcctcatccy gtctgcccc 1440
cactctgccc tggaatcaac atcttccgag tcttcttggt gggaaatagc agagccccac 1500
ttaactccat aaactgcttc ccattccgca gcccagttct gattgttgag gtgtcgctgc 1560
gttccaggtc cccagtcctc ctcttctctc tgctctctct ctgtccttca cctccccact 1620
ccagccccgg ctcagttcag ggaatgctg ttccayatca gccctctgct ctctgaggca 1680
gccgcgcctc tgactcggag ctacttgaaa cttctgctct tgctaggatt ggagtctacc 1740
tatctcttcc atttgtccca gctggagttc tggaaacttc ctctcgggg tgggggtggg 1800
ggttgtaag gatgctgggg ggctgggga aggaaggagt tcagaggaa ggtgtcccc 1860
gtcctcttga tgcacctc cgctcctggg acacgtgctc tctctgtctc tgggtcttct 1920
ggctgtgcac gtttgtgtgt ccttgtaaat atgttttagg aagaaagcaa aagggactga 1980
actagcctct ggtaggattg cagggttcca gccttgctg tttccgaagc cccacactg 2040
cctttcggcc cactgagact ggtccctca aaaggtagac aaaacagcag ctccctgtgg 2100
agctgaaggg cggcctcaaa gtggcttttt gttagacaag gttaaggttt cctcatgagc 2160
aaggttgcag atcggctcct cctcagctcc ttgatttggt accttgacca aggggcctgc 2220
caccagccc ctccagtgc ctctcctcga tgctcgtctc ctctcgtccc ccactcccc 2280
ggcttaggca ggtaggggaa ttagggccat gctggaagaa gcttaaccat gtgttcaaag 2340
aacggtttct tgcttgcttg gtcctggaac tccccttggc tgcccaggc ctcttggcc 2400
catgggtgct gggggagggt gatgtcagat ctggtagggt gcagcagaga aaataaatgt 2460
gccttgagag accactcaga gaggttccaa ggggtgatga gaaggaaagc tggcctggga 2520
gcttgaaag raggggtggg ggggtggcgg atcttgactg cccctgttg tcccacacgt 2580
gggggggtgt caccctctc actccagccc gcctgccttc agccttccat gagcttcacc 2640
tgcttccaac ttcacttttg aggggggtgg gtccgttggc atcaacacgg ggacctctg 2700
cttcacaaaa gcccagagcc tcagcccctg gggagaacaa atggctgagc tttgatacct 2760
ggggctgctg agaggctgcg ggctggcggc agtcccaggg gagagacacc acagaaggag 2820
accagacat cccgaggaag ttcccagcag agcaaaactgc tttccagcct gaagcctgct 2880
taaaactgtg gatgtgcaat aactgagctt agagttagga attgtgttca agtgcttggg 2940
tttccgtctg tagatttaac tgctgaaatt gtatctctca gtaattttag atgtctttta 3000
aaaaattgaa aaacaaagtg ttagactgtg tgcgtgtgcg ttgatgggca ctcaagagtc 3060
ccgtgagtca tccagccctg ccttccctc gcgccccat cctctcacgt cccgcccycg 3120
ctccacttgg ggacctgccc tcgtgtcgtc ttatctgccc tattactcag cctaaggaaa 3180
caagtacat ccacacatgc ataaaggaaa tcaaatgtta tttttaagaa aatggaaaa 3240
aaaaacttta taaacaccaa aaaaaaaaaa aaaaaccng ggggggggccc ggtaacccat 3300
ttcgccctaa 3309

```

<210> 274

<211> 843

<212> DNA

<213> Homo sapiens

<220>
 <221> misc feature
 <222> (780)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (833)
 <223> n equals a,t,g, or c

<400> 274
 cgcgagacggg tgagaggccg cggcggcagg tccacctggg cttgcgaagg cacagattcc 60
 ccgtccacag ctcacgacca gatgcaccag caggagtcca catcgaggac gtcctccggg 120
 cactcccacg accagtgacc aggagttaaa ctttgggatg tgcccgtgat gttggaccac 180
 aaggacttag aggccgaaat ccaccccttg aaaaatgaag aaagaaaatc gcaggaaaat 240
 ctgggaaatc catcaaaaa tgaggataay gtgaaaagcg cgcctccaca gtcccggctc 300
 tcccggtgcc gagcggcggc gttttttctt tcattgtttc tctgcctttt tgtggtgttc 360
 gtctgtctcat tcgtcatccc gtgtccagac cggccggcgt cacagcgaat gtggaggata 420
 gactacagtg ccgctgttat ctatgacttt ctggctgtgg atgatataaa cggggacagg 480
 atccaagatg ttctttttct ttataaaaac accaacagca gcaacaattt cagccgatcc 540
 tgtgtggacg aaggcttttc ctctccctgc acctttgcag ctgctgtgtc gggggccaac 600
 gcagcacgct ctgggagwga cctgtggccc aagacgtggc cctcgtggag tgtgtgtgtc 660
 cccagccaag aggcagttag gcacctcttg cctgcatcct ggtgggcaga cccagttctt 720
 tcattgcagt caactgttgc acaggggaaa ccttggaac cacagccagc agttcaggn 780
 gaatggtcca tctgagcctt ttgtgcagtt gctgatgtgg agttcgatgg ggncccaaac 840
 tgt 843

<210> 275
 <211> 2028
 <212> DNA
 <213> Homo sapiens

<400> 275
 tcggcacgag gtttttgatt tatggataat ttcttaagag tacacacttt agatacacia 60
 ataatcggtc atttaccatc tttaggatca ttgaaactca tctcactaaa gaaagttcac 120
 ttgaacctct ttatagcatt gatactaggt gaacagaaat tacctgacta ataatttgtc 180
 taacatcata tatcagaatt ttattgtata tgatgaacaa aacttaaaat tttttaaat 240
 taattyttaa atactgtttc agagttctaa aaaggcagtt ttttaaaaaa cttaagttga 300
 taaaaactgt aagaataatt tagcagaaat agaaccagaa tgtagaagag tagtcatgta 360
 acagcagtaa taacatactt cagcttccat ataggaatag aagtggtaga gccaaaagt 420
 atttaggaaa agttataagg tacaggttga gtatcccttt tccaaaaatg cttgggacaa 480
 gaagtatttc aattttcata atttttttca aagtttgaa tatttgcat atacttacca 540
 gttgggcac ccaaatctga aatctgaaat gttccatgag catttccttt gagtgtcatg 600
 ttggcactca aaaaggttca acattgagtc cacttaacac ttaggtgtta gaagacctaa 660
 ctttctgtaa caattaacct tatactttgt ttgtcatcga atatttgttg aatgcatgtc 720
 aggtaatggt cttgattgtg atagcttcaa ggtggaacat actgtaactc ccagatgcta 780
 ggaagttagt ctaataattc actgcagaaa attgattaag tggctgtcct ttttaattaag 840
 agtgtggagt cataaactta agttcttcat atagtacaa gagtccttag agattgttat 900
 tcaagttcct tagaaattgt tatttaggta taatatcatc ttgtctttga ctagagcttg 960
 aaaccttggt atctgattgt gtaccactcc aaattccctg ctttctgcaa gttgaatgtc 1020

```

ttgctgaatg tgtctagggg ttcatcttca gtaatcgaca ttccactagt gccatagtta 1080
acttcatgac atgtagacat tcaaaacttg agccttggat gttcctgtgg acctgacagt 1140
taaaaaatata aagaacctag gattcaattc caactttctc tgtttgcctt ggggtgaata 1200
acttatcttk tggagaatag ctttaagtgg cttagacact gataaaattc agctgtgttg 1260
tgacgctca tctcttttgt cttacgctta gccatattta aatcttgaat ttaatagagt 1320
ctagtgaaaa aaatgagtgg gaagaatgaa tataaaagta ataataaag gaaaaaggga 1380
aagtaaaacta tttagaatgt agttttgtta tattcccagc atttcaatat ttattagtta 1440
cttgtaaaatt actgtggctg tgtagtttat aaatgtctgt gcactatatt aattagaaga 1500
ccatagaaca tgccagcagg ttggctaata ctatgggggt ttttaccaca gttgccattg 1560
tggaagaaat tatttggtag attaataaaa aaagttggta aaacatgrtt ttataacctca 1620
gtgtataaga tgtgcaagac aaatatgctt atttcctttt ctagaatata agtgatatta 1680
tttgcttatg acactaacac tattaatgac aggagtcaat cagcctttac agctatcaaa 1740
atataatgag atcccaatga tgattctttt ttactttgaa tgtaattag tttgggactt 1800
tgattggctg gcaaacattt tatcattgtc agaatttaat ttagatttca aaaatagctt 1860
acaggatttt aaacatgggtg tggatttcta aagccttttt tttaaaaaaa gagatctttt 1920
tgagagaaac aaatgaggat tgtaaagttt ggggacttac ctctgtagca ttgtgaaaat 1980
aaactttgat taagctgaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2028

```

<210> 276

<211> 1455

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (759)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1408)

<223> n equals a,t,g, or c

<400> 276

```

tcgaccacag cgtccgcggc aatggcgggt gcgctgcggg gattaggagg gcgcttccgg 60
tggcggacgc aggccgtggc gggcgggggt cggggcgcgg cgcggggcgc acagcaggtc 120
agcgggacta tgatctcctg gtggtcggcg ggggatcttg tggcctggct tgtgccaagg 180
aggccgctca gctgggaagg aaggtggccg tggtggaacta cgtggaacct tctccccaag 240
gcacccgggtg gggcctyggc ggcacctgcg tcaacgtggg ctgcatcccc aagaagctga 300
tgcaccaggc ggcactgctg ggaggcctga tccaagatgc ccccaactat ggctgggarg 360
tggcccarcc cgtgccgcac gactggagga agatggcaga agctgttcaa aatcacgtga 420
aatccttgaa ctggggccac cgtgtccagc ttcaggacar aaaagtyaag tactttaaca 480
tcaaagccag ctttgttgac gagcacacgg tttgcggcgt tgcaaagggt ggaaaagagt 540
tctgtgtgca gccgatcaca tcatcattgc tactggaggg cggccgagat accccacgca 600
catgaaaggt accttggaat atggaatcac aagtgatgac atcttctggc tgaaggaatc 660
ccctggaaaa acgttggtag tcggggccag ctatgtggcc tgggagtgtg ctggcttcct 720
caccgggatt gggctggaca ccaccatcat gatgcgcanc cscctccgc ggcttcgacc 780
agcaaatgtc ctccatggtc atagagcaca tggcatctca tggcacccgg ttcttgaggg 840
gctgtgcccc ytcgcgggtc aggaggctcc ctgatggcca gctgcaggtc acctgggagg 900
acagcaccac cggcaaggag gacacgggca cctttgacac cgtcctgtgg gccataggtc 960
gagtcccaga caccagaagt ctgaatttgg agaaggctgg ggtagatact agccccgaca 1020

```

```

ctcagaagat cctggtggac tcccgggaag ccacctctgt gcccacatc tacgccattg 1080
gtgacgtggt ggaggggagg cctgagctga ccccacagc gatcatggcc gggaggctcc 1140
tggtgcagcg gctcttcggc gggtcctcag atctgatgga ctacgacaat gttcccacga 1200
ccgtcttcac cccgctggag tatggctgtg tggggctgtc cgaggaggag gcagtggctc 1260
gccacgggca ggagcatggt gaggtctatc acgcccatta taaaccactg gagttcacgg 1320
tggtggacg agatgcatcc cagtgttatg taaagatggt gtgcctgagg gagccccac 1380
agctggtgct gggcctgcat ttcttggncc caacgcaggc aaattactca aggatttgct 1440
ctggggacaa gtgtg                                     1455

```

<210> 277

<211> 1923

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1814)

<223> n equals a,t,g, or c.

<400> 277

```

ggccctgccc acccaggccg caagagctgc cgggacggtc cccatcttct tggagcgctt 60
taggctggcc ggcggcgctg ggaggtggag tcgttgctgt tgctgtttgt gagcctgtgg 120
cgcggtcttct gtggggccga accttaaaga tagccgcaat ggctgaaaat ggtgataatg 180
aaaagatggc tgccctggag gccaaaatct gtcataaat tgagtattat tttggcgact 240
tcaatttccc acgggacaaag tttctaaagg aacagataaa actggatgaa ggctgggtac 300
ctttggagat aatgataaaa ttcaacaggt tgaaccgtct aacaacagac tttaatgtaa 360
ttgtggaagc attgagcaaa tccaaggcag aactcatgga aatcagtga gataaaacta 420
aaatcagaag gtctccaagc aaacccttac ctgaagtgc tgatgagtat aaaaatgatg 480
taaaaaacag atctgtttat attaaaggct tcccaactga tgcaactctt gatgacataa 540
aagaatggtt agaagataaa ggtcaagtac taaatattca gatgagaaga acattgcata 600
aagcatttaa gggatcaatt tttgttgtgt ttgatagcat tgaatctgct aagaaatttg 660
tagagacccc tggccagaag taaaaagaaa cagacctgct aatacttttc aaggacgatt 720
actttgcaa aaaaaatgaa gaaagaaaac aaaataaagt ggaagctaaa ttaagagcta 780
aacaggagca agaagcaaaa caaaagttag aagaagatgc tgaatgaaa tctctagaag 840
aaaagattgg atgcttgctg aaattttcgg gtgatttaga tgatcagacc tgtagagaag 900
atttacacat acttttctca aatcatggtg aaataaaatg gatagacttc gtcagaggag 960
caaaagaggg gataattcta tttaaagaaa aagccaagga agcattgggt aaagccaaag 1020
atgcaaataa tggtaacctc caattaagga acaaagaagt gacttgggaa gtactagaag 1080
gagaggtgga aaaagaagca ctgaagaaaa taatagaaga ccaacaagaa tccctaaaca 1140
aatggaagtc aaaagtcgt agatttaaag gaaaaggaaa gggtaataaa gctgcccagc 1200
ctgggtctg taaaggaaaa gtacagtttc agggcaagaa aacgaaattt gctagtgatg 1260
atgaacatga tgaacatgat gaaaatggtg caactggacc tgtgaaaaga gcaagagaag 1320
aaacagacaa agaagaacct gcatccaaac aacagaaaac agaaaatggt gctggagacc 1380
agtagtttag taaaccaatt ttttattcat tttaaatagg ttttaaacga cttttgtttg 1440
cggggctttt aaaaggaaaa ccgaattagg tccacttcaa tgtccacctg tgagaaagga 1500
aaaatttttt tgtgttttaa cttgtctttt tggtatgcaa atgagatttc tttgaatgta 1560
ttgttctgtt tgtgttattt cagatgattc aaatatcaaa aggaagattc ttccattaaa 1620
ttgcctttgt aatatgagaa tgtattagta caaactaact aataaaatat atactatatg 1680
aaaagagcaa aaacagtttt tgattttttt tttctttttg tacccaaagc atttaggaaa 1740
gaactagaat attagctatt gacgatgggc ctttcccaca ggccatttat ggtgtctcct 1800
aggctgggct ttgnatattt acacaggaaa gttgggtaac actagaaata attacttggg 1860

```

cacaaagcct tccctttttt tttccttttc gagactgagt ctcactccta tcgcgcagct 1920
gga 1923

<210> 278

<211> 1380

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1293)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1297)

<223> n equals a,t,g, or c

<400> 278

aggggaagaa ggggtgggct ccccttcttg gatccttgcc accccctcc gcagcgcgcg 60
cggaacgaca cacacacaca cacacacaca cactcgcata ctcatgcaca 120
tttcccttca tttccagatc ctttatttca gagcagccca tttcctctg gattcattga 180
tgaatacaag taccacacacc tttggccagt aatgtcagtt acctgctgca ggttctgtgt 240
atgaggcctt catgaacggg taccttctcc atacactagg gaagcatttg tcagactctg 300
cagactgggt tctagagagg cagagtcttt aagagtattc atttcttctg gaaggaggag 360
ctttacccaa agtgggaagt agccttgctc aaagatgtgt tttgtggtag gtggtaaaaa 420
taaataaata aataaataat aaaaaaagaa acatgtattg gaggtaattt gacactgctg 480
ctggcagtag ttctctattc accattttta agccattca ggttctctct tcctgaaaag 540
aactgattgc tgtgtttaca tgaaatgaca ttggagtcag atggtctgtt ttaaagattt 600
ccatgacagc ctcttttctt gagttggaga gattggagggt ggtctatccg tacgatgtgg 660
aatcaaacgg tgggtttctt agtagctaaa gaagccatgt acttctagtg tgtttctcag 720
aatatcaact catgttcttc agatgctttt ctttttttaa tgggtaggga aaaggataaa 780
tttgggattc cacagtgcct tgcatatagt aggcgcccag taaataactg ttgaagcaaa 840
ccaagtttcc caagtcttca tctcttatag tgaccaagac atctttctcc tctgaagggc 900
ttggcagttg tggctaaaaa ataagcagta tcattatttg cttgaaatca tatatacagt 960
ttgtatgaat ttcagtatgt tgccaagaca tgattttttc ttattgtatt ttctgtaaat 1020
atttctggca ctgaactgta aagtaaaggc aaagtgtaaa tatgaaggcg tgcccgtgcc 1080
ccttgccctc tgtgtttcat ctctgtcggg tagggaagaa ggtccagagg tttgtttgta 1140
tttatgccga tcctttgtcc agaagaagcc catggaatat tgaatgtaat acatttagtc 1200
aattaaattt taaggagatt cttatctaata aactttgtgt gtgcttttgg atacaggctg 1260
aggctttact cctacactgg tgctgttaata ttncacnttt caggggatgt ctgctcggct 1320
ttgctgccc tttataattt agatctgtag tttaaatgaa cattaaatga gtatttcatg 1380

<210> 279

<211> 1018

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (818)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1017)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1018)

<223> n equals a,t,g, or c

<400> 279

```
catggccgcg ccggcccggg cctcatctcg gtgttctcga gttcccagga gctgggtgcg 60
gcgctagcgc agctggttgg ccagcgcgc asatgctgcc tggcaggggc ccgcgcccg 120
ttcgcgctcg gcttgctggg cgggagctcg tctcgatgct agcccgcgag ctaccgcgcg 180
ccgctgcccc tgccgggcca gctagcttag cgcgctggac gctgggcttc tgcgacgagc 240
gcctcgtgcc cttcgatcac gccgagagca cgtacggcct ctaccggacg catcttctct 300
ccagactgcc gatcccagaa agccaggtga tcaccattaa ccccgagctg cctgtggagg 360
aggcggctga ggactacgcc aagaagctga gacaggcatt ccaaggggac tccatccccg 420
ttttcgacct gctgacctg ggggtgggcc ccgatggtca cacctgctca ctcttcccag 480
accacccct cctacaggag cgggagaaga ttgtggctcc catcagtac tccccgaagc 540
caccgccaca gcgtgtgacc ctacacctac ctgtcctgaa tgcagcacga actgtcatct 600
ttgtggcaac tggagaaggc aaggcagctg ttctgaagcg cattttggag gaccaggagg 660
aaaaccgct gcccgccgc ctggtccagc ccacaccgg gaaactgtgc tggttcttgg 720
acgaggcggc cgccgcctc ctgaccgtgc ccttcgagaa gcattccact ttgtagctgg 780
ccagagggac gccgcagctg ggaccaggca cgcggccnat ggggctgggc ccctgctggc 840
cgccactctc cgggctctcc tttcaaaaag ccacgtcgtg ctgctgctgg aagccaacag 900
ctccggccag cagccctacc cggggctcaa cacacaggct gtggctctgg acatccggat 960
attaaaagga gcgttgctgg aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaann 1018
```

<210> 280

<211> 1192

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1105)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1130)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1154)

<223> n equals a,t,g, or c

<400> 280

```

tccgggaatt cccgggtcga cccacgcgtc cgctctgttt atatagcagg tgtcacaact 60
aacttgtctt tagccttggt gctttgatcc ttctatat ttgacccaca ggtgtggtcc 120
ggtttactta atcaggacat gggcctaaga acaaaccttt tcccttcattg ataactatcca 180
tagacaactt attagaaggg actagagttt ttgcaaattt ccctgctgga tggggcctat 240
agctatactt agtatatgcc taaacatggt aattggatag taaatggttt tctagttcca 300
ttgctgtata tttgcctaaa tggacttggt ttcaaattat ttcttcaatt gtcataagata 360
atcctgtacc aaatggggaa gaattaggaa ataatcatgt tgtctaattg tactctggat 420
tcagggcagc aactgccatt taaatggtgt cttgttcatt tctaaatctg ttccatgaag 480
tttaggtttt ccctgaaact aagttgaatt atttccaaaa tgaaacaggc ttctcaggga 540
catatccact tcttcccagt ctgcctttgg attaaagcac caagcagaga ccacattaat 600
tccctttgct atactgtgat ccttagtatg ttaattctta agaaaccaac atatcactga 660
aagaaggctg gcagaacgca agtgcatttt ttcactgtgg gaagaaagat caagtgcagt 720
attatttttt cctggttggt acttaatggg ctgagtaaaa agcttgaaaa ctcagacttt 780
cggctcttgg tctgccactc attggttatg aggaggccca gagcaggtaa gttcaccttc 840
ctggccttac tttcctgatg tgtaatacgg aattacttca cagtagcatg acagtataag 900
acaccagcag tagatacaac tatgatgaca ttccatgagt tggatatttt agttctaact 960
gctaaatttg ttctctttac gggacagatt tctaataaag tgcttggtct taaaatacat 1020
ggttgacagc aggtgcccta tcccttaact atggaggcag gtgctacctt ttggggatat 1080
ttatttttaa atttttaata ctttnggtac tccaattgtc cagtgttccn tgggtgttgt 1140
attttttatt tttnggggat agtggggggg ccttaagggg gaggaaggat ag 1192

```

<210> 281

<211> 1755

<212> DNA

<213> Homo sapiens

<400> 281

```

aaattacagg aacggagtaa gaacgtaaga aatcgcaaag cacgtgaacg tatgggaatc 60
tactgttctt tggcccttct cccgaccgt agccctgctc tgctacgact gcgtgggtga 120
agtcgtctat aaaaactcat ctctgcgctc ctcttcgcca cattcgcttc ctgctttcgg 180
tgtgtctgtt gtgtcttgtt gggggcaccg cagtcgccgt gaagatggcg tctaccagcc 240
gtttggatgc tcttccaaga gtcacatgtc caaaccatcc agatgcgatt ttagtgagg 300
actacagagc cggatgatatg atctgtcctg aatgtggctt ggttgtaggt gaccggggtta 360
ttgatgtggg atctgaatgg cgaactttca gcaatgacaa agcaacaaaa gatccatctc 420
gagttggaga ttctcagaat cctcttctga gtgatggaga tttgtctacc atgattggca 480
agggcacagg agctgcaagt tttgacgaat ttggcaattc taagtaccag aatcgagaa 540
caatgagcag ttctgatcgg gcaatgatga atgcattcaa agaaatcact accatggcag 600
acagaatcaa tctacctcga aatatagttg atcgaacaaa taattttattc aagcaagtat 660
atgaacagaa gagcctgaag ggaagagcta atgatgctat agcttctgct tgtctctata 720
ttgcctgtag acaagaaggg gttcctagga catttaaaga aatatgtgcc gtatcacgaa 780
tttctaagaa agaaattggt cgggtgttta aactattttt gaaagcgcta gaaaccagt 840
tggatttgat tacaactggg gacttcatgt ccaggttctg ttccaacctt tgtcttccta 900
aacaagtaca gatggcagct acacatatag cccgtaaagc tgtggaattg gacttggttc 960
ctgggaggag ccccatctct gtggcagcgg cagctattta catggcctca caggcatcag 1020
ctgaaaagag gacccaaaaa gaaattggag atattgctgg tgttgctgat gttacaatca 1080
gacagtccta tagactgatc tatcctcgag ccccatatct gtttcctaca gacttcaa 1140
ttgacacccc agtgacaaa ctaccacagc tataaattga ggcagctaac gtcaaattct 1200
tgaatacaaa actttgcctg ttgtacatag cctatacaaa atgctgggtt gagcctttca 1260
tgaggaaaaa caaaagacat ggtacgcatt ccagggtgta atactattgc ttggcattct 1320
gtatgtatat actagtgaat catatttaat gatttaaatt tcttatcaaa tttcttttgt 1380

```



```

agcaatctag gaaactgtat tttggaagat atttgaaatt atgtaattct tgaataaaaac 1440
atTTTTcaaa actcaagttt ttgttatatg ttacatgtaa cttatgatac ataattacaa 1500
ataatgcaaa tcattgcagc taataaagct gatagacttt atttccatta cttatatata 1560
catagttttt tattttaata aatttatgga aagagcaaaa gcttttgaga accattgtta 1620
acatcaacat catagtttcc agtttgaaag gatgtgtatg tgagatttat tatgtatatt 1680
attaaacaag aagtgatgag cttggccttg aaaggcacca gcttgagaga cattaataatg 1740
ttctaagtaa aaaaa 1755

```

<210> 282

<211> 1093

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (90)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (970)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1081)

<223> n equals a,t,g, or c

<400> 282

```

cccttcttgg ttgcgcgccc gttcctcgcg ttcttggcyt gccagcccc gagggccgca 60
gcttcgcgag atccgggccc gctcgcccn tcccatggaa ggtgctcggg tcttcggggc 120
actgggtccc atcgggtccct cctcacctgg gctcaccctc ggggggtctg ccgtgagcga 180
gcaccggctc agcaacaagc tgctggcttg gagcgcgctc ctcgagtggc aggagaaagc 240
cagaccctac tctgactcca ctgcaaagct gaagcggacc ctgccctgcc aagcctacgt 300
gaaccaaggc gagaacctgg agaccgacca gtggccgcag aagctgatca tgcagctgat 360
ccctcagcag ctgctgacca ccctgggccc cctgttccgg aactcccagt tggcacagt 420
ccacttcacc aacagagact gcgactcgct caaggggctc tgccgcatca tgggcaacgg 480
cttcgcgggc tgcatgctgt tccccacat cccccctgt gaggtgcgcg tgctcatgct 540
cctgtactcg tccaagaaga agatcttcat gggcctcatc ccctacgacc agagcggctt 600
cgtcagtgcc atccggcagg tcatcaccac ccgcaagcag gcagtgggac ctggtggtgt 660
caactcaggc ccagtccaga tcgtcaacaa caagtttctg gcatggagtg gtgtcatgga 720
gtggcaggag ccaggcctg agcccaacag tcggtccaag aggtggctgc catcccacgt 780
ctacgtgaac cagggggaga tcctgaggac cgagcagtgg ccaaggaagc tgtacatgca 840
gctatcccc cagcagctgc tgaccacct agtgccgctg ttccggaact cgcgcctggt 900
ccagttccac ttcaccaagg acctggagac actgaagagc ctgtgccgga tcatggacaa 960
tggtctcgcn ggctgcgtgc acttttccca caaagcatcg tgtgagatcc gcgtgcttat 1020
gctcctgtac tcttcagaga agaaaatytt cattggcytc atcccccatg accagggcaa 1080
ntttgttcaa agg 1093

```

<210> 283

<211> 1556

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1324)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1339)

<223> n equals a,t,g, or c

<400> 283

```
ggcacgaggg gaatcctcca cgtggctgtc ccagcacgag gaacccatgc acagtgtctgc 60
agaaactgga cagttccgga cagcggwcaa ggcaaggawg tcatgcttga aggccagggc 120
agacttgaga gaggtcacat tccactgtca gcaccagcct cagcaactgt gcagagacct 180
acaggcccac agccagtggc ctgtccgcat tgccctgtgc ccacaagcaa cagtccacag 240
cccttggtgg cttctgttcc ttgtcccctc ggcttctctt cgcagccatc aggactaggt 300
ttgtgcagga aggtgatgcc cactggaact ctcttcacac ctggcagctt catggatgtt 360
gtatctgaac taaggaccag aggtgccag atgtttctgg ctcttcacgt gtccttcagg 420
acagaacaga agcacaaga ctcagccaag agttctcttt attccctttg atcctcccc 480
aaggtgaggg cttaggcagc tgtagaacc caggaaagaa cggaatccag gcaatctgtt 540
tagagacccc ccactccaaa tttatccttt tcctttcctt cccctaagat gtttccaggg 600
ccctctggtg ccacactgtt cctcttcctt ccacttgggg gtggggaaat ccttcctgcg 660
aggtcagggc atttctctac aaagtggcct gaatgaggcc aggccctgag aaggagccac 720
cagctggagg aaaggggctc caagccttgc ttttaacacc cctgcaaac ccccaccctc 780
ccaagatgtt cacaaaaggt gagaaattca ggtacgaaac catcaatgga caacttgaaa 840
atgcatgttc ctcaggccta tgcagttccc agagactctt gacaccggtc tctgctgagg 900
ctcccagcct cagtttcccc cacagcagca cgggcccac tgtgctgtc ttcaggtccc 960
cacagccctg cctttggttc ctggacattt ggtattctgc cctccactct ggtactatca 1020
gagtagggca ggctctggat taaagctttt agccggtcta aagctacttt cttcaaagac 1080
agtgggagga gaggttgctg gggcatcagc cctgcttccc acagctcctt aggcaagagc 1140
ttaccagca gctgtgagca ccaagctggc cagcagaggc tgggggagga ctttcaggcc 1200
aacacctgcc ccagctgagt ttgggactgt ccttaagcga ggtctggaga gaggcagcgg 1260
cagcagccgg acggggagca ggccaagccg gaaccacagc ctgcaggtgt ggggtgtttg 1320
catntgctga gatgccagng caccagcaag ggggatatgt tggcagtgat gtctggcttc 1380
ggaggggtaca gtctggctc ccagacaagg ggcggggaga aactgtgtc cttccagagg 1440
ctgtaccaca ctcccactgc tgtcaccctt cactgaagcc tcgagcctcg gtagggcctc 1500
cctcttctcc ctgtcctatc aagacttaca gcaaggtccc aggttgacag ggagac 1556
```

<210> 284

<211> 1029

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (828)

<223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (958)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (972)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (976)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (987)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1007)
 <223> n equals a,t,g, or c

<400> 284
 tgatggtgtg gtccaatgag cgggtcatgg gttgggtgtc cgggctgggc tgaaggaatt 60
 tgccacgaac ctcacggaga gcggggtaca cggggcactg ctgcacctgg acgagacctt 120
 cgactactcc gacctggcct tgctcctgca gateccacg cagaatgcac aggcccgga 180
 gcttctggag aaggaattca gcaaccttat ctccttaggc acagacaggc ggctggacga 240
 ggacagcgcc aagtctttca gccgctcccc atcctggcgg aagatgttcc gggagaagga 300
 cctccgaggc gtaactcccg actcagctga gatgttgccc cccaactttc gttcggctgc 360
 agcgggagcc ctgggctctc cggggctccc tctccgcaag ctgcagccag aaggccagac 420
 ttctgggagt tcccgggcag acggcgtttc ggtccggacc tattcctgct agtgcaggcc 480
 tccaggtgac ctactcggga cggagaatc ttcccagggc tgggctgttc cctctcctgc 540
 ccggactgtg gcctcgccgg ggagagcggg cgggggagct cgcgccgagg actggaccat 600
 ctgtacagac cagcgggagt gcgcgcgccc gcctcgaca gggccggggc tggaccaaac 660
 cacatgaact ggactgagag ggggaagaag cggggaggaa gaaatcccgc cccaaacgtc 720
 cgctttcctt ttctctactt tgtaatttat tgatcagttt ctgttgggag acgggtgtcc 780
 tttaccgcg ggaagggggc ggggcttccc tcccgggccg catgcggnga gargctgtc 840
 cctccccttt ttctgccc gtcgcggggc ccaagtcttt cttctctcgt ccgaaaggag 900
 gggaggggga ctctgtctac aagcctcgcc ccctgtgcca ctcagtcga cccgccngt 960
 tccggttcgc cnggtncccc cgggttnatc tggcgggcgg ggtcccnttg tgccttcccc 1020
 ccgtgtttt 1029

<210> 285
 <211> 1583
 <212> DNA
 <213> Homo sapiens

<220>

<221> misc feature
 <222> (1411)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1531)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (1557)
 <223> n equals a,t,g, or c

<400> 285
 tgtgtctgcg ttgagggtgt tgagggtcca cgctgtgaca agtgcacgcg aggggtactcg 60
 ggggtcttcc ctgactgcac accctgccac cagtgccttg ctctctggga tgtgatcatt 120
 gccgagctga ccaacaggac acacagattc ctggagaaaag ccaaggcctt gaagatcagt 180
 ggtgtgatcg ggccttaccg tgagactgtg gactcgggtg agaggaaagt cagcgagata 240
 aaagacatcc tggcgagag cccgcagca gagccactga aaaacattgg gaatctcttt 300
 gaggaagcag agaaactgat taaagatgtt acagaaatga tggctcaagt agaagtgaaa 360
 ttatctgaca caacttccca aagcaacagc acagccaaag aactggattc tctacagaca 420
 gaagccgaaa gcctagacaa cactgtgaaa gaacttgctg aacaactgga atttatcaaa 480
 aactcagata ttcggggtgc cttggatagc attaccaagt atttccagat gtctcttgag 540
 gcagaggaga ggggtgaatgc ctccaccaca gaacccaaca gcactgtgga gcagtcagcc 600
 ctcatgagag acagagtaga agacgtgatg atggagcgag aatcccagtt caaggaaaaa 660
 caagaggagc aggtcgcct ccttgatgaa ctggcaggca agctacaaag cctagacctt 720
 tcagccgstg ccgaaatgac ctgtggaaca ccccgagggg cytcctgtty cgagaytgaa 780
 tgtggcgggc caaactgcag aactgacgaa ggagagagga agtgtggggg gcctggctgt 840
 ggtggtcttg ttactgttgc acacaacgcc tggcagaaaag ccatggactt ggaccaagat 900
 gtcctgagtg ccctggctga agtggaaacag ctctccaaga tggctctctga agcaaaactg 960
 agggcagatg agggcaaaaca aagtgtctgaa gacattctgt tgaagacaaa tgctaccaa 1020
 gaaaaaatgg acaagagcaa tgaggagctg agaaatctaa tcaagcaaat cagaaacttt 1080
 ttgaccagg atagtgtctga tttggacagc attgaagcag ttgctaataga agtattgaaa 1140
 atggagatgc ctacaccccc acagcagtta cagaacttga cagaagatat acgtgaacga 1200
 gttgaaagcc tttctcaagt agaggttatt cttcagcata gtgctgctga cattgccaga 1260
 gctgagatgt tgtagaaga agctaaaaga gcaagcaaaa gtgcaacaga tgtagaagtc 1320
 actgcagata tggtaaagga agctctggaa gaagcagaaa agggccagggt cgcagcagag 1380
 aaggcaatta acaagcaga tgaagacatt ncaaggaacc cagaacctgy taacttccsa 1440
 ttggagtctt kgaacagca gctttctgga ggaaaccttg ttcaacgcgt tcccagggca 1500
 tccagcgagt ttagagagga tgtgggaaga nctttaagcg gaaagctggc ccaaaanccc 1560
 gggggaggcc gaattttttg gaa 1583

<210> 286
 <211> 1177
 <212> DNA
 <213> Homo sapiens

<400> 286
 gctcaaaatg tttaccaatg ttttaagatg tctttatcaa gcaaccgtat cagcagagaa 60
 aagayatctc aaaatgttta ccaatgtttt aagaagcttt gtgtgatatt cttccaaatg 120

```
tagttacca atataatat gtagaaaagg ctaaatacata cttaatgagc aaattgaagt 180
aagcttttaa agtatatttc tcttttggtg aaaggccaat ggagacattg tgaatttaag 240
tgaacatttg cctcaagatg ttaactataa acacactgca tacaattttc ttctgaataa 300
caaatgaatg cttattgctg catgatgtaa gcaaaagtca ttatttttcc tattcatttg 360
aaataagtta tggcttaaaa tgcttttgga gtttatttct caaaattaaa atctgggtcac 420
atgagcttta gtttggtttc tggtttaaaa aataaaaagg tttctcttaa cagtatttcc 480
agtgacaatg caaggtaagt atatcaaagg aatcaacag ttgtgcttgg gggctttttg 540
ttatgggata ttgatttctt gtttttttcc cgtaacattg tctgctgcaa tttaaataaa 600
aattacgaca ttttaagata ttcatagac aaaccaaaca aaaatatatg tttttacttt 660
aaagtgaatg tttttctctt cagctgatct aaaaatgaaa gcaaratatc ttatgtagaa 720
atattttgat aatattttta cagtgaagct tcccatgttt ttatgtctta agtttctttg 780
ctgcgtttat gtaggttgca caagaacttt tactcacttg taattgtgcc tcagactttt 840
tgaaagtcta ctttctaaat tgccccgacg atctagattc tacatgttac cattgggtta 900
ttctgtgctt ttctgtattt aaaacttttg ctgtactaag caaatgcaag gttataattt 960
agctaatagt agtttacaga caattctgat gattatgatt tcatttggtt taactaagct 1020
gtactagttc atttcataag gaaatgatac tgtagacaaa tgtaaataaa gcctgtgagt 1080
caagcatcaa gtggtgtttg ttagaaataa actagagatt tttaaaaaaa aaaaaaaaaa 1140
aaaaaaaaaa aaaaaaaaaa acccccgggg ggggcc 1177
```

<210> 287

<211> 506

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (394)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (470)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (481)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (494)

<223> n equals a,t,g, or c

<400> 287

```
acaagtagct gcagtagcgt acggaattac agggtagacc caagcgtacg taaaatttaa 60
aaacaaagga ctatttaaaa atacagttta ttaacaaacg tgaactactt tctgttacat 120
taggtgttcc ctagtgtttc ttaatttctt tttagaaagt gtatttttat tagtattttt 180
ccggtgaaca gaagatttgt ttggatttaa acatttacta agacagtacc tattaggaaa 240
accaaataat gcaaatggtc aattcgattt taatttctca aaagatactc tgttatccag 300
aagattaaaa tgctacatt gagtgcttaa aaaaaaaaaa acmactgtga tratktgagc 360
```

223

agaatggcca gtaagttaag ccttttttga tccnggtaat ccagggtatc catttaccat 420
ggaaagggga ttccccaac tactggccca gaggaagtt tggtttttn aaatttaagg 480
nggggaaatt ttanccctat aaaatt 506

<210> 288

<211> 948

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (3)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (926)

<223> n equals a,t,g, or c

<400> 288

ttnggccgag cttgggtcat ggcggcgccg ggcgcgctgc tggatgatggg cgtgagcggc 60
tcggggaaat ccaccgtggg cgccctgctg gcatctgagc tgggatggaa attctatgat 120
gctgatgatt atcaccggga ggaaaatcga aggaagatgg gaaaaggcat accgctcaat 180
gaccaggacc ggattccatg gctctgtaac ttgcatgaca ttttactaag agatgtagcc 240
tcgggacagc gtgtggttct agcctgttca gccctgaaga aaacgtacag agacatatta 300
acacaaggaa aagatggtgt agctctgaag tgtgaggagt cgggaaagga agcaaagcag 360
gctgagatgc agctcctggt ggtccatctg agcgggtcgt ttgaggtcat ctctggacgc 420
ttactcaaaa gagagggaca ttttatgccc cctgaattat tgcagtcca gtttgagact 480
ctggagcccc cagcagctcc agaaaacttt atccaaataa gtgtggacaa aaatgtttca 540
gagataattg ctacaattat ggaaacccta aaaatgaaat gacaatgatt ttgtatcagt 600
ggtccaaaca gaactaagca taaatcattg tgccatccca aacctcgttc cagccgcctt 660
gcccatacta gattctaaat gtttctaaag gcaaacccca atgtgtcaag acagacttgt 720
ttaggtgtaa ttttaggaat tatgctggtt catcaggaag cagaggggga gttttaaaag 780
tcaagcttaa attgaagttt aaattcatct ataaccaaat caaatgatca gaggaaattc 840
tgtaatcaat gctggaaatc gttacattgt ttagaacatt cttgctcatg cctgtatttg 900
cacaaataaa tgaaacttcg ctgtcnaaaa aaaaaaaaaa aaaaaaaaaa 948

<210> 289

<211> 1034

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (376)

<223> n equals a,t,g, or c

<400> 289

ggcacgagct cgtgccggtt tgacctggag catgggtcct ggaccaaatt gccccgcagc 60
ctgcgcatga gggataagag ggcagacttt gtggttgggt cccttggggg ccacattgtg 120
gccattgggg gccttggaaa ccagccatgt cctttgggct ctgtggagag ctttagcctt 180

```

gcacggcggc gctgggaggc attgcctgcc atgcccactg cccgctgctc ctgctctagt 240
ctgcaggctg ggccccggct gtttgttatt gggggtgtgg cccagggccc cagtcaagcc 300
gtggaggcac tgtgtctgcg tgatggggtc tgaaggcttg gtgggagctg tccactggag 360
cagctcattg ccagangmrg ctatttctat ggctcctttt gctgctgagg aactcactg 420
tggtctcttg ggatgagaga ggcatggggg tgagcacttg aaactgccc ttggggcctt 480
gggttagggg agcctttgtc tttagtgcag gacacacata tgcttacacc tacctttatc 540
accattcgtt catgaatcat gcctagctcc atccttgccc tgggacctac taggccttcc 600
atccaactgg gaaatgggga gaagcaaagc tggcctcatg ctcttcaggg tcagttccta 660
tctggagtgt accaggccta cccagttgc cattcctgaa aaatctcagc tgccaggctg 720
cctttagggt ccctgtagac ccaggagagt tgagagggtg ggggacacag agagaataga 780
gaggatgtgg gaactgccag agggccggag cgcaggagtt caagtggagg aatgctggct 840
ttgagccctc tacactgctg gttgtatgac cttggacaag tcacttcacc tctctgtgcc 900
tcagcatcct catctataaa tgggatctc tgaaccttc ctaccctacc tacctcacag 960
ggctgttgtg aggaccagg gagtttgat gtggaagtaa aagtgtgct aaaacctaa 1020
aaaaaaaaa aaaa 1034

```

<210> 290

<211> 3091

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (24)

<223> n equals a,t,g, or c

<400> 290

```

cccagtagct cgtgccgctc gtgnccgcca actctcagtt tgatcttaaa gtctgaataa 60
taaaacaaat cccagcagta atacatttct taaacctcac agtgcagatg atactttttc 120
attctgatcc tgtgtttgca aaaatataca catgtatata atagttcctc actttttatt 180
catttgtttt cctattacct gtagtaata tattagttag tacatggaat ttatagcatc 240
agctaccccc aggaacagca cctgacaggc gggggatttt ttttcaagtt gttctacatt 300
tgcataaatt atttctatta ttattcatgt atgttattta tttctgaatc aactagttcc 360
tgtgaaagta caactgcaag gcagaaagtg ttaggatttt gcatctaagt ttcattatca 420
tggattgat ggacctaaag aaataaaaaat tagactaagc ccccaaataa gctgcatgca 480
tttgtaacay gattagtaga ttgaaatata tagatgtagt attttggtta tctaggtgtt 540
ttatcattat gtaaaggaat taaagtaaag gactttgtag ttgtttttat taaatatgca 600
tatagtagag tgcaaaaata tagcaaaaat aaaaactaaa ggtagaaaag cattttagat 660
atgccttaat ttagaaactg tgccagggtg cctcgggaat agatgccagg cagagaccag 720
tgccctgggtg gtgcctcctc ttgtctgccc tcatgaagaa gcttccctca cgtgatgtag 780
tgccctcgta ggtgtcatgt ggagtgtgga gaacaggcag tactgttgag aggagagcag 840
tgtgagagtt tttctgtaga agcagaactg tcagcttgtg ccttgaggct tccagaacgt 900
gtcagatgga gaagtccaag tttccatgct tcaggcaact tagctgtgta cagaagcaat 960
ccagtgtggt aataaaaagc aaggattgcc tgtataattt attataaaat aaaagggatt 1020
ttaacaacca acaattccca acacctcaaa agcttggtgc attttttggt atttgagggt 1080
tttatctgaa ggttaaaggg caagtgtttg gtatagaaga gcagtatgtg ttaagaaaag 1140
aaaaatattg gttcgcgtag agtgcaaat agaactagaa agttttatag gattatcatt 1200
ttgagatgtg ttaaagtagg ttttcaactg aaaatgtatt agtgtttctg cattgccata 1260
gggcctggtt aaaactttct cttaggtttc aggaagactg tcacatacag taagcttttt 1320
tccttctgac ttataataga aaatgttttg aaagtaaaaa aaaaaaaatc taatttgga 1380
atttgacttg ttagtttctg tgtttgaaat catggttcta gaaatgtaga aattgtgtat 1440

```

```

atcagatact catctaggct gtgtgaacca gccaagatg accaacaatcc ccacacctct 1500
acatctctgt cccctgtatc tcttcctttc taccactaaa gtgttccctg ctaccatcct 1560
ggcttgtcca catggtgctc tccatcttcc tccacatcat ggaccacagg tgtgcctgtc 1620
taggcctggc caccactccc aacttgacct agccacattc atctagagat ggttcctgat 1680
gctgggcaca gactgtgctc atggcaccca ttagaaatgc ctctagcatc tttgtatgca 1740
tcttgatttt taaaccaagt cattgtacag agcattcagt tttggctgtg gtaccaagag 1800
aaaaactaat caagaatata aaccacattc caggctgctg ttttctctcc atctacaggc 1860
cacactttta ctgtatttct tcatacttga aattcattct gctattttca tatcagggtta 1920
cagacttata aggggtgcatg ttccttaaag gtgcataatt attcttatcc cgtttgctta 1980
tattgctaca gaatgctctg ttttggtgct ttgagttctg cagacccaag aagcagtgtg 2040
gaaattcact gcctgggaca cagtcttata agaattgttg caggtgactt tgtatcagat 2100
gttgcttctc ttttctctgt acacagattg agagttacca cagtggcctg tcgggtccac 2160
cctgtgggtg cagcacagct ctctgaaagc aagaaccttc ctacctattc taacgttttt 2220
gccctctaag aaaaatggcc tcaggtatgg tatagacata gcaagagggg aagggtgtc 2280
tcactctagc aaccatccct ccattacaca cagaaagccc tcttgaagca aaagaagaag 2340
aaagaaagaa agcttatctc taaggctact gtcttcagaa tgctctgagc tgaatgctct 2400
tgctcctttc ccaagaggca gatgaaaata tagccagttt atctataccc ttcctatctg 2460
aggaggagaa tagaaaagta gggtaaataat gtaacgtaaa atatgtcatt caaggaccac 2520
caaaacttta agtaccctat cattaaaaat ctggttttaa aagtagctca agtaagggat 2580
gctttgtgac ccagggtttc tgaagtcaga tagccattct tacctgccc ttactctgac 2640
ttattgggaa agggagaact gcagtgggtg ttctgttgca gtggcaaagg taacatgtca 2700
gaaaattcag aggggttgcac accaataatc ctttggaac tggatgtctt actgggtgct 2760
agaatgaaaa tgtaggtatt tattgtcaga tgatgaagtt cattgttttt ttcaaaattg 2820
gtgttgaaat atcactgtcc aatgtgttca cttatgtgaa agctaaattg aatgaggcaa 2880
aaagagcaaa tagtttgtat atttgaata cttttgtat ttcttacaat aaaaatattg 2940
gtagcaaaata aaaataataa aaacaataac tttaaactgc tttctggaga tgaattactc 3000
tcctggctat tttctttttt actttaatgt aaaatgagta taactgtagt gagtaaaatt 3060
cattaaattc caagtttttag caaaaaaaaaa a 3091

```

<210> 291

<211> 518

<212> DNA

<213> Homo sapiens

<400> 291

```

aggcatgaag aagagtgtgg gtactgtttc ctccacagcg gccagagtca ggggtggggag 60
tgagtccagt tgagggggaa acagtaccag cactgcgggg catgaagaag agtgtggggc 120
tgccggtggc cgtgcagtgt gtggctctgc cctggcaaga agagtgtgtg ctgcggttca 180
tgccggagggt ggagcgactg atgacccctg aaagcagtc atcctgatgg ctctggctcc 240
agaggacctg agactcacac tctctgcagc ccagcctagt cagggcacag ctgccctgct 300
gccacagcaa ggaaatgtcc tgcatggggc agaggcttcc gtgtcctctc ccccaacccc 360
ctgcaagaag cgccgactcc ctgagtctgg acctccatcc ctgctctggt cccctctctt 420
cgtcctgatc cctccacccc catgtggcag cccatgggta tgacatagcc aaggcccaac 480
taacagtcaa gaaacaaaaa aaaaaaaaaa aaaaattc 518

```

<210> 292

<211> 498

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature
 <222> (447)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (468)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (475)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (479)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (482)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (489)
 <223> n equals a,t,g, or c

<400> 292
 ctcgtgccga attcggcacg agcaacgtcg ctccagctgc tcttgacgac tccacagata 60
 ccccgaaagcc atggcaagca agggccttgca ggacctgaag caacagggtgg aggggaccgc 120
 ccaggaaagcc gtgtcagcgg ccggagcggc agctcagcaa gtggtggacc aggccacaga 180
 ggcgggggcag aaagccatgg accagctggc caagaccacc caggaaacca tcgacaagac 240
 tgctaaccag gcctctgaca ccttctcttg gatcgggaaa aaattcggcc tcctgaaatg 300
 acagcaggga gacttggttc ggccctcctga aatgayagca gggagacttg ggtgaccccc 360
 cttccaggcg ccatctagca cagcctggcc ctgatctccg ggcagccacc acctcctcgg 420
 tctgccccct cattaaaatt cacgttncca aaaaaaaaaa raaagggngg ccgcntagng 480
 gntccaagnt tagttacg 498

<210> 293
 <211> 469
 <212> DNA
 <213> Homo sapiens

<400> 293
 ggccagccct ggggcgcctt aaaaaccgga gctggcgctt ggcaacgcca ctctgggcag 60
 gatccaacgt cgctccagct gctcttgacg actccacaga taccocgaag ccatggcaag 120
 caaggccttg caggacctga agcaacaggt ggaggggacc gccaggaag ccgccatgga 180
 ccagctggcc aagaccaccc aggaaccat cgacaagact gctaaccagg cctctgacac 240
 cttctctggg atygggaaaa aattcggcct cctgaaatga cagcagggag acttgggtcg 300

227

```
gcctcctgaa atgayagcag ggagacttgg gtgaccccc ttccaggcgc catctagcac 360
agcctggccc tgatctccgg gcagccacca cctcctcggg ctgccccctc attaaaattc 420
acgttcccaa aaaaaaaaaa aaaaaaaaaa gggggggccc gtccccatt 469
```

```
<210> 294
<211> 668
<212> DNA
<213> Homo sapiens
```

```
<220>
<221> misc feature
<222> (568)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (650)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (652)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (658)
<223> n equals a,t,g, or c
```

```
<400> 294
gcacagaagg gggaggccaa agtgggtggg agcgcgtgct gttgggagtt gcttggaggt 60
tggcggcgcg gggctgaagg ctagcaaacc gagcgatcat gtcgcacaaa caaatctact 120
attcggacaa atacgacgac gaggagtgtt agtatcgaca tgatcatgctg cccaaggaca 180
tagccaaagct ggtccctaaa acccatctga tgtctgaatc tgaatggagg aatcttggcg 240
ttcagcagag tcagggatgg gtccattata tgatccatga accagaacct cacatcttgc 300
tgttccggcg ccactaccc aagaaaccaa agaaatgaag ctggcaagct acttttcagc 360
ctcaagcttt acacagctgt ccttacttcc taacatcttt ctgataacat tattatgttg 420
ccttcttggt tctcactttg atatttaaaa gatgttcaat aactgtttg aatgtgctgg 480
taactgcttt gcttcttgag tagagccacc accaccatag ccagccaga tgagtgtctc 540
gtggaccaca gcctaagctg agtgtgancc cagaagccac gatgtgctct gtatccagac 600
acacttgcca gatggaggaa gcatctgatt gagacatggg gtacaggtcn gnaatgcngt 660
ttgttttc 668
```

```
<210> 295
<211> 1400
<212> DNA
<213> Homo sapiens
```

```
<400> 295
gctttgtcct ccagtggctg gtaggcagtg gctgggaggc agcggcccaa ttagtgctgt 60
gcggcccgtg gcgaggcgag gtccggggag cgagcgagca agcaaggcgg gaggggtggc 120
```

cggagctgcg gcggctggca caggaggagg agcccgggcg ggcgaggggc ggccggagag 180
cgccaggggcc tgagctgccg gagcggcgcc tgtgagtga gtcagaaaagc aggcgcccgc 240
gcgctagccg tggcaggagc agcccgacg ccgcgctctc tccctgggcg acctgcagtt 300
tgcaatatga ctttgaggga attctcggct ggagagcaga agaccgaaag gatggataag 360
gtgggggatg ccctggagga agtgctcagc aaagccctga gtcagcgcac gatcactgtc 420
ggggtgtacg aagcggccaa gctgctcaac gtcgaccccg ataacgtggt gttgtgcctg 480
ytggcggcg acgaggacga cgacagagat gtggctctgc agatccactt caccctgatc 540
caggcgtttt gctgcgagaa cgacatcaac atcctgcgcg tcacaacccg ggccggctgg 600
cggastcctg ctcttgagga ccgacgctgg ccccgcgcg agcgagggcg ccgagcagcc 660
cccgacctg cactgcgtgt ggtgacgaat ccacattcat ctcaatggaa ggatcctgcc 720
ttaagtcaac ttatttgttt ttgccgggaa agtcgctaca tggatcaatg ggttccagt 780
attaatctcc ctgaacggtg atggcatctg aatgaaaata actgaaccaa attgcactga 840
agtttttgaa atacctttgt agttactcaa gcagttactc cctacactga tgcaaggatt 900
acagaaactg atgccaaagg gctgagtga ttcaactaca tgttctgggg gcccgagat 960
agatgacttt gcagatggaa agaggtgaaa atgaagaagg aagctgtgtt gaaacagaaa 1020
aataagtcaa aaggaacaaa aattacaaa aaccatgcag gaaggaaaac tatgtattaa 1080
tttagaatgg ttgagttaca ttaaaataaa ccaaatatgt taaagttaa gtgtgcagcc 1140
atagtttggg tatttttggg ttatatgcc tcaagtaaaa gaaaagccga aagggttaat 1200
catatttgaa aaccatattt tattgtattt tgatgagata ttaaattctc aaagttttat 1260
tataaattct actaagtat tttatgacat gaaaagtat ttatgctata aattttttga 1320
aacacaatac ctacaataaa ctggtatgaa taattgcatc aaaaaaaaaa aagggggggc 1380
gctcgcgatc tagaaactag 1400

<210> 296

<211> 960

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (599)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (859)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (933)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (950)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (951)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (959)

<223> n equals a,t,g, or c

<400> 296

```
gtcagcccgga gcccggtgcr ggcctttaag ggccgggggc gtgtagcggg cccgccccct 60
ccccgcggcg cccgcagtcg gttaagtgcg agccccggcg cagggggccg atctggcccg 120
gggcccggcg cgggtgtgga gcggcgcgtc atgtacacca tcaccaagg gcccagcaag 180
ctggtcgcgc agcgcgcgac aggtcccgac cagcagcagg tggagggccg gctcggcgag 240
ctcctgaaat gccggcagcc cgcgcgcgcg acctcgcagc ccccgccggc gcagccyttt 300
gcgcascgce gggaccctgg cccctgtcga gtccagggcc aaggcttgtg ttcaatcgtg 360
tgaatggccg gcgggcccc tccacgtccc catccttcga ggggacccag gagacctaca 420
cagtgcccca cgaggagaat gtccgctttg tgtccgaagc ctggcagcag gtgcaacagc 480
agctggatgg tgcccagcc ggtgagggcg ggccaaggcc tgtgcagtac gtggagagga 540
cccccaatcc ccggtgcag aactttgtgc ccattgacct agacgagtgg tggcgccanc 600
agttcctggc gagaatcacc agctgttcct agtggctgct gggagggggc gctgctacac 660
ggccgacctg tcgccaggag agaagcatgg cgccctgccc acccactgcg cctggctggg 720
tgccggccac acctgaagtg ccagcatttg gacttttgca ccttttttc ccttgggccc 780
gtgtgtccaa ccaagctgcc atgccaaggg ccgaaccgtg ctgacctcag cctgctcac 840
tgtgccagg gaccagcgna cccccctggg gctggcaggg aggagctcca ggctaataaa 900
gtggagaaac tgtcaaaaaa aaaaaaaaaa aanctcgagg gggggcccg ncccaattnc 960
```

<210> 297

<211> 657

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (29)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (86)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (88)

<223> n equals a,t,g, or c

<400> 297

```
caaaagctgg agctccaccg cgggtgacgnc cgctctagaa ctagtggatc ccccgggctg 60
caggaattcg gcacgagctc gtgcengncc tttggagcag agaggaggca atggccacca 120
tggaagaaca ggtgatctgc gccctgggtc tgggtgtccat gctggccctc ggcaccctgg 180
ccgaggccca gacagagacg tgtacagtgg cccccctga aagacagaat tgtggttttc 240
ctgggtgtcac gccctcccag tgtgcaaata agggctgctg tttcgacgac accgttcgtg 300
```

```

gggtcccctg gtgcttctat cctaatacca tcgacgtccc tccagaagag gagtgtgaat 360
tttagacact tctgcaggga tctgcctgca tcctgacgcg gtgccgtccc cagcacggtg 420
attagtccca gagctcggtt gccacctcca ccggacacct cagacacgct tctgcagctg 480
tgctctcggt cacaacacag attgactgct ctgactttga ctactcaaaa ttggcctaaa 540
aattaaaaga gatcgatatt aaaaaaaaaa gaaaaggaaa aaaaagggcg gccgtctaag 600
aggatccaag cttacgtaac gcgtgcatgc gaaggtcata gctcttctat agtgtca 657

```

<210> 298

<211> 892

<212> DNA

<213> Homo sapiens

<400> 298

```

gcagccaggc tctcaggga ggtccatgct gcttggcctg agttcaaggc tttctgcctg 60
tagcctggac tcccgtggac ccccggtggc aggtggcttc cccgtggcat ctccacaccg 120
cctctgcctg cccctgtgga ctgatgctat cgcgcaccgt cccacgacct caccctgagc 180
tcctgaagcc ggggtctgag cctgcatcac ctctggcctc tcattcccca ctctcctgag 240
agcagtggtc acagcgccg gccgctctgc tgagaaggca gagaggcagg ctcaggcctc 300
agcgtggaca gcagggataa ggggcacgaa ggacggggac tcggcccctt cagaattcct 360
caggactctc aggtgcagct ttgccaaaaa ggaacttttc atgtcatgca gttgagggga 420
cttagtctca atcccaggct cctcttgact ctgggcagct ttaatcagggt tgggcagcct 480
ctgctacagc gtggagtggg atggctctct tccctcagcc acgccgcttg tgaggacaga 540
ggtgggggag tgggaagtgg gaagtcacca gagaacagga gagggatttg agggcgcgac 600
cccagcgctc tccacggacc agccagaggg actggagcca ggtgtgcatg ggttcaaggc 660
cctggccctg cccagcctct gtcttgggag ctcagcccca gggttcggtc gtcagcagtt 720
tccaagaac aagatgtgat ggcatctgct gctgaaaccc tgatgaggac caggccccct 780
gcaccgctgt cagcctgagg aattaaagct ttggtgctgg gaaragcaaa aaaaaaaaaa 840
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaac tc 892

```

<210> 299

<211> 1624

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1621)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1623)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1624)

<223> n equals a,t,g, or c

<400> 299

```

cccggtgctg aggaattcgg cacgagagag gaggtccac aggtcctgct cctgggctac 60

```

```

cgagtccccc gatggtggtta tacattaaat atccaggatg gagaagccac atgctactca 120
ccgaaggagg aaattatcac agcagcctgg gcacgcgttg tgagctctcc tgtgaccggg 180
gctttcgatt gattggaagg aggtcgggtgc aatgcctgcc aagccgtcgt tggctcggaa 240
ctgcctactg caggcagatg agatgccacg cactaccatt catcactagt ggcacttaca 300
cctgcacaaa tggagtgttt cttgactctc gctgtgacta cagctgttcc agtggctacc 360
acctggaagg tgatcgcagc cgaatctgca tgggaagatgg gagatggagt ggaggcgagc 420
ctgtatgtgt agacatagat ccccccaaga tccgctgtcc ccactcacgt gagaagatgg 480
cagagccaga gaaattgact gctcgagtat actgggaccc accgttggtg aaagattctg 540
ctgatggtac catcaccagg gtgacacttc gggggccctga gcctggctct cactttccc 600
aaggagagca tgtgatcgtg tacactgcct atgaccgagc ctacaaccgg gccagctgca 660
agttcattgt gaaagtacaa gtgagacgct gcccaactct gaaacctccg cagcacggct 720
acctcacctg cacctcagcg ggggacaact atggtgccac ctgtgaatac cactgtgatg 780
gcggttatga tcgccagggg acacctcccc gggctctgtca gtccagccgc cagtggctcag 840
gttcaccacc aatctgtgtt cctatgaaga ttaacgtcaa cgtcaactca gctgctggtc 900
tcttgatca attctatgag aaacagcgac tcctcatcat ctcagctcct gatccttcca 960
accgatatta taaaatgcag atctctatgc tacagcaatc cacctgtgga ctggatttgc 1020
ggcatgtgac catcattgaa ctggtgggac agccacctca ggaggtgggg cgcacccggg 1080
agcaacagct gtcagccaac atcatcgagg agctcaggca atttcagcgc ctcactcgct 1140
cctacttcaa catggtgttg attgacaagc agggatttga ccgagaccgc tacatggaac 1200
ctgtcacccc cgaggaaatc ttcacattca ttgatgacta cctactgagc aatcaggagt 1260
tgacccaagcg tcgggagcaa agggacatat gcgagtgaac ttgagccagg gcatgggttaa 1320
agtcaaggga aaagctctc tagttagctg aaactgggac ctaataaaaag gaggaaatgt 1380
tttccccagc ttctagggac aggactctga ggtgggtgag tttgacaaat cctgcagtgt 1440
ttccaggcat ccttttagga ctgtgtaata gtttccctag aagctaggta gggactgagg 1500
acaggccttg ggcagtgggt tgggggtaga agttcttcct ttcctaaccg gggccctgc 1560
ccagctctcc aaagtctttc agaaaagtaa atcctaaatt cagtgatgaa aaaaaaaaaa 1620
nann 1624

```

<210> 300

<211> 1969

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (13)

<223> n equals a,t,g, or c

<400> 300

```

ttaatttagg tgnacactat agaagggtac gcctgcaggt taccggatcc ggaattccc 60
ggatccggag ccgccgaag ccggtgccgc agccccctgc gcccccggtg cccccgacat 120
gtccttcgcg aaagtgggtcc ggcagagcaa attccggcat gtgttcgggc agccgggtcaa 180
gaacgaccag tgctatgagg acattcgcgt gtcccggtt acctgggaca gcaccttctg 240
cgccgtcaac cccaagttcc tggcgggtgat tgtggaggcc agtggagggg gtgcctttct 300
ggtgctcccc ctaagcaaga cgggccgcat tgacaaggcc taccgacgg tgtgtgggca 360
cacgggacct gtcttgaca tcgactggtg tcctcacaac gacgaatcat agccagcggy 420
tcggaggact gcacggtcat ggtgtggcag atcccagaga acgggctgac ctccccgctg 480
acagagccgg tgggtgtact ggaggggcac accaagcgag tgggcatcat cgcctggcac 540
cccacggccc gaaactgtgt gctcagtgca ggctgcgaca acgtggtact catctggaat 600
gtgggcacag cggaggagct gtaccgcctg gacagcctgc accctgacct catctacaat 660
gtcagctgga accacaatgg cagcctgttt tgctcagcat gcaaggacaa gagcgtgcgc 720

```

```
atcatcgacc cccgtcgggg caccctggtg gcagagcggg agaaggctca tgagggggcc 780
cgggcccatgc gggccatctt cctggcagat ggcaagggtg tcaccacagg cttcagccga 840
atgagcgagc ggcagctggc gctctgggac ccagaaaacc tcgaggaacc catggccctg 900
caggaactgg actcgagcaa cggggccctg ctgcccttct acgaccccga caccagtgtg 960
gtctacgtct gcggcaaggg tgaactccagc atccggtact ttgagatcac agaggagcct 1020
ccctacatcc acttcctgaa cacgttcacc agcaaggagc cgcagcgggg tatgggcagc 1080
atgcccaagc ggggcctgga ggtcagcaag tgcgagatcg cccggttcta caaactgcat 1140
gagcgcaagt gtgagcccat cgtcatgact gtgccaagaa agtcggacct cttccaggat 1200
gatctgtacc ccgacacagc cgggcccag gacgccctgg aggctgagga gtgggtgagc 1260
gggcgggatg ccgacccgat cctcatctca ctgcgggagg cctacgtgcc cagcaagcag 1320
cgggaccta gaatcagccg gcgcaacgtg ttgtctgaca gccggcccgc catggccccg 1380
ggctcctccc acctaggggc cccgcctcc accaccactg ctgctgatgc cacccccagc 1440
ggcagcctgg ccagagccgg ggaggctggg aagctggagg aggtgatgca ggagctgcgg 1500
gccctgaggg cgctggtcaa ggagcagggc gaccgcatct gccgcctgga ggagcagctg 1560
ggcgcgatgg agaacgggga tgcgtagggc cacagccaca cgccaccttc atctcctccg 1620
ccgccccctt cccactcagc ttctgccagc gggctgcacc gggctagctg gctgcccaga 1680
gcctctgagg cagcgcaggg gtcagttccc acccccacc gtcccaggcc caggccgaag 1740
ccagcgccca gcttccctca ctgttccctg ggaggatgtc tacgcccagg cgagctcctc 1800
gacctctgag ggaccatctc cccgaccact gccagccct ctgctccctc cccagaggag 1860
gcgggagggt gggctctata ttttcattcc aaataaaatt ctctttctaa aaaaaaaaaa 1920
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaacgga cgtcgtggg 1969
```

<210> 301

<211> 1882

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (22)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (223)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1840)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1849)

<223> n equals a,t,g, or c

<400> 301

```
ggagctctcg gcctcggtt tngacgacgg caacttctcg ctgctcatcc gcgcggtgga 60
ggagacggac gcggggctgt acacctgcaa cctgcacat cactactgcc acctctacga 120
gagcctggcc gtccgcctgg aggtcaccga cggccccccg gcacccccgc ctactgggac 180
```

```

ggcgagaagg aggtgctggc ggtggcgcgcg ggcacccgct ytnctgacct gcgtgaaccg 240
cgggcacgtg tggaccgacc ggcacgtgga ggaggctcaa caggtggtgc actgggaccg 300
gcagccgccc ggggtcccgc acgaccgcbc ggaccgcctg ctggacctct acgcgtcggc 360
gagcgccgcg ctacgggccc ctttttctgc cgamcgcggt gctgtgggcg cggatgcctt 420
taagcgcggt gacttctcac tgcgtatcga gccgctggag gtcgccgacg agggcaccta 480
ctctgccac ctgcaccacc attactggcg cgcgccaca acgtcatcaa tgtcatcgct 540
cccagagacc gagcccactt cttccagcag ctgggctacg tgctggccac gctgctgctc 600
ttcatcctgc tactggtcac tgtcctcctg gccgcccga ggccgcggag gctacgaata 660
ctcggaccag aagtccggaa agtcaaagg gaaggatgtt aacttgccg agttcgctgt 720
ggctgcaggg gaccagatgc tttacaggag tgaggacatc cagctagatt acaaaaacaa 780
catcctgaag gagaggcg agctggccca cagcccctg cctgccaagt acatcgacct 840
agacaaaggg ttccggaagg agaactgcaa ataggaggc cctgggctcc tggctgggccc 900
agcagctgca cctctcctgt ctgtgctcct cggggcatct cctgatgctc cggggctcac 960
cccccttcca gcggtggtc ccgctttcct ggaatttggt ctgggcgtat gcagaggccg 1020
cctccacacc cctccccag gggttggtg gcagcatagc cccacccctt gcggcctttg 1080
ctcacgggtg gccctgccc cccctggcac aacaaaaatc cactgatgc ccatcatgcc 1140
ctcagaccct tctgggtctt gccgctgggg gcctgaagac attcctggag gacactccca 1200
tcagaacctg gcagcccaa aactggggtc agcctcaggg caggagtccc actcctccag 1260
ggctctgctc gtccggggct gggagatgtt cctggaggag gacactccca tcagaacttg 1320
gcagccttga agtgggggtc agcctcggca ggagtccac tcctcctggg gtgctgcctg 1380
ccaccaagag ctccccacc tgtaccacca tgtgggactc caggcaccat ctgttctccc 1440
cagggacctg ctgacttgaa tgccagccct tgtcctctg tgttgctttg ggccaccttg 1500
ggctgcaccc cctgcccttt ctctgcccc tccctaccct agccttgctc tcagccacct 1560
tgatagtcac tgggtccct gtgacttctg accctgacac ccctcccttg gactctgctt 1620
gggtggagt ctagggttg ggctacattt ggcttctgta ctggctgagg acaggggagg 1680
gagtgaagtt ggttggggt ggctgtgtt gccactctca gcacccaca tttgcatctg 1740
ctggtggacc tgccaccatc acaataaagt ccccatctga tttttaaaaa aaaaaaaaaa 1800
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaana aaaaaaatg 1860
ggaataaaaa taacaaaaaa at 1882

```

<210> 302

<211> 2804

<212> DNA

<213> Homo sapiens

<400> 302

```

gattccaacg catcccagtc cctgtgtgac atcatccgcc tgagccggga gcagatgatc 60
caagtccagg acagcccaga gcctgaccaa ctgctggcca ccctggagaa gcaggagacg 120
attgagcagc tcttaagcaa catgttcgag ggggagcaga gccagtctgt catcgtcagt 180
gggatccagg tgctgctgac mctgctggag ccaggaggc cgaggtccga gtccgtgacc 240
gtgaacagct tcttcagcag tgtggatggg cagctggagc tcctggccca gggggccttg 300
aaagcactgt gtccagtgtg ggcgccttgc acgcctacg cccgcggctc agctgcttcc 360
accagctcct gctggagcct cccaagctgg agccgctaca gatgacatgg ggcatgctgg 420
ctccgctctg ggcaaacacg ggctgcacgt ggtcaagctc ctggccagtg ccctgagcgc 480
caatgatgca gycctgacgc acgagctcct ggcaactggc gtgcccaca ccatgctgga 540
cctctctctc cattatgtct tcaacaactt cttgcatgcc caagtagagg gatgcgtgag 600
caccatgctg agcttggggc cacytcctga cagcagccct gagacgccc tccaaaaccc 660
tgtttgtaaa catctgctgc agcatgccgc ctgggtggag ggatcctgac gtcctgggag 720
gagaacgacc gtgtacagtg tgccggaggc cctcggaag gctacatggg tcacctgaca 780
agagtggccg ktgccctggt gcagaacacg gagaaggggc ccaatgcaga gcagctgcgg 840
cagctgctga aggagctgcc cagcagacag caggagcagt ggggaagcctt cgtatcgggg 900

```



```
cccctggcgg agaccaacaa gaagaacatg gtggacctgg tgaacaccca ccacctacac 960
tcctccagtg acgatgagga cgaccggctc aaggagttca acttcctga ggaggctgtg 1020
ctgcagcagg ccttcatgga cttccagatg cagcgcata cctctgcctt cattgaccac 1080
ttcggcttca atgatgagga gtttggggag caggaggaga gtgtgaacgc accttttgac 1140
aagacagcca acatcacctt ctccctcaat gctgacgatg agaaccccaa cgccaacctt 1200
cttgagatat gctacaagga ccgcatccag cagtttgatg atgatgagga agaggaggac 1260
gaggaagagg cccagggtc aggggagtct gatggagaag atggcgctg gcagggcagc 1320
cagctggcca ggggggcccg tctgggccag ccacctggtg tccggagtgg aggcagcaca 1380
gacagtgagg acgaagaaga ggaggacgag gagggaggag aagacgagga gggcattggc 1440
tgtgcagccc gtggaggggc caccctctg tcctacccca gccctggccc tcagcctcca 1500
ggccccagct ggacagccac ctttgaccca gtgcctacag atgccccgac cagccccga 1560
gtctccgggg aggaagagct gcacactggg cctccagccc cacaggggcc cctcagtgtg 1620
ccccagggcc tccccactca gagcctggcc agcctcctg cccgtgacgc cctgcagctc 1680
aggtctcagg accccacacc cccctcagca cctcaggaag ccacagaagg cagcaaagtc 1740
acggagccct cagccccttg ccaggccttg gttagcatcg gggaccttca ggccaccttc 1800
cacgggatcc gttctgcccc cagctcctcg gacagtgcaa ccagagacce ctctacctct 1860
gtcccagcct ccggggccca ccagccccc cagaccacag aaggggagaa gagcccagag 1920
cccttggggc ttcccaaaag ccagagtgcc caggccctca cgcctcctcc gatacccaat 1980
ggctctgccc cggaagggcc tgcattccca ggctcccaat agctgcctgg tgcggcasgg 2040
cggccaaatc ttccgtcctc ccgtggatct cccggggtgg gggcagggcg ggtcccacga 2100
tgcccccat tgccctcatc accctgacac cccacattc tctcctctgg acccccagga 2160
ggctggtgcc agggagacag gccaaccca ccccatctg cactgagaag agaagttttg 2220
gagcgttgcc tcctagaata aagatacaga gagtcaaata gagagaatgg agagagagaa 2280
acatatatta tatattatat agagagaggg aggagagcga gagagagtga ggacaccgaa 2340
ctgggctggc ggctccaaag cacagccttc cctgttccgt cccagcggga gctggtgta 2400
ggggtcccaa ggttgccacc cacgtgcccc gctgtccac gctgcagcgc agacggccac 2460
gcccacaccc ggccttttag ctcagggtcca ccatggggga cggcccagcg tgggtggggg 2520
tgccagaggg tcccagtggt gggccgtgcc tttgcccaga cctgcactt tcaaccaggc 2580
cagtccggct ctggggagca gggccctccc cggcaacagc cccaggggcc ttgaggtct 2640
gaggtcccag ccctgttgcc aagtgaacct gtccccagct ccctcctccc aggctggtgt 2700
gagtgtgcgt gcgtttgtgc cgagcttcta tttcatattg caaatataaa taaaggaagg 2760
cagtttacga aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aacc 2804
```

<210> 303

<211> 3859

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (581)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (889)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (890)

<223> n equals a,t,g, or c

<400> 303

```
aagactgcat agggctcgcc gtggggktct tcaggtgatg gcagaggagc caggcacaac 60
agggaaagtaa gaggaagca tatgtggagg catggaagga tggaagaaac agcctggaga 120
tcctgggaaa ctgctaccag ttcagagagg ggtgtggggg gttggtggca ctatgtggcg 180
cgtctgtgcg cgacgggctc agaatgtagc cccatggggc ggactcgagg ctcggtggac 240
ggccttgcaag gaggtacccg gaactccacg agtgacctcg cgatctggcc cggctcccg 300
tcgtcgcaac agcgtgacta cagggtatgg cgggggtccg gcactgtgcg gctggacccc 360
cagttctggg gccacgccgc ggaaccgctt actgctgcag cttttggggg cggccggccg 420
ccgctattac agtcttcccc cgcatcagaa ggttccattg ctttctcttt cccccacaat 480
gcaggcaggc amcatagccc gttgggaaaa aaaagagggg gacaaaatca atgaaggtga 540
cctaattgca gaggttgaaa ctgataaagc cactgttgga ntttgagagc ctggaagagt 600
gttatatggc aaagatactt gttgctgaag gtaccaggga tgttcccatc ggagcgatca 660
tctgtatcac agttggcaag cctgaggata ttgagggcct taaaaattat aactggatt 720
cctcagcagc acctaccca caagcggccc cagcaccaac cctgctgcc actgcttcgc 780
cacctacacc ttctgctcag gtcctggta gctcatatcc cctcacatg caggtaactc 840
ttcctgccct ctctccacc atgacctgg gcacagttca gagatggggn aaaaaagtgg 900
gtgagaagct aagtgaaggr gacttactgg cagagataga aactgacaaa gccactatag 960
gttttgaaat acaggaagaa ggtatctgg caaaaatcct ggtccctgaa ggcacaagag 1020
atgtccctct aggaacccca ctctgtatca ttgtagaaaa agaggcagat atatcagcat 1080
ttgctgacta taggccaacc gaagtaacag atttaaaacc acaagygcc aacctaccc 1140
caccgccggt ggccgctgtt cctccaactc cccagccttt agctcctaca ccttcagcac 1200
cctgccagc tactcctgct ggaccaaagg gaagggtgtt tgttagccct cttgcaaaga 1260
agttggcagt agagaaagg attgatctta cacaagtaaa agggacagga ccagatggta 1320
gaatcaccaa gaaggatatc gactcttttg tgcttagtaa agttgctcct gctccggcag 1380
ctgttggtgc tcccacagg cctggaatgg caccagttcc tacaggtgtc ttcacagata 1440
tcccaatcag caacattcgt cgggttattg cacagcgatt aatgcaatca aagcaaacca 1500
tacctcatta ttacctttct atcratgtaa atatgggaga agttttgttg gtacggaaag 1560
aacttaataa gatattagaa gggagaagca aaatttctgt caatgacttc atcataaaag 1620
cttcagcttt ggcatgttta aaagtcccg aagcaaatc ttcttgatg gacacagtta 1680
taagacaaaa tcatgttgtt gatgtcagtg ttgcggtcag tactcctgca ggactcatca 1740
cacctattgt gttaaatgca catataaaag gagtggaaac cattgcta at gatgttgttt 1800
ctttagcaac caaagcaaga gagggtaaac tacagccaca tgaattccag ggtggcactt 1860
ttacgatctc caatttagga atgtttggaa ttaagaattt ctctgctatt attaaccac 1920
ctcaagcatg tattttggca attggtgctt cagaggataa actggtccct gcagataatg 1980
aaaaaggggt tgatgtggct agcatgatgt ctgttacact cagttgtgat caccgggtgg 2040
tggtggagc agttggagcc cagtggcttg ctgagtttag aaagtacctt gaaaaacct 2100
tcactatgtt gttgtaacta actcaagaat ttctaaactc tcccaggtca cactgattca 2160
ttcttaacaa gatatttata tgtattaaa cagggtggtt tttttatttt aaccagttat 2220
ttttattatt gactctgtcc agataagtta ttataatgg gcattactga attttataaa 2280
tgccgattac acccaaatat tgtgcacatt taataatcag acaccagatt tttagctctg 2340
tactccta atagggacat gtatgtggcc ttgcctagcc ctttgggtgat aagtacttcc 2400
tctaggaaat gtcgatagg tagaattgtg gttccctaaa gacaagtaca taaaggtgac 2460
cctgatgaaa ccttgaagtt ctgaaattta actgcctaaa atgttctcct tagatgtgag 2520
agaaagagaa atcaggaaaa ttattctctt tgggggaagg gcttgaattg aagctttact 2580
ttagaattta gccctgggtt gaaattttcc attacatgat cttggtttat catcgatggg 2640
aagggtagaa aacttcaagg aaaataagt aaattttaaa agtcagcatt ttcttagacc 2700
tcttcagctg attgtttatt ttctatgaa ttctacaca tggttattcc cccctacttg 2760
agataatcta aatataaacc agctacttga tgtaactgar aatttgtgtg gatatttatt 2820
taaacaaatg tgtaattttg agtacagaat tcaacagtta cctccaaaaa agaaacattg 2880
```

```

ttaatataat ttaacagaag ttgtgaaact aaaattttct aagattaact ggtagttcat 2940
tgtaaatgaa cataatgaac agaatttatg actccactgt ggaaaatgct atcaaataac 3000
taaggaatat atatggaata agtgtagata tgtaaaatat tgttactaga gttagatatg 3060
tgccaaagtc catttatccc aaatcctgtc tgaaaaggag gggtagattg gtaaacattt 3120
tggagtgtct aaaaatgcc aaaaacaaat ggtaatttct actttgataa agtaaaaaag 3180
ttaaatgtgt gtaaaaaagt gttctgtgtc cttctactcc agcatcgtct catgtaaaat 3240
aagaaagccc taaaatacta ttggagagaa aaaattaact aggttgctac tttatttgcc 3300
taaatacttt tttctatttt gttagatttt gcctttcttt tggaaggag gaggcgatat 3360
tctgsattat aaaaatgaat tgggaacatt atcacaattc cagactttct attaatattt 3420
atgtgtttta ataaacgttt gaaattattt atgactactt aaaatgaatc tgaccagtgc 3480
ttccyggat atgtaatatg tggagttagc ccctgaaatt tgctttaagt gtttcagtgt 3540
tgaatctgtt tctaaatatt cattattaca tggtagacaa gtgacactcc atatatcca 3600
cacagacttt taccttgctg tattattatg aaaacaatac attaatgtga tttttcagta 3660
attagtaatt ttaggttgaa gattatccaa aagaaacaag cttatcaca gggaccatca 3720
tcaatatgat ccaaatctgg ttcaaacatt caaaacttca aagataattc atctttcgct 3780
aatgcttggt gttctgttgt tcccttgaaa aaaaataaaa acagttgcct tctaataaac 3840
attgttgagt taaaaatta 3859

```

<210> 304

<211> 3378

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (29)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1350)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (3361)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (3365)

<223> n equals a,t,g, or c

<400> 304

```

tagttctaga tcgcgagcgg ccgacgagnc ggcgctgtgc ctgcagtgcg atatgaacga 60
ctgctatagc cgctgcgga ggctgggtgcc caccatcccg cccaacaaga aagtcagcaa 120
agtgagatc ctgcagcacg ttatcgacta catcctggac ctgcagctgg cgctggagac 180
gcacccggcc ctgctgaggc agccaccacc gcccgcgccg ccacaccacc cggccgggac 240
ctgtccagcc gcgcgcgcgc ggaccccgct cactgcgctc aacaccgacc cggccggcgc 300
ggtagaacaag cagggcgaca gcattctgtg ccgctgagcc gcgctgtcca ggtgtgcggc 360
cgcctgagcc cgagccagga gcactagaga gggaggggga agagcagaag ttagagaaaa 420

```

```

aaagccaccg gagaaaggaa aaaacatcgg ccaacctaga aacgttttca ttcgtcattc 480
caagagagag agaggaaaga aaaatacaac tttcattctt tctttgcacg ttcataaaca 540
ttctacatac gtattctctt ttgtctcttc atttataact gctgtgaatt gtacatttct 600
gtgttttttg gaggtgcagt taaactttta agcttaagtg tgacaggact gataaataga 660
agatcaagag tagatccgac tttagaagcc tactttgtga ccaaggagct caatttttgt 720
tttgaagctt tactaatcta ccagagcatt gtagatattt tttttttaca tctattgttt 780
aaaatagatg attataacgg ggcagagaac tttcttttct ctgcaagaat gttacatatt 840
gtatagataa atgagtgaca tttcatacca tgtatatata gagatgttct ataagtgtga 900
gaaagtatat gctttaatag atactgtaat tataagatat ttttaattaa atattttttt 960
gtaaatatta tgtgtgtgtt tttttttaat ctatgggaat atttcttttg gaaaatcatt 1020
tttcagctca attacagagc tcttgatatc ttgaatgtct tttctgtttg gcctggctct 1080
taatttgctt ttgttttgcc cagtatagac tcggaagtaa cagttatagc tagtggctct 1140
gcatgattgc atgagatgtt taatcacaaa ttaaacttgt tctgagtcga ttcaaagtgt 1200
tttttttaaa ttagatttga aatcttttga tttgaagcat acatgttgaa artacacctt 1260
atcagttttt aagtacaggg ttttatagtg taatatatac agagtaagtg tttgtttttg 1320
tttttcaact gaggtcaaaa tggattctgn aatgattttg catatgggat gaggaaatgc 1380
ttgatcctt aaggagtta cgaatctgc tgttttatca aagtgaaaaa aaattgctta 1440
ttactcttca ttttactata aagcttaatg tcactaagtt tcatgtctgt acagattatt 1500
taaatcatgg aaatgaaaaa aatgttctct gcttgctacc aaaggacaaa ctcttgga 1560
tgaacacttt ctgctttcct tcctccaaag aattaatagg caacagtggg agaaaaaaa 1620
ggcataatgg caaatccttc aagcagggat aaaagtcgat cttcaaacat taacttaagc 1680
agacaaaaaa ttctgatgac cgcactctaga ttattttttt ataaaaatga ttttactat 1740
agctatgtta cgctaagcta ctgtccaatc tcttgatgag tgtaactttt acatgtgaat 1800
attaaagtag atttctctgt cttgtactgt gatttctggg ctcatcttct taaaacctta 1860
ctcatttttc ttttaaggct cttttttctc cttaagggaag gtaatatatt ctagggttaga 1920
taggactatc aggttttgtg aacattatgc atttaatgtt atgggtactt tacacacaag 1980
ttagatggaa tttttagagt gaaagaatta agtaggattt aattgggtgc tttgtaaata 2040
gtcaactgtg tgtataacgt ggtctgtttg atttttaaaa ggaaaggatt tgtttcagat 2100
tatacaagaa taaaagtatt atagacccaa gggacttctt atgagggtcaa attcagatat 2160
ttatatgaat atgaaatacc atggtcccta gtagtcagtt gaagtggcaa tgtctaaaca 2220
gaaatgaaca aaactaatgc tagcagggtta aaatcaatca aaatgtttta aaattgattc 2280
tgtcctcagc atgttayttc ctcagctctg ataatttact ggtcttgagt attttgagaa 2340
tttgatgttg aacgttataa agtcaaagaa ctgcttggtt agatgagggt tatttttatt 2400
tttgatatta ttcattcttg tcacacatca agaagaaac actagagtgc tgctggaatt 2460
ccaaatctga agaattctaa cgactgcatt ctttgttatt aaaaaggga caatccttcc 2520
tttttatttg gcagtttaat ttcagtagga agcatgtcac atgtgcactg ttggttagaa 2580
ttatgcatct gtcatgcctg actgctgaac cctacctaag ctttttgcg cagtttaaaa 2640
cttatactgg tggactgtga acctcaaaac aaatgggtat ttttgggttt tgaggataga 2700
tgttactcct taaagtttgt atttggggca tgaaaaacta ctgaaagaag aaaagtgcta 2760
cagatactac atttcaaaga gttggcattt tccctttggc cactcaagca gcatttgatg 2820
tatctaaaga aacaaagtca ttgtttattt tttaaaaaat tatatgcagt tgtacaagat 2880
actacattcc attgaaatgt tggctatgtc ctaaccaggc aaccagataa caaaaacatt 2940
ttgagtcttt tatctaggta gttctaatta ttcagctact tagtttaaca aaggaaaata 3000
tcctgacttc tctcatttca tttgtagact tttcattgta taggcacaa caaagagtca 3060
gactggttta aaactccaga aggaaaaaaa gtatcccaca cagtggatgt tgtttctaag 3120
aatgtacaa aatcctgaca tctcagacat ctcaatgtta aaggaagaaa aaaaatacct 3180
tttcatttca aagaactaat atactttgat attgtgtaaa cttactcaa gtttattgtc 3240
aagctttaac tgccttttta gaacttttta aaatttcgag ccacaaaatc tattgtatta 3300
gttgccctct ataacaataa atcttcactg agcaaaaaaa aaaaaaaaaa aaaaaaaaaa 3360
ncccnngggg gggggccc 3378

```

<210> 305
 <211> 1014
 <212> DNA
 <213> Homo sapiens

<400> 305
 cagcggcggc ggcggcgcca ggatgatcaa gctgttctcg ctgaagcagc agaagaagga 60
 ggaggagtgc gcgggcgcca ccaagggcag cagcaagaag gcgtcggcgg cgcagctgcg 120
 gatccagaag gacataaacg agctgaacct gcccaagacg tgtgatata gcttctcaga 180
 tccagacgac ctccctcaact tcaagctggg catctgtcct gatgagggct tctacaagag 240
 tgggaagttt gtgttcagtt ttaaggtggg ccagggttac ccgcatgac cccccaaggt 300
 gaagtgtgag acaatggtct atcaccccaa cattgacctc gagggcaacg tctgcctcaa 360
 catcctcaga gaggactgga agccagtcct tacgataaac tccataattt atggcctgca 420
 gtatctcttc ttggagccca accccgagga cccactgaac aaggaggccg cagaggtcct 480
 gcagaacaac cggcggtgtg ttgagcagaa cgtgcagcgc tccatgcggg gtggctacat 540
 cggctccacc tactttgagc gctgcctgaa atagggttgg cgcataacca ccccgccac 600
 ggccacaagc cctggcatcc cctgcaaata tttattgggg gccatgggta ggggtttggg 660
 gggcgccggg tgggggaatc ccctgccttg gcctgcctc cccttcctgc cacgtgcccc 720
 tagttatttt ttttttttta acaccatgtg attaaggtcg gcgctgcctc ccccgaccca 780
 ctcagcgtg ggaaatgaat tggcttgtct agccccctg ctgggtgctt gttcagcccc 840
 cactctgggc tgtggagtgg gtgggcaacg ggccctgggta gctgggcca ggcaaccac 900
 ccctccacct ctggaggtcc caccaggcta ttaagggga atgttactgc aaaaaaaaaa 960
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaa 1014

<210> 306
 <211> 2127
 <212> DNA
 <213> Homo sapiens

<400> 306
 ggaggaggcg ccgagctgac cgggcgacgc cgcgggaggt tctggaaacg ccsggagctg 60
 cgagtgtcca gacacttccc tctgtgacca tgaaactctg ggtgtctgca ttgctgatgg 120
 cctggtttgg tgtcctgagc tgtgtgcagg ccgaattctt cacctctatt gggcacatga 180
 ctgacctgat ttatgcagag aaagagctgg tgcagtctct gaaagagtac atccttgtgg 240
 aggaagccaa gctttccaag attaagagct gggccaacaa aatggaagcc ttgactagca 300
 agtcagctgc tgatgtgag ggctacctgg ctcacctgt gaatgcctac aaactggtga 360
 agcggctaaa cacagactgg cctgcgctgg aggacctgt cctgcaggac tcagctgcag 420
 gttttatcgc caacctctct gtgcagcggc agttcttccc cactgatgag gacgagatag 480
 gagctgcca agccctgatg agacttcagg acacatacag gctggacca ggcacaattt 540
 ccagagggga acttcagga accaagtacc aggcaatgct gagtgtggat gactgctttg 600
 ggatgggccc ctcgacctac aatgaagggg actattatca tacgggtgtg tggatggagc 660
 aggtgctaaa gcagcttgat gccggggagg aggccaccac aaccaagtca cagggtgctg 720
 actacctcag ctatgtgtc ttscagttgg gtgatctgca ccgtgcctg gagctcacc 780
 gccgcctgct ctcccttgac ccaagccacg aacgagctgg agggaatctg cggtaactttg 840
 agcagttatt ggaggaagag agagaaaaaa cgtaacaaa tcagacagaa gctgagctag 900
 caaccccaga aggcattctat gagaggcctg tggactacct gcctgagagg gatgtttacg 960
 agagcctctg tcgtggggag ggtgtcaaac tgacaccccg tagacagaag aggcttttct 1020
 gtaggtacca ccatggcaac agggccccac agctgctcat tgccccctc aaagaggagg 1080
 acgagtggga cagccgcac atcgtcaggt actacgatgt catgtctgat gaggaaatcg 1140
 agaggatcaa ggagatcgca aaacctaacc ttgcacgagc caccgttcgt gatcccaaga 1200
 caggagtcct cactgtcgcc agctaccggg tttccaaaag ctctggcta saggaagatg 1260

```

atgaccctgt tgtggcccg gtaaatcgtc ggatgcagca tatcacaggg ttaacagtar 1320
agactgcaka attgttacag gttgcaaatt atggagtggg aggacagtat gaaccgcact 1380
tcgacttctc taggaatgat gagcgagata ctttcaagca tttagggacg gggaaatcgtg 1440
tggtactttt cttaaactac atgagtgatg tagaagctgg tgggtgccacc gtcttccttg 1500
atctgggggc tgcaatttgg cctaagaagg gtacagctgt gttctggtac aacctcttgc 1560
ggagcgggag aaggtgacta ccgaacaaga catgctgcct gccctgtgct tgtgggctgc 1620
aagtgggtct ccaataagtg gttccatgaa cgaggacagg agttcttgag acctgtgga 1680
tcaacagaag ttgactgaca tccttttctg tccttcccct tcctggtcct tcagcccatg 1740
tcaacgtgac agacaccttt gtatgttctt ttgtatgttc ctatcaggct gatttttggg 1800
gaaatgaatg tttgtctgga gcagaggagg accatactag ggcgactcct gtgtgactga 1860
agtcccagcc cttccattca gcctgtgcca tcctggcccc caaggctagg atcaaagtgg 1920
ctgcagcaga gttagctgtc tagcgcttag caaggtgcct ttgtacctca ggtgttttag 1980
gtgtgagatg tttcagtgaa ccaaagttct gataccttgt ttacatgttt gtttttatgg 2040
catttctatc tattgtggct ttacaaaaaa ataaaatgtc cctaccagaa gccttaaaaa 2100
aaaaaaaaaa aaaaaaaaaa ggcggcc 2127

```

<210> 307

<211> 666

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (588)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (664)

<223> n equals a,t,g, or c

<400> 307

```

gtgccctgac tgcctgacgg ccgcgaggc ccttgcagga ccgctgggga ggatgttgtt 60
aacgtaaaga gccaggctga tgaggaaggt tcatgagtcc tttgggtata agcgggagtt 120
ggggcgggcg gaaggcagat gactctgaga agggcaagca ctttaacctt ttaagcccaa 180
ccagatgagt tgcctgcagt tttggaggcc ttcagagcat ttcactagac ctctgtctgt 240
gtcgggtccag tgtcttttagc caagctttga ttaaagatga cttccttgtt tgctcaagaa 300
attcgccttt ctaaaagaca tgaagaaata gtatcacaaa gattaatgtt acttcaacaa 360
atggagaata aattgggtga tcaacacaca gaaaaggcat ctcaactcca aactgttgag 420
actgctttta aaaggaacct tagtctttta aaggatatag aagcagcaga aaagtcacta 480
cagaccagga ttcaccact tccacggcct gaggtggttt ctcttgagac tcgttactgg 540
gcatcataga agaatatatt cccaaatggg aacagtttct tttaggngga gcaccatata 600
cttttgctgt tgaaaatcaa aatgaagcag aaaataccat tcaaatgag gcacagcgat 660
aacntc 666

```

<210> 308

<211> 2171

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature
<222> (1248)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (2162)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (2166)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (2168)
<223> n equals a,t,g, or c

<400> 308
cctcggcggt acccgagct tcaggcccca ccggggcgcg gagagtccca ggcccggccg 60
ggaccgggac ggcggtccgag tgccaatggc tagctctagg tgtcccgtc cccgcgggtg 120
ccgctgcctc cccggagctt ctctcgcatg gctggggaca gtactgctac ttctcgccga 180
ctgggtgctg ctccggaccg cgctgccccg catattctcc ctgctgggtg ccaccgcgct 240
gccactgctc cgggtctggg cgggtgggct gagccgctgg gccgtgctct ggctgggggc 300
ctgcggggtc ctcagggcaa cggttggctc caagagcgaa aacgcaggtg cccagggtg 360
gctggctgct ttgaagccat tagctgcggc actgggcttg gcctgccggg acttgccttg 420
tyccgagagc tgatctcatg gggagcccc gggtccgcgg atagcamcag gctactgcac 480
tggggaagtc accctaccgc cttcgttgc agttatgcag cggcactgcc cgcagcagcc 540
ctgtggcaca aactcgggag cctctgggtg cccggcggtc agggcggtc tggaaaccct 600
gtgcgtcggc ttctaggctg cctgggctcg gagacgcgcc gcctctcgct gttcctggtc 660
ctgggtggtc ttctctctct tggggagatg gccattccat tctttacggg ccgcctcact 720
gactggattc tacaagatgg ctcagccgat accttcactc gaaacttaac tctcatgtcc 780
attctcacca tagccagtgc agtgctggag ttcgtgggtg acgggatcta taacaacacc 840
atgggccacg tgcacagcca cttgcaggga gaggtgtttg gggctgtcct gcgccaggag 900
acggagtttt tccaacagaa ccagacaggt aacatcatgt ctogggtaac agaggacacg 960
tccaccctga gtgattctct gagtgagaat ctgagcttat ttctgtggtg cctggtgcga 1020
ggcctatgtc tcttggggat catgctctgg ggatcagtg cctcaccat ggtcaccctg 1080
atcaccctgc ctctgctttt cttctgccc aagaagggtg gaaaatggta ccagttgctg 1140
gaagtgcagg tgcgggaatc tctggcaaag tccagccagg tggccattga ggctctgtcg 1200
gccatgccta cagttcgaag ctttgccaac gaggagggcg aagccagnaa gtttagggaa 1260
aagctgcaag aaataaagac actcaaccag aaggaggctg tggcctatgc agtcaactcc 1320
tggaccacta gtatttcagg tatgctgctg aaagtgggaa tcctctacat tgggtgggag 1380
ctgggtgacca gtggggctgt aagcagtggg aacctgttca catttgctct ctaccagatg 1440
cagttcacc aggtgtgga ggtactgtc tccatctacc ccagagtaca gaaggctgtg 1500
ggctcctcag agaaaatatt tgagtacctg gaccgcaccc ctcgctgccc acccagtggg 1560
ctgttgactc ctttacactt ggagggcctt gtccagttcc aagatgtctc ctttgcctac 1620
ccaaaccgcc cagatgtctt agtgctacag gggctgacat tcaccctacg cctggcgag 1680
gtgacggcgc tgggtgggacc caatgggtct gggagagca cagtggctgc cctgctgcag 1740
aatctgtacc agcccaccg gggacagctg ctgttgatg ggaagcccct tcccaatat 1800
gagcaccgct acctgcacag gcaggtggct gcagtgggac aagagccaca ggtatttgga 1860

```

agaagtcttc aagaaaatat tgcctatggc ctgacccaga agccaactat ggaggaaatc 1920
acagctgctg cagtaaagtc tggggcccat agtttcatct ctggactccc tcagggctat 1980
gacacagagg tagacgaggc tgggagccag ctgtcagggg gtcagcgaca ggcagtggcg 2040
ttggcccag cATTgatccg gaaaccgtgt gtacttatcc tggatgatgc caccagtgcc 2100
ctggatgcaa acagccagtt acagggtggag cagctcctgt acgaaagccc tgagcggtag 2160
tnccgntnaa g 2171

```

<210> 309

<211> 6163

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (6132)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (6135)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (6158)

<223> n equals a,t,g, or c

<400> 309

```

aattcggcac gagcacagcc tgagcatact ctgtgcatta ggaagacctg agtgcatttc 60
ccaccattgt ctttccaca ttatgttgta gctggctggc tgtmaggcga ctacaagact 120
gagggstttg tgccttatag atstttgtat ccccatggc tgacacatag taggtactca 180
gtaaatgggt ttataatgaa tcagtgaaca ttttgcttct atagaagtgt accttctttg 240
tttctatatt atgaaacctc tttattagaa tttgtgattg attctgacag tgtatagatt 300
taccttatat tgtctttatt ttccatgagc tactaagtca ttagagatac tctgaagcat 360
agtttagtta ggaaatcact tcatattgat tgtattagaa ttatcttgga attgaagata 420
tatccctaga gcaggggacc ccaaccccca ggccatgggc cacacagcag gaagaggtag 480
gtggtgggcc attgaggagc ttcatctgta tttatggcta cttcccatca ctcgaattac 540
cacctgaact ccacctcttg tcagctcagt ggcagcatta gattctcata gragcacaaa 600
tcctattgtg aactctgcat gcaagggatc taggctatgc gtccttatg agaatctaata 660
gcctgatgac ctgaggtgka acagtttcat cctgaaacca cccttcaccc tgcagtctgt 720
ggaaaaattg tcttccacaa aactgggtccc tggtgccaaa aatgktgggg accgctgctc 780
tagagagagg tcatgatata ataccaacca aatggaaatr acaaatgttt tatgtcaagt 840
gttaattgca gaaataaata tttttttttt ttttttggtg gaaaacaaag aggcatactc 900
tgatttttat actctgtttt tgcaagggtc cttttctttg aatggagatt tgatgagcaa 960
gtggttagga tgcagggaga gctactatgg gtgatatttt ccttgtttag gagctgtgag 1020
ttaaaattgt atcctttctg gtttatctaa ggaaagtcaa atcttgacag aaaacatttt 1080
tccttggaag gtcaactctc agacattgta ttttggtttc cctcagtcct cataacttcc 1140
ttcttgctga acatatttta ttctcttttc agagaaggaa aataaaaagg attctaaaag 1200
tttgatgcat tggaaaaatt tccttgaggc atttagcaac acatagaaaa tgggctttga 1260
ttcttttcca aaacttttag ccatagggtc ttttatagac agggatagta aaatgaaaat 1320
tgagaaatat aagatgaaaa ggaatgrtaa aaatatcttt taggggggctt ttaattggtg 1380

```



```

atctgaaatc ttgggagaag ctgttctttt caggcctgag gtgctcttga ctgtcgcttg 1440
cgactgtgt accccgagca acattctaag ggtgtgcttt cgcttggct aactcctttg 1500
acctcattct tcatatagta gtctaggaaa aagttgcagg taatttaaac tgtctagtgg 1560
tacatagtaa ctraatttct attcctatga gaaatgagaa ttatttattt gccatcaaca 1620
cattttatac tttgcatctc caaatttatt gcggcgagac ttgtccattg tgaaagttag 1680
agaacattat gtttgtatca tttctttcat aaaacctcaa gagcattttt aagccctttt 1740
catcagaccc agtgaaaact aaggatagat gtttaaaaac tggaggcttc ctgataagga 1800
gaacacaatc caccattgtc atttaagtaa taagacagga aattgacctt gacgctttct 1860
tgtaaataag atttaacagg aacatctgca catctttttt ccttgtgcac tattgttta 1920
attgcagtgg attaatacag caagagtgcc acattataac taggcaatta tccattcttc 1980
aagacttagt tattgtcaca ctaattgatc gtttaaggca taagatggc tagcattagg 2040
aacatgtgaa gctaactctg tcaaaaagat caacaaatta atattgttgc tgatatttgc 2100
ataattggct gcaattattht aatgtttaat tgggttgatc aaatgagatt cagcaattca 2160
caagtgcatt aatataaaca gaactggtgg cacttaaaat gataatgatt aacttatatt 2220
gcatgttctc ttcttttcac ttttttcagt gtctacattt cagaccgagt ttgtcagctt 2280
ttttgaaaac acatcagtag aaaccaagat tttaaaatga agtgtcaaga cgaaggcaaa 2340
acctgagcag ttcttaaaaa gatttgctgt tagaaaattt ctttgtggca gtcatttatt 2400
aaggattcaa ctctgtatag accaaaagaa gagttgactt cagagatgtg ttccatgctc 2460
tctagcacag gaatgaataa atttataaca cctgctttag ctttgtttt caaaagcaca 2520
aaggaaaagt gaaagggaaa gagaaacaag tgactgagaa gtcttggtta ggaatcaggt 2580
tttttctacc tggtaaacat tctctattct tttctcaaaa gattgttga agaaaaaatg 2640
taagacaaaa aaaaaaaaaa aaacacagag cagaggcagg cagtagcaag aaagcagagc 2700
gtaacatcag ctatagtgta acatgcaatg tcagctctct tgaagacatg ggaaacctaa 2760
gttacacctt gggttaaaat tcttcaccgt attagttttg ttgcttcata aaatttacct 2820
aagcaagtgg tcttgcttgc ctcaaatcca agcagtcttg aacacttggg ggcaattaat 2880
gagtatatct tagtcaaaag aattgttggg gctttttatt aaagctgcag tttcagttct 2940
gcttttgggg aattgtgcta tgaaagcagc tgccaaaata agctcattta ttttcttcaa 3000
tcccactcag tgctcagtca ctatattctg tttccttttt tttttttcaa gttgcatatt 3060
tggtttcccc ttatgattgg gaaagatgaa ttttcagcag aaaacagtgt ttgttcactt 3120
tcaaagagtg atagtttcta aaacatttag agcaataaat attcatcaga ggtaccaagt 3180
aagccagcag aagagttaag ggtagagaa atcccttatt tcatgtcttg actctaaaat 3240
gatcaaagta cttttccttg taatgtggat ttcttcttat gcggatatgc aaaaacttca 3300
gttatcacga gtaatgctag caggttaattt tagtggacat tttataacaa ctgtcacttt 3360
gttttgccac atgtagagtt tgttcagcta tttccagat atctcccccac aaaaggaggc 3420
aaaggggtacc agcttttcaa tgagcattac ctattacttg gcaaagatga tgaagactct 3480
attaatagtt catttgataa atgttgacat aaccaacaat agagattagg aagttagttt 3540
taagaaatca atagcatata gacattaccc tcatggagtt tgtattctac tacttgaact 3600
gattgtagct ataaaagcat agttagatag ctgaatagtt agatcataag caaagaaggc 3660
cagaacacat ctcttatcaa gaaatcaatg aatagtttat ctcattttta aagcaacttt 3720
atccttcttt aattccttcc tttcttctag tgcaaaacta cttaataagg ttggtgttta 3780
ggttagtgtt cacaccattc ctcatctggt gtgaattacc ttctctttct ttactattta 3840
ctaccaacct agtcatgtg ttgactgaat tcttttcaaa caatgttgag ttatcatggt 3900
gcacctaata aattaacacc acagattaca gcatccttgc tgattttctc agcaaagcca 3960
gatttagtgg aataaaacaa agaaaatgat cctagagtga atttttctag aaaatatcta 4020
ttatgaacca tgctgtttta agtattagct tgaaggatg ggatccagct attcagaaaa 4080
taactttcat ataaccatga ttttgacacag tatgaggtct taaatgtgtg gaaagagata 4140
aattttttat cattaccaca aacctttttt aaagattcaa aggtggaaga aagtgattta 4200
ttttttctct tcagcataca tatataaaag acttgtcaga tgtttaattt ggggaggttg 4260
ataatgaaac atatcaacag agtatagtag ttatagtagt gtttgtgggt aaataatttc 4320
ctgggggtcag acatatataa acatatttgc ttcaaaatga taaaggcatg aaatcagctc 4380
taaaaattga aatgggggtg atggggggaga aaaagaagaa caaatttgaa gtgccctttc 4440

```

```

aaatctgctg gatacaagta ttgaagtttt aagtcattctt attctgtctg aaagtgtatt 4500
tttcatttcta caatagaccc aatcaacaag acgtataact tgagttgcat gatgttcagt 4560
ttatgtaatc tactgttggg atggttaagaa ttgatgtagg ctgtggtgta agaatgaatt 4620
aaaatatagt ttcactggct tttctctaca tatccactat cacaatggct aggtttcctg 4680
ttgctcactg ttggattctg gagaaaaatt taatgaaaga tgatatcaga ggaagaataa 4740
gtggaggtag agaagaaagg agtgatagag gaggggaaaa aaacaaaaca tttttttgtg 4800
ttatccaaag gagctttttc cttattctgt caagcattga gatcttcttc agctttcaat 4860
gtagttgcta aatacaata atgctactag gtagtgacta aatatagcaa acacttcac 4920
agatattaga attaggtcac actattgagg ttataatctg aaggttgtgt tacatagaaa 4980
ccactttaga ttattatcaa cttggactag gctttatttt ataatagcat agtaagtaat 5040
atctattgtg tcatttcttc aaccatttta ttctaagatc catgaagctt cttgaggcca 5100
aataaaataa taagtttaga caagaagtag attgtgactt tttttccctt agagatacta 5160
tttactatct cctatcctga tagtggaag gtttactgaa ttggaaattg gttgactatt 5220
agtttttaac taaaatgtgc aataacacat tgcagtttcc tcaaactagt ttcctatgat 5280
cattaaactc attctcaggg ttaagaaagg aatgtaaatt tctgcctcaa tttgtacttc 5340
atcaataagt ttttgaagag tgcagatttt tagtcaggtc ttaaaaaata actcacaat 5400
ctggatgcat ttctaaattc tgcaaatgtt tcctgggggtg acttaacaag gaataatccc 5460
acaatatacc tagctaccta atacatggag ctgggggtca acccactgtt tttaggatt 5520
tgcgcttact tgtggctgag gaaaaataag tagttcgagg aagtagtttt taaatgtgag 5580
cttatagata gaaacagaat atcaacttaa ttatgaaatt gttagaacct gttctctgt 5640
atctgaatct gattgcaatt actattgtac tgatagactc cagccattgc aagtctcaga 5700
tatcttagct gtgtagtgt tcttgaaatt ctttttaaga aaaattgagt agaaagaaat 5760
aaaccctttg taaatgaggc ttgcttttg tgaaagatca tccgcaggct atgttaaaag 5820
gatttttagct cactaaaagt gtaataatgg aaatgtggaa aatatcgtag gtaaaggaaa 5880
ctacctcatg ctctgaagg tttgtagaag cacaattaaa catctaaaat ggctttgtta 5940
caccagagcc atctggtgtg aagaactcta ttttgtatg ttgagagggc atggaataat 6000
tgtattttgc tggcaataga cacattcttt attatttgca gattcctcat caaatctgta 6060
attatgcaca gtttctgtta tcaataaaac aaaagaatcc tgaaaaaaaa aaaaaaaaaa 6120
aaggggggag cnetnaagat cccccaaggg gcccaacnta ccc 6163

```

<210> 310

<211> 2086

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1763)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1769)

<223> n equals a,t,g, or c

<400> 310

```

tcccgggtca agccacgcgt ccgcggmacg wgggtgcgga cgcccggtc cggcggtgga 60
cgccatggtg ctgtgcccgg tgattgggaa gctgctgcac aagcgcgtgg tgctggccag 120
cgctcccca cgccgtcaga gatcctcagc aacgcgggtc tcaggtttga ggtggtcccc 180
tccaagttta aagagaagct ggacaaagcc tccttcgcta ctccgtatgg gtacgccatg 240
gagaccgcca agcagaaggc cctggagggtg gcccaaccggc tgtaccagaa agacctgcgg 300

```

```

gcccccgacg tggtcattgg agcggacacg atcgtgacag tcgggggggct gattctggag 360
aagccggtgg acaagcagga cgcctacagg atgctgtccc ggttgagtgg gagagaacac 420
agcgtgttca caggtgtcgc gatcgtccac tgctccagca aagaccatca gctggacacc 480
agggtctcgg aattctacga ggaaacgaag gtgaagttct cggagctgtc cgaggagctg 540
ctctgggaat acgtccacag cggggagccc atggacaaag ctggcggcta cgggatccag 600
gccctgggcg gcatgtgggt ggagtcgcta cacggggact ttctgaacgt ggtgggattc 660
ccgctgaacc acttctgcaa gcagctgggt aagctctact acccgccccg yccggaggac 720
ctgcggcgga gtgtcaagca cgactccatc ccggccgcgg acaccttcga agacctcagt 780
gacgtggagg ggggcggctc ggagcccact cagagggacg cgggcagccg cgatgagaag 840
gccgaggcgg gagaggcggg acaggccacg gcagaggctg agtgtcacag gactcgggag 900
accctgcctc cgttcccagc acgcctcctg gagctgattg agggctttat gctatccaag 960
ggcctgctca ccgcttgcaa actgaagggtg ttcgatttgt taaaagatga agcaccaccag 1020
aaggctgcgg atattgccag caaagtggac gcctctgcgt gtggaatgga gaggcttctg 1080
gacatctgtg ctgccatggg gctcctggag aagacagagc aaggttacag taacacagag 1140
acagcgaacg tctacctggc atcggatggc gaatactctc tgcacggctt catcatgcac 1200
aataatgacc tcacatggaa cctctttaca tacctggagt ttgccatccg agagggaaca 1260
aaccagcacc acagggcggt ggggaagaag gcggaagatc tgttccagga tgcgtactac 1320
cagagcccgg agacgcggct gaggttcatg cgggccatgc acggcatgac gaagctgact 1380
gcgtgccagg tggccacggc cttcaatctg tcccgttct cctccgcctg cgactggga 1440
ggctgcaccg gtgactggc ccgagagctg gcccgtagt accctcgtat gcaggtgact 1500
gtgtttgacc tcccagacat tatcgagctg gccgccact tccaaccccc cgaccgcag 1560
cagtgcagat ccacttcgca gcaggtgact ttttcaggga cccctcccc agcgtgagc 1620
tgtacgtcct gtgccgcatc ctgcatgayt ggccagacga caaagtccac aagttactca 1680
gcagggctgc cgagagctgc aagccagggg ccggcctgct gctgggtggag acgctcctgg 1740
atgaggagaa gaggggtggc cangcgccnt gatgcagtca ctgaacatgc tgggtgcagac 1800
tgaaggcaag gagcggagcc tgggcgagta tcagtgttg ctggagctgc acggcttcca 1860
ccaggtgcag gtgggtgact tggggggtgt cctggatgcc atcttgcca ccaaagtggc 1920
cccctgaagc ccaggcagca tgttcattat agggatgtcc tccccaggc tgcaggtgga 1980
ccgcccgtgc cccaagtacc ataggacagt cacataggag cgtgtagtgc tgactgaata 2040
aagaaagcaa aagccaaaaa aaaaaaaaaa aaaaatttgg gggggg 2086

```

<210> 311

<211> 2163

<212> DNA

<213> Homo sapiens

<400> 311

```

gcggccgcag ctcttcacc agcttggtgg tgggcgtgtt cgtggctctac gtgggtgcaca 60
cctgctgggt catgtacggc atcgtctaca cccgcccgtg ctccggcgac gccaaactgca 120
tccagcccta cctggcgcgg cggcccaagc tgcagctgag cgtgtacacc acgacgagg 180
cccacctggg tgctgagaac aacatcgacc tggctcttga tgtggaagac tttgatgtg 240
agtccaaatt tgaaggaga gttaattgtt ctgtaccaa gaaaacgaga aacaatggga 300
cgctgtatgc ctacatcttc ctccatcacg ctggggctcct gccgtggcac gacgggaagc 360
aggtgcacct ggtcagtcct ctgaccacct acatggctcc caagccagaa gaaatcaacc 420
tgctcaccgg ggagtctgat acacagcaga tcgaggcggg gaagaagccg acgagtggc 480
tggtatgagc agtgtccac tggcgaccgc ggctggcgct gaacgtgatg gcggacaact 540
ttgtctttga cgggtcctcc ctgcctgccg atgtgcatcg gtacatgaag atgatccagc 600
tggggaaaac cgtgcattac ctgcccaccc tgttcacga ccagctcagc aaccgcgtga 660
aggacctgat ggtcataaac cgctccacca ccgagctgcc cctcaccgtg tcctacgaca 720
aggtctcact ggggcggctg cgcttctgga tccacatgca ggacgcccgt tactccctgc 780
agcagttcgg gttttcagag aaagatgctg atgaggtgaa aggaattttt gtagatacca 840

```

```

acttatactt cctggcgctg accttctttg tcgcagcggt ccatcttctc tttgatttcc 900
tggcctttta aaatgacatc agtttctgga agaagaagaa gagcatgacg ggcattgtcca 960
ccaaggcagtg gctctggcgc tgcttcagca ccgtgggtcat ctttctgttc ctgctggacg 1020
agcagacgag cctgctggtg ctggtcccgg cggtgtgttg agccgccatt gagctgtgga 1080
aagtgaagaa ggcattgaag atgactatct tttggagagg cctgatgccc gaatttcagt 1140
ttggcactta cagcgaatct gagaggaaaa ccgaggagta cgatactcag gccatgaagt 1200
acttgtcata cctgctgtac cctctctgtg tcgggggtgc tgtctattca ctctgaata 1260
tcaaataata gagctggtac tcctgggtta tcaacagctt cgtcaacggg gtctatgcct 1320
ttggtttctt cttcatgctg cccagctctt ttgtgaacta caagttgaag tcagtggcac 1380
atctgccctg gaaggccttc acctacaagg ctttcaacac cttcattgat gacgtctttg 1440
ccttcatcat caccatgccc acgtctcacc ggctggcctg cttccgggac gacgtggtgt 1500
ttctggtcta cctgtaccag cggtggcttt atcctgtgga taaacgcaga gtgaacgagt 1560
ttggggagtc ctacgaggag aaggccacgc gggcgcccca cacggactga aggccgccc 1620
ggctgccgcc agccaagtgc aacttgaatt gtcaatgagt atttttggaa gcatttggag 1680
gaattcctag acattgcgtt ttctgtgttg ccaaaatccc ttcggacatt tctcagacat 1740
ctcccaagtt cccatcacgt cagatttggg gctggttagc cttacgatgc cccacgtgt 1800
gaacatctgt cttggtcaca gagctgggtg ctgccggtca ccttgagctg tgggtgctcc 1860
cggcacacga gtgtccgggg ttccggccatg tcctcacgcg ggcaggggtg ggagccctca 1920
caggcaaggg ggctgttggg ttccatttcc aggtgtgttt ctaagtgtc cttatgtgaa 1980
tttcaaacac gtatggaatt cattccgcac ggactctggg atcaaaggct ctttctctct 2040
ttgtttgaga gttggtgtgt ttaaagctta atgtatgttt ctattttaaa ataaattttt 2100
ctggctgtgg caaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2160
aaa 2163

```

<210> 312

<211> 1397

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1397)

<223> n equals a,t,g, or c

<400> 312

```

ctagctggga ggctgacggc ccgcgggcgt aacrgaactg cagccgcgag ctctggagg 60
cggcgggatg gaggcggcgg ccgagcctgg aaacctggcc ggctgaggc acatcatcct 120
ggctcctctca ggaaaggggg gcgttgggaa aagcaccatc tcacggagc tggccctggc 180
actgcgccat gcaggcaaga aggtgggaat cctggatgtg gacctgtgtg gcccagtat 240
accccgcatg ctcgggggcg agggcagggc tgtgcaccag tgcgaccgcg gctgggcacc 300
cgtcttctctg gaccgggagc agagcatctc gctcatgtct gtgggcttcc tgctggagaa 360
gccggacgag gccgtgggtg ggagaggccc caagaaaaac gcgctgataa agcagtttgt 420
gtccgacgtg gcctgggggg agctggacta cctgggtgtg gacacgcccc cggggacctc 480
cgatgagcac atggccacca tagaagccct gcgtccctac cagcccctgg gggccctcgt 540
ggtcaccacg cccagggcgg tgtccgtggg ggacgtgagg cgcgagctga ctttctgtag 600
gaagacgggc ttgcgggtga tgggaatcgt ggagaatatg agcggttca cctgccaca 660
ctgcacggag tgcaccagcg tcttctccag gggcgggcga gaggagctgg ccagctcgc 720
cggggtgccc ttcttaggct ccgtgcccct ggacctgcg ctcatgagga ccctggagga 780
gggccacgac ttcatccagg agttccccgg gagccccgcc ttcgctgcac tcacctccat 840
agcccagaag attctggacg cgacggccgc gtgcctcccc tgactaaggc caccttgacg 900
ccgctttcca gggccacca gggctctgct ccagcctctc agagaaacag aggcctgggc 960

```

```
tcggttcccg ggccctgcag gggcaggccc aggcagcgtc agcgggagag cttctccccg 1020
accagcccag ccccaggatg tgtcgacca gcagctctgc ctgggtggcc tgcagtgccg 1080
tggtctgcgt gctctgcagc tgtgagacgg gggcggcctg ggctctcttc ccatccatgt 1140
tgcctacctg tgccctggc agccgcgtgt ccacacagtt agcggagcgc aggacttctg 1200
cagtcctcag gtgaccccg gcctccagca ccctgggtcg ctgtcatctg tgtttagctc 1260
ggggagtgy ccctaagggg gcgaactgac ctcaggcatg tcttgtaact gtagaggcgc 1320
ctgccattaa acgtgtccgc tgctgtggcg acagaaaaaa aaaaaaaaaa aaaaaaaaaa 1380
aaaaaaaaaa aaaaaan                                     1397
```

<210> 313

<211> 4106

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (344)

<223> n equals a,t,g, or c

<400> 313

```
ttactatcag acagccccc aagcagatta cagccaaggt gcaactcagt atactcaagc 60
ccagcaaact cgacaagtga cagccataaa accagccaca ccaagtccag ctaccactac 120
tttctccatc tatcctgtat cctccaccgt acagccagta gcagctgcgg ctactgtggt 180
gccatcctat actcagagtg ctacttacag taccacagca gttacatatt ctggtacgtc 240
ttattcaggt tatgaagcag cagtgtattc agctgcatct tcctactatc aacagcagca 300
gcagcaacag aagcaggcag cagcagcagc tgtgtgctgt cganactagc tgcctggaca 360
gggaccacct ttactaaaa agcaccattc caaaataaac aactgaaacc aaaacagcct 420
cccaaaccac cacagattca ctattgtgat gtttgtraga tcagctgtgt ggaccacaga 480
cttataaaga acatttagaa ggacagaaac ataaaaaaaa agaagctgca ttgaaagcct 540
cacaaaatac cagcagcagc aacagttcta ctcgtgggac tcaaatcag ctacgtgtgt 600
agctctgcga tgtgtcttgt acaggagcag atgcgtatgc tgcccacatt cgtggtgcta 660
agcatcagaa agtggttaag ttacacacaa aacttggtta acccattcca tcaacagaac 720
caaatgttgt tagccaagct acttcttcaa cagctgtatc tgcttcaaag ccgactgcct 780
ctccttcaag cattgcagca aacaattgta ctgtgaatac gtcacatatt gcaacgtctt 840
caatgaaggg tcttacgact acaggaaact cgtctcttaa tagcacatct aacactaaag 900
tatcagcagt gcctacaaat atggctgcca agaaaacatc tacccecaaa ataaattttg 960
ttggtggtta taagctgcag tcaacaggaa ataaagcaga agacacaaaa ggaaccgaat 1020
gtgttaaaag tactcctgtc acttctgtctg tgcagattcc tgaagtaaa caagacacag 1080
tgtcagaacc agtcacacct gcatctcttg ctgctttaca gagtgtgtgt cagccagtgg 1140
gccatgatta tgtggaagag gtacgaaatg atgaaggaaa agtaattcgg ttccattgta 1200
aattatgcga gtgcagcttt aatgatccca atgctaagga gatgcacta aaagggcgaa 1260
gacacagact tcaatataaa aaaaaagtaa atccagattt gcaagtagaa gtaaaagccta 1320
gtattcgagc aagaaaagatt caagaagaga aaatgaggaa gcaaatgcag aaggaggagt 1380
actggcgaag acgagaagaa gaggagcgtt ggagaatgga aatgagacgt tatgaagagg 1440
acatgtactg gaggaagatg gaggaagaac aacatcattg ggatgatcgc cgccgaatgc 1500
cagatggagg ttatcctcat ggtcctccag gccattagg ccttctggga gtccgaccag 1560
gcatgcctcc tcagcctcag gggcctgcac ccttacgtcg tcctgactca tctgatgacc 1620
gttatgtaat gacmaaacat gccaccattt atccaaactga agaggagtta caggcagttc 1680
agaaaattgt ttctattact gaacgtgctt taaaactcgt ttcagacagt ttgtctgaac 1740
atgagaagaa caagaacaaa gagggagatg ataagaaaga gggaggtaaa gacagagctt 1800
tgaaaggagt tttgcgagtg ggagtatttg caaaaggatt acttctccga ggagatagaa 1860
```

```

atgtcaacct tgttttgctg tgctcagaga aaccttcaaa gacattatta agccgtattg 1920
cagaaaacct acccaaacag cttgctgtta taagccctga gaagtatgac ataaaatgtg 1980
ctgtatctga agcggcaata attttgaatt catgtgtgga acccaaatg caagtcacta 2040
tcacactgac atctccaatt attcgagaag agaacatgag ggaaggagat gtaacctcgg 2100
gtatggtgaa agaccaccg gacgtcttg acaggcaaaa atgccttgac gctctggctg 2160
ctctacgcca cgctaagtgg ttccaggcta gagctaattg tctgcagtcc tgtgtgatta 2220
tcatacgcat tcttcgagac ctctgtcagc gatttccaac ttggtctgat tttccaagct 2280
gggctatgga gttactagta gagaaagcaa tcagcagtg cttctagccct cagagccctg 2340
gggatgcact gagaagagtt tttgaatgca tttcttcagg gattattctt aaaggtagtc 2400
ctggacttct ggatccttgt gaaaaggatc ctttgatac cttggcaaca atgactgacc 2460
agcagcgtga agacatcaca tccagtgcac agtttgcat gagactcctt gcattccgcc 2520
agatacacia agttctaggc atggatccat taccgcaa at gagccaacgt ttaacatcc 2580
acaacaacag gaaacgaaga agagatagtg atggagttga tggatttgaa gctgagggga 2640
aaaaagacaa aaaagattat gataactttt aaaaagtgtc tgtaaactct cagtgttaaa 2700
aaaacagatg ccattttgtt ggctgtttt cattcataat aatgtctaca ttgaaaaatt 2760
tatcaagaat ttaaaggatt tcatggaaga accaagttt tctatgatat taaaaatgt 2820
acagtgttag gtattatttg aatggaaga caccacaaaa aaaaaatgtg ctccgactag 2880
ggggaaaaaca gtatttccga tttttccca ttatttttat tttattttct ggttgcccta 2940
gcttcccccc ctatttttgt gtcttttatt aactagtga ttgtcttatt aaatcttcac 3000
tgtattta at gcaggatgtg tgcttcagtt gctctgtgta ttttgatatt ttaatttaga 3060
ggttttgttt gcttttgac actagtgtga agttactttg ttatagatgg tatcctttac 3120
ccctctttaa tttttacag cagtacgttt ttttgtaacg tgagactgca gagtttgttt 3180
ttctatatgt gaaggattac aacacaaaaa gttatcctgc cattcgagtg ctcagaactg 3240
aatgtttctg cagatcttgt ggcattttgt tctagtgtga tatataaagg tgtaattaag 3300
acagagttct gttaatctaa tcaagtttgc tgtagttgt gcattagcag tataaaagct 3360
aatatatact atatggtctt gcaacagttt taaagcctct gcataattga taataaaaat 3420
gcatgacatt cttgttttta atagactttt aaaatcataa ttttaggttt aacacgtaga 3480
tctttgtaca gttgactttt tgacatagca aggccaaaaa taactttctg aatatttttt 3540
tcttgtgtat aagtggaaag ggcatttttc acatataagt gggctaacca atattttcaa 3600
aagaacttca tcattgtaca actaacaaca gtaactagcc ctttaattatg gtgacagttc 3660
cttattgtgt tgtgtgagat tactctagca actattacag tataacacag atgatcttct 3720
ccacacaccc catcacccag ataatttaca gttctgttaa cagtgaggtt gataaagtat 3780
tactgataaa aaattatcta aggaaaaaaa cagaaaatta tttggtgtgg ccatcttacc 3840
tgcttatgtc tcctacacia agctaaatat tctagcagtg atgtaatgaa aaattacatc 3900
ttactgttga tatatgtatg ctctgttaca cagatgtcat tttgttgtca cagcactaca 3960
gtgaaataca caaaaaatga aattcatata atgacttaaa tgtattatat gttagaattg 4020
acaacataaa ctacttttgc tttgaaatga tgtatgcttc agtaaaatca tattcaaatt 4080
taaaaaaaaa aaaaaaaaaa actcga 4106

```

<210> 314

<211> 532

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (497)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (498)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (502)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (524)

<223> n equals a,t,g, or c

<400> 314

```
gactggaccc gggagacatc acagcgctgg gctaggggcg cggcttgaac tcgcctaaag 60
agctgcgccc tctcaccggt gccgccccag ccgctgccgc ctgcaccgga cccggagccg 120
ccatgcccaa gtgtcccaag tgcaacaagg aggtgtactt cgccgagagg gtgacctctc 180
tgggcaagga ctggcatcgg ccctgcctga agtgcgagaa atgtgggaag acgctgacct 240
ctggggggcca cgctgagcac gaaggcaaac cctactgcaa ccaccctgc tacgcagcca 300
tgtttgggcc taaaggcttt gggcggggcg gagccgagag ccacactttc aagtaaacca 360
ggtggtggag accccatcct tggctgcttg cagggccact gtccaggcaa atgccaggcc 420
ttgtccccag atgcccaggg ctcccttggt gccctaatag ctctcagtaa acctgaacac 480
ttggaaaaaa aaaaaanngg gnggcgtttt aaagattcct cganggggcc aa 532
```

<210> 315

<211> 1938

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1270)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1455)

<223> n equals a,t,g, or c

<400> 315

```
gcggctttgg ctctgggcga ggcggcgggg ccggggcttc tcggacgagg cgggcttggc 60
gggcgcccgg cagctacagc tgcaaggagg ggccggcgac cccgacgcgc cgcccaagaa 120
gcggctgcgg gcagccgagg cggccgaggc ggccggcgcg gcggcgcgcg ccggcagcgg 180
gaaactggag gaggcgctct actcgggtgt gtgctgcacc gtgtcctgga cctgcccaag 240
gcctccgtgt accagtgtac taatggtcac ttgatgtgcg ctggctgttt tatccacctt 300
ctagcagatg cccggctgaa ggaggagcag gccacgtgcc ccaattgtcg ttgtgagatc 360
agtaagagcc tctgctgccg gaacctggcc gtggagaaaag ccgtgagcga gctgccttca 420
gagtgtggct tctgcctgcg ccagtttccc cgctccctcc tggagaggca ccagaaagag 480
gaatgccacg gacagggtaa cccagtgcga gtacaaacgc atcggctgcc catggcacgg 540
ccccttccat gagctgacgg tgcacgaggc tgcgtgcgcc caccgacca agacaggcag 600
tgagctgatg gagatcctgg atgggatgga ccagagccac cgcaaggaga tgcagctgta 660
```

```

caacagcatc ttcagcctgc tcagcttcga gaagattggc tacacagagg tccagttccg 720
gccgtaccgc acagacgact tcatcacgcg cctgtactat gagacgcca gggtcacagt 780
gctgaaccag acgtgggtcc tgaaggctcg agtcaacgac tcggagcgta accccaacct 840
gtcctgcaag cgtacgctct ccttcagct cctcctcaag agcaaggta cggcaccgct 900
ggagtgtctc ttcctgctgc tcaagggccc ctacgacgac gtgaggatca gcccgtcat 960
ctaccacttt gtcttcacca acgagagcaa cgagacggac tacgtgccac tgcccatcat 1020
tgactccgtg gagtgaaca agctgctggc tgccaagaac atcaacctgc ggctcttcct 1080
gttcagata cagaagtagg gcggggcctc aggatgtccg aggagcccac gggcggcac 1140
ccagcaccgc tgccctgtcc acctggctgg cagctgcttc acaggactat ctgatcactt 1200
tagcaaagga ggagaacaaa cgaagccaac acagggcaag tctgcatgcg tgcgcgacgg 1260
ggccccgcgn tccggctcac cccccgacc cctgcctccc ctcttccga gggccgccag 1320
aggctgggct gacccgaaga ggagacggcg caccaggcgc cccgaggcta agagacggcg 1380
gcagcaagga ggccgagagg cacagcgacc ctgccccagc ccttctgtgc agtcaggcgg 1440
cggtgctgct ccatnctgcg gggtccggcg gggcgcgggg gccttgctga catcagacgg 1500
gatatccgaa tatctgatag caattaaaag gcagccttgt ttcgtacttt ctgttttgtt 1560
cgaggggaag gcatggctgt gaatggacag cgtgggggct ttggtttggc ctgggggtca 1620
gagcctgccc cgccccatc tgtgtgcccg cacacgtccc ccgaggaaag actcagagac 1680
actgcctccc cctacgctct gtcatggggt cttgagactg aggcttgggc aggaagatcc 1740
aggtagggtc ggggctgccc tgccaaccgg ccgctcccag ggagacagga ctcagccacc 1800
agggtcagc aggcattttc ggaaagcagg gtgaaattgt ctcttcccag gaaaagatt 1860
aaactccttg caggctcttg gataagttac acaaaaaaaa aaaaaaaaag ggcgcccgt 1920
cgcatctag aactagtc

```

<210> 316

<211> 818

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (55)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (814)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (818)

<223> n equals a,t,g, or c

<400> 316

```

gcggcgccc ggcgccccca gcagcccag cggggcgca cagccggggc gcagncgcgc 60
ccccgcgcg gattgacatg atgtttccac aaagcaggca ttcggggtcc tcgcacctac 120
cccagcaact caaattcacc acctcgact cctgcgaccg catcaaagac gaatttcagc 180
tactgcaagc tcagtaccac agcctcaagc tcgaatgtga caagttggcc agtgagaagt 240
cagagatgca gcgtcactat gtgatgtact acgagatgtc ctacggcttg aacatcgaga 300
tgcacaaaca ggctgagatc gtcaaaaggc tgaacgggat ttgtgcccag gtcctgccct 360
acctctccca agagcaccag cagcaggtct tgggagccat tgagagggcc aagcaggtca 420

```


ccgctcccga gctgaactct atcatccgac agcagctcca agcccaccag ctgtcccagc 480
tgcaggccct ggccctgccc ttgacccac taccctgagg gctgcagccg ccttcgctgc 540
cggcggtcag cgcaggcacc ggccctctct cgtgtccgc gctgggttcc caggcccacc 600
tctccaagga agacaagaac gggcacgatg gtgacacca ccaggaggat gatggcgaga 660
agtcggatta gcagggggcc gggacagga. ggttgggarg ggggacarag gggagacaga 720
ggcacggaga gaaaggaatg tttagcaca gacacagcg agctcgggat tggctaaayt 780
ccatagtatt atgktggccc gggggggggc ccancan 818

<210> 317

<211> 837

<212> DNA

<213> Homo sapiens

<400> 317

gggcacgagc gacatggagc tgctcctcgc gggccgcccgg gtgctggtca cgggggcagg 60
caaaggtata gggcgcgga cggccaggc gctgcagcg acgggcgcgc ggggtggtggc 120
tgtgagcccg actcaggcgg atcttgacag ccttgtccgc gactgcccgg ggatagaacc 180
cgtgtgcgtg gacctgggtg actgggaggg caccgagcgg gcgctgggca gcgtggggcc 240
cgtggacctg ctggtgaaca acgcccgtgt cggcctgctg cagcccttcc tggaggtcac 300
caaggaggcc ttgacagat cctttgaggt gaacctgcgt gcggtcatcc aggtgtcrca 360
gattgtggcc aggggcttaa tagccgggg agtcccagg gccatcgtga atgtctccag 420
ccagtgtcc cagcgggcag taactaacca tagcgtctac tgctccacca aggggtgccct 480
ggacatgctg accaagggtg tggccctaga gctcggggcc cacaagatcc gactgaatgc 540
agtaaaccac acagtgggtg tgacgtccat gggccaggcc acctggagtg acccccacaa 600
ggccaagact atgctgaacc gaatccact tggcaagttt gctgaggtag agcacgtggt 660
gaacgccatc ctctttctgc tgagtgaccg aagtggcatg accacgggtt ccactttgcc 720
gggtgaaggg ggcttctggg cctgctgagc tccctccaca cacctcaagc cccatgccgt 780
gctcatccta ccccaatcc ctccaataaa cctgattctg ctgccccaaa aaaacga 837

<210> 318

<211> 1448

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (878)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1198)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1395)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1397)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1445)

<223> n equals a,t,g, or c

<400> 318

```

gggtctggag agcaggactg ggtcaacagg cccaagaccg tgcgcgacac gctgctggcg 60
ctgcaccagc acggccactc ggggccttcg agagcaagtt taagaaggag ccggccytga 120
ctgcaggcag gttgttgggt ttcgaggcca acggggccaa cggttctaaa gcaggtaggg 180
gcggctgtga agtgaggggg tctaggggag aaaaggggac ggagagcaga ggaagggtag 240
ttctttggat tcaccatttt accccagccc agaaacaaca aacaccccac ttcctgatct 300
cctgagggcg aaccagtgtt tggtaggaac gtgttcattg ctgaagcagc ataacaaga 360
atgagtcaga ctgggctgat acgctctgaa cacgggggtt tcctttccca gcacattctt 420
ggatgggagc atgagggcac cagtcacctt twaacctatt gggggacatt agcagtcaca 480
tggtgagtc aaacgaggta cttttgtgca tgktacaaa caggcagtta caagcgtgtc 540
attttcagtg gctccatttt aaatcagtc gctgcctcag aatcccgtac gcctgaaggt 600
tttaagttgc atgtgcacct gaaactcgta tatgagtatt ttctgtctgt gcttttagag 660
aggaggaatt ctgtaacgac ttttgtttcg ggtaggaag agaattgatct ctttcagtcg 720
accgccactt atgttacctt tttcctttta tttctttgtg tttccagttg caagaacagc 780
aaggaaaagg aagccctctc cagaaccaga aggtgaagtc gggcccccta agatcaacgg 840
agaggcccag ccgtggstgt ccacatccac agaggggntc aagatcccca tgactcctac 900
atcctctttt gtgtctccgc caccacccac tgcctcacct cattccaacc ggaccacacc 960
gcctgaagcg gccagaatg gccagtcccc catggcagcc ctgatcttag tagcagacaa 1020
tgcagggggc agtcatgcct caaaagatgc caaccagggt cactccacta ccaggaggaa 1080
tagcaacagt ccgccctctc cgtcctctat gaaccaaaga aggctggggc ccagagaggt 1140
ggggggccag ggagcaggca acacaggagg actggagcca gtgcaccctg ccagcctncc 1200
ggacttctct ctggcaacca gtgccccgct gtgctgcacc ctctgccacg agcgggtgga 1260
ggacaaccat tttgtgcagt gccgtccgct ctttgacaag ttctcttctt tgctcagaca 1320
aagataaaca gaggagtag tgagaggctt ttccagtggg gaaaatgcct ctgtgggtca 1380
atgtccctgg gcttntnaag ggaattcaa catcttcttg ggtgtaagtg aaaaaaaaaa 1440
aacntgg                                     1448

```

<210> 319

<211> 1493

<212> DNA

<213> Homo sapiens

<400> 319

```

tcgaccacg cgtccggaag taatgatgac aaaatactct aacctttcct tggagagtca 60
taacttctcg ctgactgctt cacctcttac aagtctgccc atcccgaag taatgatgac 120
aaaatactcc aaccttttct tggaaagtca taacatctca ctgactgaac attccagtgt 180
gccagtggaa aaaaatatca ctttagaacg accttctgct gtagaactca catgtcagtt 240
cacaacttct ggggatgtga attcagtaaa tgtgacttgg aaaaaagggg atgaacaact 300
taagaattac catgtcagtg ccacagaagg catcctgtat acccagtaca agttttccat 360
cattaatagc gaacaactgg gaagctattc ttgtttcttt gaagaggaaa aggaacgaag 420
gggcacattt aatttcggag tccctgaagt tcagagaaaa aacaaacat tgatcactta 480
tgtgggggat tccgttgtct tgggtgtgta atgccgacac tgtgctcctt taaattggac 540
ctggtacagt ggtaatagga gtgtacaggt tcctcttgat gttcacatga atgaaaagta 600

```

252

```

tgcgatcaat ggaacaaacg cgaatgaaac aaggcttaag ataatgcagc tttcagaaga 660
cgataaagga tcttattggt gccatgcaat gttccagttg ggcgagagcc aagaaagtgt 720
tgaactgggt gtgataagtt atttgggtgcc cctcaaacca tttcttgga tagttgttga 780
agttattctt ttagtggtcta ttattctgtt ttgtgaaatg cacacccaaa agaaaaagat 840
gcacatggat gatgggaaaag aatttgaaca agttgaacag ttgaaatcag acgatagcaa 900
cggcatagaa aataatgccc ccaggcacag aaaaaatgaa gctatgagcc agtgaaagca 960
aaacatcgtg tcaagagtaa tggaagatg tatagtttct acttcagctt tgtttatgtt 1020
tcctgtgaag aacatctgag tttttatatt tacaaggatg aaaagtttat gtgatatgct 1080
cagcagtagt tttgcaataa tacctgctat ctcagatcca aagatatatt ttccttctgt 1140
gattatttta cattaaagca aggtaaatca tattaatat gttctatgag ctataaccca 1200
ggataactaa tttcatcttg gtcattcaag gatgcacaga agagatacca gcaaaaccag 1260
ttagtagtac atgaactaat gtcattcaag acctgcgtat aaccaagaa ttcattaaag 1320
agaaaacttt ttggcattt gccttgkttt tttttctaat tatgcttact atgtgtagaa 1380
atatttgtaa taattttcat gtaatgkta cctctgtca tattggataa aaacatcttt 1440
attaagaaat gaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaggcgggc cgc 1493

```

<210> 320

<211> 609

<212> DNA

<213> Homo sapiens

<400> 320

```

ggcagcagtg gcttctgacc ctttcttccg ccactaccgc cagctcaatg agaagctagt 60
gcagctcatc gaagactata gccttgctc ctttatccct ctcaacatcc aggacaagga 120
gagcatccag cgagtcctgc aggtgtgga taaagccaat ggatactgtt tcggagccca 180
agagcagcga acttggaagc catgatgtct gccgcaatgg gagccgactt ccatttctct 240
tccacactgg gcatccagga gaagtacctg gcaccctcga accagtcagt ggagcaggaa 300
gccatgcagc tgtagcaaca aggtggaccc tggagagcag gatgcataat ccagcactgg 360
ggaaagtgga ggctcctgat gcaggctgca gacccaagag caagtcctcc cagccagagc 420
tggcgggctg gcaaggggat attcagctct gcaaaggact tctggccaaa aagccagaca 480
tggtgccaag cagaacaccc ccatactgt cagtgggtgc cgtgagctct ggccctgcca 540
ccagaaagtc gagcactggt cctagtcagg ctgtgatgaa atgtgctaca atacaagagt 600
ttattttct 609

```

<210> 321

<211> 502

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (458)

<223> n equals a,t,g, or c

<400> 321

```

tagtgatcc cccgggctgc aggaattcgg cagcagcaga gcttcgtctt tgctgctccc 60
ctgaggtgaa ctgaagccag cagccccgca tcatgtcaaa gctcggccgg gccgcccggg 120
gcctcaggaa gcccgaggtc ggcggtgtra tccgggcgat cgtgcgggca ggccctggcca 180
tgcccgggcc cccactagtc ccagtgtctg gtcagagagg cgtttccatc aaccagtttt 240
gcaaggagtt caatgagagg acaaaggaca tcaaggagg cattcctctg cctaccaaga 300
ttttagtgaa gcctgacagg acatttgaaa ttaagattgg acagcccact gtttcctact 360

```

```

tcctgaaggc agcagctggg attgaaaagg gggcccgga aacagggaag gaggtggcag 420
gcctggtgac cttgaagcat gtgtatgaga ttgccgnat caaagctcag gatgaggcat 480
ttgcctgcag gatgtacccc tg 502

```

<210> 322

<211> 2630

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1952)

<223> n equals a,t,g, or c

<400> 322

```

gggcatccag agtacgggtc gagcccgggc catggagccc ccctggggag ggggcaccag 60
ggagcctggg cgcccggggc tccgcgcga ccccatcgga tagaccacag aagctccggg 120
acccttcggg caccctctga cagcccagga tgctgttggc caccctcctc ctctcctcc 180
ttggaggcgc tctggcccat ccagaccgga ttatttttcc aaatcatgct tgtgaggacc 240
ccccagcagt gctcttagaa gtgcagggca ccttacagag gcccctggtc cgggacagcc 300
gcacctcccc tgccaaactgc acctggctca tcctggggcag caaggaacag actgtcacca 360
tcaggttcca gaagctacac ctggcctgtg gctcagagcg cttaaccta cgctcccctc 420
tccagccact gatctccctg tgtgaggcac ctcccagccc tctgcagctg cccgggggca 480
acgtcaccat cacttacagc tatgtctggg ccagagcacc catgggccag ggcttcctgc 540
tctcctacag ccaagattgg ctgatgtgcc tgcaggaaga gtttcagtgc ctgaaccacc 600
gctgtgtatc tgctgtccag cgctgtgatg ggggtgatgc ctgtggcgat ggctctgatg 660
aagcagggtg cagctcagac ccctccctg gcctgacccc aagaccgctc ccctccctgc 720
cttgcaatgt caccctggag gacttctatg ggggtcttct ctctcctgga tatacacacc 780
tagcctcagt ctcccacccc cagtcctgcc attggtgctg gaccccatga tggccggcgg 840
tggccgtgcg cttcacagcc ctggamttgg gctttggaga tgcagtgcag gtgtatgacg 900
gccctggggc ccctgagagc tcccgaactac tgcgtagtct caccacttc agcaatggca 960
aggctgtcac tgtggagaca ctgtctggcc aggtctgtgt gtcctaccac acagtgtctt 1020
ggagcaatgg tcgtggcttc aatgccacct accatgtgcg gggctattgc ttgccttggg 1080
acagaccctg tggtctaggc tctggcctgg gagctggcga aggcctaggg gagcgtgct 1140
acagtgaggc acagcgtgtg gacggctcat gggactgtgc tgacggcaca gatgaggagg 1200
actgcccagg ctgccacct ggacacttcc cctgtggggc tgcctggacc tctggtgcca 1260
cagcctgcta cctgcctgct gaccgctgca actaccagac tttctgtgct gatggagcag 1320
atgagagacg ctgtcggcat tgccagcctg gcaatttccg atgccgggac gagaagtgcg 1380
tgtatgagac gtgggtgtgc gatgggcagc cagactgtgc ggacggcagt gatgagtggg 1440
actgctccta tgttctgccc cgcaaggcca ttacagctgc agtcattggc agcctagtgt 1500
gcggcctgct cctggtcacc gccctgggct gcacctgcaa gctctatgcc attcgcaccc 1560
aggagtacag catctttgcc cccctctccc ggatggaggc tgagattgtg cagcagcagg 1620
caccctctc ctacgggcag ctcatgccc aggggtgcat cccacctgta gaagactttc 1680
ctacagagaa tcctaataatg aactcagtgc tgggcaacct gcgttctctg ctacagatct 1740
tacgccagga tatgactcca ggaggtggcc caggtgcccg ccgtcgtcag cggggccgct 1800
tgatgcgacg cctggtacgc cgtctccgcc ctgtggggctt gctccctcga accaacaccc 1860
cggctcgggc ctctgaggcc agatcccagg tcacaccttc tgctgctccc cttgaggccc 1920
tagatggtgg cacaggtcca gcccgtagg gnggggcagt ggggtgggcaa gatggggagc 1980
aggcaccccc actgccatc aaggctcccc tccatctgc tagcacgtct ccagccccca 2040
ctactgtccc tgaagcccca ggccactgc cctactgcc cctagagcca tcactattgt 2100
ctggagtggg gcaggccctg cgaggccgcc tgttggccag cctggggccc ccaggaccaa 2160

```

```

cccggagccc ccctggaccc cacacagcag tcctggccct ggaagatgag gacgatgtgc 2220
tactggtgcc actggctgag ccgggggtgt gggtagctga ggagaggat gagccactgc 2280
ttacctgagg ggacctgggg gctctactga ggctctccc ctgggggctc tactcatagt 2340
ggcacaaact tttagagggt ggtcagcctc ccctccacca cttccttccc tgtccctgga 2400
tttcagggtg ttggtggggc tcccgttgac cctatgtagc tgctataaag ttaagtgtcc 2460
ctcaggcagg gagagggtc acagagtctc ctctgtacgt ggccatggcc agacacccca 2520
gtcccttcac caccacctgc tccccacgcc accaccattt ggggtggtgt ttttaaaaag 2580
taaagtctct agaggatmaw aaaaaaaaaa aaaaaaaaaa aaaaaaaagg 2630

```

<210> 323

<211> 1874

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (67)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1735)

<223> n equals a,t,g, or c

<400> 323

```

tcgaccacag cgtccggccg gggcgccctc cggaagcttt tccaactttc cagaagtttc 60
tcgggagggg cgggaggagg ggaacgccat atatagacct ggagagccgg gagcgaggag 120
agtggaatcg gtcccgggct cgagtgggtc tctagtccgg cgccagccgc ccggcccagc 180
cctcacaggt ccttcgtggt gcataaccatc cgctcccag ccattgcgtt cctcctgctt 240
accagcactt gctgcctcct ggccatggcc ctggctgccg aggtgaagaa gccagcggcc 300
ccaggcacag cagagaagct garcccaaaa gggccacgc tggcagagcg cagtgtctggc 360
ctggccttca gcctgtacca ggccatggcc aaggaccagg cgggtggagaa catcctgctg 420
tcgcctgtgg tgggtggcctc atccctgggg cttgtgtcgc tggggggcaa ggccaccaca 480
gcgtcccagg ccaaggcggt gctgagtgc gagcagytgc gtgatgagga ggtgcacgcg 540
ggscstkggc agytgttgcg agctttcagc aacagcacgg cgcgcaactg gacctgaagc 600
tgggcagccg cctgtatggg ccagctcgg tgarcctcgc ggaggacttt gtgcgcagca 660
gcaagcagca ctacaactgc gagcactcca agatcaactt ccgcgacaag cgcagcggcc 720
tgcagtccat caatgagtgg gccgcacaga ccaccgatgg caagctgcct gaggtcacca 780
aggacgtgga gcggacggat ggcgcgctgc tgggtcaacgc catgttcttc aagccgcact 840
gggacgagaa gttccaccac aagatggtgg acaaccgagg cttcatgggtg acccgctcgt 900
ataccgttgg ggttacgatg atgcaccgca caggactcta caactactac gacgacgaga 960
aggagaagct gcagatggtg gagatgcccc tggcccacaa gctgtccagc ctcctcatcc 1020
tcatgccgca ccacgtggag cccctggagc gcctggagaa gcttctgacc aaggagcagc 1080
tgaagatctg gatggggaag atgcagaaga aagccgtcgc catctccttg cccaaggggg 1140
tgtagagggt gaccacgac ctgcagaaac acctggctgg actgggtctg actgaggcca 1200
tcgacaagaa caaggcagac ctgtcacgca tgtcaggcaa gaaggacctg tacttgcca 1260
gcgtgttcca cgctaccgcc ttcgagtggg acacagaggg caaccctttt gaccaggaca 1320
tctacgggcg tgaggagctg cgcagtccca agytcttcta cgctgaccac cccttcattt 1380
tcctggttcg agacacccag accggctccc tgctgttcat tgggcgcctg gtccggccca 1440
agggtgacaa gatgcgagat gagctgtagg gccccaggga tggcaggagg cagcccaagg 1500
ctcctgagac acatgggtgc tatggggggg agctgaggta ccgaccttgg atgtgccatg 1560

```

```

gggtgggggt gggaaaacag agcaggcttc ctggatgtct gagcagatct tcccaggcag 1620
aattgactct gtctggatgt gggcccccag ataccgtgat gctgagcccg gacacscac 1680
attctgrggr ccctgggggc agttggcgtg tcttgccctc agcatcctgg gattnaagcc 1740
tgccctcaat cagtgttcat atttatagcc aagtgccttc tcatctgtga gacagaatcg 1800
agctargggg cttcagccca gccctgtgga atggggaccg tcttttcctt accctaccat 1860
cacctcagcc ctaa 1874

```

<210> 324

<211> 2325

<212> DNA

<213> Homo sapiens

<400> 324

```

aagaaatgca gatgagtgtg aaacatctgt tctcaattat gttgatctgt gtgcgcagta 60
ctggagcatt taccatttca tgttgagcct caaatgcttg ttttctgggg tccacaaaag 120
acagttttat acattttgag ttgttcataa agtttgtctt gtgatatgcc tggcacttaa 180
agacaaatth ttctggtagt aaaagttcag atttattact atgtcatgaa acacagtaca 240
ttcaaatcaa acggcagttt tctttctaag taaatgattt ccagtcattt aaaagggtgg 300
caagatgaga taaagacatt ttgatacagt aattgttttg gttgggtttt catgtcagtt 360
tatgtttgac taaagctctc ttcataatga ggtttataaa tttgttaggt ctgttgctcc 420
atgattaaac atgsagtgcc tcctctctga tttaatattc tgcaggtcat tgtaacctgc 480
taggcaaagt cacaacattg cattaaagag gtgatatgct tgctaataac actgttttaa 540
aggacgtaca gttaaaggaa tattaagtgg gagaaagcct acaaggcttt tagaatatta 600
tcagtatctt catttctggg attcagatgt tatgtgataa aacacatttt ttttggtttt 660
cccagataca ctatatattt gttcaagggt aaatctataa aatgtatata ctttattttg 720
tggttttgct atttataaat ttaattgttt aactgttgct catttatggg ttgttttggg 780
tggtggtggt catctgtata tcaccatggt aatttgtaat ggaagtgcac ttcgtagtgt 840
atattgttac tgacattaaa atactttata gcattgtctc tgagcaaaag ctagtattta 900
attgtacaaa tgaataagca agttacatgt tattgtttgc tcttgacagg gtaggcctct 960
taaaagaaaa aaaacaactt gttttttctt tatgaatccc ctatgccaaa cacatacctt 1020
ccatgcatga catgagatct gcaaactgga ttttagccac cgtatttatt tagtcaaaaa 1080
aattgtccat tgtagcagac ccgaaaacct ttttgctgtg acatgaaacc atgttattct 1140
tatcttctta aaacacagcc tgggatggaa tggccatggc atttttttca gagaacatcc 1200
tttatctgct atgactgaat ccttaggaaa tgtaagctat aaccctttga ttttcaagaa 1260
ctaccgaata agtgtatgaa gaggtgggtt tttaaaactt caagttggaa tttttatgag 1320
gtcactgtgt aatttgaaga attgtgtgag attgtcatga tataaattcc ttttaaggac 1380
tgataaatag aatgaaaagt ttccaggtag tttaaaactc cacaggtcag tttccttttc 1440
attcctgctt cactgtgggt tataagccta cgggagagca ccgttgctca gatgctactg 1500
tgagcttcct gtccggtggt agaaagtaac tagttaaaag ttcatttttag aatgtatggt 1560
ttttggggat gaactaagaa ttagttatta gttccaaagg actgagaacc aattttaata 1620
ttttcacatt tataggaaa aaattcatat gtccctgaaa cttctaggac aaaaccaaac 1680
aagtaaggag ggaactgttg caaagccatt tcatcgagaa ggggacagaa ggagaaatac 1740
acacatgtat acacaaacag aatggttgag aaaacgtttt aataaaatgt gaggttgta 1800
tgtgtgcgtg tatatattha cacttaacct ctaaaattct cttctacagt atctctgta 1860
tgaatatgat ggaaaagcaa cattttggtg gtgagactat tgttaaaata aatttgagaa 1920
agacgaaaat tttgtgagtc ttgataatta caagtcaaca gctatcgaaa gttagcacag 1980
cttgtctgtg gtgctgtttt ttccccact gcagtggact tatgctgttt tcatgtttag 2040
aaacaaaaag gtttcatgtg attcatgtgt aagatgcaca gtatttgaca tcctgattat 2100
gtaatcccta ttccatctat ccagtcttac acttatggtt ggcctcaaat ctattgcatt 2160
tatgataatg tattatatct agttgagttt aatatttttt tattagcctg taaataaaga 2220
tggcatcttc tacattaaaa tgatattgat ctcatttttt taaataaaca ttttgtttcc 2280

```

ttgacgttaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaa

2325

<210> 325

<211> 785

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (6)

<223> n equals a,t,g, or c

<400> 325

```
ggcctncggc aaagaagcat agccacgggg ccamagccag gtgtgtcctt gcagttggaa 60
cccaggagtt ccggaagcca aagccccccc acgagggtcc cgcgaagacc tggtagcgga 120
ggagagcccg gagctgctga accctgagcc caggagactg agcccagagt tgaggctact 180
gccctatatg atcactctgg gcgacgccgt gcacaacttc gccgacgggc tggccgtggg 240
cgccgccttc gcgtcctcct ggaagaccgg gctggccacc tcgctggccg tgttctgcca 300
cgagttgcca cagagctgg gggacttcgc cgccttgctg cagcgggggc tgtccgtgcg 360
ccaagcactg ctgctgaacc tggcctccgc gctcacggcc ttcgctggtc tctacgtggc 420
actcgcgggt ggagtcagcg aggagagcga ggcctggatc ctggcagtgg ccaccggcct 480
gttcctctac gtagcactct gcgacatgct cccggcgatg ttgaaagtac gggaccgcg 540
gccctggctc ctcttcctgc tgcacaacgt gggcctgctg ggcggtgga ccgtcctgct 600
gctgctgtcc ctgtacgagg atgacatcac cttctgatac cctgccctag tccccacct 660
ttgacttaag atcccacacc tcacaaacct acagcccaga aaccagaagc ccctatagag 720
gccccagtc caactccagt aaagacactc ttgtccttgg aaaaaaaaaa aaaaaaaaaa 780
aaaaa                                             785
```

<210> 326

<211> 244

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (244)

<223> n equals a,t,g, or c

<400> 326

```
aatcactaaa ggaaaaayag tagcctgcag taccggtccg gaattcccgg gtcgaccac 60
gcgtccgacg acagaagggt acggctgcga gaagacgaca gaagggtacg gctgcgagaa 120
gacgacagaa gggtagcggt gcgagaagac kacagaaggg tacggctgcg agaagackac 180
agaagggtac ggctgcgaga agacgacaga aggtacggct gcgagaagac gacagagggg 240
acgn                                             244
```

<210> 327

<211> 2454

<212> DNA

<213> Homo sapiens

<400> 327

```

gctgcggcgg ggtctggggc gcagagcagc ggccgggagga ggccggacacg tggcaacagc 60
ggtacagccc gggcggcggc acaacagcgg cgccggcatc ggcccgagcg ccggccgccc 120
tcccaccctc ccgccccggc gcagccctag ctccctccac ttggctcccc tgggtcccgt 180
cgctcggcgg ggagctgctc tgtgcttttc tctctgattc tccagcgaca ggacccggcg 240
ccggcactga gcaccgccac catggggaag ggggttggaac gtgataagta tgagcctgca 300
gctgtttcag aacaaggtga taaaaggggc aaaaaggggc aaaaagacag ggacatggat 360
gaactgaaga aagaagtttc tatggatgat cataaactta gccttgatga acttcatcgt 420
aaatatggaa cagacttgag ccggggatta acatctgctc gtgcagctga gatcctggcg 480
cgagatggtc ccaacgccct cactccccct cccactactc ctgaatggat caagttttgt 540
cggcagctct ttgggggggt ctcaatgtta ctgtggattg gagcgattct ttgtttcttg 600
gcttatagca tccaagctgc tacagaagag gaacctcaaa acgataatct gtacctgggt 660
gtggtgctat cagccgttgt aatcataact ggttgcttct cctactatca agaagctaaa 720
agttcaaga tcatggaatc cttcaaaaac atggtccctc agcaagccct tgtgattcga 780
aatggtgaga aaatgagcat aaatgcccgg gaagtgtgtg ttggggatct ggtggaagta 840
aaaggaggag accgaattcc tgctgacctc agaatcata ctgcaaatgg ctgcaagggtg 900
gataactcct cgctcactgg tgaatcagaa ccccagacta ggtctccaga tttcacaagt 960
gaaaaccccc tggagacgag gaacattgcc ttcttttcaa ccaattgtgt tgaaggcacc 1020
gcacgtggta ttgtgtgcta cactggggat cgcactgtga tgggaagaat tgccacactt 1080
gcttctgggc tggaggaggc ccagaccccc attgctgcag aaattgaaca ttttatccac 1140
atcatcacgg gtgtggctgt gttcctgggt gtgtctttct tcatccttct tctcatcctt 1200
gagtacacct ggcttgaggc tgtcatcttc ctcatcggtg tcatcgtagc caatgtgccg 1260
gaaggtttgc tggccactgt cacggtctgt ctgacactta ctgccaaacg catggcaagg 1320
aaaaactgct tagtgaagaa cttagaagct gtggagacct tgggggtccac gtccaccatc 1380
tgctctgata aaactggaac tctgactcag aaccggatga cagtggccca catgtggttt 1440
gacaatcaaa tccatgaagc tgatacgaca gagaatcaga gtggtgtctc ttttgacaag 1500
acttcagcta cctggcttgc tctgtccaga attgcaggtc tttgtaacag ggcagtgttt 1560
caggctaacc aggaaaacct acctattctt aagcgggcag ttgcaggaga tgcctctgag 1620
tcagcactct taaagtgcac agagctgtgc tgtggttccg tgaaggagat gagagaaaga 1680
tacgccaaaa tcgtcgagat accttcaac tccaccaaca agtaccagtt gtctattcat 1740
aagaaccccc acacatcgga gccccaacac ctggttgtga tgaagggcgc cccagaaagg 1800
atcctagacc gttgcagctc tatcctcctc cacggcaagg agcagccctt ggatgaggag 1860
ctgaaagacg cctttcagaa cgctattttg gagctggggg gcctcggaga acgagtccta 1920
ggtttctgcc acctctttct gccagatgaa cagtttctctg aagggttcca gtttgacact 1980
gacgatgtga atttccctat cgataatctg tgctttgttg ggctcatctc catgattgac 2040
cctccacggg cgccggttcc tgatgccgtg ggcaaatgtc gaagtgtcgg aattaaggtc 2100
atcatgggtc caggagacca tccaatcaca gctaaagcta ttgccaaagg tgtgggcac 2160
atctcagaag gcaatgagac cgtggaagac attgctgccc gcctcaacat cccagtcagc 2220
caggtgaacc ccagggatgc caaggcctgc gtagtacacg gcagtgatct aaaggacatg 2280
acctccgagc agctggatga cattttgaag taccacactg agatagtgtt tgccaagacc 2340
tccctcagc agaagctcat cattgtgga aggctgcaa agacagggtg ctatcgtggg 2400
ctgtgactgg tgacggtgtg aatgactctc cagctttgaa gaaagccaga catt 2454

```

<210> 328

<211> 505

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (10)

<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (15)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (182)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (189)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (246)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (300)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (302)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (332)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (335)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (339)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (342)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (367)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (394)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (401)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (405)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (407)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (411)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (419)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (420)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (422)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (424)
<223> n equals a,t,g, or c

<220>

<221> misc feature
<222> (436)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (440)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (451)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (452)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (454)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (459)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (467)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (469)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (470)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (472)
<223> n equals a,t,g, or c

<220>
<221> misc feature

<222> (474)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (475)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (477)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (479)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (482)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (483)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (485)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (488)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (490)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (491)
<223> n equals a,t,g, or c

<400> 328
aattcggc an aggg nagtgc gaagtagtgg gtgacttttg ttctctttct ggcagaactt 60
tgcctacaca ttctactac ccctgggaat tctaactcag atgtgggtag cagcttcctc 120

```
aaagagaaac tttttcccag ctgggtgctg tggctcacac ctgtgaatcc cagccctttg 180
gnaggctgna gtgggcagat cgcttgagcc caggagtgtg agatcagcct gggcaacatg 240
gtgaantcca tctctgtgaa aaatacaaaa attagccagg tgtggtggtg cgcgccctgt 300
antcccagct actagggagg ctgaagggtg gnggnttgnt tnagcccagg aggttgaggc 360
tgcattnggc tgggattcaa accatgttac tccntgacca ngtnngncct ntttcaaann 420
angnaaggga aggggnaagn aaaggaaaag nngnaggng atgccgntnn tngnntngna 480
gnngnatnan ntaaaaattt gggggg 505
```

<210> 329

<211> 559

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (2)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (4)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (6)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (335)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (343)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (373)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (385)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (387)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (441)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (445)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (448)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (457)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (473)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (487)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (503)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (505)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (551)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (553)

<223> n equals a,t,g, or c

<400> 329

```
nnanancctg ggaggcagag tttgcagtga gccgagatgg cgccactgca ctccagcctg 60
ggggacagag cgagactcca tctcaaaaaa aaaaaaaaaa aaaattaaaa attaagttct 120
ttagttgcac tagccatatt tcaaatactt gatggataca tgtggctagt ggctaacata 180
agggatagca cagatataaa acatttcctc ccaaagtgtc gggattacag gcatgagcca 240
ccgcgccccg cctatcatat gaattttgag ggaacacaat catgcagtct gtagcagatg 300
gtaataggct gatataattac acttggtgat gtaanctgga tangtttctt tcttctccaa 360
ggacagcttt ttnaatatth aacantncca ttaatttttc agtttccggg agaattttat 420
aattttaaatt tgccgactta ngganaancc aattggncca accattacaa tanattttta 480
attccgntta aaaaatccca ccngnggggg aattccgctt aaaattttat tttccattat 540
tccaatggc ntnaattta 559
```

<210> 330

<211> 467

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (4)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (99)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (125)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (135)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (138)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (145)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (256)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (263)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (275)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (298)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (305)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (330)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (341)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (344)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (391)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (393)

<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (398)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (402)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (422)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (428)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (440)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (441)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (453)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (456)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (458)
<223> n equals a,t,g, or c

<400> 330
aatnatgctc tgcgtgatga tgttgccgct ggtcgtcgct ggttgccacat caaagcagtc 60
tgtcagtcag tgcgtgaagc caccaccgcc tccggtggna tgaatgcagc ctccccccga 120
ctggncagac accgntgnaa cgggnattat ttcaccctca gagagaggct gatcactatg 180
caaaaacaac tgggaggaaa cccagaagta tattgaatga gcagtgcaga ttagagttgc 240

```
ccatatcgat gggcancaat tgncaattat tgtgnagcaa tacacacggg gtttccangg 300
gagtnttaaa tgccttaaaag taattaaaaan ccgggggcaat nccntttttac ggatgttttg 360
ctgggggtttc cgttttttaac caacatTTTT ntnggggncc gnccacaaat tttgggggttg 420
gnattggncg ttttttcttn ntggccccat ttncngnaa acggggg 467
```

<210> 331

<211> 418

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (22)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (37)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (126)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (131)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (196)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (202)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (250)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (257)

<223> n equals a,t,g, or c

<220>

<221> misc feature
<222> (284)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (298)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (338)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (344)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (353)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (380)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (387)
<223> n equals a,t,g, or c

<400> 331
gagctgccaa cctggcaatt antgtctgct aagggtntct tttattcacc cttacttggga 60
cttcctttcc tgtagggaat ctcacgtaaa atgaaatctt ccctcccca aggtgtccgc 120
aatgtngcca ntgtctgtct gcagattggc tacccaactg ttgcatcagt accccattct 180
atcatcaacg ggtacnaacg antcctggcc ttgtctgtgg agacggatta caccttccca 240
cttgctgaan aagtcanggc ttcttggtg atccatctgc cttngtggct gctgccngt 300
tggtgctgc caccacaact gtcctgctg ctgctgcnc ccanccttaag ttnaaaccca 360
agaaaatccg aagatccgan aaagatntgg attgggtctc ttgactaat caccaaaa 418

<210> 332
<211> 486
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (9)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (49)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (379)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (415)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (446)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (478)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (485)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (486)

<223> n equals a,t,g, or c

<400> 332

```
acgggaccnt gggaccggcg tcgggggtcg cggggaccat gcagcgganc tccctgccct 60
tcgctatcct gacgctggtg aacgccccgt acaagcgagg attttactgc ggggatgact 120
ccatccggta cccctaccgt ccagatacca tcaccacagg gctcatggct ggggtcacca 180
tcacggccac cgtcatcctt gtctcgccg gggaaagccta cctggtgtac acagaccggc 240
tctattctcg ctcggaacttc aacaactacg tggctgctgt atacaagggtg ctggggactt 300
cctgtttggg gctgccgtga gccagtctct gacagacctg gccaaagtaca tgattgggcg 360
tctgaagccc aattctaanc gtctgcgaac ccgattgaac cgggtcaatgc tcgtnatgtg 420
cagtgagaaa gtttgcaggg aacctnttga ttcacgagca gtgtttttaa tcggaatntc 480
tttgnn                                     486
```

<210> 333

<211> 268

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (36)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (69)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (78)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (87)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (105)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (108)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (160)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (218)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (244)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (260)

<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (263)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (264)
<223> n equals a,t,g, or c

<400> 333
cccacgctgt ccgatgattt gtcacaatct tatcantaat cattactctg ttttttatat 60
ttcaactana agtatcanaa tatagcnttc cagaaaaccc cgaancanag tcactgacta 120
catcaaagtc tactacacct tgagaaaaca aatgaacgan aatctatttt cctcattcat 180
taccccaaca ataataggac tccctatcgt aattattntc actatgtttc caagcattga 240
tatncccatc acctacccgn ctnntcaa 268

<210> 334
<211> 517
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (214)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (259)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (302)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (332)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (360)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (410)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (436)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (447)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (463)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (489)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (496)

<223> n equals a,t,g, or c

<400> 334

```
cggaaggag cgcctactaa ggacgccgtc gaggtccggg gcgcctcaac tctatagctc 60
taactggcta gaagtgccca acgtggaatg tttctttttt aaaggcggct cttgaagcga 120
cccgaagcg gaagtggaag aaagttctag tggcttgaga ttaagcctga tcaagatgac 180
aacctcccaa aagcaccgag acttcgtggc agancccatg ggggagaacc agtggggaac 240
ctggctggga ttggtgaant cctgggcaag aaactggaag aaagggtttt gacaaggcta 300
tnttgtcttg gccatttctg gtgctaaaaa anataaaaac tctcccggaa tggtgaaaaa 360
ctttttgggc caccacaacat cccgaatgtc cgatgctcca aaatgtgcan cctcttttat 420
gtctttggaa tctctncccc ccccccatt tgaccaattg gancccccctt cctcaagaaa 480
atgttgttnc ccccanttcc ggttttgatt tccccac 517
```

<210> 335

<211> 297

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (19)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (155)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (156)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (164)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (166)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (167)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (171)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (201)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (224)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (226)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (244)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (245)

<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (246)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (252)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (265)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (267)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (286)
<223> n equals a,t,g, or c

<400> 335
ctccgcaaat tgaaccctnc actcaaaggg aaacaaaagc tggagctcca ccgcgggtgac 60
ggccgctcta gaactagtgg ggggcccggt acccaattcg ccctatagtg agtcgtatta 120
caattcactg gccgtcgttt tacaacgtcg tgacnnggaa aacntnnaat ncttccggct 180
cgtatgttgt gtggaattgt nagecgataa caattcacac aggnancagc tataaccatg 240
atnnnnccaa gntcgaaatt aacntnact aaaggggaca aaagtngggg ctccacg 297

<210> 336
<211> 386
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (50)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (128)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (148)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (185)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (187)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (200)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (204)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (244)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (251)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (261)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (265)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (272)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (275)

<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (286)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (302)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (304)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (314)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (315)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (322)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (328)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (337)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (344)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (346)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (359)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (363)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (365)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (380)
<223> n equals a,t,g, or c

<400> 336
gatgggcagc gactacatcc gtgaggtgaa tgtggtgaag tctgcccgtn tcggttattc 60
caaaatgctg ctgggtggtt atgcctactt tatagagcat aagcagcgca acacccttat 120
ctggttgncg acggatggtg atgcccgnga actttatgaa aaaccacgt tgagcccgac 180
tattngngat attccgtcgn tgcntggggc tggccccgtg gtatggcaaa aaagcaccgg 240
gttnaacaag ntcaaccatg naagngttcc anctnaatgg gggggncccc gtaaccaaat 300
tngncctata agtnnatggg antttaanaa ttcaatnggc cctngntttt aaatggtgng 360
tgntnggcct tttttttttn gtttgt 386

<210> 337
<211> 506
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (13)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (307)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (340)
<223> n equals a,t,g, or c

<220>
<221> misc feature

<222> (360)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (404)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (412)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (414)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (437)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (439)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (469)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (470)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (471)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (472)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (481)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (483)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (501)

<223> n equals a,t,g, or c

<400> 337

```
aattcggcag agnattgaca tcaggaagga cctctatgct aacaatgtcc tatcaggggg 60
caccactatg taccctggca ttgccgaccg aatgcagaag gagatcacgg ccctagcacc 120
cagcaccatg aagatcaaga tcattgcccc tccggaggcg caaatactct gtctggatcg 180
gtggctccat cctggcctct ctgtccacct tccagcagat gtggatcagc aaacagggaa 240
tacggtgaag ccgggccttc cattgtccac cgcaaagtct ttcttaaaac acttttcctg 300
gttcctnttc tgtcttttag gcacacaact gtggaatgtn cctgtgggaa tttatggcn 360
tttcagtttc tttttccaaa tcattcctag ggccaaagt ttgnattggt tnanccatgg 420
ggttttttta aataaantnt ggaaataggg ttaattgggt aaaaaaann nnaaaaaaaa 480
ntntgggggg ggggggcccg ntaccc 506
```

<210> 338

<211> 623

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (441)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (508)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (509)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (513)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (537)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (565)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (597)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (599)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (612)

<223> n equals a,t,g, or c

<400> 338

```
gcggaacttg ctactaccag caccatgccc taccaatatc cagcactgac cccggagcag 60
aagaaggagc tgtctgacat cgctcaccgc atcgtggcac ctggcaaggg catcctggct 120
gcagatgagt ccactgggag cattgccaag cggtgcagt ccattggcac cgagaacacc 180
gaggagaacc ggcgcttcta ccgccagctg ctgctgacag ctgacgaccg cgtgaacccc 240
tgcattgggg gtgtcatcct cttccatgag acaactctacc agaaggcgga tgatgggcgt 300
cccttcccc aagttatcaa atccaagggc ggtgttgttg gcatcaaggt agacaagggc 360
gtgggtcccc tggcagggac aaatggcgag actaccaccc aagggttgga tgggctgtct 420
gagcgctgtg cccagtacaa ngaaggacgg agctgacttc ggccaagtgg cgttgtgtgc 480
ttaagaatgg gggaacacac cccctcannc ctnggcacatc tggaaaatgc caattgntct 540
ggccccgtat gccagtatct ggcancagaa tgcattgggc cattcgggga gtctgananc 600
tcctgatggg ancatgactt gaa 623
```

<210> 339

<211> 344

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (88)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (157)

<223> n equals a,t,g, or c

<220>

<221> misc feature
<222> (171)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (210)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (298)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (317)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (330)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (343)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (344)
<223> n equals a,t,g, or c

<400> 339
tcgacccacg cgctcgcttc aacatgattt gtcacaatct tatcaataat cattactctg 60
ttttttatat ttcaactaaa agtatcanaa tatagctttc cagaaaaccc cgaaccaaag 120
tcactgacta catcaaagtc tactacacct tggaganaac aaatgaacga naatctattt 180
tcctcattca ttacccaac aataataggn ctccctatcg taattattat cactatgttt 240
ccaagcatta tattcccatc acctaccga ctaatcaata atcgactcat ctccattnca 300
acaatggatt agtgcantga acatgcaaan gcaaggatta tcnn 344

<210> 340
<211> 345
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (6)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (13)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (31)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (88)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (90)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (128)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (135)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (138)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (146)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (153)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (172)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (173)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (296)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (313)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (339)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (343)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (345)
<223> n equals a,t,g, or c

<400> 340
agacangctc tantacgact cactataggg naaagctggt acgcctgcag gtaccgggtcc 60
ggaattcccg ggtcgaccca cgcgtccngn aggaggggac agctgcgggc gcggggaggg 120
ggcgccgngc cgcgnggngc catggnggac agnagagccg ggagtccgag annccgggcc 180
gcagcccag atgtcgccgc catggcttcg ccgcagctct gccgcgcgct ggtgtcggcg 240
caatgggtgg cggaagcgt gcgggccccg cgcgctgggg cagcctctgc agctgntagg 300
acgcctcctg gtnacctggc cggaagctgg ggggcgcgna cgncn 345

<210> 341
<211> 170
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (20)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (23)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (43)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (86)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (160)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (163)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (164)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (170)

<223> n equals a,t,g, or c

<400> 341

```
accacgcgt cgcgccacgn tcncgactag ttctagatcg cgnacggccg ctctagagga 60
tccaagctta cttggacatg catgcnacgt catagctctt ctatagtgtc acctaaatto 120
aattcactgg ccgtcgtttt acaacgtcgt gactgggaan atnntaaaaan 170
```

<210> 342

<211> 387

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (238)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (273)

<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (328)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (337)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (351)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (366)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (384)
<223> n equals a,t,g, or c

<400> 342
aatgacttggtt ttgagtactc accagtcaca gaaaagcatc ttacggatgg catgacagta 60
agagaattat gcagtgtctgc cataaccatg agtgataaca ctgcggccaa cttacttctg 120
acaacgatcg gaggaccgaa ggagctaacc gcttttttgc acaacatggg ggatcatgta 180
actcgccttg atcgttggga accggagctg aatgaagcca taccaaacga cgagcgtnac 240
accacgatgc ctgtagcaat ggcaacaacg ttngcaaact attaactggc ggactactta 300
ctctagcttc ccggcaacaa tttatagnct tgggtgnggc gggtaaagtt ncaaggccca 360
tttttngggtt tggccttcog gttngtt 387

<210> 343
<211> 186
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (26)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (64)
<223> n equals a,t,g, or c

<220>

<221> misc feature
<222> (71)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (109)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (152)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (153)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (160)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (183)
<223> n equals a,t,g, or c

<400> 343
gctgcaggaa attaacagag tctacnagga aatgtacaag actgatctgg agaaagacat 60
tatntcggac ncatctgggtg acttccgcaa gctgatgggt gccctggcna aaggttaaaa 120
aacagaagaa tgggtccgtcc ttgaatatga anngaatan ccacatgccc ggatttcctt 180
ganccc 186

<210> 344
<211> 611
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (8)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (11)
<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (285)

<223> n equals a,t,g, or c

<400> 344

```
tgcaaggnga nactaccctc actaaagga acaaaagctg gagctccacc gcggtgcggc 60
cgctctagaa ctagtgatc ccccggtg caggaattcg gcacgagctg cgttgggctc 120
cggaagccg ttcgggctgg ggctgtcggc cgcggggcgg aggcactcgc gcgggggatg 180
gcccactgcg tgaccttggg tcagctgtcc atttcctgtg accatctcat tgacaaggac 240
atcggtcca agtctgacct actctgcgtc cttttacagg atgtnggagg gggcagctgg 300
gctgagcttg gccggactga acgggtgcgg aactgctcaa gccctgagtt ctccaagact 360
ctacagcttg agtaccgctt tgagacagtc cagaagctac gctttggaat ctatgacata 420
gacaacaaga cgccagagct gagggatgat gacttcctag ggggtgctga gtgttcctta 480
ggacagattg tgtccagcca ggtactgact ctccccttga tgctgaagct ggaaaacctg 540
ctggcgggg gaccatcacg gtctcagctc aggaattaaa ggacaatcgt gtagtaacca 600
tggaggtaga g 611
```

<210> 345

<211> 344

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (289)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (296)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (329)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (331)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (342)

<223> n equals a,t,g, or c

<400> 345

```
tttccttcta cagtattcct gaatttgacg aatggaaaaa acatatagaa aaccagaaaag 60
cctggaaaat aaagtactat aaaggattgg gtactagtag agctaaagaa gcaaagggaat 120
attttgctga tatggaaagg catcgcatct tgtttagata tgctgggtcct gaagatgatg 180
```

```

ctgccattac cttggcattt agtaagaaga agattgatga cagaaaagaa tggttaacaa 240
attttatgga agaccggaga cagcgtagct acatggctta ccagaggant gattcnctct 300
caactcagac atgaaagatc tataccacnc ntgttgatgg cntt 344

```

```

<210> 346
<211> 506
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc feature
<222> (392)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc feature
<222> (452)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc feature
<222> (453)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc feature
<222> (472)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc feature
<222> (480)
<223> n equals a,t,g, or c

```

```

<220>
<221> misc feature
<222> (495)
<223> n equals a,t,g, or c

```

```

<400> 346
ggaaaaagccc aaggaaaaag caaagaatag caaaaaaaag ggggccaaga aggaagtggg 60
tgggattggg cttctttttt cttcagttag ttttttcccc aacaggttct gatggtcctt 120
tggctaccag caaaccagtc cctgcagaaa agtcaggtct tccagtgggt cctgagaacg 180
gagtagaact ttccaaagag gagctgatcc gcaggaagcg cgaggagttc attcagaagc 240
atgggagggg tatggagaag tccaacaagt ccacgaagtc agatgctcca aaggagaagg 300
gcaaaaaagc accccgggtg tgggaactgg gtggctgtgc taacaaagaa atgttggtatt 360
acagtacttc caccaccaat ggaacccttg angcttgctt tgtctgagga cattaacctt 420
gattccaagg gactgggtct ggggggcact tnnngatctg gactgcacac tntgatgacn 480
aagggttgtt taaantttcc aaacta 506

```

```

<210> 347

```

<211> 444
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (289)
<223> n equals a,t,g, or c

<400> 347
cggaagggag accatgttcc gagcggcggc tccggggcag ctccggcggg cggcctcatt 60
gctacgattt cagagtaccc tggtaatagc tgagcatgca aatgattccc tagcacccat 120
tactttaaat accattactg cagccacacg ccttgagggt gaagtgtcct gcttagtagc 180
tggaacccaaa tgtgacaagg tggcacaaga tctctgtaaa gtagcaggca tagcaaaagt 240
tctggtggct cagcatgatg tgtacaaagg cctacttcca gaggaactna caccattgat 300
tttggcaact cagaagcagt tcaattacac acacatctgt gctggagcat ctgccttcgg 360
aaagaacctt ttgccagag tagcagccaa acttgagggt gccccgattt ctgacatcat 420
tgcaatcaag tcacctgaca catt 444

<210> 348
<211> 358
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (19)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (52)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (187)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (280)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (295)
<223> n equals a,t,g, or c

<220>
<221> misc feature

<222> (301)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (317)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (348)
<223> n equals a,t,g, or c

<400> 348
ggcagagaag cagaagcgnc tcagttagag tccagcaaaa ggtttgccaa anagtttatg 60
gacagacatg gaatcccaac cgcacaatgg gaaggctttc accaaacctg aaaggaagcc 120
tgcagcttca ttttgagtgc agacttcctt gctttggttg tgaaaggcca gtggtcttgc 180
agctggnaaa aggggtgatt gttgcaaaga gcaaagaaga ggcctgcaag ctgtacaaga 240
gatcatgcag gtaggctggg tcttctggaa aaatttactn ttgtattcat actgnatgaa 300
ntaccgtttt aagtttnaaa aatgttcctc acattaaggg aaattctntt ttgcaacc 358

<210> 349
<211> 321
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (187)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (206)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (240)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (294)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (295)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (301)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (316)
<223> n equals a,t,g, or c

<400> 349
ggcgctttgc tctgtccacc aagattcctg acaccaaagg ctgcttgacg tgtcgtgtgg 60
tgcggaaccc ctacacgggt gccaccttcc tgctggccgc cctgcccacc agcctgctcc 120
tgctgcagtg gtatgagccg ctgcagaagt ttctgctgct gaagaacttc tccagccctc 180
tgcccanccc agctgggatg ctgganccgc tgggtgctgga tgggaaggag ctgccgcagn 240
gttttttttg ggccgaaggg cctaaagggc ccggttgccg gttcctgttc caanncctgc 300
ncctgggagg ttggcnttaa g 321

<210> 350
<211> 742
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (618)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (653)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (658)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (683)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (689)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (702)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (707)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (714)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (719)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (722)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (734)

<223> n equals a,t,g, or c

<400> 350

```

ggtcacgctg acccagtgtc cggaagct ggtgcagctc atcctgcacg aatacaagat 60
cttcaatgca gaagtgtttt tccgagaaga ctgctccccg gacgagttca tcgatgtgat 120
cgtgggcaac cgggtgtaca tgccctgcct gtatgtttat aacaaaatcg accagatctc 180
catggaagag gtggaccgcc tggcccgaag acccaacagt gtggatcatc gctgcggcat 240
gaagctgaac ctggactatc tgctggagat gctctgggag tacttggccc tgacctgcat 300
ctacaccaag aagagaggac agaggccaga cttcacagac gccatcattc tccggaaagg 360
ggcctcagtg gagcacgtgg gcaccagcac caagtacagt ccgcagcggg tgggcctgac 420
ccacaccatg gagcatgagg acgtcatcca gatcgtgaag aagtaacggc gcctgccggg 480
ccttccgccc acctgctcgt ctcccttggg aggtggtccc actgggacac acaaacaccc 540
aaacagaaaa atacaaatac acgtacccca agaaggggtc cctcaagtct ctgctattta 600
cagaagtttc ttcagtangc agaccaaaaa tgtgttgggc aaaagggctc ggntggangc 660
atttccata agactgagcc ctnttcattg ggggttttga gnttgantgc ttancctgna 720
tntgtgcttc caanccctg ac 742

```

<210> 351

<211> 272

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (167)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (251)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (272)

<223> n equals a,t,g, or c

<400> 351

```
aatcaggcgg gactgacggc agatcgatatg ctggtcctgt ccagagccgg gcaggcggca 60
gggctgacgt ttaaccagac cagcgagtca ctcagcgac tggttaaggc gggggtaagc 120
ggtgaggctc agattgcgtc catcagccag agtggtggcg gtttctnctc tgcattccggc 180
gtggagggtg acaaggtcgt tgaagccttc gagggggggc cgtaccatt tgcctatagt 240
aagcgtatta naataattgc cgtgttttaa an 272
```

<210> 352

<211> 256

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (170)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (236)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (248)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (251)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (252)

<223> n equals a,t,g, or c

<400> 352

```
gcagacgtcc agagcagagt cagccagcat gaccgagcgc cgcgtcccct tctcgtcct 60
gcggggcccc agctgggacc ccttcgcga ctggtaccgc catagccgcc tcttcgacca 120
```

```
ggccttggg ctgccccggc tgccggagga gtggtcgcag tggtaggcn gcagcagctg 180
gccaggctac gtgcgcccc tgccccccgc cgcctcgaga gccccgcagt ggccgngccc 240
gctacagncg nncgct 256
```

```
<210> 353
<211> 592
<212> DNA
<213> Homo sapiens
```

```
<220>
<221> misc feature
<222> (35)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (54)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (93)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (277)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (480)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (485)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (522)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc feature
<222> (545)
<223> n equals a,t,g, or c
```

```
<400> 353
ggttcccttc cagcgtgtgg aagcattgta ctttnggtct tcatgataaa tctnctgtct 60
```

```

gctcactcgt tgggtccgtg ccacctttaa aanctgtaac actcaccgag aaggctctgca 120
acttcactcc tggggccagc aagaccacga gtgcaccgag aggaatgaac aactctggac 180
acaccatctt taagaaccgt aatactcacc gcaagggtct gcaacttcat tcttgaagtc 240
agtgaggcca agaaccatc aattccgtac acatttnggt gactttgaag agactgtcac 300
ctatcaccaa gtggtgagac tattgccaaag cagtgagact attgccaaagt ggtgagacca 360
tcaccaagcg gtgagactat cacctatcgc caagtgggcc taagtgtgaa cgtgaagtcc 420
ccagccctgc tgctgagcca gttgctgccc tacatggaga acaagaaggg tgctgtcatn 480
ctggnetctt ccattgcagc ttataatcca gtagtggcgc tnggtgtcta caatgtcagc 540
aaganagagc tgctgggggc tcactagaac actggcattg ggcttggccc cc 592

```

<210> 354

<211> 539

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (4)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (223)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (225)

<223> n equals a,t,g, or c

<400> 354

```

cacnaaccct cactaaaggg aacaaaagct ggagctccac cgcggtgacg gccgctctag 60
aactagtgga tccccgggc tgcaggaatt cggcacgagc cgtctcaggc tcgtagttcg 120
ccttcaacat gccggaacca gcgaagtccg ctcccgcgcc caagaagggc tcgaagaaag 180
ccgtgactaa ggcgcagaag aaggacggca agaagcgcaa ggnanccgca aggagagcta 240
ctccgtatac gtgtacaagg tgctgaagca ggtccacccc gacaccggca tctcctctaa 300
ggccatggga atcatgaact ccttcgtcaa cgacatcttc gaacgcatcg cgggtgaggc 360
ttccgccttg gcgcattaca acaagcgctc gaccatcacc tccagggaga tccagacggc 420
cgtgcgcctg ctgctgcccg gggagttggc caagcacgcc gtgtccgagg gcaccaaggc 480
cgtcaccaag tacaccagcg ctaagtaaac ttgccaagga gggactttct ctggaattt 539

```

<210> 355

<211> 435

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (296)

<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (299)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (396)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (419)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (421)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (422)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (424)
<223> n equals a,t,g, or c

<400> 355
gcttcgctca cctgcccagg agtacctttg tgttgatga atttaagcgc aagtactcca 60
atgaggacac actctctgtg gcactgccat atttctggga gcactttgat aaggacggct 120
ggtccctgtg gtactcagag tatcgcttcc ctgaagaact cactcagacc ttcattgagct 180
gcaatctcat cactggaatg ttccagcgac tggacaagct gaggaagaat gccttcgcca 240
gtgtcatcct ttttggaacc aacaatagca gctccatttc tggagtctgg gtcttncng 300
gccaggagct tgcctttccg ctgagtccag attggcaagt ggactacgaa gtcatacaca 360
tggcggaaac tggatctggc aagcgaggag acccanacgc tggttcgaga gtacttttnc 420
nngngagggg gcctt 435

<210> 356
<211> 502
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (21)
<223> n equals a,t,g, or c

<220>

<221> misc feature
<222> (168)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (239)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (243)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (252)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (275)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (288)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (292)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (298)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (316)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (317)
<223> n equals a,t,g, or c

<220>
<221> misc feature

<222> (324)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (328)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (339)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (348)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (364)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (372)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (386)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (390)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (393)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (397)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (403)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (413)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (417)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (419)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (420)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (425)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (426)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (430)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (437)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (440)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (442)

<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (445)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (449)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (452)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (457)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (458)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (459)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (461)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (476)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (478)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (485)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (497)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (499)
<223> n equals a,t,g, or c

<400> 356
aattcggcac gagagggagt ntgagcaagg ggtgtacacc tgcacagcac agggcatttg 60
gaagaatgaa cagaagggag agaagattcc tcggtgcttg ccagtttggtg ggaagcccgt 120
gaaccccgtg gaacagagggc agcgcacatcat cggagggcaa aaagccangg ggatagtggg 180
ggcgtttttg cagtaaggga cccgaacact gatcgctggg tggccacggg catcggtgnc 240
ctnngggcatc gngtgcagca gggccttatg gcttnttaca ccaaagtnc cnaacttncg 300
tggccttgga tcaagnnaga cctngganca ggaggactnc cgccccanca ttcactaggt 360
tcenaatcca gngagcagtt tcgcanaaan canccanaca cancttcccc ctntttngnn 420
accnncnagn gtctctnttn anattcctnc tngcacnnna ncccacaacc ccccnncnc 480
ccccncccc ccccnncnc cc 502

<210> 357
<211> 440
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (45)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (236)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (262)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (293)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (300)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (316)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (339)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (360)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (362)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (378)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (387)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (389)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (402)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (407)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (418)
<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (426)

<223> n equals a,t,g, or c

<400> 357

```
aatatatcga acagtcaggt taacaggctg cggcattttg tccgngccgg gcttcgctca 60
ctgttcaggc cggagccaca gaccgccgtt gaatgggagg atgctaatta ctatctcccg 120
aaagaatccg cataccagga agggcgctgg gaaacactgc cctttcagcg ggccatcatg 180
aatgcgaatg ggcagcgact acatccgtga gtggaatgtg gtgaagtgtg cccgtntcgg 240
ttattccaaa atgctgctgg gngtttatgc ctactttata gggcataagc agnggaacan 300
ccttatttgg ttccncagg atggtggatg cccgagaant ttttgaaaa cccacgttgn 360
gncgattatt tcgggganat ttccgngnt gttggggttt gnccccntgg gttttggnaa 420
aaaganccgg gtaaaagggtt                                     440
```

<210> 358

<211> 234

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (16)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (46)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (92)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (162)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (166)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (175)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (208)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (230)

<223> n equals a,t,g, or c

<400> 358

```
ggaaaggggtg tttatncctc atggactaat tatggacagg actgancgtt ttgctcgaaa 60
tgtgatgaag gagatgggag gccatcacat tntagtcctc ttttgctca aggggggcta 120
taaatttttt gctgacctgc tggattacat caaaggactg antagnaaat agtgnataga 180
tccattcctc atgaactgtg gatTTTTngc agatctgaag agctattgtn atga      234
```

<210> 359

<211> 668

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (15)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (19)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (20)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (295)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (512)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (552)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (558)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (559)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (579)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (588)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (593)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (659)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (667)

<223> n equals a,t,g, or c

<400> 359

```
ctgactccag tttgntatnn ccatgattac gccaaagctct aatacgactc actatagggg 60
aagctgggtac gcctgcaggt accgggtccgg aattcccggg tcgacccacg cgtccggggg 120
gtttgaggta cataagaaaa atgtaagggg tgaattcact tattatgaaa tacaagataa 180
tacagggaag atggaagtgg tgggtcatgg acgactgacc acaatcaact gtgaggaagg 240
agataaactg aaactcacct gctttgaatt ggcaccgaaa agtgggaata ccgngagtt 300
gagatctgta attcatagtc acatcaaggt catcaagacc aggaaaaaca agaaagacat 360
actcaatcct gattcaagta tggaaacttc accagacttt ttcttctaaa atctggatgt 420
cattgacgat aatgtttatg gagataaggt ctaagtgcct aaaaaaatgt acatatacct 480
ggttgaaata caacactata catcacacc ancatatata ctagcttggt aatcctatgg 540
aaatggggta tntggagnnc ttttttaatt tttcatagnt tttttttnat aanaatggca 600
tattttggat ctacaacttc tatgatttga aaaaatacct taacccttat cttttttgng 660
aaaaaana 668
```

<210> 360

<211> 401

<212> DNA

<213> Homo sapiens

<400> 360
caccattacc agcggcggca atcctccggc cttttccctg acaccggacg gaaagctgac 60
cgctaaaaat gcgatatca gtggcagtgt gaatgcgaac tccgggacgc tcagtaatgt 120
gacgatagct gaaaactgta cgataaacgg tacgctgagg gcggaaaaaa tcgtcgggga 180
cattgtaaag gcggcgagcg cggcttttcc gcgccagggtg gaaagcagtg tggactggcc 240
gtcagggtacc cgtactgtca ccgtgaccga tgaccatcct tttgatcgcc agatagtggg 300
gcttccgctg acgtttcgcg gaagtaagcg tactgtcagc ggcaggacaa cgtattcgat 360
gtgttatctg aaagtactga tgaacgggtgc ggtgatttat g 401

<210> 361
<211> 273
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (156)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (189)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (236)
<223> n equals a,t,g, or c

<400> 361
accggaacac ggcactgggc ggcgtgcagg tggactcgga gcagttcggc agccagcagg 60
tgagccgtaa ttatcatctg cgcgggcgta ttctgcagggt gccgtcgaac tataaccgcg 120
agacgcggca atacagcggg atctgggacg gaacgnntaa accggcatac agcaacaaca 180
tggcctggng tctgtgggat atgctgaccc atccgcgcta cggcatgggg aaacgncttg 240
gtgcggcgga tgtggataaa tgggcgctgt atg 273

<210> 362
<211> 248
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (5)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (37)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (41)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (52)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (74)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (145)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (161)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (185)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (194)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (210)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (218)
<223> n equals a,t,g, or c

<400> 362
cgctcngtcgg gcgagcgatg atgcggaagg ttacctngat nttttcaaag gnaagataac 60
cgaatcccat ctncgcaagg agctgctgga aaaagtcgag ctgacggagg ataacgccag 120
cagactggag gagttttcga aagantggaa ggatgccagt nataagtgga atgccatgtg 180
ggctntcaaa attnagcaga ccaaagacgn caaacgantt ttattctgct atttagtagt 240

aagatcag

248

<210> 363

<211> 149

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (131)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (137)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (144)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (145)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (147)

<223> n equals a,t,g, or c

<400> 363

tgccggactt tcacgtgag gatgactggt ggcgtaacgg ccagaatctc tatctggata 60
atctggaggc gacggggctg tatcagggtgc cgttgtcagc ggcacagccg ggcgatgtgc 120
tgctgtgctg ntttgntca tcannngncg 149

<210> 364

<211> 352

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (4)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (93)

<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (196)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (319)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (322)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (325)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (338)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (340)
<223> n equals a,t,g, or c

<400> 364
gcanaaagaa aatggcacag taacagctgc caatgccagt acactgaatg atggagcagc 60
tgctctgggt ctcatgacgg cagatgcagc gangaggctc aatgttacac cactggcaag 120
aatagtagca ttgctgacg ctgctgtaga acctattgat tttccaattg ctcctgtata 180
tgctgcatct atggtncctta aagatgtggg attgaaaaaa gaagatattg caatgtggga 240
agtaaatgga agccttttagt ctggttgtac tagcaaacat taaaaatgtt ggagattgga 300
tccccaaaaa gtgaatatnc anggnaggag ctgtttcncn ggggacatcc ca 352

<210> 365
<211> 272
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (37)
<223> n equals a,t,g, or c

<220>
<221> misc feature

<222> (42)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (44)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (47)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (80)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (91)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (116)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (132)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (145)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (190)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (226)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (242)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (260)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (261)

<223> n equals a,t,g, or c

<400> 365

```
aggaaaaagc ccggcctcct ggtggggcag tgccggncac ancntgntgc cctgcagagg 60
ggcttgtagc gctgctggan tgacagcctt ncgaggcttt gctgtctcgg cacggnaggt 120
ctggcaaac accaggacagac caggnacatg ggaccaaagc cggaacctcc tgctcaacgg 180
gaagtcctan cccaccaaag tgcgcctgat ctgggggggc tccctncccc cagtcaagcg 240
gncggcggat gaactggatn nacgccccgg at 272
```

<210> 366

<211> 254

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (23)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (192)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (208)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (209)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (236)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (244)

<223> n equals a,t,g, or c

<400> 366

```
ggctctacta ggactcacta tanggaaagc tggtagcct gcaggtaccg gtccggaatt 60
cccggtcgca cccacgcgtc cgcttctctg cctagaaggg ataatattat cactcttcgt 120
tataataaca atcaccatct taattaacca ccttacatta gccagcataa cccctatcat 180
ccttcttgta tntgcagcct gtgaagcnc actggggcct atccctttta gttatnatct 240
caantacata cgga 254
```

<210> 367

<211> 185

<212> DNA

<213> Homo sapiens

<400> 367

```
gattggattc gacaacaaaa aagacctgct tatctcggtg ggcgatttgg ttgatcgtgg 60
tgcagagaac gttgaatgcc tggaattaat cacattcccc tggttcagag ctgtacgtgg 120
aaaccatgag caaatgatga ttgatggcct atcagagcgt ggaaacgtta atcactggct 180
gctta 185
```

<210> 368

<211> 458

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (3)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (4)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (6)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (15)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (27)

<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (170)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (193)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (232)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (246)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (250)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (316)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (340)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (395)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (399)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (404)
<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (415)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (433)

<223> n equals a,t,g, or c

<400> 368

```
agnncnatag aaagnacgcc tgcaggnacc ggtccggaat tcccgggtcg acccagcgt 60
ccggagttag ccttgaacgc ctggacctgg acctcacagc tgacagccag ccacccgtct 120
tcaaggtctt cccaggcagt accactgagg actacaacct tattgttatn gaacgtggcg 180
ctgccgctgc acnaccggcc agccagggac tgcgcctgca ggaacccctg gngccccacc 240
cctggntggn atggccattg tcaaggagga ggagacggag gctgccattg gagccctcc 300
tactgccact gagggncctg agaccaaacc tgtgttatn gctcttgagg agggtcctgg 360
tgctgagggt tcccggctgg actcactagt ggcanaacna ctcnnggctgg aagtngtagc 420
tctgaggggac tcngccccag tgttggccgg gacctgat 458
```

<210> 369

<211> 288

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (15)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (17)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (47)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (56)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (71)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (103)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (114)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (225)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (239)

<223> n equals a,t,g, or c

<400> 369

```
gcgctggagc tgctngngca ctgcggcgtg tgcagagagc gcctgcnacc cgaganggag 60
ccccgcctgc ngccctgttt gcaactcgcc tgtagtgcc gcntagggcc cgcngccccg 120
ccgccgcaa cagctcgggg gacggcgggg cggcgggga cggcaccgtg gtggactgtc 180
ccgtgtgcaa gcaacagtgc ttctccaaag acatcgtgga gaatnatttc atgcgtgana 240
gtggcagcaa ggctgccacc gacgcccagg atgcgaacca gtgctgca 288
```

<210> 370

<211> 292

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (47)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (53)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (60)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (61)

<223> n equals a,t,g, or c

<220>

<221> misc feature
<222> (101)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (141)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (263)
<223> n equals a,t,g, or c

<400> 370
ccatctttgc attgttcctc atccgcctcc ttgctcgccg cagccgntc cgncgcgcgn 60
ntcctccgcc gccgcggact ccggcagctt tatcgccaga ntccctgaac tctcgctttc 120
tttttaatcc cctgcatcgg ntcaccggcg tgccccacca tgtcagacgc agccgtagac 180
accagctccg aaatcaccac caaggactta aaggagaaga aggaagtttt ggaaagagggc 240
agaaaaatgga agagacggcc ctnccttaacg gggaatgcta atttagggaa at 292

<210> 371
<211> 477
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (35)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (276)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (313)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (342)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (374)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (399)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (410)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (427)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (434)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (447)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (448)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (451)
<223> n equals a,t,g, or c

<400> 371
ggcacaggat aattttaagc atttaaattg aattnatctt tttcactgta ttgatccaaa 60
tggttccaag cataaaagaa cggacagatc aattttatgt tgtttacgaa aaggagaatc 120
tggccagtca tggcaagggt taacaaaaga aagggcaaag ctttaattggc ttagtggtcga 180
cttcaataat tgggaaagac tgggaagatg attcaaatga agacatgtct aattttgaat 240
cgtttctctg aggattcaca agacagtgat gatggnaaaa atgccagatc tgggagtaag 300
ggaatattgt ccntcacctg ggtttttgag gaaaggaaaa tnaactttct ctggcaagggt 360
tttcataat ttgngaggaa ttccccgagt ttgtagcnc cttaaagggn gttatgctcg 420
tatttgnccc actntaacc ctttttnnca nccggtttgt ttttttaaaa gggcttc 477

<210> 372
<211> 443
<212> DNA
<213> Homo sapiens

<220>

<221> misc feature
<222> (14)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (67)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (74)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (107)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (116)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (123)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (171)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (174)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (220)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (222)
<223> n equals a,t,g, or c

<220>
<221> misc feature

<222> (293)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (314)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (329)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (335)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (340)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (351)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (364)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (373)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (407)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (411)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (426)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (430)

<223> n equals a,t,g, or c

<400> 372

```
ggcagagcac tgtnaaacta gaacatgcta aatctgttgc ttccagagcc actgtcctcc 60
agaaganatc ctnnaccctt gtaggaatgt ttttgaaact aaatttnatg aacgtnaaat 120
ttncacgtgg ttattatgaa cttccttgtc gaagttgaaa ggtgaacaac nctnatattg 180
caaataccgt agagcttcag agtgcaagat tctccactgn angttgggca ttcacaaatg 240
ttggatcttt cccaccgtgg gatgaagggt tcagaggcat tgcacccaaa atnaccggg 300
tgaacatacc cagnccaaag cccaggggna cattnatcgn ggacaggccc nccagaattt 360
ggcntgttct ttncacgttg gtaggtgtgg aacttgggggt tgaattnatt ncttaaccga 420
attnnccgn ttccttaacc gag 443
```

<210> 373

<211> 464

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (20)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (235)

<223> n equals a,t,g, or c

<400> 373

```
cggatccgca ggcgcacgtn gcgatgttgt cctctacagc catgtattcg gctcctggca 60
gagacttggg gatggaaccg cacagagccg cgggcccttt gcagctgcga ttttcgccct 120
acgttttcaa cggaggtact atactggcaa ttgctggaga agattttgca attgttgctt 180
ctgatactcg attgagtga gggttttcaa ttcatacgcg ggatagcccc aaatnttaca 240
aattaacaga caaaacagtc attggatgca gcggttttca tggagactgt cttacgctga 300
caaagattat tgaagcaaga ctaaagatgt ataagcattc caataataag gccatgacta 360
cgggggcaat tgctgcaatg ctgtctacaa tcctgtattc aaggcgcttc tttccatact 420
atgtttacaa catcatcggg ggacttgatg aagaaggaaa gggg 464
```

<210> 374

<211> 369

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (216)

<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (218)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (219)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (221)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (332)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (357)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (360)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (363)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (369)
<223> n equals a,t,g, or c

<400> 374
ggcacagcct ctacagccat gtattcggct cctggcagag acttggggat ggaaccgcac 60
agagccgcgg gccctttgca gctgcgattt tcgcctacg ttttcaacgg aggtactata 120
ctggcaattg ctggagaaga ttttgcaatt gttgcttctg atactcgatt gagtgaagg 180
ttttcaattc atacgcggga tagcccaaaa tggtgncna ntaacagaca aaacagtcac 240
tggatgcagc ggttttcatg gagactgtct tacgctgaca aagattattg aagcaagact 300
aaagatgtat aagcattcca ataataaggc cntgactacg gggggcaatg ctggcangcn 360
gtnctacan 369

<210> 375

322

<211> 313
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc feature
 <222> (32)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (249)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (259)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (268)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (293)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (308)
 <223> n equals a,t,g, or c

<400> 375
 tacccttcat cactaaaggc cgcctgtgcg tnttttttta cgggattttt ttatgtcgat 60
 gtacacaacc gcccaactgc tggcggcaaa tgagcagaaa ttttaagttg atccgctgtt 120
 tctgcgtctc tttttccgtg agagctatcc cttcaccacg gaggaaaagtc tatctctcac 180
 aaattccggg actggtaaac atggcgctgt acgtttcggc gattgtttcc ggtgaagggt 240
 atcccgttnc cctggcggnr tccacctntg aatttaaggc cgggataatg tcnaagcccc 300
 aagcatgnaa gtg 313

<210> 376
 <211> 375
 <212> DNA
 <213> Homo sapiens

<400> 376
 cgggttccgg tgaccacgaa ggcggcaaa ggcgacggaat ggaggaggtg cctcacgact 60
 gtccaggggc cgacagcgcc caggcgggca gaggggcttc atgtcaggga tgccccaacc 120
 agcggctgtg cgcttctgga gcgggggcca ctccggacac ggctatagag gaaatcaaag 180

agaaaatgaa gactgtaaaa cacaaaatct tggattgtc tgggaaaggc ggtgttgga 240
aaagcacatt cagcgccac cttgcccac gcctagcaga ggatgaaaac acacagattg 300
ctcttctaga catcgatata tgtgggccat cgattcccaa gataatggga ttggaaggag 360
agcaggttca ccaga 375

<210> 377

<211> 434

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (9)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (17)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (22)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (32)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (33)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (47)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (58)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (64)

<223> n equals a,t,g, or c

<220>

<221> misc feature
<222> (69)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (73)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (98)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (112)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (116)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (118)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (146)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (151)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (161)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (163)
<223> n equals a,t,g, or c

<220>
<221> misc feature

<222> (193)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (212)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (214)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (228)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (235)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (243)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (250)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (262)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (263)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (264)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (265)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (267)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (279)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (301)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (320)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (330)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (337)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (351)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (370)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (381)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (409)

<223> n equals a,t,g, or c

<400> 377
ggcagcagng tggctcnagg gngtcacctt cnntgttacc accgttnaca ccaaaagncg 60
gacngagana gtncagaagc tgtgccagg ggggcagntc ccattcctgc tntatngnac 120
tgaagtgcac acagacacca acaagnttgc ngaatttctg nangcagtgc tgtgccctcc 180
caggtagccc aanctggcag ctctgaacct tnanccaac acagctgngc tgganatatt 240
tgncaaattn tctgcctaca tnnnnanttc aaaccacagna ctcaatgaca atctggagaa 300
nggactcctg aaagccctgn acgttttagn caattantta acatcccccc nctcagaaga 360
agtggatgan accagtgtg nagtgaaggt gtctctcaga agaagttnt ggatagcacg 420
agctcacct gggg 434

<210> 378
<211> 506
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (133)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (294)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (367)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (376)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (386)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (389)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (421)
<223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (440)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (443)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (472)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (479)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (492)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (493)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (496)
 <223> n equals a,t,g, or c

<220>
 <221> misc feature
 <222> (503)
 <223> n equals a,t,g, or c

<400> 378
 aattttcact cccctcagaa cataacatag taaatggatt gaattatgaa gaatggtttt 60
 tatgcgactt accgcagcaa aaataaaggg aaagataagc gctcaataaa cctgtctgtt 120
 ttccttaatt ctntgctggc tgataatcat cacctgcagg ttggctccaa ttatttgtat 180
 attcataaaa tcgatggaaa aacttttctc tttaacaaaa caaatgacaa gagtctgggt 240
 cagaagataa atcgtcttaa agcttcagtt gaagatatta agaacagcct cgtngatgac 300
 ggaatcattg ggattcccat cttttttgtt tgttgaaggc gacaccattg gtttttgcca 360
 gaactgnttt tcgggncggc cacatncgnt tttgacaggt ttttttaatc ggggaaggga 420
 ntgtccttaa ggcgtggggn gcngttcagt tggggccctg ttgggggggac cnccaaggng 480
 gtgggttatgg cnnggntttc atnggc 506

329

<210> 379
<211> 550
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (6)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (9)
<223> n equals a,t,g, or c

<400> 379
gacganacna accctcacta aagggaaaca aagctggagc tccaccgcgg tgcggccgct 60
ctagaactag tggatcccc gggctgcagg aattcggcac gaggccatcc agactgagga 120
agaccgcgaa acttaggggc cacgtgagcc acggccacgg ccgcataggc aagcaccgga 180
agcaccgccg cggccgcggt aatgctggtg gtctgcatca ccaccggatc aacttcgaca 240
aataccaccc aggctacttt gggaaagttg gtatgaagca ttaccactta aagaggaacc 300
agagcttctg cccaactgtc aaccttgaca aattgtggac tttggtcagt gaacagacac 360
gggtgaatgc tgctaaaaac aagactgggg ctgctcccat cattgatgtg gtgcgatcgg 420
gtactataaa agttctggga aagggaaagc tcccaaagca gcctgtcatc gtgaaggcca 480
aattcttcag cagaagagct gaggagaaga ttaagagtgt tggggggggc tgtgtcctgg 540
tggtttgaag 550

<210> 380
<211> 573
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (4)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (6)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (10)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (160)
<223> n equals a,t,g, or c

<400> 380

```
aagncnagan agccaaccct cactaaaggg aacaaaagct ggagctccac cgcgggtgcgg 60
ccgctctaga actagtggat cccccgggct gcaggaattc ggcacgagcg caaagaaggg 120
tggcgagaag aaaaagggcc gttctgccat caacgaaggn taacccgaga atacaccatc 180
aacattcaca agcgcaccca tggagtgggc ttcaagaagc gtgcacctcg ggcactcaaa 240
gagattcgga aatttgccat gaaggagatg ggaactccag atgtgcgcat tgacaccagg 300
ctcaacaaag ctgtctgggc caaaggaata aggaatgtgc cataccgaat ccgtgtgcgg 360
ctgtccagaa aacgtaatga ggatgaagat tcaccaaata agctatatac tttggttacc 420
tatgtacctg ttaccacttt caaaatttct gtgctaaaca gtgttacagt cgccaagagc 480
ccataaaggg agccctcctg gaagtggatg aggccttggg tctcggctct tcattgcttc 540
ctgagctgca gcagatgcct ttacaaccaa gct 573
```

<210> 381

<211> 531

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (5)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (8)

<223> n equals a,t,g, or c

<400> 381

```
gcagnacnaa ccctcactaa agggaacaaa agctggagct ccaccgcggt gcggccgctc 60
tagaactagt ggatcccccg ggctgcagga attcggcacg aggcggcggt ggcggcttgt 120
gcagcaatgg ccaagatcaa ggctcgagat cttcggcgga agaagaagga ggagctgctg 180
aaacagctgg acgacctgaa ggtggagctg tcccagctgc gcgtcgccaa agtgacaggc 240
ggtgcggcct ccaagctctc taagatccga gtcgtccgga aatccattgc ccgtgttctc 300
acagttatta accagactca gaaagaaaac ctcaaggaaat tctacaaggg caagaagtac 360
aagcccctgg acctgcggcc taagaagaca cgtgccatgc gccgccggct caacaagcac 420
gaggagaacc tgaagaccaa gaagcagcag cgggaaggagc ggctgtaccc gctgcggaag 480
tacgcggtca aggcctgagg ggcgcattgt caataaagca cagtggctga g 531
```

<210> 382

<211> 300

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (5)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (40)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (43)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (59)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (171)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (172)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (175)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (179)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (184)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (190)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (203)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (271)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (292)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (293)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (300)

<223> n equals a,t,g, or c

<400> 382

ngggngtacc acaaataaa ggcaaagagg aactgctggn cangagtacg ggggtgtggnc 60
atgaatcctg tggagcatcc ttttgaggt ggcaaccacc agcacatcgg caagccctcc 120
accatccgca gagatgcccc tgctggccgc aaagtgggtc tcattgctgc nngcnggant 180
ggangtctcn ggggaaccaa gantgtgcag gagaaagaga actagtgtc agggcctcaa 240
taaagtttgt gtttatgcc aaaaaaaaaa naaaaaaaaa aaaaaaaaaa annaaagagn 300

<210> 383

<211> 475

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (36)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (146)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (363)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (367)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (401)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (404)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (415)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (450)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (451)

<223> n equals a,t,g, or c

<400> 383

```
atgacgccgg tgcagcgggg gggcccgggg gcctgngtgg ccctgggatg gggaaccgcg 60
gtggcttccg cgaggtttcg gcagtggcat ccggggccgg ggtcgcggcc gtggacgggg 120
ccggggccga ggccgcggac tcgcgnaggc aaggccgagg ataaggagtg gatgcccgtc 180
accaagtggg gccgcttggt caaggacatg aagatcaagt ccctggagga gatctatctc 240
ttctccctgc cattaagga atcagagatc attgattctt cctgggggct ctctcaagga 300
tgagttttga agatatgcca tgcagaagca gaccctgccg gccacgcacc agttcaagca 360
ttnttгнаac gggattaaat gccactcggt tggtttaatg nccnagagtg gcacncatcc 420
tgggcaaaac tggcaaattt caagtccttn naagtatggg gaaaatggaa cccaa 475
```

<210> 384

<211> 127

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (5)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (8)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (31)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (62)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (71)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (103)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (124)

<223> n equals a,t,g, or c

<400> 384

caatntgnag accagattcc taaggctgca naggggacag tgggatctat tttaggaccg 60
angagattaa ncagagacac aggcaattgt atgtcagcag ctngatttaa cccacctaaa 120
aggngcg 127

<210> 385

<211> 317

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (30)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (151)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (187)

<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (203)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (231)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (264)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (308)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (311)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (316)
<223> n equals a,t,g, or c

<400> 385
ggcacgaggg atgtgcgacg tgtgcctggn gtagccccga ctcttgtagc gtcggcatct 60
gagaccagtg agaaacgccc cttcatgtgt gcttaccag gctgcaataa gagatatttt 120
aagctgtccc acttacagat gcacagcagg naagcacact ggtgagaaac cataccagtg 180
tgacttnaag gactgtgaac gangttttct cgttcagacc agctcaaaag ncaccaaagg 240
aggacataca ggtgtgaacc attnccagtg taaaattggt cagcgaaatt ctcccgggcc 300
gaccaacnga ngaccna 317

<210> 386
<211> 433
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (295)
<223> n equals a,t,g, or c

<220>
<221> misc feature

<222> (311)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (359)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (385)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (405)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (407)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (427)

<223> n equals a,t,g, or c

<400> 386

```

tttcaaaaagc tatttaggtg acactataga aggtagcctg caggttaccg gtccggaaat 60
tcccgggtcg acccacgcgt ccgccgagag ccttagccga cggaaactgg acactggaac 120
cggcagcgcc atgagactcc tccccgctt gctgctgctt ctcttactcg tgttccctgc 180
cactgtcttg ttccgaggcg gccccagagg ctgtgtagca gtggcacaag atcttacaga 240
ggatgaagaa acagtagaag attccataat tgaggatgaa gatgatgaag ccgangtaga 300
agaagatgaa nccacagatt ttgtagaaga taaagaggaa gaagatgtgt ctggtgaanc 360
tgaaacttta ccgagtgcag atacnactat actgttttta aaggngnaga ttttccgcca 420
ataacantgt gaa                                     433

```

<210> 387

<211> 407

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (315)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (356)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (359)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (373)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (376)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (407)

<223> n equals a,t,g, or c

<400> 387

```

atttgaagca aacaggcagc gcgcgacaat ggcggtcgct cgtgcagctt tggggccatt 60
ggtgacgggt ctgtacgacg tgcaggcttt caagtttggg gacttcgtgc tgaagagcgg 120
gctttcctcc cccatctaca tcgatctgcg gggcatcgtg tctcgaccgc gtcttctgag 180
tcagggttga gatattttat tccaaactgc ccaaaatgca ggcacagtt ttgacaccgt 240
gtgtggagtg ccttatacag ctttgccatt ggctacagtt atctgttcaa ccaatcaaat 300
tccaatgctt attanaagga aagaaacaaa ggattatgga actaagcgtc ttgtanaang 360
aatattaatc canganaaac tgtttaatca ttgaaatggt gtcccan 407

```

<210> 388

<211> 244

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (215)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (221)

<223> n equals a,t,g, or c

<400> 388

```

ttcgttcac tatcggtatcg ccacactcac aacaatgagt ggcagatata gcctgggtggt 60
tcaggcggcg cttttttatt gctgtgttgc gctgtaattc ttctattttc gatgctgaat 120
caatgatgtc tgccatcttt cattaatccc tgaactgttg gtttaatacgc ttgaggggtga 180
atgcgaataa taaaaaagga gcctgtagct ccctnatgat nttgcttttc atgttcacgc 240

```


ttcc

244

<210> 389

<211> 239

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (21)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (55)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (64)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (71)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (116)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (128)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (163)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (185)

<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (196)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (202)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (205)
<223> n equals a,t,g, or c

<400> 389
nggactggcg tcagacgtcg nattccggcg cccacggctg gcttaaacc tggtncaatc 60
ctgncgcccg ncgtgatgcc agggaagaca gggcgacctg gaagtccaac tacttnctta 120
agatcatnca acgtattggg atgattatcc taaaatgggt tcnattggtg ggtagcgagt 180
acganatggt ggggcntcct anagntagta tggcgagcta gagtcccggc taatgttcc 239

<210> 390
<211> 382
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (5)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (54)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (69)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (102)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (103)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (108)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (126)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (169)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (192)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (217)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (219)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (221)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (235)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (342)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (345)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (346)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (360)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (374)
<223> n equals a,t,g, or c

<400> 390
tcaangcgca attaaccctc actaaaggga acaaaagctg ggaacgatct ggtntctctg 60
cgcgctgcnc gcacactgag gccgcccggg acaaagcccg gnntcgngc gacctttggt 120
cccggntca gtgagcgagc gagcgcgag agagggagt gccaacttna tcactagggg 180
ttccttgtag tnaatgatta acccgccatg ctacttngc nacgtagcca tgggntacca 240
agctcgagct ctctagactc gacgcgcgta atacgactca ctatagggcg aatttgagct 300
ccaccgcggt tgcggccgct ctactagagt cgacctcatg gnttnncccc gaaacccgcn 360
aacaccgcgt gacncgccct ta 382

<210> 391
<211> 375
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (6)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (7)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (48)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (70)
<223> n equals a,t,g, or c

<220>
<221> misc feature

<222> (104)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (117)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (138)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (146)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (159)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (208)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (223)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (261)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (269)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (275)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (279)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (299)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (351)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (366)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (370)

<223> n equals a,t,g, or c

<400> 391

```

tgcaannгаа tacacactaa ggacaagtgg actcacggtg cgccctcnga ctagtgggtcc 60
cggggtgcagn tgccaggggtg gcctgagcga tctacggatg ggcngtatgg agtggangag 120
acgagatgcg ggtgttanag cagggnctga ccggagtgn acacatgagt gtcaggtgca 180
ggtagtccga gtcggcgaca tgagcctnga gtagagtcac cantcgatga gatctggagg 240
caactggcga gcaagaccgt ntgggtgcant gtcantcang ctgttgacagg tgagagcant 300
gcactcgtcg agtggcgaga cagatcaatc tctgttagcg ggtggagggt ncactcgcgc 360
tgtgngggtg cactg 375

```

<210> 392

<211> 121

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (3)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (9)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (13)

<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (56)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (67)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (113)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (118)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (120)
<223> n equals a,t,g, or c

<400> 392
gantcatcng agngtggtga ttgagccgc cgcatttttt aaccctaaat ctcganatgc 60
atcgtgnttc ctgtccattg gactgtaagg tttatgtagg catcttgga acnatggan 120
a 121

<210> 393
<211> 83
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (65)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (66)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (70)
<223> n equals a,t,g, or c

<220>

<221> misc feature
<222> (73)
<223> n equals a,t,g, or c

<400> 393
ggcagagaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 60
aaaanncccn ggngggggcc ccc 83

<210> 394
<211> 218
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (13)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (64)
<223> n equals a,t,g, or c

<400> 394
gtcggcgag aangcgcccc gcacccccgc caggcgcatg tctgcacctc cgcttgccaa 60
aggncctcgg tcagcgactg gatgctcgcc atcaagggtc agtggaagtt cttcaagagg 120
aaaggcgccc ccgccccagg cttccgcgcc cagcgctcgc cacgctcagt gcccgtttta 180
ccaataaact gagcgacccc aaaaaaaaaa aaaaaaaag 218

<210> 395
<211> 83
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (11)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (13)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (83)
<223> n equals a,t,g, or c

<400> 395
aattcggcac ngnaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 60

aaaaaaaaaa aaaaaaaaaa aan

83

<210> 396

<211> 70

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (69)

<223> n equals a,t,g, or c

<400> 396

aattcggcac agaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 60

aaaaaaaaana

70

<210> 397

<211> 140

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (50)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (57)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (74)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (93)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (113)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (114)

<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (115)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (139)
<223> n equals a,t,g, or c

<400> 397
aatttgacca gagaacaaga ataaccggc ctcagcgccg gggtttcttn gcctcangat 60
cgcccccaaa acanataacc aattgtattt atngaaaaat aaatagatac aannnactaa 120
acatagcaat tcagatctnt 140

<210> 398
<211> 157
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (10)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (65)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (121)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (122)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (123)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (126)
<223> n equals a,t,g, or c

<220>

<221> misc feature
<222> (134)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (150)
<223> n equals a,t,g, or c

<400> 398
aattcgcan agctcaagca gacggggctc aaggggggta catttaataa aaggatgaag 60
atggnaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 120
nnnccngggg gggnccccc ccccccttn cccctt 157

<210> 399
<211> 358
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (5)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (84)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (204)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (207)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (302)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (305)
<223> n equals a,t,g, or c

<220>
<221> misc feature

<222> (308)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (331)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (341)

<223> n equals a,t,g, or c

<400> 399

```
ggcanagcgg cagagcgggc tcccactctc ggaaccttgt cctgtttttc ccccagctcg 60
gcaagcgcca tatgagcctg gcgncgcca tagcgaatcc tggtgtgggc tttttggcct 120
attcccgccc ctacgtcttg ccgggatggc accgcccgc taggacttcc agggttgggc 180
tgagtgggag ttcgactgct gggncctngta attctcgctt tgggggctgc tccttccagg 240
ctggggacac actggggccc gttgttcggt ctcccgtcct ccgacatctt gtctggaact 300
tncgncctngc agtttccata ggagttggag nctgtgcggc ntaattttgg tggaaaaa 358
```

<210> 400

<211> 399

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (15)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (27)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (33)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (46)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (70)

<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (83)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (115)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (117)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (169)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (171)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (213)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (216)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (218)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (231)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (239)
<223> n equals a,t,g, or c

<220>

<221> misc feature
<222> (245)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (248)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (255)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (262)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (269)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (279)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (283)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (292)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (316)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (325)
<223> n equals a,t,g, or c

<220>
<221> misc feature

<222> (349)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (364)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (382)

<223> n equals a,t,g, or c

<400> 400

```
tttttttttt ttttnaaaag ggcacanata cantttttacc gtttanacca aaccagaatc 60
aaaacccaan tcagagtatc canaaatcca agccaggtca aaaccaaacc gaaantntca 120
agcaatccaa atcaagtcaa aaacaaaaac caaagtgccg gtacaggcnt nccgtgggtg 180
atcaggccac cttccactc aaatggagtg ggnaantncc aaagactagt nttaccaant 240
ttcanatntc cggantccaa gngcctgtnc ctccagng ttnagccgct gnattgatcc 300
tctgtggggg cctgcnaaac gccantctgg cgaggtgttc cactggggna attgcctacc 360
cggnagtgtc ctcaggttct gngtcctca agctggcca 399
```

<210> 401

<211> 189

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (1)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (11)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (162)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (165)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (166)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (187)

<223> n equals a,t,g, or c

<400> 401

```
naattcggca nagcaaacca caccttctct ttcttatgtc tttttactac aaactacaag 60
acaattgttg aaacctgcta tacatgttta ttttaataaa ttgatggcaa aaaaaaaaaa 120
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa anccnngggg gggggccccc 180
ccccccntt                                     189
```

<210> 402

<211> 174

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (10)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (73)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (103)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (107)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (130)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (132)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (146)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (149)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (167)

<223> n equals a,t,g, or c

<400> 402

```
aattcggcan agctgaggca ggagaatcgc ttgaattcgg gaggcagagc tgagatcaca 60
cctctgacac tcnagcctgg gtgacagagc gagactccgt ctnaggnaag gaaaaaaaaa 120
aaaaaaaaan cncggggggg gccccngtnc ccaattggcc ctatagnggg tcgt          174
```

<210> 403

<211> 263

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (5)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (231)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (236)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (242)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (252)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (260)

<223> n equals a,t,g, or c

355

<400> 403

```

ggcanagcca acccagcagt ccttccctca gctgcctagg aggaaggac ccagctgggt 60
ctggggaccac aagggaggag actgcacccc actgcctctg ggccctggct gtgggcagag 120
gccaccgtgt gtgtcccgag taaccgtgcc gttgtcgtgt gatgccataa gcgtctgtgc 180
gtggagtccc caatgaaacc tgtggtcctg cctgggcaaa aaaaaaaaaa naaaanaaaa 240
anaaagaaaa anaaaaaaan aaa                                     263

```

<210> 404

<211> 478

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (159)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (259)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (427)

<223> n equals a,t,g, or c

<400> 404

```

tcgacccacg cgtccggggg ctgcagcatg ttgtgagga gtgaggaata gttgagcccc 60
aagtcttgaa gaggcggggc agccaggctg acatctgtgt ttcaagtggg gctcgccatg 120
ccgggggttc ataggtcact ggctctccaa gtgccagang tgggcagggtg gtggcactga 180
gcccccccaa cactgtgccc tgggtggagaa agcactgacc tgtcatgccc ccctcaaacc 240
tcctcttctg acgtgcctnt tgcacccctc ccattaggac aatcagtcct ctcccatctg 300
ggagtccctt tttcttttct accctagcca ttcttggtac ccagccatct gcccaagggt 360
gccccctcct ctcccatccc cctgccctcg tgggcagccc ggctggtttt gtaaattgtg 420
gttgtgnaca gtgatttttt cttgtattta aaaaaggcca gcattgtggt tcattaaa 478

```

<210> 405

<211> 223

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (147)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (158)

<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (172)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (217)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (223)
<223> n equals a,t,g, or c

<400> 405
agacagcagg acggtggcca tggaagtcgg aatccgctaa ggagtgtgta acaactcacc 60
tgccgaatca actagccctg aaaatggatg gcgctggagc gtcgggcca taccggtccg 120
tcgccggcag tcgagagtgg acgggancgg cgggggcngc gcgcgcgcgc gncgtgatgg 180
tgtgcgtcgg agggcggcgg cggcggcggg ggtgtgnggt ccn 223

<210> 406
<211> 104
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (8)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (37)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (81)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (93)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (103)
<223> n equals a,t,g, or c

357

<400> 406

cccacgcntc cgccgacagc agcagcctca ccatgangtt gctgatggtc ctcatgctgg 60
cggccctctc ccagcactgc nacgcaggct ctngctgccc ctna 104

<210> 407

<211> 66

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (17)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (21)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (57)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (66)

<223> n equals a,t,g, or c

<400> 407

gccctatagt gagtctngta ncaattcact ggccgctcgtt ttacaacgtc gtgacgngga 60
aaactn 66

<210> 408

<211> 278

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (6)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (19)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (252)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (275)

<223> n equals a,t,g, or c

<400> 408

```
gggcanagca agctcctgna cctcaagtga tccacatgcc ttggttgacc aaattgctgg 60
gattacaggc atgagccaat atgaccagct caaacatctt ctttttaa at gtcagaagca 120
tgtatagtga ttatttctta ttttttcccc ctgatccat ctcaccagat gtttgttgat 180
tttataagaa ttttcaaact accagcttct ggctttgttg aacttgggat ttctgtttca 240
ctaattttct tntcctgtgc ttgtacttac ttgntgg 278
```

<210> 409

<211> 168

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (16)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (38)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (127)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (140)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (143)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (145)

<223> n equals a,t,g, or c

<220>

359

<221> misc feature

<222> (167)

<223> n equals a,t,g, or c

<400> 409

aataaaactc taaaangatc actataaaaa aagcaggnac gcctgcaggt accggtccgg 60
aattcccggg tcgaccacg cgtccgacgg ctgcgagaag acgacagaag ggcacggctg 120
cgagaanacg acagaagggn gcnantgaaa gaaggcggca gaaaggnt 168

<210> 410

<211> 415

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (307)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (347)

<223> n equals a,t,g, or c

<400> 410

tgaataccta agatttctgt cttgggggttt ttggtgcatg cagttgatta cttcttattt 60
ttcttaccaa ttgtgaatgt tgggtgtaaa caattaatga agcttttgaa tcatccctat 120
tctgtgtttt atctagtcac ataaatggat taattactaa tttcagttga gaccttctaa 180
ttggttttta ctgaaacatt gagggaaacac aaatttatgg gcttcctgat gatgattctt 240
ctaggcatca tgtcctatag tttgtcatcc ctgatgaatg taaaattaca ctgttcacaa 300
aggtttngtc tcctttccac tgctattaat catggtcact ctcccnaaa tattatattt 360
tttctattaa aagaaaaaaa tggaaaaaaa ttacaaggca atggaaacta ttata 415

<210> 411

<211> 636

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (383)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (512)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (519)

360

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (544)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (547)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (583)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (599)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (603)

<223> n equals a,t,g, or c

<400> 411

```
gcagatcaga cgtggcgacc cgctgaattt aagcatatta gtcagcggag gagaagaaac 60
taaccaggat tccctcagta acggcgagtg aacagggaag agcccagcgc cgaatccccg 120
ccccgcggcg gggcgcgagg catgtggcgt acggaagacc cgctccccgg cgccgctcgt 180
ggggggccca agtccttctg atcgaggccc agcccggtga cgggtgtgagg ccggtagcgg 240
ccccgcggcg gccgggcccc ggtcttcccc gagtcggggt gcttgggaat gcagcccaaa 300
gcgggtggta aactccatct aaggctaaat ccccttgtaa atttaactgt tagtccaaaag 360
aggaacagct ctttgacac tangaaaaaa ccttgtagag agagtaaaaa atttaacacc 420
catagtaggc ctaaaagcag ccaccaatta agaaagcgtt caagctcaac acccactacc 480
taaaaaatcc caaacatata actgaactcc tnacaccna ttggaccaat ctatcacccct 540
atanaanaac taatggtagt ataagtaaca tgaaaacatt ctnccttcgca taagcctgng 600
tanattaaaa cacttgaact gaccattaac aggcca 636
```

<210> 412

<211> 182

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (129)

<223> n equals a,t,g, or c

<220>

<221> misc feature
<222> (166)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (169)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (170)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (172)
<223> n equals a,t,g, or c

<400> 412
ccattgattt ttatcaatag tcgtattcat acggatagtc ctggtattgt tccatcacat 60
tctgaggatg ctcttcgaac tcttcaaatt cttcttccat atatcacctt aaatagtgga 120
ttgcggtant aaagattgtg cctgtctttt aaccacatca ggctcngann gntctcgtga 180
ac 182

<210> 413
<211> 387
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (157)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (253)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (317)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (323)
<223> n equals a,t,g, or c

<220>

<221> misc feature
<222> (349)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (351)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (364)
<223> n equals a,t,g, or c

<400> 413
tcgacccacg cgtccgcca cgcgtccgcc aagaccacc tcctttcatt tgctagaagg 60
actcactaga ctcaggaaag ctgttaggct cacagttaca gtttattaca gtaaaaggac 120
agagattaag atcagcaaag ggaggagggtg cacagcnacg ttccacgaca gatgaggcga 180
cggcttccat ctgccctctc ccagtggagc catataggca gcacctgatt ctcacagcaa 240
catgtgacaa canccaagaa gtactgccaa tactgccaac cagagcagct tcactcggag 300
atctttgtgt tccaganttt ttngttgtc ttggagacag ggtctgggnc ngtttgggca 360
gacnaagagt acatggtgga gattcac 387

<210> 414
<211> 276
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature
<222> (60)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (186)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (195)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (237)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (260)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (266)

<223> n equals a,t,g, or c

<400> 414

```
gcaaaggtcc atactgggta cttgggtttca ttgccaccac ttagtggatg ttcagtttan 60
aaccattttg tctgctccct ctggaagcct tgcgcatagc ttactttgta attgttggag 120
aataactgct gaatttttag ctgttttgag ttgattcgca ccactgcacc acaactcact 180
atgaanacta tttancttat ttattatctt gtgaaaagta taccatgaaa attttgntca 240
tactgtattt atcaagtatn attaanagca ctagat 276
```

<210> 415

<211> 192

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (78)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (88)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (99)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (145)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (150)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (164)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (168)

<223> n equals a,t,g, or c

<400> 415

```
aaaagattgg actaagacac tggccatacc actggacagg gttatgttaa cacctgaaat 60
tgctgggtct tgagagancc caacgcantt ctgggagang gaccacattg gggggtaggt 120
ccacgggctt ggtgatagaa ttatntctcn atcgacttct tgantgcnat atgaactgta 180
acatttgctt ag                                     192
```

<210> 416

<211> 439

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (7)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (9)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (64)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (406)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (417)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (421)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (431)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (434)

<223> n equals a,t,g, or c

<400> 416

```

gcgagantnc gacagaaggg tacggctgcg agagacgaca gaaggggtacg gctgcgagaa 60
gacnacagaa ggggtacggct gcgagaagac gacagaaggg tacggctgcg agaagacgac 120
agaaggggtac ggctgcgaga agacgacaga aggtacggct gcgagaagac gacagaagga 180
tacggctgcg agaagacgac agaagggaga atcttagttc aactttaaat ttgcccacag 240
aaccctctaa atccccttgt aaatttaact gttagtccaa agaggaacag ctctttggac 300
actaggaaaa aacctttagtag agagagtaaa aaatttaaca cccatagtag gcctaaaagc 360
agccaccaat taagaaagcg ttcaaagctc aacacccact acccanaaaa taaaaanaaa 420
naaaaaccgg nggnccgct                                     439

```

<210> 417

<211> 155

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (9)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (84)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (122)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (123)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (143)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (153)

<223> n equals a,t,g, or c

<400> 417

```

gacatcttnt tggtttttat tttgaaacaa tttttaggct tgttccgggg gtctctgtgc 60
tgctgtact gtattgacct gttntatagg tgccttttta taaaaagaa aattcaaaaa 120

```

annaaaaaaaa aaattaataa aaaaaaaaaa aanca

155

<210> 418

<211> 291

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (285)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (286)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (288)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (289)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (291)

<223> n equals a,t,g, or c

<400> 418

gaaaaaaaaa atccatatct taaagaaaca gctttcaagt gcctttctgc agtttttcag 60
gagcgcaaga tagatttgga ataggaataa gctctagttc ttaacaaccg acactcctac 120
aagatttaga aaaaagttaa caacataatc tagtttacag aaaaatcttg tgctagaata 180
ctttttaaaa ggtattttga ataccattaa aactgctttt ttttttccag caagtatcca 240
accaacttgg ttctgcttca ataaatcttt ggaaaaacta atttnnanna n 291

<210> 419

<211> 340

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (2)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (315)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 419

Val	Xaa	Asp	Trp	Phe	Leu	Trp	Tyr	Val	Lys	Lys	Cys	Gly	Gly	Thr	Thr
1				5					10					15	

Arg	Ile	Ile	Ser	Thr	Thr	Asn	Gly	Gly	Gln	Glu	Arg	Lys	Phe	Val	Gly
			20				25						30		

Gly	Ser	Gly	Gln	Val	Ser	Glu	Arg	Ile	Met	Asp	Leu	Leu	Gly	Asp	Arg
		35					40					45			

Val	Lys	Leu	Glu	Arg	Pro	Val	Ile	Tyr	Ile	Asp	Gln	Thr	Arg	Glu	Asn
	50					55					60				

Val	Leu	Val	Glu	Thr	Leu	Asn	His	Glu	Met	Tyr	Glu	Ala	Lys	Tyr	Val
65					70					75					80

Ile	Ser	Ala	Ile	Pro	Pro	Thr	Leu	Gly	Met	Lys	Ile	His	Phe	Asn	Pro
			85						90					95	

Pro	Leu	Pro	Met	Met	Arg	Asn	Gln	Met	Ile	Thr	Arg	Val	Pro	Leu	Gly
			100					105					110		

Ser	Val	Ile	Lys	Cys	Ile	Val	Tyr	Tyr	Lys	Glu	Pro	Phe	Trp	Arg	Lys
	115						120					125			

Lys	Asp	Tyr	Cys	Gly	Thr	Met	Ile	Ile	Asp	Gly	Glu	Glu	Ala	Pro	Val
130						135					140				

Ala	Tyr	Thr	Leu	Asp	Asp	Thr	Lys	Pro	Glu	Gly	Asn	Tyr	Ala	Ala	Ile
145					150					155					160

Met	Gly	Phe	Ile	Leu	Ala	His	Lys	Ala	Arg	Lys	Leu	Ala	Arg	Leu	Thr
			165					170					175		

Lys	Glu	Glu	Arg	Leu	Lys	Lys	Leu	Cys	Glu	Leu	Tyr	Ala	Lys	Val	Leu
			180					185					190		

Gly	Ser	Leu	Glu	Ala	Leu	Glu	Pro	Val	His	Tyr	Glu	Glu	Lys	Asn	Trp
		195					200						205		

Cys	Glu	Glu	Gln	Tyr	Ser	Gly	Gly	Cys	Tyr	Thr	Thr	Tyr	Phe	Pro	Pro
	210					215						220			

Gly	Ile	Leu	Thr	Gln	Tyr	Gly	Arg	Val	Leu	Arg	Gln	Pro	Val	Asp	Arg
225				230						235					240

Ile	Tyr	Phe	Ala	Gly	Thr	Glu	Thr	Ala	Thr	His	Trp	Ser	Gly	Tyr	Met
				245					250					255	

368

Glu Gly Ala Val Glu Ala Gly Glu Arg Ala Ala Arg Glu Ile Leu His
 260 265 270
 Ala Met Gly Lys Ile Pro Glu Asp Glu Ile Trp Gln Ser Glu Pro Glu
 275 280 285
 Ser Val Asp Val Pro Ala Gln Pro Ile Thr Thr Thr Phe Leu Glu Arg
 290 295 300
 His Leu Pro Ser Val Pro Gly Leu Leu Arg Xaa Ile Gly Leu Thr Thr
 305 310 315 320
 Ile Phe Ser Ala Thr Ala Leu Gly Phe Leu Ala His Lys Arg Gly Leu
 325 330 335
 Leu Val Arg Val
 340

<210> 420

<211> 111

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (48)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 420

Thr Arg Asp Leu Val Ser Phe Ile Ser Gly Ile Arg Leu Tyr Asn Leu
 1 5 10 15

Met Leu Ser Val Leu Arg His Lys Arg Gln Asn Val Ala Tyr Phe Arg
 20 25 30

Ile Cys Phe Phe Ile Glu Val Ser Gly Ile Leu Ser Lys Ile Val Xaa
 35 40 45

Ser Arg His Cys Ser Leu Cys Ser Ser Gly Thr Ser Cys Pro Leu Leu
 50 55 60

Ser Leu Gln Ala Thr Gly Asn Ala Ser Val Leu Val Ser Trp Arg Lys
 65 70 75 80

Ile Thr Trp Gly Glu Gly Thr Ser Cys Gly Lys Ser Lys Cys Arg Tyr
 85 90 95

Glu Met Arg Arg Leu Pro Gln Leu Lys Val Asp Lys Ser Ala Leu

369

100

105

110

<210> 421

<211> 61

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (1)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 421

Xaa Ile Trp Cys Ile Ile Cys Lys Glu Ser Lys Met Met Ser Phe Pro
 1 5 10 15

Arg Gly Met Asn Leu Arg Asn Ala Phe Asp Gly Asp Val Ser Val Thr
 20 25 30

Leu Cys Tyr Ser Gly Ser Ser Asn Asn Ser Lys Ala Asn Tyr Ser Lys
 35 40 45

Cys Lys Ile Phe Leu Phe Pro Arg Phe Thr Phe Val Trp
 50 55 60

<210> 422

<211> 51

<212> PRT

<213> Homo sapiens

<400> 422

Thr His Ala Tyr Cys Ser Asn Leu Ser Phe Arg Leu Tyr Asp Gln Trp
 1 5 10 15

Arg Ala Trp Met Gln Lys Ser His Lys Thr Arg Asn Gln His Arg Thr
 20 25 30

Arg Gly Ser Cys Pro Arg Ala Asp Gly Ala Arg Arg Glu Val Leu Pro
 35 40 45

Asp Lys Leu
 50

<210> 423

<211> 246

370

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (71)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (101)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (117)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (147)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 423

Thr	Arg	Asn	Asp	Met	Lys	Ala	Asp	Cys	Ile	Leu	Tyr	Tyr	Gly	Phe	Gly
1				5					10					15	

Asp	Ile	Phe	Arg	Ile	Ser	Ser	Met	Val	Val	Met	Glu	Asn	Val	Gly	Gln
			20					25					30		

Gln	Lys	Leu	Tyr	Glu	Met	Val	Ser	Tyr	Cys	Gln	Asn	Ile	Ser	Lys	Cys
		35						40				45			

Arg	Arg	Val	Leu	Met	Ala	Gln	His	Phe	Asp	Glu	Val	Trp	Asn	Ser	Glu
		50				55					60				

Ala	Cys	Asn	Lys	Met	Cys	Xaa	Asn	Cys	Cys	Lys	Asp	Ser	Ala	Phe	Glu
	65					70				75					80

Arg	Lys	Asn	Ile	Thr	Glu	Tyr	Cys	Arg	Asp	Leu	Ile	Lys	Ile	Leu	Lys
				85					90					95	

Gln	Ala	Glu	Gly	Xaa	Gly	Met	Glu	Lys	Leu	Thr	Pro	Ile	Gly	Asn	Trp
			100					105					110		

Ile	Asp	Ser	Trp	Xaa	Gly	Lys	Gly	Ala	Ala	Lys	Leu	Arg	Val	Ala	Gly
		115					120					125			

Val	Val	Ala	Pro	Thr	Leu	Pro	Arg	Glu	Asp	Leu	Glu	Lys	Ile	Ile	Ala
					130		135					140			

371

His Phe Xaa Ile Gln Gln Tyr Leu Lys Glu Asp Tyr Ser Phe Thr Ala
 145 150 155 160
 Tyr Ala Thr Ile Ser Tyr Leu Lys Ile Gly Pro Lys Ala Asn Leu Leu
 165 170 175
 Asn Asn Glu Ala His Ala Ile Thr Met Gln Val Thr Lys Ser Thr Gln
 180 185 190
 Asn Ser Phe Arg Ala Glu Ser Ser Gln Thr Cys His Ser Glu Gln Gly
 195 200 205
 Asp Lys Lys Met Glu Glu Lys Asn Ser Gly Asn Phe Gln Lys Lys Ala
 210 215 220
 Ala Asn Met Leu Gln Gln Ser Gly Ser Lys Asn Thr Gly Ala Lys Lys
 225 230 235 240
 Arg Lys Ile Asp Asp Ala
 245

<210> 424

<211> 109

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (77)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 424

Asp His Trp Pro Arg Pro Glu Trp Leu Pro Cys Thr Ser Trp Arg Arg
 1 5 10 15
 Ala Ser Cys Leu Asn His Val Asn Cys His His Leu Ala Thr Pro Ala
 20 25 30
 Pro Ala Ser Ala Leu Pro Pro Phe Pro Pro Ser Trp Ser Gly Gly Tyr
 35 40 45
 Arg Ser Leu Gly Pro Thr Leu Ala Pro Leu Ser Pro Ala Ser Val Cys
 50 55 60
 Leu Thr Val Phe Pro Pro Leu Pro Gln Leu Arg Cys Xaa Pro Gln Ala
 65 70 75 80
 Trp Cys Cys Leu Gly Gly Leu Gly Glu Gly Val Cys Gly Gly Gly Arg
 85 90 95

372

Arg Val Lys Thr Glu Ala Arg Cys Gln Asn Gly Leu Glu
 100 105

<210> 425

<211> 57

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (5)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (49)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 425

Gly Ser Glu Thr Xaa Lys Tyr Leu Val Glu Asp Lys Arg Leu Gly Leu
 1 5 10 15

Tyr Thr Trp Leu Cys Thr Asp Leu Leu Ser His Ile Gly Asn His His
 20 25 30

Thr Leu Gln Gly Ile Ser Phe Ile Cys Lys Met Gln Arg Leu Val Leu
 35 40 45

Xaa Asn His Thr Asn Phe Phe Val Leu
 50 55

<210> 426

<211> 99

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (96)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 426

Phe Gly Thr Ser Gly Asp Gly Gly Gly Ser Lys Met Ala Gln Ala Ile
 1 5 10 15

Phe Glu Ala Leu Glu Gly Met Asp Asn Gln Thr Val Leu Ala Val Gln

373

20 25 30
 Ser Leu Leu Asp Gly Gln Gly Ala Val Pro Asp Pro Thr Gly Gln Ser
 35 40 45
 Val Asn Ala Pro Pro Ala Ile Gln Pro Leu Asp Asp Glu Asp Val Phe
 50 55 60
 Leu Cys Gly Lys Cys Lys Lys Gln Phe Asn Ser Leu Pro Ala Phe Met
 65 70 75 80
 Thr His Lys Arg Glu Gln Cys Gln Gly Asn Ala Pro Ala Leu Ala Xaa
 85 90 95
 Val Ser Leu

<210> 427
 <211> 55
 <212> PRT
 <213> Homo sapiens

<400> 427
 Asn Ser Asn Ser Ser Ile Phe Ser Leu Val Ser Val Lys Cys Asp Lys
 1 5 10 15
 Ser Thr Tyr Phe Lys Leu Phe Ser Ala Leu Gly Tyr Ser Ser Asn Lys
 20 25 30
 Asn Thr Asn Leu Trp Val Phe Lys Lys Thr Trp Arg Ile Asn Ser Tyr
 35 40 45
 Phe Lys Arg Ser Lys Lys Lys
 50 55

<210> 428
 <211> 54
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (41)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 428
 His Thr Leu Ser Asn Leu Glu Phe Ala Gln Lys Val Glu Pro Cys Asn

374

1 5 10 15
 Asp His Val Arg Ala Lys Leu Ser Trp Ala Lys Lys Arg Asp Glu Asp
 20 25 30
 Asp Val Pro Thr Val Pro Ser Thr Xaa Gly Glu Glu Arg Leu Tyr Asn
 35 40 45
 Pro Phe Leu Arg Val Ala
 50

<210> 429
 <211> 39
 <212> PRT
 <213> Homo sapiens

<400> 429
 Arg Gln Thr Lys Val Asn Leu Lys Glu Thr Arg Ser Phe Glu Ile Ile
 1 5 10 15
 Val Trp Gly Phe Tyr Lys Ser Asn Tyr Cys His Leu His Pro Asp Ser
 20 25 30
 Phe Lys Leu Leu Ile His Pro
 35

<210> 430
 <211> 133
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (81)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (85)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 430
 Ala Arg Ala Pro Arg Val Pro Pro Ala Pro His Thr Pro Ser Lys Met
 1 5 10 15
 Gly Lys Glu Lys Thr His Ile Asn Ile Val Val Ile Gly His Val Asp
 20 25 30

Ser	Gly	Lys	Ser	Thr	Thr	Thr	Gly	His	Leu	Ile	Tyr	Lys	Cys	Gly	Gly	
35						40						45				
Ile	Asp	Lys	Arg	Thr	Ile	Glu	Lys	Phe	Glu	Lys	Glu	Ala	Ala	Glu	Met	
50						55						60				
Gly	Lys	Gly	Ser	Phe	Lys	Tyr	Ala	Trp	Val	Leu	Asp	Lys	Leu	Lys	Ala	
65						70						75			80	
Xaa	Val	Ser	Ala	Xaa	Ile	Thr	Ile	Asp	Ile	Ser	Leu	Trp	Lys	Phe	Glu	
			85						90						95	
Thr	Thr	Lys	Tyr	Tyr	Ile	Thr	Ile	Ile	Asp	Ala	Pro	Gly	His	Arg	Asp	
			100						105						110	
Phe	Ile	Lys	Asn	Met	Ile	Thr	Gly	Thr	Ser	Gln	Ala	Asp	Cys	Ala	Val	
115						120						125				
Leu	Ile	Val	Ala	Ala												
130																

```
<210> 431
<211> 190
<212> PRT
<213> Homo sapiens
```

```

<400> 431
Leu Cys Trp Ala Arg Pro Leu Pro Ser Gly Pro Val Leu Leu Ala Ala
  1                      5                      10                      15
Asn Lys Asp Ser Ser Trp Cys Pro Thr Cys Leu Val His Cys Cys Val
      20                      25                      30
Asn Pro Gly Gly Ser Gly His Arg Arg Gln Pro Arg Pro Arg Val Gln
      35                      40                      45
Glu Lys Cys Ser Leu Glu Ala Arg Thr Thr Ala Ser His Trp Gly Arg
      50                      55                      60
Arg Gly Pro Arg Thr Thr Ser Ala Ser Tyr Leu Pro Ala Ser Ala Arg
      65                      70                      75                      80
Gly Pro Arg Asp Ala Val Leu Phe Gln Pro Pro Ala Leu Gly Arg Gly
      85                      90                      95
His Ala Ser Arg Ile Gln Gly Ala Gly Gly Leu Ser Thr Ala Arg Thr
      100                      105                      110

```

376

Cys Leu Leu Ala Ala Ala Ala Val Gly Glu His Gly Gly Cys Gln Arg
 115 120 125
 Leu Leu Trp Lys Val Ala Ala Ser Glu Met Ala Gly Ala Ala Gly Val
 130 135 140
 Arg Leu His Thr Ala Gln Val Ser Ser Gly Arg Leu Ser Trp Gly Gly
 145 150 155 160
 Ser Ser Ser Ala Glu Gly Trp Trp Gly Val Gln Ser Val Ile Leu Gly
 165 170 175
 Ala Val Cys Pro Thr Pro Ala Trp Gly Pro His Phe Arg Arg
 180 185 190

<210> 432

<211> 310

<212> PRT

<213> Homo sapiens

<400> 432

Gly Pro His Gly Asn Gly Glu Val Arg Trp Pro Leu Pro Pro Pro Pro
 1 5 10 15
 Pro Arg Phe Val Ala Arg Arg Lys Met Ala Asp Leu Glu Glu Gln Leu
 20 25 30
 Ser Asp Glu Glu Lys Val Arg Ile Ala Ala Lys Phe Ile Ile His Ala
 35 40 45
 Pro Pro Gly Glu Phe Asn Glu Val Phe Asn Asp Val Arg Leu Leu Leu
 50 55 60
 Asn Asn Asp Asn Leu Leu Arg Glu Gly Ala Ala His Ala Phe Ala Gln
 65 70 75 80
 Tyr Asn Leu Asp Gln Phe Thr Pro Val Lys Ile Glu Gly Tyr Glu Asp
 85 90 95
 Gln Val Leu Ile Thr Glu His Gly Asp Leu Gly Asn Gly Lys Phe Leu
 100 105 110
 Asp Pro Lys Asn Arg Ile Cys Phe Lys Phe Asp His Leu Arg Lys Glu
 115 120 125
 Ala Thr Asp Pro Arg Pro Cys Glu Val Glu Asn Ala Val Glu Ser Trp
 130 135 140
 Arg Thr Ser Val Glu Thr Ala Leu Arg Ala Tyr Val Lys Glu His Tyr

377

145		150		155		160
Pro Asn Gly Val Cys Thr Val Tyr Gly Lys Lys Ile Asp Gly Gln Gln						
	165		170		175	
Thr Ile Ile Ala Cys Ile Glu Ser His Gln Phe Gln Ala Lys Asn Phe						
	180		185		190	
Trp Asn Gly Arg Trp Arg Ser Glu Trp Lys Phe Thr Ile Thr Pro Ser						
	195		200		205	
Thr Thr Gln Val Val Gly Ile Leu Lys Ile Gln Val His Tyr Tyr Glu						
	210		215		220	
Asp Gly Asn Val Gln Leu Val Ser His Lys Asp Ile Gln Asp Ser Leu						
	225		230		235	240
Thr Val Ser Asn Glu Val Gln Thr Ala Lys Glu Phe Ile Lys Ile Val						
	245		250		255	
Glu Ala Ala Glu Asn Glu Tyr Gln Thr Ala Ile Ser Glu Asn Tyr Gln						
	260		265		270	
Thr Met Ser Asp Thr Thr Phe Lys Ala Leu Arg Arg Gln Leu Pro Val						
	275		280		285	
Thr Arg Thr Lys Ile Asp Trp Asn Lys Ile Leu Ser Tyr Lys Ile Gly						
	290		295		300	
Lys Glu Met Gln Asn Ala						
	305		310			

<210> 433

<211> 289

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (287)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (288)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 433

Gln Ser Cys Thr Ser Gly Ser Ser Lys Pro Asn Ser Pro Ser Ile Ser

378

1	5	10	15
Pro Ser Ile Leu Ser Asn Thr Glu His Lys Arg Gly Pro Glu Val Thr	20	25	30
Ser Gln Gly Val Gln Thr Ser Ser Pro Ala Cys Lys Gln Glu Lys Asp	35	40	45
Asp Lys Glu Glu Lys Lys Asp Ala Ala Glu Gln Val Arg Lys Ser Thr	50	55	60
Leu Asn Pro Asn Ala Lys Glu Phe Asn Pro Arg Ser Phe Ser Gln Pro	65	70	75
Lys Pro Ser Thr Thr Pro Thr Ser Pro Arg Pro Gln Ala Gln Pro Ser	85	90	95
Pro Ser Met Val Gly His Gln Gln Pro Thr Pro Val Tyr Thr Gln Pro	100	105	110
Val Cys Phe Ala Pro Asn Met Met Tyr Pro Val Pro Val Ser Pro Gly	115	120	125
Val Gln Pro Leu Tyr Pro Ile Pro Met Thr Pro Met Pro Val Asn Gln	130	135	140
Ala Lys Thr Tyr Arg Ala Gly Lys Val Pro Asn Met Pro Gln Gln Arg	145	150	155
Gln Asp Gln His His Gln Ser Ala Met Met His Pro Ala Ser Ala Ala	165	170	175
Gly Pro Pro Ile Ala Ala Thr Pro Pro Ala Tyr Ser Thr Gln Tyr Val	180	185	190
Ala Tyr Ser Pro Gln Gln Phe Pro Asn Gln Pro Leu Val Gln His Val	195	200	205
Pro His Tyr Gln Ser Gln His Pro His Val Tyr Ser Pro Val Ile Gln	210	215	220
Gly Asn Ala Arg Met Met Ala Pro Pro Thr His Ala Gln Pro Gly Leu	225	230	235
Val Ser Ser Ser Ala Thr Gln Tyr Gly Ala His Glu Gln Thr His Ala	245	250	255
Met Tyr Ala Cys Pro Lys Leu Pro Tyr Asn Lys Glu Thr Ser Pro Ser	260	265	270
Phe Tyr Phe Ala Ile Ser Thr Gly Ser Leu Ala Gln Gln Tyr Xaa Xaa			

379

275

280

285

Pro

<210> 434

<211> 147

<212> PRT

<213> Homo sapiens

<400> 434

Lys Val Thr Pro Asp Leu Lys Pro Thr Glu Ala Ser Ser Ser Ala Phe
 1 5 10 15

Arg Leu Met Pro Ala Leu Gly Val Ser Val Ala Asp Gln Lys Gly Lys
 20 25 30

Ser Thr Val Ala Ser Ser Glu Ala Lys Pro Ala Ala Thr Ile Arg Ile
 35 40 45

Val Gln Gly Leu Gly Val Met Pro Pro Lys Ala Gly Gln Thr Ile Thr
 50 55 60

Val Ala Thr His Ala Lys Gln Gly Ala Ser Val Ala Ser Gly Ser Gly
 65 70 75 80

Thr Val His Thr Ser Ala Val Ser Leu Pro Ser Met Asn Ala Ala Val
 85 90 95

Ser Lys Thr Val Ala Val Ala Ser Gly Ala Ala Arg Pro Pro Ser Ala
 100 105 110

Ser Ala Gln Glu Pro Pro Pro Cys Gly Arg Ser Leu Ser Ala Pro Arg
 115 120 125

Leu Cys Pro Arg Pro Arg Leu Gly Ser Cys Leu His Gly Ser Gln Phe
 130 135 140

Pro Ser Leu
 145

<210> 435

<211> 151

<212> PRT

<213> Homo sapiens

<220>

380

<221> SITE

<222> (9)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (15)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (79)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 435

Gly	Ser	Gly	Thr	Lys	Asp	Pro	Ser	Xaa	Cys	Asn	Thr	Gln	Thr	Xaa	Ala
1				5					10					15	

His	Thr	His	Thr	Gly	Gly	Glu	Ile	Ser	Leu	Phe	Ser	Met	Ser	Phe	Phe
			20					25					30		

Ser	Trp	Ala	Glu	Thr	Gly	Tyr	Cys	Pro	Gly	Gln	Leu	Pro	Glu	Lys	His
		35					40					45			

Arg	Arg	Glu	Leu	Arg	Ser	Ala	Arg	Pro	Ser	Ser	Leu	Ala	Pro	Gly	Phe
		50				55					60				

Gly	Gly	Pro	Arg	Thr	Ala	Asp	Arg	Gly	Trp	Ser	Trp	Arg	Leu	Xaa	Ser
65					70					75					80

Arg	Ala	Tyr	Thr	Trp	Arg	Asn	Ala	Pro	Pro	Ser	Ser	Pro	Ser	Leu	Gln
				85				90						95	

Thr	Trp	Gly	Trp	Leu	Gly	Pro	Glu	Gly	Cys	Asp	Glu	Glu	Lys	Arg	Ala
		100						105					110		

Ser	Val	Gly	Met	Arg	Gln	Glu	Gly	Ile	Asp	Phe	Asp	Cys	Asp	Leu	Trp
		115					120					125			

Gly	Phe	Leu	Pro	Ala	Leu	Asp	Asn	Pro	Ala	Lys	Asp	Cys	Phe	Phe	Leu
		130				135					140				

Ser	Leu	Ala	Arg	Arg	Gly	Pro
145					150	

<210> 436

<211> 180

<212> PRT

<213> Homo sapiens

381

<220>

<221> SITE

<222> (42)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (123)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 436

Ala Pro Ala Ser Pro Val Met Pro Pro Gln Thr Gln Ser Pro Gly Gln
 1 5 10 15

Pro Ala Gln Pro Ala Pro Met Val Pro Leu His Gln Lys Gln Ser Arg
 20 25 30

Ile Thr Pro Ile Gln Lys Pro Arg Gly Xaa Asp Pro Val Glu Ile Leu
 35 40 45

Gln Glu Arg Glu Tyr Arg Leu Gln Ala Arg Ile Ala His Arg Ile Gln
 50 55 60

Glu Leu Glu Asn Leu Pro Gly Ser Leu Ala Gly Asp Leu Arg Thr Lys
 65 70 75 80

Ala Thr Ile Glu Leu Lys Ala Leu Arg Leu Leu Asn Phe Gln Arg Gln
 85 90 95

Leu Arg Gln Glu Val Val Val Cys Met Arg Arg Asp Thr Ala Leu Glu
 100 105 110

Thr Ala Leu Asn Ala Lys Ala Tyr Lys Arg Xaa Ser Ala Ser Pro Cys
 115 120 125

Ala Arg Pro Ala Ser Leu Arg Ser Trp Arg Ser Ser Arg Arg Ser Ser
 130 135 140

Arg Ser Ala Ser Ala Gly Arg Ser Thr Arg Asn Thr Ser Ile Ala Phe
 145 150 155 160

Ser Ser Met Pro Arg Ile Ser Arg Asn Ile Thr Asp Pro Ser Gln Ala
 165 170 175

Lys Ser Arg Ser
 180

<210> 437

382

<211> 415
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (8)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (94)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (96)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (170)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 437

Arg Lys Tyr Leu Val Pro Leu Xaa Lys Lys Leu Tyr Leu Lys Trp Ala
 1 5 10 15

Leu Glu Glu Tyr Leu Asp Glu Phe Asp Pro Cys His Cys Arg Pro Cys
 20 25 30

Gln Asn Gly Gly Leu Ala Thr Val Glu Gly Thr His Cys Leu Cys His
 35 40 45

Cys Lys Pro Tyr Thr Phe Gly Ala Ala Cys Glu Gln Gly Val Leu Val
 50 55 60

Gly Asn Gln Ala Gly Gly Val Asp Gly Gly Trp Ser Cys Trp Ser Ser
 65 70 75 80

Trp Ser Pro Cys Val Gln Gly Lys Lys Thr Arg Ser Arg Xaa Cys Xaa
 85 90 95

Asn Pro Pro Pro Ser Gly Gly Gly Arg Ser Cys Val Gly Glu Thr Thr
 100 105 110

Glu Ser Thr Gln Cys Glu Asp Glu Glu Leu Glu His Leu Arg Leu Leu
 115 120 125

Glu Pro His Cys Phe Pro Leu Ser Leu Val Pro Thr Glu Phe Cys Pro
 130 135 140

383

Ser Pro Pro Ala Leu Lys Asp Gly Phe Val Gln Asp Glu Gly Thr Met
 145 150 155 160
 Phe Pro Val Gly Lys Asn Val Val Tyr Xaa Cys Asn Glu Gly Tyr Ser
 165 170 175
 Leu Ile Gly Asn Pro Val Ala Arg Cys Gly Glu Asp Leu Arg Trp Leu
 180 185 190
 Val Gly Glu Met His Cys Gln Lys Ile Ala Cys Val Leu Pro Val Leu
 195 200 205
 Met Asp Gly Ile Gln Ser His Pro Gln Lys Pro Phe Tyr Thr Val Gly
 210 215 220
 Glu Lys Val Thr Val Ser Cys Ser Gly Gly Met Ser Leu Glu Gly Pro
 225 230 235 240
 Ser Ala Phe Leu Cys Gly Ser Ser Leu Lys Trp Ser Pro Glu Met Lys
 245 250 255
 Asn Ala Arg Cys Val Gln Lys Glu Asn Pro Leu Thr Gln Ala Val Pro
 260 265 270
 Lys Cys Gln Arg Trp Glu Lys Leu Gln Asn Ser Arg Cys Val Cys Lys
 275 280 285
 Met Pro Tyr Glu Cys Gly Pro Ser Leu Asp Val Cys Ala Gln Asp Glu
 290 295 300
 Arg Ser Lys Arg Ile Leu Pro Leu Thr Val Cys Lys Met His Val Leu
 305 310 315 320
 His Cys Gln Gly Arg Asn Tyr Thr Leu Thr Gly Arg Asp Ser Cys Thr
 325 330 335
 Leu Pro Ala Ser Ala Glu Lys Ala Cys Gly Ala Cys Pro Leu Trp Gly
 340 345 350
 Lys Cys Asp Ala Glu Ser Ser Lys Cys Val Cys Arg Glu Ala Ser Glu
 355 360 365
 Cys Glu Glu Glu Gly Phe Ser Ile Cys Val Glu Val Asn Gly Lys Glu
 370 375 380
 Gln Thr Met Ser Glu Cys Glu Ala Gly Ala Leu Arg Cys Arg Gly Gln
 385 390 395 400
 Ser Ile Ser Val Thr Ser Ile Arg Pro Cys Ala Ala Glu Thr Gln
 405 410 415

384

<210> 438
 <211> 285
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (16)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (17)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (18)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 438
 Leu Ile Arg Leu Thr Ile Gly Lys Ala Gly Ser Leu Gln Tyr Arg Xaa
 1 5 10 15
 Xaa Xaa Phe Pro Gly Met Glu Ala Phe Leu Gly Ser Arg Ser Gly Leu
 20 25 30
 Trp Ala Gly Gly Pro Ala Pro Gly Gln Phe Tyr Arg Ile Pro Ser Thr
 35 40 45
 Pro Asp Ser Phe Met Asp Pro Ala Ser Ala Leu Tyr Arg Gly Pro Ile
 50 55 60
 Thr Arg Thr Gln Asn Pro Met Val Thr Gly Thr Ser Val Leu Gly Val
 65 70 75 80
 Lys Phe Glu Gly Gly Val Val Ile Ala Ala Asp Met Leu Gly Ser Tyr
 85 90 95
 Gly Ser Leu Ala Arg Phe Arg Asn Ile Ser Arg Ile Met Arg Val Asn
 100 105 110
 Asn Ser Thr Met Leu Gly Ala Ser Gly Asp Tyr Ala Asp Phe Gln Tyr
 115 120 125
 Leu Lys Gln Val Leu Gly Gln Met Val Ile Asp Glu Glu Leu Leu Gly
 130 135 140

385

Asp Gly His Ser Tyr Ser Pro Arg Ala Ile His Ser Trp Leu Thr Arg
 145 150 155 160
 Ala Met Tyr Ser Arg Arg Ser Lys Met Asn Pro Leu Trp Asn Thr Met
 165 170 175
 Val Ile Gly Gly Tyr Ala Asp Gly Glu Ser Phe Leu Gly Tyr Val Asp
 180 185 190
 Met Leu Gly Val Ala Tyr Glu Ala Pro Ser Leu Ala Thr Gly Tyr Gly
 195 200 205
 Ala Tyr Leu Ala Gln Pro Leu Leu Arg Glu Val Leu Glu Lys Gln Pro
 210 215 220
 Val Leu Ser Gln Thr Glu Ala Arg Asp Leu Val Glu Arg Cys Met Arg
 225 230 235 240
 Val Leu Tyr Tyr Arg Asp Ala Arg Ser Tyr Asn Arg Phe Gln Ile Ala
 245 250 255
 Thr Val Thr Glu Lys Gly Val Glu Ile Glu Gly Pro Leu Ser Thr Glu
 260 265 270
 Thr Asn Trp Asp Ile Ala His Met Ile Ser Gly Phe Glu
 275 280 285

<210> 439

<211> 185

<212> PRT

<213> Homo sapiens

<400> 439

Asn Ser Ala Ala His Lys Lys Gly Lys Leu Pro Ile Val Asn Glu Asp
 1 5 10 15
 Asp Glu Leu Val Ala Ile Ile Ala Arg Thr Asp Leu Lys Lys Asn Arg
 20 25 30
 Asp Tyr Pro Leu Ala Ser Lys Asp Ala Lys Lys Gln Leu Leu Cys Gly
 35 40 45
 Ala Ala Ile Gly Thr His Glu Asp Asp Lys Tyr Arg Leu Asp Leu Leu
 50 55 60
 Ala Gln Ala Gly Val Asp Val Val Val Leu Asp Ser Ser Gln Gly Asn
 65 70 75 80
 Ser Ile Phe Gln Ile Asn Met Ile Lys Tyr Ile Lys Asp Lys Tyr Pro

386

	85		90		95
Asn Leu Gln Val Ile Gly Gly Asn Val Val Thr Ala Ala Gln Ala Lys					
	100		105		110
Asn Leu Ile Asp Ala Gly Val Asp Ala Leu Arg Val Gly Met Gly Ser					
	115		120		125
Gly Ser Ile Cys Ile Thr Gln Glu Val Leu Ala Cys Gly Arg Pro Gln					
	130		135		140
Ala Thr Ala Val Tyr Lys Val Ser Glu Tyr Ala Arg Arg Phe Gly Val					
	145		150		155
Pro Val Ile Ala Asp Gly Gly Ile Gln Asn Val Gly His Ile Ala Lys					
	165		170		175
Ala Leu Ala Leu Gly Ala Pro Gln Ser					
	180		185		

<210> 440

<211> 211

<212> PRT

<213> Homo sapiens

<400> 440

Leu Gln Gly Arg Ser Thr Pro Ile Trp Pro Ala Leu Ala Thr Val Thr					
1		5		10	15
Ser Arg Thr Pro Ala Leu Gly Pro Gln Ala Gly Ile Asp Thr Asn Glu					
	20		25		30
Ile Ala Pro Leu Glu Pro Asp Ala Pro Pro Asp Ala Cys Glu Ala Ser					
	35		40		45
Phe Asp Ala Val Ser Thr Ile Arg Gly Glu Leu Phe Phe Phe Lys Ala					
	50		55		60
Gly Phe Val Trp Arg Leu Arg Gly Gly Gln Leu Gln Pro Gly Tyr Pro					
	65		70		75
Ala Leu Ala Ser Arg His Trp Gln Gly Leu Pro Ser Pro Val Asp Ala					
	85		90		95
Ala Phe Glu Asp Ala Gln Gly His Ile Trp Phe Phe Gln Gly Ala Gln					
	100		105		110
Tyr Trp Val Tyr Asp Gly Glu Lys Pro Val Leu Gly Pro Ala Pro Leu					
	115		120		125

387

Thr Glu Leu Gly Leu Val Arg Phe Pro Val His Ala Ala Leu Val Trp
 130 135 140

Gly Pro Glu Lys Asn Lys Ile Tyr Phe Phe Arg Gly Arg Asp Tyr Trp
 145 150 155 160

Arg Phe His Pro Ser Thr Arg Arg Val Asp Ser Pro Val Pro Arg Arg
 165 170 175

Pro Leu Thr Gly Glu Gly Cys Pro Leu Arg Ser Thr Leu Pro Ser Arg
 180 185 190

Met Leu Met Ala Met Pro Thr Ser Cys Ala Ala Ala Ser Thr Gly Ser
 195 200 205

Leu Thr Leu
 210

<210> 441

<211> 80

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (40)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 441

Gly Gly Ala Gly Lys Leu Leu Ser Phe Thr His Ser Ala Pro Trp Ser
 1 5 10 15

Arg Leu Trp Ser Ser Leu Gly Lys Arg Val Thr Gly Glu Ser Gln Gly
 20 25 30

Leu Glu Lys Leu Pro Gly Thr Xaa Asp Gly Leu Ala Ala Leu Thr Gln
 35 40 45

Asp Pro Leu Pro Leu Pro Pro Pro Leu Cys Arg Asn Thr Gly Thr Pro
 50 55 60

Arg Gly Lys Met Ser Phe Ser Arg Leu Gln Phe Ser Pro Arg Lys Leu
 65 70 75 80

<210> 442
 <211> 567
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (205)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (212)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (469)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (503)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (505)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (517)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (535)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (546)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 442
 Asn Val His Leu Tyr Ile Met Tyr Tyr Met Glu Ala Lys His Ala Val
 1 5 10 15

Ser Phe Met Thr Cys Thr Gln Asn Val Ala Pro Asp Met Phe Arg Thr

389

20					25					30					
Ile	Pro	Pro	Glu	Ala	Asn	Ile	Pro	Ile	Pro	Val	Lys	Ser	Asp	Met	Val
		35					40					45			
Met	Met	His	Glu	His	His	Lys	Glu	Thr	Glu	Tyr	Lys	Asp	Lys	Ile	Pro
		50				55					60				
Leu	Leu	Gln	Gln	Pro	Lys	Arg	Glu	Glu	Glu	Glu	Val	Leu	Asp	Gln	Gly
		65				70					75				80
Asp	Phe	Tyr	Ser	Leu	Leu	Ser	Lys	Leu	Leu	Gly	Glu	Arg	Glu	Asp	Val
				85					90					95	
Val	His	Val	His	Lys	Tyr	Asn	Pro	Thr	Glu	Lys	Ala	Glu	Ser	Glu	Ser
				100					105					110	
Asp	Leu	Val	Ala	Glu	Ile	Ala	Asn	Val	Val	Gln	Lys	Lys	Asp	Leu	Gly
				115			120					125			
Arg	Ser	Asp	Ala	Arg	Glu	Gly	Ala	Glu	His	Glu	Arg	Gly	Asn	Ala	Ile
				130			135					140			
Leu	Val	Arg	Asp	Arg	Ile	His	Lys	Phe	His	Arg	Leu	Val	Ser	Thr	Leu
				145			150					155			160
Arg	Pro	Pro	Glu	Ser	Arg	Val	Phe	Ser	Leu	Gln	Gln	Pro	Pro	Pro	Gly
				165					170					175	
Glu	Gly	Thr	Trp	Glu	Pro	Glu	His	Thr	Gly	Asp	Phe	His	Met	Glu	Glu
				180					185					190	
Ala	Leu	Asp	Trp	Pro	Gly	Val	Tyr	Leu	Leu	Pro	Gly	Xaa	Val	Ser	Gly
				195			200					205			
Val	Ala	Leu	Xaa	Pro	Lys	Asn	Asn	Leu	Val	Ile	Phe	His	Arg	Gly	Asp
				210			215							220	
His	Val	Trp	Asp	Gly	Asn	Ser	Phe	Asp	Ser	Lys	Phe	Val	Tyr	Gln	Gln
				225			230					235			240
Ile	Gly	Leu	Gly	Pro	Ile	Glu	Glu	Asp	Thr	Ile	Leu	Val	Ile	Asp	Pro
				245					250					255	
Asn	Asn	Ala	Ala	Val	Leu	Gln	Ser	Ser	Gly	Lys	Asn	Leu	Phe	Tyr	Leu
				260					265					270	
Pro	His	Gly	Leu	Ser	Ile	Asp	Lys	Asp	Gly	Asn	Tyr	Trp	Val	Thr	Asp
				275			280							285	
Val	Ala	Leu	His	Gln	Val	Phe	Lys	Leu	Asp	Pro	Asn	Asn	Lys	Glu	Gly

390

290	295	300
Pro Val Leu Ile Leu Gly Arg Ser Met Gln Pro Gly Ser Asp Gln Asn		
305	310	315 320
His Phe Cys Gln Pro Thr Asp Val Ala Val Asp Pro Gly Thr Gly Ala		
	325	330 335
Ile Tyr Val Ser Asp Gly Tyr Cys Asn Ser Arg Ile Val Gln Phe Ser		
	340	345 350
Pro Ser Gly Lys Phe Ile Thr Gln Trp Gly Glu Glu Ser Ser Gly Ser		
	355	360 365
Ser Pro Leu Pro Gly Gln Phe Thr Val Pro His Ser Leu Ala Leu Val		
	370	375 380
Pro Leu Leu Gly Gln Leu Cys Val Ala Asp Arg Glu Asn Gly Arg Ile		
385	390	395 400
Gln Cys Phe Lys Thr Asp Thr Lys Glu Phe Val Arg Glu Ile Lys His		
	405	410 415
Ser Ser Phe Gly Arg Asn Val Phe Ala Ile Ser Tyr Ile Pro Gly Leu		
	420	425 430
Leu Phe Ala Val Asn Gly Lys Pro His Phe Gly Asp Gln Glu Pro Val		
	435	440 445
Gln Gly Phe Val Met Asn Phe Ser Asn Gly Glu Ile Ile Asp Ile Phe		
	450	455 460
Lys Pro Val Arg Xaa Leu Leu Asp Met Pro His Asp Ile Val Ala Ser		
465	470	475 480
Glu Asp Gly Thr Val Tyr Ile Gly Arg Cys Ser Tyr Gln His Arg Val		
	485	490 495
Gly Ser Ser Thr Leu Asp Xaa Arg Xaa Leu Gly Thr Ser Val Gln Phe		
	500	505 510
Lys Lys Gly Leu Xaa Ile Glu Val Gln Gly Asn Pro Lys Lys Pro Glu		
	515	520 525
Gly Ile Cys Cys Phe Pro Xaa Thr Thr Leu Arg Val Ile Pro Val Val		
	530	535 540
Gly Xaa Trp Arg Gly His Gly Pro Asn Leu Ile Pro Val Gly Lys Asn		
545	550	555 560
Pro Arg Gly Pro Leu Gly Arg		

391

565

<210> 443
 <211> 129
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (123)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (127)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (129)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 443
 Arg Pro Ser Cys Ser Pro Gly Ser Val Ser Ala Ala Ala Val Asn Met
 1 5 10 15

Glu Pro Pro Asp Ala Pro Ala Gln Ala Arg Gly Ala Pro Arg Leu Leu
 20 25 30

Leu Leu Ala Val Leu Leu Ala Ala His Pro Asp Ala Gln Ala Glu Val
 35 40 45

Arg Leu Ser Val Pro Pro Leu Val Glu Val Met Arg Gly Lys Ser Val
 50 55 60

Ile Leu Asp Cys Thr Pro Thr Gly Thr His Asp His Tyr Met Leu Glu
 65 70 75 80

Trp Phe Leu Thr Asp Arg Ser Gly Ala Arg Pro Arg Leu Ala Ser Ala
 85 90 95

Glu Met Gln Gly Ser Glu Leu Gln Val Thr Met His Asp Thr Arg Gly
 100 105 110

Arg Ser Pro Pro Tyr Gln Leu Gly Leu Pro Xaa Gly Ala Trp Xaa Leu
 115 120 125

Xaa

392

<210> 444

<211> 131

<212> PRT

<213> Homo sapiens

<400> 444

Glu Pro Arg Val Glu Arg Glu Thr Pro Gly Gln Pro Phe Ser Ser Ser
 1 5 10 15

Phe Pro Ser Pro Ser Pro Phe Pro Asn Val Ala Ser Met Trp Val Leu
 20 25 30

Gly Thr Trp Glu Lys Pro Leu Leu Cys His Phe Phe Ser Leu Phe Pro
 35 40 45

Ser Ser Pro Pro Thr Val Trp Leu Met Met Ser Ser Gly Val Met Val
 50 55 60

Thr Thr Pro Cys Ser Leu Phe Trp Tyr Phe Pro Cys Gln Phe Pro Leu
 65 70 75 80

Ser Ala Arg Leu Cys Pro Lys Ile Pro Ser Ala Ser Ser Leu His Val
 85 90 95

Ala Glu Gly Pro Gly Leu Pro Gln Val Pro Cys Leu Ser Asn Lys Val
 100 105 110

Glu Thr Ile Lys Pro Gly Lys Lys Lys Lys Gly Gly Arg Ser Lys Gly
 115 120 125

Ser Pro Arg
 130

<210> 445

<211> 405

<212> PRT

<213> Homo sapiens

<400> 445

Gly Thr Gly Leu Val Pro Ile Arg Gln Ser Thr Lys Phe Asp Ser Ser
 1 5 10 15

Leu Asp Arg Lys Asp Lys Phe Ser Phe Asp Leu Gly Lys Gly Glu Val
 20 25 30

Ile Lys Ala Trp Asp Ile Ala Ile Ala Thr Met Lys Val Gly Glu Val

393

35	40	45
Cys His Ile Thr Cys Lys Pro Glu Tyr Ala Tyr Gly Ser Ala Gly Ser		
50	55	60
Pro Pro Lys Ile Pro Pro Asn Ala Thr Leu Val Phe Glu Val Glu Leu		
65	70	75 80
Phe Glu Phe Lys Gly Glu Asp Leu Thr Glu Glu Glu Asp Gly Gly Ile		
	85	90 95
Ile Arg Arg Ile Gln Thr Arg Gly Glu Gly Tyr Ala Lys Pro Asn Glu		
	100	105 110
Gly Ala Ile Val Glu Val Ala Leu Glu Gly Tyr Tyr Lys Asp Lys Leu		
	115	120 125
Phe Asp Gln Arg Glu Leu Arg Phe Glu Ile Gly Glu Gly Glu Asn Leu		
	130	135 140
Asp Leu Pro Tyr Gly Leu Glu Arg Ala Ile Gln Arg Met Glu Lys Gly		
	145	150 155 160
Glu His Ser Ile Val Tyr Leu Lys Pro Ser Tyr Ala Phe Gly Ser Val		
	165	170 175
Gly Lys Glu Lys Phe Gln Ile Pro Pro Asn Ala Glu Leu Lys Tyr Glu		
	180	185 190
Leu His Leu Lys Ser Phe Glu Lys Ala Lys Glu Ser Trp Glu Met Asn		
	195	200 205
Ser Glu Glu Lys Leu Glu Gln Ser Thr Ile Val Lys Glu Arg Gly Thr		
	210	215 220
Val Tyr Phe Lys Glu Gly Lys Tyr Lys Gln Ala Leu Leu Gln Tyr Lys		
	225	230 235 240
Lys Ile Val Ser Trp Leu Glu Tyr Glu Ser Ser Phe Ser Asn Glu Glu		
	245	250 255
Ala Gln Lys Ala Gln Ala Leu Arg Leu Ala Ser His Leu Asn Leu Ala		
	260	265 270
Met Cys His Leu Lys Leu Gln Ala Phe Ser Ala Ala Ile Glu Ser Cys		
	275	280 285
Asn Lys Ala Leu Glu Leu Asp Ser Asn Asn Glu Lys Gly Leu Phe Arg		
	290	295 300
Arg Gly Glu Ala His Leu Ala Val Asn Asp Phe Glu Leu Ala Arg Ala		

394

305 310 315 320
 Asp Phe Gln Lys Val Leu Gln Leu Tyr Pro Asn Asn Lys Ala Ala Lys
 325 330 335
 Thr Gln Leu Ala Val Cys Gln Gln Arg Ile Arg Arg Gln Leu Ala Arg
 340 345 350
 Glu Lys Lys Leu Tyr Ala Asn Met Phe Glu Arg Leu Ala Glu Glu Glu
 355 360 365
 Asn Lys Ala Lys Ala Glu Ala Ser Ser Gly Asp His Pro Thr Asp Thr
 370 375 380
 Glu Met Lys Glu Glu Gln Lys Ser Asn Thr Ala Gly Ser Gln Ser Gln
 385 390 395 400
 Val Glu Thr Glu Ala
 405

<210> 446

<211> 232

<212> PRT

<213> Homo sapiens

<400> 446

Pro Leu Val Pro Ser Ser Gln Lys Ala Leu Leu Leu Glu Leu Lys Gly
 1 5 10 15
 Leu Gln Glu Glu Pro Val Glu Gly Phe Arg Val Thr Leu Val Asp Glu
 20 25 30
 Gly Asp Leu Tyr Asn Trp Glu Val Ala Ile Phe Gly Pro Pro Asn Thr
 35 40 45
 Tyr Tyr Glu Gly Gly Tyr Phe Lys Ala Arg Leu Lys Phe Pro Ile Asp
 50 55 60
 Tyr Pro Tyr Ser Pro Pro Ala Phe Arg Phe Leu Thr Lys Met Trp His
 65 70 75 80
 Pro Asn Ile Tyr Glu Thr Gly Asp Val Cys Ile Ser Ile Leu His Pro
 85 90 95
 Pro Val Asp Asp Pro Gln Ser Gly Glu Leu Pro Ser Glu Arg Trp Asn
 100 105 110
 Pro Thr Gln Asn Val Arg Thr Ile Leu Leu Ser Val Ile Ser Leu Leu
 115 120 125

395

Asn Glu Pro Asn Thr Phe Ser Pro Ala Asn Val Asp Ala Ser Val Met
 130 135 140

Tyr Arg Lys Trp Lys Glu Ser Lys Gly Lys Asp Arg Glu Tyr Thr Asp
 145 150 155 160

Ile Ile Arg Lys Gln Val Leu Gly Thr Arg Trp Thr Arg Val Asn Gly
 165 170 175

Val Lys Val Pro Thr Thr Leu Ala Glu Tyr Cys Val Lys Thr Lys Ala
 180 185 190

Pro Ala Pro Asp Glu Gly Ser Asp Leu Phe Tyr Asp Asp Tyr Tyr Glu
 195 200 205

Asp Gly Glu Val Glu Glu Glu Ala Asp Ser Cys Phe Gly Asp Asp Glu
 210 215 220

Asp Asp Ser Gly Thr Glu Glu Ser
 225 230

<210> 447

<211> 356

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (12)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (53)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (191)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (263)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 447

Cys Ser Pro Pro Pro Pro Pro Ala Ala Ala Ala Xaa Ala Ala Ala Ala

396

1	5	10	15
Ala Met Ala Gln Tyr Lys Gly Ala Ala Ser Glu Ala Gly Arg Ala Met	20	25	30
His Leu Met Lys Lys Arg Glu Lys Gln Arg Glu Gln Met Glu Gln Met	35	40	45
Lys Gln Arg Ile Xaa Glu Glu Asn Ile Met Lys Ser Asn Ile Asp Lys	50	55	60
Lys Phe Ser Ala His Tyr Asp Ala Val Glu Ala Glu Leu Lys Ser Ser	65	70	75
Thr Val Gly Leu Val Thr Leu Asn Asp Met Lys Ala Lys Gln Glu Ala	85	90	95
Leu Val Lys Glu Arg Glu Lys Gln Leu Ala Lys Lys Glu Gln Ser Lys	100	105	110
Glu Leu Gln Met Lys Leu Glu Lys Leu Arg Glu Lys Glu Arg Lys Lys	115	120	125
Glu Ala Lys Arg Lys Ile Ser Ser Leu Ser Phe Thr Leu Glu Glu Glu	130	135	140
Glu Glu Gly Gly Glu Glu Glu Glu Glu Ala Ala Met Tyr Glu Glu Glu	145	150	155
Met Glu Arg Glu Glu Ile Thr Thr Lys Lys Arg Lys Leu Gly Lys Asn	165	170	175
Pro Asp Val Asp Thr Ser Phe Leu Pro Asp Arg Asp Arg Glu Xaa Glu	180	185	190
Glu Asn Arg Leu Arg Glu Glu Leu Arg Gln Glu Trp Glu Ala Lys Gln	195	200	205
Glu Lys Ile Lys Ser Glu Glu Ile Glu Ile Thr Phe Ser Tyr Trp Asp	210	215	220
Gly Ser Gly His Arg Arg Thr Val Lys Met Arg Lys Gly Asn Thr Met	225	230	235
Gln Gln Phe Leu Gln Lys Ala Leu Glu Ile Leu Arg Lys Asp Phe Ser	245	250	255
Glu Leu Arg Ser Ala Gly Xaa Glu Gln Leu Met Tyr Ile Lys Glu Asp	260	265	270
Leu Ile Ile Pro His His His Ser Phe Tyr Asp Phe Ile Val Thr Lys			

397

275	280	285
Ala Arg Gly Lys Ser Gly Pro Leu Phe Asn Phe Asp Val His Asp Asp		
290	295	300
Val Arg Leu Leu Ser Asp Ala Thr Val Glu Lys Asp Glu Ser His Ala		
305	310	315 320
Gly Lys Val Val Leu Arg Ser Trp Tyr Glu Lys Asn Lys His Ile Phe		
	325	330 335
Pro Ala Ser Arg Trp Glu Pro Tyr Asp Pro Glu Lys Lys Trp Asp Lys		
	340	345 350
Tyr Thr Ile Arg		
355		

<210> 448

<211> 88

<212> PRT

<213> Homo sapiens

<400> 448

Lys Thr His Lys Met Cys Asp Ala Phe Val Gly Thr Trp Lys Leu Val
1 5 10 15
Ser Ser Glu Asn Phe Asp Asp Tyr Met Lys Glu Val Gly Val Gly Phe
20 25 30
Ala Thr Arg Lys Val Ala Gly Met Ala Lys Pro Asn Met Ile Ile Ser
35 40 45
Val Asn Gly Asp Val Ile Thr Ile Lys Ser Glu Ser Thr Phe Lys Asn
50 55 60
Thr Glu Ile Ser Phe Ile Leu Gly Gln Glu Phe Asp Glu Ala Leu Gln
65 70 75 80
Met Thr Gly Lys Ser Arg Ala Pro
85

<210> 449

<211> 171

<212> PRT

<213> Homo sapiens

<220>

398

<221> SITE

<222> (72)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (132)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 449

Leu Ile Leu Val Leu Met Phe Val Val Trp Met Lys Arg Arg Asp Lys
 1 5 10 15

Glu Arg Gln Ala Lys Gln Leu Leu Ile Asp Pro Glu Asp Asp Val Arg
 20 25 30

Asp Asn Ile Leu Lys Tyr Asp Glu Gly Gly Gly Glu Glu Asp Gln
 35 40 45

Asp Tyr Asp Leu Ser Gln Leu Gln Gln Pro Asp Thr Val Glu Pro Asp
 50 55 60

Ala Ile Lys Pro Val Gly Ile Xaa Arg Met Asp Glu Arg Pro Ile His
 65 70 75 80

Ala Glu Pro Gln Tyr Pro Val Arg Ser Ala Ala Pro His Pro Gly Asp
 85 90 95

Ile Gly Asp Phe Ile Asn Glu Gly Leu Lys Ala Ala Asp Asn Asp Pro
 100 105 110

Thr Ala Pro Pro Tyr Asp Ser Leu Leu Val Phe Asp Tyr Glu Gly Ser
 115 120 125

Gly Ser Thr Xaa Gly Ser Leu Ser Ser Leu Asn Ser Ser Ser Gly
 130 135 140

Gly Glu Gln Asp Tyr Asp Tyr Leu Asn Asp Trp Gly Pro Arg Phe Lys
 145 150 155 160

Lys Leu Ala Asp Met Tyr Gly Gly Gly Asp Asp
 165 170

<210> 450

<211> 34

<212> PRT

<213> Homo sapiens

<400> 450

399

Lys Val Lys Ala Cys Cys Lys Asp Ile Phe Phe Leu Leu Leu Glu Gly
 1 5 10 15
 Asn Thr Lys Arg Lys Ile Ser Phe Phe His Gly Ala Phe Asp Asn Phe
 20 25 30
 Ser Leu

<210> 451
 <211> 148
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (43)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (89)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 451
 Arg Thr Leu His Pro Ala Thr Gly Pro Arg Ala Arg Pro Pro Arg Gly
 1 5 10 15
 Trp Arg Arg Arg Leu Cys Ala Gln Gly Pro Ala Pro Asp Trp Asp Pro
 20 25 30
 Gly Val Pro Pro Gly Leu Ala Ser Cys Gly Xaa Thr Val Trp Leu His
 35 40 45
 Phe Ser Asp Pro Ser Leu Gly Arg Lys Val Lys Glu Thr Gly Pro Ala
 50 55 60
 Ser Ala Phe Gly Leu Trp Phe Leu Asp Arg Val Leu Ser Pro Ser Pro
 65 70 75 80
 Pro Ser Ser Pro Asn Leu Ser His Xaa Arg Pro Leu Pro Ala Ala Pro
 85 90 95
 Ser Leu Leu Gly Ile Gly Ser Pro Glu Pro Pro Ser Pro Glu Pro Pro
 100 105 110
 Thr Pro Leu Pro Gly Pro Cys Gly Cys Trp Ala Ser His Leu Lys Glu
 115 120 125

400

Gly Lys Val Val Gln Pro Glu Pro Val Glu Gln Cys Pro Val Trp Pro
 130 135 140

Pro Lys Pro Lys
 145

<210> 452

<211> 83

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (19)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (28)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (64)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (77)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (79)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 452

Asp Ser His Arg Pro Arg Ala Met Arg Ala Leu Trp Val Leu Gly Leu
 1 5 10 15

Ser Cys Xaa Leu Leu Thr Phe Gly Ser Val Arg Xaa Asp Asp Glu Val
 20 25 30

Asp Val Asp Gly Thr Val Glu Glu Asp Leu Gly Lys Ser Arg Glu Gly
 35 40 45

Ser Arg Thr Asp Asp Glu Val Val Gln Arg Glu Glu Glu Ala Ile Xaa
 50 55 60

401

Val Gly Trp Ile Lys Cys Ile Pro Asn Lys Arg Thr Xaa Glu Xaa Lys
 65 70 75 80

Ser Arg Lys

<210> 453

<211> 240

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (234)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 453

Gly Trp Leu Pro Cys Gly Ser Ser Val Val Pro Ala Thr Pro Gly Ser
 1 5 10 15

Pro Pro Ser Arg Phe Trp Leu Leu Pro Ala Met Ala Leu Arg Val Leu
 20 25 30

Leu Leu Thr Ala Leu Thr Leu Cys His Gly Phe Asn Leu Asp Thr Glu
 35 40 45

Asn Ala Met Thr Phe Gln Glu Asn Ala Arg Gly Phe Gly Gln Ser Val
 50 55 60

Val Gln Leu Gln Gly Ser Arg Val Val Val Gly Ala Pro Gln Glu Ile
 65 70 75 80

Val Ala Ala Asn Gln Arg Gly Ser Leu Tyr Gln Cys Asp Tyr Ser Thr
 85 90 95

Gly Ser Cys Glu Pro Ile His Leu Gln Val Pro Val Glu Ala Val Asn
 100 105 110

Met Ser Leu Gly Leu Ser Leu Ala Ala Thr Thr Ser Pro Pro Gln Leu
 115 120 125

Leu Ala Cys Gly Pro Thr Val His Gln Thr Cys Ser Glu Asn Thr Tyr
 130 135 140

Val Lys Gly Leu Cys Phe Leu Phe Gly Ser Asn Leu Arg Gln Gln Pro
 145 150 155 160

Gln Lys Phe Pro Glu Ala Leu Arg Gly Cys Pro Gln Glu Asp Ser Asp
 165 170 175

402

Ile Ala Phe Leu Ile Asp Gly Ser Gly Ser Ile Ile Pro His Asp Phe
 180 185 190
 Arg Arg Met Lys Glu Phe Val Ser Thr Val Met Glu Gln Leu Lys Lys
 195 200 205
 Ser Lys Thr Leu Phe Ser Leu Met Gln Tyr Ser Glu Glu Phe Arg Ile
 210 215 220
 His Phe Thr Ser Lys Ser Ser Arg Thr Xaa Leu Thr Gln Asp His Trp
 225 230 235 240

<210> 454

<211> 244

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (206)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (227)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (229)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (239)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 454

Lys Trp Cys Ser Trp Thr Leu Leu Lys Ile Trp Glu Val Thr Cys Thr
 1 5 10 15

Trp Lys Leu Pro Thr Leu Ala Lys Phe Ser Pro Tyr Leu Gly Gln Met
 20 25 30

Ile Asn Leu Arg Arg Leu Leu Leu Ser His Ile His Ala Ser Ser Tyr

403

35	40	45
Ile Ser Pro Glu Lys Glu Glu Gln Tyr Ile Ala Gln Phe Thr Ser Gln		
50	55	60
Phe Leu Ser Leu Gln Cys Leu Gln Leu Leu Tyr Val Asp Ser Leu Phe		
65	70	75
Phe Leu Arg Gly Arg Leu Asp Gln Leu Leu Arg His Val Met Asn Pro		
	85	90
Leu Glu Thr Leu Ser Ile Thr Asn Cys Arg Leu Ser Glu Gly Asp Val		
	100	105
Met His Leu Ser Gln Ser Pro Ser Val Ser Gln Leu Ser Val Leu Ser		
	115	120
Leu Ser Gly Val Met Leu Thr Asp Val Ser Pro Glu Pro Leu Gln Ala		
	130	140
Leu Leu Glu Arg Ala Ser Ala Thr Leu Gln Asp Leu Val Phe Asp Glu		
145	150	155
Cys Gly Ile Thr Asp Asp Gln Leu Leu Ala Leu Leu Pro Ser Leu Ser		
	165	170
His Cys Ser Gln Leu Thr Thr Leu Ser Phe Tyr Gly Asn Ser Ile Ser		
	180	185
Ile Ser Ala Leu Gln Ser Leu Leu Gln His Leu Ile Gly Xaa Ser Asn		
	195	200
Leu Thr His Val Leu Tyr Pro Val Pro Leu Glu Ser Tyr Glu Asp Ile		
	210	220
His Gly Xaa Leu Xaa Leu Glu Arg Leu Leu Ser Ala Cys Gln Xaa Gln		
225	230	235
Gly Val Ala Val		

<210> 455

<211> 195

<212> PRT

<213> Homo sapiens

<400> 455

His Glu Gly Thr Gln Ser Phe Val Phe Gln Arg Glu Glu Ile Ala Gln
1 5 10 15

404

Leu Ala Arg Gln Tyr Ala Gly Leu Asp His Glu Leu Ala Phe Ser Arg
 20 25 30
 Leu Ile Val Glu Leu Arg Arg Leu His Pro Gly His Val Leu Pro Asp
 35 40 45
 Glu Glu Leu Gln Trp Val Phe Val Asn Ala Gly Gly Trp Met Gly Ala
 50 55 60
 Met Cys Leu Leu His Ala Ser Leu Ser Glu Tyr Val Leu Leu Phe Gly
 65 70 75 80
 Thr Ala Leu Gly Ser Arg Gly His Ser Gly Arg Tyr Trp Ala Glu Ile
 85 90 95
 Ser Asp Thr Ile Ile Ser Gly Thr Phe His Gln Trp Arg Glu Gly Thr
 100 105 110
 Thr Lys Ser Glu Val Phe Tyr Pro Gly Glu Thr Val Val His Gly Pro
 115 120 125
 Gly Glu Ala Thr Ala Val Glu Trp Gly Pro Asn Thr Trp Met Val Glu
 130 135 140
 Tyr Gly Arg Gly Val Ile Pro Ser Thr Leu Ala Phe Ala Leu Ala Asp
 145 150 155 160
 Thr Val Phe Ser Thr Gln Asp Phe Leu Thr Leu Phe Tyr Thr Leu Arg
 165 170 175
 Ser Tyr Ala Arg Gly Leu Arg Leu Glu Leu Thr Thr Tyr Leu Phe Gly
 180 185 190
 Gln Asp Pro
 195

<210> 456

<211> 36

<212> PRT

<213> Homo sapiens

<400> 456

Leu Val Thr Leu Leu His Ala Met Gln Ala Arg Asp Lys Thr Leu Gly
 1 5 10 15
 Leu Ala Thr Leu Cys Ile Gly Gly Gly Gln Gly Ile Ala Met Val Ile
 20 25 30

405

Glu Arg Leu Asn
35

<210> 457
<211> 152
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (86)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (114)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 457
Val Thr Ala Ala Ala Ser Val Arg Ala Leu Gln Val Thr Val Ala Gly
1 5 10 15
Leu Leu Leu Val Phe Phe Leu Phe Gly Ala Pro Leu Asp Ser Leu Pro
20 25 30
Ser Met Lys Ala Leu Ser Pro Val Arg Gly Cys Tyr Glu Ala Val Cys
35 40 45
Cys Leu Ser Glu Arg Ser Leu Ala Ile Ala Arg Gly Arg Gly Lys Gly
50 55 60
Pro Ala Ala Glu Glu Pro Leu Ser Leu Leu Asp Asp Met Asn His Cys
65 70 75 80
Tyr Ser Arg Leu Arg Xaa Leu Val Pro Gly Val Pro Arg Gly Thr Gln
85 90 95
Leu Ser Gln Val Glu Ile Leu Gln Arg Val Ile Asp Tyr Ile Leu Asp
100 105 110
Leu Xaa Val Val Leu Ala Glu Pro Ala Pro Gly Pro Pro Asp Gly Pro
115 120 125
His Leu Pro Ile Gln Thr Ala Glu Leu Ala Pro Glu Leu Val Ile Ser
130 135 140
Asn Asp Lys Arg Ser Phe Cys His
145 150

<210> 458
<211> 31
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (17)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (25)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (31)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 458
Leu Leu Asn Asn Phe Ile Phe Leu Glu Thr His Tyr Leu Trp Ala Cys
1 5 10 15
Xaa Thr Trp Thr Ile Trp Pro Asn Xaa Leu Asp Lys Lys Gly Xaa
20 25 30

<210> 459
<211> 157
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (28)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (72)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (124)
<223> Xaa equals any of the naturally occurring L-amino acids

407

<220>

<221> SITE

<222> (130)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 459

Asp Pro Arg Val Arg Glu Thr Thr Val Lys Ala Arg Ala Arg Ser Gln
 1 5 10 15

His Ala Gly Gly Pro Glu Leu Gly Leu Ser Gln Xaa Tyr Val Thr Pro
 20 25 30

Arg Arg Pro Phe Glu Lys Ser Arg Leu Asp Gln Glu Leu Lys Leu Ile
 35 40 45

Gly Glu Tyr Gly Leu Arg Asn Lys Arg Glu Val Trp Arg Val Lys Phe
 50 55 60

Thr Leu Ala Lys Ile Arg Lys Xaa Ala Arg Glu Leu Leu Thr Leu Asp
 65 70 75 80

Glu Lys Asp Pro Arg Arg Leu Phe Glu Gly Asn Ala Leu Leu Arg Arg
 85 90 95

Leu Val Arg Ile Gly Val Leu Asp Glu Gly Lys Met Lys Leu Asp Tyr
 100 105 110

Ile Leu Gly Leu Lys Met Arg Ile Leu Gly Glu Xaa Ser Ala Asp Pro
 115 120 125

Gly Xaa Ser Ser Trp Gly Trp Pro Ile His Pro Pro Cys Pro Val Leu
 130 135 140

Ile Arg Gln Ala Thr Gln Val Arg Lys Gln Val Val Asn
 145 150 155

<210> 460

<211> 136

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (119)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (130)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (135)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 460

Ile Trp Ala Pro Phe Pro His His Gln Gly Ser Gly Ser Gln Val Ser
1 5 10 15

Ser Tyr Gly Thr Gly Ala Leu Lys Ser His Ile Met Ala Ala Lys Ala
20 25 30

Val Ala Asn Thr Met Arg Thr Ser Leu Gly Pro Asn Gly Leu Asp Lys
35 40 45

Met Met Val Asp Lys Asp Gly Asp Val Thr Val Thr Asn Asp Gly Ala
50 55 60

Thr Ile Leu Ser Met Met Asp Val Asp His Gln Ile Ala Lys Leu Met
65 70 75 80

Val Glu Leu Ser Lys Ser Gln Asp Asp Glu Ile Gly Asp Gly Asp His
85 90 95

Gly Gly Gly Cys Pro Gly Arg Arg Pro Ala Gly Arg Arg Pro Ser Ser
100 105 110

Cys Trp Thr Ala Ala Phe Xaa Arg Ser Gly Ser Pro Thr Val Thr Ser
115 120 125

Arg Xaa Pro Ala Leu Ala Xaa Glu
130 135

<210> 461

<211> 390

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (11)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (14)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (375)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (382)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (383)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (386)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (387)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 461

Cys	Gly	Asn	Trp	Trp	Val	Pro	Arg	Ala	Gly	Xaa	Asn	Trp	Xaa	Arg	Gly
1				5					10					15	

Ser	Arg	Phe	Leu	Phe	Val	Asp	Arg	Cys	Asp	Arg	His	Leu	Thr	Met	Gln
		20					25					30			

Ile	Phe	Val	Lys	Thr	Leu	Thr	Gly	Lys	Thr	Ile	Thr	Leu	Glu	Val	Glu
	35						40					45			

Pro	Ser	Asp	Thr	Ile	Glu	Asn	Val	Lys	Ala	Lys	Ile	Gln	Asp	Lys	Glu
	50					55					60				

Gly	Ile	Pro	Pro	Asp	Gln	Gln	Arg	Leu	Ile	Phe	Ala	Gly	Lys	Gln	Leu
65					70					75				80	

Glu	Asp	Gly	Arg	Thr	Leu	Ser	Asp	Tyr	Asn	Ile	Gln	Lys	Glu	Ser	Thr
				85					90					95	

Leu	His	Leu	Val	Leu	Arg	Leu	Arg	Gly	Gly	Met	Gln	Ile	Phe	Val	Lys
		100						105					110		

Thr	Leu	Thr	Gly	Lys	Thr	Ile	Thr	Leu	Glu	Val	Glu	Pro	Ser	Asp	Thr
		115						120					125		

410

Ile Glu Asn Val Lys Ala Lys Ile Gln Asp Lys Glu Gly Ile Pro Pro
 130 135 140

Asp Gln Gln Arg Leu Ile Phe Ala Gly Lys Gln Leu Glu Asp Gly Arg
 145 150 155 160

Thr Leu Ser Asp Tyr Asn Ile Gln Lys Glu Ser Thr Leu His Leu Val
 165 170 175

Leu Arg Leu Arg Gly Gly Met Gln Ile Phe Val Lys Thr Leu Thr Gly
 180 185 190

Lys Thr Ile Thr Leu Glu Val Glu Pro Ser Asp Thr Ile Glu Asn Val
 195 200 205

Lys Ala Lys Ile Gln Asp Lys Glu Gly Ile Pro Pro Asp Gln Gln Arg
 210 215 220

Leu Ile Phe Ala Gly Lys Gln Leu Glu Asp Gly Arg Thr Leu Ser Asp
 225 230 235 240

Tyr Asn Ile Gln Lys Glu Ser Thr Leu His Leu Val Leu Arg Leu Arg
 245 250 255

Gly Gly Met Gln Ile Phe Val Lys Thr Leu Thr Gly Lys Thr Ile Thr
 260 265 270

Leu Glu Val Glu Pro Ser Asp Thr Ile Glu Asn Val Lys Ala Lys Ile
 275 280 285

Gln Asp Lys Glu Gly Ile Pro Pro Asp Gln Gln Arg Leu Ile Phe Ala
 290 295 300

Gly Lys Gln Leu Glu Asp Gly Arg Thr Leu Ser Asp Tyr Asn Ile Gln
 305 310 315 320

Lys Glu Ser Thr Leu His Leu Val Leu Arg Leu Arg Gly Gly Met Gln
 325 330 335

Ile Phe Val Lys Thr Leu Thr Gly Lys Thr Ile Thr Leu Glu Val Glu
 340 345 350

Pro Ser Asp Thr Ile Glu Asn Val Lys Ala Arg Ser Arg Gln Gly Arg
 355 360 365

His Pro Pro Asp Gln Gln Xaa Leu Ile Leu Leu Gly Lys Xaa Xaa Lys
 370 375 380

Trp Xaa Xaa Pro Phe Asp
 385 390

411

<210> 462
 <211> 171
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (74)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (135)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (142)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (155)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 462
 Cys Ser Thr Val Arg Ile Pro Gly Ser Thr His Ala Ser Gly Leu Ser
 1 5 10 15
 Arg Arg Ala Ser Pro Val Tyr Leu Ala Ser Met Ser Gly Arg Gly Lys
 20 25 30
 Thr Gly Gly Lys Ala Arg Ala Lys Ala Lys Ser Arg Ser Ser Arg Ala
 35 40 45
 Gly Leu Gln Phe Pro Val Gly Arg Val His Arg Leu Leu Arg Lys Gly
 50 55 60
 His Tyr Ala Glu Arg Val Gly Ala Gly Xaa Pro Val Tyr Leu Ala Ala
 65 70 75 80
 Val Leu Glu Tyr Leu Thr Ala Glu Ile Leu Glu Leu Ala Gly Asn Ala
 85 90 95
 Ala Arg Asp Asn Lys Lys Thr Arg Ile Ile Pro Arg His Leu Gln Leu
 100 105 110
 Ala Ile Arg Asn Asp Glu Glu Leu Asn Lys Leu Leu Gly Gly Val Thr
 115 120 125

412

Ile Ala Gln Gly Arg Arg Xaa Ala Gln His Pro Gly Arg Xaa Cys Cys
 130 135 140

Pro Arg Arg Pro Ala Pro Pro Trp Gly Arg Xaa Pro Phe Gly Gly Gln
 145 150 155 160

Glu Arg Ala Thr Lys Ala Ser Gln Gly Val Leu
 165 170

<210> 463

<211> 433

<212> PRT

<213> Homo sapiens

<400> 463

Arg Val Arg Ala Pro Pro Arg Pro Pro Leu Gly Pro Ser Arg Pro Ser
 1 5 10 15

His His Val His Pro Leu Gln Leu Pro Gly Ile Arg Glu Val Thr Ile
 20 25 30

Asn Gln Ser Leu Leu Ala Pro Leu Arg Leu Asp Ala Asp Pro Ser Leu
 35 40 45

Gln Arg Val Arg Gln Glu Glu Ser Glu Gln Ile Lys Thr Leu Asn Asn
 50 55 60

Lys Phe Ala Ser Phe Ile Asp Lys Val Arg Phe Leu Glu Gln Gln Asn
 65 70 75 80

Lys Leu Leu Glu Thr Lys Trp Thr Leu Leu Gln Glu Gln Lys Ser Ala
 85 90 95

Lys Ser Ser Arg Leu Pro Asp Ile Phe Glu Ala Gln Ile Ala Gly Leu
 100 105 110

Arg Gly Gln Leu Glu Ala Leu Gln Val Asp Gly Gly Arg Leu Glu Ala
 115 120 125

Glu Leu Arg Ser Met Gln Asp Val Val Glu Asp Phe Lys Asn Lys Tyr
 130 135 140

Glu Asp Glu Ile Asn Arg Arg Thr Ala Ala Glu Asn Glu Phe Val Val
 145 150 155 160

Leu Lys Lys Asp Val Asp Ala Ala Tyr Met Ser Lys Val Glu Leu Glu
 165 170 175

413

Ala Lys Val Asp Ala Leu Asn Asp Glu Ile Asn Phe Leu Arg Thr Leu
 180 185 190
 Asn Glu Thr Glu Leu Thr Glu Leu Gln Ser Gln Ile Ser Asp Thr Ser
 195 200 205
 Val Val Leu Ser Met Asp Asn Ser Arg Ser Leu Asp Leu Asp Gly Ile
 210 215 220
 Ile Ala Glu Val Lys Ala Gln Tyr Glu Glu Met Ala Lys Cys Ser Arg
 225 230 235 240
 Ala Glu Ala Glu Ala Trp Tyr Gln Thr Lys Phe Glu Thr Leu Gln Ala
 245 250 255
 Gln Ala Gly Lys His Gly Asp Asp Leu Arg Asn Thr Arg Asn Glu Ile
 260 265 270
 Ser Glu Met Asn Arg Ala Ile Gln Arg Leu Gln Ala Glu Ile Asp Asn
 275 280 285
 Ile Lys Asn Gln Arg Ala Lys Leu Glu Ala Ala Ile Ala Glu Ala Glu
 290 295 300
 Glu Arg Gly Glu Leu Ala Leu Lys Asp Ala Arg Ala Lys Gln Glu Glu
 305 310 315 320
 Leu Glu Ala Ala Leu Gln Arg Ala Lys Gln Asp Met Ala Arg Gln Leu
 325 330 335
 Arg Glu Tyr Gln Glu Leu Met Ser Val Lys Leu Ala Leu Asp Ile Glu
 340 345 350
 Ile Ala Thr Tyr Arg Lys Leu Leu Glu Gly Glu Glu Ser Arg Leu Ala
 355 360 365
 Gly Asp Gly Val Gly Ala Val Asn Ile Ser Val Met Asn Ser Thr Gly
 370 375 380
 Gly Ser Ser Ser Gly Gly Gly Ile Gly Leu Thr Leu Gly Gly Thr Met
 385 390 395 400
 Gly Ser Asn Ala Leu Ser Phe Ser Ser Ser Ala Gly Pro Gly Leu Leu
 405 410 415
 Lys Ala Tyr Ser Ile Arg Thr Ala Ser Ala Ser Arg Arg Ser Ala Arg
 420 425 430

Asp

<210> 464
<211> 121
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (50)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (64)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (110)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (114)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (115)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (117)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 464
Gly Ser Gly Cys Val Phe Ala Ile Leu Gly Arg Arg Cys Ser Arg Pro
1 5 10 15
Trp Arg Ile Trp Pro Gly Glu Pro Leu Gln Arg Ala Pro Pro Ala Ala
20 25 30
Gly Thr Arg Trp Pro His Gly His Arg Ser Ser Pro Val Gly Thr Pro
35 40 45
Gly Xaa Ala Pro Asn Val Pro Ala Ile Trp Gln Gln Pro Leu Trp Xaa
50 55 60
Glu Tyr Ser Cys Glu Tyr Gly Ser Met Lys Phe Tyr Ala Leu Cys Gly

415

65 70 75 80
 Phe Gly Gly Val Leu Ser Cys Gly Leu Thr His Thr Ala Val Val Pro
 85 90 95
 Leu Asp Leu Val Lys Cys Arg Met Gln Val Asp Pro Gln Xaa Tyr Lys
 100 105 110
 Gly Xaa Xaa Asn Xaa Ile Leu Ile Asn
 115 120

<210> 465
 <211> 68
 <212> PRT
 <213> Homo sapiens

<400> 465
 Arg Ile Pro Ala Pro Ala Ser Ser Arg His Ser Gly Gly Arg Cys Ala
 1 5 10 15
 Ala Gly Pro Arg Gly Pro Pro Ala Thr Ala Ser Arg Ala Leu Arg Ala
 20 25 30
 Val His Arg Pro Leu Asp Ala Ala Arg Gly Arg Thr Gly Ser Thr Ser
 35 40 45
 His Leu Cys Ser Ser Ser Tyr Thr Ile Gly Cys Leu Leu Trp Phe Ser
 50 55 60
 Gln Lys Ala Met
 65

<210> 466
 <211> 224
 <212> PRT
 <213> Homo sapiens

<400> 466
 Ala Thr Ile Leu Glu Arg Glu Ala Glu Gln Ser Arg Leu Gly Ala Thr
 1 5 10 15
 Glu Arg Ala Ala Ala Ala Met Asn Pro Glu Tyr Asp Tyr Leu Phe
 20 25 30
 Lys Leu Leu Leu Ile Gly Asp Ser Gly Val Gly Lys Ser Cys Leu Leu
 35 40 45

416

```

Leu Arg Phe Ala Asp Asp Thr Tyr Thr Glu Ser Tyr Ile Ser Thr Ile
  50                      55                      60

Gly Val Asp Phe Lys Ile Arg Thr Ile Glu Leu Asp Gly Lys Thr Ile
  65                      70                      75                      80

Lys Leu Gln Ile Trp Asp Thr Ala Gly Gln Glu Arg Phe Arg Thr Ile
                      85                      90                      95

Thr Ser Ser Tyr Tyr Arg Gly Ala His Gly Ile Ile Val Val Tyr Asp
      100                      105                      110

Val Thr Asp Gln Glu Ser Tyr Ala Asn Val Lys Gln Trp Leu Gln Glu
      115                      120                      125

Ile Asp Arg Tyr Ala Ser Glu Asn Val Asn Lys Leu Leu Val Gly Asn
      130                      135                      140

Lys Ser Asp Leu Thr Thr Lys Lys Val Val Asp Asn Thr Thr Ala Lys
      145                      150                      155                      160

Glu Phe Ala Asp Ser Leu Gly Ile Pro Phe Leu Glu Thr Ser Ala Lys
      165                      170                      175

Asn Ala Thr Asn Val Glu Gln Ala Phe Met Thr Met Ala Ala Glu Ile
      180                      185                      190

Lys Lys Arg Met Gly Pro Gly Ala Ala Ser Gly Gly Glu Arg Pro Asn
      195                      200                      205

Leu Lys Ile Asp Ser Thr Pro Val Lys Pro Ala Gly Gly Gly Cys Cys
      210                      215                      220

```

<210> 467

<211> 76

<212> PRT

<213> Homo sapiens

<400> 467

```

Ser Glu Ala Pro Gly Glu Ser Val Gly Thr Thr Pro Glu Ala Gln Met
  1                      5                      10                      15

Lys Thr Gly Pro Phe Ala Glu His Ser Asn Gln Leu Trp Asn Ile Ser
      20                      25                      30

Ala Val Pro Ser Trp Ser Lys Val Asn Gln Gly Leu Ile Arg Met Tyr

```

```

<400> 468
Ser  Leu  Ala  Arg  Thr  Gly  Pro  Arg  Ser  Leu  Ala  Arg  Pro  Cys  Arg  Arg
  1              5              10              15

Arg  Pro  Ala  His  Arg  His  Pro  Leu  Gln  Pro  Cys  Pro  Pro  Gly  Xaa  Cys
                20              25              30

```



```
<210> 469
<211> 459
<212> PRT
<213> Homo sapiens
```

```

<400> 469
Pro Arg Val Arg Pro Arg Val Arg Pro Arg Val Arg Leu Ser Ser Pro
  1          5          10          15
Ser Pro Val Cys Leu Pro Pro Ala Ala Ala Thr Met Thr Thr Ser Ile
          20          25          30
Arg Gln Phe Thr Ser Ser Ser Ser Ile Lys Gly Ser Ser Gly Leu Gly
          35          40          45
Gly Gly Ser Ser Arg Thr Ser Cys Arg Leu Ser Gly Gly Leu Gly Ala
          50          55          60
Gly Ser Cys Arg Leu Gly Ser Ala Gly Gly Leu Gly Ser Thr Leu Gly
          65          70          75          80
Gly Ser Ser Tyr Ser Ser Cys Tyr Ser Phe Gly Ser Gly Gly Gly Tyr
          85          90          95
Gly Ser Ser Phe Gly Gly Val Asp Gly Leu Leu Ala Gly Gly Glu Lys
          100          105          110
Ala Thr Met Gln Asn Leu Asn Asp Arg Leu Ala Ser Tyr Leu Asp Lys
          115          120          125
Val Arg Ala Leu Glu Glu Ala Asn Thr Glu Leu Glu Val Lys Ile Arg
          130          135          140

```

Asp Trp Tyr Gln Arg Gln Ala Pro Gly Pro Ala Arg Asp Tyr Ser Gln
 145 150 155 160
 Tyr Tyr Arg Thr Ile Glu Glu Leu Gln Asn Lys Ile Leu Thr Ala Thr
 165 170 175
 Val Asp Asn Ala Asn Ile Leu Leu Gln Ile Asp Asn Ala Arg Leu Ala
 180 185 190
 Ala Asp Asp Phe Arg Thr Lys Phe Glu Thr Glu Gln Ala Leu Arg Leu
 195 200 205
 Ser Val Glu Ala Asp Ile Asn Gly Leu Arg Arg Val Leu Asp Glu Leu
 210 215 220
 Thr Leu Ala Arg Ala Asp Leu Glu Met Gln Ile Glu Asn Leu Lys Glu
 225 230 235 240
 Glu Leu Ala Tyr Leu Lys Lys Asn His Glu Glu Glu Met Asn Ala Leu
 245 250 255
 Arg Gly Gln Val Gly Gly Glu Ile Asn Val Glu Met Asp Ala Ala Pro
 260 265 270
 Gly Val Asp Leu Ser Arg Ile Leu Asn Glu Met Arg Asp Gln Tyr Glu
 275 280 285
 Lys Met Ala Glu Lys Asn Arg Lys Asp Ala Glu Asp Trp Phe Phe Ser
 290 295 300
 Lys Thr Glu Glu Leu Asn Arg Glu Val Ala Thr Asn Ser Glu Leu Val
 305 310 315 320
 Gln Ser Gly Lys Ser Glu Ile Ser Glu Leu Arg Arg Thr Met Gln Ala
 325 330 335
 Leu Glu Ile Glu Leu Gln Ser Gln Leu Ser Met Lys Ala Ser Leu Glu
 340 345 350
 Gly Asn Leu Ala Glu Thr Glu Asn Arg Tyr Cys Val Gln Leu Ser Gln
 355 360 365
 Ile Gln Gly Leu Ile Gly Ser Val Glu Glu Gln Leu Ala Gln Leu Arg
 370 375 380
 Cys Glu Met Glu Gln Gln Asn Gln Glu Tyr Lys Ile Leu Leu Asp Val
 385 390 395 400
 Lys Thr Arg Leu Glu Gln Glu Ile Ala Thr Tyr Arg Arg Leu Leu Glu
 405 410 415

420

Gly Glu Asp Ala His Leu Thr Gln Tyr Lys Lys Glu Pro Val Thr Thr
 420 425 430

Arg Gln Val Arg Thr Ile Val Glu Glu Val Gln Asp Gly Lys Val Ile
 435 440 445

Ser Ser Arg Glu Gln Val His Gln Thr Thr Arg
 450 455

<210> 470

<211> 158

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (158)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 470

Pro Pro Pro Pro Pro Pro Pro Glu Leu Cys Ser Met Ala Ser Arg Arg
 1 5 10 15

Met Glu Thr Lys Pro Val Ile Thr Cys Leu Lys Thr Leu Leu Ile Ile
 20 25 30

Tyr Ser Phe Val Phe Trp Ile Thr Gly Val Ile Leu Leu Ala Val Gly
 35 40 45

Val Trp Gly Lys Leu Thr Leu Gly Thr Tyr Ile Ser Leu Ile Ala Glu
 50 55 60

Asn Ser Thr Asn Ala Pro Tyr Val Leu Ile Gly Thr Gly Thr Thr Ile
 65 70 75 80

Val Val Phe Gly Leu Phe Gly Cys Phe Ala Thr Cys Arg Gly Ser Pro
 85 90 95

Trp Met Leu Lys Leu Tyr Ala Met Phe Leu Ser Leu Val Phe Leu Ala
 100 105 110

Glu Leu Val Ala Gly Ile Ser Gly Phe Val Phe Arg His Glu Ile Lys
 115 120 125

Asp Thr Phe Leu Arg Thr Tyr Thr Asp Ala Met Gln Thr Tyr Asn Gly
 130 135 140

Asn Asp Glu Arg Ser Arg Ala Val Asp His Val Gln Arg Xaa
 145 150 155

421

<210> 471

<211> 59

<212> PRT

<213> Homo sapiens

<400> 471

Val Leu Phe Phe Tyr Glu Cys Pro Asn Leu Cys Phe Pro Leu Pro Ser
1 5 10 15

Gln Thr Val Trp Pro Val Glu Ser Val Trp Phe Val Phe Ile Ser Pro
20 25 30

Ser Phe Leu Glu Gln Gly Leu Arg Pro Cys His Ile Ser Tyr Ala Leu
35 40 45

His Pro Arg Leu Phe Trp Thr Leu Lys Val Asp
50 55

<210> 472

<211> 320

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (48)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (49)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (53)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (105)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 472

Asp Pro Asp Glu Val Phe Pro Val Cys Leu Pro Leu Thr Gly Asp Ala
1 5 10 15

422

Gly Glu Asp Gly Gly Lys Met Leu His Leu Pro Glu Trp Pro Glu Gln
 20 25 30
 Pro Pro Gly Gly Pro Ala Ala Leu Gln Val Arg Gly Ala Glu Asp Xaa
 35 40 45
 Xaa Leu Ser Phe Xaa Asp Cys Glu Ser Leu Gln Ala Val Phe Asp Pro
 50 55 60
 Ala Ser Cys Pro His Met Leu Arg Ala Pro Ala Arg Val Leu Gly Glu
 65 70 75 80
 Ala Val Leu Pro Phe Ser Pro Ala Leu Ala Glu Val Thr Leu Gly Ile
 85 90 95
 Gly Arg Gly Ala Gly Ser Ser Trp Xaa Tyr His Glu Glu Glu Ala Asp
 100 105 110
 Ser Thr Ala Lys Ala Met Val Thr Glu Met Cys Leu Gly Glu Glu Asp
 115 120 125
 Phe Gln Gln Leu Gln Ala Gln Glu Gly Val Ala Ile Thr Phe Cys Leu
 130 135 140
 Lys Glu Phe Arg Gly Leu Leu Ser Phe Ala Glu Ser Ala Asn Leu Asn
 145 150 155 160
 Leu Ser Ile His Phe Asp Ala Pro Gly Arg Pro Ala Ile Phe Thr Ile
 165 170 175
 Lys Asp Ser Leu Leu Asp Gly His Phe Val Leu Ala Thr Leu Ser Asp
 180 185 190
 Thr Asp Ser His Ser Gln Asp Leu Gly Ser Pro Glu Arg His Gln Pro
 195 200 205
 Val Pro Gln Leu Gln Ala His Ser Thr Pro His Pro Asp Asp Phe Ala
 210 215 220
 Asn Asp Asp Ile Asp Ser Tyr Met Ile Ala Met Glu Thr Thr Ile Gly
 225 230 235 240
 Asn Glu Gly Ser Arg Val Leu Pro Ser Ile Ser Leu Ser Pro Gly Pro
 245 250 255
 Gln Pro Pro Lys Ser Pro Gly Pro His Ser Glu Glu Glu Asp Glu Ala
 260 265 270
 Glu Pro Ser Thr Val Pro Gly Thr Pro Pro Pro Lys Lys Phe Arg Ser
 275 280 285

423

Leu Phe Phe Gly Ser Ile Leu Ala Pro Val Arg Ser Pro Gln Gly Pro
 290 295 300

Ser Leu Cys Trp Arg Lys Thr Val Arg Val Lys Ala Glu Pro Arg Thr
 305 310 315 320

<210> 473

<211> 331

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (24)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (283)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (299)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (324)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 473

Pro Pro Cys Ala Val Pro Gly Pro Arg Leu Ser Pro Lys Leu Arg Thr
 1 5 10 15

Pro Ser Asn Ser Arg Glu Ser Xaa Ile Cys Val Ser Gly Arg Ala Glu
 20 25 30

Ala Leu Thr Phe Arg His Gly Ala Glu Gly Ser Asp Arg Arg Arg Gln
 35 40 45

Arg Arg Glu Gly Val Leu Gly Pro Ala Leu Leu Cys Arg Pro Trp Glu
 50 55 60

Val Leu Gly Ala His Glu Val Pro Ser Arg Asn Ile Phe Ser Glu Gln

424

65		70		75		80									
Thr	Ile	Pro	Pro	Ser	Ala	Lys	Tyr	Gly	Gly	Arg	His	Thr	Val	Thr	Met
				85					90					95	
Ile	Pro	Gly	Asp	Gly	Ile	Gly	Pro	Glu	Leu	Met	Leu	His	Val	Lys	Ser
			100					105					110		
Val	Phe	Arg	His	Ala	Cys	Val	Pro	Val	Asp	Phe	Glu	Glu	Val	His	Val
		115					120					125			
Ser	Ser	Asn	Ala	Asp	Glu	Glu	Asp	Ile	Arg	Asn	Ala	Ile	Met	Ala	Ile
	130						135				140				
Arg	Arg	Asn	Arg	Val	Ala	Leu	Lys	Gly	Asn	Ile	Glu	Thr	Asn	His	Asn
145					150				155					160	
Leu	Pro	Pro	Ser	His	Lys	Ser	Arg	Asn	Asn	Ile	Leu	Arg	Thr	Ser	Leu
				165				170						175	
Asp	Leu	Tyr	Ala	Asn	Val	Ile	His	Cys	Lys	Ser	Leu	Pro	Gly	Val	Val
			180					185					190		
Thr	Arg	His	Lys	Asp	Ile	Asp	Ile	Leu	Ile	Val	Arg	Glu	Asn	Thr	Glu
	195						200					205			
Gly	Glu	Tyr	Ser	Ser	Leu	Glu	His	Glu	Ser	Val	Ala	Gly	Val	Val	Glu
	210					215					220				
Ser	Leu	Lys	Ile	Ile	Thr	Lys	Ala	Lys	Ser	Leu	Arg	Ile	Ala	Glu	Tyr
225					230					235				240	
Ala	Phe	Lys	Leu	Ala	Gln	Glu	Ser	Gly	Arg	Lys	Lys	Val	Thr	Ala	Val
				245				250						255	
His	Lys	Ala	Asn	Ile	Met	Lys	Leu	Gly	Asp	Gly	Leu	Phe	Leu	Gln	Cys
			260					265					270		
Cys	Arg	Glu	Val	Ala	Ala	Arg	Tyr	Pro	Gln	Xaa	Thr	Phe	Glu	Asn	Met
		275					280					285			
Ile	Val	Asp	Asn	Thr	Thr	Met	Gln	Leu	Val	Xaa	Arg	Pro	Gln	Gln	Phe
	290					295					300				
Asp	Val	Met	Val	Met	Pro	Asn	Leu	Tyr	Gly	Asn	Ile	Val	Lys	Gln	Cys
305					310					315				320	
Leu	Arg	Gly	Xaa	Gly	Arg	Gly	Pro	Lys	Leu	Val					
				325					330						

425

<210> 474

<211> 30

<212> PRT

<213> Homo sapiens

<400> 474

Thr Pro Ile Ser Thr Lys Asn Thr Lys Ile Ser Gln Ala Arg Trp Arg
 1 5 10 15

Ala His Val Val Pro Ala Thr Arg Glu Ala Asp Ala Glu Glu
 20 25 30

<210> 475

<211> 124

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (110)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 475

Thr Gln Phe Ser Leu Ser Pro Val Glu Thr Ile Tyr Thr Ile Leu Cys
 1 5 10 15

Ile Asn Val Tyr Thr Leu Pro Ile Cys Ile His Ile Tyr Ile Val Tyr
 20 25 30

Ile Leu Tyr Met Tyr Arg Cys Val Tyr Val His Ile Tyr Thr His Ala
 35 40 45

His Asn Lys Ile Arg Cys Ser Leu Gln Ile Gln Met Leu Ile Thr Lys
 50 55 60

Pro Asp Ala Thr Gln Thr Ala Ala Glu Glu Thr Arg Leu Asp Ser Cys
 65 70 75 80

Asn Arg Ser Gln Lys Ile Lys Thr Ala Thr Cys Ser Asp Phe Gly His
 85 90 95

Phe Cys Met Phe Ile Lys Asn Gly Phe Val Thr Arg Lys Xaa Arg Thr
 100 105 110

Ser Val Ser Glu Lys Gly Arg Trp Gly Glu Pro Ser
 115 120

426

<210> 476

<211> 64

<212> PRT

<213> Homo sapiens

<400> 476

Asn Gly Tyr Leu Val Phe Pro Arg Lys Asn Ser Phe Leu Leu Ile Phe
 1 5 10 15

Gly Leu Phe Val Tyr Leu Glu Thr Asn Leu Asp Ser Leu Pro Leu Val
 20 25 30

Asp Thr His Ser Lys Arg Thr Leu Leu Ile Lys Thr Val Glu Thr Arg
 35 40 45

Asp Gly Gln Val Ile Asn Glu Thr Ser Gln His His Asp Asp Leu Glu
 50 55 60

<210> 477

<211> 107

<212> PRT

<213> Homo sapiens

<400> 477

Val Leu Thr Val Asp Ala Arg Asn His Gly Asp Ser Pro His Ser Pro
 1 5 10 15

Asp Met Ser Tyr Glu Ile Met Ser Gln Asp Leu Gln Asp Leu Leu Pro
 20 25 30

Gln Leu Gly Leu Val Pro Cys Val Val Val Gly His Ser Met Gly Gly
 35 40 45

Lys Thr Ala Met Leu Leu Ala Leu Gln Arg Pro Glu Leu Val Glu Arg
 50 55 60

Leu Ile Ala Val Asp Ile Ser Pro Val Glu Ser Thr Gly Val Ser His
 65 70 75 80

Phe Ala Thr Tyr Val Ala Ala Met Arg Ala Ile Asn Ile Ala Asp Arg
 85 90 95

Leu Ala Pro Leu Pro Cys Pro Lys Thr Gly Gly
 100 105

427

<210> 478

<211> 282

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (281)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 478

Arg Glu Leu Gly Gly Thr Leu Leu Ser Ala Ile Glu Val Glu Gly Ala
 1 5 10 15

Lys Met Gln Ser Asn Lys Thr Phe Asn Leu Glu Lys Gln Asn His Thr
 20 25 30

Pro Arg Lys His His Gln His His His Gln Gln Gln His His Gln Gln
 35 40 45

Gln Gln Gln Gln Pro Pro Pro Pro Pro Ile Pro Ala Asn Gly Gln Gln
 50 55 60

Ala Ser Ser Gln Asn Glu Gly Leu Thr Ile Asp Leu Lys Asn Phe Arg
 65 70 75 80

Lys Pro Gly Glu Lys Thr Phe Thr Gln Arg Ser Arg Leu Phe Val Gly
 85 90 95

Asn Leu Pro Pro Asp Ile Thr Glu Glu Glu Met Arg Lys Leu Phe Glu
 100 105 110

Lys Tyr Gly Lys Ala Gly Glu Val Phe Ile His Lys Asp Lys Gly Phe
 115 120 125

Gly Phe Ile Arg Leu Glu Thr Arg Thr Leu Ala Glu Ile Ala Lys Val
 130 135 140

Glu Leu Asp Asn Met Pro Leu Arg Gly Lys Gln Leu Arg Val Arg Phe
 145 150 155 160

Ala Cys His Ser Ala Ser Leu Thr Val Arg Asn Leu Pro Gln Tyr Val
 165 170 175

Ser Asn Glu Leu Leu Glu Glu Ala Phe Ser Val Phe Gly Gln Val Glu
 180 185 190

Arg Ala Val Val Ile Val Asp Asp Arg Gly Arg Pro Ser Gly Lys Gly
 195 200 205

428

Ile Val Glu Phe Ser Gly Lys Pro Ala Ala Arg Lys Ala Leu Asp Arg
 210 215 220

Cys Ser Glu Gly Ser Phe Leu Leu Thr Thr Phe Pro Arg Pro Val Thr
 225 230 235 240

Val Glu Pro Met Asp Gln Leu Asp Asp Glu Glu Gly Leu Pro Glu Lys
 245 250 255

Leu Val Ile Lys Asn Gln Gln Phe His Lys Glu Arg Glu Gln Pro Pro
 260 265 270

Arg Phe Ala Gln Pro Gly Ser Phe Xaa Val
 275 280

<210> 479

<211> 289

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (206)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (215)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (218)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (285)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 479

Ala Val Pro Val Arg Asn Ser Arg Val Asp Pro Arg Val Arg Val Cys
 1 5 10 15

Gly Pro Leu Ser Ala Pro Arg Gly Ser Arg Arg Pro Thr Val Pro Gly
 20 25 30

Thr Pro Ala Cys Leu Ala Arg Pro Ala Ala Gln Gly Phe Ser Ala Ala

429

35	40	45
Leu Pro Val Arg Trp Thr Gly Arg Arg Ala Gly Pro Ser Arg Pro Val		
50	55	60
Pro Ile Gly Thr Pro Ser Arg Ala Ala Asp Pro Ser Gln Gly Glu Met		
65	70	75
Ser Ala Asp Ala Ala Ala Gly Ala Pro Leu Pro Arg Leu Cys Cys Leu		
	85	90
Glu Lys Gly Pro Asn Gly Tyr Gly Phe His Leu His Gly Glu Lys Gly		
	100	110
Lys Leu Gly Gln Tyr Ile Arg Leu Val Glu Pro Gly Ser Pro Ala Glu		
	115	120
Lys Ala Gly Leu Leu Ala Gly Asp Arg Leu Val Glu Val Asn Gly Glu		
	130	140
Asn Val Glu Lys Glu Thr His Gln Gln Val Val Ser Arg Ile Arg Ala		
	145	155
Ala Leu Asn Ala Val Arg Leu Leu Val Val Asp Pro Glu Thr Asp Glu		
	165	170
Gln Leu Gln Lys Leu Gly Val Gln Val Arg Glu Glu Leu Leu Arg Ala		
	180	185
Gln Glu Ala Pro Gly Gln Ala Glu Pro Pro Ala Ala Ala Xaa Val Gln		
	195	205
Gly Ala Gly Asn Glu Asn Xaa Pro Arg Xaa Ala Asp Lys Ser His Pro		
	210	220
Glu Gln Arg Glu Leu Arg Pro Arg Leu Cys Thr Met Lys Lys Gly Pro		
	225	235
Ser Gly Tyr Gly Phe Asn Leu His Ser Asp Lys Ser Lys Pro Gly Gln		
	245	250
Phe Ile Arg Ser Val Asp Pro Asp Ser Pro Ala Glu Ala Ser Gly Leu		
	260	265
Arg Ala Gln Asp Arg Ile Val Glu Val Met Leu Leu Xaa Ser Leu Pro		
	275	285
Ile		

430

<210> 480

<211> 44

<212> PRT

<213> Homo sapiens

<400> 480

Gly Ser Thr His Ala Ser Gly Arg Asn Glu Gly Pro Pro Ala Lys Thr
1 5 10 15

Lys Ser Trp Val Gly Pro Thr Leu His Phe His Arg Lys Ser Glu His
20 25 30

Leu Val Gly Leu Lys Val Leu Cys Cys Phe Arg Leu
35 40

<210> 481

<211> 124

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (3)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (5)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (8)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (9)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (10)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 481

Ser Ile Xaa His Xaa Arg Lys Xaa Xaa Xaa Thr Val Arg Ser Asp Ser
1 5 10 15

431

Arg Val Asp Pro Arg Ser Asp Asp Phe Thr Pro Leu Glu Ile Leu Trp
 20 25 30
 Thr Phe Ser Ile Tyr Leu Glu Ser Val Ala Ile Leu Pro Gln Leu Phe
 35 40 45
 Met Val Ser Lys Thr Gly Glu Ala Glu Thr Ile Thr Ser His Tyr Leu
 50 55 60
 Phe Ala Leu Gly Val Tyr Arg Thr Leu Tyr Leu Phe Asn Trp Ile Trp
 65 70 75 80
 Arg Tyr His Phe Glu Gly Phe Phe Asp Leu Ile Ala Ile Val Ala Gly
 85 90 95
 Leu Val Gln Thr Val Leu Tyr Cys Asp Phe Phe Tyr Leu Tyr Ile Thr
 100 105 110
 Lys Val Leu Lys Gly Lys Lys Leu Ser Leu Pro Ala
 115 120

<210> 482

<211> 131

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (122)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (124)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (127)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (131)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 482

Cys Ser Ser Arg Gly Ala His His Ser His Cys Asp Arg Leu Pro His

432

```

      1             5             10             15
Ser Pro Trp Pro Gly Leu Arg Glu Val Glu Leu Leu Ala Ser Val His
      20             25             30
Thr Glu Gln Met Glu Glu Glu Leu Ala Leu Gly Pro Arg Gly Gln Gly
      35             40             45
Gly Ala Ser Leu Ala Gly Arg Asp Gly Arg Ser Ala Gly Ala Gly Ser
      50             55             60
Tyr Gly Ala Leu Ala Asn Ser Ala Trp Gly Gly Pro Arg Lys Val Ala
      65             70             75             80
Ser Ala Ser Ala Ala Ala Ser Thr Leu Ser Glu Pro Pro Arg Arg Thr
      85             90             95
Gln Glu Ser Arg Thr Arg Thr Arg Ala Leu Gly Leu Pro Thr Leu Pro
      100            105            110
Met Glu Lys Leu Ala Ala Ser Asn Arg Xaa Pro Xaa Gly Leu Xaa Gly
      115            120            125
Pro Gly Xaa
      130

```

<210> 483

<211> 221

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (168)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (174)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 483

```

Lys Lys Pro Pro Ile Thr His Pro Ser Thr Pro Ala Glu Glu Thr Tyr
  1             5             10             15

```

```

Asn Leu Gly Arg Gln Val Leu Pro Leu Ser Ala Val Thr Tyr Phe Gln
  20             25             30

```

```

Lys Ser Gly Pro Gly Leu Leu Pro Ala Pro Ala Thr Gln Ser Ala Ser

```

433

35	40	45
Val Ala Gly Thr Leu Gln Asn Ser Leu Cys Ser Gln Val Thr Lys Lys		
50	55	60
Lys Arg Ala Asn Met Leu Val Leu Leu Ala Gly Ile Phe Val Val His		
65	70	75 80
Ile Ala Thr Val Ile Met Leu Phe Val Ser Thr Ile Ala Asn Val Trp		
	85 90	95
Leu Val Ser Asn Thr Val Asp Ala Ser Val Gly Leu Trp Lys Asn Cys		
	100 105	110
Thr Asn Ile Ser Cys Ser Asp Ser Leu Ser Tyr Ala Ser Glu Asp Ala		
	115 120	125
Leu Lys Thr Val Gln Ala Phe Met Ile Leu Ser Ile Ile Phe Cys Val		
	130 135	140
Ile Ala Leu Leu Val Phe Val Phe Gln Leu Phe Thr Met Glu Lys Gly		
145	150 155	160
Asn Arg Phe Phe Leu Ser Gly Xaa Thr Thr Leu Val Cys Xaa Leu Cys		
	165 170	175
Ile Leu Val Gly Cys Pro Ser Thr Leu Val Ile Met Arg Ile Val Met		
	180 185	190
Glu Arg Ile Cys Thr Thr Ala Ile Pro Thr Ser Trp Ala Gly Ser Ala		
	195 200	205
Ser Ala Ser Ala Ser Ser Ser Ala Phe Ser Ile Trp Ser		
210	215	220

<210> 484

<211> 382

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (22)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (54)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (69)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (287)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (298)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (324)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (358)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 484
 Thr Lys Leu Trp Thr Leu Val Ser Asn Pro Asp Thr Asp Ala Leu Ile
 1 5 10 15
 Cys Trp Ser Pro Ser Xaa Asn Ser Phe His Val Phe Asp Gln Gly Gln
 20 25 30
 Phe Ala Lys Glu Val Leu Pro Lys Tyr Phe Lys His Asn Asn Met Ala
 35 40 45
 Ser Phe Val Arg Gln Xaa Asn Met Tyr Gly Phe Arg Lys Val Val His
 50 55 60
 Ile Glu Gln Gly Xaa Leu Val Lys Pro Glu Arg Asp Asp Thr Glu Phe
 65 70 75 80
 Gln His Pro Cys Phe Leu Arg Gly Gln Glu Gln Leu Leu Glu Asn Ile
 85 90 95
 Lys Arg Lys Val Thr Ser Val Ser Thr Leu Lys Ser Glu Asp Ile Lys
 100 105 110
 Ile Arg Gln Asp Ser Val Thr Lys Leu Leu Thr Asp Val Gln Leu Met
 115 120 125

435

Lys Gly Lys Gln Glu Cys Met Asp Ser Lys Leu Leu Ala Met Lys His
 130 135 140
 Glu Asn Glu Ala Leu Trp Arg Glu Val Ala Ser Leu Arg Gln Lys His
 145 150 155 160
 Ala Gln Gln Gln Lys Val Val Asn Lys Leu Ile Gln Phe Leu Ile Ser
 165 170 175
 Leu Val Gln Ser Asn Arg Ile Leu Gly Val Lys Arg Lys Ile Pro Leu
 180 185 190
 Met Leu Asn Asp Ser Gly Ser Ala His Ser Met Pro Lys Tyr Ser Arg
 195 200 205
 Gln Phe Ser Leu Glu His Val His Gly Ser Gly Pro Tyr Ser Ala Pro
 210 215 220
 Ser Pro Ala Tyr Ser Ser Ser Ser Leu Tyr Ala Pro Asp Ala Val Ala
 225 230 235 240
 Ser Ser Gly Pro Ile Ile Ser Asp Ile Thr Glu Leu Ala Pro Ala Ser
 245 250 255
 Pro Met Ala Ser Pro Gly Gly Ser Ile Asp Glu Arg Pro Leu Ser Ser
 260 265 270
 Ser Pro Leu Val Arg Val Lys Glu Glu Pro Pro Ser Pro Pro Xaa Ser
 275 280 285
 Pro Arg Val Glu Glu Ala Ser Pro Gly Xaa Pro Ser Ser Val Asp Thr
 290 295 300
 Leu Leu Ser Pro Thr Ala Leu Ile Asp Ser Ile Leu Arg Glu Ser Glu
 305 310 315 320
 Pro Ala Pro Xaa Ser Val Thr Ala Leu Thr Asp Ala Arg Gly His Thr
 325 330 335
 Asp Thr Glu Gly Arg Pro Pro Ser Pro Pro Pro Thr Ser Thr Pro Glu
 340 345 350
 Lys Cys Leu Ser Val Xaa Ala Trp Thr Arg Met Ser Ser Val Thr Thr
 355 360 365
 Trp Met Leu Trp Thr Pro Thr Trp Ile Thr Cys Arg Pro Cys
 370 375 380

<210> 485

436

<211> 416
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (399)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 485

Pro Ser Val Ala Asn Val Gly Ser His Cys Asp Leu Ser Leu Lys Ile
 1 5 10 15

Pro Glu Ile Ser Ile Gln Asp Met Thr Ala Gln Val Thr Ser Pro Ser
 20 25 30

Gly Lys Thr His Glu Ala Glu Ile Val Glu Gly Glu Asn His Thr Tyr
 35 40 45

Cys Ile Arg Phe Val Pro Ala Glu Met Gly Thr His Thr Val Ser Val
 50 55 60

Lys Tyr Lys Gly Gln His Val Pro Gly Ser Pro Phe Gln Phe Thr Val
 65 70 75 80

Gly Pro Leu Gly Glu Gly Gly Ala His Lys Val Arg Ala Gly Gly Pro
 85 90 95

Gly Leu Glu Arg Ala Glu Ala Gly Val Pro Ala Glu Phe Ser Ile Trp
 100 105 110

Thr Arg Glu Ala Gly Ala Gly Gly Leu Ala Ile Ala Val Glu Gly Pro
 115 120 125

Ser Lys Ala Glu Ile Ser Phe Glu Asp Arg Lys Asp Gly Ser Cys Gly
 130 135 140

Val Ala Tyr Val Val Gln Glu Pro Gly Asp Tyr Glu Val Ser Val Lys
 145 150 155 160

Phe Asn Glu Glu His Ile Pro Asp Ser Pro Phe Val Val Pro Val Ala
 165 170 175

Ser Pro Ser Gly Asp Ala Arg Arg Leu Thr Val Ser Ser Leu Gln Glu
 180 185 190

Ser Gly Leu Lys Val Asn Gln Pro Ala Ser Phe Ala Val Ser Leu Asn
 195 200 205

Gly Ala Lys Gly Ala Ile Asp Ala Lys Val His Ser Pro Ser Gly Ala
 210 215 220

437

Leu Glu Glu Cys Tyr Val Thr Glu Ile Asp Gln Asp Lys Tyr Ala Val
 225 230 235 240

Arg Phe Ile Pro Arg Glu Asn Gly Val Tyr Leu Ile Asp Val Lys Phe
 245 250 255

Asn Gly Thr His Ile Pro Gly Ser Pro Phe Lys Ile Arg Val Gly Glu
 260 265 270

Pro Gly His Gly Gly Asp Pro Gly Leu Val Ser Ala Tyr Gly Ala Gly
 275 280 285

Leu Glu Gly Gly Val Thr Gly Asn Pro Ala Glu Phe Val Val Asn Thr
 290 295 300

Ser Asn Ala Gly Ala Gly Ala Leu Ser Val Thr Ile Asp Gly Pro Ser
 305 310 315 320

Lys Val Lys Met Asp Cys Gln Glu Cys Pro Glu Gly Tyr Arg Val Thr
 325 330 335

Tyr Thr Pro Met Ala Pro Gly Ser Tyr Leu Ile Ser Ile Lys Tyr Gly
 340 345 350

Gly Pro Tyr His Ile Gly Gly Ser Pro Phe Lys Ala Lys Val Thr Gly
 355 360 365

Pro Arg Leu Val Ser Asn His Ser Leu His Glu Thr Ser Ser Val Phe
 370 375 380

Val Asp Ser Leu Thr Lys Ala Thr Cys Ala Pro Gln His Gly Xaa Pro
 385 390 395 400

Gly Pro Gly Pro Ala Asp Ala Ser Lys Val Val Ala Lys Gly Trp Gly
 405 410 415

<210> 486

<211> 46

<212> PRT

<213> Homo sapiens

<400> 486

Phe Val Thr Ser Gly Lys Ile Ser Leu Tyr Val Tyr Ile Leu Thr Ile
 1 5 10 15

438

Arg Leu Asp Thr Asn Lys Ala Thr Leu Leu Thr Ala Ser Gly Glu Leu
 20 25 30

Ile Leu Phe Leu Ile Phe Phe Asn Lys Asp Ile Leu Arg Tyr
 35 40 45

<210> 487

<211> 162

<212> PRT

<213> Homo sapiens

<400> 487

Leu Gly Val Ala Leu Gly Ala Val Pro Lys Leu His Leu Gly Val Leu
 1 5 10 15

Val Ser Thr Gly Leu Arg Thr Ala Val Gly Ser Pro Arg Leu Pro Pro
 20 25 30

Thr Ala Leu Gly Ala Ala Tyr Gly Thr Ala Lys Ser Gly Thr Gly Ile
 35 40 45

Ala Ala Met Ser Val Met Arg Pro Glu Gln Ile Met Lys Ser Ile Ile
 50 55 60

Pro Val Val Met Ala Gly Ile Ile Ala Ile Tyr Gly Leu Val Val Ala
 65 70 75 80

Val Leu Ile Ala Asn Ser Leu Asn Asp Asp Ile Ser Leu Tyr Lys Ser
 85 90 95

Phe Leu Gln Leu Gly Ala Gly Leu Ser Val Gly Leu Ser Gly Leu Ala
 100 105 110

Ala Gly Phe Ala Ile Gly Ile Val Gly Asp Ala Gly Val Arg Gly Thr
 115 120 125

Ala Gln Gln Pro Arg Leu Phe Val Gly Met Ile Leu Ile Leu Ile Phe
 130 135 140

Ala Glu Val Leu Gly Leu Tyr Gly Leu Ile Val Ala Leu Ile Leu Ser
 145 150 155 160

Thr Lys

<210> 488

<211> 114

439

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (95)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (111)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (113)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 488

Gln	Ala	Leu	Arg	Pro	Gly	Ser	Phe	Arg	Gly	Thr	Gly	Arg	Lys	Arg	Glu
1				5					10					15	

Arg	Glu	Arg	Glu	Arg	Met	Ser	Leu	Ser	Asp	Trp	His	Leu	Ala	Val	Lys
			20						25					30	

Leu	Ala	Asp	Gln	Pro	Leu	Ala	Pro	Lys	Ser	Ile	Leu	Gln	Leu	Pro	Glu
			35					40					45		

Ser	Glu	Leu	Gly	Glu	Tyr	Ser	Leu	Gly	Gly	Tyr	Ser	Ile	Ser	Phe	Leu

Lys	Gln	Leu	Ile	Ala	Gly	Lys	Leu	Gln	Glu	Ser	Val	Pro	Asp	Pro	Glu

Leu	Ile	Asp	Leu	Ile	Tyr	Cys	Gly	Arg	Lys	Leu	Lys	Asp	Asp	Xaa	Thr

Leu	Thr	Ser	Thr	Val	Phe	Asn	Leu	Ala	Pro	His	Pro	Cys	Ser	Xaa	Glu

Xaa Leu

<210> 489

<211> 149

<212> PRT

<213> Homo sapiens

<220>

440

<221> SITE

<222> (121)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (142)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 489

Ser Thr His Ala Ser Glu Asp Val Leu Ala Ala Pro Ser Gly Cys Arg
 1 5 10 15

Ala Ser Arg Pro Pro Thr Ser Gly Arg Glu Gln Phe Trp Ala Arg Gly
 20 25 30

Leu Ala Ala Ala Asp Met Thr Lys Gly Leu Val Leu Gly Ile Tyr Ser
 35 40 45

Lys Asp Lys Glu Asp Asp Val Pro Gln Phe Thr Ser Ala Gly Glu Asn
 50 55 60

Phe Asp Lys Leu Val Ser Gly Lys Leu Arg Glu Ile Leu Asn Ile Ser
 65 70 75 80

Gly Pro Pro Leu Lys Ala Gly Lys Thr Arg Thr Phe Tyr Gly Leu His
 85 90 95

Glu Asp Phe Pro Ser Val Val Val Val Gly Leu Gly Arg Lys Ala Ala
 100 105 110

Gly Val Asp Asp Gln Glu Asn Trp Xaa Glu Gly Lys Glu Asn Ile Arg
 115 120 125

Val Ala Met Gln Arg Gly Ala Gly Arg Phe Gln Asp Leu Xaa Ile Ser
 130 135 140

Ser Val Glu Gly Gly
 145

<210> 490

<211> 527

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (311)

<223> Xaa equals any of the naturally occurring L-amino acids

441

<400> 490

Arg Arg Arg Ser Arg Gly Leu Ile Pro Gly Arg Ala Pro Gly Arg Arg
 1 5 10 15

Arg Pro Arg Ala His Glu Val Ala Arg Ala Pro Pro Pro Ile Ala Met
 20 25 30

Asp Arg Met Lys Lys Ile Lys Arg Gln Leu Ser Met Thr Leu Arg Gly
 35 40 45

Gly Arg Gly Ile Asp Lys Thr Asn Gly Ala Pro Glu Gln Ile Gly Leu
 50 55 60

Asp Glu Ser Gly Gly Gly Gly Gly Ser Asp Pro Gly Glu Ala Pro Thr
 65 70 75 80

Arg Ala Ala Pro Gly Glu Leu Arg Ser Ala Arg Gly Pro Leu Ser Ser
 85 90 95

Ala Pro Glu Ile Val His Glu Asp Leu Lys Met Gly Ser Asp Gly Glu
 100 105 110

Ser Asp Gln Ala Ser Ala Thr Ser Ser Asp Glu Val Gln Ser Pro Val
 115 120 125

Arg Val Arg Met Arg Asn His Pro Pro Arg Lys Ile Ser Thr Glu Asp
 130 135 140

Ile Asn Lys Arg Leu Ser Leu Pro Ala Asp Ile Arg Leu Pro Glu Gly
 145 150 155 160

Tyr Leu Glu Lys Leu Thr Leu Asn Ser Pro Ile Phe Asp Lys Pro Leu
 165 170 175

Ser Arg Arg Leu Arg Arg Val Ser Leu Ser Glu Ile Gly Phe Gly Lys
 180 185 190

Leu Glu Thr Tyr Ile Lys Leu Asp Lys Leu Gly Glu Gly Thr Tyr Ala
 195 200 205

Thr Val Tyr Lys Gly Lys Ser Lys Leu Thr Asp Asn Leu Val Ala Leu
 210 215 220

Lys Glu Ile Arg Leu Glu His Glu Glu Gly Ala Pro Cys Thr Ala Ile
 225 230 235 240

Arg Glu Val Ser Leu Leu Lys Asp Leu Lys His Ala Asn Ile Val Thr
 245 250 255

Leu His Asp Ile Ile His Thr Glu Lys Ser Leu Thr Leu Val Phe Glu

442

260	265	270
Tyr Leu Asp Lys Asp Leu Lys Gln Tyr Leu Asp Asp Cys Gly Asn Ile		
275	280	285
Ile Asn Met His Asn Val Lys Leu Phe Leu Phe Gln Leu Leu Arg Gly		
290	295	300
Leu Ala Tyr Cys His Arg Xaa Lys Val Leu His Arg Asp Leu Lys Pro		
305	310	315 320
Gln Asn Leu Leu Ile Asn Glu Arg Gly Glu Leu Lys Leu Ala Asp Phe		
325	330	335
Gly Leu Ala Arg Ala Lys Ser Ile Pro Thr Lys Thr Tyr Ser Asn Glu		
340	345	350
Val Val Thr Leu Trp Tyr Arg Pro Pro Asp Ile Leu Leu Gly Ser Thr		
355	360	365
Asp Tyr Ser Thr Gln Ile Asp Met Trp Gly Val Gly Cys Ile Phe Tyr		
370	375	380
Glu Met Ala Thr Gly Arg Pro Leu Phe Pro Gly Ser Thr Val Glu Glu		
385	390	395 400
Gln Leu His Phe Ile Phe Arg Ile Leu Gly Thr Pro Thr Glu Glu Thr		
405	410	415
Trp Pro Gly Ile Leu Ser Asn Glu Glu Phe Lys Thr Tyr Asn Tyr Pro		
420	425	430
Lys Tyr Arg Ala Glu Ala Leu Leu Ser His Ala Pro Arg Leu Asp Ser		
435	440	445
Asp Gly Ala Asp Leu Leu Thr Lys Leu Leu Gln Phe Glu Gly Arg Asn		
450	455	460
Arg Ile Ser Ala Glu Asp Ala Met Lys His Pro Phe Phe Leu Ser Leu		
465	470	475 480
Gly Glu Arg Ile His Lys Leu Pro Asp Thr Thr Ser Ile Phe Ala Leu		
485	490	495
Lys Glu Ile Gln Leu Gln Lys Glu Ala Ser Leu Arg Ser Ser Ser Met		
500	505	510
Pro Asp Ser Gly Arg Pro Ala Phe Arg Val Val Asp Thr Glu Phe		
515	520	525

443

<210> 491
 <211> 125
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (125)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 491
 Cys Thr Arg Ala His Pro Lys Asn Leu Val Glu Lys Gly Ile Leu Thr
 1 5 10 15
 Thr Glu Lys Gln Asn Phe Leu Leu Phe Asp Met Thr Thr His Pro Val
 20 25 30
 Thr Asn Thr Thr Glu Lys Gln Arg Leu Val Lys Lys Leu Gln Asp Ser
 35 40 45
 Val Leu Glu Arg Trp Val Asn Asp Pro Gln Arg Met Asp Lys Arg Thr
 50 55 60
 Leu Ala Leu Leu Val Leu Ala His Ser Ser Asp Val Leu Glu Asn Val
 65 70 75 80
 Phe Ser Ser Leu Thr Asp Asp Lys Tyr Asp Val Ala Met Asn Arg Ala
 85 90 95
 Lys Asp Leu Val Glu Leu Asp Pro Glu Val Glu Gly Thr Lys Pro Ser
 100 105 110
 Ala Thr Glu Met Ile Trp Ala Val Leu Ala Ala Phe Xaa
 115 120 125

<210> 492
 <211> 53
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (3)
 <223> xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (49)

444

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (51)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 492

Val	Ser	Xaa	Ser	Ile	Leu	Ala	Leu	Leu	Phe	Asn	Thr	Asp	Ala	Leu	Phe
1				5					10					15	

Ser	Arg	Val	Tyr	Glu	Ser	Leu	Ser	Asp	Asn	His	Gly	Leu	Gln	Glu	Gln
			20					25					30		

Thr	Val	Glu	Lys	Leu	Phe	Phe	Gln	Trp	Lys	Ser	Trp	Val	Gln	Glu	Met
		35					40					45			

Xaa	Gly	Xaa	Leu	Lys
				50

<210> 493

<211> 82

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (60)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (67)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (68)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (78)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (79)

<223> Xaa equals any of the naturally occurring L-amino acids

445

<400> 493

Pro Gly Phe Phe Phe Gln Met Leu Val His Thr Tyr Ser Ser Met Asp
 1 5 10 15

Arg His Asp Gly Val Pro Ser His Ser Ser Arg Leu Ser Gln Leu Gly
 20 25 30

Ser Val Ser Gln Gly Pro Tyr Ser Ser Ala Pro Pro Leu Ser His Thr
 35 40 45

Pro Ser Ser Asp Phe Gln Pro Pro Tyr Phe Pro Xaa Pro Tyr Gln Pro
 50 55 60

Leu Pro Xaa Xaa Gln Ser Gln Asp Pro Tyr Ser His Val Xaa Xaa Pro
 65 70 75 80

Tyr Pro

<210> 494

<211> 290

<212> PRT

<213> Homo sapiens

<400> 494

Tyr Lys Asp Trp Leu Thr Lys Met Ser Gly Lys His Asp Val Gly Ala
 1 5 10 15

Tyr Met Leu Met Tyr Lys Gly Ala Asn Arg Thr Glu Thr Val Thr Ser
 20 25 30

Phe Arg Lys Arg Glu Ser Lys Val Pro Ala Asp Leu Leu Lys Arg Ala
 35 40 45

Phe Val Arg Met Ser Thr Ser Pro Glu Ala Phe Leu Ala Leu Arg Ser
 50 55 60

His Phe Ala Ser Ser His Ala Leu Ile Cys Ile Ser His Trp Ile Leu
 65 70 75 80

Gly Ile Gly Asp Arg His Leu Asn Asn Phe Met Val Ala Met Glu Thr
 85 90 95

Gly Gly Val Ile Gly Ile Asp Phe Gly His Ala Phe Gly Ser Ala Thr
 100 105 110

Gln Phe Leu Pro Val Pro Glu Leu Met Pro Phe Arg Leu Thr Arg Gln
 115 120 125

Phe Ile Asn Leu Met Leu Pro Met Lys Glu Thr Gly Leu Met Tyr Ser
 130 135 140
 Ile Met Val His Ala Leu Arg Ala Phe Arg Ser Asp Pro Gly Leu Leu
 145 150 155 160
 Thr Asn Thr Met Asp Val Phe Val Lys Glu Pro Ser Phe Asp Trp Lys
 165 170 175
 Asn Phe Glu Gln Lys Met Leu Lys Lys Gly Gly Ser Trp Ile Gln Glu
 180 185 190
 Ile Asn Val Ala Glu Lys Asn Trp Tyr Pro Arg Gln Lys Ile Cys Tyr
 195 200 205
 Ala Lys Arg Lys Leu Ala Gly Ala Asn Pro Ala Val Ile Thr Cys Asp
 210 215 220
 Glu Leu Leu Leu Gly His Glu Lys Ala Pro Ala Phe Arg Asp Tyr Val
 225 230 235 240
 Ala Val Ala Arg Gly Ser Lys Asp His Asn Ile Arg Ala Gln Glu Pro
 245 250 255
 Glu Ser Gly Leu Ser Glu Glu Thr Gln Val Lys Cys Leu Met Asp Gln
 260 265 270
 Ala Thr Asp Pro Asn Ile Leu Gly Arg Thr Trp Glu Gly Trp Glu Pro
 275 280 285
 Trp Met
 290

<210> 495

<211> 156

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (148)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 495

Cys Gln Ser His Pro Leu Pro Gly Gly Pro Ala Cys Pro Cys Leu Ala
 1 5 10 15

Cys His Ile Thr Leu Leu Phe Gly Arg Pro Trp Leu Ile Lys Glu Val

447

	20		25		30
Leu	Val	Val	Ser	Gln	Ala
	35			40	
Trp	Asn	Leu	Glu	Thr	Val
					45
Lys	Lys	Val			
Gln	Ile	Thr	Leu	Asn	Cys
	50			55	
Ile	Gln	Glu	Val	His	Phe
					60
Phe	Phe	Pro	Ile	Val	
Arg	Gly	Ser	Trp	Ser	Leu
	65			70	
Arg	Asp	Ala	Arg	Leu	Glu
				75	
Ser	Asp	Tyr	Ile		80
Ile	Ile	Gln	Asn	Gly	Asn
				85	
Ser	Gln	Gly	Asn	Ala	Phe
				90	
Phe	Phe	His	Phe	Ile	
				95	
Arg	Phe	Phe	Tyr	Pro	His
				100	
Cys	Thr	Pro	Ser	Pro	Ser
				105	
Pro	Leu	Pro	Ile		110
Trp	Met	Ala	Ser	Gln	Lys
				115	
Leu	Gly	Pro	Ser	Pro	Pro
				120	
Cys	Leu	Gly	Gly		125
Gly	Gln	Ser	Pro	Leu	Thr
				130	
Ala	Glu	Ala	Ala	Leu	Leu
				135	
Ser	Ser	Ala	Val		140
Leu	Pro	Leu	Xaa	Lys	Cys
				145	
Leu	Gln	Arg	Val	Met	Ser
				150	
				155	

<210> 496

<211> 251

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (42)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 496

Glu	Glu	Leu	Leu	Arg	Ala	Gln	Glu	Ala	Pro	Gly	Gln	Ala	Glu	Pro	Pro
1				5					10					15	
Ala	Ala	Ala	Glu	Val	Gln	Gly	Ala	Gly	Asn	Glu	Asn	Glu	Pro	Arg	Glu
			20					25						30	
Ala	Asp	Lys	Ser	His	Pro	Glu	Gln	Arg	Xaa	Leu	Arg	Pro	Arg	Leu	Cys
		35						40					45		
Thr	Met	Lys	Lys	Gly	Pro	Ser	Gly	Tyr	Gly	Phe	Asn	Leu	His	Ser	Asp
		50					55					60			

448

Lys Ser Lys Pro Gly Gln Phe Ile Arg Ser Val Asp Pro Asp Ser Pro
 65 70 75 80
 Ala Glu Ala Ser Gly Leu Arg Ala Gln Asp Arg Ile Val Glu Val Asn
 85 90 95
 Gly Val Cys Met Glu Gly Lys Gln His Gly Asp Val Val Ser Ala Ile
 100 105 110
 Arg Ala Gly Gly Asp Glu Thr Lys Leu Leu Val Val Asp Arg Glu Thr
 115 120 125
 Asp Glu Phe Phe Lys Lys Cys Arg Val Ile Pro Ser Gln Glu His Leu
 130 135 140
 Asn Gly Pro Leu Pro Val Pro Phe Thr Asn Gly Glu Ile Gln Lys Glu
 145 150 155 160
 Asn Ser Arg Glu Ala Leu Ala Glu Ala Ala Leu Glu Ser Pro Arg Pro
 165 170 175
 Ala Leu Val Arg Ser Ala Ser Ser Asp Thr Ser Glu Glu Leu Asn Ser
 180 185 190
 Gln Asp Ser Pro Pro Lys Gln Asp Ser Thr Ala Pro Ser Ser Thr Ser
 195 200 205
 Ser Ser Asp Pro Ile Leu Asp Phe Asn Ile Ser Leu Ala Met Ala Lys
 210 215 220
 Glu Arg Ala His Gln Lys Arg Ser Ser Lys Arg Ala Pro Gln Met Asp
 225 230 235 240
 Trp Ser Lys Lys Asn Glu Leu Phe Ser Asn Leu
 245 250

<210> 497

<211> 48

<212> PRT

<213> Homo sapiens

<400> 497

Asn Gly Ala Glu Ala Val Ser Thr Glu Ala Lys Met Thr Ala Phe Pro
 1 5 10 15
 Asp Trp Pro Trp Leu Phe His Thr Leu Cys Asp Pro Cys Pro Met Thr
 20 25 30
 Leu Trp Leu Thr Leu Pro Glu Ala Met Thr Thr Ala Ala Phe Cys His

449

35

40

45

<210> 498

<211> 373

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (337)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (372)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 498

Gly	Thr	Arg	Gly	Ser	Arg	Ala	Ser	Gly	Val	Cys	Ala	Arg	Gly	Cys	Leu
1				5					10					15	

Asp	Ser	Ala	Gly	Pro	Trp	Thr	Met	Ser	Arg	Ala	Leu	Arg	Pro	Pro	Leu
			20						25					30	

Pro	Pro	Leu	Cys	Phe	Phe	Leu	Leu	Leu	Leu	Ala	Ala	Ala	Gly	Ala	Arg
		35						40						45	

Ala	Gly	Gly	Tyr	Glu	Thr	Cys	Pro	Thr	Val	Gln	Pro	Asn	Met	Leu	Asn
		50					55						60		

Val	His	Leu	Leu	Pro	His	Thr	His	Asp	Asp	Val	Gly	Trp	Leu	Lys	Thr
	65					70					75				80

Val	Asp	Gln	Tyr	Phe	Tyr	Gly	Ile	Lys	Asn	Asp	Ile	Gln	His	Ala	Gly
				85					90						95

Val	Gln	Tyr	Ile	Leu	Asp	Ser	Val	Ile	Ser	Ala	Leu	Leu	Ala	Asp	Pro
				100					105					110	

Thr	Arg	Arg	Phe	Ile	Tyr	Val	Glu	Ile	Ala	Phe	Phe	Ser	Arg	Trp	Trp
				115					120					125	

His	Gln	Gln	Thr	Asn	Ala	Thr	Gln	Glu	Val	Val	Arg	Asp	Leu	Val	Arg
				130				135					140		

Gln	Gly	Arg	Leu	Glu	Phe	Ala	Asn	Gly	Gly	Trp	Val	Met	Asn	Asp	Glu
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

450

145 150 155 160
 Ala Ala Thr His Tyr Gly Ala Ile Val Asp Gln Met Thr Leu Gly Leu
 165 170 175
 Arg Phe Leu Glu Asp Thr Phe Gly Asn Asp Gly Arg Pro Arg Val Ala
 180 185 190
 Trp His Ile Asp Pro Phe Gly His Ser Arg Glu Gln Ala Ser Leu Phe
 195 200 205
 Ala Gln Met Gly Phe Asp Gly Phe Phe Phe Gly Arg Leu Asp Tyr Gln
 210 215 220
 Asp Lys Trp Val Arg Met Gln Lys Leu Glu Met Glu Gln Val Trp Arg
 225 230 235 240
 Ala Ser Thr Ser Leu Lys Pro Pro Thr Ala Asp Leu Phe Thr Gly Val
 245 250 255
 Leu Pro Asn Gly Tyr Asn Pro Pro Arg Asn Leu Cys Trp Asp Val Leu
 260 265 270
 Cys Val Asp Gln Pro Leu Val Glu Asp Pro Arg Ser Pro Glu Tyr Asn
 275 280 285
 Ala Lys Glu Leu Val Asp Tyr Phe Leu Asn Val Ala Thr Ala Gln Gly
 290 295 300
 Arg Tyr Tyr Arg Thr Asn His Thr Val Met Thr Met Gly Ser Asp Phe
 305 310 315 320
 Gln Tyr Glu Asn Ala Asn Met Trp Phe Lys Asn Leu Asp Lys Leu Ile
 325 330 335
 Xaa Leu Val Asn Ala Gln Gly Lys Arg Lys Gln Cys Pro Cys Ser Leu
 340 345 350
 Leu His Pro Arg Leu Leu Pro Leu Gly Ala Glu Gln Gly Gln Pro His
 355 360 365
 Leu Val Ser Xaa Thr
 370

<210> 499

<211> 238

<212> PRT

<213> Homo sapiens

451

<400> 499

Ala Leu Pro Gly Pro Asp Trp His Gly Ala Gly Ala Ala Asp Arg Gly
 1 5 10 15

Pro Ala Ala Pro Pro Arg Pro Gly Pro Cys Ala Tyr Ala Ala His Gly
 20 25 30

Arg Gly Ala Leu Ala Glu Ala Ala Arg Arg Cys Leu His Asp Ile Ala
 35 40 45

Leu Ala His Arg Ala Ala Thr Ala Ala Arg Pro Pro Ala Pro Pro Pro
 50 55 60

Ala Pro Gln Pro Pro Ser Pro Thr Pro Ser Pro Pro Arg Pro Thr Leu
 65 70 75 80

Ala Arg Glu Asp Asn Glu Glu Asp Glu Asp Glu Pro Thr Glu Thr Glu
 85 90 95

Thr Ser Gly Glu Gln Leu Gly Ile Ser Asp Asn Gly Gly Leu Phe Val
 100 105 110

Met Asp Glu Asp Ala Thr Leu Gln Asp Leu Pro Pro Phe Cys Glu Ser
 115 120 125

Asp Pro Glu Ser Thr Asp Asp Gly Ser Leu Ser Glu Glu Thr Pro Ala
 130 135 140

Gly Pro Pro Thr Cys Ser Val Pro Pro Ala Ser Ala Leu Pro Thr Gln
 145 150 155 160

Gln Tyr Ala Lys Ser Leu Pro Val Ser Val Pro Val Trp Gly Phe Lys
 165 170 175

Glu Lys Arg Thr Glu Ala Arg Ser Ser Asp Glu Glu Asn Gly Pro Pro
 180 185 190

Ser Ser Pro Asp Leu Asp Arg Ile Ala Ala Ser Met Arg Ala Leu Val
 195 200 205

Leu Arg Glu Ala Glu Asp Thr Gln Val Phe Gly Asp Leu Pro Arg Pro
 210 215 220

Arg Leu Asn Thr Ser Asp Phe Gln Lys Leu Lys Arg Lys Tyr
 225 230 235

<210> 500

<211> 198

<212> PRT

452

<213> Homo sapiens

<220>

<221> SITE

<222> (94)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (156)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 500

Asn	Ser	Ala	Glu	Leu	Ser	Pro	Gly	Leu	Cys	Ser	Pro	Thr	Pro	Thr	Glu
1				5				10					15		

Ala	Arg	Ala	Gly	Asp	Ala	Gly	Pro	Ala	Ala	Arg	Ser	Arg	Lys	Gln	Asn
			20				25						30		

Pro	Gln	Ser	Pro	Pro	Cys	Cys	Cys	Val	Asp	Asp	Thr	Trp	Ala	Gln	Ala
		35					40					45			

Glu	Val	Gly	Pro	Val	Thr	Ser	Cys	Thr	Gly	Phe	Val	Glu	Gly	Ser	Ser
	50					55					60				

Arg	Thr	Gly	Gly	Met	Gly	Ser	Ala	Cys	Ile	Lys	Val	Thr	Lys	Tyr	Phe
65					70					75					80

Leu	Phe	Leu	Phe	Asn	Leu	Ile	Phe	Phe	Ile	Leu	Gly	Ala	Xaa	Ile	Leu
				85					90					95	

Gly	Phe	Gly	Val	Trp	Ile	Leu	Ala	Asp	Lys	Ser	Ser	Phe	Ile	Ser	Val
			100					105					110		

Leu	Gln	Thr	Ser	Ser	Ser	Ser	Leu	Arg	Met	Gly	Ala	Tyr	Val	Phe	Ile
		115					120					125			

Gly	Val	Gly	Ala	Val	Thr	Met	Leu	Met	Gly	Phe	Leu	Gly	Cys	Ile	Gly
	130					135					140				

Ala	Val	Asn	Glu	Val	Arg	Cys	Leu	Leu	Gly	Leu	Xaa	Phe	Ala	Phe	Leu
145					150					155					160

Leu	Leu	Ile	Leu	Ile	Ala	Gln	Val	Thr	Ala	Gly	Ala	Leu	Phe	Tyr	Phe
				165					170					175	

Asn	Met	Gly	Lys	Val	Ser	Pro	Ser	Leu	Pro	Pro	Ser	Ser	Leu	Gly	Trp
			180					185					190		

Thr	Asn	His	Gly	Gly	Asp
			195		

453

<210> 501
 <211> 169
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (165)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 501
 Ser Ser Ala Ser Thr Asn Met Ser Arg Gly Ser Ser Ala Gly Phe Asp
 1 5 10 15
 Arg His Ile Thr Ile Phe Ser Pro Glu Gly Arg Leu Tyr Gln Val Glu
 20 25 30
 Tyr Ala Phe Lys Ala Ile Asn Gln Gly Gly Leu Thr Ser Val Ala Val
 35 40 45
 Arg Gly Lys Asp Cys Ala Val Ile Val Thr Gln Lys Lys Val Pro Asp
 50 55 60
 Lys Leu Leu Asp Ser Ser Thr Val Thr His Leu Phe Lys Ile Thr Glu
 65 70 75 80
 Asn Ile Gly Cys Val Met Thr Gly Met Thr Ala Asp Ser Arg Ser Gln
 85 90 95
 Val Gln Arg Ala Arg Tyr Glu Ala Ala Asn Trp Lys Tyr Lys Tyr Gly
 100 105 110
 Tyr Glu Ile Pro Val Asp Met Leu Cys Lys Arg Ile Ala Asp Ile Ser
 115 120 125
 Gln Val Tyr Thr Gln Asn Ala Glu Met Arg Pro Leu Gly Cys Cys Met
 130 135 140
 Ile Leu Ile Gly Ile Asp Glu Glu Gln Gly Pro Gln Val Tyr Lys Cys
 145 150 155 160
 Asp Pro Ala Gly Xaa Tyr Cys Gly Val
 165

<210> 502
 <211> 507

454

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (10)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (361)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (461)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 502

Val	Arg	Gln	Leu	Cys	Arg	Pro	Ala	Glu	Xaa	Asp	Ser	Val	Met	Ala	Glu
1				5					10					15	

Gln	Val	Ala	Leu	Ser	Arg	Thr	Gln	Val	Cys	Gly	Ile	Leu	Arg	Glu	Glu
			20				25						30		

Leu	Phe	Gln	Gly	Asp	Ala	Phe	His	Gln	Ser	Asp	Thr	His	Ile	Phe	Ile
		35					40					45			

Ile	Met	Gly	Ala	Ser	Gly	Asp	Leu	Ala	Lys	Lys	Lys	Ile	Tyr	Pro	Thr
	50					55					60				

Ile	Trp	Trp	Leu	Phe	Arg	Asp	Gly	Leu	Leu	Pro	Glu	Asn	Thr	Phe	Ile
65					70					75				80	

Val	Gly	Tyr	Ala	Arg	Ser	Arg	Leu	Thr	Val	Ala	Asp	Ile	Arg	Lys	Gln
					85				90					95	

Ser	Glu	Pro	Phe	Phe	Lys	Ala	Thr	Pro	Glu	Glu	Lys	Leu	Lys	Leu	Glu
		100						105					110		

Asp	Phe	Phe	Ala	Arg	Asn	Ser	Tyr	Val	Ala	Gly	Gln	Tyr	Asp	Asp	Ala
		115					120					125			

Ala	Ser	Tyr	Gln	Arg	Leu	Asn	Ser	His	Met	Asn	Ala	Leu	His	Leu	Gly
	130					135					140				

Ser	Gln	Ala	Asn	Arg	Leu	Phe	Tyr	Leu	Ala	Leu	Pro	Pro	Thr	Val	Tyr
145					150					155					160

Glu	Ala	Val	Thr	Lys	Asn	Ile	His	Glu	Ser	Cys	Met	Ser	Gln	Ile	Gly
				165					170					175	

455

Trp Asn Arg Ile Ile Val Glu Lys Pro Phe Gly Arg Asp Leu Gln Ser
 180 185 190

Ser Asp Arg Leu Ser Asn His Ile Ser Ser Leu Phe Arg Glu Asp Gln
 195 200 205

Ile Tyr Arg Ile Asp His Tyr Leu Gly Lys Glu Met Val Gln Asn Leu
 210 215 220

Met Val Leu Arg Phe Ala Asn Arg Ile Phe Gly Pro Ile Trp Asn Arg
 225 230 235 240

Asp Asn Ile Ala Cys Val Ile Leu Thr Phe Lys Glu Pro Phe Gly Thr
 245 250 255

Glu Gly Arg Gly Gly Tyr Phe Asp Glu Phe Gly Ile Ile Arg Asp Val
 260 265 270

Met Gln Asn His Leu Leu Gln Met Leu Cys Leu Val Ala Met Glu Lys
 275 280 285

Pro Ala Ser Thr Asn Ser Asp Asp Val Arg Asp Glu Lys Val Lys Val
 290 295 300

Leu Lys Cys Ile Ser Glu Val Gln Ala Asn Asn Val Val Leu Gly Gln
 305 310 315 320

Tyr Val Gly Asn Pro Asp Gly Glu Gly Glu Ala Thr Lys Gly Tyr Leu
 325 330 335

Asp Asp Pro Thr Val Pro Arg Gly Ser Thr Thr Ala Thr Phe Ala Ala
 340 345 350

Val Val Leu Tyr Val Glu Asn Glu Xaa Trp Asp Gly Val Pro Phe Ile
 355 360 365

Leu Arg Cys Gly Lys Ala Leu Asn Glu Arg Lys Ala Glu Val Arg Leu
 370 375 380

Gln Phe His Asp Val Ala Gly Asp Ile Phe His Gln Gln Cys Lys Arg
 385 390 395 400

Asn Glu Leu Val Ile Arg Val Gln Pro Asn Glu Ala Val Tyr Thr Lys
 405 410 415

Met Met Thr Lys Lys Pro Gly Met Phe Phe Asn Pro Glu Glu Ser Glu
 420 425 430

Leu Asp Leu Thr Tyr Gly Asn Arg Tyr Lys Asn Val Lys Leu Pro Asp
 435 440 445

456

Ala Tyr Glu Arg Leu Ile Leu Asp Val Phe Cys Gly Xaa Gln Met His
 450 455 460

Phe Val Arg Arg Thr Ser Ser Val Arg Pro Gly Val Phe Ser Pro His
 465 470 475 480

Cys Cys Thr Arg Leu Ser Trp Arg Ser Pro Ser Pro Ser Pro Ile Phe
 485 490 495

Met Ala Ala Glu Ala Pro Arg Arg Gln Thr Ser
 500 505

<210> 503

<211> 260

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (69)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 503

Gly Pro Glu Val Leu Pro Glu Pro Arg Val Pro Arg Glu Ala Leu Ala
 1 5 10 15

Phe Ile Ile Arg Ser Phe Gly Gly Glu Val Ser Trp Asp Lys Ser Leu
 20 25 30

Cys Ile Gly Ala Thr Tyr Asp Val Thr Asp Ser Arg Ile Thr His Gln
 35 40 45

Ile Val Asp Arg Pro Gly Gln Gln Thr Ser Val Ile Gly Arg Cys Tyr
 50 55 60

Val Gln Pro Gln Xaa Val Phe Asp Ser Val Asn Ala Arg Leu Leu Leu
 65 70 75 80

Pro Val Ala Glu Tyr Phe Ser Gly Val Gln Leu Pro Pro His Leu Ser
 85 90 95

Pro Phe Val Thr Glu Lys Glu Gly Asp Tyr Val Pro Pro Glu Lys Leu
 100 105 110

Lys Leu Leu Ala Leu Gln Arg Gly Glu Asp Pro Gly Asn Leu Asn Glu
 115 120 125

Ser Glu Glu Glu Glu Glu Asp Asp Asn Asn Glu Gly Asp Gly Asp

457

130	135	140
Glu Glu Gly Glu Asn Glu Glu Glu Glu Glu Asp Ala Glu Ala Gly Ser		
145	150	155 160
Glu Lys Glu Glu Glu Ala Arg Leu Ala Ala Leu Glu Glu Gln Arg Met		
	165	170 175
Glu Gly Lys Lys Pro Arg Val Met Ala Gly Thr Leu Lys Leu Glu Asp		
	180	185 190
Lys Gln Arg Leu Ala Gln Glu Glu Glu Ser Glu Ala Lys Arg Leu Ala		
	195	200 205
Ile Met Met Met Lys Lys Arg Glu Lys Tyr Leu Tyr Gln Lys Ile Met		
	210	215 220
Phe Gly Lys Arg Arg Lys Ile Arg Glu Ala Asn Lys Leu Ala Glu Lys		
	225	230 235 240
Arg Lys Ala His Asp Glu Ala Val Arg Ser Glu Lys Lys Ala Lys Lys		
	245	250 255
Ala Arg Pro Glu		
	260	

<210> 504

<211> 424

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (292)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (342)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 504

Leu Leu Gln Arg Cys Tyr Ala Phe Pro Gly His Arg Leu Ala His Ser
1 5 10 15

Gly Ser Asp Leu Ser Leu Leu Val Pro Glu Ile Glu Asp Met Tyr Ser
20 25 30

Ser Pro Tyr Leu Arg Pro Ser Glu Ser Pro Ile Thr Val Glu Val Asn

458

35	40	45
Cys Thr Asn Pro Gly Thr Arg Tyr Cys Trp Met Ser Thr Gly Leu Tyr		
50	55	60
Ile Pro Gly Arg Gln Ile Ile Glu Val Ser Leu Pro Glu Ala Ala Ala		
65	70	75 80
Ser Ala Asp Leu Lys Ile Gln Ile Gly Cys His Thr Asp Asp Leu Thr		
	85	90 95
Arg Ala Ser Lys Leu Phe Arg Gly Pro Leu Val Ile Asn Arg Cys Cys		
	100	105 110
Leu Asp Lys Pro Thr Lys Ser Ile Thr Cys Leu Trp Gly Gly Leu Leu		
	115	120 125
Tyr Ile Ile Val Pro Gln Asn Ser Lys Leu Gly Ser Val Pro Val Thr		
	130	135 140
Val Lys Gly Ala Val His Ala Pro Tyr Tyr Lys Leu Gly Glu Thr Thr		
145	150	155 160
Leu Glu Glu Trp Lys Arg Arg Ile Gln Glu Asn Pro Gly Pro Trp Gly		
	165	170 175
Glu Leu Ala Thr Asp Asn Ile Ile Leu Thr Val Pro Thr Ala Asn Leu		
	180	185 190
Arg Thr Leu Glu Asn Pro Glu Pro Leu Leu Arg Leu Trp Asp Glu Val		
	195	200 205
Met Gln Ala Val Ala Arg Leu Gly Ala Glu Pro Phe Pro Leu Arg Leu		
	210	215 220
Pro Gln Arg Ile Val Ala Asp Val Gln Ile Ser Val Gly Trp Met His		
225	230	235 240
Ala Gly Tyr Pro Ile Met Cys His Leu Glu Ser Val Gln Glu Leu Ile		
	245	250 255
Asn Glu Lys Leu Ile Arg Thr Lys Gly Leu Trp Gly Pro Val His Glu		
	260	265 270
Leu Gly Arg Asn Gln Gln Arg Gln Glu Trp Glu Phe Pro Pro His Thr		
	275	280 285
Thr Glu Ala Xaa Cys Asn Leu Trp Cys Val Tyr Val His Glu Thr Val		
	290	295 300
Leu Gly Ile Pro Arg Ser Arg Ala Asn Ile Ala Leu Trp Pro Pro Val		

459

305 310 315 320
 Arg Glu Lys Arg Val Arg Ile Tyr Leu Ser Lys Gly Pro Asn Val Lys
 325 330 335
 Asn Trp Asn Ala Trp Xaa Ala Leu Glu Thr Tyr Leu Gln Leu Gln Glu
 340 345 350
 Ala Phe Gly Trp Glu Pro Phe Ile Arg Leu Phe Thr Glu Tyr Arg Asn
 355 360 365
 Gln Thr Asn Leu Pro Thr Glu Asn Val Asp Lys Met Asn Leu Trp Val
 370 375 380
 Lys Met Phe Ser His Gln Val Gln Lys Asn Leu Ala Pro Phe Phe Glu
 385 390 395 400
 Ala Trp Ala Gly Pro Ser Arg Arg Lys Trp Leu Pro Ala Trp Pro Ile
 405 410 415
 Cys Leu Asn Gly Arg Lys Ile Leu
 420

<210> 505

<211> 70

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (49)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (54)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (66)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (70)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 505

460

Leu His Gln Ser Leu Leu His Leu Glu Lys Thr Asn Glu Arg Lys Ser
 1 5 10 15
 Ile Phe Leu Ile His Tyr Pro Asn Asn Asn Arg Thr Pro Tyr Arg Asn
 20 25 30
 Tyr Tyr His Tyr Val Ser Lys His Tyr Ile Pro Ile Thr Tyr Pro Thr
 35 40 45
 Xaa Ser Ile Ile Asp Xaa Ile Ser Ile Pro Thr Met Ile Ser Ala Leu
 50 55 60
 Asn Xaa Gln Asn Lys Xaa
 65 70

<210> 506

<211> 434

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (69)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (135)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (363)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 506

Ser Thr His Ala Ser Ala His Ala Ser Val Ser Thr Ala Ala Ala Ala
 1 5 10 15
 Ala Leu Ala Ala Ala Val Lys Ala Lys His Leu Ala Ala Val Glu
 20 25 30
 Glu Arg Lys Ile Lys Ser Leu Val Ala Leu Leu Val Glu Thr Gln Met
 35 40 45
 Lys Lys Leu Glu Ile Lys Leu Arg His Phe Glu Glu Leu Glu Thr Ile
 50 55 60

Met Asp Arg Glu Xaa Glu Ala Leu Glu Tyr Gln Arg Gln Gln Leu Leu

461

65		70		75		80
Ala Asp Arg Gln Ala Phe His Met Glu Gln Leu Lys Tyr Ala Glu Met						
	85		90		95	
Arg Ala Arg Gln Gln His Phe Gln Gln Met His Gln Gln Gln Gln Gln						
	100		105		110	
Pro Pro Pro Ala Leu Pro Pro Gly Ser Gln Pro Ile Pro Pro Thr Gly						
	115		120		125	
Ala Ala Gly Pro Pro Ala Xaa His Gly Leu Ala Val Ala Pro Ala Ser						
	130		135		140	
Val Val Pro Ala Pro Ala Gly Ser Gly Ala Pro Pro Gly Ser Leu Gly						
	145		150		155	160
Pro Ser Glu Gln Ile Gly Gln Ala Gly Ser Thr Ala Gly Pro Gln Gln						
	165		170		175	
Gln Gln Pro Ala Gly Ala Pro Gln Pro Gly Ala Val Pro Pro Gly Val						
	180		185		190	
Pro Pro Pro Gly Pro His Gly Pro Ser Pro Phe Pro Asn Gln Gln Thr						
	195		200		205	
Pro Pro Ser Met Met Pro Gly Ala Val Pro Gly Ser Gly His Pro Gly						
	210		215		220	
Val Ala Gly Asn Ala Pro Leu Gly Leu Pro Phe Gly Met Pro Pro Pro						
	225		230		235	240
Pro Pro Pro Pro Ala Pro Ser Ile Ile Pro Phe Gly Ser Leu Ala Asp						
	245		250		255	
Ser Ile Ser Ile Asn Leu Pro Ala Pro Pro Asn Leu His Gly His His						
	260		265		270	
His His Leu Pro Phe Ala Pro Gly Thr Leu Pro Pro Pro Asn Leu Pro						
	275		280		285	
Val Ser Met Ala Asn Pro Leu His Pro Asn Leu Pro Ala Thr Thr Thr						
	290		295		300	
Met Pro Ser Ser Leu Pro Leu Gly Pro Gly Leu Gly Ser Ala Ala Ala						
	305		310		315	320
Gln Ser Pro Ala Ile Val Ala Ala Val Gln Gly Asn Leu Leu Pro Ser						
	325		330		335	
Ala Ser Pro Leu Pro Asp Pro Gly Thr Pro Leu Pro Pro Asp Pro Thr						

462

340 345 350
 Ala Pro Ser Pro Arg His Gly His Pro Cys Xaa His Leu His Ser Glu
 355 360 365
 Glu Pro Ala Arg His Leu Ser Pro Ser Pro Pro Val Asp Ile Thr Val
 370 375 380
 Pro Gly Thr Ala Leu Pro Pro Pro Leu Gly Pro Ser Pro Ala Trp Arg
 385 390 395 400
 Val His His Tyr Val Arg Lys Ala Pro Ser Ala Pro Pro Lys Pro Ser
 405 410 415
 Pro Cys Leu Thr Glu Ala Cys Ile Phe Ile Ser Asp Tyr Ser Arg Thr
 420 425 430
 Ser Val

<210> 507

<211> 303

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (165)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (280)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 507

Glu Tyr Val Phe Pro Ala Lys Lys Lys Leu Gln Glu Tyr Arg Val Leu
 1 5 10 15

Ile Thr Thr Leu Ile Thr Ala Gly Ser Trp Ser Arg Pro Ser Phe Pro
 20 25 30

Leu Ile Thr Ser His Thr Ser Ser Ser Met Arg Leu Ala Thr Ala Trp
 35 40 45

Ser Leu Arg Ser Leu Val Ala Ile Ala Gly Leu Met Glu Val Lys Glu
 50 55 60

Thr Gly Asp Pro Gly Gly Gln Leu Val Leu Ala Gly Asp Pro Arg Gln

463

65		70		75		80
Leu Gly Pro Val	Leu Arg Ser Pro	Leu Thr Gln Lys His	Gly Leu Gly			
	85	90	95			
Tyr Ser Leu Leu	Glu Arg Leu Leu	Thr Tyr Asn Ser	Leu Tyr Lys Lys			
	100	105	110			
Gly Pro Asp Gly	Tyr Asp Pro Gln	Phe Ile Thr Lys	Leu Leu Arg Asn			
	115	120	125			
Tyr Arg Ser His	Pro Thr Ile Leu	Asp Ile Pro Asn	Gln Leu Tyr Tyr			
	130	135	140			
Glu Gly Glu Leu	Gln Ala Cys Ala	Asp Val Val Asp	Arg Glu Arg Phe			
145	150	155	160			
Cys Arg Trp Ala	Xaa Leu Pro Arg	Gln Gly Phe Pro	Ile Ile Phe His			
	165	170	175			
Gly Val Met Gly	Lys Asp Glu Arg	Glu Gly Asn Ser	Pro Ser Phe Phe			
	180	185	190			
Asn Pro Glu Glu	Ala Ala Thr Val	Thr Ser Tyr Leu	Lys Leu Leu Leu			
	195	200	205			
Ala Pro Ser Ser	Lys Lys Gly Lys	Ala Arg Leu Ser	Pro Arg Ser Val			
	210	215	220			
Gly Val Ile Ser	Pro Tyr Arg Lys	Gln Val Glu Lys	Ile Arg Tyr Cys			
225	230	235	240			
Ile Thr Lys Leu	Asp Arg Glu Leu	Arg Gly Leu Asp	Asp Ile Lys Asp			
	245	250	255			
Leu Lys Val Gly	Ser Val Glu Glu	Phe Gln Gly Gln	Glu Arg Ser Val			
	260	265	270			
Ile Leu Ile Ser	Thr Val Arg Xaa	Ala Arg Ala Leu	Cys Ser Trp Ile			
	275	280	285			
Trp Thr Leu Ile	Trp Val Ser Leu	Arg Thr Pro Arg	Gly Ser Met			
	290	295	300			

<210> 508

<211> 250

<212> PRT

<213> Homo sapiens

464

<220>

<221> SITE

<222> (16)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 508

Glu	Gln	Tyr	Leu	Pro	Leu	Thr	Glu	Glu	Glu	Leu	Glu	Lys	Glu	Ala	Xaa
1				5					10					15	
Lys	Val	Glu	Gly	Phe	Asp	Leu	Val	Gln	Lys	Pro	Ser	Tyr	Tyr	Val	Arg
		20						25					30		
Leu	Gly	Ser	Leu	Ser	Thr	Lys	Leu	His	Ser	Arg	Ala	Tyr	Gln	Gln	Ala
		35					40					45			
Leu	Ser	Arg	Val	Lys	Glu	Ala	Lys	Gln	Lys	Ser	Gln	Gln	Thr	Ile	Ser
	50					55					60				
Gln	Leu	His	Ser	Thr	Val	His	Leu	Ile	Glu	Phe	Ala	Arg	Lys	Asn	Val
65					70					75					80
Tyr	Ser	Ala	Asn	Gln	Lys	Ile	Gln	Asp	Ala	Gln	Asp	Lys	Leu	Tyr	Leu
			85					90						95	
Ser	Trp	Val	Glu	Trp	Lys	Arg	Ser	Ile	Gly	Tyr	Asp	Asp	Thr	Asp	Glu
		100						105					110		
Ser	His	Cys	Ala	Glu	His	Ile	Glu	Ser	Arg	Thr	Leu	Ala	Ile	Ala	Arg
		115					120					125			
Asn	Leu	Thr	Gln	Gln	Leu	Gln	Thr	Thr	Cys	His	Thr	Leu	Leu	Ser	Asn
	130					135					140				
Ile	Gln	Gly	Val	Pro	Gln	Asn	Ile	Gln	Asp	Gln	Ala	Lys	His	Met	Gly
145					150					155				160	
Val	Met	Ala	Gly	Asp	Ile	Tyr	Ser	Val	Phe	Arg	Asn	Ala	Ala	Ser	Phe
			165						170					175	
Lys	Glu	Val	Ser	Asp	Ser	Leu	Leu	Thr	Ser	Ser	Lys	Gly	Gln	Leu	Gln
		180						185					190		
Lys	Met	Lys	Glu	Ser	Leu	Asp	Asp	Val	Met	Asp	Tyr	Leu	Val	Asn	Asn
		195					200					205			
Thr	Pro	Leu	Asn	Trp	Leu	Val	Gly	Pro	Phe	Tyr	Pro	Gln	Leu	Thr	Glu
	210					215						220			
Ser	Gln	Asn	Ala	Gln	Asp	Gln	Gly	Ala	Glu	Met	Asp	Lys	Ser	Ser	Gln
225					230					235					240

<213> Homo sapiens

<223> Xaa equals any of the naturally occurring L-amino acids

His Glu Leu Trp Gly Cys Gly Pro Val Thr Pro Arg Arg Thr Ala Pro
1 5 10 15

Ser Gly Trp Ala Gln Ala Pro Leu Ser Asp Thr Ala Gln Val Tyr Met
20 25 30

Glu Leu Gln Gly Leu Val Asp Pro Gln Ile Gln Leu Pro Leu Leu Ala
35 40 45

Ala Arg Ser Thr Ser Cys Arg Ser Ser Leu Ile Ala Ser Gln Pro Gly
50 55 60

Pro His Gln Lys Gly Arg Gln Gly Leu Arg Gly Asn Lys Ser Phe Leu
65 70 75 80

Pro Ser Ser Trp Asn Cys Gln Asn Trp Thr Arg Gln Pro Leu Thr Ser
85 90 95

Xaa Ser

<213> Homo sapiens

Gly Ala Met Arg Gly Asp Arg Gly Arg Gly Arg Gly Gly Arg Phe Gly
1 5 10 15

Ser Arg Gly Gly Pro Gly Gly Gly Phe Arg Pro Phe Val Pro His Ile
20 25 30

466

Pro Phe Asp Phe Tyr Leu Cys Glu Met Ala Phe Pro Arg Val Lys Pro
 35 40 45
 Ala Pro Asp Glu Thr Ser Phe Ser Glu Ala Leu Leu Lys Arg Asn Gln
 50 55 60
 Asp Leu Ala Pro Asn Ser Ala Glu Gln Ala Ser Ile Leu Ser Leu Val
 65 70 75 80
 Thr Lys Ile Asn Asn Val Ile Asp Asn Leu Ile Val Ala Pro Gly Thr
 85 90 95
 Phe Glu Val Gln Ile Glu Glu Val Arg Gln Val Gly Ser Tyr Lys Lys
 100 105 110
 Gly Thr Met Thr Thr Gly His Asn Val Ala Asp Leu Val Val Ile Leu
 115 120 125
 Lys Ile Leu Pro Thr Leu Glu Ala Val Ala Ala Leu Gly Asn Lys Val
 130 135 140
 Val Glu Ser Leu Arg Ala Gln Asp Pro Ser Glu Val Leu Thr Met Leu
 145 150 155 160
 Thr Asn Glu Thr Gly Phe Glu Ile Ser Ser Ser Asp Ala Thr Val Lys
 165 170 175
 Ile Leu Ile Thr Thr Val Pro Pro Asn Leu Arg Lys Leu Asp Pro Glu
 180 185 190
 Leu His Leu Asp Ile Lys Val Leu Gln Ser Ala Leu Ala Ala Ile Arg
 195 200 205
 His Ala Arg Trp Phe Glu Glu Asn Ala Ser Gln Ser Thr Val Lys Val
 210 215 220
 Leu Ile Arg Leu Leu Lys Asp Leu Arg Ile Arg Phe Pro Gly Phe Glu
 225 230 235 240
 Pro Leu Thr Pro Trp Ile Leu Asp Leu Leu Gly His Tyr Ala Val Met
 245 250 255
 Asn Asn Pro Thr Arg Gln Pro Leu Ala Leu Asn Val Ala Tyr Arg Arg
 260 265 270
 Cys Leu Gln Ile Leu Ala Ala Gly Leu Phe Leu Pro Gly Ser Val Gly
 275 280 285
 Ile Thr Asp Pro Cys Glu Ser Gly Asn Phe Arg Val His Thr Val Met
 290 295 300

467

Thr Leu Glu Gln Gln Asp Met Val Cys Tyr Thr Ala Gln Thr Leu Val
305 310 315 320

Arg Ile Leu Ser His Gly Gly Phe Arg Lys Ile Leu Gly Gln Glu Gly
325 330 335

Asp Ala Ser Tyr Leu Ala Ser Glu Ile Ser Thr Trp Asp Gly Val Ile
340 345 350

Val Thr Pro Ser Glu Lys Ala Tyr Glu Lys Pro Pro Glu Lys Lys Glu
355 360 365

Gly Glu Glu Glu Glu Glu Asn Thr Glu Glu Pro Pro Gln Gly Glu Glu
370 375 380

Glu Glu Ser Met Glu Thr Gln Glu
385 390

<210> 511
<211> 72
<212> PRT
<213> Homo sapiens

<400> 511
His Gly Gly Gly Lys Gly Arg Gln Val Gly Leu His Ser Val Gln Arg
1 5 10 15

Pro Ala Arg Arg Glu Thr Ala Ala Ser Trp Gly Leu Cys Val Lys Ile
20 25 30

Pro Asp Leu Gly Val Ala Phe Val Tyr Lys Met Gln Glu Gly Lys Pro
35 40 45

Val Pro Asp Ser Ser Arg Gln His Ala Gln Leu Ser Gly Ser Pro Val
50 55 60

Ser Gln Gly Leu Ser Leu Pro Leu
65 70

<210> 512
<211> 181
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (14)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (33)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (135)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 512

Gly	Trp	Cys	Ser	Cys	Ala	His	Ser	Ser	Ala	Trp	Pro	Gly	Xaa	Trp	Gly
1				5					10					15	

Ala	Ser	Gly	Ile	Pro	Gln	Gln	Ala	Pro	Met	Thr	Val	Cys	Asp	Gln	Ala
			20					25					30		

Xaa	Pro	Val	Thr	Phe	Leu	Leu	Leu	His	Leu	Glu	Gly	Gly	Asp	Ile	His
		35					40					45			

Thr	Val	Ser	His	Leu	Ser	Ser	Pro	Pro	Pro	Gly	Val	Ala	His	Arg	Met
	50					55					60				

Gly	Thr	Gly	Gly	Ser	Arg	Asn	Pro	Asn	Pro	Ala	Trp	Leu	Gly	Gly	Ala
65					70					75					80

Leu	Leu	Val	Arg	Gly	Arg	Pro	Ala	Ser	Leu	Ala	Pro	Trp	Gly	His	Ser
				85					90					95	

Trp	Lys	Arg	Gly	Leu	Ala	His	Ala	Pro	Leu	Arg	Ala	Gly	Thr	Cys	Thr
			100					105					110		

Gly	His	Thr	Arg	His	Ser	Ala	Cys	Trp	Asn	Arg	Trp	Leu	Cys	Ser	Cys
		115					120					125			

Ser	Gly	Pro	Arg	Ala	Ala	Xaa	Leu	Arg	Pro	Cys	Thr	Ser	His	Met	His
	130					135					140				

Trp	Thr	Arg	Ala	Glu	Thr	Pro	Val	Cys	Tyr	Arg	Ala	Leu	Val	Leu	Cys
145					150					155					160

Gly	Pro	Gly	Ala	Thr	Ala	Gln	Ser	Ser	Gln	Trp	Arg	Ser	Thr	Pro	Leu
				165					170					175	

Asp	Ser	Ile	Phe	Phe
				180

469

<210> 513
 <211> 202
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (15)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 513

```

Leu Gly Asp Thr Ile Glu Gly Thr Pro Ala Gly Thr Val Pro Xaa Phe
  1               5               10               15

Pro Gly Arg Pro Thr Arg Ala Ile Met Ala Gln Asp Gln Gly Glu Lys
      20               25               30

Glu Asn Pro Met Arg Glu Leu Arg Ile Arg Lys Leu Cys Leu Asn Ile
      35               40               45

Cys Val Gly Glu Ser Gly Asp Arg Leu Thr Arg Ala Ala Lys Val Leu
  50               55               60

Glu Gln Leu Thr Gly Gln Thr Pro Val Phe Ser Lys Ala Arg Tyr Thr
  65               70               75               80

Val Arg Ser Phe Gly Ile Arg Arg Asn Glu Lys Ile Ala Val His Cys
      85               90               95

Thr Val Arg Gly Ala Lys Ala Glu Glu Ile Leu Glu Lys Gly Leu Lys
      100               105               110

Val Arg Glu Tyr Glu Leu Arg Lys Asn Asn Phe Ser Asp Thr Gly Asn
      115               120               125

Phe Gly Phe Gly Ile Gln Glu His Ile Asp Leu Gly Ile Lys Tyr Asp
      130               135               140

Pro Ser Ile Gly Ile Tyr Gly Leu Asp Phe Tyr Val Val Leu Gly Arg
      145               150               155               160

Pro Gly Phe Ser Ile Ala Asp Lys Lys Arg Arg Thr Gly Cys Ile Gly
      165               170               175

Ala Lys His Arg Ile Ser Lys Glu Glu Ala Met Arg Trp Phe Gln Gln
      180               185               190

Lys Tyr Asp Gly Ile Ile Leu Pro Gly Lys
      195               200

```

470

<210> 514
 <211> 63
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (1)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (2)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (5)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (16)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (35)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 514
 Xaa Xaa Lys Asn Xaa Ile Thr Pro Lys Glu Glu Ser Pro Pro His Xaa
 1 5 10 15
 Ala Leu Leu Ser Lys Cys Leu Leu Thr Pro Ser Pro Lys Met Pro Pro
 20 25 30
 Ile Leu Xaa Val Met Ala Ala Leu Gly Phe Glu Arg Arg Glu Phe Gly
 35 40 45
 Ser Thr Ser Val Glu Arg Val Gln Ser Arg Gln Leu Asp Cys Phe
 50 55 60

<210> 515
 <211> 218
 <212> PRT
 <213> Homo sapiens

471

<220>
 <221> SITE
 <222> (151)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (209)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (211)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 515
 Ser Leu Ala Arg Gly Cys Gln Arg Pro Asp Ala Val Leu Tyr Ala Arg
 1 5 10 15
 His Tyr Asn Ile Pro Val Ile His Ala Phe Arg Arg Ala Val Asp Asp
 20 25 30
 Pro Gly Leu Val Phe Asn Gln Leu Pro Lys Met Leu Tyr Pro Glu Tyr
 35 40 45
 His Lys Val His Gln Met Met Arg Glu Gln Ser Ile Leu Ser Pro Ser
 50 55 60
 Pro Tyr Glu Gly Tyr Arg Ser Leu Pro Arg His Gln Leu Leu Cys Phe
 65 70 75 80
 Lys Glu Asp Cys Gln Ala Val Phe Gln Asp Leu Glu Gly Val Glu Lys
 85 90 95
 Val Phe Gly Val Ser Leu Val Leu Val Leu Ile Gly Ser His Pro Asp
 100 105 110
 Leu Ser Phe Leu Pro Gly Ala Gly Ala Asp Phe Ala Val Asp Pro Asp
 115 120 125
 Gln Pro Leu Ser Ala Lys Arg Asn Pro Ile Asp Val Asp Pro Phe Thr
 130 135 140
 Tyr Gln Ser Thr Arg Gln Xaa Gly Leu Tyr Ala Met Gly Pro Leu Ala
 145 150 155 160
 Gly Asp Asn Phe Val Arg Phe Val Gln Gly Gly Ala Leu Ala Val Ala
 165 170 175
 Ser Ser Leu Leu Arg Lys Glu Gln Asn His Leu His Arg Gln Pro Trp
 180 185 190

472

Ser Ser Leu Arg Gly Ile His Pro Leu Ile Asp Leu Lys Ser Gly Val
195 200 205

Xaa Pro Xaa Leu Val Lys Leu Thr Ala Gln
210 215

<210> 516

<211> 41

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (22)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 516

Asn Gly Arg Pro Asp Ser Thr Gly Pro Ala Ile Pro Gly Ile Leu Ser
1 5 10 15

Trp Gly Phe Glu Thr Xaa Leu Arg Asp Arg Glu Thr Asp Pro Arg Asn
20 25 30

Val Leu Asn Cys Asn Gly Pro His Thr
35 40

<210> 517

<211> 250

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (118)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (161)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (204)

<223> Xaa equals any of the naturally occurring L-amino acids

473

<400> 517

Gly Phe Asn Arg Ser Phe Cys Gly Arg Asn Ala Thr Val Tyr Gly Lys
 1 5 10 15
 Gly Val Tyr Phe Ala Arg Arg Ala Ser Leu Ser Val Gln Asp Arg Tyr
 20 25 30
 Ser Pro Pro Asn Ala Asp Gly His Lys Ala Val Phe Val Ala Arg Val
 35 40 45
 Leu Thr Gly Asp Tyr Gly Gln Gly Arg Arg Gly Leu Arg Ala Pro Pro
 50 55 60
 Leu Arg Gly Pro Gly His Val Leu Leu Arg Tyr Asp Ser Ala Val Asp
 65 70 75 80
 Cys Ile Cys Gln Pro Ser Ile Phe Val Ile Phe His Asp Thr Gln Ala
 85 90 95
 Leu Pro Thr His Leu Ile Thr Cys Glu Ala Arg Ala Pro Arg Phe Pro
 100 105 110
 Arg Arg Pro Leu Trp Xaa Pro Gly Pro Leu Pro Arg His Leu Thr Glu
 115 120 125
 Gly Ala Thr Leu Trp Pro Pro Ala Ser Gln Ala Pro Ser Ser Ala Gln
 130 135 140
 Ala Asp Ala Pro Arg Pro Gln Leu Trp Pro Pro Glu Leu Ser Pro Gly
 145 150 155 160
 Xaa Pro Cys Leu Pro Leu Arg Ala Pro Glu Gly Gly Val Gly Asp Gly
 165 170 175
 Gly Gln Gln Arg Pro Arg Gly Ala Gly Leu Gly Pro Ser Leu Gly Arg
 180 185 190
 Pro His His Gln Gly Ser Ala Glu Pro Arg Arg Xaa His Arg Pro Pro
 195 200 205
 Ala Ala Pro Arg Pro Arg Pro Ser Arg Leu Cys Cys Leu Asn Lys Arg
 210 215 220
 Glu Arg Glu Pro Arg Arg Lys Gly Pro Gly Lys Lys Lys Lys Lys Lys
 225 230 235 240
 Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
 245 250

474

<210> 518
 <211> 100
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (3)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (7)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 518
 Asn Pro Xaa Lys Lys Leu Xaa Ile Leu Ile Lys Trp Pro Pro Pro Phe
 1 5 10 15
 Pro Pro Ser Phe Pro Pro Ser Pro Asn Ser Leu Ser Ser Ser Ser Phe
 20 25 30
 Pro Pro Pro Leu Ser Leu Phe Ser Pro Ser Phe Thr Phe Leu Ile Ser
 35 40 45
 Val Lys Leu Glu Arg Phe Glu Ile Pro Ile Lys Val Arg Leu Ser Pro
 50 55 60
 Glu Pro Trp Thr Pro Glu Thr Gly Leu Val Thr Asp Ala Phe Lys Leu
 65 70 75 80
 Lys Arg Lys Glu Leu Arg Asn His Tyr Leu Lys Asp Ile Glu Arg Met
 85 90 95
 Tyr Gly Gly Lys
 100

<210> 519
 <211> 60
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (5)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE

475

<222> (17)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 519

His	Glu	Asp	Gly	Xaa	Leu	Met	Gly	Cys	Arg	His	Arg	Trp	His	Pro	Arg
1				5					10					15	

Xaa	Val	Pro	Phe	His	Gln	Thr	Ser	Pro	Lys	Thr	Glu	Leu	Glu	Ser	Thr
			20					25					30		

Ile	Phe	Gly	Ser	Pro	Arg	Leu	Ala	Ser	Gly	Leu	Phe	Pro	Glu	Trp	Gln
		35					40					45			

Ser	Trp	Gly	Arg	Met	Glu	Asn	Leu	Ala	Ser	Tyr	Arg
	50					55				60	

<210> 520

<211> 120

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (25)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 520

Ser	His	Pro	Tyr	Ala	Pro	Ser	Cys	Gly	Leu	Arg	Gly	Pro	Gly	Ala	Ala
1				5					10					15	

Ser	Arg	Ala	Arg	Thr	Arg	Glu	Arg	Xaa	Pro	Gln	Ala	Glu	Ala	Glu	Ala
			20					25					30		

Arg	Ser	Thr	Pro	Gly	Pro	Ala	Gly	Ser	Arg	Leu	Gly	Pro	Glu	Thr	Phe
		35					40					45			

Arg	Gln	Arg	Phe	Arg	Gln	Phe	Arg	Tyr	Gln	Asp	Ala	Ala	Gly	Pro	Arg
	50					55					60				

Glu	Ala	Phe	Arg	Gln	Leu	Arg	Glu	Leu	Ser	Arg	Gln	Trp	Leu	Arg	Pro
65					70					75				80	

Asp	Ile	Arg	Thr	Lys	Glu	Gln	Ile	Val	Glu	Met	Leu	Val	Gln	Glu	Gln
				85					90					95	

Leu	Leu	Ala	Ile	Leu	Pro	Glu	Ala	Ala	Arg	Ala	Arg	Arg	Ile	Arg	Arg
		100						105					110		

Arg	Thr	Asp	Val	Arg	Ile	Thr	Gly
-----	-----	-----	-----	-----	-----	-----	-----

476

115

120

<210> 521

<211> 96

<212> PRT

<213> Homo sapiens

<400> 521

Gly His Gln Thr Val Ser Pro Ser Thr Gly Ser Arg Val Thr Arg Met
 1 5 10 15

Phe Ser Leu Ile Ser Phe Ser His Val Phe Ile Lys Asp Ile Cys Lys
 20 25 30

Leu Pro Lys Asp Glu Gly Thr Cys Arg Asp Phe Ile Leu Lys Trp Tyr
 35 40 45

Tyr Asp Pro Asn Thr Lys Ser Cys Ala Arg Phe Trp Tyr Gly Gly Cys
 50 55 60

Gly Gly Asn Glu Asn Lys Phe Gly Ser Gln Lys Glu Cys Glu Lys Val
 65 70 75 80

Cys Ala Pro Val Leu Ala Lys Pro Gly Val Ile Ser Val Met Gly Thr
 85 90 95

<210> 522

<211> 122

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (18)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 522

Asn Ser Gly Phe Arg Pro Lys Asn Pro Val Gly Arg Gly Gly Glu Pro
 1 5 10 15

Glu Xaa Cys Gly Gly Ala Gly Gly Leu Gly Cys Thr Leu Val Trp Gly
 20 25 30

Gly Thr Gly Ala Ala Val Val Thr Gly Val Val Trp Leu Leu Pro

477

35 40 45
 Asn Gly Gly Val Gly Val Gly Leu Leu Gly Pro Gln Ser Pro Val Gly
 50 55 60
 Gly Ser Asp Ser Ala Pro Tyr Ser Leu His Pro Ala Gly Arg Thr Trp
 65 70 75 80
 Gly Leu Arg Ser Glu Cys Ile Pro Pro Leu Ser Phe Asn Leu Ser Cys
 85 90 95
 Arg Thr His Ser Gly Pro Gly Ala Arg Leu Gly Glu Ala Gly Pro Asn
 100 105 110
 Tyr Gly Ser Arg Glu Leu Gln Val Pro Thr
 115 120

<210> 523

<211> 94

<212> PRT

<213> Homo sapiens

<400> 523

Leu Ile Pro Gln Val Cys Cys Lys His Ser Met Glu Asp Thr Asp Asp
 1 5 10 15
 Ser Leu Val Leu Val Phe Leu Ser Ala Val Asn Val Gln Gln Phe Ala
 20 25 30
 Gln Glu Leu Gly Asp His Ile Cys Leu Ser Gly Gln Gly Ser Glu Val
 35 40 45
 His Trp Asn Leu Leu Arg Asn Leu Phe Val Lys Thr Ile Val Asn Asn
 50 55 60
 Tyr Cys Ile Phe Leu Gln Lys Tyr Ile Leu Glu Asn Cys Ile Leu Ser
 65 70 75 80
 Ile Lys Val Phe Leu Cys Lys Lys Lys Lys Lys Lys Leu Val
 85 90

<210> 524

<211> 93

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (78)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (86)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (93)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 524

Ser	Ala	Val	Met	Gly	Arg	Lys	Lys	Lys	Lys	Gln	Leu	Lys	Pro	Trp	Cys
1				5					10					15	

Trp	Tyr	Cys	Asn	Arg	Asp	Phe	Asp	Asp	Glu	Lys	Ile	Leu	Ile	Gln	His
			20					25					30		

Gln	Lys	Ala	Lys	His	Phe	Lys	Cys	His	Ile	Cys	His	Lys	Lys	Leu	Tyr
	35						40						45		

Thr	Gly	Pro	Gly	Leu	Ala	Ile	His	Cys	Met	Gln	Val	His	Lys	Glu	Thr
	50					55					60				

Ile	Asp	Ala	Val	Pro	Asn	Ala	Tyr	Leu	Gly	Glu	Gln	Thr	Xaa	Ile	Gly
65					70					75					80

Asn	Ile	Trp	Tyr	Gly	Xaa	Tyr	Ser	Arg	Lys	Arg	Tyr	Xaa
				85						90		

<210> 525

<211> 324

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (323)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 525

Asp	Leu	Arg	Leu	Ser	Arg	Pro	Glu	Ala	Val	Glu	Ala	Glu	Ala	Met	Met
1				5					10					15	

Ala	Ala	Met	Ala	Thr	Ala	Arg	Val	Arg	Met	Gly	Pro	Arg	Cys	Ala	Gln
			20					25						30	

Ala Leu Trp Arg Met Pro Trp Leu Pro Val Phe Leu Ser Leu Ala Ala
 35 40 45
 Ala Ala Ala Ala Ala Ala Ala Glu Gln Gln Val Pro Leu Val Leu Trp
 50 55 60
 Ser Ser Asp Arg Asp Leu Trp Ala Pro Ala Ala Asp Thr His Glu Gly
 65 70 75 80
 His Ile Thr Ser Asp Leu Gln Leu Ser Thr Tyr Leu Asp Pro Ala Leu
 85 90 95
 Glu Leu Gly Pro Arg Asn Val Leu Leu Phe Leu Gln Asp Lys Leu Ser
 100 105 110
 Ile Glu Asp Phe Thr Ala Tyr Gly Gly Val Phe Gly Asn Lys Gln Asp
 115 120 125
 Ser Ala Phe Ser Asn Leu Glu Asn Ala Leu Asp Leu Ala Pro Ser Ser
 130 135 140
 Leu Val Leu Pro Ala Val Asp Trp Tyr Ala Val Ser Thr Leu Thr Thr
 145 150 155 160
 Tyr Leu Gln Glu Lys Leu Gly Ala Ser Pro Leu His Val Asp Leu Ala
 165 170 175
 Thr Leu Arg Glu Leu Lys Leu Asn Ala Ser Leu Pro Ala Leu Leu Leu
 180 185 190
 Ile Arg Leu Pro Tyr Thr Ala Ser Ser Gly Leu Met Ala Pro Arg Glu
 195 200 205
 Val Leu Thr Gly Asn Asp Glu Val Ile Gly Gln Val Leu Ser Thr Leu
 210 215 220
 Lys Ser Glu Asp Val Pro Tyr Thr Ala Ala Leu Thr Ala Val Arg Pro
 225 230 235 240
 Ser Arg Val Ala Arg Asp Val Ala Val Val Ala Gly Gly Leu Gly Arg
 245 250 255
 Gln Leu Leu Gln Lys Gln Pro Val Ser Pro Val Ile His Pro Pro Val
 260 265 270
 Ser Tyr Asn Asp Thr Ala Pro Arg Ile Leu Phe Trp Ala Gln Asn Phe
 275 280 285
 Ser Val Ala Tyr Lys Asp Gln Trp Glu Asp Leu Thr Pro Leu Thr Phe
 290 295 300

480

Gly Val Gln Glu Leu Asn Leu Thr Gly Ser Phe Trp Asn Asp Ser Phe
 305 310 315 320

Ala Ser Xaa His

<210> 526

<211> 66

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (2)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 526

Phe Xaa Val Ser Trp Thr Trp Lys Gln Val Ser Glu Phe Pro Gly Asp
 1 5 10 15

Gln Arg Asp Glu Val Leu Gln Leu Pro Pro Ser Ser Cys Asn Leu Val
 20 25 30

Ser Ser Gly Ala Gly Gly Glu Pro Glu Lys Leu Ala Ser Tyr Ile Thr
 35 40 45

Ser Leu Trp Leu Phe Phe Ile Cys Lys Thr Arg Ile Ile Leu Asn Cys
 50 55 60

Lys Gly
 65

<210> 527

<211> 62

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (40)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 527

Asn Thr Gln Leu Trp Phe Leu Cys Phe Pro Asn Cys Lys Ala Ala Asp
 1 5 10 15

481

Asn Lys Thr Pro Gly Phe His Val Ser Ser Ala Met Ser Thr Leu Thr
 20 25 30

Gln Ile Leu Lys Gln Asn Ser Xaa Asn Ala Val Leu Arg Ile Gln Leu
 35 40 45

Leu Leu Lys Pro Ile Ser Ile Cys Ile Ile Thr Thr Asn Ile
 50 55 60

<210> 528

<211> 122

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (80)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (104)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (105)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 528

Tyr Asn Lys Ile Glu Ile Met His Leu Val Met Trp Pro Thr Ser Leu
 1 5 10 15

Leu Thr Thr Met Asp Cys Phe Gln Gln Gln Leu Ile Phe Trp Ser Val
 20 25 30

Leu Arg Gly Ala Cys Met Ser Phe Val Thr Ser Gly Ser Thr Pro Ala
 35 40 45

Val Lys Tyr Cys Phe His Leu Pro Leu Gln Lys Ala Ser Cys Leu Leu
 50 55 60

Thr Ser Thr Ala Lys Ala Leu Phe Trp Thr Gly Tyr Leu Ile Lys Xaa
 65 70 75 80

Ile Ser Val Arg Leu Cys Ser Val Ile Pro Ser Glu Pro Arg Phe Val
 85 90 95

Ser Lys Ala Thr Val Leu Ser Xaa Xaa Pro Cys Val Trp Gly Gln Val

482

```

                100                105                110
Ala Ile Pro Pro Met Ser Leu Val Ile Leu
      115                120

<210> 529
<211> 182
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (25)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 529
Asp Arg Thr Arg Leu Ser Gln Ala Ser Thr Pro Thr Pro Val Cys Trp
  1      .      5      10      15

Gly Leu Leu Gln Pro Pro Pro Trp Xaa Glu Ala Trp Tyr Arg Leu Thr
      20      25      30

His Arg Gly Leu Cys Gln Val Arg Phe Cys Arg Trp Ser Gln Ala Leu
      35      40      45

Pro Glu Ala Arg Gly Gly Ala Trp Ala Gly Ser Pro Gly Glu Gly Gln
      50      55      60

Ala Gly Pro Arg Leu His Thr His Ile Gln Pro Ala Gly Leu Ser Ala
      65      70      75      80

Val Leu Ser Pro Ser Leu Ser Ser Pro Ser Ser Ala Val Thr Leu Ser
      85      90      95

Ser Pro Ser Leu Pro Ala Ser Pro Pro Ala Ala Pro Pro Val Lys Arg
      100      105      110

Met Thr Lys Asp Leu Ser Tyr Ala Gly Ser Lys Asn Gln Asn Phe Leu
      115      120      125

Leu Ala Phe Ser Phe Val Ala Ser Pro Ala Pro Ala Leu Pro Val Ser
      130      135      140

His Pro Gly Pro Arg Leu Glu Ala Ser Leu His Leu Ser Tyr Cys Phe
      145      150      155      160

Lys Pro Lys Phe Thr Val Ser Val Gly Gly Gln Asp Leu Leu Ser Pro
      165      170      175

```

Pro Leu Leu His Pro Pro
180

<210> 530

<211> 183

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (6)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (79)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (80)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (81)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 530

Ala Leu Val Leu Gly Xaa Lys Ser Val Arg Met Ala Ser Ser Arg Met
1 5 10 15

Thr Arg Arg Asp Pro Leu Thr Asn Lys Val Ala Leu Val Thr Ala Ser
20 25 30

Thr Asp Gly Ile Gly Phe Ala Ser Pro Gly Val Trp Pro Arg Thr Gly
35 40 45

Pro Arg Gly Arg Gln Gln Pro Glu Ala Ala Glu Cys Gly Pro Gly Gly
50 55 60

Gly Thr Leu Gln Gly Glu Gly Leu Ser Val Thr Gly Thr Cys Xaa Xaa
65 70 75 80

Xaa Gly Lys Ala Glu Asp Arg Glu Arg Leu Val Ala Thr Ala Val Lys
85 90 95

Leu His Gly Gly Ile Asp Ile Leu Val Ser Asn Ala Ala Val Asn Pro
100 105 110

```
<210> 531
<211> 129
<212> PRT
<213> Homo sapiens
```

```
<220>
<221> SITE
<222> (103)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```

<400> 531
Asn Ser Ala Pro Leu Ser Pro Thr Gly Leu Gly Gln Gly His Thr Gly
  1                      5                      10                      15
His Val Arg Phe Leu Ala Ala Val Gln Leu Pro Asp Gly Phe Asn Leu
      20                      25                      30
Leu Cys Pro Thr Pro Pro Pro Pro Pro Asp Thr Gly Pro Glu Lys Leu
      35                      40                      45
Pro Ser Leu Glu His Arg Asp Ser Pro Trp His Arg Gly Pro Ala Pro
      50                      55                      60
Ala Arg Pro Lys Met Leu Val Ile Ser Gly Gly Asp Gly Tyr Glu Asp
  65                      70                      75                      80
Phe Arg Leu Ser Ser Gly Gly Gly Xaa Ala Val Arg Leu Trp Val Glu
      85                      90                      95

```

485

Thr Thr Ala Gln Thr Thr Xaa Ser Cys Gly Gly Cys Asp Pro Val Cys
 100 105 110

Arg Gly Pro Gly Leu Ala Arg Pro Pro Ala Phe Ser Leu Leu Ala Ser
 115 120 125

Pro

<210> 532

<211> 91

<212> PRT

<213> Homo sapiens

<400> 532

Gly Ala Ile Ala Ser Ser Gly Pro Thr Gly Gly Arg Val Arg Lys His
 1 5 10 15

Gln Leu Leu Pro Gly Ala Val Arg Glu Trp Glu Gln Leu Trp Ala Pro
 20 25 30

His Phe Arg Gln Val Leu Pro Lys Pro Ser Asp Ala Val Arg Pro Gly
 35 40 45

Leu Pro Val Val Leu Phe Arg Leu Cys Phe Gln Asn Ala Phe Ile Ser
 50 55 60

Ser Val Pro Phe Gly Pro His Lys Ser Pro Trp Gly Val Gly Gly Gly
 65 70 75 80

Leu Cys Arg His Pro His Phe Lys Ala Gly Ser
 85 90

<210> 533

<211> 67

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (63)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 533

Asn Leu Cys Gln Val Gln Pro Thr Arg Leu Tyr Ser Ser Leu His Ser
 1 5 10 15

486

Gly Leu His His Val Arg Gln Val Thr Gln Lys Ser Tyr Lys Val Ser
 20 25 30

Thr Ser Gly Pro Arg Ala Phe Ser Ser Arg Ser Tyr Thr Ser Gly Pro
 35 40 45

Gly Ser Arg Ile Ser Ser Ser Ala Phe Ser Arg Val Gly Gly Xaa Ser
 50 55 60

Gly Gly Ala
 65

<210> 534

<211> 144

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (140)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (141)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 534

Phe Asn Arg Arg Tyr Pro Lys Ile Gln Phe Ser Leu Ser Thr Gly Pro
 1 5 10 15

Ser Gly Thr Met Leu Asp Gly Val Leu Glu Gly Lys Leu Asn Ala Ala
 20 25 30

Phe Ile Asp Gly Pro Ile Asn His Thr Ala Ile Asp Gly Ile Pro Val
 35 40 45

Tyr Arg Glu Glu Leu Met Ile Val Thr Pro Gln Gly Tyr Ala Pro Val
 50 55 60

Thr Arg Ala Ser Gln Val Asn Gly Ser Asn Ile Tyr Ala Phe Arg Ala
 65 70 75 80

Asn Cys Ser Tyr Arg Arg His Phe Glu Ser Trp Phe His Ala Asp Gly
 85 90 95

Ala Ala Pro Gly Thr Ile His Glu Met Glu Ser Tyr His Gly Met Leu
 100 105 110

487

Ala Cys Val Ile Ala Gly Ala Gly Ile Ala Leu Ile Pro Arg Ser Met
 115 120 125

Leu Glu Ser Met Pro Gly His His Gln Val Glu Xaa Xaa Ala Val Ser
 130 135 140

<210> 535

<211> 175

<212> PRT

<213> Homo sapiens

<400> 535

Arg Ala Pro Ala Arg Ile Ser Gly Gly Gly Ser Ala Met Val Gly Gly
 1 5 10 15

Gly Gly Val Gly Gly Gly Leu Leu Glu Asn Ala Asn Pro Leu Ile Tyr
 20 25 30

Gln Arg Ser Gly Glu Arg Pro Val Thr Ala Gly Glu Glu Asp Glu Gln
 35 40 45

Val Pro Asp Ser Ile Asp Ala Arg Glu Ile Phe Asp Leu Ile Arg Ser
 50 55 60

Ile Asn Asp Pro Glu His Pro Leu Thr Leu Glu Glu Leu Asn Val Val
 65 70 75 80

Glu Gln Val Arg Val Gln Val Ser Asp Pro Glu Ser Thr Val Ala Val
 85 90 95

Ala Phe Thr Pro Thr Ile Pro His Cys Ser Met Ala Thr Leu Ile Gly
 100 105 110

Leu Ser Ile Lys Val Lys Leu Leu Arg Ser Leu Pro Gln Arg Phe Lys
 115 120 125

Met Asp Val His Ile Thr Pro Gly Thr His Ala Ser Glu His Ala Val
 130 135 140

Asn Lys Gln Leu Ala Asp Lys Glu Arg Val Ala Ala Ala Leu Glu Asn
 145 150 155 160

Thr His Leu Leu Glu Val Val Asn Gln Cys Leu Ser Ala Arg Ser
 165 170 175

488

<210> 536

<211> 148

<212> PRT

<213> Homo sapiens

<400> 536

Gly Trp His Arg Thr His His Arg Gly Arg His Gln Ala Arg Glu Ala
 1 5 10 15

Glu Glu Glu Ala Trp Ala Ala Ala Glu Pro Ile Lys Lys Val Arg Lys
 20 25 30

Ser Leu Ala Leu Asp Ile Val Asp Glu Asp Val Lys Leu Met Met Ser
 35 40 45

Thr Leu Pro Lys Ser Leu Ser Leu Pro Thr Thr Ala Pro Ser Asn Ser
 50 55 60

Ser Ser Leu Thr Leu Ser Gly Ile Lys Glu Asp Asn Ser Leu Leu Asn
 65 70 75 80

Gln Gly Phe Leu Gln Ala Lys Pro Glu Lys Ala Ala Val Ala Gln Lys
 85 90 95

Pro Arg Ser His Phe Thr Thr Pro Ala Pro Met Ser Ser Ala Trp Lys
 100 105 110

Thr Val Ala Cys Gly Gly Thr Arg Asp Gln Leu Phe Met Gln Glu Lys
 115 120 125

Ala Arg Gln Leu Leu Gly Arg Leu Lys Pro Ser His Thr Ser Arg Thr
 130 135 140

Leu Ile Leu Ser
 145

<210> 537

<211> 70

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (41)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

489

<221> SITE

<222> (42)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 537

Arg Pro Thr Arg Ser Ala Trp Trp Gly Arg Leu Leu Ser Arg Val Ser
 1 5 10 15

Pro Gln Pro Arg Pro Ala Ser Pro Ser Val Ser Thr Arg Asn Gln Leu
 20 25 30

Pro Glu Ala Arg Arg Gly Val Glu Xaa Xaa Glu Cys Glu Glu Thr Ala
 35 40 45

Ala Ser Ala Glu Arg Ala Gly Pro Pro Arg Ala Leu Val Phe Gly Ala
 50 55 60

Gln Ser Arg Ser Pro Gly
 65 70

<210> 538

<211> 206

<212> PRT

<213> Homo sapiens

<400> 538

Gly Glu Val Ser Ala Ser Gly Ile Ala Arg Arg Gly Gly Pro Met Ala
 1 5 10 15

Pro Leu Gly Gly Ala Pro Arg Leu Val Leu Leu Phe Ser Gly Lys Arg
 20 25 30

Lys Ser Gly Lys Asp Phe Val Thr Glu Ala Leu Gln Ser Arg Leu Gly
 35 40 45

Ala Asp Val Cys Ala Val Leu Arg Leu Ser Gly Pro Leu Lys Glu Gln
 50 55 60

Tyr Ala Gln Glu His Gly Leu Asn Phe Gln Arg Leu Leu Asp Thr Ser
 65 70 75 80

Thr Tyr Lys Glu Ala Phe Arg Lys Asp Met Ile Arg Trp Gly Glu Glu
 85 90 95

Lys Arg Gln Ala Asp Pro Gly Phe Phe Cys Arg Lys Ile Val Glu Gly
 100 105 110

Ile Ser Gln Pro Ile Trp Leu Val Ser Asp Thr Arg Arg Val Ser Asp
 115 120 125

490

Ile Gln Trp Phe Arg Glu Ala Tyr Gly Ala Val Thr Gln Thr Val Arg
 130 135 140

Val Val Ala Leu Glu Gln Ser Arg Gln Gln Arg Gly Trp Val Phe Thr
 145 150 155 160

Pro Gly Val Asp Asp Ala Glu Ser Glu Cys Gly Leu Asp Asn Phe Gly
 165 170 175

Asp Phe Asp Trp Val Ile Glu Asn His Gly Val Glu Gln Arg Leu Glu
 180 185 190

Glu Gln Leu Glu Asn Leu Ile Glu Phe Ile Arg Ser Arg Leu
 195 200 205

<210> 539

<211> 350

<212> PRT

<213> Homo sapiens

<400> 539

Ser Thr Leu Ile Ala Phe Ile Val Ile Ser Thr Leu Phe Pro Leu Leu
 1 5 10 15

Asp Met Thr Glu Ile Tyr Phe Ser Leu Leu Asp Glu Ile Val Asp Thr
 20 25 30

Leu Gly Glu Gly Ala Phe Gly Lys Val Val Glu Cys Ile Asp His Lys
 35 40 45

Ala Gly Gly Arg His Val Ala Val Lys Ile Val Lys Asn Val Asp Arg
 50 55 60

Tyr Cys Glu Ala Ala Arg Ser Glu Ile Gln Val Leu Glu His Leu Asn
 65 70 75 80

Thr Thr Asp Pro Asn Ser Thr Phe Arg Cys Val Gln Met Leu Glu Trp
 85 90 95

Phe Glu His His Gly His Ile Cys Ile Val Phe Glu Leu Leu Gly Leu
 100 105 110

Ser Thr Tyr Asp Phe Ile Lys Glu Asn Gly Phe Leu Pro Phe Arg Leu
 115 120 125

Asp His Ile Arg Lys Met Ala Tyr Gln Ile Cys Lys Ser Val Asn Phe
 130 135 140

491

Leu His Ser Asn Lys Leu Thr His Thr Asp Leu Lys Pro Glu Asn Ile
 145 150 155 160
 Leu Phe Val Gln Ser Asp Tyr Thr Glu Ala Tyr Asn Pro Lys Ile Lys
 165 170 175
 Arg Asp Glu Arg Thr Leu Ile Asn Pro Asp Ile Lys Val Val Asp Phe
 180 185 190
 Gly Ser Ala Thr Tyr Asp Asp Glu His His Ser Thr Leu Val Ser Thr
 195 200 205
 Arg His Tyr Arg Ala Pro Glu Val Ile Leu Ala Leu Gly Trp Ser Gln
 210 215 220
 Pro Cys Asp Val Trp Ser Ile Gly Cys Ile Leu Ile Glu Tyr Tyr Leu
 225 230 235 240
 Gly Phe Thr Val Phe Pro Thr His Asp Ser Lys Glu His Leu Ala Met
 245 250 255
 Met Glu Arg Ile Leu Gly Pro Leu Pro Lys His Met Ile Gln Lys Thr
 260 265 270
 Arg Lys Arg Lys Tyr Phe His His Asp Arg Leu Asp Trp Asp Glu His
 275 280 285
 Ser Ser Ala Gly Arg Tyr Val Ser Arg Arg Cys Lys Pro Leu Lys Glu
 290 295 300
 Phe Met Leu Ser Gln Asp Val Glu His Glu Arg Leu Phe Asp Leu Ile
 305 310 315 320
 Gln Lys Met Leu Glu Tyr Asp Pro Ala Lys Arg Ile Thr Leu Arg Glu
 325 330 335
 Ala Leu Lys His Pro Phe Phe Asp Leu Leu Lys Lys Ser Ile
 340 345 350

<210> 540

<211> 324

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (54)

<223> Xaa equals any of the naturally occurring L-amino acids

492

<220>
 <221> SITE
 <222> (56)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (297)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (304)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (305)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (317)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (321)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 540
 Gln Ala Thr Met Gly Asn Val Leu Ala Ala Ser Ser Pro Pro Ala Gly
 1 5 10 15
 Pro Pro Pro Pro Pro Ala Pro Ala Leu Val Gly Leu Pro Pro Pro Pro
 20 25 30
 Pro Ser Pro Pro Gly Phe Thr Leu Pro Pro Leu Gly Gly Ser Leu Gly
 35 40 45
 Ala Gly Thr Ser Thr Xaa Arg Xaa Ser Glu Arg Thr Pro Gly Ala Ala
 50 55 60
 Thr Ala Ser Ala Ser Gly Ala Ala Glu Asp Gly Ala Cys Gly Cys Leu
 65 70 75 80
 Pro Asn Pro Gly Thr Phe Glu Glu Cys His Arg Lys Cys Lys Glu Leu
 85 90 95
 Phe Pro Ile Gln Met Glu Gly Val Lys Leu Thr Val Asn Lys Gly Leu
 100 105 110

Ser Asn His Phe Gln Val Asn His Thr Val Ala Leu Ser Thr Ile Gly
 115 120 125
 Glu Ser Asn Tyr His Phe Gly Val Thr Tyr Val Gly Thr Lys Gln Leu
 130 135 140
 Ser Pro Thr Glu Ala Phe Pro Val Leu Val Gly Asp Met Asp Asn Ser
 145 150 155 160
 Gly Ser Leu Asn Ala Gln Val Ile His Gln Leu Gly Pro Gly Leu Arg
 165 170 175
 Ser Lys Met Ala Ile Gln Thr Gln Gln Ser Lys Phe Val Asn Trp Gln
 180 185 190
 Val Asp Gly Glu Tyr Arg Gly Ser Asp Phe Thr Ala Ala Val Thr Leu
 195 200 205
 Gly Asn Pro Asp Val Leu Val Gly Ser Gly Ile Leu Val Ala His Tyr
 210 215 220
 Leu Gln Ser Ile Thr Pro Cys Leu Ala Leu Gly Gly Glu Leu Val Tyr
 225 230 235 240
 His Arg Arg Pro Gly Glu Glu Gly Thr Val Met Ser Leu Ala Gly Lys
 245 250 255
 Tyr Thr Leu Asn Asn Trp Leu Ala Thr Val Thr Leu Gly Gln Ala Gly
 260 265 270
 Met His Ala Thr Tyr Tyr His Lys Ala Ser Asp Gln Leu Gln Val Gly
 275 280 285
 Val Glu Phe Glu Ala Ser Thr Arg Xaa Gln Asp Thr Ser Val Ser Xaa
 290 295 300
 Xaa Val Pro Ala Trp Asn Leu Pro Lys Gly Gln Pro Xaa Leu Ser Lys
 305 310 315 320
 Xaa Leu Leu Gly

<210> 541

<211> 204

<212> PRT

<213> Homo sapiens

<400> 541

494

Arg Gly Pro Thr Phe Thr Pro Glu Ile Met Ala Ala Glu Asp Val Val
 1 5 10 15
 Ala Thr Gly Ala Asp Pro Ser Asp Leu Glu Ser Gly Gly Leu Leu His
 20 25 30
 Glu Ile Phe Thr Ser Pro Leu Asn Leu Leu Leu Leu Gly Leu Cys Ile
 35 40 45
 Phe Leu Leu Tyr Lys Ile Val Arg Gly Asp Gln Pro Ala Ala Ser Gly
 50 55 60
 Asp Ser Asp Asp Asp Glu Pro Pro Pro Leu Pro Arg Leu Lys Arg Arg
 65 70 75 80
 Asp Phe Thr Pro Ala Glu Leu Arg Arg Phe Asp Gly Val Gln Asp Pro
 85 90 95
 Arg Ile Leu Met Ala Ile Asn Gly Lys Val Phe Asp Val Thr Lys Gly
 100 105 110
 Arg Lys Phe Tyr Gly Pro Glu Gly Pro Tyr Gly Val Phe Ala Gly Arg
 115 120 125
 Asp Ala Ser Arg Gly Leu Ala Thr Phe Cys Leu Asp Lys Glu Ala Leu
 130 135 140
 Lys Asp Glu Tyr Asp Asp Leu Ser Asp Leu Thr Ala Ala Gln Gln Glu
 145 150 155 160
 Thr Leu Ser Asp Trp Glu Ser Gln Phe Thr Phe Lys Tyr His His Val
 165 170 175
 Gly Lys Leu Leu Lys Glu Gly Glu Glu Pro Thr Val Tyr Ser Asp Glu
 180 185 190
 Glu Glu Pro Lys Asp Glu Ser Ala Arg Lys Asn Asp
 195 200

<210> 542

<211> 193

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (183)

<223> Xaa equals any of the naturally occurring L-amino acids

495

<400> 542

Pro Ala Tyr Ser Leu Gly Leu Leu Lys Ser Val Leu Asp Gly Gly Gly
 1 5 10 15

Ala Gly Ala His Gln Ala Arg Ser Asn Pro Ser Cys Met Tyr Pro Gln
 20 25 30

Gly Thr Phe Val Ile Pro Leu Leu Val Thr Ala His Arg Asp Pro Thr
 35 40 45

Gln Phe Lys Asp Pro Asp Cys Phe Asn Pro Thr Asn Phe Leu Asp Lys
 50 55 60

Gly Lys Phe Gln Gly Asn Asp Ala Phe Met Pro Phe Ala Ser Gly Ala
 65 70 75 80

Gly Arg Gly Gly Arg Gly Pro Ala Trp Thr Gly Ser Gly Val Pro Gly
 85 90 95

Ala His Cys Ala Pro Val Tyr Pro Ala Lys Gln Met Cys Leu Gly Thr
 100 105 110

Gly Leu Ala His Ser Gly Ile Phe Leu Phe Leu Thr Ala Thr Leu Gln
 115 120 125

Arg Phe Cys Leu Leu Pro Val Val Arg Pro Gly Thr Ile Asn Leu Thr
 130 135 140

Cys Ser Ala Leu Ala Trp Ala Val Ser Pro Gln Thr Ser Ser Ser Ser
 145 150 155 160

Gln Trp Pro Ala Glu Val Arg Leu His Tyr Gly Gly Leu Thr Gly Pro
 165 170 175

Gln Thr Ser Ile Pro Ser Xaa Val Asn Lys Gly Pro Lys Leu Gln Lys
 180 185 190

Lys

<210> 543

<211> 352

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (5)

<223> Xaa equals any of the naturally occurring L-amino acids

496

<220>

<221> SITE

<222> (154)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (167)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 543

Ser	Thr	Val	Arg	Xaa	Pro	Gly	Arg	Pro	Thr	Arg	Pro	Met	Ala	Ala	Glu
1				5					10					15	
Glu	Pro	Gln	Gln	Gln	Lys	Gln	Glu	Pro	Leu	Gly	Ser	Asp	Ser	Glu	Val
		20						25					30		
Leu	Thr	Val	Trp	Pro	Met	Met	Lys	Pro	Ser	Trp	Leu	Ser	Arg	Thr	Glu
	35						40					45			
Phe	Ser	Lys	Arg	Leu	Leu	Cys	Arg	Thr	Leu	Trp	Cys	Gln	Ser	Gly	Trp
	50					55					60				
Ser	Ser	Arg	Ser	Tyr	Thr	Arg	Ser	Met	Leu	Lys	Met	Thr	Thr	Ser	Ile
65					70					75					80
Asn	Arg	Arg	Ser	Arg	Thr	Ser	Thr	Lys	Ser	Thr	Arg	Thr	Ser	Ala	Arg
				85					90					95	
Pro	Gly	Leu	Thr	Ala	Thr	Val	Ser	Ile	Gly	Leu	Ser	Asp	Ser	Pro	Thr
		100						105					110		
Trp	Arg	His	Cys	Trp	Met	Thr	Ala	Arg	Ser	Cys	Ser	Gly	Glu	Lys	Gly
		115					120					125			
Gly	His	Trp	Ala	Pro	Arg	Gln	Val	Gly	Val	Tyr	Leu	Leu	Pro	Gly	Arg
	130					135					140				
Val	Gly	Cys	Val	Ser	Ser	Arg	Val	Ser	Xaa	Ser	Phe	Pro	Gly	Asp	Gly
145					150					155					160
Leu	Asp	Ser	Gly	Leu	Ala	Xaa	Arg	Gly	Ser	Ala	Val	Ser	Ala	Leu	Ala
			165					170						175	
Ser	Gly	Leu	Val	Glu	Glu	Pro	Met	Leu	Gly	Pro	Pro	Phe	His	Pro	Thr
		180						185					190		
Pro	Arg	Phe	Lys	Ala	Val	Ser	Ala	Lys	Ser	Lys	Glu	Asp	Leu	Val	Ser
		195					200					205			

497

Gln Gly Phe Thr Glu Phe Thr Ile Glu Asp Phe His Asn Thr Phe Met
 210 215 220
 Asp Leu Ile Glu Gln Val Glu Lys Gln Thr Ser Val Ala Asp Leu Leu
 225 230 235 240
 Ala Ser Phe Asn Asp Gln Ser Thr Ser Asp Tyr Leu Val Val Tyr Leu
 245 250 255
 Arg Leu Leu Thr Ser Gly Tyr Leu Gln Arg Glu Ser Lys Phe Phe Glu
 260 265 270
 His Phe Ile Glu Gly Gly Arg Thr Val Lys Glu Phe Cys Gln Gln Glu
 275 280 285
 Val Glu Pro Met Cys Lys Glu Ser Asp His Ile His Ile Ile Ala Leu
 290 295 300
 Ala Gln Ala Leu Ser Val Ser Ile Gln Val Glu Tyr Met Asp Arg Gly
 305 310 315 320
 Glu Gly Gly Thr Thr Asn Pro His Ile Phe Pro Glu Gly Ser Glu Pro
 325 330 335
 Lys Val Tyr Leu Leu Tyr Arg Pro Gly His Tyr Asp Ile Leu Tyr Lys
 340 345 350

<210> 544

<211> 240

<212> PRT

<213> Homo sapiens

<400> 544

Ser Thr His Ala Ser Glu Met Ala Glu Arg Gly Tyr Ser Phe Ser Leu
 1 5 10 15
 Thr Thr Phe Ser Pro Ser Gly Lys Leu Val Gln Ile Glu Tyr Ala Leu
 20 25 30
 Ala Ala Val Ala Gly Gly Ala Pro Ser Val Gly Ile Lys Ala Ala Asn
 35 40 45
 Gly Val Val Leu Ala Thr Glu Lys Lys Gln Lys Ser Ile Leu Tyr Asp
 50 55 60
 Glu Arg Ser Val His Lys Val Glu Pro Ile Thr Lys His Ile Gly Leu

498

65		70		75		80
Val Tyr Ser Gly Met Gly Pro Asp Tyr Arg Val Leu Val His Arg Ala						
	85		90		95	
Arg Lys Leu Ala Gln Gln Tyr Tyr Leu Val Tyr Gln Glu Pro Ile Pro						
	100		105		110	
Thr Ala Gln Leu Val Gln Arg Val Ala Ser Val Met Gln Glu Tyr Thr						
	115		120		125	
Gln Ser Gly Gly Val Arg Pro Phe Gly Val Ser Leu Leu Ile Cys Gly						
	130		135		140	
Trp Asn Glu Gly Arg Pro Tyr Leu Phe Gln Ser Asp Pro Ser Gly Ala						
	145		150		155	160
Tyr Phe Ala Trp Lys Ala Thr Ala Met Gly Lys Asn Tyr Val Asn Gly						
	165		170		175	
Lys Thr Phe Leu Glu Lys Arg Tyr Asn Glu Asp Leu Glu Leu Glu Asp						
	180		185		190	
Ala Ile His Thr Ala Ile Leu Thr Leu Lys Glu Ser Phe Glu Gly Gln						
	195		200		205	
Met Thr Glu Asp Asn Ile Glu Val Gly Ile Cys Asn Glu Ala Gly Phe						
	210		215		220	
Arg Arg Leu Thr Pro Thr Glu Val Lys Asp Tyr Leu Ala Ala Ile Ala						
	225		230		235	240

<210> 545

<211> 181

<212> PRT

<213> Homo sapiens

<400> 545

Arg Cys Ile Leu Tyr Thr Gly Phe Met Leu Gly Ala Gln Arg Glu Val						
1		5		10		15
Asp Ser Arg Leu Leu Ala Leu Pro Gly Arg Lys Val Pro Thr Ser Trp						
	20		25		30	
Trp Asp Asp Leu Phe Lys Gly Ala Lys Glu His Gly Ala Val Ala Val						
	35		40		45	

499

Glu Arg Val Thr Lys Ser Pro Gly Glu Thr Ser Lys Pro Arg Pro Phe
 50 55 60
 Ala Gly Gly Gly Tyr Arg Leu Gly Ala Ala Pro Glu Glu Glu Ser Ala
 65 70 75 80
 Tyr Val Ala Gly Glu Lys Arg Gln His Ser Ser Gln Asp Val His Val
 85 90 95
 Val Leu Lys Leu Trp Lys Ser Gly Phe Ser Leu Asp Asn Gly Glu Leu
 100 105 110
 Arg Ser Tyr Gln Asp Pro Ser Asn Ala Gln Phe Leu Glu Ser Ile Arg
 115 120 125
 Arg Gly Glu Val Pro Ala Glu Leu Arg Arg Leu Ala His Gly Gly Gln
 130 135 140
 Val Asn Leu Asp Met Glu Asp His Arg Asp Glu Asp Phe Val Lys Pro
 145 150 155 160
 Lys Gly Ala Phe Lys Ala Phe Thr Gly Glu Gly Gln Lys Leu Gly Ser
 165 170 175
 Thr Ala Pro Arg Cys
 180

<210> 546

<211> 197

<212> PRT

<213> Homo sapiens

<400> 546

Pro Arg Val Arg Arg Ala Arg Ala Ala Ala Gly Ser Ser His Ala
 1 5 10 15
 Ala Met Ala Asp Ser Glu Leu Gln Leu Val Glu Gln Arg Ile Arg Ser
 20 25 30
 Phe Pro Asp Phe Pro Thr Pro Gly Val Val Phe Arg Asp Ile Ser Pro
 35 40 45
 Val Leu Lys Asp Pro Ala Ser Phe Arg Ala Ala Ile Gly Leu Leu Ala
 50 55 60
 Arg His Leu Lys Ala Thr His Gly Gly Arg Ile Asp Tyr Ile Ala Gly
 65 70 75 80

500

Leu Asp Ser Arg Gly Phe Leu Phe Gly Pro Ser Leu Ala Gln Glu Leu
 85 90 95
 Gly Leu Gly Cys Val Leu Ile Arg Lys Arg Gly Lys Leu Pro Gly Pro
 100 105 110
 Thr Leu Trp Ala Ser Tyr Ser Leu Glu Tyr Gly Lys Ala Glu Leu Glu
 115 120 125
 Ile Gln Lys Asp Ala Leu Glu Pro Gly Gln Arg Val Val Val Val Asp
 130 135 140
 Asp Leu Leu Ala Thr Gly Gly Thr Met Asn Ala Ala Cys Glu Leu Leu
 145 150 155 160
 Gly Arg Leu Gln Ala Glu Val Leu Glu Cys Val Ser Leu Val Glu Leu
 165 170 175
 Thr Ser Leu Lys Gly Arg Glu Lys Leu Ala Pro Val Pro Phe Phe Ser
 180 185 190
 Leu Leu Gln Tyr Glu
 195

<210> 547

<211> 93

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (84)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 547

Glu Thr Gly Lys Glu Ser Lys Ala Leu Phe Leu Pro Phe Pro Gly Ser
 1 5 10 15
 Val Tyr Ser Thr Ser Thr Gly Glu Ala Ser Gly Glu Gly Leu Ser Pro
 20 25 30
 Leu Pro His Leu His Glu Phe Trp Asn Ser Val Leu Leu Ala Ala Cys
 35 40 45
 Phe Gln Leu Pro Pro Ile Ser Ile Ala Ala Gly Ser Ser Cys Leu Phe
 50 55 60
 Tyr Ser Val Ile Lys His Pro Ala Pro Thr Leu Ser Gln Arg Ser Ile
 65 70 75 80

```
<220> .
<221> SITE
<222> (5)
<223> Xaa equals any of the naturally occurring L-amino acids
```

Leu Gln Gly Leu Gly His Phe Leu Gln Glu Asn Lys Gln Leu Leu Arg
20 25 30

Ile

```
<210> 549
<211> 379
<212> PRT
<213> Homo sapiens
```

```
<400> 549  
Val Ala Cys Cys Val Arg Ile Pro Gly Pro Pro Arg Arg Ser Gly Pro  
      1              5              10             15
```

Ala Met Ala Val Thr Ile Thr Leu Lys Thr Leu Gln Gln Gln Thr Phe
20 25 30

Lys Ile Arg Met Glu Pro Asp Glu Thr Val Lys Val Leu Lys Glu Lys
35 40 45

Ile Glu Ala Glu Lys Gly Arg Asp Ala Phe Pro Val Ala Gly Gln Lys
50 55 60

Leu Ile Tyr Ala Gly Lys Ile Leu Ser Asp Asp Val Pro Ile Arg Asp
65 70 75 80

502

Tyr Arg Ile Asp Glu Lys Asn Phe Val Val Val Met Val Thr Lys Thr
 85 90 95
 Lys Ala Gly Gln Gly Thr Ser Ala Pro Pro Glu Ala Ser Pro Thr Ala
 100 105 110
 Ala Pro Glu Ser Ser Thr Ser Phe Pro Pro Ala Pro Thr Ser Gly Met
 115 120 125
 Ser His Pro Pro Pro Ala Ala Arg Glu Asp Lys Ser Pro Ser Glu Glu
 130 135 140
 Ser Ala Pro Thr Thr Ser Pro Glu Ser Val Ser Gly Ser Val Pro Ser
 145 150 155 160
 Ser Gly Ser Ser Gly Arg Glu Glu Asp Ala Ala Ser Thr Leu Val Thr
 165 170 175
 Gly Ser Glu Tyr Glu Thr Met Leu Thr Glu Ile Met Ser Met Gly Tyr
 180 185 190
 Glu Arg Glu Arg Val Val Ala Ala Leu Arg Ala Ser Tyr Asn Asn Pro
 195 200 205
 His Arg Ala Val Glu Tyr Leu Leu Thr Gly Ile Pro Gly Ser Pro Glu
 210 215 220
 Pro Glu His Gly Ser Val Gln Glu Ser Gln Val Ser Glu Gln Pro Ala
 225 230 235 240
 Thr Glu Ala Gly Glu Asn Pro Leu Glu Phe Leu Arg Asp Gln Pro Gln
 245 250 255
 Phe Gln Asn Met Arg Gln Val Ile Gln Gln Asn Pro Ala Leu Leu Pro
 260 265 270
 Ala Leu Leu Gln Gln Leu Gly Gln Glu Asn Pro Gln Leu Leu Gln Gln
 275 280 285
 Ile Ser Arg His Gln Glu Gln Phe Ile Gln Met Leu Asn Glu Pro Pro
 290 295 300
 Gly Glu Leu Ala Asp Ile Ser Asp Val Glu Gly Glu Val Gly Ala Ile
 305 310 315 320
 Gly Glu Glu Ala Pro Gln Met Asn Tyr Ile Gln Val Thr Pro Gln Glu
 325 330 335
 Lys Glu Ala Ile Glu Arg Leu Lys Ala Leu Gly Phe Pro Glu Ser Leu
 340 345 350

Val Ile Gln Ala Tyr Phe Ala Cys Glu Lys Asn Glu Asn Leu Ala Ala
355 360 365

Asn Phe Leu Leu Ser Gln Asn Phe Asp Asp Glu
370 375

```
<210> 550
<211> 275
<212> PRT
<213> Homo sapiens
```

```
<220>  
<221> SITE  
<222> (6)  
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>  
<221> SITE  
<222> (235)  
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (260)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (261)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (267)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (272)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<400> 550  
Cys Ser Cys Lys Arg Xaa His Gln Gln Gln Val Leu Pro Pro Arg Gln  
      1              5              10             15
```

Pro Ser Ala Leu Val Pro Ser Val Thr Glu Tyr Arg Leu Asp Gly His
20 25 30

504

Thr Ile Ser Asp Leu Ser Arg Ser Ser Arg Gly Glu Leu Ile Pro Ile
 35 40 45
 Ser Pro Ser Thr Glu Val Gly Gly Ser Gly Ile Gly Thr Pro Pro Ser
 50 55 60
 Val Leu Lys Arg Gln Arg Lys Arg Arg Val Ala Leu Ser Pro Val Thr
 65 70 75 80
 Glu Asn Ser Thr Ser Leu Ser Phe Leu Asp Ser Cys Asn Ser Leu Thr
 85 90 95
 Pro Lys Ser Thr Pro Val Lys Thr Leu Pro Phe Ser Pro Ser Gln Phe
 100 105 110
 Leu Asn Phe Trp Asn Lys Gln Asp Thr Leu Glu Leu Glu Ser Pro Ser
 115 120 125
 Leu Thr Ser Thr Pro Val Cys Ser Gln Lys Val Val Val Thr Thr Pro
 130 135 140
 Leu His Arg Asp Lys Thr Pro Leu His Gln Lys His Ala Ala Phe Val
 145 150 155 160
 Thr Pro Asp Gln Lys Tyr Ser Met Asp Asn Thr Pro His Thr Pro Thr
 165 170 175
 Pro Phe Lys Asn Ala Leu Glu Lys Tyr Gly Pro Leu Lys Pro Leu Pro
 180 185 190
 Gln Thr Pro His Leu Glu Glu Asp Leu Lys Glu Val Leu Arg Ser Glu
 195 200 205
 Ala Gly Ile Glu Leu Ile Ile Glu Asp Asp Ile Arg Pro Glu Lys Gln
 210 215 220
 Lys Arg Lys Pro Gly Leu Arg Arg Ser Pro Xaa Lys Lys Val Arg Lys
 225 230 235 240
 Ser Leu Ala Leu Asp Ile Val Asp Glu Asp Val Lys Leu Met Met Ser
 245 250 255
 Thr Leu Pro Xaa Xaa Leu Ser Leu Ala Thr Xaa Ala Pro Cys Lys Xaa
 260 265 270
 Phe Gln Pro
 275

<210> 551

505

<211> 161

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (158)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 551

Asn Leu Ala Ala Ala Ser Gly Gly Gly Pro Gln Ser Val Ser Gly Thr
 1 5 10 15

Leu Leu Cys Glu Pro Val Leu Thr Met Phe Ala Thr Ser Gly Ala Val
 20 25 30

Ala Ala Gly Lys Pro Tyr Ser Cys Ser Glu Cys Gly Lys Ser Phe Cys
 35 40 45

Tyr Ser Ser Val Leu Leu Arg His Glu Arg Ala His Gly Gly Asp Gly
 50 55 60

Arg Phe Arg Cys Leu Glu Cys Gly Glu Arg Cys Ala Arg Ala Ala Asp
 65 70 75 80

Leu Arg Ala His Arg Arg Thr His Ala Gly Gln Thr Leu Tyr Ile Cys
 85 90 95

Ser Glu Cys Gly Gln Ser Phe Arg His Ser Gly Arg Leu Asp Leu His
 100 105 110

Leu Gly Ala His Arg Gln Arg Cys Arg Thr Cys Pro Cys Arg Thr Cys
 115 120 125

Gly Arg Arg Phe Pro His Leu Pro Ala Leu Leu Leu His Arg Arg Arg
 130 135 140

Gln His Leu Pro Glu Arg Pro Arg Arg Cys Pro Leu Cys Xaa Leu Arg
 145 150 155 160

Phe

<210> 552

<211> 405

<212> PRT

<213> Homo sapiens

<400> 552

506

Pro Arg Val Arg Arg Arg Ala Arg Gly Arg Arg Val Arg Pro Ala Gly
 1 5 10 15
 Gly Pro Val Arg Arg Gly Ala Ala Val Arg Gly Ala Leu Arg Gly Ala
 20 25 30
 Ser Leu Gly His Gly Ala Ala Ala Arg Ala Gly Arg Pro Leu Cys Val
 35 40 45
 Arg His Ser Glu Pro Val Cys Gly Ser Asp Ala Asn Thr Tyr Ala Asn
 50 55 60
 Leu Cys Gln Leu Arg Ala Ala Ser Arg Arg Ser Glu Arg Leu His Arg
 65 70 75 80
 Pro Pro Val Ile Val Leu Gln Arg Gly Ala Cys Gly Gln Gly Gln Glu
 85 90 95
 Asp Pro Asn Ser Leu Arg His Lys Tyr Asn Phe Ile Ala Asp Val Val
 100 105 110
 Glu Lys Ile Ala Pro Ala Val Val His Ile Glu Leu Phe Arg Lys Leu
 115 120 125
 Pro Phe Ser Lys Arg Glu Val Pro Val Ala Ser Gly Ser Gly Phe Ile
 130 135 140
 Val Ser Glu Asp Gly Leu Ile Val Thr Asn Ala His Val Val Thr Asn
 145 150 155 160
 Lys His Arg Val Lys Val Glu Leu Lys Asn Gly Ala Thr Tyr Glu Ala
 165 170 175
 Lys Ile Lys Asp Val Asp Glu Lys Ala Asp Ile Ala Leu Ile Lys Ile
 180 185 190
 Asp His Gln Gly Lys Leu Pro Val Leu Leu Leu Gly Arg Ser Ser Glu
 195 200 205
 Leu Arg Pro Gly Glu Phe Val Val Ala Ile Gly Ser Pro Phe Ser Leu
 210 215 220
 Gln Asn Thr Val Thr Thr Gly Ile Val Ser Thr Thr Gln Arg Gly Gly
 225 230 235 240
 Lys Glu Leu Gly Leu Arg Asn Ser Asp Met Asp Tyr Ile Gln Thr Asp
 245 250 255
 Ala Ile Ile Asn Tyr Gly Asn Ser Gly Gly Pro Leu Val Asn Leu Asp
 260 265 270

507

Gly Glu Val Ile Gly Ile Asn Thr Leu Lys Val Thr Ala Gly Ile Ser
 275 280 285
 Phe Ala Ile Pro Ser Asp Lys Ile Lys Lys Phe Leu Thr Glu Ser His
 290 295 300
 Asp Arg Gln Ala Lys Gly Lys Ala Ile Thr Lys Lys Lys Tyr Ile Gly
 305 310 315 320
 Ile Arg Met Met Ser Leu Thr Ser Ser Lys Ala Lys Glu Leu Lys Asp
 325 330 335
 Arg His Arg Asp Phe Pro Asp Val Ile Ser Gly Ala Tyr Ile Ile Glu
 340 345 350
 Val Ile Pro Asp Thr Pro Ala Glu Ala Gly Gly Leu Lys Glu Asn Asp
 355 360 365
 Val Ile Ile Ser Ile Asn Gly Gln Ser Val Val Ser Ala Asn Asp Val
 370 375 380
 Ser Asp Val Ile Lys Arg Glu Ser Thr Leu Asn Met Val Val Arg Arg
 385 390 395 400
 Val Met Lys Ile Ser
 405

<210> 553

<211> 107

<212> PRT

<213> Homo sapiens

<400> 553

Ala Gln Glu Asn Glu Glu Met Glu Gln Pro Met Gln Asn Gly Glu Glu
 1 5 10 15
 Asp Arg Pro Leu Gly Gly Gly Glu Gly His Gln Pro Ala Gly Asn Arg
 20 25 30
 Arg Gly Gln Ala Arg Arg Leu Ala Pro Asn Phe Arg Trp Ala Ile Pro
 35 40 45
 Asn Arg Gln Ile Asn Asp Gly Met Gly Gly Asp Gly Asp Asp Met Glu
 50 55 60
 Ile Phe Met Glu Glu Met Arg Glu Ile Arg Arg Lys Leu Arg Glu Leu
 65 70 75 80
 Gln Leu Arg Asn Cys Leu Arg Ile Leu Met Gly Glu Leu Ser Asn His

508

	85	90	95
His Asp His His Asp Glu Phe Cys Leu Met Pro			
100	105		

<210> 554
 <211> 229
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (8)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (15)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (20)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (27)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (78)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 554
 Gly Leu Ser Ala Glu Ser Thr Xaa Thr Ser Thr Met Pro Met Xaa Leu
 1 5 10 15
 Gly Tyr Trp Xaa Ile Arg Gly Leu Ala His Xaa Ile Arg Leu Leu Leu
 20 25 30
 Glu Tyr Thr Asp Ser Ser Tyr Glu Glu Lys Lys Tyr Thr Met Gly Asp
 35 40 45
 Ala Pro Asp Tyr Asp Arg Ser Gln Trp Leu Asn Glu Lys Phe Lys Leu
 50 55 60
 Gly Leu Asp Phe Pro Asn Leu Pro Tyr Leu Ile Asp Gly Xaa His Lys

509

65		70		75		80
Ile Thr Gln Ser Asn Ala Ile Leu Arg Tyr Ile Ala Arg Lys His Asn						
	85		90		95	
Leu Cys Gly Glu Ser Glu Lys Glu Gln Ile Arg Glu Asp Ile Leu Glu						
	100		105		110	
Asn Gln Phe Met Asp Ser Arg Met Gln Leu Ala Lys Leu Cys Tyr Asp						
	115		120		125	
Pro Asp Phe Glu Lys Leu Lys Pro Glu Tyr Leu Gln Ala Leu Pro Glu						
	130		135		140	
Met Leu Lys Leu Tyr Ser Gln Phe Leu Gly Lys Gln Pro Trp Phe Leu						
	145		150		155	160
Gly Asp Lys Ile Thr Phe Val Asp Phe Ile Ala Tyr Asp Val Leu Glu						
	165		170		175	
Arg Asn Gln Val Phe Glu Pro Ser Cys Leu Asp Ala Phe Pro Asn Leu						
	180		185		190	
Lys Asp Phe Ile Ser Arg Phe Glu Gly Leu Glu Lys Ile Ser Ala Tyr						
	195		200		205	
Met Lys Ser Ser Arg Phe Leu Pro Arg Pro Val Phe Thr Lys Met Ala						
	210		215		220	
Val Trp Gly Asn Lys						
225						

<210> 555

<211> 106

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (59)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (60)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

510

<222> (72)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (98)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 555

Asn Val Ile Ser Val Asp Pro Asn Asp Gln Lys Lys Thr Ala Cys Tyr
 1 5 10 15

Asp Ile Asp Val Glu Val Asp Asp Thr Leu Lys Thr Gln Met Asn Ser
 20 25 30

Phe Leu Leu Ser Thr Ala Ser Gln Gln Glu Ile Ala Thr Leu Asp Asn
 35 40 45

Lys Thr Met Thr Asp Val Val Gly Asn Gln Xaa Xaa Ser Ala Glu Leu
 50 55 60

Ser Ser Thr Ser Ser Pro Gly Xaa Gly Gly Cys Val Pro Ile Leu Leu
 65 70 75 80

Leu Gln Gly Ala Ala Glu Thr Thr Arg Ile Arg Ala Ser Pro Gly Asn
 85 90 95

Pro Xaa Tyr Ile Gly Pro Leu Pro Gln Pro
 100 105

<210> 556

<211> 86

<212> PRT

<213> Homo sapiens

<400> 556

Gly Arg Ala Thr Lys Gln Asn Thr Thr Lys Pro Asn His Arg Ile Ile
 1 5 10 15

Phe Asn Pro Thr Phe Tyr Thr Met Pro Gln Phe Pro Ile Thr Leu His
 20 25 30

Thr Ser Phe Cys Val Gln Leu Asn Cys Asn Cys Phe Leu Tyr Leu Glu
 35 40 45

Arg Val Thr Ile Glu Leu Glu Thr Phe Tyr Ser Gly Arg Leu Gly Ser
 50 55 60

Phe Trp Trp Asp Ser Val Gly Glu Arg Glu Glu Gly Glu Val Gly Gly

65	70	75	80
Leu Leu Pro Phe Arg Thr			
85			
<210> 557			
<211> 565			
<212> PRT			
<213> Homo sapiens			
<220>			
<221> SITE			
<222> (57)			
<223> Xaa equals any of the naturally occurring L-amino acids			
<220>			
<221> SITE			
<222> (71)			
<223> Xaa equals any of the naturally occurring L-amino acids			
<220>			
<221> SITE			
<222> (75)			
<223> Xaa equals any of the naturally occurring L-amino acids			
<220>			
<221> SITE			
<222> (82)			
<223> Xaa equals any of the naturally occurring L-amino acids			
<220>			
<221> SITE			
<222> (118)			
<223> Xaa equals any of the naturally occurring L-amino acids			
<220>			
<221> SITE			
<222> (120)			
<223> Xaa equals any of the naturally occurring L-amino acids			
<220>			
<221> SITE			
<222> (552)			
<223> Xaa equals any of the naturally occurring L-amino acids			
<400> 557			
Ala Ser Leu Thr Gly Thr Gln Ala Leu Pro Pro Leu Phe Ser Leu Gly			
1	5	10	15

512

Tyr His Gln Ser Arg Trp Asn Tyr Arg Asp Glu Ala Asp Val Leu Glu
 20 25 30

Val Asp Gln Gly Phe Asp Asp His Asn Leu Pro Cys Asp Val Ile Trp
 35 40 45

Leu Asp Ile Glu His Ala Asp Gly Xaa Arg Tyr Phe Thr Trp Asp Pro
 50 55 60

Ser Arg Phe Pro Gln Pro Xaa Thr Met Leu Xaa Arg Leu Ala Ser Lys
 65 70 75 80

Arg Xaa Lys Leu Val Ala Ile Val Asp Pro His Ile Lys Val Asp Ser
 85 90 95

Gly Tyr Arg Val His Glu Glu Leu Arg Asn Leu Gly Leu Tyr Val Lys
 100 105 110

Thr Arg Asp Gly Ser Xaa Tyr Xaa Gly Trp Cys Trp Pro Gly Ser Ala
 115 120 125

Gly Tyr Pro Asp Phe Thr Asn Pro Thr Met Arg Ala Trp Trp Ala Asn
 130 135 140

Met Phe Ser Tyr Asp Asn Tyr Glu Gly Ser Ala Pro Asn Leu Phe Val
 145 150 155 160

Trp Asn Asp Met Asn Glu Pro Ser Val Phe Asn Gly Pro Glu Val Thr
 165 170 175

Met Leu Lys Asp Ala Gln His Tyr Gly Gly Trp Glu His Arg Asp Val
 180 185 190

His Asn Ile Tyr Gly Leu Tyr Val His Met Ala Thr Ala Asp Gly Leu
 195 200 205

Arg Gln Arg Ser Gly Gly Met Glu Arg Pro Phe Val Leu Ala Arg Ala
 210 215 220

Phe Phe Ala Gly Ser Gln Arg Phe Gly Ala Val Trp Thr Gly Asp Asn
 225 230 235 240

Thr Ala Glu Trp Asp His Leu Lys Ile Ser Ile Pro Met Cys Leu Ser
 245 250 255

Leu Gly Leu Val Gly Leu Ser Phe Cys Gly Ala Asp Val Gly Gly Phe
 260 265 270

Phe Lys Asn Pro Glu Pro Glu Leu Leu Val Arg Trp Tyr Gln Met Gly
 275 280 285

Ala Tyr Gln Pro Phe Phe Arg Ala His Ala His Leu Asp Thr Gly Arg
 290 295 300
 Arg Glu Pro Trp Leu Leu Pro Ser Gln His Asn Asp Ile Ile Arg Asp
 305 310 315 320
 Ala Leu Gly Gln Arg Tyr Ser Leu Leu Pro Phe Trp Tyr Thr Leu Leu
 325 330 335
 Tyr Gln Ala His Arg Glu Gly Ile Pro Val Met Arg Pro Leu Trp Val
 340 345 350
 Gln Tyr Pro Gln Asp Val Thr Thr Phe Asn Ile Asp Asp Gln Tyr Leu
 355 360 365
 Leu Gly Asp Ala Leu Leu Val His Pro Val Ser Asp Ser Gly Ala His
 370 375 380
 Gly Val Gln Val Tyr Leu Pro Gly Gln Gly Glu Val Trp Tyr Asp Ile
 385 390 395 400
 Gln Ser Tyr Gln Lys His His Gly Pro Gln Thr Leu Tyr Leu Pro Val
 405 410 415
 Thr Leu Ser Ser Ile Pro Val Phe Gln Arg Gly Gly Thr Ile Val Pro
 420 425 430
 Arg Trp Met Arg Val Arg Arg Ser Ser Glu Cys Met Lys Asp Asp Pro
 435 440 445
 Ile Thr Leu Phe Val Ala Leu Ser Pro Gln Gly Thr Ala Gln Gly Glu
 450 455 460
 Leu Phe Leu Asp Asp Gly His Thr Phe Asn Tyr Gln Thr Arg Gln Glu
 465 470 475 480
 Phe Leu Leu Arg Arg Phe Ser Phe Ser Gly Asn Thr Leu Val Ser Ser
 485 490 495
 Ser Ala Asp Pro Glu Gly His Phe Glu Thr Pro Ile Trp Ile Glu Arg
 500 505 510
 Val Val Ile Ile Gly Ala Gly Lys Pro Ala Ala Val Val Leu Gln Thr
 515 520 525
 Lys Gly Ser Pro Glu Ser Arg Leu Ser Phe Gln His Asp Pro Glu Thr
 530 535 540
 Ser Val Leu Val Leu Arg Lys Xaa Gly Ile Asn Val Ala Ser Asp Trp
 545 550 555 560

514

Ser Ile His Leu Arg
565

<210> 558

<211> 160

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (39)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 558

Arg Glu Ala Val Leu Pro Gln Ala Val Leu Arg His Pro Val Arg Thr
1 5 10 15

Gln Arg Arg Glu His Arg Gly Arg Gly Leu Leu His Leu Arg Glu Ala
20 25 30

Pro Gly Gly Gly Ala Ala Xaa His Arg Pro His Arg Gly Pro Arg Gly
35 40 45

Pro Ser Arg Gly Ala Glu Gly Glu Arg Pro Pro Glu Gly Pro Ser Arg
50 55 60

Ala Ser Ser Val Thr Thr Phe Thr Gly Glu Pro Asn Thr Cys Pro Arg
65 70 75 80

Cys Ser Lys Lys Val Tyr Phe Ala Glu Lys Val Thr Ser Leu Gly Lys
85 90 95

Asp Trp His Arg Pro Cys Leu Arg Cys Glu Arg Cys Gly Lys Thr Leu
100 105 110

Thr Pro Gly Gly His Ala Glu His Asp Gly Gln Pro Tyr Cys His Lys
115 120 125

Pro Cys Tyr Gly Ile Leu Phe Gly Pro Lys Gly Val Asn Thr Gly Ala
130 135 140

Val Gly Ser Tyr Ile Tyr Asp Arg Asp Pro Glu Gly Lys Val Gln Pro
145 150 155 160

515

<210> 559

<211> 480

<212> PRT

<213> Homo sapiens

<400> 559

Gly Cys Ile Gly Tyr Leu Val Leu Leu Trp Pro Leu Pro Leu Ile His
 1 5 10 15
 Phe Gly Leu Ala Asn Gln Ser Glu Asp Leu Ser Val Phe Tyr Pro Gly
 20 25 30
 Thr Leu Leu Glu Thr Gly His Asp Ile Leu Phe Phe Trp Val Ala Arg
 35 40 45
 Met Val Met Leu Gly Leu Lys Leu Thr Gly Arg Leu Pro Phe Arg Glu
 50 55 60
 Val Tyr Leu His Ala Ile Val Arg Asp Ala His Gly Arg Lys Met Ser
 65 70 75 80
 Lys Ser Leu Gly Asn Val Ile Asp Pro Leu Asp Val Ile Tyr Gly Ile
 85 90 95
 Ser Leu Gln Gly Leu His Asn Gln Leu Leu Asn Ser Asn Leu Asp Pro
 100 105 110
 Ser Glu Val Glu Lys Ala Lys Glu Gly Gln Lys Ala Asp Phe Pro Ala
 115 120 125
 Gly Ile Pro Glu Cys Gly Thr Asp Ala Leu Arg Phe Gly Leu Cys Ala
 130 135 140
 Tyr Met Ser Gln Gly Arg Asp Ile Asn Leu Asp Val Asn Arg Ile Leu
 145 150 155 160
 Gly Tyr Arg His Phe Cys Asn Lys Leu Trp Asn Ala Thr Lys Phe Ala
 165 170 175
 Leu Arg Gly Leu Gly Lys Gly Phe Val Pro Ser Pro Thr Ser Gln Pro
 180 185 190
 Gly Gly His Glu Ser Leu Val Asp Arg Trp Ile Arg Ser Arg Leu Thr
 195 200 205
 Glu Ala Val Arg Leu Ser Asn Gln Gly Phe Gln Ala Tyr Asp Phe Pro
 210 215 220
 Ala Val Thr Thr Ala Gln Tyr Ser Phe Trp Leu Tyr Glu Leu Cys Asp
 225 230 235 240

```

Val Tyr Leu Glu Cys Leu Lys Pro Val Leu Asn Gly Val Asp Gln Val
      245                      250                      255

Ala Ala Glu Cys Ala Arg Gln Thr Leu Tyr Thr Cys Leu Asp Val Gly
      260                      265                      270

Leu Arg Leu Leu Ser Pro Phe Met Pro Phe Val Thr Glu Glu Leu Phe
      275                      280                      285

Gln Arg Leu Pro Arg Arg Met Pro Gln Ala Pro Pro Ser Leu Cys Val
      290                      295                      300

Thr Pro Tyr Pro Glu Pro Ser Glu Cys Ser Trp Lys Asp Pro Glu Ala
305                      310                      315                      320

Glu Ala Ala Leu Glu Leu Ala Leu Ser Ile Thr Arg Ala Val Arg Ser
      325                      330                      335

Leu Arg Ala Asp Tyr Asn Leu Thr Arg Ile Arg Pro Asp Cys Phe Leu
      340                      345                      350

Glu Val Ala Asp Glu Ala Thr Gly Ala Leu Ala Ser Ala Val Ser Gly
      355                      360                      365

Tyr Val Gln Ala Leu Ala Ser Ala Gly Val Val Ala Val Leu Ala Leu
      370                      375                      380

Gly Ala Pro Ala Pro Gln Gly Cys Ala Val Ala Leu Ala Ser Asp Arg
385                      390                      395                      400

Cys Ser Ile His Leu Gln Leu Gln Gly Leu Val Asp Pro Ala Arg Glu
      405                      410                      415

Leu Gly Lys Leu Gln Ala Lys Arg Val Glu Ala Gln Arg Gln Ala Gln
      420                      425                      430

Arg Leu Arg Glu Arg Arg Ala Ala Ser Gly Tyr Pro Val Lys Val Pro
      435                      440                      445

Leu Glu Val Gln Glu Ala Asp Glu Ala Lys Leu Gln Gln Thr Glu Ala
      450                      455                      460

Glu Leu Arg Lys Val Asp Glu Ala Ile Ala Leu Phe Gln Lys Met Leu
465                      470                      475                      480

```

517

<211> 96

<212> PRT

<213> Homo sapiens

<400> 560

Ala Cys Leu Glu Arg Cys Gly Ser Trp Arg Pro His Arg Pro Met Thr
1 5 10 15

Ser Gly Ala Arg Glu Asn Pro Ile Gln Val Pro Arg Ser Ser Leu Glu
20 25 30

Ala Thr Gly Ala Gln Glu Arg Trp Ala Glu Asp Val Pro Tyr Pro Thr
35 40 45

Thr Arg Ala Val Ser Leu Pro Pro Ser Leu Gly Val Gly Ser Thr Gly
50 55 60

Met Ser Ser Ser Arg Phe Leu Gly Ser Leu Gly Lys His Gly Arg Leu
65 70 75 80

Asp Ser Ser Arg Arg Ala Arg Leu Trp Gly Arg Gly Gly Arg Gly Gly
85 90 95

<210> 561

<211> 60

<212> PRT

<213> Homo sapiens

<400> 561

Ile Arg His Glu Ser Ser Ile Leu Ser Val Leu Phe Ile Arg Phe Leu
1 5 10 15

Lys Cys Ala Asp Pro Phe Lys Thr Pro Ala Tyr Leu Cys Asn Lys Glu
20 25 30

Lys Tyr Ser Lys Ile Leu Pro Ser Phe Ser His Thr Val Leu Lys Met
35 40 45

Leu Gln Asp Gln Ile Ile Ala His Lys Ile Arg Ser
50 55 60

<210> 562

<211> 241

<212> PRT

518

<213> Homo sapiens

<400> 562

Ser Ser Met Ala Lys Pro Cys Gly Val Arg Leu Ser Gly Glu Ala Arg
 1 5 10 15
 Lys Gln Val Glu Val Phe Arg Gln Asn Leu Phe Gln Glu Ala Glu Glu
 20 25 30
 Phe Leu Tyr Arg Phe Leu Pro Gln Lys Ile Ile Tyr Leu Asn Gln Leu
 35 40 45
 Leu Gln Glu Asp Ser Leu Asn Val Ala Asp Leu Thr Ser Leu Arg Ala
 50 55 60
 Pro Leu Asp Ile Pro Ile Pro Asp Pro Pro Pro Lys Asp Asp Glu Met
 65 70 75 80
 Glu Thr Asp Lys Gln Glu Lys Lys Glu Val Pro Lys Cys Gly Phe Leu
 85 90 95
 Pro Gly Asn Glu Lys Val Leu Ser Leu Leu Ala Leu Val Lys Pro Glu
 100 105 110
 Val Trp Thr Leu Lys Glu Lys Cys Ile Leu Val Ile Thr Trp Ile Gln
 115 120 125
 His Leu Ile Pro Lys Ile Glu Asp Gly Asn Asp Phe Gly Val Ala Ile
 130 135 140
 Gln Glu Lys Val Leu Glu Arg Val Asn Ala Val Lys Thr Lys Val Glu
 145 150 155 160
 Ala Phe Gln Thr Thr Ile Ser Lys Tyr Phe Ser Glu Arg Gly Asp Ala
 165 170 175
 Val Ala Lys Ala Ser Lys Glu Thr His Val Met Asp Tyr Arg Ala Leu
 180 185 190
 Val His Glu Arg Asp Glu Ala Ala Tyr Gly Glu Leu Arg Ala Met Val
 195 200 205
 Leu Asp Leu Arg Ala Phe Tyr Ala Glu Leu Tyr His Ile Ile Ser Ser
 210 215 220
 Asn Leu Glu Lys Ile Val Asn Pro Lys Gly Glu Glu Lys Pro Ser Met
 225 230 235 240
 Tyr

519

<210> 563

<211> 200

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (145)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 563

Leu Gly Ser Ile Gln Val Met Gln Ala Val Arg Asn Ala Gly Ser Arg
 1 5 10 15

Phe Leu Arg Ser Trp Thr Trp Pro Gln Thr Ala Gly Arg Val Val Ala
 20 25 30

Arg Thr Pro Ala Gly Thr Ile Cys Thr Gly Ala Arg Gln Leu Gln Asp
 35 40 45

Ala Ala Ala Lys Gln Lys Val Glu Gln Asn Ala Ala Pro Ser His Thr
 50 55 60

Lys Phe Ser Ile Tyr Pro Pro Ile Pro Gly Glu Glu Ser Ser Leu Arg
 65 70 75 80

Trp Ala Gly Lys Lys Phe Glu Glu Ile Pro Ile Ala His Ile Lys Ala
 85 90 95

Ser His Asn Asn Thr Gln Ile Gln Val Val Ser Ala Ser Asn Glu Pro
 100 105 110

Leu Ala Phe Ala Ser Cys Gly Thr Glu Gly Phe Arg Asn Ala Lys Lys
 115 120 125

Gly Thr Gly Ile Ala Ala Gln Thr Ala Gly Ile Ala Ala Ala Arg
 130 135 140

Xaa Lys Gln Lys Gly Val Ile His Ile Arg Val Val Val Lys Gly Leu
 145 150 155 160

Gly Pro Gly Arg Leu Ser Ala Met His Gly Leu Ile Met Gly Gly Leu
 165 170 175

Glu Val Ile Ser Ile Thr Asp Asn Thr Pro Ile Pro His Asn Gly Cys
 180 185 190

Arg Pro Arg Lys Ala Arg Lys Leu
 195 200

520

<210> 564

<211> 115

<212> PRT

<213> Homo sapiens

<400> 564

Val Arg Leu Val Pro Gly Ala Asp Lys Tyr Asn Asp Asp Ile Arg Lys
1 5 10 15

Gly Ile Val Leu Leu Glu Glu Leu Leu Pro Lys Gly Ser Lys Glu Glu
20 25 30

Gln Arg Asp Tyr Val Phe Tyr Leu Ala Val Gly Asn Tyr Arg Leu Lys
35 40 45

Glu Tyr Glu Lys Ala Leu Lys Tyr Val Arg Gly Leu Leu Gln Thr Glu
50 55 60

Pro Gln Asn Asn Gln Ala Lys Glu Leu Glu Arg Leu Ile Asp Lys Ala
65 70 75 80

Met Lys Lys Asp Gly Leu Val Gly Met Ala Ile Val Gly Gly Met Ala
85 90 95

Leu Gly Val Ala Gly Leu Ala Gly Leu Ile Gly Leu Ala Val Ser Lys
100 105 110

Ser Lys Ser
115

<210> 565

<211> 101

<212> PRT

<213> Homo sapiens

<400> 565

Pro Thr Arg Pro Asp Glu His Asp Glu Asn Asn Ala Glu Ala Ser Ala
1 5 10 15

Glu Leu Ser Asn Glu Gly Val Met Asn His Arg Ser Glu Glu Glu Arg
20 25 30

Val Thr Glu Thr Gln Lys Asn Glu Arg Val Lys Lys Gln Leu Gln Ala
35 40 45

Leu Ser Ser Glu Leu Ala Gln Ala Arg Asp Glu Thr Lys Lys Thr Gln

521

50 55 60
Asn Asp Val Leu His Ala Glu Asn Val Lys Ala Gly Arg Asp Lys Tyr
65 70 75 80
Lys Thr Leu Arg Gln Ile Arg Gln Gly Asn Thr Lys Gln Arg Ile Asp
85 90 95
Glu Phe Glu Ala Met
100

<210> 566
<211> 25
<212> PRT
<213> Homo sapiens

<400> 566
Thr Ala Asp Leu Val Ile Arg Pro Pro Arg Pro Leu Lys Val Leu Gly
1 5 10 15
Phe Cys Val Phe Cys Ala Pro Pro Leu
20 25

<210> 567
<211> 274
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (182)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (216)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (222)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (224)
<223> Xaa equals any of the naturally occurring L-amino acids

523

Cys Pro Val Gly Gly Pro Leu Xaa Phe Pro Gly Arg Gly Xaa Gly Xaa
 210 215 220
 Gly Val Gly Xaa Thr Leu Xaa Pro Leu Pro Pro Pro Lys Met Pro Pro
 225 230 235 240
 Pro Thr Ile Leu Ser Thr Val Pro Arg Gln Met Phe Ser Asp Ala Gly
 245 250 255
 Ser Gly Asp Asp Ala Leu Asp Gly Asp Asp Asp Leu Val Ile Asp Ile
 260 265 270
 Pro Glu

<210> 568

<211> 133

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (47)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 568

Ala Arg Gly Asp His Val Arg Ser Arg Glu Thr Gly Arg Gln Ser Ala
 1 5 10 15
 Ser Lys Gly Gln Ile Pro Leu Leu Pro Arg Gly Pro Ala Val Pro Gly
 20 25 30
 Gly Pro Ser Ala Gln Thr Ala Ala Gln Arg Glu Leu Arg Gly Xaa Val
 35 40 45
 Gly Ala Gly Ala Pro Val Tyr Leu Ala Ala Val Leu Glu Tyr Leu Thr
 50 55 60
 Ala Glu Ile Leu Glu Leu Ala Gly Asn Ala Ala Arg Asp Asn Lys Lys
 65 70 75 80
 Thr Arg Ile Ile Pro Arg His Leu Gln Leu Ala Ile Arg Asn Asp Glu
 85 90 95
 Glu Leu Asn Lys Leu Leu Gly Lys Val Thr Ile Ala Gln Gly Gly Val
 100 105 110
 Leu Pro Asn Ile Gln Ala Val Leu Leu Pro Lys Lys Thr Glu Ser Gln
 115 120 125

524

Lys Thr Lys Ser Lys
130

<210> 569

<211> 153

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (136)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (137)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (152)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 569

Met Cys Arg Gly Tyr Ala Trp Asn Pro Gly Ile Thr Leu Gln Asn Arg
1 5 10 15

Lys Thr Lys Glu Gly Pro Arg Ala Pro Pro Ser Arg Met Pro Glu Pro
20 25 30

Ala Gly Gly Leu Arg Gly Cys Glu Ala Val Gly Thr Leu Leu Met Lys
35 40 45

Glu Thr Val Phe Ala Leu His Pro Ser Leu Pro Leu Gly Ala Gly Ser
50 55 60

Ser Pro Ser Ala Thr Cys Ser Glu Gly Leu His Leu Arg Gly Glu Gly
65 70 75 80

Trp Gly Lys Ser Pro Pro Val Pro Phe Leu Trp Pro Cys Cys Pro His
85 90 95

Thr Gln Leu Arg Gly Pro Thr Leu Gly Lys Ala Gly Ser Ala Arg Ser
100 105 110

Leu Ser Pro Ile Ser Ala Leu Ser Ala Trp Ile Pro Ala Glu Ala Met
115 120 125

525

Lys Gly Asn Lys Glu Lys Arg Xaa Xaa Lys Lys Lys Lys Lys Lys Lys
 130 135 140

Lys Lys Lys Lys Lys Lys Lys Xaa Pro
 145 150

<210> 570

<211> 327

<212> PRT

<213> Homo sapiens

<400> 570

Pro Gly Ser Pro Arg Arg Cys Asp Ile Ile Ile Ile Ser Gly Arg Lys
 1 5 10 15

Glu Lys Cys Glu Ala Ala Lys Glu Ala Leu Glu Ala Leu Val Pro Val
 20 25 30

Thr Ile Glu Val Glu Val Pro Phe Asp Leu His Arg Tyr Val Ile Gly
 35 40 45

Gln Lys Gly Ser Gly Ile Arg Lys Met Met Asp Glu Phe Glu Val Asn
 50 55 60

Ile His Val Pro Ala Pro Glu Leu Gln Ser Asp Ile Ile Ala Ile Thr
 65 70 75 80

Gly Leu Ala Ala Asn Leu Asp Arg Ala Lys Ala Gly Leu Leu Glu Arg
 85 90 95

Val Lys Glu Leu Gln Ala Glu Gln Glu Asp Arg Ala Leu Arg Ser Phe
 100 105 110

Lys Leu Ser Val Thr Val Asp Pro Lys Tyr His Pro Lys Ile Ile Gly
 115 120 125

Arg Lys Gly Ala Val Ile Thr Gln Ile Arg Leu Glu His Asp Val Asn
 130 135 140

Ile Gln Phe Pro Asp Lys Asp Asp Gly Asn Gln Pro Gln Asp Gln Ile
 145 150 155 160

Thr Ile Thr Gly Tyr Glu Lys Asn Thr Glu Ala Ala Arg Asp Ala Ile
 165 170 175

Leu Arg Ile Val Gly Glu Leu Glu Gln Met Val Ser Glu Asp Val Pro
 180 185 190

Leu Asp His Arg Val His Ala Arg Ile Ile Gly Ala Arg Gly Lys Ala

526

195	200	205
Ile Arg Lys Ile Met Asp Glu Phe Lys Val Asp Ile Arg Phe Pro Gln		
210	215	220
Ser Gly Ala Pro Asp Pro Asn Cys Val Thr Val Thr Gly Leu Pro Glu		
225	230	235 240
Asn Val Glu Glu Ala Ile Asp His Ile Leu Asn Leu Glu Glu Glu Tyr		
	245	250 255
Leu Ala Asp Val Val Asp Ser Glu Ala Leu Gln Val Tyr Met Lys Pro		
	260	265 270
Pro Ala His Glu Glu Ala Lys Ala Pro Ser Arg Gly Phe Val Val Arg		
	275	280 285
Asp Ala Pro Trp Thr Ala Ser Ser Ser Glu Lys Ala Pro Asp Met Ser		
	290	295 300
Ser Ser Glu Glu Phe Pro Ser Phe Gly Ala Gln Val Ala Pro Lys Thr		
305	310	315 320
Leu Pro Trp Gly Pro Lys Arg		
	325	

<210> 571

<211> 166

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (9)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (12)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 571

Gly Asn Ser Arg Val Asp Pro Arg Xaa Arg Gly Xaa Ala His Thr Cys
1 5 10 15

Ala Pro Cys Pro Ala Pro Gly Pro Leu Ala Gly Arg Ala Val Ser Gly
20 25 30

His Gly Ser Leu Pro Pro Asp Arg Ala Pro Ser Ala Leu Ser Ser

527

35	40	45
Pro Ala Asp Glu Gly Glu Arg Arg Arg Pro Asp Leu Asp Glu Ile His		
50	55	60
Arg Glu Leu Arg Pro Gln Gly Ser Ala Arg Pro Gln Pro Asp Pro Asn		
65	70	75 80
Ala Glu Phe Asp Pro Asp Leu Pro Gly Gly Gly Leu His Arg Cys Leu		
85	90	95
Ala Cys Ala Arg Tyr Phe Ile Asp Ser Thr Asn Leu Lys Thr His Phe		
100	105	110
Arg Ser Lys Asp His Lys Lys Arg Leu Lys Gln Leu Ser Val Glu Pro		
115	120	125
Tyr Ser Gln Glu Glu Ala Glu Arg Ala Ala Gly Met Gly Ser Tyr Val		
130	135	140
Pro Pro Arg Arg Leu Ala Val Pro Thr Glu Val Ser Thr Glu Val Pro		
145	150	155 160
Glu Met Asp Thr Ser Thr		
165		

<210> 572

<211> 113

<212> PRT

<213> Homo sapiens

<400> 572

Gln Ser Ser Thr Phe His Pro Ala Pro Ala Phe Gly Ala Thr Val Ala		
1	5	10 15
Ala Phe His Arg Arg Ala Ala Leu Arg Ala Pro Glu Pro Ala Met Ser		
20	25	30
Gly Pro Asn Gly Asp Leu Gly Met Pro Val Glu Ala Gly Ala Glu Gly		
35	40	45
Glu Glu Asp Gly Phe Gly Glu Ala Glu Tyr Ala Ala Ile Asn Ser Met		
50	55	60
Leu Asp Gln Ile Asn Ser Cys Leu Asp His Leu Glu Glu Lys Asn Asp		
65	70	75 80
His Leu His Ala Arg Leu Gln Glu Leu Leu Glu Ser Asn Arg Gln Thr		
85	90	95

528

Arg Leu Glu Phe Gln Gln Gln Leu Gly Glu Ala Pro Ser Asp Ala Ser
 100 105 110

Pro

<210> 573

<211> 99

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (27)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (37)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (38)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 573

Gly Ser Gly Ser Ser Arg Asp Leu His Lys Ala Leu Trp Glu Ala Gly
 1 5 10 15

Trp Glu Thr Val Glu Gly Gly Cys Pro Leu Xaa Pro Arg Arg His Arg
 20 25 30

Ile Trp Ala Leu Xaa Xaa Ala Phe Leu Pro Glu Tyr Ala Ala Ile Asn
 35 40 45

Ser Met Leu Asp Gln Ile Asn Ser Cys Leu Asp His Leu Glu Glu Lys
 50 55 60

Asn Asp His Leu His Ala Arg Leu Gln Glu Leu Leu Glu Ser Asn Arg
 65 70 75 80

Gln Thr Arg Leu Glu Phe Gln Gln Gln Leu Gly Glu Ala Pro Ser Asp
 85 90 95

Ala Ser Pro

<210> 574
 <211> 197
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (97)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (124)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (129)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 574
 Arg Trp Ala Arg Val Glu Ala Ala Val Met Glu Gly Ala Gly Ala Gly
 1 5 10 15
 Ser Gly Phe Arg Lys Glu Leu Val Ser Arg Leu Leu His Leu His Phe
 20 25 30
 Lys Asp Asp Lys Thr Lys Val Ser Gly Asp Ala Leu Gln Leu Met Val
 35 40 45
 Glu Leu Leu Lys Val Phe Val Val Glu Ala Ala Val Arg Gly Val Arg
 50 55 60
 Gln Ala Gln Ala Glu Asp Ala Leu Arg Val Asp Val Asp Gln Leu Glu
 65 70 75 80
 Lys Val Leu Arg Ser Cys Ser Gly Leu Leu Gly Ile Ser Ala Val Ala
 85 90 95
 Xaa Ala Thr Pro Arg Gly Ala Pro Gly Pro Gln Lys Gln Ala Leu Cys
 100 105 110
 Phe Gln Arg Pro Leu Ile Arg Gly Arg Glu Gly Xaa Glu Gly Phe Gly
 115 120 125
 Xaa Asp Ser Asn Lys Ile Ser Gly Ser Leu Gln Pro Val Gln Lys Gly
 130 135 140
 Gln Asp Cys Ser Ala Leu Arg Ala Leu Glu Cys Pro Val Gly Thr Leu

530

145 150 155 160
 Val Trp Glu Gly Ala Ala Pro Gly Glu Ser Leu Pro Leu Leu Pro Gly
 165 170 175
 Thr Ile Val Cys Met Pro Pro Gly Val Leu Gln Ala Gly Ala Gly Lys
 180 185 190
 Gly Leu Ala Ser Arg
 195

<210> 575
 <211> 47
 <212> PRT
 <213> Homo sapiens

<400> 575
 Leu Pro Met Val Asp Leu Met Glu Lys Leu Asn Ile Phe His Tyr Ala
 1 5 10 15
 Leu Gln Asn Thr Val Tyr Val Ser Ala Ser Leu Gly Asn Gly Arg Gly
 20 25 30
 Gln Lys Lys Val Thr Phe Asn Leu Cys Ile Phe Ala Lys Pro Tyr
 35 40 45

<210> 576
 <211> 115
 <212> PRT
 <213> Homo sapiens

<400> 576
 Trp Ser Arg Thr Ser Gln Pro Leu Pro Ser Thr Val Gly Cys Pro Arg
 1 5 10 15
 Arg Arg Gly Phe Lys Asp Phe Gln Arg Arg Ile Leu Val Ala Thr Asn
 20 25 30
 Leu Phe Gly Arg Gly Met Asp Ile Glu Arg Val Asn Ile Ala Phe Asn
 35 40 45
 Tyr Asp Met Pro Glu Asp Ser Asp Thr Tyr Leu His Arg Val Ala Arg
 50 55 60
 Ala Gly Arg Phe Gly Thr Lys Gly Leu Ala Ile Thr Phe Val Ser Asp
 65 70 75 80

531

Glu Asn Asp Ala Lys Ile Leu Asn Asp Val Gln Asp Arg Phe Glu Val
 85 90 95

Asn Ile Ser Glu Leu Pro Asp Glu Ile Asp Ile Ser Ser Tyr Ile Glu
 100 105 110

Gln Thr Arg
 115

<210> 577

<211> 346

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (37)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 577

Val Thr Ser Cys Val Ala Leu Leu Pro Ala Arg Arg Met Thr Tyr Thr
 1 5 10 15

Thr Glu Thr Ala Leu Leu Asn Trp Ser Thr Cys Gln Met Val Leu Arg
 20 25 30

Gly Ala Glu Thr Xaa Gly Cys Val Ile Val Ser Ala Ala Lys Ala Gln
 35 40 45

Leu Leu Gln Cys Gln His His Pro Ala Trp Tyr Gly Asp Thr Leu Lys
 50 55 60

Gln Lys Thr Ser Trp Thr Cys Leu Leu Asp Gly Met Gln Tyr Phe Ala
 65 70 75 80

Thr Thr Glu Ser Ser Pro Thr Glu Gln Asp Gly Arg Gln Leu Trp Leu
 85 90 95

Glu Val Lys Asn Ile Glu Glu His Arg Gln Arg Ser Leu Asp Ser Val
 100 105 110

Gln Glu Leu Met Glu Ser Gly Gln Ala Val Gly Gly Met Val Thr Thr
 115 120 125

Thr Thr Asp Trp Asn Gln Pro Ala Glu Ala Gln Gln Ala Gln Gln Val
 130 135 140

Gln Arg Ile Ile Ser Arg Cys Asn Cys Arg Met Tyr Tyr Ile Ser Tyr
 145 150 155 160

Asn Ala Pro Pro Ala Phe Glu Ser Phe Leu Leu Phe Glu Gly Glu Lys
20 25 30

533

Ile Thr Ile Asn Lys Asp Thr Lys Val Pro Asn Ala Cys Leu Phe Thr
35 40 45

Ile Asn Lys Glu Asp His Thr Leu Gly Asn Ile Ile Lys Ser Arg Ala
50 55 60

Cys Phe Pro Phe Ala Phe Cys Arg Asp Cys Gln Phe Pro Glu Ala Ser
65 70 75 80

Pro Ala Thr Leu Pro Val Gln Pro Ala Glu Leu
85 90

<210> 579

<211> 331

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (18)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (20)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (300)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (311)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (313)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (320)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (325)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 579

Gly Arg Pro Thr Arg Pro Gly Gly Leu Gly Ser Gly Val Leu Ala Leu
 1 5 10 15

Ala Xaa Gly Xaa Pro Ala Arg Leu Ala Gly Thr Val His Glu Val Gly
 20 25 30

Asp Ala Pro Arg Arg Ala Pro Asp Gln Ala Ala Glu Ile Gly Ser Arg
 35 40 45

Gly Ser Thr Lys Ala Gln Gly Pro Gln Gln Gln Pro Gly Ser Glu Gly
 50 55 60

Pro Ser Tyr Ala Lys Lys Val Ala Leu Trp Leu Ala Gly Leu Leu Gly
 65 70 75 80

Ala Gly Gly Thr Val Ser Val Val Tyr Ile Phe Gly Asn Asn Pro Val
 85 90 95

Asp Glu Asn Gly Ala Lys Ile Pro Asp Glu Phe Asp Asn Asp Pro Ile
 100 105 110

Leu Val Gln Gln Leu Arg Arg Thr Tyr Lys Tyr Phe Lys Asp Tyr Arg
 115 120 125

Gln Met Ile Ile Glu Pro Thr Ser Pro Cys Leu Leu Pro Asp Pro Leu
 130 135 140

Gln Glu Pro Tyr Tyr Gln Pro Pro Tyr Thr Leu Val Leu Glu Leu Thr
 145 150 155 160

Gly Val Leu Leu His Pro Glu Trp Ser Leu Ala Thr Gly Trp Arg Phe
 165 170 175

Lys Lys Arg Pro Gly Ile Glu Thr Leu Phe Gln Gln Leu Ala Pro Leu
 180 185 190

Tyr Glu Ile Val Ile Phe Thr Ser Glu Thr Gly Met Thr Ala Phe Pro
 195 200 205

Leu Ile Asp Ser Val Asp Pro His Gly Phe Ile Ser Tyr Arg Leu Phe
 210 215 220

Arg Asp Ala Thr Arg Tyr Met Asp Gly His His Val Lys Asp Ile Ser
 225 230 235 240

Cys Leu Asn Arg Asp Pro Ala Arg Val Val Val Val Asp Cys Lys Lys
 245 250 255

535

Glu Ala Phe Arg Leu Gln Pro Tyr Asn Gly Val Ala Leu Arg Pro Trp
260 265 270

Asp Gly Asn Ser Asp Asp Arg Val Leu Leu Asp Leu Ser Ala Phe Leu
275 280 285

Lys Thr Ile Ala Leu Asn Gly Val Gly Gly Arg Xaa Glu Pro Cys Trp
290 295 300

Glu His Tyr Ala Leu Gly Xaa Asp Xaa Pro Arg Trp Ala Ala Phe Xaa
305 310 315 320

Asn Ser Gly Lys Xaa Gly Leu Glu Ala Gly Arg
325 330

<210> 580

<211> 374

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (235)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (285)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (307)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (319)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (324)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (341)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (359)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 580

Pro Ser Thr Val Arg Asn Ser Arg Val Asp Pro Arg Val Arg Pro Arg
1 5 10 15

Val Arg Ala Gly Val Ala Ala Leu Ala Thr Val Gly Val Ala Ser Gly
20 25 30

Pro Gly Pro Gly Arg Pro Gly Pro Leu Gln Asp Glu Thr Leu Gly Val
35 40 45

Ala Ser Val Pro Ser Gln Trp Arg Ala Val Gln Gly Ile Arg Gly Glu
50 55 60

Thr Lys Ser Cys Gln Thr Ala Ser Ile Ala Thr Ala Ser Ala Ser Ala
65 70 75 80

Gln Ala Arg Asn His Val Asp Ala Gln Val Gln Thr Glu Ala Pro Val
85 90 95

Pro Val Ser Val Gln Pro Pro Ser Gln Tyr Asp Ile Pro Arg Leu Ala
100 105 110

Ala Phe Leu Arg Arg Val Glu Ala Met Val Ile Arg Glu Leu Asn Lys
115 120 125

Asn Trp Gln Ser His Ala Phe Asp Gly Phe Glu Val Asn Trp Thr Glu
130 135 140

Gln Gln Gln Met Val Ser Cys Leu Tyr Thr Leu Gly Tyr Pro Pro Ala
145 150 155 160

Gln Ala Gln Gly Leu His Val Thr Ser Ile Ser Trp Asn Ser Thr Gly
165 170 175

Ser Val Val Ala Cys Ala Tyr Gly Arg Leu Asp His Gly Asp Trp Ser
180 185 190

Thr Leu Lys Ser Phe Val Cys Ala Trp Asn Leu Asp Arg Arg Asp Leu
195 200 205

Arg Pro Gln Gln Pro Ser Ala Val Val Glu Val Pro Ser Ala Val Leu
210 215 220

Cys Leu Ala Phe His Pro Thr Gln Pro Ser Xaa Val Ala Gly Gly Leu

537

225 230 235 240
 Tyr Ser Gly Glu Val Leu Val Trp Asp Leu Ser Arg Leu Glu Asp Pro
 245 250 255
 Leu Leu Trp Arg Thr Gly Leu Thr Asp Asp Thr His Thr Asp Pro Val
 260 265 270
 Ser Gln Val Val Trp Leu Pro Glu Pro Gly His Ser Xaa Arg Phe Gln
 275 280 285
 Val Leu Ser Val Ala Thr Asp Gly Lys Val Leu Leu Trp Gln Gly Ile
 290 295 300
 Gly Val Xaa Gln Leu Gln Phe Thr Glu Gly Phe Ala Trp Phe Xaa Gln
 305 310 315 320
 Gln Leu Pro Xaa Ser Thr Lys Leu Lys Lys His Pro Arg Gly Arg Pro
 325 330 335
 Arg Trp Ala Pro Xaa Gln Ala Phe Phe Gln Phe Asp Leu Arg Phe Ser
 340 345 350
 Phe Trp Gln Glu Ala Val Xaa Val Gln Phe Ser Trp His Trp Arg Ala
 355 360 365
 Ala Leu Arg Gly Ala His
 370

<210> 581

<211> 94

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (80)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (90)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 581

Cys Pro Asp Gln Asn Gly Trp Ala Ser Phe Gly Ala Pro Leu Ser Ala
 1 5 10 15

Gly Gly Gln Pro Cys Tyr Leu Leu Asp Ile Gly Cys Gly Ser Gly Leu

538

20 25 30
 Ser Gly Asp Tyr Leu Ser Asp Glu Gly His Tyr Trp Val Gly Ile Asp
 35 40 45
 Ile Ser Pro Ala Met Leu Asp Ala Ala Leu Asp Arg Asp Thr Glu Gly
 50 55 60
 Asp Leu Leu Leu Gly Asp Met Gly Gln Gly Ile Pro Phe Lys Pro Xaa
 65 70 75 80
 Ser Leu Met Asp Val Ser Ala Phe Cys Xaa Ser Val Ala Leu
 85 90

<210> 582
 <211> 163
 <212> PRT
 <213> Homo sapiens

<400> 582
 Pro Thr Arg Pro Ala Ala Gly Gly Ala Glu Arg Ile Ala Gly Ser Ala
 1 5 10 15
 Met Ser Ser Glu Pro Pro Pro Pro Pro Gln Pro Pro Thr His Gln Ala
 20 25 30
 Ser Val Gly Leu Leu Asp Thr Pro Arg Ser Arg Glu Arg Ser Pro Ser
 35 40 45
 Pro Leu Arg Gly Asn Val Val Pro Ser Pro Leu Pro Thr Arg Arg Thr
 50 55 60
 Arg Thr Phe Ser Ala Thr Val Arg Ala Ser Gln Gly Pro Val Tyr Lys
 65 70 75 80
 Gly Val Cys Lys Cys Phe Cys Arg Ser Lys Gly His Gly Phe Ile Thr
 85 90 95
 Pro Ala Asp Gly Gly Pro Asp Ile Phe Leu His Ile Ser Asp Val Glu
 100 105 110
 Gly Glu Tyr Val Pro Val Glu Gly Asp Glu Val Thr Tyr Lys Met Cys
 115 120 125
 Ser Ile Pro Pro Lys Asn Glu Lys Leu Gln Ala Val Glu Val Val Ile
 130 135 140
 Thr His Leu Ala Pro Gly Thr Lys His Glu Thr Trp Ser Gly His Val
 145 150 155 160

Ile Ser Ser

<210> 583
 <211> 293
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (52)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (53)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (58)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (150)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (171)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (207)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (254)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 583
 Leu Leu Gly Pro Asn Leu Thr Met Gly Ser Gln Pro Gly Arg Ile Pro
 1 5 10 15

Asp Leu Leu Glu Lys Gly Glu Arg Leu Pro Gln Pro Pro Ile Cys Thr

540

20						25						30					
Ile	Asp	Val	Tyr	Met	Ile	Met	Val	Lys	Cys	Trp	Met	Ile	Asp	Ser	Glu		
		35					40						45				
Cys	Arg	Pro	Xaa	Xaa	Arg	Glu	Leu	Val	Xaa	Glu	Phe	Ser	Arg	Met	Ala		
		50					55						60				
Arg	Asp	Pro	Gln	Arg	Phe	Val	Val	Ile	Gln	Asn	Glu	Asp	Leu	Gly	Pro		
					70						75				80		
Ala	Ser	Pro	Leu	Asp	Ser	Thr	Phe	Tyr	Arg	Ser	Leu	Leu	Glu	Asp	Asp		
				85					90					95			
Asp	Met	Gly	Asp	Leu	Val	Asp	Ala	Glu	Glu	Tyr	Leu	Val	Pro	Gln	Gln		
			100					105					110				
Gly	Phe	Phe	Cys	Pro	Asp	Pro	Ala	Pro	Gly	Ala	Gly	Gly	Met	Val	His		
		115					120						125				
His	Arg	His	Arg	Ser	Ser	Ser	Thr	Arg	Ser	Gly	Gly	Gly	Asp	Leu	Thr		
		130					135						140				
Leu	Gly	Leu	Glu	Pro	Xaa	Glu	Arg	Gly	Gly	Pro	Gln	Val	Ser	Thr	Gly		
					150					155					160		
Thr	Leu	Arg	Arg	Ala	Gly	Ser	Asp	Val	Phe	Xaa	Gly	Asp	Leu	Gly	Met		
				165					170					175			
Gly	Ala	Ala	Lys	Gly	Leu	Gln	Ser	Leu	Pro	Thr	His	Asp	Pro	Ser	Pro		
			180					185					190				
Leu	Gln	Arg	Tyr	Ser	Glu	Asp	Pro	Thr	Val	Pro	Leu	Pro	Ser	Xaa	Thr		
		195					200						205				
Asp	Gly	Tyr	Val	Ala	Pro	Leu	Thr	Cys	Ser	Pro	Gln	Pro	Glu	Tyr	Val		
		210					215				220						
Asn	Gln	Pro	Asp	Val	Arg	Pro	Gln	Pro	Pro	Ser	Pro	Arg	Glu	Gly	Pro		
					230					235					240		
Leu	Pro	Ala	Ala	Arg	Pro	Ala	Gly	Ala	Thr	Leu	Glu	Arg	Xaa	Lys	Thr		
				245					250					255			
Leu	Ser	Pro	Gly	Lys	Asn	Gly	Val	Val	Lys	Glu	Phe	Leu	Pro	Leu	Gly		
			260					265					270				
Val	Pro	Trp	Arg	Thr	Pro	Ser	Ile	Asp	Thr	Pro	Gly	Glu	Gly	Ala	Cys		
		275					280						285				
Pro	Ser	Ala	Pro	Pro													

541

290

<210> 584

<211> 132

<212> PRT

<213> Homo sapiens

<400> 584

Gly Gly Ala Gln Pro Gly Met Glu Gly Ala Ala Ala Thr Val His Leu
 1 5 10 15

Ile Ser Gln Trp Ala Val Glu Pro Asn Ala Arg Val Gly Pro Leu Leu
 20 25 30

Glu Val Glu Ala Ala Ala Ala Asp His His Glu Ala Ala Ala Gly Ala
 35 40 45

Gly Ser Ala Val Glu Lys Ile Cys Ile Asp Lys Gly Leu Thr Asp Glu
 50 55 60

Ser Glu Ile Leu Arg Phe Leu Gln His Gly Thr Leu Val Gly Leu Leu
 65 70 75 80

Pro Val Pro His Pro Ile Leu Ile Arg Lys Tyr Gln Ala Asn Ser Gly
 85 90 95

Thr Ala Met Trp Phe Arg Thr Tyr Met Trp Gly Val Ile Tyr Leu Arg
 100 105 110

Asn Val Asp Pro Pro Val Trp Tyr Asp Thr Asp Val Lys Leu Phe Glu
 115 120 125

Ile Gln Arg Val
 130

<210> 585

<211> 218

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (54)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (92)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (117)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (140)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (141)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (188)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (199)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (200)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 585

Arg	Glu	Arg	Cys	Arg	Arg	Glu	Ala	Leu	Arg	Gly	Ser	Arg	Leu	Cys	Pro
1				5					10					15	

Ala	Thr	Pro	Pro	Ser	Ala	Leu	Gly	Ser	Gln	Asp	Gly	Ser	Arg	Thr	Arg
			20					25					30		

Asp	Arg	Leu	Gly	Ala	Ala	Gly	Trp	Pro	Gly	Leu	Val	Val	Gly	Leu	Cys
		35					40					45			

Thr	Pro	Ala	Ala	Gly	Xaa	Gln	Arg	Asp	Leu	Leu	His	Arg	Arg	Gly	Gly
	50					55					60				

Thr	Ala	Ser	Phe	Gly	Lys	Ser	Phe	Ala	Gln	Lys	Ser	Gly	Tyr	Phe	Leu
	65				70					75					80

Cys	Leu	Ser	Ser	Leu	Gly	Ser	Leu	Glu	Asn	Pro	Xaa	Glu	Asn	Val	Val
				85					90					95	

543

Ala Asp Ile Gln Ile Val Val Asp Lys Ser Pro Leu Pro Leu Gly Phe
 100 105 110
 Ser Pro Val Cys Xaa Pro Met Asp Ser Lys Ala Ser Val Ser Lys Lys
 115 120 125
 Lys Arg Met Cys Val Lys Leu Leu Pro Leu Gly Xaa Xaa Asp Thr Ala
 130 135 140
 Val Phe Asp Val Arg Leu Ser Gly Lys Thr Lys Thr Val Pro Gly Tyr
 145 150 155 160
 Leu Arg Ile Gly Asp Met Gly Gly Phe Ala Ile Trp Cys Lys Lys Gly
 165 170 175
 Gln Gly Pro Glu Ala Ser Cys Pro Lys Pro Arg Xaa Pro Gln Pro Gly
 180 185 190
 Thr Cys Lys Gly Phe Ser Xaa Xaa Ala Ala Ser Gln Pro Lys Leu Arg
 195 200 205
 Ala Gly Leu Leu Gly Ser Arg Thr Ser Val
 210 215

<210> 586

<211> 233

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (41)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 586

Ala Arg Gly Glu Met Glu Gly Arg Gln Val Leu Glu Val Lys Met Gln
 1 5 10 15
 Val Glu Tyr Met Ser Phe Ser Ala His Ala Asp Ala Lys Gly Ile Met
 20 25 30
 Gln Leu Val Gly Gln Ala Glu Pro Xaa Ser Val Leu Leu Val His Gly
 35 40 45
 Glu Ala Lys Lys Met Glu Phe Leu Lys Gln Lys Ile Glu Gln Glu Leu
 50 55 60
 Arg Val Asn Cys Tyr Met Pro Ala Asn Gly Glu Thr Val Thr Leu Pro

544

65 70 75 80
 Thr Ser Pro Ser Ile Pro Val Gly Ile Ser Leu Gly Leu Leu Lys Arg
 85 90 95
 Glu Met Ala Gln Gly Leu Leu Pro Glu Ala Lys Lys Pro Arg Leu Leu
 100 105 110
 His Gly Thr Leu Ile Met Lys Asp Ser Asn Phe Arg Leu Val Ser Ser
 115 120 125
 Glu Gln Ala Leu Lys Glu Leu Gly Leu Ala Glu His Gln Leu Arg Phe
 130 135 140
 Thr Cys Arg Val His Leu His Asp Thr Arg Lys Glu Gln Glu Thr Ala
 145 150 155 160
 Leu Arg Val Tyr Ser His Leu Lys Ser Val Leu Lys Asp His Cys Val
 165 170 175
 Gln His Leu Pro Asp Gly Ser Val Thr Val Glu Ser Val Leu Leu Gln
 180 185 190
 Ala Ala Ala Pro Ser Glu Asp Pro Gly Thr Lys Val Leu Leu Val Ser
 195 200 205
 Trp Thr Tyr Gln Asp Glu Glu Leu Gly Ser Phe Leu Thr Ser Leu Leu
 210 215 220
 Lys Lys Gly Leu Pro Gln Ala Pro Ser
 225 230

<210> 587

<211> 116

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (100)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 587

Gly Pro Leu Ser His His Ile Arg Ala Gln Leu Ser Lys Met Leu Leu
 1 5 10 15

Ala Arg Lys Gln Ile Leu Cys Val Asn Val Lys Asn Phe Ala Val Ile
 20 25 30

545

Tyr Leu Val Asp Ile Thr Glu Val Pro Asp Phe Asn Lys Met Tyr Glu
 35 40 45

Leu Tyr Asp Pro Cys Thr Val Met Phe Phe Phe Arg Asn Lys His Ile
 50 55 60

Met Ile Asp Leu Gly Thr Gly Asn Asn Asn Lys Ile Asn Trp Ala Met
 65 70 75 80

Glu Asp Lys Gln Glu Met Val Asp Ile Ile Glu Thr Val Tyr Arg Gly
 85 90 95

Ala Arg Lys Xaa Arg Gly Leu Val Val Ser Pro Lys Asp Tyr Ser Thr
 100 105 110

Lys Tyr Arg Tyr
 115

<210> 588

<211> 133

<212> PRT

<213> Homo sapiens

<400> 588

Ala Arg Ala Ala Val Gly Arg Thr Ala Gly Val Arg Thr Trp Ala Pro
 1 5 10 15

Leu Ala Met Ala Ala Lys Val Asp Leu Ser Thr Ser Thr Asp Trp Lys
 20 25 30

Glu Ala Lys Ser Phe Leu Lys Gly Leu Ser Asp Lys Gln Arg Glu Glu
 35 40 45

His Tyr Phe Cys Lys Asp Phe Val Arg Leu Lys Lys Ile Pro Thr Trp
 50 55 60

Lys Glu Met Ala Lys Gly Val Ala Val Lys Val Glu Glu Pro Arg Tyr
 65 70 75 80

Lys Lys Asp Lys Gln Leu Asn Glu Lys Ile Ser Leu Leu Arg Ser Asp
 85 90 95

Ile Thr Lys Leu Glu Val Asp Ala Ile Val Asn Ala Ala Asn Ser Ser
 100 105 110

Pro Pro Pro Arg Ser Leu Ile Lys Asp Leu Arg Cys Gly Lys Lys Lys
 115 120 125

Lys Lys Lys Lys Lys

546

130

<210> 589

<211> 163

<212> PRT

<213> Homo sapiens

<400> 589

Arg His Arg Gly Gln Pro Leu Arg Gln Thr Arg Ala Ser Ser Ser Pro
 1 5 10 15

Gln Leu Ala Gly Arg Ser Ser Ser Val Leu Pro Ala Ala Ala Gln Pro
 20 25 30

Cys Thr Pro Thr Met Asp Val Phe Lys Lys Gly Phe Ser Ile Ala Lys
 35 40 45

Glu Gly Val Val Gly Ala Val Glu Lys Thr Lys Gln Gly Val Thr Glu
 50 55 60

Ala Ala Glu Lys Thr Lys Glu Gly Val Met Tyr Val Gly Ala Lys Thr
 65 70 75 80

Lys Glu Asn Val Val Gln Ser Val Thr Ser Val Ala Glu Lys Thr Lys
 85 90 95

Glu Gln Ala Asn Ala Val Ser Glu Ala Val Val Ser Ser Val Asn Thr
 100 105 110

Val Ala Thr Lys Thr Val Glu Glu Ala Glu Asn Ile Ala Val Thr Ser
 115 120 125

Gly Val Val Arg Lys Glu Asp Leu Arg Pro Ser Ala Pro Gln Gln Glu
 130 135 140

Gly Glu Ala Ser Lys Glu Lys Glu Glu Val Ala Glu Glu Ala Gln Ser
 145 150 155 160

Gly Gly Asp

<210> 590

<211> 59

<212> PRT

<213> Homo sapiens

<400> 590

547

Arg Ala Leu Leu Cys Leu Gly His His Pro Leu Leu Ala Gln Gly Val
 1 5 10 15

Pro Ala Leu Ser Asp Met Arg Leu Pro Thr Leu Leu Pro Ser Ser Pro
 20 25 30

Trp Pro Pro Leu Ala Cys Pro Pro Val Leu Leu His Gln Pro His Cys
 35 40 45

Pro Pro Ser Ala Pro Pro Thr Leu Trp Ser Phe
 50 55

<210> 591

<211> 116

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (31)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 591

Val His Ala Glu Ala Gly Arg Leu Cys His Gly Asp Cys Pro Arg Leu
 1 5 10 15

Cys Arg Pro Arg Gln Arg Ser Ala Pro Val Gln Val Tyr Thr Xaa Arg
 20 25 30

Gln Ala Ala Leu His Gly Arg Pro Gln Arg Asp Pro Cys Val Gly Gly
 35 40 45

Pro Arg Pro Leu Arg Cys Ser Arg Asp Cys Gly Gly Gly His Gln Arg
 50 55 60

Leu Val Met Pro Gly Thr Trp Thr Gln Ala Trp Gln Arg Arg Gln Val
 65 70 75 80

Val Asn Gly Leu Met Leu Gly Gln Ala Arg Ile His Val Asn Arg Leu
 85 90 95

Glu Gln Ala Val Val Asn Leu Ala Pro Cys Glu Tyr Phe His Thr Cys
 100 105 110

Cys Pro Phe Ala
 115

548

<210> 592
<211> 290
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (30)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (239)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 592
Arg Arg Ser Leu Asn Thr His Gly Ser Gly Val Ser Val Cys Leu Gln
1 5 10 15
Ser Leu Thr Leu Leu Ala Thr Leu Cys Pro Gly Asp Gln Xaa Ser Leu
20 25 30
Gly Leu Leu Thr Pro Cys Tyr Ser Gly Ser Glu Pro Ser Gly Thr Phe
35 40 45
Gly Pro Val Asn Pro Ser Leu Asn Asn Thr Tyr Glu Phe Met Ser Thr
50 55 60
Phe Phe Leu Glu Val Ser Ser Val Phe Pro Asp Phe Tyr Leu His Leu
65 70 75 80
Gly Gly Asp Glu Val Asp Phe Thr Cys Trp Lys Ser Asn Pro Glu Ile
85 90 95
Gln Asp Phe Met Arg Lys Lys Gly Phe Gly Glu Asp Phe Lys Gln Leu
100 105 110
Glu Ser Phe Tyr Ile Gln Thr Leu Leu Asp Ile Val Ser Ser Tyr Gly
115 120 125
Lys Gly Tyr Val Val Trp Gln Glu Val Phe Asp Asn Lys Val Lys Ile
130 135 140
Gln Pro Asp Thr Ile Ile Gln Val Trp Arg Glu Asp Ile Pro Val Asn
145 150 155 160
Tyr Met Lys Glu Leu Glu Leu Val Thr Lys Ala Gly Phe Arg Ala Leu
165 170 175
Leu Ser Ala Pro Trp Tyr Leu Asn Arg Ile Ser Tyr Gly Pro Asp Trp
180 185 190

549

Lys Asp Phe Tyr Val Val Glu Pro Leu Ala Phe Glu Gly Thr Pro Glu
 195 200 205

Gln Lys Ala Leu Val Ile Gly Gly Glu Ala Cys Met Trp Gly Glu Tyr
 210 215 220

Val Asp Asn Thr Asn Leu Val Pro Arg Leu Trp Pro Arg Ala Xaa Ala
 225 230 235 240

Val Ala Glu Arg Leu Trp Ser Asn Lys Leu Thr Ser Asp Leu Thr Phe
 245 250 255

Ala Tyr Glu Arg Leu Ser His Phe Arg Cys Glu Leu Leu Arg Arg Gly
 260 265 270

Val Gln Ala Gln Pro Leu Asn Val Gly Phe Cys Glu Gln Glu Phe Glu
 275 280 285

Gln Thr
 290

<210> 593

<211> 665

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (8)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 593

Asp Ala Asp Gly Arg Met Asp Xaa Leu Val Ser Glu Cys Ser Ala Arg
 1 5 10 15

Leu Leu Gln Gln Glu Glu Glu Ile Lys Ser Leu Thr Ala Glu Ile Asp
 20 25 30

Arg Leu Lys Asn Cys Gly Cys Leu Gly Ala Ser Pro Asn Leu Glu Gln
 35 40 45

Leu Gln Glu Glu Asn Leu Lys Leu Lys Tyr Arg Leu Asn Ile Leu Arg
 50 55 60

Lys Ser Leu Gln Ala Glu Arg Asn Lys Pro Thr Lys Asn Met Ile Asn
 65 70 75 80

Ile Ile Ser Arg Leu Gln Glu Val Phe Gly His Ala Ile Lys Ala Ala

550

85					90					95					
Tyr	Pro	Asp	Leu	Glu	Asn	Pro	Pro	Leu	Leu	Val	Thr	Pro	Ser	Gln	Gln
			100					105					110		
Ala	Lys	Phe	Gly	Asp	Tyr	Gln	Cys	Asn	Ser	Ala	Met	Gly	Ile	Ser	Gln
			115				120					125			
Met	Leu	Lys	Thr	Lys	Glu	Gln	Lys	Val	Asn	Pro	Arg	Glu	Ile	Ala	Glu
			130				135					140			
Asn	Ile	Thr	Lys	His	Leu	Pro	Asp	Asn	Glu	Cys	Ile	Glu	Lys	Val	Glu
			145				150					155			160
Ile	Ala	Gly	Pro	Gly	Phe	Ile	Asn	Val	His	Leu	Arg	Lys	Asp	Phe	Val
				165				170						175	
Ser	Glu	Gln	Leu	Thr	Ser	Leu	Leu	Val	Asn	Gly	Val	Gln	Leu	Pro	Ala
			180					185					190		
Leu	Gly	Glu	Asn	Lys	Lys	Val	Ile	Val	Asp	Phe	Ser	Ser	Pro	Asn	Ile
			195				200						205		
Ala	Lys	Glu	Met	His	Val	Gly	His	Leu	Arg	Ser	Thr	Ile	Ile	Gly	Glu
			210				215					220			
Ser	Ile	Ser	Arg	Leu	Phe	Glu	Phe	Ala	Gly	Tyr	Asp	Val	Leu	Arg	Leu
			225				230					235			240
Asn	His	Val	Gly	Asp	Trp	Gly	Thr	Gln	Phe	Gly	Met	Leu	Ile	Ala	His
				245				250					255		
Leu	Gln	Asp	Lys	Phe	Pro	Asp	Tyr	Leu	Thr	Val	Ser	Pro	Pro	Ile	Gly
			260					265					270		
Asp	Leu	Gln	Val	Phe	Tyr	Lys	Glu	Ser	Lys	Lys	Arg	Phe	Asp	Thr	Glu
			275				280					285			
Glu	Glu	Phe	Lys	Lys	Arg	Ala	Tyr	Gln	Cys	Val	Val	Leu	Leu	Gln	Gly
			290				295					300			
Lys	Asn	Pro	Asp	Ile	Thr	Lys	Ala	Trp	Lys	Leu	Ile	Cys	Asp	Val	Ser
			305				310					315			320
Arg	Gln	Glu	Leu	Asn	Lys	Ile	Tyr	Asp	Ala	Leu	Asp	Val	Ser	Leu	Ile
				325				330					335		
Glu	Arg	Gly	Glu	Ser	Phe	Tyr	Gln	Asp	Arg	Met	Asn	Asp	Ile	Val	Lys
			340				345						350		
Glu	Phe	Glu	Asp	Arg	Gly	Phe	Val	Gln	Val	Asp	Asp	Gly	Arg	Lys	Ile

355	360	365
Val Phe Val Pro Gly Cys Ser Ile Pro Leu Thr Ile Val Lys Ser Asp		
370	375	380
Gly Gly Tyr Thr Tyr Asp Thr Ser Asp Leu Ala Ala Ile Lys Gln Arg		
385	390	395 400
Leu Phe Glu Glu Lys Ala Asp Met Ile Ile Tyr Val Val Asp Asn Gly		
	405	410 415
Gln Ser Val His Phe Gln Thr Ile Phe Ala Ala Ala Gln Met Ile Gly		
	420	425 430
Trp Tyr Asp Pro Lys Val Thr Arg Val Phe His Ala Gly Phe Gly Val		
	435	440 445
Val Leu Gly Glu Asp Lys Lys Lys Phe Lys Thr Arg Ser Gly Glu Thr		
	450	455 460
Val Arg Leu Met Asp Leu Leu Gly Glu Gly Leu Lys Arg Ser Met Asp		
	465	470 475 480
Lys Leu Lys Glu Lys Glu Arg Asp Lys Val Leu Thr Ala Glu Glu Leu		
	485	490 495
Asn Ala Ala Gln Thr Ser Val Ala Tyr Gly Cys Ile Lys Tyr Ala Asp		
	500	505 510
Leu Ser His Asn Arg Leu Asn Asp Tyr Ile Phe Ser Phe Asp Lys Met		
	515	520 525
Leu Asp Asp Arg Gly Asn Thr Ala Ala Tyr Leu Leu Tyr Ala Phe Thr		
	530	535 540
Arg Ile Arg Ser Ile Ala Arg Leu Ala Asn Ile Asp Glu Glu Met Leu		
	545	550 555 560
Gln Lys Ala Ala Arg Glu Thr Lys Ile Leu Leu Asp His Glu Lys Glu		
	565	570 575
Trp Lys Leu Gly Arg Cys Ile Leu Arg Phe Pro Glu Ile Leu Gln Lys		
	580	585 590
Ile Leu Asp Asp Leu Phe Leu His Thr Leu Cys Asp Tyr Ile Tyr Glu		
	595	600 605
Leu Ala Thr Ala Phe Thr Glu Phe Tyr Asp Ser Cys Tyr Cys Val Glu		
	610	615 620
Lys Asp Arg Gln Thr Gly Lys Ile Leu Lys Val Asn Met Trp Arg Met		

552

625 630 635 640

Leu Leu Cys Glu Ala Val Ala Ala Val Met Ala Lys Gly Phe Asp Ile
 645 650 655

Leu Gly Ile Lys Pro Val Gln Arg Met
 660 665

<210> 594
 <211> 116
 <212> PRT
 <213> Homo sapiens

<400> 594
 Thr Val Thr Glu Thr Thr Val Thr Val Thr Thr Glu Pro Glu Asn Arg
 1 5 10 15

Ser Leu Thr Ile Lys Leu Arg Lys Arg Lys Pro Glu Lys Lys Val Glu
 20 25 30

Trp Thr Ser Asp Thr Val Asp Asn Glu His Met Gly Arg Arg Ser Ser
 35 40 45

Lys Cys Cys Cys Ile Tyr Glu Lys Pro Arg Ala Phe Gly Glu Ser Ser
 50 55 60

Thr Glu Ser Asp Glu Glu Glu Glu Gly Cys Gly His Thr His Cys
 65 70 75 80

Val Arg Gly His Arg Lys Gly Arg Arg Arg Ala Thr Leu Gly Pro Thr
 85 90 95

Pro Thr Thr Pro Pro Gln Pro Pro Asp Pro Ser Gln Pro Pro Pro Gly
 100 105 110

Pro Met Gln His
 115

<210> 595
 <211> 294
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (269)
 <223> Xaa equals any of the naturally occurring L-amino acids

553

<220>

<221> SITE

<222> (278)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 595

Thr	Gln	Leu	Arg	Val	Ser	Glu	Arg	Glu	Gly	Pro	Gly	Asp	Pro	Gln	Arg
1				5					10					15	

Phe	Ser	Asp	His	Thr	Leu	Arg	Thr	Pro	Arg	Leu	Glu	Asp	Arg	Pro	Gly
			20					25					30		

Asp	Ala	Met	Trp	Gly	Glu	Gly	Leu	Arg	Ala	Trp	Cys	Arg	Phe	Val	Glu
		35					40					45			

Asn	Arg	Trp	Cys	Leu	Lys	Arg	Val	Ser	Ala	Pro	Leu	His	Leu	Gly	Leu
	50					55						60			

Leu	Gly	Cys	Pro	Asp	Ala	Glu	Ala	His	Phe	Pro	Ala	Met	Leu	Thr	Leu
65						70				75					80

Pro	Leu	Ser	Pro	Pro	Ser	Arg	Lys	Met	Ala	Thr	Asn	Phe	Leu	Ala	His
				85					90					95	

Glu	Lys	Ile	Trp	Phe	Asp	Lys	Phe	Lys	Tyr	Asp	Asp	Ala	Glu	Arg	Arg
		100						105					110		

Phe	Tyr	Glu	Gln	Met	Asn	Gly	Pro	Val	Ala	Gly	Ala	Ser	Arg	Gln	Glu
	115						120					125			

Asn	Gly	Ala	Ser	Val	Ile	Leu	Arg	Asp	Ile	Ala	Arg	Ala	Arg	Glu	Asn
	130					135					140				

Ile	Gln	Lys	Ser	Leu	Ala	Gly	Ser	Ser	Gly	Pro	Gly	Ala	Ser	Ser	Gly
145					150					155					160

Thr	Ser	Gly	Asp	His	Gly	Glu	Leu	Val	Val	Arg	Ile	Ala	Ser	Leu	Glu
			165						170					175	

Val	Glu	Asn	Gln	Ser	Leu	Arg	Gly	Val	Val	Gln	Glu	Leu	Gln	Gln	Ala
		180						185					190		

Ile	Ser	Lys	Leu	Glu	Ala	Arg	Leu	Asn	Val	Leu	Glu	Lys	Ser	Ser	Pro
	195						200					205			

Gly	His	Arg	Ala	Thr	Ala	Pro	Gln	Thr	Gln	His	Val	Ser	Pro	Met	Arg
	210					215					220				

Gln	Val	Glu	Pro	Pro	Ala	Lys	Lys	Pro	Ala	Thr	Pro	Ala	Glu	Asp	Asp
225					230					235				240	


```
<210> 596
<211> 134
<212> PRT
<213> Homo sapiens
```

<400> 596

[illegible]

<210> 597

555

<211> 91

<212> PRT

<213> Homo sapiens

<400> 597

Glu Gly Pro Glu Gly Ala Asn Leu Phe Ile Tyr His Leu Pro Gln Glu
1 5 10 15

Phe Gly Asp Gln Asp Ile Leu Gln Met Phe Met Pro Phe Gly Asn Val
20 25 30

Ile Ser Ala Lys Val Phe Ile Asp Lys Gln Thr Asn Leu Ser Lys Cys
35 40 45

Phe Gly Phe Val Ser Tyr Asp Asn Pro Val Ser Ala Gln Ala Ala Ile
50 55 60

Gln Ala Met Asn Gly Phe Gln Ile Gly Met Lys Arg Leu Lys Val Gln
65 70 75 80

Leu Lys Arg Ser Lys Asn Asp Ser Lys Pro Tyr
85 90

<210> 598

<211> 68

<212> PRT

<213> Homo sapiens

<400> 598

Arg Pro Thr Arg Pro Glu Lys Val Gly Ser Gly Gly Ser Ser Val Gly
1 5 10 15

Ser Gly Asp Ala Ser Ser Ser Arg His His His Arg Arg Arg Arg Phe
20 25 30

His Leu Pro Gln Gln Pro Leu Leu Gln Arg Glu Val Trp Cys Val Gly
35 40 45

Thr Thr Gly Asn Ala Asn Gln Ala Gln Ser Ser Thr Glu Gln Thr Leu
50 55 60

Leu Lys Pro Lys
65

<210> 599

<211> 119

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (58)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (68)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (88)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (98)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (99)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 599

Phe	Gly	Arg	Asp	Gln	Val	Tyr	Leu	Ser	Tyr	Asn	Asn	Val	Ser	Ser	Leu
1				5					10					15	

Lys	Met	Leu	Val	Ala	Lys	Asp	Asn	Trp	Val	Leu	Ser	Ser	Glu	Ile	Ser
			20				25						30		

Gln	Val	Arg	Leu	Tyr	Thr	Leu	Glu	Asp	Asp	Lys	Phe	Leu	Ser	Phe	His
		35					40					45			

Met	Glu	Met	Val	Val	His	Val	Asp	Ala	Xaa	Gln	Ala	Phe	Leu	Leu	Leu
	50						55					60			

Ser	Asp	Leu	Xaa	Gln	Arg	Pro	Glu	Trp	Asp	Lys	His	Tyr	Arg	Ser	Val
65					70					75					80

Glu	Leu	Val	Gln	Gln	Val	Asp	Xaa	Gly	Arg	Arg	His	Leu	Pro	Arg	His
			85						90					95	

Gln	Xaa	Xaa	Pro	Arg	Arg	Ser	His	Lys	Ala	Pro	Gly	Leu	Arg	Asp	Pro
			100						105					110	

Gly	Leu	Glu	Ala	Glu	Ala	Leu
						115

<210> 600
 <211> 177
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (1)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (8)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (69)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (135)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 600
 Xaa Glu Arg Leu Arg Ala Gln Xaa Glu Lys Ser Arg Asp Ser Gln Pro
 1 5 10 15
 Arg Leu Pro Leu Arg Phe Pro Ser Trp Arg Gly Pro Trp Cys Gly Ile
 20 25 30
 Glu Ile Ala Gly Tyr Gly Ala Glu Val Phe Arg Gln Tyr Trp Asp Ile
 35 40 45
 Pro Asp Gly Thr Asp Cys His Arg Lys Ala Tyr Ser Thr Thr Ser Ile
 50 55 60
 Ala Ser Val Ala Xaa Leu Thr Ala Ala Ala Tyr Arg Val Thr Leu Asn
 65 70 75 80
 Pro Pro Gly Thr Phe Leu Glu Gly Val Ala Lys Val Gly Gln Tyr Thr
 85 90 95
 Phe Thr Ala Ala Ala Val Gly Ala Val Phe Gly Leu Thr Thr Cys Ile
 100 105 110
 Ser Ala His Val Arg Glu Lys Pro Asp Asp Pro Leu Asn Tyr Phe Leu

558

115 120 125
 Gly Gly Cys Ala Gly Gly Xaa Thr Leu Gly Ala Arg Thr His Asn Tyr
 130 135 140
 Gly Ile Gly Ala Ala Ala Cys Val Tyr Phe Gly Ile Ala Ala Ser Leu
 145 150 155 160
 Val Lys Met Gly Arg Leu Glu Gly Trp Glu Val Phe Ala Lys Pro Lys
 165 170 175
 Val

<210> 601
 <211> 218
 <212> PRT
 <213> Homo sapiens

<400> 601
 Arg Gly Gly Gly Gly Gly Ala Ser Ser Cys Cys Cys Cys Ala Pro Ser
 1 5 10 15
 Pro Arg Gly Arg Pro Val Pro Ala Arg Thr Pro Arg Arg Cys Pro Arg
 20 25 30
 Pro Ser Pro Gly Pro Ala Met Gly Leu Thr Val Ser Ala Leu Phe Ser
 35 40 45
 Arg Ile Phe Gly Lys Lys Gln Met Arg Ile Leu Met Val Gly Leu Asp
 50 55 60
 Ala Ala Gly Lys Thr Thr Ile Leu Tyr Lys Leu Lys Leu Gly Glu Ile
 65 70 75 80
 Val Thr Thr Ile Pro Thr Ile Gly Phe Asn Val Glu Thr Val Glu Tyr
 85 90 95
 Lys Asn Ile Cys Phe Thr Val Trp Asp Val Gly Gly Gln Asp Lys Ile
 100 105 110
 Arg Pro Leu Trp Arg His Tyr Phe Gln Asn Thr Gln Gly Leu Ile Phe
 115 120 125
 Val Val Asp Ser Asn Asp Arg Glu Arg Val Gln Glu Ser Ala Asp Glu
 130 135 140
 Leu Gln Lys Met Leu Gln Glu Asp Glu Leu Arg Asp Ala Val Leu Leu
 145 150 155 160

559

Val Phe Ala Asn Lys Gln Asp Met Pro Asn Ala Met Pro Val Ser Glu
 165 170 175

Leu Thr Asp Lys Leu Gly Leu Gln His Leu Arg Ser Arg Thr Trp Tyr
 180 185 190

Val Gln Ala Thr Cys Ala Thr Gln Gly Thr Gly Leu Tyr Asp Gly Leu
 195 200 205

Asp Trp Leu Ser His Glu Leu Ser Lys Arg
 210 215

<210> 602

<211> 829

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (32)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (454)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 602

Pro Gly Gln Ala Gly Ala Glu Gly His Val Arg Cys Cys Pro Gly Glu
 1 5 10 15

Glu Gln Lys Ala Gly Gly Glu Arg Arg Cys Pro Gly Pro Gln Arg Xaa
 20 25 30

Gly Ala Ala Leu Gly Pro Gly Pro Gly Glu Ala Arg Leu Asp Tyr Ser
 35 40 45

Glu Phe Phe Thr Glu Asp Val Gly Gln Leu Pro Gly Leu Thr Ile Trp
 50 55 60

Gln Ile Glu Asn Phe Val Pro Val Leu Val Glu Glu Ala Phe His Gly
 65 70 75 80

Lys Phe Tyr Glu Ala Asp Cys Tyr Ile Val Leu Lys Thr Phe Leu Asp
 85 90 95

Asp Ser Gly Ser Leu Asn Trp Glu Ile Tyr Tyr Trp Ile Gly Gly Glu
 100 105 110

560

Ala Thr Leu Asp Lys Lys Ala Cys Ser Ala Ile His Ala Val Asn Leu		
115	120	125
Arg Asn Tyr Leu Gly Ala Glu Cys Arg Thr Val Arg Glu Glu Met Gly		
130	135	140
Asp Glu Ser Glu Glu Phe Leu Gln Val Phe Asp Asn Asp Ile Ser Tyr		
145	150	155 160
Ile Glu Gly Gly Thr Ala Ser Gly Phe Tyr Thr Val Glu Asp Thr His		
165	170	175
Tyr Val Thr Arg Met Tyr Arg Val Tyr Gly Lys Lys Asn Ile Lys Leu		
180	185	190
Glu Pro Val Pro Leu Lys Gly Thr Ser Leu Asp Pro Arg Phe Val Phe		
195	200	205
Leu Leu Asp Arg Gly Leu Asp Ile Tyr Val Trp Arg Gly Ala Gln Ala		
210	215	220
Thr Leu Ser Ser Thr Thr Lys Ala Arg Leu Phe Ala Glu Lys Ile Asn		
225	230	235 240
Lys Asn Glu Arg Lys Gly Lys Ala Glu Ile Thr Leu Leu Val Gln Gly		
245	250	255
Gln Glu Leu Pro Glu Phe Trp Glu Ala Leu Gly Gly Glu Pro Ser Glu		
260	265	270
Ile Lys Lys His Val Pro Glu Asp Phe Trp Pro Pro Gln Pro Lys Leu		
275	280	285
Tyr Lys Val Gly Leu Gly Leu Gly Tyr Leu Glu Leu Pro Gln Ile Asn		
290	295	300
Tyr Lys Leu Ser Val Glu His Lys Gln Arg Pro Lys Val Glu Leu Met		
305	310	315 320
Pro Arg Met Arg Leu Leu Gln Ser Leu Leu Asp Thr Arg Cys Val Asn		
325	330	335
Ile Leu Asp Cys Trp Ser Asp Val Phe Ile Trp Leu Gly Arg Lys Ser		
340	345	350
Pro Arg Leu Val Arg Ala Ala Ala Leu Lys Leu Gly Gln Glu Leu Cys		
355	360	365
Gly Met Leu His Arg Pro Arg His Ala Thr Val Ser Arg Ser Leu Glu		
370	375	380

561

Gly Thr Glu Ala Gln Val Phe Lys Ala Lys Phe Lys Asn Trp Asp Asp
 385 390 395 400
 Val Leu Thr Val Asp Tyr Thr Arg Asn Ala Glu Ala Val Leu Gln Ser
 405 410 415
 Pro Gly Leu Ser Gly Lys Val Lys Arg Asp Ala Glu Lys Lys Asp Gln
 420 425 430
 Met Lys Ala Asp Leu Thr Ala Leu Phe Leu Pro Arg Gln Pro Pro Met
 435 440 445
 Ser Leu Ala Glu Ala Xaa Gln Leu Met Glu Glu Trp Asn Glu Asp Leu
 450 455 460
 Asp Gly Met Glu Gly Phe Val Leu Glu Gly Lys Lys Phe Ala Arg Leu
 465 470 475 480
 Pro Glu Glu Glu Phe Gly His Phe Tyr Thr Gln Asp Cys Tyr Val Phe
 485 490 495
 Leu Cys Arg Tyr Trp Val Pro Val Glu Tyr Glu Glu Glu Glu Lys Lys
 500 505 510
 Glu Asp Lys Glu Glu Lys Ala Glu Gly Lys Glu Gly Glu Glu Ala Thr
 515 520 525
 Ala Glu Ala Glu Glu Lys Gln Pro Glu Glu Asp Phe Gln Cys Ile Val
 530 535 540
 Tyr Phe Trp Gln Gly Arg Glu Ala Ser Asn Met Gly Trp Leu Thr Phe
 545 550 555 560
 Thr Phe Ser Leu Gln Lys Lys Phe Glu Ser Leu Phe Pro Gly Lys Leu
 565 570 575
 Glu Val Val Arg Met Thr Gln Gln Gln Glu Asn Pro Lys Phe Leu Ser
 580 585 590
 His Phe Lys Arg Lys Phe Ile Ile His Arg Gly Lys Arg Lys Ala Val
 595 600 605
 Gln Gly Ala Gln Gln Pro Ser Leu Tyr Gln Ile Arg Thr Asn Gly Ser
 610 615 620
 Ala Leu Cys Thr Arg Cys Ile Gln Ile Asn Thr Asp Ser Ser Leu Leu
 625 630 635 640
 Asn Ser Glu Phe Cys Phe Ile Leu Lys Val Pro Phe Glu Ser Glu Asp
 645 650 655

562

Asn Gln Gly Ile Val Tyr Ala Trp Val Gly Arg Ala Ser Asp Pro Asp
660 665 670

Glu Ala Lys Leu Ala Glu Asp Ile Leu Asn Thr Met Phe Asp Thr Ser
675 680 685

Tyr Ser Lys Gln Val Ile Asn Glu Gly Glu Glu Pro Glu Asn Phe Phe
690 695 700

Trp Val Gly Ile Gly Ala Gln Lys Pro Tyr Asp Asp Asp Ala Glu Tyr
705 710 715 720

Met Lys His Thr Arg Leu Phe Arg Cys Ser Asn Glu Lys Gly Tyr Phe
725 730 735

Ala Val Thr Glu Lys Cys Ser Asp Phe Cys Gln Asp Asp Leu Ala Asp
740 745 750

Asp Asp Ile Met Leu Leu Asp Asn Gly Gln Glu Val Tyr Met Trp Val
755 760 765

Gly Thr Gln Thr Ser Gln Val Glu Ile Lys Leu Ser Leu Lys Ala Cys
770 775 780

Gln Val Tyr Ile Gln His Met Arg Ser Lys Glu His Glu Arg Pro Arg
785 790 795 800

Arg Leu Arg Leu Val Arg Lys Gly Asn Glu Gln His Ala Phe Thr Arg
805 810 815

Cys Phe His Ala Trp Ser Ala Phe Cys Lys Ala Leu Ala
820 825

<210> 603

<211> 221

<212> PRT

<213> Homo sapiens

<400> 603

Thr Glu Pro Pro Leu Ser Cys Cys Leu Pro Ala Thr Tyr Pro Ala Asp
1 5 10 15

Met Gly Thr Ala Gly Ala Met Gln Leu Cys Trp Val Ile Leu Gly Phe
20 25 30

Leu Leu Phe Arg Gly His Asn Ser Gln Pro Thr Met Thr Gln Thr Ser
35 40 45

563

Ser Ser Gln Gly Gly Leu Gly Gly Leu Ser Leu Thr Thr Glu Pro Val
 50 55 60
 Ser Ser Asn Pro Gly Tyr Ile Pro Ser Ser Glu Ala Asn Arg Pro Ser
 65 70 75 80
 His Leu Ser Ser Thr Gly Thr Pro Gly Ala Gly Val Pro Ser Ser Gly
 85 90 95
 Arg Asp Gly Gly Thr Ser Arg Asp Thr Phe Gln Thr Val Pro Pro Asn
 100 105 110
 Ser Thr Thr Met Ser Leu Ser Met Arg Glu Asp Ala Thr Ile Leu Pro
 115 120 125
 Ser Pro Thr Ser Glu Thr Val Leu Thr Val Ala Ala Phe Gly Val Ile
 130 135 140
 Ser Phe Ile Val Ile Leu Val Val Val Val Ile Ile Leu Val Gly Val
 145 150 155 160
 Val Ser Leu Arg Phe Lys Cys Arg Lys Ser Lys Glu Ser Glu Asp Pro
 165 170 175
 Gln Lys Pro Gly Ser Ser Gly Leu Ser Glu Ser Cys Ser Thr Ala Asn
 180 185 190
 Gly Glu Lys Asp Ser Ile Thr Leu Ile Ser Met Lys Asn Ile Asn Met
 195 200 205
 Asn Asn Gly Lys Gln Ser Leu Ser Ala Glu Lys Val Leu
 210 215 220

<210> 604

<211> 97

<212> PRT

<213> Homo sapiens

<400> 604

Ser Cys Gly Leu Ser Leu Ile Lys Met Thr Thr Ser Gln Lys His Arg
 1 5 10 15
 Asp Phe Val Ala Glu Pro Met Gly Glu Lys Pro Val Gly Ser Leu Ala
 20 25 30
 Gly Ile Gly Glu Val Leu Gly Lys Lys Leu Glu Glu Arg Gly Phe Asp
 35 40 45
 Lys Ala Tyr Val Val Leu Gly Gln Phe Leu Val Leu Lys Lys Asp Glu

564

50 55 60
 Asp Leu Phe Arg Glu Trp Leu Lys Asp Thr Cys Gly Ala Asn Ala Lys
 65 70 75 80
 Gln Ser Arg Asp Cys Phe Gly Cys Leu Arg Glu Trp Cys Asp Ala Phe
 85 90 95

Leu

<210> 605

<211> 266

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (84)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 605

Gly Pro Arg Arg Leu Gly Ala Leu His Ala Ala Ala Thr Gly Ala Arg
 1 5 10 15

Cys Leu Val Glu Leu Leu Val Ala His Gly Ala Asp Leu Asn Ala Lys
 20 25 30

Ser Leu Met Asp Glu Thr Pro Leu Asp Val Cys Gly Asp Glu Glu Val
 35 40 45

Arg Ala Lys Leu Leu Glu Leu Lys His Lys His Asp Ala Leu Leu Arg
 50 55 60

Ala Gln Ser Arg Gln Arg Ser Leu Leu Arg Arg Arg Thr Ser Ser Ala
 65 70 75 80

Gly Ser Arg Xaa Lys Val Val Arg Arg Val Ser Leu Thr Gln Arg Thr
 85 90 95

Asp Leu Tyr Arg Lys Gln His Ala Gln Glu Ala Ile Val Trp Gln Gln
 100 105 110

Pro Pro Pro Thr Ser Pro Glu Pro Pro Glu Asp Asn Asp Asp Arg Gln
 115 120 125

Thr Gly Ala Glu Leu Arg Pro Pro Pro Glu Glu Asp Asn Pro Glu
 130 135 140

565

Val Val Arg Pro His Asn Gly Arg Val Gly Gly Ser Pro Val Arg His
 145 150 155 160
 Leu Tyr Ser Lys Arg Leu Asp Arg Ser Val Ser Tyr Gln Leu Ser Pro
 165 170 175
 Leu Asp Ser Thr Thr Pro His Thr Leu Val His Asp Lys Ala His His
 180 185 190
 Thr Leu Ala Asp Leu Lys Arg Gln Arg Ala Ala Ala Lys Leu Gln Arg
 195 200 205
 Pro Pro Pro Glu Gly Pro Glu Ser Pro Glu Thr Ala Glu Pro Gly Leu
 210 215 220
 Pro Gly Asp Thr Val Thr Pro Gln Pro Asp Cys Gly Phe Arg Ala Gly
 225 230 235 240
 Gly Asp Pro Pro Leu Leu Lys Leu Thr Ala Pro Ala Val Glu Ala Pro
 245 250 255
 Val Glu Arg Arg Pro Cys Cys Leu Leu Met
 260 265

<210> 606

<211> 331

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (91)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (285)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 606

His Asp Ser Cys Phe Val Glu Met Gln Ala Gln Lys Val Met His Val
 1 5 10 15

Ser Ser Ala Glu Leu Asn Tyr Ser Leu Pro Tyr Asp Ser Lys His Gln
 20 25 30

Ile Arg Asn Ala Ser Asn Val Lys His His Asp Ser Ser Ala Leu Gly
 35 40 45

566

Val	Tyr	Ser	Tyr	Ile	Pro	Leu	Val	Glu	Asn	Pro	Tyr	Phe	Ser	Ser	Trp	50	55	60	
Pro	Pro	Ser	Gly	Thr	Ser	Ser	Lys	Met	Ser	Leu	Asp	Leu	Pro	Glu	Lys	65	70	75	80
Gln	Asp	Gly	Thr	Val	Phe	Pro	Ser	Ser	Leu	Xaa	Pro	Thr	Ser	Ser	Thr	85	90	95	
Ser	Leu	Phe	Ser	Tyr	Tyr	Asn	Ser	His	Asp	Ser	Leu	Ser	Leu	Asn	Ser	100	105	110	
Pro	Thr	Asn	Ile	Ser	Ser	Leu	Leu	Asn	Gln	Glu	Ser	Ala	Val	Leu	Ala	115	120	125	
Thr	Ala	Pro	Arg	Ile	Asp	Asp	Glu	Ile	Pro	Pro	Pro	Leu	Pro	Val	Arg	130	135	140	
Thr	Pro	Glu	Ser	Phe	Ile	Val	Val	Glu	Glu	Ala	Gly	Glu	Phe	Ser	Pro	145	150	155	160
Asn	Val	Pro	Lys	Ser	Leu	Ser	Ser	Ala	Val	Lys	Val	Lys	Ile	Gly	Thr	165	170	175	
Ser	Leu	Glu	Trp	Gly	Gly	Thr	Ser	Glu	Pro	Lys	Lys	Phe	Asp	Asp	Ser	180	185	190	
Val	Ile	Leu	Arg	Pro	Ser	Lys	Ser	Val	Lys	Leu	Arg	Ser	Pro	Lys	Ser	195	200	205	
Glu	Leu	His	Gln	Asp	Arg	Ser	Ser	Pro	Pro	Pro	Pro	Leu	Pro	Glu	Arg	210	215	220	
Thr	Leu	Glu	Ser	Phe	Phe	Leu	Ala	Asp	Glu	Asp	Cys	Met	Gln	Ala	Gln	225	230	235	240
Ser	Ile	Glu	Thr	Tyr	Ser	Thr	Ser	Tyr	Pro	Asp	Thr	Met	Glu	Asn	Ser	245	250	255	
Thr	Ser	Ser	Lys	Gln	Thr	Leu	Lys	Thr	Pro	Gly	Lys	Ser	Phe	Thr	Arg	260	265	270	
Ser	Lys	Ser	Leu	Lys	Ile	Leu	Arg	Asn	Met	Lys	Lys	Xaa	Ile	Cys	Asn	275	280	285	
Ser	Cys	Pro	Pro	Asn	Lys	Pro	Ala	Glu	Ser	Val	Gln	Ser	Asn	Asn	Ser	290	295	300	
Ser	Ser	Phe	Leu	Asn	Phe	Gly	Phe	Ala	Asn	Arg	Phe	Ser	Lys	Pro	Lys	305	310	315	320

567

Gly Pro Arg Asn Pro Pro Pro Thr Trp Asn Ile
 325 330

<210> 607

<211> 192

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (78)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 607

Ala Ala Pro Ser Glu Pro Lys Ala Arg Gly Gly His Gly Gly Ala Leu
 1 5 10 15

Ala Arg Leu Glu Thr Met Pro Lys Leu Gln Gly Phe Glu Phe Trp Ser
 20 25 30

Arg Thr Leu Arg Gly Ala Arg His Val Val Ala Pro Met Val Asp Gln
 35 40 45

Ser Glu Leu Ala Trp Arg Leu Leu Ser Arg Arg His Gly Ala Gln Leu
 50 55 60

Cys Tyr Thr Pro Met Leu His Ala Gln Val Phe Val Arg Xaa Ala Asn
 65 70 75 80

Tyr Arg Lys Glu Asn Leu Tyr Cys Glu Val Cys Pro Glu Asp Arg Pro
 85 90 95

Leu Ile Val Gln Phe Cys Ala Asn Asp Pro Glu Val Phe Val Gln Ala
 100 105 110

Ala Leu Leu Ala Gln Asp Tyr Cys Asp Ala Ile Asp Leu Asn Leu Gly
 115 120 125

Cys Pro Gln Met Ile Ala Lys Arg Gly His Tyr Gly Ala Phe Leu Gln
 130 135 140

Asp Glu Trp Asp Leu Leu Gln Arg Met Ile Leu Leu Ala His Glu Lys
 145 150 155 160

Leu Ser Val Pro Val Thr Cys Lys Ile Arg Val Phe Pro Glu Ile Asp
 165 170 175

Lys Thr Val Ser Thr Pro Arg Cys Trp Arg Arg Pro Ala Ala Ser Cys
 180 185 190

568

<210> 608

<211> 415

<212> PRT

<213> Homo sapiens

<400> 608

```

His Ile Lys Cys Pro His Ser Lys Tyr Gly Cys Thr Phe Ile Gly Asn
 1             5             10             15

Gln Asp Thr Tyr Glu Thr His Leu Glu Thr Cys Arg Phe Glu Gly Leu
      20             25             30

Lys Glu Phe Leu Gln Gln Thr Asp Asp Arg Phe His Glu Met His Val
      35             40             45

Ala Leu Ala Gln Lys Asp Gln Glu Ile Ala Phe Leu Arg Ser Met Leu
      50             55             60

Gly Lys Leu Ser Glu Lys Ile Asp Gln Leu Glu Lys Ser Leu Glu Leu
      65             70             75             80

Lys Phe Asp Val Leu Asp Glu Asn Gln Ser Lys Leu Ser Glu Asp Leu
      85             90             95

Met Glu Phe Arg Arg Asp Ala Ser Met Leu Asn Asp Glu Leu Ser His
      100            105            110

Ile Asn Ala Arg Leu Asn Met Gly Ile Leu Gly Ser Tyr Asp Pro Gln
      115            120            125

Gln Ile Phe Lys Cys Lys Gly Thr Phe Val Gly His Gln Gly Pro Val
      130            135            140

Trp Cys Leu Cys Val Tyr Ser Met Gly Asp Leu Leu Phe Ser Gly Ser
      145            150            155            160

Ser Asp Lys Thr Ile Lys Val Trp Asp Thr Cys Thr Thr Tyr Lys Cys
      165            170            175

Gln Lys Thr Leu Glu Gly His Asp Gly Ile Val Leu Ala Leu Cys Ile
      180            185            190

Gln Gly Cys Lys Leu Tyr Ser Gly Ser Ala Asp Cys Thr Ile Ile Val
      195            200            205

```

569

Trp Asp Ile Gln Asn Leu Gln Lys Val Asn Thr Ile Arg Ala His Asp
 210 215 220
 Asn Pro Val Cys Thr Leu Val Ser Ser His Asn Val Leu Phe Ser Gly
 225 230 235 240
 Ser Leu Lys Ala Ile Lys Val Trp Asp Ile Val Gly Thr Glu Leu Lys
 245 250 255
 Leu Lys Lys Glu Leu Thr Gly Leu Asn His Trp Val Arg Ala Leu Val
 260 265 270
 Ala Ala Gln Ser Tyr Leu Tyr Ser Gly Ser Tyr Gln Thr Ile Lys Ile
 275 280 285
 Trp Asp Ile Arg Thr Leu Asp Cys Ile His Val Leu Gln Thr Ser Gly
 290 295 300
 Gly Ser Val Tyr Ser Ile Ala Val Thr Asn His His Ile Val Cys Gly
 305 310 315 320
 Thr Tyr Glu Asn Leu Ile His Val Trp Asp Ile Glu Ser Lys Glu Gln
 325 330 335
 Val Arg Thr Leu Thr Gly His Val Gly Thr Val Tyr Ala Leu Ala Val
 340 345 350
 Ile Ser Thr Pro Asp Gln Thr Lys Val Phe Ser Ala Ser Tyr Asp Arg
 355 360 365
 Ser Leu Arg Val Trp Ser Met Asp Asn Met Ile Cys Thr Gln Thr Leu
 370 375 380
 Leu Arg His Gln Gly Ser Val Thr Ala Leu Ala Val Ser Arg Gly Arg
 385 390 395 400
 Leu Phe Ser Gly Ala Val Asp Ser Thr Val Lys Val Trp Thr Cys
 405 410 415

<210> 609

<211> 48

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (27)

<223> Xaa equals any of the naturally occurring L-amino acids

570

<220>

<221> SITE

<222> (34)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 609

Phe	Ser	Glu	Leu	Asn	Gln	Cys	Phe	Tyr	Ile	Cys	Phe	Phe	Phe	Tyr	Ala
1				5					10					15	

Ser	Trp	Lys	Trp	Arg	Met	Lys	Ile	Gln	Leu	Xaa	Cys	Ser	Asn	Ser	Arg
			20					25					30		

Arg	Xaa	Val	Ser	Thr	Glu	Lys	Gly	Thr	Cys	Phe	Phe	Thr	Pro	Glu	Leu
		35					40					45			

<210> 610

<211> 241

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (1)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (3)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (7)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (13)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (37)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 610

571

Xaa Asp Xaa Gly Arg Pro Xaa Arg Thr Ala Glu Ser Xaa Phe Gly Ile
 1 5 10 15
 Asn Leu Lys Gly Pro Lys Ile Lys Gly Gly Ala Asp Val Ser Gly Gly
 20 25 30
 Val Ser Ala Pro Xaa Ile Ser Leu Gly Glu Gly His Leu Ser Val Lys
 35 40 45
 Gly Ser Gly Gly Glu Trp Lys Gly Pro Gln Val Ser Ser Ala Leu Asn
 50 55 60
 Leu Asp Thr Ser Lys Phe Ala Gly Gly Leu His Phe Ser Gly Pro Lys
 65 70 75 80
 Val Glu Gly Gly Val Lys Gly Gly Gln Ile Gly Leu Gln Ala Pro Gly
 85 90 95
 Leu Ser Val Ser Gly Pro Gln Gly His Leu Glu Ser Gly Ser Gly Lys
 100 105 110
 Val Thr Phe Pro Lys Met Lys Ile Pro Lys Phe Thr Phe Ser Gly Arg
 115 120 125
 Glu Leu Val Gly Arg Glu Met Gly Val Asp Val His Phe Pro Lys Ala
 130 135 140
 Glu Ala Ser Ile Gln Ala Gly Ala Gly Asp Gly Glu Trp Glu Glu Ser
 145 150 155 160
 Glu Val Lys Leu Lys Lys Ser Lys Ile Lys Met Pro Lys Phe Asn Phe
 165 170 175
 Ser Lys Pro Lys Gly Lys Gly Gly Val Thr Gly Ser Pro Glu Ala Ser
 180 185 190
 Ile Ser Gly Ser Lys Gly Asp Leu Lys Ser Ser Lys Ala Ser Leu Gly
 195 200 205
 Ser Leu Glu Gly Glu Ala Glu Ala Glu Ala Ser Ser Pro Lys Gly Lys
 210 215 220
 Phe Ser Leu Phe Lys Ser Lys Lys Pro Arg His Arg Cys Lys Phe Ile
 225 230 235 240
 Gln

<210> 611

572

<211> 77

<212> PRT

<213> Homo sapiens

<400> 611

His Tyr Arg Arg Tyr Ala Cys Arg Tyr Arg Ser Gly Ile Pro Gly Ser
 1 5 10 15
 Thr His Ala Ser Gly Val Ala Asp Gly Gly Gln Val Phe Leu Phe Pro
 20 25 30
 Glu Thr Gly Ser Val Gln Thr Ala Asn Ala His Arg Trp Pro Arg Gly
 35 40 45
 Gly Gly Ser Gln Gly Val Trp Val Phe Leu Gly Phe Phe Ser Val Val
 50 55 60
 Ser Phe Thr Gln Gly Trp Trp Ser Gln Pro Val Trp Cys
 65 70 75

<210> 612

<211> 137

<212> PRT

<213> Homo sapiens

<400> 612

Leu Gln Val Pro Val Arg Asn Ser Gly Ser Pro Thr Arg Gln Ala Ala
 1 5 10 15
 Ala Met Thr Phe Cys Arg Leu Leu Asn Arg Cys Gly Glu Ala Ala Arg
 20 25 30
 Ser Leu Pro Leu Gly Ala Arg Cys Phe Gly Val Arg Val Ser Pro Thr
 35 40 45
 Gly Glu Lys Val Thr His Thr Gly Gln Val Tyr Asp Asp Lys Asp Tyr
 50 55 60
 Arg Arg Ile Arg Phe Val Gly Arg Gln Lys Glu Val Asn Glu Asn Phe
 65 70 75 80
 Ala Ile Asp Leu Ile Ala Glu Gln Pro Val Ser Glu Val Glu Thr Arg
 85 90 95
 Val Ile Ala Cys Asp Gly Gly Gly Gly Ala Leu Gly His Pro Lys Val
 100 105 110
 Tyr Ile Asn Leu Asp Lys Glu Thr Lys Thr Gly Thr Cys Gly Tyr Cys
 115 120 125

Gly Leu Gln Phe Arg Gln His His His
130 135

<210> 613
<211> 122
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (50)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (75)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (80)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (85)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (98)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (105)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (111)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (116)
<223> Xaa equals any of the naturally occurring L-amino acids

574

<400> 613

Tyr Ser Thr Asp Asn Asn Asn Asn Trp Tyr Ser Ile Phe Tyr Leu His
 1 5 10 15
 Ser Ser Phe Leu Gly Glu Asn Ala Glu Lys Leu Leu Gln Phe Lys Arg
 20 25 30
 Trp Phe Trp Ser Ile Val Glu Lys Met Ser Met Thr Glu Arg Gln Asp
 35 40 45
 Leu Xaa Tyr Phe Trp Thr Ser Ser Pro Ser Leu Pro Ala Ser Glu Glu
 50 55 60
 Gly Phe Gln Pro Met Pro Ser Ile Thr Ile Xaa Pro Pro Asp Asp Xaa
 65 70 75 80
 His Leu Pro Thr Xaa Lys Tyr Leu His Phe Leu Asp Phe Thr Phe Pro
 85 90 95
 Leu Xaa Ser Phe Lys Gln Asp Ser Xaa Asn Arg Lys Leu Val Xaa Ser
 100 105 110
 Pro Phe Arg Xaa Gln Lys Phe Trp Val Leu
 115 120

<210> 614

<211> 62

<212> PRT

<213> Homo sapiens

<400> 614

Phe Phe Ile Gly Leu Glu Thr Arg Ala Asn Ser Ile Met Phe Ser Lys
 1 5 10 15
 Glu Thr Asp Leu Ser Cys Trp Ile Arg Gly Thr Asn Pro Thr Tyr Met
 20 25 30
 Ile Phe Phe Leu Phe Leu Ser Cys Ser Tyr Gly Thr Val Leu Phe Gly
 35 40 45
 Thr Phe Ala Thr Arg Asp Asn Thr Thr Phe Leu Thr Leu Ile
 50 55 60

<210> 615

<211> 159

<212> PRT

<213> Homo sapiens

575

<400> 615

Val Gly Leu Pro Asn Met Ala Gln Ser Ile Asn Ile Thr Glu Leu Asn
 1 5 10 15

Leu Pro Gln Leu Glu Met Leu Lys Asn Gln Leu Asp Gln Glu Val Glu
 20 25 30

Phe Leu Ser Thr Ser Ile Ala Gln Leu Lys Val Val Gln Thr Lys Tyr
 35 40 45

Val Glu Ala Lys Asp Cys Leu Asn Val Leu Asn Lys Ser Asn Glu Gly
 50 55 60

Lys Glu Leu Leu Val Pro Leu Thr Ser Ser Met Tyr Val Pro Gly Lys
 65 70 75 80

Leu His Asp Val Glu His Val Leu Ile Asp Val Gly Thr Gly Tyr Tyr
 85 90 95

Val Glu Lys Thr Ala Glu Asp Ala Lys Asp Phe Phe Lys Arg Lys Ile
 100 105 110

Asp Phe Leu Thr Lys Gln Met Glu Lys Ile Gln Pro Ala Leu Gln Glu
 115 120 125

Lys His Ala Met Lys Gln Ala Val Met Glu Met Met Ser Gln Lys Ile
 130 135 140

Gln Gln Leu Thr Ala Leu Gly Ala Ala Gln Ala Thr Ala Lys Ala
 145 150 155

<210> 616

<211> 93

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (8)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 616

Lys Val Ala Cys Arg Tyr Arg Xaa Gly Ile Pro Gly Arg Pro Thr Arg
 1 5 10 15

Pro Gly Thr Gln Asp Ala Glu Gly Lys Lys Ala Lys Gly Lys Lys Val
 20 25 30

576

Ala Pro Ala Pro Ala Val Val Lys Lys Gln Glu Ala Lys Lys Val Val
 35 40 45

Asn Pro Leu Phe Glu Lys Arg Pro Lys Asn Phe Gly Ile Gly Gln Asp
 50 55 60

Ile Gln Pro Lys Arg Asp Leu Thr Arg Phe Val Lys Trp Pro Arg Tyr
 65 70 75 80

Ile Arg Leu Gln Arg His Ala Arg Ser Ser Thr Ser Gly
 85 90

<210> 617

<211> 362

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (307)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 617

Ser Arg Val Asp Pro Arg Val Arg Arg Gly Val Pro Tyr Gln Leu Gly
 1 5 10 15

Pro His Gly His Arg Gln Gly Leu Glu Ala Pro Leu Tyr Leu Thr Pro
 20 25 30

Glu Gly Trp Ser Leu Phe Leu Gln Arg Tyr Tyr Gln Val Val His Glu
 35 40 45

Gly Ala Glu Leu Arg His Leu Asp Thr Gln Val Gln Arg Cys Glu Asp
 50 55 60

Ile Leu Gln Gln Leu Gln Ala Val Val Pro Gln Ile Asp Met Glu Gly
 65 70 75 80

Asp Arg Asn Ile Trp Ile Val Lys Pro Gly Ala Lys Ser Arg Gly Arg
 85 90 95

Gly Ile Met Cys Met Asp His Leu Glu Glu Met Leu Lys Leu Val Asn
 100 105 110

Gly Asn Pro Val Val Met Lys Asp Gly Lys Trp Val Val Gln Lys Tyr
 115 120 125

Ile Glu Arg Pro Leu Leu Ile Phe Gly Thr Lys Phe Asp Leu Arg Gln
 130 135 140

577

Trp Phe Leu Val Thr Asp Trp Asn Pro Leu Thr Val Trp Phe Tyr Arg
 145 150 155 160
 Asp Ser Tyr Ile Arg Phe Ser Thr Gln Pro Phe Ser Leu Lys Asn Leu
 165 170 175
 Asp Asn Ser Val His Leu Cys Asn Asn Ser Ile Gln Lys His Leu Glu
 180 185 190
 Asn Ser Cys His Arg His Pro Leu Leu Pro Pro Asp Asn Met Trp Ser
 195 200 205
 Ser Gln Arg Phe Gln Ala His Leu Gln Glu Met Gly Ala Pro Asn Ala
 210 215 220
 Trp Ser Thr Ile Ile Val Pro Gly Met Lys Asp Ala Val Ile His Ala
 225 230 235 240
 Leu Gln Thr Ser Gln Asp Thr Val Gln Cys Arg Lys Ala Ser Phe Glu
 245 250 255
 Leu Tyr Gly Ala Asp Phe Val Phe Gly Glu Asp Phe Gln Pro Trp Leu
 260 265 270
 Ile Glu Ile Asn Ala Ser Pro Thr Met Ala Pro Ser Thr Ala Val Thr
 275 280 285
 Ala Arg Leu Cys Ala Gly Val Gln Ala Asp Thr Leu Arg Val Val Ile
 290 295 300
 Asp Arg Xaa Leu Asp Arg Asn Cys Asp Thr Gly Ala Phe Glu Leu Ile
 305 310 315 320
 Tyr Lys Gln Pro Ala Val Glu Val Pro Gln Tyr Val Gly Ile Arg Leu
 325 330 335
 Leu Val Glu Gly Phe Thr Ile Lys Lys Pro Met Ala Met Cys His Arg
 340 345 350
 Arg Met Gly Val Arg Gln Gln Ser Leu Cys
 355 360

<210> 618

<211> 328

<212> PRT

<213> Homo sapiens

<400> 618


```

Ile Arg Met Arg Glu Trp Trp Val Gln Val Gly Leu Leu Ala Val Pro
 1           5           10           15

Leu Leu Ala Ala Tyr Leu His Ile Pro Pro Pro Gln Leu Ser Pro Ala
      20           25           30

Leu His Ser Trp Lys Ser Ser Gly Lys Phe Phe Thr Tyr Lys Gly Leu
      35           40           45

Arg Ile Phe Tyr Gln Asp Ser Val Gly Val Val Gly Ser Pro Glu Ile
      50           55           60

Val Val Leu Leu His Gly Phe Pro Thr Ser Ser Tyr Asp Trp Tyr Lys
      65           70           75           80

Ile Trp Glu Gly Leu Thr Leu Arg Phe His Arg Val Ile Ala Leu Asp
      85           90           95

Phe Leu Gly Phe Gly Phe Ser Asp Lys Pro Arg Pro His His Tyr Ser
      100          105          110

Ile Phe Glu Gln Ala Ser Ile Val Glu Ala Leu Leu Arg His Leu Gly
      115          120          125

Leu Gln Asn Arg Arg Ile Asn Leu Leu Ser His Asp Tyr Gly Asp Ile
      130          135          140

Val Ala Gln Glu Leu Leu Tyr Arg Tyr Lys Gln Asn Arg Ser Gly Arg
      145          150          155          160

Leu Thr Ile Lys Ser Leu Cys Leu Ser Asn Gly Gly Ile Phe Pro Glu
      165          170          175

Thr His Arg Pro Leu Leu Leu Gln Lys Leu Leu Lys Asp Gly Gly Val
      180          185          190

Leu Ser Pro Ile Leu Thr Arg Leu Met Asn Phe Phe Val Phe Ser Arg
      195          200          205

Gly Leu Thr Pro Val Phe Gly Pro Tyr Thr Arg Pro Ser Glu Ser Glu
      210          215          220

Leu Trp Asp Met Trp Ala Gly Ile Arg Asn Asn Asp Gly Asn Leu Val
      225          230          235          240

Ile Asp Ser Leu Leu Gln Tyr Ile Asn Gln Arg Lys Lys Phe Arg Arg
      245          250          255

Arg Trp Val Gly Ala Leu Ala Ser Val Thr Ile Pro Ile His Phe Ile
      260          265          270

```

579

Tyr Gly Pro Leu Asp Pro Val Asn Pro Tyr Pro Glu Phe Leu Glu Leu
 275 280 285

Tyr Arg Lys Thr Leu Pro Arg Ser Thr Val Ser Ile Leu Asp Asp His
 290 295 300

Ile Ser His Tyr Pro Gln Leu Glu Asp Pro Met Gly Phe Leu Asn Ala
 305 310 315 320

Tyr Met Gly Phe Ile Asn Ser Phe
 325

<210> 619

<211> 271

<212> PRT

<213> Homo sapiens

<400> 619

Asn Met Asp Pro Pro Gly Leu Gln Gly Val Gln Gly Thr Val Ala Ala
 1 5 10 15

Cys Gly Ala Cys Tyr Trp Leu Leu Gly Leu Met Ala Val Arg Ala Ser
 20 25 30

Phe Glu Asn Asn Cys Glu Ile Gly Cys Phe Ala Lys Leu Thr Asn Thr
 35 40 45

Tyr Cys Leu Val Ala Ile Gly Gly Ser Glu Asn Phe Tyr Ser Val Phe
 50 55 60

Glu Gly Glu Leu Ser Asp Thr Ile Pro Val Val His Ala Ser Ile Ala
 65 70 75 80

Gly Cys Arg Ile Ile Gly Arg Met Cys Val Gly Asn Arg His Gly Leu
 85 90 95

Leu Val Pro Asn Asn Thr Thr Asp Gln Glu Leu Gln His Ile Arg Asn
 100 105 110

Ser Leu Pro Asp Thr Val Gln Ile Arg Arg Val Glu Glu Arg Leu Ser
 115 120 125

Ala Leu Gly Asn Val Thr Thr Cys Asn Asp Tyr Val Ala Leu Val His
 130 135 140

Pro Asp Leu Asp Arg Glu Thr Glu Glu Ile Leu Ala Asp Val Leu Lys
 145 150 155 160

Val Glu Val Phe Arg Gln Thr Val Ala Asp Gln Val Leu Val Gly Ser

580

	165		170		175
Tyr Cys Val Phe Ser Asn Gln Gly Gly Leu Val His Pro Lys Thr Ser					
	180		185		190
Ile Glu Asp Gln Asp Glu Leu Ser Ser Leu Leu Gln Val Pro Leu Val					
	195		200		205
Ala Gly Thr Val Asn Arg Gly Ser Glu Val Ile Ala Ala Gly Met Val					
	210		215		220
Val Asn Asp Trp Cys Ala Phe Cys Gly Leu Asp Thr Thr Ser Thr Glu					
	225		230		235
Leu Ser Val Val Glu Ser Val Phe Lys Leu Asn Glu Ala Gln Pro Ser					
	245		250		255
Thr Ile Ala Thr Ser Met Arg Asp Ser Leu Ile Asp Ser Leu Thr					
	260		265		270

<210> 620
 <211> 88
 <212> PRT
 <213> Homo sapiens

<400> 620
 Gly Ser Ala Ala Met Lys Val Lys Ile Lys Cys Trp Asn Gly Val Ala
 1 5 10 15
 Thr Trp Leu Trp Val Ala Asn Asp Glu Asn Cys Gly Ile Cys Arg Met
 20 25 30
 Ala Phe Asn Gly Cys Cys Pro Asp Cys Lys Val Pro Gly Asp Asp Cys
 35 40 45
 Pro Leu Val Trp Gly Gln Cys Ser His Cys Phe His Met His Cys Ile
 50 55 60
 Leu Lys Trp Leu His Ala Gln Gln Val Gln Gln His Cys Pro Met Cys
 65 70 75 80
 Arg Gln Glu Trp Lys Phe Lys Glu
 85

<210> 621
 <211> 46
 <212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (35)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (41)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 621

Ala	Gly	Thr	Ser	Arg	Ser	Glu	Gly	Lys	Arg	Ser	Ser	Val	Leu	Thr	Arg
1				5				10						15	

Thr	Glu	Phe	Gln	Ile	Glu	Met	Phe	Gln	Thr	Ile	Glu	Gly	Glu	Lys	Trp
			20					25						30	

Pro	Gly	Xaa	Ser	Ile	Asn	Leu	Ser	Xaa	Phe	His	Gly	Cys	Phe
		35					40					45	

<210> 622

<211> 103

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (35)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (36)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 622

Gly	Arg	Pro	Thr	Arg	Pro	Arg	Gly	Arg	Gly	Arg	Ser	Ser	Ala	Cys	Leu
1				5				10						15	

Leu	Leu	Glu	Gly	Asp	Gly	Pro	Ala	Arg	Leu	Trp	Ala	Pro	Thr	Ser	Pro
			20					25						30	

Gly	Val	Xaa	Xaa	Glu	Arg	Phe	Ala	Glu	Glu	Arg	Gly	Ser	Gly	Arg	Ala
		35					40					45			

Leu	Asn	Ala	Gly	Pro	Lys	His	Pro	Gly	Ser	Leu	His	Ser	Pro	Arg	Pro
	50					55					60				

582

Gln Thr Leu Thr Lys Thr Trp Ile Cys Ser Arg Phe Ser Cys Ser Arg
 65 70 75 80

Ser Ser Arg Ser Cys Pro Arg Leu Leu Arg Leu Arg Ala Glu Lys Lys
 85 90 95

Val Cys Gln Ala Trp Thr Gln
 100

<210> 623

<211> 103

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (60)

<223> Xaa equals any of the naturally occurring-L-amino acids

<400> 623

Gly Arg Pro Thr Arg Pro Thr Ser Ser Arg Ser Arg Ala Ala Arg Pro
 1 5 10 15

Phe Phe Phe Phe Phe Phe Trp Phe Pro Glu Phe Gly Phe Ile Leu
 20 25 30

Gln Tyr Arg Asn His Leu Glu Pro Ser Glu Thr Asp Ile Pro Glu Ala
 35 40 45

Glu Ala Leu Ser Asn Gln Tyr Cys Val Ala Leu Xaa Pro Leu Arg Lys
 50 55 60

Pro His Leu Gly Tyr Lys Arg Ser Phe Tyr Val Tyr Pro Leu Tyr His
 65 70 75 80

Gly Phe Leu Ser Pro Leu Leu Leu Pro Ile Leu Pro Gly Glu Asn Thr
 85 90 95

Ala Gln Arg Leu Pro Ser Glu
 100

<210> 624

<211> 305

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (116)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (117)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (219)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 624

Thr	Gln	Asp	Leu	Trp	Met	Ser	Cys	Pro	Val	Gln	Thr	Met	Asp	Pro	Glu
1				5					10					15	

Val	Thr	Leu	Leu	Leu	Gln	Cys	Pro	Gly	Gly	Gly	Leu	Pro	Gln	Glu	Gln
		20						25					30		

Ile	Gln	Ala	Glu	Leu	Ser	Pro	Ala	His	Asp	Arg	Arg	Pro	Leu	Pro	Gly
		35					40					45			

Gly	Asp	Glu	Ala	Ile	Thr	Ala	Ile	Trp	Glu	Thr	Arg	Leu	Lys	Ala	Gln
	50					55					60				

Pro	Trp	Leu	Phe	Asp	Ala	Pro	Lys	Phe	Arg	Leu	His	Ser	Ala	Thr	Leu
65					70					75					80

Ala	Pro	Ile	Gly	Ser	Arg	Gly	Pro	Gln	Leu	Leu	Leu	Arg	Leu	Gly	Leu
				85				90						95	

Thr	Ser	Tyr	Arg	Asp	Phe	Leu	Gly	Thr	Asn	Trp	Ser	Ser	Ser	Ala	Ala
		100						105						110	

Trp	Leu	Arg	Xaa	Xaa	Gly	Ala	Thr	Asp	Trp	Gly	Asp	Thr	Gln	Ala	Tyr
	115					120						125			

Leu	Ala	Asp	Pro	Leu	Gly	Val	Gly	Ala	Ala	Leu	Ala	Thr	Ala	Asp	Asp
	130					135						140			

Phe	Leu	Val	Phe	Leu	Arg	Arg	Ser	Arg	Gln	Val	Ala	Glu	Ala	Pro	Gly
145					150					155					160

Leu	Val	Asp	Val	Pro	Gly	Gly	His	Pro	Glu	Pro	Gln	Ala	Leu	Cys	Pro
			165					170						175	

Gly	Gly	Ser	Pro	Gln	His	Gln	Asp	Leu	Ala	Gly	Gln	Leu	Val	Val	His
			180					185					190		

584

Glu Leu Phe Ser Ser Val Leu Gln Glu Ile Cys Asp Glu Val Asn Leu
 195 200 205

Pro Leu Leu Thr Leu Ser Gln Pro Leu Leu Xaa Gly Ile Ala Arg Asn
 210 215 220

Glu Thr Ser Ala Gly Arg Ala Ser Ala Glu Phe Tyr Val Gln Cys Ser
 225 230 235 240

Leu Thr Ser Glu Gln Val Arg Lys His Tyr Leu Ser Gly Gly Pro Glu
 245 250 255

Ala His Glu Ser Thr Gly Ile Phe Phe Val Glu Thr Gln Asn Val Arg
 260 265 270

Arg Leu Pro Glu Thr Glu Met Trp Ala Glu Leu Cys Pro Ser Pro Lys
 275 280 285

Ala Pro Ser Ser Ser Thr Thr Gly Phe Arg Glu Val Pro Leu Glu Arg
 290 295 300

Pro
 305

<210> 625

<211> 102

<212> PRT

<213> Homo sapiens

<400> 625

Ser Ala Met Lys Ala Ser Gly Thr Leu Arg Glu Tyr Lys Val Val Gly
 1 5 10 15

Arg Cys Leu Pro Thr Pro Lys Cys Arg Thr Pro Pro Leu Tyr Arg Met
 20 25 30

Arg Ile Phe Ala Pro Asn His Val Val Ala Lys Ser Arg Phe Trp Tyr
 35 40 45

Phe Val Ser Gln Leu Lys Lys Met Lys Lys Ser Ser Gly Glu Ile Val
 50 55 60

Tyr Cys Gly Gln Val Phe Glu Lys Ser Pro Leu Arg Val Lys Asn Phe
 65 70 75 80

Gly Ile Trp Leu Arg Tyr Asp Ser Arg Ser Gly Thr His Asn Met Tyr
 85 90 95

585

Arg Gly Val Pro Gly Thr
100

<210> 626

<211> 59

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (36)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 626

Ala Leu Trp Val Lys Ala Trp Arg Gln Glu Ser Glu Gly Gln Phe Gln
1 5 10 15

Glu Thr Gln Phe Ile Asn Phe His Gln His Leu Pro Gly Pro Cys Leu
20 25 30

Gly Thr Glu Xaa Pro Ser Pro Glu Ser Gly His His Phe Pro Phe Gln
35 40 45

Ser Ile Glu Cys Arg Gly Ile Gln Gly Met Gly
50 55

<210> 627

<211> 220

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (93)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 627

Arg Leu Val Val Thr Glu Glu Asp Gly Gly Ala Arg Pro Glu Ala Leu
1 5 10 15

Gly Lys Ile Ala Pro Arg Thr Pro Ala Glu Leu Gly Ala Arg Ala Asp
20 25 30

Gln Glu Leu Val Thr Ala Leu Met Cys Asp Leu Arg Arg Pro Ala Ala
35 40 45

Gly Gly Met Met Asp Leu Ala Tyr Val Cys Glu Trp Glu Lys Trp Ser

586

```

      50              55              60
Lys Ser Thr His Cys Pro Ser Val Pro Leu Ala Cys Ala Trp Ser Cys
 65              70              75              80
Arg Asn Leu Ile Ala Phe Thr Met Asp Leu Arg Thr Xaa Asp Gln Asp
      85              90              95
Leu Thr Arg Met Ile His Ile Leu Asp Thr Glu His Pro Trp Asp Leu
      100             105             110
His Ser Ile Pro Ser Glu His His Glu Ala Ile Thr Cys Leu Glu Trp
      115             120             125
Asp Gln Ser Gly Ser Arg Leu Leu Ser Ala Asp Ala Asp Gly Gln Ile
      130             135             140
Lys Cys Trp Ser Met Ala Asp His Leu Ala Asn Ser Trp Glu Ser Ser
      145             150             155             160
Val Gly Ser Leu Val Glu Gly Asp Pro Ile Val Ala Leu Ser Trp Leu
      165             170             175
His Asn Gly Val Lys Leu Ala Leu His Val Glu Lys Ser Gly Ala Ser
      180             185             190
Ser Phe Gly Glu Lys Phe Ser Arg Val Lys Phe Ser Pro Val Leu Thr
      195             200             205
Leu Phe Gly Gly Lys Pro Trp Arg Ala Gly Ser Arg
      210             215             220

```

<210> 628

<211> 119

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (115)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (117)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 628

Pro Ala Ser Val Glu Val Tyr His Asp Ser Leu Cys Arg Lys Ile Trp

587

1 5 10 15
 Arg Glu Asp Asp Lys Trp His Val Ile Phe Arg Ala Asp Gly Trp Glu
 20 25 30
 Gln His Ile Thr Ala Arg Tyr Leu Val Gly Ala Asp Gly Ala Asn Ser
 35 40 45
 Met Val Arg Arg His Leu Tyr Pro Asp His Gln Ile Arg Lys Tyr Val
 50 55 60
 Ala Ile Gln Gln Trp Phe Ala Glu Lys His Pro Val Pro Phe Tyr Ser
 65 70 75 80
 Cys Ile Phe Asp Asn Ser Ile Thr Asn Cys Tyr Ser Trp Ser Ile Ser
 85 90 95
 Lys Asp Gly Tyr Phe Ile Phe Gly Gly Ala Tyr Pro Met Glu Arg Arg
 100 105 110
 Ser Asp Xaa Phe Xaa Asp Ala
 115

<210> 629

<211> 39

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (30)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (31)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 629

Phe Gly Glu Pro Ser Leu Thr Val Arg Ala Asp Ile Thr Gly Arg Tyr
 1 5 10 15

Ser Ile Val Ser Met Leu Thr Thr Cys Arg Tyr Ser Leu Xaa Xaa His
 20 25 30

Met Lys Lys Val Ser Ser Cys
 35

588

<210> 630

<211> 267

<212> PRT

<213> Homo sapiens

<400> 630

Ser Ala Ala Leu Pro Gln Pro Thr Pro Pro Leu Thr Leu Pro Gln Ser
 1 5 10 15

Met Val Asn Thr Lys Pro Glu Lys Thr Glu Glu Asp Ser Glu Glu Val
 20 25 30

Arg Glu Gln Lys His Lys Thr Phe Val Glu Lys Tyr Glu Lys Gln Ile
 35 40 45

Lys His Phe Gly Met Leu Arg Arg Trp Asp Asp Ser Gln Lys Tyr Leu
 50 55 60

Ser Asp Asn Val His Leu Val Cys Glu Glu Thr Ala Asn Tyr Leu Val
 65 70 75 80

Ile Trp Cys Ile Asp Leu Glu Val Glu Glu Lys Cys Ala Leu Met Glu
 85 90 95

Gln Val Ala His Gln Thr Ile Val Met Gln Phe Ile Leu Glu Leu Ala
 100 105 110

Lys Ser Leu Lys Val Asp Pro Arg Ala Cys Phe Arg Gln Phe Phe Thr
 115 120 125

Lys Ile Lys Thr Ala Asp Arg Gln Tyr Met Glu Gly Phe Asn Asp Glu
 130 135 140

Leu Glu Ala Phe Lys Glu Arg Val Arg Gly Arg Ala Lys Leu Arg Ile
 145 150 155 160

Glu Lys Ala Met Lys Glu Tyr Glu Glu Glu Glu Arg Lys Lys Arg Leu
 165 170 175

Gly Pro Gly Gly Leu Asp Pro Val Glu Val Tyr Glu Ser Leu Pro Glu
 180 185 190

Glu Leu Gln Lys Cys Phe Asp Val Lys Asp Val Gln Met Leu Gln Asp
 195 200 205

Ala Ile Ser Lys Met Asp Pro Thr Asp Ala Lys Tyr His Met Gln Arg
 210 215 220

Cys Ile Asp Ser Gly Leu Trp Val Pro Asn Ser Lys Ala Ser Glu Ala
 225 230 235 240

589

Lys Glu Gly Glu Glu Ala Gly Pro Gly Asp Pro Leu Leu Glu Ala Val
 245 250 255

Pro Lys Thr Gly Asp Glu Lys Asp Val Ser Val
 260 265

<210> 631

<211> 207

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (164)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 631

Pro Thr Gly Thr Gly Ser Gly Val Pro Gly Leu Gly Arg Asn Gly Gly
 1 5 10 15

Arg Glu Gly Ala Pro Gly Thr Met Gly Leu Leu Thr Ile Leu Lys Lys
 20 25 30

Met Lys Gln Lys Glu Arg Glu Leu Arg Leu Leu Met Leu Gly Leu Asp
 35 40 45

Asn Ala Gly Lys Thr Thr Ile Leu Lys Lys Phe Asn Gly Glu Asp Ile
 50 55 60

Asp Thr Ile Ser Pro Thr Leu Gly Phe Asn Ile Lys Thr Leu Glu His
 65 70 75 80

Arg Gly Phe Lys Leu Asn Ile Trp Asp Val Gly Gly Gln Lys Ser Leu
 85 90 95

Arg Ser Tyr Trp Arg Asn Tyr Phe Glu Ser Thr Asp Gly Leu Ile Trp
 100 105 110

Val Val Asp Ser Ala Asp Arg Gln Arg Met Gln Asp Cys Gln Arg Glu
 115 120 125

Leu Gln Ser Leu Leu Val Glu Glu Arg Leu Ala Gly Ala Thr Leu Leu
 130 135 140

Ile Phe Ala Asn Lys Gln Asp Leu Pro Gly Ala Leu Ser Ser Asn Ala
 145 150 155 160

Ile Arg Glu Xaa Leu Glu Leu Asp Ser Ile Arg Ser His His Trp Cys

590

	165		170		175										
Ile	Gln	Gly	Cys	Ser	Ala	Val	Thr	Gly	Glu	Asn	Leu	Leu	Pro	Gly	Ile
			180						185				190		
Asp	Trp	Leu	Leu	Asp	Asp	Ile	Ser	Ser	Arg	Ile	Phe	Thr	Ala	Asp	
		195						200					205		

<210> 632

<211> 79

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (54)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (60)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (61)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (73)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 632

Lys	Asn	Asn	Lys	Lys	Asp	Gln	Gln	Asn	Gly	Ile	Cys	Ser	His	Thr	Met
1				5					10					15	

Ile	Lys	Thr	Tyr	Leu	Arg	Thr	Ala	Leu	Phe	Met	Gly	Lys	Arg	Ser	Leu
			20					25					30		

Ile	Asp	Ser	Gln	Phe	His	Arg	Leu	Tyr	Arg	Arg	His	Gly	Leu	Gly	Arg
		35					40					45			

Pro	Gln	Gly	Asn	Leu	Xaa	Ser	Met	Val	Glu	Gly	Xaa	Xaa	Gly	Ser	Met
	50					55					60				

His	His	Leu	His	Trp	Pro	Glu	Gln	Xaa	Glu	Arg	Glu	Gln	Ile	Trp
65					70					75				

591

<210> 633
 <211> 293
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (249)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (282)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 633
 Trp Ser Pro Ser Pro Pro Ala Thr Pro Glu Gln Gly Leu Ser Ala Phe
 1 5 10 15
 Tyr Leu Ser Tyr Phe Asp Met Leu Tyr Pro Glu Asp Ser Ser Trp Ala
 20 25 30
 Ala Lys Ala Pro Gly Ala Ser Ser Arg Glu Glu Pro Pro Glu Glu Pro
 35 40 45
 Glu Gln Cys Pro Val Ile Asp Ser Gln Ala Pro Ala Gly Ser Leu Asp
 50 55 60
 Leu Val Pro Gly Gly Leu Thr Leu Glu Glu His Ser Leu Glu Gln Val
 65 70 75 80
 Gln Ser Met Val Val Gly Glu Val Leu Lys Asp Ile Glu Thr Ala Cys
 85 90 95
 Lys Leu Leu Asn Ile Thr Ala Asp Pro Met Asp Trp Ser Pro Ser Asn
 100 105 110
 Val Gln Lys Trp Leu Leu Trp Thr Glu His Gln Tyr Arg Leu Pro Pro
 115 120 125
 Met Gly Lys Ala Phe Gln Glu Leu Ala Gly Lys Glu Leu Cys Ala Met
 130 135 140
 Ser Glu Glu Gln Phe Arg Gln Arg Ser Pro Leu Gly Gly Asp Val Leu
 145 150 155 160
 His Ala His Leu Asp Ile Trp Lys Ser Ala Ala Trp Met Lys Glu Arg
 165 170 175

592

Thr Ser Pro Gly Ala Ile His Tyr Cys Ala Ser Thr Ser Glu Glu Ser
 180 185 190
 Trp Thr Asp Ser Glu Val Asp Ser Ser Cys Ser Gly Gln Pro Ile His
 195 200 205
 Leu Trp Gln Phe Leu Lys Glu Leu Leu Lys Pro His Ser Tyr Gly
 210 215 220
 Arg Phe Ile Arg Trp Leu Asn Lys Glu Lys Gly Ile Phe Lys Ile Glu
 225 230 235 240
 Asp Ser Ala Gln Val Ala Arg Leu Xaa Gly Ile Arg Lys Asn Arg Pro
 245 250 255
 Ala Met Asn Tyr Asp Lys Leu Ser Arg Ser Ile Arg Gln Tyr Tyr Lys
 260 265 270
 Lys Gly Ile Ile Arg Lys Pro Asp Ile Xaa Gln Arg Leu Val Tyr Gln
 275 280 285
 Phe Val His Pro Ile
 290

<210> 634
 <211> 227
 <212> PRT
 <213> Homo sapiens

<400> 634
 Pro Ala Gly Thr Gly Pro Glu Phe Pro Gly Arg Pro Thr Arg Pro Ala
 1 5 10 15
 Glu Glu Glu Glu Glu Glu Asp Glu Glu Glu Glu Glu Glu Glu
 20 25 30
 Glu Glu Glu Glu Glu Pro Gln Gln Arg Gly Gln Gly Glu Lys Ser Ala
 35 40 45
 Thr Pro Ser Arg Lys Ile Leu Asp Pro Asn Thr Gly Glu Pro Ala Pro
 50 55 60
 Val Leu Ser Ser Pro Pro Pro Ala Asp Val Ser Thr Phe Leu Ala Phe
 65 70 75 80
 Pro Ser Pro Glu Lys Leu Leu Arg Leu Gly Pro Lys Ser Ser Val Leu
 85 90 95
 Ile Ala Gln Gln Thr Asp Thr Ser Asp Pro Glu Lys Val Val Ser Ala

593

100	105	110
Phe Leu Lys Val Ser Ser Val	Phe Lys Asp Glu Ala Thr	Val Arg Met
115	120	125
Ala Val Gln Asp Ala Val Asp	Ala Leu Met Gln Lys Ala	Phe Asn Ser
130	135	140
Ser Ser Phe Asn Ser Asn Thr	Phe Leu Thr Arg Leu Leu	Val His Met
145	150	155
Gly Leu Leu Lys Ser Glu Asp	Lys Val Lys Ala Ile Ala	Asn Leu Tyr
165	170	175
Gly Pro Leu Met Ala Leu Asn	His Met Val Gln Gln Asp	Tyr Phe Pro
180	185	190
Lys Ala Leu Ala Pro Leu Leu	Leu Ala Phe Val Thr Lys	Pro Asn Ser
195	200	205
Ala Leu Glu Ser Cys Ser Phe	Ala Arg His Ser Leu Leu	Gln Thr Leu
210	215	220
Tyr Lys Val		
225		

<210> 635
 <211> 126
 <212> PRT
 <213> Homo sapiens

<400> 635

Thr Ser Gly Cys Ile Ser Asn Gly Lys Met Ser Ser Asn Val Pro Ala
1 5 10 15
Asp Met Ile Asn Leu Arg Leu Ile Leu Val Ser Gly Lys Thr Lys Glu
20 25 30
Phe Leu Phe Ser Pro Asn Asp Ser Ala Ser Asp Ile Ala Lys His Val
35 40 45
Tyr Asp Asn Trp Pro Met Asp Trp Glu Glu Glu Gln Val Ser Ser Pro
50 55 60
Asn Ile Leu Arg Leu Ile Tyr Gln Gly Arg Phe Leu His Gly Asn Val
65 70 75 80
Thr Leu Gly Ala Leu Lys Leu Pro Phe Gly Lys Thr Thr Val Met His
85 90 95

594

Leu Val Ala Arg Glu Thr Leu Pro Glu Pro Asn Ser Gln Gly Gln Arg
 100 105 110

Asn Arg Glu Lys Thr Gly Glu Ser Asn Cys Cys Val Ile Leu
 115 120 125

<210> 636

<211> 195

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (96)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 636

Val Ser Gly Phe Ala Gly Pro Ala Ser Leu Ile Ser Met Lys Leu Leu
 1 5 10 15

Ser Leu Val Ala Val Val Gly Cys Leu Leu Val Pro Pro Ala Glu Ala
 20 25 30

Asn Lys Ser Ser Glu Asp Ile Arg Cys Lys Cys Ile Cys Pro Pro Tyr
 35 40 45

Arg Asn Ile Ser Gly His Ile Tyr Asn Gln Asn Val Ser Gln Lys Asp
 50 55 60

Cys Asn Cys Leu His Val Val Glu Pro Met Pro Val Pro Gly His Asp
 65 70 75 80

Val Glu Ala Tyr Cys Leu Leu Cys Glu Cys Arg Tyr Glu Glu Arg Xaa
 85 90 95

Thr Thr Thr Ile Lys Val Ile Ile Val Ile Tyr Leu Ser Val Val Gly
 100 105 110

Ala Leu Leu Leu Tyr Met Ala Phe Leu Met Leu Val Asp Pro Leu Ile
 115 120 125

Arg Lys Pro Asp Ala Tyr Thr Glu Gln Leu His Asn Glu Glu Glu Asn
 130 135 140

Glu Asp Ala Arg Ser Met Ala Ala Ala Ala Ala Ser Leu Gly Gly Pro
 145 150 155 160

Arg Ala Asn Thr Val Leu Glu Arg Val Glu Gly Ala Gln Gln Arg Trp

595

165 170 175

Lys Leu Gln Val Gln Glu Gln Arg Lys Thr Val Phe Asp Arg His Lys

180 185 190

Met Leu Ser

195

```
<210> 637
<211> 159
<212> PRT
<213> Homo sapiens
```

```
<220>  
<221> SITE  
<222> (92)  
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (115)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (138)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (151)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (156)
<223> Xaa equals any of the naturally occurring L-amino acids
```

<400> 637
Arg Pro Thr Arg Pro Gly Asn Ser Arg Arg Arg Gly Arg Arg Gly Cys
1 5 10 15

Trp Arg Leu Leu Gly Phe Gly Ala Ala Ala Ile Met Pro Gly Ile Val
20 25 30

Glu Leu Pro Thr Leu Glu Asp Leu Lys Val Gln Glu Val Lys Val Ser
35 40 45

Ser Ser Val Leu Lys Ala Ala Ala His His Tyr Gly Val Gln Cys Asp

596

50	55	60
Lys Pro Asn Lys Glu Phe Met Leu Cys Arg Trp Glu Glu Lys Asp Pro		
65	70	75 80
Arg Arg Cys Leu Glu Glu Gly Lys Leu Val Asn Xaa Cys Ala Leu Asp		
	85	90 95
Phe Phe Arg Gln Ile Lys Leu Ser Leu Cys Arg Ala Phe Tyr Arg Leu		
	100	105 110
Leu Asp Xaa His Arg Leu Leu Arg Pro Ala Val Phe Ser Ser Leu Pro		
	115	120 125
Gln Thr Ala Gly Gln Phe Asp Asp Val Xaa Gly Ala Thr Gly Met Val		
	130	135 140
Arg Leu Asn Trp Gly Lys Xaa Ser Ser His Gln Xaa Glu Asn Ser		
145	150	155

<210> 638
 <211> 20
 <212> PRT
 <213> Homo sapiens

<400> 638
 Phe Ser Arg Asp Lys Val Ser Pro Cys Trp Pro Gly Trp Ser Arg Thr
 1 5 10 15
 Pro Gly Leu Arg
 20

<210> 639
 <211> 408
 <212> PRT
 <213> Homo sapiens

<400> 639
 Thr Trp Gly Gln Thr Pro Cys Ser Pro Gly His Gly Gln Arg Pro Ser
 1 5 10 15
 Ser Thr Cys Leu Thr Val Gly Pro Gly Gly Gly Pro Ser Leu Gly Arg
 20 25 30
 Pro Cys Pro Gln Leu Leu Leu Gln Phe Gly Val Leu Phe Cys Thr Ile
 35 40 45

597

Leu Leu Leu Leu Trp Val Ser Val Phe Leu Tyr Gly Ser Phe Tyr Tyr
 50 55 60
 Ser Tyr Met Pro Thr Val Ser His Leu Ser Pro Val His Phe Tyr Tyr
 65 70 75 80
 Arg Thr Asp Cys Asp Ser Ser Thr Thr Ser Leu Cys Ser Phe Pro Val
 85 90 95
 Ala Asn Val Ser Leu Thr Lys Gly Gly Arg Asp Arg Val Leu Met Tyr
 100 105 110
 Gly Gln Pro Tyr Arg Val Thr Leu Glu Leu Glu Leu Pro Glu Ser Pro
 115 120 125
 Val Asn Gln Asp Leu Gly Met Phe Leu Val Thr Ile Ser Cys Tyr Thr
 130 135 140
 Arg Gly Gly Arg Ile Ile Ser Thr Ser Ser Arg Ser Val Met Leu His
 145 150 155 160
 Tyr Arg Ser Asp Leu Leu Gln Met Leu Asp Thr Leu Val Phe Ser Ser
 165 170 175
 Leu Leu Leu Phe Gly Phe Ala Glu Gln Lys Gln Leu Leu Glu Val Glu
 180 185 190
 Leu Tyr Ala Asp Tyr Arg Glu Asn Ser Tyr Val Pro Thr Thr Gly Ala
 195 200 205
 Ile Ile Glu Ile His Ser Lys Arg Ile Gln Leu Tyr Gly Ala Tyr Leu
 210 215 220
 Arg Ile His Ala His Phe Thr Gly Leu Arg Tyr Leu Leu Tyr Asn Phe
 225 230 235 240
 Pro Met Thr Cys Ala Phe Ile Gly Val Ala Ser Asn Phe Thr Phe Leu
 245 250 255
 Ser Val Ile Val Leu Phe Ser Tyr Met Gln Trp Val Trp Gly Gly Ile
 260 265 270
 Trp Pro Arg His Arg Phe Ser Leu Gln Val Asn Ile Arg Lys Arg Asp
 275 280 285
 Asn Ser Arg Lys Glu Val Gln Arg Arg Ile Ser Ala His Gln Pro Gly
 290 295 300
 Pro Glu Gly Gln Glu Glu Ser Thr Pro Gln Ser Asp Val Thr Glu Asp
 305 310 315 320

598

Gly Glu Ser Pro Glu Asp Pro Ser Gly Thr Glu Gly Gln Leu Ser Glu
325 330 335

Glu Glu Lys Pro Asp Gln Gln Pro Leu Ser Gly Glu Glu Glu Leu Glu
340 345 350

Pro Glu Ala Ser Asp Gly Ser Gly Ser Trp Glu Asp Ala Ala Leu Leu
355 360 365

Thr Glu Ala Asn Leu Pro Ala Pro Ala Pro Ala Ser Ala Ser Ala Pro
370 375 380

Val Leu Glu Thr Leu Gly Ser Ser Glu Pro Ala Gly Gly Ala Leu Arg
385 390 395 400

Gln Arg Pro Thr Cys Ser Ser Ser
405

<210> 640

<211> 288

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (10)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (15)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (268)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (271)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (273)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (274)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (276)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (286)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 640

Phe	Ser	Ser	Ser	Ala	Cys	Pro	Ser	Val	Xaa	Ser	Leu	Phe	Val	Xaa	Leu
1				5					10					15	

Gly	Lys	Asn	Pro	His	Asp	Ala	Gln	Gly	His	Pro	Arg	Ala	Ser	Glu	Asp
			20					25					30		

Gln	Pro	Ser	Ser	Gly	Lys	Pro	Val	Thr	Ser	Tyr	Pro	Gly	Glu	Cys	Gly
		35					40					45			

Phe	Val	Phe	Thr	Lys	Glu	Ala	Ser	Leu	Glu	Ile	Arg	Asp	Met	Leu	Leu
	50					55					60				

Ala	Asn	Lys	Val	Pro	Ala	Ala	Ala	Arg	Ala	Gly	Ala	Ile	Ala	Pro	Cys
65					70					75				80	

Glu	Val	Thr	Val	Pro	Ala	Gln	Asn	Thr	Gly	Leu	Gly	Pro	Glu	Lys	Thr
				85					90					95	

Ser	Phe	Phe	Gln	Ala	Leu	Gly	Ile	Thr	Thr	Lys	Ile	Ser	Arg	Gly	Thr
			100				105						110		

Ile	Glu	Ile	Leu	Ser	Asp	Val	Gln	Leu	Ile	Lys	Thr	Gly	Asp	Lys	Val
	115						120					125			

Gly	Ala	Ser	Glu	Ala	Thr	Leu	Leu	Asn	Met	Leu	Asn	Ile	Ser	Pro	Phe
	130					135					140				

Ser	Phe	Gly	Leu	Ile	Ile	Gln	Gln	Val	Phe	Asp	Asn	Gly	Ser	Ile	Tyr
145				150						155				160	

Asn	Pro	Glu	Val	Leu	Asp	Ile	Thr	Glu	Glu	Thr	Leu	His	Ser	Arg	Phe
			165						170					175	

Leu	Glu	Gly	Val	Arg	Asn	Val	Ala	Ser	Val	Cys	Leu	Gln	Ile	Gly	Tyr
			180					185					190		

600

Pro Thr Val Ala Ser Val Pro His Ser Ile Ile Asn Gly Tyr Lys Arg
 195 200 205
 Val Leu Ala Leu Ser Val Glu Thr Asp Tyr Thr Phe Pro Leu Ala Glu
 210 215 220
 Lys Val Lys Ala Phe Leu Ala Asp Pro Ser Ala Phe Val Ala Ala Ala
 225 230 235 240
 Pro Val Ala Ala Ala Thr Thr Ala Ala Pro Ala Ala Ala Ala Pro
 245 250 255
 Ala Lys Val Glu Ala Lys Glu Glu Ser Glu Glu Xaa Asp Glu Xaa Ile
 260 265 270
 Xaa Xaa Ser Xaa Ile Ser Lys Ser Asn Asn Ser Ser Gln Xaa Ile Val
 275 280 285

<210> 641

<211> 444

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (34)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 641

Asn Glu Gln Asp Asn Cys Val Leu Ile His Asp Val Asp Gln Arg Asn
 1 5 10 15
 Ser Asp Lys Asp Ile Phe Gly Asp Ala Cys Asp Asn Cys Leu Ser Val
 20 25 30
 Leu Xaa Asn Asp Gln Lys Asp Thr Asp Gly Asp Gly Arg Gly Asp Ala
 35 40 45
 Cys Asp Asp Asp Met Asp Gly Asp Gly Ile Lys Asn Ile Leu Asp Asn
 50 55 60
 Cys Pro Lys Phe Pro Asn Arg Asp Gln Arg Asp Lys Asp Gly Asp Gly
 65 70 75 80
 Val Gly Asp Ala Cys Asp Ser Cys Pro Asp Val Ser Asn Pro Asn Gln
 85 90 95

601

Ser Asp Val Asp Asn Asp Leu Val Gly Asp Ser Cys Asp Thr Asn Gln
 100 105 110
 Asp Ser Asp Gly Asp Gly His Gln Asp Ser Thr Asp Asn Cys Pro Thr
 115 120 125
 Val Ile Asn Ser Ala Gln Leu Asp Thr Asp Lys Asp Gly Ile Gly Asp
 130 135 140
 Glu Cys Asp Asp Asp Asp Asp Asn Asp Gly Ile Pro Asp Leu Val Pro
 145 150 155 160
 Pro Gly Pro Asp Asn Cys Arg Leu Val Pro Asn Pro Ala Gln Glu Asp
 165 170 175
 Ser Asn Ser Asp Gly Val Gly Asp Ile Cys Glu Ser Asp Phe Asp Gln
 180 185 190
 Asp Gln Val Ile Asp Arg Ile Asp Val Cys Pro Glu Asn Ala Glu Val
 195 200 205
 Thr Leu Thr Asp Phe Arg Ala Tyr Gln Thr Val Val Leu Asp Pro Glu
 210 215 220
 Gly Asp Ala Gln Ile Asp Pro Asn Trp Val Val Leu Asn Gln Gly Met
 225 230 235 240
 Glu Ile Val Gln Thr Met Asn Ser Asp Pro Gly Leu Ala Val Gly Tyr
 245 250 255
 Thr Ala Phe Asn Gly Val Asp Phe Glu Gly Thr Phe His Val Asn Thr
 260 265 270
 Gln Thr Asp Asp Asp Tyr Ala Gly Phe Ile Phe Gly Tyr Gln Asp Ser
 275 280 285
 Ser Ser Phe Tyr Val Val Met Trp Lys Gln Thr Glu Gln Thr Tyr Trp
 290 295 300
 Gln Ala Thr Pro Phe Arg Ala Val Ala Glu Pro Gly Ile Gln Leu Lys
 305 310 315 320
 Ala Val Lys Ser Lys Thr Gly Pro Gly Glu His Leu Arg Asn Ser Leu
 325 330 335
 Trp His Thr Gly Asp Thr Ser Asp Gln Val Arg Leu Leu Trp Lys Asp
 340 345 350
 Ser Arg Asn Val Gly Trp Lys Asp Lys Val Ser Tyr Arg Trp Phe Leu
 355 360 365

602

Gln His Arg Pro Gln Val Gly Tyr Ile Arg Val Arg Phe Tyr Glu Gly
 370 375 380
 Ser Glu Leu Val Ala Asp Ser Gly Val Thr Ile Asp Thr Thr Met Arg
 385 390 395 400
 Gly Gly Arg Leu Gly Val Phe Cys Phe Ser Gln Glu Asn Ile Ile Trp
 405 410 415
 Ser Asn Leu Lys Tyr Arg Cys Asn Asp Thr Ile Pro Glu Asp Phe Gln
 420 425 430
 Glu Phe Gln Thr Gln Asn Phe Asp Arg Phe Asp Asn
 435 440

<210> 642

<211> 326

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (50)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (296)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 642

Ser Ala Arg Ala Ser Asp Leu Gly Ala Pro Arg Thr Trp Thr Gly Ala
 1 5 10 15

Ala Ala Gly Pro Arg Thr Pro Ser Ala His Ile Pro Val Pro Ala Gln
 20 25 30

Arg Ala Thr Pro Gly Lys Ala Arg Leu Asp Glu Val Met Ala Ala Ala
 35 40 45

Ala Xaa Thr Ser Leu Ser Thr Ser Pro Leu Leu Leu Gly Ala Pro Val
 50 55 60

Ala Ala Phe Ser Pro Glu Pro Gly Leu Glu Pro Trp Lys Glu Ala Leu
 65 70 75 80

Val Arg Pro Pro Gly Ser Tyr Ser Ser Ser Ser Asn Ser Gly Asp Trp
 85 90 95

603

Gly Trp Asp Leu Ala Ser Asp Gln Ser Ser Pro Ser Thr Pro Ser Pro
 100 105 110
 Pro Leu Pro Pro Glu Ala Ala His Phe Leu Phe Gly Glu Pro Thr Leu
 115 120 125
 Arg Lys Arg Lys Ser Pro Ala Gln Val Met Phe Gln Cys Leu Trp Lys
 130 135 140
 Ser Cys Gly Lys Val Leu Ser Thr Ala Ser Ala Met Gln Arg His Ile
 145 150 155 160
 Arg Leu Val His Leu Gly Arg Gln Ala Glu Pro Asp Gln Ser Asp Gly
 165 170 175
 Glu Glu Asp Phe Tyr Tyr Thr Glu Leu Asp Val Gly Val Asp Thr Leu
 180 185 190
 Thr Asp Gly Leu Ser Ser Leu Thr Pro Val Ser Pro Thr Ala Ser Met
 195 200 205
 Pro Pro Ala Phe Pro Arg Leu Glu Leu Pro Glu Leu Leu Glu Pro Pro
 210 215 220
 Ala Leu Pro Ser Pro Leu Arg Pro Pro Ala Pro Pro Leu Pro Pro Pro
 225 230 235 240
 Pro Val Leu Ser Thr Val Ala Asn Pro Gln Ser Cys His Ser Asp Arg
 245 250 255
 Val Tyr Gln Gly Cys Leu Thr Pro Ala Arg Leu Glu Pro Gln Pro Thr
 260 265 270
 Glu Val Gly Ala Cys Pro Pro Ala Leu Ser Ser Arg Ile Gly Val Thr
 275 280 285
 Leu Arg Lys Pro Arg Gly Asp Xaa Lys Lys Cys Arg Lys Val Tyr Gly
 290 295 300
 Met Glu Arg Arg Asp Leu Trp Cys Thr Ala Cys Arg Trp Lys Lys Ala
 305 310 315 320
 Cys Gln Arg Phe Leu Asp
 325

<210> 643

<211> 129

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (9)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (10)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (14)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (18)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (19)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (24)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (38)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (94)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (103)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 643

Asp Val Arg Leu Ser Gly Arg Asn Xaa Xaa Val Asp Val Xaa Asp His

1

5

10

15

605

Gln Xaa Xaa Leu Leu Glu Gln Xaa Asp Leu Leu Ala Gly Leu Ile Ser
 20 25 30
 Asn Ser Ser Asp Ala Xaa Asp Lys Ile Arg Tyr Glu Ser Leu Thr Asp
 35 40 45
 Pro Ser Lys Leu Asp Ser Gly Lys Glu Leu His Ile Asn Leu Ile Pro
 50 55 60
 Asn Lys Gln Asp Arg Thr Leu Thr Ile Val Gly Tyr Arg Asp Arg Met
 65 70 75 80
 Thr Lys Ala Asp Leu Ile Asn Asn Leu Gly Thr Ile Ala Xaa Ser Gly
 85 90 95
 Thr Lys Ala Phe Met Glu Xaa Leu Gln Ala Gly Ala Asp Ile Ser Met
 100 105 110
 Ile Gly Gln Phe Gly Val Gly Phe Tyr Ser Ala Tyr Leu Val Ala Arg
 115 120 125

Arg

<210> 644

<211> 156

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (12)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 644

Ser Thr His Ala Ser Ala Ser Arg Arg Leu Leu Xaa Asp Val Cys Gln
 1 5 10 15

Asp Cys Ile Gln Met Val Thr Asp Ile Gln Thr Ala Val Arg Thr Asn
 20 25 30

Ser Thr Phe Val Glu Ala Leu Val Asp His Ala Lys Ala Gln Cys Asp
 35 40 45

Leu Leu Gly Pro Gly Met Ala Asp Met Cys Lys Asn Tyr Ile Asn Gln
 50 55 60

Tyr Ser Asp Ile Ala Val Gln Met Met Met His Met Gln Pro Lys Glu
 65 70 75 80

606

Ile Cys Gly Leu Val Gly Phe Cys Asp Gln Val Lys Glu Met Pro Met
 85 90 95
 Gln Thr Leu Ile Pro Ala Lys Ala Val Ser Glu Asn Val Ile Pro Ala
 100 105 110
 Leu Glu Leu Val Glu Pro Ile Lys Lys Asp Thr Val Gln Ala Lys Thr
 115 120 125
 Ser Val Ser Cys Gly Asp Met Arg Val Thr Trp Leu Lys Glu Val Ala
 130 135 140
 Lys Leu His Trp Thr Thr Thr Gly Leu Arg Lys Lys
 145 150 155

<210> 645

<211> 115

<212> PRT

<213> Homo sapiens

<400> 645

Ala Asp Pro Gly Val Gly Ala Val Pro Gly Leu Ala Ala Asp Leu Ala
 1 5 10 15
 Thr Ala Ala Arg Ser Leu Gly Pro Ala Leu Val Leu Asp Leu Gly Arg
 20 25 30
 Pro Pro Ser Pro Asp Pro His Glu Gly Pro Ser Pro Ser Pro Arg Arg
 35 40 45
 Ser Pro Asp Leu Val Arg Gly Pro Gly Pro Gly Leu Gly Pro Gly Val
 50 55 60
 Leu Pro Gln Cys Pro Arg Gly Asn Pro Asn Pro Gly Arg Asp Arg Arg
 65 70 75 80
 Val Pro Pro Ser Leu Leu Lys Arg Lys Glu Arg Cys Pro Leu Lys Lys
 85 90 95
 Met Val Met Ser Gly Asn Pro Arg His Ile Thr Leu Ile His Lys Trp
 100 105 110
 Asp Leu Gly
 115

<210> 646

607

<211> 153

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (127)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 646

Tyr Met Pro Asn Gly Ser Leu Asn Glu Leu Leu His Arg Lys Thr Glu
 1 5 10 15

Tyr Pro Asp Val Ala Trp Pro Leu Arg Phe Arg Ile Leu His Glu Ile
 20 25 30

Ala Leu Gly Val Asn Tyr Leu His Asn Met Thr Pro Pro Leu Leu His
 35 40 45

His Asp Leu Lys Thr Gln Asn Ile Leu Leu Asp Asn Glu Phe His Val
 50 55 60

Lys Ile Ala Asp Phe Gly Leu Ser Lys Trp Arg Met Met Ser Leu Ser
 65 70 75 80

Gln Ser Arg Ser Ser Lys Ser Ala Pro Glu Gly Gly Thr Ile Ile Tyr
 85 90 95

Met Pro Pro Glu Asn Tyr Glu Pro Gly Gln Lys Ser Arg Ala Ser Ile
 100 105 110

Lys His Asp Ile Tyr Ser Tyr Ala Val Ile Thr Trp Glu Val Xaa Ser
 115 120 125

Arg Lys Gln Pro Phe Glu Asp Val Thr Asn Pro Leu Gln Ile Met Tyr
 130 135 140

Ser Val Ser Gln Gly His Trp Thr Gly
 145 150

<210> 647

<211> 220

<212> PRT

<213> Homo sapiens

<400> 647

Ala Ser Glu Gln Gly Ala Val Gly Gln Gly Gly Leu Ala Gly Val Pro
 1 5 10 15

608

Thr Leu Thr Ser Leu Pro Ser Ser Cys Pro Glu Pro Arg Pro Ser Met
 20 25 30
 Asp Ala Val Asp Ala Thr Met Glu Lys Leu Arg Ala Gln Cys Leu Ser
 35 40 45
 Arg Gly Ala Ser Gly Ile Gln Gly Leu Ala Arg Phe Phe Arg Gln Leu
 50 55 60
 Asp Arg Asp Gly Ser Arg Ser Leu Asp Ala Asp Glu Phe Arg Gln Gly
 65 70 75 80
 Leu Ala Lys Leu Gly Leu Val Leu Asp Gln Ala Glu Ala Glu Gly Val
 85 90 95
 Cys Arg Lys Trp Asp Arg Asn Gly Ser Gly Thr Leu Asp Leu Glu Glu
 100 105 110
 Phe Leu Arg Ala Leu Arg Pro Pro Met Ser Gln Ala Arg Glu Ala Val
 115 120 125
 Ile Ala Ala Ala Phe Ala Lys Leu Asp Arg Ser Gly Asp Gly Val Val
 130 135 140
 Thr Val Asp Asp Leu Arg Gly Val Tyr Ser Gly Arg Ala His Pro Lys
 145 150 155 160
 Val Arg Ser Gly Glu Trp Thr Glu Asp Glu Val Leu Arg Arg Phe Leu
 165 170 175
 Asp Asn Phe Asp Ser Ser Glu Lys Asp Gly Gln Val Thr Leu Ala Glu
 180 185 190
 Phe Gln Asp Tyr Tyr Ser Gly Val Ser Ala Ser Met Asn Thr Asp Glu
 195 200 205
 Glu Phe Val Ala Met Met Thr Ser Ala Trp Gln Leu
 210 215 220

<210> 648

<211> 118

<212> PRT

<213> Homo sapiens

<400> 648

Asp Asn Arg Thr Leu Thr Lys Gly Pro Asp Thr Val Gly Thr Met Gly
 1 5 10 15

Gln Cys Arg Ser Ala Asn Ala Glu Asp Ala Gln Glu Phe Ser Asp Val

609

	20		25		30	
Glu Arg Ala Ile Glu Thr Leu Ile Lys Asn Phe His Gln Tyr Ser Val						
	35		40		45	
Glu Gly Gly Lys Glu Thr Leu Thr Pro Ser Glu Leu Arg Asp Leu Val						
	50		55		60	
Thr Gln Gln Leu Pro His Leu Met Pro Ser Asn Cys Gly Leu Glu Glu						
	65		70		75	80
Lys Ile Ala Asn Leu Gly Ser Cys Asn Asp Ser Lys Leu Glu Phe Arg						
		85		90		95
Ser Phe Trp Glu Leu Ile Gly Glu Ala Ala Lys Ser Val Lys Leu Glu						
	100		105		110	
Arg Pro Val Arg Gly His						
	115					

<210> 649

<211> 309

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (77)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (160)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 649

Asp His His Gln Gly Ala Glu Ser Val Pro Gly Ile Gly Val Ser Pro
1 5 10 15

Thr Ser Ser Ser Ser Cys Pro Pro Thr Ser Cys Thr Gln Pro Val Thr
20 25 30

Thr Trp Ser Pro Gly Leu Arg Val Glu Ser Leu Asp Gly Ala Lys Thr
35 40 45

Gly Lys Gly Ala Leu Thr Gly Ala Pro Gly Ser Phe Gly Ser Ser Glu
50 55 60

Phe Leu Thr Gly Leu Arg Asn Thr Ser Glu Ala Arg Xaa Thr Arg Gly

610

65		70		75		80									
Pro	Ile	Met	Gln	Glu	Pro	Arg	Arg	Val	Thr	Pro	Cys	Leu	Gly	Lys	Arg
			85						90					95	
Gly	Val	Lys	Thr	Pro	Gln	Leu	Gln	Pro	Gly	Ser	Ala	Phe	Leu	Pro	Arg
			100					105					110		
Val	Arg	Arg	Gln	Ser	Phe	Pro	Ala	Arg	Ser	Asp	Ser	Tyr	Thr	Thr	Val
			115					120					125		
Arg	Asp	Phe	Leu	Ala	Val	Pro	Arg	Thr	Ile	Ser	Ser	Ala	Ser	Ala	Thr
			130					135				140			
Leu	Ile	Met	Ala	Val	Ala	Val	Ser	His	Phe	Arg	Pro	Gly	Pro	Glu	Xaa
145					150					155					160
Trp	Asp	Thr	Ala	Ser	Met	Ala	Ala	Ser	Lys	Val	Lys	Gln	Asp	Met	Pro
				165					170					175	
Pro	Pro	Gly	Gly	Tyr	Gly	Pro	Ile	Asp	Tyr	Lys	Arg	Asn	Leu	Pro	Arg
			180					185					190		
Arg	Gly	Leu	Ser	Gly	Tyr	Ser	Met	Leu	Ala	Ile	Gly	Ile	Gly	Thr	Leu
			195					200					205		
Ile	Tyr	Gly	His	Trp	Ser	Ile	Met	Lys	Trp	Asn	Arg	Glu	Arg	Arg	Arg
			210					215				220			
Leu	Gln	Ile	Glu	Asp	Phe	Glu	Ala	Arg	Ile	Ala	Leu	Leu	Pro	Leu	Leu
225					230					235					240
Gln	Ala	Glu	Thr	Asp	Arg	Arg	Thr	Leu	Gln	Met	Leu	Arg	Glu	Asn	Leu
				245					250					255	
Glu	Glu	Glu	Ala	Ile	Ile	Met	Lys	Asp	Val	Pro	Asp	Trp	Lys	Val	Gly
			260					265					270		
Glu	Ser	Val	Phe	His	Thr	Thr	Arg	Trp	Val	Pro	Pro	Leu	Ile	Gly	Glu
			275					280				285			
Leu	Tyr	Gly	Leu	Arg	Thr	Thr	Glu	Glu	Ala	Leu	His	Ala	Ser	His	Gly
			290				295					300			
Phe	Met	Trp	Tyr	Thr											
305															

<210> 650

<211> 286

611

<212> PRT

<213> Homo sapiens

<400> 650

```

Ile Pro Thr Leu Ile Thr Ala Phe Val Leu Ala Thr Ser Gln Ala Gln
  1             5             10             15

Ala Gly Trp Leu Gln His Asp Tyr Gly His Leu Ser Val Tyr Arg Lys
          20             25             30

Pro Lys Trp Asn His Leu Val His Lys Phe Val Ile Gly His Leu Lys
          35             40             45

Gly Ala Ser Ala Asn Trp Trp Asn His Arg His Phe Gln His His Ala
          50             55             60

Lys Pro Asn Ile Phe His Lys Asp Pro Asp Val Asn Met Leu His Val
          65             70             75             80

Phe Val Leu Gly Glu Trp Gln Pro Ile Glu Tyr Gly Lys Lys Lys Leu
          85             90             95

Lys Tyr Leu Pro Tyr Asn His Gln His Glu Tyr Phe Phe Leu Ile Gly
          100            105            110

Pro Pro Leu Leu Ile Pro Met Tyr Phe Gln Tyr Gln Ile Ile Met Thr
          115            120            125

Met Ile Val His Lys Asn Trp Val Asp Leu Ala Trp Ala Val Ser Tyr
          130            135            140

Tyr Ile Arg Phe Phe Ile Thr Tyr Ile Pro Phe Tyr Gly Ile Leu Gly
          145            150            155            160

Ala Leu Leu Phe Leu Asn Phe Ile Arg Phe Leu Glu Ser His Trp Phe
          165            170            175

Val Trp Val Thr Gln Met Asn His Ile Val Met Glu Ile Asp Gln Glu
          180            185            190

Ala Tyr Arg Asp Trp Phe Ser Ser Gln Leu Thr Ala Thr Cys Asn Val
          195            200            205

Glu Gln Ser Phe Phe Asn Asp Trp Phe Ser Gly His Leu Asn Phe Gln
          210            215            220

Ile Glu His His Leu Phe Pro Thr Met Pro Arg His Asn Leu His Lys
          225            230            235            240

Ile Ala Pro Leu Val Lys Ser Leu Cys Ala Lys His Gly Ile Glu Tyr
          245            250            255

```

612

Gln Glu Lys Pro Leu Leu Arg Ala Leu Leu Asp Ile Ile Arg Ser Leu
 260 265 270

Lys Lys Ser Gly Lys Leu Trp Leu Asp Ala Tyr Leu His Lys
 275 280 285

<210> 651

<211> 184

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (35)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (57)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (71)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (106)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 651

Glu Arg Gly Pro Ile Pro Val Cys Pro His Lys Ala Ala Ser Ser Val
 1 5 10 15

Ile Ser Leu Leu Arg Ala Glu Leu Arg Leu Tyr Thr Asp Pro His Lys
 20 25 30

Tyr His Xaa Phe Cys Leu Arg Lys Asp Lys Ala His Val Cys Phe Cys
 35 40 45

Phe Arg Phe Leu Phe Ser Phe Phe Xaa Glu Ala Leu Trp Arg Ser Met
 50 55 60

Phe Leu Leu Ser Phe Leu Xaa Lys Pro Ser Phe Trp Ala Thr Gly Leu
 65 70 75 80

Ile Leu Ser Thr Ser Ser Phe Pro Pro Phe Ser Ile Val Ser Leu Pro

613

	85		90		95
Pro Ser His	Pro Thr Arg Ala	Pro Leu Xaa Leu Ser Phe	Pro Ser Ser		
100		105	110		
Pro Ala Val Ser Phe Leu Arg	Ser Gly Thr Lys Leu Ile Phe Arg Arg				
115	120	125			
Arg Pro Arg Gln Lys Glu Ala Gly Leu Ser Gln Ser His Asp Asp Leu					
130	135	140			
Ser Asn Ala Thr Ala Thr Pro Ser Val Arg Lys Lys Ala Gly Ser Phe					
145	150	155	160		
Ser Arg Arg Leu Ile Lys Arg Phe Ser Phe Lys Ser Lys Pro Lys Ala					
165	170	175			
Asn Gly Asn Pro Ser Pro Gln Leu					
180					

<210> 652

<211> 641

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (438)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 652

Gln Gly Ser Glu Pro Ser Ser Glu Asn Ala Asn Asp Thr Ile Ile Leu	
1	5 10 15

Arg Asn Leu Asn Pro His Ser Thr Met Asp Ser Ile Leu Gly Ala Leu	
20	25 30

Ala Pro Tyr Ala Val Leu Ser Ser Ser Asn Val Arg Val Ile Lys Asp	
35	40 45

Lys Gln Thr Gln Leu Asn Arg Gly Phe Ala Phe Ile Gln Leu Ser Thr	
50	55 60

Ile Glu Ala Ala Gln Leu Leu Gln Ile Leu Gln Ala Leu His Pro Pro	
65	70 75 80

Leu Thr Ile Asp Gly Lys Thr Ile Asn Val Glu Phe Ala Lys Gly Ser	
85	90 95

Lys Arg Asp Met Ala Ser Asn Glu Gly Ser Arg Ile Ser Ala Ala Ser
 100 105 110
 Val Ala Ser Thr Ala Ile Ala Ala Ala Gln Trp Ala Ile Ser Gln Ala
 115 120 125
 Ser Gln Gly Gly Glu Gly Thr Trp Ala Thr Ser Glu Glu Pro Pro Val
 130 135 140
 Asp Tyr Ser Tyr Tyr Gln Gln Asp Glu Gly Tyr Gly Asn Ser Gln Gly
 145 150 155 160
 Thr Glu Ser Ser Leu Tyr Ala His Gly Tyr Leu Lys Gly Thr Lys Gly
 165 170 175
 Pro Gly Ile Thr Gly Thr Lys Gly Asp Pro Thr Gly Ala Gly Pro Glu
 180 185 190
 Ala Ser Leu Glu Pro Gly Ala Asp Ser Val Ser Met Gln Ala Phe Ser
 195 200 205
 Arg Ala Gln Pro Gly Ala Ala Pro Gly Ile Tyr Gln Gln Ser Ala Glu
 210 215 220
 Ala Ser Ser Ser Gln Gly Thr Ala Ala Asn Ser Gln Ser Tyr Thr Ile
 225 230 235 240
 Met Ser Pro Ala Val Leu Lys Ser Glu Leu Gln Ser Pro Thr His Pro
 245 250 255
 Ser Ser Ala Leu Pro Pro Ala Thr Ser Pro Thr Ala Gln Glu Ser Tyr
 260 265 270
 Ser Gln Tyr Pro Val Pro Asp Val Ser Thr Tyr Gln Tyr Asp Glu Thr
 275 280 285
 Ser Gly Tyr Tyr Tyr Asp Pro Gln Thr Gly Leu Tyr Tyr Asp Pro Asn
 290 295 300
 Ser Gln Tyr Tyr Tyr Asn Ala Gln Ser Gln Gln Tyr Leu Tyr Trp Asp
 305 310 315 320
 Gly Glu Arg Arg Thr Tyr Val Pro Ala Leu Glu Gln Ser Ala Asp Gly
 325 330 335
 His Lys Glu Thr Gly Ala Pro Ser Lys Glu Gly Lys Glu Lys Lys Glu
 340 345 350
 Lys His Lys Thr Lys Thr Ala Gln Gln Ile Ala Lys Asp Met Glu Arg
 355 360 365

615

Trp Ala Arg Ser Leu Asn Lys Gln Lys Glu Asn Phe Lys Asn Ser Phe
 370 375 380
 Gln Pro Ile Ser Ser Leu Arg Asp Asp Glu Arg Arg Glu Ser Ala Thr
 385 390 395 400
 Ala Asp Ala Gly Tyr Ala Ile Leu Glu Lys Lys Gly Ala Leu Ala Glu
 405 410 415
 Arg Gln His Thr Ser Met Asp Leu Pro Lys Leu Ala Ser Asp Asp Arg
 420 425 430
 Pro Ser Pro Pro Arg Xaa Leu Val Ala Ala Tyr Ser Gly Glu Ser Asp
 435 440 445
 Ser Glu Glu Glu Gln Glu Arg Gly Gly Pro Glu Arg Glu Glu Lys Leu
 450 455 460
 Thr Asp Trp Gln Lys Leu Ala Cys Leu Leu Cys Arg Arg Gln Phe Pro
 465 470 475 480
 Ser Lys Glu Ala Leu Ile Arg His Gln Gln Leu Ser Gly Leu His Lys
 485 490 495
 Gln Asn Leu Glu Ile His Arg Arg Ala His Leu Ser Glu Asn Glu Leu
 500 505 510
 Glu Ala Leu Glu Lys Asn Asp Met Glu Gln Met Lys Tyr Arg Asp Arg
 515 520 525
 Ala Ala Glu Arg Arg Glu Lys Tyr Gly Ile Pro Glu Pro Pro Glu Pro
 530 535 540
 Lys Arg Arg Lys Tyr Gly Gly Ile Ser Thr Ala Ser Val Asp Phe Glu
 545 550 555 560
 Gln Pro Thr Arg Asp Gly Leu Gly Ser Asp Asn Ile Gly Ser Arg Met
 565 570 575
 Leu Gln Ala Met Gly Trp Lys Glu Gly Ser Gly Leu Gly Arg Lys Lys
 580 585 590
 Gln Gly Ile Val Thr Pro Ile Glu Ala Gln Thr Arg Val Arg Gly Ser
 595 600 605
 Gly Leu Gly Ala Arg Gly Ser Ser Tyr Gly Val Thr Ser Thr Glu Ser
 610 615 620
 Tyr Lys Glu Thr Leu His Lys Thr Met Val Thr Arg Phe Asn Glu Ala
 625 630 635 640

616

Gln

<210> 653

<211> 516

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (1)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (247)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 653

Xaa	Thr	Arg	Pro	Gly	Arg	Gln	Thr	Arg	Leu	Cys	Arg	Pro	Ala	Ile	Ser
1				5					10					15	

Leu	Leu	Trp	Leu	Val	Thr	Pro	Gly	Val	Pro	Ala	Phe	Ser	Gly	Trp	Gly
			20					25						30	

Arg	Arg	His	Arg	Gly	Arg	Thr	Gly	Arg	Arg	Ala	Met	Ala	Ser	Cys	Val
		35					40					45			

Gly	Ser	Arg	Thr	Leu	Ser	Lys	Asp	Asp	Val	Asn	Tyr	Lys	Met	His	Phe
	50					55					60				

Arg	Met	Ile	Asn	Glu	Gln	Gln	Val	Glu	Asp	Ile	Thr	Ile	Asp	Phe	Phe
65					70					75					80

Tyr	Arg	Pro	His	Thr	Ile	Thr	Leu	Leu	Ser	Phe	Thr	Ile	Val	Ser	Leu
			85						90					95	

Met	Tyr	Phe	Ala	Phe	Thr	Arg	Asp	Asp	Ser	Val	Pro	Glu	Asp	Asn	Ile
		100						105					110		

Trp	Arg	Gly	Ile	Leu	Ser	Val	Ile	Phe	Phe	Phe	Leu	Ile	Ile	Ser	Val
		115					120					125			

Leu	Ala	Phe	Pro	Asn	Gly	Pro	Phe	Thr	Arg	Pro	His	Pro	Ala	Leu	Trp
130						135						140			

Arg	Met	Val	Phe	Gly	Leu	Ser	Val	Leu	Tyr	Phe	Leu	Phe	Leu	Val	Phe
145					150					155					160

Leu Leu Phe Leu Asn Phe Glu Gln Val Lys Ser Leu Met Tyr Trp Leu
 165 170 175
 Asp Pro Asn Leu Arg Tyr Ala Thr Arg Glu Ala Asp Val Met Glu Tyr
 180 185 190
 Ala Val Asn Cys His Val Ile Thr Trp Glu Arg Ile Ile Ser His Phe
 195 200 205
 Asp Ile Phe Ala Phe Gly His Phe Trp Gly Trp Ala Met Lys Ala Leu
 210 215 220
 Leu Ile Arg Ser Tyr Gly Leu Cys Trp Thr Ile Ser Ile Thr Trp Glu
 225 230 235 240
 Leu Thr Glu Leu Phe Phe Xaa His Leu Leu Pro Asn Phe Ala Glu Cys
 245 250 255
 Trp Trp Asp Gln Val Ile Leu Asp Ile Leu Leu Cys Asn Gly Gly Gly
 260 265 270
 Ile Trp Leu Gly Met Val Val Cys Arg Phe Leu Glu Met Arg Thr Tyr
 275 280 285
 His Trp Ala Ser Phe Lys Asp Ile His Thr Thr Thr Gly Lys Ile Lys
 290 295 300
 Arg Ala Val Leu Gln Phe Thr Pro Ala Ser Trp Thr Tyr Val Arg Trp
 305 310 315 320
 Phe Asp Pro Lys Ser Ser Phe Gln Arg Val Ala Gly Val Tyr Leu Phe
 325 330 335
 Met Ile Ile Trp Gln Leu Thr Glu Leu Asn Thr Phe Phe Leu Lys His
 340 345 350
 Ile Phe Val Phe Gln Ala Ser His Pro Leu Ser Trp Gly Arg Ile Leu
 355 360 365
 Phe Ile Gly Gly Ile Thr Ala Pro Thr Val Arg Gln Tyr Tyr Ala Tyr
 370 375 380
 Leu Thr Asp Thr Gln Cys Lys Arg Val Gly Thr Gln Cys Trp Val Phe
 385 390 395 400
 Gly Val Ile Gly Phe Leu Glu Ala Ile Val Cys Ile Lys Phe Gly Gln
 405 410 415
 Asp Leu Phe Ser Lys Thr Gln Ile Leu Tyr Val Val Leu Trp Leu Leu
 420 425 430

618

Cys Val Ala Phe Thr Thr Phe Leu Cys Leu Tyr Gly Met Ile Trp Tyr
 435 440 445
 Ala Glu His Tyr Gly His Arg Glu Lys Thr Tyr Ser Glu Cys Glu Asp
 450 455 460
 Gly Thr Tyr Ser Pro Glu Ile Ser Trp His His Arg Lys Gly Thr Lys
 465 470 475 480
 Gly Ser Glu Asp Ser Pro Pro Lys His Ala Gly Asn Asn Glu Ser His
 485 490 495
 Ser Ser Arg Arg Arg Asn Arg His Ser Lys Ser Lys Val Thr Asn Gly
 500 505 510
 Val Gly Lys Lys
 515

<210> 654
 <211> 663
 <212> PRT
 <213> Homo sapiens

<400> 654
 Leu Glu Cys Arg Glu Ala His Ile Arg Asp Val Pro Val Val Arg Leu
 1 5 10 15
 Pro Ala Asp Ser Pro Ile Pro Glu Arg Gly Asp Leu Ser Cys Arg Met
 20 25 30
 His Thr Cys Phe Asp Val Tyr Arg Cys Gly Phe Asn Pro Lys Asn Lys
 35 40 45
 Ile Lys Val Tyr Ile Tyr Ala Leu Lys Lys Tyr Val Asp Asp Phe Gly
 50 55 60
 Val Ser Val Ser Asn Thr Ile Ser Arg Glu Tyr Asn Glu Leu Leu Met
 65 70 75 80
 Ala Ile Ser Asp Ser Asp Tyr Tyr Thr Asp Asp Ile Asn Arg Ala Cys
 85 90 95
 Leu Phe Val Pro Ser Ile Asp Val Leu Asn Gln Asn Thr Leu Arg Ile
 100 105 110
 Lys Glu Thr Ala Gln Ala Met Ala Gln Leu Ser Arg Trp Asp Arg Gly
 115 120 125
 Thr Asn His Leu Leu Phe Asn Met Leu Pro Gly Gly Pro Pro Asp Tyr

619

130	135	140
Asn Thr Ala Leu Asp Val Pro Arg Asp Arg Ala Leu Leu Ala Gly Gly		
145	150	155 160
Gly Phe Ser Thr Trp Thr Tyr Arg Gln Gly Tyr Asp Val Ser Ile Pro		
	165	170 175
Val Tyr Ser Pro Leu Ser Ala Glu Val Asp Leu Pro Glu Lys Gly Pro		
	180	185 190
Gly Pro Arg Gln Tyr Phe Leu Leu Ser Ser Gln Val Gly Leu His Pro		
	195	200 205
Glu Tyr Arg Glu Asp Leu Glu Ala Leu Gln Val Lys His Gly Glu Ser		
	210	215 220
Val Leu Val Leu Asp Lys Cys Thr Asn Leu Ser Glu Gly Val Leu Ser		
	225	230 235 240
Val Arg Lys Arg Cys His Lys His Gln Val Phe Asp Tyr Pro Gln Val		
	245	250 255
Leu Gln Glu Ala Thr Phe Cys Val Val Leu Arg Gly Ala Arg Leu Gly		
	260	265 270
Gln Ala Val Leu Ser Asp Val Leu Gln Ala Gly Cys Val Pro Val Val		
	275	280 285
Ile Ala Asp Ser Tyr Ile Leu Pro Phe Ser Glu Val Leu Asp Trp Lys		
	290	295 300
Arg Ala Ser Val Val Val Pro Glu Glu Lys Met Ser Asp Val Tyr Ser		
	305	310 315 320
Ile Leu Gln Ser Ile Pro Gln Arg Gln Ile Glu Glu Met Gln Arg Gln		
	325	330 335
Ala Arg Trp Phe Trp Glu Ala Tyr Phe Gln Ser Ile Lys Ala Ile Ala		
	340	345 350
Leu Ala Thr Leu Gln Ile Ile Asn Asp Arg Ile Tyr Pro Tyr Ala Ala		
	355	360 365
Ile Ser Tyr Glu Glu Trp Asn Asp Pro Pro Ala Val Lys Trp Gly Ser		
	370	375 380
Val Ser Asn Pro Leu Phe Leu Pro Leu Ile Pro Pro Gln Ser Gln Gly		
	385	390 395 400
Phe Thr Ala Ile Val Leu Thr Tyr Asp Arg Val Glu Ser Leu Phe Arg		

620

	405		410		415
Val Ile Thr Glu Val Ser Lys Val Pro Ser Leu Ser Lys Leu Leu Val					
	420		425		430
Val Trp Asn Asn Gln Asn Lys Asn Pro Pro Glu Asp Ser Leu Trp Pro					
	435		440		445
Lys Ile Arg Val Pro Leu Lys Val Val Arg Thr Ala Glu Asn Lys Leu					
	450		455		460
Ser Asn Arg Phe Phe Pro Tyr Asp Glu Ile Glu Thr Glu Ala Val Leu					
	465		470		475
Ala Ile Asp Asp Asp Ile Ile Met Leu Thr Ser Asp Glu Leu Gln Phe					
			485		490
					495
Gly Tyr Glu Val Trp Arg Glu Phe Pro Asp Arg Leu Val Gly Tyr Pro					
	500		505		510
Gly Arg Leu His Leu Trp Asp His Glu Met Asn Lys Trp Lys Tyr Glu					
	515		520		525
Ser Glu Trp Thr Asn Glu Val Ser Met Val Leu Thr Gly Ala Ala Phe					
	530		535		540
Tyr His Lys Tyr Phe Asn Tyr Leu Tyr Thr Tyr Lys Met Pro Gly Asp					
	545		550		555
					560
Ile Lys Asn Trp Val Asp Ala His Met Asn Cys Glu Asp Ile Ala Met					
	565		570		575
Asn Phe Leu Val Ala Asn Val Thr Gly Lys Ala Val Ile Lys Val Thr					
	580		585		590
Pro Arg Lys Lys Phe Lys Cys Pro Glu Cys Thr Ala Ile Asp Gly Leu					
	595		600		605
Ser Leu Asp Gln Thr His Met Val Glu Arg Ser Glu Cys Ile Asn Lys					
	610		615		620
Phe Ala Ser Val Phe Gly Thr Met Pro Leu Lys Val Val Glu His Arg					
	625		630		635
					640
Ala Asp Pro Val Leu Tyr Lys Asp Asp Phe Pro Glu Lys Leu Lys Ser					
	645		650		655
Phe Pro Asn Ile Gly Ser Leu					
	660				

621

<210> 655
 <211> 97
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (38)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (91)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 655
 Ala Thr Gln Leu Leu Ser Ser Phe Ser Val Gly Pro Leu Leu Gln Ile
 1 5 10 15
 Thr Phe Tyr Glu Asp Lys Asn Phe Gln Gly Arg Arg Tyr Asp Cys Asp
 20 25 30
 Cys Asp Cys Ala Asp Xaa His Thr Tyr Leu Ser Arg Cys Asn Ser Ile
 35 40 45
 Lys Val Glu Gly Gly Thr Trp Ala Val Tyr Glu Arg Pro Asn Phe Ala
 50 55 60
 Gly Tyr Met Tyr Ile Leu Pro Gln Gly Glu Tyr Pro Glu Tyr Gln Arg
 65 70 75 80
 Trp Met Gly Leu Asn Asp Arg Leu Ser Ser Xaa Arg Ala Val Ser Ser
 85 90 95

Ala

<210> 656
 <211> 167
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (59)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>

622

<221> SITE

<222> (73)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 656

Asp Ala Asp Leu Val Ile Trp Asp Pro Asp Ser Val Lys Thr Ile Ser
 1 5 10 15

Ala Lys Thr His Asn Ser Ser Leu Glu Tyr Asn Ile Phe Glu Gly Met
 20 25 30

Glu Cys Arg Gly Ser Pro Leu Val Val Ile Ser Gln Gly Lys Ile Val
 35 40 45

Leu Glu Asp Gly Thr Leu His Val Thr Glu Xaa Ser Gly Arg Tyr Ile
 50 55 60

Pro Arg Lys Pro Phe Pro Asp Phe Xaa Tyr Lys Arg Ile Lys Ala Arg
 65 70 75 80

Ser Arg Leu Ala Glu Leu Arg Gly Val Pro Arg Gly Leu Tyr Asp Gly
 85 90 95

Pro Val Cys Glu Val Ser Val Thr Pro Lys Thr Val Thr Pro Ala Ser
 100 105 110

Ser Ala Lys Thr Ser Pro Ala Lys Gln Gln Ala Pro Pro Val Arg Asn
 115 120 125

Leu His Gln Ser Gly Phe Ser Leu Ser Gly Ala Gln Ile Asp Asp Asn
 130 135 140

Ile Pro Arg Arg Thr Thr Gln Arg Ile Val Ala Pro Pro Gly Gly Arg
 145 150 155 160

Ala Asn Ile Thr Ser Leu Gly
 165

<210> 657

<211> 176

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (1)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

623

<221> SITE

<222> (6)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (26)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 657

Xaa Ser Leu Asn Leu Xaa Lys Leu Ala Leu His Arg Gly Gly Gly Arg
 1 5 10 15

Ser Arg Thr Ser Gly Ser Pro Gly Leu Xaa Glu Phe Gly Thr Ser Ala
 20 25 30

Val Leu Leu Arg Leu Gly Asp Glu Leu Glu Met Ile Arg Pro Ser Val
 35 40 45

Tyr Arg Asn Val Ala Arg Gln Leu His Ile Ser Leu Gln Ser Glu Pro
 50 55 60

Val Val Thr Asp Ala Phe Leu Ala Val Ala Gly His Ile Phe Ser Ala
 65 70 75 80

Gly Ile Thr Trp Gly Lys Val Val Ser Leu Tyr Ala Val Ala Ala Gly
 85 90 95

Leu Ala Val Asp Cys Val Arg Gln Ala Gln Pro Ala Met Val His Ala
 100 105 110

Leu Val Asp Cys Leu Gly Glu Phe Val Arg Lys Thr Leu Ala Thr Trp
 115 120 125

Leu Arg Arg Arg Gly Gly Trp Thr Asp Val Leu Lys Cys Val Val Ser
 130 135 140

Thr Asp Pro Gly Leu Arg Ser His Trp Leu Val Ala Ala Leu Cys Ser
 145 150 155 160

Phe Gly Arg Phe Leu Lys Ala Ala Phe Phe Val Leu Leu Pro Glu Arg
 165 170 175

<210> 658

<211> 137

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (75)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (91)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (101)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (124)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (129)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (131)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 658

Gly Pro Val Gly Ser Ser Ser Glu Ala Pro Arg Gly Ala Gly Asp Ala
1 5 10 15

Gly Met Ala Gly Glu Leu Thr Pro Glu Glu Glu Ala Gln Tyr Lys Lys
20 25 30

Ala Phe Ser Ala Val Asp Thr Asp Gly Asn Gly Thr Ile Asn Ala Gln
35 40 45

Glu Leu Gly Ala Ala Leu Lys Ala Thr Gly Lys Asn Leu Ser Glu Ala
50 55 60

Gln Leu Arg Lys Leu Ile Ser Glu Val Asp Xaa Asp Gly Asp Gly Glu
65 70 75 80

Ile Ser Phe Gln Glu Phe Leu Thr Ala Ala Xaa Lys Ala Arg Ala Gly
85 90 95

625

Leu Glu Asp Leu Xaa Val Ala Phe Arg Ala Phe Asp Gln Asp Gly Asp
 100 105 110
 Gly His Ile Thr Val Asp Glu Leu Arg Arg Ala Xaa Ala Gly Leu Gly
 115 120 125
 Xaa Leu Xaa Glu Ile Asp His Phe Gly
 130 135

<210> 659
 <211> 34
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (2)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (28)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (30)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 659
 Pro Xaa Ser Arg Gln Asp Val Met Asp Ile Val Phe Ile Glu Gln Leu
 1 5 10 15
 Ser Val Ile Thr Thr Ile Gly Val Tyr Asp Trp Xaa Gln Xaa Ser Asn
 20 25 30

Arg Ser

<210> 660
 <211> 56
 <212> PRT
 <213> Homo sapiens

<400> 660
 Asn Pro Ile Ser Pro Lys Asn Tyr Lys Lys Ile Ser Gln Ala Gln Ser
 1 5 10 15

626

Gln Leu Pro Val Ile Pro Ala Thr Gln Glu Ala Glu Ser Gly Glu Ser
 20 25 30

Leu Gly Pro Gly Ala Ala Glu Val Asn Ser Glu Pro Arg Leu His His
 35 40 45

Arg Thr Pro Ala Trp Ile Thr Lys
 50 55

<210> 661
 <211> 41
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (29)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (31)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (36)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (39)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 661
 Tyr Ile Gly Phe Val Ile Leu Val Phe Phe Ala Ser Ser Tyr Val Lys
 1 5 10 15

Glu Ile Asp Asn Lys Ile Leu Asn Asn Lys Lys Lys Xaa Lys Xaa Ser
 20 25 30

Ser Lys Gly Xaa Val Ala Xaa Ala Ile
 35 40

<210> 662
 <211> 524

627

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (124)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (191)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 662

Cys Glu Ala Trp Arg Gly Arg Ala Asp Pro Gly Gly Gln Ser Cys Leu
 1 5 10 15

Gln Ala Leu Gln Asn Ser Thr Ala Pro Gln His Pro Gly Leu His Arg
 20 25 30

Trp Thr Gly Asp Arg Lys Met Pro Pro Arg Arg Asp Arg Gly Cys Asp
 35 40 45

Pro Val Gly Asn Ile Pro Gln Gly Glu Ser Gly Gly Trp Trp Pro Glu
 50 55 60

Gly Ala Gly Asp Leu Leu Gly Ala Thr Pro Asp Arg Glu Ser Pro Gln
 65 70 75 80

Leu Pro Gly Gln Arg Leu Gln Pro His Pro Gln Gln Cys Leu His Gly
 85 90 95

Arg Arg Val Arg Gly Pro Ser Trp Arg Val Glu Ala Trp Gly Pro Gly
 100 105 110

Leu His Val Phe Gly Pro Gly Gln Arg Trp Gly Xaa Ser Pro Gln Gly
 115 120 125

Ile Pro Glu Leu Glu Gln Tyr Asp Pro Pro Glu Leu Ala Asp Ser Ser
 130 135 140

Gly Arg Val Val Arg Glu Lys Trp Ser Ala Asp Met Trp Arg Leu Gly
 145 150 155 160

Cys Leu Ile Trp Glu Val Phe Asn Gly Pro Leu Pro Arg Ala Ala Ala
 165 170 175

Leu Arg Asn Pro Gly Lys Ile Pro Lys Thr Leu Val Pro His Xaa Cys
 180 185 190

Lys Leu Val Gly Ala Asn Pro Lys Val Arg Pro Asn Pro Ala Arg Phe

628

195	200	205
Leu Gln Asn Cys Arg Ala Pro Gly Gly Phe Met Ser Asn Arg Phe Val		
210	215	220
Glu Thr Asn Leu Phe Leu Glu Glu Ile Gln Ile Lys Glu Pro Ala Glu		
225	230	235 240
Lys Gln Lys Phe Phe Gln Glu Leu Ser Lys Ser Leu Asp Ala Phe Pro		
	245	250 255
Glu Asp Phe Cys Arg His Lys Val Leu Pro Gln Leu Leu Thr Ala Phe		
	260	265 270
Glu Phe Gly Asn Ala Gly Ala Val Val Leu Thr Pro Leu Phe Lys Val		
	275	280 285
Gly Lys Phe Leu Ser Ala Glu Glu Tyr Gln Gln Lys Ile Ile Pro Val		
	290	295 300
Val Val Lys Met Phe Ser Ser Thr Asp Arg Ala Met Arg Ile Arg Leu		
305	310	315 320
Leu Gln Gln Met Glu Gln Phe Ile Gln Tyr Leu Asp Glu Pro Thr Val		
	325	330 335
Asn Thr Gln Ile Phe Pro His Val Val His Gly Phe Leu Asp Thr Asn		
	340	345 350
Pro Ala Ile Arg Glu Gln Thr Val Lys Ser Met Leu Leu Leu Ala Pro		
	355	360 365
Lys Leu Asn Glu Ala Asn Leu Asn Val Glu Leu Met Lys His Phe Ala		
	370	375 380
Arg Leu Gln Ala Lys Asp Glu Gln Gly Pro Ile Arg Cys Asn Thr Thr		
385	390	395 400
Val Cys Leu Gly Lys Ile Gly Ser Tyr Leu Ser Ala Ser Thr Arg His		
	405	410 415
Arg Val Leu Thr Ser Ala Phe Ser Arg Ala Thr Arg Asp Pro Phe Ala		
	420	425 430
Pro Ser Arg Val Ala Gly Val Leu Gly Phe Ala Ala Thr His Asn Leu		
	435	440 445
Tyr Ser Met Asn Asp Cys Ala Gln Lys Ile Leu Pro Val Leu Cys Gly		
450	455	460
Leu Thr Val Asp Pro Glu Lys Ser Val Arg Asp Gln Ala Phe Lys Ala		

629

465 470 475 480

Phe Gly Ala Ser Cys Pro Asn Trp Ser Leu Cys Arg Arg Thr Arg Pro
 485 490 495

Ser Trp Arg Lys Trp Arg Arg Met Ser Met Gln Pro Pro Ala Leu Ala
 500 505 510

Trp Glu Glu Pro Gln Leu Ala Gly Gln Ala Gly Pro
 515 520

<210> 663

<211> 272

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (29)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 663

Pro Thr Leu Asp Ser Ala Arg Ser Leu Ser Met Arg Ala Pro Ser Leu
 1 5 10 15

Thr Pro Ser Ala Ala Pro Leu Ser Thr Trp Pro Leu Xaa Ile Leu Val
 20 25 30

Arg Ser Gly His Asn Arg Ala Val Asp Trp Trp Ser Leu Gly Ala Leu
 35 40 45

Met Tyr Asp Met Leu Thr Gly Ser Pro Pro Phe Thr Ala Glu Asn Arg
 50 55 60

Lys Lys Thr Met Asp Lys Ile Ile Arg Gly Lys Leu Ala Leu Pro Pro
 65 70 75 80

Tyr Leu Thr Pro Asp Ala Arg Asp Leu Val Lys Lys Phe Leu Lys Arg
 85 90 95

Asn Pro Ser Gln Arg Ile Gly Gly Gly Pro Gly Asp Ala Ala Asp Val
 100 105 110

Gln Arg His Pro Phe Phe Arg His Met Asn Trp Asp Asp Leu Leu Ala
 115 120 125

Trp Arg Val Asp Pro Pro Phe Arg Pro Cys Leu Gln Ser Glu Glu Asp
 130 135 140

630

Val Ser Gln Phe Asp Thr Arg Phe Thr Arg Gln Thr Pro Val Asp Ser
 145 150 155 160
 Pro Asp Asp Thr Ala Leu Ser Glu Ser Ala Asn Gln Ala Phe Leu Gly
 165 170 175
 Phe Thr Tyr Val Ala Pro Ser Val Leu Asp Ser Ile Lys Glu Gly Phe
 180 185 190
 Ser Phe Gln Pro Lys Leu Arg Ser Pro Arg Arg Leu Asn Ser Ser Pro
 195 200 205
 Arg Ala Pro Val Ser Pro Leu Lys Phe Ser Pro Phe Glu Gly Phe Arg
 210 215 220
 Pro Ser Pro Ser Leu Pro Glu Pro Thr Glu Leu Pro Leu Pro Pro Leu
 225 230 235 240
 Leu Pro Pro Pro Pro Pro Ser Thr Thr Ala Pro Leu Pro Ile Arg Pro
 245 250 255
 Pro Ser Gly Thr Lys Lys Ser Lys Arg Gly Arg Gly Arg Pro Gly Arg
 260 265 270

<210> 664

<211> 256

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (99)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 664

Gly Thr Arg Arg Glu Thr Trp Arg Pro Gly Ser Met Ala Gly Leu Glu
 1 5 10 15
 Leu Leu Ser Asp Gln Gly Tyr Arg Val Asp Gly Arg Arg Ala Gly Glu
 20 25 30
 Leu Arg Lys Ile Gln Ala Arg Met Gly Val Phe Ala Gln Ala Asp Gly
 35 40 45
 Ser Ala Tyr Ile Glu Gln Gly Asn Thr Lys Ala Leu Ala Val Val Tyr
 50 55 60

631

Gly Pro His Glu Ile Arg Gly Ser Arg Ala Arg Ala Leu Pro Asp Arg
 65 70 75 80
 Ala Leu Val Asn Cys Gln Tyr Ser Ser Ala Thr Phe Ser Thr Gly Glu
 85 90 95
 Arg Lys Xaa Arg Pro His Gly Asp Arg Lys Ser Cys Glu Met Gly Leu
 100 105 110
 Gln Leu Arg Gln Thr Phe Glu Ala Ala Ile Leu Thr Gln Leu His Pro
 115 120 125
 Arg Ser Gln Ile Asp Ile Tyr Val Gln Val Leu Gln Ala Asp Gly Gly
 130 135 140
 Thr Tyr Ala Ala Cys Val Asn Ala Ala Thr Leu Ala Val Leu Asp Ala
 145 150 155 160
 Gly Ile Pro Met Arg Asp Phe Val Cys Ala Cys Ser Ala Gly Phe Val
 165 170 175
 Asp Gly Thr Ala Leu Ala Asp Leu Ser His Val Glu Glu Ala Ala Gly
 180 185 190
 Gly Pro Gln Leu Ala Leu Ala Leu Leu Pro Ala Ser Gly Gln Ile Ala
 195 200 205
 Leu Leu Glu Met Asp Ala Arg Leu His Glu Asp His Leu Glu Arg Val
 210 215 220
 Leu Glu Ala Ala Ala Gln Ala Ala Arg Asp Val His Thr Leu Leu Asp
 225 230 235 240
 Arg Val Val Arg Gln His Val Arg Glu Ala Ser Ile Leu Leu Gly Asp
 245 250 255

<210> 665

<211> 241

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (9)

<223> Xaa equals any of the naturally occurring L-amino acids

632

<220>

<221> SITE

<222> (122)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 665

```

Pro Arg Gly Asp Lys Ala Arg Thr Xaa Pro Pro Ala Ala Ser Ala Arg
 1              5              10              15

Pro Ser Arg Ser Lys Arg Gly Gly Glu Arg Val Leu Glu Lys Glu
      20              25              30

Glu Glu Glu Asp Asp Asp Glu Asp Glu Asp Glu Glu Asp Asp Val Ser
      35              40              45

Glu Gly Ser Glu Val Pro Glu Ser Asp Arg Pro Ala Gly Ala Gln His
      50              55              60

His Gln Leu Asn Gly Glu Arg Gly Pro Gln Ser Ala Lys Glu Arg Val
      65              70              75              80

Lys Glu Trp Thr Pro Cys Gly Pro His Gln Gly Gln Asp Glu Gly Arg
      85              90              95

Gly Pro Ala Pro Gly Ser Gly Thr Arg Gln Val Phe Ser Met Ala Ala
      100              105              110

Met Asn Lys Glu Gly Gly Thr Ala Ser Xaa Ala Thr Gly Pro Asp Ser
      115              120              125

Pro Ser Pro Val Pro Leu Pro Pro Gly Lys Pro Ala Leu Pro Gly Ala
      130              135              140

Asp Gly Thr Pro Phe Gly Cys Pro Pro Gly Arg Lys Glu Lys Pro Ser
      145              150              155              160

Asp Pro Val Glu Trp Thr Val Met Asp Val Val Glu Tyr Phe Thr Glu
      165              170              175

Ala Gly Phe Pro Glu Gln Ala Thr Val Phe Gln Glu Gln Glu Ile Asp
      180              185              190

Gly Lys Ser Leu Leu Leu Met Gln Arg Thr Asp Val Leu Thr Gly Leu
      195              200              205

Ser Ile Arg Leu Gly Pro Ala Leu Lys Ile Tyr Glu His His Ile Lys
      210              215              220

Val Leu Gln Gln Gly His Phe Glu Asp Asp Asp Pro Asp Gly Phe Leu
      225              230              235              240

```

633

Gly

<210> 666

<211> 131

<212> PRT

<213> Homo sapiens

<400> 666

Val Thr Gly Gly Gly Ala Val Val Leu Gly Ala Glu Ser His Ala Ser
 1 5 10 15

Lys Asp Val Ala Ile Asp Met Met Asp Ser Arg Thr Ser Gln Gln Leu
 20 25 30

Gln Leu Ile Asp Glu Gln Asp Ser Tyr Ile Gln Ser Arg Ala Asp Thr
 35 40 45

Met Gln Asn Ile Glu Ser Thr Ile Val Glu Leu Gly Ser Ile Phe Gln
 50 55 60

Gln Leu Ala His Met Val Lys Glu Gln Glu Glu Thr Ile Gln Arg Ile
 65 70 75 80

Asp Glu Asn Val Leu Gly Ala Gln Leu Asp Val Glu Ala Ala His Ser
 85 90 95

Glu Ile Leu Lys Tyr Phe Gln Ser Val Thr Ser Asn Arg Trp Leu Met
 100 105 110

Val Lys Ile Phe Leu Ile Leu Ile Val Phe Phe Ile Ile Phe Val Val
 115 120 125

Phe Leu Ala
 130

<210> 667

<211> 652

<212> PRT

<213> Homo sapiens

<400> 667

Leu Ser Trp Asn Arg Tyr Thr Ser Val Ser Pro Leu His Arg Ser Leu
 1 5 10 15

Gln Leu Pro Pro Arg Val Ser Gly Val Arg Cys Asp Gln Cys Ala Arg

634

	20		25		30
Gly Phe Ser Gly Ile Phe Pro Ala Cys His Pro Cys His Ala Cys Phe	35	40	45		
Gly Asp Trp Asp Arg Val Val Gln Asp Leu Ala Ala Arg Thr Gln Arg	50	55	60		
Leu Glu Gln Arg Ala Gln Glu Leu Gln Gln Thr Gly Val Leu Gly Ala	65	70	75	80	
Phe Glu Ser Ser Phe Trp His Met Gln Glu Lys Leu Gly Ile Val Gln	85	90	95		
Gly Ile Val Gly Ala Arg Asn Thr Ser Ala Ala Ser Thr Ala Gln Leu	100	105	110		
Val Glu Ala Thr Glu Glu Leu Arg Arg Glu Ile Gly Glu Ala Thr Glu	115	120	125		
His Leu Thr Gln Leu Glu Ala Asp Leu Thr Asp Val Gln Asp Glu Asn	130	135	140		
Phe Asn Ala Asn His Ala Leu Ser Gly Leu Glu Arg Asp Arg Leu Ala	145	150	155	160	
Leu Asn Leu Thr Leu Arg Gln Leu Asp Gln His Leu Asp Leu Leu Lys	165	170	175		
His Ser Asn Phe Leu Gly Ala Tyr Asp Ser Ile Arg His Ala His Ser	180	185	190		
Gln Ser Ala Glu Ala Glu Arg Arg Ala Asn Thr Ser Ala Leu Ala Val	195	200	205		
Pro Ser Pro Val Ser Asn Ser Ala Ser Ala Arg His Arg Thr Glu Ala	210	215	220		
Leu Met Asp Ala Gln Lys Glu Asp Phe Asn Ser Lys His Met Ala Asn	225	230	235	240	
Gln Arg Ala Leu Gly Lys Leu Ser Ala His Thr His Thr Leu Ser Leu	245	250	255		
Thr Asp Ile Asn Glu Leu Val Cys Gly Ala Pro Gly Asp Ala Pro Cys	260	265	270		
Ala Thr Ser Pro Cys Gly Gly Ala Gly Cys Arg Asp Glu Asp Gly Gln	275	280	285		
Pro Arg Cys Gly Gly Leu Ser Cys Asn Gly Ala Ala Ala Thr Ala Asp					

290

300

Gly Asp Gln Tyr Gln Thr Val Lys Ala Leu Ala Glu Arg Lys Ala Gln

636

565	570	575
Gly Val Leu Ala Ala Gln Ala Arg Ala Glu Gln Leu Arg Asp Glu Ala		
580	585	590
Arg Asp Leu Leu Gln Ala Ala Gln Asp Lys Leu Gln Arg Leu Gln Glu		
595	600	605
Leu Glu Gly Thr Tyr Glu Glu Asn Glu Arg Ala Leu Glu Ser Lys Ala		
610	615	620
Ala Gln Leu Asp Gly Leu Glu Ala Arg Met Arg Ser Val Leu Gln Ala		
625	630	635
Ile Asn Leu Gln Val Gln Ile Tyr Asn Thr Cys Gln		
645	650	
<210> 668		
<211> 406		
<212> PRT		
<213> Homo sapiens		
<220>		
<221> SITE		
<222> (84)		
<223> Xaa equals any of the naturally occurring L-amino acids		
<400> 668		
Gly Ala Val Arg Ser Ser Cys Ala Glu Leu Gln Ala Arg Val Met Ala		
1	5	10
Ala Leu Arg Gln Pro Gln Val Ala Glu Cys Trp Pro Arg Pro Gly Glu		
20	25	30
Pro Ser Gly Arg Ser Ser Gly Pro Ser Pro Ser Trp Pro Cys Gln Arg		
35	40	45
Arg Ala Ala Cys Asn Leu Ile Gly Glu His Thr Asp Tyr Asn Gln Gly		
50	55	60
Leu Val Leu Pro Met Ala Leu Glu Leu Met Thr Val Leu Val Gly Ser		
65	70	75
Pro Arg Lys Xaa Gly Leu Val Ser Leu Leu Thr Thr Ser Glu Gly Ala		
85	90	95
Asp Glu Pro Gln Arg Leu Gln Phe Pro Leu Pro Thr Ala Gln Arg Ser		
100	105	110

637

Leu Glu Pro Gly Thr Pro Arg Trp Ala Asn Tyr Val Lys Gly Val Ile
 115 120 125

Gln Tyr Tyr Pro Ala Ala Pro Leu Pro Gly Phe Ser Ala Val Val Val
 130 135 140

Ser Ser Val Pro Leu Gly Gly Gly Leu Ser Ser Ser Ala Ser Leu Glu
 145 150 155 160

Val Ala Thr Tyr Thr Phe Leu Gln Gln Leu Cys Pro Asp Ser Gly Thr
 165 170 175

Ile Ala Ala Arg Ala Gln Val Cys Gln Gln Ala Glu His Ser Phe Ala
 180 185 190

Gly Met Pro Cys Gly Ile Met Asp Gln Phe Ile Ser Leu Met Gly Gln
 195 200 205

Lys Gly His Ala Leu Leu Ile Asp Cys Arg Ser Leu Glu Thr Ser Leu
 210 215 220

Val Pro Leu Ser Asp Pro Lys Leu Ala Val Leu Ile Thr Asn Ser Asn
 225 230 235 240

Val Arg His Ser Leu Ala Ser Ser Glu Tyr Pro Val Arg Arg Arg Gln
 245 250 255

Cys Glu Glu Val Ala Arg Ala Leu Gly Lys Glu Ser Leu Arg Glu Val
 260 265 270

Gln Leu Glu Glu Leu Glu Ala Ala Arg Asp Leu Val Ser Lys Glu Gly
 275 280 285

Phe Arg Arg Ala Arg His Val Val Gly Glu Ile Arg Arg Thr Ala Gln
 290 295 300

Ala Ala Ala Ala Leu Arg Arg Gly Asp Tyr Arg Ala Phe Gly Arg Leu
 305 310 315 320

Met Val Glu Ser His Arg Ser Leu Arg Asp Asp Tyr Glu Val Ser Cys
 325 330 335

Pro Glu Leu Asp Gln Leu Val Glu Ala Ala Leu Ala Val Pro Gly Val
 340 345 350

Tyr Gly Ser Arg Met Thr Gly Gly Gly Phe Gly Gly Cys Thr Val Thr
 355 360 365

Leu Leu Glu Ala Ser Ala Ala Pro His Ala Met Arg His Ile Gln Glu
 370 375 380

638

His Tyr Gly Gly Thr Ala Thr Phe Tyr Leu Ser Gln Ala Ala Asp Gly
 385 390 395 400

Ala Lys Val Leu Cys Leu
 405

<210> 669
 <211> 86
 <212> PRT
 <213> Homo sapiens

<400> 669
 Pro Glu Pro Thr Val Val Met Ala Ala Arg Ala Leu Cys Met Leu Gly
 1 5 10 15

Leu Val Leu Ala Leu Leu Ser Ser Ser Ser Ala Glu Glu Tyr Val Gly
 20 25 30

Leu Ser Ala Asn Gln Cys Ala Val Pro Ala Lys Asp Arg Val Asp Cys
 35 40 45

Gly Tyr Pro His Val Thr Pro Lys Glu Cys Asn Asn Arg Gly Cys Cys
 50 55 60

Phe Asp Ser Arg Ile Pro Gly Val Pro Trp Cys Phe Lys Pro Leu Gln
 65 70 75 80

Glu Ala Glu Cys Thr Phe
 85

<210> 670
 <211> 392
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (6)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 670
 Gly Gly Gly Ala Arg Xaa Ser Pro Ala Thr Gln Pro Pro Pro Leu Leu
 1 5 10 15

Pro Pro Ser Ala Thr Gly Pro Asp Ala Thr Val Gly Gly Pro Ala Pro
 20 25 30

Thr Pro Leu Leu Pro Pro Ser Ala Thr Ala Ser Val Lys Met Glu Pro
 35 40 45
 Glu Asn Lys Tyr Leu Pro Glu Leu Met Ala Glu Lys Asp Ser Leu Asp
 50 55 60
 Pro Ser Phe Thr His Ala Met Gln Leu Leu Thr Ala Glu Ile Glu Lys
 65 70 75 80
 Ile Gln Lys Gly Asp Ser Lys Lys Asp Asp Glu Glu Asn Tyr Leu Asp
 85 90 95
 Leu Phe Ser His Lys Asn Met Lys Leu Lys Glu Arg Val Leu Ile Pro
 100 105 110
 Val Lys Gln Tyr Pro Lys Phe Asn Phe Val Gly Lys Ile Leu Gly Pro
 115 120 125
 Gln Gly Asn Thr Ile Lys Arg Leu Gln Glu Glu Thr Gly Ala Lys Ile
 130 135 140
 Ser Val Leu Gly Lys Gly Ser Met Arg Asp Lys Ala Lys Glu Glu Glu
 145 150 155 160
 Leu Arg Lys Gly Gly Asp Pro Lys Tyr Ala His Leu Asn Met Asp Leu
 165 170 175
 His Val Phe Ile Glu Val Phe Gly Pro Pro Cys Glu Ala Tyr Ala Leu
 180 185 190
 Met Ala His Ala Met Glu Glu Val Lys Lys Phe Leu Val Pro Asp Met
 195 200 205
 Met Asp Asp Ile Cys Gln Glu Gln Phe Leu Glu Leu Ser Tyr Leu Asn
 210 215 220
 Gly Val Pro Glu Pro Ser Arg Gly Arg Gly Val Pro Val Arg Gly Arg
 225 230 235 240
 Gly Ala Ala Pro Pro Pro Pro Val Pro Arg Gly Arg Gly Val Gly
 245 250 255
 Pro Pro Arg Gly Ala Leu Val Arg Gly Thr Pro Val Arg Gly Ala Ile
 260 265 270
 Thr Arg Gly Ala Thr Val Thr Arg Gly Val Pro Pro Pro Pro Thr Val
 275 280 285
 Arg Gly Ala Pro Ala Pro Arg Ala Arg Thr Ala Gly Ile Gln Arg Ile
 290 295 300

640

Pro Leu Pro Pro Pro Pro Ala Pro Glu Thr Tyr Glu Glu Tyr Gly Tyr
 305 310 315 320
 Asp Asp Thr Tyr Ala Glu Gln Ser Tyr Glu Gly Tyr Glu Gly Tyr Tyr
 325 330 335
 Ser Gln Ser Gln Gly Asp Ser Glu Tyr Tyr Asp Tyr Gly His Gly Glu
 340 345 350
 Val Gln Asp Ser Tyr Glu Ala Tyr Gly Gln Asp Asp Trp Asn Gly Thr
 355 360 365
 Arg Pro Ser Leu Lys Ala Pro Pro Ala Arg Pro Val Lys Gly Ala Tyr
 370 375 380
 Arg Glu His Pro Tyr Gly Arg Tyr
 385 390

<210> 671
 <211> 180
 <212> PRT
 <213> Homo sapiens

<400> 671
 Arg Asn Met Ser Ser Phe Ser Arg Ala Pro Gln Gln Trp Ala Thr Phe
 1 5 10 15
 Ala Arg Ile Trp Tyr Leu Leu Asp Gly Lys Met Gln Pro Pro Gly Lys
 20 25 30
 Leu Ala Ala Met Ala Ser Ile Arg Leu Gln Gly Leu His Lys Pro Val
 35 40 45
 Tyr His Ala Leu Ser Asp Cys Gly Asp His Val Val Ile Met Asn Thr
 50 55 60
 Arg His Ile Ala Phe Ser Gly Asn Lys Trp Glu Gln Lys Val Tyr Ser
 65 70 75 80
 Ser His Thr Gly Tyr Pro Gly Gly Phe Arg Gln Val Thr Ala Ala Gln
 85 90 95
 Leu His Leu Arg Asp Pro Val Ala Ile Val Lys Leu Ala Ile Tyr Gly
 100 105 110
 Met Leu Pro Lys Asn Leu His Arg Arg Thr Met Met Glu Arg Leu His
 115 120 125
 Leu Phe Pro Asp Glu Tyr Ile Pro Glu Asp Ile Leu Lys Asn Leu Val

641

130 135 140
Glu Glu Leu Pro Gln Pro Arg Lys Ile Pro Lys Arg Leu Asp Glu Tyr
145 150 155 160
Thr Gln Glu Glu Ile Asp Ala Phe Pro Arg Leu Trp Thr Pro Pro Glu
165 170 175
Asp Tyr Arg Leu
180

<210> 672
<211> 78
<212> PRT
<213> Homo sapiens

<400> 672
Glu Asn Tyr Gln Phe Thr Tyr Arg Arg Phe Phe Phe Pro Asn Ser Arg
1 5 10 15
Phe His Pro Arg Pro Phe Glu Glu Leu Gln Thr Leu Ser Leu Arg Lys
20 25 30
Glu Arg Gly Gln Pro Lys Ile Asn Ala Lys Phe Ala Tyr Thr Pro Ser
35 40 45
His Ser Asp Val Leu Val Val Thr Tyr Tyr Gln Cys Gly Arg Glu Pro
50 55 60
Lys Leu His Phe Arg Ser Lys Tyr Ser Leu Cys Arg Tyr Cys
65 70 75

<210> 673
<211> 139
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (113)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (132)
<223> Xaa equals any of the naturally occurring L-amino acids

642

<400> 673

Pro Thr Arg Pro Pro Leu Cys Arg Gly Ala Ala Ser Arg Gly Leu Leu
1 5 10 15

Cys Lys Trp Ala Pro Trp Pro Ser Ala Pro Val Pro Ala Thr Arg Asp
20 25 30

Arg Ala Pro Arg Pro Ala Arg Gly Arg Arg Pro Gly Arg Leu Gly Ser
35 40 45

Thr Ser Ser Asn Ser Ser Cys Ser Ser Thr Glu Cys Pro Gly Glu Ala
50 55 60

Ile Pro His Pro Pro Gly Leu Pro Lys Ala Asp Pro Gly His Trp Trp
65 70 75 80

Ala Ser Phe Phe Phe Gly Lys Ser Thr Leu Pro Phe Met Ala Thr Val
85 90 95

Leu Glu Ser Ala Glu His Ser Glu Pro Pro Gln Ala Ser Ser Ser Met
100 105 110

Xaa Ala Cys Gly Leu Ala Arg Glu Ala Pro Arg Lys Gln Pro Gly Gly
115 120 125

Gln Ser Ser Xaa Ala Ser Ala Gly Pro Pro Ser
130 135

<210> 674

<211> 279

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (7)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (58)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (193)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 674

643

Glu Arg Ala His Ser Leu Xaa His Gly Val Asp Gly Glu Pro Cys Pro
 1 5 10 15
 Glu Asp Tyr Lys Tyr Ile Ser Glu Asn Cys Glu Thr Ser Thr Met Asn
 20 25 30
 Ile Asp Arg Asn Ile Thr His Leu Gln His Cys Thr Phe Val Asp Asp
 35 40 45
 Cys Ser Ser Ser Asn Cys Leu Cys Gly Xaa Phe Ser Ile Arg Cys Trp
 50 55 60
 Tyr Asp Lys Asp Gly Arg Leu Leu Gln Glu Phe Asn Lys Ile Glu Pro
 65 70 75 80
 Pro Leu Ile Phe Glu Cys Asn Gln Ala Cys Ser Cys Trp Arg Asn Cys
 85 90 95
 Lys Asn Arg Val Val Gln Ser Gly Ile Lys Val Arg Leu Gln Leu Tyr
 100 105 110
 Arg Thr Ala Lys Met Gly Trp Gly Val Arg Ala Leu Gln Thr Ile Pro
 115 120 125
 Gln Gly Thr Phe Ile Cys Glu Tyr Val Gly Glu Leu Ile Ser Asp Ala
 130 135 140
 Glu Ala Asp Val Arg Glu Asp Asp Ser Tyr Leu Phe Asp Leu Asp Asn
 145 150 155 160
 Lys Asp Gly Glu Val Tyr Cys Ile Asp Ala Arg Tyr Tyr Gly Asn Ile
 165 170 175
 Ser Arg Phe Ile Asn His Leu Cys Asp Pro Asn Ile Ile Pro Val Arg
 180 185 190
 Xaa Phe Met Leu His Gln Asp Leu Arg Phe Pro Arg Ile Ala Phe Phe
 195 200 205
 Ser Ser Arg Asp Ile Arg Thr Gly Glu Glu Leu Gly Phe Asp Tyr Gly
 210 215 220
 Asp Arg Phe Trp Asp Ile Lys Ser Lys Tyr Phe Thr Cys Gln Cys Gly
 225 230 235 240
 Ser Glu Lys Cys Lys His Ser Ala Glu Ala Ile Ala Leu Glu Gln Ser
 245 250 255
 Arg Leu Ala Arg Leu Asp Pro His Pro Glu Leu Leu Pro Glu Leu Gly
 260 265 270

644

Ser Leu Pro Pro Val Asn Thr
275

<210> 675

<211> 405

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (393)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (394)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 675

Arg Asn Thr Leu Gly Arg Gly Thr Thr Ile Thr Leu Val Leu Lys Glu
1 5 10 15

Glu Ala Ser Asp Tyr Leu Glu Leu Asp Thr Ile Lys Asn Leu Val Lys
20 25 30

Lys Tyr Ser Gln Phe Ile Asn Phe Pro Ile Tyr Val Trp Ser Ser Lys
35 40 45

Thr Glu Thr Val Glu Glu Pro Met Glu Glu Glu Glu Ala Ala Lys Glu
50 55 60

Glu Lys Glu Glu Ser Asp Asp Glu Ala Ala Val Glu Glu Glu Glu
65 70 75 80

Glu Lys Lys Pro Lys Thr Lys Lys Val Glu Lys Thr Val Trp Asp Trp
85 90 95

Glu Leu Met Asn Asp Ile Lys Pro Ile Trp Gln Arg Pro Ser Lys Glu
100 105 110

Val Glu Glu Asp Glu Tyr Lys Ala Phe Tyr Lys Ser Phe Ser Lys Glu
115 120 125

Ser Asp Asp Pro Met Ala Tyr Ile His Phe Thr Ala Glu Gly Glu Val
130 135 140

Thr Phe Lys Ser Ile Leu Phe Val Pro Thr Ser Ala Pro Arg Gly Leu
145 150 155 160

645

Phe Asp Glu Tyr Gly Ser Lys Lys Ser Asp Tyr Ile Lys Leu Tyr Val
 165 170 175
 Arg Arg Val Phe Ile Thr Asp Asp Phe His Asp Met Met Pro Lys Tyr
 180 185 190
 Leu Asn Phe Val Lys Gly Val Val Asp Ser Asp Asp Leu Pro Leu Asn
 195 200 205
 Val Ser Arg Glu Thr Leu Gln Gln His Lys Leu Leu Lys Val Ile Arg
 210 215 220
 Lys Lys Leu Val Arg Lys Thr Leu Asp Met Ile Lys Lys Ile Ala Asp
 225 230 235 240
 Asp Lys Tyr Asn Asp Thr Phe Trp Lys Glu Phe Gly Thr Asn Ile Lys
 245 250 255
 Leu Gly Val Ile Glu Asp His Ser Asn Arg Thr Arg Leu Ala Lys Leu
 260 265 270
 Leu Arg Phe Gln Ser Ser His His Pro Thr Asp Ile Thr Ser Leu Asp
 275 280 285
 Gln Tyr Val Glu Arg Met Lys Glu Lys Gln Asp Lys Ile Tyr Phe Met
 290 295 300
 Ala Gly Ser Ser Arg Lys Glu Ala Glu Ser Ser Pro Phe Val Glu Arg
 305 310 315 320
 Leu Leu Lys Lys Gly Tyr Glu Val Ile Tyr Leu Thr Glu Pro Val Asp
 325 330 335
 Glu Tyr Cys Ile Gln Ala Leu Pro Glu Phe Asp Gly Lys Arg Phe Gln
 340 345 350
 Asn Val Ala Lys Glu Gly Val Lys Phe Asp Glu Ser Glu Lys Thr Lys
 355 360 365
 Glu Ser Arg Glu Ala Val Glu Lys Glu Phe Glu Pro Leu Leu Asn Trp
 370 375 380
 Met Lys Asp Lys Ala Leu Lys Gly Xaa Xaa Leu Trp Glu Ile Leu Pro
 385 390 395 400
 Ile Cys Gly Lys Tyr
 405

646

<211> 465

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (5)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (6)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (16)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 676

Asn	Asp	Ser	Leu	Xaa	Xaa	Lys	Ala	Gly	Thr	Pro	Ala	Gly	Asn	Arg	Xaa
1				5					10					15	

Gly	Ile	Pro	Gly	Ser	Thr	His	Ala	Ser	Ala	Ala	Ala	Pro	Phe	Ala	Ala
			20					25					30		

Ala	Leu	Ala	Arg	Asp	Pro	Asn	Pro	Ala	Ser	Pro	Leu	Pro	Glu	His	Arg
		35					40					45			

Pro	Arg	Leu	His	Arg	Gly	Pro	Gly	Pro	Pro	Ala	Arg	Leu	Ala	Ala	Ala
	50				55					60					

Met	Ala	Asp	Pro	Lys	Tyr	Ala	Asp	Leu	Pro	Gly	Ile	Ala	Arg	Asn	Glu
65					70					75					80

Pro	Asp	Val	Tyr	Glu	Thr	Ser	Asp	Leu	Pro	Glu	Asp	Asp	Gln	Ala	Glu
			85						90				95		

Phe	Asp	Ala	Glu	Glu	Leu	Thr	Ser	Thr	Ser	Val	Glu	His	Ile	Ile	Val
		100						105					110		

Asn	Pro	Asn	Ala	Ala	Tyr	Asp	Lys	Phe	Lys	Asp	Lys	Arg	Val	Gly	Thr
	115						120					125			

Lys	Gly	Leu	Asp	Phe	Ser	Asp	Arg	Ile	Gly	Lys	Thr	Lys	Arg	Thr	Gly
	130					135					140				

Tyr	Glu	Ser	Gly	Glu	Tyr	Glu	Met	Leu	Gly	Glu	Gly	Leu	Gly	Val	Lys
145					150					155					160

Glu	Thr	Pro	Gln	Gln	Lys	Tyr	Gln	Arg	Leu	Leu	His	Glu	Val	Gln	Glu
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

647

165	170	175
Leu Thr Thr Glu Val Glu Lys Ile Lys Thr Thr Val Lys Glu Ser Ala		
180	185	190
Thr Glu Glu Lys Leu Thr Pro Val Leu Leu Ala Lys Gln Leu Ala Ala		
195	200	205
Leu Lys Gln Gln Leu Val Ala Ser His Leu Glu Lys Leu Leu Gly Pro		
210	215	220
Asp Ala Ala Ile Asn Leu Thr Asp Pro Asp Gly Ala Leu Ala Lys Arg		
225	230	235
Leu Leu Leu Gln Leu Glu Ala Thr Lys Asn Ser Lys Gly Gly Ser Gly		
245	250	255
Gly Lys Thr Thr Gly Thr Pro Pro Asp Ser Ser Leu Val Thr Tyr Glu		
260	265	270
Leu His Ser Arg Pro Glu Gln Asp Lys Phe Ser Gln Ala Ala Lys Val		
275	280	285
Ala Glu Leu Glu Lys Arg Leu Thr Glu Leu Glu Thr Ala Val Arg Cys		
290	295	300
Asp Gln Asp Ala Gln Asn Pro Leu Ser Ala Gly Leu Gln Gly Ala Cys		
305	310	315
Leu Met Glu Thr Val Glu Leu Leu Gln Ala Lys Val Ser Ala Leu Asp		
325	330	335
Leu Ala Val Leu Asp Gln Val Glu Ala Arg Leu Gln Ser Val Leu Gly		
340	345	350
Lys Val Asn Glu Ile Ala Lys His Lys Ala Ser Val Glu Asp Ala Asp		
355	360	365
Thr Gln Ser Lys Val His Gln Leu Tyr Glu Thr Ile Gln Arg Trp Ser		
370	375	380
Pro Ile Ala Ser Thr Leu Pro Glu Leu Val Gln Arg Leu Val Thr Ile		
385	390	395
Lys Gln Leu His Glu Gln Ala Met Gln Phe Gly Gln Leu Leu Thr His		
405	410	415
Leu Asp Thr Thr Gln Gln Met Ile Ala Asn Ser Leu Lys Asp Asn Thr		
420	425	430
Thr Leu Leu Thr Gln Val Gln Thr Thr Met Arg Glu Asn Leu Ala Thr		

648

435 440 445
 Val Glu Gly Asn Phe Ala Ser Ile Asp Glu Arg Met Lys Lys Leu Gly
 450 455 460

Lys
 465

<210> 677
 <211> 48
 <212> PRT
 <213> Homo sapiens

<400> 677
 Ser Ser Phe Leu Asn Ser Asp Leu Gly Leu Ser Leu Ala Arg Asn Leu
 1 5 10 15
 Ala Phe Ser Phe Thr Thr Lys Glu Arg Asp Gln Lys Pro Leu Ile Phe
 20 25 30
 Asn Phe His Lys Met Leu Glu Val Tyr Ile Tyr Ile Tyr Ile Phe Leu
 35 40 45

<210> 678
 <211> 940
 <212> PRT
 <213> Homo sapiens

<400> 678
 Val Leu Gly Glu Gly Ile Ser Phe Leu Leu Ser Pro Pro Leu Pro Thr
 1 5 10 15
 Pro Ser Ile Asn Ile Ile Leu Leu Lys Ile Leu Arg Cys Gln Ala Ala
 20 25 30
 Lys Val Glu Ser Ala Ile Ala Glu Gly Gly Ala Ser Arg Phe Ser Ala
 35 40 45
 Ser Ser Gly Gly Gly Gly Ser Arg Gly Ala Pro Gln His Tyr Pro Lys
 50 55 60
 Thr Ala Gly Asn Ser Glu Phe Leu Gly Lys Thr Pro Gly Gln Asn Ala
 65 70 75 80

Gln Lys Trp Ile Pro Ala Arg Ser Thr Arg Arg Asp Asp Asn Ser Ala
 85 90 95
 Ala Asn Asn Ser Ala Asn Glu Lys Glu Arg His Asp Ala Ile Phe Arg
 100 105 110
 Lys Val Arg Gly Ile Leu Asn Lys Leu Thr Pro Glu Lys Phe Asp Lys
 115 120 125
 Leu Cys Leu Glu Leu Leu Asn Val Gly Val Glu Ser Lys Leu Ile Leu
 130 135 140
 Lys Gly Val Ile Leu Leu Ile Val Asp Lys Ala Leu Glu Glu Pro Lys
 145 150 155 160
 Tyr Ser Ser Leu Tyr Ala Gln Leu Cys Leu Arg Leu Ala Glu Asp Ala
 165 170 175
 Pro Asn Phe Asp Gly Pro Ala Ala Glu Gly Gln Pro Gly Gln Lys Gln
 180 185 190
 Ser Thr Thr Phe Arg Arg Leu Leu Ile Ser Lys Leu Gln Asp Glu Phe
 195 200 205
 Glu Asn Arg Thr Arg Asn Val Asp Val Tyr Asp Lys Arg Glu Asn Pro
 210 215 220
 Leu Leu Pro Glu Glu Glu Glu Gln Arg Ala Ile Ala Lys Ile Lys Met
 225 230 235 240
 Leu Gly Asn Ile Lys Phe Ile Gly Glu Leu Gly Lys Leu Asp Leu Ile
 245 250 255
 His Glu Ser Ile Leu His Lys Cys Ile Lys Thr Leu Leu Glu Lys Lys
 260 265 270
 Lys Arg Val Gln Leu Lys Asp Met Gly Glu Asp Leu Glu Cys Leu Cys
 275 280 285
 Gln Ile Met Arg Thr Val Gly Pro Arg Leu Asp His Glu Arg Ala Lys
 290 295 300
 Ser Leu Met Asp Gln Tyr Phe Ala Arg Met Cys Ser Leu Met Leu Ser
 305 310 315 320
 Lys Glu Leu Pro Ala Arg Ile Arg Phe Leu Leu Gln Asp Thr Val Glu
 325 330 335
 Leu Arg Glu His His Trp Val Pro Arg Lys Ala Phe Leu Asp Asn Gly
 340 345 350

650

Pro Lys Thr Ile Asn Gln Ile Arg Gln Asp Ala Val Lys Asp Leu Gly
 355 360 365
 Val Phe Ile Pro Ala Pro Met Ala Gln Gly Met Arg Ser Asp Phe Phe
 370 375 380
 Leu Glu Gly Pro Phe Met Pro Pro Arg Met Lys Met Asp Arg Asp Pro
 385 390 395 400
 Leu Gly Gly Leu Ala Asp Met Phe Gly Gln Met Pro Gly Ser Gly Ile
 405 410 415
 Gly Thr Gly Pro Gly Val Ile Gln Asp Arg Phe Ser Pro Thr Met Gly
 420 425 430
 Arg His Arg Ser Asn Gln Leu Phe Asn Gly His Gly Gly His Ile Met
 435 440 445
 Pro Pro Thr Gln Ser Gln Phe Gly Glu Met Gly Gly Lys Phe Met Lys
 450 455 460
 Ser Gln Gly Leu Ser Gln Leu Tyr His Asn Gln Ser Gln Gly Leu Leu
 465 470 475 480
 Ser Gln Leu Gln Gly Gln Ser Lys Asp Met Pro Pro Arg Phe Ser Lys
 485 490 495
 Lys Gly Gln Leu Asn Ala Asp Glu Ile Ser Leu Arg Pro Ala Gln Ser
 500 505 510
 Phe Leu Met Asn Lys Asn Gln Val Pro Lys Leu Gln Pro Gln Ile Thr
 515 520 525
 Met Ile Pro Pro Ser Ala Gln Pro Pro Arg Thr Gln Thr Pro Pro Leu
 530 535 540
 Gly Gln Thr Pro Gln Leu Gly Leu Lys Thr Asn Pro Pro Leu Ile Gln
 545 550 555 560
 Glu Lys Pro Ala Lys Thr Ser Lys Lys Pro Pro Pro Ser Lys Glu Glu
 565 570 575
 Leu Leu Lys Leu Thr Glu Thr Val Val Thr Glu Tyr Leu Asn Ser Gly
 580 585 590
 Asn Ala Asn Glu Ala Val Asn Gly Val Arg Glu Met Arg Ala Pro Lys
 595 600 605
 His Phe Leu Pro Glu Met Leu Ser Lys Val Ile Ile Leu Ser Leu Asp
 610 615 620

651

Arg Ser Asp Glu Asp Lys Glu Lys Ala Ser Ser Leu Ile Ser Leu Leu			
625	630	635	640
Lys Gln Glu Gly Ile Ala Thr Ser Asp Asn Phe Met Gln Ala Phe Leu			
	645	650	655
Asn Val Leu Asp Gln Cys Pro Lys Leu Glu Val Asp Ile Pro Leu Val			
	660	665	670
Lys Ser Tyr Leu Ala Gln Phe Ala Ala Arg Ala Ile Ile Ser Glu Leu			
	675	680	685
Val Ser Ile Ser Glu Leu Ala Gln Pro Leu Glu Ser Gly Thr His Phe			
	690	695	700
Pro Leu Phe Leu Leu Cys Leu Gln Gln Leu Ala Lys Leu Gln Asp Arg			
705	710	715	720
Glu Trp Leu Thr Glu Leu Phe Gln Gln Ser Lys Val Asn Met Gln Lys			
	725	730	735
Met Leu Pro Glu Ile Asp Gln Asn Lys Asp Arg Met Leu Glu Ile Leu			
	740	745	750
Glu Gly Lys Gly Leu Ser Phe Leu Phe Pro Leu Leu Lys Leu Glu Lys			
	755	760	765
Glu Leu Leu Lys Gln Ile Lys Leu Asp Pro Ser Pro Gln Thr Ile Tyr			
770	775	780	
Lys Trp Ile Lys Asp Asn Ile Ser Pro Lys Leu His Val Asp Lys Gly			
785	790	795	800
Phe Val Asn Ile Leu Met Thr Ser Phe Leu Gln Tyr Ile Ser Ser Glu			
	805	810	815
Val Asn Pro Pro Ser Asp Glu Thr Asp Ser Ser Ser Ala Pro Ser Lys			
	820	825	830
Glu Gln Leu Glu Gln Glu Lys Gln Leu Leu Leu Ser Phe Lys Pro Val			
	835	840	845
Met Gln Lys Phe Leu His Asp His Val Asp Leu Gln Val Ser Ala Leu			
850	855	860	
Tyr Ala Leu Gln Val His Cys Tyr Asn Ser Asn Phe Pro Lys Gly Met			
865	870	875	880
Leu Leu Arg Phe Phe Val His Phe Tyr Asp Met Glu Ile Ile Glu Glu			
	885	890	895

652

Glu Ala Phe Leu Ala Trp Lys Glu Asp Ile Thr Gln Glu Phe Pro Gly
 900 905 910

Lys Gly Lys Ala Leu Phe Gln Val Asn Gln Trp Leu Thr Trp Leu Glu
 915 920 925

Thr Ala Glu Glu Glu Glu Ser Glu Glu Glu Ala Asp
 930 935 940

<210> 679

<211> 212

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (7)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (160)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (172)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 679

Ser Trp Lys Glu Glu Glu Xaa Lys Pro His Leu Gln Gly Lys Pro Gly
 1 5 10 15

Arg Pro Leu Ser Pro Ala Asn Val Pro Ala Leu Pro Gly Glu Thr Val
 20 25 30

Thr Ser Pro Val Arg Leu His Pro Asp Tyr Leu Ser Pro Glu Glu Ile
 35 40 45

Gln Arg Gln Leu Gln Asp Ile Glu Arg Arg Leu Asp Ala Leu Glu Leu
 50 55 60

Arg Gly Val Glu Leu Glu Lys Arg Leu Arg Ala Ala Glu Gly Asp Asp
 65 70 75 80

Ala Glu Asp Ser Leu Met Val Asp Trp Phe Trp Leu Ile His Glu Lys
 85 90 95

Gln Leu Leu Leu Arg Gln Glu Ser Glu Leu Met Tyr Lys Ser Lys Ala

653

```

          100              105              110
Gln Arg Leu Glu Glu Gln Gln Leu Asp Ile Glu Gly Glu Leu Arg Arg
      115              120              125
Leu Met Ala Lys Pro Glu Ala Leu Lys Ser Leu Gln Glu Arg Arg Arg
      130              135              140
Glu Gln Glu Leu Leu Glu Gln Tyr Val Ser Thr Val Asn Asp Arg Xaa
      145              150              155              160
Asp Ile Val Asp Ser Leu Asp Glu Asp Arg Leu Xaa Glu Gln Glu Glu
      165              170              175
Asp Gln Met Leu Arg Asp Met Ile Glu Lys Leu Gly Leu Gln Arg Lys
      180              185              190
Lys Ser Lys Phe Arg Leu Ser Lys Ile Trp Ser Pro Lys Ser Lys Ser
      195              200              205
Ser Pro Ser Gln
      210

```

<210> 680

<211> 412

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (172)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (404)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 680

```

Val Ala Val Glu Leu Gly Ser Leu Arg Gly Gly Thr Met Ala Ser Glu
  1              5              10              15

```

```

Lys Pro Leu Ala Ala Val Thr Cys Thr Ala Pro Val Asn Ile Ala Val
      20              25              30

```

```

Ile Lys Tyr Trp Gly Lys Arg Asp Glu Glu Leu Val Leu Pro Ile Asn
      35              40              45

```

```

Ser Ser Leu Ser Val Thr Leu His Gln Asp Gln Leu Lys Thr Thr Thr

```

654

50	55	60
Thr Ala Val Ile Ser Lys Asp Phe Thr Glu Asp Arg Ile Trp Leu Asn		
65	70	75 80
Gly Arg Glu Glu Asp Val Gly Gln Pro Arg Leu Gln Ala Cys Leu Arg		
	85	90 95
Glu Ile Arg Cys Leu Ala Arg Lys Arg Arg Asn Ser Arg Asp Gly Asp		
	100	105 110
Pro Leu Pro Ser Ser Leu Ser Cys Lys Val His Val Ala Ser Val Asn		
	115	120 125
Asn Phe Pro Thr Ala Ala Gly Leu Ala Ser Ser Ala Ala Gly Tyr Ala		
	130	135 140
Cys Leu Ala Tyr Thr Leu Ala Arg Val Tyr Gly Val Glu Ser Asp Leu		
	145	150 155 160
Ser Glu Val Ala Arg Arg Gly Ser Gly Ser Ala Xaa Arg Ser Leu Tyr		
	165	170 175
Gly Gly Phe Val Glu Trp Gln Met Gly Glu Gln Ala Asp Gly Lys Asp		
	180	185 190
Ser Ile Ala Arg Gln Val Ala Pro Glu Ser His Trp Pro Glu Leu Arg		
	195	200 205
Val Leu Ile Leu Val Val Ser Ala Glu Lys Lys Leu Thr Gly Ser Thr		
	210	215 220
Val Gly Met Arg Ala Ser Val Glu Thr Ser Pro Leu Leu Arg Phe Arg		
	225	230 235 240
Ala Glu Ser Val Val Pro Ala Arg Met Ala Glu Met Ala Arg Cys Ile		
	245	250 255
Arg Glu Arg Asp Phe Pro Ser Phe Ala Gln Leu Thr Met Lys Asp Ser		
	260	265 270
Asn Gln Phe His Ala Thr Cys Leu Asp Thr Phe Pro Pro Ile Ser Tyr		
	275	280 285
Leu Asn Ala Ile Ser Trp Arg Ile Ile His Leu Val His Arg Phe Asn		
	290	295 300
Ala His His Gly Asp Thr Lys Val Ala Tyr Thr Phe Asp Ala Gly Pro		
	305	310 315 320
Asn Ala Val Ile Phe Thr Leu Asp Asp Thr Val Ala Glu Phe Val Ala		

655

325 330 335
 Ala Val Trp His Gly Phe Pro Pro Gly Ser Asn Gly Asp Thr Phe Leu
 340 345 350
 Lys Gly Leu Gln Val Arg Pro Ala Pro Leu Ser Ala Glu Leu Gln Ala
 355 360 365
 Ala Leu Ala Met Glu Pro Thr Pro Gly Gly Val Lys Tyr Ile Ile Val
 370 375 380
 Thr Gln Val Gly Pro Gly Pro Gln Ile Leu Asp Asp Pro Cys Ala His
 385 390 395 400
 Leu Leu Gly Xaa Asp Gly Leu Pro Lys Pro Ala Ala
 405 410

<210> 681
 <211> 61
 <212> PRT
 <213> Homo sapiens

<400> 681
 Lys Lys Thr Arg His Leu Ser Lys Ile Leu Cys Gly Lys Met Thr Val
 1 5 10 15
 Asn Lys Met Arg Val Ser Gly Pro Phe Val Leu Leu Ser Phe Phe Asp
 20 25 30
 Tyr Lys Phe Leu Leu Thr His Thr Ile Met Ser Ala Asn Pro Leu Leu
 35 40 45
 Pro Arg Glu Arg Asn Cys Ala Pro Ser Val Leu Leu Pro
 50 55 60

<210> 682
 <211> 243
 <212> PRT
 <213> Homo sapiens

<400> 682
 Ser Ala Pro Pro Pro Pro Arg Arg Lys Thr Ala Pro Pro Ala His Arg
 1 5 10 15
 Gln Arg Pro Pro Pro Gln Ser Pro Thr Ala Thr Gly Leu Gly Pro Ala
 20 25 30

656

Ala Arg Ser Cys Leu Pro Gln Pro Pro Ser Arg Gly Pro Gln Pro Pro
 35 40 45
 Pro Thr Leu Pro His Gly Pro Gly Ala Met Ser Glu Leu Glu Gln Leu
 50 55 60
 Arg Gln Glu Ala Glu Gln Leu Arg Asn Gln Ile Arg Asp Ala Arg Lys
 65 70 75 80
 Ala Cys Gly Asp Ser Thr Leu Thr Gln Ile Thr Ala Gly Leu Asp Pro
 85 90 95
 Val Gly Arg Ile Gln Met Arg Thr Arg Arg Thr Leu Arg Gly His Leu
 100 105 110
 Ala Lys Ile Tyr Ala Met His Trp Gly Thr Asp Ser Arg Leu Leu Val
 115 120 125
 Ser Ala Ser Gln Asp Gly Lys Leu Ile Ile Trp Asp Ser Tyr Thr Thr
 130 135 140
 Asn Lys Val His Ala Ile Pro Leu Arg Ser Ser Trp Val Met Thr Cys
 145 150 155 160
 Ala Tyr Ala Pro Ser Gly Asn Phe Val Ala Cys Gly Gly Leu Asp Asn
 165 170 175
 Ile Cys Ser Ile Tyr Ser Leu Lys Thr Arg Glu Ala Thr Ser Gly Ser
 180 185 190
 Ala Gly Ser Cys Leu Ala Thr Leu Gly Thr Cys Arg Val Ala Ala Ser
 195 200 205
 Trp Met Thr Thr Lys Ser Ser Pro Ala Leu Gly Ile Pro Pro Val Pro
 210 215 220
 Cys Gly Thr Leu Arg Gln Ala Ser Arg Gln Trp Val Leu Leu Asp Thr
 225 230 235 240
 Val Gly Met

<210> 683

<211> 146

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

657

<222> (133)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 683

Asp Leu Glu Gly Asp Ala Gly Tyr Thr Gly Gly Leu Arg Gln Gly His
 1 5 10 15

Ala Gly Gly Ala Gly Glu Leu Ala Arg Thr Leu Ala Leu Lys Pro Thr
 20 25 30

Ser Leu Glu Leu Phe Arg Thr Lys Val Asn Ala Leu Thr Tyr Gly Glu
 35 40 45

Val Leu Arg Leu Arg Gln Thr Glu Arg Leu His Gln Glu Gly Thr Leu
 50 55 60

Ala Pro Pro Ile Leu Glu Leu Arg Glu Lys Leu Lys Pro Glu Leu Met
 65 70 75 80

Gly Leu Ile Arg Gln Gln Arg Leu Leu Arg Leu Cys Glu Gly Thr Leu
 85 90 95

Phe Arg Lys Ile Ser Ser Arg Arg Arg Gln Asp Lys Leu Trp Phe Cys
 100 105 110

Cys Leu Ser Pro Asn His Lys Leu Leu Gln Tyr Gly Asp Met Glu Glu
 115 120 125

Gly Ala Ser Ala Xaa Pro Trp Arg Val Cys Pro Ser Asn Ser Leu Trp
 130 135 140

Pro Thr
 145

<210> 684

<211> 300

<212> PRT

<213> Homo sapiens

<400> 684

Val Tyr Ser Cys Gly Phe Gln Val Gln Ser Trp Ser Pro Arg Trp Ile
 1 5 10 15

Trp Val Thr Thr Lys Ser Lys Ile Gly Ala Pro Arg Ser Ser Phe Cys
 20 25 30

Trp His Arg Leu Pro Ser Thr Ser Gln Leu His Leu Cys Pro Ala Glu
 35 40 45

658

Gly Glu Ala Pro Ser Ala Gly Glu Ala Ala Pro Arg Ala Pro Thr Gly
 50 55 60

Ser Glu Pro Lys Pro Gly Ala Leu Pro Trp Gly Pro Arg Ala Pro Asp
 65 70 75 80

Ser Glu Gly Gly Gly Gly Ala Gly Ala Ala Asp Pro Ala Ala Asn Ala
 85 90 95

Gly His Gly Ala Ser Ser Glu Ala Glu Cys Gly Cys Gln Arg Thr Leu
 100 105 110

Arg Pro Met Pro Ser Thr Pro Gly Pro Gly Ala Ala Ala Val Arg Ala
 115 120 125

Leu Gly Gln Leu Phe His Ile Ala Cys Phe Thr Cys His Gln Cys Ala
 130 135 140

Gln Gln Leu Gln Gly Gln Gln Phe Tyr Ser Leu Glu Gly Ala Pro Tyr
 145 150 155 160

Cys Glu Gly Cys Tyr Thr Asp Thr Leu Glu Lys Cys Asn Thr Cys Gly
 165 170 175

Glu Pro Ile Thr Asp Arg Met Leu Arg Ala Thr Gly Lys Ala Tyr His
 180 185 190

Pro His Cys Phe Thr Cys Val Val Cys Ala Arg Pro Leu Glu Gly Thr
 195 200 205

Ser Phe Ile Val Asp Gln Ala Asn Arg Pro His Cys Val Pro Asp Tyr
 210 215 220

His Lys Gln Tyr Ala Pro Arg Cys Ser Val Cys Ser Glu Pro Ile Met
 225 230 235 240

Pro Glu Pro Gly Arg Asp Glu Thr Val Arg Val Val Ala Leu Asp Lys
 245 250 255

Asn Phe His Met Lys Cys Tyr Lys Cys Glu Asp Cys Gly Lys Pro Leu
 260 265 270

Ser Ile Glu Ala Asp Asp Asn Gly Cys Phe Pro Leu Asp Gly His Val
 275 280 285

Leu Cys Arg Lys Cys His Thr Ala Arg Ala Gln Thr
 290 295 300

<210> 685

659

<211> 130

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (61)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 685

Ile	Arg	His	Glu	Asp	Cys	Pro	Thr	Pro	Ser	Gln	Cys	Val	Val	Ala	Arg
1				5					10					15	

Thr	Leu	Gly	Lys	Gln	Gln	Thr	Val	Met	Ala	Ile	Ala	Thr	Lys	Ile	Ala
			20					25					30		

Leu	Gln	Met	Asn	Cys	Lys	Met	Gly	Gly	Glu	Leu	Trp	Arg	Val	Asp	Ile
		35					40					45			

Pro	Leu	Lys	Leu	Val	Met	Ile	Val	Gly	Ile	Asp	Cys	Xaa	His	Asp	Met
	50					55					60				

Thr	Ala	Gly	Arg	Arg	Ser	Ile	Ala	Gly	Phe	Val	Ala	Ser	Ile	Asn	Glu
65					70				75						80

Gly	Met	Thr	Arg	Trp	Phe	Ser	Arg	Cys	Ile	Phe	Gln	Asp	Arg	Gly	Gln
			85						90					95	

Glu	Leu	Val	Asp	Gly	Leu	Lys	Val	Cys	Leu	Gln	Ala	Ala	Leu	Arg	Ala
		100						105					110		

Trp	Asn	Ser	Cys	Asn	Glu	Tyr	Met	Pro	Ser	Arg	Ile	Ile	Val	Tyr	Arg
	115						120					125			

Val	Ala
	130

<210> 686

<211> 207

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (84)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 686

Ile	Tyr	Gln	Val	Tyr	Asn	Ala	Leu	Gln	Glu	Lys	Val	Gln	Ala	Val	Cys
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

660

```

      1             5             10             15
Ala Asp Val Glu Lys Ser Glu Arg Val Val Glu Ser Cys Gln Ala Glu
      20             25             30
Val Asn Lys Leu Arg Arg Gln Ile Thr Gln Arg Lys Asn Glu Lys Glu
      35             40             45
Gln Glu Arg Arg Leu Gln Gln Ala Val Leu Ser Arg Gln Met Pro Ser
      50             55             60
Glu Ser Leu Asp Pro Ala Phe Ser Pro Arg Met Pro Ser Ser Gly Phe
      65             70             75             80
Ala Ala Glu Xaa Arg Ser Thr Leu Gly Asp Ala Glu Ala Ser Asp Pro
      85             90             95
Pro Pro Pro Tyr Ser Asp Phe His Pro Asn Asn Gln Glu Ser Thr Leu
      100            105            110
Ser His Ser Arg Met Glu Arg Ser Val Phe Met Pro Arg Pro Gln Ala
      115            120            125
Val Gly Ser Ser Asn Tyr Ala Ser Thr Ser Ala Gly Leu Lys Tyr Pro
      130            135            140
Gly Ser Gly Ala Asp Leu Pro Pro Pro Gln Arg Ala Ala Gly Asp Ser
      145            150            155            160
Gly Glu Asp Ser Asp Asp Ser Asp Tyr Glu Asn Leu Ile Asp Pro Thr
      165            170            175
Glu Pro Ser Asn Ser Glu Tyr Ser His Ser Lys Asp Ser Arg Pro Met
      180            185            190
Ala His Pro Asp Glu Asp Pro Arg Asn Thr Gln Thr Ser Gln Ile
      195            200            205

```

<210> 687

<211> 101

<212> PRT

<213> Homo sapiens

<400> 687

```

Ala Arg Ala Gly Glu Glu Gly Val Val Thr Arg Trp Arg His Arg Leu
  1             5             10             15
Gly Gln Gly Ala Cys Pro Trp Asp Arg Ser Arg Pro Met Glu Pro Pro
      20             25             30

```

661

Gly Arg Ser Ser Arg Ser Thr Ala Ser His Thr Leu His Gln Tyr Cys
35 40 45
Cys Pro Thr Gln Val Leu Asp Ser Met Lys Leu Thr Pro Ser Gly Arg
50 55 60
Leu Ala Glu Ser Arg Glu Glu Glu Glu Glu Glu Thr Glu Glu Glu
65 70 75 80
Glu Glu Glu Asp Ala His Gln Phe Cys Cys Pro Ala Ser Glu Cys Ser
85 90 95
Ser Pro Ser Ser Arg
100

<210> 688

<211> 62

<212> PRT

<213> Homo sapiens

<400> 688

Glu Arg Asn Ala Asp Pro Pro Asp Val Ser Leu Gly Lys Ala Val Asn
1 5 10 15
Gln Leu Ile Phe Ile Glu Asp Leu Leu Cys Pro Leu His Arg Val Ala
20 25 30
Ser Val Arg Glu Ser Trp Phe Phe Pro Arg Asn Thr Asp Phe Leu Ser
35 40 45
Gly Arg Leu His Val Phe Ile Tyr Phe His His Ser Arg Phe
50 55 60

<210> 689

<211> 549

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (1)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (7)

662

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 689

Xaa	Arg	Trp	Ala	Cys	Gly	Xaa	Leu	Leu	Leu	Leu	Val	Arg	Gly	Gln	Gly
1				5				10						15	
Gln	Asp	Ser	Ala	Ser	Pro	Ile	Arg	Thr	Thr	His	Thr	Gly	Gln	Val	Leu
			20					25					30		
Gly	Ser	Leu	Val	His	Val	Lys	Gly	Ala	Asn	Ala	Gly	Val	Gln	Thr	Phe
		35					40					45			
Leu	Gly	Ile	Pro	Phe	Ala	Lys	Pro	Pro	Leu	Gly	Pro	Leu	Arg	Phe	Ala
	50					55					60				
Pro	Pro	Glu	Pro	Pro	Glu	Ser	Trp	Ser	Gly	Val	Arg	Asp	Gly	Thr	Thr
65					70					75				80	
His	Pro	Ala	Met	Cys	Leu	Gln	Asp	Leu	Thr	Ala	Val	Glu	Ser	Glu	Phe
				85					90					95	
Leu	Ser	Gln	Phe	Asn	Met	Thr	Phe	Pro	Ser	Asp	Ser	Met	Ser	Glu	Asp
		100						105					110		
Cys	Leu	Tyr	Leu	Ser	Ile	Tyr	Thr	Pro	Ala	His	Ser	His	Glu	Gly	Ser
	115						120					125			
Asn	Leu	Pro	Val	Met	Val	Trp	Ile	His	Gly	Gly	Ala	Leu	Val	Phe	Gly
	130					135					140				
Met	Ala	Ser	Leu	Tyr	Asp	Gly	Ser	Met	Leu	Ala	Ala	Leu	Glu	Asn	Val
145					150					155				160	
Val	Val	Val	Ile	Ile	Gln	Tyr	Arg	Leu	Gly	Val	Leu	Gly	Phe	Phe	Ser
			165						170				175		
Thr	Gly	Asp	Lys	His	Ala	Thr	Gly	Asn	Trp	Gly	Tyr	Leu	Asp	Gln	Val
		180						185					190		
Ala	Ala	Leu	Arg	Trp	Val	Gln	Gln	Asn	Ile	Ala	His	Phe	Gly	Gly	Asn
	195					200						205			
Pro	Asp	Arg	Val	Thr	Ile	Phe	Gly	Glu	Ser	Ala	Gly	Gly	Thr	Ser	Val
	210					215					220				
Ser	Ser	Leu	Val	Val	Ser	Pro	Ile	Ser	Gln	Gly	Leu	Phe	His	Gly	Ala
225					230					235				240	
Ile	Met	Glu	Ser	Gly	Val	Ala	Leu	Leu	Pro	Gly	Leu	Ile	Ala	Ser	Ser
			245						250				255		

Ala Asp Val Ile Ser Thr Val Val Ala Asn Leu Ser Ala Cys Asp Gln
 260 265 270
 Val Asp Ser Glu Ala Leu Val Gly Cys Leu Arg Gly Lys Ser Lys Glu
 275 280 285
 Glu Ile Leu Ala Ile Asn Lys Pro Phe Lys Met Ile Pro Gly Val Val
 290 295 300
 Asp Gly Val Phe Leu Pro Arg His Pro Gln Glu Leu Leu Ala Ser Ala
 305 310 315 320
 Asp Phe Gln Pro Val Pro Ser Ile Val Gly Val Asn Asn Asn Glu Phe
 325 330 335
 Gly Trp Leu Ile Pro Lys Val Met Arg Ile Tyr Asp Thr Gln Lys Glu
 340 345 350
 Met Asp Arg Glu Ala Ser Gln Ala Ala Leu Gln Lys Met Leu Thr Leu
 355 360 365
 Leu Met Leu Pro Pro Thr Phe Gly Asp Leu Leu Arg Glu Glu Tyr Ile
 370 375 380
 Gly Asp Asn Gly Asp Pro Gln Thr Leu Gln Ala Gln Phe Gln Glu Met
 385 390 395 400
 Met Ala Asp Ser Met Phe Val Ile Pro Ala Leu Gln Val Ala His Phe
 405 410 415
 Gln Cys Ser Arg Ala Pro Val Tyr Phe Tyr Glu Phe Gln His Gln Pro
 420 425 430
 Ser Trp Leu Lys Asn Ile Arg Pro Pro His Met Lys Ala Asp His Gly
 435 440 445
 Asp Glu Leu Pro Phe Val Phe Arg Ser Phe Phe Gly Gly Asn Tyr Ile
 450 455 460
 Lys Phe Thr Glu Glu Glu Glu Gln Leu Ser Arg Lys Met Met Lys Tyr
 465 470 475 480
 Trp Ala Asn Phe Ala Arg Asn Gly Asn Pro Asn Gly Glu Gly Leu Pro
 485 490 495
 His Trp Pro Leu Phe Asp Gln Glu Glu Gln Tyr Leu Gln Leu Asn Leu
 500 505 510
 Gln Pro Ala Val Gly Arg Ala Leu Lys Ala His Arg Leu Gln Phe Trp
 515 520 525

664

Lys Lys Ala Leu Pro Gln Lys Ile Gln Glu Leu Glu Glu Pro Glu Glu
 530 535 540

Arg His Thr Glu Leu
 545

<210> 690

<211> 155

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (36)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (46)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (50)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (85)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 690

Ser His Arg Val Thr His Cys Pro Tyr Ala Val Ala Leu Pro Glu Val
 1 5 10 15

Ala Pro Ala Gln Pro Leu Thr Glu Ala Leu Arg Ala Leu Cys His Val
 20 25 30

Gly Leu Phe Xaa Phe Ala Phe Cys Ala Leu Phe Asp Cys Xaa Arg Pro
 35 40 45

Val Xaa Gln Lys Ser Cys Asp Leu Leu Phe Leu Arg Asp Lys Ile
 50 55 60

Ala Ser Tyr Ser Ser Leu Arg Glu Ala Arg Gly Ser Pro Asn Thr Ala
 65 70 75 80

Ser Ala Glu Ala Xaa Leu Pro Arg Trp Arg Ala Gly Glu Gln Ala Gln
 85 90 95

665

Pro Pro Gly Asp Gln Glu Pro Glu Ala Val Leu Ala Met Leu Arg Ser
 100 105 110

Leu Asp Leu Glu Gly Leu Arg Ser Thr Leu Ala Glu Ser Ser Asp His
 115 120 125

Val Glu Lys Ser Pro Gln Ser Leu Leu Gln Asp Met Leu Ala Thr Gly
 130 135 140

Gly Phe Leu Gln Gly Asp Glu Ala Asp Cys Tyr
 145 150 155

<210> 691
 <211> 149
 <212> PRT
 <213> Homo sapiens

<400> 691
 Met Cys Leu Glu Arg Pro Leu Arg Glu Gly Pro Arg Val Met Glu Lys
 1 5 10 15

Glu Ala Trp Pro Gly Ser Leu Glu Gly Arg Gly Gly Gly Trp Arg His
 20 25 30

Leu Asp Cys Pro Leu Leu Ser His Thr Trp Gly Val Val Thr Pro Phe
 35 40 45

Thr Pro Ala Arg Leu Pro Ser Ala Phe His Glu Leu His Leu Leu Pro
 50 55 60

Thr Ser Leu Trp Arg Gly Trp Gly Pro Leu Ala Ser Thr Arg Gly Pro
 65 70 75 80

Ser Ala Ser Pro Lys Pro Glu Pro Ser Ala Pro Gly Glu Asn Lys Trp
 85 90 95

Leu Ser Phe Asp Thr Trp Gly Arg Arg Glu Ala Ala Gly Trp Arg Gln
 100 105 110

Ser Gln Gly Arg Asp Thr Thr Glu Gly Asp Pro Asp Ile Pro Arg Lys
 115 120 125

Phe Pro Ala Glu Gln Thr Ala Phe Gln Pro Glu Ala Cys Leu Asn Cys
 130 135 140

Val Met Cys Asn Asn
 145

666

<210> 692

<211> 218

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (160)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 692

Pro Gly Val Lys Leu Trp Asp Val Pro Val Met Leu Asp His Lys Asp
 1 5 10 15

Leu Glu Ala Glu Ile His Pro Leu Lys Asn Glu Glu Arg Lys Ser Gln
 20 25 30

Glu Asn Leu Gly Asn Pro Ser Lys Asn Glu Asp Asn Val Lys Ser Ala
 35 40 45

Pro Pro Gln Ser Arg Leu Ser Arg Cys Arg Ala Ala Ala Phe Phe Leu
 50 55 60

Ser Leu Phe Leu Cys Leu Phe Val Val Phe Val Val Ser Phe Val Ile
 65 70 75 80

Pro Cys Pro Asp Arg Pro Ala Ser Gln Arg Met Trp Arg Ile Asp Tyr
 85 90 95

Ser Ala Ala Val Ile Tyr Asp Phe Leu Ala Val Asp Asp Ile Asn Gly
 100 105 110

Asp Arg Ile Gln Asp Val Leu Phe Leu Tyr Lys Asn Thr Asn Ser Ser
 115 120 125

Asn Asn Phe Ser Arg Ser Cys Val Asp Glu Gly Phe Ser Ser Pro Cys
 130 135 140

Thr Phe Ala Ala Ala Val Ser Gly Ala Asn Ala Ala Arg Ser Gly Xaa
 145 150 155 160

Asp Leu Trp Pro Lys Thr Trp Pro Ser Trp Ser Val Leu Cys Pro Ser
 165 170 175

Gln Glu Ala Val Arg His Leu Leu Pro Ala Ser Trp Trp Ala Asp Pro
 180 185 190

Val Leu Ser Leu Gln Ser Thr Cys Ser Gln Gly Lys Pro Trp Lys Pro
 195 200 205

667

Gln Pro Ala Val Gln Gly Glu Trp Ser Ile
210 215

<210> 693
<211> 68
<212> PRT
<213> Homo sapiens

<400> 693
Ser Cys Asn Ser Ser Asn Asn Ile Leu Gln Leu Pro Tyr Arg Asn Arg
1 5 10 15

Ser Gly Arg Ala Lys Ser Asp Leu Gly Lys Val Ile Arg Tyr Arg Leu
20 25 30

Ser Ile Pro Phe Pro Lys Met Leu Gly Thr Arg Ser Ile Ser Asp Phe
35 40 45

Ile Ile Phe Phe Lys Val Trp Asn Ile Cys Ile Ile Leu Thr Ser Trp
50 55 60

Ala Ser Gln Ile
65

<210> 694
<211> 234
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (3)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (4)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (219)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 694
Cys Ala Xaa Xaa Leu Arg Gly Phe Asp Gln Gln Met Ser Ser Met Val

668

```

      1             5             10             15
Ile Glu His Met Ala Ser His Gly Thr Arg Phe Leu Arg Gly Cys Ala
      20             25             30
Pro Ser Arg Val Arg Arg Leu Pro Asp Gly Gln Leu Gln Val Thr Trp
      35             40             45
Glu Asp Ser Thr Thr Gly Lys Glu Asp Thr Gly Thr Phe Asp Thr Val
      50             55             60
Leu Trp Ala Ile Gly Arg Val Pro Asp Thr Arg Ser Leu Asn Leu Glu
      65             70             75             80
Lys Ala Gly Val Asp Thr Ser Pro Asp Thr Gln Lys Ile Leu Val Asp
      85             90             95
Ser Arg Glu Ala Thr Ser Val Pro His Ile Tyr Ala Ile Gly Asp Val
      100            105            110
Val Glu Gly Arg Pro Glu Leu Thr Pro Thr Ala Ile Met Ala Gly Arg
      115            120            125
Leu Leu Val Gln Arg Leu Phe Gly Gly Ser Ser Asp Leu Met Asp Tyr
      130            135            140
Asp Asn Val Pro Thr Thr Val Phe Thr Pro Leu Glu Tyr Gly Cys Val
      145            150            155            160
Gly Leu Ser Glu Glu Glu Ala Val Ala Arg His Gly Gln Glu His Val
      165            170            175
Glu Val Tyr His Ala His Tyr Lys Pro Leu Glu Phe Thr Val Ala Gly
      180            185            190
Arg Asp Ala Ser Gln Cys Tyr Val Lys Met Val Cys Leu Arg Glu Pro
      195            200            205
Pro Gln Leu Val Leu Gly Leu His Phe Leu Xaa Pro Thr Gln Ala Asn
      210            215            220
Tyr Ser Arg Ile Cys Ser Gly Asp Lys Cys
      225            230

```

<210> 695

<211> 460

<212> PRT

<213> Homo sapiens

669

<400> 695

```

Pro Cys Pro Pro Arg Pro Gln Glu Leu Pro Gly Arg Ser Pro Ser Ser
 1             5             10             15

Trp Ser Ala Leu Gly Trp Pro Ala Ala Leu Gly Gly Gly Val Val Ala
      20             25             30

Val Ala Val Cys Glu Pro Val Ala Arg Leu Leu Trp Ala Gly Thr Leu
      35             40             45

Lys Ile Ala Ala Met Ala Glu Asn Gly Asp Asn Glu Lys Met Ala Ala
 50             55             60

Leu Glu Ala Lys Ile Cys His Gln Ile Glu Tyr Tyr Phe Gly Asp Phe
 65             70             75             80

Asn Leu Pro Arg Asp Lys Phe Leu Lys Glu Gln Ile Lys Leu Asp Glu
      85             90             95

Gly Trp Val Pro Leu Glu Ile Met Ile Lys Phe Asn Arg Leu Asn Arg
      100             105             110

Leu Thr Thr Asp Phe Asn Val Ile Val Glu Ala Leu Ser Lys Ser Lys
      115             120             125

Ala Glu Leu Met Glu Ile Ser Glu Asp Lys Thr Lys Ile Arg Arg Ser
      130             135             140

Pro Ser Lys Pro Leu Pro Glu Val Thr Asp Glu Tyr Lys Asn Asp Val
      145             150             155             160

Lys Asn Arg Ser Val Tyr Ile Lys Gly Phe Pro Thr Asp Ala Thr Leu
      165             170             175

Asp Asp Ile Lys Glu Trp Leu Glu Asp Lys Gly Gln Val Leu Asn Ile
      180             185             190

Gln Met Arg Arg Thr Leu His Lys Ala Phe Lys Gly Ser Ile Phe Val
      195             200             205

Val Phe Asp Ser Ile Glu Ser Ala Lys Lys Phe Val Glu Thr Pro Gly
      210             215             220

Gln Lys Tyr Lys Glu Thr Asp Leu Leu Ile Leu Phe Lys Asp Asp Tyr
      225             230             235             240

Phe Ala Lys Lys Asn Glu Glu Arg Lys Gln Asn Lys Val Glu Ala Lys
      245             250             255

Leu Arg Ala Lys Gln Glu Gln Glu Ala Lys Gln Lys Leu Glu Glu Asp
      260             265             270

```

670

Ala Glu Met Lys Ser Leu Glu Glu Lys Ile Gly Cys Leu Leu Lys Phe
 275 280 285

Ser Gly Asp Leu Asp Asp Gln Thr Cys Arg Glu Asp Leu His Ile Leu
 290 295 300

Phe Ser Asn His Gly Glu Ile Lys Trp Ile Asp Phe Val Arg Gly Ala
 305 310 315 320

Lys Glu Gly Ile Ile Leu Phe Lys Glu Lys Ala Lys Glu Ala Leu Gly
 325 330 335

Lys Ala Lys Asp Ala Asn Asn Gly Asn Leu Gln Leu Arg Asn Lys Glu
 340 345 350

Val Thr Trp Glu Val Leu Glu Gly Glu Val Glu Lys Glu Ala Leu Lys
 355 360 365

Lys Ile Ile Glu Asp Gln Gln Glu Ser Leu Asn Lys Trp Lys Ser Lys
 370 375 380

Gly Arg Arg Phe Lys Gly Lys Gly Lys Gly Asn Lys Ala Ala Gln Pro
 385 390 395 400

Gly Ser Gly Lys Gly Lys Val Gln Phe Gln Gly Lys Lys Thr Lys Phe
 405 410 415

Ala Ser Asp Asp Glu His Asp Glu His Asp Glu Asn Gly Ala Thr Gly
 420 425 430

Pro Val Lys Arg Ala Arg Glu Glu Thr Asp Lys Glu Glu Pro Ala Ser
 435 440 445

Lys Gln Gln Lys Thr Glu Asn Gly Ala Gly Asp Gln
 450 455 460

<210> 696

<211> 80

<212> PRT

<213> Homo sapiens

<400> 696

Gly Glu Glu Gly Val Gly Ser Pro Ser Gly Ile Leu Ala Thr Pro Leu
 1 5 10 15

Arg Ser Ala Arg Gly Thr Thr His Thr His Thr His Thr His
 20 25 30

671

Thr His Ser His Thr His Ala His Phe Pro Ser Phe Pro Asp Pro Leu
 35 40 45

Phe Gln Ser Ser Pro Phe Ser Ser Gly Phe Ile Asp Glu Tyr Lys Tyr
 50 55 60

Pro His Leu Trp Pro Val Met Ser Val Thr Cys Cys Arg Phe Cys Val
 65 70 75 80

<210> 697

<211> 257

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (30)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 697

Trp Pro Arg Arg Pro Gly Pro His Leu Gly Val Leu Glu Phe Pro Gly
 1 5 10 15

Ala Gly Cys Gly Ala Ser Ala Ala Gly Trp Pro Ser Ala Xaa Met Leu
 20 25 30

Pro Gly Arg Gly Pro Arg Pro Phe Arg Ala Arg Leu Val Gly Arg Glu
 35 40 45

Leu Val Ser Met Leu Ala Arg Glu Leu Pro Ala Ala Val Ala Pro Ala
 50 55 60

Gly Pro Ala Ser Leu Ala Arg Trp Thr Leu Gly Phe Cys Asp Glu Arg
 65 70 75 80

Leu Val Pro Phe Asp His Ala Glu Ser Thr Tyr Gly Leu Tyr Arg Thr
 85 90 95

His Leu Leu Ser Arg Leu Pro Ile Pro Glu Ser Gln Val Ile Thr Ile
 100 105 110

Asn Pro Glu Leu Pro Val Glu Glu Ala Ala Glu Asp Tyr Ala Lys Lys
 115 120 125

Leu Arg Gln Ala Phe Gln Gly Asp Ser Ile Pro Val Phe Asp Leu Leu
 130 135 140

672

Ile Leu Gly Val Gly Pro Asp Gly His Thr Cys Ser Leu Phe Pro Asp
 145 150 155 160

His Pro Leu Leu Gln Glu Arg Glu Lys Ile Val Ala Pro Ile Ser Asp
 165 170 175

Ser Pro Lys Pro Pro Pro Gln Arg Val Thr Leu Thr Leu Pro Val Leu
 180 185 190

Asn Ala Ala Arg Thr Val Ile Phe Val Ala Thr Gly Glu Gly Lys Ala
 195 200 205

Ala Val Leu Lys Arg Ile Leu Glu Asp Gln Glu Glu Asn Pro Leu Pro
 210 215 220

Ala Ala Leu Val Gln Pro His Thr Gly Lys Leu Cys Trp Phe Leu Asp
 225 230 235 240

Glu Ala Ala Ala Arg Leu Leu Thr Val Pro Phe Glu Lys His Ser Thr
 245 250 255

Leu

<210> 698

<211> 68

<212> PRT

<213> Homo sapiens

<400> 698

Gln Tyr Lys Thr Pro Ala Val Asp Thr Thr Met Met Thr Phe His Glu
 1 5 10 15

Leu Val Phe Leu Val Leu Thr Ala Lys Phe Val Leu Phe Thr Gly Gln
 20 25 30

Ile Ser Asn Lys Val Leu Gly Leu Lys Ile His Gly Trp Thr Glu Val
 35 40 45

Pro Tyr Pro Leu Thr Met Glu Ala Gly Ala Thr Phe Trp Gly Tyr Leu
 50 55 60

Phe Leu Asn Phe
 65

<210> 699

673

<211> 360

<212> PRT

<213> Homo sapiens

<400> 699

```

Pro Cys Ser Ala Thr Thr Ala Trp Val Lys Ser Ser Ile Lys Thr His
  1              5              10              15

Leu Cys Ala Ser Leu Arg His Ile Arg Phe Leu Leu Ser Val Cys Leu
      20              25              30

Leu Cys Leu Val Ala Gly Thr Ala Val Ala Val Lys Met Ala Ser Thr
      35              40              45

Ser Arg Leu Asp Ala Leu Pro Arg Val Thr Cys Pro Asn His Pro Asp
      50              55              60

Ala Ile Leu Val Glu Asp Tyr Arg Ala Gly Asp Met Ile Cys Pro Glu
      65              70              75              80

Cys Gly Leu Val Val Gly Asp Arg Val Ile Asp Val Gly Ser Glu Trp
      85              90              95

Arg Thr Phe Ser Asn Asp Lys Ala Thr Lys Asp Pro Ser Arg Val Gly
      100             105             110

Asp Ser Gln Asn Pro Leu Leu Ser Asp Gly Asp Leu Ser Thr Met Ile
      115             120             125

Gly Lys Gly Thr Gly Ala Ala Ser Phe Asp Glu Phe Gly Asn Ser Lys
      130             135             140

Tyr Gln Asn Arg Arg Thr Met Ser Ser Ser Asp Arg Ala Met Met Asn
      145             150             155             160

Ala Phe Lys Glu Ile Thr Thr Met Ala Asp Arg Ile Asn Leu Pro Arg
      165             170             175

Asn Ile Val Asp Arg Thr Asn Asn Leu Phe Lys Gln Val Tyr Glu Gln
      180             185             190

Lys Ser Leu Lys Gly Arg Ala Asn Asp Ala Ile Ala Ser Ala Cys Leu
      195             200             205

Tyr Ile Ala Cys Arg Gln Glu Gly Val Pro Arg Thr Phe Lys Glu Ile
      210             215             220

Cys Ala Val Ser Arg Ile Ser Lys Lys Glu Ile Gly Arg Cys Phe Lys
      225             230             235             240

Leu Ile Leu Lys Ala Leu Glu Thr Ser Val Asp Leu Ile Thr Thr Gly

```


674

	245		250		255
Asp Phe Met Ser Arg Phe Cys Ser Asn Leu Cys Leu Pro Lys Gln Val					
	260		265		270
Gln Met Ala Ala Thr His Ile Ala Arg Lys Ala Val Glu Leu Asp Leu					
	275		280		285
Val Pro Gly Arg Ser Pro Ile Ser Val Ala Ala Ala Ala Ile Tyr Met					
	290		295		300
Ala Ser Gln Ala Ser Ala Glu Lys Arg Thr Gln Lys Glu Ile Gly Asp					
305		310		315	320
Ile Ala Gly Val Ala Asp Val Thr Ile Arg Gln Ser Tyr Arg Leu Ile					
	325		330		335
Tyr Pro Arg Ala Pro Asp Leu Phe Pro Thr Asp Phe Lys Phe Asp Thr					
	340		345		350
Pro Val Asp Lys Leu Pro Gln Leu					
	355		360		

<210> 700

<211> 364

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (13)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (30)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (353)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (360)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 700

675

Pro Ser Trp Leu Arg Ala Arg Ser Ser Arg Ser Trp Xaa Ala Ser Pro
 1 5 10 15
 Arg Gly Pro Gln Pro Pro Arg Ile Arg Ala Arg Ser Ala Xaa Pro Met
 20 25 30
 Glu Gly Ala Arg Val Phe Gly Ala Leu Gly Pro Ile Gly Pro Ser Ser
 35 40 45
 Pro Gly Leu Thr Leu Gly Gly Leu Ala Val Ser Glu His Arg Leu Ser
 50 55 60
 Asn Lys Leu Leu Ala Trp Ser Gly Val Leu Glu Trp Gln Glu Lys Arg
 65 70 75 80
 Arg Pro Tyr Ser Asp Ser Thr Ala Lys Leu Lys Arg Thr Leu Pro Cys
 85 90 95
 Gln Ala Tyr Val Asn Gln Gly Glu Asn Leu Glu Thr Asp Gln Trp Pro
 100 105 110
 Gln Lys Leu Ile Met Gln Leu Ile Pro Gln Gln Leu Leu Thr Thr Leu
 115 120 125
 Gly Pro Leu Phe Arg Asn Ser Gln Leu Ala Gln Phe His Phe Thr Asn
 130 135 140
 Arg Asp Cys Asp Ser Leu Lys Gly Leu Cys Arg Ile Met Gly Asn Gly
 145 150 155 160
 Phe Ala Gly Cys Met Leu Phe Pro His Ile Ser Pro Cys Glu Val Arg
 165 170 175
 Val Leu Met Leu Leu Tyr Ser Ser Lys Lys Lys Ile Phe Met Gly Leu
 180 185 190
 Ile Pro Tyr Asp Gln Ser Gly Phe Val Ser Ala Ile Arg Gln Val Ile
 195 200 205
 Thr Thr Arg Lys Gln Ala Val Gly Pro Gly Gly Val Asn Ser Gly Pro
 210 215 220
 Val Gln Ile Val Asn Asn Lys Phe Leu Ala Trp Ser Gly Val Met Glu
 225 230 235 240
 Trp Gln Glu Pro Arg Pro Glu Pro Asn Ser Arg Ser Lys Arg Trp Leu
 245 250 255
 Pro Ser His Val Tyr Val Asn Gln Gly Glu Ile Leu Arg Thr Glu Gln
 260 265 270

<213> Homo sapiens

<223> Xaa equals any of the naturally occurring L-amino acids

Gly Thr Arg Gly Ile Leu His Val Ala Val Pro Ala Arg Gly Thr His
1 5 10 15

Ala Gln Cys Cys Arg Asn Trp Thr Val Pro Asp Ser Gly Gln Gly Lys
20 25 30

Xaa Val Met Leu Glu Gly Gln Gly Arg Leu Glu Arg Val His Ile Pro
35 40 45

Leu Ser Ala Pro Ala Ser Ala Thr Val Gln Arg Pro Thr Gly Pro Gln
50 55 60

Pro	Val	Ala	Cys	Pro	His	Cys	Pro	Val	Pro	Thr	Ser	Asn	Ser	Pro	Gln
65					70					75					80

Pro Leu Val Ala Ser Val Pro Cys Pro Leu Gly Phe Ser Ser Gln Pro
85 90 95

Ser Gly Leu Gly Leu Cys Arg Lys Val Met Pro Thr Gly Thr Leu Leu
100 105 110

677

Thr Pro Gly Ser Phe Met Asp Val Val Ser Glu Leu Arg Thr Arg Gly
 115 120 125

Cys Gln Met Phe Leu Ala Pro His Val Ser Phe Arg Thr Glu Gln Lys
 130 135 140

His Lys Asp Ser Ala Lys Ser Ser Leu Tyr Ser Leu
 145 150 155

<210> 702

<211> 150

<212> PRT

<213> Homo sapiens

<400> 702

Ala Gly His Gly Leu Gly Val Arg Ala Gly Leu Lys Glu Phe Ala Thr
 1 5 10 15

Asn Leu Thr Glu Ser Gly Val His Gly Ala Leu Leu Ala Leu Asp Glu
 20 25 30

Thr Phe Asp Tyr Ser Asp Leu Ala Leu Leu Leu Gln Ile Pro Thr Gln
 35 40 45

Asn Ala Gln Ala Arg Gln Leu Leu Glu Lys Glu Phe Ser Asn Leu Ile
 50 55 60

Ser Leu Gly Thr Asp Arg Arg Leu Asp Glu Asp Ser Ala Lys Ser Phe
 65 70 75 80

Ser Arg Ser Pro Ser Trp Arg Lys Met Phe Arg Glu Lys Asp Leu Arg
 85 90 95

Gly Val Thr Pro Asp Ser Ala Glu Met Leu Pro Pro Asn Phe Arg Ser
 100 105 110

Ala Ala Ala Gly Ala Leu Gly Ser Pro Gly Leu Pro Leu Arg Lys Leu
 115 120 125

Gln Pro Glu Gly Gln Thr Ser Gly Ser Ser Arg Ala Asp Gly Val Ser
 130 135 140

Val Arg Thr Tyr Ser Cys
 145 150

<210> 703

<211> 527
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (243)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (257)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (259)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (471)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (477)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (480)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (484)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (511)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (519)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 703
Cys Val Cys Val Glu Gly Val Glu Gly Pro Arg Cys Asp Lys Cys Thr

679

1	5	10	15
Arg Gly Tyr Ser Gly Val Phe Pro Asp Cys Thr Pro Cys His Gln Cys	20	25	30
Phe Ala Leu Trp Asp Val Ile Ile Ala Glu Leu Thr Asn Arg Thr His	35	40	45
Arg Phe Leu Glu Lys Ala Lys Ala Leu Lys Ile Ser Gly Val Ile Gly	50	55	60
Pro Tyr Arg Glu Thr Val Asp Ser Val Glu Arg Lys Val Ser Glu Ile	65	70	75
Lys Asp Ile Leu Ala Gln Ser Pro Ala Ala Glu Pro Leu Lys Asn Ile	85	90	95
Gly Asn Leu Phe Glu Glu Ala Glu Lys Leu Ile Lys Asp Val Thr Glu	100	105	110
Met Met Ala Gln Val Glu Val Lys Leu Ser Asp Thr Thr Ser Gln Ser	115	120	125
Asn Ser Thr Ala Lys Glu Leu Asp Ser Leu Gln Thr Glu Ala Glu Ser	130	135	140
Leu Asp Asn Thr Val Lys Glu Leu Ala Glu Gln Leu Glu Phe Ile Lys	145	150	155
Asn Ser Asp Ile Arg Gly Ala Leu Asp Ser Ile Thr Lys Tyr Phe Gln	165	170	175
Met Ser Leu Glu Ala Glu Glu Arg Val Asn Ala Ser Thr Thr Glu Pro	180	185	190
Asn Ser Thr Val Glu Gln Ser Ala Leu Met Arg Asp Arg Val Glu Asp	195	200	205
Val Met Met Glu Arg Glu Ser Gln Phe Lys Glu Lys Gln Glu Glu Gln	210	215	220
Ala Arg Leu Leu Asp Glu Leu Ala Gly Lys Leu Gln Ser Leu Asp Leu	225	230	235
Ser Ala Xaa Ala Glu Met Thr Cys Gly Thr Pro Pro Gly Ala Ser Cys	245	250	255
Xaa Glu Xaa Glu Cys Gly Gly Pro Asn Cys Arg Thr Asp Glu Gly Glu	260	265	270
Arg Lys Cys Gly Gly Pro Gly Cys Gly Gly Leu Val Thr Val Ala His			

680

275	280	285
Asn Ala Trp Gln Lys Ala Met Asp Leu Asp Gln Asp Val Leu Ser Ala		
290	295	300
Leu Ala Glu Val Glu Gln Leu Ser Lys Met Val Ser Glu Ala Lys Leu		
305	310	315 320
Arg Ala Asp Glu Ala Lys Gln Ser Ala Glu Asp Ile Leu Leu Lys Thr		
325	330	335
Asn Ala Thr Lys Glu Lys Met Asp Lys Ser Asn Glu Glu Leu Arg Asn		
340	345	350
Leu Ile Lys Gln Ile Arg Asn Phe Leu Thr Gln Asp Ser Ala Asp Leu		
355	360	365
Asp Ser Ile Glu Ala Val Ala Asn Glu Val Leu Lys Met Glu Met Pro		
370	375	380
Ser Thr Pro Gln Gln Leu Gln Asn Leu Thr Glu Asp Ile Arg Glu Arg		
385	390	395 400
Val Glu Ser Leu Ser Gln Val Glu Val Ile Leu Gln His Ser Ala Ala		
405	410	415
Asp Ile Ala Arg Ala Glu Met Leu Leu Glu Glu Ala Lys Arg Ala Ser		
420	425	430
Lys Ser Ala Thr Asp Val Lys Val Thr Ala Asp Met Val Lys Glu Ala		
435	440	445
Leu Glu Glu Ala Glu Lys Ala Gln Val Ala Ala Glu Lys Ala Ile Lys		
450	455	460
Gln Ala Asp Glu Asp Ile Xaa Arg Asn Pro Glu Pro Xaa Asn Phe Xaa		
465	470	475 480
Leu Glu Phe Xaa Lys Gln Gln Leu Ser Gly Gly Asn Leu Val Gln Arg		
485	490	495
Val Pro Arg Ala Ser Ser Glu Phe Arg Glu Asp Val Gly Arg Xaa Leu		
500	505	510
Ser Gly Lys Leu Ala Gln Xaa Pro Gly Gly Gly Arg Ile Phe Trp		
515	520	525

<210> 704

<211> 62

681

<212> PRT

<213> Homo sapiens

<400> 704

Val Tyr Gln Arg Lys Ser Thr Val Val Leu Gly Gly Phe Leu Leu Trp
1 5 10 15

Asp Ile Asp Phe Leu Phe Phe Phe Arg Asn Ile Val Cys Cys Asn Leu
20 25 30

Asn Lys Asn Tyr Asp Ile Leu Arg Tyr Phe Ile Asp Lys Pro Asn Lys
35 40 45

Asn Ile Cys Phe Tyr Phe Lys Val Asn Val Phe Leu Phe Ser
50 55 60

<210> 705

<211> 44

<212> PRT

<213> Homo sapiens

<400> 705

Thr Glu Asp Leu Phe Gly Phe Lys His Leu Leu Arg Gln Tyr Leu Leu
1 5 10 15

Gly Lys Pro Asn Ile Ala Asn Gly Gln Phe Asp Phe Asn Phe Ser Lys
20 25 30

Asp Thr Leu Leu Ser Arg Arg Leu Lys Cys Leu His
35 40

<210> 706

<211> 193

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (1)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 706

Xaa Gly Arg Ala Trp Val Met Ala Ala Pro Gly Ala Leu Leu Val Met
1 5 10 15

Gly Val Ser Gly Ser Gly Lys Ser Thr Val Gly Ala Leu Leu Ala Ser
20 25 30

682

Glu Leu Gly Trp Lys Phe Tyr Asp Ala Asp Asp Tyr His Pro Glu Glu
 35 40 45
 Asn Arg Arg Lys Met Gly Lys Gly Ile Pro Leu Asn Asp Gln Asp Arg
 50 55 60
 Ile Pro Trp Leu Cys Asn Leu His Asp Ile Leu Leu Arg Asp Val Ala
 65 70 75 80
 Ser Gly Gln Arg Val Val Leu Ala Cys Ser Ala Leu Lys Lys Thr Tyr
 85 90 95
 Arg Asp Ile Leu Thr Gln Gly Lys Asp Gly Val Ala Leu Lys Cys Glu
 100 105 110
 Glu Ser Gly Lys Glu Ala Lys Gln Ala Glu Met Gln Leu Leu Val Val
 115 120 125
 His Leu Ser Gly Ser Phe Glu Val Ile Ser Gly Arg Leu Leu Lys Arg
 130 135 140
 Glu Gly His Phe Met Pro Pro Glu Leu Leu Gln Ser Gln Phe Glu Thr
 145 150 155 160
 Leu Glu Pro Pro Ala Ala Pro Glu Asn Phe Ile Gln Ile Ser Val Asp
 165 170 175
 Lys Asn Val Ser Glu Ile Ile Ala Thr Ile Met Glu Thr Leu Lys Met
 180 185 190
 Lys

<210> 707

<211> 121

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (102)

<223> Xaa equals any of the naturally occurring L-amino acids

<220> '

<221> SITE

<222> (103)

<223> Xaa equals any of the naturally occurring L-amino acids

683

<400> 707

Gly Ile Arg Gly Gln Thr Leu Trp Leu Gly Pro Leu Gly Ala Thr Leu
 1 5 10 15
 Trp Pro Leu Gly Ala Leu Glu Thr Ser His Val Leu Trp Ala Leu Trp
 20 25 30
 Arg Ala Leu Ala Leu His Gly Gly Ala Gly Arg His Cys Leu Pro Cys
 35 40 45
 Pro Leu Pro Ala Ala Pro Ala Leu Val Cys Arg Leu Gly Pro Gly Cys
 50 55 60
 Leu Leu Leu Gly Val Trp Pro Arg Ala Pro Val Lys Pro Trp Arg His
 65 70 75 80
 Cys Val Cys Val Met Gly Ser Glu Gly Leu Val Gly Ala Val His Trp
 85 90 95
 Ser Ser Ser Leu Pro Xaa Xaa Ala Ile Ser Met Ala Pro Phe Ala Ala
 100 105 110
 Glu Asp Thr His Cys Gly Ser Val Gly
 115 120

<210> 708

<211> 112

<212> PRT

<213> Homo sapiens

<400> 708

Asn Ser Phe Cys Tyr Phe His Ile Arg Val Gln Thr Tyr Lys Gly Ala
 1 5 10 15
 Cys Ser Leu Lys Val His Asn Tyr Ser Tyr Ser Val Cys Leu Tyr Cys
 20 25 30
 Tyr Arg Met Leu Cys Phe Gly Ala Leu Ser Ser Ala Asp Pro Arg Ser
 35 40 45
 Ser Val Glu Ile His Cys Leu Gly His Ser Leu Ile Arg Met Leu Ala
 50 55 60
 Gly Asp Phe Val Ser Asp Val Ala Ser Leu Phe Ser Val His Arg Leu
 65 70 75 80
 Arg Val Thr Thr Val Ala Cys Arg Val His Pro Val Gly Ala Ala Gln
 85 90 95

684

Leu Ser Glu Ser Lys Asn Leu Pro Thr Tyr Ser Asn Val Phe Ala Leu
 100 105 110

<210> 709

<211> 72

<212> PRT

<213> Homo sapiens

<400> 709

Arg Arg Val Trp Val Leu Phe Pro Pro Gln Arg Pro Glu Ser Gly Trp
 1 5 10 15

Gly Val Ser Pro Val Glu Gly Glu Thr Val Pro Ala Leu Arg Gly Met
 20 25 30

Lys Lys Ser Val Gly Leu Pro Val Ala Val Gln Cys Val Ala Leu Pro
 35 40 45

Trp Gln Glu Glu Leu Cys Leu Arg Phe Met Arg Glu Val Glu Arg Leu
 50 55 60

Met Thr Pro Glu Lys Gln Ser Ser
 65 70

<210> 710

<211> 84

<212> PRT

<213> Homo sapiens

<400> 710

Arg Leu His Arg Tyr Pro Glu Ala Met Ala Ser Lys Gly Leu Gln Asp
 1 5 10 15

Leu Lys Gln Gln Val Glu Gly Thr Ala Gln Glu Ala Val Ser Ala Ala
 20 25 30

Gly Ala Ala Ala Gln Gln Val Val Asp Gln Ala Thr Glu Ala Gly Gln
 35 40 45

Lys Ala Met Asp Gln Leu Ala Lys Thr Thr Gln Glu Thr Ile Asp Lys
 50 55 60

Thr Ala Asn Gln Ala Ser Asp Thr Phe Ser Gly Ile Gly Lys Lys Phe
 65 70 75 80

685

Gly Leu Leu Lys

<210> 711

<211> 63

<212> PRT

<213> Homo sapiens

<400> 711

Arg Leu His Arg Tyr Pro Glu Ala Met Ala Ser Lys Gly Leu Gln Asp
 1 5 10 15

Leu Lys Gln Gln Val Glu Gly Thr Ala Gln Glu Ala Ala Met Asp Gln
 20 25 30

Leu Ala Lys Thr Thr Gln Glu Thr Ile Asp Lys Thr Ala Asn Gln Ala
 35 40 45

Ser Asp Thr Phe Ser Gly Ile Gly Lys Lys Phe Gly Leu Leu Lys
 50 55 60

<210> 712

<211> 86

<212> PRT

<213> Homo sapiens

<400> 712

Arg Leu Ala Asn Arg Ala Ile Met Ser His Lys Gln Ile Tyr Tyr Ser
 1 5 10 15

Asp Lys Tyr Asp Asp Glu Glu Phe Glu Tyr Arg His Val Met Leu Pro
 20 25 30

Lys Asp Ile Ala Lys Leu Val Pro Lys Thr His Leu Met Ser Glu Ser
 35 40 45

Glu Trp Arg Asn Leu Gly Val Gln Gln Ser Gln Gly Trp Val His Tyr
 50 55 60

Met Ile His Glu Pro Glu Pro His Ile Leu Leu Phe Arg Arg Pro Leu
 65 70 75 80

Pro Lys Lys Pro Lys Lys
 85

686

<210> 713
 <211> 193
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (129)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 713

Val	Gln	Lys	Ala	Gly	Ala	Arg	Ala	Leu	Ala	Val	Ala	Gly	Ala	Ala	Arg	1	5	10	15
Thr	Pro	Arg	Ser	Leu	Pro	Gly	Arg	Pro	Ala	Val	Cys	Asn	Met	Thr	Leu	20	25	30	
Glu	Glu	Phe	Ser	Ala	Gly	Glu	Gln	Lys	Thr	Glu	Arg	Met	Asp	Lys	Val	35	40	45	
Gly	Asp	Ala	Leu	Glu	Glu	Val	Leu	Ser	Lys	Ala	Leu	Ser	Gln	Arg	Thr	50	55	60	
Ile	Thr	Val	Gly	Val	Tyr	Glu	Ala	Ala	Lys	Leu	Leu	Asn	Val	Asp	Pro	65	70	75	80
Asp	Asn	Val	Val	Leu	Cys	Leu	Leu	Ala	Ala	Asp	Glu	Asp	Asp	Asp	Arg	85	90	95	
Asp	Val	Ala	Leu	Gln	Ile	His	Phe	Thr	Leu	Ile	Gln	Ala	Phe	Cys	Cys	100	105	110	
Glu	Asn	Asp	Ile	Asn	Ile	Leu	Arg	Val	Thr	Thr	Arg	Ala	Gly	Trp	Arg	115	120	125	
Xaa	Pro	Ala	Leu	Gly	Asp	Arg	Arg	Trp	Pro	Arg	Gly	Glu	Arg	Gly	Arg	130	135	140	
Arg	Ala	Ala	Pro	Gly	Pro	Ala	Leu	Arg	Val	Val	Thr	Asn	Pro	His	Ser	145	150	155	160
Ser	Gln	Trp	Lys	Asp	Pro	Ala	Leu	Ser	Gln	Leu	Ile	Cys	Phe	Cys	Arg	165	170	175	
Glu	Ser	Arg	Tyr	Met	Asp	Gln	Trp	Val	Pro	Val	Ile	Asn	Leu	Pro	Glu	180	185	190	

Arg

<210> 714
 <211> 200
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (90)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (93)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (190)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 714
 Gly Pro Gly Ala Cys Ser Gly Pro Ala Pro Ser Pro Arg Arg Pro Gln
 1 5 10 15
 Ser Val Lys Cys Glu Pro Arg Arg Arg Gly Arg Ile Trp Pro Gly Ala
 20 25 30
 Gly Gly Gly Val Gly Ala Ala Arg His Val His His His Gln Gly Ala
 35 40 45
 Gln Gln Ala Gly Arg Ala Ala Pro His Arg Ser His Ala Ala Ala Gly
 50 55 60
 Gly Gly Pro Ala Arg Arg Ala Pro Glu Met Pro Ala Ala Arg Ala Ala
 65 70 75 80
 Asp Leu Ala Ala Pro Ala Gly Ala Ala Xaa Cys Ala Xaa Pro Gly Pro
 85 90 95
 Trp Pro Leu Ser Ser Pro Gly Pro Arg Leu Val Phe Asn Arg Val Asn
 100 105 110
 Gly Arg Arg Ala Pro Ser Thr Ser Pro Ser Phe Glu Gly Thr Gln Glu
 115 120 125
 Thr Tyr Thr Val Ala His Glu Glu Asn Val Arg Phe Val Ser Glu Ala
 130 135 140
 Trp Gln Gln Val Gln Gln Gln Leu Asp Gly Gly Pro Ala Gly Glu Gly

688

145 150 155 160
 Gly Pro Arg Pro Val Gln Tyr Val Glu Arg Thr Pro Asn Pro Arg Leu
 165 170 175
 Gln Asn Phe Val Pro Ile Asp Leu Asp Glu Trp Trp Ala Xaa Gln Phe
 180 185 190
 Leu Ala Arg Ile Thr Ser Cys Ser
 195 200

<210> 715
 <211> 106
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (15)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 715
 Trp Ile Pro Arg Ala Ala Gly Ile Arg His Glu Leu Val Pro Xaa Leu
 1 5 10 15
 Trp Ser Arg Glu Glu Ala Met Ala Thr Met Glu Asn Lys Val Ile Cys
 20 25 30
 Ala Leu Val Leu Val Ser Met Leu Ala Leu Gly Thr Leu Ala Glu Ala
 35 40 45
 Gln Thr Glu Thr Cys Thr Val Ala Pro Arg Glu Arg Gln Asn Cys Gly
 50 55 60
 Phe Pro Gly Val Thr Pro Ser Gln Cys Ala Asn Lys Gly Cys Cys Phe
 65 70 75 80
 Asp Asp Thr Val Arg Gly Val Pro Trp Cys Phe Tyr Pro Asn Thr Ile
 85 90 95
 Asp Val Pro Pro Glu Glu Glu Cys Glu Phe
 100 105

<210> 716
 <211> 105
 <212> PRT
 <213> Homo sapiens

689

<400> 716

Glu Gly Arg Glu Ala Gly Ser Gly Leu Ser Val Asp Ser Arg Asp Lys
 1 5 10 15
 Gly His Glu Gly Arg Gly Leu Gly Pro Phe Arg Ile Pro Gln Asp Ser
 20 25 30
 Gln Val Gln Leu Cys Gln Lys Gly Thr Phe His Val Met Gln Leu Arg
 35 40 45
 Gly Leu Ser Leu Asn Pro Arg Leu Leu Leu Thr Leu Gly Ser Phe Asn
 50 55 60
 Gln Val Gly Gln Pro Leu Leu Gln Arg Gly Val Gly Trp Leu Ser Ser
 65 70 75 80
 Leu Ser His Ala Ala Cys Glu Asp Arg Gly Gly Gly Val Gly Ser Gly
 85 90 95
 Lys Ser Pro Glu Asn Arg Arg Gly Ile
 100 105

<210> 717

<211> 431

<212> PRT

<213> Homo sapiens

<400> 717

Arg Ala Ala Gly Ile Arg His Glu Arg Gly Gly Pro Thr Gly Ser Cys
 1 5 10 15
 Pro Gly Leu Pro Ser Pro Pro Met Val Leu Tyr Ile Lys Tyr Pro Gly
 20 25 30
 Trp Arg Ser His Met Leu Leu Thr Glu Gly Gly Asn Tyr His Ser Ser
 35 40 45
 Leu Gly Thr Arg Cys Glu Leu Ser Cys Asp Arg Gly Phe Arg Leu Ile
 50 55 60
 Gly Arg Arg Ser Val Gln Cys Leu Pro Ser Arg Arg Trp Ser Gly Thr
 65 70 75 80
 Ala Tyr Cys Arg Gln Met Arg Cys His Ala Leu Pro Phe Ile Thr Ser
 85 90 95
 Gly Thr Tyr Thr Cys Thr Asn Gly Val Leu Leu Asp Ser Arg Cys Asp
 100 105 110

690

Tyr Ser Cys Ser Ser Gly Tyr His Leu Glu Gly Asp Arg Ser Arg Ile
 115 120 125
 Cys Met Glu Asp Gly Arg Trp Ser Gly Gly Glu Pro Val Cys Val Asp
 130 135 140
 Ile Asp Pro Pro Lys Ile Arg Cys Pro His Ser Arg Glu Lys Met Ala
 145 150 155 160
 Glu Pro Glu Lys Leu Thr Ala Arg Val Tyr Trp Asp Pro Pro Leu Val
 165 170 175
 Lys Asp Ser Ala Asp Gly Thr Ile Thr Arg Val Thr Leu Arg Gly Pro
 180 185 190
 Glu Pro Gly Ser His Phe Pro Glu Gly Glu His Val Ile Arg Tyr Thr
 195 200 205
 Ala Tyr Asp Arg Ala Tyr Asn Arg Ala Ser Cys Lys Phe Ile Val Lys
 210 215 220
 Val Gln Val Arg Arg Cys Pro Thr Leu Lys Pro Pro Gln His Gly Tyr
 225 230 235 240
 Leu Thr Cys Thr Ser Ala Gly Asp Asn Tyr Gly Ala Thr Cys Glu Tyr
 245 250 255
 His Cys Asp Gly Gly Tyr Asp Arg Gln Gly Thr Pro Ser Arg Val Cys
 260 265 270
 Gln Ser Ser Arg Gln Trp Ser Gly Ser Pro Pro Ile Cys Ala Pro Met
 275 280 285
 Lys Ile Asn Val Asn Val Asn Ser Ala Ala Gly Leu Leu Asp Gln Phe
 290 295 300
 Tyr Glu Lys Gln Arg Leu Leu Ile Ile Ser Ala Pro Asp Pro Ser Asn
 305 310 315 320
 Arg Tyr Tyr Lys Met Gln Ile Ser Met Leu Gln Gln Ser Thr Cys Gly
 325 330 335
 Leu Asp Leu Arg His Val Thr Ile Ile Glu Leu Val Gly Gln Pro Pro
 340 345 350
 Gln Glu Val Gly Arg Ile Arg Glu Gln Gln Leu Ser Ala Asn Ile Ile
 355 360 365
 Glu Glu Leu Arg Gln Phe Gln Arg Leu Thr Arg Ser Tyr Phe Asn Met
 370 375 380

691

Val Leu Ile Asp Lys Gln Gly Ile Asp Arg Asp Arg Tyr Met Glu Pro
 385 390 395 400

Val Thr Pro Glu Glu Ile Phe Thr Phe Ile Asp Asp Tyr Leu Leu Ser
 405 410 415

Asn Gln Glu Leu Thr Gln Arg Arg Glu Gln Arg Asp Ile Cys Glu
 420 425 430

<210> 718

<211> 417

<212> PRT

<213> Homo sapiens

<400> 718

Gln Gly Leu Pro Asp Gly Val Trp Ala His Gly Thr Cys Pro Gly His
 1 5 10 15

Arg Leu Val Ser Ser Gln Arg Arg Ile Ile Ala Ser Gly Ser Glu Asp
 20 25 30

Cys Thr Val Met Val Trp Gln Ile Pro Glu Asn Gly Leu Thr Ser Pro
 35 40 45

Leu Thr Glu Pro Val Val Val Leu Glu Gly His Thr Lys Arg Val Gly
 50 55 60

Ile Ile Ala Trp His Pro Thr Ala Arg Asn Val Leu Leu Ser Ala Gly
 65 70 75 80

Cys Asp Asn Val Val Leu Ile Trp Asn Val Gly Thr Ala Glu Glu Leu
 85 90 95

Tyr Arg Leu Asp Ser Leu His Pro Asp Leu Ile Tyr Asn Val Ser Trp
 100 105 110

Asn His Asn Gly Ser Leu Phe Cys Ser Ala Cys Lys Asp Lys Ser Val
 115 120 125

Arg Ile Ile Asp Pro Arg Arg Gly Thr Leu Val Ala Glu Arg Glu Lys
 130 135 140

Ala His Glu Gly Ala Arg Pro Met Arg Ala Ile Phe Leu Ala Asp Gly
 145 150 155 160

Lys Val Phe Thr Thr Gly Phe Ser Arg Met Ser Glu Arg Gln Leu Ala
 165 170 175

Leu Trp Asp Pro Glu Asn Leu Glu Glu Pro Met Ala Leu Gln Glu Leu
 180 185 190
 Asp Ser Ser Asn Gly Ala Leu Leu Pro Phe Tyr Asp Pro Asp Thr Ser
 195 200 205
 Val Val Tyr Val Cys Gly Lys Gly Asp Ser Ser Ile Arg Tyr Phe Glu
 210 215 220
 Ile Thr Glu Glu Pro Pro Tyr Ile His Phe Leu Asn Thr Phe Thr Ser
 225 230 235 240
 Lys Glu Pro Gln Arg Gly Met Gly Ser Met Pro Lys Arg Gly Leu Glu
 245 250 255
 Val Ser Lys Cys Glu Ile Ala Arg Phe Tyr Lys Leu His Glu Arg Lys
 260 265 270
 Cys Glu Pro Ile Val Met Thr Val Pro Arg Lys Ser Asp Leu Phe Gln
 275 280 285
 Asp Asp Leu Tyr Pro Asp Thr Ala Gly Pro Glu Ala Ala Leu Glu Ala
 290 295 300
 Glu Glu Trp Val Ser Gly Arg Asp Ala Asp Pro Ile Leu Ile Ser Leu
 305 310 315 320
 Arg Glu Ala Tyr Val Pro Ser Lys Gln Arg Asp Leu Lys Ile Ser Arg
 325 330 335
 Arg Asn Val Leu Ser Asp Ser Arg Pro Ala Met Ala Pro Gly Ser Ser
 340 345 350
 His Leu Gly Ala Pro Ala Ser Thr Thr Thr Ala Ala Asp Ala Thr Pro
 355 360 365
 Ser Gly Ser Leu Ala Arg Ala Gly Glu Ala Gly Lys Leu Glu Glu Val
 370 375 380
 Met Gln Glu Leu Arg Ala Leu Arg Ala Leu Val Lys Glu Gln Gly Asp
 385 390 395 400
 Arg Ile Cys Arg Leu Glu Glu Gln Leu Gly Arg Met Glu Asn Gly Asp
 405 410 415
 Ala

693

<211> 290
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (7)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (74)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (131)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 719

Glu Leu Ser Ala Ser Ala Xaa Asp Asp Gly Asn Phe Ser Leu Leu Ile
 1 5 10 15

Arg Ala Val Glu Glu Thr Asp Ala Gly Leu Tyr Thr Cys Asn Leu His
 20 25 30

His His Tyr Cys His Leu Tyr Glu Ser Leu Ala Val Arg Leu Glu Val
 35 40 45

Thr Asp Gly Pro Pro Ala Pro Pro Pro Thr Gly Thr Ala Arg Arg Arg
 50 55 60

Cys Trp Arg Trp Arg Ala Ala Pro Ala Xaa Leu Thr Cys Val Asn Arg
 65 70 75 80

Gly His Val Trp Thr Asp Arg His Val Glu Glu Ala Gln Gln Val Val
 85 90 95

His Trp Asp Arg Gln Pro Pro Gly Val Pro His Asp Arg Ala Asp Arg
 100 105 110

Leu Leu Asp Leu Tyr Ala Ser Ala Ser Ala Ala Leu Arg Ala Pro Phe
 115 120 125

Ser Ala Xaa Arg Val Ala Val Gly Ala Asp Ala Phe Lys Arg Gly Asp
 130 135 140

Phe Ser Leu Arg Ile Glu Pro Leu Glu Val Ala Asp Glu Gly Thr Tyr
 145 150 155 160

Ser Cys His Leu His His His Tyr Trp Arg Ala Ala Thr Thr Ser Ser

694

	165		170		175
Met Ser Ser Ser Pro Arg Ala Glu Pro Thr Ser Ser Ser Ser Trp Ala					
	180		185		190
Thr Cys Trp Pro Arg Cys Cys Ser Ser Ser Cys Tyr Trp Ser Leu Ser					
	195		200		205
Ser Trp Pro Pro Ala Gly Arg Gly Gly Tyr Glu Tyr Ser Asp Gln Lys					
	210		215		220
Ser Gly Lys Ser Lys Gly Lys Asp Val Asn Leu Ala Glu Phe Ala Val					
	225		230		240
Ala Ala Gly Asp Gln Met Leu Tyr Arg Ser Glu Asp Ile Gln Leu Asp					
	245		250		255
Tyr Lys Asn Asn Ile Leu Lys Glu Arg Ala Glu Leu Ala His Ser Pro					
	260		265		270
Leu Pro Ala Lys Tyr Ile Asp Leu Asp Lys Gly Phe Arg Lys Glu Asn					
	275		280		285
Cys Lys					
	290				

<210> 720

<211> 459

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (50)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 720

Asp Ala His Pro Lys Pro Cys Cys Glu Thr Ser Ala Ala Ala Cys Arg
1 5 10 15

Leu Val Glu Arg Ile Leu Thr Ser Trp Glu Glu Asn Asp Arg Val Gln
20 25 30

Cys Ala Gly Gly Pro Arg Lys Gly Tyr Met Gly His Leu Thr Arg Val
35 40 45

Ala Xaa Ala Leu Val Gln Asn Thr Glu Lys Gly Pro Asn Ala Glu Gln
50 55 60

695

Leu Arg Gln Leu Leu Lys Glu Leu Pro Ser Glu Gln Gln Glu Gln Trp
 65 70 75 80

Glu Ala Phe Val Ser Gly Pro Leu Ala Glu Thr Asn Lys Lys Asn Met
 85 90 95

Val Asp Leu Val Asn Thr His His Leu His Ser Ser Ser Asp Asp Glu
 100 105 110

Asp Asp Arg Leu Lys Glu Phe Asn Phe Pro Glu Glu Ala Val Leu Gln
 115 120 125

Gln Ala Phe Met Asp Phe Gln Met Gln Arg Met Thr Ser Ala Phe Ile
 130 135 140

Asp His Phe Gly Phe Asn Asp Glu Glu Phe Gly Glu Gln Glu Glu Ser
 145 150 155 160

Val Asn Ala Pro Phe Asp Lys Thr Ala Asn Ile Thr Phe Ser Leu Asn
 165 170 175

Ala Asp Asp Glu Asn Pro Asn Ala Asn Leu Leu Glu Ile Cys Tyr Lys
 180 185 190

Asp Arg Ile Gln Gln Phe Asp Asp Asp Glu Glu Glu Glu Asp Glu Glu
 195 200 205

Glu Ala Gln Gly Ser Gly Glu Ser Asp Gly Glu Asp Gly Ala Trp Gln
 210 215 220

Gly Ser Gln Leu Ala Arg Gly Ala Arg Leu Gly Gln Pro Pro Gly Val
 225 230 235 240

Arg Ser Gly Gly Ser Thr Asp Ser Glu Asp Glu Glu Glu Glu Asp Glu
 245 250 255

Glu Glu Glu Glu Asp Glu Glu Gly Ile Gly Cys Ala Ala Arg Gly Gly
 260 265 270

Ala Thr Pro Leu Ser Tyr Pro Ser Pro Gly Pro Gln Pro Pro Gly Pro
 275 280 285

Ser Trp Thr Ala Thr Phe Asp Pro Val Pro Thr Asp Ala Pro Thr Ser
 290 295 300

Pro Arg Val Ser Gly Glu Glu Glu Leu His Thr Gly Pro Pro Ala Pro
 305 310 315 320

Gln Gly Pro Leu Ser Val Pro Gln Gly Leu Pro Thr Gln Ser Leu Ala
 325 330 335

696

Ser Pro Pro Ala Arg Asp Ala Leu Gln Leu Arg Ser Gln Asp Pro Thr
340 345 350

Pro Pro Ser Ala Pro Gln Glu Ala Thr Glu Gly Ser Lys Val Thr Glu
355 360 365

Pro Ser Ala Pro Cys Gln Ala Leu Val Ser Ile Gly Asp Leu Gln Ala
370 375 380

Thr Phe His Gly Ile Arg Ser Ala Pro Ser Ser Ser Asp Ser Ala Thr
385 390 395 400

Arg Asp Pro Ser Thr Ser Val Pro Ala Ser Gly Ala His Gln Pro Pro
405 410 415

Gln Thr Thr Glu Gly Glu Lys Ser Pro Glu Pro Leu Gly Leu Pro Gln
420 425 430

Ser Gln Ser Ala Gln Ala Leu Thr Pro Pro Pro Ile Pro Asn Gly Ser
435 440 445

Ala Pro Glu Gly Pro Ala Ser Pro Gly Ser Gln
450 455

<210> 721

<211> 523

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (12)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (115)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (194)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (327)

<223> Xaa equals any of the naturally occurring L-amino acids

697

<400> 721

```

Leu Gln Arg Leu Lys Leu Ile Lys Pro Leu Leu Xaa Phe Glu Ser Leu
 1             5             10             15

Glu Glu Cys Tyr Met Ala Lys Ile Leu Val Ala Glu Gly Thr Arg Asp
      20             25             30

Val Pro Ile Gly Ala Ile Ile Cys Ile Thr Val Gly Lys Pro Glu Asp
      35             40             45

Ile Glu Ala Phe Lys Asn Tyr Thr Leu Asp Ser Ser Ala Ala Pro Thr
 50             55             60

Pro Gln Ala Ala Pro Ala Pro Thr Pro Ala Ala Thr Ala Ser Pro Pro
 65             70             75             80

Thr Pro Ser Ala Gln Ala Pro Gly Ser Ser Tyr Pro Pro His Met Gln
      85             90             95

Val Leu Leu Pro Ala Leu Ser Pro Thr Met Thr Met Gly Thr Val Gln
      100            105            110

Arg Trp Xaa Lys Lys Val Gly Glu Lys Leu Ser Glu Gly Asp Leu Leu
      115            120            125

Ala Glu Ile Glu Thr Asp Lys Ala Thr Ile Gly Phe Glu Val Gln Glu
      130            135            140

Glu Gly Tyr Leu Ala Lys Ile Leu Val Pro Glu Gly Thr Arg Asp Val
      145            150            155            160

Pro Leu Gly Thr Pro Leu Cys Ile Ile Val Glu Lys Glu Ala Asp Ile
      165            170            175

Ser Ala Phe Ala Asp Tyr Arg Pro Thr Glu Val Thr Asp Leu Lys Pro
      180            185            190

Gln Xaa Pro Pro Pro Thr Pro Pro Pro Val Ala Ala Val Pro Pro Thr
      195            200            205

Pro Gln Pro Leu Ala Pro Thr Pro Ser Ala Pro Cys Pro Ala Thr Pro
      210            215            220

Ala Gly Pro Lys Gly Arg Val Phe Val Ser Pro Leu Ala Lys Lys Leu
      225            230            235            240

Ala Val Glu Lys Gly Ile Asp Leu Thr Gln Val Lys Gly Thr Gly Pro
      245            250            255

Asp Gly Arg Ile Thr Lys Lys Asp Ile Asp Ser Phe Val Pro Ser Lys
      260            265            270

```


Val Ala Pro Ala Pro Ala Ala Val Val Pro Pro Thr Gly Pro Gly Met
 275 280 285

Ala Pro Val Pro Thr Gly Val Phe Thr Asp Ile Pro Ile Ser Asn Ile
 290 295 300

Arg Arg Val Ile Ala Gln Arg Leu Met Gln Ser Lys Gln Thr Ile Pro
 305 310 315 320

His Tyr Tyr Leu Ser Ile Xaa Val Asn Met Gly Glu Val Leu Leu Val
 325 330 335

Arg Lys Glu Leu Asn Lys Ile Leu Glu Gly Arg Ser Lys Ile Ser Val
 340 345 350

Asn Asp Phe Ile Ile Lys Ala Ser Ala Leu Ala Cys Leu Lys Val Pro
 355 360 365

Glu Ala Asn Ser Ser Trp Met Asp Thr Val Ile Arg Gln Asn His Val
 370 375 380

Val Asp Val Ser Val Ala Val Ser Thr Pro Ala Gly Leu Ile Thr Pro
 385 390 395 400

Ile Val Phe Asn Ala His Ile Lys Gly Val Glu Thr Ile Ala Asn Asp
 405 410 415

Val Val Ser Leu Ala Thr Lys Ala Arg Glu Gly Lys Leu Gln Pro His
 420 425 430

Glu Phe Gln Gly Gly Thr Phe Thr Ile Ser Asn Leu Gly Met Phe Gly
 435 440 445

Ile Lys Asn Phe Ser Ala Ile Ile Asn Pro Pro Gln Ala Cys Ile Leu
 450 455 460

Ala Ile Gly Ala Ser Glu Asp Lys Leu Val Pro Ala Asp Asn Glu Lys
 465 470 475 480

Gly Phe Asp Val Ala Ser Met Met Ser Val Thr Leu Ser Cys Asp His
 485 490 495

Arg Val Val Asp Gly Ala Val Gly Ala Gln Trp Leu Ala Glu Phe Arg
 500 505 510

Lys Tyr Leu Glu Lys Pro Ile Thr Met Leu Leu
 515 520

699

<210> 722
 <211> 111
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (10)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 722
 Ser Ser Arg Ser Arg Ala Ala Asp Glu Xaa Ala Leu Cys Leu Gln Cys
 1 5 10 15
 Asp Met Asn Asp Cys Tyr Ser Arg Leu Arg Arg Leu Val Pro Thr Ile
 20 25 30
 Pro Pro Asn Lys Lys Val Ser Lys Val Glu Ile Leu Gln His Val Ile
 35 40 45
 Asp Tyr Ile Leu Asp Leu Gln Leu Ala Leu Glu Thr His Pro Ala Leu
 50 55 60
 Leu Arg Gln Pro Pro Pro Pro Ala Pro Pro His His Pro Ala Gly Thr
 65 70 75 80
 Cys Pro Ala Ala Pro Pro Arg Thr Pro Leu Thr Ala Leu Asn Thr Asp
 85 90 95
 Pro Ala Gly Ala Val Asn Lys Gln Gly Asp Ser Ile Leu Cys Arg
 100 105 110

<210> 723
 <211> 190
 <212> PRT
 <213> Homo sapiens

<400> 723
 Ser Gly Gly Gly Gly Arg Met Ile Lys Leu Phe Ser Leu Lys Gln
 1 5 10 15
 Gln Lys Lys Glu Glu Glu Ser Ala Gly Gly Thr Lys Gly Ser Ser Lys
 20 25 30
 Lys Ala Ser Ala Ala Gln Leu Arg Ile Gln Lys Asp Ile Asn Glu Leu
 35 40 45
 Asn Leu Pro Lys Thr Cys Asp Ile Ser Phe Ser Asp Pro Asp Asp Leu
 50 55 60

700

Leu Asn Phe Lys Leu Val Ile Cys Pro Asp Glu Gly Phe Tyr Lys Ser
65 70 75 80

Gly Lys Phe Val Phe Ser Phe Lys Val Gly Gln Gly Tyr Pro His Asp
85 90 95

Pro Pro Lys Val Lys Cys Glu Thr Met Val Tyr His Pro Asn Ile Asp
100 105 110

Leu Glu Gly Asn Val Cys Leu Asn Ile Leu Arg Glu Asp Trp Lys Pro
115 120 125

Val Leu Thr Ile Asn Ser Ile Ile Tyr Gly Leu Gln Tyr Leu Phe Leu
130 135 140

Glu Pro Asn Pro Glu Asp Pro Leu Asn Lys Glu Ala Ala Glu Val Leu
145 150 155 160

Gln Asn Asn Arg Arg Leu Phe Glu Gln Asn Val Gln Arg Ser Met Arg
165 170 175

Gly Gly Tyr Ile Gly Ser Thr Tyr Phe Glu Arg Cys Leu Lys
180 185 190

<210> 724

<211> 524

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (247)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (417)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (440)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (443)

<223> Xaa equals any of the naturally occurring L-amino acids

701

<400> 724

```

Arg Arg Arg Arg Ala Asp Arg Ala Thr Pro Arg Glu Val Leu Glu Thr
 1           5           10           15

Pro Gly Ala Ala Ser Val Gln Thr Leu Pro Ser Val Thr Met Lys Leu
      20           25           30

Trp Val Ser Ala Leu Leu Met Ala Trp Phe Gly Val Leu Ser Cys Val
      35           40           45

Gln Ala Glu Phe Phe Thr Ser Ile Gly His Met Thr Asp Leu Ile Tyr
      50           55           60

Ala Glu Lys Glu Leu Val Gln Ser Leu Lys Glu Tyr Ile Leu Val Glu
      65           70           75           80

Glu Ala Lys Leu Ser Lys Ile Lys Ser Trp Ala Asn Lys Met Glu Ala
      85           90           95

Leu Thr Ser Lys Ser Ala Ala Asp Ala Glu Gly Tyr Leu Ala His Pro
      100          105          110

Val Asn Ala Tyr Lys Leu Val Lys Arg Leu Asn Thr Asp Trp Pro Ala
      115          120          125

Leu Glu Asp Leu Val Leu Gln Asp Ser Ala Ala Gly Phe Ile Ala Asn
      130          135          140

Leu Ser Val Gln Arg Gln Phe Phe Pro Thr Asp Glu Asp Glu Ile Gly
      145          150          155          160

Ala Ala Lys Ala Leu Met Arg Leu Gln Asp Thr Tyr Arg Leu Asp Pro
      165          170          175

Gly Thr Ile Ser Arg Gly Glu Leu Pro Gly Thr Lys Tyr Gln Ala Met
      180          185          190

Leu Ser Val Asp Asp Cys Phe Gly Met Gly Arg Ser Ala Tyr Asn Glu
      195          200          205

Gly Asp Tyr Tyr His Thr Val Leu Trp Met Glu Gln Val Leu Lys Gln
      210          215          220

Leu Asp Ala Gly Glu Glu Ala Thr Thr Thr Lys Ser Gln Val Leu Asp
      225          230          235          240

Tyr Leu Ser Tyr Ala Val Xaa Gln Leu Gly Asp Leu His Arg Ala Leu
      245          250          255

Glu Leu Thr Arg Arg Leu Leu Ser Leu Asp Pro Ser His Glu Arg Ala

```

702

260	265	270
Gly Gly Asn Leu Arg Tyr Phe Glu Gln Leu Leu Glu Glu Glu Arg Glu		
275	280	285
Lys Thr Leu Thr Asn Gln Thr Glu Ala Glu Leu Ala Thr Pro Glu Gly		
290	295	300
Ile Tyr Glu Arg Pro Val Asp Tyr Leu Pro Glu Arg Asp Val Tyr Glu		
305	310	315
Ser Leu Cys Arg Gly Glu Gly Val Lys Leu Thr Pro Arg Arg Gln Lys		
325	330	335
Arg Leu Phe Cys Arg Tyr His His Gly Asn Arg Ala Pro Gln Leu Leu		
340	345	350
Ile Ala Pro Phe Lys Glu Glu Asp Glu Trp Asp Ser Pro His Ile Val		
355	360	365
Arg Tyr Tyr Asp Val Met Ser Asp Glu Glu Ile Glu Arg Ile Lys Glu		
370	375	380
Ile Ala Lys Pro Lys Leu Ala Arg Ala Thr Val Arg Asp Pro Lys Thr		
385	390	395
Gly Val Leu Thr Val Ala Ser Tyr Arg Val Ser Lys Ser Ser Trp Leu		
405	410	415
Xaa Glu Asp Asp Asp Pro Val Val Ala Arg Val Asn Arg Arg Met Gln		
420	425	430
His Ile Thr Gly Leu Thr Val Xaa Thr Ala Xaa Leu Leu Gln Val Ala		
435	440	445
Asn Tyr Gly Val Gly Gly Gln Tyr Glu Pro His Phe Asp Phe Ser Arg		
450	455	460
Asn Asp Glu Arg Asp Thr Phe Lys His Leu Gly Thr Gly Asn Arg Val		
465	470	475
Ala Thr Phe Leu Asn Tyr Met Ser Asp Val Glu Ala Gly Gly Ala Thr		
485	490	495
Val Phe Pro Asp Leu Gly Ala Ala Ile Trp Pro Lys Lys Gly Thr Ala		
500	505	510
Val Phe Trp Tyr Asn Leu Leu Arg Ser Gly Arg Arg		
515	520	

703

<210> 725

<211> 92

<212> PRT

<213> Homo sapiens

<400> 725

Leu Lys Met Thr Ser Leu Phe Ala Gln Glu Ile Arg Leu Ser Lys Arg
1 5 10 15
His Glu Glu Ile Val Ser Gln Arg Leu Met Leu Leu Gln Gln Met Glu
20 25 30
Asn Lys Leu Gly Asp Gln His Thr Glu Lys Ala Ser Gln Leu Gln Thr
35 40 45
Val Glu Thr Ala Phe Lys Arg Asn Leu Ser Leu Leu Lys Asp Ile Glu
50 55 60
Ala Ala Glu Lys Ser Leu Gln Thr Arg Ile His Pro Leu Pro Arg Pro
65 70 75 80
Glu Val Val Ser Leu Glu Thr Arg Tyr Trp Ala Ser
85 90

<210> 726

<211> 690

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (108)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (123)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (383)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (688)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (690)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 726

Val	Ser	Arg	Ser	Pro	Arg	Val	Pro	Leu	Pro	Pro	Arg	Ser	Phe	Ser	Arg	
1				5					10					15		
Met	Ala	Gly	Asp	Ser	Thr	Ala	Thr	Ser	Arg	Arg	Leu	Gly	Ala	Ala	Pro	
			20					25					30			
Asp	Arg	Ala	Ala	Pro	His	Ile	Leu	Pro	Ala	Gly	Ala	His	Arg	Ala	Ala	
			35				40					45				
Thr	Ala	Pro	Gly	Leu	Gly	Gly	Gly	Pro	Glu	Pro	Leu	Gly	Arg	Ala	Leu	
			50				55					60				
Ala	Gly	Gly	Leu	Arg	Gly	Pro	Gln	Gly	Asn	Gly	Trp	Leu	Gln	Glu	Arg	
					70					75					80	
Lys	Arg	Arg	Cys	Pro	Gly	Leu	Ala	Gly	Cys	Phe	Glu	Ala	Ile	Ser	Cys	
				85					90					95		
Gly	Thr	Gly	Leu	Gly	Leu	Pro	Gly	Leu	Ala	Leu	Xaa	Arg	Glu	Leu	Ile	
			100					105					110			
Ser	Trp	Gly	Ala	Pro	Gly	Ser	Ala	Asp	Ser	Xaa	Arg	Leu	Leu	His	Trp	
			115				120					125				
Gly	Ser	His	Pro	Thr	Ala	Phe	Val	Val	Ser	Tyr	Ala	Ala	Ala	Leu	Pro	
						135					140					
Ala	Ala	Ala	Leu	Trp	His	Lys	Leu	Gly	Ser	Leu	Trp	Val	Pro	Gly	Gly	
					150					155					160	
Gln	Gly	Gly	Ser	Gly	Asn	Pro	Val	Arg	Arg	Leu	Leu	Gly	Cys	Leu	Gly	
				165					170					175		
Ser	Glu	Thr	Arg	Arg	Leu	Ser	Leu	Phe	Leu	Val	Leu	Val	Val	Leu	Ser	
				180				185					190			
Ser	Leu	Gly	Glu	Met	Ala	Ile	Pro	Phe	Phe	Thr	Gly	Arg	Leu	Thr	Asp	
				195			200					205				
Trp	Ile	Leu	Gln	Asp	Gly	Ser	Ala	Asp	Thr	Phe	Thr	Arg	Asn	Leu	Thr	
						215					220					
Leu	Met	Ser	Ile	Leu	Thr	Ile	Ala	Ser	Ala	Val	Leu	Glu	Phe	Val	Gly	
					230					235					240	

Asp Gly Ile Tyr Asn Asn Thr Met Gly His Val His Ser His Leu Gln	245	250	255
Gly Glu Val Phe Gly Ala Val Leu Arg Gln Glu Thr Glu Phe Phe Gln	260	265	270
Gln Asn Gln Thr Gly Asn Ile Met Ser Arg Val Thr Glu Asp Thr Ser	275	280	285
Thr Leu Ser Asp Ser Leu Ser Glu Asn Leu Ser Leu Phe Leu Trp Tyr	290	295	300
Leu Val Arg Gly Leu Cys Leu Leu Gly Ile Met Leu Trp Gly Ser Val	305	310	315
Ser Leu Thr Met Val Thr Leu Ile Thr Leu Pro Leu Leu Phe Leu Leu	325	330	335
Pro Lys Lys Val Gly Lys Trp Tyr Gln Leu Leu Glu Val Gln Val Arg	340	345	350
Glu Ser Leu Ala Lys Ser Ser Gln Val Ala Ile Glu Ala Leu Ser Ala	355	360	365
Met Pro Thr Val Arg Ser Phe Ala Asn Glu Glu Gly Glu Ala Xaa Lys	370	375	380
Phe Arg Glu Lys Leu Gln Glu Ile Lys Thr Leu Asn Gln Lys Glu Ala	385	390	395
Val Ala Tyr Ala Val Asn Ser Trp Thr Thr Ser Ile Ser Gly Met Leu	405	410	415
Leu Lys Val Gly Ile Leu Tyr Ile Gly Gly Gln Leu Val Thr Ser Gly	420	425	430
Ala Val Ser Ser Gly Asn Leu Val Thr Phe Val Leu Tyr Gln Met Gln	435	440	445
Phe Thr Gln Ala Val Glu Val Leu Leu Ser Ile Tyr Pro Arg Val Gln	450	455	460
Lys Ala Val Gly Ser Ser Glu Lys Ile Phe Glu Tyr Leu Asp Arg Thr	465	470	475
Pro Arg Cys Pro Pro Ser Gly Leu Leu Thr Pro Leu His Leu Glu Gly	485	490	495
Leu Val Gln Phe Gln Asp Val Ser Phe Ala Tyr Pro Asn Arg Pro Asp	500	505	510

Val Leu Val Leu Gln Gly Leu Thr Phe Thr Leu Arg Pro Gly Glu Val
 515 520 525
 Thr Ala Leu Val Gly Pro Asn Gly Ser Gly Lys Ser Thr Val Ala Ala
 530 535 540
 Leu Leu Gln Asn Leu Tyr Gln Pro Thr Gly Gly Gln Leu Leu Leu Asp
 545 550 555 560
 Gly Lys Pro Leu Pro Gln Tyr Glu His Arg Tyr Leu His Arg Gln Val
 565 570 575
 Ala Ala Val Gly Gln Glu Pro Gln Val Phe Gly Arg Ser Leu Gln Glu
 580 585 590
 Asn Ile Ala Tyr Gly Leu Thr Gln Lys Pro Thr Met Glu Glu Ile Thr
 595 600 605
 Ala Ala Ala Val Lys Ser Gly Ala His Ser Phe Ile Ser Gly Leu Pro
 610 615 620
 Gln Gly Tyr Asp Thr Glu Val Asp Glu Ala Gly Ser Gln Leu Ser Gly
 625 630 635 640
 Gly Gln Arg Gln Ala Val Ala Leu Ala Arg Ala Leu Ile Arg Lys Pro
 645 650 655
 Cys Val Leu Ile Leu Asp Asp Ala Thr Ser Ala Leu Asp Ala Asn Ser
 660 665 670
 Gln Leu Gln Val Glu Gln Leu Leu Tyr Glu Ser Pro Glu Arg Tyr Xaa
 675 680 685
 Arg Xaa
 690

<210> 727

<211> 82

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (44)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

707

<222> (73)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 727

Thr	Pro	Pro	Leu	Val	Ser	Ser	Val	Ala	Ala	Leu	Asp	Ser	His	Arg	Ser
1				5					10					15	

Thr	Asn	Pro	Ile	Val	Asn	Ser	Ala	Cys	Lys	Gly	Ser	Arg	Leu	Cys	Ala
			20					25					30		

Pro	Tyr	Glu	Asn	Leu	Met	Pro	Asp	Asp	Leu	Arg	Xaa	Asn	Ser	Phe	Ile
		35					40					45			

Leu	Lys	Pro	Pro	Phe	Thr	Leu	Gln	Ser	Val	Glu	Lys	Leu	Ser	Ser	Thr
	50					55					60				

Lys	Leu	Val	Pro	Gly	Ala	Lys	Asn	Xaa	Gly	Asp	Arg	Cys	Ser	Arg	Glu
65					70					75					80

Arg Ser

<210> 728

<211> 600

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (11)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (479)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (550)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (588)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

708

<222> (590)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 728

```

Ser Arg Val Lys Pro Arg Val Arg Gly Thr Xaa Val Arg Thr Pro Gly
 1             5             10             15

Ser Arg Arg Gly Arg His Gly Ala Val Pro Gly Asp Trp Glu Ala Ala
      20             25             30

Ala Gln Ala Arg Gly Ala Gly Gln Arg Leu Pro Thr Pro Ser Glu Ile
      35             40             45

Leu Ser Asn Ala Gly Leu Arg Phe Glu Val Val Pro Ser Lys Phe Lys
      50             55             60

Glu Lys Leu Asp Lys Ala Ser Phe Ala Thr Pro Tyr Gly Tyr Ala Met
      65             70             75             80

Glu Thr Ala Lys Gln Lys Ala Leu Glu Val Ala Asn Arg Leu Tyr Gln
      85             90             95

Lys Asp Leu Arg Ala Pro Asp Val Val Ile Gly Ala Asp Thr Ile Val
      100            105            110

Thr Val Gly Gly Leu Ile Leu Glu Lys Pro Val Asp Lys Gln Asp Ala
      115            120            125

Tyr Arg Met Leu Ser Arg Leu Ser Gly Arg Glu His Ser Val Phe Thr
      130            135            140

Gly Val Ala Ile Val His Cys Ser Ser Lys Asp His Gln Leu Asp Thr
      145            150            155            160

Arg Val Ser Glu Phe Tyr Glu Glu Thr Lys Val Lys Phe Ser Glu Leu
      165            170            175

Ser Glu Glu Leu Leu Trp Glu Tyr Val His Ser Gly Glu Pro Met Asp
      180            185            190

Lys Ala Gly Gly Tyr Gly Ile Gln Ala Leu Gly Gly Met Leu Val Glu
      195            200            205

Ser Val His Gly Asp Phe Leu Asn Val Val Gly Phe Pro Leu Asn His
      210            215            220

Phe Cys Lys Gln Leu Val Lys Leu Tyr Tyr Pro Pro Arg Pro Glu Asp
      225            230            235            240

Leu Arg Arg Ser Val Lys His Asp Ser Ile Pro Ala Ala Asp Thr Phe
      245            250            255

```

Glu Asp Leu Ser Asp Val Glu Gly Gly Gly Ser Glu Pro Thr Gln Arg
 260 265 270
 Asp Ala Gly Ser Arg Asp Glu Lys Ala Glu Ala Gly Glu Ala Gly Gln
 275 280 285
 Ala Thr Ala Glu Ala Glu Cys His Arg Thr Arg Glu Thr Leu Pro Pro
 290 295 300
 Phe Pro Thr Arg Leu Leu Glu Leu Ile Glu Gly Phe Met Leu Ser Lys
 305 310 315 320
 Gly Leu Leu Thr Ala Cys Lys Leu Lys Val Phe Asp Leu Leu Lys Asp
 325 330 335
 Glu Ala Pro Gln Lys Ala Ala Asp Ile Ala Ser Lys Val Asp Ala Ser
 340 345 350
 Ala Cys Gly Met Glu Arg Leu Leu Asp Ile Cys Ala Ala Met Gly Leu
 355 360 365
 Leu Glu Lys Thr Glu Gln Gly Tyr Ser Asn Thr Glu Thr Ala Asn Val
 370 375 380
 Tyr Leu Ala Ser Asp Gly Glu Tyr Ser Leu His Gly Phe Ile Met His
 385 390 395 400
 Asn Asn Asp Leu Thr Trp Asn Leu Phe Thr Tyr Leu Glu Phe Ala Ile
 405 410 415
 Arg Glu Gly Thr Asn Gln His His Arg Ala Leu Gly Lys Lys Ala Glu
 420 425 430
 Asp Leu Phe Gln Asp Ala Tyr Tyr Gln Ser Pro Glu Thr Arg Leu Arg
 435 440 445
 Phe Met Arg Ala Met His Gly Met Thr Lys Leu Thr Ala Cys Gln Val
 450 455 460
 Ala Thr Ala Phe Asn Leu Ser Arg Phe Ser Ser Ala Cys Asp Xaa Gly
 465 470 475 480
 Gly Cys Thr Gly Ala Leu Ala Arg Glu Leu Ala Arg Glu Tyr Pro Arg
 485 490 495
 Met Gln Val Thr Val Phe Asp Leu Pro Asp Ile Ile Glu Leu Ala Ala
 500 505 510
 His Phe Gln Pro Pro Gly Pro Gln Gln Cys Arg Ser Thr Ser Gln Gln
 515 520 525

710

Val Thr Phe Ser Gly Thr Pro Ser Pro Ala Leu Ser Cys Thr Ser Cys
 530 535 540

Ala Gly Ser Cys Met Xaa Gly Gln Thr Thr Lys Ser Thr Ser Tyr Ser
 545 550 555 560

Ala Gly Ser Pro Arg Ala Ala Ser Gln Gly Pro Ala Cys Cys Trp Trp
 565 570 575

Arg Arg Ser Trp Met Arg Arg Arg Gly Trp Arg Xaa Arg Xaa Asp Ala
 580 585 590

Val Thr Glu His Ala Gly Ala Asp
 595 600

<210> 729

<211> 535

<212> PRT

<213> Homo sapiens

<400> 729

Gly Arg Ser Ser Phe Thr Ser Leu Val Val Gly Val Phe Val Val Tyr
 1 5 10 15

Val Val His Thr Cys Trp Val Met Tyr Gly Ile Val Tyr Thr Arg Pro
 20 25 30

Cys Ser Gly Asp Ala Asn Cys Ile Gln Pro Tyr Leu Ala Arg Arg Pro
 35 40 45

Lys Leu Gln Leu Ser Val Tyr Thr Thr Thr Arg Ser His Leu Gly Ala
 50 55 60

Glu Asn Asn Ile Asp Leu Val Leu Asn Val Glu Asp Phe Asp Val Glu
 65 70 75 80

Ser Lys Phe Glu Arg Thr Val Asn Val Ser Val Pro Lys Lys Thr Arg
 85 90 95

Asn Asn Gly Thr Leu Tyr Ala Tyr Ile Phe Leu His His Ala Gly Val
 100 105 110

Leu Pro Trp His Asp Gly Lys Gln Val His Leu Val Ser Pro Leu Thr
 115 120 125

Thr Tyr Met Val Pro Lys Pro Glu Glu Ile Asn Leu Leu Thr Gly Glu
 130 135 140

711

Ser Asp Thr Gln Gln Ile Glu Ala Glu Lys Lys Pro Thr Ser Ala Leu
 145 150 155 160

Asp Glu Pro Val Ser His Trp Arg Pro Arg Leu Ala Leu Asn Val Met
 165 170 175

Ala Asp Asn Phe Val Phe Asp Gly Ser Ser Leu Pro Ala Asp Val His
 180 185 190

Arg Tyr Met Lys Met Ile Gln Leu Gly Lys Thr Val His Tyr Leu Pro
 195 200 205

Ile Leu Phe Ile Asp Gln Leu Ser Asn Arg Val Lys Asp Leu Met Val
 210 215 220

Ile Asn Arg Ser Thr Thr Glu Leu Pro Leu Thr Val Ser Tyr Asp Lys
 225 230 235 240

Val Ser Leu Gly Arg Leu Arg Phe Trp Ile His Met Gln Asp Ala Val
 245 250 255

Tyr Ser Leu Gln Gln Phe Gly Phe Ser Glu Lys Asp Ala Asp Glu Val
 260 265 270

Lys Gly Ile Phe Val Asp Thr Asn Leu Tyr Phe Leu Ala Leu Thr Phe
 275 280 285

Phe Val Ala Ala Phe His Leu Leu Phe Asp Phe Leu Ala Phe Lys Asn
 290 295 300

Asp Ile Ser Phe Trp Lys Lys Lys Lys Ser Met Ile Gly Met Ser Thr
 305 310 315 320

Lys Ala Val Leu Trp Arg Cys Phe Ser Thr Val Val Ile Phe Leu Phe
 325 330 335

Leu Leu Asp Glu Gln Thr Ser Leu Leu Val Leu Val Pro Ala Gly Val
 340 345 350

Gly Ala Ala Ile Glu Leu Trp Lys Val Lys Lys Ala Leu Lys Met Thr
 355 360 365

Ile Phe Trp Arg Gly Leu Met Pro Glu Phe Gln Phe Gly Thr Tyr Ser
 370 375 380

Glu Ser Glu Arg Lys Thr Glu Glu Tyr Asp Thr Gln Ala Met Lys Tyr
 385 390 395 400

Leu Ser Tyr Leu Leu Tyr Pro Leu Cys Val Gly Gly Ala Val Tyr Ser
 405 410 415

712

Leu Leu Asn Ile Lys Tyr Lys Ser Trp Tyr Ser Trp Leu Ile Asn Ser
 420 425 430
 Phe Val Asn Gly Val Tyr Ala Phe Gly Phe Leu Phe Met Leu Pro Gln
 435 440 445
 Leu Phe Val Asn Tyr Lys Leu Lys Ser Val Ala His Leu Pro Trp Lys
 450 455 460
 Ala Phe Thr Tyr Lys Ala Phe Asn Thr Phe Ile Asp Asp Val Phe Ala
 465 470 475 480
 Phe Ile Ile Thr Met Pro Thr Ser His Arg Leu Ala Cys Phe Arg Asp
 485 490 495
 Asp Val Val Phe Leu Val Tyr Leu Tyr Gln Arg Trp Leu Tyr Pro Val
 500 505 510
 Asp Lys Arg Arg Val Asn Glu Phe Gly Glu Ser Tyr Glu Glu Lys Ala
 515 520 525
 Thr Arg Ala Pro His Thr Asp
 530 535

<210> 730
 <211> 288
 <212> PRT
 <213> Homo sapiens

<400> 730
 Arg Pro Ala Gly Val Thr Glu Leu Gln Pro Arg Ala Pro Gly Gly Gly
 1 5 10 15
 Gly Met Glu Ala Ala Ala Glu Pro Gly Asn Leu Ala Gly Val Arg His
 20 25 30
 Ile Ile Leu Val Leu Ser Gly Lys Gly Gly Val Gly Lys Ser Thr Ile
 35 40 45
 Ser Thr Glu Leu Ala Leu Ala Leu Arg His Ala Gly Lys Lys Val Gly
 50 55 60
 Ile Leu Asp Val Asp Leu Cys Gly Pro Ser Ile Pro Arg Met Leu Gly
 65 70 75 80
 Ala Gln Gly Arg Ala Val His Gln Cys Asp Arg Gly Trp Ala Pro Val
 85 90 95
 Phe Leu Asp Arg Glu Gln Ser Ile Ser Leu Met Ser Val Gly Phe Leu

713

100	105	110
Leu Glu Lys Pro Asp Glu Ala Val Val Trp Arg Gly Pro Lys Lys Asn		
115	120	125
Ala Leu Ile Lys Gln Phe Val Ser Asp Val Ala Trp Gly Glu Leu Asp		
130	135	140
Tyr Leu Val Val Asp Thr Pro Pro Gly Thr Ser Asp Glu His Met Ala		
145	150	155
Thr Ile Glu Ala Leu Arg Pro Tyr Gln Pro Leu Gly Ala Leu Val Val		
165	170	175
Thr Thr Pro Gln Ala Val Ser Val Gly Asp Val Arg Arg Glu Leu Thr		
180	185	190
Phe Cys Arg Lys Thr Gly Leu Arg Val Met Gly Ile Val Glu Asn Met		
195	200	205
Ser Gly Phe Thr Cys Pro His Cys Thr Glu Cys Thr Ser Val Phe Ser		
210	215	220
Arg Gly Gly Gly Glu Glu Leu Ala Gln Leu Ala Gly Val Pro Phe Leu		
225	230	235
Gly Ser Val Pro Leu Asp Pro Ala Leu Met Arg Thr Leu Glu Glu Gly		
245	250	255
His Asp Phe Ile Gln Glu Phe Pro Gly Ser Pro Ala Phe Ala Ala Leu		
260	265	270
Thr Ser Ile Ala Gln Lys Ile Leu Asp Ala Thr Pro Ala Cys Leu Pro		
275	280	285

<210> 731

<211> 737

<212> PRT

<213> Homo sapiens

<400> 731

Asp Gln Leu Cys Gly Pro Gln Thr Tyr Lys Glu His Leu Glu Gly Gln
1 5 10 15

Lys His Lys Lys Lys Glu Ala Ala Leu Lys Ala Ser Gln Asn Thr Ser
20 25 30

Ser Ser Asn Ser Ser Thr Arg Gly Thr Gln Asn Gln Leu Arg Cys Glu
 35 40 45
 Leu Cys Asp Val Ser Cys Thr Gly Ala Asp Ala Tyr Ala Ala His Ile
 50 55 60
 Arg Gly Ala Lys His Gln Lys Val Val Lys Leu His Thr Lys Leu Gly
 65 70 75 80
 Lys Pro Ile Pro Ser Thr Glu Pro Asn Val Val Ser Gln Ala Thr Ser
 85 90 95
 Ser Thr Ala Val Ser Ala Ser Lys Pro Thr Ala Ser Pro Ser Ser Ile
 100 105 110
 Ala Ala Asn Asn Cys Thr Val Asn Thr Ser Ser Ile Ala Thr Ser Ser
 115 120 125
 Met Lys Gly Leu Thr Thr Thr Gly Asn Ser Ser Leu Asn Ser Thr Ser
 130 135 140
 Asn Thr Lys Val Ser Ala Val Pro Thr Asn Met Ala Ala Lys Lys Thr
 145 150 155 160
 Ser Thr Pro Lys Ile Asn Phe Val Gly Gly Asn Lys Leu Gln Ser Thr
 165 170 175
 Gly Asn Lys Ala Glu Asp Thr Lys Gly Thr Glu Cys Val Lys Ser Thr
 180 185 190
 Pro Val Thr Ser Ala Val Gln Ile Pro Glu Val Lys Gln Asp Thr Val
 195 200 205
 Ser Glu Pro Val Thr Pro Ala Ser Leu Ala Ala Leu Gln Ser Asp Val
 210 215 220
 Gln Pro Val Gly His Asp Tyr Val Glu Glu Val Arg Asn Asp Glu Gly
 225 230 235 240
 Lys Val Ile Arg Phe His Cys Lys Leu Cys Glu Cys Ser Phe Asn Asp
 245 250 255
 Pro Asn Ala Lys Glu Met His Leu Lys Gly Arg Arg His Arg Leu Gln
 260 265 270
 Tyr Lys Lys Lys Val Asn Pro Asp Leu Gln Val Glu Val Lys Pro Ser
 275 280 285
 Ile Arg Ala Arg Lys Ile Gln Glu Glu Lys Met Arg Lys Gln Met Gln
 290 295 300

Lys Glu Glu Tyr Trp Arg Arg Arg Glu Glu Glu Glu Arg Trp Arg Met
 305 310 315 320
 Glu Met Arg Arg Tyr Glu Glu Asp Met Tyr Trp Arg Arg Met Glu Glu
 325 330 335
 Glu Gln His His Trp Asp Asp Arg Arg Arg Met Pro Asp Gly Gly Tyr
 340 345 350
 Pro His Gly Pro Pro Gly Pro Leu Gly Leu Leu Gly Val Arg Pro Gly
 355 360 365
 Met Pro Pro Gln Pro Gln Gly Pro Ala Pro Leu Arg Arg Pro Asp Ser
 370 375 380
 Ser Asp Asp Arg Tyr Val Met Thr Lys His Ala Thr Ile Tyr Pro Thr
 385 390 395 400
 Glu Glu Glu Leu Gln Ala Val Gln Lys Ile Val Ser Ile Thr Glu Arg
 405 410 415
 Ala Leu Lys Leu Val Ser Asp Ser Leu Ser Glu His Glu Lys Asn Lys
 420 425 430
 Asn Lys Glu Gly Asp Asp Lys Lys Glu Gly Gly Lys Asp Arg Ala Leu
 435 440 445
 Lys Gly Val Leu Arg Val Gly Val Leu Ala Lys Gly Leu Leu Leu Arg
 450 455 460
 Gly Asp Arg Asn Val Asn Leu Val Leu Leu Cys Ser Glu Lys Pro Ser
 465 470 475 480
 Lys Thr Leu Leu Ser Arg Ile Ala Glu Asn Leu Pro Lys Gln Leu Ala
 485 490 495
 Val Ile Ser Pro Glu Lys Tyr Asp Ile Lys Cys Ala Val Ser Glu Ala
 500 505 510
 Ala Ile Ile Leu Asn Ser Cys Val Glu Pro Lys Met Gln Val Thr Ile
 515 520 525
 Thr Leu Thr Ser Pro Ile Ile Arg Glu Glu Asn Met Arg Glu Gly Asp
 530 535 540
 Val Thr Ser Gly Met Val Lys Asp Pro Pro Asp Val Leu Asp Arg Gln
 545 550 555 560
 Lys Cys Leu Asp Ala Leu Ala Ala Leu Arg His Ala Lys Trp Phe Gln
 565 570 575

716

Ala Arg Ala Asn Gly Leu Gln Ser Cys Val Ile Ile Ile Arg Ile Leu
580 585 590

Arg Asp Leu Cys Gln Arg Val Pro Thr Trp Ser Asp Phe Pro Ser Trp
595 600 605

Ala Met Glu Leu Leu Val Glu Lys Ala Ile Ser Ser Ala Ser Ser Pro
610 615 620

Gln Ser Pro Gly Asp Ala Leu Arg Arg Val Phe Glu Cys Ile Ser Ser
625 630 635 640

Gly Ile Ile Leu Lys Gly Ser Pro Gly Leu Leu Asp Pro Cys Glu Lys
645 650 655

Asp Pro Phe Asp Thr Leu Ala Thr Met Thr Asp Gln Gln Arg Glu Asp
660 665 670

Ile Thr Ser Ser Ala Gln Phe Ala Leu Arg Leu Leu Ala Phe Arg Gln
675 680 685

Ile His Lys Val Leu Gly Met Asp Pro Leu Pro Gln Met Ser Gln Arg
690 695 700

Phe Asn Ile His Asn Asn Arg Lys Arg Arg Arg Asp Ser Asp Gly Val
705 710 715 720

Asp Gly Phe Glu Ala Glu Gly Lys Lys Asp Lys Lys Asp Tyr Asp Asn
725 730 735

Phe

<210> 732

<211> 106

<212> PRT

<213> Homo sapiens

<400> 732

Gly Arg Gly Leu Asn Ser Pro Lys Glu Leu Arg Pro Leu Thr Arg Ala
1 5 10 15

Ala Pro Ala Ala Ala Ala Cys Thr Gly Pro Gly Ala Ala Met Pro Lys
20 25 30

Cys Pro Lys Cys Asn Lys Glu Val Tyr Phe Ala Glu Arg Val Thr Ser
35 40 45

717

Leu Gly Lys Asp Trp His Arg Pro Cys Leu Lys Cys Glu Lys Cys Gly
 50 55 60
 Lys Thr Leu Thr Ser Gly Gly His Ala Glu His Glu Gly Lys Pro Tyr
 65 70 75 80
 Cys Asn His Pro Cys Tyr Ala Ala Met Phe Gly Pro Lys Gly Phe Gly
 85 90 95
 Arg Gly Gly Ala Glu Ser His Thr Phe Lys
 100 105

<210> 733
 <211> 230
 <212> PRT
 <213> Homo sapiens

<400> 733
 Ala Ser Cys Leu Gln Ser Val Ala Ser Ala Cys Ala Ser Phe Pro Ala
 1 5 10 15
 Pro Ser Trp Arg Gly Thr Arg Lys Arg Asn Ala Thr Asp Arg Val Thr
 20 25 30
 Gln Cys Lys Tyr Lys Arg Ile Gly Cys Pro Trp His Gly Pro Phe His
 35 40 45
 Glu Leu Thr Val His Glu Ala Ala Cys Ala His Pro Thr Lys Thr Gly
 50 55 60
 Ser Glu Leu Met Glu Ile Leu Asp Gly Met Asp Gln Ser His Arg Lys
 65 70 75 80
 Glu Met Gln Leu Tyr Asn Ser Ile Phe Ser Leu Leu Ser Phe Glu Lys
 85 90 95
 Ile Gly Tyr Thr Glu Val Gln Phe Arg Pro Tyr Arg Thr Asp Asp Phe
 100 105 110
 Ile Thr Arg Leu Tyr Tyr Glu Thr Pro Arg Phe Thr Val Leu Asn Gln
 115 120 125
 Thr Trp Val Leu Lys Ala Arg Val Asn Asp Ser Glu Arg Asn Pro Asn
 130 135 140
 Leu Ser Cys Lys Arg Thr Leu Ser Phe Gln Leu Leu Leu Lys Ser Lys
 145 150 155 160
 Val Thr Ala Pro Leu Glu Cys Ser Phe Leu Leu Leu Lys Gly Pro Tyr

718

165										170					175				
Asp	Asp	Val	Arg	Ile	Ser	Pro	Val	Ile	Tyr	His	Phe	Val	Phe	Thr	Asn				
180								185					190						
Glu	Ser	Asn	Glu	Thr	Asp	Tyr	Val	Pro	Leu	Pro	Ile	Ile	Asp	Ser	Val				
195							200					205							
Glu	Cys	Asn	Lys	Leu	Leu	Ala	Ala	Lys	Asn	Ile	Asn	Leu	Arg	Leu	Phe				
210						215				220									
Leu	Phe	Gln	Ile	Gln	Lys														
225					230														

```
<210> 734
<211> 222
<212> PRT
<213> Homo sapiens
```

```
<220>
<221> SITE
<222> (18)
<223> Xaa equals any of the naturally occurring L-amino acids
```

<400> 734
Gly Arg Pro Ala Pro Pro Ala Ala Arg Ala Gly Ala His Ser Arg Gly
1 5 10 15

Ala Xaa Ala Pro Pro Ala Ala Ile Asp Met Met Phe Pro Gln Ser Arg
20 25 30

His Ser Gly Ser Ser His Leu Pro Gln Gln Leu Lys Phe Thr Thr Ser
35 40 45

Asp Ser Cys Asp Arg Ile Lys Asp Glu Phe Gln Leu Leu Gln Ala Gln
50 55 60

Tyr His Ser Leu Lys Leu Glu Cys Asp Lys Leu Ala Ser Glu Lys Ser
65 70 75 80

Glu Met Gln Arg His Tyr Val Met Tyr Tyr Glu Met Ser Tyr Gly Leu
85 90 95

Asn Ile Glu Met His Lys Gln Ala Glu Ile Val Lys Arg Leu Asn Gly
100 105 110

Ile Cys Ala Gln Val Leu Pro Tyr Leu Ser Gln Glu His Gln Gln Gln
115 120 125

719

Val Leu Gly Ala Ile Glu Arg Ala Lys Gln Val Thr Ala Pro Glu Leu
 130 135 140

Asn Ser Ile Ile Arg Gln Gln Leu Gln Ala His Gln Leu Ser Gln Leu
 145 150 155 160

Gln Ala Leu Ala Leu Pro Leu Thr Pro Leu Pro Val Gly Leu Gln Pro
 165 170 175

Pro Ser Leu Pro Ala Val Ser Ala Gly Thr Gly Leu Leu Ser Leu Ser
 180 185 190

Ala Leu Gly Ser Gln Ala His Leu Ser Lys Glu Asp Lys Asn Gly His
 195 200 205

Asp Gly Asp Thr His Gln Glu Asp Asp Gly Glu Lys Ser Asp
 210 215 220

<210> 735

<211> 248

<212> PRT

<213> Homo sapiens

<400> 735

Gly Thr Ser Asp Met Glu Leu Phe Leu Ala Gly Arg Arg Val Leu Val
 1 5 10 15

Thr Gly Ala Gly Lys Gly Ile Gly Arg Gly Thr Val Gln Ala Leu His
 20 25 30

Ala Thr Gly Ala Arg Val Val Ala Val Ser Arg Thr Gln Ala Asp Leu
 35 40 45

Asp Ser Leu Val Arg Glu Cys Pro Gly Ile Glu Pro Val Cys Val Asp
 50 55 60

Leu Gly Asp Trp Glu Ala Thr Glu Arg Ala Leu Gly Ser Val Gly Pro
 65 70 75 80

Val Asp Leu Leu Val Asn Asn Ala Ala Val Ala Leu Leu Gln Pro Phe
 85 90 95

Leu Glu Val Thr Lys Glu Ala Phe Asp Arg Ser Phe Glu Val Asn Leu
 100 105 110

Arg Ala Val Ile Gln Val Ser Gln Ile Val Ala Arg Gly Leu Ile Ala
 115 120 125

Arg Gly Val Pro Gly Ala Ile Val Asn Val Ser Ser Gln Cys Ser Gln

720

130	135	140
Arg Ala Val Thr Asn His Ser Val Tyr Cys Ser Thr Lys Gly Ala Leu		
145	150	155 160
Asp Met Leu Thr Lys Val Met Ala Leu Glu Leu Gly Pro His Lys Ile		
	165	170 175
Arg Val Asn Ala Val Asn Pro Thr Val Val Met Thr Ser Met Gly Gln		
	180	185 190
Ala Thr Trp Ser Asp Pro His Lys Ala Lys Thr Met Leu Asn Arg Ile		
	195	200 205
Pro Leu Gly Lys Phe Ala Glu Val Glu His Val Val Asn Ala Ile Leu		
	210	215 220
Phe Leu Leu Ser Asp Arg Ser Gly Met Thr Thr Gly Ser Thr Leu Pro		
225	230	235 240
Val Glu Gly Gly Phe Trp Ala Cys		
	245	

<210> 736

<211> 216

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (61)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (68)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 736

Arg Leu Leu Phe Arg Val Arg Lys Arg Met Ile Ser Phe Ser Ala Pro
1 5 10 15

Pro Leu Met Leu Pro Phe Ser Phe Tyr Phe Phe Val Phe Pro Val Ala
20 25 30

Arg Thr Ala Arg Lys Arg Lys Pro Ser Pro Glu Pro Glu Gly Glu Val
35 40 45

Gly Pro Pro Lys Ile Asn Gly Glu Ala Gln Pro Trp Xaa Ser Thr Ser

721

50		55		60
Thr Glu Gly Xaa Lys Ile Pro Met Thr Pro Thr Ser Ser Phe Val Ser				
65		70		75 80
Pro Pro Pro Pro Thr Ala Ser Pro His Ser Asn Arg Thr Thr Pro Pro				
	85		90	95
Glu Ala Ala Gln Asn Gly Gln Ser Pro Met Ala Ala Leu Ile Leu Val				
	100		105	110
Ala Asp Asn Ala Gly Gly Ser His Ala Ser Lys Asp Ala Asn Gln Val				
	115		120	125
His Ser Thr Thr Arg Arg Asn Ser Asn Ser Pro Pro Ser Pro Ser Ser				
	130		135	140
Met Asn Gln Arg Arg Leu Gly Pro Arg Glu Val Gly Gly Gln Gly Ala				
145		150		155 160
Gly Asn Thr Gly Gly Leu Glu Pro Val His Pro Ala Ser Leu Pro Asp				
	165		170	175
Phe Ser Leu Ala Thr Ser Ala Pro Leu Cys Cys Thr Leu Cys His Glu				
	180		185	190
Arg Leu Glu Asp Asn His Phe Val Gln Cys Arg Pro Ser Phe Asp Lys				
	195		200	205
Phe Ser Ser Leu Leu Arg Gln Arg				
	210		215	

<210> 737

<211> 317

<212> PRT

<213> Homo sapiens

<400> 737

Arg Pro Thr Arg Pro Glu Val Met Met Thr Lys Tyr Ser Asn Leu Ser				
1		5		10 15
Leu Glu Ser His Asn Phe Ser Leu Thr Ala Ser Pro Leu Thr Ser Leu				
	20		25	30
Pro Ile Pro Glu Val Met Met Thr Lys Tyr Ser Asn Leu Phe Leu Glu				
	35		40	45
Ser His Asn Ile Ser Leu Thr Glu His Ser Ser Val Pro Val Glu Lys				
	50		55	60

722

Asn Ile Thr Leu Glu Arg Pro Ser Ala Val Glu Leu Thr Cys Gln Phe			
65	70	75	80
Thr Thr Ser Gly Asp Val Asn Ser Val Asn Val Thr Trp Lys Lys Gly			
	85	90	95
Asp Glu Gln Leu Lys Asn Tyr His Val Ser Ala Thr Glu Gly Ile Leu			
	100	105	110
Tyr Thr Gln Tyr Lys Phe Ser Ile Ile Asn Ser Glu Gln Leu Gly Ser			
	115	120	125
Tyr Ser Cys Phe Phe Glu Glu Glu Lys Glu Arg Arg Gly Thr Phe Asn			
	130	135	140
Phe Gly Val Pro Glu Val Gln Arg Lys Asn Lys Pro Leu Ile Thr Tyr			
	145	150	155
Val Gly Asp Ser Val Val Leu Val Cys Lys Cys Arg His Cys Ala Pro			
	165	170	175
Leu Asn Trp Thr Trp Tyr Ser Gly Asn Arg Ser Val Gln Val Pro Leu			
	180	185	190
Asp Val His Met Asn Glu Lys Tyr Ala Ile Asn Gly Thr Asn Ala Asn			
	195	200	205
Glu Thr Arg Leu Lys Ile Met Gln Leu Ser Glu Asp Asp Lys Gly Ser			
	210	215	220
Tyr Trp Cys His Ala Met Phe Gln Leu Gly Glu Ser Gln Glu Ser Val			
	225	230	235
Glu Leu Val Val Ile Ser Tyr Leu Val Pro Leu Lys Pro Phe Leu Gly			
	245	250	255
Ile Val Val Glu Val Ile Leu Leu Val Ala Ile Ile Leu Phe Cys Glu			
	260	265	270
Met His Thr Gln Lys Lys Lys Met His Met Asp Asp Gly Lys Glu Phe			
	275	280	285
Glu Gln Val Glu Gln Leu Lys Ser Asp Asp Ser Asn Gly Ile Glu Asn			
	290	295	300
Asn Ala Pro Arg His Arg Lys Asn Glu Ala Met Ser Gln			
	305	310	315

723

<210> 738

<211> 67

<212> PRT

<213> Homo sapiens

<400> 738

Ala Arg Val Ala Ser Asp Pro Phe Phe Arg His Tyr Arg Gln Leu Asn
 1 5 10 15

Glu Lys Leu Val Gln Leu Ile Glu Asp Tyr Ser Leu Val Ser Phe Ile
 20 25 30

Pro Leu Asn Ile Gln Asp Lys Glu Ser Ile Gln Arg Val Leu Gln Ala
 35 40 45

Val Asp Lys Ala Asn Gly Tyr Cys Phe Gly Ala Gln Glu Gln Arg Thr
 50 55 60

Trp Lys Pro
 65

<210> 739

<211> 142

<212> PRT

<213> Homo sapiens

<400> 739

Ser Gln Gln Pro Arg Ile Met Ser Lys Leu Gly Arg Ala Ala Arg Gly
 1 5 10 15

Leu Arg Lys Pro Glu Val Gly Gly Val Ile Arg Ala Ile Val Arg Ala
 20 25 30

Gly Leu Ala Met Pro Gly Pro Pro Leu Gly Pro Val Leu Gly Gln Arg
 35 40 45

Gly Val Ser Ile Asn Gln Phe Cys Lys Glu Phe Asn Glu Arg Thr Lys
 50 55 60

Asp Ile Lys Glu Gly Ile Pro Leu Pro Thr Lys Ile Leu Val Lys Pro
 65 70 75 80

Asp Arg Thr Phe Glu Ile Lys Ile Gly Gln Pro Thr Val Ser Tyr Phe
 85 90 95

Leu Lys Ala Ala Ala Gly Ile Glu Lys Gly Ala Arg Gln Thr Gly Lys
 100 105 110

Glu Val Ala Gly Leu Val Thr Leu Lys His Val Tyr Glu Ile Ala Arg

724

115 120 125
 Ile Lys Ala Gln Asp Glu Ala Phe Ala Cys Arg Met Tyr Pro
 130 135 140

<210> 740
 <211> 485
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (12)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 740
 Trp Pro Ala Val Ala Val Arg Phe Thr Ala Leu Xaa Leu Gly Phe Gly
 1 5 10 15
 Asp Ala Val His Val Tyr Asp Gly Pro Gly Pro Pro Glu Ser Ser Arg
 20 25 30
 Leu Leu Arg Ser Leu Thr His Phe Ser Asn Gly Lys Ala Val Thr Val
 35 40 45
 Glu Thr Leu Ser Gly Gln Ala Val Val Ser Tyr His Thr Val Ala Trp
 50 55 60
 Ser Asn Gly Arg Gly Phe Asn Ala Thr Tyr His Val Arg Gly Tyr Cys
 65 70 75 80
 Leu Pro Trp Asp Arg Pro Cys Gly Leu Gly Ser Gly Leu Gly Ala Gly
 85 90 95
 Glu Gly Leu Gly Glu Arg Cys Tyr Ser Glu Ala Gln Arg Cys Asp Gly
 100 105 110
 Ser Trp Asp Cys Ala Asp Gly Thr Asp Glu Glu Asp Cys Pro Gly Cys
 115 120 125
 Pro Pro Gly His Phe Pro Cys Gly Ala Ala Gly Thr Ser Gly Ala Thr
 130 135 140
 Ala Cys Tyr Leu Pro Ala Asp Arg Cys Asn Tyr Gln Thr Phe Cys Ala
 145 150 155 160
 Asp Gly Ala Asp Glu Arg Arg Cys Arg His Cys Gln Pro Gly Asn Phe
 165 170 175

725

Arg Cys Arg Asp Glu Lys Cys Val Tyr Glu Thr Trp Val Cys Asp Gly
 180 185 190

Gln Pro Asp Cys Ala Asp Gly Ser Asp Glu Trp Asp Cys Ser Tyr Val
 195 200 205

Leu Pro Arg Lys Val Ile Thr Ala Ala Val Ile Gly Ser Leu Val Cys
 210 215 220

Gly Leu Leu Leu Val Ile Ala Leu Gly Cys Thr Cys Lys Leu Tyr Ala
 225 230 235 240

Ile Arg Thr Gln Glu Tyr Ser Ile Phe Ala Pro Leu Ser Arg Met Glu
 245 250 255

Ala Glu Ile Val Gln Gln Gln Ala Pro Pro Ser Tyr Gly Gln Leu Ile
 260 265 270

Ala Gln Gly Ala Ile Pro Pro Val Glu Asp Phe Pro Thr Glu Asn Pro
 275 280 285

Asn Asp Asn Ser Val Leu Gly Asn Leu Arg Ser Leu Leu Gln Ile Leu
 290 295 300

Arg Gln Asp Met Thr Pro Gly Gly Gly Pro Gly Ala Arg Arg Arg Gln
 305 310 315 320

Arg Gly Arg Leu Met Arg Arg Leu Val Arg Arg Leu Arg Arg Trp Gly
 325 330 335

Leu Leu Pro Arg Thr Asn Thr Pro Ala Arg Ala Ser Glu Ala Arg Ser
 340 345 350

Gln Val Thr Pro Ser Ala Ala Pro Leu Glu Ala Leu Asp Gly Gly Thr
 355 360 365

Gly Pro Ala Arg Glu Gly Gly Ala Val Gly Gly Gln Asp Gly Glu Gln
 370 375 380

Ala Pro Pro Leu Pro Ile Lys Ala Pro Leu Pro Ser Ala Ser Thr Ser
 385 390 395 400

Pro Ala Pro Thr Thr Val Pro Glu Ala Pro Gly Pro Leu Pro Ser Leu
 405 410 415

Pro Leu Glu Pro Ser Leu Leu Ser Gly Val Val Gln Ala Leu Arg Gly
 420 425 430

Arg Leu Leu Pro Ser Leu Gly Pro Pro Gly Pro Thr Arg Ser Pro Pro
 435 440 445

726

Gly Pro His Thr Ala Val Leu Ala Leu Glu Asp Glu Asp Asp Val Leu
450 455 460

Leu Val Pro Leu Ala Glu Pro Gly Val Trp Val Ala Glu Ala Glu Asp
465 470 475 480

Glu Pro Leu Leu Thr
485

<210> 741

<211> 313

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (6)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (7)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (9)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (36)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (276)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 741

Gly Gly Ala Arg Gly Xaa Xaa Arg Xaa Val Ala Ser Phe Gln Gln Gln
1 5 10 15

His Gly Ala Gln Arg Asp Leu Lys Leu Gly Ser Arg Leu Tyr Gly Pro
20 25 30

Ser Ser Val Xaa Phe Ala Glu Asp Phe Val Arg Ser Ser Lys Gln His
35 40 45

727

Tyr Asn Cys Glu His Ser Lys Ile Asn Phe Arg Asp Lys Arg Ser Ala
 50 55 60

Leu Gln Ser Ile Asn Glu Trp Ala Ala Gln Thr Thr Asp Gly Lys Leu
 65 70 75 80

Pro Glu Val Thr Lys Asp Val Glu Arg Thr Asp Gly Ala Leu Leu Val
 85 90 95

Asn Ala Met Phe Phe Lys Pro His Trp Asp Glu Lys Phe His His Lys
 100 105 110

Met Val Asp Asn Arg Gly Phe Met Val Thr Arg Ser Tyr Thr Val Gly
 115 120 125

Val Thr Met Met His Arg Thr Gly Leu Tyr Asn Tyr Tyr Asp Asp Glu
 130 135 140

Lys Glu Lys Leu Gln Met Val Glu Met Pro Leu Ala His Lys Leu Ser
 145 150 155 160

Ser Leu Leu Ile Leu Met Pro His His Val Glu Pro Leu Glu Arg Leu
 165 170 175

Glu Lys Leu Leu Thr Lys Glu Gln Leu Lys Ile Trp Met Gly Lys Met
 180 185 190

Gln Lys Lys Ala Val Ala Ile Ser Leu Pro Lys Gly Val Val Glu Val
 195 200 205

Thr His Asp Leu Gln Lys His Leu Ala Gly Leu Gly Leu Thr Glu Ala
 210 215 220

Ile Asp Lys Asn Lys Ala Asp Leu Ser Arg Met Ser Gly Lys Lys Asp
 225 230 235 240

Leu Tyr Leu Ala Ser Val Phe His Ala Thr Ala Phe Glu Trp Asp Thr
 245 250 255

Glu Gly Asn Pro Phe Asp Gln Asp Ile Tyr Gly Arg Glu Glu Leu Arg
 260 265 270

Ser Pro Lys Xaa Phe Tyr Ala Asp His Pro Phe Ile Phe Leu Val Arg
 275 280 285

Asp Thr Gln Thr Gly Ser Leu Leu Phe Ile Gly Arg Leu Val Arg Pro
 290 295 300

Lys Gly Asp Lys Met Arg Asp Glu Leu
 305 310

728

<210> 742

<211> 60

<212> PRT

<213> Homo sapiens

<400> 742

Arg Asn Ile Lys Trp Glu Lys Ala Tyr Lys Ala Phe Arg Ile Leu Ser
 1 5 10 15

Val Ser Ser Phe Leu Val Phe Arg Cys Tyr Val Ile Lys His Ile Phe
 20 25 30

Phe Gly Phe Pro Arg Tyr Thr Ile Tyr Leu Phe Lys Gly Lys Ser Ile
 35 40 45

Lys Cys Ile Tyr Phe Ile Leu Trp Phe Cys Tyr Leu
 50 55 60

<210> 743

<211> 204

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (4)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 743

Pro Arg Gly Xaa Ser Gln Val Cys Pro Cys Ser Trp Asn Pro Gly Val
 1 5 10 15

Pro Glu Ala Lys Ala Pro Pro Arg Gly Ser Arg Glu Asp Leu Val Ala
 20 25 30

Glu Glu Ser Pro Glu Leu Leu Asn Pro Glu Pro Arg Arg Leu Ser Pro
 35 40 45

Glu Leu Arg Leu Leu Pro Tyr Met Ile Thr Leu Gly Asp Ala Val His
 50 55 60

Asn Phe Ala Asp Gly Leu Ala Val Gly Ala Ala Phe Ala Ser Ser Trp
 65 70 75 80

Lys Thr Gly Leu Ala Thr Ser Leu Ala Val Phe Cys His Glu Leu Pro
 85 90 95

729

His Glu Leu Gly Asp Phe Ala Ala Leu Leu His Ala Gly Leu Ser Val
 100 105 110
 Arg Gln Ala Leu Leu Leu Asn Leu Ala Ser Ala Leu Thr Ala Phe Ala
 115 120 125
 Gly Leu Tyr Val Ala Leu Ala Val Gly Val Ser Glu Glu Ser Glu Ala
 130 135 140
 Trp Ile Leu Ala Val Ala Thr Gly Leu Phe Leu Tyr Val Ala Leu Cys
 145 150 155 160
 Asp Met Leu Pro Ala Met Leu Lys Val Arg Asp Pro Arg Pro Trp Leu
 165 170 175
 Leu Phe Leu Leu His Asn Val Gly Leu Leu Gly Gly Trp Thr Val Leu
 180 185 190
 Leu Leu Leu Ser Leu Tyr Glu Asp Asp Ile Thr Phe
 195 200

<210> 744

<211> 81

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (6)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 744

Ile Thr Lys Gly Lys Xaa Val Ala Cys Ser Thr Gly Pro Glu Phe Pro
 1 5 10 15
 Gly Arg Pro Thr Arg Pro Thr Thr Glu Gly Tyr Gly Cys Glu Lys Thr
 20 25 30
 Thr Glu Gly Tyr Gly Cys Glu Lys Thr Thr Glu Gly Tyr Gly Cys Glu
 35 40 45
 Lys Thr Thr Glu Gly Tyr Gly Cys Glu Lys Thr Thr Glu Gly Tyr Gly
 50 55 60
 Cys Glu Lys Thr Thr Glu Gly Thr Ala Ala Arg Arg Arg Gln Arg Val
 65 70 75 80

Arg

730

<210> 745

<211> 751

<212> PRT

<213> Homo sapiens

<400> 745

```

Leu Pro Pro Leu Gly Ser Pro Gly Pro Ala Arg Ser Ala Gly Ser Cys
  1           5           10           15

Ser Val Leu Phe Ser Leu Ile Leu Gln Arg Gln Asp Pro Ala Pro Ala
      20           25           30

Leu Ser Thr Ala Thr Met Gly Lys Gly Val Gly Arg Asp Lys Tyr Glu
      35           40           45

Pro Ala Ala Val Ser Glu Gln Gly Asp Lys Lys Gly Lys Lys Gly Lys
      50           55           60

Lys Asp Arg Asp Met Asp Glu Leu Lys Lys Glu Val Ser Met Asp Asp
      65           70           75           80

His Lys Leu Ser Leu Asp Glu Leu His Arg Lys Tyr Gly Thr Asp Leu
      85           90           95

Ser Arg Gly Leu Thr Ser Ala Arg Ala Ala Glu Ile Leu Ala Arg Asp
      100          105          110

Gly Pro Asn Ala Leu Thr Pro Pro Pro Thr Thr Pro Glu Trp Ile Lys
      115          120          125

Phe Cys Arg Gln Leu Phe Gly Gly Phe Ser Met Leu Leu Trp Ile Gly
      130          135          140

Ala Ile Leu Cys Phe Leu Ala Tyr Ser Ile Gln Ala Ala Thr Glu Glu
      145          150          155          160

Glu Pro Gln Asn Asp Asn Leu Tyr Leu Gly Val Val Leu Ser Ala Val
      165          170          175

Val Ile Ile Thr Gly Cys Phe Ser Tyr Tyr Gln Glu Ala Lys Ser Ser
      180          185          190

Lys Ile Met Glu Ser Phe Lys Asn Met Val Pro Gln Gln Ala Leu Val
      195          200          205

Ile Arg Asn Gly Glu Lys Met Ser Ile Asn Ala Glu Glu Val Val Val
      210          215          220

```

731

Gly Asp Leu Val Glu Val Lys Gly Gly Asp Arg Ile Pro Ala Asp Leu
 225 230 235 240

Arg Ile Ile Ser Ala Asn Gly Cys Lys Val Asp Asn Ser Ser Leu Thr
 245 250 255

Gly Glu Ser Glu Pro Gln Thr Arg Ser Pro Asp Phe Thr Asn Glu Asn
 260 265 270

Pro Leu Glu Thr Arg Asn Ile Ala Phe Phe Ser Thr Asn Cys Val Glu
 275 280 285

Gly Thr Ala Arg Gly Ile Val Val Tyr Thr Gly Asp Arg Thr Val Met
 290 295 300

Gly Arg Ile Ala Thr Leu Ala Ser Gly Leu Glu Gly Gly Gln Thr Pro
 305 310 315 320

Ile Ala Ala Glu Ile Glu His Phe Ile His Ile Ile Thr Gly Val Ala
 325 330 335

Val Phe Leu Gly Val Ser Phe Phe Ile Leu Ser Leu Ile Leu Glu Tyr
 340 345 350

Thr Trp Leu Glu Ala Val Ile Phe Leu Ile Gly Ile Ile Val Ala Asn
 355 360 365

Val Pro Glu Gly Leu Leu Ala Thr Val Thr Val Cys Leu Thr Leu Thr
 370 375 380

Ala Lys Arg Met Ala Arg Lys Asn Cys Leu Val Lys Asn Leu Glu Ala
 385 390 395 400

Val Glu Thr Leu Gly Ser Thr Ser Thr Ile Cys Ser Asp Lys Thr Gly
 405 410 415

Thr Leu Thr Gln Asn Arg Met Thr Val Ala His Met Trp Phe Asp Asn
 420 425 430

Gln Ile His Glu Ala Asp Thr Thr Glu Asn Gln Ser Gly Val Ser Phe
 435 440 445

Asp Lys Thr Ser Ala Thr Trp Leu Ala Leu Ser Arg Ile Ala Gly Leu
 450 455 460

Cys Asn Arg Ala Val Phe Gln Ala Asn Gln Glu Asn Leu Pro Ile Leu
 465 470 475 480

Lys Arg Ala Val Ala Gly Asp Ala Ser Glu Ser Ala Leu Leu Lys Cys
 485 490 495

732

```

Ile Glu Leu Cys Cys Gly Ser Val Lys Glu Met Arg Glu Arg Tyr Ala
      500                      505                      510

Lys Ile Val Glu Ile Pro Phe Asn Ser Thr Asn Lys Tyr Gln Leu Ser
      515                      520                      525

Ile His Lys Asn Pro Asn Thr Ser Glu Pro Gln His Leu Leu Val Met
      530                      535                      540

Lys Gly Ala Pro Glu Arg Ile Leu Asp Arg Cys Ser Ser Ile Leu Leu
545                      550                      555                      560

His Gly Lys Glu Gln Pro Leu Asp Glu Glu Leu Lys Asp Ala Phe Gln
      565                      570                      575

Asn Ala Tyr Leu Glu Leu Gly Gly Leu Gly Glu Arg Val Leu Gly Phe
      580                      585                      590

Cys His Leu Phe Leu Pro Asp Glu Gln Phe Pro Glu Gly Phe Gln Phe
      595                      600                      605

Asp Thr Asp Asp Val Asn Phe Pro Ile Asp Asn Leu Cys Phe Val Gly
      610                      615                      620

Leu Ile Ser Met Ile Asp Pro Pro Arg Ala Ala Val Pro Asp Ala Val
625                      630                      635                      640

Gly Lys Cys Arg Ser Ala Gly Ile Lys Val Ile Met Val Thr Gly Asp
      645                      650                      655

His Pro Ile Thr Ala Lys Ala Ile Ala Lys Gly Val Gly Ile Ile Ser
      660                      665                      670

Glu Gly Asn Glu Thr Val Glu Asp Ile Ala Ala Arg Leu Asn Ile Pro
      675                      680                      685

Val Ser Gln Val Asn Pro Arg Asp Ala Lys Ala Cys Val Val His Gly
      690                      695                      700

Ser Asp Leu Lys Asp Met Thr Ser Glu Gln Leu Asp Asp Ile Leu Lys
705                      710                      715                      720

Tyr His Thr Glu Ile Val Phe Ala Lys Thr Ser Pro Gln Gln Lys Leu
      725                      730                      735

Ile Ile Val Glu Arg Leu Pro Lys Thr Gly Cys Tyr Arg Gly Leu
      740                      745                      750

```

<210> 746

733

<211> 25
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (6)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (8)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 746
Ile Pro Ala Leu Trp Xaa Ala Xaa Val Gly Arg Ser Leu Glu Pro Arg
1 5 10 15

Ser Leu Arg Ser Ala Trp Ala Thr Trp
20 25

<210> 747
<211> 37
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (1)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (2)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 747
Xaa Xaa Leu Gly Gly Arg Val Cys Ser Glu Pro Arg Trp Arg His Cys
1 5 10 15

Thr Pro Ala Trp Gly Thr Glu Arg Asp Ser Ile Ser Lys Lys Lys Lys
20 25 30

Lys Lys Ile Lys Asn
35

<210> 748

734

<211> 71
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (2)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (42)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (46)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (49)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 748
 Asn Xaa Ala Leu Arg Asp Asp Val Ala Ala Gly Arg Arg Arg Leu His
 1 5 10 15
 Ile Lys Ala Val Cys Gln Ser Val Arg Glu Ala Thr Thr Ala Ser Gly
 20 25 30
 Gly Met Asn Ala Ala Ser Pro Arg Leu Xaa Arg His Arg Xaa Asn Gly
 35 40 45
 Xaa Tyr Phe Thr Leu Arg Glu Arg Leu Ile Thr Met Gln Lys Gln Leu
 50 55 60
 Gly Gly Asn Pro Glu Val Tyr
 65 70

<210> 749
 <211> 109
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (19)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (41)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (43)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (59)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (61)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (70)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (75)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (88)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (90)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (93)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (102)
<223> Xaa equals any of the naturally occurring L-amino acids

736

<220>

<221> SITE

<222> (104)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 749

Gly	Ile	Ser	Arg	Lys	Met	Lys	Ser	Ser	Leu	Pro	Gln	Gly	Val	Arg	Asn
1				5					10					15	

Val	Ala	Xaa	Val	Cys	Leu	Gln	Ile	Gly	Tyr	Pro	Thr	Val	Ala	Ser	Val
			20					25					30		

Pro	His	Ser	Ile	Ile	Asn	Gly	Tyr	Xaa	Arg	Xaa	Leu	Ala	Leu	Ser	Val
		35					40					45			

Glu	Thr	Asp	Tyr	Thr	Phe	Pro	Leu	Ala	Glu	Xaa	Val	Xaa	Ala	Ser	Trp
	50					55					60				

Leu	Ile	His	Leu	Pro	Xaa	Trp	Leu	Leu	Pro	Xaa	Trp	Leu	Leu	Pro	Pro
65					70					75					80

Gln	Leu	Leu	Leu	Leu	Leu	Leu	Xaa	Pro	Xaa	Leu	Ser	Xaa	Asn	Pro	Arg
					85				90					95	

Lys	Ser	Glu	Asp	Pro	Xaa	Lys	Xaa	Trp	Ile	Gly	Ser	Leu
			100					105				

<210> 750

<211> 105

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (3)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (16)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 750

Gly	Thr	Xaa	Gly	Pro	Ala	Ser	Gly	Val	Ala	Gly	Thr	Met	Gln	Arg	Xaa
1				5					10					15	

Ser	Leu	Pro	Phe	Ala	Ile	Leu	Thr	Leu	Val	Asn	Ala	Pro	Tyr	Lys	Arg
			20					25					30		

737

Gly Phe Tyr Cys Gly Asp Asp Ser Ile Arg Tyr Pro Tyr Arg Pro Asp
35 40 45

Thr Ile Thr His Gly Leu Met Ala Gly Val Thr Ile Thr Ala Thr Val
50 55 60

Ile Leu Val Ser Ala Gly Glu Ala Tyr Leu Val Tyr Thr Asp Arg Leu
65 70 75 80

Tyr Ser Arg Ser Asp Phe Asn Asn Tyr Val Ala Ala Val Tyr Lys Val
85 90 95

Leu Gly Thr Ser Cys Leu Gly Leu Pro
100 105

<210> 751

<211> 61

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (1)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (7)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (8)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (25)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (45)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (53)

<223> Xaa equals any of the naturally occurring L-amino acids

738

<220>

<221> SITE

<222> (59)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (60)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 751

Xaa	Ser	Arg	Lys	Pro	Arg	Xaa	Xaa	Val	Thr	Asp	Tyr	Ile	Lys	Val	Tyr
1				5					10					15	

Tyr	Thr	Leu	Arg	Lys	Gln	Met	Asn	Xaa	Asn	Leu	Phe	Ser	Ser	Phe	Ile
		20					25					30			

Thr	Pro	Thr	Ile	Ile	Gly	Leu	Pro	Ile	Val	Ile	Ile	Xaa	Thr	Met	Phe
		35				40						45			

Pro	Ser	Ile	Asp	Xaa	Pro	Ile	Thr	Tyr	Pro	Xaa	Xaa	Gln
	50				55						60	

<210> 752

<211> 58

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (33)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (48)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 752

Ser	Asp	Pro	Glu	Ala	Glu	Val	Glu	Glu	Ser	Ser	Ser	Gly	Leu	Arg	Leu
1				5					10					15	

Ser	Leu	Ile	Lys	Met	Thr	Thr	Ser	Gln	Lys	His	Arg	Asp	Phe	Val	Ala
		20					25					30			

Xaa	Pro	Met	Gly	Glu	Asn	Gln	Trp	Gly	Thr	Trp	Leu	Gly	Leu	Val	Xaa
		35				40						45			

739

Ser Trp Ala Arg Asn Trp Lys Lys Gly Phe
 50 55

<210> 753
 <211> 73
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (48)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (51)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (52)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (53)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (63)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (71)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 753
 Thr Leu His Ser Lys Gly Asn Lys Ser Trp Ser Ser Thr Ala Val Thr
 1 5 10 15

Ala Ala Leu Glu Leu Val Gly Gly Pro Val Pro Asn Ser Pro Tyr Ser
 20 25 30

Glu Ser Tyr Tyr Asn Ser Leu Ala Val Val Leu Gln Arg Arg Asp Xaa
 35 40 45

Glu Asn Xaa Xaa Xaa Phe Arg Leu Val Cys Cys Val Glu Leu Xaa Ala

740

50

55

60

Asp Asn Asn Ser His Arg Xaa Gln Leu
65 70

<210> 754

<211> 116

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (17)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (43)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (62)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (67)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (68)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (81)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (84)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (87)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (88)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (91)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (92)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (101)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (105)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (107)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (109)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (112)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (115)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 754
Met Gly Ser Asp Tyr Ile Arg Glu Val Asn Val Val Lys Ser Ala Arg
1 5 10 15
Xaa Gly Tyr Ser Lys Met Leu Leu Gly Val Tyr Ala Tyr Phe Ile Glu

742

	20		25		30										
His	Lys	Gln	Arg	Asn	Thr	Leu	Ile	Trp	Leu	Xaa	Thr	Asp	Gly	Asp	Ala
	35					40						45			
Arg	Glu	Leu	Tyr	Glu	Lys	Pro	Thr	Leu	Ser	Pro	Thr	Ile	Xaa	Asp	Ile
	50					55						60			
Pro	Ser	Xaa	Xaa	Gly	Ala	Gly	Pro	Val	Val	Trp	Gln	Lys	Ser	Thr	Gly
	65					70					75				80
Xaa	Asn	Lys	Xaa	Asn	His	Xaa	Xaa	Val	Ser	Xaa	Xaa	Trp	Gly	Gly	Pro
				85								90		95	
Arg	Asn	Pro	Ile	Xaa	Pro	Ile	Ser	Xaa	Trp	Xaa	Phe	Xaa	Asn	Ser	Xaa
		100						105						110	
Gly	Pro	Xaa	Phe												
		115													

<210> 755

<211> 148

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (4)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (120)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (135)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (137)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (138)

<223> Xaa equals any of the naturally occurring L-amino acids

743

<220>

<221> SITE

<222> (146)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 755

Ile Arg Gln Xaa Ile Asp Ile Arg Lys Asp Leu Tyr Ala Asn Asn Val
 1 5 10 15

Leu Ser Gly Gly Thr Thr Met Tyr Pro Gly Ile Ala Asp Arg Met Gln
 20 25 30

Lys Glu Ile Thr Ala Leu Ala Pro Ser Thr Met Lys Ile Lys Ile Ile
 35 40 45

Ala Pro Pro Glu Ala Gln Ile Leu Cys Leu Asp Arg Trp Leu His Pro
 50 55 60

Gly Leu Ser Val His Leu Pro Ala Asp Val Asp Gln Gln Thr Gly Asn
 65 70 75 80

Thr Val Lys Pro Gly Leu Pro Leu Ser Thr Ala Asn Ala Phe Leu Lys
 85 90 95

His Phe Ser Trp Phe Leu Phe Cys Leu Leu Gly Thr Gln Leu Trp Asn
 100 105 110

Val Pro Val Gly Ile Tyr Gly Xaa Phe Ser Phe Phe Phe Gln Ile Ile
 115 120 125

Pro Arg Ala Lys Val Leu Xaa Trp Xaa Xaa His Gly Val Phe Leu Asn
 130 135 140

Lys Xaa Trp Lys
 145

<210> 756

<211> 151

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (147)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 756

Ala Glu Leu Ala Thr Thr Ser Thr Met Pro Tyr Gln Tyr Pro Ala Leu

744

1	5	10	15												
Thr	Pro	Glu	Gln	Lys	Lys	Glu	Leu	Ser	Asp	Ile	Ala	His	Arg	Ile	Val
			20					25					30		
Ala	Pro	Gly	Lys	Gly	Ile	Leu	Ala	Ala	Asp	Glu	Ser	Thr	Gly	Ser	Ile
		35					40					45			
Ala	Lys	Arg	Leu	Gln	Ser	Ile	Gly	Thr	Glu	Asn	Thr	Glu	Glu	Asn	Arg
		50				55					60				
Arg	Phe	Tyr	Arg	Gln	Leu	Leu	Leu	Thr	Ala	Asp	Asp	Arg	Val	Asn	Pro
	65				70					75					80
Cys	Ile	Gly	Gly	Val	Ile	Leu	Phe	His	Glu	Thr	Leu	Tyr	Gln	Lys	Ala
				85					90					95	
Asp	Asp	Gly	Arg	Pro	Phe	Pro	Gln	Val	Ile	Lys	Ser	Lys	Gly	Gly	Val
			100					105					110		
Val	Gly	Ile	Lys	Val	Asp	Lys	Gly	Val	Val	Pro	Leu	Ala	Gly	Thr	Asn
		115					120						125		
Gly	Glu	Thr	Thr	Thr	Gln	Gly	Leu	Asp	Gly	Leu	Ser	Glu	Arg	Cys	Ala
	130					135					140				
Gln	Tyr	Xaa	Glu	Gly	Arg	Ser									
145					150										

<210> 757

<211> 94

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (21)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (44)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (48)

<223> Xaa equals any of the naturally occurring L-amino acids

745

<220>

<221> SITE

<222> (91)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 757

Phe Val Thr Ile Leu Ser Ile Ile Ile Thr Leu Phe Phe Ile Phe Gln
1 5 10 15

Leu Lys Val Ser Xaa Tyr Ser Phe Pro Glu Asn Pro Glu Pro Lys Ser
20 25 30

Leu Thr Thr Ser Lys Ser Thr Thr Pro Trp Arg Xaa Gln Met Asn Xaa
35 40 45

Asn Leu Phe Ser Ser Phe Ile Thr Pro Thr Ile Ile Gly Leu Pro Ile
50 55 60

Val Ile Ile Ile Thr Met Phe Pro Ser Ile Ile Phe Pro Ser Pro Thr
65 70 75 80

Arg Leu Ile Asn Asn Arg Leu Ile Ser Ile Xaa Thr Met Asp
85 90

<210> 758

<211> 115

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (2)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (5)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (11)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (30)

<223> Xaa equals any of the naturally occurring L-amino acids

746

<220>
 <221> SITE
 <222> (43)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (49)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (51)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (58)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (99)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (105)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (115)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 758
 Arg Xaa Ala Leu Xaa Arg Leu Thr Ile Gly Xaa Ser Trp Tyr Ala Cys
 1 5 10 15
 Arg Tyr Arg Ser Gly Ile Pro Gly Ser Thr His Ala Ser Xaa Arg Arg
 20 25 30
 Gly Gln Leu Arg Ala Arg Gly Gly Gly Ala Xaa Pro Arg Gly Ala Met
 35 40 45
 Xaa Asp Xaa Arg Ala Gly Ser Pro Arg Xaa Gly Pro Ala Ala Arg Asp
 50 55 60
 Val Ala Ala Met Ala Ser Pro Gln Leu Cys Arg Ala Leu Val Ser Ala
 65 70 75 80

747

Gln Trp Val Ala Glu Ala Leu Arg Ala Pro Arg Ala Gly Ala Ala Ser
 85 90 95

Ala Ala Xaa Arg Thr Pro Pro Gly Xaa Leu Ala Gly Ser Trp Gly Ala
 100 105 110

Arg Thr Xaa
 115

<210> 759
 <211> 44
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (3)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (17)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (42)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (43)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 759
 Ile Ala Xaa Gly Arg Ser Arg Gly Ser Lys Leu Thr Trp Thr Cys Met
 1 5 10 15

Xaa Arg His Ser Ser Ser Ile Val Ser Pro Lys Phe Asn Ser Leu Ala
 20 25 30

Val Val Leu Gln Arg Arg Asp Trp Glu Xaa Xaa Lys
 35 40

<210> 760
 <211> 94
 <212> PRT

748

<213> Homo sapiens

<220>

<221> SITE

<222> (80)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (91)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 760

Asn	Asp	Leu	Val	Glu	Tyr	Ser	Pro	Val	Thr	Glu	Lys	His	Leu	Thr	Asp
1															15

Gly	Met	Thr	Val	Arg	Glu	Leu	Cys	Ser	Ala	Ala	Ile	Thr	Met	Ser	Asp
			20					25						30	

Asn	Thr	Ala	Ala	Asn	Leu	Leu	Leu	Thr	Thr	Ile	Gly	Gly	Pro	Lys	Glu
		35					40					45			

Leu	Thr	Ala	Phe	Leu	His	Asn	Met	Gly	Asp	His	Val	Thr	Arg	Leu	Asp
	50					55					60				

Arg	Trp	Glu	Pro	Glu	Leu	Asn	Glu	Ala	Ile	Pro	Asn	Asp	Glu	Arg	Xaa
65					70					75					80

Thr	Thr	Met	Pro	Val	Ala	Met	Ala	Thr	Thr	Xaa	Ala	Asn	Tyr
					85					90			

<210> 761

<211> 38

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (9)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (21)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (24)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 761

Leu Gln Glu Ile Asn Arg Val Tyr Xaa Glu Met Tyr Lys Thr Asp Leu
1 5 10 15

Glu Lys Asp Ile Xaa Ser Asp Xaa Ser Gly Asp Phe Arg Lys Leu Met
20 25 30

Val Ala Leu Ala Lys Gly
35

<210> 762

<211> 192

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (3)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (4)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 762

Cys Lys Xaa Xaa Leu Pro Ser Leu Lys Gly Thr Lys Ala Gly Ala Pro
1 5 10 15

Pro Arg Cys Gly Arg Ser Arg Thr Ser Gly Ser Pro Gly Leu Gln Glu
20 25 30

Phe Gly Thr Ser Cys Val Gly Leu Arg Glu Ala Val Arg Ala Gly Ala
35 40 45

Val Gly Arg Gly Ala Glu Ala Leu Ala Arg Gly Met Ala His Cys Val
50 55 60

Thr Leu Val Gln Leu Ser Ile Ser Cys Asp His Leu Ile Asp Lys Asp
65 70 75 80

Ile Gly Ser Lys Ser Asp Pro Leu Cys Val Leu Leu Gln Asp Val Gly
85 90 95

Gly Gly Ser Trp Ala Glu Leu Gly Arg Thr Glu Arg Val Arg Asn Cys
100 105 110

750

Ser Ser Pro Glu Phe Ser Lys Thr Leu Gln Leu Glu Tyr Arg Phe Glu
 115 120 125
 Thr Val Gln Lys Leu Arg Phe Gly Ile Tyr Asp Ile Asp Asn Lys Thr
 130 135 140
 Pro Glu Leu Arg Asp Asp Asp Phe Leu Gly Gly Ala Glu Cys Ser Leu
 145 150 155 160
 Gly Gln Ile Val Ser Ser Gln Val Leu Thr Leu Pro Leu Met Leu Lys
 165 170 175
 Leu Glu Asn Leu Leu Gly Gly Gly Pro Ser Arg Ser Gln Leu Arg Asn
 180 185 190

<210> 763

<211> 103

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (96)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 763

Ser Phe Tyr Ser Ile Pro Glu Phe Asp Glu Trp Lys Lys His Ile Glu
 1 5 10 15
 Asn Gln Lys Ala Trp Lys Ile Lys Tyr Tyr Lys Gly Leu Gly Thr Ser
 20 25 30
 Thr Ala Lys Glu Ala Lys Glu Tyr Phe Ala Asp Met Glu Arg His Arg
 35 40 45
 Ile Leu Phe Arg Tyr Ala Gly Pro Glu Asp Asp Ala Ala Ile Thr Leu
 50 55 60
 Ala Phe Ser Lys Lys Lys Ile Asp Asp Arg Lys Glu Trp Leu Thr Asn
 65 70 75 80
 Phe Met Glu Asp Arg Arg Gln Arg Ser Tyr Met Ala Tyr Gln Arg Xaa
 85 90 95
 Asp Ser Leu Ser Thr Gln Thr
 100

751

<210> 764

<211> 105

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (101)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 764

Val	Phe	Ser	Pro	Thr	Gly	Ser	Asp	Gly	Pro	Leu	Ala	Thr	Ser	Lys	Pro
1				5				10					15		

Val	Pro	Ala	Glu	Lys	Ser	Gly	Leu	Pro	Val	Gly	Pro	Glu	Asn	Gly	Val
			20				25						30		

Glu	Leu	Ser	Lys	Glu	Glu	Leu	Ile	Arg	Arg	Lys	Arg	Glu	Glu	Phe	Ile
		35					40					45			

Gln	Lys	His	Gly	Arg	Gly	Met	Glu	Lys	Ser	Asn	Lys	Ser	Thr	Lys	Ser
	50					55				60					

Asp	Ala	Pro	Lys	Glu	Lys	Gly	Lys	Lys	Ala	Pro	Arg	Val	Trp	Glu	Leu
65				70					75					80	

Gly	Gly	Cys	Ala	Asn	Lys	Glu	Met	Leu	Asp	Tyr	Ser	Thr	Ser	Thr	Thr
				85				90						95	

Asn	Gly	Thr	Pro	Xaa	Ala	Cys	Leu	Val
		100					105	

<210> 765

<211> 147

<212> PRT

<213> Homo sapiens

<400> 765

Gly	Arg	Glu	Thr	Met	Phe	Arg	Ala	Ala	Ala	Pro	Gly	Gln	Leu	Arg	Arg
1				5					10				15		

Ala	Ala	Ser	Leu	Leu	Arg	Phe	Gln	Ser	Thr	Leu	Val	Ile	Ala	Glu	His
			20					25					30		

Ala	Asn	Asp	Ser	Leu	Ala	Pro	Ile	Thr	Leu	Asn	Thr	Ile	Thr	Ala	Ala
		35					40					45			

752

Thr Arg Leu Gly Gly Glu Val Ser Cys Leu Val Ala Gly Thr Lys Cys
 50 55 60
 Asp Lys Val Ala Gln Asp Leu Cys Lys Val Ala Gly Ile Ala Lys Val
 65 70 75 80
 Leu Val Ala Gln His Asp Val Tyr Lys Gly Leu Leu Pro Glu Glu Leu
 85 90 95
 Thr Pro Leu Ile Leu Ala Thr Gln Lys Gln Phe Asn Tyr Thr His Ile
 100 105 110
 Cys Ala Gly Ala Ser Ala Phe Gly Lys Asn Leu Leu Pro Arg Val Ala
 115 120 125
 Ala Lys Leu Glu Val Ala Pro Ile Ser Asp Ile Ile Ala Ile Lys Ser
 130 135 140
 Pro Asp Thr
 145

<210> 766

<211> 36

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (7)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (18)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 766

Gly Arg Glu Ala Glu Ala Xaa Gln Leu Glu Ser Ser Lys Arg Phe Ala
 1 5 10 15

Lys Xaa Phe Met Asp Arg His Gly Ile Pro Thr Ala Gln Trp Glu Gly
 20 25 30

Phe His Gln Thr
 35

753

<210> 767
 <211> 105
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (62)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (68)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (80)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (98)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (100)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (105)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 767
 Arg Phe Ala Leu Ser Thr Lys Ile Pro Asp Thr Lys Gly Cys Leu Gln
 1 5 10 15
 Cys Arg Val Val Arg Asn Pro Tyr Thr Gly Ala Thr Phe Leu Leu Ala
 20 25 30
 Ala Leu Pro Thr Ser Leu Leu Leu Leu Gln Trp Tyr Glu Pro Leu Gln
 35 40 45
 Lys Phe Leu Leu Leu Lys Asn Phe Ser Ser Pro Leu Pro Xaa Pro Ala
 50 55 60
 Gly Met Leu Xaa Pro Leu Val Leu Asp Gly Lys Glu Leu Pro Gln Xaa
 65 70 75 80

754

Phe Phe Gly Ala Glu Gly Pro Lys Gly Pro Gly Cys Arg Phe Leu Phe
 85 90 95

Gln Xaa Leu Xaa Leu Gly Gly Trp Xaa
 100 105

<210> 768

<211> 154

<212> PRT

<213> Homo sapiens

<400> 768

Val Thr Leu Thr Gln Cys Ser Glu Lys Leu Val Gln Leu Ile Leu His
 1 5 10 15

Glu Tyr Lys Ile Phe Asn Ala Glu Val Leu Phe Arg Glu Asp Cys Ser
 20 25 30

Pro Asp Glu Phe Ile Asp Val Ile Val Gly Asn Arg Val Tyr Met Pro
 35 40 45

Cys Leu Tyr Val Tyr Asn Lys Ile Asp Gln Ile Ser Met Glu Glu Val
 50 55 60

Asp Arg Leu Ala Arg Lys Pro Asn Ser Val Val Ile Ser Cys Gly Met
 65 70 75 80

Lys Leu Asn Leu Asp Tyr Leu Leu Glu Met Leu Trp Glu Tyr Leu Ala
 85 90 95

Leu Thr Cys Ile Tyr Thr Lys Lys Arg Gly Gln Arg Pro Asp Phe Thr
 100 105 110

Asp Ala Ile Ile Leu Arg Lys Gly Ala Ser Val Glu His Val Gly Thr
 115 120 125

Ser Thr Lys Tyr Ser Pro Gln Arg Val Gly Leu Thr His Thr Met Glu
 130 135 140

His Glu Asp Val Ile Gln Ile Val Lys Lys
 145 150

<210> 769

<211> 89

<212> PRT

<213> Homo sapiens

755

<220>

<221> SITE

<222> (56)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (84)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 769

Asn Gln Ala Gly Leu Thr Ala Asp Arg Met Leu Val Leu Ser Arg Ala
1 5 10 15

Gly Gln Ala Ala Gly Leu Thr Phe Asn Gln Thr Ser Glu Ser Leu Ser
20 25 30

Ala Leu Val Lys Ala Gly Val Ser Gly Glu Ala Gln Ile Ala Ser Ile
35 40 45

Ser Gln Ser Val Ala Arg Phe Xaa Ser Ala Ser Gly Val Glu Val Asp
50 55 60

Lys Val Val Glu Ala Phe Glu Gly Gly Pro Tyr Pro Phe Ala Tyr Ser
65 70 75 80

Lys Arg Ile Xaa Ile Ile Ala Val Phe
85

<210> 770

<211> 85

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (57)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (79)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (83)

<223> Xaa equals any of the naturally occurring L-amino acids

756

<220>

<221> SITE

<222> (84)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 770

Gln Thr Ser Arg Ala Glu Ser Ala Ser Met Thr Glu Arg Arg Val Pro
 1 5 10 15

Phe Ser Leu Leu Arg Gly Pro Ser Trp Asp Pro Phe Arg Asp Trp Tyr
 20 25 30

Pro His Ser Arg Leu Phe Asp Gln Ala Phe Gly Leu Pro Arg Leu Pro
 35 40 45

Glu Glu Trp Ser Gln Trp Leu Gly Xaa Ser Ser Trp Pro Gly Tyr Val
 50 55 60

Arg Pro Leu Pro Pro Ala Ala Ser Arg Ala Pro Gln Trp Pro Xaa Pro
 65 70 75 80

Leu Gln Xaa Xaa Ala
 85

<210> 771

<211> 76

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (48)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (50)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (70)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 771

Asp Tyr Cys Gln Val Val Arg Pro Ser Pro Ser Gly Glu Thr Ile Thr
 1 5 10 15

Tyr Arg Gln Val Val Leu Ser Val Asn Val Lys Ser Pro Ala Leu Leu

757

	20		25		30
Leu	Ser	Gln	Leu	Leu	Pro
	35		40		45
Leu	Xaa	Ser	Ser	Ile	Ala
	50		55		60
Tyr	Asn	Val	Ser	Lys	Xaa
	65		70		75

<210> 772

<211> 105

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (12)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 772

Gly	Ala	Glu	Glu	Gly	Arg	Gln	Glu	Ala	Gln	Gly	Xaa	Arg	Lys	Glu	Ser
1				5					10					15	

Tyr	Ser	Val	Tyr	Val	Tyr	Lys	Val	Leu	Lys	Gln	Val	His	Pro	Asp	Thr
		20					25						30		

Gly	Ile	Ser	Ser	Lys	Ala	Met	Gly	Ile	Met	Asn	Ser	Phe	Val	Asn	Asp
		35					40						45		

Ile	Phe	Glu	Arg	Ile	Ala	Gly	Glu	Ala	Ser	Arg	Leu	Ala	His	Tyr	Asn
	50					55					60				

Lys	Arg	Ser	Thr	Ile	Thr	Ser	Arg	Glu	Ile	Gln	Thr	Ala	Val	Arg	Leu
	65				70					75				80	

Leu	Leu	Pro	Gly	Glu	Leu	Ala	Lys	His	Ala	Val	Ser	Glu	Gly	Thr	Lys
			85						90					95	

Ala	Val	Thr	Lys	Tyr	Thr	Ser	Ala	Lys
		100					105	

<210> 773

<211> 144

<212> PRT

<213> Homo sapiens

758

<220>

<221> SITE

<222> (98)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (132)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (139)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (140)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (141)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 773

Phe	Ala	His	Leu	Pro	Lys	Ser	Thr	Phe	Val	Leu	Asp	Glu	Phe	Lys	Arg
1				5					10					15	

Lys	Tyr	Ser	Asn	Glu	Asp	Thr	Leu	Ser	Val	Ala	Leu	Pro	Tyr	Phe	Trp
			20					25					30		

Glu	His	Phe	Asp	Lys	Asp	Gly	Trp	Ser	Leu	Trp	Tyr	Ser	Glu	Tyr	Arg
	35						40					45			

Phe	Pro	Glu	Glu	Leu	Thr	Gln	Thr	Phe	Met	Ser	Cys	Asn	Leu	Ile	Thr
	50					55					60				

Gly	Met	Phe	Gln	Arg	Leu	Asp	Lys	Leu	Arg	Lys	Asn	Ala	Phe	Ala	Ser
65					70					75					80

Val	Ile	Leu	Phe	Gly	Thr	Asn	Asn	Ser	Ser	Ser	Ile	Ser	Gly	Val	Trp
				85					90					95	

Val	Xaa	Pro	Gly	Gln	Glu	Leu	Ala	Phe	Pro	Leu	Ser	Pro	Asp	Trp	Gln
			100					105					110		

Val	Asp	Tyr	Glu	Val	Ile	His	Met	Ala	Glu	Thr	Gly	Ser	Gly	Lys	Arg
		115					120					125			

759

Gly Asp Pro Xaa Ala Gly Ser Arg Val Leu Xaa Xaa Xaa Arg Gly Pro
 130 135 140

<210> 774

<211> 64

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (7)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (56)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 774

Ile Arg His Glu Arg Glu Xaa Glu Gln Gly Val Tyr Thr Cys Thr Ala
 1 5 10 15

Gln Gly Ile Trp Lys Asn Glu Gln Lys Gly Glu Lys Ile Pro Arg Cys
 20 25 30

Leu Pro Val Cys Gly Lys Pro Val Asn Pro Val Glu Gln Arg Gln Arg
 35 40 45

Ile Ile Gly Gly Gln Lys Ala Xaa Gly Ile Val Gly Ala Phe Leu Gln
 50 55 60

<210> 775

<211> 69

<212> PRT

<213> Homo sapiens

<400> 775

Asn Ile Ser Asn Ser Gln Val Asn Arg Leu Arg His Phe Val Arg Ala
 1 5 10 15

Gly Leu Arg Ser Leu Phe Arg Pro Glu Pro Gln Thr Ala Val Glu Trp

760

	20		25		30
Ala	Asp	Ala	Asn	Tyr	Tyr
	35		40		45
Leu	Pro	Lys	Glu	Ser	Ala
Tyr	Gln	Glu	Gly		
Arg	Trp	Glu	Thr	Leu	Pro
	50		55		60
Phe	Gln	Arg	Ala	Ile	Met
Asn	Ala	Asn	Gly		
Gln	Arg	Leu	His	Pro	
	65				

<210> 776

<211> 56

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (5)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (15)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (31)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (54)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (55)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 776

Glu	Arg	Val	Phe	Xaa	Pro	His	Gly	Leu	Ile	Met	Asp	Arg	Thr	Xaa	Arg
	1			5				10						15	

Phe	Ala	Arg	Asn	Val	Met	Lys	Glu	Met	Gly	Gly	His	His	Ile	Xaa	Val
			20				25						30		

Leu	Phe	Leu	Leu	Lys	Gly	Gly	Tyr	Lys	Phe	Phe	Ala	Asp	Leu	Leu	Asp
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

761

```

          35              40              45

Tyr Ile Lys Gly Leu Xaa Xaa Lys
   50              55

<210> 777
<211> 134
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (4)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (5)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (6)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 777
Leu Gln Phe Xaa Xaa Xaa Met Ile Thr Pro Ser Ser Asn Thr Thr His
  1              5              10              15

Tyr Arg Glu Ser Trp Tyr Ala Cys Arg Tyr Arg Ser Gly Ile Pro Gly
      20              25              30

Ser Thr His Ala Ser Gly Val Phe Glu Val His Lys Lys Asn Val Arg
      35              40              45

Gly Glu Phe Thr Tyr Tyr Glu Ile Gln Asp Asn Thr Gly Lys Met Glu
      50              55              60

Val Val Val His Gly Arg Leu Thr Thr Ile Asn Cys Glu Glu Gly Asp
      65              70              75              80

Lys Leu Lys Leu Thr Cys Phe Glu Leu Ala Pro Lys Ser Gly Asn Thr
      85              90              95

Gly Glu Leu Arg Ser Val Ile His Ser His Ile Lys Val Ile Lys Thr
      100             105             110

Arg Lys Asn Lys Lys Asp Ile Leu Asn Pro Asp Ser Ser Met Glu Thr
      115             120             125

```


762

Ser Pro Asp Phe Phe Phe
130

<210> 778

<211> 133

<212> PRT

<213> Homo sapiens

<400> 778

Thr Ile Thr Ser Gly Gly Asn Pro Pro Ala Phe Ser Leu Thr Pro Asp
1 5 10 15

Gly Lys Leu Thr Ala Lys Asn Ala Asp Ile Ser Gly Ser Val Asn Ala
20 25 30

Asn Ser Gly Thr Leu Ser Asn Val Thr Ile Ala Glu Asn Cys Thr Ile
35 40 45

Asn Gly Thr Leu Arg Ala Glu Lys Ile Val Gly Asp Ile Val Lys Ala
50 55 60

Ala Ser Ala Ala Phe Pro Arg Gln Val Glu Ser Ser Val Asp Trp Pro
65 70 75 80

Ser Gly Thr Arg Thr Val Thr Val Thr Asp Asp His Pro Phe Asp Arg
85 90 95

Gln Ile Val Val Leu Pro Leu Thr Phe Arg Gly Ser Lys Arg Thr Val
100 105 110

Ser Gly Arg Thr Thr Tyr Ser Met Cys Tyr Leu Lys Val Leu Met Asn
115 120 125

Gly Ala Val Ile Tyr
130

<210> 779

<211> 90

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (52)

<223> Xaa equals any of the naturally occurring L-amino acids

763

<220>

<221> SITE

<222> (63)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 779

Pro Asn Thr Ala Leu Val Gly Val Gln Val Asp Ser Glu Gln Phe Gly
1 5 10 15

Ser Gln Gln Val Ser Arg Asn Tyr His Leu Arg Gly Arg Ile Leu Gln
20 25 30

Val Pro Ser Asn Tyr Asn Pro Gln Thr Arg Gln Tyr Ser Gly Ile Trp
35 40 45

Asp Gly Thr Xaa Lys Pro Ala Tyr Ser Asn Asn Met Ala Trp Xaa Leu
50 55 60

Trp Asp Met Leu Thr His Pro Arg Tyr Gly Met Gly Lys Arg Leu Gly
65 70 75 80

Ala Ala Asp Val Asp Lys Trp Ala Leu Tyr
85 90

<210> 780

<211> 82

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (2)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (14)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (25)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (48)

<223> Xaa equals any of the naturally occurring L-amino acids

764

<220>
 <221> SITE
 <222> (54)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (62)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (65)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (70)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (73)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <400> 780
 Val Xaa Arg Ala Ser Asp Asp Ala Glu Gly Tyr Leu Asp Xaa Phe Lys
 1 5 10 15

 Gly Lys Ile Thr Glu Ser His Leu Xaa Lys Glu Leu Leu Glu Lys Val
 20 25 30

 Glu Leu Thr Glu Asp Asn Ala Ser Arg Leu Glu Glu Phe Ser Lys Xaa
 35 40 45

 Trp Lys Asp Ala Ser Xaa Lys Trp Asn Ala Met Trp Ala Xaa Lys Ile
 50 55 60

 Xaa Gln Thr Lys Asp Xaa Lys Arg Xaa Leu Phe Cys Tyr Leu Val Val
 65 70 75 80

 Arg Ser

<210> 781
 <211> 49
 <212> PRT
 <213> Homo sapiens

765

<220>

<221> SITE

<222> (43)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (48)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (49)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 781

Pro	Asp	Phe	His	Arg	Glu	Asp	Asp	Trp	Trp	Arg	Asn	Gly	Gln	Asn	Leu
1					5			10						15	

Tyr	Leu	Asp	Asn	Leu	Glu	Ala	Thr	Gly	Leu	Tyr	Gln	Val	Pro	Leu	Ser
			20					25					30		

Ala	Ala	Gln	Pro	Gly	Asp	Val	Leu	Leu	Cys	Xaa	Phe	Gly	Ser	Ser	Xaa
		35					40					45			

Xaa

<210> 782

<211> 85

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (1)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (31)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 782

Xaa	Lys	Glu	Asn	Gly	Thr	Val	Thr	Ala	Ala	Asn	Ala	Ser	Thr	Leu	Asn
1				5				10						15	

Asp	Gly	Ala	Ala	Ala	Leu	Val	Leu	Met	Thr	Ala	Asp	Ala	Ala	Xaa	Arg
			20					25					30		

766

Leu Asn Val Thr Pro Leu Ala Arg Ile Val Ala Phe Ala Asp Ala Ala
35 40 45

Val Glu Pro Ile Asp Phe Pro Ile Ala Pro Val Tyr Ala Ala Ser Met
50 55 60

Val Leu Lys Asp Val Gly Leu Lys Lys Glu Asp Ile Ala Met Trp Glu
65 70 75 80

Val Asn Gly Ser Leu
85

<210> 783

<211> 90

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (14)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (15)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (16)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (27)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (30)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (39)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

767

<221> SITE

<222> (44)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (63)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (81)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (87)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 783

Gly	Lys	Ser	Pro	Ala	Ser	Trp	Trp	Gly	Ser	Ala	Gly	His	Xaa	Xaa	Xaa
1				5				10					15		

Pro	Cys	Arg	Gly	Ala	Cys	Ala	Ala	Ala	Gly	Xaa	Thr	Ala	Xaa	Arg	Gly
			20					25					30		

Phe	Ala	Val	Ser	Ala	Arg	Xaa	Val	Trp	Gln	Thr	Xaa	Asp	Arg	Pro	Gly
		35					40					45			

Thr	Trp	Asp	Gln	Ser	Arg	Asn	Leu	Leu	Leu	Asn	Gly	Lys	Ser	Xaa	Pro
		50				55					60				

Thr	Lys	Val	Arg	Leu	Ile	Trp	Gly	Gly	Ser	Leu	Pro	Pro	Val	Lys	Arg
	65				70					75				80	

Xaa	Ala	Asp	Glu	Leu	Asp	Xaa	Arg	Pro	Gly
				85					90

<210> 784

<211> 84

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (8)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

768

<221> SITE
 <222> (64)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (70)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (79)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (81)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <400> 784
 Ala Leu Leu Gly Leu Thr Ile Xaa Lys Ala Gly Thr Pro Ala Gly Thr
 1 5 10 15

 Gly Pro Glu Phe Pro Gly Arg Pro Thr Arg Pro Leu Leu Cys Leu Glu
 20 25 30

 Gly Ile Ile Leu Ser Leu Phe Val Ile Ile Thr Ile Thr Ile Leu Ile
 35 40 45

 Asn His Leu Thr Leu Ala Ser Ile Thr Pro Ile Ile Leu Leu Val Xaa
 50 55 60

 Ala Ala Cys Glu Ala Xaa Leu Gly Leu Ile Pro Phe Ser Tyr Xaa Leu
 65 70 75 80

 Xaa Tyr Ile Arg

<210> 785
 <211> 61
 <212> PRT
 <213> Homo sapiens

<400> 785
 Ile Gly Phe Asp Asn Lys Lys Asp Leu Leu Ile Ser Val Gly Asp Leu
 1 5 10 15

 Val Asp Arg Gly Ala Glu Asn Val Glu Cys Leu Glu Leu Ile Thr Phe
 20 25 30

Pro Trp Phe Arg Ala Val Arg Gly Asn His Glu Gln Met Met Ile Asp
35 40 45

Gly Leu Ser Glu Arg Gly Asn Val Asn His Trp Leu Leu
50 55 60

```
<210> 786
<211> 102
<212> PRT
<213> Homo sapiens
```

```
<220>
<221> SITE
<222> (8)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (33)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (64)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>  
<221> SITE  
<222> (83)  
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (84)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (86)
<223> Xaa equals any of the naturally occurring L-amino acids
```

<400> 786
Gly Leu Gln Pro Tyr Cys Tyr Xaa Thr Trp Arg Cys Arg Cys Thr Thr
1 5 10 15
Gly Gln Pro Gly Thr Ala Pro Ala Gly Thr Pro Gly Ala Pro Pro Leu
20 25 30

770

Xaa Gly Met Ala Ile Val Lys Glu Glu Glu Thr Glu Ala Ala Ile Gly
 35 40 45
 Ala Pro Pro Thr Ala Thr Glu Gly Pro Glu Thr Lys Pro Val Leu Xaa
 50 55 60
 Ala Leu Glu Glu Gly Pro Gly Ala Glu Gly Ser Arg Leu Asp Ser Leu
 65 70 75 80
 Val Ala Xaa Xaa Leu Xaa Leu Glu Val Val Ala Leu Arg Asp Ser Ala
 85 90 95
 Pro Val Leu Ala Gly Thr
 100

<210> 787

<211> 64

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (3)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (7)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (44)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (48)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 787

Cys Leu Xaa Arg Ala Arg Xaa Pro Ala Ala Ala Asn Ser Ser Gly Asp
 1 5 10 15

Gly Gly Ala Ala Gly Asp Gly Thr Val Val Asp Cys Pro Val Cys Lys
 20 25 30

Gln Gln Cys Phe Ser Lys Asp Ile Val Glu Asn Xaa Phe Met Arg Xaa
 35 40 45

771

Ser Gly Ser Lys Ala Ala Thr Asp Ala Gln Asp Ala Asn Gln Cys Cys
 50 55 60

<210> 788

<211> 61

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (52)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 788

Thr Leu Ala Phe Phe Leu Ile Pro Cys Ile Gly Ser Pro Ala Cys Pro
 1 5 10 15

Thr Met Ser Asp Ala Ala Val Asp Thr Ser Ser Glu Ile Thr Thr Lys
 20 25 30

Asp Leu Lys Glu Lys Lys Glu Val Leu Glu Arg Gly Arg Lys Trp Lys
 35 40 45

Arg Arg Pro Xaa Leu Thr Gly Asn Ala Asn Leu Gly Lys
 50 55 60

<210> 789

<211> 69

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (12)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 789

Ala Gln Asp Asn Phe Lys His Leu Asn Gly Ile Xaa Leu Phe His Cys
 1 5 10 15

Ile Asp Pro Asn Gly Ser Lys His Lys Arg Thr Asp Arg Ser Ile Leu
 20 25 30

772

Cys Cys Leu Arg Lys Gly Glu Ser Gly Gln Ser Trp Gln Gly Leu Thr
 35 40 45

Lys Glu Arg Ala Lys Leu Asn Trp Leu Ser Val Asp Phe Asn Asn Trp
 50 55 60

Glu Arg Leu Gly Arg
 65

<210> 790

<211> 51

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (22)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (24)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (35)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (41)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 790

Gln Ser Thr Val Lys Leu Glu His Ala Lys Ser Val Ala Ser Arg Ala
 1 5 10 15

Thr Val Leu Gln Lys Xaa Ser Xaa Thr Pro Val Gly Met Phe Leu Lys
 20 25 30

Leu Asn Xaa Met Asn Val Lys Phe Xaa Ser Gly Tyr Tyr Glu Leu Pro
 35 40 45

Cys Arg Ser
 50

773

<210> 791
 <211> 154
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (78)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 791
 Asp Pro Gln Ala His Val Ala Met Leu Ser Ser Thr Ala Met Tyr Ser
 1 5 10 15
 Ala Pro Gly Arg Asp Leu Gly Met Glu Pro His Arg Ala Ala Gly Pro
 20 25 30
 Leu Gln Leu Arg Phe Ser Pro Tyr Val Phe Asn Gly Gly Thr Ile Leu
 35 40 45
 Ala Ile Ala Gly Glu Asp Phe Ala Ile Val Ala Ser Asp Thr Arg Leu
 50 55 60
 Ser Glu Gly Phe Ser Ile His Thr Arg Asp Ser Pro Lys Xaa Tyr Lys
 65 70 75 80
 Leu Thr Asp Lys Thr Val Ile Gly Cys Ser Gly Phe His Gly Asp Cys
 85 90 95
 Leu Thr Leu Thr Lys Ile Ile Glu Ala Arg Leu Lys Met Tyr Lys His
 100 105 110
 Ser Asn Asn Lys Ala Met Thr Thr Gly Ala Ile Ala Ala Met Leu Ser
 115 120 125
 Thr Ile Leu Tyr Ser Arg Arg Phe Phe Pro Tyr Tyr Val Tyr Asn Ile
 130 135 140
 Ile Gly Gly Leu Asp Glu Glu Gly Lys Gly
 145 150

<210> 792
 <211> 96
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (72)

774

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (73)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (74)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 792

Gly	Thr	Ala	Ser	Thr	Ala	Met	Tyr	Ser	Ala	Pro	Gly	Arg	Asp	Leu	Gly
1				5					10					15	

Met	Glu	Pro	His	Arg	Ala	Ala	Gly	Pro	Leu	Gln	Leu	Arg	Phe	Ser	Pro
			20					25					30		

Tyr	Val	Phe	Asn	Gly	Gly	Thr	Ile	Leu	Ala	Ile	Ala	Gly	Glu	Asp	Phe
	35						40					45			

Ala	Ile	Val	Ala	Ser	Asp	Thr	Arg	Leu	Ser	Glu	Gly	Phe	Ser	Ile	His
	50					55					60				

Thr	Arg	Asp	Ser	Pro	Lys	Cys	Xaa	Xaa	Xaa	Asn	Arg	Gln	Asn	Ser	His
65					70					75					80

Trp	Met	Gln	Arg	Phe	Ser	Trp	Arg	Leu	Ser	Tyr	Ala	Asp	Lys	Asp	Tyr
				85					90					95	

<210> 793

<211> 72

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (6)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 793

Arg	Pro	Pro	Val	Arg	Xaa	Phe	Leu	Arg	Asp	Phe	Phe	Met	Ser	Met	Tyr
1					5				10					15	

Thr	Thr	Ala	Gln	Leu	Leu	Ala	Ala	Asn	Glu	Gln	Lys	Phe	Lys	Phe	Asp
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

775

20 25 30
 Pro Leu Phe Leu Arg Leu Phe Phe Arg Glu Ser Tyr Pro Phe Thr Thr
 35 40 45
 Glu Glu Ser Leu Ser Leu Thr Asn Ser Gly Thr Gly Lys His Gly Ala
 50 55 60
 Val Arg Phe Ala Asp Cys Phe Arg
 65 70

<210> 794
 <211> 124
 <212> PRT
 <213> Homo sapiens

<400> 794
 Gly Ser Gly Asp His Glu Gly Gly Lys Gly Asp Gly Met Glu Glu Val
 1 5 10 15
 Pro His Asp Cys Pro Gly Ala Asp Ser Ala Gln Ala Gly Arg Gly Ala
 20 25 30
 Ser Cys Gln Gly Cys Pro Asn Gln Arg Leu Cys Ala Ser Gly Ala Gly
 35 40 45
 Ala Thr Pro Asp Thr Ala Ile Glu Glu Ile Lys Glu Lys Met Lys Thr
 50 55 60
 Val Lys His Lys Ile Leu Val Leu Ser Gly Lys Gly Gly Val Gly Lys
 65 70 75 80
 Ser Thr Phe Ser Ala His Leu Ala His Gly Leu Ala Glu Asp Glu Asn
 85 90 95
 Thr Gln Ile Ala Leu Leu Asp Ile Asp Ile Cys Gly Pro Ser Ile Pro
 100 105 110
 Lys Ile Met Gly Leu Glu Gly Glu Gln Val His Gln
 115 120

<210> 795
 <211> 144
 <212> PRT
 <213> Homo sapiens

<220>

<221> SITE
<222> (3)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (6)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (11)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (16)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (19)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (23)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (33)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (39)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (49)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (54)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE

<222> (64)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (71)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (76)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (78)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (81)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (83)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (87)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (88)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (89)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (93)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE,
<222> (100)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (107)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (110)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (112)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (117)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (123)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (127)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (136)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 795

Ala	Arg	Xaa	Trp	Leu	Xaa	Gly	Val	Thr	Phe	Xaa	Val	Thr	Thr	Val	Xaa
1				5					10					15	

Thr	Lys	Xaa	Arg	Thr	Glu	Xaa	Val	Gln	Lys	Leu	Cys	Pro	Gly	Gly	Gln
			20					25						30	

Xaa	Pro	Phe	Leu	Leu	Tyr	Xaa	Thr	Glu	Val	His	Thr	Asp	Thr	Asn	Lys
			35					40					45		

Xaa	Ala	Glu	Phe	Leu	Xaa	Ala	Val	Leu	Cys	Pro	Pro	Arg	Tyr	Pro	Xaa
				50				55					60		

Leu Ala Ala Leu Asn Pro Xaa Ser Asn Thr Ala Xaa Leu Xaa Ile Phe

65					70					75					80
Xaa	Lys	Xaa	Ser	Ala	Tyr	Xaa	Xaa	Xaa	Ser	Asn	Pro	Xaa	Leu	Asn	Asp
				85					90					95	
Asn	Leu	Glu	Xaa	Gly	Leu	Leu	Lys	Ala	Leu	Xaa	Val	Leu	Xaa	Asn	Xaa
			100					105					110		
Leu	Thr	Ser	Pro	Xaa	Ser	Glu	Glu	Val	Asp	Xaa	Thr	Ser	Ala	Xaa	Val
		115					120					125			
Lys	Val	Ser	Leu	Arg	Arg	Ser	Xaa	Trp	Ile	Ala	Arg	Ala	His	Pro	Gly
	130					135					140				

```
<220>
<221> SITE
<222> (31)
<223> Xaa equals any of the naturally occurring L-amino acids
```

Cys

780

<210> 797

<211> 181

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (2)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (3)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 797

Arg	Xaa	Xaa	Pro	Ser	Leu	Lys	Gly	Thr	Lys	Ala	Gly	Ala	Pro	Pro	Arg
1				5					10					15	

Cys	Gly	Arg	Ser	Arg	Thr	Ser	Gly	Ser	Pro	Gly	Leu	Gln	Glu	Phe	Gly
			20					25					30		

Thr	Arg	Pro	Ser	Arg	Leu	Arg	Lys	Thr	Arg	Lys	Leu	Arg	Gly	His	Val
		35					40						45		

Ser	His	Gly	His	Gly	Arg	Ile	Gly	Lys	His	Arg	Lys	His	Pro	Gly	Gly
	50					55					60				

Arg	Gly	Asn	Ala	Gly	Gly	Leu	His	His	His	Arg	Ile	Asn	Phe	Asp	Lys
	65					70				75					80

Tyr	His	Pro	Gly	Tyr	Phe	Gly	Lys	Val	Gly	Met	Lys	His	Tyr	His	Leu
			85						90					95	

Lys	Arg	Asn	Gln	Ser	Phe	Cys	Pro	Thr	Val	Asn	Leu	Asp	Lys	Leu	Trp
			100					105					110		

Thr	Leu	Val	Ser	Glu	Gln	Thr	Arg	Val	Asn	Ala	Ala	Lys	Asn	Lys	Thr
		115					120					125			

Gly	Ala	Ala	Pro	Ile	Ile	Asp	Val	Val	Arg	Ser	Gly	Tyr	Tyr	Lys	Val
	130					135					140				

Leu	Gly	Lys	Gly	Lys	Leu	Pro	Lys	Gln	Pro	Val	Ile	Val	Lys	Ala	Lys
145					150					155					160

Phe	Phe	Ser	Arg	Arg	Ala	Glu	Glu	Lys	Ile	Lys	Ser	Val	Gly	Gly	Ala
					165				170						175

781

Cys Val Leu Val Ala
180

<210> 798

<211> 136

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (29)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 798

Trp Ile Pro Arg Ala Ala Gly Ile Arg His Glu Arg Lys Glu Gly Trp
1 5 10 15

Arg Glu Glu Lys Gly Pro Phe Cys His Gln Arg Arg Xaa Thr Arg Glu
20 25 30

Tyr Thr Ile Asn Ile His Lys Arg Ile His Gly Val Gly Phe Lys Lys
35 40 45

Arg Ala Pro Arg Ala Leu Lys Glu Ile Arg Lys Phe Ala Met Lys Glu
50 55 60

Met Gly Thr Pro Asp Val Arg Ile Asp Thr Arg Leu Asn Lys Ala Val
65 70 75 80

Trp Ala Lys Gly Ile Arg Asn Val Pro Tyr Arg Ile Arg Val Arg Leu
85 90 95

Ser Arg Lys Arg Asn Glu Asp Glu Asp Ser Pro Asn Lys Leu Tyr Thr
100 105 110

Leu Val Thr Tyr Val Pro Val Thr Thr Phe Lys Ile Ser Val Leu Asn
115 120 125

Ser Val Thr Val Ala Lys Ser Pro
130 135

<210> 799

<211> 142

<212> PRT

<213> Homo sapiens

<400> 799

782

Trp Ile Pro Arg Ala Ala Gly Ile Arg His Glu Ala Ala Leu Ala Ala
 1 5 10 15
 Cys Ala Ala Met Ala Lys Ile Lys Ala Arg Asp Leu Arg Gly Lys Lys
 20 25 30
 Lys Glu Glu Leu Leu Lys Gln Leu Asp Asp Leu Lys Val Glu Leu Ser
 35 40 45
 Gln Leu Arg Val Ala Lys Val Thr Gly Gly Ala Ala Ser Lys Leu Ser
 50 55 60
 Lys Ile Arg Val Val Arg Lys Ser Ile Ala Arg Val Leu Thr Val Ile
 65 70 75 80
 Asn Gln Thr Gln Lys Glu Asn Leu Arg Lys Phe Tyr Lys Gly Lys Lys
 85 90 95
 Tyr Lys Pro Leu Asp Leu Arg Pro Lys Lys Thr Arg Ala Met Arg Arg
 100 105 110
 Arg Leu Asn Lys His Glu Glu Asn Leu Lys Thr Lys Lys Gln Gln Arg
 115 120 125
 Lys Glu Arg Leu Tyr Pro Leu Arg Lys Tyr Ala Val Lys Ala
 130 135 140

<210> 800

<211> 74

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (1)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (2)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (14)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (15)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (20)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (58)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (59)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (60)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (62)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (64)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (68)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <400> 800
 Xaa Xaa Tyr His Lys Tyr Lys Ala Lys Arg Asn Cys Trp Xaa Xaa Val
 1 5 10 15

 Arg Gly Val Xaa Met Asn Pro Val Glu His Pro Phe Gly Gly Gly Asn
 20 25 30

 His Gln His Ile Gly Lys Pro Ser Thr Ile Arg Arg Asp Ala Pro Ala
 35 40 45

 Gly Arg Lys Val Gly Leu Ile Ala Ala Xaa Xaa Xaa Gly Xaa Leu Xaa
 50 55 60

784

Gly Thr Lys Xaa Val Gln Glu Lys Glu Asn
65 70

<210> 801
<211> 100
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (12)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (49)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 801
Met Thr Pro Val Gln Arg Gly Gly Pro Gly Ala Xaa Val Ala Leu Gly
1 5 10 15
Trp Gly Thr Ala Val Ala Ser Ala Arg Phe Arg Gln Trp His Pro Gly
20 25 30
Pro Gly Ser Arg Pro Trp Thr Gly Pro Gly Pro Arg Pro Arg Thr Arg
35 40 45
Xaa Gly Lys Ala Glu Asp Lys Glu Trp Met Pro Val Thr Lys Leu Gly
50 55 60
Arg Leu Val Lys Asp Met Lys Ile Lys Ser Leu Glu Glu Ile Tyr Leu
65 70 75 80
Phe Ser Leu Pro Ile Lys Glu Ser Glu Ile Ile Asp Ser Ser Trp Gly
85 90 95
Leu Ser Gln Gly
100

<210> 802
<211> 19
<212> PRT
<213> Homo sapiens

<220>
<221> SITE

785

<222> (1)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 802

Xaa	Glu	Thr	Gln	Ala	Ile	Val	Cys	Gln	Gln	Leu	Asp	Leu	Thr	His	Leu
1				5					10					15	

Lys Gly Ala

<210> 803

<211> 54

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (51)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 803

Gly	Thr	Arg	Asp	Val	Arg	Arg	Val	Pro	Gly	Val	Ala	Pro	Thr	Leu	Val
1				5					10					15	

Arg	Ser	Ala	Ser	Glu	Thr	Ser	Glu	Lys	Arg	Pro	Phe	Met	Cys	Ala	Tyr
			20					25					30		

Pro	Gly	Cys	Asn	Lys	Arg	Tyr	Phe	Lys	Leu	Ser	His	Leu	Gln	Met	His
			35				40					45			

Ser	Arg	Xaa	Ala	His	Trp
					50

<210> 804

<211> 140

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (98)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (104)

<223> Xaa equals any of the naturally occurring L-amino acids

786

<220>

<221> SITE

<222> (120)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (135)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (136)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 804

Phe	Lys	Ser	Tyr	Leu	Gly	Asp	Thr	Ile	Glu	Gly	Ser	Leu	Gln	Val	Thr
1				5					10					15	

Gly	Pro	Glu	Ile	Pro	Gly	Ser	Thr	His	Ala	Ser	Ala	Glu	Ser	Leu	Ser
			20					25						30	

Arg	Arg	Lys	Leu	Asp	Thr	Gly	Thr	Gly	Ser	Ala	Met	Arg	Leu	Leu	Pro
		35				40						45			

Arg	Leu	Leu	Leu	Leu	Leu	Leu	Val	Phe	Pro	Ala	Thr	Val	Leu	Phe	
	50				55					60					

Arg	Gly	Gly	Pro	Arg	Gly	Leu	Leu	Ala	Val	Ala	Gln	Asp	Leu	Thr	Glu
	65				70					75					80

Asp	Glu	Glu	Thr	Val	Glu	Asp	Ser	Ile	Ile	Glu	Asp	Glu	Asp	Asp	Glu
				85					90					95	

Ala	Xaa	Val	Glu	Glu	Asp	Glu	Xaa	Thr	Asp	Phe	Val	Glu	Asp	Lys	Glu
		100						105						110	

Glu	Glu	Asp	Val	Ser	Gly	Glu	Xaa	Glu	Thr	Leu	Pro	Ser	Ala	Asp	Thr
		115					120						125		

Thr	Ile	Leu	Phe	Leu	Lys	Xaa	Xaa	Ile	Phe	Arg	Gln				
	130					135					140				

<210> 805

<211> 130

<212> PRT

<213> Homo sapiens

787

<220>
 <221> SITE
 <222> (105)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (119)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (120)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (124)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (125)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 805
 Phe Glu Ala Asn Arg Gln Arg Ala Thr Met Ala Val Ala Arg Ala Ala
 1 5 10 15
 Leu Gly Pro Leu Val Thr Gly Leu Tyr Asp Val Gln Ala Phe Lys Phe
 20 25 30
 Gly Asp Phe Val Leu Lys Ser Gly Leu Ser Ser Pro Ile Tyr Ile Asp
 35 40 45
 Leu Arg Gly Ile Val Ser Arg Pro Arg Leu Leu Ser Gln Val Ala Asp
 50 55 60
 Ile Leu Phe Gln Thr Ala Gln Asn Ala Gly Ile Ser Phe Asp Thr Val
 65 70 75 80
 Cys Gly Val Pro Tyr Thr Ala Leu Pro Leu Ala Thr Val Ile Cys Ser
 85 90 95
 Thr Asn Gln Ile Pro Met Leu Ile Xaa Arg Lys Glu Thr Lys Asp Tyr
 100 105 110
 Gly Thr Lys Arg Leu Val Xaa Xaa Ile Leu Ile Xaa Xaa Lys Leu Phe
 115 120 125
 Asn His

788

130

<210> 806

<211> 35

<212> PRT

<213> Homo sapiens

<400> 806

Val Ala Asp Ile Ala Trp Trp Phe Arg Arg Arg Ile Phe Ile Ala Val
1 5 10 15

Leu Arg Cys Asn Ser Ser Ile Ser Asp Ala Glu Ser Met Met Ser Ala
20 25 30

Ile Phe His
35

<210> 807

<211> 72

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (7)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (18)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (21)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (38)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (42)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (54)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (61)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (65)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (67)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (68)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 807
 Asp Trp Arg Gln Thr Ser Xaa Ser Gly Ala His Gly Arg Leu Lys Pro
 1 5 10 15
 Trp Xaa Asn Pro Xaa Ala Arg Arg Asp Ala Arg Glu Asp Arg Ala Thr
 20 25 30
 Trp Lys Ser Asn Tyr Xaa Leu Lys Ile Xaa Gln Arg Ile Gly Met Ile
 35 40 45
 Ile Leu Lys Trp Val Xaa Leu Val Gly Ser Glu Tyr Xaa Met Val Gly
 50 55 60
 Xaa Pro Xaa Xaa Ser Met Ala Ser
 65 70

<210> 808
 <211> 53
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (30)

790

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (52)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 808

Pro	Ser	Leu	Lys	Gly	Thr	Lys	Ala	Gly	Asn	Asp	Leu	Val	Ser	Leu	Arg
1				5					10					15	

Ala	Ala	Arg	Thr	Leu	Arg	Pro	Pro	Gly	Thr	Lys	Pro	Gly	Xaa	Gly	Ala
			20					25					30		

Thr	Phe	Gly	Pro	Gly	Leu	Ser	Glu	Arg	Ala	Ser	Ala	Gln	Arg	Gly	Ser
		35					40					45			

Gly	Gln	Leu	Xaa	His
		50		

<210> 809

<211> 70

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (2)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (16)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (23)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (35)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (39)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (46)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (49)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (53)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 809
 Ala Xaa Glu Tyr Thr Leu Arg Thr Ser Gly Leu Thr Val Arg Pro Xaa
 1 5 10 15
 Thr Ser Gly Pro Gly Cys Xaa Cys Gln Gly Gly Leu Ser Asp Leu Arg
 20 25 30
 Met Gly Xaa Met Glu Trp Xaa Arg Arg Asp Ala Gly Val Xaa Ala Gly
 35 40 45
 Xaa Asp Arg Ser Xaa Thr His Glu Cys Gln Val Gln Val Val Arg Val
 50 55 60
 Gly Asp Met Ser Leu Glu
 65 70

<210> 810
 <211> 39
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (1)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (3)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE

<222> (4)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (18)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (22)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (39)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 810

Xaa	Ile	Xaa	Xaa	Cys	Gly	Phe	Glu	Pro	Pro	His	Phe	Leu	Thr	Leu	Asn
1				5				10						15	

Leu	Xaa	Met	His	Arg	Xaa	Ser	Cys	Pro	Leu	Asp	Cys	Lys	Val	Tyr	Val
			20					25					30		

Gly	Ile	Leu	Gly	Thr	Met	Xaa
						35

<210> 811

<211> 27

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (22)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (24)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (25)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 811

793

Gly Arg Glu Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
 1 5 10 15

Lys Lys Lys Lys Lys Xaa Pro Xaa Xaa Gly Pro
 20 25

<210> 812

<211> 72

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (4)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (21)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 812

Arg Arg Arg Xaa Arg Pro Ala Pro Pro Pro Gly Ala Cys Leu His Leu
 1 5 10 15

Arg Leu Pro Lys Xaa Leu Gly Gln Arg Leu Asp Ala Arg His Gln Gly
 20 25 30

Pro Val Glu Val Leu Gln Glu Glu Arg Arg Pro Arg Pro Arg Leu Pro
 35 40 45

Arg Pro Ala Leu Ala Thr Leu Ser Ala Arg Phe Thr Asn Lys Leu Ser
 50 55 60

Asp Pro Lys Lys Lys Lys Lys Lys
 65 70

<210> 813

<211> 27

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (4)

<223> Xaa equals any of the naturally occurring L-amino acids

794

<220>

<221> SITE

<222> (5)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 813

Asn Ser Ala Xaa Xaa Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1 5 10 15

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
20 25

<210> 814

<211> 23

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (23)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 814

Asn Ser Ala Gln Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1 5 10 15

Lys Lys Lys Lys Lys Lys Xaa
20

<210> 815

<211> 46

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (16)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (19)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (24)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (31)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (37)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (38)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (46)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 815

Phe	Asp	Gln	Arg	Thr	Arg	Ile	Thr	Arg	Pro	Gln	Arg	Arg	Val	Phe	Xaa
1				5					10					15	

Ala	Ser	Xaa	Ser	Pro	Pro	Lys	Xaa	Ile	Thr	Asn	Cys	Ile	Tyr	Xaa	Lys
			20					25					30		

Ile	Asn	Arg	Tyr	Xaa	Xaa	Leu	Asn	Ile	Ala	Ile	Gln	Ile	Xaa
			35				40					45	

<210> 816

<211> 52

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (4)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (22)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (41)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (45)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (50)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 816

Asn	Ser	Ala	Xaa	Leu	Lys	Gln	Thr	Gly	Leu	Lys	Gly	Val	Thr	Phe	Asn
1				5				10						15	

Lys	Arg	Met	Lys	Met	Xaa	Lys	Lys	Lys	Lys	Lys	Lys	Lys	Lys	Lys	Lys
			20					25					30		

Lys	Lys	Lys	Lys	Lys	Lys	Lys	Lys	Xaa	Pro	Gly	Gly	Xaa	Pro	Pro	Pro
			35					40				45			

Pro	Xaa	Pro	Pro
			50

<210> 817

<211> 113

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (1)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (28)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (68)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (69)

797

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (100)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (110)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 817

Xaa	Ser	Gly	Arg	Gly	Gly	Ser	His	Ser	Arg	Asn	Leu	Val	Leu	Phe	Phe
1				5					10					15	

Pro	Gln	Leu	Gly	Lys	Arg	His	Met	Ser	Leu	Ala	Xaa	Pro	Ile	Ala	Asn
			20					25					30		

Pro	Val	Val	Gly	Phe	Leu	Ala	Tyr	Ser	Arg	Pro	Ser	Val	Leu	Pro	Gly
		35					40					45			

Trp	His	Arg	Pro	His	Arg	Thr	Ser	Arg	Val	Gly	Leu	Ser	Gly	Ser	Ser
	50				55						60				

Thr	Ala	Gly	Xaa	Xaa	Asn	Ser	Arg	Phe	Gly	Gly	Cys	Ser	Phe	Gln	Ala
65					70					75					80

Gly	Asp	Thr	Leu	Gly	Pro	Val	Val	Arg	Ser	Pro	Val	Leu	Arg	His	Leu
			85						90					95	

Val	Trp	Asn	Xaa	Arg	Leu	Ala	Val	Ser	Ile	Gly	Val	Gly	Xaa	Cys	Ala
			100					105					110		

Ala

<210> 818

<211> 132

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (5)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (9)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (11)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (15)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (23)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (27)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (39)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (56)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (57)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (71)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (72)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (77)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (79)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (81)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (82)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (85)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (87)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (93)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (94)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (97)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (105)

<223> Xaa equals any of the naturally occurring L-amino acids

800

<220>

<221> SITE

<222> (108)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (116)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (121)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (127)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 818

Phe	Phe	Phe	Phe	Xaa	Lys	Gly	Thr	Xaa	Thr	Xaa	Leu	Pro	Phe	Xaa	Pro
1				5				10						15	

Asn	Gln	Asn	Gln	Asn	Pro	Xaa	Gln	Ser	Ile	Xaa	Lys	Ser	Lys	Pro	Gly
			20					25					30		

Gln	Asn	Gln	Asn	Glu	Xaa	Xaa	Lys	Gln	Ser	Lys	Ser	Ser	Gln	Lys	Gln
			35				40						45		

Lys	Pro	Lys	Cys	Arg	Tyr	Arg	Xaa	Xaa	Val	Gly	Asp	Gln	Ala	Thr	Leu
	50					55					60				

Pro	Leu	Lys	Trp	Ser	Gly	Xaa	Xaa	Pro	Lys	Thr	Ser	Xaa	Thr	Xaa	Phe
65					70					75					80

Xaa	Xaa	Ser	Gly	Xaa	Gln	Xaa	Pro	Val	Pro	Ser	Gln	Xaa	Xaa	Ala	Ala
				85					90					95	

Xaa	Leu	Ile	Leu	Cys	Gly	Gly	Leu	Xaa	Asn	Ala	Xaa	Leu	Ala	Arg	Cys
			100					105						110	

Ser	Thr	Gly	Xaa	Ile	Ala	Tyr	Pro	Xaa	Val	Leu	Ser	Gly	Ser	Xaa	Ser
		115					120					125			

Leu	Lys	Leu	Ala
			130

801

<210> 819
<211> 62
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (4)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (54)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (55)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 819
Asn Ser Ala Xaa Gln Thr Thr Pro Ser Leu Ser Tyr Val Phe Leu Leu
1 5 10 15
Gln Thr Thr Arg Gln Leu Leu Lys Pro Ala Ile His Val Tyr Phe Asn
20 25 30
Lys Leu Met Ala Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
35 40 45
Lys Lys Lys Lys Lys Xaa Xaa Gly Gly Gly Pro Pro Pro Pro
50 55 60

<210> 820
<211> 40
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (7)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (17)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>

802

<221> SITE
 <222> (26)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (27)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (38)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 820
 Asp His Thr Ser Asp Thr Xaa Ala Trp Val Thr Glu Arg Asp Ser Val
 1 5 10 15

Xaa Gly Lys Glu Lys Lys Lys Lys Xaa Xaa Gly Gly Ala Pro Val
 20 25 30

Pro Asn Trp Pro Tyr Xaa Gly Ser
 35 40

<210> 821
 <211> 64
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (2)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 821
 Ala Xaa Pro Thr Gln Gln Ser Phe Pro Gln Leu Pro Arg Arg Lys Gly
 1 5 10 15

Pro Ser Trp Val Trp Asp His Lys Gly Gly Asp Cys Thr Pro Leu Pro
 20 25 30

Leu Gly Pro Gly Cys Gly Gln Arg Pro Pro Cys Val Ser Arg Val Thr
 35 40 45

Val Pro Leu Ser Cys Asp Ala Ile Ser Val Cys Ala Trp Ser Pro Gln
 50 55 60

803

<210> 822
 <211> 61
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (23)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 822
 His Leu Cys Phe Lys Trp Gly Ser Pro Cys Arg Gly Phe Ile Gly His
 1 5 10 15
 Trp Leu Ser Lys Cys Gln Xaa Trp Ala Gly Gly Gly Thr Glu Pro Pro
 20 25 30
 Gln His Cys Ala Leu Val Glu Lys Ala Leu Thr Cys His Ala Pro Leu
 35 40 45
 Lys Pro Pro Leu Leu Thr Cys Leu Leu His Pro Ser His
 50 55 60

<210> 823
 <211> 73
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (49)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (57)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (72)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 823
 Thr Ala Gly Arg Trp Pro Trp Lys Ser Glu Ser Ala Lys Glu Cys Val
 1 5 10 15

804

Thr Thr His Leu Pro Asn Gln Leu Ala Leu Lys Met Asp Gly Ala Gly
 20 25 30
 Ala Ser Gly Pro Tyr Pro Ser Val Ala Gly Ser Arg Glu Trp Thr Gly
 35 40 45
 Xaa Ala Gly Ala Ala Arg Ala Arg Xaa Val Met Val Cys Val Gly Gly
 50 55 60
 Arg Arg Arg Arg Arg Gly Cys Xaa Val
 65 70

<210> 824

<211> 34

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (3)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (12)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (27)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE.

<222> (31)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 824

Pro Arg Xaa Arg Arg Gln Gln Gln Pro His His Xaa Val Ala Asp Gly
 1 5 10 15

Pro His Ala Gly Gly Pro Leu Pro Ala Leu Xaa Arg Arg Leu Xaa Leu
 20 25 30

Pro Leu

805

<210> 825
 <211> 21
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (6)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (7)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (19)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 825
 Pro Tyr Ser Glu Ser Xaa Xaa Asn Ser Leu Ala Val Val Leu Gln Arg
 1 5 10 15

Arg Asp Xaa Glu Asn
 20

<210> 826
 <211> 56
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (48)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (56)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 826
 Met Ser Glu Ala Cys Ile Val Ile Ile Ser Tyr Phe Phe Pro Leu Asp
 1 5 10 15

Pro Ser His Gln Met Phe Val Asp Phe Ile Arg Ile Phe Lys Leu Pro
 20 25 30

806

Ala Ser Gly Phe Val Glu Leu Gly Ile Ser Val Ser Leu Ile Phe Xaa
35 40 45

Leu Leu Ser Cys Thr Tyr Phe Xaa
50 55

<210> 827

<211> 54

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (4)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (41)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (47)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 827

Asn Ser Lys Xaa Ile Thr Ile Lys Lys Ala Gly Thr Pro Ala Gly Thr
1 5 10 15

Gly Pro Glu Phe Pro Gly Arg Pro Thr Arg Pro Thr Ala Ala Arg Arg
20 25 30

Arg Gln Lys Gly Thr Ala Ala Arg Xaa Arg Gln Lys Gly Ala Xaa Glu
35 40 45

Arg Arg Arg Gln Lys Gly
50

<210> 828

<211> 78

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

807

<222> (43)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (56)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 828

Leu Val Phe Thr Glu Thr Leu Arg Glu His Lys Phe Met Gly Phe Leu
 1 5 10 15

Met Met Ile Leu Leu Gly Ile Met Ser Tyr Ser Leu Ser Ser Leu Met
 20 25 30

Asn Val Lys Leu His Cys Ser Gln Arg Phe Xaa Leu Leu Ser Thr Ala
 35 40 45

Ile Asn His Gly His Ser Pro Xaa Asn Ile Ile Phe Phe Leu Leu Lys
 50 55 60

Glu Lys Asn Gly Lys Lys Leu Gln Gly Asn Gly Asn Tyr Tyr
 65 70 75

<210> 829

<211> 89

<212> PRT

<213> Homo sapiens

<400> 829

Ser Ala Glu Glu Lys Lys Leu Thr Arg Ile Pro Ser Val Thr Ala Ser
 1 5 10 15

Glu Gln Gly Arg Ala Gln Arg Arg Ile Pro Ala Pro Arg Arg Gly Ala
 20 25 30

Gly His Val Ala Tyr Gly Arg Pro Ala Pro Arg Arg Arg Ser Trp Gly
 35 40 45

Ala Gln Val Leu Leu Ile Glu Ala Gln Pro Val Asp Gly Val Arg Pro
 50 55 60

Val Ala Ala Pro Gly Ala Pro Gly Pro Gly Leu Pro Gly Val Gly Leu
 65 70 75 80

Leu Gly Asn Ala Ala Gln Ser Gly Trp
 85

808

<210> 830
<211> 43
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (43)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 830
Pro Leu Ile Phe Ile Asn Ser Arg Ile His Thr Asp Ser Pro Gly Ile
1 5 10 15
Val Pro Ser His Ser Glu Asp Ala Leu Arg Thr Leu Gln Ile Leu Leu
20 25 30
Pro Tyr Ile Thr Leu Asn Ser Gly Leu Arg Xaa
35 40

<210> 831
<211> 110
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (34)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (66)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (87)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (89)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (98)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (99)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (103)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 831

Lys Asp Ser Leu Asp Ser Gly Lys Leu Leu Gly Ser Gln Leu Gln Phe
1 5 10 15

Ile Thr Val Lys Gly Gln Arg Leu Arg Ser Ala Lys Gly Gly Gly Ala
20 25 30

Gln Xaa Arg Ser Thr Thr Asp Glu Ala Thr Ala Ser Ile Cys Pro Leu
35 40 45

Pro Val Glu Pro Tyr Arg Gln His Leu Ile Leu Thr Ala Thr Cys Asp
50 55 60

Asn Xaa Gln Glu Val Leu Pro Ile Leu Pro Thr Arg Ala Ala Ser Leu
65 70 75 80

Gly Asp Leu Cys Val Pro Xaa Phe Xaa Val Cys Leu Gly Asp Arg Val
85 90 95

Trp Xaa Xaa Leu Gly Arg Xaa Arg Val His Gly Gly Asp Ser
100 105 110

<210> 832

<211> 50

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (20)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 832

Gln Arg Ser Ile Leu Val Thr Trp Phe His Cys His His Leu Val Asp
1 5 10 15

Val Gln Phe Xaa Thr Ile Leu Ser Ala Pro Ser Gly Ser Leu Ala His

810

	20		25		30										
Ser	Leu	Leu	Cys	Asn	Cys	Trp	Arg	Ile	Thr	Ala	Glu	Phe	Leu	Ala	Val
	35						40						45		
Leu	Ser														
	50														

<210> 833

<211> 47

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (10)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (13)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (17)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (32)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (34)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (38)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (40)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 833

811

His Leu Lys Leu Leu Gly Leu Glu Arg Xaa Gln Arg Xaa Ser Gly Arg
 1 5 10 15

Xaa Thr Thr Leu Gly Gly Arg Ser Thr Gly Leu Val Ile Glu Leu Xaa
 20 25 30

Leu Xaa Arg Leu Leu Xaa Cys Xaa Met Asn Cys Asn Ile Cys Leu
 35 40 45

<210> 834

<211> 90

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (2)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (3)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (21)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 834

Glu Xaa Xaa Thr Glu Gly Tyr Gly Cys Glu Arg Arg Gln Lys Gly Thr
 1 5 10 15

Ala Ala Arg Arg Xaa Gln Lys Gly Thr Ala Ala Arg Arg Arg Gln Lys
 20 25 30

Gly Thr Ala Ala Arg Arg Arg Gln Lys Gly Thr Ala Ala Arg Arg Arg
 35 40 45

Gln Lys Val Arg Leu Arg Glu Asp Asp Arg Arg Ile Arg Leu Arg Glu
 50 55 60

Asp Asp Arg Arg Glu Asn Leu Ser Ser Thr Leu Asn Leu Pro Thr Glu
 65 70 75 80

Pro Ser Lys Ser Pro Cys Lys Phe Asn Cys
 85 90

812

<210> 835
 <211> 51
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (3)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (28)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (41)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (48)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (51)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 835
 Asp Ile Xaa Leu Val Phe Ile Leu Lys Gln Phe Leu Gly Leu Phe Arg
 1 5 10 15
 Gly Ser Leu Cys Cys Leu Tyr Cys Ile Asp Leu Xaa Tyr Arg Cys Leu
 20 25 30
 Phe Ile Lys Lys Lys Ile Gln Lys Xaa Lys Lys Lys Ile Asn Lys Xaa
 35 40 45
 Lys Lys Xaa
 50

<210> 836
 <211> 47
 <212> PRT
 <213> Homo sapiens

813

<220>

<221> SITE

<222> (46)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (47)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 836

Ser Ser Leu Gln Lys Asn Leu Val Leu Glu Tyr Phe Leu Lys Gly Ile
 1 5 10 15

Leu Asn Thr Ile Lys Thr Ala Phe Phe Phe Pro Ala Ser Ile Gln Pro
 20 25 30

Thr Trp Phe Cys Phe Asn Lys Ser Leu Glu Lys Leu Ile Xaa Xaa
 35 40 45

<210> 837

<211> 733

<212> DNA

<213> Homo sapiens

<400> 837

gggatccgga gcccaaactct tctgacaaaa ctacacatg cccaccgtgc ccagcacctg 60
 aattcgaggg tgcaccgtca gtcttcctct tcccccaaa acccaaggac accctcatga 120
 tctcccgga tctgaggtc acatgcgtgg tggtagacgt aagccacgaa gaccctgagg 180
 tcaagttcaa ctggtacgtg gacggcgtgg aggtgcataa tgccaagaca aagccgcggg 240
 aggagcagta caacagcacg taccgtgtgg tcagcgtcct caccgtcctg caccaggact 300
 ggctgaatgg caaggagtac aagtgcagg tctccaacaa agccctccca acccccatcg 360
 agaaaacat ctccaaagcc aaagggcagc cccgagaacc acaggtgtac accctgcccc 420
 catcccgga tgagctgacc aagaaccagg tcagcctgac ctgcctgggc aaaggcttct 480
 atccaagcga catcgccgtg gagtgggaga gcaatgggca gccggagAAC aactacaaga 540
 ccacgcctcc cgtgctggac tccgacggct cttcttcct ctacagcaag ctcaccgtgg 600
 acaagagcag gtggcagcag gggaacgtct tctcatgctc cgtgatgcat gaggctctgc 660
 acaaccacta cagcagaag agcctctccc tgtctccggg taaatgagtg cgacggccgc 720
 gactctagag gat 733

<210> 838

<211> 5

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (3)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 838

Trp Ser Xaa Trp Ser
1 5

<210> 839

<211> 86

<212> DNA

<213> Homo sapiens

<400> 839

gcgcctcgag atttccccga aatctagatt tccccgaaat gatttccccg aaatgatttc 60
cccgaatat ctgccatctc aattag 86

<210> 840

<211> 27

<212> DNA

<213> Homo sapiens

<400> 840

gcggcaagct ttttgcaaag cctaggg 27

<210> 841

<211> 271

<212> DNA

<213> Homo sapiens

<400> 841

ctcgagattt ccccgaaatc tagatttccc cgaaatgatt tccccgaaat gatttccccg 60
aaatatctgc catctcaatt agtcagcaac catagtcccg cccctaactc cgcccatccc 120
gcccctaact ccgcccagtt ccgcccattc tccgcccatt ggctgactaa ttttttttat 180
ttatgcagag gccgaggccg cctcggcctc tgagctattc cagaagtagt gaggaggctt 240
ttttggaggc ctaggctttt gcaaaaagct t 271

<210> 842

<211> 32

<212> DNA

<213> Homo sapiens

<400> 842

gcgctcgagg gatgacagcg atagaacccc gg 32

<210> 843
<211> 31
<212> DNA
<213> Homo sapiens

<400> 843
gcgaagcttc gcgactcccc ggatccgcct c 31

<210> 844
<211> 12
<212> DNA
<213> Homo sapiens

<400> 844
ggggactttc cc 12

<210> 845
<211> 73
<212> DNA
<213> Homo sapiens

<400> 845
gcggcctcga ggggactttc ccggggactt tccggggact ttccgggact ttccatcctg 60
ccatctcaat tag 73

<210> 846
<211> 256
<212> DNA
<213> Homo sapiens

<400> 846
ctcgagggga ctttcccgga gactttccgg ggactttccg ggactttcca tctgccatct 60
caattagtc gcaaccatag tcccgccct aactccgcc atcccgccc taactccgcc 120
cagttccgcc cattctccgc cccatggctg actaattttt ttatttatg cagaggccga 180
ggcgcctcg gcctctgagc tattccagaa gtagtgagga ggcttttttg gaggcctagg 240
cttttgcaaa aagctt 256

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/05881

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07H 21/04; C07K 5/04, 16/00; G01N 33/53

US CL : 536/23.1; 530/300, 387.9; 436/501

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.1; 530/300, 387.9; 436/501

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

East, GenEmbl, EST, GeneSeq, PIR-63, SwissProt, SPTREMBL, Issued patents sequence database: SEQ ID NO:1 and monoamine adj oxidase

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X ----- Y	ZHU et al. Promoter organization and activity of human monoamine oxidase (MOA) A and B genes. J. Neurosci. November 1992, Vol. 12, No. 11, pages 4437-4446, especially pages 4438-4439.	1-12, 14-16, 20-23 ----- 13, 17-19
X ----- Y	CHEN et al. The deduced amino acid sequences of human platelet and frontal cortex monoamine oxidase B are identical. J. Neurochem. July 1993, Vol. 61, No. 1, pages 187-190, especially pages 188-190.	1-7, 11-12 ----- 19
X ----- Y	GRIMSBY et al. Human monoamine oxidase A and B genes exhibit identical exon-intron organization. Proc. Natl. Acad. Sci., USA. May 1991, Vol. 88, pages 3637-3641, especially 3638-3640.	1-12, 20-21 and 23 ----- 17-19

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

01 JUNE 2000

Date of mailing of the international search report

05 JUL 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

MARJORIE MORAN

Telephone No. (703) 308-1235

JOYCE BRIDGERS
PARALEGAL SPECIALIST
CHEMICAL MATRIX

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/05881

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X -----	BACH et al. cDNA cloning of human liver monoamine oxidase A and B: Molecular basis of differences in enzymatic properties.	1-16, 20-23 -----
Y	Proc. Natl. Acad. Sci., USA. July 1988, Vol. 85, pages 4934-4938, especially pages 4935-4936.	17-19
Y	US 5,783,680 A (BRUNNER et al.) 21 July 1998, columns 5-15.	13, 17-19

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/05881

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-23, SEQ ID NO:1

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/05881

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-10 and 21, drawn to isolated nucleic acid sequences, a gene, a recombinant vector and host cells comprising the sequences.

Group II, claim(s) 11-12 and 14, drawn to an isolated polypeptide and a recombinant host cell expressing the polypeptide.

Group III, claim(s) 13, drawn to an antibody.

Group IV, claim(s) 15-16, drawn to a method of making a polypeptide and the polypeptide made.

Group V, claim(s) 17, drawn to a method of preventing, treating, or ameliorating a medical condition by administering a polypeptide or a polynucleotide.

Group VI, claim(s) 18, drawn to a method of diagnosis using a polynucleotide.

Group VII, claim(s) 19, drawn to a method of diagnosis using a polypeptide.

Group VIII, claim(s) 20 and 23, drawn to a method of identifying a binding partner to a polypeptide.

Group IX, claim(s) 22, drawn to a method of identifying biological activity.

In addition, each isolated nucleic acid represented by SEQ ID NO: X is a separate product, not necessarily related to any other nucleic acid represented by SEQ ID NO: X. Each polypeptide is likewise considered a separate product, not necessarily related to any other polypeptide sequence, or to any nucleotide sequence. Applicant is required to elect either ten nucleic acid sequences or one polypeptide sequence for search.

The inventions listed as Groups I-IX do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: every nucleic acid sequence claimed is not unique (SEQ ID NO: 1 is not unique, see the Search report), and therefore does not represent a special technical feature. As the nucleic acid would be the "linking" feature, and the nucleic acid is not a special technical feature, the claims do not relate to a single inventive concept. Because there is no single inventive concept, a method of use is not included with the nucleic acids of Group I.

Although unity of invention is lacking for Groups I-IX, as previously set forth, no invitation to pay for a search for extra groups has been made. However, unity of invention is also lacking with regard to sequences and applicant was invited to pay for a search for additional groups of sequences. Applicant elected only SEQ ID NO:1, therefore no extra search fees are due.